words,sentence_id,labels
Late-onset,0,O
metachromatic,0,B-DiseaseOrPhenotypicFeature
leukodystrophy,0,I-DiseaseOrPhenotypicFeature
:,0,O
molecular,0,O
pathology,0,O
in,0,O
two,0,O
siblings,0,O
.,0,O
We,1,O
report,1,O
on,1,O
a,1,O
new,1,O
allele,1,O
at,1,O
the,1,O
arylsulfatase,1,B-GeneOrGeneProduct
A,1,I-GeneOrGeneProduct
(,1,O
ARSA,1,B-GeneOrGeneProduct
),1,O
locus,1,O
causing,1,O
late-onset,1,O
metachromatic,1,B-DiseaseOrPhenotypicFeature
leukodystrophy,1,I-DiseaseOrPhenotypicFeature
(,1,O
MLD,1,B-DiseaseOrPhenotypicFeature
),1,O
.,1,O
In,2,O
that,2,O
allele,2,O
arginine84,2,B-SequenceVariant
",",2,O
a,2,O
residue,2,O
that,2,O
is,2,O
highly,2,O
conserved,2,O
in,2,O
the,2,O
arylsulfatase,2,B-GeneOrGeneProduct
gene,2,O
family,2,O
",",2,O
is,2,O
replaced,2,O
by,2,O
glutamine,2,O
.,2,O
In,3,O
contrast,3,O
to,3,O
alleles,3,O
that,3,O
cause,3,O
early-onset,3,O
MLD,3,B-DiseaseOrPhenotypicFeature
",",3,O
the,3,O
arginine84,3,B-SequenceVariant
to,3,I-SequenceVariant
glutamine,3,I-SequenceVariant
substitution,3,O
is,3,O
associated,3,O
with,3,O
some,3,O
residual,3,O
ARSA,3,B-GeneOrGeneProduct
activity,3,O
.,3,O
A,4,O
comparison,4,O
of,4,O
genotypes,4,O
",",4,O
ARSA,4,B-GeneOrGeneProduct
activities,4,O
",",4,O
and,4,O
clinical,4,O
data,4,O
on,4,O
4,4,O
individuals,4,O
carrying,4,O
the,4,O
allele,4,O
of,4,O
81,4,O
patients,4,B-OrganismTaxon
with,4,O
MLD,4,B-DiseaseOrPhenotypicFeature
examined,4,O
",",4,O
further,4,O
validates,4,O
the,4,O
concept,4,O
that,4,O
different,4,O
degrees,4,O
of,4,O
residual,4,O
ARSA,4,B-GeneOrGeneProduct
activity,4,O
are,4,O
the,4,O
basis,4,O
of,4,O
phenotypical,4,O
variation,4,O
in,4,O
MLD,4,B-DiseaseOrPhenotypicFeature
..,4,O
Delayed,5,O
institution,5,O
of,5,O
hypertension,5,B-DiseaseOrPhenotypicFeature
during,5,O
focal,5,O
cerebral,5,B-DiseaseOrPhenotypicFeature
ischemia,5,I-DiseaseOrPhenotypicFeature
:,5,O
effect,5,O
on,5,O
brain,5,B-DiseaseOrPhenotypicFeature
edema,5,I-DiseaseOrPhenotypicFeature
.,5,O
The,6,O
effect,6,O
of,6,O
induced,6,O
hypertension,6,B-DiseaseOrPhenotypicFeature
instituted,6,O
after,6,O
a,6,O
2-h,6,O
delay,6,O
following,6,O
middle,6,B-DiseaseOrPhenotypicFeature
cerebral,6,I-DiseaseOrPhenotypicFeature
artery,6,I-DiseaseOrPhenotypicFeature
occlusion,6,I-DiseaseOrPhenotypicFeature
(,6,O
MCAO,6,B-DiseaseOrPhenotypicFeature
),6,O
on,6,O
brain,6,B-DiseaseOrPhenotypicFeature
edema,6,I-DiseaseOrPhenotypicFeature
formation,6,O
and,6,O
histochemical,6,O
injury,6,O
was,6,O
studied,6,O
.,6,O
Under,7,O
isoflurane,7,B-ChemicalEntity
anesthesia,7,O
",",7,O
the,7,O
MCA,7,O
of,7,O
14,7,O
spontaneously,7,O
hypertensive,7,B-DiseaseOrPhenotypicFeature
rats,7,B-OrganismTaxon
was,7,O
occluded,7,O
.,7,O
In,8,O
the,8,O
control,8,O
group,8,O
(,8,O
n,8,O
=,8,O
7,8,O
),8,O
",",8,O
the,8,O
mean,8,O
arterial,8,O
pressure,8,O
(,8,O
MAP,8,O
),8,O
was,8,O
not,8,O
manipulated,8,O
.,8,O
In,9,O
the,9,O
hypertensive,9,B-DiseaseOrPhenotypicFeature
group,9,O
(,9,O
n,9,O
=,9,O
7,9,O
),9,O
",",9,O
the,9,O
MAP,9,O
was,9,O
elevated,9,O
by,9,O
25-30,9,O
mm,9,O
Hg,9,O
beginning,9,O
2,9,O
h,9,O
after,9,O
MCAO,9,B-DiseaseOrPhenotypicFeature
.,9,O
Four,10,O
hours,10,O
after,10,O
MCAO,10,B-DiseaseOrPhenotypicFeature
",",10,O
the,10,O
rats,10,B-OrganismTaxon
were,10,O
killed,10,O
and,10,O
the,10,O
brains,10,O
harvested,10,O
.,10,O
The,11,O
brains,11,O
were,11,O
sectioned,11,O
along,11,O
coronal,11,O
planes,11,O
spanning,11,O
the,11,O
distribution,11,O
of,11,O
ischemia,11,B-DiseaseOrPhenotypicFeature
produced,11,O
by,11,O
MCAO,11,B-DiseaseOrPhenotypicFeature
.,11,O
Specific,12,O
gravity,12,O
(,12,O
SG,12,O
),12,O
was,12,O
determined,12,O
in,12,O
the,12,O
subcortex,12,O
and,12,O
in,12,O
two,12,O
sites,12,O
in,12,O
the,12,O
cortex,12,O
(,12,O
core,12,O
and,12,O
periphery,12,O
of,12,O
the,12,O
ischemic,12,B-DiseaseOrPhenotypicFeature
territory,12,O
),12,O
.,12,O
The,13,O
extent,13,O
of,13,O
neuronal,13,B-DiseaseOrPhenotypicFeature
injury,13,I-DiseaseOrPhenotypicFeature
was,13,O
determined,13,O
by,13,O
"2,3,5-triphenyltetrazolium",13,B-ChemicalEntity
staining,13,O
.,13,O
In,14,O
the,14,O
ischemic,14,B-DiseaseOrPhenotypicFeature
core,14,O
",",14,O
there,14,O
was,14,O
no,14,O
difference,14,O
in,14,O
SG,14,O
in,14,O
the,14,O
subcortex,14,O
and,14,O
cortex,14,O
in,14,O
the,14,O
two,14,O
groups,14,O
.,14,O
In,15,O
the,15,O
periphery,15,O
of,15,O
the,15,O
ischemic,15,B-DiseaseOrPhenotypicFeature
territory,15,O
",",15,O
SG,15,O
in,15,O
the,15,O
cortex,15,O
was,15,O
greater,15,O
(,15,O
less,15,O
edema,15,B-DiseaseOrPhenotypicFeature
accumulation,15,O
),15,O
in,15,O
the,15,O
hypertensive,15,B-DiseaseOrPhenotypicFeature
group,15,O
(,15,O
1.041,15,O
+/-,15,O
0.001,15,O
vs,15,O
1.039,15,O
+/-,15,O
0.001,15,O
",",15,O
P,15,O
less,15,O
than,15,O
0.05,15,O
),15,O
.,15,O
The,16,O
area,16,O
of,16,O
histochemical,16,O
injury,16,O
(,16,O
as,16,O
a,16,O
percent,16,O
of,16,O
the,16,O
cross-sectional,16,O
area,16,O
of,16,O
the,16,O
hemisphere,16,O
),16,O
was,16,O
less,16,O
in,16,O
the,16,O
hypertensive,16,B-DiseaseOrPhenotypicFeature
group,16,O
(,16,O
33,16,O
+/-,16,O
3,16,O
%,16,O
vs,16,O
21,16,O
+/-,16,O
2,16,O
%,16,O
",",16,O
P,16,O
less,16,O
than,16,O
0.05,16,O
),16,O
.,16,O
The,17,O
data,17,O
indicate,17,O
that,17,O
phenylephrine-induced,17,B-ChemicalEntity
hypertension,17,B-DiseaseOrPhenotypicFeature
instituted,17,O
2,17,O
h,17,O
after,17,O
MCAO,17,B-DiseaseOrPhenotypicFeature
does,17,O
not,17,O
aggravate,17,O
edema,17,B-DiseaseOrPhenotypicFeature
in,17,O
the,17,O
ischemic,17,B-DiseaseOrPhenotypicFeature
core,17,O
",",17,O
that,17,O
it,17,O
improves,17,O
edema,17,B-DiseaseOrPhenotypicFeature
in,17,O
the,17,O
periphery,17,O
of,17,O
the,17,O
ischemic,17,B-DiseaseOrPhenotypicFeature
territory,17,O
",",17,O
and,17,O
that,17,O
it,17,O
reduces,17,O
the,17,O
area,17,O
of,17,O
histochemical,17,O
neuronal,17,B-DiseaseOrPhenotypicFeature
dysfunction,17,I-DiseaseOrPhenotypicFeature
.,17,O
Midline,18,O
B3,18,O
serotonin,18,B-ChemicalEntity
nerves,18,O
in,18,O
rat,18,B-OrganismTaxon
medulla,18,O
are,18,O
involved,18,O
in,18,O
hypotensive,18,B-DiseaseOrPhenotypicFeature
effect,18,O
of,18,O
methyldopa,18,B-ChemicalEntity
.,18,O
Previous,19,O
experiments,19,O
in,19,O
this,19,O
laboratory,19,O
have,19,O
shown,19,O
that,19,O
microinjection,19,O
of,19,O
methyldopa,19,B-ChemicalEntity
onto,19,O
the,19,O
ventrolateral,19,O
cells,19,O
of,19,O
the,19,O
B3,19,O
serotonin,19,B-ChemicalEntity
neurons,19,O
in,19,O
the,19,O
medulla,19,O
elicits,19,O
a,19,O
hypotensive,19,B-DiseaseOrPhenotypicFeature
response,19,O
mediated,19,O
by,19,O
a,19,O
projection,19,O
descending,19,O
into,19,O
the,19,O
spinal,19,O
cord,19,O
.,19,O
The,20,O
present,20,O
experiments,20,O
were,20,O
designed,20,O
to,20,O
investigate,20,O
the,20,O
role,20,O
of,20,O
the,20,O
midline,20,O
cells,20,O
of,20,O
the,20,O
B3,20,O
serotonin,20,B-ChemicalEntity
neurons,20,O
in,20,O
the,20,O
medulla,20,O
",",20,O
coinciding,20,O
with,20,O
the,20,O
raphe,20,O
magnus,20,O
.,20,O
In,21,O
spontaneously,21,O
hypertensive,21,B-DiseaseOrPhenotypicFeature
",",21,O
stroke-prone,21,B-DiseaseOrPhenotypicFeature
rats,21,B-OrganismTaxon
",",21,O
microinjection,21,O
of,21,O
methyldopa,21,B-ChemicalEntity
into,21,O
the,21,O
area,21,O
of,21,O
the,21,O
midline,21,O
B3,21,O
serotonin,21,B-ChemicalEntity
cell,21,O
group,21,O
in,21,O
the,21,O
ventral,21,O
medulla,21,O
caused,21,O
a,21,O
potent,21,O
hypotension,21,B-DiseaseOrPhenotypicFeature
of,21,O
30-40,21,O
mm,21,O
Hg,21,O
",",21,O
which,21,O
was,21,O
maximal,21,O
2-3,21,O
h,21,O
after,21,O
administration,21,O
and,21,O
was,21,O
abolished,21,O
by,21,O
the,21,O
serotonin,21,B-ChemicalEntity
neurotoxin,21,O
"5,7-dihydroxytryptamine",21,B-ChemicalEntity
(,21,O
"5,7-DHT",21,B-ChemicalEntity
),21,O
injected,21,O
intracerebroventricularly,21,O
.,21,O
However,22,O
",",22,O
intraspinal,22,O
injection,22,O
of,22,O
"5,7-DHT",22,B-ChemicalEntity
to,22,O
produce,22,O
a,22,O
more,22,O
selective,22,O
lesion,22,O
of,22,O
only,22,O
descending,22,O
serotonin,22,B-ChemicalEntity
projections,22,O
in,22,O
the,22,O
spinal,22,O
cord,22,O
did,22,O
not,22,O
affect,22,O
this,22,O
hypotension,22,B-DiseaseOrPhenotypicFeature
.,22,O
Further,23,O
",",23,O
"5,7-DHT",23,B-ChemicalEntity
lesion,23,O
of,23,O
serotonin,23,B-ChemicalEntity
nerves,23,O
travelling,23,O
in,23,O
the,23,O
median,23,O
forebrain,23,O
bundle,23,O
",",23,O
one,23,O
of,23,O
the,23,O
main,23,O
ascending,23,O
pathways,23,O
from,23,O
the,23,O
B3,23,O
serotonin,23,B-ChemicalEntity
cells,23,O
",",23,O
did,23,O
not,23,O
affect,23,O
the,23,O
fall,23,O
in,23,O
blood,23,O
pressure,23,O
associated,23,O
with,23,O
a,23,O
midline,23,O
B3,23,O
serotonin,23,B-ChemicalEntity
methyldopa,23,B-ChemicalEntity
injection,23,O
.,23,O
It,24,O
is,24,O
concluded,24,O
therefore,24,O
that,24,O
",",24,O
unlike,24,O
the,24,O
ventrolateral,24,O
B3,24,O
cells,24,O
which,24,O
mediate,24,O
a,24,O
methyldopa-induced,24,B-ChemicalEntity
hypotension,24,B-DiseaseOrPhenotypicFeature
via,24,O
descending,24,O
projections,24,O
",",24,O
the,24,O
midline,24,O
serotonin,24,B-ChemicalEntity
B3,24,O
cells,24,O
in,24,O
the,24,O
medulla,24,O
contribute,24,O
to,24,O
the,24,O
hypotensive,24,B-DiseaseOrPhenotypicFeature
action,24,O
of,24,O
methyldopa,24,B-ChemicalEntity
",",24,O
either,24,O
by,24,O
way,24,O
of,24,O
an,24,O
ascending,24,O
projection,24,O
which,24,O
does,24,O
not,24,O
pass,24,O
through,24,O
the,24,O
median,24,O
forebrain,24,O
bundle,24,O
",",24,O
or,24,O
through,24,O
a,24,O
projection,24,O
restricted,24,O
to,24,O
the,24,O
caudal,24,O
brainstem,24,O
.,24,O
Pituitary,25,O
response,25,O
to,25,O
luteinizing,25,B-GeneOrGeneProduct
hormone-releasing,25,I-GeneOrGeneProduct
hormone,25,I-GeneOrGeneProduct
during,25,O
haloperidol-induced,25,B-ChemicalEntity
hyperprolactinemia,25,B-DiseaseOrPhenotypicFeature
.,25,O
The,26,O
effects,26,O
of,26,O
a,26,O
6-hour,26,O
infusion,26,O
with,26,O
haloperidol,26,B-ChemicalEntity
on,26,O
serum,26,O
prolactin,26,B-GeneOrGeneProduct
and,26,O
luteinizing,26,B-GeneOrGeneProduct
hormone,26,I-GeneOrGeneProduct
(,26,O
LH,26,B-GeneOrGeneProduct
),26,O
levels,26,O
was,26,O
studied,26,O
in,26,O
a,26,O
group,26,O
of,26,O
male,26,O
subjects,26,O
.,26,O
Five,27,O
hours,27,O
after,27,O
starting,27,O
the,27,O
infusions,27,O
",",27,O
a,27,O
study,27,O
of,27,O
the,27,O
pituitary,27,O
responses,27,O
to,27,O
LH-releasing,27,B-GeneOrGeneProduct
hormone,27,I-GeneOrGeneProduct
(,27,O
LH-RH,27,B-GeneOrGeneProduct
),27,O
was,27,O
carried,27,O
out,27,O
.,27,O
Control,28,O
patients,28,B-OrganismTaxon
received,28,O
infusions,28,O
of,28,O
0.9,28,O
%,28,O
NaCl,28,B-ChemicalEntity
solution,28,O
.,28,O
During,29,O
the,29,O
course,29,O
of,29,O
haloperidol,29,B-ChemicalEntity
infusions,29,O
",",29,O
significant,29,O
hyperprolactinemia,29,B-DiseaseOrPhenotypicFeature
was,29,O
found,29,O
",",29,O
together,29,O
with,29,O
an,29,O
abolished,29,O
pituitary,29,O
response,29,O
to,29,O
LH-RH,29,B-GeneOrGeneProduct
",",29,O
as,29,O
compared,29,O
with,29,O
responses,29,O
of,29,O
control,29,O
subjects,29,O
.,29,O
Cardiovascular,30,B-DiseaseOrPhenotypicFeature
complications,30,I-DiseaseOrPhenotypicFeature
associated,30,O
with,30,O
terbutaline,30,B-ChemicalEntity
treatment,30,O
for,30,O
preterm,30,B-DiseaseOrPhenotypicFeature
labor,30,I-DiseaseOrPhenotypicFeature
.,30,O
Severe,31,O
cardiovascular,31,B-DiseaseOrPhenotypicFeature
complications,31,I-DiseaseOrPhenotypicFeature
occurred,31,O
in,31,O
eight,31,O
of,31,O
160,31,O
patients,31,B-OrganismTaxon
treated,31,O
with,31,O
terbutaline,31,B-ChemicalEntity
for,31,O
preterm,31,B-DiseaseOrPhenotypicFeature
labor,31,I-DiseaseOrPhenotypicFeature
.,31,O
Associated,32,O
corticosteroid,32,B-ChemicalEntity
therapy,32,O
and,32,O
twin,32,O
gestations,32,O
appear,32,O
to,32,O
be,32,O
predisposing,32,O
factors,32,O
.,32,O
Potential,33,O
mechanisms,33,O
of,33,O
the,33,O
pathophysiology,33,O
are,33,O
briefly,33,O
discussed,33,O
.,33,O
Cloning,34,O
of,34,O
human,34,B-OrganismTaxon
very-long-chain,34,B-GeneOrGeneProduct
acyl-coenzyme,34,I-GeneOrGeneProduct
A,34,I-GeneOrGeneProduct
dehydrogenase,34,I-GeneOrGeneProduct
and,34,O
molecular,34,O
characterization,34,O
of,34,O
its,34,O
deficiency,34,O
in,34,O
two,34,O
patients,34,B-OrganismTaxon
.,34,O
Two,35,O
overlapping,35,O
cDNA,35,O
clones,35,O
(,35,O
1,35,O
",",35,O
991,35,O
bp,35,O
and,35,O
736,35,O
bp,35,O
",",35,O
respectively,35,O
),35,O
encoding,35,O
the,35,O
precursor,35,O
of,35,O
human,35,B-OrganismTaxon
mitochondrial,35,O
very-long-chain,35,B-GeneOrGeneProduct
acyl-coenzyme,35,I-GeneOrGeneProduct
A,35,I-GeneOrGeneProduct
dehydrogenase,35,I-GeneOrGeneProduct
(,35,O
VLCAD,35,B-GeneOrGeneProduct
),35,O
were,35,O
cloned,35,O
and,35,O
sequenced,35,O
.,35,O
The,36,O
cDNA,36,O
inserts,36,O
of,36,O
these,36,O
clones,36,O
together,36,O
encompass,36,O
a,36,O
region,36,O
of,36,O
2,36,O
",",36,O
177,36,O
bases,36,O
",",36,O
encoding,36,O
the,36,O
entire,36,O
protein,36,O
of,36,O
655,36,O
amino,36,O
acids,36,O
",",36,O
including,36,O
a,36,O
40-amino,36,O
acid,36,O
leader,36,O
peptide,36,O
and,36,O
a,36,O
615-amino,36,O
acid,36,O
mature,36,O
polypeptide,36,O
.,36,O
PCR-amplified,37,O
VLCAD,37,B-GeneOrGeneProduct
cDNAs,37,O
were,37,O
sequenced,37,O
in,37,O
cultured,37,O
fibroblasts,37,O
from,37,O
two,37,O
VLCAD-deficient,37,B-DiseaseOrPhenotypicFeature
patients,37,B-OrganismTaxon
.,37,O
In,38,O
both,38,O
patients,38,B-OrganismTaxon
",",38,O
a,38,O
105-bp,38,B-SequenceVariant
deletion,38,I-SequenceVariant
encompassing,38,I-SequenceVariant
bases,38,I-SequenceVariant
1078-1182,38,I-SequenceVariant
in,38,O
VLCAD,38,B-GeneOrGeneProduct
cDNA,38,O
was,38,O
identified,38,O
.,38,O
The,39,O
deletion,39,O
seems,39,O
to,39,O
occur,39,O
due,39,O
to,39,O
exon,39,O
skipping,39,O
during,39,O
processing,39,O
of,39,O
VLCAD,39,B-GeneOrGeneProduct
pre-mRNA,39,O
.,39,O
This,40,O
is,40,O
the,40,O
first,40,O
demonstration,40,O
of,40,O
a,40,O
mutation,40,O
causing,40,O
VLCAD,40,B-DiseaseOrPhenotypicFeature
deficiency,40,I-DiseaseOrPhenotypicFeature
.,40,O
Quantitative,41,O
cDNA,41,O
expression,41,O
of,41,O
normal,41,O
human,41,B-OrganismTaxon
VLCAD,41,B-GeneOrGeneProduct
was,41,O
performed,41,O
in,41,O
the,41,O
patients,41,B-OrganismTaxon
fibroblasts,41,O
",",41,O
using,41,O
vaccinia,41,O
viral,41,O
system,41,O
",",41,O
which,41,O
demonstrated,41,O
that,41,O
the,41,O
deficiency,41,B-DiseaseOrPhenotypicFeature
of,41,I-DiseaseOrPhenotypicFeature
the,41,I-DiseaseOrPhenotypicFeature
normal,41,I-DiseaseOrPhenotypicFeature
VLCAD,41,I-DiseaseOrPhenotypicFeature
protein,41,I-DiseaseOrPhenotypicFeature
causes,41,O
impaired,41,O
long-chain,41,B-ChemicalEntity
fatty,41,I-ChemicalEntity
acid,41,I-ChemicalEntity
beta-oxidation,41,O
activity,41,O
in,41,O
the,41,O
patients,41,B-OrganismTaxon
fibroblasts,41,O
.,41,O
In,42,O
patient,42,B-OrganismTaxon
fibroblasts,42,O
",",42,O
raising,42,O
VLCAD,42,B-GeneOrGeneProduct
activity,42,O
to,42,O
approximately,42,O
20,42,O
%,42,O
of,42,O
normal,42,O
control,42,O
fibroblast,42,O
activity,42,O
raised,42,O
palmitic,42,B-ChemicalEntity
acid,42,I-ChemicalEntity
beta-oxidation,42,O
flux,42,O
to,42,O
the,42,O
level,42,O
found,42,O
in,42,O
control,42,O
fibroblasts,42,O
",",42,O
which,42,O
may,42,O
offer,42,O
important,42,O
information,42,O
for,42,O
the,42,O
rational,42,O
design,42,O
of,42,O
future,42,O
somatic,42,O
gene,42,O
therapy,42,O
for,42,O
VLCAD,42,B-DiseaseOrPhenotypicFeature
deficiency,42,I-DiseaseOrPhenotypicFeature
..,42,O
Human,43,B-OrganismTaxon
mu,43,B-GeneOrGeneProduct
opiate,43,I-GeneOrGeneProduct
receptor,43,I-GeneOrGeneProduct
.,43,O
cDNA,44,O
and,44,O
genomic,44,O
clones,44,O
",",44,O
pharmacologic,44,O
characterization,44,O
and,44,O
chromosomal,44,O
assignment,44,O
.,44,O
A,45,O
human,45,B-OrganismTaxon
mu,45,B-GeneOrGeneProduct
opiate,45,I-GeneOrGeneProduct
receptor,45,I-GeneOrGeneProduct
cDNA,45,O
has,45,O
been,45,O
identified,45,O
from,45,O
a,45,O
cerebral,45,O
cortical,45,O
cDNA,45,O
library,45,O
using,45,O
sequences,45,O
from,45,O
the,45,O
rat,45,B-OrganismTaxon
mu,45,B-GeneOrGeneProduct
opiate,45,I-GeneOrGeneProduct
receptor,45,I-GeneOrGeneProduct
cDNA,45,O
.,45,O
The,46,O
human,46,B-OrganismTaxon
mu,46,B-GeneOrGeneProduct
opiate,46,I-GeneOrGeneProduct
receptor,46,I-GeneOrGeneProduct
(,46,O
h,46,B-GeneOrGeneProduct
mu,46,I-GeneOrGeneProduct
OR1,46,I-GeneOrGeneProduct
),46,O
shares,46,O
95,46,O
%,46,O
amino,46,O
acid,46,O
identity,46,O
with,46,O
the,46,O
rat,46,B-OrganismTaxon
sequence,46,O
.,46,O
The,47,O
expressed,47,O
mu,47,B-GeneOrGeneProduct
OR1,47,I-GeneOrGeneProduct
recognized,47,O
tested,47,O
opiate,47,B-ChemicalEntity
drugs,47,O
and,47,O
opioid,47,B-ChemicalEntity
peptides,47,I-ChemicalEntity
in,47,O
a,47,O
sodium-,47,B-ChemicalEntity
and,47,O
GTP-sensitive,47,B-ChemicalEntity
fashion,47,O
with,47,O
affinities,47,O
virtually,47,O
identical,47,O
to,47,O
those,47,O
displayed,47,O
by,47,O
the,47,O
rat,47,B-OrganismTaxon
mu,47,B-GeneOrGeneProduct
opiate,47,I-GeneOrGeneProduct
receptor,47,I-GeneOrGeneProduct
.,47,O
Effects,48,O
on,48,O
cyclic,48,B-ChemicalEntity
AMP,48,I-ChemicalEntity
are,48,O
similar,48,O
to,48,O
those,48,O
noted,48,O
for,48,O
the,48,O
rat,48,B-OrganismTaxon
mu,48,B-GeneOrGeneProduct
opiate,48,I-GeneOrGeneProduct
receptor,48,I-GeneOrGeneProduct
.,48,O
An,49,O
18,49,O
kb,49,O
genomic,49,O
clone,49,O
hybridizing,49,O
with,49,O
the,49,O
h,49,B-GeneOrGeneProduct
mu,49,I-GeneOrGeneProduct
OR1,49,I-GeneOrGeneProduct
cDNA,49,O
contains,49,O
63,49,O
and,49,O
489,49,O
bp,49,O
exonic,49,O
sequences,49,O
flanked,49,O
by,49,O
splice,49,O
donor/acceptor,49,O
sequences,49,O
.,49,O
Analysis,50,O
of,50,O
hybridization,50,O
to,50,O
DNA,50,O
prepared,50,O
from,50,O
human,50,B-OrganismTaxon
rodent,50,O
hybrid,50,O
cell,50,O
lines,50,O
and,50,O
chromosomal,50,O
in,50,O
situ,50,O
hybridization,50,O
studies,50,O
indicate,50,O
localization,50,O
to,50,O
6q24-25,50,O
.,50,O
An,51,O
MspI,51,O
polymorphism,51,O
",",51,O
producing,51,O
a,51,O
3.7,51,O
kb,51,O
band,51,O
",",51,O
may,51,O
prove,51,O
useful,51,O
in,51,O
assessing,51,O
this,51,O
gene,51,O
's,51,O
involvement,51,O
in,51,O
neuropsychiatric,51,B-DiseaseOrPhenotypicFeature
disorders,51,I-DiseaseOrPhenotypicFeature
involving,51,O
opiatergic,51,O
systems,51,O
.,51,O
Adrenoleukodystrophy,52,B-GeneOrGeneProduct
gene,52,I-GeneOrGeneProduct
encodes,52,O
an,52,O
80,52,O
kDa,52,O
membrane,52,O
protein,52,O
.,52,O
An,53,O
antibody,53,O
against,53,O
the,53,O
synthetic,53,O
C-terminal,53,O
peptides,53,O
deduced,53,O
from,53,O
the,53,O
cDNA,53,O
of,53,O
the,53,O
gene,53,O
responsible,53,O
for,53,O
X-linked,53,B-DiseaseOrPhenotypicFeature
adrenoleukodystrophy,53,I-DiseaseOrPhenotypicFeature
(,53,O
ALD,53,B-DiseaseOrPhenotypicFeature
),53,O
was,53,O
produced,53,O
to,53,O
characterize,53,O
the,53,O
product,53,O
of,53,O
the,53,O
ALD,53,B-GeneOrGeneProduct
gene,53,O
.,53,O
The,54,O
antibody,54,O
reacted,54,O
with,54,O
the,54,O
80,54,O
kDa,54,O
band,54,O
protein,54,O
in,54,O
control,54,O
fibroblasts,54,O
",",54,O
while,54,O
no,54,O
bands,54,O
were,54,O
detected,54,O
in,54,O
the,54,O
fibroblasts,54,O
from,54,O
a,54,O
patient,54,B-OrganismTaxon
with,54,O
ALD,54,B-DiseaseOrPhenotypicFeature
(,54,O
#,54,O
163,54,O
),54,O
",",54,O
in,54,O
which,54,O
mRNA,54,O
of,54,O
the,54,O
ALD,54,B-GeneOrGeneProduct
gene,54,O
was,54,O
undetectable,54,O
based,54,O
on,54,O
Northern,54,O
blot,54,O
analysis,54,O
.,54,O
The,55,O
293T,55,B-CellLine
cells,55,O
transfected,55,O
with,55,O
the,55,O
full-coding,55,O
cDNA,55,O
inserted,55,O
in,55,O
the,55,O
expression,55,O
vector,55,O
produced,55,O
a,55,O
new,55,O
80,55,O
kDa,55,O
protein,55,O
",",55,O
as,55,O
detected,55,O
by,55,O
Western,55,O
blot,55,O
.,55,O
In,56,O
an,56,O
immunocytological,56,O
study,56,O
",",56,O
the,56,O
staining,56,O
was,56,O
in,56,O
a,56,O
punctate,56,O
pattern,56,O
",",56,O
in,56,O
the,56,O
normal,56,O
fibroblasts,56,O
.,56,O
However,57,O
",",57,O
there,57,O
was,57,O
no,57,O
punctate,57,O
staining,57,O
in,57,O
the,57,O
#,57,O
163,57,O
cells,57,O
.,57,O
These,58,O
data,58,O
thus,58,O
indicate,58,O
that,58,O
the,58,O
ALD,58,B-GeneOrGeneProduct
gene,58,O
encodes,58,O
an,58,O
80,58,O
kDa,58,O
membrane,58,O
protein,58,O
..,58,O
Mutations,59,O
associated,59,O
with,59,O
variant,59,O
phenotypes,59,O
in,59,O
ataxia-telangiectasia,59,B-DiseaseOrPhenotypicFeature
.,59,O
We,60,O
have,60,O
identified,60,O
14,60,O
families,60,O
with,60,O
ataxia-telangiectasia,60,B-DiseaseOrPhenotypicFeature
(,60,O
A-T,60,B-DiseaseOrPhenotypicFeature
),60,O
in,60,O
which,60,O
mutation,60,O
of,60,O
the,60,O
ATM,60,B-GeneOrGeneProduct
gene,60,O
is,60,O
associated,60,O
with,60,O
a,60,O
less,60,O
severe,60,O
clinical,60,O
and,60,O
cellular,60,O
phenotype,60,O
(,60,O
approximately,60,O
10,60,O
%,60,O
-15,60,O
%,60,O
of,60,O
A-T,60,B-DiseaseOrPhenotypicFeature
families,60,O
identified,60,O
in,60,O
the,60,O
United,60,O
Kingdom,60,O
),60,O
.,60,O
In,61,O
10,61,O
of,61,O
these,61,O
families,61,O
",",61,O
all,61,O
the,61,O
homozygotes,61,O
have,61,O
a,61,O
137-bp,61,B-SequenceVariant
insertion,61,I-SequenceVariant
in,61,O
their,61,O
cDNA,61,O
caused,61,O
by,61,O
a,61,O
point,61,O
mutation,61,O
in,61,O
a,61,O
sequence,61,O
resembling,61,O
a,61,O
splice-donor,61,O
site,61,O
.,61,O
The,62,O
second,62,O
A-T,62,B-DiseaseOrPhenotypicFeature
allele,62,O
has,62,O
a,62,O
different,62,O
mutation,62,O
in,62,O
each,62,O
patient,62,B-OrganismTaxon
.,62,O
We,63,O
show,63,O
that,63,O
the,63,O
less,63,O
severe,63,O
phenotype,63,O
in,63,O
these,63,O
patients,63,B-OrganismTaxon
is,63,O
caused,63,O
by,63,O
some,63,O
degree,63,O
of,63,O
normal,63,O
splicing,63,O
",",63,O
which,63,O
occurs,63,O
as,63,O
an,63,O
alternative,63,O
product,63,O
from,63,O
the,63,O
insertion-containing,63,O
allele,63,O
.,63,O
The,64,O
level,64,O
of,64,O
the,64,O
137-bp,64,O
PCR,64,O
product,64,O
containing,64,O
the,64,O
insertion,64,O
was,64,O
lowest,64,O
in,64,O
two,64,O
patients,64,B-OrganismTaxon
who,64,O
showed,64,O
a,64,O
later,64,O
onset,64,O
of,64,O
cerebellar,64,B-DiseaseOrPhenotypicFeature
ataxia,64,I-DiseaseOrPhenotypicFeature
.,64,O
A,65,O
further,65,O
four,65,O
families,65,O
who,65,O
do,65,O
not,65,O
have,65,O
this,65,O
insertion,65,O
have,65,O
been,65,O
identified,65,O
.,65,O
Mutations,66,O
detected,66,O
in,66,O
two,66,O
of,66,O
four,66,O
of,66,O
these,66,O
are,66,O
missense,66,O
mutations,66,O
",",66,O
normally,66,O
rare,66,O
in,66,O
A-T,66,B-DiseaseOrPhenotypicFeature
patients,66,B-OrganismTaxon
.,66,O
The,67,O
demonstration,67,O
of,67,O
mutations,67,O
giving,67,O
rise,67,O
to,67,O
a,67,O
slightly,67,O
milder,67,O
phenotype,67,O
in,67,O
A-T,67,B-DiseaseOrPhenotypicFeature
raises,67,O
the,67,O
interesting,67,O
question,67,O
of,67,O
what,67,O
range,67,O
of,67,O
phenotypes,67,O
might,67,O
occur,67,O
in,67,O
individuals,67,O
in,67,O
whom,67,O
both,67,O
mutations,67,O
are,67,O
milder,67,O
.,67,O
One,68,O
possibility,68,O
might,68,O
be,68,O
that,68,O
individuals,68,O
who,68,O
are,68,O
compound,68,O
heterozygotes,68,O
for,68,O
ATM,68,B-GeneOrGeneProduct
mutations,68,O
are,68,O
more,68,O
common,68,O
than,68,O
we,68,O
realize,68,O
..,68,O
Myotonic,69,B-GeneOrGeneProduct
dystrophy,69,I-GeneOrGeneProduct
protein,69,I-GeneOrGeneProduct
kinase,69,I-GeneOrGeneProduct
is,69,O
involved,69,O
in,69,O
the,69,O
modulation,69,O
of,69,O
the,69,O
Ca2+,69,B-ChemicalEntity
homeostasis,69,O
in,69,O
skeletal,69,O
muscle,69,O
cells,69,O
.,69,O
Myotonic,70,B-DiseaseOrPhenotypicFeature
dystrophy,70,I-DiseaseOrPhenotypicFeature
(,70,O
DM,70,B-DiseaseOrPhenotypicFeature
),70,O
",",70,O
the,70,O
most,70,O
prevalent,70,O
muscular,70,B-DiseaseOrPhenotypicFeature
disorder,70,I-DiseaseOrPhenotypicFeature
in,70,O
adults,70,O
",",70,O
is,70,O
caused,70,O
by,70,O
(,70,O
CTG,70,O
),70,O
n-repeat,70,O
expansion,70,O
in,70,O
a,70,O
gene,70,O
encoding,70,O
a,70,O
protein,70,O
kinase,70,O
(,70,O
DM,70,B-GeneOrGeneProduct
protein,70,I-GeneOrGeneProduct
kinase,70,I-GeneOrGeneProduct
;,70,O
DMPK,70,B-GeneOrGeneProduct
),70,O
and,70,O
involves,70,O
changes,70,O
in,70,O
cytoarchitecture,70,O
and,70,O
ion,70,O
homeostasis,70,O
.,70,O
To,71,O
obtain,71,O
clues,71,O
to,71,O
the,71,O
normal,71,O
biological,71,O
role,71,O
of,71,O
DMPK,71,B-GeneOrGeneProduct
in,71,O
cellular,71,O
ion,71,O
homeostasis,71,O
",",71,O
we,71,O
have,71,O
compared,71,O
the,71,O
resting,71,O
[,71,O
Ca2,71,B-ChemicalEntity
+,71,I-ChemicalEntity
],71,O
i,71,O
",",71,O
the,71,O
amplitude,71,O
and,71,O
shape,71,O
of,71,O
depolarization-induced,71,O
Ca2,71,B-ChemicalEntity
+,71,I-ChemicalEntity
transients,71,O
",",71,O
and,71,O
the,71,O
content,71,O
of,71,O
ATP-driven,71,B-ChemicalEntity
ion,71,O
pumps,71,O
in,71,O
cultured,71,O
skeletal,71,O
muscle,71,O
cells,71,O
of,71,O
wild-type,71,O
and,71,O
DMPK,71,B-GeneOrGeneProduct
[,71,O
-/-,71,O
],71,O
knockout,71,O
mice,71,B-OrganismTaxon
.,71,O
In,72,O
vitro-differentiated,72,O
DMPK,72,B-GeneOrGeneProduct
[,72,O
-/-,72,O
],72,O
myotubes,72,O
exhibit,72,O
a,72,O
higher,72,O
resting,72,O
[,72,O
Ca2,72,B-ChemicalEntity
+,72,I-ChemicalEntity
],72,O
i,72,O
than,72,O
do,72,O
wild-type,72,O
myotubes,72,O
because,72,O
of,72,O
an,72,O
altered,72,O
open,72,O
probability,72,O
of,72,O
voltage-dependent,72,O
l-type,72,O
Ca2,72,B-ChemicalEntity
+,72,I-ChemicalEntity
and,72,O
Na,72,B-ChemicalEntity
+,72,I-ChemicalEntity
channels,72,O
.,72,O
The,73,O
mutant,73,O
myotubes,73,O
exhibit,73,O
smaller,73,O
and,73,O
slower,73,O
Ca2,73,B-ChemicalEntity
+,73,I-ChemicalEntity
responses,73,O
upon,73,O
triggering,73,O
by,73,O
acetylcholine,73,B-ChemicalEntity
or,73,O
high,73,O
external,73,O
K,73,B-ChemicalEntity
+,73,I-ChemicalEntity
.,73,O
In,74,O
addition,74,O
",",74,O
we,74,O
observed,74,O
that,74,O
these,74,O
Ca2,74,B-ChemicalEntity
+,74,I-ChemicalEntity
transients,74,O
partially,74,O
result,74,O
from,74,O
an,74,O
influx,74,O
of,74,O
extracellular,74,O
Ca2,74,B-ChemicalEntity
+,74,I-ChemicalEntity
through,74,O
the,74,O
l-type,74,O
Ca2,74,B-ChemicalEntity
+,74,I-ChemicalEntity
channel,74,O
.,74,O
Neither,75,O
the,75,O
content,75,O
nor,75,O
the,75,O
activity,75,O
of,75,O
Na,75,B-ChemicalEntity
+/K,75,I-ChemicalEntity
+,75,I-ChemicalEntity
ATPase,75,I-ChemicalEntity
and,75,O
sarcoplasmic,75,B-ChemicalEntity
reticulum,75,I-ChemicalEntity
Ca2,75,I-ChemicalEntity
+,75,I-ChemicalEntity
-ATPase,75,I-ChemicalEntity
are,75,O
affected,75,O
by,75,O
DMPK,75,B-GeneOrGeneProduct
absence,75,O
.,75,O
In,76,O
conclusion,76,O
",",76,O
our,76,O
data,76,O
suggest,76,O
that,76,O
DMPK,76,B-GeneOrGeneProduct
is,76,O
involved,76,O
in,76,O
modulating,76,O
the,76,O
initial,76,O
events,76,O
of,76,O
excitation-contraction,76,O
coupling,76,O
in,76,O
skeletal,76,O
muscle,76,O
..,76,O
cDNA,77,O
sequence,77,O
and,77,O
chromosomal,77,O
localization,77,O
of,77,O
the,77,O
remaining,77,O
three,77,O
human,77,B-OrganismTaxon
nuclear,77,B-GeneOrGeneProduct
encoded,77,I-GeneOrGeneProduct
iron,77,I-GeneOrGeneProduct
sulphur,77,I-GeneOrGeneProduct
protein,77,I-GeneOrGeneProduct
(,77,I-GeneOrGeneProduct
IP,77,I-GeneOrGeneProduct
),77,I-GeneOrGeneProduct
subunits,77,I-GeneOrGeneProduct
of,77,I-GeneOrGeneProduct
complex,77,I-GeneOrGeneProduct
I,77,I-GeneOrGeneProduct
:,77,O
the,77,O
human,77,B-OrganismTaxon
IP,77,B-GeneOrGeneProduct
fraction,77,O
is,77,O
completed,77,O
.,77,O
NADH,78,B-GeneOrGeneProduct
:,78,I-GeneOrGeneProduct
ubiquinone,78,I-GeneOrGeneProduct
oxidoreductase,78,I-GeneOrGeneProduct
(,78,I-GeneOrGeneProduct
complex,78,I-GeneOrGeneProduct
I,78,I-GeneOrGeneProduct
),78,I-GeneOrGeneProduct
of,78,O
the,78,O
mitochondrial,78,O
respiratory,78,O
chain,78,O
can,78,O
be,78,O
fragmented,78,O
in,78,O
a,78,O
flavoprotein,78,B-GeneOrGeneProduct
(,78,O
FP,78,B-GeneOrGeneProduct
),78,O
",",78,O
iron-sulfur,78,B-GeneOrGeneProduct
protein,78,I-GeneOrGeneProduct
(,78,O
IP,78,B-GeneOrGeneProduct
),78,O
",",78,O
and,78,O
hydrophobic,78,B-GeneOrGeneProduct
protein,78,I-GeneOrGeneProduct
(,78,O
HP,78,B-GeneOrGeneProduct
),78,O
subfraction,78,O
.,78,O
The,79,O
IP,79,B-GeneOrGeneProduct
subfraction,79,O
is,79,O
hypothesized,79,O
to,79,O
be,79,O
significant,79,O
",",79,O
since,79,O
it,79,O
contains,79,O
important,79,O
prosthetic,79,O
groups,79,O
highly,79,O
conserved,79,O
among,79,O
species,79,O
.,79,O
We,80,O
cloned,80,O
the,80,O
cDNA,80,O
of,80,O
three,80,O
remaining,80,O
human,80,B-OrganismTaxon
NADH,80,B-GeneOrGeneProduct
:,80,I-GeneOrGeneProduct
ubiquinone,80,I-GeneOrGeneProduct
oxidoreductase,80,I-GeneOrGeneProduct
subunits,80,I-GeneOrGeneProduct
of,80,O
this,80,O
IP,80,B-GeneOrGeneProduct
fraction,80,O
:,80,O
the,80,O
NDUFS2,80,B-GeneOrGeneProduct
(,80,O
49,80,O
kDa,80,O
),80,O
",",80,O
NDUFS3,80,B-GeneOrGeneProduct
(,80,O
30,80,O
kDa,80,O
),80,O
",",80,O
and,80,O
NDUFS6,80,B-GeneOrGeneProduct
(,80,O
13,80,O
kDa,80,O
),80,O
subunits,80,O
.,80,O
All,81,O
presented,81,O
cDNAs,81,O
include,81,O
the,81,O
complete,81,O
open,81,O
reading,81,O
frame,81,O
(,81,O
ORF,81,O
),81,O
",",81,O
which,81,O
consist,81,O
of,81,O
1392,81,O
",",81,O
795,81,O
",",81,O
and,81,O
375,81,O
base,81,O
pairs,81,O
",",81,O
coding,81,O
for,81,O
463,81,O
",",81,O
264,81,O
",",81,O
and,81,O
124,81,O
amino,81,O
acids,81,O
",",81,O
respectively,81,O
.,81,O
The,82,O
latter,82,O
show,82,O
96,82,O
",",82,O
90,82,O
",",82,O
and,82,O
83,82,O
%,82,O
homology,82,O
with,82,O
the,82,O
corresponding,82,O
bovine,82,B-OrganismTaxon
translation,82,O
products,82,O
.,82,O
The,83,O
3,83,O
',83,O
untranslated,83,O
regions,83,O
(,83,O
UTR,83,O
),83,O
are,83,O
complete,83,O
in,83,O
all,83,O
three,83,O
cDNAs,83,O
.,83,O
Polymerase,84,O
chain,84,O
reaction,84,O
performed,84,O
with,84,O
DNA,84,O
isolated,84,O
from,84,O
somatic,84,O
human-rodent,84,B-OrganismTaxon
cell,84,O
hybrids,84,O
containing,84,O
defined,84,O
human,84,B-OrganismTaxon
chromosomes,84,O
as,84,O
template,84,O
gave,84,O
a,84,O
human-specific,84,B-OrganismTaxon
signal,84,O
which,84,O
mapped,84,O
the,84,O
NDUFS2,84,B-GeneOrGeneProduct
and,84,O
NDUFS3,84,B-GeneOrGeneProduct
subunits,84,O
to,84,O
chromosomes,84,O
1,84,O
and,84,O
11,84,O
",",84,O
respectively,84,O
.,84,O
In,85,O
the,85,O
case,85,O
of,85,O
the,85,O
NDUFS6,85,B-GeneOrGeneProduct
subunit,85,O
a,85,O
pseudogene,85,O
may,85,O
be,85,O
present,85,O
since,85,O
signals,85,O
were,85,O
seen,85,O
in,85,O
the,85,O
lanes,85,O
containing,85,O
chromosomes,85,O
5,85,O
and,85,O
6,85,O
.,85,O
The,86,O
NDUFS2,86,B-GeneOrGeneProduct
contains,86,O
a,86,O
highly,86,O
conserved,86,O
protein,86,B-GeneOrGeneProduct
kinase,86,I-GeneOrGeneProduct
C,86,I-GeneOrGeneProduct
phosphorylation,86,O
site,86,O
and,86,O
the,86,O
NDUFS3,86,B-GeneOrGeneProduct
subunit,86,O
contains,86,O
a,86,O
highly,86,O
conserved,86,O
casein,86,B-GeneOrGeneProduct
kinase,86,I-GeneOrGeneProduct
II,86,I-GeneOrGeneProduct
phosphorylation,86,O
site,86,O
which,86,O
make,86,O
them,86,O
strong,86,O
candidates,86,O
for,86,O
future,86,O
mutation,86,O
detection,86,O
studies,86,O
in,86,O
enzymatic,86,B-DiseaseOrPhenotypicFeature
complex,86,I-DiseaseOrPhenotypicFeature
I-deficient,86,I-DiseaseOrPhenotypicFeature
patients,86,B-OrganismTaxon
.,86,O
Inappropriate,87,O
use,87,O
of,87,O
carbamazepine,87,B-ChemicalEntity
and,87,O
vigabatrin,87,B-ChemicalEntity
in,87,O
typical,87,O
absence,87,B-DiseaseOrPhenotypicFeature
seizures,87,I-DiseaseOrPhenotypicFeature
.,87,O
Carbamazepine,88,B-ChemicalEntity
and,88,O
vigabatrin,88,B-ChemicalEntity
are,88,O
contraindicated,88,O
in,88,O
typical,88,O
absence,88,B-DiseaseOrPhenotypicFeature
seizures,88,I-DiseaseOrPhenotypicFeature
.,88,O
Of,89,O
18,89,O
consecutive,89,O
referrals,89,O
of,89,O
children,89,O
with,89,O
resistant,89,O
typical,89,O
absences,89,O
only,89,O
",",89,O
eight,89,O
were,89,O
erroneously,89,O
treated,89,O
with,89,O
carbamazepine,89,B-ChemicalEntity
either,89,O
as,89,O
monotherapy,89,O
or,89,O
as,89,O
an,89,O
add-on,89,O
.,89,O
Vigabatrin,90,B-ChemicalEntity
was,90,O
also,90,O
used,90,O
in,90,O
the,90,O
treatment,90,O
of,90,O
two,90,O
children,90,O
.,90,O
Frequency,91,O
of,91,O
absences,91,O
increased,91,O
in,91,O
four,91,O
children,91,O
treated,91,O
with,91,O
carbamazepine,91,B-ChemicalEntity
and,91,O
two,91,O
of,91,O
these,91,O
developed,91,O
myoclonic,91,B-DiseaseOrPhenotypicFeature
jerks,91,I-DiseaseOrPhenotypicFeature
",",91,O
which,91,O
resolved,91,O
on,91,O
withdrawal,91,O
of,91,O
carbamazepine,91,B-ChemicalEntity
.,91,O
Absences,92,O
were,92,O
aggravated,92,O
in,92,O
both,92,O
cases,92,O
where,92,O
vigabatrin,92,B-ChemicalEntity
was,92,O
added,92,O
on,92,O
to,92,O
concurrent,92,O
treatment,92,O
.,92,O
Optimal,93,O
control,93,O
of,93,O
the,93,O
absences,93,O
was,93,O
achieved,93,O
with,93,O
sodium,93,B-ChemicalEntity
valproate,93,I-ChemicalEntity
",",93,O
lamotrigine,93,B-ChemicalEntity
",",93,O
or,93,O
ethosuximide,93,B-ChemicalEntity
alone,93,O
or,93,O
in,93,O
combination,93,O
.,93,O
Hepatocyte,94,B-GeneOrGeneProduct
nuclear,94,I-GeneOrGeneProduct
factor-6,94,I-GeneOrGeneProduct
:,94,O
associations,94,O
between,94,O
genetic,94,O
variability,94,O
and,94,O
type,94,B-DiseaseOrPhenotypicFeature
II,94,I-DiseaseOrPhenotypicFeature
diabetes,94,I-DiseaseOrPhenotypicFeature
and,94,O
between,94,O
genetic,94,O
variability,94,O
and,94,O
estimates,94,O
of,94,O
insulin,94,B-GeneOrGeneProduct
secretion,94,O
.,94,O
The,95,O
transcription,95,O
factor,95,O
hepatocyte,95,B-GeneOrGeneProduct
nuclear,95,I-GeneOrGeneProduct
factor,95,I-GeneOrGeneProduct
(,95,I-GeneOrGeneProduct
HNF,95,I-GeneOrGeneProduct
),95,I-GeneOrGeneProduct
-6,95,I-GeneOrGeneProduct
is,95,O
an,95,O
upstream,95,O
regulator,95,O
of,95,O
several,95,O
genes,95,O
involved,95,O
in,95,O
the,95,O
pathogenesis,95,O
of,95,O
maturity-onset,95,B-DiseaseOrPhenotypicFeature
diabetes,95,I-DiseaseOrPhenotypicFeature
of,95,O
the,95,O
young,95,O
.,95,O
We,96,O
therefore,96,O
tested,96,O
the,96,O
hypothesis,96,O
that,96,O
variability,96,O
in,96,O
the,96,O
HNF-6,96,B-GeneOrGeneProduct
gene,96,O
is,96,O
associated,96,O
with,96,O
subsets,96,O
of,96,O
Type,96,B-DiseaseOrPhenotypicFeature
II,96,I-DiseaseOrPhenotypicFeature
(,96,I-DiseaseOrPhenotypicFeature
non-insulin-dependent,96,I-DiseaseOrPhenotypicFeature
),96,I-DiseaseOrPhenotypicFeature
diabetes,96,I-DiseaseOrPhenotypicFeature
mellitus,96,I-DiseaseOrPhenotypicFeature
and,96,O
estimates,96,O
of,96,O
insulin,96,B-GeneOrGeneProduct
secretion,96,O
in,96,O
glucose,96,B-ChemicalEntity
tolerant,96,O
subjects,96,O
.,96,O
We,97,O
cloned,97,O
the,97,O
coding,97,O
region,97,O
as,97,O
well,97,O
as,97,O
the,97,O
intron-exon,97,O
boundaries,97,O
of,97,O
the,97,O
HNF-6,97,O
gene,97,O
.,97,O
We,98,O
then,98,O
examined,98,O
them,98,O
on,98,O
genomic,98,O
DNA,98,O
in,98,O
six,98,O
MODY,98,O
probands,98,O
without,98,O
mutations,98,O
in,98,O
the,98,O
MODY1,98,O
",",98,I-GeneOrGeneProduct
MODY3,98,O
and,98,O
MODY4,98,O
genes,98,O
and,98,O
in,98,O
54,98,O
patients,98,O
with,98,O
late-onset,98,O
Type,98,O
II,98,I-DiseaseOrPhenotypicFeature
diabetes,98,I-DiseaseOrPhenotypicFeature
by,98,O
combined,98,O
single,98,O
strand,98,O
conformational,98,O
polymorphism-heteroduplex,98,O
analysis,98,O
followed,98,O
by,98,O
direct,98,O
sequencing,98,O
of,98,O
identified,98,O
variants,98,O
.,98,O
An,99,O
identified,99,O
missense,99,O
variant,99,O
was,99,O
examined,99,O
in,99,O
association,99,O
studies,99,O
and,99,O
genotype-phenotype,99,O
studies,99,O
.,99,O
We,100,O
identified,100,O
two,100,O
silent,100,O
and,100,O
one,100,O
missense,100,O
(,100,O
Pro75,100,O
Ala,100,I-SequenceVariant
),100,I-SequenceVariant
variant,100,O
.,100,O
In,101,O
an,101,O
association,101,O
study,101,O
the,101,O
allelic,101,O
frequency,101,O
of,101,O
the,101,O
Pro75Ala,101,O
polymorphism,101,O
was,101,O
3.2,101,O
%,101,O
(,101,O
95,101,O
%,101,O
confidence,101,O
interval,101,O
",",101,O
1.9-4.5,101,O
),101,O
in,101,O
330,101,O
patients,101,O
with,101,O
Type,101,O
II,101,I-DiseaseOrPhenotypicFeature
diabetes,101,I-DiseaseOrPhenotypicFeature
mellitus,101,I-DiseaseOrPhenotypicFeature
compared,101,O
with,101,O
4.2,101,O
%,101,O
(,101,O
2.4-6.0,101,O
),101,O
in,101,O
238,101,O
age-matched,101,O
glucose,101,O
tolerant,101,O
control,101,O
subjects,101,O
.,101,O
Moreover,102,O
",",102,O
in,102,O
studies,102,O
of,102,O
238,102,O
middle-aged,102,O
glucose,102,O
tolerant,102,O
subjects,102,O
",",102,O
of,102,O
226,102,O
glucose,102,O
tolerant,102,O
offspring,102,O
of,102,O
Type,102,O
II,102,I-DiseaseOrPhenotypicFeature
diabetic,102,I-DiseaseOrPhenotypicFeature
patients,102,O
and,102,I-OrganismTaxon
of,102,O
367,102,O
young,102,O
healthy,102,O
subjects,102,O
",",102,O
the,102,O
carriers,102,O
of,102,O
the,102,O
polymorphism,102,O
did,102,O
not,102,O
differ,102,O
from,102,O
non-carriers,102,O
in,102,O
glucose,102,O
induced,102,O
serum,102,O
insulin,102,O
or,102,I-GeneOrGeneProduct
C-peptide,102,O
responses,102,O
.,102,O
Mutations,103,O
in,103,O
the,103,O
coding,103,O
region,103,O
of,103,O
the,103,O
HNF-6,103,O
gene,103,B-GeneOrGeneProduct
are,103,O
not,103,O
associated,103,O
with,103,O
Type,103,O
II,103,O
diabetes,103,I-DiseaseOrPhenotypicFeature
or,103,I-DiseaseOrPhenotypicFeature
with,103,O
changes,103,O
in,103,O
insulin,103,O
responses,103,O
to,103,O
glucose,103,O
among,103,I-ChemicalEntity
the,103,O
Caucasians,103,O
examined,103,O
.,103,O
Langerin,104,B-GeneOrGeneProduct
",",104,O
a,104,O
novel,104,O
C-type,104,B-GeneOrGeneProduct
lectin,104,I-GeneOrGeneProduct
specific,104,O
to,104,O
Langerhans,104,O
cells,104,O
",",104,O
is,104,O
an,104,O
endocytic,104,O
receptor,104,O
that,104,O
induces,104,O
the,104,O
formation,104,O
of,104,O
Birbeck,104,O
granules,104,O
.,104,O
We,105,O
have,105,O
identified,105,O
a,105,O
type,105,B-GeneOrGeneProduct
II,105,I-GeneOrGeneProduct
Ca2+-dependent,105,I-GeneOrGeneProduct
lectin,105,I-GeneOrGeneProduct
displaying,105,O
mannose-binding,105,B-ChemicalEntity
specificity,105,O
",",105,O
exclusively,105,O
expressed,105,O
by,105,O
Langerhans,105,O
cells,105,O
(,105,O
LC,105,O
),105,O
",",105,O
and,105,O
named,105,O
Langerin,105,B-GeneOrGeneProduct
.,105,O
LC,106,O
are,106,O
uniquely,106,O
characterized,106,O
by,106,O
Birbeck,106,O
granules,106,O
(,106,O
BG,106,O
),106,O
",",106,O
which,106,O
are,106,O
organelles,106,O
consisting,106,O
of,106,O
superimposed,106,O
and,106,O
zippered,106,O
membranes,106,O
.,106,O
Here,107,O
",",107,O
we,107,O
have,107,O
shown,107,O
that,107,O
Langerin,107,B-GeneOrGeneProduct
is,107,O
constitutively,107,O
associated,107,O
with,107,O
BG,107,O
and,107,O
that,107,O
antibody,107,O
to,107,O
Langerin,107,B-GeneOrGeneProduct
is,107,O
internalized,107,O
into,107,O
these,107,O
structures,107,O
.,107,O
Remarkably,108,O
",",108,O
transfection,108,O
of,108,O
Langerin,108,B-GeneOrGeneProduct
cDNA,108,O
into,108,O
fibroblasts,108,O
created,108,O
a,108,O
compact,108,O
network,108,O
of,108,O
membrane,108,O
structures,108,O
with,108,O
typical,108,O
features,108,O
of,108,O
BG,108,O
.,108,O
Langerin,109,B-GeneOrGeneProduct
is,109,O
thus,109,O
a,109,O
potent,109,O
inducer,109,O
of,109,O
membrane,109,O
superimposition,109,O
and,109,O
zippering,109,O
leading,109,O
to,109,O
BG,109,O
formation,109,O
.,109,O
Our,110,O
data,110,O
suggest,110,O
that,110,O
induction,110,O
of,110,O
BG,110,O
is,110,O
a,110,O
consequence,110,O
of,110,O
the,110,O
antigen-capture,110,O
function,110,O
of,110,O
Langerin,110,B-GeneOrGeneProduct
",",110,O
allowing,110,O
routing,110,O
into,110,O
these,110,O
organelles,110,O
and,110,O
providing,110,O
access,110,O
to,110,O
a,110,O
nonclassical,110,O
antigen-processing,110,O
pathway,110,O
.,110,O
Founder,111,O
mutations,111,O
in,111,O
the,111,O
BRCA1,111,B-GeneOrGeneProduct
gene,111,O
in,111,O
Polish,111,O
families,111,O
with,111,O
breast-ovarian,111,B-DiseaseOrPhenotypicFeature
cancer,111,I-DiseaseOrPhenotypicFeature
.,111,O
We,112,O
have,112,O
undertaken,112,O
a,112,O
hospital-based,112,O
study,112,O
",",112,O
to,112,O
identify,112,O
possible,112,O
BRCA1,112,B-GeneOrGeneProduct
and,112,O
BRCA2,112,B-GeneOrGeneProduct
founder,112,O
mutations,112,O
in,112,O
the,112,O
Polish,112,O
population,112,O
.,112,O
The,113,O
study,113,O
group,113,O
consisted,113,O
of,113,O
66,113,O
Polish,113,O
families,113,O
with,113,O
cancer,113,B-DiseaseOrPhenotypicFeature
who,113,O
have,113,O
at,113,O
least,113,O
three,113,O
related,113,O
females,113,O
affected,113,O
with,113,O
breast,113,B-DiseaseOrPhenotypicFeature
or,113,I-DiseaseOrPhenotypicFeature
ovarian,113,I-DiseaseOrPhenotypicFeature
cancer,113,I-DiseaseOrPhenotypicFeature
and,113,O
who,113,O
had,113,O
cancer,113,B-DiseaseOrPhenotypicFeature
diagnosed,113,O
",",113,O
in,113,O
at,113,O
least,113,O
one,113,O
of,113,O
the,113,O
three,113,O
affected,113,O
females,113,O
",",113,O
at,113,O
age,113,O
<,113,O
50,113,O
years,113,O
.,113,O
A,114,O
total,114,O
of,114,O
26,114,O
families,114,O
had,114,O
both,114,O
breast,114,B-DiseaseOrPhenotypicFeature
and,114,I-DiseaseOrPhenotypicFeature
ovarian,114,I-DiseaseOrPhenotypicFeature
cancers,114,I-DiseaseOrPhenotypicFeature
",",114,O
4,114,O
families,114,O
had,114,O
ovarian,114,B-DiseaseOrPhenotypicFeature
cancers,114,I-DiseaseOrPhenotypicFeature
only,114,O
",",114,O
and,114,O
36,114,O
families,114,O
had,114,O
breast,114,B-DiseaseOrPhenotypicFeature
cancers,114,I-DiseaseOrPhenotypicFeature
only,114,O
.,114,O
Genomic,115,O
DNA,115,O
was,115,O
prepared,115,O
from,115,O
the,115,O
peripheral,115,O
blood,115,O
leukocytes,115,O
of,115,O
at,115,O
least,115,O
one,115,O
affected,115,O
woman,115,B-OrganismTaxon
from,115,O
each,115,O
family,115,O
.,115,O
The,116,O
entire,116,O
coding,116,O
region,116,O
of,116,O
BRCA1,116,B-GeneOrGeneProduct
and,116,O
BRCA2,116,B-GeneOrGeneProduct
was,116,O
screened,116,O
for,116,O
the,116,O
presence,116,O
of,116,O
germline,116,O
mutations,116,O
",",116,O
by,116,O
use,116,O
of,116,O
SSCP,116,O
followed,116,O
by,116,O
direct,116,O
sequencing,116,O
of,116,O
observed,116,O
variants,116,O
.,116,O
Mutations,117,O
were,117,O
found,117,O
in,117,O
35,117,O
(,117,O
53,117,O
%,117,O
),117,O
of,117,O
the,117,O
66,117,O
families,117,O
studied,117,O
.,117,O
All,118,O
but,118,O
one,118,O
of,118,O
the,118,O
mutations,118,O
were,118,O
detected,118,O
within,118,O
the,118,O
BRCA1,118,B-GeneOrGeneProduct
gene,118,O
.,118,O
BRCA1,119,B-DiseaseOrPhenotypicFeature
abnormalities,119,I-DiseaseOrPhenotypicFeature
were,119,O
identified,119,O
in,119,O
all,119,O
four,119,O
families,119,O
with,119,O
ovarian,119,B-DiseaseOrPhenotypicFeature
cancer,119,I-DiseaseOrPhenotypicFeature
only,119,O
",",119,O
in,119,O
67,119,O
%,119,O
of,119,O
27,119,O
families,119,O
with,119,O
both,119,O
breast,119,B-DiseaseOrPhenotypicFeature
and,119,I-DiseaseOrPhenotypicFeature
ovarian,119,I-DiseaseOrPhenotypicFeature
cancer,119,I-DiseaseOrPhenotypicFeature
",",119,O
and,119,O
in,119,O
34,119,O
%,119,O
of,119,O
35,119,O
families,119,O
with,119,O
breast,119,B-DiseaseOrPhenotypicFeature
cancer,119,I-DiseaseOrPhenotypicFeature
only,119,O
.,119,O
The,120,O
single,120,O
family,120,O
with,120,O
a,120,O
BRCA2,120,B-GeneOrGeneProduct
mutation,120,O
had,120,O
the,120,O
breast-ovarian,120,B-DiseaseOrPhenotypicFeature
cancer,120,I-DiseaseOrPhenotypicFeature
syndrome,120,I-DiseaseOrPhenotypicFeature
.,120,O
Seven,121,O
distinct,121,O
mutations,121,O
were,121,O
identified,121,O
;,121,O
five,121,O
of,121,O
these,121,O
occurred,121,O
in,121,O
two,121,O
or,121,O
more,121,O
families,121,O
.,121,O
In,122,O
total,122,O
",",122,O
recurrent,122,O
mutations,122,O
were,122,O
found,122,O
in,122,O
33,122,O
(,122,O
94,122,O
%,122,O
),122,O
of,122,O
the,122,O
35,122,O
families,122,O
with,122,O
detected,122,O
mutations,122,O
.,122,O
Three,123,O
BRCA1,123,B-DiseaseOrPhenotypicFeature
abnormalities,123,I-DiseaseOrPhenotypicFeature
-,123,O
5382insC,123,B-SequenceVariant
",",123,O
C61G,123,B-SequenceVariant
",",123,O
and,123,O
4153delA,123,B-SequenceVariant
-,123,O
accounted,123,O
for,123,O
51,123,O
%,123,O
",",123,O
20,123,O
%,123,O
",",123,O
and,123,O
11,123,O
%,123,O
of,123,O
the,123,O
identified,123,O
mutations,123,O
",",123,O
respectively,123,O
..,123,O
Apomorphine,124,B-ChemicalEntity
:,124,O
an,124,O
underutilized,124,O
therapy,124,O
for,124,O
Parkinson,124,B-DiseaseOrPhenotypicFeature
's,124,I-DiseaseOrPhenotypicFeature
disease,124,I-DiseaseOrPhenotypicFeature
.,124,O
Apomorphine,125,B-ChemicalEntity
was,125,O
the,125,O
first,125,O
dopaminergic,125,B-ChemicalEntity
drug,125,I-ChemicalEntity
ever,125,O
used,125,O
to,125,O
treat,125,O
symptoms,125,O
of,125,O
Parkinson,125,B-DiseaseOrPhenotypicFeature
's,125,I-DiseaseOrPhenotypicFeature
disease,125,I-DiseaseOrPhenotypicFeature
.,125,O
While,126,O
powerful,126,O
antiparkinsonian,126,O
effects,126,O
had,126,O
been,126,O
observed,126,O
as,126,O
early,126,O
as,126,O
1951,126,O
",",126,O
the,126,O
potential,126,O
of,126,O
treating,126,O
fluctuating,126,O
Parkinson,126,B-DiseaseOrPhenotypicFeature
's,126,I-DiseaseOrPhenotypicFeature
disease,126,I-DiseaseOrPhenotypicFeature
by,126,O
subcutaneous,126,O
administration,126,O
of,126,O
apomorphine,126,B-ChemicalEntity
has,126,O
only,126,O
recently,126,O
become,126,O
the,126,O
subject,126,O
of,126,O
systematic,126,O
study,126,O
.,126,O
A,127,O
number,127,O
of,127,O
small,127,O
scale,127,O
clinical,127,O
trials,127,O
have,127,O
unequivocally,127,O
shown,127,O
that,127,O
intermittent,127,O
subcutaneous,127,O
apomorphine,127,B-ChemicalEntity
injections,127,O
produce,127,O
antiparkinsonian,127,O
benefit,127,O
close,127,O
if,127,O
not,127,O
identical,127,O
to,127,O
that,127,O
seen,127,O
with,127,O
levodopa,127,B-ChemicalEntity
and,127,O
that,127,O
apomorphine,127,B-ChemicalEntity
rescue,127,O
injections,127,O
can,127,O
reliably,127,O
revert,127,O
off-periods,127,O
even,127,O
in,127,O
patients,127,B-OrganismTaxon
with,127,O
complex,127,O
on-off,127,O
motor,127,O
swings,127,O
.,127,O
Continuous,128,O
subcutaneous,128,O
apomorphine,128,B-ChemicalEntity
infusions,128,O
can,128,O
reduce,128,O
daily,128,O
off-time,128,O
by,128,O
more,128,O
than,128,O
50,128,O
%,128,O
in,128,O
this,128,O
group,128,O
of,128,O
patients,128,B-OrganismTaxon
",",128,O
which,128,O
appears,128,O
to,128,O
be,128,O
a,128,O
stronger,128,O
effect,128,O
than,128,O
that,128,O
generally,128,O
seen,128,O
with,128,O
add-on,128,O
therapy,128,O
with,128,O
oral,128,O
dopamine,128,B-ChemicalEntity
agonists,128,I-ChemicalEntity
or,128,O
COMT,128,B-ChemicalEntity
inhibitors,128,I-ChemicalEntity
.,128,O
Extended,129,O
follow-up,129,O
studies,129,O
of,129,O
up,129,O
to,129,O
8,129,O
years,129,O
have,129,O
demonstrated,129,O
long-term,129,O
persistence,129,O
of,129,O
apomorphine,129,B-ChemicalEntity
efficacy,129,O
.,129,O
In,130,O
addition,130,O
",",130,O
there,130,O
is,130,O
convincing,130,O
clinical,130,O
evidence,130,O
that,130,O
monotherapy,130,O
with,130,O
continuous,130,O
subcutaneous,130,O
apomorphine,130,B-ChemicalEntity
infusions,130,O
is,130,O
associated,130,O
with,130,O
marked,130,O
reductions,130,O
of,130,O
preexisting,130,O
levodopa-induced,130,B-ChemicalEntity
dyskinesias,130,B-DiseaseOrPhenotypicFeature
.,130,O
The,131,O
main,131,O
side,131,O
effects,131,O
of,131,O
subcutaneous,131,O
apomorphine,131,B-ChemicalEntity
treatment,131,O
are,131,O
related,131,O
to,131,O
cutaneous,131,O
tolerability,131,O
problems,131,O
",",131,O
whereas,131,O
sedation,131,O
and,131,O
psychiatric,131,B-DiseaseOrPhenotypicFeature
complications,131,I-DiseaseOrPhenotypicFeature
play,131,O
a,131,O
lesser,131,O
role,131,O
.,131,O
Given,132,O
the,132,O
marked,132,O
degree,132,O
of,132,O
efficacy,132,O
of,132,O
subcutaneous,132,O
apomorphine,132,B-ChemicalEntity
treatment,132,O
in,132,O
fluctuating,132,O
Parkinson,132,B-DiseaseOrPhenotypicFeature
's,132,I-DiseaseOrPhenotypicFeature
disease,132,I-DiseaseOrPhenotypicFeature
",",132,O
this,132,O
approach,132,O
seems,132,O
to,132,O
deserve,132,O
more,132,O
widespread,132,O
clinical,132,O
use,132,O
.,132,O
Rab6c,133,B-GeneOrGeneProduct
",",133,O
a,133,O
new,133,O
member,133,O
of,133,O
the,133,O
rab,133,B-GeneOrGeneProduct
gene,133,O
family,133,O
",",133,O
is,133,O
involved,133,O
in,133,O
drug,133,O
resistance,133,O
in,133,O
MCF7/AdrR,133,B-CellLine
cells,133,O
.,133,O
A,134,O
new,134,O
Rab6,134,B-GeneOrGeneProduct
homolog,134,O
cDNA,134,O
",",134,O
Rab6c,134,B-GeneOrGeneProduct
",",134,O
was,134,O
discovered,134,O
by,134,O
a,134,O
hypermethylated,134,O
DNA,134,O
fragment,134,O
probe,134,O
that,134,O
was,134,O
isolated,134,O
from,134,O
a,134,O
human,134,B-OrganismTaxon
multidrug,134,O
resistant,134,O
(,134,O
MDR,134,O
),134,O
breast,134,B-DiseaseOrPhenotypicFeature
cancer,134,I-DiseaseOrPhenotypicFeature
cell,134,O
line,134,O
",",134,O
MCF7/AdrR,134,B-CellLine
",",134,O
by,134,O
the,134,O
methylation,134,O
sensitive-representational,134,O
difference,134,O
analysis,134,O
(,134,O
MS-RDA,134,O
),134,O
technique,134,O
.,134,O
Rab6c,135,B-GeneOrGeneProduct
was,135,O
found,135,O
to,135,O
be,135,O
under-expressed,135,O
in,135,O
MCF7/AdrR,135,B-CellLine
and,135,O
MES-SA/Dx5,135,B-CellLine
(,135,O
a,135,O
human,135,B-OrganismTaxon
MDR,135,O
uterine,135,B-DiseaseOrPhenotypicFeature
sarcoma,135,I-DiseaseOrPhenotypicFeature
cell,135,O
line,135,O
),135,O
compared,135,O
with,135,O
their,135,O
non-MDR,135,O
parental,135,O
cell,135,O
lines,135,O
.,135,O
MCF7/AdrR,136,B-CellLine
cells,136,O
expressing,136,O
the,136,O
exogenous,136,O
Rab6c,136,B-GeneOrGeneProduct
exhibited,136,O
less,136,O
resistance,136,O
to,136,O
several,136,O
anti-cancer,136,O
drugs,136,O
",",136,O
such,136,O
as,136,O
doxorubicin,136,B-ChemicalEntity
(,136,O
DOX,136,B-ChemicalEntity
),136,O
",",136,O
taxol,136,B-ChemicalEntity
",",136,O
vinblastine,136,B-ChemicalEntity
",",136,O
and,136,O
vincristine,136,B-ChemicalEntity
",",136,O
than,136,O
the,136,O
control,136,O
cells,136,O
containing,136,O
the,136,O
empty,136,O
vector,136,O
.,136,O
Flow,137,O
cytometry,137,O
experiments,137,O
confirmed,137,O
that,137,O
the,137,O
transfectants,137,O
',137,O
diminished,137,O
resistance,137,O
to,137,O
DOX,137,B-ChemicalEntity
was,137,O
caused,137,O
by,137,O
increased,137,O
drug,137,O
accumulation,137,O
induced,137,O
by,137,O
the,137,O
exogenous,137,O
Rab6c,137,B-GeneOrGeneProduct
.,137,O
These,138,O
results,138,O
indicate,138,O
that,138,O
Rab6c,138,B-GeneOrGeneProduct
is,138,O
involved,138,O
in,138,O
drug,138,O
resistance,138,O
in,138,O
MCF7/AdrR,138,B-CellLine
cells,138,O
.,138,O
End-stage,139,B-DiseaseOrPhenotypicFeature
renal,139,I-DiseaseOrPhenotypicFeature
disease,139,I-DiseaseOrPhenotypicFeature
(,139,O
ESRD,139,B-DiseaseOrPhenotypicFeature
),139,O
after,139,O
orthotopic,139,O
liver,139,O
transplantation,139,O
(,139,O
OLTX,139,O
),139,O
using,139,O
calcineurin-based,139,B-GeneOrGeneProduct
immunotherapy,139,O
:,139,O
risk,139,O
of,139,O
development,139,O
and,139,O
treatment,139,O
.,139,O
BACKGROUND,140,O
:,140,O
The,140,O
calcineurin,140,B-GeneOrGeneProduct
inhibitors,140,O
cyclosporine,140,B-ChemicalEntity
and,140,O
tacrolimus,140,B-ChemicalEntity
are,140,O
both,140,O
known,140,O
to,140,O
be,140,O
nephrotoxic,140,B-DiseaseOrPhenotypicFeature
.,140,O
Their,141,O
use,141,O
in,141,O
orthotopic,141,O
liver,141,O
transplantation,141,O
(,141,O
OLTX,141,O
),141,O
has,141,O
dramatically,141,O
improved,141,O
success,141,O
rates,141,O
.,141,O
Recently,142,O
",",142,O
however,142,O
",",142,O
we,142,O
have,142,O
had,142,O
an,142,O
increase,142,O
of,142,O
patients,142,B-OrganismTaxon
who,142,O
are,142,O
presenting,142,O
after,142,O
OLTX,142,O
with,142,O
end-stage,142,B-DiseaseOrPhenotypicFeature
renal,142,I-DiseaseOrPhenotypicFeature
disease,142,I-DiseaseOrPhenotypicFeature
(,142,O
ESRD,142,B-DiseaseOrPhenotypicFeature
),142,O
.,142,O
This,143,O
retrospective,143,O
study,143,O
examines,143,O
the,143,O
incidence,143,O
and,143,O
treatment,143,O
of,143,O
ESRD,143,B-DiseaseOrPhenotypicFeature
and,143,O
chronic,143,B-DiseaseOrPhenotypicFeature
renal,143,I-DiseaseOrPhenotypicFeature
failure,143,I-DiseaseOrPhenotypicFeature
(,143,O
CRF,143,B-DiseaseOrPhenotypicFeature
),143,O
in,143,O
OLTX,143,O
patients,143,B-OrganismTaxon
.,143,O
METHODS,144,O
:,144,O
Patients,144,B-OrganismTaxon
receiving,144,O
an,144,O
OLTX,144,O
only,144,O
from,144,O
June,144,O
1985,144,O
through,144,O
December,144,O
of,144,O
1994,144,O
who,144,O
survived,144,O
6,144,O
months,144,O
postoperatively,144,O
were,144,O
studied,144,O
(,144,O
n=834,144,O
),144,O
.,144,O
Our,145,O
prospectively,145,O
collected,145,O
database,145,O
was,145,O
the,145,O
source,145,O
of,145,O
information,145,O
.,145,O
Patients,146,B-OrganismTaxon
were,146,O
divided,146,O
into,146,O
three,146,O
groups,146,O
:,146,O
Controls,146,O
",",146,O
no,146,O
CRF,146,B-DiseaseOrPhenotypicFeature
or,146,O
ESRD,146,B-DiseaseOrPhenotypicFeature
",",146,O
n=748,146,O
;,146,O
CRF,146,B-DiseaseOrPhenotypicFeature
",",146,O
sustained,146,O
serum,146,O
creatinine,146,B-ChemicalEntity
>,146,O
2.5,146,O
mg/dl,146,O
",",146,O
n=41,146,O
;,146,O
and,146,O
ESRD,146,B-DiseaseOrPhenotypicFeature
",",146,O
n=45,146,O
.,146,O
Groups,147,O
were,147,O
compared,147,O
for,147,O
preoperative,147,O
laboratory,147,O
variables,147,O
",",147,O
diagnosis,147,O
",",147,O
postoperative,147,O
variables,147,O
",",147,O
survival,147,O
",",147,O
type,147,O
of,147,O
ESRD,147,B-DiseaseOrPhenotypicFeature
therapy,147,O
",",147,O
and,147,O
survival,147,O
from,147,O
onset,147,O
of,147,O
ESRD,147,B-DiseaseOrPhenotypicFeature
.,147,O
RESULTS,148,O
:,148,O
At,148,O
13,148,O
years,148,O
after,148,O
OLTX,148,O
",",148,O
the,148,O
incidence,148,O
of,148,O
severe,148,O
renal,148,B-DiseaseOrPhenotypicFeature
dysfunction,148,I-DiseaseOrPhenotypicFeature
was,148,O
18.1,148,O
%,148,O
(,148,O
CRF,148,B-DiseaseOrPhenotypicFeature
8.6,148,O
%,148,O
and,148,O
ESRD,148,B-DiseaseOrPhenotypicFeature
9.5,148,O
%,148,O
),148,O
.,148,O
Compared,149,O
with,149,O
control,149,O
patients,149,B-OrganismTaxon
",",149,O
CRF,149,B-DiseaseOrPhenotypicFeature
and,149,O
ESRD,149,B-DiseaseOrPhenotypicFeature
patients,149,B-OrganismTaxon
had,149,O
higher,149,O
preoperative,149,O
serum,149,O
creatinine,149,B-ChemicalEntity
levels,149,O
",",149,O
a,149,O
greater,149,O
percentage,149,O
of,149,O
patients,149,B-OrganismTaxon
with,149,O
hepatorenal,149,B-DiseaseOrPhenotypicFeature
syndrome,149,I-DiseaseOrPhenotypicFeature
",",149,O
higher,149,O
percentage,149,O
requirement,149,O
for,149,O
dialysis,149,O
in,149,O
the,149,O
first,149,O
3,149,O
months,149,O
postoperatively,149,O
",",149,O
and,149,O
a,149,O
higher,149,O
1-year,149,O
serum,149,O
creatinine,149,B-ChemicalEntity
.,149,O
Multivariate,150,O
stepwise,150,O
logistic,150,O
regression,150,O
analysis,150,O
using,150,O
preoperative,150,O
and,150,O
postoperative,150,O
variables,150,O
identified,150,O
that,150,O
an,150,O
increase,150,O
of,150,O
serum,150,O
creatinine,150,B-ChemicalEntity
compared,150,O
with,150,O
average,150,O
at,150,O
1,150,O
year,150,O
",",150,O
3,150,O
months,150,O
",",150,O
and,150,O
4,150,O
weeks,150,O
postoperatively,150,O
were,150,O
independent,150,O
risk,150,O
factors,150,O
for,150,O
the,150,O
development,150,O
of,150,O
CRF,150,B-DiseaseOrPhenotypicFeature
or,150,O
ESRD,150,B-DiseaseOrPhenotypicFeature
with,150,O
odds,150,O
ratios,150,O
of,150,O
2.6,150,O
",",150,O
2.2,150,O
",",150,O
and,150,O
1.6,150,O
",",150,O
respectively,150,O
.,150,O
Overall,151,O
survival,151,O
from,151,O
the,151,O
time,151,O
of,151,O
OLTX,151,O
was,151,O
not,151,O
significantly,151,O
different,151,O
among,151,O
groups,151,O
",",151,O
but,151,O
by,151,O
year,151,O
13,151,O
",",151,O
the,151,O
survival,151,O
of,151,O
the,151,O
patients,151,B-OrganismTaxon
who,151,O
had,151,O
ESRD,151,B-DiseaseOrPhenotypicFeature
was,151,O
only,151,O
28.2,151,O
%,151,O
compared,151,O
with,151,O
54.6,151,O
%,151,O
in,151,O
the,151,O
control,151,O
group,151,O
.,151,O
Patients,152,B-OrganismTaxon
developing,152,O
ESRD,152,B-DiseaseOrPhenotypicFeature
had,152,O
a,152,O
6-year,152,O
survival,152,O
after,152,O
onset,152,O
of,152,O
ESRD,152,B-DiseaseOrPhenotypicFeature
of,152,O
27,152,O
%,152,O
for,152,O
the,152,O
patients,152,B-OrganismTaxon
receiving,152,O
hemodialysis,152,O
versus,152,O
71.4,152,O
%,152,O
for,152,O
the,152,O
patients,152,B-OrganismTaxon
developing,152,O
ESRD,152,B-DiseaseOrPhenotypicFeature
who,152,O
subsequently,152,O
received,152,O
kidney,152,O
transplants,152,O
.,152,O
CONCLUSIONS,153,O
:,153,O
Patients,153,B-OrganismTaxon
who,153,O
are,153,O
more,153,O
than,153,O
10,153,O
years,153,O
post-OLTX,153,O
have,153,O
CRF,153,B-DiseaseOrPhenotypicFeature
and,153,O
ESRD,153,B-DiseaseOrPhenotypicFeature
at,153,O
a,153,O
high,153,O
rate,153,O
.,153,O
The,154,O
development,154,O
of,154,O
ESRD,154,B-DiseaseOrPhenotypicFeature
decreases,154,O
survival,154,O
",",154,O
particularly,154,O
in,154,O
those,154,O
patients,154,B-OrganismTaxon
treated,154,O
with,154,O
dialysis,154,O
only,154,O
.,154,O
Patients,155,B-OrganismTaxon
who,155,O
develop,155,O
ESRD,155,B-DiseaseOrPhenotypicFeature
have,155,O
a,155,O
higher,155,O
preoperative,155,O
and,155,O
1-year,155,O
serum,155,O
creatinine,155,B-ChemicalEntity
and,155,O
are,155,O
more,155,O
likely,155,O
to,155,O
have,155,O
hepatorenal,155,B-DiseaseOrPhenotypicFeature
syndrome,155,I-DiseaseOrPhenotypicFeature
.,155,O
However,156,O
",",156,O
an,156,O
increase,156,O
of,156,O
serum,156,O
creatinine,156,B-ChemicalEntity
at,156,O
various,156,O
times,156,O
postoperatively,156,O
is,156,O
more,156,O
predictive,156,O
of,156,O
the,156,O
development,156,O
of,156,O
CRF,156,B-DiseaseOrPhenotypicFeature
or,156,O
ESRD,156,B-DiseaseOrPhenotypicFeature
.,156,O
New,157,O
strategies,157,O
for,157,O
long-term,157,O
immunosuppression,157,O
may,157,O
be,157,O
needed,157,O
to,157,O
decrease,157,O
this,157,O
complication,157,O
.,157,O
D90A-SOD1,158,B-SequenceVariant
mediated,158,O
amyotrophic,158,B-DiseaseOrPhenotypicFeature
lateral,158,I-DiseaseOrPhenotypicFeature
sclerosis,158,I-DiseaseOrPhenotypicFeature
:,158,O
a,158,O
single,158,O
founder,158,O
for,158,O
all,158,O
cases,158,O
with,158,O
evidence,158,O
for,158,O
a,158,O
Cis-acting,158,O
disease,158,O
modifier,158,O
in,158,O
the,158,O
recessive,158,O
haplotype,158,O
.,158,O
More,159,O
than,159,O
100,159,O
different,159,O
heterozygous,159,O
mutations,159,O
in,159,O
copper/zinc,159,B-GeneOrGeneProduct
superoxide,159,I-GeneOrGeneProduct
dismutase,159,I-GeneOrGeneProduct
(,159,O
SOD1,159,B-GeneOrGeneProduct
),159,O
have,159,O
been,159,O
found,159,O
in,159,O
patients,159,B-OrganismTaxon
with,159,O
amyotrophic,159,B-DiseaseOrPhenotypicFeature
lateral,159,I-DiseaseOrPhenotypicFeature
sclerosis,159,I-DiseaseOrPhenotypicFeature
(,159,O
ALS,159,B-DiseaseOrPhenotypicFeature
),159,O
",",159,O
a,159,O
fatal,159,O
neurodegenerative,159,B-DiseaseOrPhenotypicFeature
disease,159,I-DiseaseOrPhenotypicFeature
.,159,O
Uniquely,160,O
",",160,O
D90A-SOD1,160,B-SequenceVariant
has,160,O
been,160,O
identified,160,O
in,160,O
recessive,160,O
",",160,O
dominant,160,O
and,160,O
apparently,160,O
sporadic,160,O
pedigrees,160,O
.,160,O
The,161,O
phenotype,161,O
of,161,O
homozygotes,161,O
is,161,O
stereotyped,161,O
with,161,O
an,161,O
extended,161,O
survival,161,O
",",161,O
whereas,161,O
that,161,O
of,161,O
affected,161,O
heterozygotes,161,O
varies,161,O
.,161,O
The,162,O
frequency,162,O
of,162,O
D90A-SOD1,162,B-SequenceVariant
is,162,O
50,162,O
times,162,O
higher,162,O
in,162,O
Scandinavia,162,O
(,162,O
2.5,162,O
%,162,O
),162,O
than,162,O
elsewhere,162,O
",",162,O
though,162,O
ALS,162,B-DiseaseOrPhenotypicFeature
prevalence,162,O
is,162,O
not,162,O
raised,162,O
there,162,O
.,162,O
Our,163,O
earlier,163,O
study,163,O
indicated,163,O
separate,163,O
founders,163,O
for,163,O
recessive,163,O
and,163,O
dominant/sporadic,163,O
ALS,163,B-DiseaseOrPhenotypicFeature
and,163,O
we,163,O
proposed,163,O
a,163,O
disease-modifying,163,O
factor,163,O
linked,163,O
to,163,O
the,163,O
recessive,163,O
mutation,163,O
.,163,O
Here,164,O
we,164,O
have,164,O
doubled,164,O
our,164,O
sample,164,O
set,164,O
and,164,O
employed,164,O
novel,164,O
markers,164,O
to,164,O
characterise,164,O
the,164,O
mutation,164,O
's,164,O
origin,164,O
and,164,O
localise,164,O
any,164,O
modifying,164,O
factor,164,O
.,164,O
Linkage,165,O
disequilibrium,165,O
analysis,165,O
indicates,165,O
that,165,O
D90A,165,B-SequenceVariant
homozygotes,165,O
and,165,O
heterozygotes,165,O
share,165,O
a,165,O
rare,165,O
haplotype,165,O
and,165,O
are,165,O
all,165,O
descended,165,O
from,165,O
a,165,O
single,165,O
ancient,165,O
founder,165,O
(,165,O
alpha,165,O
0.974,165,O
),165,O
c.895,165,O
generations,165,O
ago,165,O
.,165,O
Homozygotes,166,O
arose,166,O
subsequently,166,O
only,166,O
c.63,166,O
generations,166,O
ago,166,O
(,166,O
alpha,166,O
0.878,166,O
),166,O
.,166,O
Recombination,167,O
has,167,O
reduced,167,O
the,167,O
region,167,O
shared,167,O
by,167,O
recessive,167,O
kindreds,167,O
to,167,O
97-265,167,O
kb,167,O
around,167,O
SOD1,167,B-GeneOrGeneProduct
",",167,O
excluding,167,O
all,167,O
neighbouring,167,O
genes,167,O
.,167,O
We,168,O
propose,168,O
that,168,O
a,168,O
cis-acting,168,O
regulatory,168,O
polymorphism,168,O
has,168,O
arisen,168,O
close,168,O
to,168,O
D90A-SOD1,168,B-SequenceVariant
in,168,O
the,168,O
recessive,168,O
founder,168,O
",",168,O
which,168,O
decreases,168,O
ALS,168,B-DiseaseOrPhenotypicFeature
susceptibility,168,O
in,168,O
heterozygotes,168,O
and,168,O
slows,168,O
disease,168,O
progression,168,O
.,168,O
Low,169,O
frequency,169,O
of,169,O
deafness-associated,169,B-DiseaseOrPhenotypicFeature
GJB2,169,B-GeneOrGeneProduct
variants,169,O
in,169,O
Kenya,169,O
and,169,O
Sudan,169,O
and,169,O
novel,169,O
GJB2,169,B-GeneOrGeneProduct
variants,169,O
.,169,O
A,170,O
large,170,O
proportion,170,O
of,170,O
non-syndromic,170,B-DiseaseOrPhenotypicFeature
autosomal,170,I-DiseaseOrPhenotypicFeature
recessive,170,I-DiseaseOrPhenotypicFeature
deafness,170,I-DiseaseOrPhenotypicFeature
(,170,O
NSARD,170,B-DiseaseOrPhenotypicFeature
),170,O
in,170,O
many,170,O
populations,170,O
is,170,O
caused,170,O
by,170,O
variants,170,O
of,170,O
the,170,O
GJB2,170,B-GeneOrGeneProduct
gene,170,O
.,170,O
Here,171,O
",",171,O
the,171,O
frequency,171,O
of,171,O
GJB2,171,B-GeneOrGeneProduct
variants,171,O
was,171,O
studied,171,O
in,171,O
406,171,O
and,171,O
183,171,O
apparently,171,O
unrelated,171,O
children,171,O
from,171,O
Kenya,171,O
and,171,O
Sudan,171,O
",",171,O
respectively,171,O
",",171,O
with,171,O
mostly,171,O
severe,171,O
to,171,O
profound,171,O
non-syndromic,171,B-DiseaseOrPhenotypicFeature
deafness,171,I-DiseaseOrPhenotypicFeature
.,171,O
Nine,172,O
(,172,O
2.2,172,O
%,172,O
),172,O
Kenyan,172,O
and,172,O
12,172,O
(,172,O
6.6,172,O
%,172,O
),172,O
of,172,O
the,172,O
Sudanese,172,O
children,172,O
only,172,O
were,172,O
carriers,172,O
of,172,O
variants,172,O
within,172,O
the,172,O
coding,172,O
sequence,172,O
of,172,O
the,172,O
GJB2,172,B-GeneOrGeneProduct
gene,172,O
.,172,O
Variants,173,O
in,173,O
the,173,O
5'-adjacent,173,O
region,173,O
were,173,O
detected,173,O
in,173,O
further,173,O
115,173,O
individuals,173,O
.,173,O
A,174,O
total,174,O
of,174,O
10,174,O
novel,174,O
variants,174,O
was,174,O
recognized,174,O
",",174,O
among,174,O
them,174,O
four,174,O
variants,174,O
in,174,O
the,174,O
adjacent,174,O
5'-region,174,O
of,174,O
the,174,O
GJB2,174,B-GeneOrGeneProduct
coding,174,O
exon,174,O
2,174,O
(,174,O
g.3318-6T,174,B-SequenceVariant
>,174,I-SequenceVariant
A,174,I-SequenceVariant
",",174,O
g.3318-15C,174,B-SequenceVariant
>,174,I-SequenceVariant
T,174,I-SequenceVariant
",",174,O
g.3318-34C,174,B-SequenceVariant
>,174,I-SequenceVariant
T,174,I-SequenceVariant
",",174,O
g.3318-35T,174,B-SequenceVariant
>,174,I-SequenceVariant
G,174,I-SequenceVariant
),174,O
",",174,O
a,174,O
6,174,O
base-pair,174,O
deletion,174,O
(,174,O
g.3455_3460del,174,B-SequenceVariant
[,174,O
p.Asp46_Gln48delinsGlu,174,B-SequenceVariant
],174,O
),174,O
",",174,O
a,174,O
variant,174,O
leading,174,O
to,174,O
a,174,O
stop,174,O
codon,174,O
(,174,O
g.3512C,174,B-SequenceVariant
>,174,I-SequenceVariant
A,174,I-SequenceVariant
[,174,O
p.Tyr65X,174,B-SequenceVariant
],174,O
),174,O
",",174,O
synonymous,174,O
variants,174,O
(,174,O
g.3395C,174,B-SequenceVariant
>,174,I-SequenceVariant
T,174,I-SequenceVariant
[,174,O
p.Thr26,174,B-SequenceVariant
],174,O
",",174,O
g.3503C,174,B-SequenceVariant
>,174,I-SequenceVariant
T,174,I-SequenceVariant
[,174,O
p.Asn62,174,B-SequenceVariant
],174,O
",",174,O
g.3627A,174,B-SequenceVariant
>,174,I-SequenceVariant
C,174,I-SequenceVariant
[,174,O
p.Arg104,174,B-SequenceVariant
],174,O
),174,O
",",174,O
and,174,O
one,174,O
non-synonymous,174,O
variant,174,O
(,174,O
g.3816C,174,B-SequenceVariant
>,174,I-SequenceVariant
A,174,I-SequenceVariant
[,174,O
p.Val167Met,174,B-SequenceVariant
],174,O
),174,O
.,174,O
In,175,O
addition,175,O
",",175,O
the,175,O
previously,175,O
described,175,O
variants,175,O
g.3352delG,175,B-SequenceVariant
(,175,O
commonly,175,O
designated,175,O
30delG,175,B-SequenceVariant
or,175,O
35,175,B-SequenceVariant
delG,175,I-SequenceVariant
),175,O
",",175,O
g.3426G,175,B-SequenceVariant
>,175,I-SequenceVariant
A,175,I-SequenceVariant
[,175,O
p.Val37Ile,175,B-SequenceVariant
],175,O
",",175,O
g.3697G,175,B-SequenceVariant
>,175,I-SequenceVariant
A,175,I-SequenceVariant
[,175,O
p.Arg127His,175,B-SequenceVariant
],175,O
",",175,O
g.3774G,175,B-SequenceVariant
>,175,I-SequenceVariant
A,175,I-SequenceVariant
[,175,O
p.Val153Ile,175,B-SequenceVariant
],175,O
",",175,O
and,175,O
g.3795G,175,B-SequenceVariant
>,175,I-SequenceVariant
A,175,I-SequenceVariant
[,175,O
p.Gly160Ser,175,B-SequenceVariant
],175,O
were,175,O
identified,175,O
.,175,O
With,176,O
the,176,O
exception,176,O
of,176,O
g.3318-34C,176,B-SequenceVariant
>,176,I-SequenceVariant
T,176,I-SequenceVariant
and,176,O
g.3352delG,176,B-SequenceVariant
",",176,O
all,176,O
variants,176,O
occurred,176,O
heterozygously,176,O
.,176,O
For,177,O
most,177,O
of,177,O
the,177,O
variants,177,O
identified,177,O
in,177,O
the,177,O
Kenyan,177,O
and,177,O
Sudanese,177,O
study,177,O
population,177,O
",",177,O
a,177,O
causative,177,O
association,177,O
with,177,O
NSARD,177,B-DiseaseOrPhenotypicFeature
appears,177,O
to,177,O
be,177,O
unlikely,177,O
.,177,O
Compared,178,O
to,178,O
many,178,O
other,178,O
ethnic,178,O
groups,178,O
",",178,O
deafness-associated,178,B-DiseaseOrPhenotypicFeature
variants,178,O
of,178,O
the,178,O
coding,178,O
region,178,O
of,178,O
GJB2,178,B-GeneOrGeneProduct
are,178,O
rare,178,O
in,178,O
Sudan,178,O
and,178,O
Kenya,178,O
",",178,O
suggesting,178,O
a,178,O
role,178,O
of,178,O
other,178,O
genetic,178,O
",",178,O
or,178,O
epigenetic,178,O
factors,178,O
as,178,O
a,178,O
cause,178,O
for,178,O
deafness,178,B-DiseaseOrPhenotypicFeature
in,178,O
these,178,O
countries,178,O
.,178,O
Nijmegen,179,B-DiseaseOrPhenotypicFeature
breakage,179,I-DiseaseOrPhenotypicFeature
syndrome,179,I-DiseaseOrPhenotypicFeature
in,179,O
13,179,O
%,179,O
of,179,O
age-matched,179,O
Czech,179,O
children,179,O
with,179,O
primary,179,B-DiseaseOrPhenotypicFeature
microcephaly,179,I-DiseaseOrPhenotypicFeature
.,179,O
The,180,O
Nijmegen,180,B-DiseaseOrPhenotypicFeature
breakage,180,I-DiseaseOrPhenotypicFeature
syndrome,180,I-DiseaseOrPhenotypicFeature
is,180,O
a,180,O
rare,180,O
autosomal,180,B-DiseaseOrPhenotypicFeature
recessive,180,I-DiseaseOrPhenotypicFeature
chromosomal,180,I-DiseaseOrPhenotypicFeature
instability,180,I-DiseaseOrPhenotypicFeature
disorder,180,I-DiseaseOrPhenotypicFeature
characterized,180,O
by,180,O
early,180,O
growth,180,B-DiseaseOrPhenotypicFeature
retardation,180,I-DiseaseOrPhenotypicFeature
",",180,O
congenital,180,B-DiseaseOrPhenotypicFeature
microcephaly,180,I-DiseaseOrPhenotypicFeature
",",180,O
immunodeficiency,180,B-DiseaseOrPhenotypicFeature
",",180,O
borderline,180,O
mental,180,O
development,180,O
",",180,O
and,180,O
a,180,O
high,180,O
tendency,180,O
to,180,O
lymphoreticular,180,B-DiseaseOrPhenotypicFeature
malignancies,180,I-DiseaseOrPhenotypicFeature
.,180,O
Most,181,O
Nijmegen,181,B-DiseaseOrPhenotypicFeature
breakage,181,I-DiseaseOrPhenotypicFeature
syndrome,181,I-DiseaseOrPhenotypicFeature
patients,181,B-OrganismTaxon
are,181,O
of,181,O
Slavonic,181,O
origin,181,O
",",181,O
and,181,O
all,181,O
of,181,O
them,181,O
known,181,O
so,181,O
far,181,O
carry,181,O
a,181,O
founder,181,O
homozygous,181,O
5,181,B-SequenceVariant
nucleotide,181,I-SequenceVariant
deletion,181,I-SequenceVariant
in,181,O
the,181,O
NBS1,181,B-GeneOrGeneProduct
gene,181,O
.,181,O
Microcephaly,182,B-DiseaseOrPhenotypicFeature
was,182,O
present,182,O
in,182,O
100,182,O
%,182,O
of,182,O
Nijmegen,182,B-DiseaseOrPhenotypicFeature
breakage,182,I-DiseaseOrPhenotypicFeature
syndrome,182,I-DiseaseOrPhenotypicFeature
patients,182,B-OrganismTaxon
in,182,O
a,182,O
recent,182,O
large,182,O
international,182,O
cooperative,182,O
study,182,O
.,182,O
The,183,O
frequency,183,O
of,183,O
Nijmegen,183,B-DiseaseOrPhenotypicFeature
breakage,183,I-DiseaseOrPhenotypicFeature
syndrome,183,I-DiseaseOrPhenotypicFeature
among,183,O
children,183,O
with,183,O
primary,183,B-DiseaseOrPhenotypicFeature
microcephaly,183,I-DiseaseOrPhenotypicFeature
was,183,O
not,183,O
known,183,O
.,183,O
Early,184,O
correct,184,O
diagnosis,184,O
of,184,O
the,184,O
syndrome,184,O
is,184,O
crucial,184,O
for,184,O
appropriate,184,O
preventive,184,O
care,184,O
and,184,O
therapy,184,O
.,184,O
We,185,O
tested,185,O
67,185,O
Czech,185,O
patients,185,B-OrganismTaxon
of,185,O
different,185,O
ages,185,O
with,185,O
simple,185,O
microcephaly,185,O
for,185,O
the,185,O
presence,185,O
of,185,O
the,185,O
most,185,O
common,185,O
mutation,185,O
in,185,O
the,185,O
NBS1,185,B-GeneOrGeneProduct
gene,185,O
.,185,O
Three,186,O
new,186,O
Nijmegen,186,B-DiseaseOrPhenotypicFeature
breakage,186,I-DiseaseOrPhenotypicFeature
syndrome,186,I-DiseaseOrPhenotypicFeature
cases,186,O
were,186,O
detected,186,O
in,186,O
this,186,O
cohort,186,O
",",186,O
representing,186,O
4.5,186,O
%,186,O
of,186,O
the,186,O
cohort,186,O
.,186,O
All,187,O
these,187,O
newly,187,O
diagnosed,187,O
Nijmegen,187,B-DiseaseOrPhenotypicFeature
breakage,187,I-DiseaseOrPhenotypicFeature
syndrome,187,I-DiseaseOrPhenotypicFeature
patients,187,B-OrganismTaxon
were,187,O
younger,187,O
than,187,O
10,187,O
months,187,O
at,187,O
the,187,O
time,187,O
of,187,O
diagnosis,187,O
.,187,O
They,188,O
were,188,O
all,188,O
born,188,O
within,188,O
a,188,O
2.5-year,188,O
period,188,O
.,188,O
Twenty-three,189,O
of,189,O
the,189,O
67,189,O
children,189,O
in,189,O
the,189,O
cohort,189,O
were,189,O
born,189,O
within,189,O
this,189,O
2.5-year,189,O
period,189,O
",",189,O
representing,189,O
a,189,O
13,189,O
%,189,O
incidence,189,O
of,189,O
Nijmegen,189,B-DiseaseOrPhenotypicFeature
breakage,189,I-DiseaseOrPhenotypicFeature
syndrome,189,I-DiseaseOrPhenotypicFeature
.,189,O
Frequency,190,O
of,190,O
Nijmegen,190,B-DiseaseOrPhenotypicFeature
breakage,190,I-DiseaseOrPhenotypicFeature
syndrome,190,I-DiseaseOrPhenotypicFeature
heterozygotes,190,O
among,190,O
infants,190,O
in,190,O
the,190,O
Czech,190,O
Republic,190,O
is,190,O
1,190,O
:,190,O
130-158,190,O
and,190,O
the,190,O
birth,190,O
rate,190,O
is,190,O
"90,000",190,O
per,190,O
year,190,O
",",190,O
therefore,190,O
in,190,O
the,190,O
time,190,O
span,190,O
of,190,O
2.5,190,O
years,190,O
",",190,O
three,190,O
new,190,O
Nijmegen,190,B-DiseaseOrPhenotypicFeature
breakage,190,I-DiseaseOrPhenotypicFeature
syndrome,190,I-DiseaseOrPhenotypicFeature
homozygotes,190,O
are,190,O
expected,190,O
to,190,O
be,190,O
born,190,O
.,190,O
Therefore,191,O
we,191,O
assume,191,O
that,191,O
by,191,O
DNA,191,O
testing,191,O
of,191,O
Czech,191,O
primary,191,O
microcephalic,191,O
children,191,O
it,191,O
is,191,O
possible,191,O
to,191,O
detect,191,O
all,191,O
Nijmegen,191,B-DiseaseOrPhenotypicFeature
breakage,191,I-DiseaseOrPhenotypicFeature
syndrome,191,I-DiseaseOrPhenotypicFeature
patients,191,B-OrganismTaxon
to,191,O
be,191,O
expected,191,O
.,191,O
The,192,O
age,192,O
at,192,O
correct,192,O
diagnosis,192,O
was,192,O
lowered,192,O
from,192,O
7.1,192,O
years,192,O
at,192,O
the,192,O
time,192,O
before,192,O
DNA,192,O
testing,192,O
",",192,O
to,192,O
well,192,O
under,192,O
1,192,O
year,192,O
of,192,O
age,192,O
.,192,O
All,193,O
new,193,O
Nijmegen,193,B-DiseaseOrPhenotypicFeature
breakage,193,I-DiseaseOrPhenotypicFeature
syndrome,193,I-DiseaseOrPhenotypicFeature
patients,193,B-OrganismTaxon
could,193,O
receive,193,O
appropriate,193,O
preventive,193,O
care,193,O
",",193,O
which,193,O
should,193,O
significantly,193,O
improve,193,O
their,193,O
life,193,O
expectancy,193,O
and,193,O
prognosis,193,O
.,193,O
Atrial,194,B-DiseaseOrPhenotypicFeature
fibrillation,194,I-DiseaseOrPhenotypicFeature
following,194,O
chemotherapy,194,O
for,194,O
stage,194,O
IIIE,194,O
diffuse,194,O
large,194,O
B-cell,194,O
gastric,194,B-DiseaseOrPhenotypicFeature
lymphoma,194,I-DiseaseOrPhenotypicFeature
in,194,O
a,194,O
patient,194,B-OrganismTaxon
with,194,O
myotonic,194,B-DiseaseOrPhenotypicFeature
dystrophy,194,I-DiseaseOrPhenotypicFeature
(,194,O
Steinert,194,B-DiseaseOrPhenotypicFeature
's,194,I-DiseaseOrPhenotypicFeature
disease,194,I-DiseaseOrPhenotypicFeature
),194,O
.,194,O
The,195,O
authors,195,O
describe,195,O
the,195,O
unusual,195,O
association,195,O
between,195,O
diffuse,195,O
B-cell,195,O
gastric,195,B-DiseaseOrPhenotypicFeature
lymphoma,195,I-DiseaseOrPhenotypicFeature
and,195,O
myotonic,195,B-DiseaseOrPhenotypicFeature
dystrophy,195,I-DiseaseOrPhenotypicFeature
",",195,O
the,195,O
most,195,O
common,195,O
form,195,O
of,195,O
adult,195,O
muscular,195,B-DiseaseOrPhenotypicFeature
dystrophy,195,I-DiseaseOrPhenotypicFeature
",",195,O
and,195,O
sudden,195,O
atrial,195,B-DiseaseOrPhenotypicFeature
fibrillation,195,I-DiseaseOrPhenotypicFeature
following,195,O
one,195,O
cycle,195,O
of,195,O
doxorubicin-based,195,B-ChemicalEntity
chemotherapy,195,O
in,195,O
the,195,O
same,195,O
patient,195,B-OrganismTaxon
.,195,O
Atrial,196,B-DiseaseOrPhenotypicFeature
fibrillation,196,I-DiseaseOrPhenotypicFeature
or,196,O
other,196,O
cardiac,196,B-DiseaseOrPhenotypicFeature
arrhythmias,196,I-DiseaseOrPhenotypicFeature
are,196,O
unusual,196,O
complications,196,O
in,196,O
patients,196,B-OrganismTaxon
treated,196,O
with,196,O
chemotherapy,196,O
.,196,O
The,197,O
cardiac,197,B-DiseaseOrPhenotypicFeature
toxicity,197,I-DiseaseOrPhenotypicFeature
intrinsically,197,O
associated,197,O
with,197,O
the,197,O
aggressive,197,O
chemotherapy,197,O
employed,197,O
could,197,O
function,197,O
as,197,O
a,197,O
triggering,197,O
factor,197,O
for,197,O
the,197,O
arrhythmia,197,B-DiseaseOrPhenotypicFeature
in,197,O
the,197,O
predisposed,197,O
myocardium,197,O
of,197,O
this,197,O
patient,197,B-OrganismTaxon
.,197,O
Compound,198,O
heterozygous,198,O
mutations,198,O
in,198,O
the,198,O
SRD5A2,198,B-GeneOrGeneProduct
gene,198,O
exon,198,O
4,198,O
in,198,O
a,198,O
male,198,B-DiseaseOrPhenotypicFeature
pseudohermaphrodite,198,I-DiseaseOrPhenotypicFeature
patient,198,B-OrganismTaxon
of,198,O
Chinese,198,O
origin,198,O
.,198,O
The,199,O
goal,199,O
of,199,O
this,199,O
study,199,O
was,199,O
to,199,O
perform,199,O
5-alpha-reductase,199,B-GeneOrGeneProduct
type,199,I-GeneOrGeneProduct
2,199,I-GeneOrGeneProduct
gene,199,O
(,199,O
SRD5A2,199,B-GeneOrGeneProduct
),199,O
analysis,199,O
in,199,O
a,199,O
male,199,B-DiseaseOrPhenotypicFeature
pseudohermaphrodite,199,I-DiseaseOrPhenotypicFeature
(,199,O
MPH,199,B-DiseaseOrPhenotypicFeature
),199,O
patient,199,B-OrganismTaxon
with,199,O
normal,199,O
testosterone,199,B-ChemicalEntity
(,199,O
T,199,B-ChemicalEntity
),199,O
production,199,O
and,199,O
normal,199,O
androgen,199,B-GeneOrGeneProduct
receptor,199,I-GeneOrGeneProduct
(,199,O
AR,199,B-GeneOrGeneProduct
),199,O
gene,199,O
coding,199,O
sequences,199,O
.,199,O
A,200,O
patient,200,B-OrganismTaxon
of,200,O
Chinese,200,O
origin,200,O
with,200,O
ambiguous,200,O
genitalia,200,O
at,200,O
14,200,O
months,200,O
",",200,O
a,200,O
46,200,O
",",200,O
XY,200,O
karyotype,200,O
",",200,O
and,200,O
normal,200,O
T,200,B-ChemicalEntity
secretion,200,O
under,200,O
human,200,B-ChemicalEntity
chorionic,200,I-ChemicalEntity
gonadotropin,200,I-ChemicalEntity
(,200,O
hCG,200,B-ChemicalEntity
),200,O
stimulation,200,O
underwent,200,O
a,200,O
gonadectomy,200,O
at,200,O
20,200,O
months,200,O
.,200,O
Exons,201,O
1-8,201,O
of,201,O
the,201,O
AR,201,B-GeneOrGeneProduct
gene,201,O
and,201,O
exons,201,O
1-5,201,O
of,201,O
the,201,O
SRD5A2,201,B-GeneOrGeneProduct
gene,201,O
were,201,O
sequenced,201,O
from,201,O
peripheral,201,O
blood,201,O
DNA,201,O
.,201,O
AR,202,B-GeneOrGeneProduct
gene,202,O
coding,202,O
sequences,202,O
were,202,O
normal,202,O
.,202,O
SRD5A2,203,B-GeneOrGeneProduct
gene,203,O
analysis,203,O
revealed,203,O
2,203,O
consecutive,203,O
mutations,203,O
in,203,O
exon,203,O
4,203,O
",",203,O
each,203,O
located,203,O
in,203,O
a,203,O
different,203,O
allele,203,O
:,203,O
1,203,O
),203,O
a,203,O
T,203,B-SequenceVariant
nucleotide,203,I-SequenceVariant
deletion,203,I-SequenceVariant
",",203,I-SequenceVariant
which,203,I-SequenceVariant
predicts,203,I-SequenceVariant
a,203,I-SequenceVariant
frameshift,203,I-SequenceVariant
mutation,203,I-SequenceVariant
from,203,I-SequenceVariant
codon,203,I-SequenceVariant
219,203,I-SequenceVariant
",",203,O
and,203,O
2,203,O
),203,O
a,203,O
missense,203,O
mutation,203,O
at,203,O
codon,203,O
227,203,O
",",203,O
where,203,O
the,203,O
substitution,203,O
of,203,O
guanine,203,B-SequenceVariant
(,203,I-SequenceVariant
CGA,203,I-SequenceVariant
),203,I-SequenceVariant
by,203,I-SequenceVariant
adenine,203,I-SequenceVariant
(,203,I-SequenceVariant
CAA,203,I-SequenceVariant
),203,I-SequenceVariant
predicts,203,O
a,203,O
glutamine,203,B-SequenceVariant
replacement,203,I-SequenceVariant
of,203,I-SequenceVariant
arginine,203,I-SequenceVariant
(,203,O
R227Q,203,B-SequenceVariant
),203,O
.,203,O
Testes,204,O
located,204,O
in,204,O
the,204,O
inguinal,204,O
canal,204,O
showed,204,O
a,204,O
normal,204,O
morphology,204,O
for,204,O
age,204,O
.,204,O
The,205,O
patient,205,B-OrganismTaxon
was,205,O
a,205,O
compound,205,O
heterozygote,205,O
for,205,O
SRD5A2,205,B-GeneOrGeneProduct
mutations,205,O
",",205,O
carrying,205,O
2,205,O
mutations,205,O
in,205,O
exon,205,O
4,205,O
.,205,O
The,206,O
patient,206,B-OrganismTaxon
showed,206,O
an,206,O
R227Q,206,B-SequenceVariant
mutation,206,O
that,206,O
has,206,O
been,206,O
described,206,O
in,206,O
an,206,O
Asian,206,O
population,206,O
and,206,O
MPH,206,B-DiseaseOrPhenotypicFeature
patients,206,B-OrganismTaxon
",",206,O
along,206,O
with,206,O
a,206,O
novel,206,O
frameshift,206,O
mutation,206,O
",",206,O
Tdel219,206,B-SequenceVariant
.,206,O
Testis,207,O
morphology,207,O
showed,207,O
that,207,O
",",207,O
during,207,O
early,207,O
infancy,207,O
",",207,O
the,207,O
5-alpha-reductase,207,B-GeneOrGeneProduct
enzyme,207,O
deficiency,207,O
may,207,O
not,207,O
have,207,O
affected,207,O
interstitial,207,O
or,207,O
tubular,207,O
development,207,O
.,207,O
Increased,208,O
expression,208,O
and,208,O
apical,208,O
targeting,208,O
of,208,O
renal,208,O
ENaC,208,B-GeneOrGeneProduct
subunits,208,I-GeneOrGeneProduct
in,208,O
puromycin,208,B-ChemicalEntity
aminonucleoside-induced,208,O
nephrotic,208,B-DiseaseOrPhenotypicFeature
syndrome,208,I-DiseaseOrPhenotypicFeature
in,208,O
rats,208,B-OrganismTaxon
.,208,O
Nephrotic,209,B-DiseaseOrPhenotypicFeature
syndrome,209,I-DiseaseOrPhenotypicFeature
is,209,O
often,209,O
accompanied,209,O
by,209,O
sodium,209,B-ChemicalEntity
retention,209,O
and,209,O
generalized,209,O
edema,209,B-DiseaseOrPhenotypicFeature
.,209,O
However,210,O
",",210,O
the,210,O
molecular,210,O
basis,210,O
for,210,O
the,210,O
decreased,210,O
renal,210,O
sodium,210,B-ChemicalEntity
excretion,210,O
remains,210,O
undefined,210,O
.,210,O
We,211,O
hypothesized,211,O
that,211,O
epithelial,211,B-GeneOrGeneProduct
Na,211,I-GeneOrGeneProduct
channel,211,I-GeneOrGeneProduct
(,211,I-GeneOrGeneProduct
ENaC,211,I-GeneOrGeneProduct
),211,I-GeneOrGeneProduct
subunit,211,I-GeneOrGeneProduct
dysregulation,211,O
may,211,O
be,211,O
responsible,211,O
for,211,O
the,211,O
increased,211,O
sodium,211,B-ChemicalEntity
retention,211,O
.,211,O
An,212,O
experimental,212,O
group,212,O
of,212,O
rats,212,B-OrganismTaxon
was,212,O
treated,212,O
with,212,O
puromycin,212,B-ChemicalEntity
aminonucleoside,212,I-ChemicalEntity
(,212,O
PAN,212,B-ChemicalEntity
;,212,O
180,212,O
mg/kg,212,O
iv,212,O
),212,O
",",212,O
whereas,212,O
the,212,O
control,212,O
group,212,O
received,212,O
only,212,O
vehicle,212,O
.,212,O
After,213,O
7,213,O
days,213,O
",",213,O
PAN,213,B-ChemicalEntity
treatment,213,O
induced,213,O
significant,213,O
proteinuria,213,B-DiseaseOrPhenotypicFeature
",",213,O
hypoalbuminemia,213,B-DiseaseOrPhenotypicFeature
",",213,O
decreased,213,O
urinary,213,O
sodium,213,B-ChemicalEntity
excretion,213,O
",",213,O
and,213,O
extensive,213,O
ascites,213,B-DiseaseOrPhenotypicFeature
.,213,O
The,214,O
protein,214,O
abundance,214,O
of,214,O
alpha-ENaC,214,B-GeneOrGeneProduct
and,214,O
beta-ENaC,214,B-GeneOrGeneProduct
was,214,O
increased,214,O
in,214,O
the,214,O
inner,214,O
stripe,214,O
of,214,O
the,214,O
outer,214,O
medulla,214,O
(,214,O
ISOM,214,O
),214,O
and,214,O
in,214,O
the,214,O
inner,214,O
medulla,214,O
(,214,O
IM,214,O
),214,O
but,214,O
was,214,O
not,214,O
altered,214,O
in,214,O
the,214,O
cortex,214,O
.,214,O
gamma-ENaC,215,B-GeneOrGeneProduct
abundance,215,O
was,215,O
increased,215,O
in,215,O
the,215,O
cortex,215,O
",",215,O
ISOM,215,O
",",215,O
and,215,O
IM,215,O
.,215,O
Immunoperoxidase,216,O
brightfield-,216,O
and,216,O
laser-scanning,216,O
confocal,216,O
fluorescence,216,O
microscopy,216,O
demonstrated,216,O
increased,216,O
targeting,216,O
of,216,O
alpha-ENaC,216,B-GeneOrGeneProduct
",",216,O
beta-ENaC,216,B-GeneOrGeneProduct
",",216,O
and,216,O
gamma-ENaC,216,B-GeneOrGeneProduct
subunits,216,O
to,216,O
the,216,O
apical,216,O
plasma,216,O
membrane,216,O
in,216,O
the,216,O
distal,216,O
convoluted,216,O
tubule,216,O
(,216,O
DCT2,216,O
),216,O
",",216,O
connecting,216,O
tubule,216,O
",",216,O
and,216,O
cortical,216,O
and,216,O
medullary,216,O
collecting,216,O
duct,216,O
segments,216,O
.,216,O
Immunoelectron,217,O
microscopy,217,O
further,217,O
revealed,217,O
an,217,O
increased,217,O
labeling,217,O
of,217,O
alpha-ENaC,217,B-GeneOrGeneProduct
in,217,O
the,217,O
apical,217,O
plasma,217,O
membrane,217,O
of,217,O
cortical,217,O
collecting,217,O
duct,217,O
principal,217,O
cells,217,O
of,217,O
PAN-treated,217,B-ChemicalEntity
rats,217,B-OrganismTaxon
",",217,O
indicating,217,O
enhanced,217,O
apical,217,O
targeting,217,O
of,217,O
alpha-ENaC,217,B-GeneOrGeneProduct
subunits,217,O
.,217,O
In,218,O
contrast,218,O
",",218,O
the,218,O
protein,218,O
abundances,218,O
of,218,O
Na,218,B-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
+,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
/H,218,I-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
+,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
exchanger,218,I-GeneOrGeneProduct
type,218,I-GeneOrGeneProduct
3,218,I-GeneOrGeneProduct
(,218,O
NHE3,218,B-GeneOrGeneProduct
),218,O
",",218,O
Na,218,B-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
+,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
-K,218,I-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
+,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
-2Cl,218,I-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
-,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
cotransporter,218,I-GeneOrGeneProduct
(,218,O
BSC-1,218,B-GeneOrGeneProduct
),218,O
",",218,O
and,218,O
thiazide-sensitive,218,B-GeneOrGeneProduct
Na,218,I-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
+,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
-Cl,218,I-GeneOrGeneProduct
(,218,I-GeneOrGeneProduct
-,218,I-GeneOrGeneProduct
),218,I-GeneOrGeneProduct
cotransporter,218,I-GeneOrGeneProduct
(,218,O
TSC,218,B-GeneOrGeneProduct
),218,O
were,218,O
decreased,218,O
.,218,O
Moreover,219,O
",",219,O
the,219,O
abundance,219,O
of,219,O
the,219,O
alpha,219,B-GeneOrGeneProduct
(,219,I-GeneOrGeneProduct
1,219,I-GeneOrGeneProduct
),219,I-GeneOrGeneProduct
-subunit,219,I-GeneOrGeneProduct
of,219,I-GeneOrGeneProduct
the,219,I-GeneOrGeneProduct
Na-K-ATPase,219,I-GeneOrGeneProduct
was,219,O
decreased,219,O
in,219,O
the,219,O
cortex,219,O
and,219,O
ISOM,219,O
",",219,O
but,219,O
it,219,O
remained,219,O
unchanged,219,O
in,219,O
the,219,O
IM,219,O
.,219,O
In,220,O
conclusion,220,O
",",220,O
the,220,O
increased,220,O
or,220,O
sustained,220,O
expression,220,O
of,220,O
ENaC,220,B-GeneOrGeneProduct
subunits,220,I-GeneOrGeneProduct
combined,220,O
with,220,O
increased,220,O
apical,220,O
targeting,220,O
in,220,O
the,220,O
DCT2,220,O
",",220,O
connecting,220,O
tubule,220,O
",",220,O
and,220,O
collecting,220,O
duct,220,O
are,220,O
likely,220,O
to,220,O
play,220,O
a,220,O
role,220,O
in,220,O
the,220,O
sodium,220,B-ChemicalEntity
retention,220,O
associated,220,O
with,220,O
PAN-induced,220,B-ChemicalEntity
nephrotic,220,B-DiseaseOrPhenotypicFeature
syndrome,220,I-DiseaseOrPhenotypicFeature
.,220,O
The,221,O
decreased,221,O
abundance,221,O
of,221,O
NHE3,221,B-GeneOrGeneProduct
",",221,O
BSC-1,221,B-GeneOrGeneProduct
",",221,O
TSC,221,B-GeneOrGeneProduct
",",221,O
and,221,O
Na-K-ATPase,221,B-GeneOrGeneProduct
may,221,O
play,221,O
a,221,O
compensatory,221,O
role,221,O
to,221,O
promote,221,O
sodium,221,B-ChemicalEntity
excretion,221,O
.,221,O
Mutations,222,O
in,222,O
the,222,O
PCSK9,222,B-GeneOrGeneProduct
gene,222,O
in,222,O
Norwegian,222,O
subjects,222,O
with,222,O
autosomal,222,B-DiseaseOrPhenotypicFeature
dominant,222,I-DiseaseOrPhenotypicFeature
hypercholesterolemia,222,I-DiseaseOrPhenotypicFeature
.,222,O
Proprotein,223,B-GeneOrGeneProduct
convertase,223,I-GeneOrGeneProduct
subtilisin/kexin,223,I-GeneOrGeneProduct
type,223,I-GeneOrGeneProduct
9,223,I-GeneOrGeneProduct
(,223,O
PCSK9,223,B-GeneOrGeneProduct
),223,O
is,223,O
at,223,O
a,223,O
locus,223,O
for,223,O
autosomal,223,B-DiseaseOrPhenotypicFeature
dominant,223,I-DiseaseOrPhenotypicFeature
hypercholesterolemia,223,I-DiseaseOrPhenotypicFeature
",",223,O
and,223,O
recent,223,O
data,223,O
indicate,223,O
that,223,O
the,223,O
PCSK9,223,B-GeneOrGeneProduct
gene,223,O
is,223,O
involved,223,O
in,223,O
cholesterol,223,B-ChemicalEntity
biosynthesis,223,O
.,223,O
Mutations,224,O
within,224,O
this,224,O
gene,224,O
have,224,O
previously,224,O
been,224,O
found,224,O
to,224,O
segregate,224,O
with,224,O
hypercholesterolemia,224,B-DiseaseOrPhenotypicFeature
.,224,O
In,225,O
this,225,O
study,225,O
",",225,O
DNA,225,O
sequencing,225,O
of,225,O
the,225,O
12,225,O
exons,225,O
of,225,O
the,225,O
PCSK9,225,B-GeneOrGeneProduct
gene,225,O
has,225,O
been,225,O
performed,225,O
in,225,O
51,225,O
Norwegian,225,O
subjects,225,O
with,225,O
a,225,O
clinical,225,O
diagnosis,225,O
of,225,O
familial,225,B-DiseaseOrPhenotypicFeature
hypercholesterolemia,225,I-DiseaseOrPhenotypicFeature
where,225,O
mutations,225,O
in,225,O
the,225,O
low-density,225,B-GeneOrGeneProduct
lipoprotein,225,I-GeneOrGeneProduct
receptor,225,I-GeneOrGeneProduct
gene,225,O
and,225,O
mutation,225,O
R3500Q,225,B-SequenceVariant
in,225,O
the,225,O
apolipoprotein,225,B-GeneOrGeneProduct
B-100,225,I-GeneOrGeneProduct
gene,225,O
had,225,O
been,225,O
excluded,225,O
.,225,O
Two,226,O
novel,226,O
missense,226,O
mutations,226,O
were,226,O
detected,226,O
in,226,O
the,226,O
catalytic,226,O
subdomain,226,O
of,226,O
the,226,O
PCSK9,226,B-GeneOrGeneProduct
gene,226,O
.,226,O
Two,227,O
patients,227,B-OrganismTaxon
were,227,O
heterozygotes,227,O
for,227,O
D374Y,227,B-SequenceVariant
",",227,O
and,227,O
one,227,O
patient,227,B-OrganismTaxon
was,227,O
a,227,O
double,227,O
heterozygote,227,O
for,227,O
D374Y,227,B-SequenceVariant
and,227,O
N157K,227,B-SequenceVariant
.,227,O
D374Y,228,B-SequenceVariant
segregated,228,O
with,228,O
hypercholesterolemia,228,B-DiseaseOrPhenotypicFeature
in,228,O
the,228,O
two,228,O
former,228,O
families,228,O
where,228,O
family,228,O
members,228,O
were,228,O
available,228,O
for,228,O
study,228,O
.,228,O
Our,229,O
findings,229,O
support,229,O
the,229,O
notion,229,O
that,229,O
mutations,229,O
in,229,O
the,229,O
PCSK9,229,B-GeneOrGeneProduct
gene,229,O
cause,229,O
autosomal,229,B-DiseaseOrPhenotypicFeature
dominant,229,I-DiseaseOrPhenotypicFeature
hypercholesterolemia,229,I-DiseaseOrPhenotypicFeature
.,229,O
Desmin-related,230,B-DiseaseOrPhenotypicFeature
myopathy,230,I-DiseaseOrPhenotypicFeature
with,230,O
Mallory,230,O
body-like,230,O
inclusions,230,O
is,230,O
caused,230,O
by,230,O
mutations,230,O
of,230,O
the,230,O
selenoprotein,230,B-GeneOrGeneProduct
N,230,I-GeneOrGeneProduct
gene,230,O
.,230,O
Desmin-related,231,B-DiseaseOrPhenotypicFeature
myopathies,231,I-DiseaseOrPhenotypicFeature
(,231,O
DRMs,231,B-DiseaseOrPhenotypicFeature
),231,O
are,231,O
a,231,O
heterogeneous,231,O
group,231,O
of,231,O
muscle,231,B-DiseaseOrPhenotypicFeature
disorders,231,I-DiseaseOrPhenotypicFeature
",",231,O
morphologically,231,O
defined,231,O
by,231,O
intrasarcoplasmic,231,O
aggregates,231,O
of,231,O
desmin,231,B-GeneOrGeneProduct
.,231,O
Mutations,232,O
in,232,O
the,232,O
desmin,232,B-GeneOrGeneProduct
and,232,O
the,232,O
alpha-B,232,B-GeneOrGeneProduct
crystallin,232,I-GeneOrGeneProduct
genes,232,O
account,232,O
for,232,O
approximately,232,O
one,232,O
third,232,O
of,232,O
the,232,O
DRM,232,B-DiseaseOrPhenotypicFeature
cases,232,O
.,232,O
The,233,O
genetic,233,O
basis,233,O
of,233,O
the,233,O
other,233,O
forms,233,O
remain,233,O
unknown,233,O
",",233,O
including,233,O
the,233,O
early-onset,233,O
",",233,O
recessive,233,O
form,233,O
with,233,O
Mallory,233,O
body-like,233,O
inclusions,233,O
(,233,O
MB-DRMs,233,O
),233,O
",",233,O
first,233,O
described,233,O
in,233,O
five,233,O
related,233,O
German,233,O
patients,233,B-OrganismTaxon
.,233,O
Recently,234,O
",",234,O
we,234,O
identified,234,O
the,234,O
selenoprotein,234,B-GeneOrGeneProduct
N,234,I-GeneOrGeneProduct
gene,234,O
(,234,O
SEPN1,234,B-GeneOrGeneProduct
),234,O
as,234,O
responsible,234,O
for,234,O
SEPN-related,234,B-DiseaseOrPhenotypicFeature
myopathy,234,I-DiseaseOrPhenotypicFeature
(,234,O
SEPN-RM,234,B-DiseaseOrPhenotypicFeature
),234,O
",",234,O
a,234,O
unique,234,O
early-onset,234,O
myopathy,234,B-DiseaseOrPhenotypicFeature
formerly,234,O
divided,234,O
in,234,O
two,234,O
different,234,O
nosological,234,O
categories,234,O
:,234,O
rigid,234,B-DiseaseOrPhenotypicFeature
spine,234,I-DiseaseOrPhenotypicFeature
muscular,234,I-DiseaseOrPhenotypicFeature
dystrophy,234,I-DiseaseOrPhenotypicFeature
and,234,O
the,234,O
severe,234,O
form,234,O
of,234,O
classical,234,O
multiminicore,234,B-DiseaseOrPhenotypicFeature
disease,234,I-DiseaseOrPhenotypicFeature
.,234,O
The,235,O
finding,235,O
of,235,O
Mallory,235,O
body-like,235,O
inclusions,235,O
in,235,O
two,235,O
cases,235,O
of,235,O
genetically,235,O
documented,235,O
SEPN-RM,235,B-DiseaseOrPhenotypicFeature
led,235,O
us,235,O
to,235,O
suspect,235,O
a,235,O
relationship,235,O
between,235,O
MB-DRM,235,O
and,235,O
SEPN1,235,B-GeneOrGeneProduct
.,235,O
In,236,O
the,236,O
original,236,O
MB-DRM,236,O
German,236,O
family,236,O
",",236,O
we,236,O
demonstrated,236,O
a,236,O
linkage,236,O
of,236,O
the,236,O
disease,236,O
to,236,O
the,236,O
SEPN1,236,B-GeneOrGeneProduct
locus,236,O
(,236,O
1p36,236,O
),236,O
",",236,O
and,236,O
subsequently,236,O
a,236,O
homozygous,236,O
SEPN1,236,B-GeneOrGeneProduct
deletion,236,O
(,236,O
del,236,B-SequenceVariant
92,236,I-SequenceVariant
nucleotide,236,I-SequenceVariant
-19/+73,236,I-SequenceVariant
),236,O
in,236,O
the,236,O
affected,236,O
patients,236,B-OrganismTaxon
.,236,O
A,237,O
comparative,237,O
reevaluation,237,O
showed,237,O
that,237,O
MB-DRM,237,O
and,237,O
SEPN-RM,237,B-DiseaseOrPhenotypicFeature
share,237,O
identical,237,O
clinical,237,O
features,237,O
.,237,O
Therefore,238,O
",",238,O
we,238,O
propose,238,O
that,238,O
MB-DRM,238,O
should,238,O
be,238,O
categorized,238,O
as,238,O
SEPN-RM,238,B-DiseaseOrPhenotypicFeature
.,238,O
These,239,O
findings,239,O
substantiate,239,O
the,239,O
molecular,239,O
heterogeneity,239,O
of,239,O
DRM,239,B-DiseaseOrPhenotypicFeature
",",239,O
expand,239,O
the,239,O
morphological,239,O
spectrum,239,O
of,239,O
SEPN-RM,239,B-DiseaseOrPhenotypicFeature
",",239,O
and,239,O
implicate,239,O
a,239,O
necessary,239,O
reassessment,239,O
of,239,O
the,239,O
nosological,239,O
boundaries,239,O
in,239,O
early-onset,239,O
myopathies,239,B-DiseaseOrPhenotypicFeature
.,239,O
POLG,240,B-GeneOrGeneProduct
mutations,240,O
associated,240,O
with,240,O
Alpers,240,B-DiseaseOrPhenotypicFeature
',240,I-DiseaseOrPhenotypicFeature
syndrome,240,I-DiseaseOrPhenotypicFeature
and,240,O
mitochondrial,240,B-DiseaseOrPhenotypicFeature
DNA,240,I-DiseaseOrPhenotypicFeature
depletion,240,I-DiseaseOrPhenotypicFeature
.,240,O
Alpers,241,B-DiseaseOrPhenotypicFeature
',241,I-DiseaseOrPhenotypicFeature
syndrome,241,I-DiseaseOrPhenotypicFeature
is,241,O
a,241,O
fatal,241,O
neurogenetic,241,B-DiseaseOrPhenotypicFeature
disorder,241,I-DiseaseOrPhenotypicFeature
first,241,O
described,241,O
more,241,O
than,241,O
70,241,O
years,241,O
ago,241,O
.,241,O
It,242,O
is,242,O
an,242,O
autosomal,242,O
recessive,242,O
",",242,O
developmental,242,O
mitochondrial,242,B-DiseaseOrPhenotypicFeature
DNA,242,I-DiseaseOrPhenotypicFeature
depletion,242,I-DiseaseOrPhenotypicFeature
disorder,242,O
characterized,242,O
by,242,O
deficiency,242,O
in,242,O
mitochondrial,242,O
DNA,242,B-GeneOrGeneProduct
polymerase,242,I-GeneOrGeneProduct
gamma,242,I-GeneOrGeneProduct
(,242,O
POLG,242,B-GeneOrGeneProduct
),242,O
catalytic,242,O
activity,242,O
",",242,O
refractory,242,O
seizures,242,B-DiseaseOrPhenotypicFeature
",",242,O
neurodegeneration,242,B-DiseaseOrPhenotypicFeature
",",242,O
and,242,O
liver,242,B-DiseaseOrPhenotypicFeature
disease,242,I-DiseaseOrPhenotypicFeature
.,242,O
In,243,O
two,243,O
unrelated,243,O
pedigrees,243,O
of,243,O
Alpers,243,B-DiseaseOrPhenotypicFeature
',243,I-DiseaseOrPhenotypicFeature
syndrome,243,I-DiseaseOrPhenotypicFeature
",",243,O
each,243,O
affected,243,O
child,243,O
was,243,O
found,243,O
to,243,O
carry,243,O
a,243,O
homozygous,243,O
mutation,243,O
in,243,O
exon,243,O
17,243,O
of,243,O
the,243,O
POLG,243,B-GeneOrGeneProduct
locus,243,O
that,243,O
led,243,O
to,243,O
a,243,O
Glu873Stop,243,B-SequenceVariant
mutation,243,O
just,243,O
upstream,243,O
of,243,O
the,243,O
polymerase,243,O
domain,243,O
of,243,O
the,243,O
protein,243,O
.,243,O
In,244,O
addition,244,O
",",244,O
each,244,O
affected,244,O
child,244,O
was,244,O
heterozygous,244,O
for,244,O
the,244,O
G1681A,244,B-SequenceVariant
mutation,244,O
in,244,O
exon,244,O
7,244,O
that,244,O
led,244,O
to,244,O
an,244,O
Ala467Thr,244,B-SequenceVariant
substitution,244,O
in,244,O
POLG,244,B-GeneOrGeneProduct
",",244,O
within,244,O
the,244,O
linker,244,O
region,244,O
of,244,O
the,244,O
protein,244,O
.,244,O
Differential,245,O
modulation,245,O
by,245,O
estrogen,245,B-ChemicalEntity
of,245,O
alpha2-adrenergic,245,B-GeneOrGeneProduct
and,245,I-GeneOrGeneProduct
I1-imidazoline,245,I-GeneOrGeneProduct
receptor-mediated,245,O
hypotension,245,B-DiseaseOrPhenotypicFeature
in,245,O
female,245,O
rats,245,B-OrganismTaxon
.,245,O
We,246,O
have,246,O
recently,246,O
shown,246,O
that,246,O
estrogen,246,B-ChemicalEntity
negatively,246,O
modulates,246,O
the,246,O
hypotensive,246,B-DiseaseOrPhenotypicFeature
effect,246,O
of,246,O
clonidine,246,B-ChemicalEntity
(,246,O
mixed,246,O
alpha2-/I1-receptor,246,B-GeneOrGeneProduct
agonist,246,O
),246,O
in,246,O
female,246,O
rats,246,B-OrganismTaxon
and,246,O
implicates,246,O
the,246,O
cardiovascular,246,O
autonomic,246,O
control,246,O
in,246,O
this,246,O
interaction,246,O
.,246,O
The,247,O
present,247,O
study,247,O
investigated,247,O
whether,247,O
this,247,O
effect,247,O
of,247,O
estrogen,247,B-ChemicalEntity
involves,247,O
interaction,247,O
with,247,O
alpha2-,247,B-GeneOrGeneProduct
and/or,247,I-GeneOrGeneProduct
I1-receptors,247,I-GeneOrGeneProduct
.,247,O
Changes,248,O
evoked,248,O
by,248,O
a,248,O
single,248,O
intraperitoneal,248,O
injection,248,O
of,248,O
rilmenidine,248,B-ChemicalEntity
(,248,O
600,248,O
microg/kg,248,O
),248,O
or,248,O
alpha-methyldopa,248,B-ChemicalEntity
(,248,O
100,248,O
mg/kg,248,O
),248,O
",",248,O
selective,248,O
I1-,248,B-GeneOrGeneProduct
and,248,I-GeneOrGeneProduct
alpha2-receptor,248,I-GeneOrGeneProduct
agonists,248,O
",",248,O
respectively,248,O
",",248,O
in,248,O
blood,248,O
pressure,248,O
",",248,O
hemodynamic,248,O
variability,248,O
",",248,O
and,248,O
locomotor,248,O
activity,248,O
were,248,O
assessed,248,O
in,248,O
radiotelemetered,248,O
sham-operated,248,O
and,248,O
ovariectomized,248,O
(,248,O
Ovx,248,O
),248,O
Sprague-Dawley,248,O
female,248,O
rats,248,B-OrganismTaxon
with,248,O
or,248,O
without,248,O
12-wk,248,O
estrogen,248,B-ChemicalEntity
replacement,248,O
.,248,O
Three,249,O
time,249,O
domain,249,O
indexes,249,O
of,249,O
hemodynamic,249,O
variability,249,O
were,249,O
employed,249,O
:,249,O
the,249,O
standard,249,O
deviation,249,O
of,249,O
mean,249,O
arterial,249,O
pressure,249,O
as,249,O
a,249,O
measure,249,O
of,249,O
blood,249,O
pressure,249,O
variability,249,O
and,249,O
the,249,O
standard,249,O
deviation,249,O
of,249,O
beat-to-beat,249,O
intervals,249,O
(,249,O
SDRR,249,O
),249,O
and,249,O
the,249,O
root,249,O
mean,249,O
square,249,O
of,249,O
successive,249,O
differences,249,O
in,249,O
R-wave-to-R-wave,249,O
intervals,249,O
as,249,O
measures,249,O
of,249,O
heart,249,O
rate,249,O
variability,249,O
.,249,O
In,250,O
sham-operated,250,O
rats,250,B-OrganismTaxon
",",250,O
rilmenidine,250,B-ChemicalEntity
or,250,O
alpha-methyldopa,250,B-ChemicalEntity
elicited,250,O
similar,250,O
hypotension,250,B-DiseaseOrPhenotypicFeature
that,250,O
lasted,250,O
at,250,O
least,250,O
5,250,O
h,250,O
and,250,O
was,250,O
associated,250,O
with,250,O
reductions,250,O
in,250,O
standard,250,O
deviation,250,O
of,250,O
mean,250,O
arterial,250,O
pressure,250,O
.,250,O
SDRR,251,O
was,251,O
reduced,251,O
only,251,O
by,251,O
alpha-methyldopa,251,B-ChemicalEntity
.,251,O
Ovx,252,O
significantly,252,O
enhanced,252,O
the,252,O
hypotensive,252,B-DiseaseOrPhenotypicFeature
response,252,O
to,252,O
alpha-methyldopa,252,B-ChemicalEntity
",",252,O
in,252,O
contrast,252,O
to,252,O
no,252,O
effect,252,O
on,252,O
rilmenidine,252,B-ChemicalEntity
hypotension,252,B-DiseaseOrPhenotypicFeature
.,252,O
The,253,O
enhanced,253,O
alpha-methyldopa,253,B-ChemicalEntity
hypotension,253,B-DiseaseOrPhenotypicFeature
in,253,O
Ovx,253,O
rats,253,B-OrganismTaxon
was,253,O
paralleled,253,O
with,253,O
further,253,O
reduction,253,O
in,253,O
SDRR,253,O
and,253,O
a,253,B-DiseaseOrPhenotypicFeature
reduced,253,I-DiseaseOrPhenotypicFeature
locomotor,253,I-DiseaseOrPhenotypicFeature
activity,253,I-DiseaseOrPhenotypicFeature
.,253,O
Estrogen,254,O
replacement,254,O
(,254,O
17beta-estradiol,254,B-ChemicalEntity
subcutaneous,254,O
pellet,254,O
",",254,O
14.2,254,O
microg/day,254,O
",",254,O
12,254,O
wk,254,O
),254,O
of,254,O
Ovx,254,O
rats,254,B-OrganismTaxon
restored,254,O
the,254,O
hemodynamic,254,O
and,254,O
locomotor,254,O
effects,254,O
of,254,O
alpha-methyldopa,254,B-ChemicalEntity
to,254,O
sham-operated,254,O
levels,254,O
.,254,O
These,255,O
findings,255,O
suggest,255,O
that,255,O
estrogen,255,B-ChemicalEntity
downregulates,255,O
alpha2-,255,B-GeneOrGeneProduct
but,255,I-GeneOrGeneProduct
not,255,I-GeneOrGeneProduct
I1-receptor-mediated,255,O
hypotension,255,B-DiseaseOrPhenotypicFeature
and,255,O
highlight,255,O
a,255,O
role,255,O
for,255,O
the,255,O
cardiac,255,O
autonomic,255,O
control,255,O
in,255,O
alpha-methyldopa-estrogen,255,B-ChemicalEntity
interaction,255,O
.,255,O
Altered,256,O
replication,256,O
timing,256,O
of,256,O
the,256,O
HIRA/Tuple1,256,B-GeneOrGeneProduct
locus,256,O
in,256,O
the,256,O
DiGeorge,256,B-DiseaseOrPhenotypicFeature
and,256,I-DiseaseOrPhenotypicFeature
Velocardiofacial,256,I-DiseaseOrPhenotypicFeature
syndromes,256,I-DiseaseOrPhenotypicFeature
.,256,O
DiGeorge,257,B-DiseaseOrPhenotypicFeature
and,257,I-DiseaseOrPhenotypicFeature
Velocardiofacial,257,I-DiseaseOrPhenotypicFeature
syndromes,257,I-DiseaseOrPhenotypicFeature
(,257,O
DGS/VCFS,257,B-DiseaseOrPhenotypicFeature
),257,O
are,257,O
endowed,257,O
by,257,O
a,257,O
similar,257,O
complex,257,O
phenotype,257,O
including,257,O
cardiovascular,257,B-DiseaseOrPhenotypicFeature
",",257,I-DiseaseOrPhenotypicFeature
craniofacial,257,I-DiseaseOrPhenotypicFeature
",",257,I-DiseaseOrPhenotypicFeature
and,257,I-DiseaseOrPhenotypicFeature
thymic,257,I-DiseaseOrPhenotypicFeature
malformations,257,I-DiseaseOrPhenotypicFeature
",",257,O
and,257,O
are,257,O
associated,257,O
with,257,O
heterozygous,257,O
deletions,257,O
of,257,O
22q11,257,O
chromosomal,257,O
band,257,O
.,257,O
The,258,O
Typically,258,O
Deleted,258,O
Region,258,O
in,258,O
the,258,O
22q11.21,258,O
subband,258,O
(,258,O
here,258,O
called,258,O
TDR22,258,O
),258,O
is,258,O
very,258,O
gene-dense,258,O
",",258,O
and,258,O
the,258,O
extent,258,O
of,258,O
the,258,O
deletion,258,O
has,258,O
been,258,O
defined,258,O
precisely,258,O
in,258,O
several,258,O
studies,258,O
.,258,O
However,259,O
",",259,O
to,259,O
date,259,O
there,259,O
is,259,O
no,259,O
evidence,259,O
for,259,O
a,259,O
mechanism,259,O
of,259,O
haploinsufficiency,259,O
that,259,O
can,259,O
fully,259,O
explain,259,O
the,259,O
DGS/VCFS,259,B-DiseaseOrPhenotypicFeature
phenotype,259,O
.,259,O
In,260,O
this,260,O
study,260,O
",",260,O
we,260,O
show,260,O
that,260,O
the,260,O
candidate,260,O
gene,260,O
HIRA/Tuple1,260,B-GeneOrGeneProduct
mapping,260,O
on,260,O
the,260,O
non-deleted,260,O
TDR22,260,O
",",260,O
in,260,O
DGS/VCFS,260,B-DiseaseOrPhenotypicFeature
subjects,260,O
presents,260,O
a,260,O
delayed,260,O
replication,260,O
timing,260,O
.,260,O
Moreover,261,O
",",261,O
we,261,O
observed,261,O
an,261,O
increase,261,O
in,261,O
the,261,O
cell,261,O
ratio,261,O
showing,261,O
the,261,O
HIRA/Tuple1,261,B-GeneOrGeneProduct
locus,261,O
localised,261,O
toward,261,O
the,261,O
nuclear,261,O
periphery,261,O
.,261,O
It,262,O
is,262,O
known,262,O
that,262,O
replication,262,O
timing,262,O
and,262,O
nuclear,262,O
location,262,O
are,262,O
generally,262,O
correlated,262,O
to,262,O
the,262,O
transcription,262,O
activity,262,O
of,262,O
the,262,O
relative,262,O
DNA,262,O
region,262,O
.,262,O
We,263,O
propose,263,O
that,263,O
the,263,O
alteration,263,O
in,263,O
the,263,O
replication/nuclear,263,O
location,263,O
pattern,263,O
of,263,O
the,263,O
non-deleted,263,O
TDR22,263,O
indicates,263,O
an,263,O
altered,263,O
gene,263,O
regulation,263,O
hence,263,O
an,263,O
altered,263,O
transcritpion,263,O
in,263,O
DGS/VCFS,263,B-DiseaseOrPhenotypicFeature
.,263,O
Ca2+,264,B-ChemicalEntity
dependence,264,O
of,264,O
the,264,O
Ca2+-selective,264,B-ChemicalEntity
TRPV6,264,B-GeneOrGeneProduct
channel,264,O
.,264,O
Microfluorimetry,265,O
and,265,O
patch-clamp,265,O
experiments,265,O
were,265,O
performed,265,O
on,265,O
TRPV6-expressing,265,B-GeneOrGeneProduct
HEK,265,B-CellLine
cells,265,O
to,265,O
determine,265,O
whether,265,O
this,265,O
Ca,265,B-ChemicalEntity
(,265,I-ChemicalEntity
2+,265,I-ChemicalEntity
),265,I-ChemicalEntity
-sensing,265,O
Ca,265,B-ChemicalEntity
(,265,I-ChemicalEntity
2+,265,I-ChemicalEntity
),265,I-ChemicalEntity
channel,265,O
is,265,O
constitutively,265,O
active,265,O
.,265,O
Intact,266,O
cells,266,O
loaded,266,O
with,266,O
fura-2,266,B-ChemicalEntity
had,266,O
an,266,O
elevated,266,O
intracellular,266,O
free,266,O
Ca,266,B-ChemicalEntity
(,266,I-ChemicalEntity
2+,266,I-ChemicalEntity
),266,I-ChemicalEntity
concentration,266,O
(,266,O
(,266,O
i,266,O
),266,O
),266,O
",",266,O
which,266,O
decreased,266,O
to,266,O
the,266,O
same,266,O
level,266,O
such,266,O
as,266,O
in,266,O
non-transfected,266,O
cells,266,O
if,266,O
external,266,O
Ca,266,B-ChemicalEntity
(,266,I-ChemicalEntity
2+,266,I-ChemicalEntity
),266,I-ChemicalEntity
was,266,O
chelated,266,O
by,266,O
EGTA,266,B-ChemicalEntity
.,266,O
Whole,267,O
cell,267,O
recordings,267,O
from,267,O
non-transfected,267,O
HEK,267,B-CellLine
cells,267,O
and,267,O
cells,267,O
expressing,267,O
human,267,B-OrganismTaxon
TRPV6,267,B-GeneOrGeneProduct
revealed,267,O
the,267,O
presence,267,O
of,267,O
a,267,O
basal,267,O
inward,267,O
current,267,O
in,267,O
both,267,O
types,267,O
of,267,O
cells,267,O
when,267,O
the,267,O
internal,267,O
solution,267,O
contained,267,O
0.1,267,O
mm,267,O
EGTA,267,B-ChemicalEntity
and,267,O
100,267,O
nm,267,O
(,267,O
i,267,O
),267,O
or,267,O
if,267,O
the,267,O
cytosolic,267,O
Ca,267,B-ChemicalEntity
(,267,I-ChemicalEntity
2+,267,I-ChemicalEntity
),267,I-ChemicalEntity
buffering,267,O
remained,267,O
undisturbed,267,O
in,267,O
perforated,267,O
patch-clamp,267,O
experiments,267,O
.,267,O
If,268,O
recombinantly,268,O
expressed,268,O
TRPV6,268,B-GeneOrGeneProduct
forms,268,O
open,268,O
channels,268,O
",",268,O
one,268,O
would,268,O
expect,268,O
Ca,268,B-ChemicalEntity
(,268,I-ChemicalEntity
2+,268,I-ChemicalEntity
),268,I-ChemicalEntity
-induced,268,O
current,268,O
inhibition,268,O
",",268,O
because,268,O
TRPV6,268,B-GeneOrGeneProduct
is,268,O
negatively,268,O
regulated,268,O
by,268,O
internal,268,O
Ca,268,B-ChemicalEntity
(,268,I-ChemicalEntity
2+,268,I-ChemicalEntity
),268,I-ChemicalEntity
.,268,O
However,269,O
",",269,O
dialyzing,269,O
solutions,269,O
with,269,O
high,269,O
such,269,O
as,269,O
1,269,O
microm,269,O
into,269,O
TRPV6-expressing,269,B-GeneOrGeneProduct
cells,269,O
did,269,O
not,269,O
block,269,O
the,269,O
basal,269,O
inward,269,O
current,269,O
",",269,O
which,269,O
was,269,O
not,269,O
different,269,O
from,269,O
the,269,O
recordings,269,O
from,269,O
non-transfected,269,O
cells,269,O
.,269,O
In,270,O
contrast,270,O
",",270,O
dialyzing,270,O
0.5,270,O
mm,270,O
EGTA,270,B-ChemicalEntity
into,270,O
TRPV6-expressing,270,B-GeneOrGeneProduct
cells,270,O
readily,270,O
activated,270,O
Ca,270,B-ChemicalEntity
(,270,I-ChemicalEntity
2+,270,I-ChemicalEntity
),270,I-ChemicalEntity
inward,270,O
currents,270,O
",",270,O
which,270,O
were,270,O
undetectable,270,O
in,270,O
non-transfected,270,O
cells,270,O
.,270,O
Interestingly,271,O
",",271,O
monovalent,271,O
cations,271,O
permeated,271,O
the,271,O
TRPV6,271,B-GeneOrGeneProduct
channels,271,O
under,271,O
conditions,271,O
where,271,O
no,271,O
Ca,271,B-ChemicalEntity
(,271,I-ChemicalEntity
2+,271,I-ChemicalEntity
),271,I-ChemicalEntity
permeation,271,O
was,271,O
detectable,271,O
",",271,O
indicating,271,O
that,271,O
divalent,271,O
cations,271,O
block,271,O
TRPV6,271,B-GeneOrGeneProduct
channels,271,O
from,271,O
the,271,O
extracellular,271,O
side,271,O
.,271,O
Like,272,O
human,272,B-OrganismTaxon
TRPV6,272,B-GeneOrGeneProduct
",",272,O
the,272,O
truncated,272,O
human,272,B-OrganismTaxon
TRPV6,272,B-GeneOrGeneProduct
(,272,O
Delta695-725,272,B-SequenceVariant
),272,O
",",272,O
which,272,O
lacks,272,O
the,272,O
C-terminal,272,O
domain,272,O
required,272,O
for,272,O
Ca,272,B-ChemicalEntity
(,272,I-ChemicalEntity
2+,272,I-ChemicalEntity
),272,I-ChemicalEntity
-calmodulin,272,O
binding,272,O
",",272,O
does,272,O
not,272,O
form,272,O
constitutive,272,O
active,272,O
channels,272,O
",",272,O
whereas,272,O
the,272,O
human,272,B-OrganismTaxon
TRPV6,272,B-GeneOrGeneProduct
(,272,O
D542A,272,B-SequenceVariant
),272,O
",",272,O
carrying,272,O
a,272,O
point,272,O
mutation,272,O
in,272,O
the,272,O
presumed,272,O
pore,272,O
region,272,O
",",272,O
does,272,O
not,272,O
function,272,O
as,272,O
a,272,O
channel,272,O
.,272,O
In,273,O
summary,273,O
",",273,O
no,273,O
constitutive,273,O
open,273,O
TRPV6,273,B-GeneOrGeneProduct
channels,273,O
were,273,O
detected,273,O
in,273,O
patch-clamp,273,O
experiments,273,O
from,273,O
transfected,273,O
HEK,273,B-CellLine
cells,273,O
.,273,O
However,274,O
",",274,O
channel,274,O
activity,274,O
is,274,O
highly,274,O
regulated,274,O
by,274,O
intracellular,274,O
and,274,O
extracellular,274,O
divalent,274,O
cations,274,O
.,274,O
Severe,275,O
reversible,275,O
left,275,B-DiseaseOrPhenotypicFeature
ventricular,275,I-DiseaseOrPhenotypicFeature
systolic,275,I-DiseaseOrPhenotypicFeature
and,275,I-DiseaseOrPhenotypicFeature
diastolic,275,I-DiseaseOrPhenotypicFeature
dysfunction,275,I-DiseaseOrPhenotypicFeature
due,275,O
to,275,O
accidental,275,O
iatrogenic,275,O
epinephrine,275,B-ChemicalEntity
overdose,275,O
.,275,O
Catecholamine-induced,276,B-ChemicalEntity
cardiomyopathy,276,B-DiseaseOrPhenotypicFeature
due,276,O
to,276,O
chronic,276,O
excess,276,O
of,276,O
endogenous,276,O
catecholamines,276,B-ChemicalEntity
has,276,O
been,276,O
recognized,276,O
for,276,O
decades,276,O
as,276,O
a,276,O
clinical,276,O
phenomenon,276,O
.,276,O
In,277,O
contrast,277,O
",",277,O
reports,277,O
of,277,O
myocardial,277,B-DiseaseOrPhenotypicFeature
dysfunction,277,I-DiseaseOrPhenotypicFeature
due,277,O
to,277,O
acute,277,O
iatrogenic,277,O
overdose,277,O
are,277,O
rare,277,O
.,277,O
A,278,O
35-year-old,278,O
woman,278,B-OrganismTaxon
whose,278,O
cervix,278,O
uteri,278,O
was,278,O
inadvertently,278,O
injected,278,O
with,278,O
8,278,O
mg,278,O
of,278,O
epinephrine,278,B-ChemicalEntity
developed,278,O
myocardial,278,B-DiseaseOrPhenotypicFeature
stunning,278,I-DiseaseOrPhenotypicFeature
that,278,O
was,278,O
characterized,278,O
by,278,O
severe,278,O
hemodynamic,278,O
compromise,278,O
",",278,O
profound,278,O
",",278,O
albeit,278,O
transient,278,O
",",278,O
left,278,B-DiseaseOrPhenotypicFeature
ventricular,278,I-DiseaseOrPhenotypicFeature
systolic,278,I-DiseaseOrPhenotypicFeature
and,278,I-DiseaseOrPhenotypicFeature
diastolic,278,I-DiseaseOrPhenotypicFeature
dysfunction,278,I-DiseaseOrPhenotypicFeature
",",278,O
and,278,O
only,278,O
modestly,278,O
elevated,278,O
biochemical,278,O
markers,278,O
of,278,O
myocardial,278,B-DiseaseOrPhenotypicFeature
necrosis,278,I-DiseaseOrPhenotypicFeature
.,278,O
Our,279,O
case,279,O
illustrates,279,O
the,279,O
serious,279,O
consequences,279,O
of,279,O
medical,279,O
errors,279,O
that,279,O
can,279,O
be,279,O
avoided,279,O
through,279,O
improved,279,O
medication,279,O
labeling,279,O
and,279,O
staff,279,O
supervision,279,O
.,279,O
Severe,280,O
form,280,O
of,280,O
thyroid,280,B-DiseaseOrPhenotypicFeature
hormone,280,I-DiseaseOrPhenotypicFeature
resistance,280,I-DiseaseOrPhenotypicFeature
in,280,O
a,280,O
patient,280,B-OrganismTaxon
with,280,O
homozygous/hemizygous,280,O
mutation,280,O
of,280,O
T3,280,B-GeneOrGeneProduct
receptor,280,I-GeneOrGeneProduct
gene,280,O
.,280,O
Resistance,281,B-DiseaseOrPhenotypicFeature
to,281,I-DiseaseOrPhenotypicFeature
thyroid,281,I-DiseaseOrPhenotypicFeature
hormone,281,I-DiseaseOrPhenotypicFeature
syndrome,281,I-DiseaseOrPhenotypicFeature
(,281,O
RTH,281,B-DiseaseOrPhenotypicFeature
),281,O
is,281,O
a,281,O
rare,281,O
disorder,281,O
",",281,O
usually,281,O
inherited,281,O
as,281,O
an,281,O
autosomal,281,O
dominant,281,O
trait,281,O
.,281,O
Patients,282,B-OrganismTaxon
with,282,O
RTH,282,B-DiseaseOrPhenotypicFeature
are,282,O
usually,282,O
euthyroid,282,O
but,282,O
can,282,O
occasionally,282,O
present,282,O
with,282,O
signs,282,O
and,282,O
symptoms,282,O
of,282,O
thyrotoxicosis,282,B-DiseaseOrPhenotypicFeature
or,282,O
rarely,282,O
with,282,O
hypothyroidism,282,B-DiseaseOrPhenotypicFeature
.,282,O
Affected,283,O
individuals,283,O
are,283,O
usually,283,O
heterozygous,283,O
for,283,O
mutations,283,O
in,283,O
the,283,O
thyroid,283,B-GeneOrGeneProduct
hormone,283,I-GeneOrGeneProduct
receptor,283,I-GeneOrGeneProduct
beta,283,I-GeneOrGeneProduct
gene,283,O
(,283,O
TR-beta,283,B-GeneOrGeneProduct
),283,O
.,283,O
We,284,O
present,284,O
a,284,O
patient,284,B-OrganismTaxon
with,284,O
RTH,284,B-DiseaseOrPhenotypicFeature
found,284,O
to,284,O
be,284,O
homo-/hemizygous,284,O
for,284,O
a,284,O
mutation,284,O
in,284,O
the,284,O
TR-beta,284,B-GeneOrGeneProduct
gene,284,O
.,284,O
The,285,O
single,285,O
nucleotide,285,O
substitution,285,O
I280S,285,B-SequenceVariant
(,285,O
1123T,285,B-SequenceVariant
--,285,I-SequenceVariant
>,285,I-SequenceVariant
G,285,I-SequenceVariant
),285,O
was,285,O
present,285,O
either,285,O
on,285,O
both,285,O
alleles,285,O
or,285,O
in,285,O
a,285,O
hemizygous,285,O
form,285,O
with,285,O
complete,285,O
deletion,285,O
of,285,O
the,285,O
second,285,O
allele,285,O
.,285,O
The,286,O
I280S,286,B-SequenceVariant
mutation,286,O
was,286,O
recently,286,O
reported,286,O
in,286,O
a,286,O
heterozygous,286,O
patient,286,B-OrganismTaxon
.,286,O
The,287,O
severe,287,O
phenotype,287,O
with,287,O
seriously,287,O
impaired,287,B-DiseaseOrPhenotypicFeature
intellectual,287,I-DiseaseOrPhenotypicFeature
development,287,I-DiseaseOrPhenotypicFeature
",",287,O
hyperkinetic,287,B-DiseaseOrPhenotypicFeature
behaviour,287,O
",",287,O
tachycardia,287,B-DiseaseOrPhenotypicFeature
",",287,O
hearing,287,B-DiseaseOrPhenotypicFeature
and,287,I-DiseaseOrPhenotypicFeature
visual,287,I-DiseaseOrPhenotypicFeature
impairment,287,I-DiseaseOrPhenotypicFeature
is,287,O
probably,287,O
due,287,O
to,287,O
the,287,O
dominant,287,O
negative,287,O
effect,287,O
of,287,O
the,287,O
I280S,287,B-SequenceVariant
mutant,287,O
protein,287,O
and,287,O
the,287,O
absence,287,O
of,287,O
any,287,O
functional,287,O
TR-beta,287,B-GeneOrGeneProduct
.,287,O
Evaluation,288,O
of,288,O
the,288,O
Lys198Asn,288,B-SequenceVariant
and,288,O
-134delA,288,B-SequenceVariant
genetic,288,O
polymorphisms,288,O
of,288,O
the,288,O
endothelin-1,288,B-GeneOrGeneProduct
gene,288,O
.,288,O
Endothelin-1,289,B-GeneOrGeneProduct
(,289,O
ET-1,289,B-GeneOrGeneProduct
),289,O
is,289,O
a,289,O
potent,289,O
vasoconstrictor,289,O
and,289,O
shows,289,O
various,289,O
pharmacological,289,O
responses,289,O
.,289,O
Two,290,O
single,290,O
nucleotide,290,O
polymorphisms,290,O
in,290,O
the,290,O
ET-1,290,B-GeneOrGeneProduct
gene,290,O
(,290,O
EDN1,290,B-GeneOrGeneProduct
),290,O
have,290,O
been,290,O
reported,290,O
to,290,O
be,290,O
associated,290,O
with,290,O
blood,290,O
pressure,290,O
(,290,O
BP,290,O
),290,O
.,290,O
One,291,O
is,291,O
the,291,O
Lys198Asn,291,B-SequenceVariant
polymorphism,291,O
",",291,O
which,291,O
showed,291,O
a,291,O
positive,291,O
association,291,O
with,291,O
BP,291,O
in,291,O
overweight,291,B-DiseaseOrPhenotypicFeature
people,291,O
.,291,O
Another,292,O
is,292,O
the,292,O
3A/4A,292,O
polymorphism,292,O
(,292,O
-134delA,292,B-SequenceVariant
),292,O
located,292,O
in,292,O
the,292,O
5'-untranslated,292,O
region,292,O
.,292,O
In,293,O
this,293,O
study,293,O
",",293,O
we,293,O
investigated,293,O
the,293,O
expression,293,O
of,293,O
the,293,O
Lys198Asn,293,B-SequenceVariant
polymorphism,293,O
in,293,O
ET-1,293,B-GeneOrGeneProduct
in,293,O
vitro,293,O
",",293,O
as,293,O
well,293,O
as,293,O
the,293,O
association,293,O
between,293,O
either,293,O
of,293,O
the,293,O
two,293,O
polymorphisms,293,O
and,293,O
the,293,O
plasma,293,O
ET-1,293,B-GeneOrGeneProduct
level,293,O
.,293,O
We,294,O
expressed,294,O
both,294,O
the,294,O
major,294,O
(,294,O
Lys-type,294,O
),294,O
and,294,O
minor,294,O
type,294,O
(,294,O
Asn-type,294,O
),294,O
preproET-1,294,O
in,294,O
three,294,O
different,294,O
cell,294,O
lines,294,O
",",294,O
and,294,O
measured,294,O
the,294,O
levels,294,O
of,294,O
ET-1,294,B-GeneOrGeneProduct
and,294,O
big,294,O
ET-1,294,B-GeneOrGeneProduct
in,294,O
the,294,O
culture,294,O
supernatant,294,O
.,294,O
There,295,O
was,295,O
no,295,O
significant,295,O
difference,295,O
in,295,O
the,295,O
levels,295,O
of,295,O
ET-1,295,B-GeneOrGeneProduct
or,295,O
big,295,O
ET-1,295,B-GeneOrGeneProduct
between,295,O
the,295,O
Asn-type,295,B-SequenceVariant
and,295,I-SequenceVariant
Lys-type,295,I-SequenceVariant
transfectant,295,I-SequenceVariant
.,295,O
In,296,O
the,296,O
association,296,O
study,296,O
",",296,O
the,296,O
plasma,296,O
levels,296,O
of,296,O
ET-1,296,B-GeneOrGeneProduct
in,296,O
54,296,O
hypertensive,296,B-DiseaseOrPhenotypicFeature
patients,296,B-OrganismTaxon
having,296,O
an,296,O
amino,296,O
acid,296,O
substitution,296,O
from,296,O
Lys,296,B-SequenceVariant
to,296,I-SequenceVariant
Asn,296,I-SequenceVariant
at,296,I-SequenceVariant
position,296,I-SequenceVariant
198,296,I-SequenceVariant
were,296,O
not,296,O
different,296,O
from,296,O
those,296,O
of,296,O
hypertensives,296,B-DiseaseOrPhenotypicFeature
without,296,O
the,296,O
substitution,296,O
.,296,O
However,297,O
",",297,O
we,297,O
found,297,O
a,297,O
significant,297,O
difference,297,O
in,297,O
ET-1,297,B-GeneOrGeneProduct
levels,297,O
between,297,O
individuals,297,O
with,297,O
the,297,O
3A/3A,297,O
and,297,O
3A/4A,297,O
genotypes,297,O
.,297,O
Our,298,O
transient,298,O
expression,298,O
study,298,O
indicates,298,O
that,298,O
the,298,O
Lys198Asn,298,B-SequenceVariant
polymorphism,298,O
may,298,O
not,298,O
directly,298,O
affect,298,O
ET-1,298,B-GeneOrGeneProduct
and,298,O
big,298,O
ET-1,298,B-GeneOrGeneProduct
production,298,O
.,298,O
Another,299,O
variant,299,O
in,299,O
the,299,O
EDN1,299,B-GeneOrGeneProduct
gene,299,O
in,299,O
linkage,299,O
disequilibrium,299,O
with,299,O
the,299,O
Lys198Asn,299,B-SequenceVariant
polymorphism,299,O
may,299,O
be,299,O
responsible,299,O
for,299,O
the,299,O
association,299,O
with,299,O
BP,299,O
",",299,O
or,299,O
the,299,O
interaction,299,O
between,299,O
the,299,O
EDN1,299,B-GeneOrGeneProduct
Lys198Asn,299,B-SequenceVariant
polymorphism,299,O
and,299,O
other,299,O
factors,299,O
such,299,O
as,299,O
obesity,299,B-DiseaseOrPhenotypicFeature
may,299,O
be,299,O
involved,299,O
in,299,O
the,299,O
mechanisms,299,O
elevating,299,O
BP,299,O
in,299,O
vivo,299,O
.,299,O
Lack,300,O
of,300,O
major,300,O
involvement,300,O
of,300,O
human,300,B-OrganismTaxon
uroplakin,300,B-GeneOrGeneProduct
genes,300,O
in,300,O
vesicoureteral,300,B-DiseaseOrPhenotypicFeature
reflux,300,I-DiseaseOrPhenotypicFeature
:,300,O
implications,300,O
for,300,O
disease,300,O
heterogeneity,300,O
.,300,O
BACKGROUND,301,O
:,301,O
Primary,301,O
vesicoureteral,301,B-DiseaseOrPhenotypicFeature
reflux,301,I-DiseaseOrPhenotypicFeature
(,301,O
VUR,301,B-DiseaseOrPhenotypicFeature
),301,O
is,301,O
a,301,O
hereditary,301,B-DiseaseOrPhenotypicFeature
disorder,301,I-DiseaseOrPhenotypicFeature
characterized,301,O
by,301,O
the,301,O
retrograde,301,O
flow,301,O
of,301,O
urine,301,O
into,301,O
the,301,O
ureters,301,O
and,301,O
kidneys,301,O
.,301,O
It,302,O
affects,302,O
about,302,O
1,302,O
%,302,O
of,302,O
the,302,O
young,302,O
children,302,O
and,302,O
is,302,O
thus,302,O
one,302,O
of,302,O
the,302,O
most,302,O
common,302,O
hereditary,302,B-DiseaseOrPhenotypicFeature
diseases,302,I-DiseaseOrPhenotypicFeature
.,302,O
Its,303,O
associated,303,O
nephropathy,303,B-DiseaseOrPhenotypicFeature
is,303,O
an,303,O
important,303,O
cause,303,O
of,303,O
end-stage,303,B-DiseaseOrPhenotypicFeature
renal,303,I-DiseaseOrPhenotypicFeature
failure,303,I-DiseaseOrPhenotypicFeature
in,303,O
children,303,O
and,303,O
adults,303,O
.,303,O
Recent,304,O
studies,304,O
indicate,304,O
that,304,O
genetic,304,O
ablation,304,O
of,304,O
mouse,304,B-OrganismTaxon
uroplakin,304,B-GeneOrGeneProduct
(,304,I-GeneOrGeneProduct
UP,304,I-GeneOrGeneProduct
),304,I-GeneOrGeneProduct
III,304,I-GeneOrGeneProduct
gene,304,O
",",304,O
which,304,O
encodes,304,O
a,304,O
47,304,O
kD,304,O
urothelial-specific,304,O
integral,304,O
membrane,304,O
protein,304,O
forming,304,O
urothelial,304,O
plaques,304,O
",",304,O
causes,304,O
VUR,304,B-DiseaseOrPhenotypicFeature
and,304,O
hydronephrosis,304,B-DiseaseOrPhenotypicFeature
.,304,O
METHODS,305,O
:,305,O
To,305,O
begin,305,O
to,305,O
determine,305,O
whether,305,O
mutations,305,O
in,305,O
UP,305,B-GeneOrGeneProduct
genes,305,O
might,305,O
play,305,O
a,305,O
role,305,O
in,305,O
human,305,B-OrganismTaxon
VUR,305,B-DiseaseOrPhenotypicFeature
",",305,O
we,305,O
genotyped,305,O
all,305,O
four,305,O
UP,305,B-GeneOrGeneProduct
genes,305,O
in,305,O
76,305,O
patients,305,B-OrganismTaxon
with,305,O
radiologically,305,O
proven,305,O
primary,305,O
VUR,305,B-DiseaseOrPhenotypicFeature
by,305,O
polymerase,305,O
chain,305,O
reaction,305,O
(,305,O
PCR,305,O
),305,O
amplification,305,O
and,305,O
sequencing,305,O
of,305,O
all,305,O
their,305,O
exons,305,O
plus,305,O
50,305,O
to,305,O
150,305,O
bp,305,O
of,305,O
flanking,305,O
intronic,305,O
sequences,305,O
.,305,O
RESULTS,306,O
:,306,O
Eighteen,306,O
single,306,O
nucleotide,306,O
polymorphisms,306,O
(,306,O
SNPs,306,O
),306,O
were,306,O
identified,306,O
",",306,O
seven,306,O
of,306,O
which,306,O
were,306,O
missense,306,O
",",306,O
with,306,O
no,306,O
truncation,306,O
or,306,O
frame,306,O
shift,306,O
mutations,306,O
.,306,O
Since,307,O
healthy,307,O
relatives,307,O
of,307,O
the,307,O
VUR,307,B-DiseaseOrPhenotypicFeature
probands,307,O
are,307,O
not,307,O
reliable,307,O
negative,307,O
controls,307,O
for,307,O
VUR,307,B-DiseaseOrPhenotypicFeature
",",307,O
we,307,O
used,307,O
a,307,O
population,307,O
of,307,O
90,307,O
race-matched,307,O
",",307,O
healthy,307,O
individuals,307,O
",",307,O
unrelated,307,O
to,307,O
the,307,O
VUR,307,B-DiseaseOrPhenotypicFeature
patients,307,B-OrganismTaxon
",",307,O
as,307,O
controls,307,O
to,307,O
perform,307,O
an,307,O
association,307,O
study,307,O
.,307,O
Most,308,O
of,308,O
the,308,O
SNPs,308,O
were,308,O
not,308,O
found,308,O
to,308,O
be,308,O
significantly,308,O
associated,308,O
with,308,O
VUR,308,B-DiseaseOrPhenotypicFeature
.,308,O
However,309,O
",",309,O
SNP1,309,O
of,309,O
UP,309,B-GeneOrGeneProduct
Ia,309,I-GeneOrGeneProduct
gene,309,O
affecting,309,O
a,309,O
C,309,B-SequenceVariant
to,309,I-SequenceVariant
T,309,I-SequenceVariant
conversion,309,O
and,309,O
an,309,O
Ala7Val,309,B-SequenceVariant
change,309,O
",",309,O
and,309,O
SNP7,309,O
of,309,O
UP,309,B-GeneOrGeneProduct
III,309,I-GeneOrGeneProduct
affecting,309,O
a,309,O
C,309,B-SequenceVariant
to,309,I-SequenceVariant
G,309,I-SequenceVariant
conversion,309,O
and,309,O
a,309,O
Pro154Ala,309,B-SequenceVariant
change,309,O
",",309,O
were,309,O
marginally,309,O
associated,309,O
with,309,O
VUR,309,B-DiseaseOrPhenotypicFeature
(,309,O
both,309,O
P=,309,O
0.08,309,O
),309,O
.,309,O
Studies,310,O
of,310,O
additional,310,O
cases,310,O
yielded,310,O
a,310,O
second,310,O
set,310,O
of,310,O
data,310,O
that,310,O
",",310,O
in,310,O
combination,310,O
with,310,O
the,310,O
first,310,O
set,310,O
",",310,O
confirmed,310,O
a,310,O
weak,310,O
association,310,O
of,310,O
UP,310,B-GeneOrGeneProduct
III,310,I-GeneOrGeneProduct
SNP7,310,O
in,310,O
VUR,310,B-DiseaseOrPhenotypicFeature
(,310,O
P=,310,O
0.036,310,O
adjusted,310,O
for,310,O
both,310,O
subsets,310,O
of,310,O
cases,310,O
vs.,310,O
controls,310,O
),310,O
.,310,O
CONCLUSION,311,O
:,311,O
Such,311,O
a,311,O
weak,311,O
association,311,O
and,311,O
the,311,O
lack,311,O
of,311,O
families,311,O
with,311,O
simple,311,O
dominant,311,O
Mendelian,311,O
inheritance,311,O
suggest,311,O
that,311,O
missense,311,O
changes,311,O
of,311,O
uroplakin,311,B-GeneOrGeneProduct
genes,311,O
can,311,O
not,311,O
play,311,O
a,311,O
dominant,311,O
role,311,O
in,311,O
causing,311,O
VUR,311,B-DiseaseOrPhenotypicFeature
in,311,O
humans,311,B-OrganismTaxon
",",311,O
although,311,O
they,311,O
may,311,O
be,311,O
weak,311,O
risk,311,O
factors,311,O
contributing,311,O
to,311,O
a,311,O
complex,311,O
polygenic,311,O
disease,311,O
.,311,O
The,312,O
fact,312,O
that,312,O
no,312,O
truncation,312,O
or,312,O
frame,312,O
shift,312,O
mutations,312,O
have,312,O
been,312,O
found,312,O
in,312,O
any,312,O
of,312,O
the,312,O
VUR,312,B-DiseaseOrPhenotypicFeature
patients,312,B-OrganismTaxon
",",312,O
coupled,312,O
with,312,O
our,312,O
recent,312,O
finding,312,O
that,312,O
some,312,O
breeding,312,O
pairs,312,O
of,312,O
UP,312,B-GeneOrGeneProduct
III,312,I-GeneOrGeneProduct
knockout,312,O
mice,312,B-OrganismTaxon
yield,312,O
litters,312,O
that,312,O
show,312,O
not,312,O
only,312,O
VUR,312,B-DiseaseOrPhenotypicFeature
",",312,O
but,312,O
also,312,O
severe,312,O
hydronephrosis,312,B-DiseaseOrPhenotypicFeature
and,312,O
neonatal,312,B-DiseaseOrPhenotypicFeature
death,312,I-DiseaseOrPhenotypicFeature
",",312,O
raises,312,O
the,312,O
possibility,312,O
that,312,O
major,312,O
uroplakin,312,B-GeneOrGeneProduct
mutations,312,O
could,312,O
be,312,O
embryonically,312,O
or,312,O
postnatally,312,O
lethal,312,O
in,312,O
humans,312,B-OrganismTaxon
.,312,O
Paraoxonase,313,B-GeneOrGeneProduct
1,313,I-GeneOrGeneProduct
polymorphisms,313,O
and,313,O
survival,313,O
.,313,O
The,314,O
antioxidant,314,O
enzyme,314,O
paraoxonase,314,B-GeneOrGeneProduct
1,314,I-GeneOrGeneProduct
(,314,O
PON1,314,B-GeneOrGeneProduct
),314,O
has,314,O
previously,314,O
been,314,O
suggested,314,O
to,314,O
confer,314,O
protection,314,O
against,314,O
coronary,314,B-DiseaseOrPhenotypicFeature
heart,314,I-DiseaseOrPhenotypicFeature
disease,314,I-DiseaseOrPhenotypicFeature
(,314,O
CHD,314,B-DiseaseOrPhenotypicFeature
),314,O
",",314,O
one,314,O
of,314,O
the,314,O
main,314,O
causes,314,O
of,314,O
death,314,B-DiseaseOrPhenotypicFeature
in,314,O
the,314,O
Western,314,O
world,314,O
.,314,O
Two,315,O
coding,315,O
polymorphisms,315,O
",",315,O
55M/L,315,B-SequenceVariant
and,315,O
192Q/R,315,B-SequenceVariant
",",315,O
and,315,O
a,315,O
promoter,315,O
variant,315,O
",",315,O
-107C/T,315,B-SequenceVariant
",",315,O
has,315,O
been,315,O
extensively,315,O
studied,315,O
with,315,O
respect,315,O
to,315,O
susceptibility,315,O
to,315,O
CHD,315,B-DiseaseOrPhenotypicFeature
.,315,O
In,316,O
this,316,O
study,316,O
",",316,O
we,316,O
have,316,O
investigated,316,O
the,316,O
impact,316,O
of,316,O
these,316,O
three,316,O
polymorphisms,316,O
on,316,O
mortality,316,O
using,316,O
a,316,O
sample,316,O
of,316,O
1932,316,O
Danish,316,O
individuals,316,O
aged,316,O
47-93,316,O
years,316,O
",",316,O
previously,316,O
used,316,O
in,316,O
gene-longevity,316,O
studies,316,O
.,316,O
A,317,O
cross-sectional,317,O
study,317,O
comparing,317,O
the,317,O
genotype,317,O
distribution,317,O
of,317,O
the,317,O
three,317,O
polymorphisms,317,O
separately,317,O
as,317,O
well,317,O
as,317,O
the,317,O
haplotype,317,O
distribution,317,O
in,317,O
different,317,O
age,317,O
groups,317,O
did,317,O
not,317,O
reveal,317,O
any,317,O
difference,317,O
.,317,O
However,318,O
",",318,O
a,318,O
longitudinal,318,O
follow-up,318,O
study,318,O
on,318,O
survival,318,O
in,318,O
the,318,O
same,318,O
sample,318,O
indicated,318,O
that,318,O
192RR,318,B-SequenceVariant
homozygotes,318,O
have,318,O
a,318,O
poorer,318,O
survival,318,O
compared,318,O
to,318,O
QQ,318,O
homozygotes,318,O
(,318,O
hazard,318,O
rate,318,O
:,318,O
1.38,318,O
",",318,O
P,318,O
=,318,O
0.04,318,O
),318,O
.,318,O
We,319,O
hereafter,319,O
used,319,O
an,319,O
independent,319,O
sample,319,O
of,319,O
541,319,O
Danish,319,O
individuals,319,O
from,319,O
the,319,O
oldest,319,O
cohort,319,O
and,319,O
confirmed,319,O
the,319,O
initial,319,O
findings,319,O
(,319,O
hazard,319,O
rate,319,O
:,319,O
1.38,319,O
",",319,O
P,319,O
=,319,O
0.09,319,O
),319,O
.,319,O
In,320,O
both,320,O
samples,320,O
",",320,O
the,320,O
effect,320,O
was,320,O
most,320,O
pronounced,320,O
in,320,O
women,320,B-OrganismTaxon
.,320,O
Using,321,O
self-reported,321,O
data,321,O
on,321,O
ischemic,321,B-DiseaseOrPhenotypicFeature
heart,321,I-DiseaseOrPhenotypicFeature
disease,321,I-DiseaseOrPhenotypicFeature
to,321,O
evaluate,321,O
the,321,O
impact,321,O
of,321,O
the,321,O
PON,321,B-GeneOrGeneProduct
192Q/R,321,B-SequenceVariant
polymorphism,321,O
on,321,O
susceptibility,321,O
to,321,O
CHD,321,B-DiseaseOrPhenotypicFeature
",",321,O
we,321,O
found,321,O
only,321,O
a,321,O
nonsignificant,321,O
trend,321,O
of,321,O
192RR,321,B-SequenceVariant
homozygosity,321,O
in,321,O
women,321,B-OrganismTaxon
being,321,O
a,321,O
risk,321,O
factor,321,O
.,321,O
Our,322,O
results,322,O
thus,322,O
indicates,322,O
that,322,O
PON1,322,B-GeneOrGeneProduct
192RR,322,B-SequenceVariant
homozygosity,322,O
is,322,O
associated,322,O
with,322,O
increased,322,O
mortality,322,O
in,322,O
women,322,B-OrganismTaxon
in,322,O
the,322,O
second,322,O
half,322,O
of,322,O
life,322,O
and,322,O
that,322,O
this,322,O
increased,322,O
mortality,322,O
is,322,O
possibly,322,O
related,322,O
to,322,O
CHD,322,B-DiseaseOrPhenotypicFeature
severity,322,O
and,322,O
survival,322,O
after,322,O
CHD,322,B-DiseaseOrPhenotypicFeature
rather,322,O
than,322,O
susceptibility,322,O
to,322,O
development,322,O
of,322,O
CHD,322,B-DiseaseOrPhenotypicFeature
.,322,O
Effects,323,O
of,323,O
the,323,O
cyclooxygenase-2,323,B-GeneOrGeneProduct
specific,323,O
inhibitor,323,O
valdecoxib,323,B-ChemicalEntity
versus,323,O
nonsteroidal,323,B-ChemicalEntity
antiinflammatory,323,I-ChemicalEntity
agents,323,I-ChemicalEntity
and,323,O
placebo,323,O
on,323,O
cardiovascular,323,O
thrombotic,323,B-DiseaseOrPhenotypicFeature
events,323,O
in,323,O
patients,323,B-OrganismTaxon
with,323,O
arthritis,323,B-DiseaseOrPhenotypicFeature
.,323,O
There,324,O
have,324,O
been,324,O
concerns,324,O
that,324,O
the,324,O
risk,324,O
of,324,O
cardiovascular,324,O
thrombotic,324,B-DiseaseOrPhenotypicFeature
events,324,O
may,324,O
be,324,O
higher,324,O
with,324,O
cyclooxygenase,324,B-GeneOrGeneProduct
(,324,I-GeneOrGeneProduct
COX,324,I-GeneOrGeneProduct
),324,I-GeneOrGeneProduct
-2-specific,324,O
inhibitors,324,O
than,324,O
nonselective,324,O
nonsteroidal,324,B-ChemicalEntity
antiinflammatory,324,I-ChemicalEntity
drugs,324,I-ChemicalEntity
(,324,O
NSAIDs,324,B-ChemicalEntity
),324,O
.,324,O
We,325,O
evaluated,325,O
cardiovascular,325,O
event,325,O
data,325,O
for,325,O
valdecoxib,325,B-ChemicalEntity
",",325,O
a,325,O
new,325,O
COX-2-specific,325,B-GeneOrGeneProduct
inhibitor,325,O
in,325,O
approximately,325,O
8000,325,O
patients,325,B-OrganismTaxon
with,325,O
osteoarthritis,325,B-DiseaseOrPhenotypicFeature
and,325,O
rheumatoid,325,B-DiseaseOrPhenotypicFeature
arthritis,325,I-DiseaseOrPhenotypicFeature
treated,325,O
with,325,O
this,325,O
agent,325,O
in,325,O
randomized,325,O
clinical,325,O
trials,325,O
.,325,O
The,326,O
incidence,326,O
of,326,O
cardiovascular,326,O
thrombotic,326,B-DiseaseOrPhenotypicFeature
events,326,O
(,326,O
cardiac,326,O
",",326,O
cerebrovascular,326,O
and,326,O
peripheral,326,O
vascular,326,O
",",326,O
or,326,O
arterial,326,O
thrombotic,326,B-DiseaseOrPhenotypicFeature
),326,O
was,326,O
determined,326,O
by,326,O
analyzing,326,O
pooled,326,O
valdecoxib,326,B-ChemicalEntity
(,326,O
10-80,326,O
mg,326,O
daily,326,O
),326,O
",",326,O
nonselective,326,O
NSAID,326,B-ChemicalEntity
(,326,O
diclofenac,326,B-ChemicalEntity
75,326,O
mg,326,O
bid,326,O
",",326,O
ibuprofen,326,B-ChemicalEntity
800,326,O
mg,326,O
tid,326,O
",",326,O
or,326,O
naproxen,326,B-ChemicalEntity
500,326,O
mg,326,O
bid,326,O
),326,O
and,326,O
placebo,326,O
data,326,O
from,326,O
10,326,O
randomized,326,O
osteoarthritis,326,B-DiseaseOrPhenotypicFeature
and,326,O
rheumatoid,326,B-DiseaseOrPhenotypicFeature
arthritis,326,I-DiseaseOrPhenotypicFeature
trials,326,O
that,326,O
were,326,O
6-52,326,O
weeks,326,O
in,326,O
duration,326,O
.,326,O
The,327,O
incidence,327,O
rates,327,O
of,327,O
events,327,O
were,327,O
determined,327,O
in,327,O
all,327,O
patients,327,B-OrganismTaxon
(,327,O
n,327,O
=,327,O
7934,327,O
),327,O
and,327,O
in,327,O
users,327,O
of,327,O
low-dose,327,O
(,327,O
<,327,O
or,327,O
=325,327,O
mg,327,O
daily,327,O
),327,O
aspirin,327,B-ChemicalEntity
(,327,O
n,327,O
=,327,O
1051,327,O
),327,O
and,327,O
nonusers,327,O
of,327,O
aspirin,327,B-ChemicalEntity
(,327,O
n,327,O
=,327,O
6883,327,O
),327,O
.,327,O
Crude,328,O
and,328,O
exposure-adjusted,328,O
incidences,328,O
of,328,O
thrombotic,328,B-DiseaseOrPhenotypicFeature
events,328,O
were,328,O
similar,328,O
for,328,O
valdecoxib,328,B-ChemicalEntity
",",328,O
NSAIDs,328,B-ChemicalEntity
",",328,O
and,328,O
placebo,328,O
.,328,O
The,329,O
risk,329,O
of,329,O
serious,329,O
thrombotic,329,B-DiseaseOrPhenotypicFeature
events,329,O
was,329,O
also,329,O
similar,329,O
for,329,O
each,329,O
valdecoxib,329,B-ChemicalEntity
dose,329,O
.,329,O
Thrombotic,330,B-DiseaseOrPhenotypicFeature
risk,330,O
was,330,O
consistently,330,O
higher,330,O
for,330,O
users,330,O
of,330,O
aspirin,330,B-ChemicalEntity
users,330,O
than,330,O
nonusers,330,O
of,330,O
aspirin,330,B-ChemicalEntity
(,330,O
placebo,330,O
",",330,O
1.4,330,O
%,330,O
vs.,330,O
0,330,O
%,330,O
;,330,O
valdecoxib,330,B-ChemicalEntity
",",330,O
1.7,330,O
%,330,O
vs.,330,O
0.2,330,O
%,330,O
;,330,O
NSAIDs,330,B-ChemicalEntity
",",330,O
1.9,330,O
%,330,O
vs.,330,O
0.5,330,O
%,330,O
),330,O
.,330,O
The,331,O
rates,331,O
of,331,O
events,331,O
in,331,O
users,331,O
of,331,O
aspirin,331,B-ChemicalEntity
were,331,O
similar,331,O
for,331,O
all,331,O
3,331,O
treatment,331,O
groups,331,O
and,331,O
across,331,O
valdecoxib,331,B-ChemicalEntity
doses,331,O
.,331,O
Short-,332,O
and,332,O
intermediate-term,332,O
treatment,332,O
with,332,O
therapeutic,332,O
(,332,O
10,332,O
or,332,O
20,332,O
mg,332,O
daily,332,O
),332,O
and,332,O
supratherapeutic,332,O
(,332,O
40,332,O
or,332,O
80,332,O
mg,332,O
daily,332,O
),332,O
valdecoxib,332,B-ChemicalEntity
doses,332,O
was,332,O
not,332,O
associated,332,O
with,332,O
an,332,O
increased,332,O
incidence,332,O
of,332,O
thrombotic,332,B-DiseaseOrPhenotypicFeature
events,332,O
relative,332,O
to,332,O
nonselective,332,O
NSAIDs,332,B-ChemicalEntity
or,332,O
placebo,332,O
in,332,O
osteoarthritis,332,B-DiseaseOrPhenotypicFeature
and,332,O
rheumatoid,332,B-DiseaseOrPhenotypicFeature
arthritis,332,I-DiseaseOrPhenotypicFeature
patients,332,B-OrganismTaxon
in,332,O
controlled,332,O
clinical,332,O
trials,332,O
.,332,O
The,333,O
effects,333,O
of,333,O
sevoflurane,333,B-ChemicalEntity
on,333,O
lidocaine-induced,333,B-ChemicalEntity
convulsions,333,B-DiseaseOrPhenotypicFeature
.,333,O
The,334,O
influence,334,O
of,334,O
sevoflurane,334,B-ChemicalEntity
on,334,O
lidocaine-induced,334,B-ChemicalEntity
convulsions,334,B-DiseaseOrPhenotypicFeature
was,334,O
studied,334,O
in,334,O
cats,334,B-OrganismTaxon
.,334,O
The,335,O
convulsive,335,B-DiseaseOrPhenotypicFeature
threshold,335,O
(,335,O
mean,335,O
+/-,335,O
SD,335,O
),335,O
was,335,O
41.4,335,O
+/-,335,O
6.5,335,O
mg.,335,O
l,335,O
(,335,O
-1,335,O
),335,O
with,335,O
lidocaine,335,B-ChemicalEntity
infusion,335,O
(,335,O
6,335,O
mg.kg,335,O
(,335,O
-1,335,O
),335,O
.min,335,O
(,335,O
-1,335,O
),335,O
),335,O
",",335,O
increasing,335,O
significantly,335,O
to,335,O
66.6,335,O
+/-,335,O
10.9,335,O
mg.,335,O
l,335,O
(,335,O
-1,335,O
),335,O
when,335,O
the,335,O
end-tidal,335,O
concentration,335,O
of,335,O
sevoflurane,335,B-ChemicalEntity
was,335,O
0.8,335,O
%,335,O
.,335,O
However,336,O
",",336,O
the,336,O
threshold,336,O
(,336,O
61.6,336,O
+/-,336,O
8.7,336,O
mg.,336,O
l,336,O
(,336,O
-1,336,O
),336,O
),336,O
during,336,O
1.6,336,O
%,336,O
sevoflurane,336,B-ChemicalEntity
was,336,O
not,336,O
significant,336,O
from,336,O
that,336,O
during,336,O
0.8,336,O
%,336,O
sevoflurane,336,B-ChemicalEntity
",",336,O
indicating,336,O
a,336,O
celling,336,O
effect,336,O
.,336,O
There,337,O
was,337,O
no,337,O
significant,337,O
difference,337,O
in,337,O
the,337,O
convulsive,337,B-DiseaseOrPhenotypicFeature
threshold,337,O
between,337,O
sevoflurane,337,B-ChemicalEntity
and,337,O
enflurane,337,B-ChemicalEntity
.,337,O
The,338,O
rise,338,O
in,338,O
blood,338,O
pressure,338,O
became,338,O
less,338,O
marked,338,O
when,338,O
higher,338,O
concentrations,338,O
of,338,O
sevoflurane,338,B-ChemicalEntity
or,338,O
enflurane,338,B-ChemicalEntity
were,338,O
administered,338,O
and,338,O
the,338,O
blood,338,O
pressure,338,O
at,338,O
convulsions,338,B-DiseaseOrPhenotypicFeature
decreased,338,O
significantly,338,O
in,338,O
1.6,338,O
%,338,O
sevoflurane,338,B-ChemicalEntity
",",338,O
and,338,O
in,338,O
0.8,338,O
%,338,O
and,338,O
1.6,338,O
%,338,O
enflurane,338,B-ChemicalEntity
.,338,O
However,339,O
",",339,O
there,339,O
was,339,O
no,339,O
significant,339,O
difference,339,O
in,339,O
the,339,O
lidocaine,339,B-ChemicalEntity
concentrations,339,O
measured,339,O
when,339,O
the,339,O
systolic,339,O
blood,339,O
pressure,339,O
became,339,O
70,339,O
mmHg,339,O
.,339,O
Apamin,340,B-ChemicalEntity
",",340,O
a,340,O
selective,340,O
blocker,340,O
of,340,O
calcium-dependent,340,B-ChemicalEntity
potassium,340,B-ChemicalEntity
channels,340,O
",",340,O
was,340,O
administered,340,O
intracerebroventricularly,340,O
in,340,O
rats,340,B-OrganismTaxon
anesthetized,340,O
with,340,O
0.8,340,O
%,340,O
sevoflurane,340,B-ChemicalEntity
to,340,O
investigate,340,O
the,340,O
mechanism,340,O
of,340,O
the,340,O
anticonvulsive,340,O
effects,340,O
.,340,O
Apamin,341,B-ChemicalEntity
(,341,O
10,341,O
ng,341,O
),341,O
had,341,O
a,341,O
tendency,341,O
to,341,O
decrease,341,O
the,341,O
convulsive,341,B-DiseaseOrPhenotypicFeature
threshold,341,O
(,341,O
21.6,341,O
+/-,341,O
2.2,341,O
to,341,O
19.9,341,O
+/-,341,O
2.5,341,O
mg.,341,O
l,341,O
(,341,O
-1,341,O
),341,O
),341,O
but,341,O
this,341,O
was,341,O
not,341,O
statistically,341,O
significant,341,O
.,341,O
It,342,O
is,342,O
suggested,342,O
that,342,O
sevoflurane,342,B-ChemicalEntity
reduces,342,O
the,342,O
convulsive,342,B-DiseaseOrPhenotypicFeature
effect,342,O
of,342,O
lidocaine,342,B-ChemicalEntity
toxicity,342,B-DiseaseOrPhenotypicFeature
but,342,O
carries,342,O
some,342,O
risk,342,O
due,342,O
to,342,O
circulatory,342,O
depression,342,B-DiseaseOrPhenotypicFeature
.,342,O
CD72,343,B-GeneOrGeneProduct
polymorphisms,343,O
associated,343,O
with,343,O
alternative,343,O
splicing,343,O
modify,343,O
susceptibility,343,O
to,343,O
human,343,B-OrganismTaxon
systemic,343,B-DiseaseOrPhenotypicFeature
lupus,343,I-DiseaseOrPhenotypicFeature
erythematosus,343,I-DiseaseOrPhenotypicFeature
through,343,O
epistatic,343,O
interaction,343,O
with,343,O
FCGR2B,343,B-GeneOrGeneProduct
.,343,O
We,344,O
previously,344,O
reported,344,O
association,344,O
of,344,O
FCGR2B-Ile232Thr,344,B-GeneOrGeneProduct
with,344,O
systemic,344,B-DiseaseOrPhenotypicFeature
lupus,344,I-DiseaseOrPhenotypicFeature
erythematosus,344,I-DiseaseOrPhenotypicFeature
(,344,O
SLE,344,B-DiseaseOrPhenotypicFeature
),344,O
in,344,O
three,344,O
Asian,344,O
populations,344,O
.,344,O
Because,345,O
polymorphism,345,O
of,345,O
CD72,345,B-GeneOrGeneProduct
",",345,O
another,345,O
inhibitory,345,O
receptor,345,O
of,345,O
B,345,O
cells,345,O
",",345,O
was,345,O
associated,345,O
with,345,O
murine,345,B-OrganismTaxon
SLE,345,B-DiseaseOrPhenotypicFeature
",",345,O
we,345,O
identified,345,O
human,345,B-OrganismTaxon
CD72,345,B-GeneOrGeneProduct
polymorphisms,345,O
",",345,O
tested,345,O
their,345,O
association,345,O
with,345,O
SLE,345,B-DiseaseOrPhenotypicFeature
and,345,O
examined,345,O
genetic,345,O
interaction,345,O
with,345,O
FCGR2B,345,B-GeneOrGeneProduct
in,345,O
the,345,O
Japanese,345,O
(,345,O
160,345,O
SLE,345,B-DiseaseOrPhenotypicFeature
",",345,O
277,345,O
controls,345,O
),345,O
",",345,O
Thais,345,O
(,345,O
87,345,O
SLE,345,B-DiseaseOrPhenotypicFeature
",",345,O
187,345,O
controls,345,O
),345,O
and,345,O
Caucasians,345,O
(,345,O
94,345,O
families,345,O
containing,345,O
SLE,345,B-DiseaseOrPhenotypicFeature
members,345,O
),345,O
.,345,O
Four,346,O
polymorphisms,346,O
and,346,O
six,346,O
rare,346,O
variations,346,O
were,346,O
detected,346,O
.,346,O
The,347,O
former,347,O
constituted,347,O
two,347,O
major,347,O
haplotypes,347,O
that,347,O
contained,347,O
one,347,O
or,347,O
two,347,O
repeats,347,O
of,347,O
13,347,O
nucleotides,347,O
in,347,O
intron,347,O
8,347,O
(,347,O
designated,347,O
as,347,O
*,347,O
1,347,O
and,347,O
*,347,O
2,347,O
",",347,O
respectively,347,O
),347,O
.,347,O
Although,348,O
association,348,O
with,348,O
susceptibility,348,O
to,348,O
SLE,348,B-DiseaseOrPhenotypicFeature
was,348,O
not,348,O
detected,348,O
",",348,O
the,348,O
*,348,O
1,348,O
allele,348,O
was,348,O
significantly,348,O
associated,348,O
with,348,O
nephritis,348,B-DiseaseOrPhenotypicFeature
among,348,O
the,348,O
Japanese,348,O
patients,348,B-OrganismTaxon
(,348,O
P=0.024,348,O
),348,O
.,348,O
RT-PCR,349,O
identified,349,O
a,349,O
novel,349,O
alternatively,349,O
spliced,349,O
(,349,O
AS,349,O
),349,O
transcript,349,O
that,349,O
was,349,O
expressed,349,O
at,349,O
the,349,O
protein,349,O
level,349,O
in,349,O
COS-7,349,B-CellLine
transfectants,349,O
.,349,O
The,350,O
ratio,350,O
of,350,O
AS/common,350,O
isoforms,350,O
was,350,O
strikingly,350,O
increased,350,O
in,350,O
individuals,350,O
with,350,O
*,350,O
2/,350,O
*,350,O
2,350,O
genotype,350,O
when,350,O
compared,350,O
with,350,O
*,350,O
1/,350,O
*,350,O
1,350,O
(,350,O
P=0.000038,350,O
),350,O
or,350,O
*,350,O
1/,350,O
*,350,O
2,350,O
(,350,O
P=0.0085,350,O
),350,O
genotypes,350,O
.,350,O
Using,351,O
the,351,O
two,351,O
Asian,351,O
cohorts,351,O
",",351,O
significant,351,O
association,351,O
of,351,O
FCGR2B-232Thr/Thr,351,B-GeneOrGeneProduct
with,351,O
SLE,351,B-DiseaseOrPhenotypicFeature
was,351,O
observed,351,O
only,351,O
in,351,O
the,351,O
presence,351,O
of,351,O
CD72-,351,B-GeneOrGeneProduct
*,351,O
1/,351,O
*,351,O
1,351,O
genotype,351,O
(,351,O
OR,351,O
4.63,351,O
",",351,O
95,351,O
%,351,O
CI,351,O
1.47-14.6,351,O
",",351,O
P=0.009,351,O
versus,351,O
FCGR2B-232Ile/Ile,351,B-GeneOrGeneProduct
plus,351,O
CD72-,351,B-GeneOrGeneProduct
*,351,O
2/,351,O
*,351,O
2,351,O
),351,O
.,351,O
Minigene,352,O
assays,352,O
demonstrated,352,O
that,352,O
the,352,O
13-nucleotide,352,O
repeat,352,O
and,352,O
4,352,O
bp,352,O
deletion,352,O
within,352,O
the,352,O
same,352,O
haplotype,352,O
of,352,O
intron,352,O
8,352,O
could,352,O
regulate,352,O
alternative,352,O
splicing,352,O
.,352,O
The,353,O
AS,353,O
isoform,353,O
lacks,353,O
exon,353,O
8,353,O
",",353,O
and,353,O
is,353,O
deduced,353,O
to,353,O
contain,353,O
49,353,O
amino,353,O
acid,353,O
changes,353,O
in,353,O
the,353,O
membrane-distal,353,O
portion,353,O
of,353,O
the,353,O
extracellular,353,O
domain,353,O
",",353,O
where,353,O
considerable,353,O
amino,353,O
acid,353,O
changes,353,O
are,353,O
known,353,O
in,353,O
CD72,353,B-GeneOrGeneProduct
(,353,O
c,353,O
),353,O
allele,353,O
associated,353,O
with,353,O
murine,353,B-OrganismTaxon
SLE,353,B-DiseaseOrPhenotypicFeature
.,353,O
These,354,O
results,354,O
indicated,354,O
that,354,O
the,354,O
presence,354,O
of,354,O
CD72-,354,B-GeneOrGeneProduct
*,354,O
2,354,O
allele,354,O
decreases,354,O
risk,354,O
for,354,O
human,354,B-OrganismTaxon
SLE,354,B-DiseaseOrPhenotypicFeature
conferred,354,O
by,354,O
FCGR2B-232Thr,354,B-GeneOrGeneProduct
",",354,O
possibly,354,O
by,354,O
increasing,354,O
the,354,O
AS,354,O
isoform,354,O
of,354,O
CD72,354,B-GeneOrGeneProduct
.,354,O
Vaccine,355,O
candidates,355,O
derived,355,O
from,355,O
a,355,O
novel,355,O
infectious,355,O
cDNA,355,O
clone,355,O
of,355,O
an,355,O
American,355,O
genotype,355,O
dengue,355,B-OrganismTaxon
virus,355,I-OrganismTaxon
type,355,I-OrganismTaxon
2,355,I-OrganismTaxon
.,355,O
BACKGROUND,356,O
:,356,O
A,356,O
dengue,356,B-OrganismTaxon
virus,356,I-OrganismTaxon
type,356,I-OrganismTaxon
2,356,I-OrganismTaxon
(,356,O
DEN-2,356,B-OrganismTaxon
Tonga/74,356,O
),356,O
isolated,356,O
from,356,O
a,356,O
1974,356,O
epidemic,356,O
was,356,O
characterized,356,O
by,356,O
mild,356,O
illness,356,O
and,356,O
belongs,356,O
to,356,O
the,356,O
American,356,O
genotype,356,O
of,356,O
DEN-2,356,B-OrganismTaxon
viruses,356,O
.,356,O
To,357,O
prepare,357,O
a,357,O
vaccine,357,O
candidate,357,O
",",357,O
a,357,O
previously,357,O
described,357,O
30,357,B-SequenceVariant
nucleotide,357,I-SequenceVariant
deletion,357,I-SequenceVariant
(,357,O
Delta30,357,B-SequenceVariant
),357,O
in,357,O
the,357,O
3,357,O
',357,O
untranslated,357,O
region,357,O
of,357,O
DEN-4,357,B-OrganismTaxon
has,357,O
been,357,O
engineered,357,O
into,357,O
the,357,O
DEN-2,357,B-OrganismTaxon
isolate,357,O
.,357,O
METHODS,358,O
:,358,O
A,358,O
full-length,358,O
cDNA,358,O
clone,358,O
was,358,O
generated,358,O
from,358,O
the,358,O
DEN-2,358,B-OrganismTaxon
virus,358,O
and,358,O
used,358,O
to,358,O
produce,358,O
recombinant,358,O
DEN-2,358,B-OrganismTaxon
(,358,O
rDEN-2,358,B-OrganismTaxon
),358,O
and,358,O
rDEN2Delta30,358,B-OrganismTaxon
.,358,O
Viruses,359,O
were,359,O
evaluated,359,O
for,359,O
replication,359,O
in,359,O
SCID,359,O
mice,359,B-OrganismTaxon
transplanted,359,O
with,359,O
human,359,B-OrganismTaxon
hepatoma,359,B-DiseaseOrPhenotypicFeature
cells,359,O
(,359,O
SCID-HuH-7,359,B-CellLine
mice,359,B-OrganismTaxon
),359,O
",",359,O
in,359,O
mosquitoes,359,O
",",359,O
and,359,O
in,359,O
rhesus,359,B-OrganismTaxon
monkeys,359,I-OrganismTaxon
.,359,O
Neutralizing,360,O
antibody,360,O
induction,360,O
and,360,O
protective,360,O
efficacy,360,O
were,360,O
also,360,O
assessed,360,O
in,360,O
rhesus,360,B-OrganismTaxon
monkeys,360,I-OrganismTaxon
.,360,O
RESULTS,361,O
:,361,O
The,361,O
rDEN2Delta30,361,B-OrganismTaxon
virus,361,O
was,361,O
ten-fold,361,O
reduced,361,O
in,361,O
replication,361,O
in,361,O
SCID-HuH-7,361,B-CellLine
mice,361,B-OrganismTaxon
when,361,O
compared,361,O
to,361,O
the,361,O
parent,361,O
virus,361,O
.,361,O
The,362,O
rDEN-2,362,B-OrganismTaxon
viruses,362,O
were,362,O
not,362,O
infectious,362,O
for,362,O
Aedes,362,B-OrganismTaxon
mosquitoes,362,I-OrganismTaxon
",",362,O
but,362,O
both,362,O
readily,362,O
infected,362,O
Toxorynchites,362,B-OrganismTaxon
mosquitoes,362,I-OrganismTaxon
.,362,O
In,363,O
rhesus,363,B-OrganismTaxon
monkeys,363,I-OrganismTaxon
",",363,O
rDEN2Delta30,363,B-OrganismTaxon
appeared,363,O
to,363,O
be,363,O
slightly,363,O
attenuated,363,O
when,363,O
compared,363,O
to,363,O
the,363,O
parent,363,O
virus,363,O
as,363,O
measured,363,O
by,363,O
duration,363,O
and,363,O
peak,363,O
of,363,O
viremia,363,B-DiseaseOrPhenotypicFeature
and,363,O
neutralizing,363,O
antibody,363,O
induction,363,O
.,363,O
A,364,O
derivative,364,O
of,364,O
rDEN2Delta30,364,B-OrganismTaxon
",",364,O
designated,364,O
rDEN2Delta30-4995,364,B-OrganismTaxon
",",364,O
was,364,O
generated,364,O
by,364,O
incorporation,364,O
of,364,O
a,364,O
point,364,O
mutation,364,O
previously,364,O
identified,364,O
in,364,O
the,364,O
NS3,364,B-GeneOrGeneProduct
gene,364,O
of,364,O
DEN-4,364,B-OrganismTaxon
and,364,O
was,364,O
found,364,O
to,364,O
be,364,O
more,364,O
attenuated,364,O
than,364,O
rDEN2Delta30,364,B-OrganismTaxon
in,364,O
SCID-HuH-7,364,B-CellLine
mice,364,B-OrganismTaxon
.,364,O
CONCLUSIONS,365,O
:,365,O
The,365,O
rDEN2Delta30,365,B-OrganismTaxon
and,365,O
rDEN2Delta30-4995,365,B-OrganismTaxon
viruses,365,O
can,365,O
be,365,O
considered,365,O
for,365,O
evaluation,365,O
in,365,O
humans,365,B-OrganismTaxon
and,365,O
for,365,O
inclusion,365,O
in,365,O
a,365,O
tetravalent,365,O
dengue,365,B-DiseaseOrPhenotypicFeature
vaccine,365,O
.,365,O
Haplotype,366,O
structure,366,O
of,366,O
the,366,O
beta,366,B-GeneOrGeneProduct
adrenergic,366,I-GeneOrGeneProduct
receptor,366,I-GeneOrGeneProduct
genes,366,O
in,366,O
US,366,O
Caucasians,366,O
and,366,O
African,366,O
Americans,366,O
.,366,O
The,367,O
beta-adrenergic,367,B-GeneOrGeneProduct
receptors,367,I-GeneOrGeneProduct
(,367,O
beta-AR,367,B-GeneOrGeneProduct
),367,O
are,367,O
G,367,O
protein-coupled,367,O
receptors,367,O
activated,367,O
by,367,O
epinephrine,367,B-ChemicalEntity
and,367,O
norepinephrine,367,B-ChemicalEntity
and,367,O
are,367,O
involved,367,O
in,367,O
a,367,O
variety,367,O
of,367,O
their,367,O
physiological,367,O
functions,367,O
.,367,O
Previously,368,O
",",368,O
three,368,O
beta-AR,368,B-GeneOrGeneProduct
genes,368,O
(,368,O
ADRB1,368,B-GeneOrGeneProduct
",",368,O
ADRB2,368,B-GeneOrGeneProduct
and,368,O
ADRB3,368,B-GeneOrGeneProduct
),368,O
were,368,O
resequenced,368,O
",",368,O
identifying,368,O
polymorphisms,368,O
that,368,O
were,368,O
used,368,O
in,368,O
genetic,368,O
association,368,O
studies,368,O
of,368,O
cardiovascular,368,B-DiseaseOrPhenotypicFeature
and,368,I-DiseaseOrPhenotypicFeature
metabolic,368,I-DiseaseOrPhenotypicFeature
disorders,368,I-DiseaseOrPhenotypicFeature
.,368,O
These,369,O
studies,369,O
have,369,O
produced,369,O
intriguing,369,O
but,369,O
inconsistent,369,O
results,369,O
",",369,O
potentially,369,O
because,369,O
the,369,O
known,369,O
functional,369,O
variants,369,O
:,369,O
ADRB1,369,B-GeneOrGeneProduct
Arg389Gly,369,B-SequenceVariant
and,369,O
Gly49Ser,369,B-SequenceVariant
",",369,O
ADRB2,369,B-GeneOrGeneProduct
Arg16Gly,369,B-SequenceVariant
and,369,O
Gln27Glu,369,B-SequenceVariant
",",369,O
and,369,O
ADRB3,369,B-GeneOrGeneProduct
Arg64Trp,369,B-SequenceVariant
provided,369,O
an,369,O
incomplete,369,O
picture,369,O
of,369,O
the,369,O
total,369,O
functional,369,O
diversity,369,O
at,369,O
these,369,O
genes,369,O
.,369,O
Therefore,370,O
",",370,O
we,370,O
created,370,O
marker,370,O
panels,370,O
for,370,O
each,370,O
beta-AR,370,B-GeneOrGeneProduct
gene,370,O
that,370,O
included,370,O
the,370,O
known,370,O
functional,370,O
markers,370,O
and,370,O
also,370,O
other,370,O
markers,370,O
evenly,370,O
spaced,370,O
and,370,O
with,370,O
sufficient,370,O
density,370,O
to,370,O
identify,370,O
haplotype,370,O
block,370,O
structure,370,O
and,370,O
to,370,O
maximize,370,O
haplotype,370,O
diversity,370,O
.,370,O
A,371,O
total,371,O
of,371,O
27,371,O
markers,371,O
were,371,O
genotyped,371,O
in,371,O
96,371,O
US,371,O
Caucasians,371,O
and,371,O
96,371,O
African,371,O
Americans,371,O
.,371,O
In,372,O
both,372,O
populations,372,O
and,372,O
for,372,O
each,372,O
gene,372,O
",",372,O
a,372,O
single,372,O
block,372,O
with,372,O
little,372,O
evidence,372,O
of,372,O
historical,372,O
recombination,372,O
was,372,O
observed,372,O
.,372,O
For,373,O
each,373,O
gene,373,O
",",373,O
haplotype,373,O
captured,373,O
most,373,O
of,373,O
the,373,O
information,373,O
content,373,O
of,373,O
each,373,O
functional,373,O
locus,373,O
",",373,O
even,373,O
if,373,O
that,373,O
locus,373,O
was,373,O
not,373,O
genotyped,373,O
",",373,O
and,373,O
presumably,373,O
haplotype,373,O
would,373,O
capture,373,O
the,373,O
signal,373,O
from,373,O
unknown,373,O
functional,373,O
loci,373,O
whose,373,O
alleles,373,O
are,373,O
of,373,O
moderate,373,O
abundance,373,O
.,373,O
This,374,O
study,374,O
demonstrates,374,O
the,374,O
utility,374,O
of,374,O
using,374,O
beta-AR,374,B-GeneOrGeneProduct
gene,374,O
haplotype,374,O
maps,374,O
and,374,O
marker,374,O
panels,374,O
as,374,O
tools,374,O
for,374,O
linkage,374,O
studies,374,O
on,374,O
beta-AR,374,B-GeneOrGeneProduct
function,374,O
.,374,O
Tumor,375,B-DiseaseOrPhenotypicFeature
associated,375,O
antigen,375,O
recognition,375,O
by,375,O
autologous,375,O
serum,375,O
in,375,O
patients,375,B-OrganismTaxon
with,375,O
breast,375,B-DiseaseOrPhenotypicFeature
cancer,375,I-DiseaseOrPhenotypicFeature
.,375,O
Breast,376,B-DiseaseOrPhenotypicFeature
cancer,376,I-DiseaseOrPhenotypicFeature
accounts,376,O
for,376,O
30-40,376,O
%,376,O
of,376,O
all,376,O
deaths,376,O
from,376,O
cancers,376,B-DiseaseOrPhenotypicFeature
in,376,O
females,376,O
.,376,O
In,377,O
an,377,O
effort,377,O
to,377,O
identify,377,O
tumor,377,B-DiseaseOrPhenotypicFeature
associated,377,O
antigens,377,O
that,377,O
may,377,O
be,377,O
useful,377,O
for,377,O
immunotherapy,377,O
",",377,O
we,377,O
utilized,377,O
serological,377,O
analysis,377,O
of,377,O
recombinant,377,O
cDNA,377,O
expression,377,O
libraries,377,O
(,377,O
SEREX,377,O
),377,O
technique,377,O
to,377,O
identify,377,O
breast,377,B-DiseaseOrPhenotypicFeature
cancer-associated,377,O
antigens,377,O
.,377,O
SEREX,378,O
screening,378,O
of,378,O
cDNA,378,O
expression,378,O
libraries,378,O
derived,378,O
from,378,O
3,378,O
breast,378,B-DiseaseOrPhenotypicFeature
cancer,378,I-DiseaseOrPhenotypicFeature
patients,378,B-OrganismTaxon
identified,378,O
a,378,O
total,378,O
of,378,O
88,378,O
positive,378,O
clones,378,O
(,378,O
bcg-1,378,O
to,378,O
bcg-88,378,O
),378,O
",",378,O
including,378,O
27,378,O
hitherto,378,O
unknown,378,O
sequences,378,O
.,378,O
The,379,O
cDNA,379,O
sequences,379,O
and,379,O
mRNA,379,O
expression,379,O
patterns,379,O
were,379,O
characterized,379,O
.,379,O
Seroreactivity,380,O
of,380,O
the,380,O
SEREX,380,O
clones,380,O
were,380,O
determined,380,O
in,380,O
sera,380,O
from,380,O
75,380,O
breast,380,B-DiseaseOrPhenotypicFeature
cancer,380,I-DiseaseOrPhenotypicFeature
patients,380,B-OrganismTaxon
",",380,O
75,380,O
colon,380,B-DiseaseOrPhenotypicFeature
cancer,380,I-DiseaseOrPhenotypicFeature
patients,380,B-OrganismTaxon
",",380,O
and,380,O
25,380,O
healthy,380,O
donors,380,O
.,380,O
Expression,381,O
analysis,381,O
on,381,O
a,381,O
cDNA,381,O
panel,381,O
from,381,O
17,381,O
different,381,O
normal,381,O
tissues,381,O
by,381,O
reverse,381,O
transcription-PCR,381,O
(,381,O
RT-PCR,381,O
),381,O
revealed,381,O
tissue,381,O
restricted,381,O
mRNA,381,O
expression,381,O
of,381,O
2,381,O
of,381,O
the,381,O
27,381,O
unknown,381,O
antigens,381,O
.,381,O
Bcg-72,382,O
is,382,O
expressed,382,O
only,382,O
in,382,O
breast,382,O
",",382,O
prostate,382,O
and,382,O
thymus,382,O
",",382,O
while,382,O
bcg-84,382,O
is,382,O
expressed,382,O
at,382,O
moderate,382,O
levels,382,O
in,382,O
testis,382,O
",",382,O
spleen,382,O
and,382,O
breast,382,O
.,382,O
The,383,O
other,383,O
25,383,O
unknown,383,O
antigens,383,O
were,383,O
expressed,383,O
in,383,O
most,383,O
other,383,O
tissues,383,O
.,383,O
Serologic,384,O
assay,384,O
revealed,384,O
that,384,O
7,384,O
out,384,O
of,384,O
the,384,O
88,384,O
clones,384,O
showed,384,O
reactivity,384,O
to,384,O
at,384,O
least,384,O
one,384,O
serum,384,O
from,384,O
either,384,O
75,384,O
breast,384,O
or,384,O
75,384,O
colon,384,B-DiseaseOrPhenotypicFeature
cancer,384,I-DiseaseOrPhenotypicFeature
patients,384,B-OrganismTaxon
.,384,O
These,385,O
clones,385,O
did,385,O
not,385,O
react,385,O
with,385,O
sera,385,O
from,385,O
a,385,O
panel,385,O
of,385,O
25,385,O
healthy,385,O
adult,385,O
individuals,385,O
.,385,O
Our,386,O
results,386,O
demonstrate,386,O
the,386,O
utility,386,O
of,386,O
the,386,O
SEREX,386,O
approach,386,O
for,386,O
the,386,O
identification,386,O
of,386,O
potential,386,O
tumor,386,B-DiseaseOrPhenotypicFeature
associated,386,O
antigens,386,O
in,386,O
human,386,B-OrganismTaxon
breast,386,B-DiseaseOrPhenotypicFeature
cancer,386,I-DiseaseOrPhenotypicFeature
.,386,O
Polymorphic,387,O
forms,387,O
of,387,O
prostate,387,B-GeneOrGeneProduct
specific,387,I-GeneOrGeneProduct
antigen,387,I-GeneOrGeneProduct
and,387,O
their,387,O
interaction,387,O
with,387,O
androgen,387,B-GeneOrGeneProduct
receptor,387,I-GeneOrGeneProduct
trinucleotide,387,O
repeats,387,O
in,387,O
prostate,387,B-DiseaseOrPhenotypicFeature
cancer,387,I-DiseaseOrPhenotypicFeature
.,387,O
BACKGROUND,388,O
:,388,O
Recent,388,O
data,388,O
has,388,O
suggested,388,O
that,388,O
polymorphisms,388,O
in,388,O
the,388,O
prostate,388,B-GeneOrGeneProduct
specific,388,I-GeneOrGeneProduct
antigen,388,I-GeneOrGeneProduct
(,388,O
PSA,388,B-GeneOrGeneProduct
),388,O
may,388,O
increase,388,O
prostate,388,B-DiseaseOrPhenotypicFeature
cancer,388,I-DiseaseOrPhenotypicFeature
(,388,O
PC,388,B-DiseaseOrPhenotypicFeature
),388,O
risk,388,O
.,388,O
The,389,O
PSA,389,B-GeneOrGeneProduct
gene,389,O
contains,389,O
a,389,O
G/A,389,B-SequenceVariant
substitution,389,O
in,389,O
the,389,O
androgen,389,B-ChemicalEntity
response,389,O
element,389,O
(,389,O
ARE,389,O
),389,O
1,389,O
region,389,O
.,389,O
The,390,O
androgen,390,B-GeneOrGeneProduct
receptor,390,I-GeneOrGeneProduct
(,390,O
AR,390,B-GeneOrGeneProduct
),390,O
gene,390,O
has,390,O
polymorphic,390,O
regions,390,O
containing,390,O
variable,390,O
length,390,O
glutamine,390,O
and,390,O
glycine,390,O
repeats,390,O
and,390,O
these,390,O
are,390,O
believed,390,O
to,390,O
be,390,O
associated,390,O
with,390,O
PC,390,B-DiseaseOrPhenotypicFeature
risk,390,O
.,390,O
The,391,O
effect,391,O
on,391,O
PC,391,B-DiseaseOrPhenotypicFeature
risks,391,O
from,391,O
PSA,391,B-GeneOrGeneProduct
polymorphisms,391,O
alone,391,O
and,391,O
synergistically,391,O
with,391,O
the,391,O
AR,391,B-GeneOrGeneProduct
gene,391,O
was,391,O
examined,391,O
in,391,O
this,391,O
report,391,O
.,391,O
METHODS,392,O
:,392,O
One,392,O
hundred,392,O
PC,392,B-DiseaseOrPhenotypicFeature
patients,392,B-OrganismTaxon
and,392,O
an,392,O
age,392,O
matched,392,O
cohort,392,O
of,392,O
79,392,O
benign,392,B-DiseaseOrPhenotypicFeature
prostate,392,I-DiseaseOrPhenotypicFeature
hyperplasia,392,I-DiseaseOrPhenotypicFeature
and,392,O
67,392,O
population,392,O
controls,392,O
were,392,O
entered,392,O
in,392,O
this,392,O
study,392,O
.,392,O
DNA,393,O
was,393,O
extracted,393,O
from,393,O
blood,393,O
and,393,O
PSA/ARE,393,B-GeneOrGeneProduct
promoter,393,O
region,393,O
amplified,393,O
by,393,O
PCR,393,O
.,393,O
PCR,394,O
products,394,O
were,394,O
cut,394,O
with,394,O
Nhe,394,B-GeneOrGeneProduct
1,394,I-GeneOrGeneProduct
restriction,394,O
enzyme,394,O
to,394,O
distinguish,394,O
G/A,394,B-SequenceVariant
alleles,394,O
.,394,O
AR/CAG,395,B-GeneOrGeneProduct
and,395,I-SequenceVariant
GGC,395,I-SequenceVariant
repeat,395,I-SequenceVariant
length,395,O
was,395,O
detected,395,O
by,395,O
automated,395,O
fluorescence,395,O
from,395,O
PCR,395,O
products,395,O
.,395,O
RESULTS,396,O
:,396,O
We,396,O
found,396,O
a,396,O
significantly,396,O
higher,396,O
PSA/GG,396,B-GeneOrGeneProduct
distribution,396,O
in,396,O
PC,396,B-DiseaseOrPhenotypicFeature
(,396,O
30,396,O
%,396,O
),396,O
than,396,O
either,396,O
benign,396,B-DiseaseOrPhenotypicFeature
prostatic,396,I-DiseaseOrPhenotypicFeature
hyperplasia,396,I-DiseaseOrPhenotypicFeature
(,396,O
BPH,396,B-DiseaseOrPhenotypicFeature
),396,O
(,396,O
18,396,O
%,396,O
),396,O
or,396,O
population,396,O
controls,396,O
(,396,O
16,396,O
%,396,O
),396,O
(,396,O
P,396,O
=,396,O
0.025,396,O
),396,O
.,396,O
Furthermore,397,O
the,397,O
GG,397,O
distribution,397,O
within,397,O
cases,397,O
was,397,O
even,397,O
greater,397,O
in,397,O
younger,397,O
men,397,B-OrganismTaxon
(,397,O
<,397,O
65,397,O
years,397,O
;,397,O
42,397,O
%,397,O
;,397,O
P,397,O
=,397,O
0.012,397,O
),397,O
.,397,O
Additionally,398,O
",",398,O
when,398,O
PSA,398,B-GeneOrGeneProduct
genotype,398,O
was,398,O
cross,398,O
classified,398,O
with,398,O
CAG,398,B-SequenceVariant
repeat,398,I-SequenceVariant
",",398,O
significantly,398,O
more,398,O
cases,398,O
than,398,O
both,398,O
BPH,398,B-DiseaseOrPhenotypicFeature
and,398,O
population,398,O
controls,398,O
were,398,O
observed,398,O
to,398,O
have,398,O
a,398,O
short,398,O
(,398,O
<,398,O
22,398,O
),398,O
CAG/GG,398,O
genotype,398,O
(,398,O
P,398,O
=,398,O
0.006,398,O
),398,O
.,398,O
CONCLUSIONS,399,O
:,399,O
Our,399,O
results,399,O
indicate,399,O
that,399,O
the,399,O
PSA/ARE,399,B-GeneOrGeneProduct
GG,399,O
genotype,399,O
confers,399,O
an,399,O
increased,399,O
risk,399,O
of,399,O
PC,399,B-DiseaseOrPhenotypicFeature
especially,399,O
among,399,O
younger,399,O
men,399,B-OrganismTaxon
.,399,O
Moreover,400,O
",",400,O
we,400,O
confirm,400,O
previous,400,O
results,400,O
that,400,O
a,400,O
short,400,O
glutamine,400,B-SequenceVariant
repeat,400,I-SequenceVariant
in,400,O
conjunction,400,O
with,400,O
GG,400,O
genotype,400,O
significantly,400,O
increases,400,O
the,400,O
risk,400,O
of,400,O
malignant,400,B-DiseaseOrPhenotypicFeature
disease,400,I-DiseaseOrPhenotypicFeature
.,400,O
Recurrent,401,O
acute,401,O
interstitial,401,B-DiseaseOrPhenotypicFeature
nephritis,401,I-DiseaseOrPhenotypicFeature
induced,401,O
by,401,O
azithromycin,401,B-ChemicalEntity
.,401,O
A,402,O
14-year-old,402,O
girl,402,O
is,402,O
reported,402,O
with,402,O
recurrent,402,O
",",402,O
azithromycin-induced,402,B-ChemicalEntity
",",402,O
acute,402,O
interstitial,402,B-DiseaseOrPhenotypicFeature
nephritis,402,I-DiseaseOrPhenotypicFeature
.,402,O
The,403,O
second,403,O
episode,403,O
was,403,O
more,403,O
severe,403,O
than,403,O
the,403,O
first,403,O
;,403,O
and,403,O
although,403,O
both,403,O
were,403,O
treated,403,O
with,403,O
intensive,403,O
corticosteroid,403,B-ChemicalEntity
therapy,403,O
",",403,O
renal,403,O
function,403,O
remained,403,O
impaired,403,O
.,403,O
Although,404,O
most,404,O
cases,404,O
of,404,O
antibiotic,404,B-ChemicalEntity
induced,404,O
acute,404,O
interstitial,404,B-DiseaseOrPhenotypicFeature
nephritis,404,I-DiseaseOrPhenotypicFeature
are,404,O
benign,404,O
and,404,O
self-limited,404,O
",",404,O
some,404,O
patients,404,B-OrganismTaxon
are,404,O
at,404,O
risk,404,O
for,404,O
permanent,404,O
renal,404,B-DiseaseOrPhenotypicFeature
injury,404,I-DiseaseOrPhenotypicFeature
.,404,O
Compound,405,O
heterozygosity,405,O
for,405,O
a,405,O
novel,405,O
nine-nucleotide,405,O
deletion,405,O
and,405,O
the,405,O
Asn45Ser,405,B-SequenceVariant
missense,405,O
mutation,405,O
in,405,O
the,405,O
glycoprotein,405,B-GeneOrGeneProduct
IX,405,I-GeneOrGeneProduct
gene,405,O
in,405,O
a,405,O
patient,405,B-OrganismTaxon
with,405,O
Bernard-Soulier,405,B-DiseaseOrPhenotypicFeature
syndrome,405,I-DiseaseOrPhenotypicFeature
.,405,O
Bernard-Soulier,406,B-DiseaseOrPhenotypicFeature
syndrome,406,I-DiseaseOrPhenotypicFeature
(,406,O
BSS,406,B-DiseaseOrPhenotypicFeature
),406,O
is,406,O
a,406,O
rare,406,O
inherited,406,B-DiseaseOrPhenotypicFeature
bleeding,406,I-DiseaseOrPhenotypicFeature
disorder,406,I-DiseaseOrPhenotypicFeature
due,406,O
to,406,O
quantitative,406,O
or,406,O
qualitative,406,O
abnormalities,406,O
in,406,O
the,406,O
platelet,406,O
glycoprotein,406,B-GeneOrGeneProduct
(,406,I-GeneOrGeneProduct
GP,406,I-GeneOrGeneProduct
),406,I-GeneOrGeneProduct
Ib/IX/V,406,I-GeneOrGeneProduct
complex,406,O
",",406,O
the,406,O
major,406,O
von,406,B-GeneOrGeneProduct
Willebrand,406,I-GeneOrGeneProduct
factor,406,I-GeneOrGeneProduct
receptor,406,O
.,406,O
The,407,O
complex,407,O
comprises,407,O
four,407,O
subunits,407,O
",",407,O
each,407,O
encoded,407,O
by,407,O
a,407,O
separate,407,O
gene,407,O
.,407,O
Several,408,O
mutations,408,O
have,408,O
been,408,O
described,408,O
for,408,O
each,408,O
of,408,O
the,408,O
subunits,408,O
",",408,O
except,408,O
for,408,O
GPV,408,B-GeneOrGeneProduct
",",408,O
as,408,O
a,408,O
cause,408,O
of,408,O
BSS,408,B-DiseaseOrPhenotypicFeature
.,408,O
We,409,O
describe,409,O
here,409,O
the,409,O
genetic,409,O
basis,409,O
of,409,O
the,409,O
disorder,409,O
in,409,O
a,409,O
child,409,O
with,409,O
BSS,409,B-DiseaseOrPhenotypicFeature
.,409,O
Flow-cytometric,410,O
analysis,410,O
of,410,O
the,410,O
patient,410,B-OrganismTaxon
's,410,O
platelets,410,O
showed,410,O
a,410,O
markedly,410,O
reduced,410,O
surface,410,O
expression,410,O
of,410,O
all,410,O
three,410,O
glycoproteins,410,B-GeneOrGeneProduct
of,410,O
the,410,O
GPIb/IX/V,410,B-GeneOrGeneProduct
complex,410,O
.,410,O
DNA,411,O
sequencing,411,O
analysis,411,O
showed,411,O
the,411,O
patient,411,B-OrganismTaxon
to,411,O
be,411,O
a,411,O
compound,411,O
heterozygote,411,O
for,411,O
two,411,O
mutations,411,O
in,411,O
the,411,O
GPIX,411,B-GeneOrGeneProduct
gene,411,O
",",411,O
a,411,O
novel,411,O
nine-nucleotide,411,B-SequenceVariant
deletion,411,I-SequenceVariant
starting,411,I-SequenceVariant
at,411,I-SequenceVariant
position,411,I-SequenceVariant
1952,411,I-SequenceVariant
of,411,O
the,411,O
gene,411,O
that,411,O
changes,411,B-SequenceVariant
asparagine,411,I-SequenceVariant
86,411,I-SequenceVariant
for,411,I-SequenceVariant
alanine,411,I-SequenceVariant
and,411,I-SequenceVariant
eliminates,411,I-SequenceVariant
amino,411,I-SequenceVariant
acids,411,I-SequenceVariant
87,411,I-SequenceVariant
",",411,I-SequenceVariant
88,411,I-SequenceVariant
",",411,I-SequenceVariant
and,411,I-SequenceVariant
89,411,I-SequenceVariant
(,411,I-SequenceVariant
arginine,411,I-SequenceVariant
",",411,I-SequenceVariant
threonine,411,I-SequenceVariant
",",411,I-SequenceVariant
and,411,I-SequenceVariant
proline,411,I-SequenceVariant
),411,I-SequenceVariant
and,411,O
a,411,O
previously,411,O
reported,411,O
point,411,O
mutation,411,O
that,411,O
changes,411,O
the,411,O
codon,411,O
asparagine,411,B-SequenceVariant
(,411,I-SequenceVariant
AAC,411,I-SequenceVariant
),411,I-SequenceVariant
for,411,I-SequenceVariant
serine,411,I-SequenceVariant
(,411,I-SequenceVariant
AGC,411,I-SequenceVariant
),411,I-SequenceVariant
at,411,I-SequenceVariant
residue,411,I-SequenceVariant
45,411,I-SequenceVariant
.,411,O
Her,412,O
mother,412,O
was,412,O
heterozygous,412,O
for,412,O
the,412,O
Asn45Ser,412,B-SequenceVariant
mutation,412,O
",",412,O
and,412,O
her,412,O
father,412,O
",",412,O
for,412,O
the,412,O
nine-nucleotide,412,O
deletion,412,O
.,412,O
Our,413,O
findings,413,O
suggest,413,O
that,413,O
the,413,O
additive,413,O
effects,413,O
of,413,O
both,413,O
mutations,413,O
in,413,O
the,413,O
GPIX,413,B-GeneOrGeneProduct
gene,413,O
are,413,O
responsible,413,O
for,413,O
the,413,O
BSS,413,B-DiseaseOrPhenotypicFeature
phenotype,413,O
of,413,O
the,413,O
patient,413,B-OrganismTaxon
.,413,O
Effects,414,O
of,414,O
the,414,O
antidepressant,414,O
trazodone,414,B-ChemicalEntity
",",414,O
a,414,O
5-HT,414,B-GeneOrGeneProduct
2A/2C,414,I-GeneOrGeneProduct
receptor,414,I-GeneOrGeneProduct
antagonist,414,O
",",414,O
on,414,O
dopamine-dependent,414,B-ChemicalEntity
behaviors,414,O
in,414,O
rats,414,B-OrganismTaxon
.,414,O
RATIONALE,415,O
:,415,O
5-Hydroxytryptamine,415,B-ChemicalEntity
",",415,O
via,415,O
stimulation,415,O
of,415,O
5-HT,415,B-GeneOrGeneProduct
2C,415,I-GeneOrGeneProduct
receptors,415,I-GeneOrGeneProduct
",",415,O
exerts,415,O
a,415,O
tonic,415,O
inhibitory,415,O
influence,415,O
on,415,O
dopaminergic,415,O
neurotransmission,415,O
",",415,O
whereas,415,O
activation,415,O
of,415,O
5-HT,415,B-GeneOrGeneProduct
2A,415,I-GeneOrGeneProduct
receptors,415,I-GeneOrGeneProduct
enhances,415,O
stimulated,415,O
DAergic,415,O
neurotransmission,415,O
.,415,O
The,416,O
antidepressant,416,O
trazodone,416,B-ChemicalEntity
is,416,O
a,416,O
5-HT,416,B-GeneOrGeneProduct
2A/2C,416,I-GeneOrGeneProduct
receptor,416,I-GeneOrGeneProduct
antagonist,416,O
.,416,O
OBJECTIVES,417,O
:,417,O
To,417,O
evaluate,417,O
the,417,O
effect,417,O
of,417,O
trazodone,417,B-ChemicalEntity
treatment,417,O
on,417,O
behaviors,417,O
dependent,417,O
on,417,O
the,417,O
functional,417,O
status,417,O
of,417,O
the,417,O
nigrostriatal,417,O
DAergic,417,O
system,417,O
.,417,O
METHODS,418,O
:,418,O
The,418,O
effect,418,O
of,418,O
pretreatment,418,O
with,418,O
trazodone,418,B-ChemicalEntity
on,418,O
dexamphetamine-,418,B-ChemicalEntity
and,418,O
apomorphine-induced,418,B-ChemicalEntity
oral,418,B-DiseaseOrPhenotypicFeature
stereotypies,418,I-DiseaseOrPhenotypicFeature
",",418,O
on,418,O
catalepsy,418,B-DiseaseOrPhenotypicFeature
induced,418,O
by,418,O
haloperidol,418,B-ChemicalEntity
and,418,O
apomorphine,418,B-ChemicalEntity
(,418,O
0.05,418,O
mg/kg,418,O
",",418,O
i.p,418,O
.,418,O
),419,O
",",419,O
on,419,O
ergometrine-induced,419,O
wet,419,O
dog,419,O
shake,419,O
(,419,O
WDS,419,O
),419,O
behavior,419,O
and,419,O
fluoxetine-induced,419,O
penile,419,O
erections,419,O
was,419,O
studied,419,O
in,419,O
rats,419,O
.,419,O
We,420,O
also,420,O
investigated,420,O
whether,420,O
trazodone,420,O
induces,420,O
catalepsy,420,O
in,420,O
rats,420,O
.,420,O
RESULTS,421,O
:,421,O
Trazodone,421,O
at,421,O
2.5-20,421,O
mg/kg,421,O
i.p,421,O
.,421,O
did,422,O
not,422,O
induce,422,O
catalepsy,422,O
",",422,O
and,422,O
did,422,O
not,422,O
antagonize,422,O
apomorphine,422,O
(,422,O
1.5,422,O
and,422,O
3,422,O
mg/kg,422,O
),422,O
stereotypy,422,O
and,422,O
apomorphine,422,O
(,422,O
0.05,422,O
mg/kg,422,O
),422,O
-induced,422,O
catalepsy,422,O
.,422,O
However,423,O
",",423,O
pretreatment,423,O
with,423,O
5,423,O
",",423,O
10,423,O
and,423,O
20,423,O
mg/kg,423,O
i.p,423,O
.,423,O
trazodone,424,O
enhanced,424,O
dexamphetamine,424,O
stereotypy,424,O
",",424,O
and,424,O
antagonized,424,O
haloperidol,424,O
catalepsy,424,O
",",424,O
ergometrine-induced,424,O
WDS,424,O
behavior,424,O
and,424,O
fluoxetine-induced,424,O
penile,424,O
erections,424,O
.,424,O
Trazodone,425,O
at,425,O
30,425,O
",",425,O
40,425,O
and,425,O
50,425,O
mg/kg,425,O
i.p,425,O
.,425,O
induced,426,O
catalepsy,426,O
and,426,O
antagonized,426,O
apomorphine,426,O
and,426,O
dexamphetamine,426,O
stereotypies,426,O
.,426,O
CONCLUSIONS,427,O
:,427,O
Our,427,O
results,427,O
indicate,427,O
that,427,O
trazodone,427,O
at,427,O
2.5-20,427,O
mg/kg,427,O
does,427,O
not,427,O
block,427,O
pre-,427,O
and,427,O
postsynaptic,427,O
striatal,427,O
D2,427,I-GeneOrGeneProduct
DA,427,I-GeneOrGeneProduct
receptors,427,O
",",427,O
while,427,O
at,427,O
30,427,O
",",427,O
40,427,O
and,427,O
50,427,O
mg/kg,427,O
it,427,O
blocks,427,O
postsynaptic,427,O
striatal,427,O
D2,427,I-GeneOrGeneProduct
DA,427,I-GeneOrGeneProduct
receptors,427,O
.,427,O
Furthermore,428,O
",",428,O
at,428,O
5,428,O
",",428,O
10,428,O
and,428,O
20,428,O
mg/kg,428,O
",",428,O
trazodone,428,O
blocks,428,O
5-HT,428,I-GeneOrGeneProduct
2A,428,I-GeneOrGeneProduct
and,428,I-GeneOrGeneProduct
5-HT,428,I-GeneOrGeneProduct
2C,428,I-GeneOrGeneProduct
receptors,428,O
.,428,O
We,429,O
suggest,429,O
that,429,O
trazodone,429,O
(,429,O
5,429,O
",",429,O
10,429,O
and,429,O
20,429,O
mg/kg,429,O
),429,O
",",429,O
by,429,O
blocking,429,O
the,429,O
5-HT,429,I-GeneOrGeneProduct
2C,429,I-GeneOrGeneProduct
receptors,429,O
",",429,O
releases,429,O
the,429,O
nigrostriatal,429,O
DAergic,429,O
neurons,429,O
from,429,O
tonic,429,O
inhibition,429,O
caused,429,O
by,429,O
5-HT,429,O
",",429,O
and,429,O
thereby,429,O
potentiates,429,O
dexamphetamine,429,O
stereotypy,429,O
and,429,O
antagonizes,429,O
haloperidol,429,O
catalepsy,429,O
.,429,O
TGFBI,430,B-GeneOrGeneProduct
gene,430,O
mutations,430,O
causing,430,O
lattice,430,B-DiseaseOrPhenotypicFeature
and,430,I-DiseaseOrPhenotypicFeature
granular,430,I-DiseaseOrPhenotypicFeature
corneal,430,I-DiseaseOrPhenotypicFeature
dystrophies,430,I-DiseaseOrPhenotypicFeature
in,430,O
Indian,430,O
patients,430,B-OrganismTaxon
.,430,O
PURPOSE,431,O
:,431,O
To,431,O
identify,431,O
mutations,431,O
in,431,O
the,431,O
TGFBI,431,B-GeneOrGeneProduct
gene,431,O
in,431,O
Indian,431,O
patients,431,B-OrganismTaxon
with,431,O
lattice,431,B-DiseaseOrPhenotypicFeature
corneal,431,I-DiseaseOrPhenotypicFeature
dystrophy,431,I-DiseaseOrPhenotypicFeature
(,431,O
LCD,431,B-DiseaseOrPhenotypicFeature
),431,O
or,431,O
granular,431,B-DiseaseOrPhenotypicFeature
corneal,431,I-DiseaseOrPhenotypicFeature
dystrophy,431,I-DiseaseOrPhenotypicFeature
(,431,O
GCD,431,B-DiseaseOrPhenotypicFeature
),431,O
and,431,O
to,431,O
look,431,O
for,431,O
genotype-phenotype,431,O
correlations,431,O
.,431,O
METHODS,432,O
:,432,O
Thirty-seven,432,O
unrelated,432,O
patients,432,B-OrganismTaxon
were,432,O
studied,432,O
",",432,O
18,432,O
with,432,O
LCD,432,B-DiseaseOrPhenotypicFeature
and,432,O
19,432,O
with,432,O
GCD,432,B-DiseaseOrPhenotypicFeature
.,432,O
The,433,O
diagnosis,433,O
of,433,O
LCD,433,B-DiseaseOrPhenotypicFeature
or,433,O
GCD,433,B-DiseaseOrPhenotypicFeature
was,433,O
made,433,O
on,433,O
the,433,O
basis,433,O
of,433,O
clinical,433,O
and/or,433,O
histopathological,433,O
evaluation,433,O
.,433,O
Exons,434,O
and,434,O
flanking,434,O
intron,434,O
sequences,434,O
of,434,O
the,434,O
TGFBI,434,B-GeneOrGeneProduct
gene,434,O
were,434,O
amplified,434,O
by,434,O
PCR,434,O
with,434,O
specific,434,O
primers,434,O
.,434,O
PCR,435,O
products,435,O
were,435,O
screened,435,O
by,435,O
the,435,O
method,435,O
of,435,O
single-strand,435,O
conformation,435,O
polymorphism,435,O
followed,435,O
by,435,O
sequencing,435,O
.,435,O
Mutations,436,O
were,436,O
confirmed,436,O
by,436,O
screening,436,O
at,436,O
least,436,O
100,436,O
unrelated,436,O
normal,436,O
control,436,O
subjects,436,O
.,436,O
RESULTS,437,O
:,437,O
Mutations,437,O
were,437,O
identified,437,O
in,437,O
14,437,O
of,437,O
18,437,O
patients,437,B-OrganismTaxon
with,437,O
LCD,437,B-DiseaseOrPhenotypicFeature
and,437,O
in,437,O
all,437,O
19,437,O
patients,437,B-OrganismTaxon
with,437,O
GCD,437,B-DiseaseOrPhenotypicFeature
.,437,O
In,438,O
LCD,438,B-DiseaseOrPhenotypicFeature
",",438,O
three,438,O
novel,438,O
heterozygous,438,O
mutations,438,O
found,438,O
were,438,O
glycine-594-valine,438,B-SequenceVariant
(,438,O
Gly594Val,438,B-SequenceVariant
),438,O
in,438,O
2,438,O
of,438,O
18,438,O
patients,438,B-OrganismTaxon
",",438,O
valine-539-aspartic,438,B-SequenceVariant
acid,438,I-SequenceVariant
(,438,O
Val539Asp,438,B-SequenceVariant
),438,O
in,438,O
1,438,O
patient,438,B-OrganismTaxon
",",438,O
and,438,O
deletion,438,B-SequenceVariant
of,438,I-SequenceVariant
valine,438,I-SequenceVariant
624,438,I-SequenceVariant
",",438,I-SequenceVariant
valine,438,I-SequenceVariant
625,438,I-SequenceVariant
(,438,O
Val624-Val625del,438,B-SequenceVariant
),438,O
in,438,O
1,438,O
patient,438,B-OrganismTaxon
.,438,O
In,439,O
addition,439,O
",",439,O
mutation,439,O
of,439,O
arginine,439,B-SequenceVariant
124-to-cysteine,439,I-SequenceVariant
(,439,O
Arg124Cys,439,B-SequenceVariant
),439,O
was,439,O
found,439,O
in,439,O
8,439,O
of,439,O
18,439,O
patients,439,B-OrganismTaxon
and,439,O
histidine,439,B-SequenceVariant
626-to-arginine,439,I-SequenceVariant
(,439,O
His626Arg,439,B-SequenceVariant
),439,O
in,439,O
2,439,O
of,439,O
18,439,O
patients,439,B-OrganismTaxon
.,439,O
Atypical,440,O
clinical,440,O
features,440,O
for,440,O
LCD,440,B-DiseaseOrPhenotypicFeature
were,440,O
noted,440,O
in,440,O
patients,440,B-OrganismTaxon
with,440,O
the,440,O
Gly594Val,440,B-SequenceVariant
and,440,O
Val624-Val625del,440,B-SequenceVariant
mutations,440,O
.,440,O
In,441,O
GCD,441,B-DiseaseOrPhenotypicFeature
",",441,O
18,441,O
patients,441,B-OrganismTaxon
with,441,O
GCD,441,B-DiseaseOrPhenotypicFeature
type,441,I-DiseaseOrPhenotypicFeature
I,441,I-DiseaseOrPhenotypicFeature
had,441,O
a,441,O
mutation,441,O
of,441,O
arginine,441,B-SequenceVariant
555-to-tryptophan,441,I-SequenceVariant
(,441,O
Arg555Trp,441,B-SequenceVariant
),441,O
and,441,O
1,441,O
patient,441,B-OrganismTaxon
with,441,O
GCD,441,B-DiseaseOrPhenotypicFeature
type,441,I-DiseaseOrPhenotypicFeature
III,441,I-DiseaseOrPhenotypicFeature
(,441,O
Reis-Bucklers,441,B-DiseaseOrPhenotypicFeature
dystrophy,441,I-DiseaseOrPhenotypicFeature
),441,O
",",441,O
had,441,O
the,441,O
Arg124Leu,441,B-SequenceVariant
mutation,441,O
.,441,O
Seven,442,O
novel,442,O
single-nucleotide,442,O
polymorphisms,442,O
(,442,O
SNPs,442,O
),442,O
were,442,O
also,442,O
found,442,O
",",442,O
of,442,O
which,442,O
a,442,O
change,442,O
of,442,O
leucine,442,B-SequenceVariant
269,442,I-SequenceVariant
to,442,I-SequenceVariant
phenylalanine,442,I-SequenceVariant
(,442,O
Leu269Phe,442,B-SequenceVariant
),442,O
was,442,O
found,442,O
in,442,O
12,442,O
of,442,O
18,442,O
patients,442,B-OrganismTaxon
with,442,O
the,442,O
Arg555Trp,442,B-SequenceVariant
mutation,442,O
.,442,O
CONCLUSIONS,443,O
:,443,O
Arg124Cys,443,B-SequenceVariant
and,443,O
Arg555Trp,443,B-SequenceVariant
appear,443,O
to,443,O
be,443,O
the,443,O
predominant,443,O
mutations,443,O
causing,443,O
LCD,443,B-DiseaseOrPhenotypicFeature
and,443,O
GCD,443,B-DiseaseOrPhenotypicFeature
",",443,O
respectively,443,O
",",443,O
in,443,O
the,443,O
population,443,O
studied,443,O
.,443,O
The,444,O
novel,444,O
mutations,444,O
identified,444,O
in,444,O
this,444,O
study,444,O
are,444,O
associated,444,O
with,444,O
distinct,444,O
phenotypes,444,O
.,444,O
Glucose,445,B-ChemicalEntity
metabolism,445,O
in,445,O
patients,445,B-OrganismTaxon
with,445,O
schizophrenia,445,B-DiseaseOrPhenotypicFeature
treated,445,O
with,445,O
atypical,445,O
antipsychotic,445,B-ChemicalEntity
agents,445,I-ChemicalEntity
:,445,O
a,445,O
frequently,445,O
sampled,445,O
intravenous,445,O
glucose,445,B-ChemicalEntity
tolerance,445,O
test,445,O
and,445,O
minimal,445,O
model,445,O
analysis,445,O
.,445,O
BACKGROUND,446,O
:,446,O
While,446,O
the,446,O
incidence,446,O
of,446,O
new-onset,446,O
diabetes,446,B-DiseaseOrPhenotypicFeature
mellitus,446,I-DiseaseOrPhenotypicFeature
may,446,O
be,446,O
increasing,446,O
in,446,O
patients,446,B-OrganismTaxon
with,446,O
schizophrenia,446,B-DiseaseOrPhenotypicFeature
treated,446,O
with,446,O
certain,446,O
atypical,446,O
antipsychotic,446,B-ChemicalEntity
agents,446,I-ChemicalEntity
",",446,O
it,446,O
remains,446,O
unclear,446,O
whether,446,O
atypical,446,O
agents,446,O
are,446,O
directly,446,O
affecting,446,O
glucose,446,B-ChemicalEntity
metabolism,446,O
or,446,O
simply,446,O
increasing,446,O
known,446,O
risk,446,O
factors,446,O
for,446,O
diabetes,446,B-DiseaseOrPhenotypicFeature
.,446,O
OBJECTIVE,447,O
:,447,O
To,447,O
study,447,O
the,447,O
2,447,O
drugs,447,O
most,447,O
clearly,447,O
implicated,447,O
(,447,O
clozapine,447,B-ChemicalEntity
and,447,O
olanzapine,447,B-ChemicalEntity
),447,O
and,447,O
risperidone,447,B-ChemicalEntity
using,447,O
a,447,O
frequently,447,O
sampled,447,O
intravenous,447,O
glucose,447,B-ChemicalEntity
tolerance,447,O
test,447,O
.,447,O
DESIGN,448,O
:,448,O
A,448,O
cross-sectional,448,O
design,448,O
in,448,O
stable,448,O
",",448,O
treated,448,O
patients,448,B-OrganismTaxon
with,448,O
schizophrenia,448,B-DiseaseOrPhenotypicFeature
evaluated,448,O
using,448,O
a,448,O
frequently,448,O
sampled,448,O
intravenous,448,O
glucose,448,B-ChemicalEntity
tolerance,448,O
test,448,O
and,448,O
the,448,O
Bergman,448,O
minimal,448,O
model,448,O
analysis,448,O
.,448,O
SETTING,449,O
:,449,O
Subjects,449,O
were,449,O
recruited,449,O
from,449,O
an,449,O
urban,449,O
community,449,O
mental,449,O
health,449,O
clinic,449,O
and,449,O
were,449,O
studied,449,O
at,449,O
a,449,O
general,449,O
clinical,449,O
research,449,O
center,449,O
.,449,O
Patients,450,B-OrganismTaxon
Fifty,450,O
subjects,450,O
signed,450,O
informed,450,O
consent,450,O
and,450,O
41,450,O
underwent,450,O
the,450,O
frequently,450,O
sampled,450,O
intravenous,450,O
glucose,450,B-ChemicalEntity
tolerance,450,O
test,450,O
.,450,O
Thirty-six,451,O
nonobese,451,O
subjects,451,O
with,451,O
schizophrenia,451,B-DiseaseOrPhenotypicFeature
or,451,O
schizoaffective,451,B-DiseaseOrPhenotypicFeature
disorder,451,I-DiseaseOrPhenotypicFeature
",",451,O
matched,451,O
by,451,O
body,451,O
mass,451,O
index,451,O
and,451,O
treated,451,O
with,451,O
either,451,O
clozapine,451,B-ChemicalEntity
",",451,O
olanzapine,451,B-ChemicalEntity
",",451,O
or,451,O
risperidone,451,B-ChemicalEntity
",",451,O
were,451,O
included,451,O
in,451,O
the,451,O
analysis,451,O
.,451,O
MAIN,452,O
OUTCOME,452,O
MEASURES,452,O
:,452,O
Fasting,452,O
plasma,452,O
glucose,452,B-ChemicalEntity
and,452,O
fasting,452,O
serum,452,O
insulin,452,B-ChemicalEntity
levels,452,O
",",452,O
insulin,452,O
sensitivity,452,O
index,452,O
",",452,O
homeostasis,452,O
model,452,O
assessment,452,O
of,452,O
insulin,452,B-DiseaseOrPhenotypicFeature
resistance,452,I-DiseaseOrPhenotypicFeature
",",452,O
and,452,O
glucose,452,B-ChemicalEntity
effectiveness,452,O
.,452,O
RESULTS,453,O
:,453,O
The,453,O
mean,453,O
+/-,453,O
SD,453,O
duration,453,O
of,453,O
treatment,453,O
with,453,O
the,453,O
identified,453,O
atypical,453,O
antipsychotic,453,B-ChemicalEntity
agent,453,I-ChemicalEntity
was,453,O
68.3,453,O
+/-,453,O
28.9,453,O
months,453,O
(,453,O
clozapine,453,B-ChemicalEntity
),453,O
",",453,O
29.5,453,O
+/-,453,O
17.5,453,O
months,453,O
(,453,O
olanzapine,453,B-ChemicalEntity
),453,O
",",453,O
and,453,O
40.9,453,O
+/-,453,O
33.7,453,O
(,453,O
risperidone,453,B-ChemicalEntity
),453,O
.,453,O
Fasting,454,O
serum,454,O
insulin,454,B-ChemicalEntity
concentrations,454,O
differed,454,O
among,454,O
groups,454,O
(,454,O
F,454,O
(,454,O
33,454,O
),454,O
=,454,O
3.35,454,O
;,454,O
P,454,O
=,454,O
.047,454,O
),454,O
(,454,O
clozapine,454,B-ChemicalEntity
>,454,O
olanzapine,454,B-ChemicalEntity
>,454,O
risperidone,454,B-ChemicalEntity
),454,O
with,454,O
significant,454,O
differences,454,O
between,454,O
clozapine,454,B-ChemicalEntity
and,454,O
risperidone,454,B-ChemicalEntity
(,454,O
t,454,O
(,454,O
33,454,O
),454,O
=,454,O
2.32,454,O
;,454,O
P,454,O
=,454,O
.03,454,O
),454,O
and,454,O
olanzapine,454,B-ChemicalEntity
and,454,O
risperidone,454,B-ChemicalEntity
(,454,O
t,454,O
(,454,O
33,454,O
),454,O
=,454,O
2.15,454,O
;,454,O
P,454,O
=,454,O
.04,454,O
),454,O
.,454,O
There,455,O
was,455,O
a,455,O
significant,455,O
difference,455,O
in,455,O
insulin,455,O
sensitivity,455,O
index,455,O
among,455,O
groups,455,O
(,455,O
F,455,O
(,455,O
33,455,O
),455,O
=,455,O
10.66,455,O
;,455,O
P,455,O
<,455,O
.001,455,O
),455,O
(,455,O
clozapine,455,B-ChemicalEntity
<,455,O
olanzapine,455,B-ChemicalEntity
<,455,O
risperidone,455,B-ChemicalEntity
),455,O
",",455,O
with,455,O
subjects,455,O
who,455,O
received,455,O
clozapine,455,B-ChemicalEntity
and,455,O
olanzapine,455,B-ChemicalEntity
exhibiting,455,O
significant,455,O
insulin,455,B-DiseaseOrPhenotypicFeature
resistance,455,I-DiseaseOrPhenotypicFeature
compared,455,O
with,455,O
subjects,455,O
who,455,O
were,455,O
treated,455,O
with,455,O
risperidone,455,B-ChemicalEntity
(,455,O
clozapine,455,B-ChemicalEntity
vs,455,O
risperidone,455,B-ChemicalEntity
",",455,O
t,455,O
(,455,O
33,455,O
),455,O
=,455,O
-4.29,455,O
;,455,O
P,455,O
<,455,O
.001,455,O
;,455,O
olanzapine,455,B-ChemicalEntity
vs,455,O
risperidone,455,B-ChemicalEntity
",",455,O
t,455,O
(,455,O
33,455,O
),455,O
=,455,O
-3.62,455,O
;,455,O
P,455,O
=,455,O
.001,455,O
[,455,O
P,455,O
<,455,O
.001,455,O
],455,O
),455,O
.,455,O
The,456,O
homeostasis,456,O
model,456,O
assessment,456,O
of,456,O
insulin,456,B-DiseaseOrPhenotypicFeature
resistance,456,I-DiseaseOrPhenotypicFeature
also,456,O
differed,456,O
significantly,456,O
among,456,O
groups,456,O
(,456,O
F,456,O
(,456,O
33,456,O
),456,O
=,456,O
4.92,456,O
;,456,O
P,456,O
=,456,O
.01,456,O
),456,O
(,456,O
clozapine,456,B-ChemicalEntity
>,456,O
olanzapine,456,B-ChemicalEntity
>,456,O
risperidone,456,B-ChemicalEntity
),456,O
(,456,O
clozapine,456,B-ChemicalEntity
vs,456,O
risperidone,456,B-ChemicalEntity
",",456,O
t,456,O
(,456,O
33,456,O
),456,O
=,456,O
2.94,456,O
;,456,O
P,456,O
=,456,O
.006,456,O
;,456,O
olanzapine,456,B-ChemicalEntity
vs,456,O
risperidone,456,B-ChemicalEntity
",",456,O
t,456,O
(,456,O
33,456,O
),456,O
=,456,O
2.42,456,O
;,456,O
P,456,O
=,456,O
.02,456,O
),456,O
.,456,O
There,457,O
was,457,O
a,457,O
significant,457,O
difference,457,O
among,457,O
groups,457,O
in,457,O
glucose,457,B-ChemicalEntity
effectiveness,457,O
(,457,O
F,457,O
(,457,O
30,457,O
),457,O
=,457,O
4.18,457,O
;,457,O
P,457,O
=,457,O
.02,457,O
),457,O
(,457,O
clozapine,457,B-ChemicalEntity
<,457,O
olanzapine,457,B-ChemicalEntity
<,457,O
risperidone,457,B-ChemicalEntity
),457,O
with,457,O
significant,457,O
differences,457,O
between,457,O
clozapine,457,B-ChemicalEntity
and,457,O
risperidone,457,B-ChemicalEntity
(,457,O
t,457,O
(,457,O
30,457,O
),457,O
=,457,O
-2.59,457,O
;,457,O
P,457,O
=,457,O
.02,457,O
),457,O
and,457,O
olanzapine,457,B-ChemicalEntity
and,457,O
risperidone,457,B-ChemicalEntity
(,457,O
t,457,O
(,457,O
30,457,O
),457,O
=,457,O
-2.34,457,O
",",457,O
P,457,O
=,457,O
.03,457,O
),457,O
.,457,O
CONCLUSIONS,458,O
:,458,O
Both,458,O
nonobese,458,O
clozapine-,458,B-ChemicalEntity
and,458,O
olanzapine-treated,458,B-ChemicalEntity
groups,458,O
displayed,458,O
significant,458,O
insulin,458,B-DiseaseOrPhenotypicFeature
resistance,458,I-DiseaseOrPhenotypicFeature
and,458,O
impairment,458,O
of,458,O
glucose,458,B-ChemicalEntity
effectiveness,458,O
compared,458,O
with,458,O
risperidone-treated,458,B-ChemicalEntity
subjects,458,O
.,458,O
Patients,459,B-OrganismTaxon
taking,459,O
clozapine,459,B-ChemicalEntity
and,459,O
olanzapine,459,B-ChemicalEntity
must,459,O
be,459,O
examined,459,O
for,459,O
insulin,459,B-DiseaseOrPhenotypicFeature
resistance,459,I-DiseaseOrPhenotypicFeature
and,459,O
its,459,O
consequences,459,O
.,459,O
Primary,460,B-DiseaseOrPhenotypicFeature
malignant,460,I-DiseaseOrPhenotypicFeature
lymphoma,460,I-DiseaseOrPhenotypicFeature
of,460,I-DiseaseOrPhenotypicFeature
the,460,I-DiseaseOrPhenotypicFeature
brain,460,I-DiseaseOrPhenotypicFeature
:,460,O
frequent,460,O
abnormalities,460,O
and,460,O
inactivation,460,O
of,460,O
p14,460,B-GeneOrGeneProduct
tumor,460,B-DiseaseOrPhenotypicFeature
suppressor,460,O
gene,460,O
.,460,O
Ten,461,O
primary,461,B-DiseaseOrPhenotypicFeature
central,461,I-DiseaseOrPhenotypicFeature
nervous,461,I-DiseaseOrPhenotypicFeature
system,461,I-DiseaseOrPhenotypicFeature
lymphomas,461,I-DiseaseOrPhenotypicFeature
(,461,O
PCNSL,461,B-DiseaseOrPhenotypicFeature
",",461,O
brain,461,B-DiseaseOrPhenotypicFeature
lymphomas,461,I-DiseaseOrPhenotypicFeature
),461,O
were,461,O
examined,461,O
for,461,O
p14,461,B-GeneOrGeneProduct
gene,461,O
exon,461,O
1beta,461,O
deletion,461,O
",",461,O
mutation,461,O
and,461,O
methylation,461,O
by,461,O
Southern,461,O
blot,461,O
analysis,461,O
",",461,O
nucleotide,461,O
analysis,461,O
of,461,O
polymerase,461,O
chain,461,O
reaction,461,O
clones,461,O
and,461,O
Southern,461,O
blot-based,461,O
methylation,461,O
assay,461,O
.,461,O
In,462,O
Southern,462,O
blot,462,O
analysis,462,O
",",462,O
from,462,O
the,462,O
signal,462,O
densities,462,O
of,462,O
the,462,O
hybridized,462,O
bands,462,O
and,462,O
their,462,O
similarities,462,O
to,462,O
those,462,O
of,462,O
exons,462,O
2,462,O
and,462,O
3,462,O
in,462,O
our,462,O
previous,462,O
quantitative,462,O
study,462,O
",",462,O
we,462,O
found,462,O
that,462,O
exon,462,O
1beta,462,O
was,462,O
homozygously,462,O
deleted,462,O
in,462,O
four,462,O
cases,462,O
",",462,O
hemizygously,462,O
deleted,462,O
in,462,O
five,462,O
cases,462,O
and,462,O
not,462,O
deleted,462,O
in,462,O
one,462,O
case,462,O
.,462,O
Thus,463,O
",",463,O
the,463,O
same,463,O
deletion,463,O
patterns,463,O
covered,463,O
the,463,O
entire,463,O
p14,463,B-GeneOrGeneProduct
gene,463,O
for,463,O
all,463,O
cases,463,O
except,463,O
for,463,O
one,463,O
case,463,O
",",463,O
which,463,O
suggested,463,O
the,463,O
hemizygous,463,O
deletion,463,O
of,463,O
exons,463,O
1beta,463,O
and,463,O
2,463,O
and,463,O
homozygous,463,O
deletion,463,O
of,463,O
exon,463,O
3,463,O
.,463,O
In,464,O
addition,464,O
",",464,O
although,464,O
exon,464,O
1beta,464,O
mutation,464,O
is,464,O
rare,464,O
in,464,O
various,464,O
tumors,464,B-DiseaseOrPhenotypicFeature
",",464,O
we,464,O
detected,464,O
a,464,O
missense,464,O
mutation,464,O
(,464,O
L50R,464,B-SequenceVariant
),464,O
in,464,O
one,464,O
case,464,O
with,464,O
a,464,O
hemizygous,464,O
deletion,464,O
.,464,O
Methylation,465,O
of,465,O
the,465,O
5'CpG,465,O
island,465,O
of,465,O
the,465,O
p14,465,B-GeneOrGeneProduct
gene,465,O
was,465,O
not,465,O
suggested,465,O
for,465,O
any,465,O
case,465,O
without,465,O
homozygous,465,O
deletion,465,O
.,465,O
Our,466,O
observation,466,O
of,466,O
frequent,466,O
p14,466,B-GeneOrGeneProduct
gene,466,O
abnormalities,466,O
(,466,O
90,466,O
%,466,O
),466,O
and,466,O
inactivation,466,O
(,466,O
40-60,466,O
%,466,O
),466,O
was,466,O
in,466,O
striking,466,O
contrast,466,O
to,466,O
the,466,O
same,466,O
pathological,466,O
subtype,466,O
of,466,O
systemic,466,B-DiseaseOrPhenotypicFeature
lymphoma,466,I-DiseaseOrPhenotypicFeature
in,466,O
which,466,O
p14,466,B-GeneOrGeneProduct
gene,466,O
abnormalities,466,O
and,466,O
inactivation,466,O
were,466,O
infrequent,466,O
",",466,O
suggesting,466,O
a,466,O
difference,466,O
in,466,O
carcinogenesis,466,B-DiseaseOrPhenotypicFeature
between,466,O
PCNSL,466,B-DiseaseOrPhenotypicFeature
and,466,O
systemic,466,B-DiseaseOrPhenotypicFeature
lymphoma,466,I-DiseaseOrPhenotypicFeature
.,466,O
Acute,467,O
low,467,B-DiseaseOrPhenotypicFeature
back,467,I-DiseaseOrPhenotypicFeature
pain,467,I-DiseaseOrPhenotypicFeature
during,467,O
intravenous,467,O
administration,467,O
of,467,O
amiodarone,467,B-ChemicalEntity
:,467,O
a,467,O
report,467,O
of,467,O
two,467,O
cases,467,O
.,467,O
Amiodarone,468,B-ChemicalEntity
represents,468,O
an,468,O
effective,468,O
antiarrhythmic,468,B-ChemicalEntity
drug,468,I-ChemicalEntity
for,468,O
cardioversion,468,O
of,468,O
recent-onset,468,O
atrial,468,B-DiseaseOrPhenotypicFeature
fibrillation,468,I-DiseaseOrPhenotypicFeature
(,468,O
AF,468,B-DiseaseOrPhenotypicFeature
),468,O
and,468,O
maintenance,468,O
of,468,O
sinus,468,O
rhythm,468,O
.,468,O
We,469,O
briefly,469,O
describe,469,O
two,469,O
patients,469,B-OrganismTaxon
suffering,469,O
from,469,O
recent-onset,469,O
atrial,469,B-DiseaseOrPhenotypicFeature
fibrillation,469,I-DiseaseOrPhenotypicFeature
",",469,O
who,469,O
experienced,469,O
an,469,O
acute,469,O
devastating,469,O
low,469,B-DiseaseOrPhenotypicFeature
back,469,I-DiseaseOrPhenotypicFeature
pain,469,I-DiseaseOrPhenotypicFeature
a,469,O
few,469,O
minutes,469,O
after,469,O
initiation,469,O
of,469,O
intravenous,469,O
amiodarone,469,B-ChemicalEntity
loading,469,O
.,469,O
Notably,470,O
",",470,O
this,470,O
side,470,O
effect,470,O
has,470,O
not,470,O
been,470,O
ever,470,O
reported,470,O
in,470,O
the,470,O
medical,470,O
literature,470,O
.,470,O
Clinicians,471,O
should,471,O
be,471,O
aware,471,O
of,471,O
this,471,O
reaction,471,O
since,471,O
prompt,471,O
termination,471,O
of,471,O
parenteral,471,O
administration,471,O
leads,471,O
to,471,O
complete,471,O
resolution,471,O
.,471,O
Photochemoprevention,472,O
of,472,O
ultraviolet,472,O
B,472,O
signaling,472,O
and,472,O
photocarcinogenesis,472,O
.,472,O
Exposure,473,O
to,473,O
solar,473,O
radiation,473,O
",",473,O
particularly,473,O
its,473,O
ultraviolet,473,O
(,473,O
UV,473,O
),473,O
B,473,O
component,473,O
",",473,O
has,473,O
a,473,O
variety,473,O
of,473,O
harmful,473,O
effects,473,O
on,473,O
human,473,B-OrganismTaxon
health,473,O
.,473,O
Some,474,O
of,474,O
these,474,O
effects,474,O
include,474,O
sunburn,474,O
cell,474,O
formation,474,O
",",474,O
basal,474,B-DiseaseOrPhenotypicFeature
and,474,I-DiseaseOrPhenotypicFeature
squamous,474,I-DiseaseOrPhenotypicFeature
cell,474,I-DiseaseOrPhenotypicFeature
cancers,474,I-DiseaseOrPhenotypicFeature
",",474,O
melanoma,474,B-DiseaseOrPhenotypicFeature
",",474,O
cataracts,474,B-DiseaseOrPhenotypicFeature
",",474,O
photoaging,474,O
of,474,O
the,474,O
skin,474,O
",",474,O
and,474,O
immune,474,O
suppression,474,O
.,474,O
Amongst,475,O
these,475,O
various,475,O
adverse,475,O
effects,475,O
of,475,O
UV,475,O
radiation,475,O
",",475,O
skin,475,B-DiseaseOrPhenotypicFeature
cancer,475,I-DiseaseOrPhenotypicFeature
is,475,O
of,475,O
the,475,O
greatest,475,O
concern,475,O
.,475,O
Over,476,O
the,476,O
years,476,O
",",476,O
changes,476,O
in,476,O
lifestyle,476,O
has,476,O
led,476,O
to,476,O
a,476,O
significant,476,O
increase,476,O
in,476,O
the,476,O
amount,476,O
of,476,O
UV,476,O
radiation,476,O
that,476,O
people,476,O
receive,476,O
",",476,O
and,476,O
this,476,O
consequently,476,O
has,476,O
led,476,O
to,476,O
a,476,O
surge,476,O
in,476,O
the,476,O
incidence,476,O
of,476,O
skin,476,B-DiseaseOrPhenotypicFeature
cancer,476,I-DiseaseOrPhenotypicFeature
.,476,O
The,477,O
development,477,O
of,477,O
skin,477,B-DiseaseOrPhenotypicFeature
cancer,477,I-DiseaseOrPhenotypicFeature
is,477,O
a,477,O
complex,477,O
multistage,477,O
phenomenon,477,O
involving,477,O
three,477,O
distinct,477,O
stages,477,O
exemplified,477,O
by,477,O
initiation,477,O
",",477,O
promotion,477,O
and,477,O
progression,477,O
stages,477,O
.,477,O
Each,478,O
of,478,O
these,478,O
stages,478,O
is,478,O
mediated,478,O
via,478,O
alterations,478,O
in,478,O
various,478,O
cellular,478,O
",",478,O
biochemical,478,O
",",478,O
and,478,O
molecular,478,O
changes,478,O
.,478,O
Initiation,479,O
",",479,O
the,479,O
first,479,O
step,479,O
in,479,O
the,479,O
carcinogenesis,479,B-DiseaseOrPhenotypicFeature
process,479,O
is,479,O
essentially,479,O
an,479,O
irreversible,479,O
step,479,O
in,479,O
which,479,O
genetic,479,O
alterations,479,O
occur,479,O
in,479,O
genes,479,O
that,479,O
ultimately,479,O
leads,479,O
to,479,O
DNA,479,O
modification,479,O
and,479,O
fixation,479,O
of,479,O
mutation,479,O
.,479,O
Tumor,480,B-DiseaseOrPhenotypicFeature
promotion,480,O
is,480,O
the,480,O
essential,480,O
process,480,O
in,480,O
cancer,480,B-DiseaseOrPhenotypicFeature
development,480,O
involving,480,O
clonal,480,O
expansion,480,O
of,480,O
initiated,480,O
cells,480,O
giving,480,O
rise,480,O
to,480,O
pre-malignant,480,O
and,480,O
then,480,O
to,480,O
malignant,480,O
lesions,480,O
",",480,O
essentially,480,O
by,480,O
alterations,480,O
in,480,O
signal,480,O
transduction,480,O
pathways,480,O
.,480,O
Tumor,481,B-DiseaseOrPhenotypicFeature
progression,481,O
involves,481,O
the,481,O
conversion,481,O
of,481,O
pre-malignant,481,O
and,481,O
malignant,481,O
lesions,481,O
into,481,O
an,481,O
invasive,481,O
and,481,O
potentially,481,O
metastatic,481,O
malignant,481,O
tumor,481,B-DiseaseOrPhenotypicFeature
.,481,O
All,482,O
these,482,O
processes,482,O
for,482,O
skin,482,B-DiseaseOrPhenotypicFeature
cancer,482,I-DiseaseOrPhenotypicFeature
development,482,O
involve,482,O
stimulation,482,O
of,482,O
DNA,482,O
synthesis,482,O
",",482,O
DNA,482,O
damage,482,O
and,482,O
proliferation,482,O
",",482,O
inflammation,482,B-DiseaseOrPhenotypicFeature
",",482,O
immunosuppression,482,O
",",482,O
epidermal,482,B-DiseaseOrPhenotypicFeature
hyperplasia,482,I-DiseaseOrPhenotypicFeature
",",482,O
cell,482,O
cycle,482,O
dysregulation,482,O
",",482,O
depletion,482,O
of,482,O
antioxidant,482,B-ChemicalEntity
defenses,482,O
",",482,O
impairment,482,O
of,482,O
signal,482,O
transduction,482,O
pathways,482,O
",",482,O
induction,482,O
of,482,O
cyclooxygenase,482,B-GeneOrGeneProduct
",",482,O
increase,482,O
in,482,O
prostaglandin,482,B-ChemicalEntity
synthesis,482,O
",",482,O
and,482,O
induction,482,O
of,482,O
ornithine,482,B-GeneOrGeneProduct
decarboxylase,482,I-GeneOrGeneProduct
.,482,O
Photochemoprevention,483,O
has,483,O
been,483,O
appreciated,483,O
as,483,O
a,483,O
viable,483,O
approach,483,O
to,483,O
reduce,483,O
the,483,O
occurrence,483,O
of,483,O
skin,483,B-DiseaseOrPhenotypicFeature
cancer,483,I-DiseaseOrPhenotypicFeature
and,483,O
in,483,O
recent,483,O
years,483,O
",",483,O
the,483,O
use,483,O
of,483,O
agents,483,O
",",483,O
especially,483,O
botanical,483,O
antioxidants,483,B-ChemicalEntity
",",483,O
present,483,O
in,483,O
the,483,O
common,483,O
diet,483,O
and,483,O
beverages,483,O
consumed,483,O
by,483,O
human,483,B-OrganismTaxon
population,483,O
have,483,O
gained,483,O
considerable,483,O
attention,483,O
as,483,O
photochemopreventive,483,O
agents,483,O
for,483,O
human,483,B-OrganismTaxon
use,483,O
.,483,O
Many,484,O
such,484,O
agents,484,O
have,484,O
also,484,O
found,484,O
a,484,O
place,484,O
in,484,O
skin,484,O
care,484,O
products,484,O
.,484,O
Although,485,O
this,485,O
is,485,O
more,485,O
common,485,O
in,485,O
oriental,485,O
countries,485,O
",",485,O
its,485,O
popularity,485,O
is,485,O
significantly,485,O
growing,485,O
in,485,O
western,485,O
countries,485,O
.,485,O
In,486,O
this,486,O
article,486,O
",",486,O
we,486,O
have,486,O
summarized,486,O
the,486,O
available,486,O
information,486,O
of,486,O
laboratory,486,O
studies,486,O
on,486,O
UVB-mediated,486,O
signaling,486,O
that,486,O
can,486,O
be,486,O
exploited,486,O
as,486,O
targets,486,O
for,486,O
photochemoprevention,486,O
.,486,O
We,487,O
suggest,487,O
that,487,O
the,487,O
use,487,O
of,487,O
skin,487,O
care,487,O
products,487,O
supplemented,487,O
with,487,O
proven,487,O
chemopreventive,487,O
agents,487,O
in,487,O
conjunction,487,O
with,487,O
the,487,O
use,487,O
of,487,O
sunscreens,487,O
along,487,O
with,487,O
educational,487,O
efforts,487,O
may,487,O
be,487,O
an,487,O
effective,487,O
strategy,487,O
for,487,O
reducing,487,O
UV-induced,487,O
photodamage,487,O
and,487,O
skin,487,B-DiseaseOrPhenotypicFeature
cancer,487,I-DiseaseOrPhenotypicFeature
in,487,O
humans,487,B-OrganismTaxon
.,487,O
The,488,O
mechanistic,488,O
basis,488,O
for,488,O
the,488,O
use,488,O
of,488,O
such,488,O
products,488,O
is,488,O
discussed,488,O
.,488,O
Two,489,O
novel,489,O
mutations,489,O
",",489,O
L490R,489,B-SequenceVariant
and,489,O
V561X,489,B-SequenceVariant
",",489,O
of,489,O
the,489,O
transferrin,489,B-GeneOrGeneProduct
receptor,489,I-GeneOrGeneProduct
2,489,I-GeneOrGeneProduct
gene,489,O
in,489,O
Japanese,489,O
patients,489,B-OrganismTaxon
with,489,O
hemochromatosis,489,B-DiseaseOrPhenotypicFeature
.,489,O
BACKGROUND,490,O
AND,490,O
OBJECTIVES,490,O
:,490,O
The,490,O
low,490,O
prevalence,490,O
of,490,O
the,490,O
C282Y,490,B-SequenceVariant
mutation,490,O
of,490,O
the,490,O
HFE,490,B-GeneOrGeneProduct
gene,490,O
in,490,O
Japan,490,O
means,490,O
that,490,O
the,490,O
genetic,490,O
background,490,O
of,490,O
hemochromatosis,490,B-DiseaseOrPhenotypicFeature
in,490,O
Japanese,490,O
patients,490,B-OrganismTaxon
remains,490,O
unclear,490,O
.,490,O
In,491,O
a,491,O
previous,491,O
report,491,O
",",491,O
we,491,O
showed,491,O
that,491,O
3,491,O
patients,491,B-OrganismTaxon
from,491,O
one,491,O
family,491,O
had,491,O
an,491,O
AVAQ,491,B-SequenceVariant
594-597,491,I-SequenceVariant
deletion,491,I-SequenceVariant
of,491,O
the,491,O
transferrin,491,B-GeneOrGeneProduct
receptor,491,I-GeneOrGeneProduct
(,491,O
TfR2,491,B-GeneOrGeneProduct
),491,O
gene,491,O
.,491,O
This,492,O
suggests,492,O
that,492,O
the,492,O
TfR2,492,B-GeneOrGeneProduct
gene,492,O
is,492,O
involved,492,O
in,492,O
hemochromatosis,492,B-DiseaseOrPhenotypicFeature
in,492,O
Japanese,492,O
patients,492,B-OrganismTaxon
.,492,O
DESIGN,493,O
AND,493,O
METHODS,493,O
:,493,O
Nine,493,O
patients,493,B-OrganismTaxon
clinically,493,O
diagnosed,493,O
with,493,O
hemochromatosis,493,B-DiseaseOrPhenotypicFeature
were,493,O
included,493,O
in,493,O
the,493,O
study,493,O
.,493,O
DNA,494,O
was,494,O
extracted,494,O
from,494,O
whole,494,O
blood,494,O
samples,494,O
collected,494,O
with,494,O
informed,494,O
consent,494,O
.,494,O
The,495,O
HFE,495,B-GeneOrGeneProduct
and,495,O
TfR2,495,B-GeneOrGeneProduct
genes,495,O
were,495,O
analyzed,495,O
by,495,O
sequencing,495,O
the,495,O
coding,495,O
region,495,O
and,495,O
splicing,495,O
sites,495,O
.,495,O
RESULTS,496,O
:,496,O
There,496,O
were,496,O
no,496,O
mutations,496,O
in,496,O
the,496,O
HFE,496,B-GeneOrGeneProduct
gene,496,O
.,496,O
In,497,O
the,497,O
TfR2,497,B-GeneOrGeneProduct
gene,497,O
",",497,O
2,497,O
novel,497,O
mutations,497,O
",",497,O
1469T-,497,B-SequenceVariant
>,497,I-SequenceVariant
G,497,I-SequenceVariant
(,497,O
L490R,497,B-SequenceVariant
),497,O
and,497,O
1665delC,497,B-SequenceVariant
(,497,O
V561X,497,B-SequenceVariant
),497,O
",",497,O
were,497,O
found,497,O
in,497,O
2,497,O
patients,497,B-OrganismTaxon
.,497,O
A,498,O
known,498,O
variation,498,O
",",498,O
714C-,498,B-SequenceVariant
>,498,O
(,498,O
I238M,498,B-SequenceVariant
),498,O
",",498,O
was,498,O
also,498,O
found,498,O
in,498,O
the,498,O
patient,498,B-OrganismTaxon
with,498,O
L490R,498,B-SequenceVariant
.,498,O
The,499,O
patient,499,B-OrganismTaxon
homozygous,499,O
for,499,O
both,499,O
L490R,499,B-SequenceVariant
and,499,O
I238M,499,B-SequenceVariant
presented,499,O
with,499,O
a,499,O
mild,499,O
manifestation,499,O
of,499,O
hemochromatosis,499,B-DiseaseOrPhenotypicFeature
at,499,O
the,499,O
age,499,O
of,499,O
41,499,O
years,499,O
.,499,O
His,500,O
liver,500,O
was,500,O
cirrhotic,500,B-DiseaseOrPhenotypicFeature
with,500,O
parenchymal,500,O
iron,500,B-ChemicalEntity
deposits,500,O
and,500,O
the,500,O
result,500,O
of,500,O
a,500,O
glucose,500,B-ChemicalEntity
tolerance,500,O
test,500,O
was,500,O
compatible,500,O
with,500,O
diabetes,500,B-DiseaseOrPhenotypicFeature
mellitus,500,I-DiseaseOrPhenotypicFeature
.,500,O
The,501,O
patient,501,B-OrganismTaxon
homozygous,501,O
for,501,O
V561X,501,B-SequenceVariant
had,501,O
severe,501,O
iron,501,B-DiseaseOrPhenotypicFeature
overload,501,I-DiseaseOrPhenotypicFeature
with,501,O
the,501,O
triad,501,O
of,501,O
cirrhosis,501,B-DiseaseOrPhenotypicFeature
",",501,O
diabetes,501,B-DiseaseOrPhenotypicFeature
mellitus,501,I-DiseaseOrPhenotypicFeature
and,501,O
skin,501,B-DiseaseOrPhenotypicFeature
pigmentation,501,I-DiseaseOrPhenotypicFeature
at,501,O
the,501,O
age,501,O
of,501,O
58,501,O
years,501,O
.,501,O
INTERPRETATION,502,O
AND,502,O
CONCLUSIONS,502,O
:,502,O
Taken,502,O
together,502,O
with,502,O
the,502,O
previous,502,O
report,502,O
",",502,O
5,502,O
of,502,O
our,502,O
12,502,O
patients,502,B-OrganismTaxon
with,502,O
hemochromatosis,502,B-DiseaseOrPhenotypicFeature
manifesting,502,O
in,502,O
middle,502,O
age,502,O
had,502,O
mutations,502,O
in,502,O
the,502,O
TfR2,502,B-GeneOrGeneProduct
gene,502,O
.,502,O
Thus,503,O
",",503,O
TfR2,503,B-GeneOrGeneProduct
plays,503,O
a,503,O
role,503,O
in,503,O
the,503,O
pathogenesis,503,O
of,503,O
hemochromatosis,503,B-DiseaseOrPhenotypicFeature
in,503,O
Japan,503,O
.,503,O
Common,504,O
dihydrofolate,504,B-GeneOrGeneProduct
reductase,504,I-GeneOrGeneProduct
19-base,504,B-SequenceVariant
pair,504,I-SequenceVariant
deletion,504,I-SequenceVariant
allele,504,O
:,504,O
a,504,O
novel,504,O
risk,504,O
factor,504,O
for,504,O
preterm,504,B-DiseaseOrPhenotypicFeature
delivery,504,I-DiseaseOrPhenotypicFeature
.,504,O
BACKGROUND,505,O
:,505,O
Folate,505,B-ChemicalEntity
is,505,O
critical,505,O
for,505,O
cell,505,O
division,505,O
",",505,O
a,505,O
major,505,O
feature,505,O
of,505,O
in,505,O
utero,505,O
development,505,O
.,505,O
Dihydrofolate,506,B-GeneOrGeneProduct
reductase,506,I-GeneOrGeneProduct
(,506,O
DHFR,506,B-GeneOrGeneProduct
),506,O
is,506,O
required,506,O
to,506,O
convert,506,O
the,506,O
folic,506,B-ChemicalEntity
acid,506,I-ChemicalEntity
used,506,O
in,506,O
supplements,506,O
and,506,O
for,506,O
food,506,O
fortification,506,O
and,506,O
the,506,O
dihydrofolate,506,B-ChemicalEntity
produced,506,O
by,506,O
thymidylate,506,B-GeneOrGeneProduct
synthase,506,I-GeneOrGeneProduct
during,506,O
DNA,506,O
synthesis,506,O
to,506,O
the,506,O
reduced,506,O
folate,506,B-ChemicalEntity
forms,506,O
used,506,O
by,506,O
the,506,O
cell,506,O
.,506,O
OBJECTIVE,507,O
:,507,O
We,507,O
aimed,507,O
to,507,O
determine,507,O
whether,507,O
a,507,O
common,507,O
",",507,O
recently,507,O
discovered,507,O
deletion,507,O
polymorphism,507,O
in,507,O
the,507,O
DHFR,507,B-GeneOrGeneProduct
gene,507,O
is,507,O
a,507,O
risk,507,O
factor,507,O
for,507,O
preterm,507,B-DiseaseOrPhenotypicFeature
delivery,507,I-DiseaseOrPhenotypicFeature
or,507,O
low,507,O
birth,507,O
weight,507,O
.,507,O
DESIGN,508,O
:,508,O
We,508,O
studied,508,O
324,508,O
pregnant,508,O
women,508,B-OrganismTaxon
from,508,O
Camden,508,O
",",508,O
NJ,508,O
.,508,O
Folate,509,B-ChemicalEntity
intake,509,O
was,509,O
computed,509,O
from,509,O
folate,509,B-ChemicalEntity
supplement,509,O
intake,509,O
plus,509,O
the,509,O
mean,509,O
of,509,O
two,509,O
24-h,509,O
recalls,509,O
completed,509,O
during,509,O
the,509,O
course,509,O
of,509,O
pregnancy,509,O
.,509,O
Genomic,510,O
DNA,510,O
was,510,O
extracted,510,O
from,510,O
the,510,O
women,510,B-OrganismTaxon
's,510,O
leukocytes,510,O
and,510,O
genotyped,510,O
.,510,O
RESULTS,511,O
:,511,O
Women,511,B-OrganismTaxon
with,511,O
a,511,O
deletion,511,O
allele,511,O
had,511,O
a,511,O
significantly,511,O
greater,511,O
risk,511,O
of,511,O
preterm,511,B-DiseaseOrPhenotypicFeature
delivery,511,I-DiseaseOrPhenotypicFeature
[,511,O
adjusted,511,O
odds,511,O
ratio,511,O
(,511,O
AOR,511,O
),511,O
:,511,O
3.0,511,O
;,511,O
95,511,O
%,511,O
CI,511,O
:,511,O
1.0,511,O
",",511,O
8.8,511,O
;,511,O
P,511,O
<,511,O
0.05,511,O
],511,O
than,511,O
did,511,O
those,511,O
without,511,O
a,511,O
deletion,511,O
allele,511,O
.,511,O
Women,512,B-OrganismTaxon
with,512,O
both,512,O
a,512,O
DHFR,512,B-GeneOrGeneProduct
deletion,512,O
allele,512,O
and,512,O
low,512,O
folate,512,B-ChemicalEntity
intake,512,O
(,512,O
<,512,O
400,512,O
microg/d,512,O
from,512,O
diet,512,O
plus,512,O
supplements,512,O
),512,O
had,512,O
a,512,O
significantly,512,O
greater,512,O
risk,512,O
of,512,O
preterm,512,B-DiseaseOrPhenotypicFeature
delivery,512,I-DiseaseOrPhenotypicFeature
(,512,O
AOR,512,O
:,512,O
5.5,512,O
;,512,O
95,512,O
%,512,O
CI,512,O
:,512,O
1.5,512,O
",",512,O
20.4,512,O
;,512,O
P,512,O
=,512,O
0.01,512,O
),512,O
and,512,O
a,512,O
significantly,512,O
greater,512,O
risk,512,O
of,512,O
having,512,O
an,512,O
infant,512,O
with,512,O
a,512,O
low,512,O
birth,512,O
weight,512,O
(,512,O
AOR,512,O
:,512,O
8.3,512,O
;,512,O
95,512,O
%,512,O
CI,512,O
:,512,O
1.8,512,O
",",512,O
38.6,512,O
;,512,O
P,512,O
=,512,O
0.01,512,O
),512,O
than,512,O
did,512,O
women,512,B-OrganismTaxon
without,512,O
a,512,O
deletion,512,O
allele,512,O
and,512,O
with,512,O
a,512,O
folate,512,B-ChemicalEntity
intake,512,O
>,512,O
/=400,512,O
microg/d,512,O
.,512,O
CONCLUSIONS,513,O
:,513,O
The,513,O
DHFR,513,B-GeneOrGeneProduct
19-base,513,B-SequenceVariant
pair,513,I-SequenceVariant
deletion,513,I-SequenceVariant
allele,513,O
may,513,O
be,513,O
a,513,O
risk,513,O
factor,513,O
for,513,O
preterm,513,B-DiseaseOrPhenotypicFeature
delivery,513,I-DiseaseOrPhenotypicFeature
.,513,O
In,514,O
the,514,O
presence,514,O
of,514,O
low,514,O
dietary,514,O
folate,514,B-ChemicalEntity
",",514,O
the,514,O
allele,514,O
may,514,O
also,514,O
be,514,O
a,514,O
risk,514,O
factor,514,O
for,514,O
low,514,O
birth,514,O
weight,514,O
.,514,O
This,515,O
may,515,O
be,515,O
a,515,O
gene-environment,515,O
interaction,515,O
.,515,O
New,516,O
mutations,516,O
",",516,O
hotspots,516,O
",",516,O
and,516,O
founder,516,O
effects,516,O
in,516,O
Brazilian,516,O
patients,516,B-OrganismTaxon
with,516,O
steroid,516,B-DiseaseOrPhenotypicFeature
5alpha-reductase,516,I-DiseaseOrPhenotypicFeature
deficiency,516,I-DiseaseOrPhenotypicFeature
type,516,I-DiseaseOrPhenotypicFeature
2,516,I-DiseaseOrPhenotypicFeature
.,516,O
Mutations,517,O
of,517,O
the,517,O
steroid,517,B-GeneOrGeneProduct
5alpha-reductase,517,I-GeneOrGeneProduct
type,517,I-GeneOrGeneProduct
2,517,I-GeneOrGeneProduct
(,517,O
SRD5A2,517,B-GeneOrGeneProduct
),517,O
gene,517,O
in,517,O
46,517,O
",",517,O
XY,517,O
subjects,517,O
cause,517,O
masculinization,517,O
defects,517,O
of,517,O
varying,517,O
degrees,517,O
",",517,O
due,517,O
to,517,O
reduced,517,O
or,517,O
impaired,517,O
enzymatic,517,O
activity,517,O
.,517,O
In,518,O
this,518,O
study,518,O
",",518,O
sequence,518,O
abnormalities,518,O
of,518,O
the,518,O
SRD5A2,518,B-GeneOrGeneProduct
gene,518,O
were,518,O
assessed,518,O
by,518,O
polymerase,518,O
chain,518,O
reaction,518,O
with,518,O
specific,518,O
primers,518,O
and,518,O
automated,518,O
sequencing,518,O
analysis,518,O
in,518,O
DNA,518,O
samples,518,O
from,518,O
20,518,O
patients,518,B-OrganismTaxon
with,518,O
suspected,518,O
steroid,518,B-DiseaseOrPhenotypicFeature
5alpha-reductase,518,I-DiseaseOrPhenotypicFeature
type,518,I-DiseaseOrPhenotypicFeature
2,518,I-DiseaseOrPhenotypicFeature
deficiency,518,I-DiseaseOrPhenotypicFeature
from,518,O
18,518,O
Brazilian,518,O
families,518,O
.,518,O
Eleven,519,O
subjects,519,O
presented,519,O
SRD5A2,519,B-GeneOrGeneProduct
homozygous,519,O
single-base,519,O
mutations,519,O
(,519,O
two,519,O
first,519,O
cousins,519,O
and,519,O
four,519,O
unrelated,519,O
patients,519,B-OrganismTaxon
with,519,O
G183S,519,B-SequenceVariant
",",519,O
two,519,O
with,519,O
R246W,519,B-SequenceVariant
",",519,O
one,519,O
with,519,O
del642T,519,B-SequenceVariant
",",519,O
one,519,O
with,519,O
G196S,519,B-SequenceVariant
",",519,O
and,519,O
one,519,O
with,519,O
217_218insC,519,B-SequenceVariant
plus,519,O
the,519,O
A49T,519,B-SequenceVariant
variant,519,O
in,519,O
heterozygosis,519,O
),519,O
",",519,O
whereas,519,O
four,519,O
were,519,O
compound,519,O
heterozygotes,519,O
(,519,O
one,519,O
with,519,O
Q126R/IVS3+1G,519,B-SequenceVariant
>,519,I-SequenceVariant
A,519,I-SequenceVariant
",",519,O
one,519,O
with,519,O
Q126R/del418T,519,B-SequenceVariant
",",519,O
and,519,O
two,519,O
brothers,519,O
with,519,O
Q126R/G158R,519,B-SequenceVariant
),519,O
.,519,O
Three,520,O
patients,520,B-OrganismTaxon
were,520,O
heterozygous,520,O
for,520,O
A207D,520,B-SequenceVariant
",",520,O
G196S,520,B-SequenceVariant
",",520,O
and,520,O
R266W,520,B-SequenceVariant
substitutions,520,O
.,520,O
The,521,O
V89L,521,B-SequenceVariant
polymorphism,521,O
was,521,O
found,521,O
in,521,O
heterozygosis,521,O
in,521,O
one,521,O
of,521,O
them,521,O
(,521,O
with,521,O
A207D,521,B-SequenceVariant
),521,O
and,521,O
in,521,O
one,521,O
case,521,O
with,521,O
an,521,O
otherwise,521,O
normal,521,O
gene,521,O
sequence,521,O
.,521,O
The,522,O
A49T,522,B-SequenceVariant
variant,522,O
was,522,O
also,522,O
detected,522,O
in,522,O
heterozygosis,522,O
in,522,O
the,522,O
second,522,O
case,522,O
without,522,O
other,522,O
sequencing,522,O
abnormalities,522,O
.,522,O
Four,523,O
patients,523,B-OrganismTaxon
harbor,523,O
yet,523,O
non-described,523,O
SRD5A2,523,B-GeneOrGeneProduct
gene,523,O
mutations,523,O
:,523,O
a,523,O
single,523,O
nucleotide,523,O
deletion,523,O
(,523,O
del642T,523,B-SequenceVariant
),523,O
",",523,O
a,523,O
G158R,523,B-SequenceVariant
amino,523,O
acid,523,O
substitution,523,O
",",523,O
a,523,O
splice,523,O
junction,523,O
mutation,523,O
(,523,O
IVS3+1G,523,B-SequenceVariant
>,523,I-SequenceVariant
A,523,I-SequenceVariant
),523,O
",",523,O
and,523,O
the,523,O
insertion,523,O
of,523,O
a,523,O
cytosine,523,O
(,523,O
217_218insC,523,B-SequenceVariant
),523,O
occurring,523,O
at,523,O
a,523,O
CCCC,523,O
motif,523,O
.,523,O
This,524,O
is,524,O
the,524,O
first,524,O
report,524,O
of,524,O
a,524,O
single-nucleotide,524,O
insertion,524,O
in,524,O
the,524,O
coding,524,O
sequence,524,O
of,524,O
the,524,O
SRD5A2,524,B-GeneOrGeneProduct
gene,524,O
.,524,O
In,525,O
addition,525,O
to,525,O
these,525,O
new,525,O
mutations,525,O
",",525,O
this,525,O
investigation,525,O
reveals,525,O
the,525,O
prevalence,525,O
of,525,O
G183S,525,B-SequenceVariant
substitution,525,O
among,525,O
a,525,O
subset,525,O
of,525,O
African-Brazilian,525,O
patients,525,B-OrganismTaxon
and,525,O
presents,525,O
evidences,525,O
of,525,O
the,525,O
recurrence,525,O
of,525,O
already,525,O
known,525,O
mutations,525,O
.,525,O
Identification,526,O
of,526,O
novel,526,O
type,526,O
VII,526,B-GeneOrGeneProduct
collagen,526,I-GeneOrGeneProduct
gene,526,O
mutations,526,O
resulting,526,O
in,526,O
severe,526,O
recessive,526,B-DiseaseOrPhenotypicFeature
dystrophic,526,I-DiseaseOrPhenotypicFeature
epidermolysis,526,I-DiseaseOrPhenotypicFeature
bullosa,526,I-DiseaseOrPhenotypicFeature
.,526,O
In,527,O
this,527,O
work,527,O
",",527,O
we,527,O
studied,527,O
the,527,O
proband,527,O
in,527,O
a,527,O
small,527,O
nuclear,527,O
family,527,O
of,527,O
Chinese,527,O
and,527,O
Dutch/German,527,O
descent,527,O
and,527,O
identified,527,O
two,527,O
novel,527,O
mutations,527,O
in,527,O
the,527,O
type,527,O
VII,527,B-GeneOrGeneProduct
collagen,527,I-GeneOrGeneProduct
gene,527,O
leading,527,O
to,527,O
recessive,527,B-DiseaseOrPhenotypicFeature
dystrophic,527,I-DiseaseOrPhenotypicFeature
epidermolysis,527,I-DiseaseOrPhenotypicFeature
bullosa,527,I-DiseaseOrPhenotypicFeature
",",527,O
Hallopeau-Siemens,527,B-DiseaseOrPhenotypicFeature
variant,527,O
(,527,O
HS-RDEB,527,B-DiseaseOrPhenotypicFeature
),527,O
.,527,O
The,528,O
maternal,528,O
mutation,528,O
is,528,O
a,528,O
single,528,B-SequenceVariant
base,528,I-SequenceVariant
pair,528,I-SequenceVariant
deletion,528,I-SequenceVariant
of,528,I-SequenceVariant
a,528,I-SequenceVariant
cytosine,528,I-SequenceVariant
nucleotide,528,I-SequenceVariant
in,528,O
exon,528,O
26,528,O
",",528,O
designated,528,O
3472delC,528,B-SequenceVariant
",",528,O
resulting,528,O
in,528,O
a,528,O
frameshift,528,O
and,528,O
a,528,O
premature,528,O
termination,528,O
codon,528,O
(,528,O
PTC,528,O
),528,O
within,528,O
the,528,O
same,528,O
exon,528,O
",",528,O
7,528,O
bp,528,O
downstream,528,O
of,528,O
the,528,O
site,528,O
of,528,O
the,528,O
mutation,528,O
.,528,O
The,529,O
paternal,529,O
mutation,529,O
is,529,O
a,529,O
G,529,B-SequenceVariant
--,529,I-SequenceVariant
>,529,I-SequenceVariant
A,529,I-SequenceVariant
transition,529,O
located,529,O
at,529,O
the,529,O
5,529,O
',529,O
donor,529,O
splice,529,O
site,529,O
within,529,O
intron,529,O
51,529,O
",",529,O
designated,529,O
IVS51,529,B-SequenceVariant
+,529,I-SequenceVariant
1G,529,I-SequenceVariant
--,529,I-SequenceVariant
>,529,I-SequenceVariant
A,529,I-SequenceVariant
.,529,O
This,530,O
mutation,530,O
leads,530,O
to,530,O
the,530,O
activation,530,O
of,530,O
a,530,O
cryptic,530,O
splice,530,O
site,530,O
",",530,O
32,530,O
bp,530,O
downstream,530,O
of,530,O
the,530,O
mutation,530,O
site,530,O
and,530,O
to,530,O
subsequent,530,O
aberrant,530,O
out-of-frame,530,O
splicing,530,O
",",530,O
resulting,530,O
in,530,O
two,530,O
alternative,530,O
mRNA,530,O
transcripts,530,O
and,530,O
a,530,O
downstream,530,O
PTC,530,O
.,530,O
To,531,O
our,531,O
knowledge,531,O
",",531,O
these,531,O
two,531,O
mutations,531,O
have,531,O
not,531,O
been,531,O
previously,531,O
reported,531,O
.,531,O
These,532,O
findings,532,O
extend,532,O
the,532,O
body,532,O
of,532,O
evidence,532,O
for,532,O
compound,532,O
heterozygous,532,O
mutations,532,O
leading,532,O
to,532,O
HS-RDEB,532,B-DiseaseOrPhenotypicFeature
and,532,O
provide,532,O
the,532,O
basis,532,O
for,532,O
prenatal,532,O
diagnosis,532,O
in,532,O
this,532,O
family,532,O
.,532,O
The,533,O
number,533,O
of,533,O
lymph,533,B-DiseaseOrPhenotypicFeature
node,533,I-DiseaseOrPhenotypicFeature
metastases,533,I-DiseaseOrPhenotypicFeature
in,533,O
gastric,533,B-DiseaseOrPhenotypicFeature
cancer,533,I-DiseaseOrPhenotypicFeature
correlates,533,O
with,533,O
the,533,O
angiotensin,533,B-GeneOrGeneProduct
I-converting,533,I-GeneOrGeneProduct
enzyme,533,I-GeneOrGeneProduct
gene,533,O
insertion/deletion,533,O
polymorphism,533,O
.,533,O
PURPOSE,534,O
:,534,O
In,534,O
the,534,O
present,534,O
study,534,O
",",534,O
we,534,O
aimed,534,O
to,534,O
substantiate,534,O
the,534,O
putative,534,O
significance,534,O
of,534,O
angiotensin,534,B-GeneOrGeneProduct
I-converting,534,I-GeneOrGeneProduct
enzyme,534,I-GeneOrGeneProduct
(,534,O
ACE,534,B-GeneOrGeneProduct
),534,O
on,534,O
gastric,534,B-DiseaseOrPhenotypicFeature
cancer,534,I-DiseaseOrPhenotypicFeature
biology,534,O
by,534,O
investigating,534,O
the,534,O
influence,534,O
of,534,O
its,534,O
gene,534,O
polymorphism,534,O
on,534,O
gastric,534,B-DiseaseOrPhenotypicFeature
cancer,534,I-DiseaseOrPhenotypicFeature
progression,534,O
.,534,O
EXPERIMENTAL,535,O
DESIGN,535,O
:,535,O
Genomic,535,O
DNA,535,O
was,535,O
purified,535,O
from,535,O
peripheral,535,O
blood,535,O
mononuclear,535,O
cells,535,O
or,535,O
tissue,535,O
specimens,535,O
.,535,O
Amplified,536,O
ACE,536,B-GeneOrGeneProduct
gene,536,O
fragments,536,O
were,536,O
separated,536,O
on,536,O
agarose,536,B-ChemicalEntity
gels,536,O
.,536,O
D,537,O
or,537,O
I,537,O
alleles,537,O
were,537,O
identified,537,O
by,537,O
the,537,O
presence,537,O
of,537,O
190-,537,O
or,537,O
490-bp,537,O
fragments,537,O
",",537,O
respectively,537,O
.,537,O
Local,538,O
expression,538,O
of,538,O
ACE,538,B-GeneOrGeneProduct
was,538,O
investigated,538,O
by,538,O
immunohistochemistry,538,O
.,538,O
RESULTS,539,O
:,539,O
Twenty-four,539,O
of,539,O
113,539,O
(,539,O
21,539,O
%,539,O
),539,O
gastric,539,B-DiseaseOrPhenotypicFeature
cancer,539,I-DiseaseOrPhenotypicFeature
patients,539,B-OrganismTaxon
had,539,O
the,539,O
II,539,O
",",539,O
57,539,O
(,539,O
51,539,O
%,539,O
),539,O
the,539,O
ID,539,O
",",539,O
and,539,O
32,539,O
(,539,O
28,539,O
%,539,O
),539,O
the,539,O
DD,539,O
genotype,539,O
.,539,O
The,540,O
distribution,540,O
of,540,O
the,540,O
ACE,540,B-GeneOrGeneProduct
genotypes,540,O
did,540,O
not,540,O
differ,540,O
significantly,540,O
from,540,O
the,540,O
control,540,O
group,540,O
of,540,O
189,540,O
patients,540,B-OrganismTaxon
without,540,O
gastric,540,B-DiseaseOrPhenotypicFeature
cancer,540,I-DiseaseOrPhenotypicFeature
.,540,O
However,541,O
",",541,O
the,541,O
ACE,541,B-GeneOrGeneProduct
genotypes,541,O
correlated,541,O
with,541,O
the,541,O
number,541,O
of,541,O
lymph,541,B-DiseaseOrPhenotypicFeature
node,541,I-DiseaseOrPhenotypicFeature
metastases,541,I-DiseaseOrPhenotypicFeature
and,541,O
the,541,O
Unio,541,O
Internationale,541,O
Contra,541,O
Cancrum,541,O
(,541,O
UICC,541,O
),541,O
tumor,541,B-DiseaseOrPhenotypicFeature
stage,541,O
.,541,O
Patients,542,B-OrganismTaxon
with,542,O
the,542,O
II,542,O
genotype,542,O
had,542,O
a,542,O
highly,542,O
significantly,542,O
smaller,542,O
number,542,O
of,542,O
lymph,542,B-DiseaseOrPhenotypicFeature
node,542,I-DiseaseOrPhenotypicFeature
metastases,542,I-DiseaseOrPhenotypicFeature
(,542,O
P,542,O
<,542,O
0.001,542,O
),542,O
and,542,O
a,542,O
significantly,542,O
lower,542,O
UICC,542,O
tumor,542,B-DiseaseOrPhenotypicFeature
stage,542,O
(,542,O
P,542,O
=,542,O
0.01,542,O
),542,O
than,542,O
patients,542,B-OrganismTaxon
with,542,O
the,542,O
DD,542,O
genotype,542,O
.,542,O
No,543,O
correlation,543,O
was,543,O
found,543,O
between,543,O
tumor,543,B-DiseaseOrPhenotypicFeature
type,543,O
",",543,O
tumor,543,B-DiseaseOrPhenotypicFeature
location,543,O
",",543,O
local,543,O
tumor,543,B-DiseaseOrPhenotypicFeature
growth,543,O
",",543,O
distant,543,O
metastases,543,B-DiseaseOrPhenotypicFeature
",",543,O
and,543,O
the,543,O
ACE,543,B-GeneOrGeneProduct
genotype,543,O
.,543,O
The,544,O
expression,544,O
of,544,O
ACE,544,B-GeneOrGeneProduct
in,544,O
gastric,544,B-DiseaseOrPhenotypicFeature
cancer,544,I-DiseaseOrPhenotypicFeature
was,544,O
investigated,544,O
by,544,O
immunohistochemistry,544,O
in,544,O
100,544,O
of,544,O
113,544,O
patients,544,B-OrganismTaxon
.,544,O
ACE,545,B-GeneOrGeneProduct
was,545,O
expressed,545,O
by,545,O
endothelial,545,O
cells,545,O
in,545,O
all,545,O
(,545,O
100,545,O
%,545,O
),545,O
specimens,545,O
and,545,O
by,545,O
tumor,545,B-DiseaseOrPhenotypicFeature
cells,545,O
in,545,O
56,545,O
(,545,O
56,545,O
%,545,O
),545,O
specimens,545,O
.,545,O
CONCLUSIONS,546,O
:,546,O
Our,546,O
study,546,O
shows,546,O
that,546,O
ACE,546,B-GeneOrGeneProduct
is,546,O
expressed,546,O
locally,546,O
in,546,O
gastric,546,B-DiseaseOrPhenotypicFeature
cancer,546,I-DiseaseOrPhenotypicFeature
and,546,O
that,546,O
the,546,O
gene,546,O
polymorphism,546,O
influences,546,O
metastatic,546,O
behavior,546,O
.,546,O
People,547,O
aged,547,O
over,547,O
75,547,O
in,547,O
atrial,547,B-DiseaseOrPhenotypicFeature
fibrillation,547,I-DiseaseOrPhenotypicFeature
on,547,O
warfarin,547,B-ChemicalEntity
:,547,O
the,547,O
rate,547,O
of,547,O
major,547,O
hemorrhage,547,B-DiseaseOrPhenotypicFeature
and,547,O
stroke,547,B-DiseaseOrPhenotypicFeature
in,547,O
more,547,O
than,547,O
500,547,O
patient-years,547,B-OrganismTaxon
of,547,O
follow-up,547,O
.,547,O
OBJECTIVES,548,O
:,548,O
To,548,O
determine,548,O
the,548,O
incidence,548,O
of,548,O
major,548,O
hemorrhage,548,B-DiseaseOrPhenotypicFeature
and,548,O
stroke,548,B-DiseaseOrPhenotypicFeature
in,548,O
people,548,O
aged,548,O
76,548,O
and,548,O
older,548,O
with,548,O
atrial,548,B-DiseaseOrPhenotypicFeature
fibrillation,548,I-DiseaseOrPhenotypicFeature
on,548,O
adjusted-dose,548,O
warfarin,548,B-ChemicalEntity
who,548,O
had,548,O
been,548,O
recently,548,O
been,548,O
admitted,548,O
to,548,O
hospital,548,O
.,548,O
DESIGN,549,O
:,549,O
A,549,O
retrospective,549,O
observational,549,O
cohort,549,O
study,549,O
.,549,O
SETTING,550,O
:,550,O
A,550,O
major,550,O
healthcare,550,O
network,550,O
involving,550,O
four,550,O
tertiary,550,O
hospitals,550,O
.,550,O
PARTICIPANTS,551,O
:,551,O
Two,551,O
hundred,551,O
thirty-five,551,O
patients,551,B-OrganismTaxon
aged,551,O
76,551,O
and,551,O
older,551,O
admitted,551,O
to,551,O
a,551,O
major,551,O
healthcare,551,O
network,551,O
between,551,O
July,551,O
1,551,O
",",551,O
2001,551,O
",",551,O
and,551,O
June,551,O
30,551,O
",",551,O
2002,551,O
",",551,O
with,551,O
atrial,551,B-DiseaseOrPhenotypicFeature
fibrillation,551,I-DiseaseOrPhenotypicFeature
on,551,O
warfarin,551,B-ChemicalEntity
were,551,O
enrolled,551,O
.,551,O
MEASUREMENTS,552,O
:,552,O
Information,552,O
regarding,552,O
major,552,O
bleeding,552,B-DiseaseOrPhenotypicFeature
episodes,552,O
",",552,O
strokes,552,B-DiseaseOrPhenotypicFeature
",",552,O
and,552,O
warfarin,552,B-ChemicalEntity
use,552,O
was,552,O
obtained,552,O
from,552,O
patients,552,B-OrganismTaxon
",",552,O
relatives,552,O
",",552,O
primary,552,O
physicians,552,O
",",552,O
and,552,O
medical,552,O
records,552,O
.,552,O
RESULTS,553,O
:,553,O
Two,553,O
hundred,553,O
twenty-eight,553,O
patients,553,B-OrganismTaxon
(,553,O
42,553,O
%,553,O
men,553,B-OrganismTaxon
),553,O
with,553,O
a,553,O
mean,553,O
age,553,O
of,553,O
81.1,553,O
(,553,O
range,553,O
76-94,553,O
),553,O
were,553,O
included,553,O
in,553,O
the,553,O
analysis,553,O
.,553,O
Total,554,O
follow-up,554,O
on,554,O
warfarin,554,B-ChemicalEntity
was,554,O
530,554,O
years,554,O
(,554,O
mean,554,O
28,554,O
months,554,O
),554,O
.,554,O
There,555,O
were,555,O
53,555,O
major,555,O
hemorrhages,555,B-DiseaseOrPhenotypicFeature
",",555,O
for,555,O
an,555,O
annual,555,O
rate,555,O
of,555,O
10.0,555,O
%,555,O
",",555,O
including,555,O
24,555,O
(,555,O
45.3,555,O
%,555,O
),555,O
life-threatening,555,O
and,555,O
five,555,O
(,555,O
9.4,555,O
%,555,O
),555,O
fatal,555,O
bleeds,555,B-DiseaseOrPhenotypicFeature
.,555,O
The,556,O
annual,556,O
stroke,556,B-DiseaseOrPhenotypicFeature
rate,556,O
after,556,O
initiation,556,O
of,556,O
warfarin,556,B-ChemicalEntity
was,556,O
2.6,556,O
%,556,O
.,556,O
CONCLUSION,557,O
:,557,O
The,557,O
rate,557,O
of,557,O
major,557,O
hemorrhage,557,B-DiseaseOrPhenotypicFeature
was,557,O
high,557,O
in,557,O
this,557,O
old,557,O
",",557,O
frail,557,O
group,557,O
",",557,O
but,557,O
excluding,557,O
fatalities,557,O
",",557,O
resulted,557,O
in,557,O
no,557,O
long-term,557,O
sequelae,557,O
",",557,O
and,557,O
the,557,O
stroke,557,B-DiseaseOrPhenotypicFeature
rate,557,O
on,557,O
warfarin,557,B-ChemicalEntity
was,557,O
low,557,O
",",557,O
demonstrating,557,O
how,557,O
effective,557,O
warfarin,557,B-ChemicalEntity
treatment,557,O
is,557,O
.,557,O
Mild,558,O
glycine,558,B-DiseaseOrPhenotypicFeature
encephalopathy,558,I-DiseaseOrPhenotypicFeature
(,558,O
NKH,558,B-DiseaseOrPhenotypicFeature
),558,O
in,558,O
a,558,O
large,558,O
kindred,558,O
due,558,O
to,558,O
a,558,O
silent,558,O
exonic,558,O
GLDC,558,B-GeneOrGeneProduct
splice,558,O
mutation,558,O
.,558,O
BACKGROUND,559,O
:,559,O
Classic,559,O
neonatal-onset,559,O
glycine,559,B-DiseaseOrPhenotypicFeature
encephalopathy,559,I-DiseaseOrPhenotypicFeature
(,559,O
GE,559,B-DiseaseOrPhenotypicFeature
),559,O
is,559,O
devastating,559,O
and,559,O
life,559,O
threatening,559,O
.,559,O
Milder,560,O
",",560,O
later,560,O
onset,560,O
variants,560,O
have,560,O
been,560,O
reported,560,O
but,560,O
were,560,O
usually,560,O
sporadic,560,O
and,560,O
incompletely,560,O
defined,560,O
.,560,O
OBJECTIVE,561,O
:,561,O
To,561,O
determine,561,O
the,561,O
clinical,561,O
and,561,O
biochemical,561,O
phenotype,561,O
and,561,O
molecular,561,O
basis,561,O
of,561,O
mild,561,O
GE,561,B-DiseaseOrPhenotypicFeature
in,561,O
nine,561,O
children,561,O
from,561,O
a,561,O
consanguineous,561,O
Israeli,561,O
Bedouin,561,O
kindred,561,O
.,561,O
METHODS,562,O
:,562,O
Genomic,562,O
DNA,562,O
was,562,O
screened,562,O
for,562,O
GLDC,562,B-GeneOrGeneProduct
",",562,O
AMT,562,B-GeneOrGeneProduct
",",562,O
and,562,O
GCSH,562,B-GeneOrGeneProduct
gene,562,O
mutations,562,O
.,562,O
GLDC,563,B-GeneOrGeneProduct
expression,563,O
in,563,O
lymphoblasts,563,O
was,563,O
studied,563,O
by,563,O
Northern,563,O
blot,563,O
and,563,O
reverse,563,O
transcriptase,563,O
PCR,563,O
analysis,563,O
.,563,O
RESULTS,564,O
:,564,O
Clinical,564,O
features,564,O
included,564,O
hypotonia,564,B-DiseaseOrPhenotypicFeature
",",564,O
abnormal,564,B-DiseaseOrPhenotypicFeature
movements,564,I-DiseaseOrPhenotypicFeature
",",564,O
convulsions,564,B-DiseaseOrPhenotypicFeature
",",564,O
and,564,O
moderate,564,O
mental,564,B-DiseaseOrPhenotypicFeature
retardation,564,I-DiseaseOrPhenotypicFeature
with,564,O
relative,564,O
sparing,564,O
of,564,O
gross,564,O
motor,564,O
function,564,O
",",564,O
activities,564,O
of,564,O
daily,564,O
living,564,O
skills,564,O
",",564,O
and,564,O
receptive,564,O
language,564,O
.,564,O
Aggression,565,B-DiseaseOrPhenotypicFeature
and,565,O
irritability,565,B-DiseaseOrPhenotypicFeature
were,565,O
prominent,565,O
.,565,O
CSF-to-plasma,566,O
glycine,566,O
ratio,566,O
was,566,O
mildly,566,O
to,566,O
moderately,566,O
elevated,566,O
.,566,O
All,567,O
nine,567,O
patients,567,B-OrganismTaxon
were,567,O
homozygous,567,O
and,567,O
their,567,O
parents,567,O
heterozygous,567,O
for,567,O
a,567,O
novel,567,O
",",567,O
translationally,567,O
silent,567,O
GLDC,567,B-GeneOrGeneProduct
exon,567,O
22,567,O
transversion,567,O
c.2607C,567,B-SequenceVariant
>,567,I-SequenceVariant
A,567,I-SequenceVariant
.,567,O
Lymphoblast,568,O
GLDC,568,B-GeneOrGeneProduct
mRNA,568,O
levels,568,O
were,568,O
considerably,568,O
reduced,568,O
.,568,O
Three,569,O
aberrantly,569,O
spliced,569,O
cDNA,569,O
species,569,O
were,569,O
identified,569,O
:,569,O
exon,569,O
22,569,O
and,569,O
exon,569,O
22,569,O
to,569,O
23,569,O
skipping,569,O
",",569,O
and,569,O
insertion,569,O
of,569,O
an,569,O
87-base,569,O
pair,569,O
cryptic,569,O
exon,569,O
.,569,O
Homozygosity,570,O
for,570,O
c.2607C,570,B-SequenceVariant
>,570,I-SequenceVariant
A,570,I-SequenceVariant
was,570,O
also,570,O
identified,570,O
in,570,O
an,570,O
unrelated,570,O
but,570,O
haplotypically,570,O
identical,570,O
patient,570,B-OrganismTaxon
with,570,O
an,570,O
unusually,570,O
favorable,570,O
outcome,570,O
despite,570,O
severe,570,O
neonatal-onset,570,O
GE,570,B-DiseaseOrPhenotypicFeature
.,570,O
Mutation,571,O
analysis,571,O
enabled,571,O
prenatal,571,O
diagnosis,571,O
of,571,O
three,571,O
unaffected,571,O
and,571,O
one,571,O
affected,571,O
pregnancies,571,O
.,571,O
CONCLUSIONS,572,O
:,572,O
The,572,O
mutation,572,O
in,572,O
this,572,O
kindred,572,O
led,572,O
to,572,O
missplicing,572,O
and,572,O
reduced,572,O
GLDC,572,B-GeneOrGeneProduct
(,572,O
glycine,572,B-GeneOrGeneProduct
decarboxylase,572,I-GeneOrGeneProduct
),572,O
expression,572,O
.,572,O
The,573,O
4,573,O
to,573,O
6,573,O
%,573,O
of,573,O
normally,573,O
spliced,573,O
GLDC,573,B-GeneOrGeneProduct
mRNA,573,O
in,573,O
the,573,O
patients,573,B-OrganismTaxon
may,573,O
account,573,O
for,573,O
their,573,O
relatively,573,O
favorable,573,O
clinical,573,O
outcome,573,O
compared,573,O
with,573,O
patients,573,B-OrganismTaxon
with,573,O
classic,573,O
glycine,573,B-DiseaseOrPhenotypicFeature
encephalopathy,573,I-DiseaseOrPhenotypicFeature
.,573,O
Valproic,574,B-ChemicalEntity
acid,574,I-ChemicalEntity
I,574,O
:,574,O
time,574,O
course,574,O
of,574,O
lipid,574,B-ChemicalEntity
peroxidation,574,O
biomarkers,574,O
",",574,O
liver,574,B-DiseaseOrPhenotypicFeature
toxicity,574,I-DiseaseOrPhenotypicFeature
",",574,O
and,574,O
valproic,574,B-ChemicalEntity
acid,574,I-ChemicalEntity
metabolite,574,O
levels,574,O
in,574,O
rats,574,B-OrganismTaxon
.,574,O
A,575,O
single,575,O
dose,575,O
of,575,O
valproic,575,B-ChemicalEntity
acid,575,I-ChemicalEntity
(,575,O
VPA,575,B-ChemicalEntity
),575,O
",",575,O
which,575,O
is,575,O
a,575,O
widely,575,O
used,575,O
antiepileptic,575,B-ChemicalEntity
drug,575,I-ChemicalEntity
",",575,O
is,575,O
associated,575,O
with,575,O
oxidative,575,O
stress,575,O
in,575,O
rats,575,B-OrganismTaxon
",",575,O
as,575,O
recently,575,O
demonstrated,575,O
by,575,O
elevated,575,O
levels,575,O
of,575,O
15-F,575,B-ChemicalEntity
(,575,I-ChemicalEntity
2t,575,I-ChemicalEntity
),575,I-ChemicalEntity
-isoprostane,575,I-ChemicalEntity
(,575,O
15-F,575,B-ChemicalEntity
(,575,I-ChemicalEntity
2t,575,I-ChemicalEntity
),575,I-ChemicalEntity
-IsoP,575,I-ChemicalEntity
),575,O
.,575,O
To,576,O
determine,576,O
whether,576,O
there,576,O
was,576,O
a,576,O
temporal,576,O
relationship,576,O
between,576,O
VPA-associated,576,B-ChemicalEntity
oxidative,576,O
stress,576,O
and,576,O
hepatotoxicity,576,B-DiseaseOrPhenotypicFeature
",",576,O
adult,576,O
male,576,O
Sprague-Dawley,576,O
rats,576,B-OrganismTaxon
were,576,O
treated,576,O
ip,576,O
with,576,O
VPA,576,B-ChemicalEntity
(,576,O
500,576,O
mg/kg,576,O
),576,O
or,576,O
0.9,576,O
%,576,O
saline,576,O
(,576,O
vehicle,576,O
),576,O
once,576,O
daily,576,O
for,576,O
2,576,O
",",576,O
4,576,O
",",576,O
7,576,O
",",576,O
10,576,O
",",576,O
or,576,O
14,576,O
days,576,O
.,576,O
Oxidative,577,O
stress,577,O
was,577,O
assessed,577,O
by,577,O
determining,577,O
plasma,577,O
and,577,O
liver,577,O
levels,577,O
of,577,O
15-F,577,B-ChemicalEntity
(,577,I-ChemicalEntity
2t,577,I-ChemicalEntity
),577,I-ChemicalEntity
-IsoP,577,I-ChemicalEntity
",",577,O
lipid,577,B-ChemicalEntity
hydroperoxides,577,I-ChemicalEntity
(,577,O
LPO,577,B-ChemicalEntity
),577,O
",",577,O
and,577,O
thiobarbituric,577,B-ChemicalEntity
acid,577,I-ChemicalEntity
reactive,577,I-ChemicalEntity
substances,577,I-ChemicalEntity
(,577,O
TBARs,577,B-ChemicalEntity
),577,O
.,577,O
Plasma,578,O
and,578,O
liver,578,O
15-F,578,B-ChemicalEntity
(,578,I-ChemicalEntity
2t,578,I-ChemicalEntity
),578,I-ChemicalEntity
-IsoP,578,I-ChemicalEntity
were,578,O
elevated,578,O
and,578,O
reached,578,O
a,578,O
plateau,578,O
after,578,O
day,578,O
2,578,O
of,578,O
VPA,578,B-ChemicalEntity
treatment,578,O
compared,578,O
to,578,O
control,578,O
.,578,O
Liver,579,O
LPO,579,B-ChemicalEntity
levels,579,O
were,579,O
not,579,O
elevated,579,O
until,579,O
day,579,O
7,579,O
of,579,O
treatment,579,O
(,579,O
1.8-fold,579,O
versus,579,O
control,579,O
",",579,O
p,579,O
<,579,O
0.05,579,O
),579,O
.,579,O
Liver,580,O
and,580,O
plasma,580,O
TBARs,580,B-ChemicalEntity
were,580,O
not,580,O
increased,580,O
until,580,O
14,580,O
days,580,O
(,580,O
2-fold,580,O
vs.,580,O
control,580,O
",",580,O
p,580,O
<,580,O
0.05,580,O
),580,O
.,580,O
Liver,581,B-DiseaseOrPhenotypicFeature
toxicity,581,I-DiseaseOrPhenotypicFeature
was,581,O
evaluated,581,O
based,581,O
on,581,O
serum,581,O
levels,581,O
of,581,O
alpha-glutathione,581,B-GeneOrGeneProduct
S-transferase,581,I-GeneOrGeneProduct
(,581,O
alpha-GST,581,B-GeneOrGeneProduct
),581,O
and,581,O
by,581,O
histology,581,O
.,581,O
Serum,582,O
alpha-GST,582,B-GeneOrGeneProduct
levels,582,O
were,582,O
significantly,582,O
elevated,582,O
by,582,O
day,582,O
4,582,O
",",582,O
which,582,O
corresponded,582,O
to,582,O
hepatotoxicity,582,B-DiseaseOrPhenotypicFeature
as,582,O
shown,582,O
by,582,O
the,582,O
increasing,582,O
incidence,582,O
of,582,O
inflammation,582,B-DiseaseOrPhenotypicFeature
of,582,I-DiseaseOrPhenotypicFeature
the,582,I-DiseaseOrPhenotypicFeature
liver,582,I-DiseaseOrPhenotypicFeature
capsule,582,I-DiseaseOrPhenotypicFeature
",",582,O
necrosis,582,B-DiseaseOrPhenotypicFeature
",",582,O
and,582,O
steatosis,582,B-DiseaseOrPhenotypicFeature
throughout,582,O
the,582,O
study,582,O
.,582,O
The,583,O
liver,583,O
levels,583,O
of,583,O
beta-oxidation,583,O
metabolites,583,O
of,583,O
VPA,583,B-ChemicalEntity
were,583,O
decreased,583,O
by,583,O
day,583,O
14,583,O
",",583,O
while,583,O
the,583,O
levels,583,O
of,583,O
4-ene-VPA,583,B-ChemicalEntity
and,583,O
(,583,O
E,583,O
),583,O
"-2,4-diene-VPA",583,O
were,583,O
not,583,O
elevated,583,O
throughout,583,O
the,583,O
study,583,O
.,583,O
Overall,584,O
",",584,O
these,584,O
findings,584,O
indicate,584,O
that,584,O
VPA,584,B-ChemicalEntity
treatment,584,O
results,584,O
in,584,O
oxidative,584,O
stress,584,O
",",584,O
as,584,O
measured,584,O
by,584,O
levels,584,O
of,584,O
15-F,584,B-ChemicalEntity
(,584,I-ChemicalEntity
2t,584,I-ChemicalEntity
),584,I-ChemicalEntity
-IsoP,584,I-ChemicalEntity
",",584,O
which,584,O
precedes,584,O
the,584,O
onset,584,O
of,584,O
necrosis,584,B-DiseaseOrPhenotypicFeature
",",584,O
steatosis,584,B-DiseaseOrPhenotypicFeature
",",584,O
and,584,O
elevated,584,O
levels,584,O
of,584,O
serum,584,O
alpha-GST,584,B-GeneOrGeneProduct
.,584,O
Safety,585,O
of,585,O
celecoxib,585,B-ChemicalEntity
in,585,O
patients,585,B-OrganismTaxon
with,585,O
adverse,585,O
skin,585,B-DiseaseOrPhenotypicFeature
reactions,585,I-DiseaseOrPhenotypicFeature
to,585,O
acetaminophen,585,B-ChemicalEntity
(,585,O
paracetamol,585,B-ChemicalEntity
),585,O
and,585,O
nimesulide,585,B-ChemicalEntity
associated,585,O
or,585,O
not,585,O
with,585,O
common,585,O
non-steroidal,585,B-ChemicalEntity
anti-inflammatory,585,I-ChemicalEntity
drugs,585,I-ChemicalEntity
.,585,O
BACKGROUND,586,O
:,586,O
Acetaminophen,586,B-ChemicalEntity
(,586,O
paracetamol,586,B-ChemicalEntity
--,586,O
P,586,B-ChemicalEntity
),586,O
and,586,O
Nimesulide,586,B-ChemicalEntity
(,586,O
N,586,B-ChemicalEntity
),586,O
are,586,O
widely,586,O
used,586,O
analgesic-antipyretic/anti-inflammatory,586,O
drugs,586,I-ChemicalEntity
.,586,O
The,587,O
rate,587,O
of,587,O
adverse,587,O
hypersensitivity,587,B-DiseaseOrPhenotypicFeature
reactions,587,O
to,587,O
these,587,O
agents,587,O
is,587,O
generally,587,O
low,587,O
.,587,O
On,588,O
the,588,O
contrary,588,O
non-steroidal,588,B-ChemicalEntity
anti-inflammatory,588,I-ChemicalEntity
drugs,588,I-ChemicalEntity
(,588,O
NSAIDs,588,B-ChemicalEntity
),588,O
are,588,O
commonly,588,O
involved,588,O
in,588,O
such,588,O
reactions,588,O
.,588,O
Celecoxib,589,B-ChemicalEntity
(,589,O
CE,589,B-ChemicalEntity
),589,O
is,589,O
a,589,O
novel,589,O
drug,589,O
",",589,O
with,589,O
high,589,O
selectivity,589,O
and,589,O
affinity,589,O
for,589,O
COX-2,589,B-GeneOrGeneProduct
enzyme,589,O
.,589,O
OBJECTIVE,590,O
:,590,O
We,590,O
evaluated,590,O
the,590,O
tolerability,590,O
of,590,O
CE,590,B-ChemicalEntity
in,590,O
a,590,O
group,590,O
of,590,O
patients,590,B-OrganismTaxon
with,590,O
documented,590,O
history,590,O
of,590,O
adverse,590,O
cutaneous,590,B-DiseaseOrPhenotypicFeature
reactions,590,I-DiseaseOrPhenotypicFeature
to,590,O
P,590,B-ChemicalEntity
and,590,O
N,590,B-ChemicalEntity
associated,590,O
or,590,O
not,590,O
to,590,O
classic,590,O
NSAIDs,590,B-ChemicalEntity
.,590,O
METHODS,591,O
:,591,O
We,591,O
studied,591,O
9,591,O
patients,591,B-OrganismTaxon
with,591,O
hypersensitivity,591,B-DiseaseOrPhenotypicFeature
to,591,O
P,591,B-ChemicalEntity
and,591,O
N,591,B-ChemicalEntity
with,591,O
or,591,O
without,591,O
associated,591,O
reactions,591,O
to,591,O
classic,591,O
NSAIDs,591,B-ChemicalEntity
.,591,O
The,592,O
diagnosis,592,O
of,592,O
P,592,B-ChemicalEntity
and,592,O
N-induced,592,B-ChemicalEntity
skin,592,B-DiseaseOrPhenotypicFeature
reactions,592,I-DiseaseOrPhenotypicFeature
was,592,O
based,592,O
in,592,O
vivo,592,O
challenge,592,O
.,592,O
The,593,O
placebo,593,O
was,593,O
blindly,593,O
administered,593,O
at,593,O
the,593,O
beginning,593,O
of,593,O
each,593,O
challenge,593,O
.,593,O
After,594,O
three,594,O
days,594,O
",",594,O
a,594,O
cumulative,594,O
dosage,594,O
of,594,O
200,594,O
mg,594,O
of,594,O
CE,594,B-ChemicalEntity
in,594,O
refracted,594,O
doses,594,O
were,594,O
given,594,O
.,594,O
After,595,O
2-3,595,O
days,595,O
",",595,O
a,595,O
single,595,O
dose,595,O
of,595,O
200,595,O
mg,595,O
was,595,O
administered,595,O
.,595,O
All,596,O
patients,596,B-OrganismTaxon
were,596,O
observed,596,O
for,596,O
6,596,O
hours,596,O
after,596,O
each,596,O
challenge,596,O
",",596,O
and,596,O
controlled,596,O
again,596,O
after,596,O
24,596,O
hours,596,O
to,596,O
exclude,596,O
delayed,596,O
reactions,596,O
.,596,O
The,597,O
challenge,597,O
was,597,O
considered,597,O
positive,597,O
if,597,O
one,597,O
or,597,O
more,597,O
of,597,O
the,597,O
following,597,O
appeared,597,O
:,597,O
erythema,597,B-DiseaseOrPhenotypicFeature
",",597,O
rush,597,O
or,597,O
urticaria-angioedema,597,B-DiseaseOrPhenotypicFeature
.,597,O
RESULTS,598,O
:,598,O
No,598,O
reaction,598,O
was,598,O
observed,598,O
with,598,O
placebo,598,O
and,598,O
eight,598,O
patients,598,B-OrganismTaxon
(,598,O
88.8,598,O
%,598,O
),598,O
tolerated,598,O
CE,598,B-ChemicalEntity
.,598,O
Only,599,O
one,599,O
patient,599,B-OrganismTaxon
developed,599,O
a,599,O
moderate,599,O
angioedema,599,B-DiseaseOrPhenotypicFeature
of,599,O
the,599,O
lips,599,O
.,599,O
CONCLUSION,600,O
:,600,O
Only,600,O
one,600,O
hypersensitivity,600,B-DiseaseOrPhenotypicFeature
reaction,600,O
to,600,O
CE,600,B-ChemicalEntity
was,600,O
documented,600,O
among,600,O
9,600,O
P,600,B-ChemicalEntity
and,600,O
N-highly,600,B-ChemicalEntity
NSAIDs,600,B-ChemicalEntity
intolerant,600,O
patients,600,B-OrganismTaxon
.,600,O
Thus,601,O
",",601,O
we,601,O
conclude,601,O
that,601,O
CE,601,B-ChemicalEntity
is,601,O
a,601,O
reasonably,601,O
safe,601,O
alternative,601,O
to,601,O
be,601,O
used,601,O
in,601,O
subjects,601,O
who,601,O
do,601,O
not,601,O
tolerate,601,O
P,601,B-ChemicalEntity
and,601,O
N,601,B-ChemicalEntity
.,601,O
Succinylcholine-induced,602,B-ChemicalEntity
masseter,602,B-DiseaseOrPhenotypicFeature
muscle,602,I-DiseaseOrPhenotypicFeature
rigidity,602,I-DiseaseOrPhenotypicFeature
during,602,O
bronchoscopic,602,O
removal,602,O
of,602,O
a,602,O
tracheal,602,O
foreign,602,O
body,602,O
.,602,O
Masseter,603,B-DiseaseOrPhenotypicFeature
muscle,603,I-DiseaseOrPhenotypicFeature
rigidity,603,I-DiseaseOrPhenotypicFeature
during,603,O
general,603,O
anesthesia,603,O
is,603,O
considered,603,O
an,603,O
early,603,O
warning,603,O
sign,603,O
of,603,O
a,603,O
possible,603,O
episode,603,O
of,603,O
malignant,603,B-DiseaseOrPhenotypicFeature
hyperthermia,603,I-DiseaseOrPhenotypicFeature
.,603,O
The,604,O
decision,604,O
whether,604,O
to,604,O
continue,604,O
or,604,O
discontinue,604,O
the,604,O
procedure,604,O
depends,604,O
on,604,O
the,604,O
urgency,604,O
of,604,O
the,604,O
surgery,604,O
and,604,O
severity,604,O
of,604,O
masseter,604,B-DiseaseOrPhenotypicFeature
muscle,604,I-DiseaseOrPhenotypicFeature
rigidity,604,I-DiseaseOrPhenotypicFeature
.,604,O
Here,605,O
",",605,O
we,605,O
describe,605,O
a,605,O
case,605,O
of,605,O
severe,605,O
masseter,605,B-DiseaseOrPhenotypicFeature
muscle,605,I-DiseaseOrPhenotypicFeature
rigidity,605,I-DiseaseOrPhenotypicFeature
(,605,O
jaw,605,B-DiseaseOrPhenotypicFeature
of,605,I-DiseaseOrPhenotypicFeature
steel,605,I-DiseaseOrPhenotypicFeature
),605,O
after,605,O
succinylcholine,605,B-ChemicalEntity
(,605,O
Sch,605,B-ChemicalEntity
),605,O
administration,605,O
during,605,O
general,605,O
anesthetic,605,O
management,605,O
for,605,O
rigid,605,O
bronchoscopic,605,O
removal,605,O
of,605,O
a,605,O
tracheal,605,O
foreign,605,O
body,605,O
.,605,O
Anesthesia,606,O
was,606,O
continued,606,O
uneventfully,606,O
with,606,O
propofol,606,B-ChemicalEntity
infusion,606,O
while,606,O
all,606,O
facilities,606,O
were,606,O
available,606,O
to,606,O
detect,606,O
and,606,O
treat,606,O
malignant,606,B-DiseaseOrPhenotypicFeature
hyperthermia,606,I-DiseaseOrPhenotypicFeature
.,606,O
Dexrazoxane,607,B-ChemicalEntity
protects,607,O
against,607,O
myelosuppression,607,B-DiseaseOrPhenotypicFeature
from,607,O
the,607,O
DNA,607,O
cleavage-enhancing,607,O
drugs,607,O
etoposide,607,B-ChemicalEntity
and,607,O
daunorubicin,607,B-ChemicalEntity
but,607,O
not,607,O
doxorubicin,607,B-ChemicalEntity
.,607,O
PURPOSE,608,O
:,608,O
The,608,O
anthracyclines,608,B-ChemicalEntity
daunorubicin,608,B-ChemicalEntity
and,608,O
doxorubicin,608,B-ChemicalEntity
and,608,O
the,608,O
epipodophyllotoxin,608,B-ChemicalEntity
etoposide,608,B-ChemicalEntity
are,608,O
potent,608,O
DNA,608,O
cleavage-enhancing,608,O
drugs,608,O
that,608,O
are,608,O
widely,608,O
used,608,O
in,608,O
clinical,608,O
oncology,608,O
;,608,O
however,608,O
",",608,O
myelosuppression,608,B-DiseaseOrPhenotypicFeature
and,608,O
cardiac,608,B-DiseaseOrPhenotypicFeature
toxicity,608,I-DiseaseOrPhenotypicFeature
limit,608,O
their,608,O
use,608,O
.,608,O
Dexrazoxane,609,B-ChemicalEntity
(,609,O
ICRF-187,609,B-ChemicalEntity
),609,O
is,609,O
recommended,609,O
for,609,O
protection,609,O
against,609,O
anthracycline-induced,609,B-ChemicalEntity
cardiotoxicity,609,B-DiseaseOrPhenotypicFeature
.,609,O
EXPERIMENTAL,610,O
DESIGN,610,O
:,610,O
Because,610,O
of,610,O
their,610,O
widespread,610,O
use,610,O
",",610,O
the,610,O
hematologic,610,B-DiseaseOrPhenotypicFeature
toxicity,610,I-DiseaseOrPhenotypicFeature
following,610,O
coadministration,610,O
of,610,O
dexrazoxane,610,B-ChemicalEntity
and,610,O
these,610,O
three,610,O
structurally,610,O
different,610,O
DNA,610,O
cleavage,610,O
enhancers,610,O
was,610,O
investigated,610,O
:,610,O
Sensitivity,610,O
of,610,O
human,610,B-OrganismTaxon
and,610,O
murine,610,B-OrganismTaxon
blood,610,O
progenitor,610,O
cells,610,O
to,610,O
etoposide,610,B-ChemicalEntity
",",610,O
daunorubicin,610,B-ChemicalEntity
",",610,O
and,610,O
doxorubicin,610,B-ChemicalEntity
+/-,610,O
dexrazoxane,610,B-ChemicalEntity
was,610,O
determined,610,O
in,610,O
granulocyte-macrophage,610,O
colony,610,O
forming,610,O
assays,610,O
.,610,O
Likewise,611,O
",",611,O
in,611,O
vivo,611,O
",",611,O
B6D2F1,611,O
mice,611,B-OrganismTaxon
were,611,O
treated,611,O
with,611,O
etoposide,611,B-ChemicalEntity
",",611,O
daunorubicin,611,B-ChemicalEntity
",",611,O
and,611,O
doxorubicin,611,B-ChemicalEntity
",",611,O
with,611,O
or,611,O
without,611,O
dexrazoxane,611,B-ChemicalEntity
over,611,O
a,611,O
wide,611,O
range,611,O
of,611,O
doses,611,O
:,611,O
posttreatment,611,O
",",611,O
a,611,O
full,611,O
hematologic,611,O
evaluation,611,O
was,611,O
done,611,O
.,611,O
RESULTS,612,O
:,612,O
Nontoxic,612,O
doses,612,O
of,612,O
dexrazoxane,612,B-ChemicalEntity
reduced,612,O
myelosuppression,612,B-DiseaseOrPhenotypicFeature
and,612,O
weight,612,B-DiseaseOrPhenotypicFeature
loss,612,I-DiseaseOrPhenotypicFeature
from,612,O
daunorubicin,612,B-ChemicalEntity
and,612,O
etoposide,612,B-ChemicalEntity
in,612,O
mice,612,B-OrganismTaxon
and,612,O
antagonized,612,O
their,612,O
antiproliferative,612,O
effects,612,O
in,612,O
the,612,O
colony,612,O
assay,612,O
;,612,O
however,612,O
",",612,O
dexrazoxane,612,B-ChemicalEntity
neither,612,O
reduced,612,O
myelosuppression,612,B-DiseaseOrPhenotypicFeature
",",612,O
weight,612,B-DiseaseOrPhenotypicFeature
loss,612,I-DiseaseOrPhenotypicFeature
",",612,O
nor,612,O
the,612,O
in,612,O
vitro,612,O
cytotoxicity,612,B-DiseaseOrPhenotypicFeature
from,612,O
doxorubicin,612,B-ChemicalEntity
.,612,O
CONCLUSION,613,O
:,613,O
Although,613,O
our,613,O
findings,613,O
support,613,O
the,613,O
observation,613,O
that,613,O
dexrazoxane,613,B-ChemicalEntity
reduces,613,O
neither,613,O
hematologic,613,O
activity,613,O
nor,613,O
antitumor,613,O
activity,613,O
from,613,O
doxorubicin,613,B-ChemicalEntity
clinically,613,O
",",613,O
the,613,O
potent,613,O
antagonism,613,O
of,613,O
daunorubicin,613,B-ChemicalEntity
activity,613,O
raises,613,O
concern,613,O
;,613,O
a,613,O
possible,613,O
interference,613,O
with,613,O
anticancer,613,O
efficacy,613,O
certainly,613,O
would,613,O
call,613,O
for,613,O
renewed,613,O
attention,613,O
.,613,O
Our,614,O
data,614,O
also,614,O
suggest,614,O
that,614,O
significant,614,O
etoposide,614,B-ChemicalEntity
dose,614,O
escalation,614,O
is,614,O
perhaps,614,O
possible,614,O
by,614,O
the,614,O
use,614,O
of,614,O
dexrazoxane,614,B-ChemicalEntity
.,614,O
Clinical,615,O
trials,615,O
in,615,O
patients,615,B-OrganismTaxon
with,615,O
brain,615,O
metastases,615,B-DiseaseOrPhenotypicFeature
combining,615,O
dexrazoxane,615,B-ChemicalEntity
and,615,O
high,615,O
doses,615,O
of,615,O
etoposide,615,B-ChemicalEntity
is,615,O
ongoing,615,O
with,615,O
the,615,O
aim,615,O
of,615,O
improving,615,O
efficacy,615,O
without,615,O
aggravating,615,O
hematologic,615,B-DiseaseOrPhenotypicFeature
toxicity,615,I-DiseaseOrPhenotypicFeature
.,615,O
If,616,O
successful,616,O
",",616,O
this,616,O
represents,616,O
an,616,O
exciting,616,O
mechanism,616,O
for,616,O
pharmacologic,616,O
regulation,616,O
of,616,O
side,616,O
effects,616,O
from,616,O
cytotoxic,616,B-DiseaseOrPhenotypicFeature
chemotherapy,616,O
.,616,O
The,617,O
selective,617,O
5-HT6,617,B-GeneOrGeneProduct
receptor,617,I-GeneOrGeneProduct
antagonist,617,O
Ro4368554,617,B-ChemicalEntity
restores,617,O
memory,617,O
performance,617,O
in,617,O
cholinergic,617,B-ChemicalEntity
and,617,O
serotonergic,617,B-ChemicalEntity
models,617,O
of,617,O
memory,617,B-DiseaseOrPhenotypicFeature
deficiency,617,I-DiseaseOrPhenotypicFeature
in,617,O
the,617,O
rat,617,B-OrganismTaxon
.,617,O
Antagonists,618,O
at,618,O
serotonin,618,B-GeneOrGeneProduct
type,618,I-GeneOrGeneProduct
6,618,I-GeneOrGeneProduct
(,618,I-GeneOrGeneProduct
5-HT,618,I-GeneOrGeneProduct
(,618,I-GeneOrGeneProduct
6,618,I-GeneOrGeneProduct
),618,I-GeneOrGeneProduct
),618,I-GeneOrGeneProduct
receptors,618,I-GeneOrGeneProduct
show,618,O
activity,618,O
in,618,O
models,618,O
of,618,O
learning,618,O
and,618,O
memory,618,O
.,618,O
Although,619,O
the,619,O
underlying,619,O
mechanism,619,O
(,619,O
s,619,O
),619,O
are,619,O
not,619,O
well,619,O
understood,619,O
",",619,O
these,619,O
effects,619,O
may,619,O
involve,619,O
an,619,O
increase,619,O
in,619,O
acetylcholine,619,B-ChemicalEntity
(,619,O
ACh,619,B-ChemicalEntity
),619,O
levels,619,O
.,619,O
The,620,O
present,620,O
study,620,O
sought,620,O
to,620,O
characterize,620,O
the,620,O
cognitive-enhancing,620,O
effects,620,O
of,620,O
the,620,O
5-HT,620,B-GeneOrGeneProduct
(,620,I-GeneOrGeneProduct
6,620,I-GeneOrGeneProduct
),620,I-GeneOrGeneProduct
antagonist,620,O
Ro4368554,620,B-ChemicalEntity
(,620,O
3-benzenesulfonyl-7-,620,B-ChemicalEntity
(,620,I-ChemicalEntity
4-methyl-piperazin-1-yl,620,I-ChemicalEntity
),620,I-ChemicalEntity
1H-indole,620,I-ChemicalEntity
),620,O
in,620,O
a,620,O
rat,620,B-OrganismTaxon
object,620,O
recognition,620,O
task,620,O
employing,620,O
a,620,O
cholinergic,620,B-ChemicalEntity
(,620,O
scopolamine,620,B-ChemicalEntity
pretreatment,620,O
),620,O
and,620,O
a,620,O
serotonergic-,620,B-ChemicalEntity
(,620,O
tryptophan,620,B-ChemicalEntity
(,620,O
TRP,620,B-ChemicalEntity
),620,O
depletion,620,O
),620,O
deficient,620,O
model,620,O
",",620,O
and,620,O
compared,620,O
its,620,O
pattern,620,O
of,620,O
action,620,O
with,620,O
that,620,O
of,620,O
the,620,O
acetylcholinesterase,620,B-GeneOrGeneProduct
inhibitor,620,O
metrifonate,620,B-ChemicalEntity
.,620,O
Initial,621,O
testing,621,O
in,621,O
a,621,O
time-dependent,621,O
forgetting,621,O
task,621,O
employing,621,O
a,621,O
24-h,621,O
delay,621,O
between,621,O
training,621,O
and,621,O
testing,621,O
showed,621,O
that,621,O
metrifonate,621,B-ChemicalEntity
improved,621,O
object,621,O
recognition,621,O
(,621,O
at,621,O
10,621,O
and,621,O
30,621,O
mg/kg,621,O
",",621,O
p.o,621,O
.,621,O
),622,O
",",622,O
whereas,622,O
Ro4368554,622,O
was,622,O
inactive,622,O
.,622,O
Both,623,O
",",623,O
Ro4368554,623,O
(,623,O
3,623,O
and,623,O
10,623,O
mg/kg,623,O
",",623,O
intraperitoneally,623,O
(,623,O
i.p,623,O
.,623,O
),623,O
),623,O
and,624,O
metrifonate,624,O
(,624,O
10,624,O
mg/kg,624,O
",",624,O
p.o.,624,O
",",624,O
respectively,624,O
),624,O
reversed,624,O
memory,624,I-DiseaseOrPhenotypicFeature
deficits,624,O
induced,624,O
by,624,O
scopolamine,624,O
and,624,O
TRP,624,O
depletion,624,O
(,624,O
10,624,O
mg/kg,624,O
",",624,O
i.p.,624,O
",",624,O
and,624,O
3,624,O
mg/kg,624,O
",",624,O
p.o.,624,O
",",624,O
respectively,624,O
),624,O
.,624,O
In,625,O
conclusion,625,O
",",625,O
although,625,O
Ro4368554,625,O
did,625,O
not,625,O
improve,625,O
a,625,O
time-related,625,O
retention,625,O
deficit,625,O
",",625,O
it,625,O
reversed,625,O
a,625,O
cholinergic,625,O
and,625,O
a,625,O
serotonergic,625,O
memory,625,I-DiseaseOrPhenotypicFeature
deficit,625,O
",",625,O
suggesting,625,O
that,625,O
both,625,O
mechanisms,625,O
may,625,O
be,625,O
involved,625,O
in,625,O
the,625,O
facilitation,625,O
of,625,O
object,625,O
memory,625,O
by,625,O
Ro4368554,625,O
and,625,O
",",625,O
possibly,625,O
",",625,O
other,625,O
5-HT,625,I-ChemicalEntity
(,625,I-ChemicalEntity
6,625,I-ChemicalEntity
),625,I-ChemicalEntity
receptor,625,I-ChemicalEntity
antagonists,625,O
.,625,O
Functional,626,O
characterization,626,O
of,626,O
SLCO1B1,626,B-GeneOrGeneProduct
(,626,O
OATP-C,626,B-GeneOrGeneProduct
),626,O
variants,626,O
",",626,O
SLCO1B1,626,B-GeneOrGeneProduct
*,626,O
5,626,O
",",626,O
SLCO1B1,626,B-GeneOrGeneProduct
*,626,O
15,626,O
and,626,O
SLCO1B1,626,B-GeneOrGeneProduct
*,626,O
15+C1007G,626,O
",",626,O
by,626,O
using,626,O
transient,626,O
expression,626,O
systems,626,O
of,626,O
HeLa,626,B-CellLine
and,626,O
HEK293,626,B-CellLine
cells,626,O
.,626,O
OBJECTIVES,627,O
:,627,O
SLCO1B1,627,B-GeneOrGeneProduct
*,627,O
5,627,O
and,627,O
SLCO1B1,627,B-GeneOrGeneProduct
*,627,O
15,627,O
have,627,O
been,627,O
reported,627,O
to,627,O
reduce,627,O
the,627,O
clearance,627,O
of,627,O
pravastatin,627,B-ChemicalEntity
in,627,O
healthy,627,O
volunteers,627,O
.,627,O
However,628,O
",",628,O
there,628,O
remains,628,O
controversy,628,O
in,628,O
the,628,O
effects,628,O
of,628,O
SLCO1B1,628,B-GeneOrGeneProduct
*,628,O
5,628,O
on,628,O
the,628,O
activity,628,O
of,628,O
OATP1B1,628,B-GeneOrGeneProduct
in,628,O
vitro,628,O
.,628,O
In,629,O
addition,629,O
",",629,O
the,629,O
effect,629,O
of,629,O
SLCO1B1,629,B-GeneOrGeneProduct
*,629,O
15,629,O
on,629,O
the,629,O
function,629,O
of,629,O
OATP1B1,629,B-GeneOrGeneProduct
has,629,O
not,629,O
been,629,O
studied,629,O
using,629,O
cDNA-expression,629,O
systems,629,O
.,629,O
Object,630,O
of,630,O
the,630,O
present,630,O
study,630,O
was,630,O
to,630,O
study,630,O
the,630,O
influence,630,O
of,630,O
SLCO1B1,630,B-GeneOrGeneProduct
*,630,O
5,630,O
",",630,O
*,630,O
15,630,O
and,630,O
*,630,O
15+C1007G,630,O
",",630,O
a,630,O
novel,630,O
haplotype,630,O
found,630,O
in,630,O
a,630,O
patient,630,B-OrganismTaxon
with,630,O
pravastatin-induced,630,B-ChemicalEntity
myopathy,630,B-DiseaseOrPhenotypicFeature
",",630,O
on,630,O
the,630,O
functional,630,O
properties,630,O
of,630,O
OATP1B1,630,B-GeneOrGeneProduct
by,630,O
transient,630,O
expression,630,O
systems,630,O
of,630,O
HEK293,630,B-CellLine
and,630,O
HeLa,630,B-CellLine
cells,630,O
using,630,O
endogenous,630,O
conjugates,630,O
and,630,O
statins,630,O
as,630,O
substrates,630,O
.,630,O
METHODS,631,O
:,631,O
Transporting,631,O
assays,631,O
for,631,O
endogenous,631,O
substrates,631,O
were,631,O
performed,631,O
using,631,O
tritium,631,B-ChemicalEntity
labeled,631,O
estradiol-17beta-D-glucuronide,631,B-ChemicalEntity
and,631,O
estrone-3-sulfate,631,B-ChemicalEntity
.,631,O
Quantitation,632,O
of,632,O
pravastatin,632,B-ChemicalEntity
",",632,O
atorvastatin,632,B-ChemicalEntity
",",632,O
cerivastatin,632,B-ChemicalEntity
and,632,O
simvastatin,632,B-ChemicalEntity
were,632,O
carried,632,O
out,632,O
using,632,O
HPLC,632,O
tandem,632,O
mass,632,O
spectrometry,632,O
.,632,O
RESULTS,633,O
:,633,O
The,633,O
transporting,633,O
activities,633,O
of,633,O
cells,633,O
expressing,633,O
SLCO1B1,633,B-GeneOrGeneProduct
*,633,O
5,633,O
",",633,O
*,633,O
15,633,O
and,633,O
*,633,O
15+C1007G,633,O
decreased,633,O
significantly,633,O
but,633,O
those,633,O
of,633,O
SLCO1B1,633,B-GeneOrGeneProduct
*,633,O
1b,633,O
",",633,O
*,633,O
1a+C1007G,633,O
and,633,O
*,633,O
1b+C1007G,633,O
were,633,O
not,633,O
altered,633,O
for,633,O
all,633,O
of,633,O
the,633,O
substrates,633,O
tested,633,O
except,633,O
for,633,O
simvastatin,633,B-ChemicalEntity
.,633,O
Kinetic,634,O
analysis,634,O
of,634,O
pravastatin,634,B-ChemicalEntity
and,634,O
atorvastatin,634,B-ChemicalEntity
showed,634,O
that,634,O
Km,634,O
values,634,O
were,634,O
not,634,O
altered,634,O
but,634,O
Vmax,634,O
values,634,O
decreased,634,O
significantly,634,O
in,634,O
cells,634,O
expressing,634,O
SLCO1B1,634,B-GeneOrGeneProduct
*,634,O
5,634,O
",",634,O
*,634,O
15,634,O
and,634,O
*,634,O
15+C1007G,634,O
.,634,O
Immunocytochemical,635,O
study,635,O
showed,635,O
that,635,O
SLCO1B1,635,B-GeneOrGeneProduct
*,635,O
5,635,O
",",635,O
*,635,O
15,635,O
and,635,O
*,635,O
15+C1007G,635,O
proteins,635,O
are,635,O
localized,635,O
not,635,O
only,635,O
at,635,O
the,635,O
plasma,635,O
membrane,635,O
but,635,O
also,635,O
in,635,O
the,635,O
intracellular,635,O
space,635,O
.,635,O
CONCLUSIONS,636,O
:,636,O
These,636,O
findings,636,O
suggest,636,O
that,636,O
521T,636,B-SequenceVariant
>,636,I-SequenceVariant
C,636,I-SequenceVariant
",",636,O
existing,636,O
commonly,636,O
in,636,O
SLCO1B1,636,B-GeneOrGeneProduct
*,636,O
5,636,O
",",636,O
*,636,O
15,636,O
and,636,O
*,636,O
15+C1007G,636,O
",",636,O
is,636,O
the,636,O
key,636,O
single,636,O
nucleotide,636,O
polymorphism,636,O
(,636,O
SNP,636,O
),636,O
that,636,O
determines,636,O
the,636,O
functional,636,O
properties,636,O
of,636,O
SLCO1B1,636,B-GeneOrGeneProduct
*,636,O
5,636,O
",",636,O
*,636,O
15,636,O
and,636,O
*,636,O
15+C1007G,636,O
allelic,636,O
proteins,636,O
and,636,O
that,636,O
decreased,636,O
activities,636,O
of,636,O
these,636,O
variant,636,O
proteins,636,O
are,636,O
mainly,636,O
caused,636,O
by,636,O
a,636,O
sorting,636,O
error,636,O
produced,636,O
by,636,O
this,636,O
SNP,636,O
.,636,O
Polymorphisms,637,O
in,637,O
the,637,O
SLC2A2,637,B-GeneOrGeneProduct
(,637,O
GLUT2,637,B-GeneOrGeneProduct
),637,O
gene,637,O
are,637,O
associated,637,O
with,637,O
the,637,O
conversion,637,O
from,637,O
impaired,637,B-DiseaseOrPhenotypicFeature
glucose,637,I-DiseaseOrPhenotypicFeature
tolerance,637,I-DiseaseOrPhenotypicFeature
to,637,O
type,637,B-DiseaseOrPhenotypicFeature
2,637,I-DiseaseOrPhenotypicFeature
diabetes,637,I-DiseaseOrPhenotypicFeature
:,637,O
the,637,O
Finnish,637,O
Diabetes,637,B-DiseaseOrPhenotypicFeature
Prevention,637,O
Study,637,O
.,637,O
Impaired,638,B-DiseaseOrPhenotypicFeature
insulin,638,I-DiseaseOrPhenotypicFeature
secretion,638,I-DiseaseOrPhenotypicFeature
is,638,O
a,638,O
fundamental,638,O
defect,638,O
in,638,O
type,638,B-DiseaseOrPhenotypicFeature
2,638,I-DiseaseOrPhenotypicFeature
diabetes,638,I-DiseaseOrPhenotypicFeature
.,638,O
The,639,O
aim,639,O
of,639,O
this,639,O
study,639,O
was,639,O
to,639,O
investigate,639,O
whether,639,O
single,639,O
nucleotide,639,O
polymorphisms,639,O
(,639,O
SNPs,639,O
),639,O
in,639,O
the,639,O
genes,639,O
regulating,639,O
insulin,639,B-GeneOrGeneProduct
secretion,639,O
(,639,O
SLC2A2,639,B-GeneOrGeneProduct
[,639,O
encoding,639,O
GLUT2,639,B-GeneOrGeneProduct
],639,O
",",639,O
GCK,639,B-GeneOrGeneProduct
",",639,O
TCF1,639,B-GeneOrGeneProduct
[,639,O
encoding,639,O
HNF-1alpha,639,B-GeneOrGeneProduct
],639,O
",",639,O
HNF4A,639,B-GeneOrGeneProduct
",",639,O
GIP,639,B-GeneOrGeneProduct
",",639,O
and,639,O
GLP1R,639,B-GeneOrGeneProduct
),639,O
are,639,O
associated,639,O
with,639,O
the,639,O
conversion,639,O
from,639,O
impaired,639,B-DiseaseOrPhenotypicFeature
glucose,639,I-DiseaseOrPhenotypicFeature
tolerance,639,I-DiseaseOrPhenotypicFeature
(,639,O
IGT,639,B-DiseaseOrPhenotypicFeature
),639,O
to,639,O
type,639,B-DiseaseOrPhenotypicFeature
2,639,I-DiseaseOrPhenotypicFeature
diabetes,639,I-DiseaseOrPhenotypicFeature
in,639,O
participants,639,O
of,639,O
the,639,O
Finnish,639,O
Diabetes,639,B-DiseaseOrPhenotypicFeature
Prevention,639,O
Study,639,O
.,639,O
With,640,O
the,640,O
exception,640,O
of,640,O
SLC2A2,640,B-GeneOrGeneProduct
",",640,O
other,640,O
genes,640,O
were,640,O
not,640,O
associated,640,O
with,640,O
the,640,O
risk,640,O
of,640,O
type,640,B-DiseaseOrPhenotypicFeature
2,640,I-DiseaseOrPhenotypicFeature
diabetes,640,I-DiseaseOrPhenotypicFeature
.,640,O
All,641,O
four,641,O
SNPs,641,O
of,641,O
SLC2A2,641,B-GeneOrGeneProduct
predicted,641,O
the,641,O
conversion,641,O
to,641,O
diabetes,641,B-DiseaseOrPhenotypicFeature
",",641,O
and,641,O
rs5393,641,B-SequenceVariant
(,641,O
AA,641,O
genotype,641,O
),641,O
increased,641,O
the,641,O
risk,641,O
of,641,O
type,641,B-DiseaseOrPhenotypicFeature
2,641,I-DiseaseOrPhenotypicFeature
diabetes,641,I-DiseaseOrPhenotypicFeature
in,641,O
the,641,O
entire,641,O
study,641,O
population,641,O
by,641,O
threefold,641,O
(,641,O
odds,641,O
ratio,641,O
3.04,641,O
",",641,O
95,641,O
%,641,O
CI,641,O
1.34-6.88,641,O
",",641,O
P,641,O
=,641,O
0.008,641,O
),641,O
.,641,O
The,642,O
risk,642,O
for,642,O
type,642,B-DiseaseOrPhenotypicFeature
2,642,I-DiseaseOrPhenotypicFeature
diabetes,642,I-DiseaseOrPhenotypicFeature
in,642,O
the,642,O
AA,642,O
genotype,642,O
carriers,642,O
was,642,O
increased,642,O
in,642,O
the,642,O
control,642,O
group,642,O
(,642,O
5.56,642,O
[,642,O
1.78-17.39,642,O
],642,O
",",642,O
P,642,O
=,642,O
0.003,642,O
),642,O
but,642,O
not,642,O
in,642,O
the,642,O
intervention,642,O
group,642,O
.,642,O
We,643,O
conclude,643,O
that,643,O
the,643,O
SNPs,643,O
of,643,O
SLC2A2,643,B-GeneOrGeneProduct
predict,643,O
the,643,O
conversion,643,O
to,643,O
diabetes,643,B-DiseaseOrPhenotypicFeature
in,643,O
obese,643,B-DiseaseOrPhenotypicFeature
subjects,643,O
with,643,O
IGT,643,B-DiseaseOrPhenotypicFeature
.,643,O
An,644,O
autosomal,644,B-DiseaseOrPhenotypicFeature
dominant,644,I-DiseaseOrPhenotypicFeature
cerebellar,644,I-DiseaseOrPhenotypicFeature
ataxia,644,I-DiseaseOrPhenotypicFeature
linked,644,O
to,644,O
chromosome,644,O
16q22.1,644,O
is,644,O
associated,644,O
with,644,O
a,644,O
single-nucleotide,644,O
substitution,644,O
in,644,O
the,644,O
5,644,O
',644,O
untranslated,644,O
region,644,O
of,644,O
the,644,O
gene,644,O
encoding,644,O
a,644,O
protein,644,O
with,644,O
spectrin,644,O
repeat,644,O
and,644,O
Rho,644,B-GeneOrGeneProduct
guanine-nucleotide,644,I-GeneOrGeneProduct
exchange-factor,644,I-GeneOrGeneProduct
domains,644,O
.,644,O
Autosomal,645,B-DiseaseOrPhenotypicFeature
dominant,645,I-DiseaseOrPhenotypicFeature
cerebellar,645,I-DiseaseOrPhenotypicFeature
ataxia,645,I-DiseaseOrPhenotypicFeature
(,645,O
ADCA,645,B-DiseaseOrPhenotypicFeature
),645,O
is,645,O
a,645,O
group,645,O
of,645,O
heterogeneous,645,O
neurodegenerative,645,B-DiseaseOrPhenotypicFeature
disorders,645,I-DiseaseOrPhenotypicFeature
.,645,O
By,646,O
positional,646,O
cloning,646,O
",",646,O
we,646,O
have,646,O
identified,646,O
the,646,O
gene,646,O
strongly,646,O
associated,646,O
with,646,O
a,646,O
form,646,O
of,646,O
degenerative,646,B-DiseaseOrPhenotypicFeature
ataxia,646,I-DiseaseOrPhenotypicFeature
(,646,O
chromosome,646,O
16q22.1-linked,646,O
ADCA,646,B-DiseaseOrPhenotypicFeature
),646,O
that,646,O
clinically,646,O
shows,646,O
progressive,646,O
pure,646,O
cerebellar,646,B-DiseaseOrPhenotypicFeature
ataxia,646,I-DiseaseOrPhenotypicFeature
.,646,O
Detailed,647,O
examination,647,O
by,647,O
use,647,O
of,647,O
audiogram,647,O
suggested,647,O
that,647,O
sensorineural,647,B-DiseaseOrPhenotypicFeature
hearing,647,I-DiseaseOrPhenotypicFeature
impairment,647,I-DiseaseOrPhenotypicFeature
may,647,O
be,647,O
associated,647,O
with,647,O
ataxia,647,B-DiseaseOrPhenotypicFeature
in,647,O
our,647,O
families,647,O
.,647,O
After,648,O
restricting,648,O
the,648,O
candidate,648,O
region,648,O
in,648,O
chromosome,648,O
16q22.1,648,O
by,648,O
haplotype,648,O
analysis,648,O
",",648,O
we,648,O
found,648,O
that,648,O
all,648,O
patients,648,B-OrganismTaxon
from,648,O
52,648,O
unrelated,648,O
Japanese,648,O
families,648,O
harbor,648,O
a,648,O
heterozygous,648,O
C,648,B-SequenceVariant
--,648,I-SequenceVariant
>,648,I-SequenceVariant
T,648,I-SequenceVariant
single-nucleotide,648,O
substitution,648,O
",",648,O
16,648,O
nt,648,O
upstream,648,O
of,648,O
the,648,O
putative,648,O
translation,648,O
initiation,648,O
site,648,O
of,648,O
the,648,O
gene,648,O
for,648,O
a,648,O
hypothetical,648,O
protein,648,O
DKFZP434I216,648,B-GeneOrGeneProduct
",",648,O
which,648,O
we,648,O
have,648,O
called,648,O
``,648,O
puratrophin-1,648,B-GeneOrGeneProduct
'',648,O
(,648,O
Purkinje,648,B-GeneOrGeneProduct
cell,648,I-GeneOrGeneProduct
atrophy,648,I-GeneOrGeneProduct
associated,648,I-GeneOrGeneProduct
protein-1,648,I-GeneOrGeneProduct
),648,O
.,648,O
The,649,O
full-length,649,O
puratrophin-1,649,B-GeneOrGeneProduct
mRNA,649,O
had,649,O
an,649,O
open,649,O
reading,649,O
frame,649,O
of,649,O
"3,576",649,O
nt,649,O
",",649,O
predicted,649,O
to,649,O
contain,649,O
important,649,O
domains,649,O
",",649,O
including,649,O
the,649,O
spectrin,649,O
repeat,649,O
and,649,O
the,649,O
guanine-nucleotide,649,B-GeneOrGeneProduct
exchange,649,I-GeneOrGeneProduct
factor,649,I-GeneOrGeneProduct
(,649,O
GEF,649,B-GeneOrGeneProduct
),649,O
for,649,O
Rho,649,B-GeneOrGeneProduct
GTPases,649,I-GeneOrGeneProduct
",",649,O
followed,649,O
by,649,O
the,649,O
Dbl-homologous,649,O
domain,649,O
",",649,O
which,649,O
indicates,649,O
the,649,O
role,649,O
of,649,O
puratrophin-1,649,B-GeneOrGeneProduct
in,649,O
intracellular,649,O
signaling,649,O
and,649,O
actin,649,B-GeneOrGeneProduct
dynamics,649,O
at,649,O
the,649,O
Golgi,649,O
apparatus,649,O
.,649,O
Puratrophin-1,650,B-GeneOrGeneProduct
--,650,O
normally,650,O
expressed,650,O
in,650,O
a,650,O
wide,650,O
range,650,O
of,650,O
cells,650,O
",",650,O
including,650,O
epithelial,650,O
hair,650,O
cells,650,O
in,650,O
the,650,O
cochlea,650,O
--,650,O
was,650,O
aggregated,650,O
in,650,O
Purkinje,650,O
cells,650,O
of,650,O
the,650,O
chromosome,650,O
16q22.1-linked,650,O
ADCA,650,B-DiseaseOrPhenotypicFeature
brains,650,O
.,650,O
Consistent,651,O
with,651,O
the,651,O
protein,651,O
prediction,651,O
data,651,O
of,651,O
puratrophin-1,651,B-GeneOrGeneProduct
",",651,O
the,651,O
Golgi-apparatus,651,O
membrane,651,O
protein,651,O
and,651,O
spectrin,651,O
also,651,O
formed,651,O
aggregates,651,O
in,651,O
Purkinje,651,O
cells,651,O
.,651,O
The,652,O
present,652,O
study,652,O
highlights,652,O
the,652,O
importance,652,O
of,652,O
the,652,O
5,652,O
',652,O
untranslated,652,O
region,652,O
(,652,O
UTR,652,O
),652,O
in,652,O
identification,652,O
of,652,O
genes,652,O
of,652,O
human,652,B-OrganismTaxon
disease,652,O
",",652,O
suggests,652,O
that,652,O
a,652,O
single-nucleotide,652,O
substitution,652,O
in,652,O
the,652,O
5,652,O
',652,O
UTR,652,O
could,652,O
be,652,O
associated,652,O
with,652,O
protein,652,O
aggregation,652,O
",",652,O
and,652,O
indicates,652,O
that,652,O
the,652,O
GEF,652,B-GeneOrGeneProduct
protein,652,O
is,652,O
associated,652,O
with,652,O
cerebellar,652,B-DiseaseOrPhenotypicFeature
degeneration,652,I-DiseaseOrPhenotypicFeature
in,652,O
humans,652,B-OrganismTaxon
.,652,O
Identification,653,O
of,653,O
a,653,O
novel,653,O
WFS1,653,B-GeneOrGeneProduct
mutation,653,O
(,653,O
AFF344-345ins,653,B-SequenceVariant
),653,O
in,653,O
Japanese,653,O
patients,653,B-OrganismTaxon
with,653,O
Wolfram,653,B-DiseaseOrPhenotypicFeature
syndrome,653,I-DiseaseOrPhenotypicFeature
.,653,O
Wolfram,654,B-DiseaseOrPhenotypicFeature
syndrome,654,I-DiseaseOrPhenotypicFeature
(,654,O
WFS,654,B-DiseaseOrPhenotypicFeature
),654,O
is,654,O
an,654,O
autosomal,654,B-DiseaseOrPhenotypicFeature
recessive,654,I-DiseaseOrPhenotypicFeature
disorder,654,I-DiseaseOrPhenotypicFeature
characterized,654,O
by,654,O
early,654,O
onset,654,O
diabetes,654,B-DiseaseOrPhenotypicFeature
mellitus,654,I-DiseaseOrPhenotypicFeature
",",654,O
progressive,654,O
optic,654,B-DiseaseOrPhenotypicFeature
atrophy,654,I-DiseaseOrPhenotypicFeature
",",654,O
sensorineural,654,B-DiseaseOrPhenotypicFeature
deafness,654,I-DiseaseOrPhenotypicFeature
and,654,O
diabetes,654,B-DiseaseOrPhenotypicFeature
insipidus,654,I-DiseaseOrPhenotypicFeature
.,654,O
Affected,655,O
individuals,655,O
may,655,O
also,655,O
have,655,O
renal,655,B-DiseaseOrPhenotypicFeature
tract,655,I-DiseaseOrPhenotypicFeature
abnormalities,655,I-DiseaseOrPhenotypicFeature
as,655,O
well,655,O
as,655,O
neurogical,655,O
and,655,O
psychiatric,655,B-DiseaseOrPhenotypicFeature
syndromes,655,I-DiseaseOrPhenotypicFeature
.,655,O
WFS1,656,B-GeneOrGeneProduct
encoding,656,O
a,656,O
transmembrane,656,O
protein,656,O
was,656,O
identified,656,O
as,656,O
the,656,O
gene,656,O
responsible,656,O
for,656,O
WFS,656,B-DiseaseOrPhenotypicFeature
.,656,O
We,657,O
report,657,O
herein,657,O
a,657,O
Japanese,657,O
family,657,O
",",657,O
of,657,O
which,657,O
two,657,O
members,657,O
had,657,O
this,657,O
syndrome,657,O
.,657,O
In,658,O
the,658,O
WFS1,658,B-GeneOrGeneProduct
gene,658,O
of,658,O
these,658,O
patients,658,B-OrganismTaxon
",",658,O
we,658,O
identified,658,O
a,658,O
novel,658,O
mutation,658,O
",",658,O
a,658,O
nine,658,B-SequenceVariant
nucleotide,658,I-SequenceVariant
insertion,658,I-SequenceVariant
(,658,O
AFF344-345ins,658,B-SequenceVariant
),658,O
.,658,O
In,659,O
addition,659,O
",",659,O
one,659,O
of,659,O
these,659,O
patients,659,B-OrganismTaxon
had,659,O
preclinical,659,O
hypopituitarism,659,B-DiseaseOrPhenotypicFeature
",",659,O
which,659,O
is,659,O
an,659,O
unusual,659,O
feature,659,O
of,659,O
WFS,659,B-DiseaseOrPhenotypicFeature
.,659,O
As,660,O
only,660,O
the,660,O
two,660,O
family,660,O
members,660,O
homozygous,660,O
for,660,O
the,660,O
mutation,660,O
showed,660,O
WFS,660,B-DiseaseOrPhenotypicFeature
",",660,O
these,660,O
data,660,O
support,660,O
the,660,O
notion,660,O
that,660,O
this,660,O
mutation,660,O
is,660,O
the,660,O
cause,660,O
of,660,O
WFS,660,B-DiseaseOrPhenotypicFeature
.,660,O
A,661,O
single-nucleotide,661,O
polymorphism,661,O
in,661,O
the,661,O
5'-untranslated,661,O
region,661,O
of,661,O
the,661,O
hPER2,661,B-GeneOrGeneProduct
gene,661,O
is,661,O
associated,661,O
with,661,O
diurnal,661,O
preference,661,O
.,661,O
The,662,O
PERIOD2,662,B-GeneOrGeneProduct
(,662,O
PER2,662,B-GeneOrGeneProduct
),662,O
gene,662,O
is,662,O
a,662,O
key,662,O
component,662,O
of,662,O
the,662,O
molecular,662,O
mechanism,662,O
that,662,O
generates,662,O
circadian,662,O
rhythms,662,O
in,662,O
mammals,662,O
.,662,O
A,663,O
missense,663,O
mutation,663,O
in,663,O
the,663,O
human,663,B-OrganismTaxon
PER2,663,B-GeneOrGeneProduct
gene,663,O
has,663,O
previously,663,O
been,663,O
linked,663,O
to,663,O
advanced,663,B-DiseaseOrPhenotypicFeature
sleep,663,I-DiseaseOrPhenotypicFeature
phase,663,I-DiseaseOrPhenotypicFeature
syndrome,663,I-DiseaseOrPhenotypicFeature
(,663,O
ASPS,663,B-DiseaseOrPhenotypicFeature
),663,O
.,663,O
We,664,O
have,664,O
investigated,664,O
three,664,O
other,664,O
single-nucleotide,664,O
polymorphisms,664,O
in,664,O
the,664,O
hPER2,664,B-GeneOrGeneProduct
gene,664,O
",",664,O
one,664,O
downstream,664,O
of,664,O
the,664,O
transcription,664,O
start,664,O
site,664,O
(,664,O
C-1228T,664,B-SequenceVariant
),664,O
",",664,O
one,664,O
in,664,O
exon,664,O
2,664,O
in,664,O
the,664,O
5'-untranslated,664,O
region,664,O
(,664,O
5'-UTR,664,O
),664,O
(,664,O
C111G,664,B-SequenceVariant
),664,O
",",664,O
and,664,O
one,664,O
missense,664,O
mutation,664,O
(,664,O
G3853A,664,B-SequenceVariant
),664,O
causing,664,O
a,664,O
glycine,664,B-SequenceVariant
to,664,I-SequenceVariant
glutamine,664,I-SequenceVariant
substitution,664,O
in,664,O
the,664,O
predicted,664,O
protein,664,O
.,664,O
Subjects,665,O
selected,665,O
from,665,O
a,665,O
group,665,O
of,665,O
484,665,O
volunteers,665,O
for,665,O
extreme,665,O
morning,665,O
or,665,O
evening,665,O
preference,665,O
",",665,O
or,665,O
intermediate,665,O
diurnal,665,O
preference,665,O
were,665,O
genotyped,665,O
with,665,O
regard,665,O
to,665,O
the,665,O
three,665,O
polymorphisms,665,O
(,665,O
n=35,665,O
for,665,O
each,665,O
group,665,O
),665,O
.,665,O
Whereas,666,O
allele,666,O
frequencies,666,O
for,666,O
the,666,O
other,666,O
two,666,O
polymorphisms,666,O
did,666,O
not,666,O
differ,666,O
significantly,666,O
between,666,O
any,666,O
of,666,O
the,666,O
groups,666,O
",",666,O
the,666,O
111G,666,B-SequenceVariant
allele,666,O
frequency,666,O
was,666,O
significantly,666,O
higher,666,O
in,666,O
subjects,666,O
with,666,O
extreme,666,O
morning,666,O
preference,666,O
(,666,O
0.14,666,O
),666,O
than,666,O
in,666,O
subjects,666,O
with,666,O
extreme,666,O
evening,666,O
preference,666,O
(,666,O
0.03,666,O
),666,O
(,666,O
Fisher,666,O
's,666,O
exact,666,O
test,666,O
",",666,O
two-sided,666,O
P,666,O
value=0.031,666,O
",",666,O
odds,666,O
ratio=5.67,666,O
),666,O
.,666,O
No,667,O
significant,667,O
difference,667,O
in,667,O
111G,667,B-SequenceVariant
allele,667,O
frequency,667,O
was,667,O
observed,667,O
between,667,O
either,667,O
of,667,O
these,667,O
groups,667,O
and,667,O
subjects,667,O
with,667,O
intermediate,667,O
diurnal,667,O
preference,667,O
.,667,O
Computer,668,O
prediction,668,O
indicated,668,O
that,668,O
the,668,O
C111G,668,B-SequenceVariant
polymorphism,668,O
",",668,O
which,668,O
occurs,668,O
12,668,O
bases,668,O
upstream,668,O
from,668,O
the,668,O
translation,668,O
start,668,O
codon,668,O
",",668,O
might,668,O
alter,668,O
the,668,O
secondary,668,O
structure,668,O
of,668,O
the,668,O
transcript,668,O
.,668,O
The,669,O
PER2,669,B-GeneOrGeneProduct
111G,669,B-SequenceVariant
allele,669,O
associates,669,O
with,669,O
morning,669,O
preference,669,O
and,669,O
is,669,O
a,669,O
potential,669,O
candidate,669,O
allele,669,O
for,669,O
ASPS,669,B-DiseaseOrPhenotypicFeature
.,669,O
A,670,O
Cys,670,B-SequenceVariant
23-Ser,670,I-SequenceVariant
23,670,I-SequenceVariant
substitution,670,O
in,670,O
the,670,O
5-HT,670,B-GeneOrGeneProduct
(,670,I-GeneOrGeneProduct
2C,670,I-GeneOrGeneProduct
),670,I-GeneOrGeneProduct
receptor,670,I-GeneOrGeneProduct
gene,670,O
influences,670,O
body,670,O
weight,670,O
regulation,670,O
in,670,O
females,670,O
with,670,O
seasonal,670,B-DiseaseOrPhenotypicFeature
affective,670,I-DiseaseOrPhenotypicFeature
disorder,670,I-DiseaseOrPhenotypicFeature
:,670,O
an,670,O
Austrian-Canadian,670,O
collaborative,670,O
study,670,O
.,670,O
Most,671,O
females,671,O
with,671,O
seasonal,671,B-DiseaseOrPhenotypicFeature
affective,671,I-DiseaseOrPhenotypicFeature
disorder,671,I-DiseaseOrPhenotypicFeature
(,671,O
SAD,671,B-DiseaseOrPhenotypicFeature
),671,O
exhibit,671,O
atypical,671,O
vegetative,671,O
symptoms,671,O
such,671,O
as,671,O
overeating,671,O
",",671,O
and,671,O
weight,671,B-DiseaseOrPhenotypicFeature
gain,671,I-DiseaseOrPhenotypicFeature
when,671,I-DiseaseOrPhenotypicFeature
depressed,671,I-DiseaseOrPhenotypicFeature
.,671,O
The,672,O
serotonin,672,B-GeneOrGeneProduct
2C,672,I-GeneOrGeneProduct
receptor,672,I-GeneOrGeneProduct
(,672,O
5-HT,672,B-GeneOrGeneProduct
(,672,I-GeneOrGeneProduct
2C,672,I-GeneOrGeneProduct
),672,I-GeneOrGeneProduct
),672,O
plays,672,O
a,672,O
key,672,O
role,672,O
in,672,O
control,672,O
of,672,O
appetite,672,O
and,672,O
satiety,672,O
.,672,O
A,673,O
5-HT,673,B-GeneOrGeneProduct
(,673,I-GeneOrGeneProduct
2C,673,I-GeneOrGeneProduct
),673,I-GeneOrGeneProduct
Cys,673,B-SequenceVariant
23,673,I-SequenceVariant
Ser,673,I-SequenceVariant
substitution,673,O
",",673,O
coded,673,O
for,673,O
by,673,O
a,673,O
single,673,O
nucleotide,673,O
polymorphism,673,O
(,673,O
Cys,673,B-SequenceVariant
23,673,I-SequenceVariant
Ser,673,I-SequenceVariant
),673,O
within,673,O
the,673,O
5-HT,673,B-GeneOrGeneProduct
(,673,I-GeneOrGeneProduct
2C,673,I-GeneOrGeneProduct
),673,I-GeneOrGeneProduct
gene,673,O
",",673,O
has,673,O
been,673,O
shown,673,O
to,673,O
influence,673,O
5-HT,673,B-GeneOrGeneProduct
(,673,I-GeneOrGeneProduct
2C,673,I-GeneOrGeneProduct
),673,I-GeneOrGeneProduct
function,673,O
.,673,O
We,674,O
hypothesized,674,O
that,674,O
Cys,674,B-SequenceVariant
23,674,I-SequenceVariant
Ser,674,I-SequenceVariant
influences,674,O
weight,674,O
regulation,674,O
in,674,O
females,674,O
with,674,O
SAD,674,B-DiseaseOrPhenotypicFeature
.,674,O
Two,675,O
independent,675,O
samples,675,O
from,675,O
Austria,675,O
(,675,O
162,675,O
females,675,O
with,675,O
SAD,675,B-DiseaseOrPhenotypicFeature
",",675,O
119,675,O
controls,675,O
),675,O
",",675,O
and,675,O
Canada,675,O
(,675,O
90,675,O
females,675,O
with,675,O
SAD,675,B-DiseaseOrPhenotypicFeature
",",675,O
42,675,O
controls,675,O
),675,O
were,675,O
genotyped,675,O
for,675,O
Cys,675,B-SequenceVariant
23,675,I-SequenceVariant
Ser,675,I-SequenceVariant
.,675,O
Influence,676,O
on,676,O
weight,676,O
regulation,676,O
was,676,O
analyzed,676,O
within,676,O
patients,676,B-OrganismTaxon
with,676,O
atypical,676,O
features,676,O
.,676,O
In,677,O
Austrians,677,O
",",677,O
genotype,677,O
distribution,677,O
differed,677,O
between,677,O
patients,677,B-OrganismTaxon
and,677,O
controls,677,O
(,677,O
p=0.044,677,O
),677,O
and,677,O
Cys,677,B-SequenceVariant
23,677,I-SequenceVariant
Ser,677,I-SequenceVariant
was,677,O
associated,677,O
with,677,O
weight,677,O
(,677,O
p=0.039,677,O
),677,O
",",677,O
body,677,O
mass,677,O
index,677,O
(,677,O
BMI,677,O
;,677,O
p=0.038,677,O
),677,O
",",677,O
and,677,O
seasonal,677,O
appetite,677,O
change,677,O
(,677,O
p=0.031,677,O
),677,O
.,677,O
All,678,O
values,678,O
were,678,O
highest,678,O
in,678,O
Cys/Cys,678,O
",",678,O
intermediate,678,O
in,678,O
Cys/Ser,678,O
",",678,O
and,678,O
lowest,678,O
in,678,O
Ser/Ser,678,O
carriers,678,O
.,678,O
In,679,O
Canadian,679,O
patients,679,B-OrganismTaxon
",",679,O
Cys,679,B-SequenceVariant
23,679,I-SequenceVariant
Ser,679,I-SequenceVariant
was,679,O
associated,679,O
with,679,O
minimum,679,O
lifetime,679,O
BMI,679,O
(,679,O
p=0.046,679,O
),679,O
",",679,O
with,679,O
lowest,679,O
values,679,O
in,679,O
Ser/Ser,679,O
carriers,679,O
.,679,O
Our,680,O
data,680,O
provide,680,O
evidence,680,O
that,680,O
Cys,680,B-SequenceVariant
23,680,I-SequenceVariant
Ser,680,I-SequenceVariant
mediates,680,O
severity,680,O
of,680,O
weight,680,O
regulation,680,O
disturbances,680,O
in,680,O
females,680,O
with,680,O
SAD,680,B-DiseaseOrPhenotypicFeature
",",680,O
and,680,O
the,680,O
gene-dose,680,O
effect-like,680,O
differences,680,O
suggest,680,O
a,680,O
direct,680,O
functional,680,O
role,680,O
of,680,O
Cys,680,B-SequenceVariant
23,680,I-SequenceVariant
Ser,680,I-SequenceVariant
in,680,O
the,680,O
behavioral,680,O
regulation,680,O
of,680,O
body,680,O
weight,680,O
.,680,O
Delineation,681,O
of,681,O
the,681,O
clinical,681,O
phenotype,681,O
associated,681,O
with,681,O
OPHN1,681,B-GeneOrGeneProduct
mutations,681,O
based,681,O
on,681,O
the,681,O
clinical,681,O
and,681,O
neuropsychological,681,O
evaluation,681,O
of,681,O
three,681,O
families,681,O
.,681,O
Recent,682,O
reports,682,O
have,682,O
demonstrated,682,O
that,682,O
mutations,682,O
in,682,O
the,682,O
OPHN1,682,B-GeneOrGeneProduct
gene,682,O
were,682,O
responsible,682,O
for,682,O
a,682,O
syndromic,682,O
rather,682,O
than,682,O
non-specific,682,O
mental,682,B-DiseaseOrPhenotypicFeature
retardation,682,I-DiseaseOrPhenotypicFeature
.,682,O
Abnormalities,683,O
of,683,O
the,683,O
posterior,683,O
fossa,683,O
with,683,O
cerebellar,683,B-DiseaseOrPhenotypicFeature
hypoplasia,683,I-DiseaseOrPhenotypicFeature
have,683,O
been,683,O
demonstrated,683,O
in,683,O
all,683,O
male,683,O
patients,683,B-OrganismTaxon
reported,683,O
to,683,O
date,683,O
.,683,O
We,684,O
report,684,O
here,684,O
a,684,O
new,684,O
family,684,O
with,684,O
X-linked,684,B-DiseaseOrPhenotypicFeature
mental,684,I-DiseaseOrPhenotypicFeature
retardation,684,I-DiseaseOrPhenotypicFeature
due,684,O
to,684,O
mutation,684,O
in,684,O
OPHN1,684,B-GeneOrGeneProduct
and,684,O
present,684,O
unpublished,684,O
data,684,O
about,684,O
two,684,O
families,684,O
previously,684,O
reported,684,O
",",684,O
concerning,684,O
the,684,O
facial,684,O
and,684,O
psychological,684,O
phenotype,684,O
of,684,O
affected,684,O
males,684,O
and,684,O
carrier,684,O
females,684,O
.,684,O
Our,685,O
study,685,O
confirms,685,O
that,685,O
cerebellar,685,B-DiseaseOrPhenotypicFeature
hypoplasia,685,I-DiseaseOrPhenotypicFeature
is,685,O
a,685,O
hallmark,685,O
of,685,O
this,685,O
syndrome,685,O
.,685,O
In,686,O
addition,686,O
",",686,O
affected,686,O
males,686,O
display,686,O
facial,686,O
similarities,686,O
that,686,O
can,686,O
help,686,O
the,686,O
diagnosis,686,O
.,686,O
Most,687,O
carrier,687,O
females,687,O
have,687,O
mild,687,O
mental,687,B-DiseaseOrPhenotypicFeature
retardation,687,I-DiseaseOrPhenotypicFeature
and,687,O
subtle,687,O
facial,687,O
changes,687,O
.,687,O
Behavioral,688,O
effects,688,O
of,688,O
urotensin-II,688,B-GeneOrGeneProduct
centrally,688,O
administered,688,O
in,688,O
mice,688,B-OrganismTaxon
.,688,O
Urotensin-II,689,B-GeneOrGeneProduct
(,689,O
U-II,689,B-GeneOrGeneProduct
),689,O
receptors,689,O
are,689,O
widely,689,O
distributed,689,O
in,689,O
the,689,O
central,689,O
nervous,689,O
system,689,O
.,689,O
Intracerebroventricular,690,O
(,690,O
i.c.v,690,O
.,690,O
),690,O
injection,691,O
of,691,O
U-II,691,B-GeneOrGeneProduct
causes,691,O
hypertension,691,B-DiseaseOrPhenotypicFeature
and,691,O
bradycardia,691,B-DiseaseOrPhenotypicFeature
and,691,O
stimulates,691,O
prolactin,691,B-GeneOrGeneProduct
and,691,O
thyrotropin,691,B-GeneOrGeneProduct
secretion,691,O
.,691,O
However,692,O
",",692,O
the,692,O
behavioral,692,O
effects,692,O
of,692,O
centrally,692,O
administered,692,O
U-II,692,B-GeneOrGeneProduct
have,692,O
received,692,O
little,692,O
attention,692,O
.,692,O
In,693,O
the,693,O
present,693,O
study,693,O
",",693,O
we,693,O
tested,693,O
the,693,O
effects,693,O
of,693,O
i.c.v,693,O
.,693,O
injections,694,O
of,694,O
U-II,694,B-GeneOrGeneProduct
on,694,O
behavioral,694,O
",",694,O
metabolic,694,O
",",694,O
and,694,O
endocrine,694,O
responses,694,O
in,694,O
mice,694,B-OrganismTaxon
.,694,O
Administration,695,O
of,695,O
graded,695,O
doses,695,O
of,695,O
U-II,695,B-GeneOrGeneProduct
(,695,O
"1-10,000",695,O
ng/mouse,695,O
),695,O
provoked,695,O
:,695,O
(,695,O
1,695,O
),695,O
a,695,O
dose-dependent,695,O
reduction,695,O
in,695,O
the,695,O
number,695,O
of,695,O
head,695,O
dips,695,O
in,695,O
the,695,O
hole-board,695,O
test,695,O
;,695,O
(,695,O
2,695,O
),695,O
a,695,O
dose-dependent,695,O
reduction,695,O
in,695,O
the,695,O
number,695,O
of,695,O
entries,695,O
in,695,O
the,695,O
white,695,O
chamber,695,O
in,695,O
the,695,O
black-and-white,695,O
compartment,695,O
test,695,O
",",695,O
and,695,O
in,695,O
the,695,O
number,695,O
of,695,O
entries,695,O
in,695,O
the,695,O
central,695,O
platform,695,O
and,695,O
open,695,O
arms,695,O
in,695,O
the,695,O
plus-maze,695,O
test,695,O
;,695,O
and,695,O
(,695,O
3,695,O
),695,O
a,695,O
dose-dependent,695,O
increase,695,O
in,695,O
the,695,O
duration,695,O
of,695,O
immobility,695,O
in,695,O
the,695,O
forced-swimming,695,O
test,695,O
and,695,O
tail,695,O
suspension,695,O
test,695,O
.,695,O
Intracerebroventricular,696,O
injection,696,O
of,696,O
U-II,696,B-GeneOrGeneProduct
also,696,O
caused,696,O
an,696,O
increase,696,O
in,696,O
:,696,O
food,696,O
intake,696,O
at,696,O
doses,696,O
of,696,O
100,696,O
and,696,O
"1,000",696,O
ng/mouse,696,O
",",696,O
water,696,O
intake,696,O
at,696,O
doses,696,O
of,696,O
"100-10,000",696,O
ng/mouse,696,O
",",696,O
and,696,O
horizontal,696,O
locomotion,696,O
activity,696,O
at,696,O
a,696,O
dose,696,O
of,696,O
"10,000",696,O
ng/mouse,696,O
.,696,O
Whatever,697,O
was,697,O
the,697,O
dose,697,O
",",697,O
the,697,O
central,697,O
administration,697,O
of,697,O
U-II,697,B-GeneOrGeneProduct
had,697,O
no,697,O
effect,697,O
on,697,O
body,697,O
temperature,697,O
",",697,O
nociception,697,O
",",697,O
apomorphine-induced,697,B-ChemicalEntity
penile,697,O
erection,697,O
and,697,O
climbing,697,O
behavior,697,O
",",697,O
and,697,O
stress-induced,697,O
plasma,697,O
corticosterone,697,B-ChemicalEntity
level,697,O
.,697,O
Taken,698,O
together,698,O
",",698,O
the,698,O
present,698,O
study,698,O
demonstrates,698,O
that,698,O
the,698,O
central,698,O
injection,698,O
of,698,O
U-II,698,B-GeneOrGeneProduct
at,698,O
doses,698,O
of,698,O
"1-10,000",698,O
ng/mouse,698,O
induces,698,O
anxiogenic-,698,B-DiseaseOrPhenotypicFeature
and,698,O
depressant-like,698,B-DiseaseOrPhenotypicFeature
effects,698,O
in,698,O
mouse,698,B-OrganismTaxon
.,698,O
These,699,O
data,699,O
suggest,699,O
that,699,O
U-II,699,B-GeneOrGeneProduct
may,699,O
be,699,O
involved,699,O
in,699,O
some,699,O
aspects,699,O
of,699,O
psychiatric,699,B-DiseaseOrPhenotypicFeature
disorders,699,I-DiseaseOrPhenotypicFeature
.,699,O
The,700,O
effects,700,O
of,700,O
short-term,700,O
raloxifene,700,B-ChemicalEntity
therapy,700,O
on,700,O
fibrinolysis,700,O
markers,700,O
:,700,O
TAFI,700,B-GeneOrGeneProduct
",",700,O
tPA,700,B-GeneOrGeneProduct
",",700,O
and,700,O
PAI-1,700,B-GeneOrGeneProduct
.,700,O
BACKGROUND,701,O
:,701,O
Markers,701,O
of,701,O
fibrinolysis,701,O
",",701,O
thrombin-activatable,701,B-GeneOrGeneProduct
fibrinolysis,701,I-GeneOrGeneProduct
inhibitor,701,I-GeneOrGeneProduct
(,701,O
TAFI,701,B-GeneOrGeneProduct
),701,O
",",701,O
tissue-type,701,B-GeneOrGeneProduct
plasminogen,701,I-GeneOrGeneProduct
activator,701,I-GeneOrGeneProduct
(,701,O
tPA,701,B-GeneOrGeneProduct
),701,O
",",701,O
and,701,O
plasminogen,701,B-GeneOrGeneProduct
activator,701,I-GeneOrGeneProduct
inhibitor-1,701,I-GeneOrGeneProduct
(,701,O
PAI-1,701,B-GeneOrGeneProduct
),701,O
levels,701,O
were,701,O
studied,701,O
for,701,O
the,701,O
evaluation,701,O
of,701,O
short-term,701,O
effects,701,O
of,701,O
raloxifene,701,B-ChemicalEntity
administration,701,O
in,701,O
postmenopausal,701,O
women,701,B-OrganismTaxon
.,701,O
METHODS,702,O
:,702,O
Thirty-nine,702,O
postmenopausal,702,O
women,702,B-OrganismTaxon
with,702,O
osteopenia,702,B-DiseaseOrPhenotypicFeature
or,702,O
osteoporosis,702,B-DiseaseOrPhenotypicFeature
were,702,O
included,702,O
in,702,O
this,702,O
prospective,702,O
",",702,O
controlled,702,O
clinical,702,O
study,702,O
.,702,O
Twenty-five,703,O
women,703,B-OrganismTaxon
were,703,O
given,703,O
raloxifene,703,B-ChemicalEntity
hydrochloride,703,I-ChemicalEntity
(,703,O
60,703,O
mg/day,703,O
),703,O
plus,703,O
calcium,703,B-ChemicalEntity
(,703,O
500,703,O
mg/day,703,O
),703,O
.,703,O
Age-matched,704,O
controls,704,O
(,704,O
n,704,O
=,704,O
14,704,O
),704,O
were,704,O
given,704,O
only,704,O
calcium,704,B-ChemicalEntity
.,704,O
Plasma,705,O
TAFI,705,B-GeneOrGeneProduct
",",705,O
tPA,705,B-GeneOrGeneProduct
",",705,O
and,705,O
PAI-1,705,B-GeneOrGeneProduct
antigen,705,O
levels,705,O
were,705,O
measured,705,O
at,705,O
baseline,705,O
and,705,O
after,705,O
3,705,O
months,705,O
of,705,O
treatment,705,O
by,705,O
commercially,705,O
available,705,O
ELISA,705,O
kits,705,O
.,705,O
Variations,706,O
of,706,O
individuals,706,O
were,706,O
assessed,706,O
by,706,O
Wilcoxon,706,O
's,706,O
test,706,O
.,706,O
Relationship,707,O
between,707,O
those,707,O
markers,707,O
and,707,O
demographic,707,O
characteristics,707,O
were,707,O
investigated,707,O
.,707,O
RESULTS,708,O
:,708,O
Three,708,O
months,708,O
of,708,O
raloxifene,708,B-ChemicalEntity
treatment,708,O
was,708,O
associated,708,O
with,708,O
a,708,O
significant,708,O
decrease,708,O
in,708,O
the,708,O
plasma,708,O
TAFI,708,B-GeneOrGeneProduct
antigen,708,O
concentrations,708,O
(,708,O
16,708,O
%,708,O
change,708,O
",",708,O
P,708,O
<,708,O
0.01,708,O
),708,O
",",708,O
and,708,O
a,708,O
significant,708,O
increase,708,O
in,708,O
tPA,708,B-GeneOrGeneProduct
antigen,708,O
concentrations,708,O
(,708,O
25,708,O
%,708,O
change,708,O
",",708,O
P,708,O
<,708,O
0.05,708,O
),708,O
.,708,O
A,709,O
significant,709,O
correlation,709,O
was,709,O
found,709,O
between,709,O
baseline,709,O
TAFI,709,B-GeneOrGeneProduct
antigen,709,O
concentrations,709,O
and,709,O
the,709,O
duration,709,O
of,709,O
amenorrhea,709,O
(,709,O
P,709,O
<,709,O
0.05,709,O
;,709,O
r,709,O
=,709,O
0.33,709,O
),709,O
.,709,O
CONCLUSION,710,O
:,710,O
We,710,O
suggest,710,O
that,710,O
the,710,O
increased,710,O
risk,710,O
of,710,O
venous,710,B-DiseaseOrPhenotypicFeature
thromboembolism,710,I-DiseaseOrPhenotypicFeature
due,710,O
to,710,O
raloxifene,710,B-ChemicalEntity
treatment,710,O
may,710,O
be,710,O
related,710,O
to,710,O
increased,710,O
tPA,710,B-GeneOrGeneProduct
levels,710,O
",",710,O
but,710,O
not,710,O
TAFI,710,B-GeneOrGeneProduct
levels,710,O
.,710,O
A,711,O
genetic,711,O
analysis,711,O
of,711,O
serotonergic,711,O
biosynthetic,711,O
and,711,O
metabolic,711,O
enzymes,711,O
in,711,O
migraine,711,B-DiseaseOrPhenotypicFeature
using,711,O
a,711,O
DNA,711,O
pooling,711,O
approach,711,O
.,711,O
Migraine,712,B-DiseaseOrPhenotypicFeature
is,712,O
a,712,O
common,712,O
debilitating,712,O
primary,712,O
headache,712,B-DiseaseOrPhenotypicFeature
disorder,712,I-DiseaseOrPhenotypicFeature
with,712,O
significant,712,O
mental,712,O
",",712,O
physical,712,O
and,712,O
social,712,O
health,712,O
implications,712,O
.,712,O
The,713,O
brain,713,O
neurotransmitter,713,B-ChemicalEntity
5-hydroxytryptamine,713,B-ChemicalEntity
(,713,O
5-HT,713,B-ChemicalEntity
;,713,O
serotonin,713,B-ChemicalEntity
),713,O
is,713,O
involved,713,O
in,713,O
nociceptive,713,O
pathways,713,O
and,713,O
has,713,O
been,713,O
implicated,713,O
in,713,O
the,713,O
pathophysiology,713,O
of,713,O
migraine,713,B-DiseaseOrPhenotypicFeature
.,713,O
With,714,O
few,714,O
genetic,714,O
studies,714,O
investigating,714,O
biosynthetic,714,O
and,714,O
metabolic,714,O
enzymes,714,O
governing,714,O
the,714,O
rate,714,O
of,714,O
5-HT,714,B-ChemicalEntity
activity,714,O
and,714,O
their,714,O
relationship,714,O
to,714,O
migraine,714,B-DiseaseOrPhenotypicFeature
",",714,O
it,714,O
was,714,O
the,714,O
objective,714,O
of,714,O
this,714,O
study,714,O
to,714,O
assess,714,O
genetic,714,O
variants,714,O
within,714,O
the,714,O
human,714,B-OrganismTaxon
tryptophan,714,B-GeneOrGeneProduct
hydroxylase,714,I-GeneOrGeneProduct
(,714,O
TPH,714,B-GeneOrGeneProduct
),714,O
",",714,O
amino,714,B-GeneOrGeneProduct
acid,714,I-GeneOrGeneProduct
decarboxylase,714,I-GeneOrGeneProduct
(,714,O
AADC,714,B-GeneOrGeneProduct
),714,O
and,714,O
monoamine,714,B-GeneOrGeneProduct
oxidase,714,I-GeneOrGeneProduct
A,714,I-GeneOrGeneProduct
(,714,O
MAOA,714,B-GeneOrGeneProduct
),714,O
genes,714,O
in,714,O
migraine,714,B-DiseaseOrPhenotypicFeature
susceptibility,714,O
.,714,O
This,715,O
objective,715,O
was,715,O
undertaken,715,O
using,715,O
a,715,O
high-throughput,715,O
DNA,715,O
pooling,715,O
experimental,715,O
design,715,O
",",715,O
which,715,O
proved,715,O
to,715,O
be,715,O
a,715,O
very,715,O
accurate,715,O
",",715,O
sensitive,715,O
and,715,O
specific,715,O
method,715,O
of,715,O
estimating,715,O
allele,715,O
frequencies,715,O
for,715,O
single,715,O
nucleotide,715,O
polymorphism,715,O
",",715,O
insertion,715,O
deletion,715,O
and,715,O
variable,715,O
number,715,O
tandem,715,O
repeat,715,O
loci,715,O
.,715,O
Application,716,O
of,716,O
DNA,716,O
pooling,716,O
to,716,O
a,716,O
wide,716,O
array,716,O
of,716,O
genetic,716,O
loci,716,O
provides,716,O
greater,716,O
scope,716,O
in,716,O
the,716,O
assessment,716,O
of,716,O
population-based,716,O
genetic,716,O
association,716,O
study,716,O
designs,716,O
.,716,O
Despite,717,O
the,717,O
application,717,O
of,717,O
this,717,O
high-throughput,717,O
genotyping,717,O
method,717,O
",",717,O
negative,717,O
results,717,O
from,717,O
the,717,O
two-stage,717,O
DNA,717,O
pooling,717,O
design,717,O
used,717,O
to,717,O
screen,717,O
loci,717,O
within,717,O
the,717,O
TPH,717,B-GeneOrGeneProduct
",",717,O
AADC,717,B-GeneOrGeneProduct
and,717,O
MAOA,717,B-GeneOrGeneProduct
genes,717,O
did,717,O
not,717,O
support,717,O
their,717,O
role,717,O
in,717,O
migraine,717,B-DiseaseOrPhenotypicFeature
susceptibility,717,O
.,717,O
Genetic,718,O
homogeneity,718,O
for,718,O
inherited,718,O
congenital,718,B-DiseaseOrPhenotypicFeature
microcoria,718,I-DiseaseOrPhenotypicFeature
loci,718,O
in,718,O
an,718,O
Asian,718,O
Indian,718,O
pedigree,718,O
.,718,O
PURPOSE,719,O
:,719,O
Congenital,719,B-DiseaseOrPhenotypicFeature
microcoria,719,I-DiseaseOrPhenotypicFeature
is,719,O
a,719,O
rare,719,O
autosomal,719,B-DiseaseOrPhenotypicFeature
dominant,719,I-DiseaseOrPhenotypicFeature
developmental,719,I-DiseaseOrPhenotypicFeature
disorder,719,I-DiseaseOrPhenotypicFeature
of,719,I-DiseaseOrPhenotypicFeature
the,719,I-DiseaseOrPhenotypicFeature
iris,719,I-DiseaseOrPhenotypicFeature
associated,719,O
with,719,O
myopia,719,B-DiseaseOrPhenotypicFeature
and,719,O
juvenile,719,B-DiseaseOrPhenotypicFeature
open,719,I-DiseaseOrPhenotypicFeature
angle,719,I-DiseaseOrPhenotypicFeature
glaucoma,719,I-DiseaseOrPhenotypicFeature
.,719,O
Linkage,720,O
to,720,O
the,720,O
chromosomal,720,O
locus,720,O
13q31-q32,720,O
has,720,O
previously,720,O
been,720,O
reported,720,O
in,720,O
a,720,O
large,720,O
French,720,O
family,720,O
.,720,O
In,721,O
the,721,O
current,721,O
study,721,O
",",721,O
a,721,O
three,721,O
generation,721,O
Asian,721,O
Indian,721,O
family,721,O
with,721,O
15,721,O
congenital,721,B-DiseaseOrPhenotypicFeature
microcoria,721,I-DiseaseOrPhenotypicFeature
(,721,O
pupils,721,O
with,721,O
a,721,O
diameter,721,O
<,721,O
2,721,O
mm,721,O
),721,O
affected,721,O
members,721,O
was,721,O
studied,721,O
for,721,O
linkage,721,O
to,721,O
candidate,721,O
microsatellite,721,O
markers,721,O
at,721,O
the,721,O
13q31-q32,721,O
locus,721,O
.,721,O
METHODS,722,O
:,722,O
Twenty-four,722,O
members,722,O
of,722,O
the,722,O
family,722,O
were,722,O
clinically,722,O
examined,722,O
and,722,O
genomic,722,O
DNA,722,O
was,722,O
extracted,722,O
.,722,O
Microsatellite,723,O
markers,723,O
at,723,O
13q31-q32,723,O
were,723,O
PCR,723,O
amplified,723,O
and,723,O
run,723,O
on,723,O
an,723,O
ABI,723,O
Prism,723,O
310,723,O
genetic,723,O
analyzer,723,O
and,723,O
genotyped,723,O
with,723,O
the,723,O
GeneScan,723,O
analysis,723,O
.,723,O
Two,724,O
point,724,O
and,724,O
multipoint,724,O
linkage,724,O
analyses,724,O
were,724,O
performed,724,O
using,724,O
the,724,O
MLINK,724,O
and,724,O
SUPERLINK,724,O
programs,724,O
.,724,O
RESULTS,725,O
:,725,O
Peak,725,O
two,725,O
point,725,O
LOD,725,O
scores,725,O
of,725,O
3.5,725,O
",",725,O
4.7,725,O
",",725,O
and,725,O
5.3,725,O
were,725,O
found,725,O
co-incident,725,O
with,725,O
consecutive,725,O
markers,725,O
D13S154,725,O
",",725,O
DCT,725,B-GeneOrGeneProduct
",",725,O
and,725,O
D13S1280,725,O
.,725,O
Multipoint,726,O
analysis,726,O
revealed,726,O
a,726,O
4,726,O
cM,726,O
region,726,O
encompassing,726,O
D13S1300,726,O
to,726,O
D13S1280,726,O
where,726,O
the,726,O
LOD,726,O
remains,726,O
just,726,O
over,726,O
6.0,726,O
Thus,726,O
we,726,O
confirm,726,O
localization,726,O
of,726,O
the,726,O
congenital,726,B-DiseaseOrPhenotypicFeature
microcoria,726,I-DiseaseOrPhenotypicFeature
locus,726,O
to,726,O
chromosomal,726,O
locus,726,O
13q31-q32,726,O
.,726,O
In,727,O
addition,727,O
",",727,O
eight,727,O
individuals,727,O
who,727,O
had,727,O
both,727,O
microcoria,727,B-DiseaseOrPhenotypicFeature
and,727,O
glaucoma,727,B-DiseaseOrPhenotypicFeature
were,727,O
screened,727,O
for,727,O
glaucoma,727,B-DiseaseOrPhenotypicFeature
genes,727,O
:,727,O
myocilin,727,B-GeneOrGeneProduct
(,727,O
MYOC,727,B-GeneOrGeneProduct
),727,O
",",727,O
optineurin,727,B-GeneOrGeneProduct
(,727,O
OPTN,727,B-GeneOrGeneProduct
),727,O
and,727,O
CYP1B1,727,B-GeneOrGeneProduct
.,727,O
Using,728,O
direct,728,O
sequencing,728,O
a,728,O
point,728,O
mutation,728,O
(,728,O
144,728,B-SequenceVariant
G,728,I-SequenceVariant
>,728,I-SequenceVariant
A,728,I-SequenceVariant
),728,O
resulting,728,O
in,728,O
a,728,O
Q48H,728,B-SequenceVariant
substitution,728,O
in,728,O
exon,728,O
1,728,O
of,728,O
the,728,O
MYOC,728,B-GeneOrGeneProduct
gene,728,O
was,728,O
observed,728,O
in,728,O
five,728,O
of,728,O
the,728,O
eight,728,O
glaucoma,728,B-DiseaseOrPhenotypicFeature
patients,728,B-OrganismTaxon
",",728,O
but,728,O
not,728,O
in,728,O
unaffected,728,O
family,728,O
members,728,O
and,728,O
100,728,O
unrelated,728,O
controls,728,O
.,728,O
CONCLUSIONS,729,O
:,729,O
We,729,O
have,729,O
confirmed,729,O
the,729,O
localization,729,O
of,729,O
the,729,O
congenital,729,B-DiseaseOrPhenotypicFeature
microcoria,729,I-DiseaseOrPhenotypicFeature
locus,729,O
(,729,O
MCOR,729,B-GeneOrGeneProduct
),729,O
to,729,O
13q31-q32,729,O
in,729,O
a,729,O
large,729,O
Asian,729,O
Indian,729,O
family,729,O
and,729,O
conclude,729,O
that,729,O
current,729,O
information,729,O
suggests,729,O
this,729,O
is,729,O
a,729,O
single,729,O
locus,729,O
disorder,729,O
and,729,O
genetically,729,O
homogeneous,729,O
.,729,O
When,730,O
combined,730,O
with,730,O
the,730,O
initial,730,O
linkage,730,O
paper,730,O
our,730,O
haplotype,730,O
and,730,O
linkage,730,O
data,730,O
map,730,O
the,730,O
MCOR,730,B-GeneOrGeneProduct
locus,730,O
to,730,O
a,730,O
6-7,730,O
cM,730,O
region,730,O
between,730,O
D13S265,730,O
and,730,O
D13S1280,730,O
.,730,O
The,731,O
DCT,731,B-GeneOrGeneProduct
locus,731,O
",",731,O
a,731,O
member,731,O
of,731,O
the,731,O
tyrosinase,731,B-GeneOrGeneProduct
family,731,O
involved,731,O
in,731,O
pigmentation,731,B-DiseaseOrPhenotypicFeature
",",731,O
maps,731,O
within,731,O
this,731,O
region,731,O
.,731,O
Data,732,O
presented,732,O
here,732,O
supports,732,O
the,732,O
hypothesis,732,O
that,732,O
congenital,732,B-DiseaseOrPhenotypicFeature
microcoria,732,I-DiseaseOrPhenotypicFeature
is,732,O
a,732,O
potential,732,O
risk,732,O
factor,732,O
for,732,O
glaucoma,732,B-DiseaseOrPhenotypicFeature
",",732,O
although,732,O
this,732,O
observation,732,O
is,732,O
complicated,732,O
by,732,O
the,732,O
partial,732,O
segregation,732,O
of,732,O
MYOC,732,B-GeneOrGeneProduct
Q48H,732,B-SequenceVariant
(,732,O
1q24.3-q25.2,732,O
),732,O
",",732,O
a,732,O
mutation,732,O
known,732,O
to,732,O
be,732,O
associated,732,O
with,732,O
glaucoma,732,B-DiseaseOrPhenotypicFeature
in,732,O
India,732,O
.,732,O
Fine,733,O
mapping,733,O
and,733,O
candidate,733,O
gene,733,O
analysis,733,O
continues,733,O
with,733,O
the,733,O
hope,733,O
that,733,O
characterizing,733,O
the,733,O
micocoria,733,B-GeneOrGeneProduct
gene,733,O
will,733,O
lead,733,O
to,733,O
a,733,O
better,733,O
understanding,733,O
of,733,O
microcoria,733,B-DiseaseOrPhenotypicFeature
and,733,O
glaucoma,733,B-DiseaseOrPhenotypicFeature
causation,733,O
.,733,O
The,734,O
relationship,734,O
between,734,O
microcoria,734,B-DiseaseOrPhenotypicFeature
",",734,O
glaucoma,734,B-DiseaseOrPhenotypicFeature
",",734,O
and,734,O
the,734,O
MYOC,734,B-GeneOrGeneProduct
Q48H,734,B-SequenceVariant
mutation,734,O
in,734,O
this,734,O
family,734,O
is,734,O
discussed,734,O
.,734,O
The,735,O
promoter,735,O
of,735,O
inducible,735,O
nitric,735,B-GeneOrGeneProduct
oxide,735,I-GeneOrGeneProduct
synthase,735,I-GeneOrGeneProduct
implicated,735,O
in,735,O
glaucoma,735,B-DiseaseOrPhenotypicFeature
based,735,O
on,735,O
genetic,735,O
analysis,735,O
and,735,O
nuclear,735,O
factor,735,O
binding,735,O
.,735,O
PURPOSE,736,O
:,736,O
Nitric,736,B-ChemicalEntity
oxide,736,I-ChemicalEntity
has,736,O
many,736,O
beneficial,736,O
functions,736,O
in,736,O
the,736,O
human,736,B-OrganismTaxon
body,736,O
at,736,O
the,736,O
right,736,O
amounts,736,O
",",736,O
but,736,O
it,736,O
can,736,O
also,736,O
be,736,O
hazardous,736,O
if,736,O
it,736,O
is,736,O
produced,736,O
in,736,O
amounts,736,O
more,736,O
than,736,O
needed,736,O
and,736,O
has,736,O
therefore,736,O
been,736,O
studied,736,O
in,736,O
relation,736,O
to,736,O
several,736,O
neurological,736,B-DiseaseOrPhenotypicFeature
and,736,I-DiseaseOrPhenotypicFeature
non-neurological,736,I-DiseaseOrPhenotypicFeature
disorders,736,I-DiseaseOrPhenotypicFeature
.,736,O
In,737,O
vitro,737,O
and,737,O
in,737,O
vivo,737,O
studies,737,O
demonstrate,737,O
a,737,O
connection,737,O
between,737,O
the,737,O
inducible,737,O
form,737,O
of,737,O
Nitric,737,B-GeneOrGeneProduct
Oxide,737,I-GeneOrGeneProduct
Synthase,737,I-GeneOrGeneProduct
",",737,O
iNOS,737,B-GeneOrGeneProduct
",",737,O
and,737,O
the,737,O
neuropathological,737,B-DiseaseOrPhenotypicFeature
disorder,737,I-DiseaseOrPhenotypicFeature
glaucoma,737,I-DiseaseOrPhenotypicFeature
",",737,O
one,737,O
of,737,O
the,737,O
major,737,O
causes,737,O
of,737,O
blindness,737,B-DiseaseOrPhenotypicFeature
in,737,O
the,737,O
world,737,O
.,737,O
In,738,O
this,738,O
study,738,O
",",738,O
we,738,O
sought,738,O
to,738,O
establish,738,O
the,738,O
genetic,738,O
association,738,O
between,738,O
iNOS,738,B-GeneOrGeneProduct
and,738,O
primary,738,B-DiseaseOrPhenotypicFeature
open,738,I-DiseaseOrPhenotypicFeature
angle,738,I-DiseaseOrPhenotypicFeature
glaucoma,738,I-DiseaseOrPhenotypicFeature
",",738,O
POAG,738,B-DiseaseOrPhenotypicFeature
",",738,O
and,738,O
to,738,O
find,738,O
the,738,O
functional,738,O
element,738,O
(,738,O
s,738,O
),738,O
connected,738,O
with,738,O
the,738,O
pathogenesis,738,O
of,738,O
the,738,O
disease,738,O
.,738,O
METHODS,739,O
:,739,O
Two,739,O
microsatellites,739,O
",",739,O
1,739,O
insertion/deletion,739,O
",",739,O
and,739,O
8,739,O
single,739,O
nucleotide,739,O
polymorphisms,739,O
(,739,O
SNPs,739,O
),739,O
in,739,O
the,739,O
regulatory,739,O
region,739,O
of,739,O
iNOS,739,B-GeneOrGeneProduct
were,739,O
genotyped,739,O
in,739,O
200,739,O
POAG,739,B-DiseaseOrPhenotypicFeature
patients,739,B-OrganismTaxon
and,739,O
200,739,O
age-matched,739,O
controls,739,O
.,739,O
Also,740,O
",",740,O
the,740,O
CCTTT-microsatellite,740,O
was,740,O
examined,740,O
for,740,O
its,740,O
protein-binding,740,O
capability,740,O
in,740,O
an,740,O
electrophoretic,740,O
mobility,740,O
shift,740,O
assay,740,O
",",740,O
EMSA,740,O
.,740,O
RESULTS,741,O
:,741,O
There,741,O
was,741,O
a,741,O
significant,741,O
difference,741,O
in,741,O
allele,741,O
distribution,741,O
of,741,O
the,741,O
CCTTT-microsatellite,741,O
",",741,O
between,741,O
patients,741,B-OrganismTaxon
and,741,O
controls,741,O
.,741,O
(,742,B-SequenceVariant
CCTTT,742,I-SequenceVariant
),742,I-SequenceVariant
14,742,I-SequenceVariant
",",742,O
which,742,O
has,742,O
been,742,O
reported,742,O
to,742,O
have,742,O
a,742,O
higher,742,O
activity,742,O
in,742,O
a,742,O
reporter-construct,742,O
",",742,O
was,742,O
significantly,742,O
more,742,O
abundant,742,O
in,742,O
POAG,742,B-DiseaseOrPhenotypicFeature
patients,742,B-OrganismTaxon
",",742,O
while,742,O
(,742,B-SequenceVariant
CCTTT,742,I-SequenceVariant
),742,I-SequenceVariant
10,742,I-SequenceVariant
and,742,O
(,742,B-SequenceVariant
CCTTT,742,I-SequenceVariant
),742,I-SequenceVariant
13,742,I-SequenceVariant
were,742,O
less,742,O
common,742,O
.,742,O
In,743,O
EMSA,743,O
",",743,O
the,743,O
(,743,B-SequenceVariant
CCTTT,743,I-SequenceVariant
),743,I-SequenceVariant
14,743,I-SequenceVariant
allele,743,O
exhibited,743,O
specific,743,O
binding,743,O
of,743,O
nuclear,743,O
proteins,743,O
.,743,O
CONCLUSIONS,744,O
:,744,O
These,744,O
results,744,O
",",744,O
together,744,O
with,744,O
other,744,O
studies,744,O
on,744,O
this,744,O
gene,744,O
and,744,O
the,744,O
CCTTT-microsatellite,744,O
",",744,O
establish,744,O
",",744,O
for,744,O
the,744,O
first,744,O
time,744,O
",",744,O
a,744,O
genetic,744,O
association,744,O
of,744,O
iNOS,744,B-GeneOrGeneProduct
with,744,O
POAG,744,B-DiseaseOrPhenotypicFeature
and,744,O
suggest,744,O
a,744,O
regulatory,744,O
function,744,O
for,744,O
the,744,O
microsatellite,744,O
.,744,O
Does,745,O
domperidone,745,B-ChemicalEntity
potentiate,745,O
mirtazapine-associated,745,B-ChemicalEntity
restless,745,B-DiseaseOrPhenotypicFeature
legs,745,I-DiseaseOrPhenotypicFeature
syndrome,745,I-DiseaseOrPhenotypicFeature
?,745,O
There,746,O
is,746,O
now,746,O
evidence,746,O
to,746,O
suggest,746,O
a,746,O
central,746,O
role,746,O
for,746,O
the,746,O
dopaminergic,746,O
system,746,O
in,746,O
restless,746,B-DiseaseOrPhenotypicFeature
legs,746,I-DiseaseOrPhenotypicFeature
syndrome,746,I-DiseaseOrPhenotypicFeature
(,746,O
RLS,746,B-DiseaseOrPhenotypicFeature
),746,O
.,746,O
For,747,O
example,747,O
",",747,O
the,747,O
symptoms,747,O
of,747,O
RLS,747,B-DiseaseOrPhenotypicFeature
can,747,O
be,747,O
dramatically,747,O
improved,747,O
by,747,O
levodopa,747,B-ChemicalEntity
and,747,O
dopamine,747,B-ChemicalEntity
agonists,747,O
",",747,O
whereas,747,O
central,747,O
dopamine,747,B-ChemicalEntity
D2,747,I-ChemicalEntity
receptor,747,I-ChemicalEntity
antagonists,747,I-ChemicalEntity
can,747,O
induce,747,O
or,747,O
aggravate,747,O
RLS,747,B-DiseaseOrPhenotypicFeature
symptoms,747,O
.,747,O
To,748,O
our,748,O
knowledge,748,O
",",748,O
there,748,O
is,748,O
no,748,O
previous,748,O
report,748,O
regarding,748,O
whether,748,O
domperidone,748,B-ChemicalEntity
",",748,O
a,748,O
peripheral,748,O
dopamine,748,B-GeneOrGeneProduct
D2,748,I-GeneOrGeneProduct
receptor,748,I-GeneOrGeneProduct
antagonist,748,O
",",748,O
can,748,O
also,748,O
induce,748,O
or,748,O
aggravate,748,O
symptoms,748,O
of,748,O
RLS,748,B-DiseaseOrPhenotypicFeature
.,748,O
Mirtazapine,749,B-ChemicalEntity
",",749,O
the,749,O
first,749,O
noradrenergic,749,B-ChemicalEntity
and,749,I-ChemicalEntity
specific,749,I-ChemicalEntity
serotonergic,749,I-ChemicalEntity
antidepressant,749,I-ChemicalEntity
(,749,O
NaSSA,749,B-ChemicalEntity
),749,O
",",749,O
has,749,O
been,749,O
associated,749,O
with,749,O
RLS,749,B-DiseaseOrPhenotypicFeature
in,749,O
several,749,O
recent,749,O
publications,749,O
.,749,O
The,750,O
authors,750,O
report,750,O
here,750,O
a,750,O
depressed,750,B-DiseaseOrPhenotypicFeature
patient,750,B-OrganismTaxon
comorbid,750,O
with,750,O
postprandial,750,B-DiseaseOrPhenotypicFeature
dyspepsia,750,I-DiseaseOrPhenotypicFeature
who,750,O
developed,750,O
RLS,750,B-DiseaseOrPhenotypicFeature
after,750,O
mirtazapine,750,B-ChemicalEntity
had,750,O
been,750,O
added,750,O
to,750,O
his,750,O
domperidone,750,B-ChemicalEntity
therapy,750,O
.,750,O
Our,751,O
patient,751,B-OrganismTaxon
started,751,O
to,751,O
have,751,O
symptoms,751,O
of,751,O
RLS,751,B-DiseaseOrPhenotypicFeature
only,751,O
after,751,O
he,751,O
had,751,O
been,751,O
treated,751,O
with,751,O
mirtazapine,751,B-ChemicalEntity
",",751,O
and,751,O
his,751,O
RLS,751,B-DiseaseOrPhenotypicFeature
symptoms,751,O
resolved,751,O
completely,751,O
upon,751,O
discontinuation,751,O
of,751,O
his,751,O
mirtazapine,751,B-ChemicalEntity
.,751,O
Such,752,O
a,752,O
temporal,752,O
relationship,752,O
between,752,O
the,752,O
use,752,O
of,752,O
mirtazapine,752,B-ChemicalEntity
and,752,O
the,752,O
symptoms,752,O
of,752,O
RLS,752,B-DiseaseOrPhenotypicFeature
in,752,O
our,752,O
patient,752,B-OrganismTaxon
did,752,O
not,752,O
support,752,O
a,752,O
potentiating,752,O
effect,752,O
of,752,O
domperione,752,B-ChemicalEntity
on,752,O
mirtazapine-associated,752,B-ChemicalEntity
RLS,752,B-DiseaseOrPhenotypicFeature
.,752,O
However,753,O
",",753,O
physicians,753,O
should,753,O
be,753,O
aware,753,O
of,753,O
the,753,O
possibility,753,O
that,753,O
mirtazapine,753,B-ChemicalEntity
can,753,O
be,753,O
associated,753,O
with,753,O
RLS,753,B-DiseaseOrPhenotypicFeature
in,753,O
some,753,O
individuals,753,O
",",753,O
especially,753,O
those,753,O
receiving,753,O
concomitant,753,O
dopamine,753,B-ChemicalEntity
D2,753,I-ChemicalEntity
receptor,753,I-ChemicalEntity
antagonists,753,I-ChemicalEntity
.,753,O
Congenital,754,B-DiseaseOrPhenotypicFeature
disorder,754,I-DiseaseOrPhenotypicFeature
of,754,I-DiseaseOrPhenotypicFeature
glycosylation,754,I-DiseaseOrPhenotypicFeature
Ic,754,I-DiseaseOrPhenotypicFeature
due,754,O
to,754,O
a,754,O
de,754,O
novo,754,O
deletion,754,O
and,754,O
an,754,O
hALG-6,754,B-GeneOrGeneProduct
mutation,754,O
.,754,O
We,755,O
describe,755,O
a,755,O
new,755,O
cause,755,O
of,755,O
congenital,755,B-DiseaseOrPhenotypicFeature
disorder,755,I-DiseaseOrPhenotypicFeature
of,755,I-DiseaseOrPhenotypicFeature
glycosylation-Ic,755,I-DiseaseOrPhenotypicFeature
(,755,O
CDG-Ic,755,B-DiseaseOrPhenotypicFeature
),755,O
in,755,O
a,755,O
young,755,O
girl,755,O
with,755,O
a,755,O
rather,755,O
mild,755,O
CDG,755,B-DiseaseOrPhenotypicFeature
phenotype,755,O
.,755,O
Her,756,O
cells,756,O
accumulated,756,O
lipid-linked,756,B-ChemicalEntity
oligosaccharides,756,I-ChemicalEntity
lacking,756,O
three,756,O
glucose,756,B-ChemicalEntity
residues,756,O
",",756,O
and,756,O
sequencing,756,O
of,756,O
the,756,O
ALG6,756,B-GeneOrGeneProduct
gene,756,O
showed,756,O
what,756,O
initially,756,O
appeared,756,O
to,756,O
be,756,O
a,756,O
homozygous,756,O
novel,756,O
point,756,O
mutation,756,O
(,756,O
338G,756,B-SequenceVariant
>,756,I-SequenceVariant
A,756,I-SequenceVariant
),756,O
.,756,O
However,757,O
",",757,O
haplotype,757,O
analysis,757,O
showed,757,O
that,757,O
the,757,O
patient,757,B-OrganismTaxon
does,757,O
not,757,O
carry,757,O
any,757,O
paternal,757,O
DNA,757,O
markers,757,O
extending,757,O
33kb,757,O
in,757,O
the,757,O
telomeric,757,O
direction,757,O
from,757,O
the,757,O
ALG6,757,B-GeneOrGeneProduct
region,757,O
",",757,O
and,757,O
microsatellite,757,O
analysis,757,O
extended,757,O
the,757,O
abnormal,757,O
region,757,O
to,757,O
at,757,O
least,757,O
2.5Mb,757,O
.,757,O
We,758,O
used,758,O
high-resolution,758,O
karyotyping,758,O
to,758,O
confirm,758,O
a,758,O
deletion,758,B-SequenceVariant
(,758,I-SequenceVariant
10-12Mb,758,I-SequenceVariant
),758,I-SequenceVariant
[,758,O
del,758,B-SequenceVariant
(,758,I-SequenceVariant
1,758,I-SequenceVariant
),758,I-SequenceVariant
(,758,I-SequenceVariant
p31.2p32.3,758,I-SequenceVariant
),758,I-SequenceVariant
],758,O
and,758,O
found,758,O
no,758,O
structural,758,O
abnormalities,758,O
in,758,O
the,758,O
father,758,O
",",758,O
suggesting,758,O
a,758,O
de,758,O
novo,758,O
event,758,O
.,758,O
Our,759,O
findings,759,O
extend,759,O
the,759,O
causes,759,O
of,759,O
CDG,759,B-DiseaseOrPhenotypicFeature
to,759,O
larger,759,O
DNA,759,O
deletions,759,O
and,759,O
identify,759,O
the,759,O
first,759,O
Japanese,759,O
CDG-Ic,759,B-DiseaseOrPhenotypicFeature
mutation,759,O
.,759,O
Microinjection,760,O
of,760,O
ritanserin,760,B-ChemicalEntity
into,760,O
the,760,O
CA1,760,O
region,760,O
of,760,O
hippocampus,760,O
improves,760,O
scopolamine-induced,760,B-ChemicalEntity
amnesia,760,B-DiseaseOrPhenotypicFeature
in,760,O
adult,760,O
male,760,O
rats,760,B-OrganismTaxon
.,760,O
The,761,O
effect,761,O
of,761,O
ritanserin,761,B-ChemicalEntity
(,761,O
5-HT2,761,B-GeneOrGeneProduct
antagonist,761,O
),761,O
on,761,O
scopolamine,761,B-ChemicalEntity
(,761,O
muscarinic,761,B-GeneOrGeneProduct
cholinergic,761,I-GeneOrGeneProduct
antagonist,761,O
),761,O
-induced,761,O
amnesia,761,B-DiseaseOrPhenotypicFeature
in,761,O
Morris,761,O
water,761,O
maze,761,O
(,761,O
MWM,761,O
),761,O
was,761,O
investigated,761,O
.,761,O
Rats,762,B-OrganismTaxon
were,762,O
divided,762,O
into,762,O
eight,762,O
groups,762,O
and,762,O
bilaterally,762,O
cannulated,762,O
into,762,O
CA1,762,O
region,762,O
of,762,O
the,762,O
hippocampus,762,O
.,762,O
One,763,O
week,763,O
later,763,O
",",763,O
they,763,O
received,763,O
repeatedly,763,O
vehicles,763,O
(,763,O
saline,763,O
",",763,O
DMSO,763,B-ChemicalEntity
",",763,O
saline+DMSO,763,O
),763,O
",",763,O
scopolamine,763,B-ChemicalEntity
(,763,O
2,763,O
microg/0.5,763,O
microl,763,O
saline/side,763,O
;,763,O
30,763,O
min,763,O
before,763,O
training,763,O
),763,O
",",763,O
ritanserin,763,B-ChemicalEntity
(,763,O
2,763,O
",",763,O
4,763,O
and,763,O
8,763,O
microg/0.5,763,O
microl,763,O
DMSO/side,763,B-ChemicalEntity
;,763,O
20,763,O
min,763,O
before,763,O
training,763,O
),763,O
and,763,O
scopolamine,763,B-ChemicalEntity
(,763,O
2,763,O
microg/0.5,763,O
microl,763,O
;,763,O
30,763,O
min,763,O
before,763,O
ritanserin,763,B-ChemicalEntity
injection,763,O
),763,O
+ritanserin,763,O
(,763,O
4,763,O
microg/0.5,763,O
microl,763,O
DMSO,763,B-ChemicalEntity
),763,O
through,763,O
cannulae,763,O
each,763,O
day,763,O
.,763,O
Animals,764,O
were,764,O
tested,764,O
for,764,O
four,764,O
consecutive,764,O
days,764,O
(,764,O
4,764,O
trial/day,764,O
),764,O
in,764,O
MWM,764,O
during,764,O
which,764,O
the,764,O
position,764,O
of,764,O
hidden,764,O
platform,764,O
was,764,O
unchanged,764,O
.,764,O
In,765,O
the,765,O
fifth,765,O
day,765,O
",",765,O
the,765,O
platform,765,O
was,765,O
elevated,765,O
above,765,O
the,765,O
water,765,O
surface,765,O
in,765,O
another,765,O
position,765,O
to,765,O
evaluate,765,O
the,765,O
function,765,O
of,765,O
motor,765,O
",",765,O
motivational,765,O
and,765,O
visual,765,O
systems,765,O
.,765,O
The,766,O
results,766,O
showed,766,O
a,766,O
significant,766,O
increase,766,O
in,766,O
escape,766,O
latencies,766,O
and,766,O
traveled,766,O
distances,766,O
to,766,O
find,766,O
platform,766,O
in,766,O
scopolamine-treated,766,B-ChemicalEntity
group,766,O
as,766,O
compared,766,O
to,766,O
saline,766,O
group,766,O
.,766,O
Ritanserin-treated,767,B-ChemicalEntity
rats,767,B-OrganismTaxon
(,767,O
4,767,O
microg/0.5,767,O
microl/side,767,O
),767,O
showed,767,O
a,767,O
significant,767,O
decrease,767,O
in,767,O
the,767,O
mentioned,767,O
parameters,767,O
as,767,O
compared,767,O
to,767,O
DMSO-treated,767,B-ChemicalEntity
group,767,O
.,767,O
However,768,O
",",768,O
scopolamine,768,B-ChemicalEntity
and,768,O
ritanserin,768,B-ChemicalEntity
co-administration,768,O
resulted,768,O
in,768,O
a,768,O
significant,768,O
decrease,768,O
in,768,O
escape,768,O
latencies,768,O
and,768,O
traveled,768,O
distances,768,O
as,768,O
compared,768,O
to,768,O
the,768,O
scopolamine-treated,768,B-ChemicalEntity
rats,768,B-OrganismTaxon
.,768,O
Our,769,O
findings,769,O
show,769,O
that,769,O
microinjection,769,O
of,769,O
ritanserin,769,B-ChemicalEntity
into,769,O
the,769,O
CA1,769,O
region,769,O
of,769,O
the,769,O
hippocampus,769,O
improves,769,O
the,769,O
scopolamine-induced,769,B-ChemicalEntity
amnesia,769,B-DiseaseOrPhenotypicFeature
.,769,O
5-Fluorouracil,770,B-ChemicalEntity
cardiotoxicity,770,B-DiseaseOrPhenotypicFeature
induced,770,O
by,770,O
alpha-fluoro-beta-alanine,770,B-ChemicalEntity
.,770,O
Cardiotoxicity,771,B-DiseaseOrPhenotypicFeature
is,771,O
a,771,O
rare,771,O
complication,771,O
occurring,771,O
during,771,O
5-fluorouracil,771,B-ChemicalEntity
(,771,O
5-FU,771,B-ChemicalEntity
),771,O
treatment,771,O
for,771,O
malignancies,771,B-DiseaseOrPhenotypicFeature
.,771,O
We,772,O
herein,772,O
report,772,O
the,772,O
case,772,O
of,772,O
a,772,O
70-year-old,772,O
man,772,B-OrganismTaxon
with,772,O
5-FU-induced,772,B-ChemicalEntity
cardiotoxicity,772,B-DiseaseOrPhenotypicFeature
",",772,O
in,772,O
whom,772,O
a,772,O
high,772,O
serum,772,O
level,772,O
of,772,O
alpha-fluoro-beta-alanine,772,B-ChemicalEntity
(,772,O
FBAL,772,B-ChemicalEntity
),772,O
was,772,O
observed,772,O
.,772,O
The,773,O
patient,773,B-OrganismTaxon
",",773,O
who,773,O
had,773,O
unresectable,773,O
colon,773,B-DiseaseOrPhenotypicFeature
cancer,773,I-DiseaseOrPhenotypicFeature
metastases,773,B-DiseaseOrPhenotypicFeature
to,773,O
the,773,O
liver,773,O
and,773,O
lung,773,O
",",773,O
was,773,O
referred,773,O
to,773,O
us,773,O
for,773,O
chemotherapy,773,O
from,773,O
an,773,O
affiliated,773,O
hospital,773,O
;,773,O
he,773,O
had,773,O
no,773,O
cardiac,773,O
history,773,O
.,773,O
After,774,O
admission,774,O
",",774,O
the,774,O
patient,774,B-OrganismTaxon
received,774,O
a,774,O
continuous,774,O
intravenous,774,O
infusion,774,O
of,774,O
5-FU,774,B-ChemicalEntity
(,774,O
1000,774,O
mg/day,774,O
),774,O
",",774,O
during,774,O
which,774,O
precordial,774,B-DiseaseOrPhenotypicFeature
pain,774,I-DiseaseOrPhenotypicFeature
with,774,O
right,774,B-DiseaseOrPhenotypicFeature
bundle,774,I-DiseaseOrPhenotypicFeature
branch,774,I-DiseaseOrPhenotypicFeature
block,774,I-DiseaseOrPhenotypicFeature
occurred,774,O
concomitantly,774,O
with,774,O
a,774,O
high,774,O
serum,774,O
FBAL,774,B-ChemicalEntity
concentration,774,O
of,774,O
1955,774,O
ng/ml,774,O
.,774,O
Both,775,O
the,775,O
precordial,775,B-DiseaseOrPhenotypicFeature
pain,775,I-DiseaseOrPhenotypicFeature
and,775,O
the,775,O
electrocardiographic,775,O
changes,775,O
disappeared,775,O
spontaneously,775,O
after,775,O
the,775,O
discontinuation,775,O
of,775,O
5-FU,775,B-ChemicalEntity
.,775,O
As,776,O
the,776,O
precordial,776,B-DiseaseOrPhenotypicFeature
pain,776,I-DiseaseOrPhenotypicFeature
in,776,O
this,776,O
patient,776,B-OrganismTaxon
was,776,O
considered,776,O
to,776,O
have,776,O
been,776,O
due,776,O
to,776,O
5-FU-induced,776,B-ChemicalEntity
cardiotoxicity,776,B-DiseaseOrPhenotypicFeature
",",776,O
the,776,O
administration,776,O
of,776,O
5-FU,776,B-ChemicalEntity
was,776,O
abandoned,776,O
.,776,O
Instead,777,O
",",777,O
oral,777,O
administration,777,O
of,777,O
S-1,777,B-ChemicalEntity
(,777,O
a,777,O
derivative,777,O
of,777,O
5-FU,777,B-ChemicalEntity
),777,O
",",777,O
at,777,O
200,777,O
mg/day,777,O
twice,777,O
a,777,O
week,777,O
",",777,O
was,777,O
instituted,777,O
",",777,O
because,777,O
S-1,777,B-ChemicalEntity
has,777,O
a,777,O
strong,777,O
inhibitory,777,O
effect,777,O
on,777,O
dihydropyrimidine,777,B-ChemicalEntity
dehydrogenase,777,O
",",777,O
which,777,O
catalyzes,777,O
the,777,O
degradative,777,O
of,777,O
5-FU,777,B-ChemicalEntity
into,777,O
FBAL,777,B-ChemicalEntity
.,777,O
The,778,O
serum,778,O
FBAL,778,B-ChemicalEntity
concentration,778,O
subsequently,778,O
decreased,778,O
to,778,O
352,778,O
ng/ml,778,O
",",778,O
the,778,O
same,778,O
as,778,O
the,778,O
value,778,O
measured,778,O
on,778,O
the,778,O
first,778,O
day,778,O
of,778,O
S-1,778,B-ChemicalEntity
administration,778,O
.,778,O
Thereafter,779,O
",",779,O
no,779,O
cardiac,779,B-DiseaseOrPhenotypicFeature
symptoms,779,I-DiseaseOrPhenotypicFeature
were,779,O
observed,779,O
.,779,O
The,780,O
patient,780,B-OrganismTaxon
achieved,780,O
a,780,O
partial,780,O
response,780,O
6,780,O
months,780,O
after,780,O
the,780,O
initiation,780,O
of,780,O
the,780,O
S-1,780,B-ChemicalEntity
treatment,780,O
.,780,O
The,781,O
experience,781,O
of,781,O
this,781,O
case,781,O
",",781,O
together,781,O
with,781,O
a,781,O
review,781,O
of,781,O
the,781,O
literature,781,O
",",781,O
suggests,781,O
that,781,O
FBAL,781,B-ChemicalEntity
is,781,O
related,781,O
to,781,O
5-FU-induced,781,B-ChemicalEntity
cardiotoxicity,781,B-DiseaseOrPhenotypicFeature
.,781,O
S-1,782,B-ChemicalEntity
may,782,O
be,782,O
administered,782,O
safely,782,O
to,782,O
patients,782,B-OrganismTaxon
with,782,O
5-FU-induced,782,B-ChemicalEntity
cardiotoxicity,782,B-DiseaseOrPhenotypicFeature
.,782,O
Homozygous,783,O
deletion,783,O
and,783,O
reduced,783,O
expression,783,O
of,783,O
the,783,O
DOCK8,783,B-GeneOrGeneProduct
gene,783,O
in,783,O
human,783,B-OrganismTaxon
lung,783,B-DiseaseOrPhenotypicFeature
cancer,783,I-DiseaseOrPhenotypicFeature
.,783,O
A,784,O
homozygous,784,O
deletion,784,O
of,784,O
the,784,O
DOCK8,784,B-GeneOrGeneProduct
(,784,O
dedicator,784,B-GeneOrGeneProduct
of,784,I-GeneOrGeneProduct
cytokinesis,784,I-GeneOrGeneProduct
8,784,I-GeneOrGeneProduct
),784,O
locus,784,O
at,784,O
chromosome,784,O
9p24,784,O
was,784,O
found,784,O
in,784,O
a,784,O
lung,784,B-DiseaseOrPhenotypicFeature
cancer,784,I-DiseaseOrPhenotypicFeature
cell,784,O
line,784,O
by,784,O
array-CGH,784,O
analysis,784,O
.,784,O
Cloning,785,O
of,785,O
the,785,O
full-length,785,O
DOCK8,785,B-GeneOrGeneProduct
cDNA,785,O
led,785,O
us,785,O
to,785,O
define,785,O
that,785,O
the,785,O
DOCK8,785,B-GeneOrGeneProduct
gene,785,O
encodes,785,O
a,785,O
protein,785,O
consisting,785,O
of,785,O
"2,099",785,O
amino,785,O
acids,785,O
.,785,O
DOCK8,786,B-GeneOrGeneProduct
was,786,O
expressed,786,O
in,786,O
a,786,O
variety,786,O
of,786,O
human,786,B-OrganismTaxon
organs,786,O
",",786,O
including,786,O
the,786,O
lungs,786,O
",",786,O
and,786,O
was,786,O
also,786,O
expressed,786,O
in,786,O
type,786,O
II,786,O
alveolar,786,O
",",786,O
bronchiolar,786,O
epithelial,786,O
and,786,O
bronchial,786,O
epithelial,786,O
cells,786,O
",",786,O
which,786,O
are,786,O
considered,786,O
as,786,O
being,786,O
progenitors,786,O
for,786,O
lung,786,B-DiseaseOrPhenotypicFeature
cancer,786,I-DiseaseOrPhenotypicFeature
cells,786,O
.,786,O
DOCK8,787,B-GeneOrGeneProduct
expression,787,O
was,787,O
reduced,787,O
in,787,O
62/71,787,O
(,787,O
87,787,O
%,787,O
),787,O
primary,787,O
lung,787,B-DiseaseOrPhenotypicFeature
cancers,787,I-DiseaseOrPhenotypicFeature
compared,787,O
with,787,O
normal,787,O
lung,787,O
tissue,787,O
",",787,O
and,787,O
the,787,O
reduction,787,O
occurred,787,O
irrespective,787,O
of,787,O
the,787,O
histological,787,O
type,787,O
of,787,O
lung,787,B-DiseaseOrPhenotypicFeature
cancer,787,I-DiseaseOrPhenotypicFeature
.,787,O
5-Aza-2'-deoxy-cytidine,788,B-ChemicalEntity
and/or,788,O
Trichostatin,788,B-ChemicalEntity
A,788,I-ChemicalEntity
treatments,788,O
induced,788,O
DOCK8,788,B-GeneOrGeneProduct
expression,788,O
in,788,O
lung,788,B-DiseaseOrPhenotypicFeature
cancer,788,I-DiseaseOrPhenotypicFeature
cell,788,O
lines,788,O
with,788,O
reduced,788,O
DOCK8,788,B-GeneOrGeneProduct
expression,788,O
.,788,O
Therefore,789,O
",",789,O
epigenetic,789,O
mechanisms,789,O
",",789,O
including,789,O
DNA,789,O
methylation,789,O
and,789,O
histone,789,O
deacetylation,789,O
",",789,O
were,789,O
indicated,789,O
to,789,O
be,789,O
involved,789,O
in,789,O
DOCK8,789,B-GeneOrGeneProduct
down-regulation,789,O
in,789,O
lung,789,B-DiseaseOrPhenotypicFeature
cancer,789,I-DiseaseOrPhenotypicFeature
cells,789,O
.,789,O
Further,790,O
screening,790,O
revealed,790,O
homozygous,790,O
deletions,790,O
of,790,O
the,790,O
DOCK8,790,B-GeneOrGeneProduct
gene,790,O
in,790,O
a,790,O
gastric,790,O
and,790,O
a,790,O
breast,790,B-DiseaseOrPhenotypicFeature
cancer,790,I-DiseaseOrPhenotypicFeature
cell,790,O
line,790,O
.,790,O
DOCK,791,B-GeneOrGeneProduct
family,791,O
proteins,791,O
have,791,O
been,791,O
shown,791,O
to,791,O
play,791,O
roles,791,O
in,791,O
regulation,791,O
of,791,O
migration,791,O
",",791,O
morphology,791,O
",",791,O
adhesion,791,O
and,791,O
growth,791,O
of,791,O
cells,791,O
.,791,O
Thus,792,O
",",792,O
the,792,O
present,792,O
results,792,O
suggest,792,O
that,792,O
genetic,792,O
and,792,O
epigenetic,792,O
inactivation,792,O
of,792,O
DOCK8,792,B-GeneOrGeneProduct
is,792,O
involved,792,O
in,792,O
the,792,O
development,792,O
and/or,792,O
progression,792,O
of,792,O
lung,792,B-DiseaseOrPhenotypicFeature
and,792,I-DiseaseOrPhenotypicFeature
other,792,I-DiseaseOrPhenotypicFeature
cancers,792,I-DiseaseOrPhenotypicFeature
by,792,O
disturbing,792,O
such,792,O
regulations,792,O
.,792,O
Genetic,793,O
alterations,793,O
in,793,O
primary,793,O
glioblastomas,793,B-DiseaseOrPhenotypicFeature
in,793,O
Japan,793,O
.,793,O
Current,794,O
knowledge,794,O
of,794,O
genetic,794,O
alterations,794,O
in,794,O
glioblastomas,794,B-DiseaseOrPhenotypicFeature
is,794,O
based,794,O
largely,794,O
on,794,O
genetic,794,O
analyses,794,O
of,794,O
tumors,794,B-DiseaseOrPhenotypicFeature
from,794,O
mainly,794,O
caucasian,794,O
patients,794,B-OrganismTaxon
in,794,O
the,794,O
United,794,O
States,794,O
and,794,O
Europe,794,O
.,794,O
In,795,O
the,795,O
present,795,O
study,795,O
",",795,O
screening,795,O
for,795,O
several,795,O
key,795,O
genetic,795,O
alterations,795,O
was,795,O
performed,795,O
on,795,O
77,795,O
primary,795,O
(,795,O
de,795,O
novo,795,O
),795,O
glioblastomas,795,B-DiseaseOrPhenotypicFeature
in,795,O
Japanese,795,O
patients,795,B-OrganismTaxon
.,795,O
SSCP,796,O
followed,796,O
by,796,O
DNA,796,O
sequencing,796,O
revealed,796,O
TP53,796,B-GeneOrGeneProduct
mutations,796,O
in,796,O
16,796,O
of,796,O
73,796,O
(,796,O
22,796,O
%,796,O
),796,O
glioblastomas,796,B-DiseaseOrPhenotypicFeature
and,796,O
PTEN,796,B-GeneOrGeneProduct
mutations,796,O
in,796,O
13,796,O
of,796,O
63,796,O
(,796,O
21,796,O
%,796,O
),796,O
cases,796,O
analyzed,796,O
.,796,O
Polymerase,797,O
chain,797,O
reaction,797,O
(,797,O
PCR,797,O
),797,O
showed,797,O
EGFR,797,B-GeneOrGeneProduct
amplification,797,O
in,797,O
25,797,O
of,797,O
77,797,O
(,797,O
32,797,O
%,797,O
),797,O
cases,797,O
and,797,O
p16,797,B-GeneOrGeneProduct
homozygous,797,O
deletion,797,O
in,797,O
32,797,O
of,797,O
77,797,O
(,797,O
42,797,O
%,797,O
),797,O
cases,797,O
.,797,O
Quantitative,798,O
microsatellite,798,O
analysis,798,O
revealed,798,O
LOH,798,O
10q,798,O
in,798,O
41,798,O
of,798,O
59,798,O
(,798,O
69,798,O
%,798,O
),798,O
glioblastomas,798,B-DiseaseOrPhenotypicFeature
.,798,O
The,799,O
frequencies,799,O
of,799,O
these,799,O
genetic,799,O
alterations,799,O
were,799,O
similar,799,O
to,799,O
those,799,O
reported,799,O
for,799,O
primary,799,O
glioblastomas,799,B-DiseaseOrPhenotypicFeature
at,799,O
the,799,O
population,799,O
level,799,O
in,799,O
Switzerland,799,O
.,799,O
As,800,O
previously,800,O
observed,800,O
for,800,O
glioblastomas,800,B-DiseaseOrPhenotypicFeature
in,800,O
Europe,800,O
",",800,O
there,800,O
was,800,O
a,800,O
positive,800,O
association,800,O
between,800,O
EGFR,800,B-GeneOrGeneProduct
amplification,800,O
and,800,O
p16,800,B-GeneOrGeneProduct
deletion,800,O
(,800,O
p=0.009,800,O
),800,O
",",800,O
whereas,800,O
there,800,O
was,800,O
an,800,O
inverse,800,O
association,800,O
between,800,O
TP53,800,B-GeneOrGeneProduct
mutations,800,O
and,800,O
p16,800,B-GeneOrGeneProduct
deletion,800,O
(,800,O
p=0.049,800,O
),800,O
in,800,O
glioblastomas,800,B-DiseaseOrPhenotypicFeature
in,800,O
Japan,800,O
.,800,O
Multivariate,801,O
analyses,801,O
showed,801,O
that,801,O
radiotherapy,801,O
was,801,O
significantly,801,O
predictive,801,O
for,801,O
longer,801,O
survival,801,O
of,801,O
glioblastoma,801,B-DiseaseOrPhenotypicFeature
patients,801,B-OrganismTaxon
(,801,O
p=0.002,801,O
),801,O
.,801,O
SSCP,802,O
followed,802,O
by,802,O
DNA,802,O
sequencing,802,O
of,802,O
the,802,O
kinase,802,O
domain,802,O
(,802,O
exons,802,O
18-21,802,O
),802,O
of,802,O
the,802,O
EGFR,802,B-GeneOrGeneProduct
gene,802,O
revealed,802,O
mutations,802,O
in,802,O
2,802,O
ou,802,O
of,802,O
69,802,O
(,802,O
3,802,O
%,802,O
),802,O
glioblastomas,802,B-DiseaseOrPhenotypicFeature
in,802,O
Japan,802,O
and,802,O
in,802,O
4,802,O
of,802,O
81,802,O
(,802,O
5,802,O
%,802,O
),802,O
glioblastomas,802,B-DiseaseOrPhenotypicFeature
in,802,O
Switzerland,802,O
.,802,O
The,803,O
allele,803,O
frequencies,803,O
of,803,O
polymorphisms,803,O
at,803,O
codon,803,B-SequenceVariant
787,803,I-SequenceVariant
CAG/CAA,803,I-SequenceVariant
(,803,O
Gln/Gln,803,B-SequenceVariant
),803,O
in,803,O
glioblastomas,803,B-DiseaseOrPhenotypicFeature
in,803,O
Japan,803,O
were,803,O
G/G,803,O
(,803,O
82.4,803,O
%,803,O
),803,O
",",803,O
G/A,803,O
(,803,O
10.8,803,O
%,803,O
),803,O
",",803,O
A/A,803,O
(,803,O
6.8,803,O
%,803,O
),803,O
",",803,O
corresponding,803,O
to,803,O
G,803,O
0.878,803,O
versus,803,O
A,803,O
0.122,803,O
",",803,O
significantly,803,O
different,803,O
from,803,O
those,803,O
in,803,O
glioblastomas,803,B-DiseaseOrPhenotypicFeature
in,803,O
Switzerland,803,O
:,803,O
G/G,803,O
(,803,O
27.2,803,O
%,803,O
),803,O
",",803,O
G/A,803,O
(,803,O
28.4,803,O
%,803,O
),803,O
",",803,O
A/A,803,O
(,803,O
44.4,803,O
%,803,O
),803,O
",",803,O
corresponding,803,O
to,803,O
G,803,O
0.414,803,O
versus,803,O
A,803,O
0.586,803,O
(,803,O
p,803,O
<,803,O
0.0001,803,O
),803,O
.,803,O
These,804,O
results,804,O
suggest,804,O
that,804,O
primary,804,O
glioblastomas,804,B-DiseaseOrPhenotypicFeature
in,804,O
Japan,804,O
show,804,O
genetic,804,O
alterations,804,O
similar,804,O
to,804,O
those,804,O
in,804,O
Switzerland,804,O
",",804,O
suggesting,804,O
a,804,O
similar,804,O
molecular,804,O
basis,804,O
in,804,O
caucasians,804,O
and,804,O
Asians,804,O
",",804,O
despite,804,O
different,804,O
genetic,804,O
backgrounds,804,O
",",804,O
including,804,O
different,804,O
status,804,O
of,804,O
a,804,O
polymorphism,804,O
in,804,O
the,804,O
EGFR,804,B-GeneOrGeneProduct
gene,804,O
.,804,O
Peroxisomal,805,B-GeneOrGeneProduct
proliferator,805,I-GeneOrGeneProduct
activated,805,I-GeneOrGeneProduct
receptor-gamma,805,I-GeneOrGeneProduct
deficiency,805,O
in,805,O
a,805,O
Canadian,805,O
kindred,805,O
with,805,O
familial,805,B-DiseaseOrPhenotypicFeature
partial,805,I-DiseaseOrPhenotypicFeature
lipodystrophy,805,I-DiseaseOrPhenotypicFeature
type,805,I-DiseaseOrPhenotypicFeature
3,805,I-DiseaseOrPhenotypicFeature
(,805,O
FPLD3,805,B-DiseaseOrPhenotypicFeature
),805,O
.,805,O
BACKGROUND,806,O
:,806,O
Familial,806,B-DiseaseOrPhenotypicFeature
partial,806,I-DiseaseOrPhenotypicFeature
lipodystrophy,806,I-DiseaseOrPhenotypicFeature
(,806,I-DiseaseOrPhenotypicFeature
Dunnigan,806,I-DiseaseOrPhenotypicFeature
),806,I-DiseaseOrPhenotypicFeature
type,806,I-DiseaseOrPhenotypicFeature
3,806,I-DiseaseOrPhenotypicFeature
(,806,O
FPLD3,806,B-DiseaseOrPhenotypicFeature
",",806,O
Mendelian,806,B-DiseaseOrPhenotypicFeature
Inheritance,806,I-DiseaseOrPhenotypicFeature
in,806,I-DiseaseOrPhenotypicFeature
Man,806,I-DiseaseOrPhenotypicFeature
[,806,I-DiseaseOrPhenotypicFeature
MIM,806,I-DiseaseOrPhenotypicFeature
],806,I-DiseaseOrPhenotypicFeature
604367,806,I-DiseaseOrPhenotypicFeature
),806,O
results,806,O
from,806,O
heterozygous,806,O
mutations,806,O
in,806,O
PPARG,806,B-GeneOrGeneProduct
encoding,806,O
peroxisomal,806,B-GeneOrGeneProduct
proliferator-activated,806,I-GeneOrGeneProduct
receptor-gamma,806,I-GeneOrGeneProduct
.,806,O
Both,807,O
dominant-negative,807,O
and,807,O
haploinsufficiency,807,O
mechanisms,807,O
have,807,O
been,807,O
suggested,807,O
for,807,O
this,807,O
condition,807,O
.,807,O
METHODS,808,O
:,808,O
We,808,O
present,808,O
a,808,O
Canadian,808,O
FPLD3,808,B-DiseaseOrPhenotypicFeature
kindred,808,O
with,808,O
an,808,O
affected,808,O
mother,808,O
who,808,O
had,808,O
loss,808,O
of,808,O
fat,808,O
on,808,O
arms,808,O
and,808,O
legs,808,O
",",808,O
but,808,O
no,808,O
increase,808,O
in,808,O
facial,808,O
",",808,O
neck,808,O
",",808,O
suprascapular,808,O
or,808,O
abdominal,808,O
fat,808,O
.,808,O
She,809,O
had,809,O
profound,809,O
insulin,809,B-DiseaseOrPhenotypicFeature
resistance,809,I-DiseaseOrPhenotypicFeature
",",809,O
diabetes,809,B-DiseaseOrPhenotypicFeature
",",809,O
severe,809,O
hypertriglyceridemia,809,B-DiseaseOrPhenotypicFeature
and,809,O
relapsing,809,O
pancreatitis,809,B-DiseaseOrPhenotypicFeature
",",809,O
while,809,O
her,809,O
pre-pubescent,809,O
daughter,809,O
had,809,O
normal,809,O
fat,809,O
distribution,809,O
but,809,O
elevated,809,O
plasma,809,O
triglycerides,809,B-ChemicalEntity
and,809,O
C-peptide,809,B-ChemicalEntity
and,809,O
depressed,809,O
high-density,809,B-ChemicalEntity
lipoprotein,809,I-ChemicalEntity
cholesterol,809,I-ChemicalEntity
.,809,O
RESULTS,810,O
:,810,O
The,810,O
mother,810,O
and,810,O
daughter,810,O
were,810,O
each,810,O
heterozygous,810,O
for,810,O
PPARG,810,B-GeneOrGeneProduct
nonsense,810,O
mutation,810,O
Y355X,810,B-SequenceVariant
",",810,O
whose,810,O
protein,810,O
product,810,O
in,810,O
vitro,810,O
was,810,O
transcriptionally,810,O
inactive,810,O
with,810,O
no,810,O
dominant-negative,810,O
activity,810,O
against,810,O
the,810,O
wild-type,810,O
receptor,810,O
.,810,O
In,811,O
addition,811,O
the,811,O
mutant,811,O
protein,811,O
appeared,811,O
to,811,O
be,811,O
markedly,811,O
unstable,811,O
.,811,O
CONCLUSION,812,O
:,812,O
Taken,812,O
together,812,O
with,812,O
previous,812,O
studies,812,O
of,812,O
human,812,B-OrganismTaxon
PPARG,812,B-GeneOrGeneProduct
mutations,812,O
",",812,O
these,812,O
findings,812,O
suggest,812,O
that,812,O
PPAR-gamma,812,B-GeneOrGeneProduct
deficiency,812,O
due,812,O
either,812,O
to,812,O
haploinsufficiency,812,O
or,812,O
to,812,O
substantial,812,O
activity,812,O
loss,812,O
due,812,O
to,812,O
dominant,812,O
negative,812,O
interference,812,O
of,812,O
the,812,O
normal,812,O
allele,812,O
product,812,O
's,812,O
function,812,O
can,812,O
each,812,O
contribute,812,O
to,812,O
the,812,O
FPLD3,812,B-DiseaseOrPhenotypicFeature
phenotype,812,O
.,812,O
Genetic,813,O
investigation,813,O
of,813,O
the,813,O
TSPYL1,813,B-GeneOrGeneProduct
gene,813,O
in,813,O
sudden,813,B-DiseaseOrPhenotypicFeature
infant,813,I-DiseaseOrPhenotypicFeature
death,813,I-DiseaseOrPhenotypicFeature
syndrome,813,I-DiseaseOrPhenotypicFeature
.,813,O
BACKGROUND,814,O
:,814,O
Sudden,814,B-DiseaseOrPhenotypicFeature
infant,814,I-DiseaseOrPhenotypicFeature
death,814,I-DiseaseOrPhenotypicFeature
syndrome,814,I-DiseaseOrPhenotypicFeature
(,814,O
SIDS,814,B-DiseaseOrPhenotypicFeature
),814,O
constitutes,814,O
the,814,O
most,814,O
frequent,814,O
cause,814,O
of,814,O
death,814,B-DiseaseOrPhenotypicFeature
in,814,O
the,814,O
postperinatal,814,O
period,814,O
in,814,O
Germany,814,O
.,814,O
Recently,815,O
",",815,O
a,815,O
lethal,815,O
phenotype,815,O
characterized,815,O
by,815,O
sudden,815,B-DiseaseOrPhenotypicFeature
infant,815,I-DiseaseOrPhenotypicFeature
death,815,I-DiseaseOrPhenotypicFeature
with,815,I-DiseaseOrPhenotypicFeature
dysgenesis,815,I-DiseaseOrPhenotypicFeature
of,815,I-DiseaseOrPhenotypicFeature
the,815,I-DiseaseOrPhenotypicFeature
testes,815,I-DiseaseOrPhenotypicFeature
syndrome,815,I-DiseaseOrPhenotypicFeature
(,815,O
SIDDT,815,B-DiseaseOrPhenotypicFeature
),815,O
was,815,O
identified,815,O
to,815,O
be,815,O
caused,815,O
by,815,O
loss,815,O
of,815,O
function,815,O
mutations,815,O
in,815,O
the,815,O
TSPYL1,815,B-GeneOrGeneProduct
gene,815,O
.,815,O
PURPOSE,816,O
:,816,O
The,816,O
study,816,O
's,816,O
purpose,816,O
was,816,O
to,816,O
reveal,816,O
a,816,O
possible,816,O
role,816,O
of,816,O
TSPYL1,816,B-GeneOrGeneProduct
in,816,O
SIDS,816,B-DiseaseOrPhenotypicFeature
.,816,O
METHODS,817,O
:,817,O
DNA,817,O
samples,817,O
of,817,O
126,817,O
SIDS,817,B-DiseaseOrPhenotypicFeature
cases,817,O
and,817,O
261,817,O
controls,817,O
were,817,O
investigated,817,O
.,817,O
RESULTS,818,O
:,818,O
We,818,O
found,818,O
five,818,O
sequence,818,O
variations,818,O
",",818,O
each,818,O
of,818,O
them,818,O
causing,818,O
an,818,O
amino,818,O
acid,818,O
substitution,818,O
.,818,O
No,819,O
Hardy,819,O
Weinberg,819,O
disequilibrium,819,O
and,819,O
no,819,O
significant,819,O
difference,819,O
in,819,O
allele,819,O
frequencies,819,O
between,819,O
patients,819,B-OrganismTaxon
and,819,O
controls,819,O
were,819,O
observed,819,O
for,819,O
any,819,O
variation,819,O
.,819,O
In,820,O
one,820,O
female,820,O
patient,820,B-OrganismTaxon
a,820,O
p.F366L,820,B-SequenceVariant
amino,820,O
acid,820,O
polymorphism,820,O
was,820,O
found,820,O
heterozygous,820,O
",",820,O
which,820,O
could,820,O
not,820,O
be,820,O
displayed,820,O
in,820,O
controls,820,O
.,820,O
A,821,O
pathogenic,821,O
implication,821,O
of,821,O
this,821,O
substitution,821,O
",",821,O
which,821,O
is,821,O
conserved,821,O
in,821,O
primates,821,O
and,821,O
rodents,821,O
",",821,O
can,821,O
not,821,O
be,821,O
ruled,821,O
out,821,O
completely,821,O
.,821,O
Because,822,O
SIDDT,822,B-DiseaseOrPhenotypicFeature
is,822,O
the,822,O
result,822,O
of,822,O
homozygous,822,O
TSPYL1,822,B-GeneOrGeneProduct
mutations,822,O
",",822,O
this,822,O
heterozygous,822,O
exchange,822,O
can,822,O
not,822,O
solely,822,O
explain,822,O
the,822,O
sudden,822,B-DiseaseOrPhenotypicFeature
death,822,I-DiseaseOrPhenotypicFeature
in,822,O
this,822,O
child,822,O
.,822,O
The,823,O
reported,823,O
mutation,823,O
associated,823,O
with,823,O
SIDDT,823,B-DiseaseOrPhenotypicFeature
(,823,O
457_458insG,823,B-SequenceVariant
),823,O
was,823,O
not,823,O
detectable,823,O
in,823,O
our,823,O
cohort,823,O
.,823,O
CONCLUSION,824,O
:,824,O
No,824,O
association,824,O
of,824,O
sequence,824,O
variations,824,O
in,824,O
the,824,O
TSPYL1,824,B-GeneOrGeneProduct
gene,824,O
and,824,O
SIDS,824,B-DiseaseOrPhenotypicFeature
has,824,O
been,824,O
found,824,O
in,824,O
a,824,O
German,824,O
cohort,824,O
.,824,O
Genetic,825,O
analysis,825,O
of,825,O
TSPYL1,825,B-GeneOrGeneProduct
seems,825,O
to,825,O
be,825,O
of,825,O
limited,825,O
significance,825,O
in,825,O
the,825,O
differential,825,O
diagnosis,825,O
of,825,O
SIDS,825,B-DiseaseOrPhenotypicFeature
without,825,O
dysgenesis,825,B-DiseaseOrPhenotypicFeature
of,825,I-DiseaseOrPhenotypicFeature
the,825,I-DiseaseOrPhenotypicFeature
testes,825,I-DiseaseOrPhenotypicFeature
.,825,O
Genetic,826,O
variation,826,O
in,826,O
the,826,O
COX-2,826,B-GeneOrGeneProduct
gene,826,O
and,826,O
the,826,O
association,826,O
with,826,O
prostate,826,B-DiseaseOrPhenotypicFeature
cancer,826,I-DiseaseOrPhenotypicFeature
risk,826,O
.,826,O
COX-2,827,B-GeneOrGeneProduct
is,827,O
a,827,O
key,827,O
enzyme,827,O
in,827,O
the,827,O
conversion,827,O
of,827,O
arachidonic,827,B-ChemicalEntity
acid,827,I-ChemicalEntity
to,827,O
prostaglandins,827,B-ChemicalEntity
.,827,O
The,828,O
prostaglandins,828,B-ChemicalEntity
produced,828,O
by,828,O
COX-2,828,B-GeneOrGeneProduct
are,828,O
involved,828,O
in,828,O
inflammation,828,B-DiseaseOrPhenotypicFeature
and,828,O
pain,828,B-DiseaseOrPhenotypicFeature
response,828,O
in,828,O
different,828,O
tissues,828,O
in,828,O
the,828,O
body,828,O
.,828,O
Accumulating,829,O
evidence,829,O
from,829,O
epidemiologic,829,O
studies,829,O
",",829,O
chemical,829,O
carcinogen-induced,829,O
rodent,829,O
models,829,O
and,829,O
clinical,829,O
trials,829,O
indicate,829,O
that,829,O
COX-2,829,B-GeneOrGeneProduct
plays,829,O
a,829,O
role,829,O
in,829,O
human,829,B-OrganismTaxon
carcinogenesis,829,B-DiseaseOrPhenotypicFeature
and,829,O
is,829,O
overexpressed,829,O
in,829,O
prostate,829,B-DiseaseOrPhenotypicFeature
cancer,829,I-DiseaseOrPhenotypicFeature
tissue,829,O
.,829,O
We,830,O
examined,830,O
whether,830,O
sequence,830,O
variants,830,O
in,830,O
the,830,O
COX-2,830,B-GeneOrGeneProduct
gene,830,O
are,830,O
associated,830,O
with,830,O
prostate,830,B-DiseaseOrPhenotypicFeature
cancer,830,I-DiseaseOrPhenotypicFeature
risk,830,O
.,830,O
We,831,O
analyzed,831,O
a,831,O
large,831,O
population-based,831,O
case-control,831,O
study,831,O
",",831,O
cancer,831,B-DiseaseOrPhenotypicFeature
prostate,831,I-DiseaseOrPhenotypicFeature
in,831,O
Sweden,831,O
(,831,O
CAPS,831,O
),831,O
consisting,831,O
of,831,O
"1,378",831,O
cases,831,O
and,831,O
782,831,O
controls,831,O
.,831,O
We,832,O
evaluated,832,O
16,832,O
single,832,O
nucleotide,832,O
polymorphisms,832,O
(,832,O
SNPs,832,O
),832,O
spanning,832,O
the,832,O
entire,832,O
COX-2,832,B-GeneOrGeneProduct
gene,832,O
in,832,O
94,832,O
subjects,832,O
of,832,O
the,832,O
control,832,O
group,832,O
.,832,O
Five,833,O
SNPs,833,O
had,833,O
a,833,O
minor,833,O
allele,833,O
frequency,833,O
of,833,O
more,833,O
than,833,O
5,833,O
%,833,O
in,833,O
our,833,O
study,833,O
population,833,O
and,833,O
these,833,O
were,833,O
genotyped,833,O
in,833,O
all,833,O
case,833,O
patients,833,B-OrganismTaxon
and,833,O
control,833,O
subjects,833,O
and,833,O
gene-specific,833,O
haplotypes,833,O
were,833,O
constructed,833,O
.,833,O
A,834,O
statistically,834,O
significant,834,O
difference,834,O
in,834,O
allele,834,O
frequency,834,O
between,834,O
cases,834,O
and,834,O
controls,834,O
was,834,O
observed,834,O
for,834,O
2,834,O
of,834,O
the,834,O
SNPs,834,O
(,834,O
+3100,834,B-SequenceVariant
T/G,834,I-SequenceVariant
and,834,O
+8365,834,B-SequenceVariant
C/T,834,I-SequenceVariant
),834,O
",",834,O
with,834,O
an,834,O
odds,834,O
ratio,834,O
of,834,O
0.78,834,O
(,834,O
95,834,O
%,834,O
CI=0.64-0.96,834,O
),834,O
and,834,O
0.65,834,O
(,834,O
95,834,O
%,834,O
CI=0.45-0.94,834,O
),834,O
respectively,834,O
.,834,O
In,835,O
the,835,O
haplotype,835,O
analysis,835,O
",",835,O
1,835,O
haplotype,835,O
carrying,835,O
the,835,O
variant,835,O
allele,835,O
from,835,O
both,835,O
+3100,835,B-SequenceVariant
T/G,835,I-SequenceVariant
and,835,O
+8365,835,B-SequenceVariant
C/T,835,I-SequenceVariant
",",835,O
with,835,O
a,835,O
population,835,O
frequency,835,O
of,835,O
3,835,O
%,835,O
",",835,O
was,835,O
also,835,O
significantly,835,O
associated,835,O
with,835,O
decreased,835,O
risk,835,O
of,835,O
prostate,835,B-DiseaseOrPhenotypicFeature
cancer,835,I-DiseaseOrPhenotypicFeature
(,835,O
p=0.036,835,O
",",835,O
global,835,O
simulated,835,O
p-value=0.046,835,O
),835,O
.,835,O
This,836,O
study,836,O
supports,836,O
the,836,O
hypothesis,836,O
that,836,O
inflammation,836,B-DiseaseOrPhenotypicFeature
is,836,O
involved,836,O
in,836,O
prostate,836,B-DiseaseOrPhenotypicFeature
carcinogenesis,836,I-DiseaseOrPhenotypicFeature
and,836,O
that,836,O
sequence,836,O
variation,836,O
within,836,O
the,836,O
COX-2,836,B-GeneOrGeneProduct
gene,836,O
influence,836,O
the,836,O
risk,836,O
of,836,O
prostate,836,B-DiseaseOrPhenotypicFeature
cancer,836,I-DiseaseOrPhenotypicFeature
.,836,O
Evaluation,837,O
of,837,O
RGS4,837,B-GeneOrGeneProduct
as,837,O
a,837,O
candidate,837,O
gene,837,O
for,837,O
schizophrenia,837,B-DiseaseOrPhenotypicFeature
.,837,O
Several,838,O
studies,838,O
have,838,O
suggested,838,O
that,838,O
the,838,O
regulator,838,B-GeneOrGeneProduct
of,838,I-GeneOrGeneProduct
G-protein,838,I-GeneOrGeneProduct
signaling,838,I-GeneOrGeneProduct
4,838,I-GeneOrGeneProduct
(,838,O
RGS4,838,B-GeneOrGeneProduct
),838,O
may,838,O
be,838,O
a,838,O
positional,838,O
and,838,O
functional,838,O
candidate,838,O
gene,838,O
for,838,O
schizophrenia,838,B-DiseaseOrPhenotypicFeature
.,838,O
Three,839,O
single,839,O
nucleotide,839,O
polymorphisms,839,O
(,839,O
SNP,839,O
),839,O
located,839,O
at,839,O
the,839,O
promoter,839,O
region,839,O
(,839,O
SNP4,839,O
and,839,O
SNP7,839,O
),839,O
and,839,O
the,839,O
intron,839,O
1,839,O
(,839,O
SNP18,839,O
),839,O
of,839,O
RGS4,839,B-GeneOrGeneProduct
have,839,O
been,839,O
verified,839,O
in,839,O
different,839,O
ethnic,839,O
groups,839,O
.,839,O
Positive,840,O
results,840,O
have,840,O
been,840,O
reported,840,O
in,840,O
these,840,O
SNPs,840,O
with,840,O
different,840,O
numbers,840,O
of,840,O
SNP,840,O
combinatory,840,O
haplotypes,840,O
.,840,O
In,841,O
this,841,O
study,841,O
",",841,O
these,841,O
three,841,O
SNP,841,O
markers,841,O
were,841,O
genotyped,841,O
in,841,O
218,841,O
schizophrenia,841,B-DiseaseOrPhenotypicFeature
pedigrees,841,O
of,841,O
Taiwan,841,O
(,841,O
864,841,O
individuals,841,O
),841,O
for,841,O
association,841,O
analysis,841,O
.,841,O
Among,842,O
these,842,O
three,842,O
SNPs,842,O
",",842,O
neither,842,O
SNP4,842,O
",",842,O
SNP7,842,O
",",842,O
SNP18,842,O
has,842,O
shown,842,O
significant,842,O
association,842,O
with,842,O
schizophrenia,842,B-DiseaseOrPhenotypicFeature
in,842,O
single,842,O
locus,842,O
association,842,O
analysis,842,O
",",842,O
nor,842,O
any,842,O
compositions,842,O
of,842,O
the,842,O
three,842,O
SNP,842,O
haplotypes,842,O
has,842,O
shown,842,O
significantly,842,O
associations,842,O
with,842,O
the,842,O
DSM-IV,842,O
diagnosed,842,O
schizophrenia,842,B-DiseaseOrPhenotypicFeature
.,842,O
Our,843,O
results,843,O
fail,843,O
to,843,O
support,843,O
the,843,O
RGS4,843,B-GeneOrGeneProduct
as,843,O
a,843,O
candidate,843,O
gene,843,O
for,843,O
schizophrenia,843,B-DiseaseOrPhenotypicFeature
when,843,O
evaluated,843,O
from,843,O
these,843,O
three,843,O
SNP,843,O
markers,843,O
.,843,O
Distinct,844,O
patterns,844,O
of,844,O
germ-line,844,O
deletions,844,O
in,844,O
MLH1,844,B-GeneOrGeneProduct
and,844,O
MSH2,844,B-GeneOrGeneProduct
:,844,O
the,844,O
implication,844,O
of,844,O
Alu,844,O
repetitive,844,O
element,844,O
in,844,O
the,844,O
genetic,844,O
etiology,844,O
of,844,O
Lynch,844,B-DiseaseOrPhenotypicFeature
syndrome,844,I-DiseaseOrPhenotypicFeature
(,844,O
HNPCC,844,B-DiseaseOrPhenotypicFeature
),844,O
.,844,O
A,845,O
relatively,845,O
high,845,O
frequency,845,O
of,845,O
germ-line,845,O
genomic,845,O
rearrangements,845,O
in,845,O
MLH1,845,B-GeneOrGeneProduct
and,845,O
MSH2,845,B-GeneOrGeneProduct
has,845,O
been,845,O
reported,845,O
among,845,O
Lynch,845,B-DiseaseOrPhenotypicFeature
Syndrome,845,I-DiseaseOrPhenotypicFeature
(,845,O
HNPCC,845,B-DiseaseOrPhenotypicFeature
),845,O
patients,845,B-OrganismTaxon
from,845,O
different,845,O
ethnic,845,O
populations,845,O
.,845,O
To,846,O
investigate,846,O
the,846,O
underlying,846,O
molecular,846,O
mechanisms,846,O
",",846,O
we,846,O
characterized,846,O
the,846,O
DNA,846,O
breakpoints,846,O
of,846,O
11,846,O
germ-line,846,O
deletions,846,O
",",846,O
six,846,O
for,846,O
MLH1,846,B-GeneOrGeneProduct
and,846,O
five,846,O
for,846,O
MSH2,846,B-GeneOrGeneProduct
.,846,O
Distinct,847,O
deletion,847,O
patterns,847,O
were,847,O
found,847,O
for,847,O
the,847,O
two,847,O
genes,847,O
.,847,O
The,848,O
five,848,O
cases,848,O
of,848,O
MSH2,848,B-GeneOrGeneProduct
deletions,848,O
result,848,O
exclusively,848,O
from,848,O
intragenic,848,O
unequal,848,O
recombination,848,O
mediated,848,O
by,848,O
repetitive,848,O
Alu,848,O
sequences,848,O
.,848,O
In,849,O
contrast,849,O
",",849,O
five,849,O
out,849,O
of,849,O
the,849,O
six,849,O
MLH1,849,B-GeneOrGeneProduct
deletions,849,O
are,849,O
due,849,O
to,849,O
recombinations,849,O
involving,849,O
sequences,849,O
of,849,O
no,849,O
significant,849,O
homology,849,O
(,849,O
P=0.015,849,O
),849,O
.,849,O
A,850,O
detailed,850,O
analysis,850,O
of,850,O
the,850,O
DNA,850,O
breakpoints,850,O
in,850,O
the,850,O
two,850,O
genes,850,O
",",850,O
previously,850,O
characterized,850,O
by,850,O
other,850,O
groups,850,O
",",850,O
validated,850,O
the,850,O
observation,850,O
that,850,O
Alu-mediated,850,O
unequal,850,O
recombination,850,O
is,850,O
the,850,O
main,850,O
type,850,O
of,850,O
deletion,850,O
in,850,O
MSH2,850,B-GeneOrGeneProduct
(,850,O
n=34,850,O
),850,O
",",850,O
but,850,O
not,850,O
in,850,O
MLH1,850,B-GeneOrGeneProduct
(,850,O
n=21,850,O
),850,O
(,850,O
P,850,O
<,850,O
0.0001,850,O
),850,O
.,850,O
Plotting,851,O
the,851,O
distribution,851,O
of,851,O
known,851,O
DNA,851,O
breakpoints,851,O
among,851,O
the,851,O
introns,851,O
of,851,O
the,851,O
two,851,O
genes,851,O
showed,851,O
that,851,O
",",851,O
the,851,O
highest,851,O
breakpoint,851,O
density,851,O
is,851,O
co-localized,851,O
with,851,O
the,851,O
highest,851,O
Alu,851,O
density,851,O
.,851,O
Our,852,O
study,852,O
suggests,852,O
that,852,O
Alu,852,O
is,852,O
a,852,O
promoting,852,O
factor,852,O
for,852,O
the,852,O
genomic,852,O
recombinations,852,O
in,852,O
both,852,O
MLH1,852,B-GeneOrGeneProduct
and,852,O
MSH2,852,B-GeneOrGeneProduct
",",852,O
and,852,O
the,852,O
local,852,O
Alu,852,O
density,852,O
may,852,O
be,852,O
involved,852,O
in,852,O
shaping,852,O
the,852,O
deletion,852,O
pattern,852,O
.,852,O
A,853,O
G1103R,853,B-SequenceVariant
mutation,853,O
in,853,O
CRB1,853,B-GeneOrGeneProduct
is,853,O
co-inherited,853,O
with,853,O
high,853,O
hyperopia,853,B-DiseaseOrPhenotypicFeature
and,853,O
Leber,853,B-DiseaseOrPhenotypicFeature
congenital,853,I-DiseaseOrPhenotypicFeature
amaurosis,853,I-DiseaseOrPhenotypicFeature
.,853,O
PURPOSE,854,O
:,854,O
To,854,O
identify,854,O
the,854,O
genetic,854,O
basis,854,O
of,854,O
recessive,854,O
inheritance,854,O
of,854,O
high,854,B-DiseaseOrPhenotypicFeature
hyperopia,854,I-DiseaseOrPhenotypicFeature
and,854,O
Leber,854,B-DiseaseOrPhenotypicFeature
congenital,854,I-DiseaseOrPhenotypicFeature
amaurosis,854,I-DiseaseOrPhenotypicFeature
(,854,O
LCA,854,B-DiseaseOrPhenotypicFeature
),854,O
in,854,O
a,854,O
family,854,O
of,854,O
Middle,854,O
Eastern,854,O
origin,854,O
.,854,O
MATERIALS,855,O
AND,855,O
METHODS,855,O
:,855,O
The,855,O
patients,855,B-OrganismTaxon
were,855,O
examined,855,O
using,855,O
standard,855,O
ophthalmic,855,O
techniques,855,O
.,855,O
DNA,856,O
samples,856,O
were,856,O
obtained,856,O
and,856,O
genetic,856,O
linkage,856,O
was,856,O
carried,856,O
out,856,O
using,856,O
polymorphic,856,O
markers,856,O
flanking,856,O
the,856,O
known,856,O
genes,856,O
and,856,O
loci,856,O
for,856,O
LCA,856,B-DiseaseOrPhenotypicFeature
.,856,O
Exons,857,O
were,857,O
amplified,857,O
and,857,O
sequenced,857,O
.,857,O
RESULTS,858,O
:,858,O
All,858,O
four,858,O
members,858,O
of,858,O
this,858,O
family,858,O
affected,858,O
by,858,O
LCA,858,B-DiseaseOrPhenotypicFeature
showed,858,O
high,858,O
to,858,O
extreme,858,O
hyperopia,858,B-DiseaseOrPhenotypicFeature
",",858,O
with,858,O
average,858,O
spherical,858,O
refractive,858,O
errors,858,O
ranging,858,O
from,858,O
+5.00,858,O
to,858,O
+10.00,858,O
.,858,O
Linkage,859,O
was,859,O
obtained,859,O
to,859,O
1q31.3,859,O
with,859,O
a,859,O
maximal,859,O
LOD,859,O
score,859,O
of,859,O
5.20,859,O
and,859,O
a,859,O
mutation,859,O
found,859,O
in,859,O
exon,859,O
9,859,O
of,859,O
the,859,O
CRB1,859,B-GeneOrGeneProduct
gene,859,O
",",859,O
causing,859,O
a,859,O
G1103R,859,B-SequenceVariant
substitution,859,O
at,859,O
a,859,O
highly,859,O
conserved,859,O
site,859,O
in,859,O
the,859,O
protein,859,O
.,859,O
CRB1,860,B-GeneOrGeneProduct
is,860,O
a,860,O
vertebrate,860,O
homolog,860,O
of,860,O
the,860,O
Drosophila,860,B-OrganismTaxon
crumbs,860,B-GeneOrGeneProduct
gene,860,O
",",860,O
which,860,O
is,860,O
required,860,O
for,860,O
photoreceptor,860,O
morphogenesis,860,O
",",860,O
and,860,O
has,860,O
been,860,O
associated,860,O
with,860,O
either,860,O
retinitis,860,B-DiseaseOrPhenotypicFeature
pigmentosa,860,I-DiseaseOrPhenotypicFeature
(,860,O
RP,860,B-DiseaseOrPhenotypicFeature
),860,O
or,860,O
LCA,860,B-DiseaseOrPhenotypicFeature
.,860,O
This,861,O
sequence,861,O
variant,861,O
has,861,O
previously,861,O
been,861,O
reported,861,O
as,861,O
a,861,O
compound,861,O
heterozygote,861,O
in,861,O
one,861,O
sporadic,861,O
LCA,861,B-DiseaseOrPhenotypicFeature
patient,861,B-OrganismTaxon
.,861,O
CONCLUSION,862,O
:,862,O
Although,862,O
hyperopia,862,B-DiseaseOrPhenotypicFeature
has,862,O
been,862,O
associated,862,O
with,862,O
LCA,862,B-DiseaseOrPhenotypicFeature
",",862,O
it,862,O
is,862,O
typically,862,O
moderate,862,O
and,862,O
variable,862,O
between,862,O
patients,862,B-OrganismTaxon
with,862,O
the,862,O
same,862,O
mutation,862,O
.,862,O
In,863,O
addition,863,O
",",863,O
some,863,O
CRB1,863,B-GeneOrGeneProduct
mutations,863,O
can,863,O
be,863,O
associated,863,O
with,863,O
either,863,O
RP,863,B-DiseaseOrPhenotypicFeature
or,863,O
LCA,863,B-DiseaseOrPhenotypicFeature
.,863,O
We,864,O
have,864,O
shown,864,O
that,864,O
hyperopia,864,B-DiseaseOrPhenotypicFeature
and,864,O
LCA,864,B-DiseaseOrPhenotypicFeature
are,864,O
linked,864,O
to,864,O
the,864,O
mutant,864,O
CRB1,864,B-GeneOrGeneProduct
gene,864,O
itself,864,O
and,864,O
are,864,O
not,864,O
dependent,864,O
on,864,O
unlinked,864,O
modifiers,864,O
.,864,O
MDMA,865,B-ChemicalEntity
polydrug,865,O
users,865,O
show,865,O
process-specific,865,O
central,865,O
executive,865,O
impairments,865,O
coupled,865,O
with,865,O
impaired,865,B-DiseaseOrPhenotypicFeature
social,865,I-DiseaseOrPhenotypicFeature
and,865,I-DiseaseOrPhenotypicFeature
emotional,865,I-DiseaseOrPhenotypicFeature
judgement,865,I-DiseaseOrPhenotypicFeature
processes,865,I-DiseaseOrPhenotypicFeature
.,865,O
In,866,O
recent,866,O
years,866,O
working,866,O
memory,866,B-DiseaseOrPhenotypicFeature
deficits,866,I-DiseaseOrPhenotypicFeature
have,866,O
been,866,O
reported,866,O
in,866,O
users,866,O
of,866,O
MDMA,866,B-ChemicalEntity
(,866,O
"3,4-methylenedioxymethamphetamine",866,B-ChemicalEntity
",",866,O
ecstasy,866,B-ChemicalEntity
),866,O
.,866,O
The,867,O
current,867,O
study,867,O
aimed,867,O
to,867,O
assess,867,O
the,867,O
impact,867,O
of,867,O
MDMA,867,B-ChemicalEntity
use,867,O
on,867,O
three,867,O
separate,867,O
central,867,O
executive,867,O
processes,867,O
(,867,O
set,867,O
shifting,867,O
",",867,O
inhibition,867,O
and,867,O
memory,867,O
updating,867,O
),867,O
and,867,O
also,867,O
on,867,O
``,867,O
prefrontal,867,O
'',867,O
mediated,867,O
social,867,O
and,867,O
emotional,867,O
judgement,867,O
processes,867,O
.,867,O
Fifteen,868,O
polydrug,868,O
ecstasy,868,B-ChemicalEntity
users,868,O
and,868,O
15,868,O
polydrug,868,O
non-ecstasy,868,O
user,868,O
controls,868,O
completed,868,O
a,868,O
general,868,O
drug,868,O
use,868,O
questionnaire,868,O
",",868,O
the,868,O
Brixton,868,O
Spatial,868,O
Anticipation,868,O
task,868,O
(,868,O
set,868,O
shifting,868,O
),868,O
",",868,O
Backward,868,O
Digit,868,O
Span,868,O
procedure,868,O
(,868,O
memory,868,O
updating,868,O
),868,O
",",868,O
Inhibition,868,O
of,868,O
Return,868,O
(,868,O
inhibition,868,O
),868,O
",",868,O
an,868,O
emotional,868,O
intelligence,868,O
scale,868,O
",",868,O
the,868,O
Tromso,868,O
Social,868,O
Intelligence,868,O
Scale,868,O
and,868,O
the,868,O
Dysexecutive,868,O
Questionnaire,868,O
(,868,O
DEX,868,O
),868,O
.,868,O
Compared,869,O
with,869,O
MDMA-free,869,B-ChemicalEntity
polydrug,869,O
controls,869,O
",",869,O
MDMA,869,B-ChemicalEntity
polydrug,869,O
users,869,O
showed,869,O
impairments,869,O
in,869,O
set,869,O
shifting,869,O
and,869,O
memory,869,O
updating,869,O
",",869,O
and,869,O
also,869,O
in,869,O
social,869,O
and,869,O
emotional,869,O
judgement,869,O
processes,869,O
.,869,O
The,870,O
latter,870,O
two,870,O
deficits,870,O
remained,870,O
significant,870,O
after,870,O
controlling,870,O
for,870,O
other,870,O
drug,870,O
use,870,O
.,870,O
These,871,O
data,871,O
lend,871,O
further,871,O
support,871,O
to,871,O
the,871,O
proposal,871,O
that,871,O
cognitive,871,O
processes,871,O
mediated,871,O
by,871,O
the,871,O
prefrontal,871,O
cortex,871,O
may,871,O
be,871,O
impaired,871,O
by,871,O
recreational,871,O
ecstasy,871,B-ChemicalEntity
use,871,O
.,871,O
Memory,872,O
function,872,O
and,872,O
serotonin,872,B-GeneOrGeneProduct
transporter,872,I-GeneOrGeneProduct
promoter,872,O
gene,872,O
polymorphism,872,O
in,872,O
ecstasy,872,B-ChemicalEntity
(,872,O
MDMA,872,B-ChemicalEntity
),872,O
users,872,O
.,872,O
Although,873,O
"3,4-methylenedioxymethamphetamine",873,B-ChemicalEntity
(,873,O
MDMA,873,B-ChemicalEntity
or,873,O
ecstasy,873,B-ChemicalEntity
),873,O
has,873,O
been,873,O
shown,873,O
to,873,O
damage,873,O
brain,873,O
serotonin,873,B-ChemicalEntity
(,873,O
5-HT,873,B-ChemicalEntity
),873,O
neurons,873,O
in,873,O
animals,873,O
and,873,O
possibly,873,O
humans,873,B-OrganismTaxon
",",873,O
little,873,O
is,873,O
known,873,O
about,873,O
the,873,O
long-term,873,O
consequences,873,O
of,873,O
MDMA-induced,873,B-ChemicalEntity
5-HT,873,B-ChemicalEntity
neurotoxic,873,B-DiseaseOrPhenotypicFeature
lesions,873,I-DiseaseOrPhenotypicFeature
on,873,O
functions,873,O
in,873,O
which,873,O
5-HT,873,B-ChemicalEntity
is,873,O
involved,873,O
",",873,O
such,873,O
as,873,O
cognitive,873,O
function,873,O
.,873,O
Because,874,O
5-HT,874,B-ChemicalEntity
transporters,874,O
play,874,O
a,874,O
key,874,O
element,874,O
in,874,O
the,874,O
regulation,874,O
of,874,O
synaptic,874,O
5-HT,874,B-ChemicalEntity
transmission,874,O
it,874,O
may,874,O
be,874,O
important,874,O
to,874,O
control,874,O
for,874,O
the,874,O
potential,874,O
covariance,874,O
effect,874,O
of,874,O
a,874,O
polymorphism,874,O
in,874,O
the,874,O
5-HT,874,B-GeneOrGeneProduct
transporter,874,I-GeneOrGeneProduct
promoter,874,I-GeneOrGeneProduct
gene,874,I-GeneOrGeneProduct
region,874,I-GeneOrGeneProduct
(,874,O
5-HTTLPR,874,B-GeneOrGeneProduct
),874,O
when,874,O
studying,874,O
the,874,O
effects,874,O
of,874,O
MDMA,874,B-ChemicalEntity
as,874,O
well,874,O
as,874,O
cognitive,874,O
functioning,874,O
.,874,O
The,875,O
aim,875,O
of,875,O
the,875,O
study,875,O
was,875,O
to,875,O
investigate,875,O
the,875,O
effects,875,O
of,875,O
moderate,875,O
and,875,O
heavy,875,O
MDMA,875,B-ChemicalEntity
use,875,O
on,875,O
cognitive,875,O
function,875,O
",",875,O
as,875,O
well,875,O
as,875,O
the,875,O
effects,875,O
of,875,O
long-term,875,O
abstention,875,O
from,875,O
MDMA,875,B-ChemicalEntity
",",875,O
in,875,O
subjects,875,O
genotyped,875,O
for,875,O
5-HTTLPR,875,B-GeneOrGeneProduct
.,875,O
A,876,O
second,876,O
aim,876,O
of,876,O
the,876,O
study,876,O
was,876,O
to,876,O
determine,876,O
whether,876,O
these,876,O
effects,876,O
differ,876,O
for,876,O
females,876,O
and,876,O
males,876,O
.,876,O
Fifteen,877,O
moderate,877,O
MDMA,877,B-ChemicalEntity
users,877,O
(,877,O
<,877,O
55,877,O
lifetime,877,O
tablets,877,O
),877,O
",",877,O
22,877,O
heavy,877,O
MDMA+,877,B-ChemicalEntity
users,877,O
(,877,O
>,877,O
55,877,O
lifetime,877,O
tablets,877,O
),877,O
",",877,O
16,877,O
ex-MDMA+,877,O
users,877,O
(,877,O
last,877,O
tablet,877,O
>,877,O
1,877,O
year,877,O
ago,877,O
),877,O
and,877,O
13,877,O
controls,877,O
were,877,O
compared,877,O
on,877,O
a,877,O
battery,877,O
of,877,O
neuropsychological,877,O
tests,877,O
.,877,O
DNA,878,O
from,878,O
peripheral,878,O
nuclear,878,O
blood,878,O
cells,878,O
was,878,O
genotyped,878,O
for,878,O
5-HTTLPR,878,B-GeneOrGeneProduct
using,878,O
standard,878,O
polymerase,878,O
chain,878,O
reaction,878,O
methods.A,878,O
significant,878,O
group,878,O
effect,878,O
was,878,O
observed,878,O
only,878,O
on,878,O
memory,878,O
function,878,O
tasks,878,O
(,878,O
p,878,O
=,878,O
0.04,878,O
),878,O
but,878,O
not,878,O
on,878,O
reaction,878,O
times,878,O
(,878,O
p,878,O
=,878,O
0.61,878,O
),878,O
or,878,O
attention/executive,878,O
functioning,878,O
(,878,O
p,878,O
=,878,O
0.59,878,O
),878,O
.,878,O
Heavy,879,O
and,879,O
ex-MDMA+,879,O
users,879,O
performed,879,O
significantly,879,O
poorer,879,O
on,879,O
memory,879,O
tasks,879,O
than,879,O
controls,879,O
.,879,O
In,880,O
contrast,880,O
",",880,O
no,880,O
evidence,880,O
of,880,O
memory,880,B-DiseaseOrPhenotypicFeature
impairment,880,I-DiseaseOrPhenotypicFeature
was,880,O
observed,880,O
in,880,O
moderate,880,O
MDMA,880,B-ChemicalEntity
users,880,O
.,880,O
No,881,O
significant,881,O
effect,881,O
of,881,O
5-HTTLPR,881,B-GeneOrGeneProduct
or,881,O
gender,881,O
was,881,O
observed,881,O
.,881,O
While,882,O
the,882,O
use,882,O
of,882,O
MDMA,882,B-ChemicalEntity
in,882,O
quantities,882,O
that,882,O
may,882,O
be,882,O
considered,882,O
``,882,O
moderate,882,O
'',882,O
is,882,O
not,882,O
associated,882,O
with,882,O
impaired,882,B-DiseaseOrPhenotypicFeature
memory,882,I-DiseaseOrPhenotypicFeature
functioning,882,I-DiseaseOrPhenotypicFeature
",",882,O
heavy,882,O
use,882,O
of,882,O
MDMA,882,B-ChemicalEntity
use,882,O
may,882,O
lead,882,O
to,882,O
long,882,O
lasting,882,O
memory,882,B-DiseaseOrPhenotypicFeature
impairments,882,I-DiseaseOrPhenotypicFeature
.,882,O
No,883,O
effect,883,O
of,883,O
5-HTTLPR,883,B-GeneOrGeneProduct
or,883,O
gender,883,O
on,883,O
memory,883,O
function,883,O
or,883,O
MDMA,883,B-ChemicalEntity
use,883,O
was,883,O
observed,883,O
.,883,O
Tumor,884,B-DiseaseOrPhenotypicFeature
thymidylate,884,B-GeneOrGeneProduct
synthase,884,I-GeneOrGeneProduct
1494del6,884,B-SequenceVariant
genotype,884,O
as,884,O
a,884,O
prognostic,884,O
factor,884,O
in,884,O
colorectal,884,B-DiseaseOrPhenotypicFeature
cancer,884,I-DiseaseOrPhenotypicFeature
patients,884,B-OrganismTaxon
receiving,884,O
fluorouracil-based,884,B-ChemicalEntity
adjuvant,884,O
treatment,884,O
.,884,O
PURPOSE,885,O
:,885,O
The,885,O
purpose,885,O
of,885,O
this,885,O
study,885,O
was,885,O
to,885,O
analyze,885,O
the,885,O
value,885,O
of,885,O
germline,885,O
and,885,O
tumor,885,B-DiseaseOrPhenotypicFeature
thymidylate,885,B-GeneOrGeneProduct
synthase,885,I-GeneOrGeneProduct
(,885,O
TS,885,B-GeneOrGeneProduct
),885,O
genotyping,885,O
as,885,O
a,885,O
prognostic,885,O
marker,885,O
in,885,O
a,885,O
series,885,O
of,885,O
colorectal,885,B-DiseaseOrPhenotypicFeature
cancer,885,I-DiseaseOrPhenotypicFeature
patients,885,B-OrganismTaxon
receiving,885,O
adjuvant,885,O
fluorouracil,885,B-ChemicalEntity
(,885,O
FU,885,B-ChemicalEntity
),885,O
-based,885,O
treatment,885,O
.,885,O
PATIENTS,886,B-OrganismTaxon
AND,886,O
METHODS,886,O
:,886,O
One,886,O
hundred,886,O
twenty-nine,886,O
colorectal,886,B-DiseaseOrPhenotypicFeature
cancer,886,I-DiseaseOrPhenotypicFeature
patients,886,B-OrganismTaxon
homogeneously,886,O
treated,886,O
with,886,O
FU,886,B-ChemicalEntity
plus,886,O
levamisole,886,B-ChemicalEntity
or,886,O
leucovorin,886,B-ChemicalEntity
in,886,O
the,886,O
adjuvant,886,O
setting,886,O
were,886,O
included,886,O
.,886,O
TS,887,B-GeneOrGeneProduct
enhancer,887,O
region,887,O
",",887,O
3R,887,O
G,887,B-SequenceVariant
>,887,I-SequenceVariant
C,887,I-SequenceVariant
single,887,O
nucleotide,887,O
polymorphism,887,O
(,887,O
SNP,887,O
),887,O
",",887,O
and,887,O
TS,887,B-GeneOrGeneProduct
1494del6,887,B-SequenceVariant
polymorphisms,887,O
were,887,O
assessed,887,O
in,887,O
both,887,O
fresh-frozen,887,O
normal,887,O
mucosa,887,O
and,887,O
tumor,887,B-DiseaseOrPhenotypicFeature
.,887,O
Mutational,888,O
analyses,888,O
of,888,O
TS,888,B-GeneOrGeneProduct
and,888,O
allelic,888,O
imbalances,888,O
were,888,O
studied,888,O
in,888,O
all,888,O
primary,888,O
tumors,888,B-DiseaseOrPhenotypicFeature
and,888,O
in,888,O
18,888,O
additional,888,O
metachronic,888,O
metastases,888,B-DiseaseOrPhenotypicFeature
.,888,O
TS,889,B-GeneOrGeneProduct
protein,889,O
immunostaining,889,O
was,889,O
assessed,889,O
in,889,O
an,889,O
expanded,889,O
series,889,O
of,889,O
214,889,O
tumors,889,B-DiseaseOrPhenotypicFeature
.,889,O
Multivariate,890,O
Cox,890,O
models,890,O
were,890,O
adjusted,890,O
for,890,O
stage,890,O
",",890,O
differentiation,890,O
",",890,O
and,890,O
location,890,O
.,890,O
RESULTS,891,O
:,891,O
Tumor,891,B-DiseaseOrPhenotypicFeature
genotyping,891,O
(,891,O
frequency,891,O
of,891,O
allelic,891,O
loss,891,O
",",891,O
26,891,O
%,891,O
),891,O
showed,891,O
that,891,O
the,891,O
3R/3R,891,O
genotype,891,O
was,891,O
associated,891,O
with,891,O
a,891,O
better,891,O
outcome,891,O
(,891,O
hazard,891,O
ratio,891,O
[,891,O
HR,891,O
],891,O
=,891,O
0.38,891,O
;,891,O
95,891,O
%,891,O
CI,891,O
",",891,O
0.16,891,O
to,891,O
0.93,891,O
;,891,O
P,891,O
=,891,O
.020,891,O
for,891,O
the,891,O
recessive,891,O
model,891,O
),891,O
.,891,O
3R,892,O
G,892,B-SequenceVariant
>,892,I-SequenceVariant
C,892,I-SequenceVariant
SNP,892,O
genotyping,892,O
did,892,O
not,892,O
add,892,O
prognostic,892,O
information,892,O
.,892,O
Tumor,893,B-DiseaseOrPhenotypicFeature
TS,893,B-GeneOrGeneProduct
1494del6,893,B-SequenceVariant
allele,893,O
(,893,O
frequency,893,O
of,893,O
allelic,893,O
loss,893,O
",",893,O
36,893,O
%,893,O
),893,O
was,893,O
protective,893,O
(,893,O
for,893,O
each,893,O
allele,893,O
with,893,O
the,893,O
deletion,893,O
",",893,O
based,893,O
on,893,O
an,893,O
additive,893,O
model,893,O
",",893,O
HR,893,O
=,893,O
0.42,893,O
;,893,O
95,893,O
%,893,O
CI,893,O
",",893,O
0.22,893,O
to,893,O
0.82,893,O
;,893,O
P,893,O
=,893,O
.0034,893,O
),893,O
.,893,O
Both,894,O
polymorphisms,894,O
were,894,O
in,894,O
strong,894,O
linkage,894,O
disequilibrium,894,O
(,894,O
D,894,O
',894,O
=,894,O
0.71,894,O
",",894,O
P,894,O
<,894,O
.001,894,O
),894,O
",",894,O
and,894,O
the,894,O
3R/-6,894,O
base,894,O
pair,894,O
(,894,O
bp,894,O
),894,O
haplotype,894,O
showed,894,O
a,894,O
significant,894,O
overall,894,O
survival,894,O
benefit,894,O
compared,894,O
with,894,O
the,894,O
most,894,O
prevalent,894,O
haplotype,894,O
2R/+6bp,894,O
(,894,O
HR,894,O
=,894,O
0.42,894,O
;,894,O
95,894,O
%,894,O
CI,894,O
",",894,O
0.20,894,O
to,894,O
0.85,894,O
;,894,O
P,894,O
=,894,O
.017,894,O
),894,O
.,894,O
No,895,O
TS,895,B-GeneOrGeneProduct
point,895,O
mutation,895,O
was,895,O
detected,895,O
in,895,O
primary,895,O
tumors,895,B-DiseaseOrPhenotypicFeature
or,895,O
metastases,895,B-DiseaseOrPhenotypicFeature
.,895,O
TS,896,B-GeneOrGeneProduct
protein,896,O
immunostaining,896,O
was,896,O
not,896,O
associated,896,O
with,896,O
survival,896,O
or,896,O
any,896,O
of,896,O
the,896,O
genotypes,896,O
analyzed,896,O
.,896,O
CONCLUSION,897,O
:,897,O
Tumor,897,B-DiseaseOrPhenotypicFeature
TS,897,B-GeneOrGeneProduct
1494del6,897,B-SequenceVariant
genotype,897,O
may,897,O
be,897,O
a,897,O
prognostic,897,O
factor,897,O
in,897,O
FU-based,897,B-ChemicalEntity
adjuvant,897,O
treatment,897,O
of,897,O
colorectal,897,B-DiseaseOrPhenotypicFeature
cancer,897,I-DiseaseOrPhenotypicFeature
patients,897,B-OrganismTaxon
.,897,O
Role,898,O
of,898,O
mangiferin,898,B-ChemicalEntity
on,898,O
biochemical,898,O
alterations,898,O
and,898,O
antioxidant,898,O
status,898,O
in,898,O
isoproterenol-induced,898,B-ChemicalEntity
myocardial,898,B-DiseaseOrPhenotypicFeature
infarction,898,I-DiseaseOrPhenotypicFeature
in,898,O
rats,898,B-OrganismTaxon
.,898,O
The,899,O
current,899,O
study,899,O
dealt,899,O
with,899,O
the,899,O
protective,899,O
role,899,O
of,899,O
mangiferin,899,B-ChemicalEntity
",",899,O
a,899,O
polyphenol,899,B-ChemicalEntity
from,899,O
Mangifera,899,B-OrganismTaxon
indica,899,I-OrganismTaxon
Linn,899,I-OrganismTaxon
.,899,O
(,900,O
Anacardiaceae,900,O
),900,O
",",900,O
on,900,O
isoproterenol,900,B-ChemicalEntity
(,900,O
ISPH,900,B-ChemicalEntity
),900,O
-induced,900,O
myocardial,900,B-DiseaseOrPhenotypicFeature
infarction,900,I-DiseaseOrPhenotypicFeature
(,900,O
MI,900,B-DiseaseOrPhenotypicFeature
),900,O
in,900,O
rats,900,B-OrganismTaxon
through,900,O
its,900,O
antioxidative,900,O
mechanism,900,O
.,900,O
Subcutaneous,901,O
injection,901,O
of,901,O
ISPH,901,B-ChemicalEntity
(,901,O
200,901,O
mg/kg,901,O
body,901,O
weight,901,O
in,901,O
1,901,O
ml,901,O
saline,901,O
),901,O
to,901,O
rats,901,B-OrganismTaxon
for,901,O
2,901,O
consecutive,901,O
days,901,O
caused,901,O
myocardial,901,B-DiseaseOrPhenotypicFeature
damage,901,I-DiseaseOrPhenotypicFeature
in,901,O
rat,901,B-OrganismTaxon
heart,901,O
",",901,O
which,901,O
was,901,O
determined,901,O
by,901,O
the,901,O
increased,901,O
activity,901,O
of,901,O
serum,901,O
lactate,901,B-GeneOrGeneProduct
dehydrogenase,901,I-GeneOrGeneProduct
(,901,O
LDH,901,B-GeneOrGeneProduct
),901,O
and,901,O
creatine,901,B-GeneOrGeneProduct
phosphokinase,901,I-GeneOrGeneProduct
isoenzymes,901,I-GeneOrGeneProduct
(,901,O
CK-MB,901,B-GeneOrGeneProduct
),901,O
",",901,O
increased,901,O
uric,901,B-ChemicalEntity
acid,901,I-ChemicalEntity
level,901,O
and,901,O
reduced,901,O
plasma,901,O
iron,901,B-ChemicalEntity
binding,901,O
capacity,901,O
.,901,O
The,902,O
protective,902,O
role,902,O
of,902,O
mangiferin,902,B-ChemicalEntity
was,902,O
analyzed,902,O
by,902,O
triphenyl,902,B-ChemicalEntity
tetrazolium,902,I-ChemicalEntity
chloride,902,I-ChemicalEntity
(,902,O
TTC,902,B-ChemicalEntity
),902,O
test,902,O
used,902,O
for,902,O
macroscopic,902,O
enzyme,902,O
mapping,902,O
assay,902,O
of,902,O
the,902,O
ischemic,902,B-DiseaseOrPhenotypicFeature
myocardium,902,I-DiseaseOrPhenotypicFeature
.,902,O
The,903,O
heart,903,O
tissue,903,O
antioxidant,903,O
enzymes,903,O
such,903,O
as,903,O
superoxide,903,B-GeneOrGeneProduct
dismutase,903,I-GeneOrGeneProduct
",",903,O
catalase,903,B-GeneOrGeneProduct
",",903,O
glutathione,903,B-GeneOrGeneProduct
peroxidase,903,I-GeneOrGeneProduct
",",903,O
glutathione,903,B-GeneOrGeneProduct
transferase,903,I-GeneOrGeneProduct
and,903,O
glutathione,903,B-GeneOrGeneProduct
reductase,903,I-GeneOrGeneProduct
activities,903,O
",",903,O
non-enzymic,903,O
antioxidants,903,O
such,903,O
as,903,O
cerruloplasmin,903,B-GeneOrGeneProduct
",",903,O
Vitamin,903,B-ChemicalEntity
C,903,I-ChemicalEntity
",",903,O
Vitamin,903,B-ChemicalEntity
E,903,I-ChemicalEntity
and,903,O
glutathione,903,B-ChemicalEntity
levels,903,O
were,903,O
altered,903,O
in,903,O
MI,903,B-DiseaseOrPhenotypicFeature
rats,903,B-OrganismTaxon
.,903,O
Upon,904,O
pretreatment,904,O
with,904,O
mangiferin,904,B-ChemicalEntity
(,904,O
100,904,O
mg/kg,904,O
body,904,O
weight,904,O
suspended,904,O
in,904,O
2,904,O
ml,904,O
of,904,O
dimethyl,904,B-ChemicalEntity
sulphoxide,904,I-ChemicalEntity
),904,O
given,904,O
intraperitoneally,904,O
for,904,O
28,904,O
days,904,O
to,904,O
MI,904,B-DiseaseOrPhenotypicFeature
rats,904,B-OrganismTaxon
protected,904,O
the,904,O
above-mentioned,904,O
parameters,904,O
to,904,O
fall,904,O
from,904,O
the,904,O
normal,904,O
levels,904,O
.,904,O
Activities,905,O
of,905,O
heart,905,O
tissue,905,O
enzymic,905,O
antioxidants,905,O
and,905,O
serum,905,O
non-enzymic,905,O
antioxidants,905,O
levels,905,O
rose,905,O
significantly,905,O
upon,905,O
mangiferin,905,B-ChemicalEntity
administration,905,O
as,905,O
compared,905,O
to,905,O
ISPH-induced,905,B-ChemicalEntity
MI,905,B-DiseaseOrPhenotypicFeature
rats,905,B-OrganismTaxon
.,905,O
From,906,O
the,906,O
present,906,O
study,906,O
it,906,O
is,906,O
concluded,906,O
that,906,O
mangiferin,906,B-ChemicalEntity
exerts,906,O
a,906,O
beneficial,906,O
effect,906,O
against,906,O
ISPH-induced,906,B-ChemicalEntity
MI,906,B-DiseaseOrPhenotypicFeature
due,906,O
to,906,O
its,906,O
antioxidant,906,O
potential,906,O
",",906,O
which,906,O
regulated,906,O
the,906,O
tissues,906,O
defense,906,O
system,906,O
against,906,O
cardiac,906,B-DiseaseOrPhenotypicFeature
damage,906,I-DiseaseOrPhenotypicFeature
.,906,O
Cardiovascular,907,O
risk,907,O
with,907,O
cyclooxygenase,907,B-ChemicalEntity
inhibitors,907,I-ChemicalEntity
:,907,O
general,907,O
problem,907,O
with,907,O
substance,907,O
specific,907,O
differences,907,O
?,907,O
Randomised,908,O
clinical,908,O
trials,908,O
and,908,O
observational,908,O
studies,908,O
have,908,O
shown,908,O
an,908,O
increased,908,O
risk,908,O
of,908,O
myocardial,908,B-DiseaseOrPhenotypicFeature
infarction,908,I-DiseaseOrPhenotypicFeature
",",908,O
stroke,908,B-DiseaseOrPhenotypicFeature
",",908,O
hypertension,908,B-DiseaseOrPhenotypicFeature
and,908,O
heart,908,B-DiseaseOrPhenotypicFeature
failure,908,I-DiseaseOrPhenotypicFeature
during,908,O
treatment,908,O
with,908,O
cyclooxygenase,908,B-ChemicalEntity
inhibitors,908,I-ChemicalEntity
.,908,O
Adverse,909,O
cardiovascular,909,O
effects,909,O
occurred,909,O
mainly,909,O
",",909,O
but,909,O
not,909,O
exclusively,909,O
",",909,O
in,909,O
patients,909,B-OrganismTaxon
with,909,O
concomitant,909,O
risk,909,O
factors,909,O
.,909,O
Cyclooxygenase,910,B-ChemicalEntity
inhibitors,910,I-ChemicalEntity
cause,910,O
complex,910,O
changes,910,O
in,910,O
renal,910,O
",",910,O
vascular,910,O
and,910,O
cardiac,910,O
prostanoid,910,B-ChemicalEntity
profiles,910,O
thereby,910,O
increasing,910,O
vascular,910,O
resistance,910,O
and,910,O
fluid,910,O
retention,910,O
.,910,O
The,911,O
incidence,911,O
of,911,O
cardiovascular,911,B-DiseaseOrPhenotypicFeature
adverse,911,I-DiseaseOrPhenotypicFeature
events,911,I-DiseaseOrPhenotypicFeature
tends,911,O
to,911,O
increase,911,O
with,911,O
the,911,O
daily,911,O
dose,911,O
and,911,O
total,911,O
exposure,911,O
time,911,O
.,911,O
A,912,O
comparison,912,O
of,912,O
individual,912,O
selective,912,O
and,912,O
unselective,912,O
cyclooxygenase,912,B-ChemicalEntity
inhibitors,912,I-ChemicalEntity
suggests,912,O
substance-specific,912,O
differences,912,O
",",912,O
which,912,O
may,912,O
depend,912,O
on,912,O
differences,912,O
in,912,O
pharmacokinetic,912,O
parameters,912,O
or,912,O
inhibitory,912,O
potency,912,O
and,912,O
may,912,O
be,912,O
contributed,912,O
by,912,O
prostaglandin-independent,912,B-ChemicalEntity
effects,912,O
.,912,O
Diagnostic,913,O
markers,913,O
such,913,O
as,913,O
N-terminal,913,B-ChemicalEntity
pro,913,I-ChemicalEntity
brain,913,I-ChemicalEntity
natriuretic,913,I-ChemicalEntity
peptide,913,I-ChemicalEntity
(,913,O
NT-proBNP,913,B-ChemicalEntity
),913,O
or,913,O
high-sensitive,913,O
C-reactive,913,B-GeneOrGeneProduct
protein,913,I-GeneOrGeneProduct
might,913,O
help,913,O
in,913,O
the,913,O
early,913,O
identification,913,O
of,913,O
patients,913,B-OrganismTaxon
at,913,O
risk,913,O
",",913,O
thus,913,O
avoiding,913,O
the,913,O
occurrence,913,O
of,913,O
serious,913,O
cardiovascular,913,B-DiseaseOrPhenotypicFeature
toxicity,913,I-DiseaseOrPhenotypicFeature
.,913,O
Pilocarpine,914,B-ChemicalEntity
seizures,914,B-DiseaseOrPhenotypicFeature
cause,914,O
age-dependent,914,O
impairment,914,B-DiseaseOrPhenotypicFeature
in,914,I-DiseaseOrPhenotypicFeature
auditory,914,I-DiseaseOrPhenotypicFeature
location,914,I-DiseaseOrPhenotypicFeature
discrimination,914,I-DiseaseOrPhenotypicFeature
.,914,O
Children,915,O
who,915,O
have,915,O
status,915,B-DiseaseOrPhenotypicFeature
epilepticus,915,I-DiseaseOrPhenotypicFeature
have,915,O
continuous,915,O
or,915,O
rapidly,915,O
repeating,915,O
seizures,915,B-DiseaseOrPhenotypicFeature
that,915,O
may,915,O
be,915,O
life-threatening,915,O
and,915,O
may,915,O
cause,915,O
life-long,915,O
changes,915,O
in,915,O
brain,915,O
and,915,O
behavior,915,O
.,915,O
The,916,O
extent,916,O
to,916,O
which,916,O
status,916,B-DiseaseOrPhenotypicFeature
epilepticus,916,I-DiseaseOrPhenotypicFeature
causes,916,O
deficits,916,B-DiseaseOrPhenotypicFeature
in,916,I-DiseaseOrPhenotypicFeature
auditory,916,I-DiseaseOrPhenotypicFeature
discrimination,916,I-DiseaseOrPhenotypicFeature
is,916,O
unknown,916,O
.,916,O
A,917,O
naturalistic,917,O
auditory,917,O
location,917,O
discrimination,917,O
method,917,O
was,917,O
used,917,O
to,917,O
evaluate,917,O
this,917,O
question,917,O
using,917,O
an,917,O
animal,917,O
model,917,O
of,917,O
status,917,B-DiseaseOrPhenotypicFeature
epilepticus,917,I-DiseaseOrPhenotypicFeature
.,917,O
Male,918,O
Sprague-Dawley,918,O
rats,918,B-OrganismTaxon
were,918,O
injected,918,O
with,918,O
saline,918,O
on,918,O
postnatal,918,O
day,918,O
(,918,O
P,918,O
),918,O
20,918,O
",",918,O
or,918,O
a,918,O
convulsant,918,O
dose,918,O
of,918,O
pilocarpine,918,B-ChemicalEntity
on,918,O
P20,918,O
or,918,O
P45,918,O
.,918,O
Pilocarpine,919,B-ChemicalEntity
on,919,O
either,919,O
day,919,O
induced,919,O
status,919,B-DiseaseOrPhenotypicFeature
epilepticus,919,I-DiseaseOrPhenotypicFeature
;,919,O
status,919,B-DiseaseOrPhenotypicFeature
epilepticus,919,I-DiseaseOrPhenotypicFeature
at,919,O
P45,919,O
resulted,919,O
in,919,O
CA3,919,B-CellLine
cell,919,O
loss,919,O
and,919,O
spontaneous,919,O
seizures,919,B-DiseaseOrPhenotypicFeature
",",919,O
whereas,919,O
P20,919,O
rats,919,B-OrganismTaxon
had,919,O
no,919,O
cell,919,O
loss,919,O
or,919,O
spontaneous,919,O
seizures,919,B-DiseaseOrPhenotypicFeature
.,919,O
Mature,920,O
rats,920,B-OrganismTaxon
were,920,O
trained,920,O
with,920,O
sound-source,920,O
location,920,O
and,920,O
sound-silence,920,O
discriminations,920,O
.,920,O
Control,921,O
(,921,O
saline,921,O
P20,921,O
),921,O
rats,921,B-OrganismTaxon
acquired,921,O
both,921,O
discriminations,921,O
immediately,921,O
.,921,O
In,922,O
status,922,B-DiseaseOrPhenotypicFeature
epilepticus,922,I-DiseaseOrPhenotypicFeature
(,922,O
P20,922,O
),922,O
rats,922,B-OrganismTaxon
",",922,O
acquisition,922,O
of,922,O
the,922,O
sound-source,922,O
location,922,O
discrimination,922,O
was,922,O
moderately,922,O
impaired,922,O
.,922,O
Status,923,B-DiseaseOrPhenotypicFeature
epilepticus,923,I-DiseaseOrPhenotypicFeature
(,923,O
P45,923,O
),923,O
rats,923,B-OrganismTaxon
failed,923,O
to,923,O
acquire,923,O
either,923,O
sound-source,923,O
location,923,O
or,923,O
sound-silence,923,O
discriminations,923,O
.,923,O
Status,924,B-DiseaseOrPhenotypicFeature
epilepticus,924,I-DiseaseOrPhenotypicFeature
in,924,O
rat,924,B-OrganismTaxon
causes,924,O
an,924,O
age-dependent,924,O
",",924,O
long-term,924,O
impairment,924,B-DiseaseOrPhenotypicFeature
in,924,I-DiseaseOrPhenotypicFeature
auditory,924,I-DiseaseOrPhenotypicFeature
discrimination,924,I-DiseaseOrPhenotypicFeature
.,924,O
This,925,O
impairment,925,O
may,925,O
explain,925,O
one,925,O
cause,925,O
of,925,O
impaired,925,B-DiseaseOrPhenotypicFeature
auditory,925,I-DiseaseOrPhenotypicFeature
location,925,I-DiseaseOrPhenotypicFeature
discrimination,925,I-DiseaseOrPhenotypicFeature
in,925,O
humans,925,B-OrganismTaxon
.,925,O
Impact,926,O
of,926,O
alcohol,926,B-ChemicalEntity
exposure,926,O
after,926,O
pregnancy,926,O
recognition,926,O
on,926,O
ultrasonographic,926,O
fetal,926,O
growth,926,O
measures,926,O
.,926,O
BACKGROUND,927,O
:,927,O
More,927,O
than,927,O
3,927,O
decades,927,O
after,927,O
Jones,927,O
and,927,O
Smith,927,O
(,927,O
1973,927,O
),927,O
reported,927,O
on,927,O
the,927,O
devastation,927,O
caused,927,O
by,927,O
alcohol,927,B-ChemicalEntity
exposure,927,O
on,927,O
fetal,927,O
development,927,O
",",927,O
the,927,O
rates,927,O
of,927,O
heavy,927,O
drinking,927,O
during,927,O
pregnancy,927,O
remain,927,O
relatively,927,O
unchanged,927,O
.,927,O
Early,928,O
identification,928,O
of,928,O
fetal,928,O
alcohol,928,B-ChemicalEntity
exposure,928,O
and,928,O
maternal,928,O
abstinence,928,O
led,928,O
to,928,O
better,928,O
infant,928,O
outcomes,928,O
.,928,O
This,929,O
study,929,O
examined,929,O
the,929,O
utility,929,O
of,929,O
biometry,929,O
for,929,O
detecting,929,O
alcohol-related,929,B-ChemicalEntity
fetal,929,O
growth,929,B-DiseaseOrPhenotypicFeature
impairment,929,I-DiseaseOrPhenotypicFeature
.,929,O
METHODS,930,O
:,930,O
We,930,O
obtained,930,O
fetal,930,O
ultrasound,930,O
measures,930,O
from,930,O
routine,930,O
ultrasound,930,O
examinations,930,O
for,930,O
167,930,O
pregnant,930,O
hazardous,930,O
drinkers,930,O
who,930,O
were,930,O
enrolled,930,O
in,930,O
a,930,O
brief,930,O
alcohol,930,B-ChemicalEntity
intervention,930,O
study,930,O
.,930,O
The,931,O
fetal,931,O
measures,931,O
for,931,O
women,931,B-OrganismTaxon
who,931,O
quit,931,O
after,931,O
learning,931,O
of,931,O
their,931,O
pregnancies,931,O
were,931,O
compared,931,O
with,931,O
measures,931,O
for,931,O
women,931,B-OrganismTaxon
who,931,O
continued,931,O
some,931,O
drinking,931,O
throughout,931,O
the,931,O
course,931,O
of,931,O
their,931,O
pregnancies,931,O
.,931,O
Because,932,O
intensity,932,O
of,932,O
alcohol,932,B-ChemicalEntity
consumption,932,O
is,932,O
associated,932,O
with,932,O
poorer,932,O
fetal,932,O
outcomes,932,O
",",932,O
separate,932,O
analyses,932,O
were,932,O
conducted,932,O
for,932,O
the,932,O
heavy,932,O
(,932,O
average,932,O
of,932,O
>,932,O
or=5,932,O
drinks,932,O
per,932,O
drinking,932,O
day,932,O
),932,O
alcohol,932,B-ChemicalEntity
consumers,932,O
.,932,O
Fetal,933,O
measures,933,O
from,933,O
the,933,O
heavy-exposed,933,O
fetuses,933,O
were,933,O
also,933,O
compared,933,O
with,933,O
measures,933,O
from,933,O
a,933,O
nondrinking,933,O
group,933,O
that,933,O
was,933,O
representative,933,O
of,933,O
normal,933,O
",",933,O
uncomplicated,933,O
pregnancies,933,O
from,933,O
our,933,O
clinics,933,O
.,933,O
Analyses,934,O
of,934,O
covariance,934,O
were,934,O
used,934,O
to,934,O
determine,934,O
whether,934,O
there,934,O
were,934,O
differences,934,O
between,934,O
groups,934,O
after,934,O
controlling,934,O
for,934,O
influences,934,O
of,934,O
gestational,934,O
age,934,O
and,934,O
drug,934,B-DiseaseOrPhenotypicFeature
abuse,934,I-DiseaseOrPhenotypicFeature
.,934,O
RESULTS,935,O
:,935,O
Nearly,935,O
half,935,O
of,935,O
the,935,O
pregnant,935,O
drinkers,935,O
abstained,935,O
after,935,O
learning,935,O
of,935,O
their,935,O
pregnancies,935,O
.,935,O
When,936,O
women,936,B-OrganismTaxon
reportedly,936,O
quit,936,O
drinking,936,O
early,936,O
in,936,O
their,936,O
pregnancies,936,O
",",936,O
fetal,936,O
growth,936,O
measures,936,O
were,936,O
not,936,O
significantly,936,O
different,936,O
from,936,O
a,936,O
non-alcohol-exposed,936,O
group,936,O
",",936,O
regardless,936,O
of,936,O
prior,936,O
drinking,936,O
patterns,936,O
.,936,O
Any,937,O
alcohol,937,B-ChemicalEntity
consumption,937,O
postpregnancy,937,O
recognition,937,O
among,937,O
the,937,O
heavy,937,O
drinkers,937,O
resulted,937,O
in,937,O
reduced,937,B-DiseaseOrPhenotypicFeature
cerebellar,937,I-DiseaseOrPhenotypicFeature
growth,937,I-DiseaseOrPhenotypicFeature
as,937,O
well,937,O
as,937,O
decreased,937,B-DiseaseOrPhenotypicFeature
cranial,937,I-DiseaseOrPhenotypicFeature
to,937,I-DiseaseOrPhenotypicFeature
body,937,I-DiseaseOrPhenotypicFeature
growth,937,I-DiseaseOrPhenotypicFeature
in,937,O
comparison,937,O
with,937,O
women,937,B-OrganismTaxon
who,937,O
either,937,O
quit,937,O
drinking,937,O
or,937,O
who,937,O
were,937,O
nondrinkers,937,O
.,937,O
Amphetamine,938,B-ChemicalEntity
abuse,938,O
was,938,O
predictive,938,O
of,938,O
larger,938,O
cranial,938,O
to,938,O
body,938,O
growth,938,O
ratios,938,O
.,938,O
CONCLUSIONS,939,O
:,939,O
Alterations,939,O
in,939,O
fetal,939,O
biometric,939,O
measurements,939,O
were,939,O
observed,939,O
among,939,O
the,939,O
heavy,939,O
drinkers,939,O
only,939,O
when,939,O
they,939,O
continued,939,O
drinking,939,O
after,939,O
becoming,939,O
aware,939,O
of,939,O
their,939,O
pregnancies,939,O
.,939,O
Although,940,O
the,940,O
reliance,940,O
on,940,O
self-reported,940,O
drinking,940,O
is,940,O
a,940,O
limitation,940,O
in,940,O
this,940,O
study,940,O
",",940,O
these,940,O
findings,940,O
support,940,O
the,940,O
benefits,940,O
of,940,O
early,940,O
abstinence,940,O
and,940,O
the,940,O
potential,940,O
for,940,O
ultrasound,940,O
examinations,940,O
in,940,O
the,940,O
detection,940,O
of,940,O
fetal,940,O
alcohol,940,B-ChemicalEntity
effects,940,O
.,940,O
Possible,941,O
neuroleptic,941,B-DiseaseOrPhenotypicFeature
malignant,941,I-DiseaseOrPhenotypicFeature
syndrome,941,I-DiseaseOrPhenotypicFeature
related,941,O
to,941,O
concomitant,941,O
treatment,941,O
with,941,O
paroxetine,941,B-ChemicalEntity
and,941,O
alprazolam,941,B-ChemicalEntity
.,941,O
A,942,O
74-year-old,942,O
man,942,B-OrganismTaxon
with,942,O
depressive,942,B-DiseaseOrPhenotypicFeature
symptoms,942,I-DiseaseOrPhenotypicFeature
was,942,O
admitted,942,O
to,942,O
a,942,O
psychiatric,942,B-DiseaseOrPhenotypicFeature
hospital,942,O
due,942,O
to,942,O
insomnia,942,B-DiseaseOrPhenotypicFeature
",",942,O
loss,942,B-DiseaseOrPhenotypicFeature
of,942,I-DiseaseOrPhenotypicFeature
appetite,942,I-DiseaseOrPhenotypicFeature
",",942,O
exhaustion,942,O
",",942,O
and,942,O
agitation,942,B-DiseaseOrPhenotypicFeature
.,942,O
Medical,943,O
treatment,943,O
was,943,O
initiated,943,O
at,943,O
a,943,O
daily,943,O
dose,943,O
of,943,O
20,943,O
mg,943,O
paroxetine,943,B-ChemicalEntity
and,943,O
1.2,943,O
mg,943,O
alprazolam,943,B-ChemicalEntity
.,943,O
On,944,O
the,944,O
10th,944,O
day,944,O
of,944,O
paroxetine,944,B-ChemicalEntity
and,944,O
alprazolam,944,B-ChemicalEntity
treatment,944,O
",",944,O
the,944,O
patient,944,B-OrganismTaxon
exhibited,944,O
marked,944,O
psychomotor,944,B-DiseaseOrPhenotypicFeature
retardation,944,I-DiseaseOrPhenotypicFeature
",",944,O
disorientation,944,O
",",944,O
and,944,O
severe,944,O
muscle,944,B-DiseaseOrPhenotypicFeature
rigidity,944,I-DiseaseOrPhenotypicFeature
with,944,O
tremors,944,B-DiseaseOrPhenotypicFeature
.,944,O
The,945,O
patient,945,B-OrganismTaxon
had,945,O
a,945,O
fever,945,B-DiseaseOrPhenotypicFeature
(,945,O
38.2,945,O
degrees,945,O
C,945,O
),945,O
",",945,O
fluctuating,945,O
blood,945,O
pressure,945,O
(,945,O
between,945,O
165/90,945,O
and,945,O
130/70,945,O
mg,945,O
mm,945,O
Hg,945,O
),945,O
",",945,O
and,945,O
severe,945,O
extrapyramidal,945,B-DiseaseOrPhenotypicFeature
symptoms,945,I-DiseaseOrPhenotypicFeature
.,945,O
Laboratory,946,O
tests,946,O
showed,946,O
an,946,O
elevation,946,O
of,946,O
creatine,946,B-ChemicalEntity
phosphokinase,946,I-ChemicalEntity
(,946,O
2218,946,O
IU/L,946,O
),946,O
",",946,O
aspartate,946,B-ChemicalEntity
aminotransferase,946,I-ChemicalEntity
(,946,O
134,946,O
IU/L,946,O
),946,O
",",946,O
alanine,946,B-ChemicalEntity
aminotransferase,946,I-ChemicalEntity
(,946,O
78,946,O
IU/L,946,O
),946,O
",",946,O
and,946,O
BUN,946,O
(,946,O
27.9,946,O
mg/ml,946,O
),946,O
levels,946,O
.,946,O
The,947,O
patient,947,B-OrganismTaxon
received,947,O
bromocriptine,947,B-ChemicalEntity
and,947,O
diazepam,947,B-ChemicalEntity
to,947,O
treat,947,O
his,947,O
symptoms,947,O
.,947,O
7,948,O
days,948,O
later,948,O
",",948,O
the,948,O
fever,948,B-DiseaseOrPhenotypicFeature
disappeared,948,O
and,948,O
the,948,O
patient,948,B-OrganismTaxon
's,948,O
serum,948,O
CPK,948,B-ChemicalEntity
levels,948,O
were,948,O
normalized,948,O
(,948,O
175,948,O
IU/L,948,O
),948,O
.,948,O
This,949,O
patient,949,B-OrganismTaxon
presented,949,O
with,949,O
symptoms,949,O
of,949,O
neuroleptic,949,B-DiseaseOrPhenotypicFeature
malignant,949,I-DiseaseOrPhenotypicFeature
syndrome,949,I-DiseaseOrPhenotypicFeature
(,949,O
NMS,949,B-DiseaseOrPhenotypicFeature
),949,O
",",949,O
thus,949,O
demonstrating,949,O
that,949,O
NMS-like,949,B-DiseaseOrPhenotypicFeature
symptoms,949,O
can,949,O
occur,949,O
after,949,O
combined,949,O
paroxetine,949,B-ChemicalEntity
and,949,O
alprazolam,949,B-ChemicalEntity
treatment,949,O
.,949,O
The,950,O
adverse,950,O
drug,950,O
reaction,950,O
score,950,O
obtained,950,O
by,950,O
the,950,O
Naranjo,950,O
algorithm,950,O
was,950,O
6,950,O
in,950,O
our,950,O
case,950,O
",",950,O
indicating,950,O
a,950,O
probable,950,O
relationship,950,O
between,950,O
the,950,O
patient,950,B-OrganismTaxon
's,950,O
NMS-like,950,B-DiseaseOrPhenotypicFeature
adverse,950,O
symptoms,950,O
and,950,O
the,950,O
combined,950,O
treatment,950,O
used,950,O
in,950,O
this,950,O
case,950,O
.,950,O
The,951,O
involvement,951,O
of,951,O
physiologic,951,O
and,951,O
environmental,951,O
aspects,951,O
specific,951,O
to,951,O
this,951,O
patient,951,B-OrganismTaxon
was,951,O
suspected,951,O
.,951,O
Several,952,O
risk,952,O
factors,952,O
for,952,O
NMS,952,B-DiseaseOrPhenotypicFeature
should,952,O
be,952,O
noted,952,O
in,952,O
elderly,952,O
depressive,952,B-DiseaseOrPhenotypicFeature
patients,952,B-OrganismTaxon
whose,952,O
symptoms,952,O
often,952,O
include,952,O
dehydration,952,B-DiseaseOrPhenotypicFeature
",",952,O
agitation,952,B-DiseaseOrPhenotypicFeature
",",952,O
malnutrition,952,B-DiseaseOrPhenotypicFeature
",",952,O
and,952,O
exhaustion,952,O
.,952,O
Careful,953,O
therapeutic,953,O
intervention,953,O
is,953,O
necessary,953,O
in,953,O
cases,953,O
involving,953,O
elderly,953,O
patients,953,B-OrganismTaxon
who,953,O
suffer,953,O
from,953,O
depression,953,B-DiseaseOrPhenotypicFeature
.,953,O
Down-regulation,954,O
of,954,O
norepinephrine,954,B-GeneOrGeneProduct
transporter,954,I-GeneOrGeneProduct
function,954,O
induced,954,O
by,954,O
chronic,954,O
administration,954,O
of,954,O
desipramine,954,B-ChemicalEntity
linking,954,O
to,954,O
the,954,O
alteration,954,O
of,954,O
sensitivity,954,O
of,954,O
local-anesthetics-induced,954,O
convulsions,954,B-DiseaseOrPhenotypicFeature
and,954,O
the,954,O
counteraction,954,O
by,954,O
co-administration,954,O
with,954,O
local,954,O
anesthetics,954,B-ChemicalEntity
.,954,O
Alterations,955,O
of,955,O
norepinephrine,955,B-GeneOrGeneProduct
transporter,955,I-GeneOrGeneProduct
(,955,O
NET,955,B-GeneOrGeneProduct
),955,O
function,955,O
by,955,O
chronic,955,O
inhibition,955,O
of,955,O
NET,955,B-GeneOrGeneProduct
in,955,O
relation,955,O
to,955,O
sensitization,955,O
to,955,O
seizures,955,B-DiseaseOrPhenotypicFeature
induce,955,O
by,955,O
cocaine,955,B-ChemicalEntity
and,955,O
local,955,O
anesthetics,955,B-ChemicalEntity
were,955,O
studied,955,O
in,955,O
mice,955,B-OrganismTaxon
.,955,O
Daily,956,O
administration,956,O
of,956,O
desipramine,956,B-ChemicalEntity
",",956,O
an,956,O
inhibitor,956,O
of,956,O
the,956,O
NET,956,B-GeneOrGeneProduct
",",956,O
for,956,O
5,956,O
days,956,O
decreased,956,O
[,956,B-ChemicalEntity
(,956,I-ChemicalEntity
3,956,I-ChemicalEntity
),956,I-ChemicalEntity
H,956,I-ChemicalEntity
],956,I-ChemicalEntity
norepinephrine,956,I-ChemicalEntity
uptake,956,O
in,956,O
the,956,O
P2,956,O
fractions,956,O
of,956,O
hippocampus,956,O
but,956,O
not,956,O
cortex,956,O
",",956,O
striatum,956,O
or,956,O
amygdalae,956,O
.,956,O
Co-administration,957,O
of,957,O
lidocaine,957,B-ChemicalEntity
",",957,O
bupivacaine,957,B-ChemicalEntity
or,957,O
tricaine,957,B-ChemicalEntity
with,957,O
desipramine,957,B-ChemicalEntity
reversed,957,O
this,957,O
effect,957,O
.,957,O
Daily,958,O
treatment,958,O
of,958,O
cocaine,958,B-ChemicalEntity
increased,958,O
[,958,B-ChemicalEntity
(,958,I-ChemicalEntity
3,958,I-ChemicalEntity
),958,I-ChemicalEntity
H,958,I-ChemicalEntity
],958,I-ChemicalEntity
norepinephrine,958,I-ChemicalEntity
uptake,958,O
into,958,O
the,958,O
hippocampus,958,O
.,958,O
Daily,959,O
administration,959,O
of,959,O
desipramine,959,B-ChemicalEntity
increased,959,O
the,959,O
incidence,959,O
of,959,O
appearance,959,O
of,959,O
lidocaine-induced,959,B-ChemicalEntity
convulsions,959,B-DiseaseOrPhenotypicFeature
and,959,O
decreased,959,O
that,959,O
of,959,O
cocaine-induced,959,B-ChemicalEntity
convulsions,959,B-DiseaseOrPhenotypicFeature
.,959,O
Co-administration,960,O
of,960,O
lidocaine,960,B-ChemicalEntity
with,960,O
desipramine,960,B-ChemicalEntity
reversed,960,O
the,960,O
changes,960,O
of,960,O
convulsive,960,B-DiseaseOrPhenotypicFeature
activity,960,O
of,960,O
lidocaine,960,B-ChemicalEntity
and,960,O
cocaine,960,B-ChemicalEntity
induced,960,O
by,960,O
repeated,960,O
administration,960,O
of,960,O
desipramine,960,B-ChemicalEntity
.,960,O
These,961,O
results,961,O
suggest,961,O
that,961,O
down-regulation,961,O
of,961,O
hippocampal,961,O
NET,961,B-GeneOrGeneProduct
induced,961,O
by,961,O
chronic,961,O
administration,961,O
of,961,O
desipramine,961,B-ChemicalEntity
may,961,O
be,961,O
relevant,961,O
to,961,O
desipramine-induced,961,B-ChemicalEntity
sensitization,961,O
of,961,O
lidocaine,961,B-ChemicalEntity
convulsions,961,B-DiseaseOrPhenotypicFeature
.,961,O
Inhibition,962,O
of,962,O
Na,962,B-ChemicalEntity
(,962,I-ChemicalEntity
+,962,I-ChemicalEntity
),962,I-ChemicalEntity
channels,962,O
by,962,O
local,962,O
anesthetics,962,B-ChemicalEntity
may,962,O
regulate,962,O
desipramine-induced,962,B-ChemicalEntity
down-regulation,962,O
of,962,O
NET,962,B-GeneOrGeneProduct
function,962,O
.,962,O
Repeated,963,O
administration,963,O
of,963,O
cocaine,963,B-ChemicalEntity
induces,963,O
up-regulation,963,O
of,963,O
hippocampal,963,O
NET,963,B-GeneOrGeneProduct
function,963,O
.,963,O
Desipramine-induced,964,B-ChemicalEntity
sensitization,964,O
of,964,O
lidocaine,964,B-ChemicalEntity
seizures,964,B-DiseaseOrPhenotypicFeature
may,964,O
have,964,O
a,964,O
mechanism,964,O
distinct,964,O
from,964,O
kindling,964,O
resulting,964,O
from,964,O
repeated,964,O
administration,964,O
of,964,O
cocaine,964,B-ChemicalEntity
.,964,O
Identification,965,O
of,965,O
the,965,O
nuclear,965,O
localization,965,O
motif,965,O
in,965,O
the,965,O
ETV6,965,B-GeneOrGeneProduct
(,965,O
TEL,965,B-GeneOrGeneProduct
),965,O
protein,965,O
.,965,O
ETV6,966,B-GeneOrGeneProduct
",",966,O
or,966,O
Translocation-Ets-Leukemia,966,B-GeneOrGeneProduct
(,966,O
TEL,966,B-GeneOrGeneProduct
),966,O
",",966,O
is,966,O
an,966,O
ETS,966,O
family,966,O
transcriptional,966,O
repressor,966,O
that,966,O
is,966,O
essential,966,O
for,966,O
establishing,966,O
hematopoiesis,966,O
in,966,O
neonatal,966,O
bone,966,O
marrow,966,O
",",966,O
and,966,O
is,966,O
frequently,966,O
a,966,O
target,966,O
of,966,O
chromosomal,966,O
translocations,966,O
in,966,O
human,966,B-OrganismTaxon
cancer,966,B-DiseaseOrPhenotypicFeature
.,966,O
ETV6,967,B-GeneOrGeneProduct
is,967,O
predominantly,967,O
a,967,O
nuclear,967,O
phosphoprotein,967,O
that,967,O
represses,967,O
transcription,967,O
by,967,O
binding,967,O
directly,967,O
to,967,O
the,967,O
promoters,967,O
of,967,O
target,967,O
genes,967,O
.,967,O
The,968,O
nuclear,968,O
localization,968,O
mechanism,968,O
of,968,O
ETV6,968,B-GeneOrGeneProduct
",",968,O
however,968,O
",",968,O
is,968,O
not,968,O
well,968,O
understood,968,O
.,968,O
In,969,O
this,969,O
report,969,O
",",969,O
we,969,O
provide,969,O
evidence,969,O
that,969,O
a,969,O
nuclear,969,O
localization,969,O
signal,969,O
(,969,O
NLS,969,O
),969,O
exists,969,O
in,969,O
the,969,O
C-terminal,969,O
region,969,O
of,969,O
ETV6,969,B-GeneOrGeneProduct
.,969,O
ETV6,970,B-GeneOrGeneProduct
proteins,970,O
with,970,O
mutations,970,O
outside,970,O
of,970,O
amino,970,O
acids,970,O
332-452,970,O
localize,970,O
to,970,O
the,970,O
nucleus,970,O
",",970,O
whereas,970,O
proteins,970,O
with,970,O
mutations,970,O
within,970,O
amino,970,O
acids,970,O
332-452,970,O
remain,970,O
in,970,O
the,970,O
cytoplasm,970,O
.,970,O
Furthermore,971,O
",",971,O
when,971,O
a,971,O
fragment,971,O
of,971,O
ETV6,971,B-GeneOrGeneProduct
comprised,971,O
of,971,O
amino,971,O
acids,971,O
332-452,971,O
was,971,O
fused,971,O
to,971,O
cytoplasmic,971,O
beta-galactosidase,971,B-GeneOrGeneProduct
protein,971,O
",",971,O
the,971,O
fusion,971,O
protein,971,O
was,971,O
able,971,O
to,971,O
enter,971,O
the,971,O
nucleus,971,O
.,971,O
These,972,O
results,972,O
strongly,972,O
indicate,972,O
that,972,O
residues,972,O
332-452,972,O
mediate,972,O
nuclear,972,O
localization,972,O
of,972,O
ETV6,972,B-GeneOrGeneProduct
.,972,O
Pharmacological,973,O
evidence,973,O
for,973,O
the,973,O
potential,973,O
of,973,O
Daucus,973,B-OrganismTaxon
carota,973,I-OrganismTaxon
in,973,O
the,973,O
management,973,O
of,973,O
cognitive,973,B-DiseaseOrPhenotypicFeature
dysfunctions,973,I-DiseaseOrPhenotypicFeature
.,973,O
The,974,O
present,974,O
study,974,O
was,974,O
aimed,974,O
at,974,O
investigating,974,O
the,974,O
effects,974,O
of,974,O
Daucus,974,B-OrganismTaxon
carota,974,I-OrganismTaxon
seeds,974,O
on,974,O
cognitive,974,O
functions,974,O
",",974,O
total,974,O
serum,974,O
cholesterol,974,B-ChemicalEntity
levels,974,O
and,974,O
brain,974,O
cholinesterase,974,B-GeneOrGeneProduct
activity,974,O
in,974,O
mice,974,B-OrganismTaxon
.,974,O
The,975,O
ethanolic,975,O
extract,975,B-ChemicalEntity
of,975,I-ChemicalEntity
Daucus,975,I-ChemicalEntity
carota,975,I-ChemicalEntity
seeds,975,I-ChemicalEntity
(,975,O
DCE,975,B-ChemicalEntity
),975,O
was,975,O
administered,975,O
orally,975,O
in,975,O
three,975,O
doses,975,O
(,975,O
100,975,O
",",975,O
200,975,O
",",975,O
400,975,O
mg/kg,975,O
),975,O
for,975,O
seven,975,O
successive,975,O
days,975,O
to,975,O
different,975,O
groups,975,O
of,975,O
young,975,O
and,975,O
aged,975,O
mice,975,B-OrganismTaxon
.,975,O
Elevated,976,O
plus,976,O
maze,976,O
and,976,O
passive,976,O
avoidance,976,O
apparatus,976,O
served,976,O
as,976,O
the,976,O
exteroceptive,976,O
behavioral,976,O
models,976,O
for,976,O
testing,976,O
memory,976,O
.,976,O
Diazepam-,977,B-ChemicalEntity
",",977,O
scopolamine-,977,B-ChemicalEntity
and,977,O
ageing-induced,977,O
amnesia,977,B-DiseaseOrPhenotypicFeature
served,977,O
as,977,O
the,977,O
interoceptive,977,O
behavioral,977,O
models,977,O
.,977,O
DCE,978,B-ChemicalEntity
(,978,O
200,978,O
",",978,O
400,978,O
mg/kg,978,O
",",978,O
p.o,978,O
.,978,O
),978,O
showed,979,O
significant,979,O
improvement,979,O
in,979,O
memory,979,O
scores,979,O
of,979,O
young,979,O
and,979,O
aged,979,O
mice,979,B-OrganismTaxon
.,979,O
The,980,O
extent,980,O
of,980,O
memory,980,O
improvement,980,O
evoked,980,O
by,980,O
DCE,980,B-ChemicalEntity
was,980,O
23,980,O
%,980,O
at,980,O
the,980,O
dose,980,O
of,980,O
200,980,O
mg/kg,980,O
and,980,O
35,980,O
%,980,O
at,980,O
the,980,O
dose,980,O
of,980,O
400,980,O
mg/kg,980,O
in,980,O
young,980,O
mice,980,B-OrganismTaxon
using,980,O
elevated,980,O
plus,980,O
maze,980,O
.,980,O
Similarly,981,O
",",981,O
significant,981,O
improvements,981,O
in,981,O
memory,981,O
scores,981,O
were,981,O
observed,981,O
using,981,O
passive,981,O
avoidance,981,O
apparatus,981,O
and,981,O
aged,981,O
mice,981,B-OrganismTaxon
.,981,O
Furthermore,982,O
",",982,O
DCE,982,B-ChemicalEntity
reversed,982,O
the,982,O
amnesia,982,B-DiseaseOrPhenotypicFeature
induced,982,O
by,982,O
scopolamine,982,B-ChemicalEntity
(,982,O
0.4,982,O
mg/kg,982,O
",",982,O
i.p,982,O
.,982,O
),982,O
and,983,O
diazepam,983,B-ChemicalEntity
(,983,O
1,983,O
mg/kg,983,O
",",983,O
i.p,983,O
.,983,O
),983,O
.,983,O
Daucus,984,B-ChemicalEntity
carota,984,I-ChemicalEntity
extract,984,I-ChemicalEntity
(,984,O
200,984,O
",",984,O
400,984,O
mg/kg,984,O
",",984,O
p.o,984,O
.,984,O
),984,O
reduced,985,O
significantly,985,O
the,985,O
brain,985,O
acetylcholinesterase,985,B-GeneOrGeneProduct
activity,985,O
and,985,O
cholesterol,985,B-ChemicalEntity
levels,985,O
in,985,O
young,985,O
and,985,O
aged,985,O
mice,985,B-OrganismTaxon
.,985,O
The,986,O
extent,986,O
of,986,O
inhibition,986,O
of,986,O
brain,986,O
cholinesterase,986,B-GeneOrGeneProduct
activity,986,O
evoked,986,O
by,986,O
DCE,986,B-ChemicalEntity
at,986,O
the,986,O
dose,986,O
of,986,O
400,986,O
mg/kg,986,O
was,986,O
22,986,O
%,986,O
in,986,O
young,986,O
and,986,O
19,986,O
%,986,O
in,986,O
aged,986,O
mice,986,B-OrganismTaxon
.,986,O
There,987,O
was,987,O
a,987,O
remarkable,987,O
reduction,987,O
in,987,O
total,987,O
cholesterol,987,B-ChemicalEntity
level,987,O
as,987,O
well,987,O
",",987,O
to,987,O
the,987,O
extent,987,O
of,987,O
23,987,O
%,987,O
in,987,O
young,987,O
and,987,O
21,987,O
%,987,O
in,987,O
aged,987,O
animals,987,O
with,987,O
this,987,O
dose,987,O
of,987,O
DCE,987,B-ChemicalEntity
.,987,O
Therefore,988,O
",",988,O
DCE,988,B-ChemicalEntity
may,988,O
prove,988,O
to,988,O
be,988,O
a,988,O
useful,988,O
remedy,988,O
for,988,O
the,988,O
management,988,O
of,988,O
cognitive,988,B-DiseaseOrPhenotypicFeature
dysfunctions,988,I-DiseaseOrPhenotypicFeature
on,988,O
account,988,O
of,988,O
its,988,O
multifarious,988,O
beneficial,988,O
effects,988,O
such,988,O
as,988,O
",",988,O
memory,988,O
improving,988,O
property,988,O
",",988,O
cholesterol,988,B-ChemicalEntity
lowering,988,O
property,988,O
and,988,O
anticholinesterase,988,O
activity,988,O
.,988,O
Ectodermal,989,B-DiseaseOrPhenotypicFeature
dysplasia-skin,989,I-DiseaseOrPhenotypicFeature
fragility,989,I-DiseaseOrPhenotypicFeature
syndrome,989,I-DiseaseOrPhenotypicFeature
resulting,989,O
from,989,O
a,989,O
new,989,O
homozygous,989,O
mutation,989,O
",",989,O
888delC,989,B-SequenceVariant
",",989,O
in,989,O
the,989,O
desmosomal,989,O
protein,989,O
plakophilin,989,B-GeneOrGeneProduct
1,989,I-GeneOrGeneProduct
.,989,O
We,990,O
report,990,O
an,990,O
unusual,990,O
case,990,O
of,990,O
an,990,O
inherited,990,B-DiseaseOrPhenotypicFeature
disorder,990,I-DiseaseOrPhenotypicFeature
of,990,O
the,990,O
desmosomal,990,O
protein,990,O
plakophilin,990,B-GeneOrGeneProduct
1,990,I-GeneOrGeneProduct
",",990,O
resulting,990,O
in,990,O
ectodermal,990,B-DiseaseOrPhenotypicFeature
dysplasia-skin,990,I-DiseaseOrPhenotypicFeature
fragility,990,I-DiseaseOrPhenotypicFeature
syndrome,990,I-DiseaseOrPhenotypicFeature
.,990,O
The,991,O
affected,991,O
6-year-old,991,O
boy,991,O
had,991,O
red,991,O
skin,991,O
at,991,O
birth,991,O
and,991,O
subsequently,991,O
developed,991,O
skin,991,B-DiseaseOrPhenotypicFeature
fragility,991,I-DiseaseOrPhenotypicFeature
",",991,O
progressive,991,O
plantar,991,B-DiseaseOrPhenotypicFeature
keratoderma,991,I-DiseaseOrPhenotypicFeature
",",991,O
nail,991,B-DiseaseOrPhenotypicFeature
dystrophy,991,I-DiseaseOrPhenotypicFeature
",",991,O
and,991,O
alopecia,991,B-DiseaseOrPhenotypicFeature
.,991,O
Skin,992,O
biopsy,992,O
revealed,992,O
widening,992,O
of,992,O
intercellular,992,O
spaces,992,O
in,992,O
the,992,O
epidermis,992,O
and,992,O
a,992,O
reduced,992,O
number,992,O
of,992,O
small,992,O
",",992,O
poorly,992,O
formed,992,O
desmosomes,992,O
.,992,O
Mutation,993,O
analysis,993,O
of,993,O
the,993,O
plakophilin,993,B-GeneOrGeneProduct
1,993,I-GeneOrGeneProduct
gene,993,O
PKP1,993,B-GeneOrGeneProduct
revealed,993,O
a,993,O
homozygous,993,O
deletion,993,B-SequenceVariant
of,993,I-SequenceVariant
C,993,I-SequenceVariant
at,993,I-SequenceVariant
nucleotide,993,I-SequenceVariant
888,993,I-SequenceVariant
within,993,O
exon,993,O
5,993,O
.,993,O
This,994,O
mutation,994,O
differs,994,O
from,994,O
the,994,O
PKP1,994,B-GeneOrGeneProduct
gene,994,O
pathology,994,O
reported,994,O
in,994,O
8,994,O
previously,994,O
published,994,O
individuals,994,O
with,994,O
this,994,O
rare,994,O
genodermatosis,994,B-DiseaseOrPhenotypicFeature
.,994,O
However,995,O
",",995,O
all,995,O
cases,995,O
show,995,O
similar,995,O
clinical,995,O
features,995,O
",",995,O
highlighting,995,O
the,995,O
importance,995,O
of,995,O
functional,995,O
plakophilin,995,B-GeneOrGeneProduct
1,995,I-GeneOrGeneProduct
in,995,O
maintaining,995,O
desmosomal,995,O
adhesion,995,O
in,995,O
skin,995,O
",",995,O
as,995,O
well,995,O
as,995,O
the,995,O
role,995,O
of,995,O
this,995,O
protein,995,O
in,995,O
aspects,995,O
of,995,O
ectodermal,995,O
development,995,O
.,995,O
McArdle,996,B-DiseaseOrPhenotypicFeature
disease,996,I-DiseaseOrPhenotypicFeature
:,996,O
the,996,O
mutation,996,O
spectrum,996,O
of,996,O
PYGM,996,B-GeneOrGeneProduct
in,996,O
a,996,O
large,996,O
Italian,996,O
cohort,996,O
.,996,O
Deficiency,997,B-DiseaseOrPhenotypicFeature
of,997,I-DiseaseOrPhenotypicFeature
the,997,I-DiseaseOrPhenotypicFeature
muscle,997,I-DiseaseOrPhenotypicFeature
isozyme,997,I-DiseaseOrPhenotypicFeature
of,997,I-DiseaseOrPhenotypicFeature
glycogen,997,I-DiseaseOrPhenotypicFeature
phosphorylase,997,I-DiseaseOrPhenotypicFeature
is,997,O
causative,997,O
of,997,O
McArdle,997,B-DiseaseOrPhenotypicFeature
disease,997,I-DiseaseOrPhenotypicFeature
or,997,O
Glycogen,997,B-DiseaseOrPhenotypicFeature
storage,997,I-DiseaseOrPhenotypicFeature
disease,997,I-DiseaseOrPhenotypicFeature
type,997,I-DiseaseOrPhenotypicFeature
V,997,I-DiseaseOrPhenotypicFeature
(,997,O
GSD-V,997,B-DiseaseOrPhenotypicFeature
),997,O
",",997,O
the,997,O
most,997,O
common,997,O
autosomal,997,B-DiseaseOrPhenotypicFeature
recessive,997,I-DiseaseOrPhenotypicFeature
disorder,997,I-DiseaseOrPhenotypicFeature
of,997,O
glycogen,997,B-ChemicalEntity
metabolism,997,O
.,997,O
The,998,O
typical,998,O
clinical,998,O
presentation,998,O
is,998,O
characterized,998,O
by,998,O
exercise,998,O
intolerance,998,O
with,998,O
cramps,998,B-DiseaseOrPhenotypicFeature
",",998,O
and,998,O
recurrent,998,O
myoglobinuria,998,B-DiseaseOrPhenotypicFeature
.,998,O
To,999,O
date,999,O
",",999,O
46,999,O
mutations,999,O
in,999,O
the,999,O
PYGM,999,B-GeneOrGeneProduct
gene,999,O
have,999,O
been,999,O
detected,999,O
in,999,O
GSD-V,999,B-DiseaseOrPhenotypicFeature
patients,999,B-OrganismTaxon
.,999,O
We,1000,O
report,1000,O
the,1000,O
mutational,1000,O
spectrum,1000,O
in,1000,O
68,1000,O
Italian,1000,O
patients,1000,B-OrganismTaxon
.,1000,O
We,1001,O
identified,1001,O
30,1001,O
different,1001,O
mutations,1001,O
in,1001,O
the,1001,O
PYGM,1001,B-GeneOrGeneProduct
gene,1001,O
",",1001,O
including,1001,O
19,1001,O
mutations,1001,O
that,1001,O
have,1001,O
not,1001,O
been,1001,O
reported,1001,O
previously,1001,O
.,1001,O
The,1002,O
novel,1002,O
mutations,1002,O
include,1002,O
:,1002,O
eight,1002,O
missense,1002,O
mutations,1002,O
(,1002,O
c.475G,1002,B-SequenceVariant
>,1002,I-SequenceVariant
A,1002,I-SequenceVariant
",",1002,O
p.G159R,1002,B-SequenceVariant
;,1002,O
c.689C,1002,B-SequenceVariant
>,1002,I-SequenceVariant
G,1002,I-SequenceVariant
",",1002,O
p.P230R,1002,B-SequenceVariant
;,1002,O
c.1094C,1002,B-SequenceVariant
>,1002,I-SequenceVariant
T,1002,I-SequenceVariant
",",1002,O
p.A365E,1002,B-SequenceVariant
;,1002,O
c.1151C,1002,B-SequenceVariant
>,1002,I-SequenceVariant
A,1002,I-SequenceVariant
",",1002,O
p.A384D,1002,B-SequenceVariant
;,1002,O
c.1182C,1002,B-SequenceVariant
>,1002,I-SequenceVariant
T,1002,I-SequenceVariant
",",1002,I-SequenceVariant
p.R428C,1002,B-SequenceVariant
;,1002,O
c.1471C,1002,B-SequenceVariant
>,1002,I-SequenceVariant
T,1002,I-SequenceVariant
",",1002,O
p.R491C,1002,B-SequenceVariant
;,1002,O
c.2444A,1002,B-SequenceVariant
>,1002,I-SequenceVariant
C,1002,I-SequenceVariant
",",1002,O
p.D815A,1002,B-SequenceVariant
;,1002,O
c.2477G,1002,B-SequenceVariant
>,1002,I-SequenceVariant
C,1002,I-SequenceVariant
",",1002,O
p.W826S,1002,B-SequenceVariant
),1002,O
",",1002,O
two,1002,O
nonsense,1002,O
mutations,1002,O
(,1002,O
c.1475G,1002,B-SequenceVariant
>,1002,I-SequenceVariant
A,1002,I-SequenceVariant
",",1002,O
p.W492X,1002,B-SequenceVariant
;,1002,O
c.1627A,1002,B-SequenceVariant
>,1002,I-SequenceVariant
T,1002,I-SequenceVariant
",",1002,O
p.K543X,1002,B-SequenceVariant
),1002,O
",",1002,O
five,1002,O
splice,1002,O
site,1002,O
mutations,1002,O
(,1002,O
c.855,1002,B-SequenceVariant
+1G,1002,I-SequenceVariant
>,1002,I-SequenceVariant
C,1002,I-SequenceVariant
;,1002,O
c.1092,1002,B-SequenceVariant
+1G,1002,I-SequenceVariant
>,1002,I-SequenceVariant
A,1002,I-SequenceVariant
;,1002,O
c.,1002,B-SequenceVariant
1093-1G,1002,I-SequenceVariant
>,1002,I-SequenceVariant
T,1002,I-SequenceVariant
;,1002,O
c.1239,1002,B-SequenceVariant
+1G,1002,I-SequenceVariant
>,1002,I-SequenceVariant
A,1002,I-SequenceVariant
;,1002,O
c.2380,1002,B-SequenceVariant
+1G,1002,I-SequenceVariant
>,1002,I-SequenceVariant
A,1002,I-SequenceVariant
),1002,O
",",1002,O
and,1002,O
four,1002,O
deletions,1002,O
(,1002,O
c.715_717delGTC,1002,B-SequenceVariant
",",1002,O
p.V239del,1002,B-SequenceVariant
;,1002,O
c.304delA,1002,B-SequenceVariant
",",1002,O
p.N102DfsX4,1002,B-SequenceVariant
;,1002,O
c.1970_2177del,1002,B-SequenceVariant
",",1002,O
p.V657_G726,1002,B-SequenceVariant
;,1002,O
c.2113_2114delGG,1002,B-SequenceVariant
",",1002,O
p.G705RfsX16,1002,B-SequenceVariant
),1002,O
.,1002,O
Whereas,1003,O
we,1003,O
confirmed,1003,O
lack,1003,O
of,1003,O
direct,1003,O
correlation,1003,O
between,1003,O
the,1003,O
clinical,1003,O
phenotype,1003,O
and,1003,O
the,1003,O
genotype,1003,O
",",1003,O
we,1003,O
also,1003,O
found,1003,O
that,1003,O
the,1003,O
so-called,1003,O
'common,1003,O
mutation,1003,O
',1003,O
(,1003,O
p.R50X,1003,B-SequenceVariant
),1003,O
accounted,1003,O
for,1003,O
about,1003,O
43,1003,O
%,1003,O
of,1003,O
alleles,1003,O
in,1003,O
our,1003,O
cohort,1003,O
and,1003,O
that,1003,O
no,1003,O
population-related,1003,O
mutations,1003,O
are,1003,O
clearly,1003,O
identified,1003,O
in,1003,O
Italian,1003,O
patients,1003,B-OrganismTaxon
.,1003,O
Drug-induced,1004,O
long,1004,B-DiseaseOrPhenotypicFeature
QT,1004,I-DiseaseOrPhenotypicFeature
syndrome,1004,I-DiseaseOrPhenotypicFeature
in,1004,O
injection,1004,O
drug,1004,O
users,1004,O
receiving,1004,O
methadone,1004,B-ChemicalEntity
:,1004,O
high,1004,O
frequency,1004,O
in,1004,O
hospitalized,1004,O
patients,1004,B-OrganismTaxon
and,1004,O
risk,1004,O
factors,1004,O
.,1004,O
BACKGROUND,1005,O
:,1005,O
Drug-induced,1005,O
long,1005,B-DiseaseOrPhenotypicFeature
QT,1005,I-DiseaseOrPhenotypicFeature
syndrome,1005,I-DiseaseOrPhenotypicFeature
is,1005,O
a,1005,O
serious,1005,O
adverse,1005,O
drug,1005,O
reaction,1005,O
.,1005,O
Methadone,1006,B-ChemicalEntity
prolongs,1006,O
the,1006,O
QT,1006,O
interval,1006,O
in,1006,O
vitro,1006,O
in,1006,O
a,1006,O
dose-dependent,1006,O
manner,1006,O
.,1006,O
In,1007,O
the,1007,O
inpatient,1007,B-OrganismTaxon
setting,1007,O
",",1007,O
the,1007,O
frequency,1007,O
of,1007,O
QT,1007,B-DiseaseOrPhenotypicFeature
interval,1007,I-DiseaseOrPhenotypicFeature
prolongation,1007,I-DiseaseOrPhenotypicFeature
with,1007,O
methadone,1007,B-ChemicalEntity
treatment,1007,O
",",1007,O
its,1007,O
dose,1007,O
dependence,1007,O
",",1007,O
and,1007,O
the,1007,O
importance,1007,O
of,1007,O
cofactors,1007,O
such,1007,O
as,1007,O
drug-drug,1007,O
interactions,1007,O
remain,1007,O
unknown,1007,O
.,1007,O
METHODS,1008,O
:,1008,O
We,1008,O
performed,1008,O
a,1008,O
systematic,1008,O
",",1008,O
retrospective,1008,O
study,1008,O
comparing,1008,O
active,1008,O
or,1008,O
former,1008,O
intravenous,1008,O
drug,1008,O
users,1008,O
receiving,1008,O
methadone,1008,B-ChemicalEntity
and,1008,O
those,1008,O
not,1008,O
receiving,1008,O
methadone,1008,B-ChemicalEntity
among,1008,O
all,1008,O
patients,1008,B-OrganismTaxon
hospitalized,1008,O
over,1008,O
a,1008,O
5-year,1008,O
period,1008,O
in,1008,O
a,1008,O
tertiary,1008,O
care,1008,O
hospital,1008,O
.,1008,O
A,1009,O
total,1009,O
of,1009,O
167,1009,O
patients,1009,B-OrganismTaxon
receiving,1009,O
methadone,1009,B-ChemicalEntity
fulfilled,1009,O
the,1009,O
inclusion,1009,O
criteria,1009,O
and,1009,O
were,1009,O
compared,1009,O
with,1009,O
a,1009,O
control,1009,O
group,1009,O
of,1009,O
80,1009,O
injection,1009,O
drug,1009,O
users,1009,O
not,1009,O
receiving,1009,O
methadone,1009,B-ChemicalEntity
.,1009,O
In,1010,O
addition,1010,O
to,1010,O
methadone,1010,B-ChemicalEntity
dose,1010,O
",",1010,O
15,1010,O
demographic,1010,O
",",1010,O
biological,1010,O
",",1010,O
and,1010,O
pharmacological,1010,O
variables,1010,O
were,1010,O
considered,1010,O
as,1010,O
potential,1010,O
risk,1010,O
factors,1010,O
for,1010,O
QT,1010,B-DiseaseOrPhenotypicFeature
prolongation,1010,I-DiseaseOrPhenotypicFeature
.,1010,O
RESULTS,1011,O
:,1011,O
Among,1011,O
167,1011,O
methadone,1011,B-ChemicalEntity
maintenance,1011,O
patients,1011,B-OrganismTaxon
",",1011,O
the,1011,O
prevalence,1011,O
of,1011,O
QTc,1011,B-DiseaseOrPhenotypicFeature
prolongation,1011,I-DiseaseOrPhenotypicFeature
to,1011,O
0.50,1011,O
second,1011,O
(,1011,O
(,1011,O
1/2,1011,O
),1011,O
),1011,O
or,1011,O
longer,1011,O
was,1011,O
16.2,1011,O
%,1011,O
compared,1011,O
with,1011,O
0,1011,O
%,1011,O
in,1011,O
80,1011,O
control,1011,O
subjects,1011,O
.,1011,O
Six,1012,O
patients,1012,B-OrganismTaxon
(,1012,O
3.6,1012,O
%,1012,O
),1012,O
in,1012,O
the,1012,O
methadone,1012,B-ChemicalEntity
group,1012,O
presented,1012,O
torsades,1012,B-DiseaseOrPhenotypicFeature
de,1012,I-DiseaseOrPhenotypicFeature
pointes,1012,I-DiseaseOrPhenotypicFeature
.,1012,O
QTc,1013,O
length,1013,O
was,1013,O
weakly,1013,O
but,1013,O
significantly,1013,O
associated,1013,O
with,1013,O
methadone,1013,B-ChemicalEntity
daily,1013,O
dose,1013,O
(,1013,O
Spearman,1013,O
rank,1013,O
correlation,1013,O
coefficient,1013,O
",",1013,O
0.20,1013,O
;,1013,O
P,1013,O
<,1013,O
.01,1013,O
),1013,O
.,1013,O
Multivariate,1014,O
regression,1014,O
analysis,1014,O
allowed,1014,O
attribution,1014,O
of,1014,O
31.8,1014,O
%,1014,O
of,1014,O
QTc,1014,O
variability,1014,O
to,1014,O
methadone,1014,B-ChemicalEntity
dose,1014,O
",",1014,O
cytochrome,1014,B-GeneOrGeneProduct
P-450,1014,I-GeneOrGeneProduct
3A4,1014,I-GeneOrGeneProduct
drug-drug,1014,O
interactions,1014,O
",",1014,O
hypokalemia,1014,B-DiseaseOrPhenotypicFeature
",",1014,O
and,1014,O
altered,1014,O
liver,1014,O
function,1014,O
.,1014,O
CONCLUSIONS,1015,O
:,1015,O
QT,1015,B-DiseaseOrPhenotypicFeature
interval,1015,I-DiseaseOrPhenotypicFeature
prolongation,1015,I-DiseaseOrPhenotypicFeature
in,1015,O
methadone,1015,B-ChemicalEntity
maintenance,1015,O
patients,1015,B-OrganismTaxon
hospitalized,1015,O
in,1015,O
a,1015,O
tertiary,1015,O
care,1015,O
center,1015,O
is,1015,O
a,1015,O
frequent,1015,O
finding,1015,O
.,1015,O
Methadone,1016,B-ChemicalEntity
dose,1016,O
",",1016,O
presence,1016,O
of,1016,O
cytochrome,1016,B-ChemicalEntity
P-450,1016,I-ChemicalEntity
3A4,1016,I-ChemicalEntity
inhibitors,1016,I-ChemicalEntity
",",1016,O
potassium,1016,B-ChemicalEntity
level,1016,O
",",1016,O
and,1016,O
liver,1016,O
function,1016,O
contribute,1016,O
to,1016,O
QT,1016,B-DiseaseOrPhenotypicFeature
prolongation,1016,I-DiseaseOrPhenotypicFeature
.,1016,O
Long,1017,B-DiseaseOrPhenotypicFeature
QT,1017,I-DiseaseOrPhenotypicFeature
syndrome,1017,I-DiseaseOrPhenotypicFeature
can,1017,O
occur,1017,O
with,1017,O
low,1017,O
doses,1017,O
of,1017,O
methadone,1017,B-ChemicalEntity
.,1017,O
Mechanisms,1018,O
of,1018,O
hypertension,1018,B-DiseaseOrPhenotypicFeature
induced,1018,O
by,1018,O
nitric,1018,B-ChemicalEntity
oxide,1018,I-ChemicalEntity
(,1018,O
NO,1018,B-ChemicalEntity
),1018,O
deficiency,1018,O
:,1018,O
focus,1018,O
on,1018,O
venous,1018,O
function,1018,O
.,1018,O
Loss,1019,O
of,1019,O
endothelial,1019,O
cell-derived,1019,O
nitric,1019,B-ChemicalEntity
oxide,1019,I-ChemicalEntity
(,1019,O
NO,1019,B-ChemicalEntity
),1019,O
in,1019,O
hypertension,1019,B-DiseaseOrPhenotypicFeature
is,1019,O
a,1019,O
hallmark,1019,O
of,1019,O
arterial,1019,B-DiseaseOrPhenotypicFeature
dysfunction,1019,I-DiseaseOrPhenotypicFeature
.,1019,O
Experimental,1020,O
hypertension,1020,B-DiseaseOrPhenotypicFeature
created,1020,O
by,1020,O
the,1020,O
removal,1020,O
of,1020,O
NO,1020,B-ChemicalEntity
",",1020,O
however,1020,O
",",1020,O
involves,1020,O
mechanisms,1020,O
in,1020,O
addition,1020,O
to,1020,O
decreased,1020,O
arterial,1020,O
vasodilator,1020,O
activity,1020,O
.,1020,O
These,1021,O
include,1021,O
augmented,1021,O
endothelin-1,1021,B-GeneOrGeneProduct
(,1021,O
ET-1,1021,B-GeneOrGeneProduct
),1021,O
release,1021,O
",",1021,O
increased,1021,O
sympathetic,1021,O
nervous,1021,O
system,1021,O
activity,1021,O
",",1021,O
and,1021,O
elevated,1021,O
tissue,1021,O
oxidative,1021,O
stress,1021,O
.,1021,O
We,1022,O
hypothesized,1022,O
that,1022,O
increased,1022,O
venous,1022,O
smooth,1022,O
muscle,1022,O
(,1022,O
venomotor,1022,O
),1022,O
tone,1022,O
plays,1022,O
a,1022,O
role,1022,O
in,1022,O
Nomega-nitro-L-arginine,1022,B-ChemicalEntity
(,1022,O
LNNA,1022,B-ChemicalEntity
),1022,O
hypertension,1022,B-DiseaseOrPhenotypicFeature
through,1022,O
these,1022,O
mechanisms,1022,O
.,1022,O
Rats,1023,B-OrganismTaxon
were,1023,O
treated,1023,O
with,1023,O
the,1023,O
NO,1023,B-GeneOrGeneProduct
synthase,1023,I-GeneOrGeneProduct
inhibitor,1023,O
LNNA,1023,B-ChemicalEntity
(,1023,O
0.5,1023,O
g/L,1023,O
in,1023,O
drinking,1023,O
water,1023,O
),1023,O
for,1023,O
2,1023,O
weeks,1023,O
.,1023,O
Mean,1024,O
arterial,1024,O
pressure,1024,O
of,1024,O
conscious,1024,O
rats,1024,B-OrganismTaxon
was,1024,O
119,1024,O
+/-,1024,O
2,1024,O
mm,1024,O
Hg,1024,O
in,1024,O
control,1024,O
and,1024,O
194,1024,O
+/-,1024,O
5,1024,O
mm,1024,O
Hg,1024,O
in,1024,O
LNNA,1024,B-ChemicalEntity
rats,1024,B-OrganismTaxon
(,1024,O
P,1024,O
<,1024,O
0.05,1024,O
),1024,O
.,1024,O
Carotid,1025,O
arteries,1025,O
and,1025,O
vena,1025,O
cava,1025,O
were,1025,O
removed,1025,O
for,1025,O
measurement,1025,O
of,1025,O
isometric,1025,O
contraction,1025,O
.,1025,O
Maximal,1026,O
contraction,1026,O
to,1026,O
norepinephrine,1026,B-ChemicalEntity
was,1026,O
modestly,1026,O
reduced,1026,O
in,1026,O
arteries,1026,O
from,1026,O
LNNA,1026,B-ChemicalEntity
compared,1026,O
with,1026,O
control,1026,O
rats,1026,B-OrganismTaxon
whereas,1026,O
the,1026,O
maximum,1026,O
contraction,1026,O
to,1026,O
ET-1,1026,B-GeneOrGeneProduct
was,1026,O
significantly,1026,O
reduced,1026,O
(,1026,O
54,1026,O
%,1026,O
control,1026,O
),1026,O
.,1026,O
Maximum,1027,O
contraction,1027,O
of,1027,O
vena,1027,O
cava,1027,O
to,1027,O
norepinephrine,1027,B-ChemicalEntity
(,1027,O
37,1027,O
%,1027,O
control,1027,O
),1027,O
also,1027,O
was,1027,O
reduced,1027,O
but,1027,O
no,1027,O
change,1027,O
in,1027,O
response,1027,O
to,1027,O
ET-1,1027,B-GeneOrGeneProduct
was,1027,O
observed,1027,O
.,1027,O
Mean,1028,O
circulatory,1028,O
filling,1028,O
pressure,1028,O
",",1028,O
an,1028,O
in,1028,O
vivo,1028,O
measure,1028,O
of,1028,O
venomotor,1028,O
tone,1028,O
",",1028,O
was,1028,O
not,1028,O
elevated,1028,O
in,1028,O
LNNA,1028,B-ChemicalEntity
hypertension,1028,B-DiseaseOrPhenotypicFeature
at,1028,O
1,1028,O
or,1028,O
2,1028,O
weeks,1028,O
after,1028,O
LNNA,1028,B-ChemicalEntity
.,1028,O
The,1029,O
superoxide,1029,B-ChemicalEntity
scavenger,1029,O
tempol,1029,B-ChemicalEntity
(,1029,O
30,1029,O
",",1029,O
100,1029,O
",",1029,O
and,1029,O
300,1029,O
micromol,1029,O
kg,1029,O
(,1029,O
-1,1029,O
),1029,O
",",1029,O
IV,1029,O
),1029,O
did,1029,O
not,1029,O
change,1029,O
arterial,1029,O
pressure,1029,O
in,1029,O
control,1029,O
rats,1029,B-OrganismTaxon
but,1029,O
caused,1029,O
a,1029,O
dose-dependent,1029,O
decrease,1029,O
in,1029,O
LNNA,1029,B-ChemicalEntity
rats,1029,B-OrganismTaxon
(,1029,O
-18,1029,O
+/-,1029,O
8,1029,O
",",1029,O
-26,1029,O
+/-,1029,O
15,1029,O
",",1029,O
and,1029,O
-54,1029,O
+/-,1029,O
11,1029,O
mm,1029,O
Hg,1029,O
),1029,O
.,1029,O
Similarly,1030,O
",",1030,O
ganglionic,1030,O
blockade,1030,O
with,1030,O
hexamethonium,1030,B-ChemicalEntity
caused,1030,O
a,1030,O
significantly,1030,O
greater,1030,O
fall,1030,O
in,1030,O
LNNA,1030,B-ChemicalEntity
hypertensive,1030,B-DiseaseOrPhenotypicFeature
rats,1030,B-OrganismTaxon
(,1030,O
76,1030,O
+/-,1030,O
9,1030,O
mm,1030,O
Hg,1030,O
),1030,O
compared,1030,O
with,1030,O
control,1030,O
rats,1030,B-OrganismTaxon
(,1030,O
35,1030,O
+/-,1030,O
10,1030,O
mm,1030,O
Hg,1030,O
),1030,O
.,1030,O
Carotid,1031,O
arteries,1031,O
",",1031,O
vena,1031,O
cava,1031,O
",",1031,O
and,1031,O
sympathetic,1031,O
ganglia,1031,O
from,1031,O
LNNA,1031,B-ChemicalEntity
rats,1031,B-OrganismTaxon
had,1031,O
higher,1031,O
basal,1031,O
levels,1031,O
of,1031,O
superoxide,1031,B-ChemicalEntity
compared,1031,O
with,1031,O
those,1031,O
from,1031,O
control,1031,O
rats,1031,B-OrganismTaxon
.,1031,O
These,1032,O
data,1032,O
suggest,1032,O
that,1032,O
while,1032,O
NO,1032,B-ChemicalEntity
deficiency,1032,O
increases,1032,O
oxidative,1032,O
stress,1032,O
and,1032,O
sympathetic,1032,O
activity,1032,O
in,1032,O
both,1032,O
arterial,1032,O
and,1032,O
venous,1032,O
vessels,1032,O
",",1032,O
the,1032,O
impact,1032,O
on,1032,O
veins,1032,O
does,1032,O
not,1032,O
make,1032,O
a,1032,O
major,1032,O
contribution,1032,O
to,1032,O
this,1032,O
form,1032,O
of,1032,O
hypertension,1032,B-DiseaseOrPhenotypicFeature
.,1032,O
Genotyping,1033,O
of,1033,O
five,1033,O
chinese,1033,O
patients,1033,B-OrganismTaxon
with,1033,O
17alpha-hydroxylase,1033,B-DiseaseOrPhenotypicFeature
deficiency,1033,I-DiseaseOrPhenotypicFeature
diagnosed,1033,O
through,1033,O
high-performance,1033,O
liquid,1033,O
chromatography,1033,O
serum,1033,O
adrenal,1033,O
profile,1033,O
:,1033,O
identification,1033,O
of,1033,O
two,1033,O
novel,1033,O
CYP17,1033,B-GeneOrGeneProduct
mutations,1033,O
.,1033,O
CONTEXT,1034,O
:,1034,O
17alpha-Hydroxylase,1034,B-DiseaseOrPhenotypicFeature
deficiency,1034,I-DiseaseOrPhenotypicFeature
is,1034,O
a,1034,O
rare,1034,O
form,1034,O
of,1034,O
congenital,1034,B-DiseaseOrPhenotypicFeature
adrenal,1034,I-DiseaseOrPhenotypicFeature
hyperplasia,1034,I-DiseaseOrPhenotypicFeature
caused,1034,O
by,1034,O
CYP17,1034,B-GeneOrGeneProduct
gene,1034,O
mutations,1034,O
.,1034,O
OBJECTIVE,1035,O
:,1035,O
Five,1035,O
Chinese,1035,O
patients,1035,B-OrganismTaxon
with,1035,O
17alpha-hydroxylase,1035,B-DiseaseOrPhenotypicFeature
deficiency,1035,I-DiseaseOrPhenotypicFeature
were,1035,O
genotyped,1035,O
.,1035,O
PATIENTS,1036,B-OrganismTaxon
:,1036,O
The,1036,O
five,1036,O
patients,1036,B-OrganismTaxon
derived,1036,O
from,1036,O
four,1036,O
families,1036,O
living,1036,O
in,1036,O
Shandong,1036,O
Province,1036,O
",",1036,O
China,1036,O
.,1036,O
The,1037,O
diagnosis,1037,O
of,1037,O
17alpha-hydroxylase,1037,B-DiseaseOrPhenotypicFeature
deficiency,1037,I-DiseaseOrPhenotypicFeature
was,1037,O
initially,1037,O
established,1037,O
through,1037,O
HPLC,1037,O
serum,1037,O
adrenal,1037,O
profiles,1037,O
in,1037,O
Qilu,1037,O
Hospital,1037,O
",",1037,O
China,1037,O
",",1037,O
from,1037,O
1983-1993,1037,O
.,1037,O
RESULTS,1038,O
:,1038,O
Three,1038,O
CYP17,1038,B-GeneOrGeneProduct
gene,1038,O
mutations,1038,O
were,1038,O
identified,1038,O
from,1038,O
these,1038,O
patients,1038,B-OrganismTaxon
.,1038,O
Among,1039,O
them,1039,O
",",1039,O
V311fs,1039,B-SequenceVariant
and,1039,O
Y329fs,1039,B-SequenceVariant
are,1039,O
two,1039,O
novel,1039,O
frame-shifting,1039,O
mutations,1039,O
.,1039,O
V311fs,1040,B-SequenceVariant
is,1040,O
an,1040,O
8-bp,1040,B-SequenceVariant
nucleotide,1040,I-SequenceVariant
(,1040,I-SequenceVariant
TTAAATGG,1040,I-SequenceVariant
),1040,I-SequenceVariant
deletion,1040,I-SequenceVariant
in,1040,O
exon,1040,O
5,1040,O
.,1040,O
Y329fs,1041,B-SequenceVariant
is,1041,O
a,1041,O
deletion-insertion,1041,O
combined,1041,O
mutation,1041,O
(,1041,B-SequenceVariant
TAC,1041,I-SequenceVariant
--,1041,I-SequenceVariant
>,1041,I-SequenceVariant
AA,1041,I-SequenceVariant
),1041,I-SequenceVariant
at,1041,I-SequenceVariant
codon,1041,I-SequenceVariant
329,1041,I-SequenceVariant
in,1041,O
exon,1041,O
6,1041,O
.,1041,O
Two,1042,O
homozygotes,1042,O
for,1042,O
Y329fs,1042,B-SequenceVariant
and,1042,O
one,1042,O
compound,1042,O
heterozygote,1042,O
for,1042,O
Y329fs,1042,B-SequenceVariant
and,1042,O
V311fs,1042,B-SequenceVariant
were,1042,O
identified,1042,O
from,1042,O
three,1042,O
different,1042,O
families,1042,O
.,1042,O
Two,1043,O
homozygous,1043,O
sisters,1043,O
for,1043,O
the,1043,O
D487_S488_F489,1043,B-SequenceVariant
deletion,1043,I-SequenceVariant
were,1043,O
identified,1043,O
.,1043,O
CONCLUSION,1044,O
:,1044,O
The,1044,O
results,1044,O
confirmed,1044,O
the,1044,O
diagnostic,1044,O
value,1044,O
of,1044,O
the,1044,O
HPLC,1044,O
serum,1044,O
adrenal,1044,O
profile,1044,O
for,1044,O
17alpha-hydroxylase,1044,B-DiseaseOrPhenotypicFeature
deficiency,1044,I-DiseaseOrPhenotypicFeature
.,1044,O
The,1045,O
D487_S488_F489,1045,B-SequenceVariant
deletion,1045,I-SequenceVariant
had,1045,O
been,1045,O
identified,1045,O
in,1045,O
two,1045,O
previously,1045,O
genotyped,1045,O
Chinese,1045,O
families,1045,O
.,1045,O
In,1046,O
our,1046,O
present,1046,O
study,1046,O
",",1046,O
a,1046,O
third,1046,O
Chinese,1046,O
family,1046,O
with,1046,O
this,1046,O
mutation,1046,O
was,1046,O
identified,1046,O
",",1046,O
suggesting,1046,O
that,1046,O
this,1046,O
mutation,1046,O
is,1046,O
a,1046,O
prevalent,1046,O
CYP17,1046,B-GeneOrGeneProduct
mutation,1046,O
in,1046,O
the,1046,O
Chinese,1046,O
population,1046,O
.,1046,O
The,1047,O
identification,1047,O
of,1047,O
Y329fs,1047,B-SequenceVariant
mutation,1047,O
in,1047,O
addition,1047,O
to,1047,O
three,1047,O
previously,1047,O
identified,1047,O
mutations,1047,O
at,1047,O
codon,1047,O
329,1047,O
suggests,1047,O
that,1047,O
codon,1047,O
329,1047,O
is,1047,O
an,1047,O
unstable,1047,O
point,1047,O
of,1047,O
the,1047,O
CYP17,1047,B-GeneOrGeneProduct
gene,1047,O
.,1047,O
The,1048,O
mutations,1048,O
identified,1048,O
from,1048,O
our,1048,O
five,1048,O
patients,1048,B-OrganismTaxon
appear,1048,O
to,1048,O
be,1048,O
random,1048,O
",",1048,O
but,1048,O
the,1048,O
recurrence,1048,O
of,1048,O
the,1048,O
Y329fs,1048,B-SequenceVariant
mutation,1048,O
may,1048,O
be,1048,O
attributed,1048,O
to,1048,O
a,1048,O
founder,1048,O
effect,1048,O
.,1048,O
Our,1049,O
studies,1049,O
suggest,1049,O
that,1049,O
17alpha-hydroxylase,1049,B-DiseaseOrPhenotypicFeature
deficiency,1049,I-DiseaseOrPhenotypicFeature
may,1049,O
not,1049,O
be,1049,O
rare,1049,O
in,1049,O
the,1049,O
Chinese,1049,O
population,1049,O
.,1049,O
DNA,1050,O
damage,1050,O
and,1050,O
repair,1050,O
in,1050,O
gastric,1050,B-DiseaseOrPhenotypicFeature
cancer,1050,I-DiseaseOrPhenotypicFeature
--,1050,O
a,1050,O
correlation,1050,O
with,1050,O
the,1050,O
hOGG1,1050,B-GeneOrGeneProduct
and,1050,O
RAD51,1050,B-GeneOrGeneProduct
genes,1050,O
polymorphisms,1050,O
.,1050,O
The,1051,O
cell,1051,O
's,1051,O
susceptibility,1051,O
to,1051,O
mutagens,1051,O
and,1051,O
its,1051,O
ability,1051,O
to,1051,O
repair,1051,O
DNA,1051,O
lesions,1051,O
are,1051,O
important,1051,O
for,1051,O
cancer,1051,B-DiseaseOrPhenotypicFeature
induction,1051,O
",",1051,O
promotion,1051,O
and,1051,O
progression,1051,O
.,1051,O
Both,1052,O
the,1052,O
mutagens,1052,O
',1052,O
sensitivity,1052,O
and,1052,O
the,1052,O
efficacy,1052,O
of,1052,O
DNA,1052,O
repair,1052,O
may,1052,O
be,1052,O
affected,1052,O
by,1052,O
variation,1052,O
in,1052,O
several,1052,O
genes,1052,O
",",1052,O
including,1052,O
DNA,1052,O
repair,1052,O
genes,1052,O
.,1052,O
The,1053,O
hOGG1,1053,B-GeneOrGeneProduct
gene,1053,O
encodes,1053,O
glycosylase,1053,O
of,1053,O
base,1053,O
excision,1053,O
repair,1053,O
and,1053,O
RAD51,1053,B-GeneOrGeneProduct
specifies,1053,O
a,1053,O
key,1053,O
protein,1053,O
in,1053,O
homologues,1053,O
recombination,1053,O
repair,1053,O
.,1053,O
Both,1054,O
can,1054,O
be,1054,O
involved,1054,O
in,1054,O
the,1054,O
repair,1054,O
of,1054,O
oxidative,1054,O
DNA,1054,O
lesions,1054,O
",",1054,O
which,1054,O
can,1054,O
contribute,1054,O
to,1054,O
stomach,1054,B-DiseaseOrPhenotypicFeature
cancer,1054,I-DiseaseOrPhenotypicFeature
.,1054,O
In,1055,O
the,1055,O
present,1055,O
work,1055,O
we,1055,O
determined,1055,O
the,1055,O
level,1055,O
of,1055,O
basal,1055,O
and,1055,O
oxidative,1055,O
DNA,1055,O
damage,1055,O
and,1055,O
the,1055,O
kinetics,1055,O
of,1055,O
removal,1055,O
of,1055,O
DNA,1055,O
damage,1055,O
induced,1055,O
by,1055,O
hydrogen,1055,B-ChemicalEntity
peroxide,1055,I-ChemicalEntity
in,1055,O
peripheral,1055,O
blood,1055,O
lymphocytes,1055,O
of,1055,O
30,1055,O
gastric,1055,B-DiseaseOrPhenotypicFeature
cancer,1055,I-DiseaseOrPhenotypicFeature
patients,1055,B-OrganismTaxon
and,1055,O
30,1055,O
healthy,1055,O
individuals,1055,O
.,1055,O
The,1056,O
metrics,1056,O
from,1056,O
DNA,1056,O
damage,1056,O
and,1056,O
repair,1056,O
study,1056,O
were,1056,O
correlated,1056,O
with,1056,O
the,1056,O
genotypes,1056,O
of,1056,O
common,1056,O
polymorphisms,1056,O
of,1056,O
the,1056,O
hOGG1,1056,B-GeneOrGeneProduct
and,1056,O
RAD51,1056,B-GeneOrGeneProduct
genes,1056,O
:,1056,O
a,1056,O
G,1056,B-SequenceVariant
--,1056,I-SequenceVariant
>,1056,I-SequenceVariant
C,1056,I-SequenceVariant
transversion,1056,I-SequenceVariant
at,1056,I-SequenceVariant
1245,1056,I-SequenceVariant
position,1056,I-SequenceVariant
of,1056,O
the,1056,O
hOGG1,1056,B-GeneOrGeneProduct
gene,1056,O
producing,1056,O
a,1056,O
Ser,1056,B-SequenceVariant
--,1056,I-SequenceVariant
>,1056,I-SequenceVariant
Cys,1056,I-SequenceVariant
substitution,1056,I-SequenceVariant
at,1056,I-SequenceVariant
the,1056,I-SequenceVariant
codon,1056,I-SequenceVariant
326,1056,I-SequenceVariant
(,1056,O
the,1056,O
Ser326Cys,1056,B-SequenceVariant
polymorphism,1056,O
),1056,O
and,1056,O
a,1056,O
G,1056,B-SequenceVariant
--,1056,I-SequenceVariant
>,1056,I-SequenceVariant
C,1056,I-SequenceVariant
substitution,1056,I-SequenceVariant
at,1056,I-SequenceVariant
position,1056,I-SequenceVariant
135,1056,I-SequenceVariant
(,1056,O
5'-untranslated,1056,O
region,1056,O
),1056,O
of,1056,O
the,1056,O
RAD51,1056,B-GeneOrGeneProduct
gene,1056,O
(,1056,O
the,1056,O
G135C,1056,B-SequenceVariant
polymorphism,1056,O
),1056,O
.,1056,O
DNA,1057,O
damage,1057,O
and,1057,O
repair,1057,O
were,1057,O
evaluated,1057,O
by,1057,O
alkaline,1057,O
single,1057,O
cell,1057,O
gel,1057,O
electrophoresis,1057,O
(,1057,O
comet,1057,O
assay,1057,O
),1057,O
assisted,1057,O
by,1057,O
DNA,1057,O
repair,1057,O
enzymes,1057,O
:,1057,O
endonuclease,1057,B-GeneOrGeneProduct
III,1057,I-GeneOrGeneProduct
(,1057,O
Nth,1057,B-GeneOrGeneProduct
),1057,O
and,1057,O
formamidopyrimidine-DNA,1057,B-GeneOrGeneProduct
glycosylase,1057,I-GeneOrGeneProduct
(,1057,O
Fpg,1057,B-GeneOrGeneProduct
),1057,O
",",1057,O
preferentially,1057,O
recognizing,1057,O
oxidized,1057,O
DNA,1057,O
bases,1057,O
.,1057,O
The,1058,O
genotypes,1058,O
of,1058,O
the,1058,O
polymorphism,1058,O
were,1058,O
determined,1058,O
by,1058,O
restriction,1058,O
fragment,1058,O
length,1058,O
polymorphism,1058,O
PCR,1058,O
.,1058,O
We,1059,O
observed,1059,O
a,1059,O
strong,1059,O
association,1059,O
between,1059,O
gastric,1059,B-DiseaseOrPhenotypicFeature
cancer,1059,I-DiseaseOrPhenotypicFeature
occurrence,1059,O
",",1059,O
impaired,1059,O
DNA,1059,O
repair,1059,O
in,1059,O
human,1059,B-OrganismTaxon
lymphocytes,1059,O
and,1059,O
the,1059,O
G/C,1059,B-SequenceVariant
genotype,1059,O
of,1059,O
the,1059,O
G135C,1059,B-SequenceVariant
polymorphism,1059,O
of,1059,O
the,1059,O
RAD51,1059,B-GeneOrGeneProduct
gene,1059,O
.,1059,O
Moreover,1060,O
",",1060,O
there,1060,O
was,1060,O
a,1060,O
strong,1060,O
correlation,1060,O
between,1060,O
that,1060,O
genotype,1060,O
and,1060,O
stomach,1060,B-DiseaseOrPhenotypicFeature
cancer,1060,I-DiseaseOrPhenotypicFeature
occurrence,1060,O
in,1060,O
subjects,1060,O
with,1060,O
high,1060,O
level,1060,O
of,1060,O
oxidatively,1060,O
damaged,1060,O
DNA,1060,O
.,1060,O
We,1061,O
did,1061,O
not,1061,O
observe,1061,O
any,1061,O
correlation,1061,O
between,1061,O
the,1061,O
Ser1245Cys,1061,B-SequenceVariant
polymorphism,1061,O
of,1061,O
the,1061,O
hOGG1,1061,B-GeneOrGeneProduct
gene,1061,O
and,1061,O
gastric,1061,B-DiseaseOrPhenotypicFeature
cancer,1061,I-DiseaseOrPhenotypicFeature
",",1061,O
including,1061,O
subjects,1061,O
with,1061,O
impaired,1061,O
DNA,1061,O
repair,1061,O
and/or,1061,O
high,1061,O
levels,1061,O
of,1061,O
endogenous,1061,O
oxidative,1061,O
DNA,1061,O
lesions,1061,O
.,1061,O
Therefore,1062,O
",",1062,O
our,1062,O
result,1062,O
suggest,1062,O
that,1062,O
the,1062,O
G135C,1062,B-SequenceVariant
polymorphism,1062,O
of,1062,O
the,1062,O
RAD51,1062,B-GeneOrGeneProduct
gene,1062,O
may,1062,O
be,1062,O
linked,1062,O
with,1062,O
gastric,1062,B-DiseaseOrPhenotypicFeature
cancer,1062,I-DiseaseOrPhenotypicFeature
by,1062,O
the,1062,O
modulation,1062,O
of,1062,O
the,1062,O
cellular,1062,O
response,1062,O
to,1062,O
oxidative,1062,O
stress,1062,O
and,1062,O
this,1062,O
polymorphism,1062,O
may,1062,O
be,1062,O
a,1062,O
useful,1062,O
additional,1062,O
marker,1062,O
in,1062,O
this,1062,O
disease,1062,O
along,1062,O
with,1062,O
the,1062,O
genetic,1062,O
or/and,1062,O
environmental,1062,O
indicators,1062,O
of,1062,O
oxidative,1062,O
stress,1062,O
.,1062,O
Cauda,1063,B-DiseaseOrPhenotypicFeature
equina,1063,I-DiseaseOrPhenotypicFeature
syndrome,1063,I-DiseaseOrPhenotypicFeature
after,1063,O
epidural,1063,O
steroid,1063,B-ChemicalEntity
injection,1063,O
:,1063,O
a,1063,O
case,1063,O
report,1063,O
.,1063,O
OBJECTIVE,1064,O
:,1064,O
Conventional,1064,O
treatment,1064,O
methods,1064,O
of,1064,O
lumbusacral,1064,O
radiculopathy,1064,B-DiseaseOrPhenotypicFeature
are,1064,O
physical,1064,O
therapy,1064,O
",",1064,O
epidural,1064,O
steroid,1064,B-ChemicalEntity
injections,1064,O
",",1064,O
oral,1064,O
medications,1064,O
",",1064,O
and,1064,O
spinal,1064,O
manipulative,1064,O
therapy,1064,O
.,1064,O
Cauda,1065,B-DiseaseOrPhenotypicFeature
equina,1065,I-DiseaseOrPhenotypicFeature
syndrome,1065,I-DiseaseOrPhenotypicFeature
is,1065,O
a,1065,O
rare,1065,O
complication,1065,O
of,1065,O
epidural,1065,O
anesthesia,1065,O
.,1065,O
The,1066,O
following,1066,O
case,1066,O
is,1066,O
a,1066,O
report,1066,O
of,1066,O
cauda,1066,B-DiseaseOrPhenotypicFeature
equina,1066,I-DiseaseOrPhenotypicFeature
syndrome,1066,I-DiseaseOrPhenotypicFeature
possibly,1066,O
caused,1066,O
by,1066,O
epidural,1066,O
injection,1066,O
of,1066,O
triamcinolone,1066,B-ChemicalEntity
and,1066,O
bupivacaine,1066,B-ChemicalEntity
.,1066,O
CLINICAL,1067,O
FEATURES,1067,O
:,1067,O
A,1067,O
50-year-old,1067,O
woman,1067,B-OrganismTaxon
with,1067,O
low,1067,B-DiseaseOrPhenotypicFeature
back,1067,I-DiseaseOrPhenotypicFeature
and,1067,I-DiseaseOrPhenotypicFeature
right,1067,I-DiseaseOrPhenotypicFeature
leg,1067,I-DiseaseOrPhenotypicFeature
pain,1067,I-DiseaseOrPhenotypicFeature
was,1067,O
scheduled,1067,O
for,1067,O
epidural,1067,O
steroid,1067,B-ChemicalEntity
injection,1067,O
.,1067,O
INTERVENTION,1068,O
AND,1068,O
OUTCOME,1068,O
:,1068,O
An,1068,O
18-gauge,1068,O
Touhy,1068,O
needle,1068,O
was,1068,O
inserted,1068,O
until,1068,O
loss,1068,O
of,1068,O
resistance,1068,O
occurred,1068,O
at,1068,O
the,1068,O
L4-5,1068,O
level,1068,O
.,1068,O
Spread,1069,O
of,1069,O
the,1069,O
contrast,1069,O
medium,1069,O
within,1069,O
the,1069,O
epidural,1069,O
space,1069,O
was,1069,O
determined,1069,O
by,1069,O
radiographic,1069,O
imaging,1069,O
.,1069,O
After,1070,O
verifying,1070,O
the,1070,O
epidural,1070,O
space,1070,O
",",1070,O
bupivacaine,1070,B-ChemicalEntity
and,1070,O
triamcinolone,1070,B-ChemicalEntity
diacetate,1070,I-ChemicalEntity
were,1070,O
injected,1070,O
.,1070,O
After,1071,O
the,1071,O
injection,1071,O
",",1071,O
there,1071,O
was,1071,O
a,1071,O
reduction,1071,O
in,1071,O
radicular,1071,O
symptoms,1071,O
.,1071,O
Three,1072,O
hours,1072,O
later,1072,O
",",1072,O
she,1072,O
complained,1072,O
of,1072,O
perineal,1072,O
numbness,1072,B-DiseaseOrPhenotypicFeature
and,1072,O
lower,1072,B-DiseaseOrPhenotypicFeature
extremity,1072,I-DiseaseOrPhenotypicFeature
weakness,1072,I-DiseaseOrPhenotypicFeature
.,1072,O
The,1073,O
neurologic,1073,O
evaluation,1073,O
revealed,1073,O
loss,1073,B-DiseaseOrPhenotypicFeature
of,1073,I-DiseaseOrPhenotypicFeature
sensation,1073,I-DiseaseOrPhenotypicFeature
in,1073,O
the,1073,O
saddle,1073,O
area,1073,O
and,1073,O
medial,1073,O
aspect,1073,O
of,1073,O
her,1073,O
right,1073,O
leg,1073,O
.,1073,O
There,1074,O
was,1074,O
a,1074,O
decrease,1074,O
in,1074,O
the,1074,O
perception,1074,O
of,1074,O
pinprick,1074,O
test,1074,O
.,1074,O
Deep-tendon,1075,O
reflexes,1075,O
were,1075,O
decreased,1075,O
especially,1075,O
in,1075,O
the,1075,O
right,1075,O
leg,1075,O
.,1075,O
She,1076,O
was,1076,O
unable,1076,O
to,1076,O
urinate,1076,O
.,1076,O
The,1077,O
patient,1077,B-OrganismTaxon
's,1077,O
symptoms,1077,O
improved,1077,O
slightly,1077,O
over,1077,O
the,1077,O
next,1077,O
few,1077,O
hours,1077,O
.,1077,O
She,1078,O
had,1078,O
a,1078,O
gradual,1078,O
return,1078,O
of,1078,O
motor,1078,O
function,1078,O
and,1078,O
ability,1078,O
of,1078,O
feeling,1078,O
Foley,1078,O
catheter,1078,O
.,1078,O
All,1079,O
of,1079,O
the,1079,O
symptoms,1079,O
were,1079,O
completely,1079,O
resolved,1079,O
over,1079,O
the,1079,O
next,1079,O
8,1079,O
hours,1079,O
.,1079,O
CONCLUSION,1080,O
:,1080,O
Complications,1080,O
associated,1080,O
with,1080,O
epidural,1080,O
steroid,1080,B-ChemicalEntity
injections,1080,O
are,1080,O
rare,1080,O
.,1080,O
Clinical,1081,O
examination,1081,O
and,1081,O
continued,1081,O
vigilance,1081,O
for,1081,O
neurologic,1081,B-DiseaseOrPhenotypicFeature
deterioration,1081,I-DiseaseOrPhenotypicFeature
after,1081,O
epidural,1081,O
steroid,1081,B-ChemicalEntity
injections,1081,O
is,1081,O
important,1081,O
.,1081,O
Anticonvulsant,1082,O
effect,1082,O
of,1082,O
eslicarbazepine,1082,B-ChemicalEntity
acetate,1082,I-ChemicalEntity
(,1082,O
BIA,1082,B-ChemicalEntity
2-093,1082,I-ChemicalEntity
),1082,O
on,1082,O
seizures,1082,B-DiseaseOrPhenotypicFeature
induced,1082,O
by,1082,O
microperfusion,1082,O
of,1082,O
picrotoxin,1082,B-ChemicalEntity
in,1082,O
the,1082,O
hippocampus,1082,O
of,1082,O
freely,1082,O
moving,1082,O
rats,1082,B-OrganismTaxon
.,1082,O
Eslicarbazepine,1083,B-ChemicalEntity
acetate,1083,I-ChemicalEntity
(,1083,O
BIA,1083,B-ChemicalEntity
2-093,1083,I-ChemicalEntity
",",1083,O
S-,1083,B-ChemicalEntity
(,1083,I-ChemicalEntity
-,1083,I-ChemicalEntity
),1083,I-ChemicalEntity
"-10-acetoxy-10,11-dihydro-5H-dibenzo/b",1083,I-ChemicalEntity
",",1083,I-ChemicalEntity
f/azepine-5-carboxamide,1083,I-ChemicalEntity
),1083,O
is,1083,O
a,1083,O
novel,1083,O
antiepileptic,1083,B-ChemicalEntity
drug,1083,I-ChemicalEntity
",",1083,O
now,1083,O
in,1083,O
Phase,1083,O
III,1083,O
clinical,1083,O
trials,1083,O
",",1083,O
designed,1083,O
with,1083,O
the,1083,O
aim,1083,O
of,1083,O
improving,1083,O
efficacy,1083,O
and,1083,O
safety,1083,O
in,1083,O
comparison,1083,O
with,1083,O
the,1083,O
structurally,1083,O
related,1083,O
drugs,1083,O
carbamazepine,1083,B-ChemicalEntity
(,1083,O
CBZ,1083,B-ChemicalEntity
),1083,O
and,1083,O
oxcarbazepine,1083,B-ChemicalEntity
(,1083,O
OXC,1083,B-ChemicalEntity
),1083,O
.,1083,O
We,1084,O
have,1084,O
studied,1084,O
the,1084,O
effects,1084,O
of,1084,O
oral,1084,O
treatment,1084,O
with,1084,O
eslicarbazepine,1084,B-ChemicalEntity
acetate,1084,I-ChemicalEntity
on,1084,O
a,1084,O
whole-animal,1084,O
model,1084,O
in,1084,O
which,1084,O
partial,1084,O
seizures,1084,B-DiseaseOrPhenotypicFeature
can,1084,O
be,1084,O
elicited,1084,O
repeatedly,1084,O
on,1084,O
different,1084,O
days,1084,O
without,1084,O
changes,1084,O
in,1084,O
threshold,1084,O
or,1084,O
seizure,1084,B-DiseaseOrPhenotypicFeature
patterns,1084,O
.,1084,O
In,1085,O
the,1085,O
animals,1085,O
treated,1085,O
with,1085,O
threshold,1085,O
doses,1085,O
of,1085,O
picrotoxin,1085,B-ChemicalEntity
",",1085,O
the,1085,O
average,1085,O
number,1085,O
of,1085,O
seizures,1085,B-DiseaseOrPhenotypicFeature
was,1085,O
2.3+/-1.2,1085,O
",",1085,O
and,1085,O
average,1085,O
seizure,1085,B-DiseaseOrPhenotypicFeature
duration,1085,O
was,1085,O
39.5+/-8.4s,1085,O
.,1085,O
Pre-treatment,1086,O
with,1086,O
a,1086,O
dose,1086,O
of,1086,O
30,1086,O
mg/kg,1086,O
2h,1086,O
before,1086,O
picrotoxin,1086,B-ChemicalEntity
microperfusion,1086,O
prevented,1086,O
seizures,1086,B-DiseaseOrPhenotypicFeature
in,1086,O
the,1086,O
75,1086,O
%,1086,O
of,1086,O
the,1086,O
rats,1086,B-OrganismTaxon
.,1086,O
Lower,1087,O
doses,1087,O
(,1087,O
3,1087,O
and,1087,O
10mg/kg,1087,O
),1087,O
did,1087,O
not,1087,O
suppress,1087,O
seizures,1087,B-DiseaseOrPhenotypicFeature
",",1087,O
however,1087,O
",",1087,O
after,1087,O
administration,1087,O
of,1087,O
10mg/kg,1087,O
",",1087,O
significant,1087,O
reductions,1087,O
in,1087,O
seizures,1087,B-DiseaseOrPhenotypicFeature
duration,1087,O
(,1087,O
24.3+/-6.8s,1087,O
),1087,O
and,1087,O
seizure,1087,B-DiseaseOrPhenotypicFeature
number,1087,O
(,1087,O
1.6+/-0.34,1087,O
),1087,O
were,1087,O
found,1087,O
.,1087,O
No,1088,O
adverse,1088,O
effects,1088,O
of,1088,O
eslicarbazepine,1088,B-ChemicalEntity
acetate,1088,I-ChemicalEntity
were,1088,O
observed,1088,O
in,1088,O
the,1088,O
behavioral/EEG,1088,O
patterns,1088,O
studied,1088,O
",",1088,O
including,1088,O
sleep/wakefulness,1088,O
cycle,1088,O
",",1088,O
at,1088,O
the,1088,O
doses,1088,O
studied,1088,O
.,1088,O
No,1089,O
independent,1089,O
role,1089,O
of,1089,O
the,1089,O
-1123,1089,B-SequenceVariant
G,1089,I-SequenceVariant
>,1089,I-SequenceVariant
C,1089,I-SequenceVariant
and+2740,1089,O
A,1089,I-SequenceVariant
>,1089,I-SequenceVariant
G,1089,I-SequenceVariant
variants,1089,O
in,1089,O
the,1089,O
association,1089,O
of,1089,O
PTPN22,1089,B-GeneOrGeneProduct
with,1089,O
type,1089,B-DiseaseOrPhenotypicFeature
1,1089,I-DiseaseOrPhenotypicFeature
diabetes,1089,I-DiseaseOrPhenotypicFeature
and,1089,O
juvenile,1089,B-DiseaseOrPhenotypicFeature
idiopathic,1089,I-DiseaseOrPhenotypicFeature
arthritis,1089,I-DiseaseOrPhenotypicFeature
in,1089,O
two,1089,O
Caucasian,1089,O
populations,1089,O
.,1089,O
INTRODUCTION,1090,O
:,1090,O
The,1090,O
PTPN22,1090,B-GeneOrGeneProduct
is,1090,O
a,1090,O
negative,1090,O
regulator,1090,O
of,1090,O
the,1090,O
T,1090,O
cell,1090,O
response,1090,O
.,1090,O
Its,1091,O
+1858C,1091,B-SequenceVariant
>,1091,I-SequenceVariant
T,1091,I-SequenceVariant
(,1091,O
R620W,1091,B-SequenceVariant
),1091,O
polymorphism,1091,O
has,1091,O
been,1091,O
shown,1091,O
to,1091,O
associate,1091,O
with,1091,O
a,1091,O
risk,1091,O
for,1091,O
multiple,1091,O
autoimmune,1091,B-DiseaseOrPhenotypicFeature
diseases,1091,I-DiseaseOrPhenotypicFeature
",",1091,O
including,1091,O
type,1091,B-DiseaseOrPhenotypicFeature
1,1091,I-DiseaseOrPhenotypicFeature
diabetes,1091,I-DiseaseOrPhenotypicFeature
(,1091,O
T1D,1091,B-DiseaseOrPhenotypicFeature
),1091,O
and,1091,O
juvenile,1091,B-DiseaseOrPhenotypicFeature
idiopathic,1091,I-DiseaseOrPhenotypicFeature
arthritis,1091,I-DiseaseOrPhenotypicFeature
(,1091,O
JIA,1091,B-DiseaseOrPhenotypicFeature
),1091,O
.,1091,O
The,1092,O
minor,1092,O
(,1092,O
susceptibility,1092,O
),1092,O
allele,1092,O
is,1092,O
absent,1092,O
in,1092,O
Asian,1092,O
populations,1092,O
",",1092,O
but,1092,O
a,1092,O
recent,1092,O
study,1092,O
suggested,1092,O
an,1092,O
independent,1092,O
involvement,1092,O
of,1092,O
another,1092,O
polymorphism,1092,O
located,1092,O
within,1092,O
the,1092,O
promoter,1092,O
-1123,1092,O
nucleotides,1092,O
relative,1092,O
to,1092,O
the,1092,O
translational,1092,O
start,1092,O
site,1092,O
.,1092,O
AIMS,1093,O
:,1093,O
We,1093,O
aimed,1093,O
to,1093,O
analyse,1093,O
the,1093,O
association,1093,O
of,1093,O
three,1093,O
PTPN22,1093,B-GeneOrGeneProduct
polymorphisms,1093,O
in,1093,O
two,1093,O
distinct,1093,O
Caucasian,1093,O
populations,1093,O
",",1093,O
the,1093,O
Czechs,1093,O
(,1093,O
with,1093,O
T1D,1093,B-DiseaseOrPhenotypicFeature
and,1093,O
with,1093,O
JIA,1093,B-DiseaseOrPhenotypicFeature
),1093,O
and,1093,O
Azeri,1093,O
(,1093,O
with,1093,O
T1D,1093,B-DiseaseOrPhenotypicFeature
),1093,O
.,1093,O
METHODS,1094,O
:,1094,O
The,1094,O
single,1094,O
nucleotide,1094,O
polymorphisms,1094,O
(,1094,O
SNP,1094,O
),1094,O
at,1094,O
positions,1094,O
-1123,1094,O
(,1094,O
rs2488457,1094,B-SequenceVariant
),1094,O
",",1094,O
+1858,1094,O
(,1094,O
rs2476601,1094,B-SequenceVariant
",",1094,O
the,1094,O
R620W,1094,B-SequenceVariant
substitution,1094,O
),1094,O
",",1094,O
and,1094,O
+2740,1094,O
(,1094,O
rs1217412,1094,B-SequenceVariant
),1094,O
were,1094,O
genotyped,1094,O
using,1094,O
TaqMan,1094,O
assays,1094,O
in,1094,O
372,1094,O
subjects,1094,O
with,1094,O
childhood-onset,1094,O
T1D,1094,B-DiseaseOrPhenotypicFeature
",",1094,O
130,1094,O
subjects,1094,O
with,1094,O
JIA,1094,B-DiseaseOrPhenotypicFeature
",",1094,O
and,1094,O
400,1094,O
control,1094,O
subjects,1094,O
of,1094,O
Czech,1094,O
origin,1094,O
",",1094,O
and,1094,O
in,1094,O
160,1094,O
subjects,1094,O
with,1094,O
T1D,1094,B-DiseaseOrPhenotypicFeature
and,1094,O
271,1094,O
healthy,1094,O
controls,1094,O
of,1094,O
Azeri,1094,O
origin,1094,O
.,1094,O
RESULTS,1095,O
:,1095,O
In,1095,O
the,1095,O
Czechs,1095,O
",",1095,O
all,1095,O
three,1095,O
SNPs,1095,O
were,1095,O
in,1095,O
a,1095,O
tight,1095,O
linkage,1095,O
disequlibrium,1095,O
",",1095,O
while,1095,O
in,1095,O
the,1095,O
Azeri,1095,O
",",1095,O
the,1095,O
linkage,1095,O
disequlibrium,1095,O
was,1095,O
limited,1095,O
to,1095,O
between,1095,O
the,1095,O
promoter,1095,O
and,1095,O
3'-UTR,1095,O
polymorphism,1095,O
",",1095,O
D,1095,O
',1095,O
(,1095,O
-1123,1095,O
",",1095,O
+2740,1095,O
),1095,O
=0.99,1095,O
",",1095,O
r,1095,O
(,1095,O
2,1095,O
),1095,O
=0.72,1095,O
.,1095,O
Haplotype,1096,O
reconstruction,1096,O
via,1096,O
the,1096,O
expectation-maximization,1096,O
algorithm,1096,O
showed,1096,O
in,1096,O
both,1096,O
populations,1096,O
that,1096,O
only,1096,O
the,1096,O
haplotype,1096,O
containing,1096,O
the,1096,O
minor,1096,O
(,1096,B-SequenceVariant
W,1096,I-SequenceVariant
),1096,I-SequenceVariant
allele,1096,I-SequenceVariant
at,1096,I-SequenceVariant
codon,1096,I-SequenceVariant
620,1096,I-SequenceVariant
was,1096,O
associated,1096,O
with,1096,O
T1D,1096,B-DiseaseOrPhenotypicFeature
(,1096,O
OR=2.26,1096,O
",",1096,O
95,1096,O
%,1096,O
CI,1096,O
1.68-3.02,1096,O
in,1096,O
Czechs,1096,O
",",1096,O
OR=14.8,1096,O
",",1096,O
95,1096,O
%,1096,O
CI,1096,O
2.0-651,1096,O
in,1096,O
Azeri,1096,O
),1096,O
or,1096,O
JIA,1096,B-DiseaseOrPhenotypicFeature
(,1096,O
OR=2.43,1096,O
",",1096,O
95,1096,O
%,1096,O
CI,1096,O
1.66-3.56,1096,O
in,1096,O
Czechs,1096,O
),1096,O
.,1096,O
The,1097,O
haplotypes,1097,O
having,1097,O
the,1097,O
wild-type,1097,O
(,1097,B-SequenceVariant
R,1097,I-SequenceVariant
),1097,I-SequenceVariant
allele,1097,I-SequenceVariant
at,1097,I-SequenceVariant
codon,1097,I-SequenceVariant
620,1097,I-SequenceVariant
and,1097,O
minor,1097,O
alleles,1097,O
at,1097,O
-1123,1097,O
and/or,1097,O
+2740,1097,O
were,1097,O
neutral,1097,O
as,1097,O
to,1097,O
the,1097,O
risk,1097,O
of,1097,O
autoimmune,1097,B-DiseaseOrPhenotypicFeature
conditions,1097,I-DiseaseOrPhenotypicFeature
in,1097,O
both,1097,O
populations,1097,O
.,1097,O
CONCLUSIONS,1098,O
:,1098,O
In,1098,O
two,1098,O
different,1098,O
Caucasian,1098,O
populations,1098,O
",",1098,O
the,1098,O
Czechs,1098,O
and,1098,O
the,1098,O
Azeri,1098,O
",",1098,O
no,1098,O
independent,1098,O
contribution,1098,O
can,1098,O
be,1098,O
detected,1098,O
either,1098,O
of,1098,O
the,1098,O
-1123,1098,O
promoter,1098,O
SNP,1098,O
or,1098,O
the,1098,O
+2740,1098,O
3'-UTR,1098,O
SNP,1098,O
",",1098,O
and,1098,O
only,1098,O
the,1098,O
minor,1098,O
allele,1098,O
at,1098,O
PTPN22,1098,B-GeneOrGeneProduct
codon,1098,O
620,1098,O
contributes,1098,O
to,1098,O
the,1098,O
risk,1098,O
of,1098,O
autoimmunity,1098,O
.,1098,O
A,1099,O
haplotype-based,1099,O
analysis,1099,O
of,1099,O
the,1099,O
PTPN22,1099,B-GeneOrGeneProduct
locus,1099,O
in,1099,O
type,1099,B-DiseaseOrPhenotypicFeature
1,1099,I-DiseaseOrPhenotypicFeature
diabetes,1099,I-DiseaseOrPhenotypicFeature
.,1099,O
A,1100,O
recent,1100,O
addition,1100,O
to,1100,O
the,1100,O
list,1100,O
of,1100,O
widely,1100,O
confirmed,1100,O
type,1100,B-DiseaseOrPhenotypicFeature
1,1100,I-DiseaseOrPhenotypicFeature
diabetes,1100,I-DiseaseOrPhenotypicFeature
risk,1100,O
loci,1100,O
is,1100,O
the,1100,O
PTPN22,1100,B-GeneOrGeneProduct
gene,1100,O
encoding,1100,O
a,1100,O
lymphoid-specific,1100,B-GeneOrGeneProduct
phosphatase,1100,I-GeneOrGeneProduct
(,1100,O
Lyp,1100,B-GeneOrGeneProduct
),1100,O
.,1100,O
However,1101,O
",",1101,O
evidence,1101,O
supporting,1101,O
a,1101,O
role,1101,O
for,1101,O
PTPN22,1101,B-GeneOrGeneProduct
in,1101,O
type,1101,B-DiseaseOrPhenotypicFeature
1,1101,I-DiseaseOrPhenotypicFeature
diabetes,1101,I-DiseaseOrPhenotypicFeature
derives,1101,O
entirely,1101,O
from,1101,O
the,1101,O
study,1101,O
of,1101,O
just,1101,O
one,1101,O
coding,1101,O
single,1101,O
nucleotide,1101,O
polymorphism,1101,O
",",1101,O
1858C/T,1101,B-SequenceVariant
.,1101,O
In,1102,O
the,1102,O
current,1102,O
study,1102,O
",",1102,O
the,1102,O
haplotype,1102,O
structure,1102,O
of,1102,O
the,1102,O
PTPN22,1102,B-GeneOrGeneProduct
region,1102,O
was,1102,O
determined,1102,O
",",1102,O
and,1102,O
individual,1102,O
haplotypes,1102,O
were,1102,O
tested,1102,O
for,1102,O
association,1102,O
with,1102,O
type,1102,B-DiseaseOrPhenotypicFeature
1,1102,I-DiseaseOrPhenotypicFeature
diabetes,1102,I-DiseaseOrPhenotypicFeature
in,1102,O
family-based,1102,O
tests,1102,O
.,1102,O
The,1103,O
1858T,1103,B-SequenceVariant
risk,1103,O
allele,1103,O
occurred,1103,O
on,1103,O
only,1103,O
a,1103,O
single,1103,O
haplotype,1103,O
that,1103,O
was,1103,O
strongly,1103,O
associated,1103,O
with,1103,O
type,1103,B-DiseaseOrPhenotypicFeature
1,1103,I-DiseaseOrPhenotypicFeature
diabetes,1103,I-DiseaseOrPhenotypicFeature
(,1103,O
P,1103,O
=,1103,O
7.9,1103,O
x,1103,O
10,1103,O
(,1103,O
-5,1103,O
),1103,O
),1103,O
.,1103,O
After,1104,O
controlling,1104,O
for,1104,O
the,1104,O
effects,1104,O
of,1104,O
this,1104,O
allele,1104,O
",",1104,O
two,1104,O
other,1104,O
haplotypes,1104,O
were,1104,O
observed,1104,O
to,1104,O
be,1104,O
weakly,1104,O
associated,1104,O
with,1104,O
type,1104,B-DiseaseOrPhenotypicFeature
1,1104,I-DiseaseOrPhenotypicFeature
diabetes,1104,I-DiseaseOrPhenotypicFeature
(,1104,O
P,1104,O
<,1104,O
0.05,1104,O
),1104,O
.,1104,O
Sequencing,1105,O
of,1105,O
the,1105,O
coding,1105,O
region,1105,O
of,1105,O
PTPN22,1105,B-GeneOrGeneProduct
on,1105,O
these,1105,O
haplotypes,1105,O
revealed,1105,O
a,1105,O
novel,1105,O
variant,1105,O
(,1105,O
2250G/C,1105,B-SequenceVariant
),1105,O
predicted,1105,O
to,1105,O
result,1105,O
in,1105,O
a,1105,O
nonsynonymous,1105,O
amino,1105,O
acid,1105,O
substitution,1105,O
.,1105,O
Analysis,1106,O
of,1106,O
PTPN22,1106,B-GeneOrGeneProduct
transcripts,1106,O
from,1106,O
a,1106,O
subject,1106,O
heterozygous,1106,O
for,1106,O
this,1106,O
variant,1106,O
indicated,1106,O
that,1106,O
it,1106,O
interfered,1106,O
with,1106,O
normal,1106,O
mRNA,1106,O
splicing,1106,O
",",1106,O
resulting,1106,O
in,1106,O
a,1106,O
premature,1106,O
termination,1106,O
codon,1106,O
after,1106,O
exon,1106,O
17,1106,O
.,1106,O
These,1107,O
results,1107,O
support,1107,O
the,1107,O
conclusion,1107,O
that,1107,O
the,1107,O
1858C/T,1107,B-SequenceVariant
allele,1107,O
is,1107,O
the,1107,O
major,1107,O
risk,1107,O
variant,1107,O
for,1107,O
type,1107,B-DiseaseOrPhenotypicFeature
1,1107,I-DiseaseOrPhenotypicFeature
diabetes,1107,I-DiseaseOrPhenotypicFeature
in,1107,O
the,1107,O
PTPN22,1107,B-GeneOrGeneProduct
locus,1107,O
",",1107,O
but,1107,O
they,1107,O
suggest,1107,O
that,1107,O
additional,1107,O
infrequent,1107,O
coding,1107,O
variants,1107,O
at,1107,O
PTPN22,1107,B-GeneOrGeneProduct
may,1107,O
also,1107,O
contribute,1107,O
to,1107,O
type,1107,B-DiseaseOrPhenotypicFeature
1,1107,I-DiseaseOrPhenotypicFeature
diabetes,1107,I-DiseaseOrPhenotypicFeature
risk,1107,O
.,1107,O
A,1108,O
polymorphism,1108,O
of,1108,O
C-to-T,1108,B-SequenceVariant
substitution,1108,I-SequenceVariant
at,1108,I-SequenceVariant
-31,1108,I-SequenceVariant
IL1B,1108,B-GeneOrGeneProduct
is,1108,O
associated,1108,O
with,1108,O
the,1108,O
risk,1108,O
of,1108,O
advanced,1108,O
gastric,1108,B-DiseaseOrPhenotypicFeature
adenocarcinoma,1108,I-DiseaseOrPhenotypicFeature
in,1108,O
a,1108,O
Japanese,1108,O
population,1108,O
.,1108,O
Proinflammatory,1109,B-GeneOrGeneProduct
cytokine,1109,I-GeneOrGeneProduct
gene,1109,O
polymorphisms,1109,O
have,1109,O
been,1109,O
demonstrated,1109,O
to,1109,O
associate,1109,O
with,1109,O
gastric,1109,B-DiseaseOrPhenotypicFeature
cancer,1109,I-DiseaseOrPhenotypicFeature
risk,1109,O
",",1109,O
of,1109,O
which,1109,O
IL1B-31T/C,1109,B-GeneOrGeneProduct
and,1109,O
-511C/T,1109,B-SequenceVariant
changes,1109,O
have,1109,O
been,1109,O
well,1109,O
investigated,1109,O
due,1109,O
to,1109,O
the,1109,O
possibility,1109,O
that,1109,O
they,1109,O
may,1109,O
alter,1109,O
the,1109,O
IL1B,1109,B-GeneOrGeneProduct
transcription,1109,O
.,1109,O
The,1110,O
signal,1110,O
transduction,1110,O
target,1110,O
upon,1110,O
interleukin,1110,B-GeneOrGeneProduct
1,1110,I-GeneOrGeneProduct
beta,1110,I-GeneOrGeneProduct
(,1110,O
IL1beta,1110,B-GeneOrGeneProduct
),1110,O
stimulation,1110,O
",",1110,O
the,1110,O
nuclear,1110,B-GeneOrGeneProduct
factor,1110,I-GeneOrGeneProduct
of,1110,I-GeneOrGeneProduct
kappa,1110,I-GeneOrGeneProduct
B,1110,I-GeneOrGeneProduct
(,1110,O
NFkappaB,1110,B-GeneOrGeneProduct
),1110,O
activation,1110,O
",",1110,O
supports,1110,O
cancer,1110,B-DiseaseOrPhenotypicFeature
development,1110,O
",",1110,O
signal,1110,O
transduction,1110,O
in,1110,O
which,1110,O
is,1110,O
mediated,1110,O
by,1110,O
FS-7,1110,B-GeneOrGeneProduct
cell-associated,1110,I-GeneOrGeneProduct
cell,1110,I-GeneOrGeneProduct
surface,1110,I-GeneOrGeneProduct
antigen,1110,I-GeneOrGeneProduct
(,1110,O
FAS,1110,B-GeneOrGeneProduct
),1110,O
signaling,1110,O
.,1110,O
Based,1111,O
on,1111,O
recent,1111,O
papers,1111,O
describing,1111,O
the,1111,O
prognostic,1111,O
roles,1111,O
of,1111,O
the,1111,O
polymorphisms,1111,O
and,1111,O
the,1111,O
NFkappaB,1111,B-GeneOrGeneProduct
functions,1111,O
on,1111,O
cancer,1111,B-DiseaseOrPhenotypicFeature
development,1111,O
",",1111,O
we,1111,O
sought,1111,O
to,1111,O
determine,1111,O
if,1111,O
Japanese,1111,O
gastric,1111,B-DiseaseOrPhenotypicFeature
cancer,1111,I-DiseaseOrPhenotypicFeature
patients,1111,B-OrganismTaxon
were,1111,O
affected,1111,O
by,1111,O
the,1111,O
IL1B,1111,B-GeneOrGeneProduct
-31/-511,1111,O
and,1111,O
FAS-670,1111,B-GeneOrGeneProduct
polymorphisms,1111,O
.,1111,O
A,1112,O
case-control,1112,O
study,1112,O
was,1112,O
conducted,1112,O
on,1112,O
incident,1112,O
gastric,1112,B-DiseaseOrPhenotypicFeature
adenocarcinoma,1112,I-DiseaseOrPhenotypicFeature
patients,1112,B-OrganismTaxon
(,1112,O
n=271,1112,O
),1112,O
and,1112,O
age-gender,1112,O
frequency-matched,1112,O
control,1112,O
subjects,1112,O
(,1112,O
n=271,1112,O
),1112,O
.,1112,O
We,1113,O
observed,1113,O
strong,1113,O
linkage,1113,O
disequilibrium,1113,O
between,1113,O
the,1113,O
T,1113,B-SequenceVariant
allele,1113,I-SequenceVariant
at,1113,I-SequenceVariant
-511,1113,I-SequenceVariant
and,1113,O
the,1113,O
C,1113,B-SequenceVariant
allele,1113,I-SequenceVariant
at,1113,I-SequenceVariant
-31,1113,I-SequenceVariant
and,1113,O
between,1113,O
the,1113,O
C,1113,B-SequenceVariant
allele,1113,I-SequenceVariant
at,1113,I-SequenceVariant
-511,1113,I-SequenceVariant
and,1113,O
the,1113,O
T,1113,B-SequenceVariant
allele,1113,I-SequenceVariant
at,1113,I-SequenceVariant
-31,1113,I-SequenceVariant
in,1113,O
IL1B,1113,B-GeneOrGeneProduct
in,1113,O
both,1113,O
the,1113,O
cases,1113,O
and,1113,O
controls,1113,O
(,1113,O
R,1113,O
(,1113,O
2,1113,O
),1113,O
=0.94,1113,O
),1113,O
.,1113,O
Neither,1114,O
IL1B-31,1114,B-GeneOrGeneProduct
",",1114,O
-511,1114,O
nor,1114,O
FAS-670,1114,B-GeneOrGeneProduct
polymorphisms,1114,O
showed,1114,O
significantly,1114,O
different,1114,O
risks,1114,O
of,1114,O
gastric,1114,B-DiseaseOrPhenotypicFeature
adenocarcinoma,1114,I-DiseaseOrPhenotypicFeature
.,1114,O
Though,1115,O
FAS-670,1115,B-GeneOrGeneProduct
polymorphisms,1115,O
did,1115,O
not,1115,O
show,1115,O
any,1115,O
significant,1115,O
difference,1115,O
",",1115,O
the,1115,O
proportion,1115,O
of,1115,O
subjects,1115,O
with,1115,O
IL1B-31TT,1115,B-GeneOrGeneProduct
(,1115,O
or,1115,O
IL1B-511CC,1115,B-GeneOrGeneProduct
),1115,O
increased,1115,O
according,1115,O
to,1115,O
stage,1115,O
(,1115,O
trend,1115,O
P=0.019,1115,O
),1115,O
.,1115,O
In,1116,O
particular,1116,O
",",1116,O
subjects,1116,O
with,1116,O
stage,1116,O
IV,1116,O
had,1116,O
a,1116,O
two,1116,O
times,1116,O
higher,1116,O
probability,1116,O
of,1116,O
having,1116,O
either,1116,O
IL1B-31TT,1116,B-GeneOrGeneProduct
(,1116,O
or,1116,O
IL1B-511CC,1116,B-GeneOrGeneProduct
),1116,O
genotype,1116,O
compared,1116,O
with,1116,O
stage,1116,O
I,1116,O
subjects,1116,O
.,1116,O
These,1117,O
observations,1117,O
suggest,1117,O
that,1117,O
IL1B-31TT,1117,B-GeneOrGeneProduct
and,1117,O
IL1B-511CC,1117,B-GeneOrGeneProduct
are,1117,O
associated,1117,O
with,1117,O
disease,1117,O
progression,1117,O
.,1117,O
A,1118,O
two,1118,O
base,1118,O
pair,1118,O
deletion,1118,O
in,1118,O
the,1118,O
PQBP1,1118,B-GeneOrGeneProduct
gene,1118,O
is,1118,O
associated,1118,O
with,1118,O
microphthalmia,1118,B-DiseaseOrPhenotypicFeature
",",1118,O
microcephaly,1118,B-DiseaseOrPhenotypicFeature
",",1118,O
and,1118,O
mental,1118,B-DiseaseOrPhenotypicFeature
retardation,1118,I-DiseaseOrPhenotypicFeature
.,1118,O
X-linked,1119,B-DiseaseOrPhenotypicFeature
mental,1119,I-DiseaseOrPhenotypicFeature
retardation,1119,I-DiseaseOrPhenotypicFeature
has,1119,O
been,1119,O
traditionally,1119,O
divided,1119,O
into,1119,O
syndromic,1119,O
(,1119,O
S-XLMR,1119,O
),1119,O
and,1119,O
non-syndromic,1119,O
forms,1119,O
(,1119,O
NS-XLMR,1119,O
),1119,O
",",1119,O
although,1119,O
the,1119,O
borderlines,1119,O
between,1119,O
these,1119,O
phenotypes,1119,O
begin,1119,O
to,1119,O
vanish,1119,O
and,1119,O
mutations,1119,O
in,1119,O
a,1119,O
single,1119,O
gene,1119,O
",",1119,O
for,1119,O
example,1119,O
PQBP1,1119,B-GeneOrGeneProduct
",",1119,O
can,1119,O
cause,1119,O
S-XLMR,1119,O
as,1119,O
well,1119,O
as,1119,O
NS-XLMR,1119,O
.,1119,O
Here,1120,O
",",1120,O
we,1120,O
report,1120,O
two,1120,O
maternal,1120,O
cousins,1120,O
with,1120,O
an,1120,O
apparently,1120,O
X-linked,1120,B-DiseaseOrPhenotypicFeature
phenotype,1120,I-DiseaseOrPhenotypicFeature
of,1120,I-DiseaseOrPhenotypicFeature
mental,1120,I-DiseaseOrPhenotypicFeature
retardation,1120,I-DiseaseOrPhenotypicFeature
(,1120,O
MR,1120,B-DiseaseOrPhenotypicFeature
),1120,O
",",1120,O
microphthalmia,1120,B-DiseaseOrPhenotypicFeature
",",1120,O
choroid,1120,B-DiseaseOrPhenotypicFeature
coloboma,1120,I-DiseaseOrPhenotypicFeature
",",1120,O
microcephaly,1120,B-DiseaseOrPhenotypicFeature
",",1120,O
renal,1120,B-DiseaseOrPhenotypicFeature
hypoplasia,1120,I-DiseaseOrPhenotypicFeature
",",1120,O
and,1120,O
spastic,1120,B-DiseaseOrPhenotypicFeature
paraplegia,1120,I-DiseaseOrPhenotypicFeature
.,1120,O
By,1121,O
multipoint,1121,O
linkage,1121,O
analysis,1121,O
with,1121,O
markers,1121,O
spanning,1121,O
the,1121,O
entire,1121,O
X-chromosome,1121,O
we,1121,O
mapped,1121,O
the,1121,O
disease,1121,O
locus,1121,O
to,1121,O
a,1121,O
28-Mb,1121,O
interval,1121,O
between,1121,O
Xp11.4,1121,O
and,1121,O
Xq12,1121,O
",",1121,O
including,1121,O
the,1121,O
BCOR,1121,B-GeneOrGeneProduct
gene,1121,O
.,1121,O
A,1122,O
missense,1122,O
mutation,1122,O
in,1122,O
BCOR,1122,B-GeneOrGeneProduct
was,1122,O
described,1122,O
in,1122,O
a,1122,O
family,1122,O
with,1122,O
Lenz,1122,B-DiseaseOrPhenotypicFeature
microphthalmia,1122,I-DiseaseOrPhenotypicFeature
syndrome,1122,I-DiseaseOrPhenotypicFeature
",",1122,O
a,1122,O
phenotype,1122,O
showing,1122,O
substantial,1122,O
overlapping,1122,O
features,1122,O
with,1122,O
that,1122,O
described,1122,O
in,1122,O
the,1122,O
two,1122,O
cousins,1122,O
.,1122,O
However,1123,O
",",1123,O
no,1123,O
mutation,1123,O
in,1123,O
the,1123,O
BCOR,1123,B-GeneOrGeneProduct
gene,1123,O
was,1123,O
found,1123,O
in,1123,O
both,1123,O
patients,1123,B-OrganismTaxon
.,1123,O
Subsequent,1124,O
mutation,1124,O
analysis,1124,O
of,1124,O
PQBP1,1124,B-GeneOrGeneProduct
",",1124,O
located,1124,O
within,1124,O
the,1124,O
delineated,1124,O
linkage,1124,O
interval,1124,O
in,1124,O
Xp11.23,1124,O
",",1124,O
revealed,1124,O
a,1124,O
2-bp,1124,O
deletion,1124,O
",",1124,O
c.461_462delAG,1124,B-SequenceVariant
",",1124,O
that,1124,O
cosegregated,1124,O
with,1124,O
the,1124,O
disease,1124,O
.,1124,O
Notably,1125,O
",",1125,O
the,1125,O
same,1125,O
mutation,1125,O
is,1125,O
associated,1125,O
with,1125,O
the,1125,O
Hamel,1125,B-DiseaseOrPhenotypicFeature
cerebropalatocardiac,1125,I-DiseaseOrPhenotypicFeature
syndrome,1125,I-DiseaseOrPhenotypicFeature
",",1125,O
another,1125,O
form,1125,O
of,1125,O
S-XLMR,1125,O
.,1125,O
Haplotype,1126,O
analysis,1126,O
suggests,1126,O
a,1126,O
germline,1126,O
mosaicism,1126,O
of,1126,O
the,1126,O
2-bp,1126,O
deletion,1126,O
in,1126,O
the,1126,O
maternal,1126,O
grandmother,1126,O
of,1126,O
both,1126,O
affected,1126,O
individuals,1126,O
.,1126,O
In,1127,O
summary,1127,O
",",1127,O
our,1127,O
findings,1127,O
demonstrate,1127,O
for,1127,O
the,1127,O
first,1127,O
time,1127,O
that,1127,O
mutations,1127,O
in,1127,O
PQBP1,1127,B-GeneOrGeneProduct
are,1127,O
associated,1127,O
with,1127,O
an,1127,O
S-XLMR,1127,O
phenotype,1127,O
including,1127,O
microphthalmia,1127,B-DiseaseOrPhenotypicFeature
",",1127,O
thereby,1127,O
further,1127,O
extending,1127,O
the,1127,O
clinical,1127,O
spectrum,1127,O
of,1127,O
phenotypes,1127,O
associated,1127,O
with,1127,O
PQBP1,1127,B-GeneOrGeneProduct
mutations,1127,O
.,1127,O
Chloroacetaldehyde,1128,B-ChemicalEntity
as,1128,O
a,1128,O
sulfhydryl,1128,B-ChemicalEntity
reagent,1128,I-ChemicalEntity
:,1128,O
the,1128,O
role,1128,O
of,1128,O
critical,1128,O
thiol,1128,B-ChemicalEntity
groups,1128,O
in,1128,O
ifosfamide,1128,B-ChemicalEntity
nephropathy,1128,B-DiseaseOrPhenotypicFeature
.,1128,O
Chloroacetaldehyde,1129,B-ChemicalEntity
(,1129,O
CAA,1129,B-ChemicalEntity
),1129,O
is,1129,O
a,1129,O
metabolite,1129,O
of,1129,O
the,1129,O
alkylating,1129,B-ChemicalEntity
agent,1129,I-ChemicalEntity
ifosfamide,1129,B-ChemicalEntity
(,1129,O
IFO,1129,B-ChemicalEntity
),1129,O
and,1129,O
putatively,1129,O
responsible,1129,O
for,1129,O
renal,1129,B-DiseaseOrPhenotypicFeature
damage,1129,I-DiseaseOrPhenotypicFeature
following,1129,O
anti-tumor,1129,O
therapy,1129,O
with,1129,O
IFO,1129,B-ChemicalEntity
.,1129,O
Depletion,1130,O
of,1130,O
sulfhydryl,1130,B-ChemicalEntity
(,1130,O
SH,1130,B-ChemicalEntity
),1130,O
groups,1130,O
has,1130,O
been,1130,O
reported,1130,O
from,1130,O
cell,1130,O
culture,1130,O
",",1130,O
animal,1130,O
and,1130,O
clinical,1130,O
studies,1130,O
.,1130,O
In,1131,O
this,1131,O
work,1131,O
the,1131,O
effect,1131,O
of,1131,O
CAA,1131,B-ChemicalEntity
on,1131,O
human,1131,B-OrganismTaxon
proximal,1131,O
tubule,1131,O
cells,1131,O
in,1131,O
primary,1131,O
culture,1131,O
(,1131,O
hRPTEC,1131,B-CellLine
),1131,O
was,1131,O
investigated,1131,O
.,1131,O
Toxicity,1132,B-DiseaseOrPhenotypicFeature
of,1132,O
CAA,1132,B-ChemicalEntity
was,1132,O
determined,1132,O
by,1132,O
protein,1132,O
content,1132,O
",",1132,O
cell,1132,O
number,1132,O
",",1132,O
LDH,1132,B-ChemicalEntity
release,1132,O
",",1132,O
trypan,1132,B-ChemicalEntity
blue,1132,I-ChemicalEntity
exclusion,1132,O
assay,1132,O
and,1132,O
caspase-3,1132,B-GeneOrGeneProduct
activity,1132,O
.,1132,O
Free,1133,O
thiols,1133,B-ChemicalEntity
were,1133,O
measured,1133,O
by,1133,O
the,1133,O
method,1133,O
of,1133,O
Ellman,1133,O
.,1133,O
CAA,1134,B-ChemicalEntity
reduced,1134,O
hRPTEC,1134,B-CellLine
cell,1134,O
number,1134,O
and,1134,O
protein,1134,O
",",1134,O
induced,1134,O
a,1134,O
loss,1134,O
in,1134,O
free,1134,O
intracellular,1134,O
thiols,1134,B-ChemicalEntity
and,1134,O
an,1134,O
increase,1134,O
in,1134,O
necrosis,1134,B-DiseaseOrPhenotypicFeature
markers,1134,O
.,1134,O
CAA,1135,B-ChemicalEntity
but,1135,O
not,1135,O
acrolein,1135,B-ChemicalEntity
inhibited,1135,O
the,1135,O
cysteine,1135,B-GeneOrGeneProduct
proteases,1135,I-GeneOrGeneProduct
caspase-3,1135,B-GeneOrGeneProduct
",",1135,O
caspase-8,1135,B-GeneOrGeneProduct
and,1135,O
cathepsin,1135,B-GeneOrGeneProduct
B.,1135,O
Caspase,1135,B-GeneOrGeneProduct
activation,1135,O
by,1135,O
cisplatin,1135,B-ChemicalEntity
was,1135,O
inhibited,1135,O
by,1135,O
CAA,1135,B-ChemicalEntity
.,1135,O
In,1136,O
cells,1136,O
stained,1136,O
with,1136,O
fluorescent,1136,O
dyes,1136,O
targeting,1136,O
lysosomes,1136,O
",",1136,O
CAA,1136,B-ChemicalEntity
induced,1136,O
an,1136,O
increase,1136,O
in,1136,O
lysosomal,1136,O
size,1136,O
and,1136,O
lysosomal,1136,O
leakage,1136,O
.,1136,O
The,1137,O
effects,1137,O
of,1137,O
CAA,1137,B-ChemicalEntity
on,1137,O
cysteine,1137,B-GeneOrGeneProduct
protease,1137,I-GeneOrGeneProduct
activities,1137,O
and,1137,O
thiols,1137,B-ChemicalEntity
could,1137,O
be,1137,O
reproduced,1137,O
in,1137,O
cell,1137,O
lysate,1137,O
.,1137,O
Acidification,1138,O
",",1138,O
which,1138,O
slowed,1138,O
the,1138,O
reaction,1138,O
of,1138,O
CAA,1138,B-ChemicalEntity
with,1138,O
thiol,1138,B-ChemicalEntity
donors,1138,O
",",1138,O
could,1138,O
also,1138,O
attenuate,1138,O
effects,1138,O
of,1138,O
CAA,1138,B-ChemicalEntity
on,1138,O
necrosis,1138,B-DiseaseOrPhenotypicFeature
markers,1138,O
",",1138,O
thiol,1138,B-ChemicalEntity
depletion,1138,O
and,1138,O
cysteine,1138,B-GeneOrGeneProduct
protease,1138,I-GeneOrGeneProduct
inhibition,1138,O
in,1138,O
living,1138,O
cells,1138,O
.,1138,O
Thus,1139,O
",",1139,O
CAA,1139,B-ChemicalEntity
directly,1139,O
reacts,1139,O
with,1139,O
cellular,1139,O
protein,1139,O
and,1139,O
non-protein,1139,O
thiols,1139,B-ChemicalEntity
",",1139,O
mediating,1139,O
its,1139,O
toxicity,1139,B-DiseaseOrPhenotypicFeature
on,1139,O
hRPTEC,1139,B-CellLine
.,1139,O
This,1140,O
effect,1140,O
can,1140,O
be,1140,O
reduced,1140,O
by,1140,O
acidification,1140,O
.,1140,O
Therefore,1141,O
",",1141,O
urinary,1141,O
acidification,1141,O
could,1141,O
be,1141,O
an,1141,O
option,1141,O
to,1141,O
prevent,1141,O
IFO,1141,B-ChemicalEntity
nephropathy,1141,B-DiseaseOrPhenotypicFeature
in,1141,O
patients,1141,B-OrganismTaxon
.,1141,O
Anti-oxidant,1142,O
effects,1142,O
of,1142,O
atorvastatin,1142,B-ChemicalEntity
in,1142,O
dexamethasone-induced,1142,B-ChemicalEntity
hypertension,1142,B-DiseaseOrPhenotypicFeature
in,1142,O
the,1142,O
rat,1142,B-OrganismTaxon
.,1142,O
1,1143,O
.,1143,O
Dexamethasone,1144,B-ChemicalEntity
(,1144,O
Dex,1144,B-ChemicalEntity
),1144,O
-induced,1144,O
hypertension,1144,B-DiseaseOrPhenotypicFeature
is,1144,O
characterized,1144,O
by,1144,O
endothelial,1144,O
dysfunction,1144,O
associated,1144,O
with,1144,O
nitric,1144,B-ChemicalEntity
oxide,1144,I-ChemicalEntity
(,1144,O
NO,1144,B-ChemicalEntity
),1144,O
deficiency,1144,O
and,1144,O
increased,1144,O
superoxide,1144,B-ChemicalEntity
(,1144,O
O2-,1144,B-ChemicalEntity
),1144,O
production,1144,O
.,1144,O
Atorvastatin,1145,B-ChemicalEntity
(,1145,O
Ato,1145,B-ChemicalEntity
),1145,O
possesses,1145,O
pleiotropic,1145,O
properties,1145,O
that,1145,O
have,1145,O
been,1145,O
reported,1145,O
to,1145,O
improve,1145,O
endothelial,1145,O
function,1145,O
through,1145,O
increased,1145,O
availability,1145,O
of,1145,O
NO,1145,B-ChemicalEntity
and,1145,O
reduced,1145,O
O2-,1145,B-ChemicalEntity
production,1145,O
in,1145,O
various,1145,O
forms,1145,O
of,1145,O
hypertension,1145,B-DiseaseOrPhenotypicFeature
.,1145,O
In,1146,O
the,1146,O
present,1146,O
study,1146,O
",",1146,O
we,1146,O
investigated,1146,O
whether,1146,O
50,1146,O
mg/kg,1146,O
per,1146,O
day,1146,O
",",1146,O
p.o.,1146,O
",",1146,O
Ato,1146,B-ChemicalEntity
could,1146,O
prevent,1146,O
endothelial,1146,B-GeneOrGeneProduct
NO,1146,I-GeneOrGeneProduct
synthase,1146,I-GeneOrGeneProduct
(,1146,O
eNOS,1146,B-GeneOrGeneProduct
),1146,O
downregulation,1146,O
and,1146,O
the,1146,O
increase,1146,O
in,1146,O
O2-,1146,B-ChemicalEntity
in,1146,O
Sprague-Dawley,1146,O
(,1146,O
SD,1146,O
),1146,O
rats,1146,B-OrganismTaxon
",",1146,O
thereby,1146,O
reducing,1146,O
blood,1146,O
pressure,1146,O
.,1146,O
2,1147,O
.,1147,O
Male,1148,O
SD,1148,O
rats,1148,B-OrganismTaxon
(,1148,O
n,1148,O
=,1148,O
30,1148,O
),1148,O
were,1148,O
treated,1148,O
with,1148,O
Ato,1148,B-ChemicalEntity
(,1148,O
50,1148,O
mg/kg,1148,O
per,1148,O
day,1148,O
in,1148,O
drinking,1148,O
water,1148,O
),1148,O
or,1148,O
tap,1148,O
water,1148,O
for,1148,O
15,1148,O
days,1148,O
.,1148,O
Dexamethasone,1149,B-ChemicalEntity
(,1149,O
10,1149,O
microg/kg,1149,O
per,1149,O
day,1149,O
",",1149,O
s.c.,1149,O
),1149,O
or,1149,O
saline,1149,O
was,1149,O
started,1149,O
after,1149,O
4,1149,O
days,1149,O
in,1149,O
Ato-treated,1149,B-ChemicalEntity
and,1149,O
non-treated,1149,O
rats,1149,B-OrganismTaxon
and,1149,O
continued,1149,O
for,1149,O
11-13,1149,O
days,1149,O
.,1149,O
Systolic,1150,O
blood,1150,O
pressure,1150,O
(,1150,O
SBP,1150,O
),1150,O
was,1150,O
measured,1150,O
on,1150,O
alternate,1150,O
days,1150,O
using,1150,O
the,1150,O
tail-cuff,1150,O
method,1150,O
.,1150,O
Endothelial,1151,O
function,1151,O
was,1151,O
assessed,1151,O
by,1151,O
acetylcholine-induced,1151,B-ChemicalEntity
vasorelaxation,1151,O
and,1151,O
phenylephrine-induced,1151,B-ChemicalEntity
vasoconstriction,1151,O
in,1151,O
aortic,1151,O
segments,1151,O
.,1151,O
Vascular,1152,O
eNOS,1152,B-GeneOrGeneProduct
mRNA,1152,O
was,1152,O
assessed,1152,O
by,1152,O
semi-quantitative,1152,O
reverse,1152,O
transcription-polymerase,1152,O
chain,1152,O
reaction,1152,O
.,1152,O
3,1153,O
.,1153,O
In,1154,O
rats,1154,B-OrganismTaxon
treated,1154,O
with,1154,O
Dex,1154,B-ChemicalEntity
alone,1154,O
",",1154,O
SBP,1154,O
was,1154,O
increased,1154,O
from,1154,O
109,1154,O
+/-,1154,O
2,1154,O
to,1154,O
133,1154,O
+/-,1154,O
2,1154,O
mmHg,1154,O
on,1154,O
Days,1154,O
4,1154,O
and,1154,O
Day,1154,O
14,1154,O
",",1154,O
respectively,1154,O
(,1154,O
P,1154,O
<,1154,O
0.001,1154,O
),1154,O
.,1154,O
In,1155,O
the,1155,O
Ato,1155,B-ChemicalEntity
+,1155,O
Dex,1155,B-ChemicalEntity
group,1155,O
",",1155,O
SBP,1155,O
was,1155,O
increased,1155,O
from,1155,O
113,1155,O
+/-,1155,O
2,1155,O
to,1155,O
119,1155,O
+/-,1155,O
2,1155,O
mmHg,1155,O
on,1155,O
Days,1155,O
4,1155,O
to,1155,O
14,1155,O
",",1155,O
respectively,1155,O
(,1155,O
P,1155,O
<,1155,O
0.001,1155,O
),1155,O
",",1155,O
but,1155,O
was,1155,O
significantly,1155,O
lower,1155,O
than,1155,O
SBP,1155,O
in,1155,O
the,1155,O
group,1155,O
treated,1155,O
with,1155,O
Dex,1155,B-ChemicalEntity
alone,1155,O
(,1155,O
P,1155,O
<,1155,O
0.05,1155,O
),1155,O
.,1155,O
Endothelial-dependent,1156,O
relaxation,1156,O
and,1156,O
eNOS,1156,B-GeneOrGeneProduct
mRNA,1156,O
expression,1156,O
were,1156,O
greater,1156,O
in,1156,O
the,1156,O
Dex,1156,B-ChemicalEntity
+,1156,O
Ato,1156,B-ChemicalEntity
group,1156,O
than,1156,O
in,1156,O
the,1156,O
Dex,1156,B-ChemicalEntity
only,1156,O
group,1156,O
(,1156,O
P,1156,O
<,1156,O
0.05,1156,O
and,1156,O
P,1156,O
<,1156,O
0.0001,1156,O
",",1156,O
respectively,1156,O
),1156,O
.,1156,O
Aortic,1157,O
superoxide,1157,B-ChemicalEntity
production,1157,O
was,1157,O
lower,1157,O
in,1157,O
the,1157,O
Dex,1157,B-ChemicalEntity
+,1157,O
Ato,1157,B-ChemicalEntity
group,1157,O
compared,1157,O
with,1157,O
the,1157,O
group,1157,O
treated,1157,O
with,1157,O
Dex,1157,B-ChemicalEntity
alone,1157,O
(,1157,O
P,1157,O
<,1157,O
0.0001,1157,O
),1157,O
.,1157,O
4,1158,O
.,1158,O
Treatment,1159,O
with,1159,O
Ato,1159,B-ChemicalEntity
improved,1159,O
endothelial,1159,O
function,1159,O
",",1159,O
reduced,1159,O
superoxide,1159,B-ChemicalEntity
production,1159,O
and,1159,O
reduced,1159,O
SBP,1159,O
in,1159,O
Dex-treated,1159,B-ChemicalEntity
SD,1159,O
rats,1159,B-OrganismTaxon
.,1159,O
Analysis,1160,O
of,1160,O
skin,1160,B-DiseaseOrPhenotypicFeature
cancer,1160,I-DiseaseOrPhenotypicFeature
risk,1160,O
factors,1160,O
in,1160,O
immunosuppressed,1160,O
renal,1160,O
transplant,1160,O
patients,1160,B-OrganismTaxon
shows,1160,O
high,1160,O
levels,1160,O
of,1160,O
UV-specific,1160,O
tandem,1160,O
CC,1160,B-SequenceVariant
to,1160,I-SequenceVariant
TT,1160,I-SequenceVariant
mutations,1160,O
of,1160,O
the,1160,O
p53,1160,B-GeneOrGeneProduct
gene,1160,O
.,1160,O
Immunosuppressed,1161,O
renal,1161,O
transplant,1161,O
recipients,1161,O
(,1161,O
RTRs,1161,O
),1161,O
are,1161,O
predisposed,1161,O
to,1161,O
non-melanoma,1161,B-DiseaseOrPhenotypicFeature
skin,1161,I-DiseaseOrPhenotypicFeature
cancers,1161,I-DiseaseOrPhenotypicFeature
(,1161,O
NMSCs,1161,B-DiseaseOrPhenotypicFeature
),1161,O
",",1161,O
predominantly,1161,O
squamous,1161,B-DiseaseOrPhenotypicFeature
cell,1161,I-DiseaseOrPhenotypicFeature
carcinomas,1161,I-DiseaseOrPhenotypicFeature
(,1161,O
SCCs,1161,B-DiseaseOrPhenotypicFeature
),1161,O
.,1161,O
We,1162,O
have,1162,O
analyzed,1162,O
skin,1162,B-DiseaseOrPhenotypicFeature
lesions,1162,I-DiseaseOrPhenotypicFeature
from,1162,O
RTRs,1162,O
with,1162,O
aggressive,1162,O
tumors,1162,B-DiseaseOrPhenotypicFeature
for,1162,O
p53,1162,B-GeneOrGeneProduct
gene,1162,O
modifications,1162,O
",",1162,O
the,1162,O
presence,1162,O
of,1162,O
Human,1162,B-OrganismTaxon
Papillomas,1162,I-OrganismTaxon
Virus,1162,I-OrganismTaxon
(,1162,O
HPV,1162,B-OrganismTaxon
),1162,O
DNA,1162,O
in,1162,O
relation,1162,O
to,1162,O
the,1162,O
p53,1162,B-GeneOrGeneProduct
codon,1162,O
72,1162,O
genotype,1162,O
and,1162,O
polymorphisms,1162,O
of,1162,O
the,1162,O
XPD,1162,B-GeneOrGeneProduct
repair,1162,O
gene,1162,O
.,1162,O
We,1163,O
detected,1163,O
24,1163,O
p53,1163,B-GeneOrGeneProduct
mutations,1163,O
in,1163,O
15/25,1163,O
(,1163,O
60,1163,O
%,1163,O
),1163,O
NMSCs,1163,B-DiseaseOrPhenotypicFeature
",",1163,O
1,1163,O
deletion,1163,O
and,1163,O
23,1163,O
base,1163,O
substitutions,1163,O
",",1163,O
the,1163,O
majority,1163,O
(,1163,O
78,1163,O
%,1163,O
),1163,O
being,1163,O
UV-specific,1163,O
C,1163,B-SequenceVariant
to,1163,I-SequenceVariant
T,1163,I-SequenceVariant
transitions,1163,O
at,1163,O
bipyrimidine,1163,O
sites,1163,O
.,1163,O
Importantly,1164,O
",",1164,O
35,1164,O
%,1164,O
(,1164,O
6/17,1164,O
),1164,O
are,1164,O
tandem,1164,O
mutations,1164,O
",",1164,O
including,1164,O
4,1164,O
UV,1164,O
signature,1164,O
CC,1164,B-SequenceVariant
to,1164,I-SequenceVariant
TT,1164,I-SequenceVariant
transitions,1164,O
possibly,1164,O
linked,1164,O
to,1164,O
modulated,1164,O
DNA,1164,O
repair,1164,O
caused,1164,O
by,1164,O
the,1164,O
immunosuppressive,1164,O
drug,1164,O
cyclosporin,1164,B-ChemicalEntity
A,1164,I-ChemicalEntity
(,1164,O
CsA,1164,B-ChemicalEntity
),1164,O
.,1164,O
We,1165,O
found,1165,O
8,1165,O
p53,1165,B-GeneOrGeneProduct
mutations,1165,O
in,1165,O
7/17,1165,O
(,1165,O
41,1165,O
%,1165,O
),1165,O
precancerous,1165,B-DiseaseOrPhenotypicFeature
actinic,1165,B-DiseaseOrPhenotypicFeature
keratosis,1165,I-DiseaseOrPhenotypicFeature
(,1165,O
AK,1165,B-DiseaseOrPhenotypicFeature
),1165,O
",",1165,O
suggesting,1165,O
that,1165,O
p53,1165,B-GeneOrGeneProduct
mutations,1165,O
are,1165,O
early,1165,O
events,1165,O
in,1165,O
RTR,1165,O
skin,1165,B-DiseaseOrPhenotypicFeature
carcinogenesis,1165,I-DiseaseOrPhenotypicFeature
.,1165,O
Immunohistochemical,1166,O
analysis,1166,O
shows,1166,O
a,1166,O
good,1166,O
correlation,1166,O
between,1166,O
p53,1166,B-GeneOrGeneProduct
accumulation,1166,O
and,1166,O
mutations,1166,O
.,1166,O
HPV,1167,B-OrganismTaxon
DNA,1167,O
was,1167,O
detected,1167,O
in,1167,O
78,1167,O
%,1167,O
of,1167,O
skin,1167,B-DiseaseOrPhenotypicFeature
lesions,1167,I-DiseaseOrPhenotypicFeature
(,1167,O
60,1167,O
%,1167,O
Basal,1167,B-DiseaseOrPhenotypicFeature
Cell,1167,I-DiseaseOrPhenotypicFeature
Carcinomas,1167,I-DiseaseOrPhenotypicFeature
",",1167,O
82,1167,O
%,1167,O
AK,1167,B-DiseaseOrPhenotypicFeature
and,1167,O
79,1167,O
%,1167,O
SCCs,1167,B-DiseaseOrPhenotypicFeature
),1167,O
.,1167,O
Thus,1168,O
",",1168,O
immunosuppression,1168,O
has,1168,O
increased,1168,O
the,1168,O
risk,1168,O
of,1168,O
infections,1168,B-DiseaseOrPhenotypicFeature
by,1168,O
HPVs,1168,B-OrganismTaxon
",",1168,O
predominantly,1168,O
epidermodysplasia,1168,B-DiseaseOrPhenotypicFeature
verruciformis,1168,I-DiseaseOrPhenotypicFeature
",",1168,O
speculated,1168,O
to,1168,O
play,1168,O
a,1168,O
role,1168,O
in,1168,O
skin,1168,B-DiseaseOrPhenotypicFeature
cancer,1168,I-DiseaseOrPhenotypicFeature
development,1168,O
.,1168,O
No,1169,O
association,1169,O
is,1169,O
found,1169,O
between,1169,O
HPV,1169,B-OrganismTaxon
status,1169,O
and,1169,O
p53,1169,B-GeneOrGeneProduct
mutation,1169,O
.,1169,O
Moreover,1170,O
",",1170,O
p53,1170,B-GeneOrGeneProduct
codon,1170,O
72,1170,O
or,1170,O
frequencies,1170,O
of,1170,O
three,1170,O
XPD,1170,B-GeneOrGeneProduct
genotypes,1170,O
of,1170,O
RTRs,1170,O
are,1170,O
comparable,1170,O
with,1170,O
control,1170,O
populations,1170,O
.,1170,O
The,1171,O
p53,1171,B-GeneOrGeneProduct
mutation,1171,O
spectrum,1171,O
",",1171,O
presenting,1171,O
a,1171,O
high,1171,O
level,1171,O
of,1171,O
CC,1171,B-SequenceVariant
to,1171,I-SequenceVariant
TT,1171,I-SequenceVariant
mutations,1171,O
",",1171,O
shows,1171,O
that,1171,O
the,1171,O
UV,1171,O
component,1171,O
of,1171,O
sunlight,1171,O
is,1171,O
the,1171,O
major,1171,O
risk,1171,O
factor,1171,O
and,1171,O
modulated,1171,O
DNA,1171,O
repair,1171,O
by,1171,O
immunosuppressive,1171,O
drug,1171,O
treatment,1171,O
may,1171,O
be,1171,O
significant,1171,O
in,1171,O
the,1171,O
skin,1171,B-DiseaseOrPhenotypicFeature
carcinogenesis,1171,I-DiseaseOrPhenotypicFeature
of,1171,O
RTRs,1171,O
.,1171,O
Valproate-induced,1172,B-ChemicalEntity
chorea,1172,B-DiseaseOrPhenotypicFeature
and,1172,O
encephalopathy,1172,B-DiseaseOrPhenotypicFeature
in,1172,O
atypical,1172,O
nonketotic,1172,B-DiseaseOrPhenotypicFeature
hyperglycinemia,1172,I-DiseaseOrPhenotypicFeature
.,1172,O
Nonketotic,1173,B-DiseaseOrPhenotypicFeature
hyperglycinemia,1173,I-DiseaseOrPhenotypicFeature
is,1173,O
a,1173,O
disorder,1173,B-DiseaseOrPhenotypicFeature
of,1173,I-DiseaseOrPhenotypicFeature
amino,1173,I-DiseaseOrPhenotypicFeature
acid,1173,I-DiseaseOrPhenotypicFeature
metabolism,1173,I-DiseaseOrPhenotypicFeature
in,1173,O
which,1173,O
a,1173,O
defect,1173,O
in,1173,O
the,1173,O
glycine,1173,B-ChemicalEntity
cleavage,1173,O
system,1173,O
leads,1173,O
to,1173,O
an,1173,O
accumulation,1173,O
of,1173,O
glycine,1173,B-ChemicalEntity
in,1173,O
the,1173,O
brain,1173,O
and,1173,O
other,1173,O
body,1173,O
compartments,1173,O
.,1173,O
In,1174,O
the,1174,O
classical,1174,O
form,1174,O
it,1174,O
presents,1174,O
as,1174,O
neonatal,1174,O
apnea,1174,B-DiseaseOrPhenotypicFeature
",",1174,O
intractable,1174,O
seizures,1174,B-DiseaseOrPhenotypicFeature
",",1174,O
and,1174,O
hypotonia,1174,B-DiseaseOrPhenotypicFeature
",",1174,O
followed,1174,O
by,1174,O
significant,1174,O
psychomotor,1174,B-DiseaseOrPhenotypicFeature
retardation,1174,I-DiseaseOrPhenotypicFeature
.,1174,O
An,1175,O
important,1175,O
subset,1175,O
of,1175,O
children,1175,O
with,1175,O
nonketotic,1175,B-DiseaseOrPhenotypicFeature
hyperglycinemia,1175,I-DiseaseOrPhenotypicFeature
are,1175,O
atypical,1175,O
variants,1175,O
who,1175,O
present,1175,O
in,1175,O
a,1175,O
heterogeneous,1175,O
manner,1175,O
.,1175,O
This,1176,O
report,1176,O
describes,1176,O
a,1176,O
patient,1176,B-OrganismTaxon
with,1176,O
mild,1176,O
language,1176,B-DiseaseOrPhenotypicFeature
delay,1176,I-DiseaseOrPhenotypicFeature
and,1176,O
mental,1176,B-DiseaseOrPhenotypicFeature
retardation,1176,I-DiseaseOrPhenotypicFeature
",",1176,O
who,1176,O
was,1176,O
found,1176,O
to,1176,O
have,1176,O
nonketotic,1176,B-DiseaseOrPhenotypicFeature
hyperglycinemia,1176,I-DiseaseOrPhenotypicFeature
following,1176,O
her,1176,O
presentation,1176,O
with,1176,O
acute,1176,O
encephalopathy,1176,B-DiseaseOrPhenotypicFeature
and,1176,O
chorea,1176,B-DiseaseOrPhenotypicFeature
shortly,1176,O
after,1176,O
initiation,1176,O
of,1176,O
valproate,1176,B-ChemicalEntity
therapy,1176,O
.,1176,O
Genetic,1177,O
polymorphism,1177,O
of,1177,O
the,1177,O
binding,1177,O
domain,1177,O
of,1177,O
surfactant,1177,B-GeneOrGeneProduct
protein-A2,1177,I-GeneOrGeneProduct
increases,1177,O
susceptibility,1177,O
to,1177,O
meningococcal,1177,B-DiseaseOrPhenotypicFeature
disease,1177,I-DiseaseOrPhenotypicFeature
.,1177,O
BACKGROUND,1178,O
:,1178,O
Meningococcal,1178,B-DiseaseOrPhenotypicFeature
disease,1178,I-DiseaseOrPhenotypicFeature
occurs,1178,O
after,1178,O
colonization,1178,O
of,1178,O
the,1178,O
nasopharynx,1178,O
with,1178,O
Neisseria,1178,B-DiseaseOrPhenotypicFeature
meningitidis,1178,I-DiseaseOrPhenotypicFeature
.,1178,O
Surfactant,1179,B-GeneOrGeneProduct
protein,1179,I-GeneOrGeneProduct
(,1179,I-GeneOrGeneProduct
SP,1179,I-GeneOrGeneProduct
),1179,I-GeneOrGeneProduct
-A,1179,I-GeneOrGeneProduct
and,1179,O
SP-D,1179,B-GeneOrGeneProduct
are,1179,O
pattern-recognition,1179,O
molecules,1179,O
of,1179,O
the,1179,O
respiratory,1179,O
tract,1179,O
that,1179,O
activate,1179,O
inflammatory,1179,B-DiseaseOrPhenotypicFeature
and,1179,O
phagocytic,1179,O
defences,1179,O
after,1179,O
binding,1179,O
to,1179,O
microbial,1179,O
sugars,1179,B-ChemicalEntity
.,1179,O
Variation,1180,O
in,1180,O
the,1180,O
genes,1180,O
of,1180,O
the,1180,O
surfactant,1180,O
proteins,1180,O
affects,1180,O
the,1180,O
expression,1180,O
and,1180,O
function,1180,O
of,1180,O
these,1180,O
molecules,1180,O
.,1180,O
METHODS,1181,O
:,1181,O
Allele,1181,O
frequencies,1181,O
of,1181,O
SP-A1,1181,B-GeneOrGeneProduct
",",1181,O
SP-A2,1181,B-GeneOrGeneProduct
",",1181,O
and,1181,O
SP-D,1181,B-GeneOrGeneProduct
were,1181,O
determined,1181,O
by,1181,O
polymerase,1181,O
chain,1181,O
reaction,1181,O
in,1181,O
303,1181,O
patients,1181,B-OrganismTaxon
with,1181,O
microbiologically,1181,O
proven,1181,O
meningococcal,1181,B-DiseaseOrPhenotypicFeature
disease,1181,I-DiseaseOrPhenotypicFeature
",",1181,O
including,1181,O
18,1181,O
patients,1181,B-OrganismTaxon
who,1181,O
died,1181,B-DiseaseOrPhenotypicFeature
",",1181,O
and,1181,O
222,1181,O
healthy,1181,O
control,1181,O
subjects,1181,O
.,1181,O
RESULTS,1182,O
:,1182,O
Homozygosity,1182,O
of,1182,O
allele,1182,O
1A1,1182,O
of,1182,O
SP-A2,1182,B-GeneOrGeneProduct
increased,1182,O
the,1182,O
risk,1182,O
of,1182,O
meningococcal,1182,B-DiseaseOrPhenotypicFeature
disease,1182,I-DiseaseOrPhenotypicFeature
(,1182,O
odds,1182,O
ratio,1182,O
[,1182,O
OR,1182,O
],1182,O
",",1182,O
7.4,1182,O
;,1182,O
95,1182,O
%,1182,O
confidence,1182,O
interval,1182,O
[,1182,O
CI,1182,O
],1182,O
",",1182,O
1.3-42.4,1182,O
),1182,O
;,1182,O
carriage,1182,O
of,1182,O
1A5,1182,O
reduced,1182,O
the,1182,O
risk,1182,O
(,1182,O
OR,1182,O
",",1182,O
0.3,1182,O
;,1182,O
95,1182,O
%,1182,O
CI,1182,O
",",1182,O
0.1-0.97,1182,O
),1182,O
.,1182,O
An,1183,O
analysis,1183,O
of,1183,O
the,1183,O
multiple,1183,O
single-nucleotide,1183,O
polymorphisms,1183,O
in,1183,O
SP-A,1183,B-GeneOrGeneProduct
demonstrated,1183,O
that,1183,O
homozygosity,1183,O
for,1183,O
alleles,1183,O
encoding,1183,O
lysine,1183,B-SequenceVariant
(,1183,I-SequenceVariant
in,1183,I-SequenceVariant
1A1,1183,I-SequenceVariant
),1183,I-SequenceVariant
rather,1183,I-SequenceVariant
than,1183,I-SequenceVariant
glutamine,1183,I-SequenceVariant
(,1183,I-SequenceVariant
in,1183,I-SequenceVariant
1A5,1183,I-SequenceVariant
),1183,I-SequenceVariant
at,1183,I-SequenceVariant
amino,1183,I-SequenceVariant
acid,1183,I-SequenceVariant
223,1183,I-SequenceVariant
in,1183,O
the,1183,O
carbohydrate,1183,B-ChemicalEntity
recognition,1183,O
domain,1183,O
was,1183,O
associated,1183,O
with,1183,O
an,1183,O
increased,1183,O
risk,1183,O
of,1183,O
meningococcal,1183,B-DiseaseOrPhenotypicFeature
disease,1183,I-DiseaseOrPhenotypicFeature
(,1183,O
OR,1183,O
",",1183,O
6.7,1183,O
;,1183,O
95,1183,O
%,1183,O
CI,1183,O
",",1183,O
1.4-31.5,1183,O
),1183,O
.,1183,O
Carriage,1184,O
of,1184,O
alleles,1184,O
encoding,1184,O
lysine,1184,B-SequenceVariant
at,1184,I-SequenceVariant
residue,1184,I-SequenceVariant
223,1184,I-SequenceVariant
was,1184,O
found,1184,O
in,1184,O
61,1184,O
%,1184,O
of,1184,O
patients,1184,B-OrganismTaxon
who,1184,O
died,1184,B-DiseaseOrPhenotypicFeature
",",1184,O
compared,1184,O
with,1184,O
35,1184,O
%,1184,O
of,1184,O
those,1184,O
who,1184,O
survived,1184,O
(,1184,O
OR,1184,O
adjusted,1184,O
for,1184,O
age,1184,O
",",1184,O
2.9,1184,O
;,1184,O
95,1184,O
%,1184,O
CI,1184,O
",",1184,O
1.1-7.7,1184,O
),1184,O
.,1184,O
Genetic,1185,O
variation,1185,O
of,1185,O
SP-A1,1185,B-GeneOrGeneProduct
and,1185,O
SP-D,1185,B-GeneOrGeneProduct
was,1185,O
not,1185,O
associated,1185,O
with,1185,O
meningococcal,1185,B-DiseaseOrPhenotypicFeature
disease,1185,I-DiseaseOrPhenotypicFeature
.,1185,O
CONCLUSIONS,1186,O
:,1186,O
Gene,1186,O
polymorphism,1186,O
resulting,1186,O
in,1186,O
the,1186,O
substitution,1186,O
of,1186,O
glutamine,1186,B-SequenceVariant
with,1186,I-SequenceVariant
lysine,1186,I-SequenceVariant
at,1186,I-SequenceVariant
residue,1186,I-SequenceVariant
223,1186,I-SequenceVariant
in,1186,O
the,1186,O
carbohydrate,1186,B-ChemicalEntity
recognition,1186,O
domain,1186,O
of,1186,O
SP-A2,1186,B-GeneOrGeneProduct
increases,1186,O
susceptibility,1186,O
to,1186,O
meningococcal,1186,B-DiseaseOrPhenotypicFeature
disease,1186,I-DiseaseOrPhenotypicFeature
",",1186,O
as,1186,O
well,1186,O
as,1186,O
the,1186,O
risk,1186,O
of,1186,O
death,1186,B-DiseaseOrPhenotypicFeature
.,1186,O
A,1187,O
novel,1187,O
mutation,1187,O
(,1187,O
E333D,1187,B-SequenceVariant
),1187,O
in,1187,O
the,1187,O
thyroid,1187,B-GeneOrGeneProduct
hormone,1187,I-GeneOrGeneProduct
beta,1187,I-GeneOrGeneProduct
receptor,1187,I-GeneOrGeneProduct
causing,1187,O
resistance,1187,B-DiseaseOrPhenotypicFeature
to,1187,I-DiseaseOrPhenotypicFeature
thyroid,1187,I-DiseaseOrPhenotypicFeature
hormone,1187,I-DiseaseOrPhenotypicFeature
syndrome,1187,I-DiseaseOrPhenotypicFeature
.,1187,O
Resistance,1188,B-DiseaseOrPhenotypicFeature
to,1188,I-DiseaseOrPhenotypicFeature
thyroid,1188,I-DiseaseOrPhenotypicFeature
hormone,1188,I-DiseaseOrPhenotypicFeature
(,1188,O
RTH,1188,B-DiseaseOrPhenotypicFeature
),1188,O
is,1188,O
an,1188,O
inherited,1188,O
syndrome,1188,O
characterized,1188,O
by,1188,O
elevated,1188,O
serum,1188,O
thyroid,1188,B-ChemicalEntity
hormones,1188,I-ChemicalEntity
(,1188,O
TH,1188,B-ChemicalEntity
),1188,O
",",1188,O
failure,1188,O
to,1188,O
suppress,1188,O
pituitary,1188,O
thyroid,1188,B-GeneOrGeneProduct
stimulating,1188,I-GeneOrGeneProduct
hormone,1188,I-GeneOrGeneProduct
(,1188,O
TSH,1188,B-GeneOrGeneProduct
),1188,O
secretion,1188,O
",",1188,O
and,1188,O
variable,1188,O
peripheral,1188,O
tissue,1188,O
responsiveness,1188,O
to,1188,O
TH,1188,B-ChemicalEntity
.,1188,O
The,1189,O
disorder,1189,O
is,1189,O
associated,1189,O
with,1189,O
diverse,1189,O
mutations,1189,O
in,1189,O
the,1189,O
thyroid,1189,B-GeneOrGeneProduct
hormone,1189,I-GeneOrGeneProduct
beta,1189,I-GeneOrGeneProduct
receptor,1189,I-GeneOrGeneProduct
(,1189,O
TRbeta,1189,B-GeneOrGeneProduct
),1189,O
.,1189,O
Here,1190,O
",",1190,O
we,1190,O
report,1190,O
a,1190,O
novel,1190,O
natural,1190,O
RTH,1190,B-DiseaseOrPhenotypicFeature
mutation,1190,O
(,1190,O
E333D,1190,B-SequenceVariant
),1190,O
located,1190,O
in,1190,O
the,1190,O
large,1190,O
carboxy-terminal,1190,O
ligand,1190,O
binding,1190,O
domain,1190,O
of,1190,O
TRbeta,1190,B-GeneOrGeneProduct
.,1190,O
The,1191,O
mutation,1191,O
was,1191,O
identified,1191,O
in,1191,O
a,1191,O
22-year-old,1191,O
French,1191,O
woman,1191,B-OrganismTaxon
coming,1191,O
to,1191,O
medical,1191,O
attention,1191,O
because,1191,O
of,1191,O
an,1191,O
increasing,1191,O
overweight,1191,B-DiseaseOrPhenotypicFeature
.,1191,O
Biochemical,1192,O
tests,1192,O
showed,1192,O
elevated,1192,O
free,1192,O
thyroxine,1192,B-ChemicalEntity
(,1192,O
T4,1192,B-ChemicalEntity
:,1192,O
20.8,1192,O
pg/ml,1192,O
(,1192,O
normal,1192,O
",",1192,O
8.5-18,1192,O
),1192,O
),1192,O
and,1192,O
triiodothyronine,1192,B-ChemicalEntity
(,1192,O
T3,1192,B-ChemicalEntity
:,1192,O
5.7,1192,O
pg/ml,1192,O
(,1192,O
normal,1192,O
",",1192,O
1.4-4,1192,O
),1192,O
),1192,O
in,1192,O
the,1192,O
serum,1192,O
",",1192,O
together,1192,O
with,1192,O
an,1192,O
inappropriately,1192,O
nonsuppressed,1192,O
TSH,1192,B-GeneOrGeneProduct
level,1192,O
of,1192,O
4.7,1192,O
mU/ml,1192,O
(,1192,O
normal,1192,O
",",1192,O
0.4-4,1192,O
),1192,O
.,1192,O
Her,1193,O
father,1193,O
and,1193,O
her,1193,O
brother,1193,O
's,1193,O
serum,1193,O
tests,1193,O
also,1193,O
showed,1193,O
biochemical,1193,O
abnormalities,1193,O
consistent,1193,O
with,1193,O
RTH,1193,B-DiseaseOrPhenotypicFeature
.,1193,O
Direct,1194,O
sequencing,1194,O
of,1194,O
the,1194,O
TRbeta,1194,B-GeneOrGeneProduct
gene,1194,O
revealed,1194,O
a,1194,O
heterozygous,1194,O
transition,1194,O
1284A,1194,B-SequenceVariant
>,1194,I-SequenceVariant
C,1194,I-SequenceVariant
in,1194,O
exon,1194,O
9,1194,O
resulting,1194,O
in,1194,O
substitution,1194,O
of,1194,O
glutamic,1194,B-SequenceVariant
acid,1194,I-SequenceVariant
333,1194,I-SequenceVariant
by,1194,I-SequenceVariant
aspartic,1194,I-SequenceVariant
acid,1194,I-SequenceVariant
residue,1194,O
(,1194,O
E333D,1194,B-SequenceVariant
),1194,O
.,1194,O
Further,1195,O
functional,1195,O
analyses,1195,O
of,1195,O
the,1195,O
novel,1195,O
TRbeta,1195,B-GeneOrGeneProduct
mutant,1195,O
were,1195,O
conducted,1195,O
.,1195,O
We,1196,O
found,1196,O
that,1196,O
the,1196,O
E333D,1196,B-SequenceVariant
mutation,1196,O
neither,1196,O
significantly,1196,O
affected,1196,O
the,1196,O
affinity,1196,O
of,1196,O
the,1196,O
receptor,1196,O
for,1196,O
T3,1196,B-ChemicalEntity
nor,1196,O
modified,1196,O
heterodimer,1196,O
formation,1196,O
with,1196,O
retinoid,1196,B-GeneOrGeneProduct
X,1196,I-GeneOrGeneProduct
receptor,1196,I-GeneOrGeneProduct
(,1196,O
RXR,1196,B-GeneOrGeneProduct
),1196,O
when,1196,O
bound,1196,O
to,1196,O
DNA,1196,O
.,1196,O
However,1197,O
",",1197,O
in,1197,O
transient,1197,O
transfection,1197,O
assays,1197,O
",",1197,O
the,1197,O
E333D,1197,B-SequenceVariant
TRbeta,1197,B-GeneOrGeneProduct
mutant,1197,O
exhibited,1197,O
impaired,1197,O
transcriptional,1197,O
regulation,1197,O
on,1197,O
two,1197,O
distinct,1197,O
positively,1197,O
regulated,1197,O
thyroid,1197,O
response,1197,O
elements,1197,O
(,1197,O
F2-,1197,O
and,1197,O
DR4-TREs,1197,O
),1197,O
as,1197,O
well,1197,O
as,1197,O
on,1197,O
the,1197,O
negatively,1197,O
regulated,1197,O
human,1197,B-OrganismTaxon
TSHalpha,1197,B-GeneOrGeneProduct
promoter,1197,O
.,1197,O
Moreover,1198,O
",",1198,O
a,1198,O
dominant,1198,O
inhibition,1198,O
of,1198,O
the,1198,O
wild-type,1198,O
TRbeta,1198,B-GeneOrGeneProduct
counterpart,1198,O
transactivation,1198,O
function,1198,O
was,1198,O
observed,1198,O
on,1198,O
both,1198,O
a,1198,O
positive,1198,O
(,1198,O
F2-TRE,1198,O
),1198,O
and,1198,O
a,1198,O
negative,1198,O
(,1198,O
TSHalpha,1198,B-GeneOrGeneProduct
),1198,O
promoter,1198,O
.,1198,O
These,1199,O
results,1199,O
strongly,1199,O
suggest,1199,O
that,1199,O
the,1199,O
E333D,1199,B-SequenceVariant
TRbeta,1199,B-GeneOrGeneProduct
mutation,1199,O
is,1199,O
responsible,1199,O
for,1199,O
the,1199,O
RTH,1199,B-DiseaseOrPhenotypicFeature
phenotype,1199,O
in,1199,O
the,1199,O
proposita,1199,O
's,1199,O
family,1199,O
.,1199,O
Families,1200,O
with,1200,O
the,1200,O
risk,1200,O
allele,1200,O
of,1200,O
DISC1,1200,B-GeneOrGeneProduct
reveal,1200,O
a,1200,O
link,1200,O
between,1200,O
schizophrenia,1200,B-DiseaseOrPhenotypicFeature
and,1200,O
another,1200,O
component,1200,O
of,1200,O
the,1200,O
same,1200,O
molecular,1200,O
pathway,1200,O
",",1200,O
NDE1,1200,B-GeneOrGeneProduct
.,1200,O
We,1201,O
have,1201,O
previously,1201,O
reported,1201,O
a,1201,O
robust,1201,O
association,1201,O
between,1201,O
an,1201,O
allelic,1201,O
haplotype,1201,O
of,1201,O
'Disrupted,1201,O
in,1201,I-GeneOrGeneProduct
Schizophrenia,1201,I-GeneOrGeneProduct
1,1201,I-GeneOrGeneProduct
',1201,O
(,1201,O
DISC1,1201,B-GeneOrGeneProduct
),1201,O
and,1201,O
schizophrenia,1201,B-DiseaseOrPhenotypicFeature
in,1201,O
a,1201,O
nationwide,1201,O
collection,1201,O
of,1201,O
Finnish,1201,O
schizophrenia,1201,B-DiseaseOrPhenotypicFeature
families,1201,O
.,1201,O
This,1202,O
specific,1202,O
DISC1,1202,B-GeneOrGeneProduct
allele,1202,O
was,1202,O
later,1202,O
identified,1202,O
to,1202,O
associate,1202,O
with,1202,O
visual,1202,O
working,1202,O
memory,1202,O
",",1202,O
selectively,1202,O
in,1202,O
males,1202,O
.,1202,O
DISC1,1203,B-GeneOrGeneProduct
association,1203,O
to,1203,O
schizophrenia,1203,B-DiseaseOrPhenotypicFeature
has,1203,O
since,1203,O
been,1203,O
replicated,1203,O
in,1203,O
multiple,1203,O
independent,1203,O
study,1203,O
samples,1203,O
from,1203,O
different,1203,O
populations,1203,O
.,1203,O
In,1204,O
this,1204,O
study,1204,O
",",1204,O
we,1204,O
conditioned,1204,O
our,1204,O
sample,1204,O
of,1204,O
Finnish,1204,O
families,1204,O
for,1204,O
the,1204,O
presence,1204,O
of,1204,O
the,1204,O
Finnish,1204,O
tentative,1204,O
risk,1204,O
allele,1204,O
for,1204,O
DISC1,1204,B-GeneOrGeneProduct
and,1204,O
re-analyzed,1204,O
our,1204,O
genome-wide,1204,O
scan,1204,O
data,1204,O
of,1204,O
443,1204,O
markers,1204,O
on,1204,O
the,1204,O
basis,1204,O
of,1204,O
this,1204,O
stratification,1204,O
.,1204,O
Two,1205,O
additional,1205,O
loci,1205,O
displayed,1205,O
an,1205,O
evidence,1205,O
of,1205,O
linkage,1205,O
(,1205,O
LOD,1205,O
>,1205,O
3,1205,O
),1205,O
and,1205,O
included,1205,O
a,1205,O
locus,1205,O
on,1205,O
16p13,1205,O
",",1205,O
proximal,1205,O
to,1205,O
the,1205,O
gene,1205,O
encoding,1205,O
NDE1,1205,B-GeneOrGeneProduct
",",1205,O
which,1205,O
has,1205,O
been,1205,O
shown,1205,O
to,1205,O
biologically,1205,O
interact,1205,O
with,1205,O
DISC1,1205,B-GeneOrGeneProduct
.,1205,O
Although,1206,O
none,1206,O
of,1206,O
the,1206,O
observed,1206,O
linkages,1206,O
remained,1206,O
significant,1206,O
after,1206,O
multiple,1206,O
test,1206,O
correction,1206,O
through,1206,O
simulation,1206,O
",",1206,O
further,1206,O
analysis,1206,O
of,1206,O
NDE1,1206,B-GeneOrGeneProduct
revealed,1206,O
an,1206,O
association,1206,O
between,1206,O
a,1206,O
tag-haplotype,1206,O
and,1206,O
schizophrenia,1206,B-DiseaseOrPhenotypicFeature
(,1206,O
P,1206,O
=,1206,O
0.00046,1206,O
),1206,O
specific,1206,O
to,1206,O
females,1206,O
",",1206,O
which,1206,O
proved,1206,O
to,1206,O
be,1206,O
significant,1206,O
(,1206,O
P,1206,O
=,1206,O
0.011,1206,O
),1206,O
after,1206,O
multiple,1206,O
test,1206,O
correction,1206,O
.,1206,O
Our,1207,O
finding,1207,O
would,1207,O
support,1207,O
the,1207,O
concept,1207,O
that,1207,O
initial,1207,O
gene,1207,O
findings,1207,O
in,1207,O
multifactorial,1207,O
diseases,1207,O
will,1207,O
assist,1207,O
in,1207,O
the,1207,O
identification,1207,O
of,1207,O
other,1207,O
components,1207,O
of,1207,O
complex,1207,O
genetic,1207,O
etiology,1207,O
.,1207,O
Notably,1208,O
",",1208,O
this,1208,O
and,1208,O
other,1208,O
converging,1208,O
lines,1208,O
of,1208,O
evidence,1208,O
underline,1208,O
the,1208,O
importance,1208,O
of,1208,O
DISC1-related,1208,B-GeneOrGeneProduct
functional,1208,O
pathways,1208,O
in,1208,O
the,1208,O
etiology,1208,O
of,1208,O
schizophrenia,1208,B-DiseaseOrPhenotypicFeature
.,1208,O
Cytochrome,1209,B-GeneOrGeneProduct
p4501A1,1209,I-GeneOrGeneProduct
gene,1209,O
variants,1209,O
as,1209,O
susceptibility,1209,O
marker,1209,O
for,1209,O
prostate,1209,B-DiseaseOrPhenotypicFeature
cancer,1209,I-DiseaseOrPhenotypicFeature
.,1209,O
CYP1A1,1210,B-GeneOrGeneProduct
activates,1210,O
environmental,1210,O
procarcinogens,1210,O
and,1210,O
catalyzes,1210,O
oxidative,1210,O
metabolism,1210,O
of,1210,O
estrogens,1210,O
and,1210,O
is,1210,O
likely,1210,O
to,1210,O
play,1210,O
an,1210,O
important,1210,O
role,1210,O
in,1210,O
the,1210,O
etiology,1210,O
of,1210,O
prostate,1210,B-DiseaseOrPhenotypicFeature
cancer,1210,I-DiseaseOrPhenotypicFeature
.,1210,O
To,1211,O
evaluate,1211,O
this,1211,O
phenomenon,1211,O
",",1211,O
the,1211,O
association,1211,O
between,1211,O
two,1211,O
single,1211,O
nucleotide,1211,O
polymorphisms,1211,O
(,1211,O
A,1211,B-SequenceVariant
to,1211,I-SequenceVariant
G,1211,I-SequenceVariant
transition,1211,O
in,1211,O
exon7,1211,O
leading,1211,O
to,1211,O
amino,1211,O
acid,1211,O
substitution,1211,O
Ile462Val,1211,B-SequenceVariant
and,1211,O
T3801C,1211,B-SequenceVariant
at,1211,O
3'UTR,1211,O
),1211,O
of,1211,O
CYP1A1,1211,B-GeneOrGeneProduct
gene,1211,O
in,1211,O
prostate,1211,B-DiseaseOrPhenotypicFeature
cancer,1211,I-DiseaseOrPhenotypicFeature
were,1211,O
analyzed,1211,O
in,1211,O
a,1211,O
case-control,1211,O
study,1211,O
of,1211,O
100,1211,O
individuals,1211,O
in,1211,O
South,1211,O
Indian,1211,O
population,1211,O
.,1211,O
The,1212,O
estimated,1212,O
relative,1212,O
risk,1212,O
was,1212,O
significantly,1212,O
high,1212,O
for,1212,O
individuals,1212,O
with,1212,O
w1/m1,1212,O
genotype,1212,O
at,1212,O
3'UTR,1212,O
of,1212,O
CYP1A1,1212,B-GeneOrGeneProduct
gene,1212,O
(,1212,O
OR-4.64,1212,O
;,1212,O
95,1212,O
%,1212,O
CI,1212,O
=,1212,O
1.51-14.86,1212,O
;,1212,O
P,1212,O
<,1212,O
0.01,1212,O
),1212,O
whereas,1212,O
the,1212,O
CYP1A1,1212,B-GeneOrGeneProduct
Ile/Val,1212,B-SequenceVariant
genotype,1212,O
(,1212,O
w2/m2,1212,O
),1212,O
on,1212,O
exon,1212,O
7,1212,O
was,1212,O
found,1212,O
to,1212,O
be,1212,O
associated,1212,O
with,1212,O
a,1212,O
decreased,1212,O
risk,1212,O
for,1212,O
prostate,1212,B-DiseaseOrPhenotypicFeature
cancer,1212,I-DiseaseOrPhenotypicFeature
(,1212,O
OR-0.17,1212,O
;,1212,O
95,1212,O
%,1212,O
CI,1212,O
=,1212,O
0.02-0.89,1212,O
;,1212,O
P=0.03,1212,O
),1212,O
.,1212,O
A,1213,O
Stratified,1213,O
analysis,1213,O
of,1213,O
the,1213,O
genotypes,1213,O
with,1213,O
age,1213,O
of,1213,O
onset,1213,O
and,1213,O
tumor,1213,B-DiseaseOrPhenotypicFeature
grade,1213,O
showed,1213,O
the,1213,O
w1/m1,1213,O
genotype,1213,O
to,1213,O
be,1213,O
significantly,1213,O
associated,1213,O
with,1213,O
an,1213,O
early,1213,O
age,1213,O
of,1213,O
onset,1213,O
;,1213,O
however,1213,O
the,1213,O
tumor,1213,B-DiseaseOrPhenotypicFeature
grades,1213,O
did,1213,O
not,1213,O
have,1213,O
significant,1213,O
association,1213,O
with,1213,O
the,1213,O
variant,1213,O
genotypes,1213,O
.,1213,O
Thus,1214,O
the,1214,O
present,1214,O
study,1214,O
indicates,1214,O
that,1214,O
individuals,1214,O
with,1214,O
the,1214,O
variant,1214,O
w1/m1,1214,O
genotype,1214,O
exhibit,1214,O
an,1214,O
increased,1214,O
risk,1214,O
while,1214,O
those,1214,O
with,1214,O
w2/m2,1214,O
genotype,1214,O
exhibit,1214,O
a,1214,O
decreased,1214,O
risk,1214,O
for,1214,O
prostate,1214,B-DiseaseOrPhenotypicFeature
cancer,1214,I-DiseaseOrPhenotypicFeature
.,1214,O
Behavioral,1215,O
effects,1215,O
of,1215,O
pubertal,1215,O
anabolic,1215,B-ChemicalEntity
androgenic,1215,I-ChemicalEntity
steroid,1215,I-ChemicalEntity
exposure,1215,O
in,1215,O
male,1215,O
rats,1215,B-OrganismTaxon
with,1215,O
low,1215,O
serotonin,1215,B-ChemicalEntity
.,1215,O
The,1216,O
goal,1216,O
of,1216,O
this,1216,O
study,1216,O
was,1216,O
to,1216,O
assess,1216,O
the,1216,O
interactive,1216,O
effects,1216,O
of,1216,O
chronic,1216,O
anabolic,1216,B-ChemicalEntity
androgenic,1216,I-ChemicalEntity
steroid,1216,I-ChemicalEntity
(,1216,O
AAS,1216,B-ChemicalEntity
),1216,O
exposure,1216,O
and,1216,O
brain,1216,O
serotonin,1216,B-ChemicalEntity
(,1216,O
5-hydroxytryptamine,1216,B-ChemicalEntity
",",1216,O
5-HT,1216,B-ChemicalEntity
),1216,O
depletion,1216,O
on,1216,O
behavior,1216,O
of,1216,O
pubertal,1216,O
male,1216,O
rats,1216,B-OrganismTaxon
.,1216,O
Serotonin,1217,B-ChemicalEntity
was,1217,O
depleted,1217,O
beginning,1217,O
on,1217,O
postnatal,1217,O
day,1217,O
26,1217,O
with,1217,O
parachlorophenylalanine,1217,B-ChemicalEntity
(,1217,O
PCPA,1217,B-ChemicalEntity
100,1217,O
mg/kg,1217,O
",",1217,O
every,1217,O
other,1217,O
day,1217,O
),1217,O
;,1217,O
controls,1217,O
received,1217,O
saline,1217,O
.,1217,O
At,1218,O
puberty,1218,O
(,1218,O
P40,1218,O
),1218,O
",",1218,O
half,1218,O
the,1218,O
PCPA-treated,1218,B-ChemicalEntity
rats,1218,B-OrganismTaxon
and,1218,O
half,1218,O
the,1218,O
saline-treated,1218,O
rats,1218,B-OrganismTaxon
began,1218,O
treatment,1218,O
with,1218,O
testosterone,1218,B-ChemicalEntity
(,1218,O
T,1218,B-ChemicalEntity
",",1218,O
5,1218,O
mg/kg,1218,O
",",1218,O
5,1218,O
days/week,1218,O
),1218,O
.,1218,O
Behavioral,1219,O
measures,1219,O
included,1219,O
locomotion,1219,O
",",1219,O
irritability,1219,B-DiseaseOrPhenotypicFeature
",",1219,O
copulation,1219,O
",",1219,O
partner,1219,O
preference,1219,O
",",1219,O
and,1219,O
aggression,1219,B-DiseaseOrPhenotypicFeature
.,1219,O
Animals,1220,O
were,1220,O
tested,1220,O
for,1220,O
aggression,1220,B-DiseaseOrPhenotypicFeature
in,1220,O
their,1220,O
home,1220,O
cage,1220,O
",",1220,O
both,1220,O
with,1220,O
and,1220,O
without,1220,O
physical,1220,O
provocation,1220,O
(,1220,O
mild,1220,O
tail,1220,O
pinch,1220,O
),1220,O
.,1220,O
Brain,1221,O
levels,1221,O
of,1221,O
5-HT,1221,B-ChemicalEntity
and,1221,O
its,1221,O
metabolite,1221,O
",",1221,O
5-hydroxyindoleacetic,1221,B-ChemicalEntity
acid,1221,I-ChemicalEntity
(,1221,O
5-HIAA,1221,B-ChemicalEntity
),1221,O
",",1221,O
were,1221,O
determined,1221,O
using,1221,O
HPLC,1221,O
.,1221,O
PCPA,1222,B-ChemicalEntity
significantly,1222,O
and,1222,O
substantially,1222,O
depleted,1222,O
5-HT,1222,B-ChemicalEntity
and,1222,O
5-HIAA,1222,B-ChemicalEntity
in,1222,O
all,1222,O
brain,1222,O
regions,1222,O
examined,1222,O
.,1222,O
Chronic,1223,O
T,1223,B-ChemicalEntity
treatment,1223,O
significantly,1223,O
decreased,1223,O
5-HT,1223,B-ChemicalEntity
and,1223,O
5-HIAA,1223,B-ChemicalEntity
in,1223,O
certain,1223,O
brain,1223,O
areas,1223,O
",",1223,O
but,1223,O
to,1223,O
a,1223,O
much,1223,O
lesser,1223,O
extent,1223,O
than,1223,O
PCPA,1223,B-ChemicalEntity
.,1223,O
Chronic,1224,O
exposure,1224,O
to,1224,O
PCPA,1224,B-ChemicalEntity
alone,1224,O
significantly,1224,O
decreased,1224,O
locomotor,1224,O
activity,1224,O
and,1224,O
increased,1224,O
irritability,1224,B-DiseaseOrPhenotypicFeature
but,1224,O
had,1224,O
no,1224,O
effect,1224,O
on,1224,O
sexual,1224,O
behavior,1224,O
",",1224,O
partner,1224,O
preference,1224,O
",",1224,O
or,1224,O
aggression,1224,B-DiseaseOrPhenotypicFeature
.,1224,O
T,1225,B-ChemicalEntity
alone,1225,O
had,1225,O
no,1225,O
effect,1225,O
on,1225,O
locomotion,1225,O
",",1225,O
irritability,1225,B-DiseaseOrPhenotypicFeature
",",1225,O
or,1225,O
sexual,1225,O
behavior,1225,O
but,1225,O
increased,1225,O
partner,1225,O
preference,1225,O
and,1225,O
aggression,1225,B-DiseaseOrPhenotypicFeature
.,1225,O
The,1226,O
most,1226,O
striking,1226,O
effect,1226,O
of,1226,O
combining,1226,O
T+PCPA,1226,B-ChemicalEntity
was,1226,O
a,1226,O
significant,1226,O
increase,1226,O
in,1226,O
attack,1226,O
frequency,1226,O
as,1226,O
well,1226,O
as,1226,O
a,1226,O
significant,1226,O
decrease,1226,O
in,1226,O
the,1226,O
latency,1226,O
to,1226,O
attack,1226,O
",",1226,O
particularly,1226,O
following,1226,O
physical,1226,O
provocation,1226,O
.,1226,O
Based,1227,O
on,1227,O
these,1227,O
data,1227,O
",",1227,O
it,1227,O
can,1227,O
be,1227,O
speculated,1227,O
that,1227,O
pubertal,1227,O
AAS,1227,B-ChemicalEntity
users,1227,O
with,1227,O
low,1227,O
central,1227,O
5-HT,1227,B-ChemicalEntity
may,1227,O
be,1227,O
especially,1227,O
prone,1227,O
to,1227,O
exhibit,1227,O
aggressive,1227,B-DiseaseOrPhenotypicFeature
behavior,1227,I-DiseaseOrPhenotypicFeature
.,1227,O
The,1228,O
G51S,1228,B-SequenceVariant
purine,1228,B-GeneOrGeneProduct
nucleoside,1228,I-GeneOrGeneProduct
phosphorylase,1228,I-GeneOrGeneProduct
polymorphism,1228,O
is,1228,O
associated,1228,O
with,1228,O
cognitive,1228,B-DiseaseOrPhenotypicFeature
decline,1228,I-DiseaseOrPhenotypicFeature
in,1228,O
Alzheimer,1228,B-DiseaseOrPhenotypicFeature
's,1228,I-DiseaseOrPhenotypicFeature
disease,1228,I-DiseaseOrPhenotypicFeature
patients,1228,B-OrganismTaxon
.,1228,O
Alzheimer,1229,B-DiseaseOrPhenotypicFeature
's,1229,I-DiseaseOrPhenotypicFeature
disease,1229,I-DiseaseOrPhenotypicFeature
(,1229,O
AD,1229,B-DiseaseOrPhenotypicFeature
),1229,O
is,1229,O
a,1229,O
polygenic,1229,O
and,1229,O
multifactorial,1229,O
complex,1229,O
disease,1229,O
",",1229,O
whose,1229,O
etiopathology,1229,O
is,1229,O
still,1229,O
unclear,1229,O
",",1229,O
however,1229,O
several,1229,O
genetic,1229,O
factors,1229,O
have,1229,O
shown,1229,O
to,1229,O
increase,1229,O
the,1229,O
risk,1229,O
of,1229,O
developing,1229,O
the,1229,O
disease,1229,O
.,1229,O
Purine,1230,O
nucleotides,1230,O
and,1230,O
nucleosides,1230,O
play,1230,O
an,1230,O
important,1230,O
role,1230,O
in,1230,O
the,1230,O
brain,1230,O
.,1230,O
Besides,1231,O
their,1231,O
role,1231,O
in,1231,O
neurotransmission,1231,O
and,1231,O
neuromodulation,1231,O
",",1231,O
they,1231,O
are,1231,O
involved,1231,O
in,1231,O
trophic,1231,O
factor,1231,O
release,1231,O
",",1231,O
apoptosis,1231,O
",",1231,O
and,1231,O
inflammatory,1231,B-DiseaseOrPhenotypicFeature
responses,1231,O
.,1231,O
These,1232,O
mediators,1232,O
may,1232,O
also,1232,O
have,1232,O
a,1232,O
pivotal,1232,O
role,1232,O
in,1232,O
the,1232,O
control,1232,O
of,1232,O
neurodegenerative,1232,O
processes,1232,O
associated,1232,O
with,1232,O
AD,1232,B-DiseaseOrPhenotypicFeature
.,1232,O
In,1233,O
this,1233,O
report,1233,O
the,1233,O
distribution,1233,O
of,1233,O
the,1233,O
exonic,1233,O
G/A,1233,B-SequenceVariant
single,1233,O
nucleotide,1233,O
polymorphism,1233,O
(,1233,O
SNP,1233,O
),1233,O
in,1233,O
purine,1233,B-GeneOrGeneProduct
nucleoside,1233,I-GeneOrGeneProduct
phosphorylase,1233,I-GeneOrGeneProduct
(,1233,O
PNP,1233,B-GeneOrGeneProduct
),1233,O
gene,1233,O
",",1233,O
resulting,1233,O
in,1233,O
the,1233,O
amino,1233,O
acid,1233,O
substitution,1233,O
serine,1233,B-SequenceVariant
to,1233,I-SequenceVariant
glycine,1233,I-SequenceVariant
at,1233,I-SequenceVariant
position,1233,I-SequenceVariant
51,1233,I-SequenceVariant
(,1233,O
G51S,1233,B-SequenceVariant
),1233,O
",",1233,O
was,1233,O
investigated,1233,O
in,1233,O
a,1233,O
large,1233,O
population,1233,O
of,1233,O
AD,1233,B-DiseaseOrPhenotypicFeature
patients,1233,B-OrganismTaxon
(,1233,O
n=321,1233,O
),1233,O
and,1233,O
non-demented,1233,O
control,1233,O
(,1233,O
n=208,1233,O
),1233,O
.,1233,O
The,1234,O
PNP,1234,B-GeneOrGeneProduct
polymorphism,1234,O
distribution,1234,O
was,1234,O
not,1234,O
different,1234,O
between,1234,O
patients,1234,B-OrganismTaxon
and,1234,O
controls,1234,O
.,1234,O
The,1235,O
polymorphism,1235,O
distribution,1235,O
was,1235,O
also,1235,O
analyzed,1235,O
in,1235,O
AD,1235,B-DiseaseOrPhenotypicFeature
patients,1235,B-OrganismTaxon
stratified,1235,O
according,1235,O
to,1235,O
differential,1235,O
progressive,1235,O
rate,1235,O
of,1235,O
cognitive,1235,B-DiseaseOrPhenotypicFeature
decline,1235,I-DiseaseOrPhenotypicFeature
during,1235,O
a,1235,O
2-year,1235,O
follow-up,1235,O
.,1235,O
An,1236,O
increased,1236,O
representation,1236,O
of,1236,O
the,1236,O
PNP,1236,B-GeneOrGeneProduct
AA,1236,O
genotype,1236,O
was,1236,O
observed,1236,O
in,1236,O
AD,1236,B-DiseaseOrPhenotypicFeature
patients,1236,B-OrganismTaxon
with,1236,O
fast,1236,O
cognitive,1236,B-DiseaseOrPhenotypicFeature
deterioration,1236,I-DiseaseOrPhenotypicFeature
in,1236,O
comparison,1236,O
with,1236,O
that,1236,O
from,1236,O
patients,1236,B-OrganismTaxon
with,1236,O
slow,1236,O
deterioration,1236,O
rate,1236,O
.,1236,O
Our,1237,O
findings,1237,O
suggest,1237,O
that,1237,O
the,1237,O
G51S,1237,B-SequenceVariant
PNP,1237,B-GeneOrGeneProduct
polymorphism,1237,O
is,1237,O
associated,1237,O
with,1237,O
a,1237,O
faster,1237,O
rate,1237,O
of,1237,O
cognitive,1237,B-DiseaseOrPhenotypicFeature
decline,1237,I-DiseaseOrPhenotypicFeature
in,1237,O
AD,1237,B-DiseaseOrPhenotypicFeature
patients,1237,B-OrganismTaxon
",",1237,O
highlighting,1237,O
the,1237,O
important,1237,O
role,1237,O
of,1237,O
purine,1237,O
metabolism,1237,O
in,1237,O
the,1237,O
progression,1237,O
of,1237,O
this,1237,O
neurodegenerative,1237,B-DiseaseOrPhenotypicFeature
disorder,1237,I-DiseaseOrPhenotypicFeature
.,1237,O
In,1238,O
vitro,1238,O
characterization,1238,O
of,1238,O
parasympathetic,1238,O
and,1238,O
sympathetic,1238,O
responses,1238,O
in,1238,O
cyclophosphamide-induced,1238,B-ChemicalEntity
cystitis,1238,B-DiseaseOrPhenotypicFeature
in,1238,O
the,1238,O
rat,1238,B-OrganismTaxon
.,1238,O
In,1239,O
cyclophosphamide-induced,1239,B-ChemicalEntity
cystitis,1239,B-DiseaseOrPhenotypicFeature
in,1239,O
the,1239,O
rat,1239,B-OrganismTaxon
",",1239,O
detrusor,1239,O
function,1239,O
is,1239,O
impaired,1239,O
and,1239,O
the,1239,O
expression,1239,O
and,1239,O
effects,1239,O
of,1239,O
muscarinic,1239,B-GeneOrGeneProduct
receptors,1239,I-GeneOrGeneProduct
altered,1239,O
.,1239,O
Whether,1240,O
or,1240,O
not,1240,O
the,1240,O
neuronal,1240,O
transmission,1240,O
may,1240,O
be,1240,O
affected,1240,O
by,1240,O
cystitis,1240,B-DiseaseOrPhenotypicFeature
was,1240,O
presently,1240,O
investigated,1240,O
.,1240,O
Responses,1241,O
of,1241,O
urinary,1241,O
strip,1241,O
preparations,1241,O
from,1241,O
control,1241,O
and,1241,O
cyclophosphamide-pretreated,1241,B-ChemicalEntity
rats,1241,B-OrganismTaxon
to,1241,O
electrical,1241,O
field,1241,O
stimulation,1241,O
and,1241,O
to,1241,O
agonists,1241,O
were,1241,O
assessed,1241,O
in,1241,O
the,1241,O
absence,1241,O
and,1241,O
presence,1241,O
of,1241,O
muscarinic,1241,B-ChemicalEntity
",",1241,I-ChemicalEntity
adrenergic,1241,I-ChemicalEntity
and,1241,I-ChemicalEntity
purinergic,1241,I-ChemicalEntity
receptor,1241,I-ChemicalEntity
antagonists,1241,I-ChemicalEntity
.,1241,O
Generally,1242,O
",",1242,O
atropine,1242,B-ChemicalEntity
reduced,1242,O
contractions,1242,O
",",1242,O
but,1242,O
in,1242,O
contrast,1242,O
to,1242,O
controls,1242,O
",",1242,O
it,1242,O
also,1242,O
reduced,1242,O
responses,1242,O
to,1242,O
low,1242,O
electrical,1242,O
field,1242,O
stimulation,1242,O
intensity,1242,O
(,1242,O
1-5,1242,O
Hz,1242,O
),1242,O
in,1242,O
inflamed,1242,O
preparations,1242,O
.,1242,O
In,1243,O
both,1243,O
types,1243,O
",",1243,O
purinoceptor,1243,O
desensitization,1243,O
with,1243,O
alpha,1243,B-ChemicalEntity
",",1243,I-ChemicalEntity
beta-methylene,1243,I-ChemicalEntity
adenosine-5'-triphosphate,1243,I-ChemicalEntity
(,1243,O
alpha,1243,B-ChemicalEntity
",",1243,I-ChemicalEntity
beta-meATP,1243,I-ChemicalEntity
),1243,O
caused,1243,O
further,1243,O
reductions,1243,O
at,1243,O
low,1243,O
frequencies,1243,O
(,1243,O
<,1243,O
10,1243,O
Hz,1243,O
),1243,O
.,1243,O
The,1244,O
muscarinic,1244,B-GeneOrGeneProduct
receptor,1244,I-GeneOrGeneProduct
antagonists,1244,O
atropine,1244,B-ChemicalEntity
",",1244,O
4-diphenylacetoxy-N-methylpiperidine,1244,B-ChemicalEntity
(,1244,O
4-DAMP,1244,B-ChemicalEntity
),1244,O
(,1244,O
'M,1244,O
(,1244,O
1,1244,O
),1244,O
/M,1244,O
(,1244,O
3,1244,O
),1244,O
/M,1244,O
(,1244,O
5,1244,O
),1244,O
-selective,1244,O
',1244,O
),1244,O
",",1244,O
methoctramine,1244,B-ChemicalEntity
(,1244,O
'M,1244,O
(,1244,O
2,1244,O
),1244,O
-selective,1244,O
',1244,O
),1244,O
and,1244,O
pirenzepine,1244,B-ChemicalEntity
(,1244,O
'M,1244,O
(,1244,O
1,1244,O
),1244,O
-selective,1244,O
',1244,O
),1244,O
antagonized,1244,O
the,1244,O
tonic,1244,O
component,1244,O
of,1244,O
the,1244,O
electrical,1244,O
field,1244,O
stimulation-evoked,1244,O
contractile,1244,O
response,1244,O
more,1244,O
potently,1244,O
than,1244,O
the,1244,O
phasic,1244,O
component,1244,O
.,1244,O
4-DAMP,1245,B-ChemicalEntity
inhibited,1245,O
the,1245,O
tonic,1245,O
contractions,1245,O
in,1245,O
controls,1245,O
more,1245,O
potently,1245,O
than,1245,O
methoctramine,1245,B-ChemicalEntity
and,1245,O
pirenzepine,1245,B-ChemicalEntity
.,1245,O
In,1246,O
inflamed,1246,O
preparations,1246,O
",",1246,O
the,1246,O
muscarinic,1246,B-ChemicalEntity
receptor,1246,I-ChemicalEntity
antagonism,1246,I-ChemicalEntity
on,1246,O
the,1246,O
phasic,1246,O
component,1246,O
of,1246,O
the,1246,O
electrical,1246,O
field,1246,O
stimulation-evoked,1246,O
contraction,1246,O
was,1246,O
decreased,1246,O
and,1246,O
the,1246,O
pirenzepine,1246,B-ChemicalEntity
and,1246,O
4-DAMP,1246,B-ChemicalEntity
antagonism,1246,O
on,1246,O
the,1246,O
tonic,1246,O
component,1246,O
was,1246,O
much,1246,O
less,1246,O
efficient,1246,O
than,1246,O
in,1246,O
controls,1246,O
.,1246,O
In,1247,O
contrast,1247,O
to,1247,O
controls,1247,O
",",1247,O
methoctramine,1247,B-ChemicalEntity
increased,1247,O
--,1247,O
instead,1247,O
of,1247,O
decreased,1247,O
--,1247,O
the,1247,O
tonic,1247,O
responses,1247,O
at,1247,O
high,1247,O
frequencies,1247,O
.,1247,O
While,1248,O
contractions,1248,O
to,1248,O
carbachol,1248,B-ChemicalEntity
and,1248,O
ATP,1248,B-ChemicalEntity
were,1248,O
the,1248,O
same,1248,O
in,1248,O
inflamed,1248,O
and,1248,O
in,1248,O
control,1248,O
strips,1248,O
when,1248,O
related,1248,O
to,1248,O
a,1248,O
reference,1248,O
potassium,1248,B-ChemicalEntity
response,1248,O
",",1248,O
isoprenaline-induced,1248,B-ChemicalEntity
relaxations,1248,O
were,1248,O
smaller,1248,O
in,1248,O
inflamed,1248,O
strips,1248,O
.,1248,O
Thus,1249,O
",",1249,O
in,1249,O
cystitis,1249,B-DiseaseOrPhenotypicFeature
substantial,1249,O
changes,1249,O
of,1249,O
the,1249,O
efferent,1249,O
functional,1249,O
responses,1249,O
occur,1249,O
.,1249,O
While,1250,O
postjunctional,1250,O
beta-adrenoceptor-mediated,1250,B-GeneOrGeneProduct
relaxations,1250,O
are,1250,O
reduced,1250,O
",",1250,O
effects,1250,O
by,1250,O
prejunctional,1250,O
inhibitory,1250,O
muscarinic,1250,B-GeneOrGeneProduct
receptors,1250,I-GeneOrGeneProduct
may,1250,O
be,1250,O
increased,1250,O
.,1250,O
A,1251,O
novel,1251,O
mutation,1251,O
at,1251,O
the,1251,O
DFNA36,1251,B-GeneOrGeneProduct
hearing,1251,B-DiseaseOrPhenotypicFeature
loss,1251,I-DiseaseOrPhenotypicFeature
locus,1251,O
reveals,1251,O
a,1251,O
critical,1251,O
function,1251,O
and,1251,O
potential,1251,O
genotype-phenotype,1251,O
correlation,1251,O
for,1251,O
amino,1251,O
acid-572,1251,O
of,1251,O
TMC1,1251,B-GeneOrGeneProduct
.,1251,O
We,1252,O
ascertained,1252,O
a,1252,O
North,1252,O
American,1252,O
Caucasian,1252,O
family,1252,O
(,1252,O
LMG248,1252,O
),1252,O
segregating,1252,O
autosomal,1252,O
dominant,1252,O
",",1252,O
non-syndromic,1252,O
",",1252,O
post-lingual,1252,O
",",1252,O
progressive,1252,O
sensorineural,1252,B-DiseaseOrPhenotypicFeature
hearing,1252,I-DiseaseOrPhenotypicFeature
loss,1252,I-DiseaseOrPhenotypicFeature
.,1252,O
The,1253,O
hearing,1253,B-DiseaseOrPhenotypicFeature
loss,1253,I-DiseaseOrPhenotypicFeature
begins,1253,O
in,1253,O
the,1253,O
second,1253,O
decade,1253,O
of,1253,O
life,1253,O
and,1253,O
initially,1253,O
affects,1253,O
high,1253,O
frequencies,1253,O
.,1253,O
It,1254,O
progresses,1254,O
to,1254,O
profound,1254,O
deafness,1254,B-DiseaseOrPhenotypicFeature
at,1254,O
all,1254,O
frequencies,1254,O
by,1254,O
the,1254,O
fourth,1254,O
or,1254,O
fifth,1254,O
decade,1254,O
.,1254,O
The,1255,O
phenotype,1255,O
co-segregates,1255,O
with,1255,O
short-tandem,1255,O
repeat,1255,O
markers,1255,O
flanking,1255,O
the,1255,O
TMC1,1255,B-GeneOrGeneProduct
gene,1255,O
at,1255,O
the,1255,O
DFNA36,1255,B-GeneOrGeneProduct
locus,1255,O
on,1255,O
chromosome,1255,O
9q31-q21,1255,O
.,1255,O
The,1256,O
affected,1256,O
individuals,1256,O
carry,1256,O
a,1256,O
novel,1256,O
missense,1256,O
substitution,1256,O
",",1256,O
p.D572H,1256,B-SequenceVariant
(,1256,O
c.G1714C,1256,B-SequenceVariant
),1256,O
",",1256,O
of,1256,O
the,1256,O
TMC1,1256,B-GeneOrGeneProduct
gene,1256,O
.,1256,O
This,1257,O
mutation,1257,O
is,1257,O
at,1257,O
the,1257,O
same,1257,O
nucleotide,1257,O
and,1257,O
amino,1257,O
acid,1257,O
position,1257,O
as,1257,O
the,1257,O
only,1257,O
other,1257,O
reported,1257,O
DFNA36,1257,B-GeneOrGeneProduct
mutation,1257,O
",",1257,O
p.D572N,1257,B-SequenceVariant
(,1257,O
c.G1714A,1257,B-SequenceVariant
),1257,O
.,1257,O
Our,1258,O
observations,1258,O
implicate,1258,O
a,1258,O
critical,1258,O
function,1258,O
for,1258,O
amino,1258,O
acid-572,1258,O
for,1258,O
wild-type,1258,O
TMC1,1258,B-GeneOrGeneProduct
function,1258,O
or,1258,O
the,1258,O
pathogenesis,1258,O
of,1258,O
DFNA36,1258,B-GeneOrGeneProduct
hearing,1258,B-DiseaseOrPhenotypicFeature
loss,1258,I-DiseaseOrPhenotypicFeature
.,1258,O
The,1259,O
slower,1259,O
progression,1259,O
of,1259,O
hearing,1259,B-DiseaseOrPhenotypicFeature
loss,1259,I-DiseaseOrPhenotypicFeature
associated,1259,O
with,1259,O
p.D572H,1259,B-SequenceVariant
",",1259,O
in,1259,O
comparison,1259,O
with,1259,O
that,1259,O
caused,1259,O
by,1259,O
p.D572N,1259,B-SequenceVariant
",",1259,O
may,1259,O
reflect,1259,O
a,1259,O
correlation,1259,O
of,1259,O
DFNA36,1259,B-GeneOrGeneProduct
phenotype,1259,O
with,1259,O
TMC1,1259,B-GeneOrGeneProduct
genotype,1259,O
.,1259,O
Human,1260,B-OrganismTaxon
TBX1,1260,B-GeneOrGeneProduct
missense,1260,O
mutations,1260,O
cause,1260,O
gain,1260,O
of,1260,O
function,1260,O
resulting,1260,O
in,1260,O
the,1260,O
same,1260,O
phenotype,1260,O
as,1260,O
22q11.2,1260,B-DiseaseOrPhenotypicFeature
deletions,1260,I-DiseaseOrPhenotypicFeature
.,1260,O
Deletion,1261,B-DiseaseOrPhenotypicFeature
22q11.2,1261,I-DiseaseOrPhenotypicFeature
syndrome,1261,I-DiseaseOrPhenotypicFeature
is,1261,O
the,1261,O
most,1261,O
frequent,1261,O
known,1261,O
microdeletion,1261,O
syndrome,1261,O
and,1261,O
is,1261,O
associated,1261,O
with,1261,O
a,1261,O
highly,1261,O
variable,1261,O
phenotype,1261,O
",",1261,O
including,1261,O
DiGeorge,1261,B-DiseaseOrPhenotypicFeature
and,1261,I-DiseaseOrPhenotypicFeature
Shprintzen,1261,I-DiseaseOrPhenotypicFeature
(,1261,I-DiseaseOrPhenotypicFeature
velocardiofacial,1261,I-DiseaseOrPhenotypicFeature
),1261,I-DiseaseOrPhenotypicFeature
syndromes,1261,I-DiseaseOrPhenotypicFeature
.,1261,O
Although,1262,O
haploinsufficiency,1262,O
of,1262,O
the,1262,O
T-box,1262,B-GeneOrGeneProduct
transcription,1262,I-GeneOrGeneProduct
factor,1262,I-GeneOrGeneProduct
gene,1262,O
TBX1,1262,B-GeneOrGeneProduct
is,1262,O
thought,1262,O
to,1262,O
cause,1262,O
the,1262,O
phenotype,1262,O
",",1262,O
to,1262,O
date,1262,O
",",1262,O
only,1262,O
four,1262,O
different,1262,O
point,1262,O
mutations,1262,O
in,1262,O
TBX1,1262,B-GeneOrGeneProduct
have,1262,O
been,1262,O
reported,1262,O
in,1262,O
association,1262,O
with,1262,O
six,1262,O
of,1262,O
the,1262,O
major,1262,O
features,1262,O
of,1262,O
22q11.2,1262,B-DiseaseOrPhenotypicFeature
deletion,1262,I-DiseaseOrPhenotypicFeature
syndrome,1262,I-DiseaseOrPhenotypicFeature
.,1262,O
Although,1263,O
",",1263,O
for,1263,O
the,1263,O
two,1263,O
truncating,1263,O
mutations,1263,O
",",1263,O
loss,1263,O
of,1263,O
function,1263,O
was,1263,O
previously,1263,O
shown,1263,O
",",1263,O
the,1263,O
pathomechanism,1263,O
of,1263,O
the,1263,O
missense,1263,O
mutations,1263,O
remains,1263,O
unknown,1263,O
.,1263,O
We,1264,O
report,1264,O
a,1264,O
novel,1264,O
heterozygous,1264,O
missense,1264,O
mutation,1264,O
",",1264,O
H194Q,1264,B-SequenceVariant
",",1264,O
in,1264,O
a,1264,O
familial,1264,O
case,1264,O
of,1264,O
Shprintzen,1264,B-DiseaseOrPhenotypicFeature
syndrome,1264,I-DiseaseOrPhenotypicFeature
and,1264,O
show,1264,O
that,1264,O
this,1264,O
and,1264,O
the,1264,O
two,1264,O
previously,1264,O
reported,1264,O
missense,1264,O
mutations,1264,O
result,1264,O
in,1264,O
gain,1264,O
of,1264,O
function,1264,O
",",1264,O
possibly,1264,O
through,1264,O
stabilization,1264,O
of,1264,O
the,1264,O
protein,1264,O
dimer,1264,O
DNA,1264,O
complex,1264,O
.,1264,O
We,1265,O
therefore,1265,O
conclude,1265,O
that,1265,O
TBX1,1265,B-GeneOrGeneProduct
gain-of-function,1265,O
mutations,1265,O
can,1265,O
result,1265,O
in,1265,O
the,1265,O
same,1265,O
phenotypic,1265,O
spectrum,1265,O
as,1265,O
haploinsufficiency,1265,O
caused,1265,O
by,1265,O
loss-of-function,1265,O
mutations,1265,O
or,1265,O
deletions,1265,O
.,1265,O
Polymorphic,1266,O
Alu,1266,O
insertions,1266,O
and,1266,O
the,1266,O
genetic,1266,O
structure,1266,O
of,1266,O
Iberian,1266,O
Basques,1266,O
.,1266,O
Eight,1267,O
Alu,1267,O
sequences,1267,O
(,1267,O
ACE,1267,B-GeneOrGeneProduct
",",1267,O
TPA25,1267,B-GeneOrGeneProduct
",",1267,O
PV92,1267,B-GeneOrGeneProduct
",",1267,O
APO,1267,B-GeneOrGeneProduct
",",1267,O
FXIIIB,1267,B-GeneOrGeneProduct
",",1267,O
D1,1267,B-GeneOrGeneProduct
",",1267,O
A25,1267,B-GeneOrGeneProduct
and,1267,O
B65,1267,B-GeneOrGeneProduct
),1267,O
were,1267,O
analyzed,1267,O
in,1267,O
two,1267,O
samples,1267,O
from,1267,O
Navarre,1267,O
and,1267,O
Guipuzcoa,1267,O
provinces,1267,O
(,1267,O
Basque,1267,O
Country,1267,O
",",1267,O
Spain,1267,O
),1267,O
.,1267,O
Alu,1268,O
data,1268,O
for,1268,O
other,1268,O
European,1268,O
",",1268,O
Caucasus,1268,O
and,1268,O
North,1268,O
African,1268,O
populations,1268,O
were,1268,O
compiled,1268,O
from,1268,O
the,1268,O
literature,1268,O
for,1268,O
comparison,1268,O
purposes,1268,O
to,1268,O
assess,1268,O
the,1268,O
genetic,1268,O
relationships,1268,O
of,1268,O
the,1268,O
Basques,1268,O
in,1268,O
a,1268,O
broader,1268,O
geographic,1268,O
context,1268,O
.,1268,O
Results,1269,O
of,1269,O
both,1269,O
MDS,1269,O
plot,1269,O
and,1269,O
AMOVA,1269,O
revealed,1269,O
spatial,1269,O
heterogeneity,1269,O
among,1269,O
these,1269,O
three,1269,O
population,1269,O
clusters,1269,O
clearly,1269,O
defined,1269,O
by,1269,O
geography,1269,O
.,1269,O
On,1270,O
the,1270,O
contrary,1270,O
",",1270,O
no,1270,O
substantial,1270,O
genetic,1270,O
heterogeneity,1270,O
was,1270,O
found,1270,O
between,1270,O
the,1270,O
Basque,1270,O
samples,1270,O
",",1270,O
or,1270,O
between,1270,O
Basques,1270,O
and,1270,O
other,1270,O
Europeans,1270,O
(,1270,O
excluding,1270,O
Caucasus,1270,O
populations,1270,O
),1270,O
.,1270,O
Moreover,1271,O
",",1271,O
the,1271,O
genetic,1271,O
information,1271,O
obtained,1271,O
from,1271,O
Alu,1271,O
data,1271,O
conflicts,1271,O
with,1271,O
hypotheses,1271,O
linking,1271,O
the,1271,O
origin,1271,O
of,1271,O
Basques,1271,O
with,1271,O
populations,1271,O
from,1271,O
North,1271,O
Africa,1271,O
(,1271,O
Berbers,1271,O
),1271,O
or,1271,O
from,1271,O
the,1271,O
Caucasus,1271,O
region,1271,O
(,1271,O
Georgia,1271,O
),1271,O
.,1271,O
In,1272,O
order,1272,O
to,1272,O
explain,1272,O
the,1272,O
reduced,1272,O
genetic,1272,O
heterogeneity,1272,O
detected,1272,O
by,1272,O
Alu,1272,O
insertions,1272,O
among,1272,O
Basque,1272,O
subpopulations,1272,O
",",1272,O
values,1272,O
of,1272,O
the,1272,O
Wright,1272,O
's,1272,O
F,1272,O
(,1272,O
ST,1272,O
),1272,O
statistic,1272,O
were,1272,O
estimated,1272,O
for,1272,O
both,1272,O
Alu,1272,O
markers,1272,O
and,1272,O
a,1272,O
set,1272,O
of,1272,O
short,1272,O
tandem,1272,O
repeats,1272,O
(,1272,O
STRs,1272,O
),1272,O
in,1272,O
terms,1272,O
of,1272,O
two,1272,O
geographical,1272,O
scales,1272,O
:,1272,O
(,1272,O
1,1272,O
),1272,O
the,1272,O
Basque,1272,O
Country,1272,O
",",1272,O
(,1272,O
2,1272,O
),1272,O
Europe,1272,O
(,1272,O
including,1272,O
Basques,1272,O
),1272,O
.,1272,O
In,1273,O
the,1273,O
Basque,1273,O
area,1273,O
",",1273,O
estimates,1273,O
of,1273,O
Wahlund,1273,O
's,1273,O
effect,1273,O
for,1273,O
both,1273,O
genetic,1273,O
markers,1273,O
showed,1273,O
no,1273,O
statistical,1273,O
difference,1273,O
between,1273,O
Basque,1273,O
subpopulations,1273,O
.,1273,O
However,1274,O
",",1274,O
when,1274,O
this,1274,O
analysis,1274,O
was,1274,O
performed,1274,O
on,1274,O
a,1274,O
European,1274,O
scale,1274,O
",",1274,O
F,1274,O
(,1274,O
ST,1274,O
),1274,O
values,1274,O
were,1274,O
significantly,1274,O
higher,1274,O
for,1274,O
Alu,1274,O
insertions,1274,O
than,1274,O
for,1274,O
STR,1274,O
alleles,1274,O
.,1274,O
From,1275,O
these,1275,O
results,1275,O
",",1275,O
we,1275,O
suggest,1275,O
that,1275,O
the,1275,O
spatial,1275,O
heterogeneity,1275,O
of,1275,O
the,1275,O
Basque,1275,O
gene,1275,O
pool,1275,O
identified,1275,O
in,1275,O
previous,1275,O
polymorphism,1275,O
studies,1275,O
is,1275,O
relatively,1275,O
recent,1275,O
and,1275,O
probably,1275,O
caused,1275,O
by,1275,O
a,1275,O
differential,1275,O
process,1275,O
of,1275,O
genetic,1275,O
admixture,1275,O
with,1275,O
non-Basque,1275,O
neighboring,1275,O
populations,1275,O
modulated,1275,O
by,1275,O
the,1275,O
effect,1275,O
of,1275,O
a,1275,O
linguistic,1275,O
barrier,1275,O
to,1275,O
random,1275,O
mating,1275,O
.,1275,O
Retinoblastoma,1276,B-DiseaseOrPhenotypicFeature
in,1276,O
India,1276,O
:,1276,O
microsatellite,1276,O
analysis,1276,O
and,1276,O
its,1276,O
application,1276,O
in,1276,O
genetic,1276,O
counseling,1276,O
.,1276,O
OBJECTIVES,1277,O
:,1277,O
This,1277,O
study,1277,O
was,1277,O
conducted,1277,O
with,1277,O
two,1277,O
objectives,1277,O
.,1277,O
The,1278,O
first,1278,O
was,1278,O
to,1278,O
estimate,1278,O
the,1278,O
frequency,1278,O
of,1278,O
loss,1278,O
of,1278,O
heterozygosity,1278,O
(,1278,O
LOH,1278,O
),1278,O
of,1278,O
the,1278,O
RB1,1278,B-GeneOrGeneProduct
gene,1278,O
as,1278,O
a,1278,O
mechanism,1278,O
in,1278,O
disease,1278,O
causation,1278,O
in,1278,O
tumors,1278,B-DiseaseOrPhenotypicFeature
of,1278,O
patients,1278,B-OrganismTaxon
from,1278,O
India,1278,O
.,1278,O
The,1279,O
second,1279,O
objective,1279,O
was,1279,O
to,1279,O
employ,1279,O
RB1,1279,B-GeneOrGeneProduct
molecular,1279,O
deletion,1279,O
and,1279,O
microsatellite-based,1279,O
linkage,1279,O
analysis,1279,O
as,1279,O
laboratory,1279,O
tools,1279,O
",",1279,O
while,1279,O
counseling,1279,O
families,1279,O
with,1279,O
a,1279,O
history,1279,O
of,1279,O
retinoblastoma,1279,B-DiseaseOrPhenotypicFeature
(,1279,O
RB,1279,B-DiseaseOrPhenotypicFeature
),1279,O
.,1279,O
METHODS,1280,O
:,1280,O
DNA,1280,O
was,1280,O
extracted,1280,O
from,1280,O
peripheral,1280,O
blood,1280,O
and,1280,O
tumors,1280,B-DiseaseOrPhenotypicFeature
of,1280,O
54,1280,O
RB,1280,B-DiseaseOrPhenotypicFeature
patients,1280,B-OrganismTaxon
and,1280,O
their,1280,O
relatives,1280,O
.,1280,O
Eight,1281,O
fluorescent,1281,O
microsatellite,1281,O
markers,1281,O
",",1281,O
both,1281,O
intragenic,1281,O
and,1281,O
flanking,1281,O
the,1281,O
RB1,1281,B-GeneOrGeneProduct
gene,1281,O
",",1281,O
were,1281,O
used,1281,O
.,1281,O
After,1282,O
PCR,1282,O
amplification,1282,O
",",1282,O
samples,1282,O
were,1282,O
run,1282,O
on,1282,O
an,1282,O
ABI,1282,O
PRISM,1282,O
310,1282,O
genetic,1282,O
analyzer,1282,O
for,1282,O
LOH,1282,O
",",1282,O
deletion,1282,O
detection,1282,O
",",1282,O
and,1282,O
haplotype,1282,O
generation,1282,O
.,1282,O
RESULTS,1283,O
:,1283,O
LOH,1283,O
was,1283,O
found,1283,O
in,1283,O
conjunction,1283,O
with,1283,O
tumor,1283,B-DiseaseOrPhenotypicFeature
formation,1283,O
in,1283,O
72.9,1283,O
%,1283,O
of,1283,O
RB,1283,B-DiseaseOrPhenotypicFeature
patients,1283,B-OrganismTaxon
(,1283,O
39/54,1283,O
patients,1283,B-OrganismTaxon
;,1283,O
p=0.001,1283,O
;,1283,O
95,1283,O
%,1283,O
CI,1283,O
0.6028,1283,O
",",1283,O
0.8417,1283,O
),1283,O
;,1283,O
however,1283,O
",",1283,O
we,1283,O
could,1283,O
not,1283,O
associate,1283,O
various,1283,O
other,1283,O
clinical,1283,O
parameters,1283,O
of,1283,O
RB,1283,B-DiseaseOrPhenotypicFeature
patients,1283,B-OrganismTaxon
with,1283,O
the,1283,O
presence,1283,O
or,1283,O
absence,1283,O
of,1283,O
RB1,1283,B-GeneOrGeneProduct
LOH,1283,O
.,1283,O
Seven,1284,O
germline,1284,O
deletions,1284,O
(,1284,O
13,1284,O
%,1284,O
of,1284,O
RB,1284,B-DiseaseOrPhenotypicFeature
patients,1284,B-OrganismTaxon
),1284,O
were,1284,O
identified,1284,O
",",1284,O
and,1284,O
the,1284,O
maternal,1284,O
allele,1284,O
was,1284,O
more,1284,O
frequently,1284,O
lost,1284,O
(,1284,O
p=0.01,1284,O
),1284,O
.,1284,O
A,1285,O
disease,1285,O
co-segregating,1285,O
haplotype,1285,O
was,1285,O
detected,1285,O
in,1285,O
two,1285,O
hereditary,1285,O
autosomal,1285,O
dominant,1285,O
cases,1285,O
.,1285,O
CONCLUSION,1286,O
:,1286,O
LOH,1286,O
of,1286,O
the,1286,O
RB1,1286,B-GeneOrGeneProduct
gene,1286,O
could,1286,O
play,1286,O
an,1286,O
important,1286,O
role,1286,O
in,1286,O
tumor,1286,B-DiseaseOrPhenotypicFeature
formation,1286,O
.,1286,O
Large,1287,O
deletions,1287,O
involving,1287,O
RB1,1287,B-GeneOrGeneProduct
were,1287,O
observed,1287,O
",",1287,O
and,1287,O
a,1287,O
disease,1287,O
co-segregating,1287,O
haplotype,1287,O
was,1287,O
used,1287,O
for,1287,O
indirect,1287,O
genetic,1287,O
testing,1287,O
.,1287,O
This,1288,O
is,1288,O
the,1288,O
first,1288,O
report,1288,O
from,1288,O
India,1288,O
where,1288,O
molecular,1288,O
testing,1288,O
has,1288,O
been,1288,O
applied,1288,O
for,1288,O
RB,1288,B-DiseaseOrPhenotypicFeature
families,1288,O
in,1288,O
conjunction,1288,O
with,1288,O
genetic,1288,O
counseling,1288,O
.,1288,O
In,1289,O
tertiary,1289,O
ophthalmic,1289,O
practice,1289,O
in,1289,O
India,1289,O
",",1289,O
there,1289,O
is,1289,O
an,1289,O
emerging,1289,O
trend,1289,O
towards,1289,O
the,1289,O
application,1289,O
of,1289,O
genetical,1289,O
knowledge,1289,O
in,1289,O
clinical,1289,O
practice,1289,O
.,1289,O
Disruption,1290,O
of,1290,O
a,1290,O
synaptotagmin,1290,B-GeneOrGeneProduct
(,1290,O
SYT14,1290,B-GeneOrGeneProduct
),1290,O
associated,1290,O
with,1290,O
neurodevelopmental,1290,B-DiseaseOrPhenotypicFeature
abnormalities,1290,I-DiseaseOrPhenotypicFeature
.,1290,O
We,1291,O
report,1291,O
cytogenetic,1291,O
and,1291,O
molecular,1291,O
studies,1291,O
of,1291,O
a,1291,O
de,1291,O
novo,1291,O
",",1291,O
apparently,1291,O
balanced,1291,O
t,1291,O
(,1291,O
1,1291,O
;,1291,O
3,1291,O
),1291,O
(,1291,O
q32.1,1291,O
;,1291,O
q25.1,1291,O
),1291,O
identified,1291,O
in,1291,O
a,1291,O
12-year-old,1291,O
female,1291,O
(,1291,O
designated,1291,O
DGAP128,1291,O
),1291,O
with,1291,O
cerebral,1291,B-DiseaseOrPhenotypicFeature
atrophy,1291,I-DiseaseOrPhenotypicFeature
",",1291,O
macrocephaly,1291,B-DiseaseOrPhenotypicFeature
seizures,1291,B-DiseaseOrPhenotypicFeature
",",1291,O
and,1291,O
developmental,1291,B-DiseaseOrPhenotypicFeature
delay,1291,I-DiseaseOrPhenotypicFeature
.,1291,O
A,1292,O
combination,1292,O
of,1292,O
fluorescence,1292,O
in,1292,O
situ,1292,O
hybridization,1292,O
(,1292,O
FISH,1292,O
),1292,O
and,1292,O
Southern,1292,O
blot,1292,O
analysis,1292,O
demonstrated,1292,O
disruption,1292,O
of,1292,O
a,1292,O
synaptotagmin,1292,B-GeneOrGeneProduct
gene,1292,O
(,1292,O
SYT14,1292,B-GeneOrGeneProduct
),1292,O
at,1292,O
the,1292,O
1q32,1292,O
breakpoint,1292,O
.,1292,O
Expression,1293,O
of,1293,O
SYT14,1293,B-GeneOrGeneProduct
in,1293,O
human,1293,B-OrganismTaxon
brain,1293,O
was,1293,O
confirmed,1293,O
using,1293,O
Northern,1293,O
analysis,1293,O
.,1293,O
Because,1294,O
members,1294,O
of,1294,O
the,1294,O
synaptotagmin,1294,B-GeneOrGeneProduct
family,1294,O
of,1294,O
proteins,1294,O
function,1294,O
as,1294,O
sensors,1294,O
that,1294,O
link,1294,O
changes,1294,O
in,1294,O
calcium,1294,B-ChemicalEntity
levels,1294,O
with,1294,O
a,1294,O
variety,1294,O
of,1294,O
biological,1294,O
processes,1294,O
",",1294,O
including,1294,O
neurotransmission,1294,O
and,1294,O
hormone-responsiveness,1294,O
",",1294,O
SYT14,1294,B-GeneOrGeneProduct
is,1294,O
an,1294,O
intriguing,1294,O
candidate,1294,O
gene,1294,O
for,1294,O
the,1294,O
abnormal,1294,O
development,1294,O
in,1294,O
this,1294,O
child,1294,O
.,1294,O
This,1295,O
is,1295,O
the,1295,O
first,1295,O
known,1295,O
constitutional,1295,O
rearrangement,1295,O
of,1295,O
SYT14,1295,B-GeneOrGeneProduct
",",1295,O
and,1295,O
further,1295,O
systematic,1295,O
genetic,1295,O
analysis,1295,O
and,1295,O
clinical,1295,O
studies,1295,O
of,1295,O
DGAP128,1295,O
may,1295,O
offer,1295,O
unique,1295,O
insights,1295,O
into,1295,O
the,1295,O
role,1295,O
of,1295,O
SYT14,1295,B-GeneOrGeneProduct
in,1295,O
neurodevelopment,1295,O
.,1295,O
Interferon,1296,B-GeneOrGeneProduct
regulatory,1296,I-GeneOrGeneProduct
factor,1296,I-GeneOrGeneProduct
6,1296,I-GeneOrGeneProduct
(,1296,O
IRF6,1296,B-GeneOrGeneProduct
),1296,O
and,1296,O
fibroblast,1296,B-GeneOrGeneProduct
growth,1296,I-GeneOrGeneProduct
factor,1296,I-GeneOrGeneProduct
receptor,1296,I-GeneOrGeneProduct
1,1296,I-GeneOrGeneProduct
(,1296,O
FGFR1,1296,B-GeneOrGeneProduct
),1296,O
contribute,1296,O
to,1296,O
human,1296,B-OrganismTaxon
tooth,1296,B-DiseaseOrPhenotypicFeature
agenesis,1296,I-DiseaseOrPhenotypicFeature
.,1296,O
Phenotypic,1297,O
characteristics,1297,O
expressed,1297,O
in,1297,O
syndromes,1297,O
give,1297,O
clues,1297,O
to,1297,O
the,1297,O
factors,1297,O
involved,1297,O
in,1297,O
the,1297,O
cause,1297,O
of,1297,O
isolated,1297,O
forms,1297,O
of,1297,O
the,1297,O
same,1297,O
defects,1297,O
.,1297,O
We,1298,O
investigated,1298,O
two,1298,O
genes,1298,O
responsible,1298,O
for,1298,O
craniofacial,1298,B-DiseaseOrPhenotypicFeature
syndromes,1298,I-DiseaseOrPhenotypicFeature
",",1298,O
FGFR1,1298,B-GeneOrGeneProduct
and,1298,O
IRF6,1298,B-GeneOrGeneProduct
",",1298,O
in,1298,O
a,1298,O
collection,1298,O
of,1298,O
families,1298,O
with,1298,O
isolated,1298,O
tooth,1298,B-DiseaseOrPhenotypicFeature
agenesis,1298,I-DiseaseOrPhenotypicFeature
.,1298,O
Cheek,1299,O
swab,1299,O
samples,1299,O
were,1299,O
obtained,1299,O
for,1299,O
DNA,1299,O
analysis,1299,O
from,1299,O
116,1299,O
case/parent,1299,O
trios,1299,O
.,1299,O
Probands,1300,O
had,1300,O
at,1300,O
least,1300,O
one,1300,O
developmentally,1300,O
missing,1300,O
tooth,1300,O
",",1300,O
excluding,1300,O
third,1300,O
molars,1300,O
.,1300,O
In,1301,O
addition,1301,O
",",1301,O
we,1301,O
studied,1301,O
89,1301,O
cases,1301,O
and,1301,O
50,1301,O
controls,1301,O
from,1301,O
Ohio,1301,O
to,1301,O
replicate,1301,O
any,1301,O
positive,1301,O
findings,1301,O
.,1301,O
Genotyping,1302,O
was,1302,O
performed,1302,O
by,1302,O
kinetic,1302,O
polymerase,1302,O
chain-reaction,1302,O
or,1302,O
TaqMan,1302,O
assays,1302,O
.,1302,O
Linkage,1303,O
disequilibrium,1303,O
analysis,1303,O
and,1303,O
transmission,1303,O
distortion,1303,O
of,1303,O
the,1303,O
marker,1303,O
alleles,1303,O
were,1303,O
performed,1303,O
.,1303,O
The,1304,O
same,1304,O
variants,1304,O
in,1304,O
the,1304,O
IRF6,1304,B-GeneOrGeneProduct
gene,1304,O
that,1304,O
are,1304,O
associated,1304,O
with,1304,O
isolated,1304,O
orofacial,1304,B-DiseaseOrPhenotypicFeature
clefts,1304,I-DiseaseOrPhenotypicFeature
are,1304,O
also,1304,O
associated,1304,O
with,1304,O
human,1304,B-OrganismTaxon
tooth,1304,B-DiseaseOrPhenotypicFeature
agenesis,1304,I-DiseaseOrPhenotypicFeature
(,1304,O
rs861019,1304,B-SequenceVariant
",",1304,O
P,1304,O
=,1304,O
0.058,1304,O
;,1304,O
rs17015215-V274I,1304,B-SequenceVariant
",",1304,O
P,1304,O
=,1304,O
0.0006,1304,O
;,1304,O
rs7802,1304,B-SequenceVariant
",",1304,O
P,1304,O
=,1304,O
0.004,1304,O
),1304,O
.,1304,O
Mutations,1305,O
in,1305,O
IRF6,1305,B-GeneOrGeneProduct
cause,1305,O
Van,1305,B-DiseaseOrPhenotypicFeature
der,1305,I-DiseaseOrPhenotypicFeature
Woude,1305,I-DiseaseOrPhenotypicFeature
and,1305,I-DiseaseOrPhenotypicFeature
popliteal,1305,I-DiseaseOrPhenotypicFeature
pterygium,1305,I-DiseaseOrPhenotypicFeature
syndromes,1305,I-DiseaseOrPhenotypicFeature
.,1305,O
The,1306,O
craniofacial,1306,O
phenotypic,1306,O
characteristics,1306,O
of,1306,O
these,1306,O
syndromes,1306,O
include,1306,O
oral,1306,B-DiseaseOrPhenotypicFeature
clefts,1306,I-DiseaseOrPhenotypicFeature
and,1306,O
preferential,1306,O
tooth,1306,B-DiseaseOrPhenotypicFeature
agenesis,1306,I-DiseaseOrPhenotypicFeature
of,1306,O
incisors,1306,O
and,1306,O
premolars,1306,O
",",1306,O
besides,1306,O
pits,1306,B-DiseaseOrPhenotypicFeature
on,1306,I-DiseaseOrPhenotypicFeature
the,1306,I-DiseaseOrPhenotypicFeature
lower,1306,I-DiseaseOrPhenotypicFeature
lips,1306,I-DiseaseOrPhenotypicFeature
.,1306,O
Also,1307,O
it,1307,O
appears,1307,O
that,1307,O
preferential,1307,O
premolar,1307,O
agenesis,1307,O
is,1307,O
associated,1307,O
with,1307,O
FGFR1,1307,B-GeneOrGeneProduct
(,1307,O
P,1307,O
=,1307,O
0.014,1307,O
),1307,O
and,1307,O
IRF6,1307,B-GeneOrGeneProduct
(,1307,O
P,1307,O
=,1307,O
0.002,1307,O
),1307,O
markers,1307,O
.,1307,O
There,1308,O
were,1308,O
statistically,1308,O
significant,1308,O
data,1308,O
suggesting,1308,O
that,1308,O
IRF6,1308,B-GeneOrGeneProduct
interacts,1308,O
not,1308,O
only,1308,O
with,1308,O
MSX1,1308,B-GeneOrGeneProduct
(,1308,O
P,1308,O
=,1308,O
0.001,1308,O
),1308,O
",",1308,O
but,1308,O
also,1308,O
with,1308,O
TGFA,1308,B-GeneOrGeneProduct
(,1308,O
P,1308,O
=,1308,O
0.03,1308,O
),1308,O
.,1308,O
Molecular,1309,O
analysis,1309,O
of,1309,O
the,1309,O
CYP2F1,1309,B-GeneOrGeneProduct
gene,1309,O
:,1309,O
identification,1309,O
of,1309,O
a,1309,O
frequent,1309,O
non-functional,1309,O
allelic,1309,O
variant,1309,O
.,1309,O
The,1310,O
CYP2F1,1310,B-GeneOrGeneProduct
is,1310,O
a,1310,O
human,1310,B-OrganismTaxon
cytochrome,1310,B-GeneOrGeneProduct
P450,1310,I-GeneOrGeneProduct
that,1310,O
is,1310,O
selectively,1310,O
expressed,1310,O
in,1310,O
lung,1310,O
tissue,1310,O
and,1310,O
involved,1310,O
in,1310,O
the,1310,O
metabolism,1310,O
of,1310,O
various,1310,O
pneumotoxicants,1310,O
with,1310,O
potential,1310,O
carcinogenic,1310,B-DiseaseOrPhenotypicFeature
effects,1310,O
.,1310,O
In,1311,O
the,1311,O
present,1311,O
study,1311,O
",",1311,O
we,1311,O
report,1311,O
the,1311,O
first,1311,O
systematic,1311,O
investigation,1311,O
of,1311,O
the,1311,O
genetic,1311,O
polymorphism,1311,O
of,1311,O
this,1311,O
enzyme,1311,O
.,1311,O
We,1312,O
analyzed,1312,O
the,1312,O
nucleotidic,1312,O
sequence,1312,O
of,1312,O
the,1312,O
CYP2F1,1312,B-GeneOrGeneProduct
gene,1312,O
in,1312,O
DNA,1312,O
samples,1312,O
from,1312,O
90,1312,O
French,1312,O
Caucasians,1312,O
consisting,1312,O
in,1312,O
44,1312,O
patients,1312,B-OrganismTaxon
with,1312,O
lung,1312,B-DiseaseOrPhenotypicFeature
cancer,1312,I-DiseaseOrPhenotypicFeature
and,1312,O
46,1312,O
control,1312,O
individuals,1312,O
",",1312,O
using,1312,O
single-strand,1312,O
conformation,1312,O
polymorphism,1312,O
analysis,1312,O
of,1312,O
PCR,1312,O
products,1312,O
(,1312,O
PCR-SSCP,1312,O
),1312,O
.,1312,O
We,1313,O
identified,1313,O
24,1313,O
novel,1313,O
mutations,1313,O
distributed,1313,O
in,1313,O
the,1313,O
promoter,1313,O
region,1313,O
of,1313,O
the,1313,O
gene,1313,O
",",1313,O
as,1313,O
well,1313,O
as,1313,O
in,1313,O
the,1313,O
coding,1313,O
regions,1313,O
and,1313,O
their,1313,O
flanking,1313,O
intronic,1313,O
sequences,1313,O
.,1313,O
In,1314,O
addition,1314,O
to,1314,O
the,1314,O
wild-type,1314,O
CYP2F1,1314,B-GeneOrGeneProduct
*,1314,O
1,1314,O
allele,1314,O
",",1314,O
seven,1314,O
allelic,1314,O
variant,1314,O
",",1314,O
CYP2F1,1314,B-GeneOrGeneProduct
*,1314,O
2A,1314,O
",",1314,O
*,1314,O
2B,1314,O
",",1314,O
*,1314,O
3,1314,O
",",1314,O
*,1314,O
4,1314,O
",",1314,O
*,1314,O
5A,1314,O
",",1314,O
*,1314,O
5B,1314,O
and,1314,O
*,1314,O
6,1314,O
",",1314,O
were,1314,O
characterized,1314,O
.,1314,O
The,1315,O
most,1315,O
frequent,1315,O
allelic,1315,O
variant,1315,O
",",1315,O
CYP2F1,1315,B-GeneOrGeneProduct
*,1315,O
2A,1315,O
(,1315,O
25.6,1315,O
%,1315,O
),1315,O
",",1315,O
harbors,1315,O
a,1315,O
combination,1315,O
of,1315,O
9,1315,O
mutations,1315,O
",",1315,O
including,1315,O
2,1315,O
missense,1315,O
mutations,1315,O
(,1315,O
Asp218Asn,1315,B-SequenceVariant
and,1315,O
Gln266His,1315,B-SequenceVariant
),1315,O
and,1315,O
a,1315,O
1-bp,1315,B-SequenceVariant
insertion,1315,I-SequenceVariant
(,1315,O
c.14_15insC,1315,B-SequenceVariant
),1315,O
that,1315,O
creates,1315,O
a,1315,O
premature,1315,O
stop,1315,O
codon,1315,O
in,1315,O
exon,1315,O
2,1315,O
",",1315,O
probably,1315,O
leading,1315,O
to,1315,O
the,1315,O
synthesis,1315,O
of,1315,O
a,1315,O
severely,1315,O
truncated,1315,O
protein,1315,O
with,1315,O
no,1315,O
catalytic,1315,O
activity,1315,O
.,1315,O
The,1316,O
identification,1316,O
of,1316,O
around,1316,O
7,1316,O
%,1316,O
of,1316,O
homozygotes,1316,O
for,1316,O
the,1316,O
frameshift,1316,O
mutation,1316,O
in,1316,O
our,1316,O
Caucasian,1316,O
population,1316,O
suggests,1316,O
the,1316,O
existence,1316,O
of,1316,O
an,1316,O
interindividual,1316,O
variation,1316,O
of,1316,O
the,1316,O
CYP2F1,1316,B-GeneOrGeneProduct
activity,1316,O
and,1316,O
",",1316,O
consequently,1316,O
",",1316,O
the,1316,O
possibility,1316,O
of,1316,O
interindividual,1316,O
differences,1316,O
in,1316,O
the,1316,O
toxic,1316,O
response,1316,O
to,1316,O
some,1316,O
pneumotoxicants,1316,O
and,1316,O
in,1316,O
the,1316,O
susceptibility,1316,O
to,1316,O
certain,1316,O
chemically,1316,O
induced,1316,O
diseases,1316,O
.,1316,O
However,1317,O
",",1317,O
our,1317,O
preliminary,1317,O
results,1317,O
did,1317,O
not,1317,O
show,1317,O
any,1317,O
evidence,1317,O
that,1317,O
the,1317,O
CYP2F1,1317,B-GeneOrGeneProduct
genetic,1317,O
polymorphism,1317,O
has,1317,O
implications,1317,O
in,1317,O
the,1317,O
pathogenesis,1317,O
of,1317,O
lung,1317,B-DiseaseOrPhenotypicFeature
cancer,1317,I-DiseaseOrPhenotypicFeature
.,1317,O
Syncope,1318,B-DiseaseOrPhenotypicFeature
and,1318,O
QT,1318,B-DiseaseOrPhenotypicFeature
prolongation,1318,I-DiseaseOrPhenotypicFeature
among,1318,O
patients,1318,B-OrganismTaxon
treated,1318,O
with,1318,O
methadone,1318,B-ChemicalEntity
for,1318,O
heroin,1318,B-DiseaseOrPhenotypicFeature
dependence,1318,I-DiseaseOrPhenotypicFeature
in,1318,O
the,1318,O
city,1318,O
of,1318,O
Copenhagen,1318,O
.,1318,O
BACKGROUND,1319,O
:,1319,O
Methadone,1319,B-ChemicalEntity
is,1319,O
prescribed,1319,O
to,1319,O
heroin,1319,B-DiseaseOrPhenotypicFeature
addicts,1319,I-DiseaseOrPhenotypicFeature
to,1319,O
decrease,1319,O
illicit,1319,O
opioid,1319,B-ChemicalEntity
use,1319,O
.,1319,O
Prolongation,1320,B-DiseaseOrPhenotypicFeature
of,1320,I-DiseaseOrPhenotypicFeature
the,1320,I-DiseaseOrPhenotypicFeature
QT,1320,I-DiseaseOrPhenotypicFeature
interval,1320,I-DiseaseOrPhenotypicFeature
in,1320,O
the,1320,O
ECG,1320,O
of,1320,O
patients,1320,B-OrganismTaxon
with,1320,O
torsade,1320,B-DiseaseOrPhenotypicFeature
de,1320,I-DiseaseOrPhenotypicFeature
pointes,1320,I-DiseaseOrPhenotypicFeature
(,1320,O
TdP,1320,B-DiseaseOrPhenotypicFeature
),1320,O
has,1320,O
been,1320,O
reported,1320,O
in,1320,O
methadone,1320,B-ChemicalEntity
users,1320,O
.,1320,O
As,1321,O
heroin,1321,B-DiseaseOrPhenotypicFeature
addicts,1321,I-DiseaseOrPhenotypicFeature
sometimes,1321,O
faint,1321,O
while,1321,O
using,1321,O
illicit,1321,O
drugs,1321,O
",",1321,O
doctors,1321,O
might,1321,O
attribute,1321,O
too,1321,O
many,1321,O
episodes,1321,O
of,1321,O
syncope,1321,B-DiseaseOrPhenotypicFeature
to,1321,O
illicit,1321,O
drug,1321,O
use,1321,O
and,1321,O
thereby,1321,O
underestimate,1321,O
the,1321,O
incidence,1321,O
of,1321,O
TdP,1321,B-DiseaseOrPhenotypicFeature
in,1321,O
this,1321,O
special,1321,O
population,1321,O
",",1321,O
and,1321,O
the,1321,O
high,1321,O
mortality,1321,O
in,1321,O
this,1321,O
population,1321,O
may,1321,O
",",1321,O
in,1321,O
part,1321,O
",",1321,O
be,1321,O
caused,1321,O
by,1321,O
the,1321,O
proarrhythmic,1321,O
effect,1321,O
of,1321,O
methadone,1321,B-ChemicalEntity
.,1321,O
METHODS,1322,O
:,1322,O
In,1322,O
this,1322,O
cross-sectional,1322,O
study,1322,O
interview,1322,O
",",1322,O
ECGs,1322,O
and,1322,O
blood,1322,O
samples,1322,O
were,1322,O
collected,1322,O
in,1322,O
a,1322,O
population,1322,O
of,1322,O
adult,1322,O
heroin,1322,B-DiseaseOrPhenotypicFeature
addicts,1322,I-DiseaseOrPhenotypicFeature
treated,1322,O
with,1322,O
methadone,1322,B-ChemicalEntity
or,1322,O
buprenorphine,1322,B-ChemicalEntity
on,1322,O
a,1322,O
daily,1322,O
basis,1322,O
.,1322,O
Of,1323,O
the,1323,O
patients,1323,B-OrganismTaxon
at,1323,O
the,1323,O
Drug,1323,O
Addiction,1323,O
Service,1323,O
in,1323,O
the,1323,O
municipal,1323,O
of,1323,O
Copenhagen,1323,O
",",1323,O
450,1323,O
(,1323,O
approximately,1323,O
52,1323,O
%,1323,O
),1323,O
were,1323,O
included,1323,O
.,1323,O
The,1324,O
QT,1324,O
interval,1324,O
was,1324,O
estimated,1324,O
from,1324,O
12,1324,O
lead,1324,O
ECGs,1324,O
.,1324,O
All,1325,O
participants,1325,O
were,1325,O
interviewed,1325,O
about,1325,O
any,1325,O
experience,1325,O
of,1325,O
syncope,1325,B-DiseaseOrPhenotypicFeature
.,1325,O
The,1326,O
association,1326,O
between,1326,O
opioid,1326,B-ChemicalEntity
dose,1326,O
and,1326,O
QT,1326,O
",",1326,O
and,1326,O
methadone,1326,B-ChemicalEntity
dose,1326,O
and,1326,O
reporting,1326,O
of,1326,O
syncope,1326,B-DiseaseOrPhenotypicFeature
was,1326,O
assessed,1326,O
using,1326,O
multivariate,1326,O
linear,1326,O
regression,1326,O
and,1326,O
logistic,1326,O
regression,1326,O
",",1326,O
respectively,1326,O
.,1326,O
RESULTS,1327,O
:,1327,O
Methadone,1327,B-ChemicalEntity
dose,1327,O
was,1327,O
associated,1327,O
with,1327,O
longer,1327,B-DiseaseOrPhenotypicFeature
QT,1327,I-DiseaseOrPhenotypicFeature
interval,1327,I-DiseaseOrPhenotypicFeature
of,1327,O
0.140,1327,O
ms/mg,1327,O
(,1327,O
p,1327,O
=,1327,O
0.002,1327,O
),1327,O
.,1327,O
No,1328,O
association,1328,O
between,1328,O
buprenorphine,1328,B-ChemicalEntity
and,1328,O
QTc,1328,O
was,1328,O
found,1328,O
.,1328,O
Among,1329,O
the,1329,O
subjects,1329,O
treated,1329,O
with,1329,O
methadone,1329,B-ChemicalEntity
",",1329,O
28,1329,O
%,1329,O
men,1329,B-OrganismTaxon
and,1329,O
32,1329,O
%,1329,O
women,1329,B-OrganismTaxon
had,1329,O
prolonged,1329,B-DiseaseOrPhenotypicFeature
QTc,1329,I-DiseaseOrPhenotypicFeature
interval,1329,I-DiseaseOrPhenotypicFeature
.,1329,O
None,1330,O
of,1330,O
the,1330,O
subjects,1330,O
treated,1330,O
with,1330,O
buprenorphine,1330,B-ChemicalEntity
had,1330,O
QTc,1330,O
interval,1330,O
>,1330,O
0.440,1330,O
s,1330,O
(,1330,O
(,1330,O
1/2,1330,O
),1330,O
),1330,O
.,1330,O
A,1331,O
50,1331,O
mg,1331,O
higher,1331,O
methadone,1331,B-ChemicalEntity
dose,1331,O
was,1331,O
associated,1331,O
with,1331,O
a,1331,O
1.2,1331,O
(,1331,O
95,1331,O
%,1331,O
CI,1331,O
1.1,1331,O
to,1331,O
1.4,1331,O
),1331,O
times,1331,O
higher,1331,O
odds,1331,O
for,1331,O
syncope,1331,B-DiseaseOrPhenotypicFeature
.,1331,O
CONCLUSIONS,1332,O
:,1332,O
Methadone,1332,B-ChemicalEntity
is,1332,O
associated,1332,O
with,1332,O
QT,1332,B-DiseaseOrPhenotypicFeature
prolongation,1332,I-DiseaseOrPhenotypicFeature
and,1332,O
higher,1332,O
reporting,1332,O
of,1332,O
syncope,1332,B-DiseaseOrPhenotypicFeature
in,1332,O
a,1332,O
population,1332,O
of,1332,O
heroin,1332,B-DiseaseOrPhenotypicFeature
addicts,1332,I-DiseaseOrPhenotypicFeature
.,1332,O
A,1333,O
dramatic,1333,O
drop,1333,B-DiseaseOrPhenotypicFeature
in,1333,I-DiseaseOrPhenotypicFeature
blood,1333,I-DiseaseOrPhenotypicFeature
pressure,1333,I-DiseaseOrPhenotypicFeature
following,1333,O
prehospital,1333,O
GTN,1333,B-ChemicalEntity
administration,1333,O
.,1333,O
A,1334,O
male,1334,O
in,1334,O
his,1334,O
sixties,1334,O
with,1334,O
no,1334,O
history,1334,O
of,1334,O
cardiac,1334,O
chest,1334,B-DiseaseOrPhenotypicFeature
pain,1334,I-DiseaseOrPhenotypicFeature
awoke,1334,O
with,1334,O
chest,1334,B-DiseaseOrPhenotypicFeature
pain,1334,I-DiseaseOrPhenotypicFeature
following,1334,O
an,1334,O
afternoon,1334,O
sleep,1334,O
.,1334,O
The,1335,O
patient,1335,B-OrganismTaxon
did,1335,O
not,1335,O
self,1335,O
medicate,1335,O
.,1335,O
The,1336,O
patient,1336,B-OrganismTaxon
's,1336,O
observations,1336,O
were,1336,O
within,1336,O
normal,1336,O
limits,1336,O
",",1336,O
he,1336,O
was,1336,O
administered,1336,O
oxygen,1336,B-ChemicalEntity
via,1336,O
a,1336,O
face,1336,O
mask,1336,O
and,1336,O
glyceryl,1336,B-ChemicalEntity
trinitrate,1336,I-ChemicalEntity
(,1336,O
GTN,1336,B-ChemicalEntity
),1336,O
.,1336,O
Several,1337,O
minutes,1337,O
after,1337,O
the,1337,O
GTN,1337,B-ChemicalEntity
the,1337,O
patient,1337,B-OrganismTaxon
experienced,1337,O
a,1337,O
sudden,1337,O
drop,1337,B-DiseaseOrPhenotypicFeature
in,1337,I-DiseaseOrPhenotypicFeature
blood,1337,I-DiseaseOrPhenotypicFeature
pressure,1337,I-DiseaseOrPhenotypicFeature
and,1337,O
heart,1337,O
rate,1337,O
",",1337,O
this,1337,O
was,1337,O
rectified,1337,O
by,1337,O
atropine,1337,B-ChemicalEntity
sulphate,1337,I-ChemicalEntity
and,1337,O
a,1337,O
fluid,1337,O
challenge,1337,O
.,1337,O
There,1338,O
was,1338,O
no,1338,O
further,1338,O
deterioration,1338,O
in,1338,O
the,1338,O
patient,1338,B-OrganismTaxon
's,1338,O
condition,1338,O
during,1338,O
transport,1338,O
to,1338,O
hospital,1338,O
.,1338,O
There,1339,O
are,1339,O
very,1339,O
few,1339,O
documented,1339,O
case,1339,O
like,1339,O
this,1339,O
in,1339,O
the,1339,O
prehospital,1339,O
scientific,1339,O
literature,1339,O
.,1339,O
The,1340,O
cause,1340,O
appears,1340,O
to,1340,O
be,1340,O
the,1340,O
Bezold-Jarish,1340,O
reflex,1340,O
",",1340,O
stimulation,1340,O
of,1340,O
the,1340,O
ventricular,1340,O
walls,1340,O
which,1340,O
in,1340,O
turn,1340,O
decreases,1340,O
sympathetic,1340,O
outflow,1340,O
from,1340,O
the,1340,O
vasomotor,1340,O
centre,1340,O
.,1340,O
Prehospital,1341,O
care,1341,O
providers,1341,O
who,1341,O
are,1341,O
managing,1341,O
any,1341,O
patient,1341,B-OrganismTaxon
with,1341,O
a,1341,O
syncopal,1341,B-DiseaseOrPhenotypicFeature
episode,1341,I-DiseaseOrPhenotypicFeature
that,1341,O
fails,1341,O
to,1341,O
recover,1341,O
within,1341,O
a,1341,O
reasonable,1341,O
time,1341,O
frame,1341,O
should,1341,O
consider,1341,O
the,1341,O
Bezold-Jarisch,1341,O
reflex,1341,O
as,1341,O
the,1341,O
cause,1341,O
and,1341,O
manage,1341,O
the,1341,O
patient,1341,B-OrganismTaxon
accordingly,1341,O
.,1341,O
Comparison,1342,O
of,1342,O
valsartan/hydrochlorothiazide,1342,B-ChemicalEntity
combination,1342,O
therapy,1342,O
at,1342,O
doses,1342,O
up,1342,O
to,1342,O
320/25,1342,O
mg,1342,O
versus,1342,O
monotherapy,1342,O
:,1342,O
a,1342,O
double-blind,1342,O
",",1342,O
placebo-controlled,1342,O
study,1342,O
followed,1342,O
by,1342,O
long-term,1342,O
combination,1342,O
therapy,1342,O
in,1342,O
hypertensive,1342,B-DiseaseOrPhenotypicFeature
adults,1342,O
.,1342,O
BACKGROUND,1343,O
:,1343,O
One,1343,O
third,1343,O
of,1343,O
patients,1343,B-OrganismTaxon
treated,1343,O
for,1343,O
hypertension,1343,B-DiseaseOrPhenotypicFeature
attain,1343,O
adequate,1343,O
blood,1343,O
pressure,1343,O
(,1343,O
BP,1343,O
),1343,O
control,1343,O
",",1343,O
and,1343,O
multidrug,1343,O
regimens,1343,O
are,1343,O
often,1343,O
required,1343,O
.,1343,O
Given,1344,O
the,1344,O
lifelong,1344,O
nature,1344,O
of,1344,O
hypertension,1344,B-DiseaseOrPhenotypicFeature
",",1344,O
there,1344,O
is,1344,O
a,1344,O
need,1344,O
to,1344,O
evaluate,1344,O
the,1344,O
long-term,1344,O
efficacy,1344,O
and,1344,O
tolerability,1344,O
of,1344,O
higher,1344,O
doses,1344,O
of,1344,O
combination,1344,O
anti-hypertensive,1344,O
therapies,1344,O
.,1344,O
OBJECTIVE,1345,O
:,1345,O
This,1345,O
study,1345,O
investigated,1345,O
the,1345,O
efficacy,1345,O
and,1345,O
tolerability,1345,O
of,1345,O
valsartan,1345,B-ChemicalEntity
(,1345,O
VAL,1345,B-ChemicalEntity
),1345,O
or,1345,O
hydrochlorothiazide,1345,B-ChemicalEntity
(,1345,O
HCTZ,1345,B-ChemicalEntity
),1345,O
-monotherapy,1345,O
and,1345,O
higher-dose,1345,O
combinations,1345,O
in,1345,O
patients,1345,B-OrganismTaxon
with,1345,O
essential,1345,B-DiseaseOrPhenotypicFeature
hypertension,1345,I-DiseaseOrPhenotypicFeature
.,1345,O
METHODS,1346,O
:,1346,O
The,1346,O
first,1346,O
part,1346,O
of,1346,O
this,1346,O
study,1346,O
was,1346,O
an,1346,O
8-week,1346,O
",",1346,O
multicenter,1346,O
",",1346,O
randomized,1346,O
",",1346,O
double-blind,1346,O
",",1346,O
placebo,1346,O
controlled,1346,O
",",1346,O
parallel-group,1346,O
trial,1346,O
.,1346,O
Patients,1347,B-OrganismTaxon
with,1347,O
essential,1347,B-DiseaseOrPhenotypicFeature
hypertension,1347,I-DiseaseOrPhenotypicFeature
(,1347,O
mean,1347,O
sitting,1347,O
diastolic,1347,O
BP,1347,O
[,1347,O
MSDBP,1347,O
],1347,O
",",1347,O
>,1347,O
or,1347,O
=95,1347,O
mm,1347,O
Hg,1347,O
and,1347,O
<,1347,O
110,1347,O
mm,1347,O
Hg,1347,O
),1347,O
were,1347,O
randomized,1347,O
to,1347,O
1,1347,O
of,1347,O
8,1347,O
treatment,1347,O
groups,1347,O
:,1347,O
VAL,1347,B-ChemicalEntity
160,1347,O
or,1347,O
320,1347,O
mg,1347,O
;,1347,O
HCTZ,1347,B-ChemicalEntity
12.5,1347,O
or,1347,O
25,1347,O
mg,1347,O
;,1347,O
VAL/HCTZ,1347,B-ChemicalEntity
160/12.5,1347,O
",",1347,O
320/12.5,1347,O
",",1347,O
or,1347,O
320/25,1347,O
mg,1347,O
;,1347,O
or,1347,O
placebo,1347,O
.,1347,O
Mean,1348,O
changes,1348,O
in,1348,O
MSDBP,1348,O
and,1348,O
mean,1348,O
sitting,1348,O
systolic,1348,O
BP,1348,O
(,1348,O
MSSBP,1348,O
),1348,O
were,1348,O
analyzed,1348,O
at,1348,O
the,1348,O
8-week,1348,O
core,1348,O
study,1348,O
end,1348,O
point,1348,O
.,1348,O
VAL/HCTZ,1349,B-ChemicalEntity
320/12.5,1349,O
and,1349,O
320/25,1349,O
mg,1349,O
were,1349,O
further,1349,O
investigated,1349,O
in,1349,O
a,1349,O
54-week,1349,O
",",1349,O
open-label,1349,O
extension,1349,O
.,1349,O
Response,1350,O
was,1350,O
defined,1350,O
as,1350,O
MSDBP,1350,O
<,1350,O
90,1350,O
mm,1350,O
Hg,1350,O
or,1350,O
a,1350,O
>,1350,O
or,1350,O
=10,1350,O
mm,1350,O
Hg,1350,O
decrease,1350,O
compared,1350,O
to,1350,O
baseline,1350,O
.,1350,O
Control,1351,O
was,1351,O
defined,1351,O
as,1351,O
MSDBP,1351,O
<,1351,O
90,1351,O
mm,1351,O
Hg,1351,O
compared,1351,O
with,1351,O
baseline,1351,O
.,1351,O
Tolerability,1352,O
was,1352,O
assessed,1352,O
by,1352,O
monitoring,1352,O
adverse,1352,O
events,1352,O
at,1352,O
randomization,1352,O
and,1352,O
all,1352,O
subsequent,1352,O
study,1352,O
visits,1352,O
and,1352,O
regular,1352,O
evaluation,1352,O
of,1352,O
hematology,1352,O
and,1352,O
blood,1352,O
chemistry,1352,O
.,1352,O
RESULTS,1353,O
:,1353,O
A,1353,O
total,1353,O
of,1353,O
1346,1353,O
patients,1353,B-OrganismTaxon
were,1353,O
randomized,1353,O
into,1353,O
the,1353,O
8-week,1353,O
core,1353,O
study,1353,O
(,1353,O
734,1353,O
men,1353,B-OrganismTaxon
",",1353,O
612,1353,O
women,1353,B-OrganismTaxon
;,1353,O
924,1353,O
white,1353,O
",",1353,O
291,1353,O
black,1353,O
",",1353,O
23,1353,O
Asian,1353,O
",",1353,O
108,1353,O
other,1353,O
;,1353,O
mean,1353,O
age,1353,O
",",1353,O
52.7,1353,O
years,1353,O
;,1353,O
mean,1353,O
weight,1353,O
",",1353,O
92.6,1353,O
kg,1353,O
),1353,O
.,1353,O
All,1354,O
active,1354,O
treatments,1354,O
were,1354,O
associated,1354,O
with,1354,O
significantly,1354,O
reduced,1354,O
MSSBP,1354,O
and,1354,O
MSDBP,1354,O
during,1354,O
the,1354,O
core,1354,O
8-week,1354,O
study,1354,O
",",1354,O
with,1354,O
each,1354,O
monotherapy,1354,O
significantly,1354,O
contributing,1354,O
to,1354,O
the,1354,O
overall,1354,O
effect,1354,O
of,1354,O
combination,1354,O
therapy,1354,O
(,1354,O
VAL,1354,B-ChemicalEntity
and,1354,O
HCTZ,1354,B-ChemicalEntity
",",1354,O
P,1354,O
<,1354,O
0.001,1354,O
),1354,O
.,1354,O
Each,1355,O
combination,1355,O
was,1355,O
associated,1355,O
with,1355,O
significantly,1355,O
greater,1355,O
reductions,1355,O
in,1355,O
MSSBP,1355,O
and,1355,O
MSDBP,1355,O
compared,1355,O
with,1355,O
the,1355,O
monotherapies,1355,O
and,1355,O
placebo,1355,O
(,1355,O
all,1355,O
",",1355,O
P,1355,O
<,1355,O
0.001,1355,O
),1355,O
.,1355,O
The,1356,O
mean,1356,O
reduction,1356,O
in,1356,O
MSSBP/MSDBP,1356,O
with,1356,O
VAL/HCTZ,1356,B-ChemicalEntity
320/25,1356,O
mg,1356,O
was,1356,O
24.7/16.6,1356,O
mm,1356,O
Hg,1356,O
",",1356,O
compared,1356,O
with,1356,O
5.9/7.0,1356,O
mm,1356,O
Hg,1356,O
with,1356,O
placebo,1356,O
.,1356,O
The,1357,O
reduction,1357,O
in,1357,O
MSSBP,1357,O
was,1357,O
significantly,1357,O
greater,1357,O
with,1357,O
VAL/HCTZ,1357,B-ChemicalEntity
320/25,1357,O
mg,1357,O
compared,1357,O
with,1357,O
VAL/HCTZ,1357,B-ChemicalEntity
160/12.5,1357,O
mg,1357,O
(,1357,O
P,1357,O
<,1357,O
0.002,1357,O
),1357,O
.,1357,O
Rates,1358,O
of,1358,O
response,1358,O
and,1358,O
BP,1358,O
control,1358,O
were,1358,O
significantly,1358,O
higher,1358,O
in,1358,O
the,1358,O
groups,1358,O
that,1358,O
received,1358,O
combination,1358,O
treatment,1358,O
compared,1358,O
with,1358,O
those,1358,O
that,1358,O
received,1358,O
monotherapy,1358,O
.,1358,O
The,1359,O
incidence,1359,O
of,1359,O
hypokalemia,1359,B-DiseaseOrPhenotypicFeature
was,1359,O
lower,1359,O
with,1359,O
VAL/HCTZ,1359,B-ChemicalEntity
combinations,1359,O
(,1359,O
1.8,1359,O
%,1359,O
-6.1,1359,O
%,1359,O
),1359,O
than,1359,O
with,1359,O
HCTZ,1359,B-ChemicalEntity
monotherapies,1359,O
(,1359,O
7.1,1359,O
%,1359,O
-13.3,1359,O
%,1359,O
),1359,O
.,1359,O
The,1360,O
majority,1360,O
of,1360,O
adverse,1360,O
events,1360,O
in,1360,O
the,1360,O
core,1360,O
study,1360,O
were,1360,O
of,1360,O
mild,1360,O
to,1360,O
moderate,1360,O
severity,1360,O
.,1360,O
The,1361,O
efficacy,1361,O
and,1361,O
tolerability,1361,O
of,1361,O
VAL/HCTZ,1361,B-ChemicalEntity
combinations,1361,O
were,1361,O
maintained,1361,O
during,1361,O
the,1361,O
extension,1361,O
(,1361,O
797,1361,O
patients,1361,B-OrganismTaxon
),1361,O
.,1361,O
CONCLUSIONS,1362,O
:,1362,O
In,1362,O
this,1362,O
study,1362,O
population,1362,O
",",1362,O
combination,1362,O
therapies,1362,O
with,1362,O
VAL/HCTZ,1362,B-ChemicalEntity
were,1362,O
associated,1362,O
with,1362,O
significantly,1362,O
greater,1362,O
BP,1362,O
reductions,1362,O
compared,1362,O
with,1362,O
either,1362,O
monotherapy,1362,O
",",1362,O
were,1362,O
well,1362,O
tolerated,1362,O
",",1362,O
and,1362,O
were,1362,O
associated,1362,O
with,1362,O
less,1362,O
hypokalemia,1362,B-DiseaseOrPhenotypicFeature
than,1362,O
HCTZ,1362,B-ChemicalEntity
alone,1362,O
.,1362,O
The,1363,O
phosphatidylethanolamine,1363,B-GeneOrGeneProduct
N-methyltransferase,1363,I-GeneOrGeneProduct
gene,1363,O
V175M,1363,B-SequenceVariant
single,1363,O
nucleotide,1363,O
polymorphism,1363,O
confers,1363,O
the,1363,O
susceptibility,1363,O
to,1363,O
NASH,1363,B-DiseaseOrPhenotypicFeature
in,1363,O
Japanese,1363,O
population,1363,O
.,1363,O
BACKGROUND/AIMS,1364,O
:,1364,O
The,1364,O
genetic,1364,O
predisposition,1364,O
on,1364,O
the,1364,O
development,1364,O
of,1364,O
nonalcoholic,1364,B-DiseaseOrPhenotypicFeature
steatohepatitis,1364,I-DiseaseOrPhenotypicFeature
(,1364,O
NASH,1364,B-DiseaseOrPhenotypicFeature
),1364,O
has,1364,O
been,1364,O
poorly,1364,O
understood,1364,O
.,1364,O
A,1365,O
functional,1365,O
polymorphism,1365,O
Val175Met,1365,B-SequenceVariant
was,1365,O
reported,1365,O
in,1365,O
phosphatidylethanolamine,1365,B-GeneOrGeneProduct
N-methyltransferase,1365,I-GeneOrGeneProduct
(,1365,O
PEMT,1365,B-GeneOrGeneProduct
),1365,O
that,1365,O
catalyzes,1365,O
the,1365,O
conversion,1365,O
of,1365,O
phosphatidylethanolamine,1365,B-ChemicalEntity
to,1365,O
phosphatidylcholine,1365,B-ChemicalEntity
.,1365,O
The,1366,O
aim,1366,O
of,1366,O
this,1366,O
study,1366,O
was,1366,O
to,1366,O
investigate,1366,O
whether,1366,O
the,1366,O
carriers,1366,O
of,1366,O
Val175Met,1366,B-SequenceVariant
variant,1366,O
impaired,1366,O
in,1366,O
PEMT,1366,B-GeneOrGeneProduct
activity,1366,O
are,1366,O
more,1366,O
susceptible,1366,O
to,1366,O
NASH,1366,B-DiseaseOrPhenotypicFeature
.,1366,O
METHODS,1367,O
:,1367,O
Blood,1367,O
samples,1367,O
of,1367,O
107,1367,O
patients,1367,B-OrganismTaxon
with,1367,O
biopsy-proven,1367,O
NASH,1367,B-DiseaseOrPhenotypicFeature
and,1367,O
of,1367,O
150,1367,O
healthy,1367,O
volunteers,1367,O
were,1367,O
analyzed,1367,O
by,1367,O
the,1367,O
polymerase,1367,O
chain,1367,O
reaction,1367,O
(,1367,O
PCR,1367,O
),1367,O
and,1367,O
restriction,1367,O
fragment,1367,O
length,1367,O
polymorphism,1367,O
.,1367,O
RESULTS,1368,O
:,1368,O
Val175Met,1368,B-SequenceVariant
variant,1368,O
allele,1368,O
of,1368,O
the,1368,O
PEMT,1368,B-GeneOrGeneProduct
gene,1368,O
was,1368,O
significantly,1368,O
more,1368,O
frequent,1368,O
in,1368,O
NASH,1368,B-DiseaseOrPhenotypicFeature
patients,1368,B-OrganismTaxon
than,1368,O
in,1368,O
healthy,1368,O
volunteers,1368,O
(,1368,O
p,1368,O
<,1368,O
0.001,1368,O
),1368,O
",",1368,O
and,1368,O
carriers,1368,O
of,1368,O
Val175Met,1368,B-SequenceVariant
variant,1368,O
were,1368,O
significantly,1368,O
more,1368,O
frequent,1368,O
in,1368,O
NASH,1368,B-DiseaseOrPhenotypicFeature
patients,1368,B-OrganismTaxon
than,1368,O
in,1368,O
healthy,1368,O
volunteers,1368,O
(,1368,O
p,1368,O
<,1368,O
0.01,1368,O
),1368,O
.,1368,O
Among,1369,O
NASH,1369,B-DiseaseOrPhenotypicFeature
patients,1369,B-OrganismTaxon
",",1369,O
body,1369,O
mass,1369,O
index,1369,O
was,1369,O
significantly,1369,O
lower,1369,O
(,1369,O
p,1369,O
<,1369,O
0.05,1369,O
),1369,O
",",1369,O
and,1369,O
non-obese,1369,O
patients,1369,B-OrganismTaxon
were,1369,O
significantly,1369,O
more,1369,O
frequent,1369,O
(,1369,O
p,1369,O
<,1369,O
0.001,1369,O
),1369,O
in,1369,O
carriers,1369,O
of,1369,O
Val175Met,1369,B-SequenceVariant
variant,1369,O
than,1369,O
in,1369,O
homozygotes,1369,O
of,1369,O
wild,1369,O
type,1369,O
PEMT,1369,B-GeneOrGeneProduct
.,1369,O
CONCLUSIONS,1370,O
:,1370,O
Val175Met,1370,B-SequenceVariant
variant,1370,O
of,1370,O
PEMT,1370,B-GeneOrGeneProduct
could,1370,O
be,1370,O
a,1370,O
candidate,1370,O
molecule,1370,O
that,1370,O
determines,1370,O
the,1370,O
susceptibility,1370,O
to,1370,O
NASH,1370,B-DiseaseOrPhenotypicFeature
",",1370,O
because,1370,O
it,1370,O
is,1370,O
more,1370,O
frequently,1370,O
observed,1370,O
in,1370,O
NASH,1370,B-DiseaseOrPhenotypicFeature
patients,1370,B-OrganismTaxon
and,1370,O
non-obese,1370,O
persons,1370,O
with,1370,O
Val175Met,1370,B-SequenceVariant
variant,1370,O
of,1370,O
PEMT,1370,B-GeneOrGeneProduct
are,1370,O
facilitated,1370,O
to,1370,O
develop,1370,O
NASH,1370,B-DiseaseOrPhenotypicFeature
.,1370,O
Role,1371,O
of,1371,O
xanthine,1371,B-ChemicalEntity
oxidase,1371,I-ChemicalEntity
in,1371,O
dexamethasone-induced,1371,B-ChemicalEntity
hypertension,1371,B-DiseaseOrPhenotypicFeature
in,1371,O
rats,1371,B-OrganismTaxon
.,1371,O
1,1372,O
.,1372,O
Glucocorticoid-induced,1373,B-ChemicalEntity
hypertension,1373,B-DiseaseOrPhenotypicFeature
(,1373,O
GC-HT,1373,B-ChemicalEntity
),1373,O
in,1373,O
the,1373,O
rat,1373,B-OrganismTaxon
is,1373,O
associated,1373,O
with,1373,O
nitric,1373,B-ChemicalEntity
oxide-redox,1373,O
imbalance,1373,O
.,1373,O
2,1374,O
.,1374,O
We,1375,O
studied,1375,O
the,1375,O
role,1375,O
of,1375,O
xanthine,1375,B-ChemicalEntity
oxidase,1375,I-ChemicalEntity
(,1375,O
XO,1375,B-ChemicalEntity
),1375,O
",",1375,O
which,1375,O
is,1375,O
implicated,1375,O
in,1375,O
the,1375,O
production,1375,O
of,1375,O
reactive,1375,B-ChemicalEntity
oxygen,1375,I-ChemicalEntity
species,1375,I-ChemicalEntity
",",1375,O
in,1375,O
dexamethasone-induced,1375,B-ChemicalEntity
hypertension,1375,B-DiseaseOrPhenotypicFeature
(,1375,O
dex-HT,1375,B-ChemicalEntity
),1375,O
.,1375,O
3,1376,O
.,1376,O
Thirty,1377,O
male,1377,O
Sprague-Dawley,1377,O
rats,1377,B-OrganismTaxon
were,1377,O
divided,1377,O
randomly,1377,O
into,1377,O
four,1377,O
treatment,1377,O
groups,1377,O
:,1377,O
saline,1377,O
",",1377,O
dexamethasone,1377,B-ChemicalEntity
(,1377,O
dex,1377,B-ChemicalEntity
),1377,O
",",1377,O
allopurinol,1377,B-ChemicalEntity
plus,1377,O
saline,1377,O
",",1377,O
and,1377,O
allopurinol,1377,B-ChemicalEntity
plus,1377,O
dex,1377,B-ChemicalEntity
.,1377,O
4,1378,O
.,1378,O
Systolic,1379,O
blood,1379,O
pressures,1379,O
(,1379,O
SBP,1379,O
),1379,O
and,1379,O
bodyweights,1379,O
were,1379,O
recorded,1379,O
each,1379,O
alternate,1379,O
day,1379,O
.,1379,O
Thymus,1380,O
weight,1380,O
was,1380,O
used,1380,O
as,1380,O
a,1380,O
marker,1380,O
of,1380,O
glucocorticoid,1380,B-ChemicalEntity
activity,1380,O
",",1380,O
and,1380,O
serum,1380,O
urate,1380,B-ChemicalEntity
to,1380,O
assess,1380,O
XO,1380,B-ChemicalEntity
inhibition,1380,O
.,1380,O
5,1381,O
.,1381,O
Dex,1382,B-ChemicalEntity
increased,1382,O
SBP,1382,O
(,1382,O
110,1382,O
+/-,1382,O
2-126,1382,O
+/-,1382,O
3,1382,O
mmHg,1382,O
;,1382,O
P,1382,O
<,1382,O
0.001,1382,O
),1382,O
and,1382,O
decreased,1382,O
thymus,1382,O
(,1382,O
P,1382,O
<,1382,O
0.001,1382,O
),1382,O
and,1382,O
bodyweights,1382,O
(,1382,O
P,1382,O
'',1382,O
<,1382,O
0.01,1382,O
),1382,O
.,1382,O
Allopurinol,1383,B-ChemicalEntity
decreased,1383,O
serum,1383,O
urate,1383,B-ChemicalEntity
from,1383,O
76,1383,O
+/-,1383,O
5,1383,O
to,1383,O
30,1383,O
+/-,1383,O
3,1383,O
micromol/L,1383,O
(,1383,O
P,1383,O
<,1383,O
0.001,1383,O
),1383,O
in,1383,O
saline,1383,O
and,1383,O
from,1383,O
84,1383,O
+/-,1383,O
13,1383,O
to,1383,O
28,1383,O
+/-,1383,O
2,1383,O
micromol/L,1383,O
in,1383,O
dex-treated,1383,B-ChemicalEntity
(,1383,O
P,1383,O
<,1383,O
0.01,1383,O
),1383,O
groups,1383,O
.,1383,O
6,1384,O
.,1384,O
Allopurinol,1385,B-ChemicalEntity
did,1385,O
not,1385,O
prevent,1385,O
dex-HT,1385,B-ChemicalEntity
.,1385,O
This,1386,O
",",1386,O
together,1386,O
with,1386,O
our,1386,O
previous,1386,O
findings,1386,O
that,1386,O
allopurinol,1386,B-ChemicalEntity
failed,1386,O
to,1386,O
prevent,1386,O
adrenocorticotrophic,1386,B-GeneOrGeneProduct
hormone,1386,I-GeneOrGeneProduct
induced,1386,O
hypertension,1386,B-DiseaseOrPhenotypicFeature
",",1386,O
suggests,1386,O
that,1386,O
XO,1386,B-ChemicalEntity
activity,1386,O
is,1386,O
not,1386,O
a,1386,O
major,1386,O
determinant,1386,O
of,1386,O
GC-HT,1386,B-ChemicalEntity
in,1386,O
the,1386,O
rat,1386,B-OrganismTaxon
.,1386,O
Tenomodulin,1387,B-GeneOrGeneProduct
is,1387,O
associated,1387,O
with,1387,O
obesity,1387,B-DiseaseOrPhenotypicFeature
and,1387,O
diabetes,1387,B-DiseaseOrPhenotypicFeature
risk,1387,O
:,1387,O
the,1387,O
Finnish,1387,O
diabetes,1387,B-DiseaseOrPhenotypicFeature
prevention,1387,O
study,1387,O
.,1387,O
We,1388,O
recently,1388,O
showed,1388,O
that,1388,O
long-term,1388,O
weight,1388,O
reduction,1388,O
changes,1388,O
the,1388,O
gene,1388,O
expression,1388,O
profile,1388,O
of,1388,O
adipose,1388,O
tissue,1388,O
in,1388,O
overweight,1388,B-DiseaseOrPhenotypicFeature
individuals,1388,O
with,1388,O
impaired,1388,B-DiseaseOrPhenotypicFeature
glucose,1388,I-DiseaseOrPhenotypicFeature
tolerance,1388,I-DiseaseOrPhenotypicFeature
(,1388,O
IGT,1388,B-DiseaseOrPhenotypicFeature
),1388,O
.,1388,O
One,1389,O
of,1389,O
the,1389,O
responding,1389,O
genes,1389,O
was,1389,O
X-chromosomal,1389,O
tenomodulin,1389,B-GeneOrGeneProduct
(,1389,O
TNMD,1389,B-GeneOrGeneProduct
),1389,O
",",1389,O
a,1389,O
putative,1389,O
angiogenesis,1389,O
inhibitor,1389,O
.,1389,O
Our,1390,O
aim,1390,O
was,1390,O
to,1390,O
study,1390,O
the,1390,O
associations,1390,O
of,1390,O
individual,1390,O
single,1390,O
nucleotide,1390,O
polymorphisms,1390,O
and,1390,O
haplotypes,1390,O
with,1390,O
adiposity,1390,B-DiseaseOrPhenotypicFeature
",",1390,O
glucose,1390,B-ChemicalEntity
metabolism,1390,O
",",1390,O
and,1390,O
the,1390,O
risk,1390,O
of,1390,O
type,1390,B-DiseaseOrPhenotypicFeature
2,1390,I-DiseaseOrPhenotypicFeature
diabetes,1390,I-DiseaseOrPhenotypicFeature
(,1390,O
T2D,1390,B-DiseaseOrPhenotypicFeature
),1390,O
.,1390,O
Seven,1391,O
single,1391,O
nucleotide,1391,O
polymorphisms,1391,O
from,1391,O
two,1391,O
different,1391,O
haploblocks,1391,O
were,1391,O
genotyped,1391,O
from,1391,O
507,1391,O
participants,1391,O
of,1391,O
the,1391,O
Finnish,1391,O
Diabetes,1391,B-DiseaseOrPhenotypicFeature
Prevention,1391,O
Study,1391,O
(,1391,O
DPS,1391,O
),1391,O
.,1391,O
Sex-specific,1392,O
genotype,1392,O
effects,1392,O
were,1392,O
observed,1392,O
.,1392,O
Three,1393,O
markers,1393,O
of,1393,O
haploblock,1393,O
1,1393,O
were,1393,O
associated,1393,O
with,1393,O
features,1393,O
of,1393,O
adiposity,1393,B-DiseaseOrPhenotypicFeature
in,1393,O
women,1393,B-OrganismTaxon
(,1393,O
rs5966709,1393,B-SequenceVariant
",",1393,O
rs4828037,1393,B-SequenceVariant
),1393,O
and,1393,O
men,1393,B-OrganismTaxon
(,1393,O
rs11798018,1393,B-SequenceVariant
),1393,O
.,1393,O
Markers,1394,O
rs2073163,1394,B-SequenceVariant
and,1394,O
rs1155794,1394,B-SequenceVariant
from,1394,O
haploblock,1394,O
2,1394,O
were,1394,O
associated,1394,O
with,1394,O
2-hour,1394,O
plasma,1394,O
glucose,1394,B-ChemicalEntity
levels,1394,O
in,1394,O
men,1394,B-OrganismTaxon
during,1394,O
the,1394,O
3-year,1394,O
follow-up,1394,O
.,1394,O
The,1395,O
same,1395,O
two,1395,O
markers,1395,O
together,1395,O
with,1395,O
rs2073162,1395,B-SequenceVariant
associated,1395,O
with,1395,O
the,1395,O
conversion,1395,O
of,1395,O
IGT,1395,B-DiseaseOrPhenotypicFeature
to,1395,O
T2D,1395,B-DiseaseOrPhenotypicFeature
in,1395,O
men,1395,B-OrganismTaxon
.,1395,O
The,1396,O
risk,1396,O
of,1396,O
developing,1396,O
T2D,1396,B-DiseaseOrPhenotypicFeature
was,1396,O
approximately,1396,O
2-fold,1396,O
in,1396,O
individuals,1396,O
with,1396,O
genotypes,1396,O
associated,1396,O
with,1396,O
higher,1396,O
2-hour,1396,O
plasma,1396,O
glucose,1396,B-ChemicalEntity
levels,1396,O
;,1396,O
the,1396,O
hazard,1396,O
ratios,1396,O
were,1396,O
2.192,1396,O
(,1396,O
p,1396,O
=,1396,O
0.025,1396,O
),1396,O
for,1396,O
rs2073162-A,1396,B-SequenceVariant
",",1396,O
2.191,1396,O
(,1396,O
p,1396,O
=,1396,O
0.027,1396,O
),1396,O
for,1396,O
rs2073163-C,1396,B-SequenceVariant
",",1396,O
and,1396,O
1.998,1396,O
(,1396,O
p,1396,O
=,1396,O
0.054,1396,O
),1396,O
for,1396,O
rs1155974-T,1396,B-SequenceVariant
.,1396,O
These,1397,O
results,1397,O
suggest,1397,O
that,1397,O
TNMD,1397,B-GeneOrGeneProduct
polymorphisms,1397,O
are,1397,O
associated,1397,O
with,1397,O
adiposity,1397,B-DiseaseOrPhenotypicFeature
and,1397,O
also,1397,O
with,1397,O
glucose,1397,B-ChemicalEntity
metabolism,1397,O
and,1397,O
conversion,1397,O
from,1397,O
IGT,1397,B-DiseaseOrPhenotypicFeature
to,1397,O
T2D,1397,B-DiseaseOrPhenotypicFeature
in,1397,O
men,1397,B-OrganismTaxon
.,1397,O
Neuroprotective,1398,O
effects,1398,O
of,1398,O
melatonin,1398,B-ChemicalEntity
upon,1398,O
the,1398,O
offspring,1398,O
cerebellar,1398,O
cortex,1398,O
in,1398,O
the,1398,O
rat,1398,B-OrganismTaxon
model,1398,O
of,1398,O
BCNU-induced,1398,B-ChemicalEntity
cortical,1398,B-DiseaseOrPhenotypicFeature
dysplasia,1398,I-DiseaseOrPhenotypicFeature
.,1398,O
Cortical,1399,B-DiseaseOrPhenotypicFeature
dysplasia,1399,I-DiseaseOrPhenotypicFeature
is,1399,O
a,1399,O
malformation,1399,O
characterized,1399,O
by,1399,O
defects,1399,O
in,1399,O
proliferation,1399,O
",",1399,O
migration,1399,O
and,1399,O
maturation,1399,O
.,1399,O
This,1400,O
study,1400,O
was,1400,O
designed,1400,O
to,1400,O
evaluate,1400,O
the,1400,O
alterations,1400,O
in,1400,O
offspring,1400,O
rat,1400,B-OrganismTaxon
cerebellum,1400,O
induced,1400,O
by,1400,O
maternal,1400,O
exposure,1400,O
to,1400,O
carmustine-,1400,B-ChemicalEntity
[,1400,O
"1,3-bis",1400,B-ChemicalEntity
(,1400,I-ChemicalEntity
2-chloroethyl,1400,I-ChemicalEntity
),1400,I-ChemicalEntity
-1-nitrosoure,1400,I-ChemicalEntity
],1400,O
(,1400,O
BCNU,1400,B-ChemicalEntity
),1400,O
and,1400,O
to,1400,O
investigate,1400,O
the,1400,O
effects,1400,O
of,1400,O
exogenous,1400,O
melatonin,1400,B-ChemicalEntity
upon,1400,O
cerebellar,1400,O
BCNU-induced,1400,B-ChemicalEntity
cortical,1400,B-DiseaseOrPhenotypicFeature
dysplasia,1400,I-DiseaseOrPhenotypicFeature
",",1400,O
using,1400,O
histological,1400,O
and,1400,O
biochemical,1400,O
analyses,1400,O
.,1400,O
Pregnant,1401,O
Wistar,1401,O
rats,1401,B-OrganismTaxon
were,1401,O
assigned,1401,O
to,1401,O
five,1401,O
groups,1401,O
:,1401,O
intact-control,1401,O
",",1401,O
saline-control,1401,O
",",1401,O
melatonin-treated,1401,B-ChemicalEntity
",",1401,O
BCNU-exposed,1401,B-ChemicalEntity
and,1401,O
BCNU-exposed,1401,B-ChemicalEntity
plus,1401,O
melatonin,1401,B-ChemicalEntity
.,1401,O
Rats,1402,B-OrganismTaxon
were,1402,O
exposed,1402,O
to,1402,O
BCNU,1402,B-ChemicalEntity
on,1402,O
embryonic,1402,O
day,1402,O
15,1402,O
and,1402,O
melatonin,1402,B-ChemicalEntity
was,1402,O
given,1402,O
until,1402,O
delivery,1402,O
.,1402,O
Immuno/histochemistry,1403,O
and,1403,O
electron,1403,O
microscopy,1403,O
were,1403,O
carried,1403,O
out,1403,O
on,1403,O
the,1403,O
offspring,1403,O
cerebellum,1403,O
",",1403,O
and,1403,O
levels,1403,O
of,1403,O
malondialdehyde,1403,B-ChemicalEntity
and,1403,O
superoxide,1403,B-ChemicalEntity
dismutase,1403,O
were,1403,O
determined,1403,O
.,1403,O
Histopathologically,1404,O
",",1404,O
typical,1404,O
findings,1404,O
were,1404,O
observed,1404,O
in,1404,O
the,1404,O
cerebella,1404,O
from,1404,O
the,1404,O
control,1404,O
groups,1404,O
",",1404,O
but,1404,O
the,1404,O
findings,1404,O
consistent,1404,O
with,1404,O
early,1404,O
embryonic,1404,O
development,1404,O
were,1404,O
noted,1404,O
in,1404,O
BCNU-exposed,1404,B-ChemicalEntity
cortical,1404,B-DiseaseOrPhenotypicFeature
dysplasia,1404,I-DiseaseOrPhenotypicFeature
group,1404,O
.,1404,O
There,1405,O
was,1405,O
a,1405,O
marked,1405,O
increase,1405,O
in,1405,O
the,1405,O
number,1405,O
of,1405,O
TUNEL,1405,O
positive,1405,O
cells,1405,O
and,1405,O
nestin,1405,O
positive,1405,O
cells,1405,O
in,1405,O
BCNU-exposed,1405,B-ChemicalEntity
group,1405,O
",",1405,O
but,1405,O
a,1405,O
decreased,1405,O
immunoreactivity,1405,O
to,1405,O
glial,1405,B-GeneOrGeneProduct
fibrillary,1405,I-GeneOrGeneProduct
acidic,1405,I-GeneOrGeneProduct
protein,1405,I-GeneOrGeneProduct
",",1405,O
synaptophysin,1405,B-GeneOrGeneProduct
and,1405,O
transforming,1405,B-GeneOrGeneProduct
growth,1405,I-GeneOrGeneProduct
factor,1405,I-GeneOrGeneProduct
beta1,1405,I-GeneOrGeneProduct
was,1405,O
observed,1405,O
",",1405,O
indicating,1405,O
a,1405,O
delayed,1405,O
maturation,1405,O
",",1405,O
and,1405,O
melatonin,1405,B-ChemicalEntity
significantly,1405,O
reversed,1405,O
these,1405,O
changes,1405,O
.,1405,O
Malondialdehyde,1406,B-ChemicalEntity
level,1406,O
in,1406,O
BCNU-exposed,1406,B-ChemicalEntity
group,1406,O
was,1406,O
higher,1406,O
than,1406,O
those,1406,O
in,1406,O
control,1406,O
groups,1406,O
and,1406,O
melatonin,1406,B-ChemicalEntity
decreased,1406,O
malondialdehyde,1406,B-ChemicalEntity
levels,1406,O
in,1406,O
BCNU,1406,B-ChemicalEntity
group,1406,O
(,1406,O
P,1406,O
<,1406,O
0.01,1406,O
),1406,O
",",1406,O
while,1406,O
there,1406,O
were,1406,O
no,1406,O
significant,1406,O
differences,1406,O
in,1406,O
the,1406,O
superoxide,1406,B-GeneOrGeneProduct
dismutase,1406,I-GeneOrGeneProduct
levels,1406,O
between,1406,O
these,1406,O
groups,1406,O
.,1406,O
These,1407,O
data,1407,O
suggest,1407,O
that,1407,O
exposure,1407,O
of,1407,O
animals,1407,O
to,1407,O
BCNU,1407,B-ChemicalEntity
during,1407,O
pregnancy,1407,O
leads,1407,O
to,1407,O
delayed,1407,O
maturation,1407,O
of,1407,O
offspring,1407,O
cerebellum,1407,O
and,1407,O
melatonin,1407,B-ChemicalEntity
protects,1407,O
the,1407,O
cerebellum,1407,O
against,1407,O
the,1407,O
effects,1407,O
of,1407,O
BCNU,1407,B-ChemicalEntity
.,1407,O
Mutations,1408,O
in,1408,O
pattern,1408,O
recognition,1408,O
receptor,1408,O
genes,1408,O
modulate,1408,O
seroreactivity,1408,O
to,1408,O
microbial,1408,O
antigens,1408,O
in,1408,O
patients,1408,B-OrganismTaxon
with,1408,O
inflammatory,1408,B-DiseaseOrPhenotypicFeature
bowel,1408,I-DiseaseOrPhenotypicFeature
disease,1408,I-DiseaseOrPhenotypicFeature
.,1408,O
BACKGROUND,1409,O
AND,1409,O
AIMS,1409,O
:,1409,O
A,1409,O
number,1409,O
of,1409,O
antibodies,1409,O
against,1409,O
microbial,1409,O
epitopes,1409,O
or,1409,O
self-antigens,1409,O
have,1409,O
been,1409,O
associated,1409,O
with,1409,O
Crohn,1409,B-DiseaseOrPhenotypicFeature
's,1409,I-DiseaseOrPhenotypicFeature
disease,1409,I-DiseaseOrPhenotypicFeature
.,1409,O
The,1410,O
development,1410,O
of,1410,O
antibodies,1410,O
reflects,1410,O
a,1410,O
loss,1410,O
of,1410,O
tolerance,1410,O
to,1410,O
intestinal,1410,O
bacteria,1410,B-OrganismTaxon
that,1410,O
underlies,1410,O
Crohn,1410,B-DiseaseOrPhenotypicFeature
's,1410,I-DiseaseOrPhenotypicFeature
disease,1410,I-DiseaseOrPhenotypicFeature
",",1410,O
resulting,1410,O
in,1410,O
an,1410,O
exaggerated,1410,O
adaptive,1410,O
immune,1410,O
response,1410,O
to,1410,O
these,1410,O
bacteria,1410,B-OrganismTaxon
.,1410,O
It,1411,O
was,1411,O
hypothesised,1411,O
that,1411,O
the,1411,O
development,1411,O
of,1411,O
antimicrobial,1411,O
antibodies,1411,O
is,1411,O
influenced,1411,O
by,1411,O
the,1411,O
presence,1411,O
of,1411,O
genetic,1411,O
variants,1411,O
in,1411,O
pattern,1411,O
recognition,1411,O
receptor,1411,O
genes,1411,O
.,1411,O
The,1412,O
aim,1412,O
of,1412,O
this,1412,O
study,1412,O
was,1412,O
therefore,1412,O
to,1412,O
investigate,1412,O
the,1412,O
influence,1412,O
of,1412,O
mutations,1412,O
in,1412,O
these,1412,O
innate,1412,B-GeneOrGeneProduct
immune,1412,I-GeneOrGeneProduct
receptor,1412,I-GeneOrGeneProduct
genes,1412,O
(,1412,O
nucleotide,1412,B-GeneOrGeneProduct
oligomerisation,1412,I-GeneOrGeneProduct
domain,1412,I-GeneOrGeneProduct
(,1412,I-GeneOrGeneProduct
NOD,1412,I-GeneOrGeneProduct
),1412,I-GeneOrGeneProduct
2/caspase,1412,O
recruitment,1412,I-GeneOrGeneProduct
domain,1412,I-GeneOrGeneProduct
(,1412,I-GeneOrGeneProduct
CARD,1412,I-GeneOrGeneProduct
),1412,I-GeneOrGeneProduct
15,1412,I-GeneOrGeneProduct
",",1412,O
NOD1/CARD4,1412,B-GeneOrGeneProduct
",",1412,O
TUCAN/CARDINAL/CARD8,1412,B-GeneOrGeneProduct
",",1412,O
Toll-like,1412,B-GeneOrGeneProduct
receptor,1412,I-GeneOrGeneProduct
(,1412,I-GeneOrGeneProduct
TLR,1412,I-GeneOrGeneProduct
),1412,I-GeneOrGeneProduct
4,1412,I-GeneOrGeneProduct
",",1412,O
TLR2,1412,B-GeneOrGeneProduct
",",1412,O
TLR1,1412,B-GeneOrGeneProduct
and,1412,O
TLR6,1412,B-GeneOrGeneProduct
),1412,O
on,1412,O
the,1412,O
development,1412,O
of,1412,O
antimicrobial,1412,O
and,1412,O
antiglycan,1412,O
antibodies,1412,O
in,1412,O
inflammatory,1412,B-DiseaseOrPhenotypicFeature
bowel,1412,I-DiseaseOrPhenotypicFeature
disease,1412,I-DiseaseOrPhenotypicFeature
(,1412,O
IBD,1412,B-DiseaseOrPhenotypicFeature
),1412,O
.,1412,O
Materials,1413,O
and,1413,O
METHODS,1413,O
:,1413,O
A,1413,O
cohort,1413,O
of,1413,O
1163,1413,O
unrelated,1413,O
patients,1413,B-OrganismTaxon
with,1413,O
IBD,1413,B-DiseaseOrPhenotypicFeature
(,1413,O
874,1413,O
Crohn,1413,B-DiseaseOrPhenotypicFeature
's,1413,I-DiseaseOrPhenotypicFeature
disease,1413,I-DiseaseOrPhenotypicFeature
",",1413,O
259,1413,O
ulcerative,1413,B-DiseaseOrPhenotypicFeature
colitis,1413,I-DiseaseOrPhenotypicFeature
",",1413,O
30,1413,O
indeterminate,1413,O
colitis,1413,B-DiseaseOrPhenotypicFeature
),1413,O
and,1413,O
312,1413,O
controls,1413,O
were,1413,O
analysed,1413,O
for,1413,O
anti-Saccharomyces,1413,O
cerevisiae,1413,I-OrganismTaxon
antibodies,1413,O
(,1413,O
gASCA,1413,O
),1413,O
IgG,1413,O
",",1413,O
anti-laminaribioside,1413,O
antibodies,1413,O
(,1413,O
ALCA,1413,O
),1413,O
IgG,1413,O
",",1413,O
anti-chitobioside,1413,O
antibodies,1413,O
(,1413,O
ACCA,1413,O
),1413,O
IgA,1413,O
",",1413,O
anti-mannobioside,1413,O
antibodies,1413,O
(,1413,O
AMCA,1413,O
),1413,O
IgG,1413,O
and,1413,O
outer,1413,O
membrane,1413,O
porin,1413,O
(,1413,O
Omp,1413,O
),1413,O
IgA,1413,O
and,1413,O
were,1413,O
genotyped,1413,O
for,1413,O
variants,1413,O
in,1413,O
NOD2/CARD15,1413,B-GeneOrGeneProduct
",",1413,O
TUCAN/CARDINAL/CARD8,1413,B-GeneOrGeneProduct
",",1413,O
NOD1/CARD4,1413,B-GeneOrGeneProduct
",",1413,O
TLR4,1413,B-GeneOrGeneProduct
",",1413,O
TLR1,1413,B-GeneOrGeneProduct
",",1413,O
TLR2,1413,B-GeneOrGeneProduct
and,1413,O
TLR6,1413,B-GeneOrGeneProduct
.,1413,O
RESULTS,1414,O
:,1414,O
When,1414,O
compared,1414,O
with,1414,O
Crohn,1414,B-DiseaseOrPhenotypicFeature
's,1414,I-DiseaseOrPhenotypicFeature
disease,1414,I-DiseaseOrPhenotypicFeature
patients,1414,B-OrganismTaxon
without,1414,O
CARD15,1414,B-GeneOrGeneProduct
mutations,1414,O
",",1414,O
the,1414,O
presence,1414,O
of,1414,O
at,1414,O
least,1414,O
one,1414,O
CARD15,1414,B-GeneOrGeneProduct
variant,1414,O
in,1414,O
Crohn,1414,B-DiseaseOrPhenotypicFeature
's,1414,I-DiseaseOrPhenotypicFeature
disease,1414,I-DiseaseOrPhenotypicFeature
patients,1414,B-OrganismTaxon
more,1414,O
frequently,1414,O
led,1414,O
to,1414,O
gASCA,1414,O
positivity,1414,O
(,1414,O
66.1,1414,O
%,1414,O
versus,1414,O
51.5,1414,O
%,1414,O
",",1414,O
p,1414,O
<,1414,O
0.0001,1414,O
),1414,O
and,1414,O
ALCA,1414,O
positivity,1414,O
(,1414,O
43.3,1414,O
%,1414,O
versus,1414,O
34.9,1414,O
%,1414,O
",",1414,O
p,1414,O
=,1414,O
0.018,1414,O
),1414,O
and,1414,O
higher,1414,O
gASCA,1414,O
titers,1414,O
(,1414,O
85.7,1414,O
versus,1414,O
51.8,1414,O
ELISA,1414,O
units,1414,O
",",1414,O
p,1414,O
<,1414,O
0.0001,1414,O
),1414,O
",",1414,O
independent,1414,O
of,1414,O
ileal,1414,O
involvement,1414,O
.,1414,O
A,1415,O
gene,1415,O
dosage,1415,O
effect,1415,O
",",1415,O
with,1415,O
increasing,1415,O
gASCA,1415,O
and,1415,O
ALCA,1415,O
positivity,1415,O
for,1415,O
patients,1415,B-OrganismTaxon
carrying,1415,O
none,1415,O
",",1415,O
one,1415,O
and,1415,O
two,1415,O
CARD15,1415,B-GeneOrGeneProduct
variants,1415,O
",",1415,O
respectively,1415,O
",",1415,O
was,1415,O
seen,1415,O
for,1415,O
both,1415,O
markers,1415,O
.,1415,O
Similarly,1416,O
",",1416,O
Crohn,1416,B-DiseaseOrPhenotypicFeature
's,1416,I-DiseaseOrPhenotypicFeature
disease,1416,I-DiseaseOrPhenotypicFeature
patients,1416,B-OrganismTaxon
carrying,1416,O
NOD1/CARD4,1416,B-GeneOrGeneProduct
indel,1416,O
had,1416,O
a,1416,O
higher,1416,O
prevalence,1416,O
of,1416,O
gASCA,1416,O
antibodies,1416,O
than,1416,O
wild-type,1416,O
patients,1416,B-OrganismTaxon
(,1416,O
63.8,1416,O
%,1416,O
versus,1416,O
55.2,1416,O
%,1416,O
",",1416,O
p,1416,O
=,1416,O
0.014,1416,O
),1416,O
",",1416,O
also,1416,O
with,1416,O
a,1416,O
gene,1416,O
dosage,1416,O
effect,1416,O
.,1416,O
An,1417,O
opposite,1417,O
effect,1417,O
was,1417,O
observed,1417,O
for,1417,O
the,1417,O
TLR4,1417,B-GeneOrGeneProduct
D299G,1417,B-SequenceVariant
and,1417,O
TLR2,1417,B-GeneOrGeneProduct
P631H,1417,B-SequenceVariant
variants,1417,O
",",1417,O
with,1417,O
a,1417,O
lower,1417,O
prevalence,1417,O
of,1417,O
ACCA,1417,O
antibodies,1417,O
(,1417,O
23.4,1417,O
%,1417,O
versus,1417,O
35,1417,O
%,1417,O
",",1417,O
p,1417,O
=,1417,O
0.013,1417,O
),1417,O
and,1417,O
Omp,1417,O
antibodies,1417,O
(,1417,O
20.5,1417,O
%,1417,O
versus,1417,O
34.6,1417,O
%,1417,O
",",1417,O
p,1417,O
=,1417,O
0.009,1417,O
),1417,O
",",1417,O
respectively,1417,O
.,1417,O
CONCLUSION,1418,O
:,1418,O
Variants,1418,O
in,1418,O
innate,1418,B-GeneOrGeneProduct
immune,1418,I-GeneOrGeneProduct
receptor,1418,I-GeneOrGeneProduct
genes,1418,O
were,1418,O
found,1418,O
to,1418,O
influence,1418,O
antibody,1418,O
formation,1418,O
against,1418,O
microbial,1418,O
epitopes,1418,O
.,1418,O
In,1419,O
this,1419,O
respect,1419,O
",",1419,O
it,1419,O
is,1419,O
intriguing,1419,O
that,1419,O
an,1419,O
opposite,1419,O
effect,1419,O
of,1419,O
CARD15,1419,B-GeneOrGeneProduct
and,1419,O
TLR4,1419,B-GeneOrGeneProduct
variants,1419,O
was,1419,O
observed,1419,O
.,1419,O
These,1420,O
findings,1420,O
may,1420,O
contribute,1420,O
to,1420,O
an,1420,O
understanding,1420,O
of,1420,O
the,1420,O
aetiology,1420,O
of,1420,O
the,1420,O
seroreactivity,1420,O
observed,1420,O
in,1420,O
IBD,1420,B-DiseaseOrPhenotypicFeature
.,1420,O
Severe,1421,O
rhabdomyolysis,1421,B-DiseaseOrPhenotypicFeature
and,1421,O
acute,1421,B-DiseaseOrPhenotypicFeature
renal,1421,I-DiseaseOrPhenotypicFeature
failure,1421,I-DiseaseOrPhenotypicFeature
secondary,1421,O
to,1421,O
concomitant,1421,O
use,1421,O
of,1421,O
simvastatin,1421,B-ChemicalEntity
",",1421,O
amiodarone,1421,B-ChemicalEntity
",",1421,O
and,1421,O
atazanavir,1421,B-ChemicalEntity
.,1421,O
OBJECTIVE,1422,O
:,1422,O
To,1422,O
report,1422,O
a,1422,O
case,1422,O
of,1422,O
a,1422,O
severe,1422,O
interaction,1422,O
between,1422,O
simvastatin,1422,B-ChemicalEntity
",",1422,O
amiodarone,1422,B-ChemicalEntity
",",1422,O
and,1422,O
atazanavir,1422,B-ChemicalEntity
resulting,1422,O
in,1422,O
rhabdomyolysis,1422,B-DiseaseOrPhenotypicFeature
and,1422,O
acute,1422,B-DiseaseOrPhenotypicFeature
renal,1422,I-DiseaseOrPhenotypicFeature
failure,1422,I-DiseaseOrPhenotypicFeature
.,1422,O
BACKGROUND,1423,O
:,1423,O
A,1423,O
72-year-old,1423,O
white,1423,O
man,1423,B-OrganismTaxon
with,1423,O
underlying,1423,O
human,1423,B-OrganismTaxon
immunodeficiency,1423,I-OrganismTaxon
virus,1423,I-OrganismTaxon
",",1423,O
atrial,1423,B-DiseaseOrPhenotypicFeature
fibrillation,1423,I-DiseaseOrPhenotypicFeature
",",1423,O
coronary,1423,B-DiseaseOrPhenotypicFeature
artery,1423,I-DiseaseOrPhenotypicFeature
disease,1423,I-DiseaseOrPhenotypicFeature
",",1423,O
and,1423,O
hyperlipidemia,1423,B-DiseaseOrPhenotypicFeature
presented,1423,O
with,1423,O
generalized,1423,O
pain,1423,B-DiseaseOrPhenotypicFeature
",",1423,O
fatigue,1423,B-DiseaseOrPhenotypicFeature
",",1423,O
and,1423,O
dark,1423,O
orange,1423,O
urine,1423,O
for,1423,O
3,1423,O
days,1423,O
.,1423,O
The,1424,O
patient,1424,B-OrganismTaxon
was,1424,O
taking,1424,O
80,1424,O
mg,1424,O
simvastatin,1424,B-ChemicalEntity
at,1424,O
bedtime,1424,O
(,1424,O
initiated,1424,O
27,1424,O
days,1424,O
earlier,1424,O
),1424,O
;,1424,O
amiodarone,1424,B-ChemicalEntity
at,1424,O
a,1424,O
dose,1424,O
of,1424,O
400,1424,O
mg,1424,O
daily,1424,O
for,1424,O
7,1424,O
days,1424,O
",",1424,O
then,1424,O
200,1424,O
mg,1424,O
daily,1424,O
(,1424,O
initiated,1424,O
19,1424,O
days,1424,O
earlier,1424,O
),1424,O
;,1424,O
and,1424,O
400,1424,O
mg,1424,O
atazanavir,1424,B-ChemicalEntity
daily,1424,O
(,1424,O
initiated,1424,O
at,1424,O
least,1424,O
2,1424,O
years,1424,O
previously,1424,O
),1424,O
.,1424,O
Laboratory,1425,O
evaluation,1425,O
revealed,1425,O
"66,680",1425,O
U/L,1425,O
creatine,1425,B-ChemicalEntity
kinase,1425,I-ChemicalEntity
",",1425,O
93,1425,O
mg/dL,1425,O
blood,1425,B-ChemicalEntity
urea,1425,I-ChemicalEntity
nitrogen,1425,I-ChemicalEntity
",",1425,O
4.6,1425,O
mg/dL,1425,O
creatinine,1425,B-ChemicalEntity
",",1425,O
1579,1425,O
U/L,1425,O
aspartate,1425,B-ChemicalEntity
aminotransferase,1425,I-ChemicalEntity
",",1425,O
and,1425,O
738,1425,O
U/L,1425,O
alanine,1425,B-ChemicalEntity
aminotransferase,1425,I-ChemicalEntity
.,1425,O
Simvastatin,1426,B-ChemicalEntity
",",1426,O
amiodarone,1426,B-ChemicalEntity
",",1426,O
and,1426,O
the,1426,O
patient,1426,B-OrganismTaxon
's,1426,O
human,1426,B-OrganismTaxon
immunodeficiency,1426,I-OrganismTaxon
virus,1426,I-OrganismTaxon
medications,1426,O
were,1426,O
all,1426,O
temporarily,1426,O
discontinued,1426,O
and,1426,O
the,1426,O
patient,1426,B-OrganismTaxon
was,1426,O
given,1426,O
forced,1426,O
alkaline,1426,O
diuresis,1426,O
and,1426,O
started,1426,O
on,1426,O
dialysis,1426,O
.,1426,O
Nine,1427,O
days,1427,O
later,1427,O
the,1427,O
patient,1427,B-OrganismTaxon
's,1427,O
creatine,1427,B-ChemicalEntity
kinase,1427,I-ChemicalEntity
had,1427,O
dropped,1427,O
to,1427,O
1695,1427,O
U/L,1427,O
and,1427,O
creatinine,1427,B-ChemicalEntity
was,1427,O
3.3,1427,O
mg/dL,1427,O
.,1427,O
The,1428,O
patient,1428,B-OrganismTaxon
was,1428,O
discharged,1428,O
and,1428,O
continued,1428,O
outpatient,1428,B-OrganismTaxon
dialysis,1428,O
for,1428,O
1,1428,O
month,1428,O
until,1428,O
his,1428,O
renal,1428,O
function,1428,O
recovered,1428,O
.,1428,O
DISCUSSION,1429,O
:,1429,O
The,1429,O
risk,1429,O
of,1429,O
rhabdomyolysis,1429,B-DiseaseOrPhenotypicFeature
is,1429,O
increased,1429,O
in,1429,O
the,1429,O
presence,1429,O
of,1429,O
concomitant,1429,O
drugs,1429,O
that,1429,O
inhibit,1429,O
simvastatin,1429,B-ChemicalEntity
metabolism,1429,O
.,1429,O
Simvastatin,1430,B-ChemicalEntity
is,1430,O
metabolized,1430,O
by,1430,O
CYP3A4,1430,B-GeneOrGeneProduct
.,1430,O
Amiodarone,1431,B-ChemicalEntity
and,1431,O
atazanavir,1431,B-ChemicalEntity
are,1431,O
recognized,1431,O
CYP3A4,1431,B-GeneOrGeneProduct
inhibitors,1431,O
.,1431,O
CONCLUSIONS,1432,O
:,1432,O
Pharmacokinetic,1432,O
differences,1432,O
in,1432,O
statins,1432,B-ChemicalEntity
are,1432,O
an,1432,O
important,1432,O
consideration,1432,O
for,1432,O
assessing,1432,O
the,1432,O
risk,1432,O
of,1432,O
potential,1432,O
drug,1432,O
interactions,1432,O
.,1432,O
In,1433,O
patients,1433,B-OrganismTaxon
requiring,1433,O
the,1433,O
concurrent,1433,O
use,1433,O
of,1433,O
statins,1433,B-ChemicalEntity
and,1433,O
CYP3A4,1433,B-GeneOrGeneProduct
inhibitors,1433,O
",",1433,O
pravastatin,1433,B-ChemicalEntity
",",1433,O
fluvastatin,1433,B-ChemicalEntity
",",1433,O
and,1433,O
rosuvastatin,1433,B-ChemicalEntity
carry,1433,O
the,1433,O
lowest,1433,O
risk,1433,O
of,1433,O
drug,1433,O
interactions,1433,O
;,1433,O
atorvastatin,1433,B-ChemicalEntity
carries,1433,O
moderate,1433,O
risk,1433,O
",",1433,O
whereas,1433,O
simvastatin,1433,B-ChemicalEntity
and,1433,O
lovastatin,1433,B-ChemicalEntity
have,1433,O
the,1433,O
highest,1433,O
risk,1433,O
and,1433,O
should,1433,O
be,1433,O
avoided,1433,O
in,1433,O
patients,1433,B-OrganismTaxon
taking,1433,O
concomitant,1433,O
CYP3A4,1433,B-ChemicalEntity
inhibitors,1433,I-ChemicalEntity
.,1433,O
Manganese,1434,B-GeneOrGeneProduct
superoxide,1434,I-GeneOrGeneProduct
dismutase,1434,I-GeneOrGeneProduct
(,1434,O
Mn-SOD,1434,B-GeneOrGeneProduct
),1434,O
gene,1434,O
polymorphisms,1434,O
in,1434,O
urolithiasis,1434,B-DiseaseOrPhenotypicFeature
.,1434,O
Polymorphism,1435,O
in,1435,O
manganese,1435,B-GeneOrGeneProduct
superoxide,1435,I-GeneOrGeneProduct
dismutase,1435,I-GeneOrGeneProduct
gene,1435,O
(,1435,O
Mn-SOD,1435,B-GeneOrGeneProduct
),1435,O
is,1435,O
a,1435,O
new,1435,O
approach,1435,O
to,1435,O
identify,1435,O
its,1435,O
probable,1435,O
association,1435,O
with,1435,O
urolithiasis,1435,B-DiseaseOrPhenotypicFeature
.,1435,O
Oxidative,1436,O
stress,1436,O
may,1436,O
be,1436,O
involved,1436,O
in,1436,O
the,1436,O
development,1436,O
of,1436,O
stone,1436,B-DiseaseOrPhenotypicFeature
formation,1436,I-DiseaseOrPhenotypicFeature
in,1436,O
the,1436,O
renal,1436,O
system,1436,O
.,1436,O
MnSOD,1437,B-GeneOrGeneProduct
is,1437,O
one,1437,O
of,1437,O
the,1437,O
primary,1437,O
enzymes,1437,O
that,1437,O
directly,1437,O
scavenges,1437,O
potential,1437,O
harmful,1437,O
oxidizing,1437,O
species,1437,O
.,1437,O
A,1438,O
valine,1438,B-SequenceVariant
(,1438,I-SequenceVariant
Val,1438,I-SequenceVariant
),1438,I-SequenceVariant
to,1438,I-SequenceVariant
alanine,1438,I-SequenceVariant
(,1438,I-SequenceVariant
Ala,1438,I-SequenceVariant
),1438,I-SequenceVariant
substitution,1438,I-SequenceVariant
at,1438,I-SequenceVariant
amino,1438,I-SequenceVariant
acid,1438,I-SequenceVariant
16,1438,I-SequenceVariant
",",1438,O
occurring,1438,O
in,1438,O
the,1438,O
mitochondrial,1438,O
targeting,1438,O
sequence,1438,O
of,1438,O
the,1438,O
MnSOD,1438,B-GeneOrGeneProduct
gene,1438,O
",",1438,O
has,1438,O
been,1438,O
associated,1438,O
with,1438,O
an,1438,O
increase,1438,O
in,1438,O
urolithiasis,1438,B-DiseaseOrPhenotypicFeature
risk,1438,O
.,1438,O
This,1439,O
study,1439,O
was,1439,O
conducted,1439,O
to,1439,O
investigate,1439,O
the,1439,O
association,1439,O
of,1439,O
MnSOD,1439,B-GeneOrGeneProduct
gene,1439,O
polymorphism,1439,O
with,1439,O
the,1439,O
risk,1439,O
of,1439,O
urolithiasis,1439,B-DiseaseOrPhenotypicFeature
.,1439,O
We,1440,O
investigated,1440,O
the,1440,O
MnSOD,1440,B-GeneOrGeneProduct
in,1440,O
66,1440,O
stone-forming,1440,B-DiseaseOrPhenotypicFeature
adults,1440,O
and,1440,O
72,1440,O
healthy,1440,O
volunteers,1440,O
.,1440,O
DNA,1441,O
was,1441,O
isolated,1441,O
from,1441,O
peripheral,1441,O
blood,1441,O
and,1441,O
genotyping,1441,O
was,1441,O
performed,1441,O
with,1441,O
PCR-based,1441,O
methods,1441,O
.,1441,O
Then,1442,O
PCR,1442,O
products,1442,O
were,1442,O
cut,1442,O
by,1442,O
BsaW1,1442,O
.,1442,O
Products,1443,O
were,1443,O
run,1443,O
on,1443,O
3,1443,O
%,1443,O
agarose,1443,B-ChemicalEntity
gel,1443,O
",",1443,O
246,1443,O
bp,1443,O
regions,1443,O
were,1443,O
1-Ala-9,1443,O
",",1443,O
164,1443,O
and,1443,O
82,1443,O
bp,1443,O
products,1443,O
were,1443,O
determined,1443,O
as,1443,O
2,1443,O
Val-9,1443,O
.,1443,O
Chi-square,1444,O
test,1444,O
was,1444,O
used,1444,O
for,1444,O
comparison,1444,O
between,1444,O
patients,1444,B-OrganismTaxon
and,1444,O
controls,1444,O
.,1444,O
In,1445,O
the,1445,O
control,1445,O
group,1445,O
the,1445,O
homozygote,1445,O
Ala,1445,O
allele,1445,O
was,1445,O
significantly,1445,O
higher,1445,O
than,1445,O
in,1445,O
the,1445,O
patient,1445,B-OrganismTaxon
group,1445,O
(,1445,O
P,1445,O
<,1445,O
0.01,1445,O
),1445,O
.,1445,O
The,1446,O
distribution,1446,O
of,1446,O
Ala/Val,1446,O
and,1446,O
homozygote,1446,O
Val,1446,O
alleles,1446,O
in,1446,O
the,1446,O
patient,1446,B-OrganismTaxon
group,1446,O
was,1446,O
significantly,1446,O
higher,1446,O
than,1446,O
in,1446,O
the,1446,O
control,1446,O
group,1446,O
(,1446,O
P,1446,O
<,1446,O
0.05,1446,O
),1446,O
.,1446,O
MnSOD,1447,B-GeneOrGeneProduct
genotype,1447,O
determination,1447,O
may,1447,O
provide,1447,O
a,1447,O
tool,1447,O
to,1447,O
identify,1447,O
individuals,1447,O
who,1447,O
are,1447,O
at,1447,O
risk,1447,O
of,1447,O
urolithiasis,1447,B-DiseaseOrPhenotypicFeature
.,1447,O
This,1448,O
experiment,1448,O
also,1448,O
provides,1448,O
data,1448,O
about,1448,O
antioxidant,1448,O
status,1448,O
and,1448,O
stone,1448,B-DiseaseOrPhenotypicFeature
formation,1448,I-DiseaseOrPhenotypicFeature
.,1448,O
Common,1449,O
germline,1449,O
genetic,1449,O
variation,1449,O
in,1449,O
antioxidant,1449,O
defense,1449,O
genes,1449,O
and,1449,O
survival,1449,O
after,1449,O
diagnosis,1449,O
of,1449,O
breast,1449,B-DiseaseOrPhenotypicFeature
cancer,1449,I-DiseaseOrPhenotypicFeature
.,1449,O
PURPOSE,1450,O
:,1450,O
The,1450,O
prognosis,1450,O
of,1450,O
breast,1450,B-DiseaseOrPhenotypicFeature
cancer,1450,I-DiseaseOrPhenotypicFeature
varies,1450,O
considerably,1450,O
among,1450,O
individuals,1450,O
",",1450,O
and,1450,O
inherited,1450,O
genetic,1450,O
factors,1450,O
may,1450,O
help,1450,O
explain,1450,O
this,1450,O
variability,1450,O
.,1450,O
Of,1451,O
particular,1451,O
interest,1451,O
are,1451,O
genes,1451,O
involved,1451,O
in,1451,O
defense,1451,O
against,1451,O
reactive,1451,B-ChemicalEntity
oxygen,1451,I-ChemicalEntity
species,1451,I-ChemicalEntity
(,1451,O
ROS,1451,B-ChemicalEntity
),1451,O
because,1451,O
ROS,1451,B-ChemicalEntity
are,1451,O
thought,1451,O
to,1451,O
cause,1451,O
DNA,1451,O
damage,1451,O
and,1451,O
contribute,1451,O
to,1451,O
the,1451,O
pathogenesis,1451,O
of,1451,O
cancer,1451,B-DiseaseOrPhenotypicFeature
.,1451,O
PATIENTS,1452,B-OrganismTaxon
AND,1452,O
METHODS,1452,O
:,1452,O
We,1452,O
examined,1452,O
associations,1452,O
between,1452,O
54,1452,O
polymorphisms,1452,O
that,1452,O
tag,1452,O
the,1452,O
known,1452,O
common,1452,O
variants,1452,O
(,1452,O
minor,1452,O
allele,1452,O
frequency,1452,O
>,1452,O
0.05,1452,O
),1452,O
in,1452,O
10,1452,O
genes,1452,O
involved,1452,O
in,1452,O
oxidative,1452,O
damage,1452,O
repair,1452,O
(,1452,O
CAT,1452,B-GeneOrGeneProduct
",",1452,O
SOD1,1452,B-GeneOrGeneProduct
",",1452,O
SOD2,1452,B-GeneOrGeneProduct
",",1452,O
GPX1,1452,B-GeneOrGeneProduct
",",1452,O
GPX4,1452,B-GeneOrGeneProduct
",",1452,O
GSR,1452,B-GeneOrGeneProduct
",",1452,O
TXN,1452,B-GeneOrGeneProduct
",",1452,O
TXN2,1452,B-GeneOrGeneProduct
",",1452,O
TXNRD1,1452,B-GeneOrGeneProduct
",",1452,O
and,1452,O
TXNRD2,1452,B-GeneOrGeneProduct
),1452,O
and,1452,O
survival,1452,O
in,1452,O
"4,470",1452,O
women,1452,B-OrganismTaxon
with,1452,O
breast,1452,B-DiseaseOrPhenotypicFeature
cancer,1452,I-DiseaseOrPhenotypicFeature
.,1452,O
RESULTS,1453,O
:,1453,O
Two,1453,O
single,1453,O
nucleotide,1453,O
polymorphisms,1453,O
(,1453,O
SNPs,1453,O
),1453,O
in,1453,O
GPX4,1453,B-GeneOrGeneProduct
(,1453,O
rs713041,1453,B-SequenceVariant
and,1453,O
rs757229,1453,B-SequenceVariant
),1453,O
were,1453,O
associated,1453,O
with,1453,O
all-cause,1453,O
mortality,1453,O
even,1453,O
after,1453,O
adjusting,1453,O
for,1453,O
multiple,1453,O
hypothesis,1453,O
testing,1453,O
(,1453,O
adjusted,1453,O
P,1453,O
=,1453,O
.0041,1453,O
and,1453,O
P,1453,O
=,1453,O
.0035,1453,O
),1453,O
.,1453,O
These,1454,O
SNPs,1454,O
are,1454,O
correlated,1454,O
with,1454,O
each,1454,O
other,1454,O
(,1454,O
r2,1454,O
=,1454,O
0.61,1454,O
),1454,O
.,1454,O
GPX4,1455,B-GeneOrGeneProduct
rs713041,1455,B-SequenceVariant
is,1455,O
located,1455,O
near,1455,O
the,1455,O
selenocysteine,1455,B-ChemicalEntity
insertion,1455,O
sequence,1455,O
element,1455,O
in,1455,O
the,1455,O
GPX4,1455,B-GeneOrGeneProduct
3,1455,O
',1455,O
untranslated,1455,O
region,1455,O
",",1455,O
and,1455,O
the,1455,O
rare,1455,O
allele,1455,O
of,1455,O
this,1455,O
SNP,1455,O
is,1455,O
associated,1455,O
with,1455,O
an,1455,O
increased,1455,O
risk,1455,O
of,1455,O
death,1455,B-DiseaseOrPhenotypicFeature
",",1455,O
with,1455,O
a,1455,O
hazard,1455,O
ratio,1455,O
of,1455,O
1.27,1455,O
per,1455,O
rare,1455,O
allele,1455,O
carried,1455,O
(,1455,O
95,1455,O
%,1455,O
CI,1455,O
",",1455,O
1.13,1455,O
to,1455,O
11.43,1455,O
),1455,O
.,1455,O
This,1456,O
effect,1456,O
was,1456,O
not,1456,O
attenuated,1456,O
after,1456,O
adjusting,1456,O
for,1456,O
tumor,1456,B-DiseaseOrPhenotypicFeature
stage,1456,O
",",1456,O
grade,1456,O
",",1456,O
or,1456,O
estrogen,1456,B-GeneOrGeneProduct
receptor,1456,I-GeneOrGeneProduct
status,1456,O
.,1456,O
We,1457,O
found,1457,O
that,1457,O
the,1457,O
common,1457,O
allele,1457,O
is,1457,O
preferentially,1457,O
expressed,1457,O
in,1457,O
normal,1457,O
lymphocytes,1457,O
",",1457,O
normal,1457,O
breast,1457,O
",",1457,O
and,1457,O
breast,1457,B-DiseaseOrPhenotypicFeature
tumors,1457,I-DiseaseOrPhenotypicFeature
compared,1457,O
with,1457,O
the,1457,O
rare,1457,O
allele,1457,O
",",1457,O
but,1457,O
there,1457,O
were,1457,O
no,1457,O
differences,1457,O
in,1457,O
total,1457,O
levels,1457,O
of,1457,O
GPX4,1457,B-GeneOrGeneProduct
mRNA,1457,O
across,1457,O
genotypes,1457,O
.,1457,O
CONCLUSION,1458,O
:,1458,O
These,1458,O
data,1458,O
provide,1458,O
strong,1458,O
support,1458,O
for,1458,O
the,1458,O
hypothesis,1458,O
that,1458,O
common,1458,O
variation,1458,O
in,1458,O
GPX4,1458,B-GeneOrGeneProduct
is,1458,O
associated,1458,O
with,1458,O
prognosis,1458,O
after,1458,O
a,1458,O
diagnosis,1458,O
of,1458,O
breast,1458,B-DiseaseOrPhenotypicFeature
cancer,1458,I-DiseaseOrPhenotypicFeature
.,1458,O
Interaction,1459,O
between,1459,O
warfarin,1459,B-ChemicalEntity
and,1459,O
levofloxacin,1459,B-ChemicalEntity
:,1459,O
case,1459,O
series,1459,O
.,1459,O
Warfarin,1460,B-ChemicalEntity
is,1460,O
the,1460,O
most,1460,O
widely,1460,O
used,1460,O
oral,1460,O
anticoagulant,1460,O
and,1460,O
is,1460,O
indicated,1460,O
for,1460,O
many,1460,O
clinical,1460,O
conditions,1460,O
.,1460,O
Levofloxacin,1461,B-ChemicalEntity
",",1461,O
a,1461,O
fluoroquinolone,1461,B-ChemicalEntity
",",1461,O
is,1461,O
one,1461,O
of,1461,O
the,1461,O
most,1461,O
commonly,1461,O
prescribed,1461,O
antibiotics,1461,O
in,1461,O
clinical,1461,O
practice,1461,O
and,1461,O
is,1461,O
effective,1461,O
against,1461,O
Gram-positive,1461,O
",",1461,O
Gram-negative,1461,O
",",1461,O
and,1461,O
atypical,1461,O
bacteria,1461,B-OrganismTaxon
.,1461,O
While,1462,O
small,1462,O
prospective,1462,O
studies,1462,O
have,1462,O
not,1462,O
revealed,1462,O
any,1462,O
significant,1462,O
drug-drug,1462,O
interaction,1462,O
between,1462,O
warfarin,1462,B-ChemicalEntity
and,1462,O
levofloxacin,1462,B-ChemicalEntity
",",1462,O
several,1462,O
case,1462,O
reports,1462,O
have,1462,O
indicated,1462,O
that,1462,O
levofloxacin,1462,B-ChemicalEntity
may,1462,O
significantly,1462,O
potentiate,1462,O
the,1462,O
anticoagulation,1462,O
effect,1462,O
of,1462,O
warfarin,1462,B-ChemicalEntity
.,1462,O
We,1463,O
report,1463,O
3,1463,O
cases,1463,O
of,1463,O
serious,1463,O
bleeding,1463,B-DiseaseOrPhenotypicFeature
complications,1463,O
that,1463,O
appear,1463,O
to,1463,O
be,1463,O
the,1463,O
result,1463,O
of,1463,O
the,1463,O
interaction,1463,O
between,1463,O
warfarin,1463,B-ChemicalEntity
and,1463,O
levofloxacin,1463,B-ChemicalEntity
.,1463,O
Physicians,1464,O
should,1464,O
be,1464,O
aware,1464,O
of,1464,O
this,1464,O
potential,1464,O
interaction,1464,O
and,1464,O
use,1464,O
caution,1464,O
when,1464,O
prescribing,1464,O
levofloxacin,1464,B-ChemicalEntity
to,1464,O
patients,1464,B-OrganismTaxon
taking,1464,O
warfarin,1464,B-ChemicalEntity
.,1464,O
An,1465,O
improved,1465,O
tetra-primer,1465,O
PCR,1465,O
approach,1465,O
for,1465,O
the,1465,O
detection,1465,O
of,1465,O
the,1465,O
FGFR3,1465,B-GeneOrGeneProduct
G380R,1465,B-SequenceVariant
mutation,1465,O
responsible,1465,O
for,1465,O
achondroplasia,1465,B-DiseaseOrPhenotypicFeature
.,1465,O
Achondroplasia,1466,B-DiseaseOrPhenotypicFeature
is,1466,O
the,1466,O
most,1466,O
common,1466,O
form,1466,O
of,1466,O
dwarfism,1466,B-DiseaseOrPhenotypicFeature
and,1466,O
has,1466,O
an,1466,O
incidence,1466,O
of,1466,O
approximately,1466,O
1/7500,1466,O
.,1466,O
In,1467,O
more,1467,O
than,1467,O
98,1467,O
%,1467,O
of,1467,O
cases,1467,O
",",1467,O
the,1467,O
disease,1467,O
is,1467,O
associated,1467,O
with,1467,O
a,1467,O
G,1467,B-SequenceVariant
to,1467,I-SequenceVariant
A,1467,I-SequenceVariant
or,1467,I-SequenceVariant
G,1467,I-SequenceVariant
to,1467,I-SequenceVariant
C,1467,I-SequenceVariant
substitution,1467,I-SequenceVariant
at,1467,I-SequenceVariant
nucleotide,1467,I-SequenceVariant
position,1467,I-SequenceVariant
1138,1467,I-SequenceVariant
(,1467,O
p.G380R,1467,B-SequenceVariant
),1467,O
of,1467,O
the,1467,O
fibroblast,1467,B-GeneOrGeneProduct
growth,1467,I-GeneOrGeneProduct
factor,1467,I-GeneOrGeneProduct
receptor,1467,I-GeneOrGeneProduct
3,1467,I-GeneOrGeneProduct
(,1467,O
FGFR3,1467,B-GeneOrGeneProduct
),1467,O
gene,1467,O
.,1467,O
We,1468,O
have,1468,O
developed,1468,O
a,1468,O
sensitive,1468,O
single,1468,O
tube,1468,O
tetra-primer,1468,O
PCR,1468,O
assay,1468,O
to,1468,O
detect,1468,O
both,1468,O
the,1468,O
c.1138G,1468,B-SequenceVariant
>,1468,I-SequenceVariant
A,1468,I-SequenceVariant
and,1468,O
c.1138G,1468,B-SequenceVariant
>,1468,I-SequenceVariant
C,1468,I-SequenceVariant
mutations,1468,O
and,1468,O
can,1468,O
successfully,1468,O
distinguish,1468,O
DNA,1468,O
samples,1468,O
that,1468,O
are,1468,O
homozygous,1468,O
and,1468,O
heterozygous,1468,O
for,1468,O
the,1468,O
c.1138G,1468,B-SequenceVariant
>,1468,I-SequenceVariant
A,1468,I-SequenceVariant
mutation,1468,O
.,1468,O
Titration,1469,O
studies,1469,O
showed,1469,O
that,1469,O
the,1469,O
assay,1469,O
could,1469,O
reliably,1469,O
detect,1469,O
one,1469,O
copy,1469,O
of,1469,O
the,1469,O
mutant,1469,O
allele,1469,O
in,1469,O
a,1469,O
mix,1469,O
of,1469,O
100,1469,O
wild-type,1469,O
alleles,1469,O
.,1469,O
The,1470,O
assay,1470,O
has,1470,O
been,1470,O
tested,1470,O
in,1470,O
50,1470,O
healthy,1470,O
controls,1470,O
",",1470,O
3,1470,O
known,1470,O
patients,1470,B-OrganismTaxon
with,1470,O
achondroplasia,1470,B-DiseaseOrPhenotypicFeature
",",1470,O
and,1470,O
5,1470,O
amniotic,1470,O
fluids,1470,O
suspected,1470,O
of,1470,O
having,1470,O
achondroplasia,1470,B-DiseaseOrPhenotypicFeature
and,1470,O
for,1470,O
whom,1470,O
we,1470,O
had,1470,O
previously,1470,O
determined,1470,O
the,1470,O
genotypes,1470,O
for,1470,O
the,1470,O
c.1138G,1470,B-SequenceVariant
>,1470,I-SequenceVariant
A,1470,I-SequenceVariant
mutation,1470,O
by,1470,O
PCR-RFLP,1470,O
.,1470,O
We,1471,O
have,1471,O
observed,1471,O
complete,1471,O
concordance,1471,O
between,1471,O
methods,1471,O
.,1471,O
Our,1472,O
tetra-primer,1472,O
PCR,1472,O
assay,1472,O
is,1472,O
sensitive,1472,O
",",1472,O
low-cost,1472,O
",",1472,O
and,1472,O
easy,1472,O
to,1472,O
use,1472,O
method,1472,O
for,1472,O
FGFR3,1472,B-GeneOrGeneProduct
p.G380R,1472,B-SequenceVariant
genotyping,1472,O
",",1472,O
which,1472,O
could,1472,O
be,1472,O
used,1472,O
even,1472,O
in,1472,O
``,1472,O
low-tech,1472,O
'',1472,O
laboratories,1472,O
.,1472,O
Mutations,1473,O
associated,1473,O
with,1473,O
lamivudine-resistance,1473,B-ChemicalEntity
in,1473,O
therapy-na,1473,O
ve,1473,O
hepatitis,1473,B-DiseaseOrPhenotypicFeature
B,1473,I-DiseaseOrPhenotypicFeature
virus,1473,I-DiseaseOrPhenotypicFeature
(,1473,I-DiseaseOrPhenotypicFeature
HBV,1473,I-DiseaseOrPhenotypicFeature
),1473,I-DiseaseOrPhenotypicFeature
infected,1473,I-DiseaseOrPhenotypicFeature
patients,1473,B-OrganismTaxon
with,1473,O
and,1473,O
without,1473,O
HIV,1473,B-DiseaseOrPhenotypicFeature
co-infection,1473,I-DiseaseOrPhenotypicFeature
:,1473,O
implications,1473,O
for,1473,O
antiretroviral,1473,O
therapy,1473,O
in,1473,O
HBV,1473,B-DiseaseOrPhenotypicFeature
and,1473,I-DiseaseOrPhenotypicFeature
HIV,1473,I-DiseaseOrPhenotypicFeature
co-infected,1473,I-DiseaseOrPhenotypicFeature
South,1473,O
African,1473,O
patients,1473,B-OrganismTaxon
.,1473,O
This,1474,O
was,1474,O
an,1474,O
exploratory,1474,O
study,1474,O
to,1474,O
investigate,1474,O
lamivudine-resistant,1474,B-ChemicalEntity
hepatitis,1474,B-OrganismTaxon
B,1474,I-OrganismTaxon
virus,1474,I-OrganismTaxon
(,1474,O
HBV,1474,B-OrganismTaxon
),1474,O
strains,1474,O
in,1474,O
selected,1474,O
lamivudine-na,1474,B-ChemicalEntity
ve,1474,O
HBV,1474,B-OrganismTaxon
carriers,1474,O
with,1474,O
and,1474,O
without,1474,O
human,1474,B-DiseaseOrPhenotypicFeature
immunodeficiency,1474,I-DiseaseOrPhenotypicFeature
virus,1474,I-DiseaseOrPhenotypicFeature
(,1474,I-DiseaseOrPhenotypicFeature
HIV,1474,I-DiseaseOrPhenotypicFeature
),1474,I-DiseaseOrPhenotypicFeature
co-infection,1474,I-DiseaseOrPhenotypicFeature
in,1474,O
South,1474,O
African,1474,O
patients,1474,B-OrganismTaxon
.,1474,O
Thirty-five,1475,O
lamivudine-na,1475,B-ChemicalEntity
ve,1475,O
HBV,1475,B-DiseaseOrPhenotypicFeature
infected,1475,I-DiseaseOrPhenotypicFeature
patients,1475,B-OrganismTaxon
with,1475,O
or,1475,O
without,1475,O
HIV,1475,B-DiseaseOrPhenotypicFeature
co-infection,1475,I-DiseaseOrPhenotypicFeature
were,1475,O
studied,1475,O
:,1475,O
15,1475,O
chronic,1475,O
HBV,1475,B-DiseaseOrPhenotypicFeature
mono-infected,1475,I-DiseaseOrPhenotypicFeature
patients,1475,B-OrganismTaxon
and,1475,O
20,1475,O
HBV-HIV,1475,B-DiseaseOrPhenotypicFeature
co-infected,1475,I-DiseaseOrPhenotypicFeature
patients,1475,B-OrganismTaxon
.,1475,O
The,1476,O
latter,1476,O
group,1476,O
was,1476,O
further,1476,O
sub-divided,1476,O
into,1476,O
13,1476,O
occult,1476,O
HBV,1476,B-OrganismTaxon
(,1476,O
HBsAg-negative,1476,B-ChemicalEntity
),1476,O
and,1476,O
7,1476,O
overt,1476,O
HBV,1476,B-OrganismTaxon
(,1476,O
HBsAg-,1476,B-ChemicalEntity
positive,1476,O
),1476,O
patients,1476,B-OrganismTaxon
.,1476,O
HBsAg,1477,B-ChemicalEntity
",",1477,O
anti-HBs,1477,O
",",1477,O
anti-HBc,1477,O
",",1477,O
and,1477,O
anti-HIV,1477,O
1/2,1477,I-OrganismTaxon
were,1477,O
determined,1477,O
as,1477,O
part,1477,O
of,1477,O
routine,1477,O
diagnosis,1477,O
using,1477,O
Axsym,1477,O
assays,1477,O
(,1477,O
Abbott,1477,O
Laboratories,1477,O
",",1477,O
North,1477,O
Chicago,1477,O
",",1477,O
IL,1477,O
),1477,O
.,1477,O
Serum,1478,O
samples,1478,O
were,1478,O
PCR,1478,O
amplified,1478,O
with,1478,O
HBV,1478,B-OrganismTaxon
reverse,1478,O
transcriptase,1478,O
(,1478,O
RT,1478,O
),1478,O
primers,1478,O
",",1478,O
followed,1478,O
by,1478,O
direct,1478,O
sequencing,1478,O
across,1478,O
the,1478,O
tyrosine-methionine-aspartate-aspartate,1478,O
(,1478,O
YMDD,1478,O
),1478,O
motif,1478,O
of,1478,O
the,1478,O
major,1478,O
catalytic,1478,O
region,1478,O
in,1478,O
the,1478,O
C,1478,O
domain,1478,O
of,1478,O
the,1478,O
HBV,1478,B-OrganismTaxon
RT,1478,O
enzyme,1478,O
.,1478,O
HBV,1479,B-OrganismTaxon
viral,1479,O
load,1479,O
was,1479,O
performed,1479,O
with,1479,O
Amplicor,1479,O
HBV,1479,B-OrganismTaxon
Monitor,1479,O
test,1479,O
v2.0,1479,O
(,1479,O
Roche,1479,O
Diagnostics,1479,O
",",1479,O
Penzberg,1479,O
",",1479,O
Germany,1479,O
),1479,O
.,1479,O
HBV,1480,B-OrganismTaxon
lamivudine-resistant,1480,B-ChemicalEntity
strains,1480,O
were,1480,O
detected,1480,O
in,1480,O
3,1480,O
of,1480,O
15,1480,O
mono-infected,1480,O
chronic,1480,O
hepatitis,1480,B-DiseaseOrPhenotypicFeature
B,1480,I-DiseaseOrPhenotypicFeature
patients,1480,B-OrganismTaxon
and,1480,O
10,1480,O
of,1480,O
20,1480,O
HBV-HIV,1480,B-DiseaseOrPhenotypicFeature
co-infected,1480,I-DiseaseOrPhenotypicFeature
patients,1480,B-OrganismTaxon
.,1480,O
To,1481,O
the,1481,O
best,1481,O
of,1481,O
our,1481,O
knowledge,1481,O
",",1481,O
this,1481,O
constitutes,1481,O
the,1481,O
first,1481,O
report,1481,O
of,1481,O
HBV,1481,B-OrganismTaxon
lamivudine-resistant,1481,B-ChemicalEntity
strains,1481,O
in,1481,O
therapy-na,1481,O
ve,1481,O
HBV-HIV,1481,B-DiseaseOrPhenotypicFeature
co-infected,1481,I-DiseaseOrPhenotypicFeature
patients,1481,B-OrganismTaxon
.,1481,O
The,1482,O
HBV,1482,B-OrganismTaxon
viral,1482,O
loads,1482,O
for,1482,O
mono-infected,1482,O
and,1482,O
co-infected,1482,O
patients,1482,B-OrganismTaxon
ranged,1482,O
from,1482,O
3.32,1482,O
x,1482,O
10,1482,O
(,1482,O
2,1482,O
),1482,O
to,1482,O
3.82,1482,O
x,1482,O
10,1482,O
(,1482,O
7,1482,O
),1482,O
and,1482,O
<,1482,O
200,1482,O
to,1482,O
4.40,1482,O
x,1482,O
10,1482,O
(,1482,O
3,1482,O
),1482,O
copies/ml,1482,O
",",1482,O
respectively,1482,O
.,1482,O
It,1483,O
remains,1483,O
to,1483,O
be,1483,O
seen,1483,O
whether,1483,O
such,1483,O
pre-existing,1483,O
antiviral,1483,O
mutations,1483,O
could,1483,O
result,1483,O
in,1483,O
widespread,1483,O
emergence,1483,O
of,1483,O
HBV,1483,B-OrganismTaxon
resistant,1483,O
strains,1483,O
when,1483,O
lamivudine-containing,1483,B-ChemicalEntity
highly,1483,O
active,1483,O
antiretroviral,1483,O
(,1483,O
ARV,1483,O
),1483,O
treatment,1483,O
(,1483,O
HAART,1483,O
),1483,O
regimens,1483,O
become,1483,O
widely,1483,O
applied,1483,O
in,1483,O
South,1483,O
Africa,1483,O
",",1483,O
as,1483,O
this,1483,O
is,1483,O
likely,1483,O
to,1483,O
have,1483,O
potential,1483,O
implications,1483,O
in,1483,O
the,1483,O
management,1483,O
of,1483,O
HBV-HIV,1483,B-DiseaseOrPhenotypicFeature
co-infected,1483,I-DiseaseOrPhenotypicFeature
patients,1483,B-OrganismTaxon
.,1483,O
Identities,1484,O
",",1484,O
frequencies,1484,O
and,1484,O
origins,1484,O
of,1484,O
TMC1,1484,B-GeneOrGeneProduct
mutations,1484,O
causing,1484,O
DFNB7/B11,1484,B-DiseaseOrPhenotypicFeature
deafness,1484,I-DiseaseOrPhenotypicFeature
in,1484,O
Pakistan,1484,O
.,1484,O
Non-syndromic,1485,B-DiseaseOrPhenotypicFeature
deafness,1485,I-DiseaseOrPhenotypicFeature
is,1485,O
genetically,1485,O
heterogeneous,1485,O
.,1485,O
We,1486,O
previously,1486,O
reported,1486,O
that,1486,O
mutations,1486,O
of,1486,O
transmembrane,1486,B-GeneOrGeneProduct
channel-like,1486,I-GeneOrGeneProduct
gene,1486,I-GeneOrGeneProduct
1,1486,I-GeneOrGeneProduct
(,1486,O
TMC1,1486,B-GeneOrGeneProduct
),1486,O
cause,1486,O
non-syndromic,1486,B-DiseaseOrPhenotypicFeature
recessive,1486,I-DiseaseOrPhenotypicFeature
deafness,1486,I-DiseaseOrPhenotypicFeature
at,1486,O
the,1486,O
DFNB7/B11,1486,B-GeneOrGeneProduct
locus,1486,O
on,1486,O
chromosome,1486,O
9q13-q21,1486,O
in,1486,O
nine,1486,O
Pakistani,1486,O
families,1486,O
.,1486,O
The,1487,O
goal,1487,O
of,1487,O
this,1487,O
study,1487,O
was,1487,O
to,1487,O
define,1487,O
the,1487,O
identities,1487,O
",",1487,O
origins,1487,O
and,1487,O
frequencies,1487,O
of,1487,O
TMC1,1487,B-GeneOrGeneProduct
mutations,1487,O
in,1487,O
an,1487,O
expanded,1487,O
cohort,1487,O
of,1487,O
557,1487,O
large,1487,O
Pakistani,1487,O
families,1487,O
segregating,1487,O
recessive,1487,B-DiseaseOrPhenotypicFeature
deafness,1487,I-DiseaseOrPhenotypicFeature
.,1487,O
We,1488,O
screened,1488,O
affected,1488,O
family,1488,O
members,1488,O
for,1488,O
homozygosity,1488,O
at,1488,O
short-tandem,1488,O
repeats,1488,O
flanking,1488,O
known,1488,O
autosomal,1488,B-DiseaseOrPhenotypicFeature
recessive,1488,I-DiseaseOrPhenotypicFeature
(,1488,I-DiseaseOrPhenotypicFeature
DFNB,1488,I-DiseaseOrPhenotypicFeature
),1488,I-DiseaseOrPhenotypicFeature
deafness,1488,I-DiseaseOrPhenotypicFeature
loci,1488,O
",",1488,O
followed,1488,O
by,1488,O
TMC1,1488,B-GeneOrGeneProduct
sequence,1488,O
analysis,1488,O
in,1488,O
families,1488,O
segregating,1488,O
deafness,1488,B-DiseaseOrPhenotypicFeature
linked,1488,O
to,1488,O
DFNB7/B11,1488,B-GeneOrGeneProduct
.,1488,O
We,1489,O
identified,1489,O
10,1489,O
new,1489,O
families,1489,O
segregating,1489,O
DFNB7/B11,1489,B-DiseaseOrPhenotypicFeature
deafness,1489,I-DiseaseOrPhenotypicFeature
and,1489,O
TMC1,1489,B-GeneOrGeneProduct
mutations,1489,O
",",1489,O
including,1489,O
three,1489,O
novel,1489,O
alleles,1489,O
.,1489,O
Overall,1490,O
",",1490,O
9,1490,O
different,1490,O
TMC1,1490,B-GeneOrGeneProduct
mutations,1490,O
account,1490,O
for,1490,O
deafness,1490,B-DiseaseOrPhenotypicFeature
in,1490,O
19,1490,O
(,1490,O
3.4,1490,O
%,1490,O
),1490,O
of,1490,O
the,1490,O
557,1490,O
Pakistani,1490,O
families,1490,O
.,1490,O
A,1491,O
single,1491,O
mutation,1491,O
",",1491,O
p.R34X,1491,B-SequenceVariant
",",1491,O
causes,1491,O
deafness,1491,B-DiseaseOrPhenotypicFeature
in,1491,O
10,1491,O
(,1491,O
1.8,1491,O
%,1491,O
),1491,O
of,1491,O
the,1491,O
families,1491,O
.,1491,O
Genotype,1492,O
analysis,1492,O
of,1492,O
p.R34X-linked,1492,B-SequenceVariant
markers,1492,O
indicates,1492,O
that,1492,O
it,1492,O
arose,1492,O
from,1492,O
a,1492,O
common,1492,O
founder,1492,O
.,1492,O
We,1493,O
also,1493,O
detected,1493,O
p.R34X,1493,B-SequenceVariant
among,1493,O
normal,1493,O
control,1493,O
samples,1493,O
of,1493,O
African-American,1493,O
and,1493,O
northern,1493,O
European,1493,O
origins,1493,O
",",1493,O
raising,1493,O
the,1493,O
possibility,1493,O
that,1493,O
p.R34X,1493,B-SequenceVariant
and,1493,O
other,1493,O
mutations,1493,O
of,1493,O
TMC1,1493,B-GeneOrGeneProduct
are,1493,O
prevalent,1493,O
contributors,1493,O
to,1493,O
the,1493,O
genetic,1493,O
load,1493,O
of,1493,O
deafness,1493,B-DiseaseOrPhenotypicFeature
across,1493,O
a,1493,O
variety,1493,O
of,1493,O
populations,1493,O
and,1493,O
continents,1493,O
.,1493,O
A,1494,O
novel,1494,O
missense,1494,O
mutation,1494,O
in,1494,O
the,1494,O
paired,1494,O
domain,1494,O
of,1494,O
human,1494,B-OrganismTaxon
PAX9,1494,B-GeneOrGeneProduct
causes,1494,O
oligodontia,1494,B-DiseaseOrPhenotypicFeature
.,1494,O
PAX9,1495,B-GeneOrGeneProduct
and,1495,O
MSX1,1495,B-GeneOrGeneProduct
are,1495,O
transcription,1495,O
factors,1495,O
that,1495,O
play,1495,O
essential,1495,O
roles,1495,O
in,1495,O
craniofacial,1495,O
and,1495,O
limb,1495,O
development,1495,O
.,1495,O
In,1496,O
humans,1496,B-OrganismTaxon
",",1496,O
mutations,1496,O
in,1496,O
both,1496,O
genes,1496,O
are,1496,O
associated,1496,O
with,1496,O
nonsyndromic,1496,B-DiseaseOrPhenotypicFeature
and,1496,I-DiseaseOrPhenotypicFeature
syndromic,1496,I-DiseaseOrPhenotypicFeature
oligodontia,1496,I-DiseaseOrPhenotypicFeature
",",1496,O
respectively,1496,O
.,1496,O
We,1497,O
screened,1497,O
one,1497,O
family,1497,O
with,1497,O
nonsyndromic,1497,B-DiseaseOrPhenotypicFeature
oligodontia,1497,I-DiseaseOrPhenotypicFeature
for,1497,O
mutations,1497,O
in,1497,O
PAX9,1497,B-GeneOrGeneProduct
and,1497,O
MSX1,1497,B-GeneOrGeneProduct
.,1497,O
Single,1498,O
stranded,1498,O
conformational,1498,O
polymorphism,1498,O
(,1498,O
SSCP,1498,O
),1498,O
analysis,1498,O
and,1498,O
sequencing,1498,O
revealed,1498,O
a,1498,O
novel,1498,O
heterozygous,1498,O
C139T,1498,B-SequenceVariant
transition,1498,O
in,1498,O
PAX9,1498,B-GeneOrGeneProduct
in,1498,O
the,1498,O
affected,1498,O
members,1498,O
of,1498,O
the,1498,O
family,1498,O
.,1498,O
There,1499,O
were,1499,O
no,1499,O
mutations,1499,O
detected,1499,O
in,1499,O
the,1499,O
entire,1499,O
coding,1499,O
sequence,1499,O
of,1499,O
MSX1,1499,B-GeneOrGeneProduct
.,1499,O
The,1500,O
C139T,1500,B-SequenceVariant
mutation,1500,O
",",1500,O
predicted,1500,O
to,1500,O
result,1500,O
in,1500,O
the,1500,O
substitution,1500,O
of,1500,O
an,1500,O
arginine,1500,B-SequenceVariant
by,1500,I-SequenceVariant
a,1500,I-SequenceVariant
tryptophan,1500,I-SequenceVariant
(,1500,O
R47W,1500,B-SequenceVariant
),1500,O
in,1500,O
the,1500,O
N-terminal,1500,O
subdomain,1500,O
",",1500,O
affected,1500,O
conserved,1500,O
residues,1500,O
in,1500,O
the,1500,O
PAX9,1500,B-GeneOrGeneProduct
paired,1500,O
domain,1500,O
.,1500,O
To,1501,O
elucidate,1501,O
the,1501,O
pathogenic,1501,O
mechanism,1501,O
producing,1501,O
oligodontia,1501,B-DiseaseOrPhenotypicFeature
phenotype,1501,I-DiseaseOrPhenotypicFeature
caused,1501,O
by,1501,O
this,1501,O
mutation,1501,O
",",1501,O
we,1501,O
analyzed,1501,O
the,1501,O
binding,1501,O
of,1501,O
wild-type,1501,O
and,1501,O
mutant,1501,O
PAX9,1501,B-GeneOrGeneProduct
paired,1501,O
domain,1501,O
protein,1501,O
to,1501,O
double-stranded,1501,O
DNA,1501,O
targets,1501,O
.,1501,O
The,1502,O
R47W,1502,B-SequenceVariant
mutation,1502,O
dramatically,1502,O
reduced,1502,O
DNA,1502,O
binding,1502,O
suggesting,1502,O
that,1502,O
the,1502,O
mutant,1502,O
protein,1502,O
with,1502,O
consequent,1502,O
haploinsufficiency,1502,O
results,1502,O
in,1502,O
a,1502,O
clinical,1502,O
phenotype,1502,O
.,1502,O
Focal,1503,B-DiseaseOrPhenotypicFeature
dermal,1503,I-DiseaseOrPhenotypicFeature
hypoplasia,1503,I-DiseaseOrPhenotypicFeature
resulting,1503,O
from,1503,O
a,1503,O
new,1503,O
nonsense,1503,O
mutation,1503,O
",",1503,O
p.E300X,1503,B-SequenceVariant
",",1503,O
in,1503,O
the,1503,O
PORCN,1503,B-GeneOrGeneProduct
gene,1503,O
.,1503,O
BACKGROUND,1504,O
:,1504,O
Focal,1504,B-DiseaseOrPhenotypicFeature
dermal,1504,I-DiseaseOrPhenotypicFeature
hypoplasia,1504,I-DiseaseOrPhenotypicFeature
(,1504,O
FDH,1504,B-DiseaseOrPhenotypicFeature
),1504,O
(,1504,O
OMIM,1504,B-DiseaseOrPhenotypicFeature
305600,1504,I-DiseaseOrPhenotypicFeature
),1504,O
is,1504,O
an,1504,O
X-linked,1504,B-DiseaseOrPhenotypicFeature
dominant,1504,I-DiseaseOrPhenotypicFeature
disorder,1504,I-DiseaseOrPhenotypicFeature
of,1504,O
ecto-mesodermal,1504,O
development,1504,O
.,1504,O
Also,1505,O
known,1505,O
as,1505,O
Goltz,1505,B-DiseaseOrPhenotypicFeature
syndrome,1505,I-DiseaseOrPhenotypicFeature
",",1505,O
FDH,1505,B-DiseaseOrPhenotypicFeature
presents,1505,O
with,1505,O
characteristic,1505,O
linear,1505,O
streaks,1505,O
of,1505,O
hypoplastic,1505,B-DiseaseOrPhenotypicFeature
dermis,1505,I-DiseaseOrPhenotypicFeature
and,1505,O
variable,1505,O
abnormalities,1505,O
of,1505,O
bone,1505,O
",",1505,O
nails,1505,O
",",1505,O
hair,1505,O
",",1505,O
limbs,1505,O
",",1505,O
teeth,1505,O
and,1505,O
eyes,1505,O
.,1505,O
The,1506,O
molecular,1506,O
basis,1506,O
of,1506,O
FDH,1506,B-DiseaseOrPhenotypicFeature
involves,1506,O
mutations,1506,O
in,1506,O
the,1506,O
PORCN,1506,B-GeneOrGeneProduct
gene,1506,O
",",1506,O
which,1506,O
encodes,1506,O
an,1506,O
enzyme,1506,O
that,1506,O
allows,1506,O
membrane,1506,O
targeting,1506,O
and,1506,O
secretion,1506,O
of,1506,O
several,1506,O
Wnt,1506,O
proteins,1506,O
critical,1506,O
for,1506,O
normal,1506,O
tissue,1506,O
development,1506,O
.,1506,O
OBJECTIVES,1507,O
:,1507,O
To,1507,O
investigate,1507,O
the,1507,O
molecular,1507,O
basis,1507,O
of,1507,O
FDH,1507,B-DiseaseOrPhenotypicFeature
in,1507,O
a,1507,O
2-year-old,1507,O
Thai,1507,O
girl,1507,O
who,1507,O
presented,1507,O
at,1507,O
birth,1507,O
with,1507,O
depressed,1507,B-DiseaseOrPhenotypicFeature
",",1507,O
pale,1507,O
linear,1507,O
scars,1507,O
on,1507,O
the,1507,O
trunk,1507,O
and,1507,O
limbs,1507,O
",",1507,O
sparse,1507,O
brittle,1507,O
hair,1507,O
",",1507,O
syndactyly,1507,O
of,1507,O
the,1507,O
right,1507,O
middle,1507,O
and,1507,O
ring,1507,O
fingers,1507,O
",",1507,O
dental,1507,B-DiseaseOrPhenotypicFeature
caries,1507,I-DiseaseOrPhenotypicFeature
and,1507,O
radiological,1507,O
features,1507,O
of,1507,O
osteopathia,1507,O
striata,1507,O
.,1507,O
METHODS,1508,O
:,1508,O
Sequencing,1508,O
of,1508,O
genomic,1508,O
DNA,1508,O
from,1508,O
the,1508,O
affected,1508,O
individual,1508,O
and,1508,O
both,1508,O
parents,1508,O
to,1508,O
search,1508,O
for,1508,O
pathogenic,1508,O
mutations,1508,O
in,1508,O
PORCN,1508,B-GeneOrGeneProduct
gene,1508,O
.,1508,O
RESULTS,1509,O
:,1509,O
DNA,1509,O
sequencing,1509,O
disclosed,1509,O
a,1509,O
heterozygous,1509,O
G,1509,B-SequenceVariant
>,1509,I-SequenceVariant
T,1509,I-SequenceVariant
substitution,1509,I-SequenceVariant
at,1509,I-SequenceVariant
nucleotide,1509,I-SequenceVariant
c.898,1509,I-SequenceVariant
within,1509,O
exon,1509,O
10,1509,O
(,1509,O
NM_203475.1,1509,O
),1509,O
",",1509,O
converting,1509,O
a,1509,O
glutamic,1509,B-SequenceVariant
acid,1509,I-SequenceVariant
residue,1509,I-SequenceVariant
(,1509,I-SequenceVariant
GAA,1509,I-SequenceVariant
),1509,I-SequenceVariant
to,1509,I-SequenceVariant
a,1509,I-SequenceVariant
premature,1509,I-SequenceVariant
termination,1509,I-SequenceVariant
codon,1509,I-SequenceVariant
(,1509,I-SequenceVariant
TAA,1509,I-SequenceVariant
),1509,I-SequenceVariant
.,1509,O
This,1510,O
mutation,1510,O
",",1510,O
designated,1510,O
p.E300X,1510,B-SequenceVariant
",",1510,O
was,1510,O
not,1510,O
detected,1510,O
in,1510,O
DNA,1510,O
from,1510,O
either,1510,O
parent,1510,O
or,1510,O
in,1510,O
100,1510,O
control,1510,O
chromosomes,1510,O
.,1510,O
CONCLUSION,1511,O
:,1511,O
Identification,1511,O
of,1511,O
this,1511,O
new,1511,O
de,1511,O
novo,1511,O
nonsense,1511,O
mutation,1511,O
confirms,1511,O
the,1511,O
diagnosis,1511,O
of,1511,O
FDH,1511,B-DiseaseOrPhenotypicFeature
in,1511,O
this,1511,O
child,1511,O
and,1511,O
highlights,1511,O
the,1511,O
clinical,1511,O
importance,1511,O
of,1511,O
PORCN,1511,B-GeneOrGeneProduct
and,1511,O
Wnt,1511,O
signalling,1511,O
pathways,1511,O
in,1511,O
embryogenesis,1511,O
.,1511,O
Polymorphic,1512,O
MLH1,1512,B-GeneOrGeneProduct
and,1512,O
risk,1512,O
of,1512,O
cancer,1512,B-DiseaseOrPhenotypicFeature
after,1512,O
methylating,1512,O
chemotherapy,1512,O
for,1512,O
Hodgkin,1512,B-DiseaseOrPhenotypicFeature
lymphoma,1512,I-DiseaseOrPhenotypicFeature
.,1512,O
BACKGROUND,1513,O
AND,1513,O
OBJECTIVE,1513,O
:,1513,O
Methylating,1513,O
agents,1513,O
are,1513,O
effective,1513,O
chemotherapy,1513,O
agents,1513,O
for,1513,O
Hodgkin,1513,B-DiseaseOrPhenotypicFeature
lymphoma,1513,I-DiseaseOrPhenotypicFeature
",",1513,O
but,1513,O
are,1513,O
associated,1513,O
with,1513,O
the,1513,O
development,1513,O
of,1513,O
second,1513,O
primary,1513,O
cancers,1513,B-DiseaseOrPhenotypicFeature
.,1513,O
Cytotoxicity,1514,B-DiseaseOrPhenotypicFeature
of,1514,O
methylating,1514,O
agents,1514,O
is,1514,O
mediated,1514,O
primarily,1514,O
by,1514,O
the,1514,O
DNA,1514,O
mismatch,1514,O
repair,1514,O
(,1514,O
MMR,1514,O
),1514,O
system,1514,O
.,1514,O
Loss,1515,O
of,1515,O
MLH1,1515,B-GeneOrGeneProduct
",",1515,O
a,1515,O
major,1515,O
component,1515,O
of,1515,O
DNA,1515,O
MMR,1515,O
",",1515,O
results,1515,O
in,1515,O
tolerance,1515,O
to,1515,O
the,1515,O
cytotoxic,1515,B-DiseaseOrPhenotypicFeature
effects,1515,O
of,1515,O
methylating,1515,O
agents,1515,O
and,1515,O
persistence,1515,O
of,1515,O
mutagenised,1515,O
cells,1515,O
at,1515,O
high,1515,O
risk,1515,O
of,1515,O
malignant,1515,O
transformation,1515,O
.,1515,O
We,1516,O
hypothesised,1516,O
that,1516,O
a,1516,O
common,1516,O
substitution,1516,O
in,1516,O
the,1516,O
basal,1516,O
promoter,1516,O
of,1516,O
MLH1,1516,B-GeneOrGeneProduct
(,1516,O
position,1516,O
-93,1516,O
",",1516,O
rs1800734,1516,B-SequenceVariant
),1516,O
modifies,1516,O
the,1516,O
risk,1516,O
of,1516,O
cancer,1516,B-DiseaseOrPhenotypicFeature
after,1516,O
methylating,1516,O
chemotherapy,1516,O
.,1516,O
METHODS,1517,O
:,1517,O
133,1517,O
patients,1517,B-OrganismTaxon
who,1517,O
developed,1517,O
cancer,1517,B-DiseaseOrPhenotypicFeature
following,1517,O
chemotherapy,1517,O
and/or,1517,O
radiotherapy,1517,O
(,1517,O
n,1517,O
=,1517,O
133,1517,O
),1517,O
",",1517,O
420,1517,O
patients,1517,B-OrganismTaxon
diagnosed,1517,O
with,1517,O
de,1517,O
novo,1517,O
myeloid,1517,B-DiseaseOrPhenotypicFeature
leukaemia,1517,I-DiseaseOrPhenotypicFeature
",",1517,O
242,1517,O
patients,1517,B-OrganismTaxon
diagnosed,1517,O
with,1517,O
primary,1517,B-DiseaseOrPhenotypicFeature
Hodgkin,1517,I-DiseaseOrPhenotypicFeature
lymphoma,1517,I-DiseaseOrPhenotypicFeature
",",1517,O
and,1517,O
1177,1517,O
healthy,1517,O
controls,1517,O
were,1517,O
genotyped,1517,O
for,1517,O
the,1517,O
MLH1,1517,B-GeneOrGeneProduct
-93,1517,O
polymorphism,1517,O
by,1517,O
allelic,1517,O
discrimination,1517,O
polymerase,1517,O
chain,1517,O
reaction,1517,O
(,1517,O
PCR,1517,O
),1517,O
and,1517,O
restriction,1517,O
fragment,1517,O
length,1517,O
polymorphism,1517,O
assay,1517,O
.,1517,O
Odds,1518,O
ratios,1518,O
and,1518,O
95,1518,O
%,1518,O
confidence,1518,O
intervals,1518,O
for,1518,O
cancer,1518,B-DiseaseOrPhenotypicFeature
risk,1518,O
by,1518,O
MLH1,1518,B-GeneOrGeneProduct
-93,1518,O
polymorphism,1518,O
status,1518,O
",",1518,O
and,1518,O
stratified,1518,O
by,1518,O
previous,1518,O
exposure,1518,O
to,1518,O
methylating,1518,O
chemotherapy,1518,O
",",1518,O
were,1518,O
calculated,1518,O
using,1518,O
unconditional,1518,O
logistic,1518,O
regression,1518,O
.,1518,O
RESULTS,1519,O
:,1519,O
Carrier,1519,O
frequency,1519,O
of,1519,O
the,1519,O
MLH1,1519,B-GeneOrGeneProduct
-93,1519,O
variant,1519,O
was,1519,O
higher,1519,O
in,1519,O
patients,1519,B-OrganismTaxon
who,1519,O
developed,1519,O
therapy,1519,O
related,1519,O
acute,1519,B-DiseaseOrPhenotypicFeature
myeloid,1519,I-DiseaseOrPhenotypicFeature
leukaemia,1519,I-DiseaseOrPhenotypicFeature
(,1519,O
t-AML,1519,O
),1519,O
(,1519,O
75.0,1519,O
%,1519,O
",",1519,O
n,1519,O
=,1519,O
12,1519,O
),1519,O
or,1519,O
breast,1519,B-DiseaseOrPhenotypicFeature
cancer,1519,I-DiseaseOrPhenotypicFeature
(,1519,O
53.3,1519,O
%,1519,O
.,1519,O
n,1520,O
=,1520,O
15,1520,O
),1520,O
after,1520,O
methylating,1520,O
chemotherapy,1520,O
for,1520,O
Hodgkin,1520,B-DiseaseOrPhenotypicFeature
lymphoma,1520,I-DiseaseOrPhenotypicFeature
compared,1520,O
to,1520,O
patients,1520,B-OrganismTaxon
without,1520,O
previous,1520,O
methylating,1520,O
exposure,1520,O
(,1520,O
t-AML,1520,O
",",1520,O
30.4,1520,O
%,1520,O
",",1520,O
n,1520,O
=,1520,O
69,1520,O
;,1520,O
breast,1520,B-DiseaseOrPhenotypicFeature
cancer,1520,I-DiseaseOrPhenotypicFeature
patients,1520,B-OrganismTaxon
",",1520,O
27.2,1520,O
%,1520,O
",",1520,O
n,1520,O
=,1520,O
22,1520,O
),1520,O
.,1520,O
The,1521,O
MLH1,1521,B-GeneOrGeneProduct
-93,1521,O
variant,1521,O
allele,1521,O
was,1521,O
also,1521,O
over-represented,1521,O
in,1521,O
t-AML,1521,O
cases,1521,O
when,1521,O
compared,1521,O
to,1521,O
de,1521,O
novo,1521,O
AML,1521,B-DiseaseOrPhenotypicFeature
cases,1521,O
(,1521,O
36.9,1521,O
%,1521,O
",",1521,O
n,1521,O
=,1521,O
420,1521,O
),1521,O
and,1521,O
healthy,1521,O
controls,1521,O
(,1521,O
36.3,1521,O
%,1521,O
",",1521,O
n,1521,O
=,1521,O
952,1521,O
),1521,O
",",1521,O
and,1521,O
was,1521,O
associated,1521,O
with,1521,O
a,1521,O
significantly,1521,O
increased,1521,O
risk,1521,O
of,1521,O
developing,1521,O
t-AML,1521,O
(,1521,O
odds,1521,O
ratio,1521,O
5.31,1521,O
",",1521,O
95,1521,O
%,1521,O
confidence,1521,O
interval,1521,O
1.40,1521,O
to,1521,O
20.15,1521,O
),1521,O
",",1521,O
but,1521,O
only,1521,O
in,1521,O
patients,1521,B-OrganismTaxon
previously,1521,O
treated,1521,O
with,1521,O
a,1521,O
methylating,1521,O
agent,1521,O
.,1521,O
CONCLUSIONS,1522,O
:,1522,O
These,1522,O
data,1522,O
support,1522,O
the,1522,O
hypothesis,1522,O
that,1522,O
the,1522,O
common,1522,O
polymorphism,1522,O
at,1522,O
position,1522,O
-93,1522,O
in,1522,O
the,1522,O
core,1522,O
promoter,1522,O
of,1522,O
MLH1,1522,B-GeneOrGeneProduct
defines,1522,O
a,1522,O
risk,1522,O
allele,1522,O
for,1522,O
the,1522,O
development,1522,O
of,1522,O
cancer,1522,B-DiseaseOrPhenotypicFeature
after,1522,O
methylating,1522,O
chemotherapy,1522,O
for,1522,O
Hodgkin,1522,B-DiseaseOrPhenotypicFeature
lymphoma,1522,I-DiseaseOrPhenotypicFeature
.,1522,O
However,1523,O
",",1523,O
replication,1523,O
of,1523,O
this,1523,O
finding,1523,O
in,1523,O
larger,1523,O
studies,1523,O
is,1523,O
suggested,1523,O
.,1523,O
Gastrointestinal,1524,O
tolerability,1524,O
of,1524,O
etoricoxib,1524,B-ChemicalEntity
in,1524,O
rheumatoid,1524,B-DiseaseOrPhenotypicFeature
arthritis,1524,I-DiseaseOrPhenotypicFeature
patients,1524,B-OrganismTaxon
:,1524,O
results,1524,O
of,1524,O
the,1524,O
etoricoxib,1524,B-ChemicalEntity
vs,1524,O
diclofenac,1524,B-ChemicalEntity
sodium,1524,I-ChemicalEntity
gastrointestinal,1524,O
tolerability,1524,O
and,1524,O
effectiveness,1524,O
trial,1524,O
(,1524,O
EDGE-II,1524,O
),1524,O
.,1524,O
OBJECTIVE,1525,O
:,1525,O
A,1525,O
randomised,1525,O
",",1525,O
double-blind,1525,O
study,1525,O
to,1525,O
compare,1525,O
the,1525,O
gastrointestinal,1525,O
(,1525,O
GI,1525,O
),1525,O
tolerability,1525,O
",",1525,O
safety,1525,O
and,1525,O
efficacy,1525,O
of,1525,O
etoricoxib,1525,B-ChemicalEntity
and,1525,O
diclofenac,1525,B-ChemicalEntity
in,1525,O
patients,1525,B-OrganismTaxon
with,1525,O
rheumatoid,1525,B-DiseaseOrPhenotypicFeature
arthritis,1525,I-DiseaseOrPhenotypicFeature
(,1525,O
RA,1525,B-DiseaseOrPhenotypicFeature
),1525,O
.,1525,O
PATIENTS,1526,B-OrganismTaxon
AND,1526,O
METHODS,1526,O
:,1526,O
A,1526,O
total,1526,O
of,1526,O
4086,1526,O
patients,1526,B-OrganismTaxon
(,1526,O
mean,1526,O
age,1526,O
60.8,1526,O
years,1526,O
),1526,O
diagnosed,1526,O
with,1526,O
RA,1526,B-DiseaseOrPhenotypicFeature
were,1526,O
enrolled,1526,O
and,1526,O
received,1526,O
etoricoxib,1526,B-ChemicalEntity
90,1526,O
mg,1526,O
daily,1526,O
(,1526,O
n,1526,O
=,1526,O
2032,1526,O
),1526,O
or,1526,O
diclofenac,1526,B-ChemicalEntity
75,1526,O
mg,1526,O
twice,1526,O
daily,1526,O
(,1526,O
n,1526,O
=,1526,O
2054,1526,O
),1526,O
.,1526,O
Use,1527,O
of,1527,O
gastroprotective,1527,O
agents,1527,O
and,1527,O
low-dose,1527,O
aspirin,1527,B-ChemicalEntity
was,1527,O
allowed,1527,O
.,1527,O
The,1528,O
prespecified,1528,O
primary,1528,O
end,1528,O
point,1528,O
consisted,1528,O
of,1528,O
the,1528,O
cumulative,1528,O
rate,1528,O
of,1528,O
patient,1528,B-OrganismTaxon
discontinuations,1528,O
due,1528,O
to,1528,O
clinical,1528,O
and,1528,O
laboratory,1528,O
GI,1528,B-DiseaseOrPhenotypicFeature
adverse,1528,I-DiseaseOrPhenotypicFeature
experiences,1528,I-DiseaseOrPhenotypicFeature
(,1528,O
AEs,1528,O
),1528,O
.,1528,O
General,1529,O
safety,1529,O
was,1529,O
also,1529,O
assessed,1529,O
",",1529,O
including,1529,O
adjudicated,1529,O
thrombotic,1529,B-DiseaseOrPhenotypicFeature
cardiovascular,1529,I-DiseaseOrPhenotypicFeature
event,1529,O
data,1529,O
.,1529,O
Efficacy,1530,O
was,1530,O
evaluated,1530,O
using,1530,O
the,1530,O
Patient,1530,B-OrganismTaxon
Global,1530,O
Assessment,1530,O
of,1530,O
Disease,1530,O
Status,1530,O
(,1530,O
PGADS,1530,O
;,1530,O
0-4,1530,O
point,1530,O
scale,1530,O
),1530,O
.,1530,O
RESULTS,1531,O
:,1531,O
Mean,1531,O
(,1531,O
SD,1531,O
;,1531,O
maximum,1531,O
),1531,O
duration,1531,O
of,1531,O
treatment,1531,O
was,1531,O
19.3,1531,O
(,1531,O
10.3,1531,O
;,1531,O
32.9,1531,O
),1531,O
and,1531,O
19.1,1531,O
(,1531,O
10.4,1531,O
;,1531,O
33.1,1531,O
),1531,O
months,1531,O
in,1531,O
the,1531,O
etoricoxib,1531,B-ChemicalEntity
and,1531,O
diclofenac,1531,B-ChemicalEntity
groups,1531,O
",",1531,O
respectively,1531,O
.,1531,O
The,1532,O
cumulative,1532,O
discontinuation,1532,O
rate,1532,O
due,1532,O
to,1532,O
GI,1532,B-DiseaseOrPhenotypicFeature
AEs,1532,I-DiseaseOrPhenotypicFeature
was,1532,O
significantly,1532,O
lower,1532,O
with,1532,O
etoricoxib,1532,B-ChemicalEntity
than,1532,O
diclofenac,1532,B-ChemicalEntity
(,1532,O
5.2,1532,O
vs,1532,O
8.5,1532,O
events,1532,O
per,1532,O
100,1532,O
patient-years,1532,B-OrganismTaxon
",",1532,O
respectively,1532,O
;,1532,O
hazard,1532,O
ratio,1532,O
0.62,1532,O
(,1532,O
95,1532,O
%,1532,O
CI,1532,O
:,1532,O
0.47,1532,O
",",1532,O
0.81,1532,O
;,1532,O
p,1532,O
<,1532,O
or=0.001,1532,O
),1532,O
),1532,O
.,1532,O
The,1533,O
incidence,1533,O
of,1533,O
discontinuations,1533,O
for,1533,O
hypertension-related,1533,B-DiseaseOrPhenotypicFeature
and,1533,O
oedema-related,1533,B-DiseaseOrPhenotypicFeature
AEs,1533,O
were,1533,O
significantly,1533,O
higher,1533,O
with,1533,O
etoricoxib,1533,B-ChemicalEntity
(,1533,O
2.5,1533,O
%,1533,O
and,1533,O
1.1,1533,O
%,1533,O
respectively,1533,O
),1533,O
compared,1533,O
with,1533,O
diclofenac,1533,B-ChemicalEntity
(,1533,O
1.5,1533,O
%,1533,O
and,1533,O
0.4,1533,O
%,1533,O
respectively,1533,O
;,1533,O
p,1533,O
<,1533,O
0.001,1533,O
for,1533,O
hypertension,1533,B-DiseaseOrPhenotypicFeature
and,1533,O
p,1533,O
<,1533,O
0.01,1533,O
for,1533,O
oedema,1533,B-DiseaseOrPhenotypicFeature
),1533,O
.,1533,O
Etoricoxib,1534,B-ChemicalEntity
and,1534,O
diclofenac,1534,B-ChemicalEntity
treatment,1534,O
resulted,1534,O
in,1534,O
similar,1534,O
efficacy,1534,O
(,1534,O
PGADS,1534,O
mean,1534,O
changes,1534,O
from,1534,O
baseline,1534,O
-0.62,1534,O
vs,1534,O
-0.58,1534,O
",",1534,O
respectively,1534,O
),1534,O
.,1534,O
CONCLUSIONS,1535,O
:,1535,O
Etoricoxib,1535,B-ChemicalEntity
90,1535,O
mg,1535,O
demonstrated,1535,O
a,1535,O
significantly,1535,O
lower,1535,O
risk,1535,O
for,1535,O
discontinuing,1535,O
treatment,1535,O
due,1535,O
to,1535,O
GI,1535,B-DiseaseOrPhenotypicFeature
AEs,1535,I-DiseaseOrPhenotypicFeature
compared,1535,O
with,1535,O
diclofenac,1535,B-ChemicalEntity
150,1535,O
mg.,1535,O
Discontinuations,1535,O
from,1535,O
renovascular,1535,O
AEs,1535,O
",",1535,O
although,1535,O
less,1535,O
common,1535,O
than,1535,O
discontinuations,1535,O
from,1535,O
GI,1535,B-DiseaseOrPhenotypicFeature
AEs,1535,I-DiseaseOrPhenotypicFeature
",",1535,O
were,1535,O
significantly,1535,O
higher,1535,O
with,1535,O
etoricoxib,1535,B-ChemicalEntity
.,1535,O
Anxiogenic,1536,B-DiseaseOrPhenotypicFeature
potential,1536,O
of,1536,O
ciprofloxacin,1536,B-ChemicalEntity
and,1536,O
norfloxacin,1536,B-ChemicalEntity
in,1536,O
rats,1536,B-OrganismTaxon
.,1536,O
INTRODUCTION,1537,O
:,1537,O
The,1537,O
possible,1537,O
anxiogenic,1537,B-DiseaseOrPhenotypicFeature
effects,1537,O
of,1537,O
fluoroquinolones,1537,B-ChemicalEntity
",",1537,O
namely,1537,O
ciprofloxacin,1537,B-ChemicalEntity
and,1537,O
norfloxacin,1537,B-ChemicalEntity
",",1537,O
were,1537,O
investigated,1537,O
in,1537,O
adult,1537,O
Charles,1537,O
Foster,1537,O
albino,1537,O
rats,1537,B-OrganismTaxon
of,1537,O
either,1537,O
sex,1537,O
",",1537,O
weighing,1537,O
150-200,1537,O
g.,1537,O
METHODS,1537,O
:,1537,O
The,1537,O
drugs,1537,O
were,1537,O
given,1537,O
orally,1537,O
",",1537,O
in,1537,O
doses,1537,O
of,1537,O
50,1537,O
mg/kg,1537,O
for,1537,O
five,1537,O
consecutive,1537,O
days,1537,O
and,1537,O
the,1537,O
experiments,1537,O
were,1537,O
performed,1537,O
on,1537,O
the,1537,O
fifth,1537,O
day,1537,O
.,1537,O
The,1538,O
tests,1538,O
included,1538,O
open-field,1538,O
exploratory,1538,O
behaviour,1538,O
",",1538,O
elevated,1538,O
plus,1538,O
maze,1538,O
and,1538,O
elevated,1538,O
zero,1538,O
maze,1538,O
",",1538,O
social,1538,O
interaction,1538,O
and,1538,O
novelty-suppressed,1538,O
feeding,1538,O
latency,1538,O
behaviour,1538,O
.,1538,O
RESULTS,1539,O
:,1539,O
The,1539,O
results,1539,O
indicate,1539,O
that,1539,O
ciprofloxacin-,1539,B-ChemicalEntity
and,1539,O
norfloxacin-treated,1539,B-ChemicalEntity
rats,1539,B-OrganismTaxon
showed,1539,O
anxious,1539,B-DiseaseOrPhenotypicFeature
behaviour,1539,I-DiseaseOrPhenotypicFeature
in,1539,O
comparison,1539,O
to,1539,O
control,1539,O
rats,1539,B-OrganismTaxon
in,1539,O
all,1539,O
the,1539,O
parameters,1539,O
studied,1539,O
.,1539,O
However,1540,O
",",1540,O
ciprofloxacin-,1540,B-ChemicalEntity
and,1540,O
norfloxacin-treated,1540,B-ChemicalEntity
rats,1540,B-OrganismTaxon
did,1540,O
not,1540,O
differ,1540,O
significantly,1540,O
from,1540,O
each,1540,O
other,1540,O
in,1540,O
various,1540,O
behavioural,1540,O
parameters,1540,O
.,1540,O
CONCLUSION,1541,O
:,1541,O
The,1541,O
present,1541,O
experimental,1541,O
findings,1541,O
substantiate,1541,O
the,1541,O
clinically,1541,O
observed,1541,O
anxiogenic,1541,B-DiseaseOrPhenotypicFeature
potential,1541,O
of,1541,O
ciprofloxacin,1541,B-ChemicalEntity
and,1541,O
norfloxacin,1541,B-ChemicalEntity
.,1541,O
Regional,1542,O
analysis,1542,O
on,1542,O
the,1542,O
occurrence,1542,O
of,1542,O
oral,1542,B-DiseaseOrPhenotypicFeature
clefts,1542,I-DiseaseOrPhenotypicFeature
in,1542,O
South,1542,O
America,1542,O
.,1542,O
The,1543,O
aim,1543,O
of,1543,O
this,1543,O
work,1543,O
was,1543,O
to,1543,O
search,1543,O
for,1543,O
unequal,1543,O
birth,1543,O
prevalence,1543,O
rates,1543,O
(,1543,O
BPRs,1543,O
),1543,O
of,1543,O
cleft,1543,B-DiseaseOrPhenotypicFeature
lip,1543,I-DiseaseOrPhenotypicFeature
+/-,1543,O
cleft,1543,B-DiseaseOrPhenotypicFeature
palate,1543,I-DiseaseOrPhenotypicFeature
(,1543,O
CL/P,1543,B-DiseaseOrPhenotypicFeature
),1543,O
",",1543,O
and,1543,O
cleft,1543,B-DiseaseOrPhenotypicFeature
palate,1543,I-DiseaseOrPhenotypicFeature
only,1543,O
(,1543,O
CPO,1543,B-DiseaseOrPhenotypicFeature
),1543,O
",",1543,O
among,1543,O
different,1543,O
geographic,1543,O
areas,1543,O
in,1543,O
South,1543,O
America,1543,O
",",1543,O
and,1543,O
to,1543,O
analyze,1543,O
phenotypic,1543,O
characteristics,1543,O
and,1543,O
associated,1543,O
risk,1543,O
factors,1543,O
in,1543,O
each,1543,O
identified,1543,O
cluster,1543,O
.,1543,O
Included,1544,O
were,1544,O
"5,128",1544,O
CL/P,1544,B-DiseaseOrPhenotypicFeature
cases,1544,O
",",1544,O
"1,745",1544,O
CPO,1544,B-DiseaseOrPhenotypicFeature
cases,1544,O
",",1544,O
and,1544,O
"3,712",1544,O
controls,1544,O
(,1544,O
like-sexed,1544,O
",",1544,O
non-malformed,1544,O
liveborn,1544,O
infant,1544,O
",",1544,O
born,1544,O
immediately,1544,O
after,1544,O
a,1544,O
malformed,1544,O
one,1544,O
",",1544,O
in,1544,O
the,1544,O
same,1544,O
hospital,1544,O
),1544,O
",",1544,O
over,1544,O
"4,199,630",1544,O
consecutive,1544,O
births,1544,O
.,1544,O
They,1545,O
were,1545,O
ascertained,1545,O
between,1545,O
1967,1545,O
and,1545,O
2004,1545,O
",",1545,O
in,1545,O
190,1545,O
maternity,1545,O
hospitals,1545,O
of,1545,O
the,1545,O
ECLAMC,1545,O
(,1545,O
Estudio,1545,O
Colaborativo,1545,O
Latinoamericano,1545,O
de,1545,O
Malformaciones,1545,O
Congenitas,1545,O
),1545,O
network,1545,O
",",1545,O
in,1545,O
102,1545,O
cities,1545,O
of,1545,O
all,1545,O
10,1545,O
South,1545,O
American,1545,O
countries,1545,O
.,1545,O
Non-predefined,1546,O
geographical,1546,O
areas,1546,O
with,1546,O
significantly,1546,O
unusual,1546,O
cleft,1546,O
BPRs,1546,O
were,1546,O
identified,1546,O
with,1546,O
Kulldorf,1546,O
and,1546,O
Nagarwalla,1546,O
's,1546,O
spatial,1546,O
scan,1546,O
statistic,1546,O
",",1546,O
employing,1546,O
number,1546,O
of,1546,O
cases,1546,O
and,1546,O
births,1546,O
",",1546,O
and,1546,O
exact,1546,O
location,1546,O
of,1546,O
each,1546,O
hospital,1546,O
.,1546,O
Expected,1547,O
values,1547,O
were,1547,O
cleft,1547,O
BPRs,1547,O
registered,1547,O
for,1547,O
the,1547,O
entire,1547,O
ECLAMC,1547,O
hospital,1547,O
network,1547,O
.,1547,O
Syndromic,1548,O
and,1548,O
non-syndromic,1548,O
clefts,1548,B-DiseaseOrPhenotypicFeature
were,1548,O
considered,1548,O
for,1548,O
cluster,1548,O
analysis,1548,O
",",1548,O
and,1548,O
phenotypic,1548,O
characterization,1548,O
",",1548,O
while,1548,O
only,1548,O
non-syndromic,1548,O
for,1548,O
risk,1548,O
factor,1548,O
analysis,1548,O
.,1548,O
Seven,1549,O
clusters,1549,O
for,1549,O
CL/P,1549,B-DiseaseOrPhenotypicFeature
",",1549,O
and,1549,O
four,1549,O
for,1549,O
CPO,1549,B-DiseaseOrPhenotypicFeature
",",1549,O
with,1549,O
unusual,1549,O
BPRs,1549,O
were,1549,O
identified,1549,O
.,1549,O
CL/P,1550,B-DiseaseOrPhenotypicFeature
cases,1550,O
in,1550,O
high,1550,O
BPR,1550,O
areas,1550,O
were,1550,O
more,1550,O
severe,1550,O
than,1550,O
elsewhere,1550,O
in,1550,O
the,1550,O
sample,1550,O
",",1550,O
similar,1550,O
to,1550,O
a,1550,O
previous,1550,O
ECLAMC,1550,O
report,1550,O
on,1550,O
microtia,1550,B-DiseaseOrPhenotypicFeature
.,1550,O
For,1551,O
CL/P,1551,B-DiseaseOrPhenotypicFeature
",",1551,O
high,1551,O
BPR,1551,O
clusters,1551,O
were,1551,O
associated,1551,O
with,1551,O
high,1551,O
altitude,1551,O
above,1551,O
sea,1551,O
level,1551,O
",",1551,O
Amerindian,1551,O
ancestry,1551,O
",",1551,O
and,1551,O
low,1551,O
socioeconomic,1551,O
strata,1551,O
;,1551,O
low,1551,O
BPR,1551,O
clusters,1551,O
showed,1551,O
association,1551,O
with,1551,O
African,1551,O
Black,1551,O
ancestry,1551,O
.,1551,O
Advanced,1552,O
maternal,1552,O
age,1552,O
",",1552,O
a,1552,O
recognized,1552,O
risk,1552,O
factor,1552,O
for,1552,O
CPO,1552,B-DiseaseOrPhenotypicFeature
",",1552,O
was,1552,O
also,1552,O
associated,1552,O
with,1552,O
the,1552,O
only,1552,O
identified,1552,O
geographic,1552,O
cluster,1552,O
for,1552,O
CPO,1552,B-DiseaseOrPhenotypicFeature
.,1552,O
Identification,1553,O
of,1553,O
novel,1553,O
susceptibility,1553,O
genes,1553,O
in,1553,O
childhood-onset,1553,O
systemic,1553,B-DiseaseOrPhenotypicFeature
lupus,1553,I-DiseaseOrPhenotypicFeature
erythematosus,1553,I-DiseaseOrPhenotypicFeature
using,1553,O
a,1553,O
uniquely,1553,O
designed,1553,O
candidate,1553,O
gene,1553,O
pathway,1553,O
platform,1553,O
.,1553,O
OBJECTIVE,1554,O
:,1554,O
Childhood-onset,1554,O
systemic,1554,B-DiseaseOrPhenotypicFeature
lupus,1554,I-DiseaseOrPhenotypicFeature
erythematosus,1554,I-DiseaseOrPhenotypicFeature
(,1554,O
SLE,1554,B-DiseaseOrPhenotypicFeature
),1554,O
presents,1554,O
a,1554,O
unique,1554,O
subgroup,1554,O
of,1554,O
patients,1554,B-OrganismTaxon
for,1554,O
genetic,1554,O
study,1554,O
.,1554,O
The,1555,O
present,1555,O
study,1555,O
was,1555,O
undertaken,1555,O
to,1555,O
identify,1555,O
susceptibility,1555,O
genes,1555,O
contributing,1555,O
to,1555,O
SLE,1555,B-DiseaseOrPhenotypicFeature
",",1555,O
using,1555,O
a,1555,O
novel,1555,O
candidate,1555,O
gene,1555,O
pathway,1555,O
microarray,1555,O
platform,1555,O
to,1555,O
investigate,1555,O
gene,1555,O
expression,1555,O
in,1555,O
patients,1555,B-OrganismTaxon
with,1555,O
childhood-onset,1555,O
SLE,1555,B-DiseaseOrPhenotypicFeature
and,1555,O
both,1555,O
of,1555,O
their,1555,O
parents,1555,O
.,1555,O
METHODS,1556,O
:,1556,O
Utilizing,1556,O
bioinformatic,1556,O
tools,1556,O
",",1556,O
a,1556,O
platform,1556,O
of,1556,O
"9,412",1556,O
single-nucleotide,1556,O
polymorphisms,1556,O
(,1556,O
SNPs,1556,O
),1556,O
from,1556,O
"1,204",1556,O
genes,1556,O
was,1556,O
designed,1556,O
and,1556,O
validated,1556,O
.,1556,O
Molecular,1557,O
inversion,1557,O
probes,1557,O
and,1557,O
high-throughput,1557,O
SNP,1557,O
technologies,1557,O
were,1557,O
used,1557,O
for,1557,O
assay,1557,O
development,1557,O
.,1557,O
Seven,1558,O
hundred,1558,O
fifty,1558,O
three,1558,O
subjects,1558,O
",",1558,O
corresponding,1558,O
to,1558,O
251,1558,O
full,1558,O
trios,1558,O
of,1558,O
childhood-onset,1558,O
SLE,1558,B-DiseaseOrPhenotypicFeature
families,1558,O
",",1558,O
were,1558,O
genotyped,1558,O
and,1558,O
analyzed,1558,O
using,1558,O
transmission,1558,O
disequilibrium,1558,O
testing,1558,O
(,1558,O
TDT,1558,O
),1558,O
and,1558,O
multitest,1558,O
corrections,1558,O
.,1558,O
RESULTS,1559,O
:,1559,O
Family-based,1559,O
TDT,1559,O
showed,1559,O
a,1559,O
significant,1559,O
association,1559,O
of,1559,O
SLE,1559,B-DiseaseOrPhenotypicFeature
with,1559,O
a,1559,O
N673S,1559,B-SequenceVariant
polymorphism,1559,O
in,1559,O
the,1559,O
P-selectin,1559,B-GeneOrGeneProduct
gene,1559,O
(,1559,O
SELP,1559,B-GeneOrGeneProduct
),1559,O
(,1559,O
P,1559,O
=,1559,O
5.74,1559,O
x,1559,O
10,1559,O
(,1559,O
-6,1559,O
),1559,O
),1559,O
and,1559,O
a,1559,O
C203S,1559,B-SequenceVariant
polymorphism,1559,O
in,1559,O
the,1559,O
interleukin-1,1559,B-GeneOrGeneProduct
receptor-associated,1559,I-GeneOrGeneProduct
kinase,1559,I-GeneOrGeneProduct
1,1559,I-GeneOrGeneProduct
gene,1559,O
(,1559,O
IRAK1,1559,B-GeneOrGeneProduct
),1559,O
(,1559,O
P,1559,O
=,1559,O
9.58,1559,O
x,1559,O
10,1559,O
(,1559,O
-6,1559,O
),1559,O
),1559,O
.,1559,O
These,1560,O
2,1560,O
SNPs,1560,O
had,1560,O
a,1560,O
false,1560,O
discovery,1560,O
rate,1560,O
for,1560,O
multitest,1560,O
correction,1560,O
of,1560,O
<,1560,O
0.05,1560,O
",",1560,O
and,1560,O
therefore,1560,O
a,1560,O
>,1560,O
95,1560,O
%,1560,O
probability,1560,O
of,1560,O
being,1560,O
considered,1560,O
as,1560,O
proven,1560,O
.,1560,O
Furthermore,1561,O
",",1561,O
7,1561,O
additional,1561,O
SNPs,1561,O
showed,1561,O
q,1561,O
values,1561,O
of,1561,O
<,1561,O
0.5,1561,O
",",1561,O
suggesting,1561,O
association,1561,O
with,1561,O
SLE,1561,B-DiseaseOrPhenotypicFeature
and,1561,O
providing,1561,O
a,1561,O
direction,1561,O
for,1561,O
followup,1561,O
studies,1561,O
.,1561,O
These,1562,O
additional,1562,O
genes,1562,O
notably,1562,O
included,1562,O
TNFRSF6,1562,B-GeneOrGeneProduct
(,1562,O
Fas,1562,B-GeneOrGeneProduct
),1562,O
and,1562,O
IRF5,1562,B-GeneOrGeneProduct
",",1562,O
supporting,1562,O
previous,1562,O
findings,1562,O
of,1562,O
their,1562,O
association,1562,O
with,1562,O
SLE,1562,B-DiseaseOrPhenotypicFeature
pathogenesis,1562,O
.,1562,O
CONCLUSION,1563,O
:,1563,O
SELP,1563,B-GeneOrGeneProduct
and,1563,O
IRAK1,1563,B-GeneOrGeneProduct
were,1563,O
identified,1563,O
as,1563,O
novel,1563,O
SLE-associated,1563,B-DiseaseOrPhenotypicFeature
genes,1563,O
with,1563,O
a,1563,O
high,1563,O
degree,1563,O
of,1563,O
significance,1563,O
",",1563,O
suggesting,1563,O
new,1563,O
directions,1563,O
in,1563,O
understanding,1563,O
the,1563,O
pathogenesis,1563,O
of,1563,O
SLE,1563,B-DiseaseOrPhenotypicFeature
.,1563,O
The,1564,O
overall,1564,O
design,1564,O
and,1564,O
results,1564,O
of,1564,O
this,1564,O
study,1564,O
demonstrate,1564,O
that,1564,O
the,1564,O
candidate,1564,O
gene,1564,O
pathway,1564,O
microarray,1564,O
platform,1564,O
used,1564,O
provides,1564,O
a,1564,O
novel,1564,O
and,1564,O
powerful,1564,O
approach,1564,O
that,1564,O
is,1564,O
generally,1564,O
applicable,1564,O
in,1564,O
identifying,1564,O
genetic,1564,O
foundations,1564,O
of,1564,O
complex,1564,O
diseases,1564,O
.,1564,O
Norepinephrine,1565,B-ChemicalEntity
signaling,1565,O
through,1565,O
beta-adrenergic,1565,B-GeneOrGeneProduct
receptors,1565,I-GeneOrGeneProduct
is,1565,O
critical,1565,O
for,1565,O
expression,1565,O
of,1565,O
cocaine-induced,1565,B-ChemicalEntity
anxiety,1565,B-DiseaseOrPhenotypicFeature
.,1565,O
BACKGROUND,1566,O
:,1566,O
Cocaine,1566,B-ChemicalEntity
is,1566,O
a,1566,O
widely,1566,O
abused,1566,O
psychostimulant,1566,O
that,1566,O
has,1566,O
both,1566,O
rewarding,1566,O
and,1566,O
aversive,1566,O
properties,1566,O
.,1566,O
While,1567,O
the,1567,O
mechanisms,1567,O
underlying,1567,O
cocaine,1567,B-ChemicalEntity
's,1567,O
rewarding,1567,O
effects,1567,O
have,1567,O
been,1567,O
studied,1567,O
extensively,1567,O
",",1567,O
less,1567,O
attention,1567,O
has,1567,O
been,1567,O
paid,1567,O
to,1567,O
the,1567,O
unpleasant,1567,O
behavioral,1567,O
states,1567,O
induced,1567,O
by,1567,O
cocaine,1567,B-ChemicalEntity
",",1567,O
such,1567,O
as,1567,O
anxiety,1567,B-DiseaseOrPhenotypicFeature
.,1567,O
METHODS,1568,O
:,1568,O
In,1568,O
this,1568,O
study,1568,O
",",1568,O
we,1568,O
evaluated,1568,O
the,1568,O
performance,1568,O
of,1568,O
dopamine,1568,B-GeneOrGeneProduct
beta-hydroxylase,1568,I-GeneOrGeneProduct
knockout,1568,O
(,1568,O
Dbh,1568,B-GeneOrGeneProduct
-/-,1568,O
),1568,O
mice,1568,B-OrganismTaxon
",",1568,O
which,1568,O
lack,1568,O
norepinephrine,1568,B-ChemicalEntity
(,1568,O
NE,1568,B-ChemicalEntity
),1568,O
",",1568,O
in,1568,O
the,1568,O
elevated,1568,O
plus,1568,O
maze,1568,O
(,1568,O
EPM,1568,O
),1568,O
to,1568,O
examine,1568,O
the,1568,O
contribution,1568,O
of,1568,O
noradrenergic,1568,O
signaling,1568,O
to,1568,O
cocaine-induced,1568,B-ChemicalEntity
anxiety,1568,B-DiseaseOrPhenotypicFeature
.,1568,O
RESULTS,1569,O
:,1569,O
We,1569,O
found,1569,O
that,1569,O
cocaine,1569,B-ChemicalEntity
dose-dependently,1569,O
increased,1569,O
anxiety-like,1569,B-DiseaseOrPhenotypicFeature
behavior,1569,O
in,1569,O
control,1569,O
(,1569,O
Dbh,1569,B-GeneOrGeneProduct
+/-,1569,O
),1569,O
mice,1569,B-OrganismTaxon
",",1569,O
as,1569,O
measured,1569,O
by,1569,O
a,1569,O
decrease,1569,O
in,1569,O
open,1569,O
arm,1569,O
exploration,1569,O
.,1569,O
The,1570,O
Dbh,1570,B-GeneOrGeneProduct
-/-,1570,O
mice,1570,B-OrganismTaxon
had,1570,O
normal,1570,O
baseline,1570,O
performance,1570,O
in,1570,O
the,1570,O
EPM,1570,O
but,1570,O
were,1570,O
completely,1570,O
resistant,1570,O
to,1570,O
the,1570,O
anxiogenic,1570,O
effects,1570,O
of,1570,O
cocaine,1570,B-ChemicalEntity
.,1570,O
Cocaine-induced,1571,B-ChemicalEntity
anxiety,1571,B-DiseaseOrPhenotypicFeature
was,1571,O
also,1571,O
attenuated,1571,O
in,1571,O
Dbh,1571,B-GeneOrGeneProduct
+/-,1571,O
mice,1571,B-OrganismTaxon
following,1571,O
administration,1571,O
of,1571,O
disulfiram,1571,B-ChemicalEntity
",",1571,O
a,1571,O
dopamine,1571,B-GeneOrGeneProduct
beta-hydroxylase,1571,I-GeneOrGeneProduct
(,1571,O
DBH,1571,B-GeneOrGeneProduct
),1571,O
inhibitor,1571,O
.,1571,O
In,1572,O
experiments,1572,O
using,1572,O
specific,1572,O
adrenergic,1572,B-ChemicalEntity
antagonists,1572,I-ChemicalEntity
",",1572,O
we,1572,O
found,1572,O
that,1572,O
pretreatment,1572,O
with,1572,O
the,1572,O
beta-adrenergic,1572,B-GeneOrGeneProduct
receptor,1572,I-GeneOrGeneProduct
antagonist,1572,O
propranolol,1572,B-ChemicalEntity
blocked,1572,O
cocaine-induced,1572,B-ChemicalEntity
anxiety-like,1572,B-DiseaseOrPhenotypicFeature
behavior,1572,O
in,1572,O
Dbh,1572,B-GeneOrGeneProduct
+/-,1572,O
and,1572,O
wild-type,1572,O
C57BL6/J,1572,O
mice,1572,B-OrganismTaxon
",",1572,O
while,1572,O
the,1572,O
alpha,1572,B-GeneOrGeneProduct
(,1572,I-GeneOrGeneProduct
1,1572,I-GeneOrGeneProduct
),1572,I-GeneOrGeneProduct
antagonist,1572,O
prazosin,1572,B-ChemicalEntity
and,1572,O
the,1572,O
alpha,1572,B-GeneOrGeneProduct
(,1572,I-GeneOrGeneProduct
2,1572,I-GeneOrGeneProduct
),1572,I-GeneOrGeneProduct
antagonist,1572,O
yohimbine,1572,B-ChemicalEntity
had,1572,O
no,1572,O
effect,1572,O
.,1572,O
CONCLUSIONS,1573,O
:,1573,O
These,1573,O
results,1573,O
indicate,1573,O
that,1573,O
noradrenergic,1573,O
signaling,1573,O
via,1573,O
beta-adrenergic,1573,B-GeneOrGeneProduct
receptors,1573,I-GeneOrGeneProduct
is,1573,O
required,1573,O
for,1573,O
cocaine-induced,1573,B-ChemicalEntity
anxiety,1573,B-DiseaseOrPhenotypicFeature
in,1573,O
mice,1573,B-OrganismTaxon
.,1573,O
The,1574,O
differential,1574,O
effects,1574,O
of,1574,O
bupivacaine,1574,B-ChemicalEntity
and,1574,O
lidocaine,1574,B-ChemicalEntity
on,1574,O
prostaglandin,1574,B-GeneOrGeneProduct
E2,1574,I-GeneOrGeneProduct
release,1574,O
",",1574,O
cyclooxygenase,1574,B-GeneOrGeneProduct
gene,1574,O
expression,1574,O
and,1574,O
pain,1574,B-DiseaseOrPhenotypicFeature
in,1574,O
a,1574,O
clinical,1574,O
pain,1574,B-DiseaseOrPhenotypicFeature
model,1574,O
.,1574,O
BACKGROUND,1575,O
:,1575,O
In,1575,O
addition,1575,O
to,1575,O
blocking,1575,O
nociceptive,1575,O
input,1575,O
from,1575,O
surgical,1575,O
sites,1575,O
",",1575,O
long-acting,1575,O
local,1575,O
anesthetics,1575,O
might,1575,O
directly,1575,O
modulate,1575,O
inflammation,1575,B-DiseaseOrPhenotypicFeature
.,1575,O
In,1576,O
the,1576,O
present,1576,O
study,1576,O
",",1576,O
we,1576,O
describe,1576,O
the,1576,O
proinflammatory,1576,O
effects,1576,O
of,1576,O
bupivacaine,1576,B-ChemicalEntity
on,1576,O
local,1576,O
prostaglandin,1576,B-GeneOrGeneProduct
E2,1576,I-GeneOrGeneProduct
(,1576,O
PGE2,1576,B-GeneOrGeneProduct
),1576,O
production,1576,O
and,1576,O
cyclooxygenase,1576,B-GeneOrGeneProduct
(,1576,O
COX,1576,B-GeneOrGeneProduct
),1576,O
gene,1576,O
expression,1576,O
that,1576,O
increases,1576,O
postoperative,1576,B-DiseaseOrPhenotypicFeature
pain,1576,I-DiseaseOrPhenotypicFeature
in,1576,O
human,1576,B-OrganismTaxon
subjects,1576,O
.,1576,O
METHODS,1577,O
:,1577,O
Subjects,1577,O
(,1577,O
n,1577,O
=,1577,O
114,1577,O
),1577,O
undergoing,1577,O
extraction,1577,O
of,1577,O
impacted,1577,O
third,1577,O
molars,1577,O
received,1577,O
either,1577,O
2,1577,O
%,1577,O
lidocaine,1577,B-ChemicalEntity
or,1577,O
0.5,1577,O
%,1577,O
bupivacaine,1577,B-ChemicalEntity
before,1577,O
surgery,1577,O
and,1577,O
either,1577,O
rofecoxib,1577,B-ChemicalEntity
50,1577,O
mg,1577,O
or,1577,O
placebo,1577,O
orally,1577,O
90,1577,O
min,1577,O
before,1577,O
surgery,1577,O
and,1577,O
for,1577,O
the,1577,O
following,1577,O
48,1577,O
h.,1577,O
Oral,1577,O
mucosal,1577,O
biopsies,1577,O
were,1577,O
taken,1577,O
before,1577,O
surgery,1577,O
and,1577,O
48,1577,O
h,1577,O
after,1577,O
surgery,1577,O
.,1577,O
After,1578,O
extraction,1578,O
",",1578,O
a,1578,O
microdialysis,1578,O
probe,1578,O
was,1578,O
placed,1578,O
at,1578,O
the,1578,O
surgical,1578,O
site,1578,O
for,1578,O
PGE2,1578,B-GeneOrGeneProduct
and,1578,O
thromboxane,1578,B-ChemicalEntity
B2,1578,I-ChemicalEntity
(,1578,O
TXB2,1578,B-ChemicalEntity
),1578,O
measurements,1578,O
.,1578,O
RESULTS,1579,O
:,1579,O
The,1579,O
bupivacaine/rofecoxib,1579,B-ChemicalEntity
group,1579,O
reported,1579,O
significantly,1579,O
less,1579,O
pain,1579,B-DiseaseOrPhenotypicFeature
",",1579,O
as,1579,O
assessed,1579,O
by,1579,O
a,1579,O
visual,1579,O
analog,1579,O
scale,1579,O
",",1579,O
compared,1579,O
with,1579,O
the,1579,O
other,1579,O
three,1579,O
treatment,1579,O
groups,1579,O
over,1579,O
the,1579,O
first,1579,O
4,1579,O
h.,1579,O
However,1579,O
",",1579,O
the,1579,O
bupivacaine/placebo,1579,B-ChemicalEntity
group,1579,O
reported,1579,O
significantly,1579,O
more,1579,O
pain,1579,B-DiseaseOrPhenotypicFeature
at,1579,O
24,1579,O
h,1579,O
and,1579,O
PGE2,1579,B-GeneOrGeneProduct
levels,1579,O
during,1579,O
the,1579,O
first,1579,O
4,1579,O
h,1579,O
were,1579,O
significantly,1579,O
higher,1579,O
than,1579,O
the,1579,O
other,1579,O
three,1579,O
treatment,1579,O
groups,1579,O
.,1579,O
Moreover,1580,O
",",1580,O
bupivacaine,1580,B-ChemicalEntity
significantly,1580,O
increased,1580,O
COX-2,1580,B-GeneOrGeneProduct
gene,1580,O
expression,1580,O
at,1580,O
48,1580,O
h,1580,O
as,1580,O
compared,1580,O
with,1580,O
the,1580,O
lidocaine/placebo,1580,B-ChemicalEntity
group,1580,O
.,1580,O
Thromboxane,1581,B-ChemicalEntity
levels,1581,O
were,1581,O
not,1581,O
significantly,1581,O
affected,1581,O
by,1581,O
any,1581,O
of,1581,O
the,1581,O
treatments,1581,O
",",1581,O
indicating,1581,O
that,1581,O
the,1581,O
effects,1581,O
seen,1581,O
were,1581,O
attributable,1581,O
to,1581,O
inhibition,1581,O
of,1581,O
COX-2,1581,B-GeneOrGeneProduct
",",1581,O
but,1581,O
not,1581,O
COX-1,1581,B-GeneOrGeneProduct
.,1581,O
CONCLUSIONS,1582,O
:,1582,O
These,1582,O
results,1582,O
suggest,1582,O
that,1582,O
bupivacaine,1582,B-ChemicalEntity
stimulates,1582,O
COX-2,1582,B-GeneOrGeneProduct
gene,1582,O
expression,1582,O
after,1582,O
tissue,1582,B-DiseaseOrPhenotypicFeature
injury,1582,I-DiseaseOrPhenotypicFeature
",",1582,O
which,1582,O
is,1582,O
associated,1582,O
with,1582,O
higher,1582,O
PGE2,1582,B-GeneOrGeneProduct
production,1582,O
and,1582,O
pain,1582,B-DiseaseOrPhenotypicFeature
after,1582,O
the,1582,O
local,1582,O
anesthetic,1582,O
effect,1582,O
dissipates,1582,O
.,1582,O
Genetic,1583,O
investigation,1583,O
of,1583,O
four,1583,O
meiotic,1583,O
genes,1583,O
in,1583,O
women,1583,B-OrganismTaxon
with,1583,O
premature,1583,B-DiseaseOrPhenotypicFeature
ovarian,1583,I-DiseaseOrPhenotypicFeature
failure,1583,I-DiseaseOrPhenotypicFeature
.,1583,O
OBJECTIVE,1584,O
:,1584,O
The,1584,O
goal,1584,O
of,1584,O
this,1584,O
study,1584,O
was,1584,O
to,1584,O
determine,1584,O
whether,1584,O
mutations,1584,O
of,1584,O
meiotic,1584,O
genes,1584,O
",",1584,O
such,1584,O
as,1584,O
disrupted,1584,O
meiotic,1584,O
cDNA,1584,O
(,1584,O
DMC1,1584,B-GeneOrGeneProduct
),1584,O
",",1584,O
MutS,1584,B-GeneOrGeneProduct
homolog,1584,O
(,1584,O
MSH4,1584,B-GeneOrGeneProduct
),1584,O
",",1584,O
MSH5,1584,B-GeneOrGeneProduct
",",1584,O
and,1584,O
S.,1584,B-OrganismTaxon
cerevisiae,1584,I-OrganismTaxon
homolog,1584,O
(,1584,O
SPO11,1584,B-GeneOrGeneProduct
),1584,O
",",1584,O
were,1584,O
associated,1584,O
with,1584,O
premature,1584,B-DiseaseOrPhenotypicFeature
ovarian,1584,I-DiseaseOrPhenotypicFeature
failure,1584,I-DiseaseOrPhenotypicFeature
(,1584,O
POF,1584,B-DiseaseOrPhenotypicFeature
),1584,O
.,1584,O
DESIGN,1585,O
:,1585,O
Case-control,1585,O
study,1585,O
.,1585,O
METHODS,1586,O
:,1586,O
Blood,1586,O
sampling,1586,O
",",1586,O
karyotype,1586,O
",",1586,O
hormonal,1586,O
dosage,1586,O
",",1586,O
ultrasound,1586,O
",",1586,O
and,1586,O
ovarian,1586,O
biopsy,1586,O
were,1586,O
carried,1586,O
out,1586,O
on,1586,O
most,1586,O
patients,1586,B-OrganismTaxon
.,1586,O
However,1587,O
",",1587,O
the,1587,O
main,1587,O
outcome,1587,O
measure,1587,O
was,1587,O
the,1587,O
sequencing,1587,O
of,1587,O
genomic,1587,O
DNA,1587,O
from,1587,O
peripheral,1587,O
blood,1587,O
samples,1587,O
of,1587,O
41,1587,O
women,1587,B-OrganismTaxon
with,1587,O
POF,1587,B-DiseaseOrPhenotypicFeature
and,1587,O
36,1587,O
fertile,1587,O
women,1587,B-OrganismTaxon
(,1587,O
controls,1587,O
),1587,O
.,1587,O
RESULTS,1588,O
:,1588,O
A,1588,O
single,1588,O
heterozygous,1588,O
missense,1588,O
mutation,1588,O
",",1588,O
substitution,1588,O
of,1588,O
a,1588,O
cytosine,1588,B-SequenceVariant
residue,1588,I-SequenceVariant
with,1588,I-SequenceVariant
thymidine,1588,I-SequenceVariant
in,1588,O
exon,1588,O
2,1588,O
of,1588,O
MSH5,1588,B-GeneOrGeneProduct
",",1588,O
was,1588,O
found,1588,O
in,1588,O
two,1588,O
Caucasian,1588,O
women,1588,B-OrganismTaxon
in,1588,O
whom,1588,O
POF,1588,B-DiseaseOrPhenotypicFeature
developed,1588,O
at,1588,O
18,1588,O
and,1588,O
36,1588,O
years,1588,O
of,1588,O
age,1588,O
.,1588,O
This,1589,O
mutation,1589,O
resulted,1589,O
in,1589,O
replacement,1589,O
of,1589,O
a,1589,O
non-polar,1589,O
amino,1589,O
acid,1589,O
(,1589,B-SequenceVariant
proline,1589,I-SequenceVariant
),1589,I-SequenceVariant
with,1589,I-SequenceVariant
a,1589,I-SequenceVariant
polar,1589,I-SequenceVariant
amino,1589,I-SequenceVariant
acid,1589,I-SequenceVariant
(,1589,I-SequenceVariant
serine,1589,I-SequenceVariant
),1589,I-SequenceVariant
at,1589,I-SequenceVariant
position,1589,I-SequenceVariant
29,1589,I-SequenceVariant
(,1589,O
P29S,1589,B-SequenceVariant
),1589,O
.,1589,O
Neither,1590,O
36,1590,O
control,1590,O
women,1590,B-OrganismTaxon
nor,1590,O
39,1590,O
other,1590,O
patients,1590,B-OrganismTaxon
with,1590,O
POF,1590,B-DiseaseOrPhenotypicFeature
possessed,1590,O
this,1590,O
genetic,1590,O
perturbation,1590,O
.,1590,O
Another,1591,O
POF,1591,B-DiseaseOrPhenotypicFeature
patient,1591,B-OrganismTaxon
of,1591,O
African,1591,O
origin,1591,O
showed,1591,O
a,1591,O
homozygous,1591,O
nucleotide,1591,O
change,1591,O
in,1591,O
the,1591,O
tenth,1591,O
of,1591,O
DMC1,1591,B-GeneOrGeneProduct
gene,1591,O
that,1591,O
led,1591,O
to,1591,O
an,1591,O
alteration,1591,O
of,1591,O
the,1591,O
amino,1591,O
acid,1591,O
composition,1591,O
of,1591,O
the,1591,O
protein,1591,O
(,1591,O
M200V,1591,B-SequenceVariant
),1591,O
.,1591,O
CONCLUSIONS,1592,O
:,1592,O
The,1592,O
symptoms,1592,O
of,1592,O
infertility,1592,B-DiseaseOrPhenotypicFeature
observed,1592,O
in,1592,O
the,1592,O
DMC1,1592,B-GeneOrGeneProduct
homozygote,1592,O
mutation,1592,O
carrier,1592,O
and,1592,O
in,1592,O
both,1592,O
patients,1592,B-OrganismTaxon
with,1592,O
a,1592,O
heterozygous,1592,O
substitution,1592,O
in,1592,O
exon,1592,O
2,1592,O
of,1592,O
the,1592,O
MSH5,1592,B-GeneOrGeneProduct
gene,1592,O
provide,1592,O
indirect,1592,O
evidence,1592,O
of,1592,O
the,1592,O
role,1592,O
of,1592,O
genes,1592,O
involved,1592,O
in,1592,O
meiotic,1592,O
recombination,1592,O
in,1592,O
the,1592,O
regulation,1592,O
of,1592,O
ovarian,1592,O
function,1592,O
.,1592,O
MSH5,1593,B-GeneOrGeneProduct
and,1593,O
DMC1,1593,B-GeneOrGeneProduct
mutations,1593,O
may,1593,O
be,1593,O
one,1593,O
explanation,1593,O
for,1593,O
POF,1593,B-DiseaseOrPhenotypicFeature
",",1593,O
albeit,1593,O
uncommon,1593,O
.,1593,O
Clonidine,1594,B-ChemicalEntity
for,1594,O
attention-deficit/hyperactivity,1594,B-DiseaseOrPhenotypicFeature
disorder,1594,I-DiseaseOrPhenotypicFeature
:,1594,O
II,1594,O
.,1594,O
ECG,1595,O
changes,1595,O
and,1595,O
adverse,1595,O
events,1595,O
analysis,1595,O
.,1595,O
OBJECTIVE,1596,O
:,1596,O
To,1596,O
examine,1596,O
the,1596,O
safety,1596,O
and,1596,O
tolerability,1596,O
of,1596,O
clonidine,1596,B-ChemicalEntity
used,1596,O
alone,1596,O
or,1596,O
with,1596,O
methylphenidate,1596,B-ChemicalEntity
in,1596,O
children,1596,O
with,1596,O
attention-deficit/hyperactivity,1596,B-DiseaseOrPhenotypicFeature
disorder,1596,I-DiseaseOrPhenotypicFeature
(,1596,O
ADHD,1596,B-DiseaseOrPhenotypicFeature
),1596,O
.,1596,O
METHOD,1597,O
:,1597,O
In,1597,O
a,1597,O
16-week,1597,O
multicenter,1597,O
",",1597,O
double-blind,1597,O
trial,1597,O
",",1597,O
122,1597,O
children,1597,O
with,1597,O
ADHD,1597,B-DiseaseOrPhenotypicFeature
were,1597,O
randomly,1597,O
assigned,1597,O
to,1597,O
clonidine,1597,B-ChemicalEntity
(,1597,O
n,1597,O
=,1597,O
31,1597,O
),1597,O
",",1597,O
methylphenidate,1597,B-ChemicalEntity
(,1597,O
n,1597,O
=,1597,O
29,1597,O
),1597,O
",",1597,O
clonidine,1597,B-ChemicalEntity
and,1597,O
methylphenidate,1597,B-ChemicalEntity
(,1597,O
n,1597,O
=,1597,O
32,1597,O
),1597,O
",",1597,O
or,1597,O
placebo,1597,O
(,1597,O
n,1597,O
=,1597,O
30,1597,O
),1597,O
.,1597,O
Doses,1598,O
were,1598,O
flexibly,1598,O
titrated,1598,O
up,1598,O
to,1598,O
0.6,1598,O
mg/day,1598,O
for,1598,O
clonidine,1598,B-ChemicalEntity
and,1598,O
60,1598,O
mg/day,1598,O
for,1598,O
methylphenidate,1598,B-ChemicalEntity
(,1598,O
both,1598,O
with,1598,O
divided,1598,O
dosing,1598,O
),1598,O
.,1598,O
Groups,1599,O
were,1599,O
compared,1599,O
regarding,1599,O
adverse,1599,O
events,1599,O
and,1599,O
changes,1599,O
from,1599,O
baseline,1599,O
to,1599,O
week,1599,O
16,1599,O
in,1599,O
electrocardiograms,1599,O
and,1599,O
vital,1599,O
signs,1599,O
.,1599,O
RESULTS,1600,O
:,1600,O
There,1600,O
were,1600,O
more,1600,O
incidents,1600,O
of,1600,O
bradycardia,1600,B-DiseaseOrPhenotypicFeature
in,1600,O
subjects,1600,O
treated,1600,O
with,1600,O
clonidine,1600,B-ChemicalEntity
compared,1600,O
with,1600,O
those,1600,O
not,1600,O
treated,1600,O
with,1600,O
clonidine,1600,B-ChemicalEntity
(,1600,O
17.5,1600,O
%,1600,O
versus,1600,O
3.4,1600,O
%,1600,O
;,1600,O
p,1600,O
=.02,1600,O
),1600,O
",",1600,O
but,1600,O
no,1600,O
other,1600,O
significant,1600,O
group,1600,O
differences,1600,O
regarding,1600,O
electrocardiogram,1600,O
and,1600,O
other,1600,O
cardiovascular,1600,O
outcomes,1600,O
.,1600,O
There,1601,O
were,1601,O
no,1601,O
suggestions,1601,O
of,1601,O
interactions,1601,O
between,1601,O
clonidine,1601,B-ChemicalEntity
and,1601,O
methylphenidate,1601,B-ChemicalEntity
regarding,1601,O
cardiovascular,1601,O
outcomes,1601,O
.,1601,O
Moderate,1602,O
or,1602,O
severe,1602,O
adverse,1602,O
events,1602,O
were,1602,O
more,1602,O
common,1602,O
in,1602,O
subjects,1602,O
on,1602,O
clonidine,1602,B-ChemicalEntity
(,1602,O
79.4,1602,O
%,1602,O
versus,1602,O
49.2,1602,O
%,1602,O
;,1602,O
p,1602,O
=.0006,1602,O
),1602,O
but,1602,O
not,1602,O
associated,1602,O
with,1602,O
higher,1602,O
rates,1602,O
of,1602,O
early,1602,O
study,1602,O
withdrawal,1602,O
.,1602,O
Drowsiness,1603,B-DiseaseOrPhenotypicFeature
was,1603,O
common,1603,O
on,1603,O
clonidine,1603,B-ChemicalEntity
",",1603,O
but,1603,O
generally,1603,O
resolved,1603,O
by,1603,O
6,1603,O
to,1603,O
8,1603,O
weeks,1603,O
.,1603,O
CONCLUSIONS,1604,O
:,1604,O
Clonidine,1604,B-ChemicalEntity
",",1604,O
used,1604,O
alone,1604,O
or,1604,O
with,1604,O
methylphenidate,1604,B-ChemicalEntity
",",1604,O
appears,1604,O
safe,1604,O
and,1604,O
well,1604,O
tolerated,1604,O
in,1604,O
childhood,1604,O
ADHD,1604,B-DiseaseOrPhenotypicFeature
.,1604,O
Physicians,1605,O
prescribing,1605,O
clonidine,1605,B-ChemicalEntity
should,1605,O
monitor,1605,O
for,1605,O
bradycardia,1605,B-DiseaseOrPhenotypicFeature
and,1605,O
advise,1605,O
patients,1605,B-OrganismTaxon
about,1605,O
the,1605,O
high,1605,O
likelihood,1605,O
of,1605,O
initial,1605,O
drowsiness,1605,B-DiseaseOrPhenotypicFeature
.,1605,O
RNASEL,1606,B-GeneOrGeneProduct
and,1606,O
RNASEL-inhibitor,1606,B-GeneOrGeneProduct
variation,1606,O
and,1606,O
prostate,1606,B-DiseaseOrPhenotypicFeature
cancer,1606,I-DiseaseOrPhenotypicFeature
risk,1606,O
in,1606,O
Afro-Caribbeans,1606,O
.,1606,O
BACKGROUND,1607,O
:,1607,O
Afro-Caribbeans,1607,O
from,1607,O
Tobago,1607,O
are,1607,O
at,1607,O
high,1607,O
risk,1607,O
of,1607,O
developing,1607,O
prostate,1607,B-DiseaseOrPhenotypicFeature
cancer,1607,I-DiseaseOrPhenotypicFeature
.,1607,O
This,1608,O
elevated,1608,O
risk,1608,O
of,1608,O
prostate,1608,B-DiseaseOrPhenotypicFeature
cancer,1608,I-DiseaseOrPhenotypicFeature
is,1608,O
shared,1608,O
by,1608,O
populations,1608,O
of,1608,O
African,1608,O
ancestry,1608,O
living,1608,O
in,1608,O
diverse,1608,O
environments,1608,O
in,1608,O
the,1608,O
Western,1608,O
hemisphere,1608,O
.,1608,O
Variation,1609,O
in,1609,O
the,1609,O
ribonuclease,1609,B-GeneOrGeneProduct
L,1609,I-GeneOrGeneProduct
(,1609,O
RNASEL,1609,B-GeneOrGeneProduct
),1609,O
gene,1609,O
has,1609,O
recently,1609,O
been,1609,O
reported,1609,O
to,1609,O
be,1609,O
associated,1609,O
with,1609,O
an,1609,O
increased,1609,O
risk,1609,O
of,1609,O
prostate,1609,B-DiseaseOrPhenotypicFeature
cancer,1609,I-DiseaseOrPhenotypicFeature
.,1609,O
However,1610,O
",",1610,O
whether,1610,O
RNASEL,1610,B-GeneOrGeneProduct
variation,1610,O
contributes,1610,O
to,1610,O
the,1610,O
increased,1610,O
risk,1610,O
of,1610,O
prostate,1610,B-DiseaseOrPhenotypicFeature
cancer,1610,I-DiseaseOrPhenotypicFeature
observed,1610,O
in,1610,O
populations,1610,O
of,1610,O
African,1610,O
ancestry,1610,O
remains,1610,O
unclear,1610,O
.,1610,O
METHODS,1611,O
:,1611,O
We,1611,O
resequenced,1611,O
the,1611,O
positional,1611,O
candidate,1611,O
gene,1611,O
RNASEL,1611,B-GeneOrGeneProduct
in,1611,O
48,1611,O
prostate,1611,B-DiseaseOrPhenotypicFeature
cancer,1611,I-DiseaseOrPhenotypicFeature
cases,1611,O
and,1611,O
genotyped,1611,O
the,1611,O
previously,1611,O
reported,1611,O
R462Q,1611,B-SequenceVariant
and,1611,O
D541E,1611,B-SequenceVariant
polymorphisms,1611,O
in,1611,O
230,1611,O
prostate,1611,B-DiseaseOrPhenotypicFeature
cancer,1611,I-DiseaseOrPhenotypicFeature
cases,1611,O
and,1611,O
458,1611,O
controls,1611,O
.,1611,O
We,1612,O
also,1612,O
examined,1612,O
the,1612,O
inhibitor,1612,O
of,1612,O
RNASEL,1612,B-GeneOrGeneProduct
(,1612,O
ABCE1,1612,B-GeneOrGeneProduct
),1612,O
for,1612,O
variation,1612,O
associated,1612,O
with,1612,O
prostate,1612,B-DiseaseOrPhenotypicFeature
cancer,1612,I-DiseaseOrPhenotypicFeature
risk,1612,O
.,1612,O
RESULTS,1613,O
:,1613,O
We,1613,O
found,1613,O
no,1613,O
evidence,1613,O
of,1613,O
association,1613,O
between,1613,O
R462Q,1613,B-SequenceVariant
and,1613,O
D541E,1613,B-SequenceVariant
polymorphisms,1613,O
and,1613,O
prostate,1613,B-DiseaseOrPhenotypicFeature
cancer,1613,I-DiseaseOrPhenotypicFeature
risk,1613,O
in,1613,O
our,1613,O
case/control,1613,O
analysis,1613,O
.,1613,O
A,1614,O
novel,1614,O
variant,1614,O
(,1614,O
K294E,1614,B-SequenceVariant
),1614,O
was,1614,O
identified,1614,O
in,1614,O
a,1614,O
single,1614,O
heterozygous,1614,O
individual,1614,O
with,1614,O
prostate,1614,B-DiseaseOrPhenotypicFeature
cancer,1614,I-DiseaseOrPhenotypicFeature
.,1614,O
We,1615,O
also,1615,O
observed,1615,O
a,1615,O
20,1615,B-SequenceVariant
bp,1615,I-SequenceVariant
insertion/deletion,1615,I-SequenceVariant
polymorphism,1615,I-SequenceVariant
"1,109",1615,I-SequenceVariant
bp,1615,I-SequenceVariant
upstream,1615,I-SequenceVariant
of,1615,I-SequenceVariant
the,1615,I-SequenceVariant
initiation,1615,I-SequenceVariant
codon,1615,I-SequenceVariant
",",1615,O
but,1615,O
this,1615,O
variant,1615,O
was,1615,O
not,1615,O
associated,1615,O
with,1615,O
prostate,1615,B-DiseaseOrPhenotypicFeature
cancer,1615,I-DiseaseOrPhenotypicFeature
.,1615,O
We,1616,O
identified,1616,O
16,1616,O
single,1616,O
nucleotide,1616,O
polymorphisms,1616,O
in,1616,O
the,1616,O
ABCE1,1616,B-GeneOrGeneProduct
gene,1616,O
",",1616,O
only,1616,O
3,1616,O
of,1616,O
which,1616,O
had,1616,O
a,1616,O
minor,1616,O
allele,1616,O
frequency,1616,O
>,1616,O
5,1616,O
%,1616,O
.,1616,O
A,1617,O
common,1617,O
A/G,1617,B-SequenceVariant
transition,1617,I-SequenceVariant
"-1,071",1617,I-SequenceVariant
bp,1617,I-SequenceVariant
from,1617,O
the,1617,O
transcriptional,1617,O
start,1617,O
site,1617,O
was,1617,O
genotyped,1617,O
and,1617,O
showed,1617,O
no,1617,O
evidence,1617,O
of,1617,O
association,1617,O
with,1617,O
prostate,1617,B-DiseaseOrPhenotypicFeature
cancer,1617,I-DiseaseOrPhenotypicFeature
.,1617,O
CONCLUSIONS,1618,O
:,1618,O
Our,1618,O
results,1618,O
suggest,1618,O
that,1618,O
common,1618,O
variation,1618,O
in,1618,O
the,1618,O
putative,1618,O
prostate,1618,B-DiseaseOrPhenotypicFeature
cancer,1618,I-DiseaseOrPhenotypicFeature
susceptibility,1618,O
gene,1618,O
",",1618,O
RNASEL,1618,B-GeneOrGeneProduct
",",1618,O
or,1618,O
its,1618,O
inhibitor,1618,O
does,1618,O
not,1618,O
contribute,1618,O
significantly,1618,O
to,1618,O
prostate,1618,B-DiseaseOrPhenotypicFeature
cancer,1618,I-DiseaseOrPhenotypicFeature
risk,1618,O
in,1618,O
this,1618,O
Afro-Caribbean,1618,O
population,1618,O
.,1618,O
Cone,1619,B-DiseaseOrPhenotypicFeature
dystrophy,1619,I-DiseaseOrPhenotypicFeature
with,1619,I-DiseaseOrPhenotypicFeature
supernormal,1619,I-DiseaseOrPhenotypicFeature
rod,1619,I-DiseaseOrPhenotypicFeature
response,1619,I-DiseaseOrPhenotypicFeature
is,1619,O
strictly,1619,O
associated,1619,O
with,1619,O
mutations,1619,O
in,1619,O
KCNV2,1619,B-GeneOrGeneProduct
.,1619,O
PURPOSE,1620,O
:,1620,O
Cone,1620,B-DiseaseOrPhenotypicFeature
dystrophy,1620,I-DiseaseOrPhenotypicFeature
with,1620,I-DiseaseOrPhenotypicFeature
supernormal,1620,I-DiseaseOrPhenotypicFeature
rod,1620,I-DiseaseOrPhenotypicFeature
response,1620,I-DiseaseOrPhenotypicFeature
(,1620,O
CDSRR,1620,B-DiseaseOrPhenotypicFeature
),1620,O
is,1620,O
a,1620,O
retinal,1620,B-DiseaseOrPhenotypicFeature
disorder,1620,I-DiseaseOrPhenotypicFeature
characterized,1620,O
by,1620,O
reduced,1620,O
visual,1620,O
acuity,1620,O
",",1620,O
color,1620,B-DiseaseOrPhenotypicFeature
vision,1620,I-DiseaseOrPhenotypicFeature
defects,1620,I-DiseaseOrPhenotypicFeature
",",1620,O
and,1620,O
specific,1620,O
alterations,1620,O
of,1620,O
ERG,1620,O
responses,1620,O
that,1620,O
feature,1620,O
elevated,1620,O
scotopic,1620,O
b-wave,1620,O
amplitudes,1620,O
at,1620,O
high,1620,O
luminance,1620,O
intensities,1620,O
.,1620,O
Mutations,1621,O
in,1621,O
PDE6H,1621,B-GeneOrGeneProduct
and,1621,O
in,1621,O
KCNV2,1621,B-GeneOrGeneProduct
have,1621,O
been,1621,O
described,1621,O
in,1621,O
CDSRR,1621,B-DiseaseOrPhenotypicFeature
.,1621,O
A,1622,O
combined,1622,O
clinical,1622,O
and,1622,O
genetic,1622,O
study,1622,O
was,1622,O
conducted,1622,O
in,1622,O
a,1622,O
cohort,1622,O
of,1622,O
patients,1622,B-OrganismTaxon
with,1622,O
CDSRR,1622,B-DiseaseOrPhenotypicFeature
",",1622,O
to,1622,O
substantiate,1622,O
these,1622,O
prior,1622,O
RESULTS,1622,O
:,1622,O
Seventeen,1622,O
patients,1622,B-OrganismTaxon
from,1622,O
13,1622,O
families,1622,O
underwent,1622,O
a,1622,O
detailed,1622,O
ophthalmic,1622,O
examination,1622,O
including,1622,O
color,1622,O
vision,1622,O
testing,1622,O
",",1622,O
Goldmann,1622,O
visual,1622,O
fields,1622,O
",",1622,O
fundus,1622,O
photography,1622,O
",",1622,O
Ganzfeld,1622,O
and,1622,O
multifocal,1622,O
ERGs,1622,O
",",1622,O
and,1622,O
optical,1622,O
coherence,1622,O
tomography,1622,O
.,1622,O
The,1623,O
coding,1623,O
sequences,1623,O
and,1623,O
flanking,1623,O
intron/UTR,1623,O
sequences,1623,O
of,1623,O
PDE6C,1623,B-GeneOrGeneProduct
and,1623,O
KCNV2,1623,B-GeneOrGeneProduct
were,1623,O
screened,1623,O
for,1623,O
mutations,1623,O
by,1623,O
means,1623,O
of,1623,O
DHPLC,1623,O
and,1623,O
direct,1623,O
DNA,1623,O
sequencing,1623,O
of,1623,O
PCR-amplified,1623,O
genomic,1623,O
DNA,1623,O
.,1623,O
results,1624,O
.,1624,O
Whereas,1625,O
no,1625,O
mutations,1625,O
were,1625,O
detected,1625,O
in,1625,O
the,1625,O
PDE6H,1625,B-GeneOrGeneProduct
gene,1625,O
",",1625,O
mutations,1625,O
in,1625,O
KCNV2,1625,B-GeneOrGeneProduct
were,1625,O
identified,1625,O
in,1625,O
all,1625,O
patients,1625,B-OrganismTaxon
",",1625,O
in,1625,O
either,1625,O
the,1625,O
homozygous,1625,O
or,1625,O
compound,1625,O
heterozygous,1625,O
state,1625,O
.,1625,O
Ten,1626,O
of,1626,O
the,1626,O
11,1626,O
identified,1626,O
mutations,1626,O
were,1626,O
novel,1626,O
",",1626,O
including,1626,O
three,1626,O
missense,1626,O
and,1626,O
six,1626,O
truncating,1626,O
mutations,1626,O
and,1626,O
one,1626,O
gross,1626,O
deletion,1626,O
.,1626,O
The,1627,O
mutations,1627,O
concordantly,1627,O
segregate,1627,O
in,1627,O
all,1627,O
available,1627,O
families,1627,O
according,1627,O
a,1627,O
recessive,1627,O
mode,1627,O
of,1627,O
inheritance,1627,O
.,1627,O
The,1628,O
CDSRR,1628,B-DiseaseOrPhenotypicFeature
phenotype,1628,O
was,1628,O
associated,1628,O
with,1628,O
reduced,1628,O
visual,1628,O
acuity,1628,O
of,1628,O
variable,1628,O
degree,1628,O
and,1628,O
color,1628,B-DiseaseOrPhenotypicFeature
vision,1628,I-DiseaseOrPhenotypicFeature
defects,1628,I-DiseaseOrPhenotypicFeature
.,1628,O
Macular,1629,O
defects,1629,O
ranging,1629,O
from,1629,O
mild,1629,O
pigmentary,1629,O
changes,1629,O
to,1629,O
distinct,1629,O
foveal,1629,O
atrophy,1629,B-DiseaseOrPhenotypicFeature
were,1629,O
present,1629,O
in,1629,O
nine,1629,O
patients,1629,B-OrganismTaxon
.,1629,O
Progression,1630,O
of,1630,O
the,1630,O
disease,1630,O
was,1630,O
observed,1630,O
in,1630,O
only,1630,O
three,1630,O
of,1630,O
seven,1630,O
patients,1630,B-OrganismTaxon
with,1630,O
follow-up,1630,O
data,1630,O
.,1630,O
CONCLUSIONS,1631,O
:,1631,O
The,1631,O
phenotype,1631,O
of,1631,O
cone,1631,B-DiseaseOrPhenotypicFeature
dystrophy,1631,I-DiseaseOrPhenotypicFeature
with,1631,I-DiseaseOrPhenotypicFeature
supernormal,1631,I-DiseaseOrPhenotypicFeature
rod,1631,I-DiseaseOrPhenotypicFeature
response,1631,I-DiseaseOrPhenotypicFeature
is,1631,O
tightly,1631,O
linked,1631,O
with,1631,O
mutations,1631,O
in,1631,O
KCNV2,1631,B-GeneOrGeneProduct
.,1631,O
A,1632,O
family,1632,O
with,1632,O
two,1632,O
consecutive,1632,O
nonsense,1632,O
mutations,1632,O
in,1632,O
BMPR1A,1632,B-GeneOrGeneProduct
causing,1632,O
juvenile,1632,B-DiseaseOrPhenotypicFeature
polyposis,1632,I-DiseaseOrPhenotypicFeature
.,1632,O
We,1633,O
describe,1633,O
a,1633,O
novel,1633,O
germline,1633,O
mutation,1633,O
of,1633,O
BMPR1A,1633,B-GeneOrGeneProduct
in,1633,O
a,1633,O
family,1633,O
with,1633,O
juvenile,1633,B-DiseaseOrPhenotypicFeature
polyposis,1633,I-DiseaseOrPhenotypicFeature
and,1633,O
colon,1633,B-DiseaseOrPhenotypicFeature
cancer,1633,I-DiseaseOrPhenotypicFeature
.,1633,O
This,1634,O
mutation,1634,O
consists,1634,O
of,1634,O
two,1634,O
consecutive,1634,O
substitutions,1634,O
(,1634,O
735-6,1634,B-SequenceVariant
TG,1634,I-SequenceVariant
>,1634,I-SequenceVariant
AT,1634,I-SequenceVariant
),1634,O
that,1634,O
cause,1634,O
two,1634,O
nonsense,1634,O
mutations,1634,O
(,1634,O
Y245X,1634,B-SequenceVariant
",",1634,O
G246X,1634,B-SequenceVariant
),1634,O
",",1634,O
inherited,1634,O
in,1634,O
an,1634,O
autosomal,1634,O
dominant,1634,O
fashion,1634,O
",",1634,O
on,1634,O
one,1634,O
parental,1634,O
chromosome,1634,O
.,1634,O
This,1635,O
mutation,1635,O
caused,1635,O
protein,1635,O
truncation,1635,O
",",1635,O
and,1635,O
represents,1635,O
a,1635,O
novel,1635,O
case,1635,O
of,1635,O
consecutive,1635,O
nonsense,1635,O
mutations,1635,O
in,1635,O
human,1635,B-OrganismTaxon
disease,1635,O
.,1635,O
Catechol-O-methyltransferase,1636,B-GeneOrGeneProduct
(,1636,O
COMT,1636,B-GeneOrGeneProduct
),1636,O
gene,1636,O
variants,1636,O
:,1636,O
possible,1636,O
association,1636,O
of,1636,O
the,1636,O
Val158Met,1636,B-SequenceVariant
variant,1636,O
with,1636,O
opiate,1636,B-DiseaseOrPhenotypicFeature
addiction,1636,I-DiseaseOrPhenotypicFeature
in,1636,O
Hispanic,1636,O
women,1636,B-OrganismTaxon
.,1636,O
Catechol-O-methyltransferase,1637,B-GeneOrGeneProduct
(,1637,O
COMT,1637,B-GeneOrGeneProduct
),1637,O
catalyzes,1637,O
the,1637,O
breakdown,1637,O
of,1637,O
catechol,1637,B-ChemicalEntity
neurotransmitters,1637,I-ChemicalEntity
",",1637,O
including,1637,O
dopamine,1637,B-ChemicalEntity
",",1637,O
which,1637,O
plays,1637,O
a,1637,O
prominent,1637,O
role,1637,O
in,1637,O
drug,1637,O
reward,1637,O
.,1637,O
A,1638,O
common,1638,O
single,1638,O
nucleotide,1638,O
polymorphism,1638,O
(,1638,O
SNP,1638,O
),1638,O
",",1638,O
G472A,1638,B-SequenceVariant
",",1638,O
codes,1638,O
for,1638,O
a,1638,O
Val158Met,1638,B-SequenceVariant
substitution,1638,O
and,1638,O
results,1638,O
in,1638,O
a,1638,O
fourfold,1638,O
down,1638,O
regulation,1638,O
of,1638,O
enzyme,1638,O
activity,1638,O
.,1638,O
We,1639,O
sequenced,1639,O
exon,1639,O
IV,1639,O
of,1639,O
COMT,1639,B-GeneOrGeneProduct
gene,1639,O
in,1639,O
search,1639,O
for,1639,O
novel,1639,O
polymorphisms,1639,O
and,1639,O
then,1639,O
genotyped,1639,O
four,1639,O
out,1639,O
of,1639,O
five,1639,O
identified,1639,O
by,1639,O
direct,1639,O
sequencing,1639,O
",",1639,O
using,1639,O
TaqMan,1639,O
assay,1639,O
on,1639,O
266,1639,O
opioid-dependent,1639,B-ChemicalEntity
and,1639,O
173,1639,O
control,1639,O
subjects,1639,O
.,1639,O
Genotype,1640,O
frequencies,1640,O
of,1640,O
the,1640,O
G472A,1640,B-SequenceVariant
SNP,1640,O
varied,1640,O
significantly,1640,O
(,1640,O
P,1640,O
=,1640,O
0.029,1640,O
),1640,O
among,1640,O
the,1640,O
three,1640,O
main,1640,O
ethnic/cultural,1640,O
groups,1640,O
(,1640,O
Caucasians,1640,O
",",1640,O
Hispanics,1640,O
",",1640,O
and,1640,O
African,1640,O
Americans,1640,O
),1640,O
.,1640,O
Using,1641,O
a,1641,O
genotype,1641,O
test,1641,O
",",1641,O
we,1641,O
found,1641,O
a,1641,O
trend,1641,O
to,1641,O
point-wise,1641,O
association,1641,O
(,1641,O
P,1641,O
=,1641,O
0.053,1641,O
),1641,O
of,1641,O
the,1641,O
G472A,1641,B-SequenceVariant
SNP,1641,O
in,1641,O
Hispanic,1641,O
subjects,1641,O
with,1641,O
opiate,1641,B-DiseaseOrPhenotypicFeature
addiction,1641,I-DiseaseOrPhenotypicFeature
.,1641,O
Further,1642,O
analysis,1642,O
of,1642,O
G472A,1642,B-SequenceVariant
genotypes,1642,O
in,1642,O
Hispanic,1642,O
subjects,1642,O
with,1642,O
data,1642,O
stratified,1642,O
by,1642,O
gender,1642,O
identified,1642,O
a,1642,O
point-wise,1642,O
significant,1642,O
(,1642,O
P,1642,O
=,1642,O
0.049,1642,O
),1642,O
association,1642,O
of,1642,O
G/A,1642,O
and,1642,O
A/A,1642,O
genotypes,1642,O
with,1642,O
opiate,1642,B-DiseaseOrPhenotypicFeature
addiction,1642,I-DiseaseOrPhenotypicFeature
in,1642,O
women,1642,B-OrganismTaxon
",",1642,O
but,1642,O
not,1642,O
men,1642,B-OrganismTaxon
.,1642,O
These,1643,O
point-wise,1643,O
significant,1643,O
results,1643,O
are,1643,O
not,1643,O
significant,1643,O
experiment-wise,1643,O
(,1643,O
at,1643,O
P,1643,O
<,1643,O
0.05,1643,O
),1643,O
after,1643,O
correction,1643,O
for,1643,O
multiple,1643,O
testing,1643,O
.,1643,O
No,1644,O
significant,1644,O
association,1644,O
was,1644,O
found,1644,O
with,1644,O
haplotypes,1644,O
of,1644,O
the,1644,O
three,1644,O
most,1644,O
common,1644,O
SNPs,1644,O
.,1644,O
Linkage,1645,O
disequilibrium,1645,O
patterns,1645,O
were,1645,O
similar,1645,O
for,1645,O
the,1645,O
three,1645,O
ethnic/cultural,1645,O
groups,1645,O
.,1645,O
Bone,1646,B-GeneOrGeneProduct
morphogenetic,1646,I-GeneOrGeneProduct
protein-4,1646,I-GeneOrGeneProduct
interacts,1646,O
with,1646,O
activin,1646,B-GeneOrGeneProduct
and,1646,O
GnRH,1646,B-GeneOrGeneProduct
to,1646,O
modulate,1646,O
gonadotrophin,1646,B-GeneOrGeneProduct
secretion,1646,O
in,1646,O
LbetaT2,1646,B-CellLine
gonadotrophs,1646,O
.,1646,O
We,1647,O
have,1647,O
shown,1647,O
previously,1647,O
that,1647,O
",",1647,O
in,1647,O
sheep,1647,B-OrganismTaxon
primary,1647,O
pituitary,1647,O
cells,1647,O
",",1647,O
bone,1647,B-GeneOrGeneProduct
morphogenetic,1647,I-GeneOrGeneProduct
proteins,1647,I-GeneOrGeneProduct
(,1647,I-GeneOrGeneProduct
BMP,1647,I-GeneOrGeneProduct
),1647,I-GeneOrGeneProduct
-4,1647,I-GeneOrGeneProduct
inhibits,1647,O
FSHbeta,1647,B-GeneOrGeneProduct
mRNA,1647,O
expression,1647,O
and,1647,O
FSH,1647,B-GeneOrGeneProduct
release,1647,O
.,1647,O
In,1648,O
contrast,1648,O
",",1648,O
in,1648,O
mouse,1648,B-OrganismTaxon
LbetaT2,1648,B-CellLine
gonadotrophs,1648,O
",",1648,O
others,1648,O
have,1648,O
shown,1648,O
a,1648,O
stimulatory,1648,O
effect,1648,O
of,1648,O
BMPs,1648,B-GeneOrGeneProduct
on,1648,O
basal,1648,O
or,1648,O
activin-stimulated,1648,B-GeneOrGeneProduct
FSHbeta,1648,B-GeneOrGeneProduct
promoter-driven,1648,O
transcription,1648,O
.,1648,O
As,1649,O
a,1649,O
species,1649,O
comparison,1649,O
with,1649,O
our,1649,O
previous,1649,O
results,1649,O
",",1649,O
we,1649,O
used,1649,O
LbetaT2,1649,B-CellLine
cells,1649,O
to,1649,O
investigate,1649,O
the,1649,O
effects,1649,O
of,1649,O
BMP-4,1649,B-GeneOrGeneProduct
on,1649,O
gonadotrophin,1649,B-GeneOrGeneProduct
mRNA,1649,O
and,1649,O
secretion,1649,O
modulated,1649,O
by,1649,O
activin,1649,B-GeneOrGeneProduct
and,1649,O
GnRH,1649,B-GeneOrGeneProduct
.,1649,O
BMP-4,1650,B-GeneOrGeneProduct
alone,1650,O
had,1650,O
no,1650,O
effect,1650,O
on,1650,O
FSH,1650,B-GeneOrGeneProduct
production,1650,O
",",1650,O
but,1650,O
enhanced,1650,O
the,1650,O
activin+GnRH-induced,1650,B-GeneOrGeneProduct
stimulation,1650,O
of,1650,O
FSHbeta,1650,B-GeneOrGeneProduct
mRNA,1650,O
and,1650,O
FSH,1650,B-GeneOrGeneProduct
secretion,1650,O
",",1650,O
without,1650,O
any,1650,O
effect,1650,O
on,1650,O
follistatin,1650,B-GeneOrGeneProduct
mRNA,1650,O
.,1650,O
BMP-4,1651,B-GeneOrGeneProduct
reduced,1651,O
LHbeta,1651,B-GeneOrGeneProduct
mRNA,1651,O
up-regulation,1651,O
in,1651,O
response,1651,O
to,1651,O
GnRH,1651,B-GeneOrGeneProduct
(,1651,O
+/-activin,1651,O
),1651,O
and,1651,O
decreased,1651,O
GnRH,1651,B-GeneOrGeneProduct
receptor,1651,I-GeneOrGeneProduct
expression,1651,O
",",1651,O
which,1651,O
would,1651,O
favour,1651,O
FSH,1651,B-GeneOrGeneProduct
",",1651,O
rather,1651,O
than,1651,O
LH,1651,B-GeneOrGeneProduct
",",1651,O
synthesis,1651,O
and,1651,O
secretion,1651,O
.,1651,O
In,1652,O
contrast,1652,O
to,1652,O
sheep,1652,B-OrganismTaxon
pituitary,1652,O
gonadotrophs,1652,O
",",1652,O
which,1652,O
express,1652,O
only,1652,O
BMP,1652,B-GeneOrGeneProduct
receptor,1652,I-GeneOrGeneProduct
types,1652,I-GeneOrGeneProduct
IA,1652,I-GeneOrGeneProduct
(,1652,I-GeneOrGeneProduct
BMPRIA,1652,I-GeneOrGeneProduct
),1652,I-GeneOrGeneProduct
and,1652,I-GeneOrGeneProduct
II,1652,I-GeneOrGeneProduct
(,1652,I-GeneOrGeneProduct
BMPRII,1652,I-GeneOrGeneProduct
),1652,I-GeneOrGeneProduct
",",1652,O
LbetaT2,1652,B-CellLine
cells,1652,O
also,1652,O
express,1652,O
BMPRIB,1652,B-GeneOrGeneProduct
.,1652,O
Smad1/5,1653,B-GeneOrGeneProduct
phosphorylation,1653,O
induced,1653,O
by,1653,O
BMP-4,1653,B-GeneOrGeneProduct
",",1653,O
indicating,1653,O
activation,1653,O
of,1653,O
BMP,1653,B-GeneOrGeneProduct
signalling,1653,O
",",1653,O
was,1653,O
the,1653,O
same,1653,O
whether,1653,O
BMP-4,1653,B-GeneOrGeneProduct
was,1653,O
used,1653,O
alone,1653,O
or,1653,O
combined,1653,O
with,1653,O
activin+/-GnRH,1653,B-GeneOrGeneProduct
.,1653,O
We,1654,O
hypothesized,1654,O
that,1654,O
activin,1654,B-GeneOrGeneProduct
and/or,1654,O
GnRH,1654,B-GeneOrGeneProduct
pathways,1654,O
may,1654,O
be,1654,O
modulated,1654,O
by,1654,O
BMP-4,1654,B-GeneOrGeneProduct
",",1654,O
but,1654,O
neither,1654,O
the,1654,O
activin-stimulated,1654,B-GeneOrGeneProduct
phosphorylation,1654,O
of,1654,O
Smad2/3,1654,B-GeneOrGeneProduct
nor,1654,O
the,1654,O
GnRH-induced,1654,B-GeneOrGeneProduct
ERK1/2,1654,B-GeneOrGeneProduct
or,1654,O
cAMP,1654,B-GeneOrGeneProduct
response,1654,I-GeneOrGeneProduct
element-binding,1654,I-GeneOrGeneProduct
phosphorylation,1654,O
were,1654,O
modified,1654,O
.,1654,O
However,1655,O
",",1655,O
the,1655,O
GnRH-induced,1655,B-GeneOrGeneProduct
activation,1655,O
of,1655,O
p38,1655,B-GeneOrGeneProduct
MAPK,1655,I-GeneOrGeneProduct
was,1655,O
decreased,1655,O
by,1655,O
BMP-4,1655,B-GeneOrGeneProduct
.,1655,O
This,1656,O
was,1656,O
associated,1656,O
with,1656,O
increased,1656,O
FSHbeta,1656,B-GeneOrGeneProduct
mRNA,1656,O
levels,1656,O
and,1656,O
FSH,1656,B-GeneOrGeneProduct
secretion,1656,O
",",1656,O
but,1656,O
decreased,1656,O
LHbeta,1656,B-GeneOrGeneProduct
mRNA,1656,O
levels,1656,O
.,1656,O
These,1657,O
results,1657,O
confirm,1657,O
1,1657,O
.,1657,O
BMPs,1658,B-GeneOrGeneProduct
as,1658,O
important,1658,O
modulators,1658,O
of,1658,O
activin,1658,B-GeneOrGeneProduct
and/or,1658,O
GnRH-stimulated,1658,B-GeneOrGeneProduct
gonadotrophin,1658,B-GeneOrGeneProduct
synthesis,1658,O
and,1658,O
release,1658,O
and,1658,O
2.,1658,O
important,1658,O
species,1658,O
differences,1658,O
in,1658,O
these,1658,O
effects,1658,O
",",1658,O
which,1658,O
could,1658,O
relate,1658,O
to,1658,O
differences,1658,O
in,1658,O
BMP,1658,B-GeneOrGeneProduct
receptor,1658,I-GeneOrGeneProduct
expression,1658,O
in,1658,O
gonadotrophs,1658,O
.,1658,O
Azathioprine-induced,1659,B-ChemicalEntity
suicidal,1659,O
erythrocyte,1659,O
death,1659,O
.,1659,O
BACKGROUND,1660,O
:,1660,O
Azathioprine,1660,B-ChemicalEntity
is,1660,O
widely,1660,O
used,1660,O
as,1660,O
an,1660,O
immunosuppressive,1660,O
drug,1660,O
.,1660,O
The,1661,O
side,1661,O
effects,1661,O
of,1661,O
azathioprine,1661,B-ChemicalEntity
include,1661,O
anemia,1661,B-DiseaseOrPhenotypicFeature
",",1661,O
which,1661,O
has,1661,O
been,1661,O
attributed,1661,O
to,1661,O
bone,1661,B-DiseaseOrPhenotypicFeature
marrow,1661,I-DiseaseOrPhenotypicFeature
suppression,1661,I-DiseaseOrPhenotypicFeature
.,1661,O
Alternatively,1662,O
",",1662,O
anemia,1662,B-DiseaseOrPhenotypicFeature
could,1662,O
result,1662,O
from,1662,O
accelerated,1662,O
suicidal,1662,O
erythrocyte,1662,O
death,1662,O
or,1662,O
eryptosis,1662,O
",",1662,O
which,1662,O
is,1662,O
characterized,1662,O
by,1662,O
exposure,1662,O
of,1662,O
phosphatidylserine,1662,B-ChemicalEntity
(,1662,O
PS,1662,B-ChemicalEntity
),1662,O
at,1662,O
the,1662,O
erythrocyte,1662,O
surface,1662,O
and,1662,O
by,1662,O
cell,1662,O
shrinkage,1662,O
.,1662,O
METHODS,1663,O
:,1663,O
The,1663,O
present,1663,O
experiments,1663,O
explored,1663,O
whether,1663,O
azathioprine,1663,B-ChemicalEntity
influences,1663,O
eryptosis,1663,O
.,1663,O
According,1664,O
to,1664,O
annexin,1664,B-GeneOrGeneProduct
V,1664,I-GeneOrGeneProduct
binding,1664,O
",",1664,O
erythrocytes,1664,O
from,1664,O
patients,1664,B-OrganismTaxon
indeed,1664,O
showed,1664,O
a,1664,O
significant,1664,O
increase,1664,O
of,1664,O
PS,1664,B-ChemicalEntity
exposure,1664,O
within,1664,O
1,1664,O
week,1664,O
of,1664,O
treatment,1664,O
with,1664,O
azathioprine,1664,B-ChemicalEntity
.,1664,O
In,1665,O
a,1665,O
second,1665,O
series,1665,O
",",1665,O
cytosolic,1665,O
Ca2+,1665,B-ChemicalEntity
activity,1665,O
(,1665,O
Fluo3,1665,B-ChemicalEntity
fluorescence,1665,O
),1665,O
",",1665,O
cell,1665,O
volume,1665,O
(,1665,O
forward,1665,O
scatter,1665,O
),1665,O
",",1665,O
and,1665,O
PS-exposure,1665,B-ChemicalEntity
(,1665,O
annexin,1665,B-GeneOrGeneProduct
V,1665,I-GeneOrGeneProduct
binding,1665,O
),1665,O
were,1665,O
determined,1665,O
by,1665,O
FACS,1665,O
analysis,1665,O
in,1665,O
erythrocytes,1665,O
from,1665,O
healthy,1665,O
volunteers,1665,O
.,1665,O
RESULTS,1666,O
:,1666,O
Exposure,1666,O
to,1666,O
azathioprine,1666,B-ChemicalEntity
(,1666,O
>,1666,O
or,1666,O
=2,1666,O
microg/mL,1666,O
),1666,O
for,1666,O
48,1666,O
hours,1666,O
increased,1666,O
cytosolic,1666,O
Ca2+,1666,B-ChemicalEntity
activity,1666,O
and,1666,O
annexin,1666,B-GeneOrGeneProduct
V,1666,I-GeneOrGeneProduct
binding,1666,O
and,1666,O
decreased,1666,O
forward,1666,O
scatter,1666,O
.,1666,O
The,1667,O
effect,1667,O
of,1667,O
azathioprine,1667,B-ChemicalEntity
on,1667,O
both,1667,O
annexin,1667,B-GeneOrGeneProduct
V,1667,I-GeneOrGeneProduct
binding,1667,O
and,1667,O
forward,1667,O
scatter,1667,O
was,1667,O
significantly,1667,O
blunted,1667,O
in,1667,O
the,1667,O
nominal,1667,O
absence,1667,O
of,1667,O
extracellular,1667,O
Ca2+,1667,B-ChemicalEntity
.,1667,O
CONCLUSIONS,1668,O
:,1668,O
Azathioprine,1668,B-ChemicalEntity
triggers,1668,O
suicidal,1668,O
erythrocyte,1668,O
death,1668,O
",",1668,O
an,1668,O
effect,1668,O
presumably,1668,O
contributing,1668,O
to,1668,O
azathioprine-induced,1668,B-ChemicalEntity
anemia,1668,B-DiseaseOrPhenotypicFeature
.,1668,O
An,1669,O
evaluation,1669,O
of,1669,O
amikacin,1669,B-ChemicalEntity
nephrotoxicity,1669,B-DiseaseOrPhenotypicFeature
in,1669,O
the,1669,O
hematology/oncology,1669,O
population,1669,O
.,1669,O
Amikacin,1670,B-ChemicalEntity
is,1670,O
an,1670,O
aminoglycoside,1670,B-ChemicalEntity
commonly,1670,O
used,1670,O
to,1670,O
provide,1670,O
empirical,1670,O
double,1670,O
gram-negative,1670,O
treatment,1670,O
for,1670,O
febrile,1670,B-DiseaseOrPhenotypicFeature
neutropenia,1670,I-DiseaseOrPhenotypicFeature
and,1670,O
other,1670,O
suspected,1670,O
infections,1670,B-DiseaseOrPhenotypicFeature
.,1670,O
Strategies,1671,O
of,1671,O
extended-interval,1671,O
and,1671,O
conventional,1671,O
dosing,1671,O
have,1671,O
been,1671,O
utilized,1671,O
extensively,1671,O
in,1671,O
the,1671,O
general,1671,O
medical,1671,O
population,1671,O
;,1671,O
however,1671,O
",",1671,O
data,1671,O
are,1671,O
lacking,1671,O
to,1671,O
support,1671,O
a,1671,O
dosing,1671,O
strategy,1671,O
in,1671,O
the,1671,O
hematology/oncology,1671,O
population,1671,O
.,1671,O
To,1672,O
evaluate,1672,O
amikacin-associated,1672,B-ChemicalEntity
nephrotoxicity,1672,B-DiseaseOrPhenotypicFeature
in,1672,O
an,1672,O
adult,1672,O
hematology/oncology,1672,O
population,1672,O
",",1672,O
a,1672,O
prospective,1672,O
",",1672,O
randomized,1672,O
",",1672,O
open-label,1672,O
trial,1672,O
was,1672,O
conducted,1672,O
at,1672,O
a,1672,O
university-affiliated,1672,O
medical,1672,O
center,1672,O
.,1672,O
Forty,1673,O
patients,1673,B-OrganismTaxon
with,1673,O
a,1673,O
diagnosis,1673,O
consistent,1673,O
with,1673,O
a,1673,O
hematologic/oncologic,1673,B-DiseaseOrPhenotypicFeature
disorder,1673,I-DiseaseOrPhenotypicFeature
that,1673,O
required,1673,O
treatment,1673,O
with,1673,O
an,1673,O
aminoglycoside,1673,B-ChemicalEntity
were,1673,O
randomized,1673,O
to,1673,O
either,1673,O
conventional,1673,O
or,1673,O
extended-interval,1673,O
amikacin,1673,B-ChemicalEntity
.,1673,O
The,1674,O
occurrence,1674,O
of,1674,O
nephrotoxicity,1674,B-DiseaseOrPhenotypicFeature
by,1674,O
means,1674,O
of,1674,O
an,1674,O
increase,1674,O
in,1674,O
serum,1674,O
creatinine,1674,B-ChemicalEntity
and,1674,O
evaluation,1674,O
of,1674,O
efficacy,1674,O
via,1674,O
amikacin,1674,B-ChemicalEntity
serum,1674,O
concentrations,1674,O
with,1674,O
respective,1674,O
pathogens,1674,O
were,1674,O
assessed,1674,O
.,1674,O
The,1675,O
occurrence,1675,O
of,1675,O
nephrotoxicity,1675,B-DiseaseOrPhenotypicFeature
was,1675,O
similar,1675,O
between,1675,O
the,1675,O
conventional,1675,O
and,1675,O
extended-interval,1675,O
groups,1675,O
",",1675,O
at,1675,O
10,1675,O
%,1675,O
and,1675,O
5,1675,O
%,1675,O
",",1675,O
respectively,1675,O
(,1675,O
P,1675,O
=,1675,O
1.00,1675,O
),1675,O
.,1675,O
Six,1676,O
patients,1676,B-OrganismTaxon
in,1676,O
the,1676,O
conventional,1676,O
group,1676,O
had,1676,O
a,1676,O
positive,1676,O
culture,1676,O
",",1676,O
compared,1676,O
with,1676,O
none,1676,O
in,1676,O
the,1676,O
extended-interval,1676,O
group,1676,O
(,1676,O
P,1676,O
=,1676,O
0.002,1676,O
),1676,O
.,1676,O
The,1677,O
occurrence,1677,O
of,1677,O
nephrotoxicity,1677,B-DiseaseOrPhenotypicFeature
was,1677,O
similar,1677,O
between,1677,O
the,1677,O
two,1677,O
dosing,1677,O
regimens,1677,O
",",1677,O
but,1677,O
the,1677,O
distribution,1677,O
of,1677,O
risk,1677,O
factors,1677,O
was,1677,O
variable,1677,O
between,1677,O
the,1677,O
two,1677,O
groups,1677,O
.,1677,O
Efficacy,1678,O
could,1678,O
not,1678,O
be,1678,O
assessed,1678,O
.,1678,O
The,1679,O
FH,1679,B-GeneOrGeneProduct
mutation,1679,O
database,1679,O
:,1679,O
an,1679,O
online,1679,O
database,1679,O
of,1679,O
fumarate,1679,B-GeneOrGeneProduct
hydratase,1679,I-GeneOrGeneProduct
mutations,1679,O
involved,1679,O
in,1679,O
the,1679,O
MCUL,1679,B-DiseaseOrPhenotypicFeature
(,1679,O
HLRCC,1679,B-DiseaseOrPhenotypicFeature
),1679,O
tumor,1679,B-DiseaseOrPhenotypicFeature
syndrome,1679,I-DiseaseOrPhenotypicFeature
and,1679,O
congenital,1679,O
fumarase,1679,B-DiseaseOrPhenotypicFeature
deficiency,1679,I-DiseaseOrPhenotypicFeature
.,1679,O
BACKGROUND,1680,O
:,1680,O
Fumarate,1680,B-GeneOrGeneProduct
hydratase,1680,I-GeneOrGeneProduct
(,1680,O
HGNC,1680,O
approved,1680,O
gene,1680,O
symbol,1680,O
-,1680,O
FH,1680,B-GeneOrGeneProduct
),1680,O
",",1680,O
also,1680,O
known,1680,O
as,1680,O
fumarase,1680,B-GeneOrGeneProduct
",",1680,O
is,1680,O
an,1680,O
enzyme,1680,O
of,1680,O
the,1680,O
tricarboxylic,1680,B-ChemicalEntity
acid,1680,I-ChemicalEntity
(,1680,O
TCA,1680,B-ChemicalEntity
),1680,O
cycle,1680,O
",",1680,O
involved,1680,O
in,1680,O
fundamental,1680,O
cellular,1680,O
energy,1680,O
production,1680,O
.,1680,O
First,1681,O
described,1681,O
by,1681,O
Zinn,1681,O
et,1681,O
al,1681,O
in,1681,O
1986,1681,O
",",1681,O
deficiency,1681,B-DiseaseOrPhenotypicFeature
of,1681,I-DiseaseOrPhenotypicFeature
FH,1681,I-DiseaseOrPhenotypicFeature
results,1681,O
in,1681,O
early,1681,O
onset,1681,O
",",1681,O
severe,1681,O
encephalopathy,1681,B-DiseaseOrPhenotypicFeature
.,1681,O
In,1682,O
2002,1682,O
",",1682,O
the,1682,O
Multiple,1682,O
Leiomyoma,1682,B-DiseaseOrPhenotypicFeature
Consortium,1682,O
identified,1682,O
heterozygous,1682,O
germline,1682,O
mutations,1682,O
of,1682,O
FH,1682,B-GeneOrGeneProduct
in,1682,O
patients,1682,B-OrganismTaxon
with,1682,O
multiple,1682,B-DiseaseOrPhenotypicFeature
cutaneous,1682,I-DiseaseOrPhenotypicFeature
and,1682,I-DiseaseOrPhenotypicFeature
uterine,1682,I-DiseaseOrPhenotypicFeature
leiomyomas,1682,I-DiseaseOrPhenotypicFeature
",",1682,O
(,1682,O
MCUL,1682,B-DiseaseOrPhenotypicFeature
:,1682,O
OMIM,1682,B-DiseaseOrPhenotypicFeature
150800,1682,I-DiseaseOrPhenotypicFeature
),1682,O
.,1682,O
In,1683,O
some,1683,O
families,1683,O
renal,1683,B-DiseaseOrPhenotypicFeature
cell,1683,I-DiseaseOrPhenotypicFeature
cancer,1683,I-DiseaseOrPhenotypicFeature
also,1683,O
forms,1683,O
a,1683,O
component,1683,O
of,1683,O
the,1683,O
complex,1683,O
and,1683,O
as,1683,O
such,1683,O
has,1683,O
been,1683,O
described,1683,O
as,1683,O
hereditary,1683,B-DiseaseOrPhenotypicFeature
leiomyomatosis,1683,I-DiseaseOrPhenotypicFeature
and,1683,I-DiseaseOrPhenotypicFeature
renal,1683,I-DiseaseOrPhenotypicFeature
cell,1683,I-DiseaseOrPhenotypicFeature
cancer,1683,I-DiseaseOrPhenotypicFeature
(,1683,O
HLRCC,1683,B-DiseaseOrPhenotypicFeature
:,1683,O
OMIM,1683,B-DiseaseOrPhenotypicFeature
605839,1683,I-DiseaseOrPhenotypicFeature
),1683,O
.,1683,O
The,1684,O
identification,1684,O
of,1684,O
FH,1684,B-GeneOrGeneProduct
as,1684,O
a,1684,O
tumor,1684,B-DiseaseOrPhenotypicFeature
suppressor,1684,O
was,1684,O
an,1684,O
unexpected,1684,O
finding,1684,O
and,1684,O
following,1684,O
the,1684,O
identification,1684,O
of,1684,O
subunits,1684,O
of,1684,O
succinate,1684,O
dehydrogenase,1684,O
in,1684,O
2000,1684,O
and,1684,O
2001,1684,O
",",1684,O
was,1684,O
only,1684,O
the,1684,O
second,1684,O
description,1684,O
of,1684,O
the,1684,O
involvement,1684,O
of,1684,O
an,1684,O
enzyme,1684,O
of,1684,O
intermediary,1684,O
metabolism,1684,O
in,1684,O
tumorigenesis,1684,B-DiseaseOrPhenotypicFeature
.,1684,O
DESCRIPTION,1685,O
:,1685,O
The,1685,O
FH,1685,B-GeneOrGeneProduct
mutation,1685,O
database,1685,O
is,1685,O
a,1685,O
part,1685,O
of,1685,O
the,1685,O
TCA,1685,B-ChemicalEntity
cycle,1685,O
gene,1685,O
mutation,1685,O
database,1685,O
(,1685,O
formerly,1685,O
the,1685,O
succinate,1685,O
dehydrogenase,1685,O
gene,1685,O
mutation,1685,O
database,1685,O
),1685,O
and,1685,O
is,1685,O
based,1685,O
on,1685,O
the,1685,O
Leiden,1685,O
Open,1685,O
(,1685,O
source,1685,O
),1685,O
Variation,1685,O
Database,1685,O
(,1685,O
LOVD,1685,O
),1685,O
system,1685,O
.,1685,O
The,1686,O
variants,1686,O
included,1686,O
in,1686,O
the,1686,O
database,1686,O
were,1686,O
derived,1686,O
from,1686,O
the,1686,O
published,1686,O
literature,1686,O
and,1686,O
annotated,1686,O
to,1686,O
conform,1686,O
to,1686,O
current,1686,O
mutation,1686,O
nomenclature,1686,O
.,1686,O
The,1687,O
FH,1687,B-GeneOrGeneProduct
database,1687,O
applies,1687,O
HGVS,1687,O
nomenclature,1687,O
guidelines,1687,O
",",1687,O
and,1687,O
will,1687,O
assist,1687,O
researchers,1687,O
in,1687,O
applying,1687,O
these,1687,O
guidelines,1687,O
when,1687,O
directly,1687,O
submitting,1687,O
new,1687,O
sequence,1687,O
variants,1687,O
online,1687,O
.,1687,O
Since,1688,O
the,1688,O
first,1688,O
molecular,1688,O
characterization,1688,O
of,1688,O
an,1688,O
FH,1688,B-GeneOrGeneProduct
mutation,1688,O
by,1688,O
Bourgeron,1688,O
et,1688,O
al,1688,O
in,1688,O
1994,1688,O
",",1688,O
a,1688,O
series,1688,O
of,1688,O
reports,1688,O
of,1688,O
both,1688,O
FH,1688,B-DiseaseOrPhenotypicFeature
deficiency,1688,I-DiseaseOrPhenotypicFeature
patients,1688,B-OrganismTaxon
and,1688,O
patients,1688,B-OrganismTaxon
with,1688,O
MCUL/HLRRC,1688,B-DiseaseOrPhenotypicFeature
have,1688,O
described,1688,O
107,1688,O
variants,1688,O
",",1688,O
of,1688,O
which,1688,O
93,1688,O
are,1688,O
thought,1688,O
to,1688,O
be,1688,O
pathogenic,1688,O
.,1688,O
The,1689,O
most,1689,O
common,1689,O
type,1689,O
of,1689,O
mutation,1689,O
is,1689,O
missense,1689,O
(,1689,O
57,1689,O
%,1689,O
),1689,O
",",1689,O
followed,1689,O
by,1689,O
frameshifts,1689,O
&,1689,O
nonsense,1689,O
(,1689,O
27,1689,O
%,1689,O
),1689,O
",",1689,O
and,1689,O
diverse,1689,O
deletions,1689,O
",",1689,O
insertions,1689,O
and,1689,O
duplications,1689,O
.,1689,O
Here,1690,O
we,1690,O
introduce,1690,O
an,1690,O
online,1690,O
database,1690,O
detailing,1690,O
all,1690,O
reported,1690,O
FH,1690,B-GeneOrGeneProduct
sequence,1690,O
variants,1690,O
.,1690,O
CONCLUSION,1691,O
:,1691,O
The,1691,O
FH,1691,B-GeneOrGeneProduct
mutation,1691,O
database,1691,O
strives,1691,O
to,1691,O
systematically,1691,O
unify,1691,O
all,1691,O
current,1691,O
genetic,1691,O
knowledge,1691,O
of,1691,O
FH,1691,B-GeneOrGeneProduct
variants,1691,O
.,1691,O
We,1692,O
believe,1692,O
that,1692,O
this,1692,O
knowledge,1692,O
will,1692,O
assist,1692,O
clinical,1692,O
geneticists,1692,O
and,1692,O
treating,1692,O
physicians,1692,O
when,1692,O
advising,1692,O
patients,1692,B-OrganismTaxon
and,1692,O
their,1692,O
families,1692,O
",",1692,O
will,1692,O
provide,1692,O
a,1692,O
rapid,1692,O
and,1692,O
convenient,1692,O
resource,1692,O
for,1692,O
research,1692,O
scientists,1692,O
",",1692,O
and,1692,O
may,1692,O
eventually,1692,O
assist,1692,O
in,1692,O
gaining,1692,O
novel,1692,O
insights,1692,O
into,1692,O
FH,1692,B-GeneOrGeneProduct
and,1692,O
its,1692,O
related,1692,O
clinical,1692,O
syndromes,1692,O
.,1692,O
L1503R,1693,B-SequenceVariant
is,1693,O
a,1693,O
member,1693,O
of,1693,O
group,1693,O
I,1693,O
mutation,1693,O
and,1693,O
has,1693,O
dominant-negative,1693,O
effect,1693,O
on,1693,O
secretion,1693,O
of,1693,O
full-length,1693,O
VWF,1693,B-GeneOrGeneProduct
multimers,1693,O
:,1693,O
an,1693,O
analysis,1693,O
of,1693,O
two,1693,O
patients,1693,B-OrganismTaxon
with,1693,O
type,1693,B-DiseaseOrPhenotypicFeature
2A,1693,I-DiseaseOrPhenotypicFeature
von,1693,I-DiseaseOrPhenotypicFeature
Willebrand,1693,I-DiseaseOrPhenotypicFeature
disease,1693,I-DiseaseOrPhenotypicFeature
.,1693,O
Type,1694,B-DiseaseOrPhenotypicFeature
2A,1694,I-DiseaseOrPhenotypicFeature
von,1694,I-DiseaseOrPhenotypicFeature
Willebrand,1694,I-DiseaseOrPhenotypicFeature
disease,1694,I-DiseaseOrPhenotypicFeature
(,1694,O
VWD,1694,B-DiseaseOrPhenotypicFeature
),1694,O
is,1694,O
characterized,1694,O
by,1694,O
decreased,1694,O
platelet-dependent,1694,O
function,1694,O
of,1694,O
von,1694,B-GeneOrGeneProduct
Willebrand,1694,I-GeneOrGeneProduct
factor,1694,I-GeneOrGeneProduct
(,1694,O
VWF,1694,B-GeneOrGeneProduct
),1694,O
;,1694,O
this,1694,O
in,1694,O
turn,1694,O
is,1694,O
associated,1694,O
with,1694,O
an,1694,O
absence,1694,O
of,1694,O
high-molecular-weight,1694,O
multimers,1694,O
.,1694,O
Sequence,1695,O
analysis,1695,O
of,1695,O
the,1695,O
VWF,1695,B-GeneOrGeneProduct
gene,1695,O
from,1695,O
two,1695,O
unrelated,1695,O
type,1695,B-DiseaseOrPhenotypicFeature
2A,1695,I-DiseaseOrPhenotypicFeature
VWD,1695,I-DiseaseOrPhenotypicFeature
patients,1695,B-OrganismTaxon
showed,1695,O
an,1695,O
identical,1695,O
",",1695,O
novel,1695,O
",",1695,O
heterozygous,1695,O
T,1695,B-SequenceVariant
--,1695,I-SequenceVariant
>,1695,I-SequenceVariant
G,1695,I-SequenceVariant
transversion,1695,I-SequenceVariant
at,1695,I-SequenceVariant
nucleotide,1695,I-SequenceVariant
4508,1695,I-SequenceVariant
",",1695,O
resulting,1695,O
in,1695,O
the,1695,O
substitution,1695,O
of,1695,O
L1503R,1695,B-SequenceVariant
in,1695,O
the,1695,O
VWF,1695,B-GeneOrGeneProduct
A2,1695,O
domain,1695,O
.,1695,O
This,1696,O
substitution,1696,O
",",1696,O
which,1696,O
was,1696,O
not,1696,O
found,1696,O
in,1696,O
60,1696,O
unrelated,1696,O
normal,1696,O
individuals,1696,O
",",1696,O
was,1696,O
introduced,1696,O
into,1696,O
a,1696,O
full-length,1696,O
VWF,1696,B-GeneOrGeneProduct
cDNA,1696,O
and,1696,O
subsequently,1696,O
expressed,1696,O
in,1696,O
293T,1696,B-CellLine
cells,1696,O
.,1696,O
Only,1697,O
trace,1697,O
amount,1697,O
of,1697,O
the,1697,O
mutant,1697,O
VWF,1697,B-GeneOrGeneProduct
protein,1697,O
was,1697,O
secreted,1697,O
but,1697,O
most,1697,O
of,1697,O
the,1697,O
same,1697,O
was,1697,O
retained,1697,O
in,1697,O
293T,1697,B-CellLine
cells,1697,O
.,1697,O
Co-transfection,1698,O
experiment,1698,O
of,1698,O
both,1698,O
wild-type,1698,O
and,1698,O
mutant,1698,O
plasmids,1698,O
indicated,1698,O
the,1698,O
dominant-negative,1698,O
mechanism,1698,O
of,1698,O
disease,1698,O
development,1698,O
;,1698,O
as,1698,O
more,1698,O
of,1698,O
mutant,1698,O
DNA,1698,O
was,1698,O
transfected,1698,O
",",1698,O
VWF,1698,B-GeneOrGeneProduct
secretion,1698,O
was,1698,O
impaired,1698,O
in,1698,O
the,1698,O
media,1698,O
",",1698,O
whereas,1698,O
more,1698,O
of,1698,O
VWF,1698,B-GeneOrGeneProduct
was,1698,O
stored,1698,O
in,1698,O
the,1698,O
cell,1698,O
lysates,1698,O
.,1698,O
Molecular,1699,O
dynamic,1699,O
simulations,1699,O
of,1699,O
structural,1699,O
changes,1699,O
induced,1699,O
by,1699,O
L1503R,1699,B-SequenceVariant
indicated,1699,O
that,1699,O
the,1699,O
mean,1699,O
value,1699,O
of,1699,O
all-atom,1699,O
root-mean-squared-deviation,1699,O
was,1699,O
shifted,1699,O
from,1699,O
those,1699,O
with,1699,O
wild,1699,O
type,1699,O
or,1699,O
another,1699,O
mutation,1699,O
L1503Q,1699,B-SequenceVariant
that,1699,O
has,1699,O
been,1699,O
reported,1699,O
to,1699,O
be,1699,O
a,1699,O
group,1699,O
II,1699,O
mutation,1699,O
",",1699,O
which,1699,O
is,1699,O
susceptible,1699,O
to,1699,O
ADAMTS13,1699,B-GeneOrGeneProduct
proteolysis,1699,O
.,1699,O
Protein,1700,O
instability,1700,O
of,1700,O
L1503R,1700,B-SequenceVariant
may,1700,O
be,1700,O
responsible,1700,O
for,1700,O
its,1700,O
intracellular,1700,O
retention,1700,O
and,1700,O
perhaps,1700,O
the,1700,O
larger,1700,O
VWF,1700,B-GeneOrGeneProduct
multimers,1700,O
",",1700,O
containing,1700,O
more,1700,O
mutant,1700,O
VWF,1700,B-GeneOrGeneProduct
subunits,1700,O
",",1700,O
are,1700,O
likely,1700,O
to,1700,O
be,1700,O
mal-processed,1700,O
and,1700,O
retained,1700,O
within,1700,O
the,1700,O
cell,1700,O
.,1700,O
A,1701,O
single,1701,O
nucleotide,1701,O
polymorphism,1701,O
in,1701,O
the,1701,O
IRF5,1701,B-GeneOrGeneProduct
promoter,1701,O
region,1701,O
is,1701,O
associated,1701,O
with,1701,O
susceptibility,1701,O
to,1701,O
rheumatoid,1701,B-DiseaseOrPhenotypicFeature
arthritis,1701,I-DiseaseOrPhenotypicFeature
in,1701,O
the,1701,O
Japanese,1701,O
population,1701,O
.,1701,O
OBJECTIVES,1702,O
:,1702,O
Interferon,1702,B-GeneOrGeneProduct
regulatory,1702,I-GeneOrGeneProduct
factor,1702,I-GeneOrGeneProduct
5,1702,I-GeneOrGeneProduct
(,1702,O
IRF5,1702,B-GeneOrGeneProduct
),1702,O
is,1702,O
a,1702,O
member,1702,O
of,1702,O
the,1702,O
IRF,1702,B-GeneOrGeneProduct
family,1702,O
of,1702,O
transcription,1702,O
factors,1702,O
",",1702,O
which,1702,O
regulate,1702,O
the,1702,O
production,1702,O
of,1702,O
proinflammatory,1702,B-GeneOrGeneProduct
cytokines,1702,I-GeneOrGeneProduct
.,1702,O
Polymorphisms,1703,O
in,1703,O
the,1703,O
IRF5,1703,B-GeneOrGeneProduct
gene,1703,O
have,1703,O
been,1703,O
associated,1703,O
with,1703,O
susceptibility,1703,O
to,1703,O
systemic,1703,B-DiseaseOrPhenotypicFeature
lupus,1703,I-DiseaseOrPhenotypicFeature
erythaematosus,1703,I-DiseaseOrPhenotypicFeature
(,1703,O
SLE,1703,B-DiseaseOrPhenotypicFeature
),1703,O
in,1703,O
Caucasian,1703,O
and,1703,O
Asian,1703,O
populations,1703,O
",",1703,O
but,1703,O
their,1703,O
involvement,1703,O
in,1703,O
other,1703,O
autoimmune,1703,B-DiseaseOrPhenotypicFeature
diseases,1703,I-DiseaseOrPhenotypicFeature
is,1703,O
still,1703,O
uncertain,1703,O
.,1703,O
Here,1704,O
",",1704,O
we,1704,O
assessed,1704,O
the,1704,O
genetic,1704,O
role,1704,O
of,1704,O
IRF5,1704,B-GeneOrGeneProduct
in,1704,O
susceptibility,1704,O
to,1704,O
rheumatoid,1704,B-DiseaseOrPhenotypicFeature
arthritis,1704,I-DiseaseOrPhenotypicFeature
(,1704,O
RA,1704,B-DiseaseOrPhenotypicFeature
),1704,O
in,1704,O
Japanese,1704,O
subjects,1704,O
.,1704,O
METHODS,1705,O
:,1705,O
We,1705,O
selected,1705,O
13,1705,O
single,1705,O
nucleotide,1705,O
polymorphisms,1705,O
(,1705,O
SNPs,1705,O
),1705,O
and,1705,O
a,1705,O
CGGGG,1705,O
insertion-deletion,1705,O
polymorphism,1705,O
in,1705,O
the,1705,O
IRF5,1705,B-GeneOrGeneProduct
gene,1705,O
.,1705,O
We,1706,O
performed,1706,O
2,1706,O
sets,1706,O
of,1706,O
case-control,1706,O
comparisons,1706,O
using,1706,O
Japanese,1706,O
subjects,1706,O
(,1706,O
first,1706,O
set,1706,O
:,1706,O
830,1706,O
patients,1706,B-OrganismTaxon
with,1706,O
RA,1706,B-DiseaseOrPhenotypicFeature
and,1706,O
658,1706,O
controls,1706,O
;,1706,O
second,1706,O
set,1706,O
:,1706,O
1112,1706,O
patients,1706,B-OrganismTaxon
with,1706,O
RA,1706,B-DiseaseOrPhenotypicFeature
and,1706,O
940,1706,O
controls,1706,O
),1706,O
",",1706,O
and,1706,O
then,1706,O
performed,1706,O
a,1706,O
stratified,1706,O
analysis,1706,O
using,1706,O
human,1706,B-OrganismTaxon
leukocyte,1706,B-GeneOrGeneProduct
antigen,1706,I-GeneOrGeneProduct
(,1706,I-GeneOrGeneProduct
HLA,1706,I-GeneOrGeneProduct
),1706,I-GeneOrGeneProduct
-DRB1,1706,I-GeneOrGeneProduct
shared,1706,O
epitope,1706,O
(,1706,O
SE,1706,O
),1706,O
status,1706,O
.,1706,O
We,1707,O
genotyped,1707,O
the,1707,O
SNPs,1707,O
using,1707,O
TaqMan,1707,O
assays,1707,O
.,1707,O
RESULTS,1708,O
:,1708,O
A,1708,O
significant,1708,O
association,1708,O
of,1708,O
the,1708,O
rs729302,1708,B-SequenceVariant
A,1708,O
allele,1708,O
with,1708,O
RA,1708,B-DiseaseOrPhenotypicFeature
susceptibility,1708,O
was,1708,O
found,1708,O
in,1708,O
both,1708,O
sets,1708,O
(,1708,O
odds,1708,O
ratio,1708,O
(,1708,O
OR,1708,O
),1708,O
1.22,1708,O
",",1708,O
95,1708,O
%,1708,O
CI,1708,O
1.09,1708,O
to,1708,O
1.35,1708,O
",",1708,O
p,1708,O
<,1708,O
0.001,1708,O
in,1708,O
the,1708,O
combined,1708,O
analysis,1708,O
),1708,O
.,1708,O
When,1709,O
the,1709,O
patients,1709,B-OrganismTaxon
were,1709,O
stratified,1709,O
by,1709,O
the,1709,O
SE,1709,O
",",1709,O
the,1709,O
rs729302,1709,B-SequenceVariant
A,1709,O
allele,1709,O
was,1709,O
found,1709,O
to,1709,O
confer,1709,O
increased,1709,O
risk,1709,O
to,1709,O
RA,1709,B-DiseaseOrPhenotypicFeature
in,1709,O
patients,1709,B-OrganismTaxon
that,1709,O
were,1709,O
SE,1709,O
negative,1709,O
(,1709,O
OR,1709,O
1.50,1709,O
",",1709,O
95,1709,O
%,1709,O
CI,1709,O
1.17,1709,O
to,1709,O
1.92,1709,O
",",1709,O
p,1709,O
=,1709,O
0.001,1709,O
),1709,O
as,1709,O
compared,1709,O
with,1709,O
patients,1709,B-OrganismTaxon
carrying,1709,O
the,1709,O
SE,1709,O
(,1709,O
OR,1709,O
1.11,1709,O
",",1709,O
95,1709,O
%,1709,O
CI,1709,O
0.93,1709,O
to,1709,O
1.33,1709,O
",",1709,O
p,1709,O
=,1709,O
0.24,1709,O
),1709,O
.,1709,O
In,1710,O
both,1710,O
sets,1710,O
",",1710,O
no,1710,O
genotyped,1710,O
polymorphisms,1710,O
were,1710,O
significantly,1710,O
associated,1710,O
with,1710,O
RA,1710,B-DiseaseOrPhenotypicFeature
susceptibility,1710,O
",",1710,O
but,1710,O
rs729302,1710,B-SequenceVariant
was,1710,O
significantly,1710,O
associated,1710,O
.,1710,O
CONCLUSIONS,1711,O
:,1711,O
These,1711,O
findings,1711,O
indicate,1711,O
that,1711,O
the,1711,O
promoter,1711,O
polymorphism,1711,O
of,1711,O
IRF5,1711,B-GeneOrGeneProduct
is,1711,O
a,1711,O
genetic,1711,O
factor,1711,O
conferring,1711,O
predisposition,1711,O
to,1711,O
RA,1711,B-DiseaseOrPhenotypicFeature
",",1711,O
and,1711,O
that,1711,O
it,1711,O
contributes,1711,O
considerably,1711,O
to,1711,O
disease,1711,O
pathogenesis,1711,O
in,1711,O
patients,1711,B-OrganismTaxon
that,1711,O
were,1711,O
SE,1711,O
negative,1711,O
.,1711,O
Methamphetamine-induced,1712,B-ChemicalEntity
neurotoxicity,1712,B-DiseaseOrPhenotypicFeature
and,1712,O
microglial,1712,O
activation,1712,O
are,1712,O
not,1712,O
mediated,1712,O
by,1712,O
fractalkine,1712,B-GeneOrGeneProduct
receptor,1712,I-GeneOrGeneProduct
signaling,1712,O
.,1712,O
Methamphetamine,1713,B-ChemicalEntity
(,1713,O
METH,1713,B-ChemicalEntity
),1713,O
damages,1713,O
dopamine,1713,B-ChemicalEntity
(,1713,O
DA,1713,B-ChemicalEntity
),1713,O
nerve,1713,O
endings,1713,O
by,1713,O
a,1713,O
process,1713,O
that,1713,O
has,1713,O
been,1713,O
linked,1713,O
to,1713,O
microglial,1713,O
activation,1713,O
but,1713,O
the,1713,O
signaling,1713,O
pathways,1713,O
that,1713,O
mediate,1713,O
this,1713,O
response,1713,O
have,1713,O
not,1713,O
yet,1713,O
been,1713,O
delineated,1713,O
.,1713,O
Cardona,1714,O
et,1714,O
al,1714,O
.,1714,O
[,1715,O
Nat,1715,O
.,1715,O
Neurosci,1716,O
.,1716,O
9,1717,O
(,1717,O
2006,1717,O
),1717,O
",",1717,O
917,1717,O
],1717,O
recently,1717,O
identified,1717,O
the,1717,O
microglial-specific,1717,O
fractalkine,1717,B-GeneOrGeneProduct
receptor,1717,I-GeneOrGeneProduct
(,1717,O
CX3CR1,1717,B-GeneOrGeneProduct
),1717,O
as,1717,O
an,1717,O
important,1717,O
mediator,1717,O
of,1717,O
MPTP-induced,1717,B-ChemicalEntity
neurodegeneration,1717,B-DiseaseOrPhenotypicFeature
of,1717,O
DA,1717,B-ChemicalEntity
neurons,1717,O
.,1717,O
Because,1718,O
the,1718,O
CNS,1718,B-DiseaseOrPhenotypicFeature
damage,1718,I-DiseaseOrPhenotypicFeature
caused,1718,O
by,1718,O
METH,1718,B-ChemicalEntity
and,1718,O
MPTP,1718,B-ChemicalEntity
is,1718,O
highly,1718,O
selective,1718,O
for,1718,O
the,1718,O
DA,1718,B-ChemicalEntity
neuronal,1718,O
system,1718,O
in,1718,O
mouse,1718,B-OrganismTaxon
models,1718,O
of,1718,O
neurotoxicity,1718,B-DiseaseOrPhenotypicFeature
",",1718,O
we,1718,O
hypothesized,1718,O
that,1718,O
the,1718,O
CX3CR1,1718,B-GeneOrGeneProduct
plays,1718,O
a,1718,O
role,1718,O
in,1718,O
METH-induced,1718,B-ChemicalEntity
neurotoxicity,1718,B-DiseaseOrPhenotypicFeature
and,1718,O
microglial,1718,O
activation,1718,O
.,1718,O
Mice,1719,B-OrganismTaxon
in,1719,O
which,1719,O
the,1719,O
CX3CR1,1719,B-GeneOrGeneProduct
gene,1719,O
has,1719,O
been,1719,O
deleted,1719,O
and,1719,O
replaced,1719,O
with,1719,O
a,1719,O
cDNA,1719,O
encoding,1719,O
enhanced,1719,B-ChemicalEntity
green,1719,I-ChemicalEntity
fluorescent,1719,I-ChemicalEntity
protein,1719,I-ChemicalEntity
(,1719,O
eGFP,1719,B-ChemicalEntity
),1719,O
were,1719,O
treated,1719,O
with,1719,O
METH,1719,B-ChemicalEntity
and,1719,O
examined,1719,O
for,1719,O
striatal,1719,O
neurotoxicity,1719,B-DiseaseOrPhenotypicFeature
.,1719,O
METH,1720,B-ChemicalEntity
depleted,1720,O
DA,1720,B-ChemicalEntity
",",1720,O
caused,1720,O
microglial,1720,O
activation,1720,O
",",1720,O
and,1720,O
increased,1720,O
body,1720,O
temperature,1720,O
in,1720,O
CX3CR1,1720,B-GeneOrGeneProduct
knockout,1720,O
mice,1720,B-OrganismTaxon
to,1720,O
the,1720,O
same,1720,O
extent,1720,O
and,1720,O
over,1720,O
the,1720,O
same,1720,O
time,1720,O
course,1720,O
seen,1720,O
in,1720,O
wild-type,1720,O
controls,1720,O
.,1720,O
The,1721,O
effects,1721,O
of,1721,O
METH,1721,B-ChemicalEntity
in,1721,O
CX3CR1,1721,B-GeneOrGeneProduct
knockout,1721,O
mice,1721,B-OrganismTaxon
were,1721,O
not,1721,O
gender-dependent,1721,O
and,1721,O
did,1721,O
not,1721,O
extend,1721,O
beyond,1721,O
the,1721,O
striatum,1721,O
.,1721,O
Striatal,1722,O
microglia,1722,O
expressing,1722,O
eGFP,1722,B-ChemicalEntity
constitutively,1722,O
show,1722,O
morphological,1722,O
changes,1722,O
after,1722,O
METH,1722,B-ChemicalEntity
that,1722,O
are,1722,O
characteristic,1722,O
of,1722,O
activation,1722,O
.,1722,O
This,1723,O
response,1723,O
was,1723,O
restricted,1723,O
to,1723,O
the,1723,O
striatum,1723,O
and,1723,O
contrasted,1723,O
sharply,1723,O
with,1723,O
unresponsive,1723,O
eGFP-microglia,1723,B-ChemicalEntity
in,1723,O
surrounding,1723,O
brain,1723,O
areas,1723,O
that,1723,O
are,1723,O
not,1723,O
damaged,1723,O
by,1723,O
METH,1723,B-ChemicalEntity
.,1723,O
We,1724,O
conclude,1724,O
from,1724,O
these,1724,O
studies,1724,O
that,1724,O
CX3CR1,1724,B-GeneOrGeneProduct
signaling,1724,O
does,1724,O
not,1724,O
modulate,1724,O
METH,1724,B-ChemicalEntity
neurotoxicity,1724,B-DiseaseOrPhenotypicFeature
or,1724,O
microglial,1724,O
activation,1724,O
.,1724,O
Furthermore,1725,O
",",1725,O
it,1725,O
appears,1725,O
that,1725,O
striatal-resident,1725,O
microglia,1725,O
respond,1725,O
to,1725,O
METH,1725,B-ChemicalEntity
with,1725,O
an,1725,O
activation,1725,O
cascade,1725,O
and,1725,O
then,1725,O
return,1725,O
to,1725,O
a,1725,O
surveying,1725,O
state,1725,O
without,1725,O
undergoing,1725,O
apoptosis,1725,O
or,1725,O
migration,1725,O
.,1725,O
Aryl,1726,B-GeneOrGeneProduct
hydrocarbon,1726,I-GeneOrGeneProduct
receptor,1726,I-GeneOrGeneProduct
interacting,1726,I-GeneOrGeneProduct
protein,1726,I-GeneOrGeneProduct
(,1726,O
AIP,1726,B-GeneOrGeneProduct
),1726,O
gene,1726,O
mutation,1726,O
analysis,1726,O
in,1726,O
children,1726,O
and,1726,O
adolescents,1726,O
with,1726,O
sporadic,1726,O
pituitary,1726,B-DiseaseOrPhenotypicFeature
adenomas,1726,I-DiseaseOrPhenotypicFeature
.,1726,O
OBJECTIVE,1727,O
:,1727,O
Pituitary,1727,B-DiseaseOrPhenotypicFeature
adenomas,1727,I-DiseaseOrPhenotypicFeature
occur,1727,O
rarely,1727,O
in,1727,O
childhood,1727,O
and,1727,O
adolescence,1727,O
.,1727,O
Pituitary,1728,B-DiseaseOrPhenotypicFeature
adenoma,1728,I-DiseaseOrPhenotypicFeature
predisposition,1728,O
(,1728,O
PAP,1728,O
),1728,O
has,1728,O
been,1728,O
recently,1728,O
associated,1728,O
with,1728,O
germline,1728,O
mutations,1728,O
in,1728,O
the,1728,O
aryl,1728,B-GeneOrGeneProduct
hydrocarbon,1728,I-GeneOrGeneProduct
receptor,1728,I-GeneOrGeneProduct
interacting,1728,I-GeneOrGeneProduct
protein,1728,I-GeneOrGeneProduct
(,1728,O
AIP,1728,B-GeneOrGeneProduct
),1728,O
gene,1728,O
.,1728,O
The,1729,O
aim,1729,O
of,1729,O
the,1729,O
study,1729,O
was,1729,O
to,1729,O
examine,1729,O
the,1729,O
proportion,1729,O
of,1729,O
germline,1729,O
AIP,1729,B-GeneOrGeneProduct
mutations,1729,O
in,1729,O
apparently,1729,O
sporadic,1729,O
paediatric,1729,O
pituitary,1729,B-DiseaseOrPhenotypicFeature
adenomas,1729,I-DiseaseOrPhenotypicFeature
.,1729,O
DESIGN,1730,O
:,1730,O
Genomic,1730,O
DNA,1730,O
was,1730,O
analysed,1730,O
for,1730,O
mutations,1730,O
in,1730,O
the,1730,O
AIP,1730,B-GeneOrGeneProduct
gene,1730,O
",",1730,O
by,1730,O
PCR,1730,O
amplification,1730,O
and,1730,O
direct,1730,O
sequencing,1730,O
.,1730,O
PATIENTS,1731,B-OrganismTaxon
:,1731,O
A,1731,O
population-based,1731,O
cohort,1731,O
consisting,1731,O
of,1731,O
36,1731,O
apparently,1731,O
sporadic,1731,O
paediatric,1731,O
pituitary,1731,B-DiseaseOrPhenotypicFeature
adenoma,1731,I-DiseaseOrPhenotypicFeature
patients,1731,B-OrganismTaxon
",",1731,O
referred,1731,O
to,1731,O
two,1731,O
medical,1731,O
centres,1731,O
in,1731,O
Italy,1731,O
",",1731,O
was,1731,O
included,1731,O
in,1731,O
the,1731,O
study,1731,O
.,1731,O
Patients,1732,B-OrganismTaxon
were,1732,O
either,1732,O
less,1732,O
than,1732,O
18,1732,O
years,1732,O
at,1732,O
diagnosis,1732,O
",",1732,O
or,1732,O
showed,1732,O
clinical,1732,O
evidence,1732,O
of,1732,O
adenoma,1732,B-DiseaseOrPhenotypicFeature
development,1732,O
before,1732,O
the,1732,O
age,1732,O
of,1732,O
18,1732,O
years,1732,O
.,1732,O
RESULTS,1733,O
:,1733,O
A,1733,O
heterozygous,1733,O
in-frame,1733,O
deletion,1733,O
Y248del,1733,B-SequenceVariant
(,1733,O
c.742_744delTAC,1733,B-SequenceVariant
),1733,O
was,1733,O
identified,1733,O
in,1733,O
one,1733,O
GH-secreting,1733,B-DiseaseOrPhenotypicFeature
adenoma,1733,I-DiseaseOrPhenotypicFeature
patient,1733,B-OrganismTaxon
.,1733,O
Loss,1734,O
of,1734,O
heterozygosity,1734,O
(,1734,O
LOH,1734,O
),1734,O
analysis,1734,O
of,1734,O
tumour,1734,B-DiseaseOrPhenotypicFeature
DNA,1734,O
revealed,1734,O
the,1734,O
loss,1734,O
of,1734,O
the,1734,O
wild-type,1734,O
allele,1734,O
.,1734,O
First,1735,O
degree,1735,O
relatives,1735,O
carrying,1735,O
the,1735,O
mutation,1735,O
were,1735,O
clinically,1735,O
unaffected,1735,O
.,1735,O
CONCLUSIONS,1736,O
:,1736,O
While,1736,O
mutations,1736,O
were,1736,O
absent,1736,O
in,1736,O
non-GH-secreting,1736,O
adenoma,1736,I-DiseaseOrPhenotypicFeature
patients,1736,B-OrganismTaxon
",",1736,O
germline,1736,O
AIP,1736,B-GeneOrGeneProduct
mutations,1736,O
can,1736,O
be,1736,O
found,1736,O
in,1736,O
children,1736,O
and,1736,O
adolescents,1736,O
with,1736,O
GH-secreting,1736,B-DiseaseOrPhenotypicFeature
tumours,1736,I-DiseaseOrPhenotypicFeature
",",1736,O
even,1736,O
in,1736,O
the,1736,O
absence,1736,O
of,1736,O
family,1736,O
history,1736,O
.,1736,O
The,1737,O
present,1737,O
study,1737,O
reports,1737,O
the,1737,O
AIP,1737,B-GeneOrGeneProduct
mutation,1737,O
analysis,1737,O
results,1737,O
on,1737,O
patients,1737,B-OrganismTaxon
of,1737,O
a,1737,O
single,1737,O
ethnic,1737,O
origin,1737,O
.,1737,O
Clearly,1738,O
",",1738,O
further,1738,O
studies,1738,O
are,1738,O
needed,1738,O
to,1738,O
improve,1738,O
our,1738,O
knowledge,1738,O
on,1738,O
the,1738,O
role,1738,O
of,1738,O
AIP,1738,B-GeneOrGeneProduct
in,1738,O
paediatric,1738,O
pituitary,1738,B-DiseaseOrPhenotypicFeature
adenomas,1738,I-DiseaseOrPhenotypicFeature
.,1738,O
Spectrum,1739,O
of,1739,O
adverse,1739,O
events,1739,O
after,1739,O
generic,1739,O
HAART,1739,O
in,1739,O
southern,1739,O
Indian,1739,O
HIV-infected,1739,B-DiseaseOrPhenotypicFeature
patients,1739,B-OrganismTaxon
.,1739,O
To,1740,O
determine,1740,O
the,1740,O
incidence,1740,O
of,1740,O
clinically,1740,O
significant,1740,O
adverse,1740,O
events,1740,O
after,1740,O
long-term,1740,O
",",1740,O
fixed-dose,1740,O
",",1740,O
generic,1740,O
highly,1740,O
active,1740,O
antiretroviral,1740,O
therapy,1740,O
(,1740,O
HAART,1740,O
),1740,O
use,1740,O
among,1740,O
HIV-infected,1740,B-DiseaseOrPhenotypicFeature
individuals,1740,O
in,1740,O
South,1740,O
India,1740,O
",",1740,O
we,1740,O
examined,1740,O
the,1740,O
experiences,1740,O
of,1740,O
3154,1740,O
HIV-infected,1740,B-DiseaseOrPhenotypicFeature
individuals,1740,O
who,1740,O
received,1740,O
a,1740,O
minimum,1740,O
of,1740,O
3,1740,O
months,1740,O
of,1740,O
generic,1740,O
HAART,1740,O
between,1740,O
February,1740,O
1996,1740,O
and,1740,O
December,1740,O
2006,1740,O
at,1740,O
a,1740,O
tertiary,1740,O
HIV,1740,O
care,1740,O
referral,1740,O
center,1740,O
in,1740,O
South,1740,O
India,1740,O
.,1740,O
The,1741,O
most,1741,O
common,1741,O
regimens,1741,O
were,1741,O
3TC,1741,B-ChemicalEntity
+,1741,O
d4T,1741,B-ChemicalEntity
+,1741,O
nevirapine,1741,B-ChemicalEntity
(,1741,O
NVP,1741,B-ChemicalEntity
),1741,O
(,1741,O
54.8,1741,O
%,1741,O
),1741,O
",",1741,O
zidovudine,1741,B-ChemicalEntity
(,1741,O
AZT,1741,B-ChemicalEntity
),1741,O
+,1741,O
3TC,1741,B-ChemicalEntity
+,1741,O
NVP,1741,B-ChemicalEntity
(,1741,O
14.5,1741,O
%,1741,O
),1741,O
",",1741,O
3TC,1741,B-ChemicalEntity
+,1741,O
d4T,1741,B-ChemicalEntity
+,1741,O
efavirenz,1741,B-ChemicalEntity
(,1741,O
EFV,1741,B-ChemicalEntity
),1741,O
(,1741,O
20.1,1741,O
%,1741,O
),1741,O
",",1741,O
and,1741,O
AZT,1741,B-ChemicalEntity
+,1741,O
3TC,1741,B-ChemicalEntity
+,1741,O
EFV,1741,B-ChemicalEntity
(,1741,O
5.4,1741,O
%,1741,O
),1741,O
.,1741,O
The,1742,O
most,1742,O
common,1742,O
adverse,1742,O
events,1742,O
and,1742,O
median,1742,O
CD4,1742,B-GeneOrGeneProduct
at,1742,O
time,1742,O
of,1742,O
event,1742,O
were,1742,O
rash,1742,B-DiseaseOrPhenotypicFeature
(,1742,O
15.2,1742,O
%,1742,O
;,1742,O
CD4,1742,B-GeneOrGeneProduct
",",1742,O
285,1742,O
cells/microL,1742,O
),1742,O
and,1742,O
peripheral,1742,B-DiseaseOrPhenotypicFeature
neuropathy,1742,I-DiseaseOrPhenotypicFeature
(,1742,O
9.0,1742,O
%,1742,O
and,1742,O
348,1742,O
cells/microL,1742,O
),1742,O
.,1742,O
Clinically,1743,O
significant,1743,O
anemia,1743,B-DiseaseOrPhenotypicFeature
(,1743,O
hemoglobin,1743,B-GeneOrGeneProduct
<,1743,O
7,1743,O
g/dL,1743,O
),1743,O
was,1743,O
observed,1743,O
in,1743,O
5.4,1743,O
%,1743,O
of,1743,O
patients,1743,B-OrganismTaxon
(,1743,O
CD4,1743,B-GeneOrGeneProduct
",",1743,O
165,1743,O
cells/microL,1743,O
),1743,O
and,1743,O
hepatitis,1743,B-DiseaseOrPhenotypicFeature
(,1743,O
clinical,1743,O
jaundice,1743,B-DiseaseOrPhenotypicFeature
with,1743,O
alanine,1743,B-ChemicalEntity
aminotransferase,1743,I-ChemicalEntity
>,1743,O
5,1743,O
times,1743,O
upper,1743,O
limits,1743,O
of,1743,O
normal,1743,O
),1743,O
in,1743,O
3.5,1743,O
%,1743,O
of,1743,O
patients,1743,B-OrganismTaxon
(,1743,O
CD4,1743,B-GeneOrGeneProduct
",",1743,O
260,1743,O
cells/microL,1743,O
),1743,O
.,1743,O
Women,1744,B-OrganismTaxon
were,1744,O
significantly,1744,O
more,1744,O
likely,1744,O
to,1744,O
experience,1744,O
lactic,1744,B-DiseaseOrPhenotypicFeature
acidosis,1744,I-DiseaseOrPhenotypicFeature
",",1744,O
while,1744,O
men,1744,B-OrganismTaxon
were,1744,O
significantly,1744,O
more,1744,O
likely,1744,O
to,1744,O
experience,1744,O
immune,1744,B-DiseaseOrPhenotypicFeature
reconstitution,1744,I-DiseaseOrPhenotypicFeature
syndrome,1744,I-DiseaseOrPhenotypicFeature
(,1744,O
p,1744,O
<,1744,O
0.05,1744,O
),1744,O
.,1744,O
Among,1745,O
the,1745,O
patients,1745,B-OrganismTaxon
with,1745,O
1,1745,O
year,1745,O
of,1745,O
follow-up,1745,O
",",1745,O
NVP,1745,B-ChemicalEntity
therapy,1745,O
was,1745,O
significantly,1745,O
associated,1745,O
with,1745,O
developing,1745,O
rash,1745,B-DiseaseOrPhenotypicFeature
and,1745,O
d4T,1745,B-ChemicalEntity
therapy,1745,O
with,1745,O
developing,1745,O
peripheral,1745,B-DiseaseOrPhenotypicFeature
neuropathy,1745,I-DiseaseOrPhenotypicFeature
(,1745,O
p,1745,O
<,1745,O
0.05,1745,O
),1745,O
.,1745,O
Anemia,1746,B-DiseaseOrPhenotypicFeature
and,1746,O
hepatitis,1746,B-DiseaseOrPhenotypicFeature
often,1746,O
occur,1746,O
within,1746,O
12,1746,O
weeks,1746,O
of,1746,O
initiating,1746,O
generic,1746,O
HAART,1746,O
.,1746,O
Frequent,1747,O
and,1747,O
early,1747,O
monitoring,1747,O
for,1747,O
these,1747,O
toxicities,1747,B-DiseaseOrPhenotypicFeature
is,1747,O
warranted,1747,O
in,1747,O
developing,1747,O
countries,1747,O
where,1747,O
generic,1747,O
HAART,1747,O
is,1747,O
increasingly,1747,O
available,1747,O
.,1747,O
Association,1748,O
between,1748,O
promoter,1748,O
-1607,1748,O
polymorphism,1748,O
of,1748,O
MMP1,1748,B-GeneOrGeneProduct
and,1748,O
lumbar,1748,B-DiseaseOrPhenotypicFeature
disc,1748,I-DiseaseOrPhenotypicFeature
disease,1748,I-DiseaseOrPhenotypicFeature
in,1748,O
Southern,1748,O
Chinese,1748,O
.,1748,O
BACKGROUND,1749,O
:,1749,O
Matrix,1749,B-GeneOrGeneProduct
metalloproteinases,1749,I-GeneOrGeneProduct
(,1749,O
MMPs,1749,B-GeneOrGeneProduct
),1749,O
are,1749,O
involved,1749,O
in,1749,O
the,1749,O
degradation,1749,O
of,1749,O
the,1749,O
extracellular,1749,O
matrix,1749,O
of,1749,O
the,1749,O
intervertebral,1749,O
disc,1749,O
.,1749,O
A,1750,O
SNP,1750,O
for,1750,O
guanine,1750,B-SequenceVariant
insertion/deletion,1750,I-SequenceVariant
(,1750,I-SequenceVariant
G/D,1750,I-SequenceVariant
),1750,I-SequenceVariant
",",1750,I-SequenceVariant
the,1750,I-SequenceVariant
-1607,1750,I-SequenceVariant
promoter,1750,I-SequenceVariant
polymorphism,1750,I-SequenceVariant
",",1750,O
of,1750,O
the,1750,O
MMP1,1750,B-GeneOrGeneProduct
gene,1750,O
was,1750,O
found,1750,O
significantly,1750,O
affecting,1750,O
promoter,1750,O
activity,1750,O
and,1750,O
corresponding,1750,O
transcription,1750,O
level,1750,O
.,1750,O
Hence,1751,O
it,1751,O
is,1751,O
a,1751,O
good,1751,O
candidate,1751,O
for,1751,O
genetic,1751,O
studies,1751,O
in,1751,O
DDD,1751,B-DiseaseOrPhenotypicFeature
.,1751,O
METHODS,1752,O
:,1752,O
Southern,1752,O
Chinese,1752,O
volunteers,1752,O
between,1752,O
18,1752,O
and,1752,O
55,1752,O
years,1752,O
were,1752,O
recruited,1752,O
from,1752,O
the,1752,O
population,1752,O
.,1752,O
DDD,1753,B-DiseaseOrPhenotypicFeature
in,1753,O
the,1753,O
lumbar,1753,O
spine,1753,O
was,1753,O
defined,1753,O
by,1753,O
MRI,1753,O
using,1753,O
Schneiderman,1753,O
's,1753,O
classification,1753,O
.,1753,O
Genomic,1754,O
DNA,1754,O
was,1754,O
isolated,1754,O
from,1754,O
the,1754,O
leukocytes,1754,O
and,1754,O
genotyping,1754,O
was,1754,O
performed,1754,O
using,1754,O
the,1754,O
Sequenom,1754,O
platform,1754,O
.,1754,O
Association,1755,O
and,1755,O
Hardy-Weinberg,1755,O
equilibrium,1755,O
checking,1755,O
were,1755,O
assessed,1755,O
by,1755,O
Chi-square,1755,O
test,1755,O
and,1755,O
Mann-Whitney,1755,O
U,1755,O
test,1755,O
.,1755,O
RESULTS,1756,O
:,1756,O
Our,1756,O
results,1756,O
showed,1756,O
substantial,1756,O
evidence,1756,O
of,1756,O
association,1756,O
between,1756,O
-1607,1756,O
promoter,1756,O
polymorphism,1756,O
of,1756,O
MMP1,1756,B-GeneOrGeneProduct
and,1756,O
DDD,1756,B-DiseaseOrPhenotypicFeature
in,1756,O
the,1756,O
Southern,1756,O
Chinese,1756,O
subjects,1756,O
.,1756,O
D,1757,O
allelic,1757,O
was,1757,O
significantly,1757,O
associated,1757,O
with,1757,O
DDD,1757,B-DiseaseOrPhenotypicFeature
(,1757,O
p,1757,O
value,1757,O
=,1757,O
0.027,1757,O
",",1757,O
odds,1757,O
ratio,1757,O
=,1757,O
1.41,1757,O
with,1757,O
95,1757,O
%,1757,O
CI,1757,O
=,1757,O
1.04-1.90,1757,O
),1757,O
while,1757,O
Genotypic,1757,O
association,1757,O
on,1757,O
the,1757,O
presence,1757,O
of,1757,O
D,1757,O
allele,1757,O
was,1757,O
also,1757,O
significantly,1757,O
associated,1757,O
with,1757,O
DDD,1757,B-DiseaseOrPhenotypicFeature
(,1757,O
p,1757,O
value,1757,O
=,1757,O
0.046,1757,O
",",1757,O
odds,1757,O
ratio,1757,O
=,1757,O
1.50,1757,O
with,1757,O
95,1757,O
%,1757,O
CI,1757,O
=,1757,O
1.01-2.24,1757,O
),1757,O
.,1757,O
Further,1758,O
age,1758,O
stratification,1758,O
showed,1758,O
significant,1758,O
genotypic,1758,O
as,1758,O
well,1758,O
as,1758,O
allelic,1758,O
association,1758,O
in,1758,O
the,1758,O
group,1758,O
of,1758,O
over,1758,O
40,1758,O
years,1758,O
(,1758,O
genotypic,1758,O
:,1758,O
p,1758,O
value,1758,O
=,1758,O
0.035,1758,O
",",1758,O
odds,1758,O
ratio,1758,O
=,1758,O
1.617,1758,O
with,1758,O
95,1758,O
%,1758,O
CI,1758,O
=,1758,O
1.033-2.529,1758,O
;,1758,O
allelic,1758,O
:,1758,O
p,1758,O
value,1758,O
=,1758,O
0.033,1758,O
",",1758,O
odds,1758,O
ratio,1758,O
=,1758,O
1.445,1758,O
with,1758,O
95,1758,O
%,1758,O
CI,1758,O
=,1758,O
1.029-2.029,1758,O
),1758,O
.,1758,O
Disc,1759,O
bulge,1759,O
",",1759,O
annular,1759,O
tears,1759,O
and,1759,O
the,1759,O
Schmorl,1759,O
's,1759,O
nodes,1759,O
were,1759,O
not,1759,O
associated,1759,O
with,1759,O
the,1759,O
D,1759,O
allele,1759,O
.,1759,O
CONCLUSION,1760,O
:,1760,O
We,1760,O
demonstrated,1760,O
that,1760,O
individuals,1760,O
with,1760,O
the,1760,O
presence,1760,O
of,1760,O
D,1760,B-SequenceVariant
allele,1760,I-SequenceVariant
for,1760,I-SequenceVariant
the,1760,I-SequenceVariant
-1607,1760,I-SequenceVariant
promoter,1760,O
polymorphism,1760,O
of,1760,O
MMP1,1760,B-GeneOrGeneProduct
are,1760,O
about,1760,O
1.5,1760,O
times,1760,O
more,1760,O
susceptible,1760,O
to,1760,O
develop,1760,O
DDD,1760,B-DiseaseOrPhenotypicFeature
when,1760,O
compared,1760,O
with,1760,O
those,1760,O
having,1760,O
G,1760,O
allele,1760,O
only,1760,O
.,1760,O
Further,1761,O
association,1761,O
was,1761,O
identified,1761,O
in,1761,O
individuals,1761,O
over,1761,O
40,1761,O
years,1761,O
of,1761,O
age,1761,O
.,1761,O
Disc,1762,O
bulge,1762,O
",",1762,O
annular,1762,O
tear,1762,O
as,1762,O
well,1762,O
as,1762,O
Schmorl,1762,O
's,1762,O
nodes,1762,O
were,1762,O
not,1762,O
associated,1762,O
with,1762,O
this,1762,O
polymorphism,1762,O
.,1762,O
Protective,1763,O
effect,1763,O
of,1763,O
verapamil,1763,B-ChemicalEntity
on,1763,O
gastric,1763,B-DiseaseOrPhenotypicFeature
hemorrhagic,1763,I-DiseaseOrPhenotypicFeature
ulcers,1763,I-DiseaseOrPhenotypicFeature
in,1763,O
severe,1763,O
atherosclerotic,1763,B-DiseaseOrPhenotypicFeature
rats,1763,B-OrganismTaxon
.,1763,O
Studies,1764,O
concerning,1764,O
with,1764,O
pathogenesis,1764,O
of,1764,O
gastric,1764,B-DiseaseOrPhenotypicFeature
hemorrhage,1764,I-DiseaseOrPhenotypicFeature
and,1764,O
mucosal,1764,O
ulceration,1764,O
produced,1764,O
in,1764,O
atherosclerotic,1764,B-DiseaseOrPhenotypicFeature
rats,1764,B-OrganismTaxon
are,1764,O
lacking,1764,O
.,1764,O
The,1765,O
aim,1765,O
of,1765,O
this,1765,O
study,1765,O
is,1765,O
to,1765,O
examine,1765,O
the,1765,O
role,1765,O
of,1765,O
gastric,1765,O
acid,1765,O
back-diffusion,1765,O
",",1765,O
mast,1765,O
cell,1765,O
histamine,1765,B-ChemicalEntity
release,1765,O
",",1765,O
lipid,1765,B-ChemicalEntity
peroxide,1765,I-ChemicalEntity
(,1765,O
LPO,1765,B-ChemicalEntity
),1765,O
generation,1765,O
and,1765,O
mucosal,1765,O
microvascular,1765,O
permeability,1765,O
in,1765,O
modulating,1765,O
gastric,1765,B-DiseaseOrPhenotypicFeature
hemorrhage,1765,I-DiseaseOrPhenotypicFeature
and,1765,I-DiseaseOrPhenotypicFeature
ulcer,1765,I-DiseaseOrPhenotypicFeature
in,1765,O
rats,1765,B-OrganismTaxon
with,1765,O
atherosclerosis,1765,B-DiseaseOrPhenotypicFeature
induced,1765,O
by,1765,O
coadministration,1765,O
of,1765,O
vitamin,1765,B-ChemicalEntity
D2,1765,I-ChemicalEntity
and,1765,O
cholesterol,1765,B-ChemicalEntity
.,1765,O
Additionally,1766,O
",",1766,O
the,1766,O
protective,1766,O
effect,1766,O
of,1766,O
verapamil,1766,B-ChemicalEntity
on,1766,O
this,1766,O
ulcer,1766,B-DiseaseOrPhenotypicFeature
model,1766,O
was,1766,O
evaluated,1766,O
.,1766,O
Male,1767,O
Wistar,1767,O
rats,1767,B-OrganismTaxon
were,1767,O
challenged,1767,O
intragastrically,1767,O
once,1767,O
daily,1767,O
for,1767,O
9,1767,O
days,1767,O
with,1767,O
1.0,1767,O
ml/kg,1767,O
of,1767,O
corn,1767,B-ChemicalEntity
oil,1767,I-ChemicalEntity
containing,1767,O
vitamin,1767,B-ChemicalEntity
D2,1767,I-ChemicalEntity
and,1767,O
cholesterol,1767,B-ChemicalEntity
to,1767,O
induce,1767,O
atherosclerosis,1767,B-DiseaseOrPhenotypicFeature
.,1767,O
Control,1768,O
rats,1768,B-OrganismTaxon
received,1768,O
corn,1768,B-ChemicalEntity
oil,1768,I-ChemicalEntity
only,1768,O
.,1768,O
After,1769,O
gastric,1769,O
surgery,1769,O
",",1769,O
rat,1769,B-OrganismTaxon
stomachs,1769,O
were,1769,O
irrigated,1769,O
for,1769,O
3,1769,O
h,1769,O
with,1769,O
either,1769,O
simulated,1769,O
gastric,1769,O
juice,1769,O
or,1769,O
normal,1769,O
saline,1769,O
.,1769,O
Gastric,1770,O
acid,1770,O
back-diffusion,1770,O
",",1770,O
mucosal,1770,O
LPO,1770,B-ChemicalEntity
generation,1770,O
",",1770,O
histamine,1770,B-ChemicalEntity
concentration,1770,O
",",1770,O
microvascular,1770,O
permeability,1770,O
",",1770,O
luminal,1770,B-ChemicalEntity
hemoglobin,1770,B-GeneOrGeneProduct
content,1770,O
and,1770,O
ulcer,1770,B-DiseaseOrPhenotypicFeature
areas,1770,O
were,1770,O
determined,1770,O
.,1770,O
Elevated,1771,O
atherosclerotic,1771,B-DiseaseOrPhenotypicFeature
parameters,1771,O
",",1771,O
such,1771,O
as,1771,O
serum,1771,O
calcium,1771,B-ChemicalEntity
",",1771,O
total,1771,O
cholesterol,1771,B-ChemicalEntity
and,1771,O
low-density,1771,B-ChemicalEntity
lipoprotein,1771,I-ChemicalEntity
concentration,1771,O
were,1771,O
obtained,1771,O
in,1771,O
atherosclerotic,1771,B-DiseaseOrPhenotypicFeature
rats,1771,B-OrganismTaxon
.,1771,O
Severe,1772,O
gastric,1772,B-DiseaseOrPhenotypicFeature
ulcers,1772,I-DiseaseOrPhenotypicFeature
accompanied,1772,O
with,1772,O
increased,1772,O
ulcerogenic,1772,O
factors,1772,O
",",1772,O
including,1772,O
gastric,1772,O
acid,1772,O
back-diffusion,1772,O
",",1772,O
histamine,1772,B-ChemicalEntity
release,1772,O
",",1772,O
LPO,1772,B-ChemicalEntity
generation,1772,O
and,1772,O
luminal,1772,B-ChemicalEntity
hemoglobin,1772,B-GeneOrGeneProduct
content,1772,O
were,1772,O
also,1772,O
observed,1772,O
in,1772,O
these,1772,O
rats,1772,B-OrganismTaxon
.,1772,O
Moreover,1773,O
",",1773,O
a,1773,O
positive,1773,O
correlation,1773,O
of,1773,O
histamine,1773,B-ChemicalEntity
to,1773,O
gastric,1773,B-DiseaseOrPhenotypicFeature
hemorrhage,1773,I-DiseaseOrPhenotypicFeature
and,1773,O
to,1773,O
ulcer,1773,B-DiseaseOrPhenotypicFeature
was,1773,O
found,1773,O
in,1773,O
those,1773,O
atherosclerotic,1773,B-DiseaseOrPhenotypicFeature
rats,1773,B-OrganismTaxon
.,1773,O
This,1774,O
hemorrhagic,1774,B-DiseaseOrPhenotypicFeature
ulcer,1774,I-DiseaseOrPhenotypicFeature
and,1774,O
various,1774,O
ulcerogenic,1774,O
parameters,1774,O
were,1774,O
dose-dependently,1774,O
ameliorated,1774,O
by,1774,O
daily,1774,O
intragastric,1774,O
verapamil,1774,B-ChemicalEntity
.,1774,O
Atherosclerosis,1775,B-DiseaseOrPhenotypicFeature
could,1775,O
produce,1775,O
gastric,1775,B-DiseaseOrPhenotypicFeature
hemorrhagic,1775,I-DiseaseOrPhenotypicFeature
ulcer,1775,I-DiseaseOrPhenotypicFeature
via,1775,O
aggravation,1775,O
of,1775,O
gastric,1775,O
acid,1775,O
back-diffusion,1775,O
",",1775,O
LPO,1775,B-ChemicalEntity
generation,1775,O
",",1775,O
histamine,1775,B-ChemicalEntity
release,1775,O
and,1775,O
microvascular,1775,O
permeability,1775,O
that,1775,O
could,1775,O
be,1775,O
ameliorated,1775,O
by,1775,O
verapamil,1775,B-ChemicalEntity
in,1775,O
rats,1775,B-OrganismTaxon
.,1775,O
Anticipation,1776,O
in,1776,O
familial,1776,O
lattice,1776,B-DiseaseOrPhenotypicFeature
corneal,1776,I-DiseaseOrPhenotypicFeature
dystrophy,1776,I-DiseaseOrPhenotypicFeature
type,1776,I-DiseaseOrPhenotypicFeature
I,1776,I-DiseaseOrPhenotypicFeature
with,1776,O
R124C,1776,B-SequenceVariant
mutation,1776,O
in,1776,O
the,1776,O
TGFBI,1776,B-GeneOrGeneProduct
(,1776,O
BIGH3,1776,B-GeneOrGeneProduct
),1776,O
gene,1776,O
.,1776,O
PURPOSE,1777,O
:,1777,O
To,1777,O
report,1777,O
the,1777,O
clinical,1777,O
",",1777,O
ophthalmic,1777,O
",",1777,O
and,1777,O
genetic,1777,O
characteristics,1777,O
for,1777,O
lattice,1777,B-DiseaseOrPhenotypicFeature
corneal,1777,I-DiseaseOrPhenotypicFeature
dystrophy,1777,I-DiseaseOrPhenotypicFeature
type,1777,I-DiseaseOrPhenotypicFeature
I,1777,I-DiseaseOrPhenotypicFeature
(,1777,O
LCDI,1777,B-DiseaseOrPhenotypicFeature
),1777,O
in,1777,O
a,1777,O
Chilean,1777,O
family,1777,O
.,1777,O
METHODS,1778,O
:,1778,O
Six,1778,O
affected,1778,O
family,1778,O
members,1778,O
were,1778,O
examined,1778,O
clinically,1778,O
including,1778,O
visual,1778,O
acuity,1778,O
",",1778,O
color,1778,O
cornea,1778,O
photography,1778,O
",",1778,O
applanation,1778,O
tonography,1778,O
",",1778,O
and,1778,O
fundoscopy,1778,O
.,1778,O
Genomic,1779,O
DNA,1779,O
was,1779,O
extracted,1779,O
from,1779,O
peripheral,1779,O
leukocytes,1779,O
from,1779,O
six,1779,O
affected,1779,O
and,1779,O
three,1779,O
unaffected,1779,O
members,1779,O
of,1779,O
a,1779,O
family,1779,O
with,1779,O
lattice,1779,B-DiseaseOrPhenotypicFeature
corneal,1779,I-DiseaseOrPhenotypicFeature
dystrophy,1779,I-DiseaseOrPhenotypicFeature
type,1779,I-DiseaseOrPhenotypicFeature
I.,1779,O
Exon,1779,O
4,1779,O
of,1779,O
the,1779,O
transforming,1779,B-GeneOrGeneProduct
growth,1779,I-GeneOrGeneProduct
factor-induced,1779,I-GeneOrGeneProduct
gene,1779,I-GeneOrGeneProduct
(,1779,O
TGFBI,1779,B-GeneOrGeneProduct
),1779,O
was,1779,O
screened,1779,O
for,1779,O
the,1779,O
most,1779,O
frequent,1779,O
mutation,1779,O
",",1779,O
R124C,1779,B-SequenceVariant
",",1779,O
in,1779,O
the,1779,O
proband,1779,O
by,1779,O
sequencing,1779,O
.,1779,O
We,1780,O
also,1780,O
designed,1780,O
a,1780,O
rapid,1780,O
polymerase,1780,O
chain,1780,O
reaction-restriction,1780,O
fragment,1780,O
length,1780,O
polymorphism,1780,O
(,1780,O
PCR-RFLP,1780,O
),1780,O
method,1780,O
to,1780,O
analyze,1780,O
the,1780,O
same,1780,O
mutation,1780,O
",",1780,O
amplifying,1780,O
exon,1780,O
4,1780,O
and,1780,O
digesting,1780,O
with,1780,O
PstI,1780,B-GeneOrGeneProduct
restriction,1780,O
enzyme,1780,O
.,1780,O
Using,1781,O
this,1781,O
strategy,1781,O
",",1781,O
we,1781,O
analyzed,1781,O
the,1781,O
mutation,1781,O
in,1781,O
six,1781,O
affected,1781,O
and,1781,O
three,1781,O
healthy,1781,O
family,1781,O
members,1781,O
.,1781,O
RESULTS,1782,O
:,1782,O
Three,1782,O
generations,1782,O
of,1782,O
family,1782,O
members,1782,O
were,1782,O
positively,1782,O
diagnosed,1782,O
with,1782,O
lattice,1782,B-DiseaseOrPhenotypicFeature
corneal,1782,I-DiseaseOrPhenotypicFeature
dystrophy,1782,I-DiseaseOrPhenotypicFeature
.,1782,O
Six,1783,O
participants,1783,O
demonstrated,1783,O
LCD1,1783,B-DiseaseOrPhenotypicFeature
in,1783,O
both,1783,O
eyes,1783,O
",",1783,O
most,1783,O
of,1783,O
whom,1783,O
were,1783,O
symmetric,1783,O
.,1783,O
Age,1784,O
at,1784,O
onset,1784,O
of,1784,O
symptoms,1784,O
was,1784,O
variable,1784,O
(,1784,O
3-42,1784,O
years,1784,O
old,1784,O
),1784,O
.,1784,O
Moreover,1785,O
",",1785,O
in,1785,O
this,1785,O
family,1785,O
",",1785,O
the,1785,O
age,1785,O
of,1785,O
onset,1785,O
of,1785,O
the,1785,O
disease,1785,O
decreased,1785,O
in,1785,O
succeeding,1785,O
generations,1785,O
",",1785,O
which,1785,O
could,1785,O
be,1785,O
interpreted,1785,O
as,1785,O
anticipation,1785,O
.,1785,O
Visual,1786,O
acuity,1786,O
varied,1786,O
from,1786,O
1.0,1786,O
to,1786,O
0.13,1786,O
.,1786,O
Two,1787,O
patients,1787,B-OrganismTaxon
",",1787,O
ages,1787,O
69,1787,O
and,1787,O
44,1787,O
years,1787,O
old,1787,O
",",1787,O
demonstrated,1787,O
a,1787,O
degree,1787,O
of,1787,O
severity,1787,O
``,1787,O
Bad,1787,O
'',1787,O
according,1787,O
to,1787,O
best-corrected,1787,O
vision,1787,O
and,1787,O
corneal,1787,O
commitment,1787,O
.,1787,O
The,1788,O
exon,1788,O
4,1788,O
sequence,1788,O
of,1788,O
TGFBI,1788,B-GeneOrGeneProduct
of,1788,O
the,1788,O
proband,1788,O
exhibits,1788,O
the,1788,O
heterozygous,1788,O
single-nucleotide,1788,O
mutation,1788,O
",",1788,O
C417T,1788,B-SequenceVariant
",",1788,O
leading,1788,O
to,1788,O
amino,1788,O
acid,1788,O
substitution,1788,O
(,1788,O
R124C,1788,B-SequenceVariant
),1788,O
in,1788,O
the,1788,O
encoded,1788,O
TGF-induced,1788,B-GeneOrGeneProduct
protein,1788,I-GeneOrGeneProduct
.,1788,O
Using,1789,O
PCR-RFLP,1789,O
",",1789,O
we,1789,O
confirmed,1789,O
the,1789,O
heterozygous,1789,O
mutation,1789,O
in,1789,O
six,1789,O
affected,1789,O
family,1789,O
members,1789,O
and,1789,O
excluded,1789,O
it,1789,O
in,1789,O
three,1789,O
healthy,1789,O
members,1789,O
.,1789,O
CONCLUSIONS,1790,O
:,1790,O
The,1790,O
R124C,1790,B-SequenceVariant
mutation,1790,O
in,1790,O
TGFBI,1790,B-GeneOrGeneProduct
cosegregated,1790,O
with,1790,O
LCD,1790,B-DiseaseOrPhenotypicFeature
type,1790,I-DiseaseOrPhenotypicFeature
I,1790,I-DiseaseOrPhenotypicFeature
in,1790,O
the,1790,O
investigated,1790,O
family,1790,O
.,1790,O
This,1791,O
is,1791,O
the,1791,O
first,1791,O
report,1791,O
of,1791,O
a,1791,O
molecular,1791,O
analysis,1791,O
of,1791,O
LCD,1791,B-DiseaseOrPhenotypicFeature
type,1791,I-DiseaseOrPhenotypicFeature
I,1791,I-DiseaseOrPhenotypicFeature
in,1791,O
Chilean,1791,O
patients,1791,B-OrganismTaxon
.,1791,O
The,1792,O
early,1792,O
onset,1792,O
affected,1792,O
persons,1792,O
in,1792,O
the,1792,O
fourth,1792,O
generation,1792,O
raises,1792,O
the,1792,O
possibility,1792,O
of,1792,O
anticipation,1792,O
.,1792,O
Exaggerated,1793,O
expression,1793,O
of,1793,O
inflammatory,1793,B-DiseaseOrPhenotypicFeature
mediators,1793,O
in,1793,O
vasoactive,1793,B-GeneOrGeneProduct
intestinal,1793,I-GeneOrGeneProduct
polypeptide,1793,I-GeneOrGeneProduct
knockout,1793,O
(,1793,O
VIP-/-,1793,B-GeneOrGeneProduct
),1793,O
mice,1793,B-OrganismTaxon
with,1793,O
cyclophosphamide,1793,B-ChemicalEntity
(,1793,O
CYP,1793,B-ChemicalEntity
),1793,O
-induced,1793,O
cystitis,1793,B-DiseaseOrPhenotypicFeature
.,1793,O
Vasoactive,1794,B-GeneOrGeneProduct
intestinal,1794,I-GeneOrGeneProduct
polypeptide,1794,I-GeneOrGeneProduct
(,1794,O
VIP,1794,B-GeneOrGeneProduct
),1794,O
is,1794,O
an,1794,O
immunomodulatory,1794,O
neuropeptide,1794,O
distributed,1794,O
in,1794,O
micturition,1794,O
pathways,1794,O
.,1794,O
VIP,1795,B-GeneOrGeneProduct
(,1795,O
-/-,1795,O
),1795,O
mice,1795,B-OrganismTaxon
exhibit,1795,O
altered,1795,O
bladder,1795,O
function,1795,O
and,1795,O
neurochemical,1795,O
properties,1795,O
in,1795,O
micturition,1795,O
pathways,1795,O
after,1795,O
cyclophosphamide,1795,B-ChemicalEntity
(,1795,O
CYP,1795,B-ChemicalEntity
),1795,O
-induced,1795,O
cystitis,1795,B-DiseaseOrPhenotypicFeature
.,1795,O
Given,1796,O
VIP,1796,B-GeneOrGeneProduct
's,1796,O
role,1796,O
as,1796,O
an,1796,O
anti-inflammatory,1796,O
mediator,1796,O
",",1796,O
we,1796,O
hypothesized,1796,O
that,1796,O
VIP,1796,B-GeneOrGeneProduct
(,1796,O
-/-,1796,O
),1796,O
mice,1796,B-OrganismTaxon
would,1796,O
exhibit,1796,O
enhanced,1796,O
inflammatory,1796,B-DiseaseOrPhenotypicFeature
mediator,1796,O
expression,1796,O
after,1796,O
cystitis,1796,B-DiseaseOrPhenotypicFeature
.,1796,O
A,1797,O
mouse,1797,B-OrganismTaxon
inflammatory,1797,B-DiseaseOrPhenotypicFeature
cytokine,1797,O
and,1797,O
receptor,1797,O
RT2,1797,O
profiler,1797,O
array,1797,O
was,1797,O
used,1797,O
to,1797,O
determine,1797,O
regulated,1797,O
transcripts,1797,O
in,1797,O
the,1797,O
urinary,1797,O
bladder,1797,O
of,1797,O
wild,1797,O
type,1797,O
(,1797,O
WT,1797,O
),1797,O
and,1797,O
VIP,1797,B-GeneOrGeneProduct
(,1797,O
-/-,1797,O
),1797,O
mice,1797,B-OrganismTaxon
with,1797,O
or,1797,O
without,1797,O
CYP-induced,1797,B-ChemicalEntity
cystitis,1797,B-DiseaseOrPhenotypicFeature
(,1797,O
150,1797,O
mg/kg,1797,O
;,1797,O
i.p,1797,O
.,1797,O
;,1798,O
48,1798,O
h,1798,O
),1798,O
.,1798,O
Four,1799,O
binary,1799,O
comparisons,1799,O
were,1799,O
made,1799,O
:,1799,O
WT,1799,O
control,1799,O
versus,1799,O
CYP,1799,O
treatment,1799,O
(,1799,O
48,1799,O
h,1799,O
),1799,O
",",1799,O
VIP,1799,O
(,1799,O
-/-,1799,O
),1799,O
control,1799,O
versus,1799,O
CYP,1799,O
treatment,1799,O
(,1799,O
48,1799,O
h,1799,O
),1799,O
",",1799,O
WT,1799,O
control,1799,O
versus,1799,O
VIP,1799,O
(,1799,O
-/-,1799,O
),1799,O
control,1799,O
",",1799,O
and,1799,O
WT,1799,O
with,1799,O
CYP,1799,O
treatment,1799,O
(,1799,O
48,1799,O
h,1799,O
),1799,O
versus,1799,O
VIP,1799,O
(,1799,O
-/-,1799,O
),1799,O
with,1799,O
CYP,1799,O
treatment,1799,O
(,1799,O
48,1799,O
h,1799,O
),1799,O
.,1799,O
The,1800,O
genes,1800,O
presented,1800,O
represent,1800,O
(,1800,O
1,1800,O
),1800,O
greater,1800,O
than,1800,O
1.5-fold,1800,O
change,1800,O
in,1800,O
either,1800,O
direction,1800,O
and,1800,O
(,1800,O
2,1800,O
),1800,O
the,1800,O
p,1800,O
value,1800,O
is,1800,O
less,1800,O
than,1800,O
0.05,1800,O
for,1800,O
the,1800,O
comparison,1800,O
being,1800,O
made,1800,O
.,1800,O
Several,1801,O
regulated,1801,O
genes,1801,O
were,1801,O
validated,1801,O
using,1801,O
enzyme-linked,1801,O
immunoassays,1801,O
including,1801,O
IL-1beta,1801,O
and,1801,O
CXCL1,1801,O
.,1801,O
CYP,1802,O
treatment,1802,O
significantly,1802,O
(,1802,O
p,1802,O
<,1802,O
or,1802,O
=,1802,O
0.001,1802,O
),1802,O
increased,1802,O
expression,1802,O
of,1802,O
CXCL1,1802,O
and,1802,O
IL-1beta,1802,O
in,1802,O
the,1802,O
urinary,1802,O
bladder,1802,O
of,1802,O
WT,1802,O
and,1802,O
VIP,1802,O
(,1802,O
-/-,1802,O
),1802,O
mice,1802,O
",",1802,O
but,1802,O
expression,1802,O
in,1802,O
VIP,1802,O
(,1802,O
-/-,1802,O
),1802,O
mice,1802,O
with,1802,O
CYP,1802,O
treatment,1802,O
was,1802,O
significantly,1802,O
(,1802,O
p,1802,O
<,1802,O
or,1802,O
=,1802,O
0.001,1802,O
),1802,O
greater,1802,O
(,1802,O
4.2-,1802,O
to,1802,O
13-fold,1802,O
increase,1802,O
),1802,O
than,1802,O
that,1802,O
observed,1802,O
in,1802,O
WT,1802,O
urinary,1802,O
bladder,1802,O
(,1802,O
3.6-,1802,O
to,1802,O
5-fold,1802,O
increase,1802,O
),1802,O
.,1802,O
The,1803,O
data,1803,O
suggest,1803,O
that,1803,O
in,1803,O
VIP,1803,O
(,1803,O
-/-,1803,O
),1803,O
mice,1803,O
with,1803,O
bladder,1803,I-DiseaseOrPhenotypicFeature
inflammation,1803,O
",",1803,O
inflammatory,1803,O
mediators,1803,O
are,1803,O
increased,1803,O
above,1803,O
that,1803,O
observed,1803,O
in,1803,O
WT,1803,O
with,1803,O
CYP,1803,O
.,1803,O
This,1804,O
shift,1804,O
in,1804,O
balance,1804,O
may,1804,O
contribute,1804,O
to,1804,O
increased,1804,O
bladder,1804,I-DiseaseOrPhenotypicFeature
dysfunction,1804,O
in,1804,O
VIP,1804,O
(,1804,O
-/-,1804,O
),1804,O
mice,1804,O
with,1804,O
bladder,1804,I-DiseaseOrPhenotypicFeature
inflammation,1804,O
and,1804,O
altered,1804,O
neurochemical,1804,O
expression,1804,O
in,1804,O
micturition,1804,O
pathways,1804,O
.,1804,O
Depletion,1805,O
of,1805,O
mitochondrial,1805,O
DNA,1805,O
in,1805,O
fibroblast,1805,O
cultures,1805,O
from,1805,O
patients,1805,B-OrganismTaxon
with,1805,O
POLG1,1805,B-GeneOrGeneProduct
mutations,1805,O
is,1805,O
a,1805,O
consequence,1805,O
of,1805,O
catalytic,1805,O
mutations,1805,O
.,1805,O
We,1806,O
investigated,1806,O
clinical,1806,O
and,1806,O
cellular,1806,O
phenotypes,1806,O
of,1806,O
24,1806,O
children,1806,O
with,1806,O
mutations,1806,O
in,1806,O
the,1806,O
catalytic,1806,O
(,1806,O
alpha,1806,O
),1806,O
subunit,1806,O
of,1806,O
the,1806,O
mitochondrial,1806,B-GeneOrGeneProduct
DNA,1806,I-GeneOrGeneProduct
(,1806,I-GeneOrGeneProduct
mtDNA,1806,I-GeneOrGeneProduct
),1806,I-GeneOrGeneProduct
gamma,1806,I-GeneOrGeneProduct
polymerase,1806,I-GeneOrGeneProduct
(,1806,O
POLG1,1806,B-GeneOrGeneProduct
),1806,O
.,1806,O
Twenty-one,1807,O
had,1807,O
Alpers,1807,B-DiseaseOrPhenotypicFeature
syndrome,1807,I-DiseaseOrPhenotypicFeature
",",1807,O
the,1807,O
commonest,1807,O
severe,1807,O
POLG1,1807,B-GeneOrGeneProduct
autosomal,1807,O
recessive,1807,O
phenotype,1807,O
",",1807,O
comprising,1807,O
hepatoencephalopathy,1807,B-DiseaseOrPhenotypicFeature
and,1807,O
often,1807,O
mtDNA,1807,O
depletion,1807,O
.,1807,O
The,1808,O
cellular,1808,O
mtDNA,1808,O
content,1808,O
reflected,1808,O
the,1808,O
genotype,1808,O
more,1808,O
closely,1808,O
than,1808,O
did,1808,O
clinical,1808,O
features,1808,O
.,1808,O
Patients,1809,B-OrganismTaxon
with,1809,O
tissue,1809,O
depletion,1809,O
of,1809,O
mtDNA,1809,O
all,1809,O
had,1809,O
at,1809,O
least,1809,O
one,1809,O
allele,1809,O
with,1809,O
either,1809,O
a,1809,O
missense,1809,O
mutation,1809,O
in,1809,O
a,1809,O
catalytic,1809,O
domain,1809,O
or,1809,O
a,1809,O
nonsense,1809,O
mutation,1809,O
.,1809,O
Four,1810,O
out,1810,O
of,1810,O
12,1810,O
patients,1810,B-OrganismTaxon
exhibited,1810,O
a,1810,O
progressive,1810,O
",",1810,O
mosaic,1810,O
pattern,1810,O
of,1810,O
mtDNA,1810,O
depletion,1810,O
in,1810,O
cultured,1810,O
fibroblasts,1810,O
.,1810,O
All,1811,O
these,1811,O
patients,1811,B-OrganismTaxon
had,1811,O
mutations,1811,O
in,1811,O
a,1811,O
catalytic,1811,O
domain,1811,O
in,1811,O
both,1811,O
POLG1,1811,B-GeneOrGeneProduct
alleles,1811,O
",",1811,O
in,1811,O
either,1811,O
the,1811,O
polymerase,1811,O
or,1811,O
exonuclease,1811,O
domain,1811,O
or,1811,O
both,1811,O
.,1811,O
The,1812,O
tissue,1812,O
mtDNA,1812,O
content,1812,O
of,1812,O
patients,1812,B-OrganismTaxon
who,1812,O
had,1812,O
two,1812,O
linker,1812,O
mutations,1812,O
was,1812,O
normal,1812,O
",",1812,O
and,1812,O
their,1812,O
phenotypes,1812,O
the,1812,O
mildest,1812,O
.,1812,O
Epilepsy,1813,B-DiseaseOrPhenotypicFeature
and/or,1813,O
movement,1813,B-DiseaseOrPhenotypicFeature
disorder,1813,I-DiseaseOrPhenotypicFeature
were,1813,O
major,1813,O
features,1813,O
in,1813,O
all,1813,O
21,1813,O
.,1813,O
Previous,1814,O
studies,1814,O
have,1814,O
implicated,1814,O
replication,1814,O
stalling,1814,O
as,1814,O
a,1814,O
mechanism,1814,O
for,1814,O
mtDNA,1814,O
depletion,1814,O
.,1814,O
The,1815,O
mosaic,1815,O
cellular,1815,O
depletion,1815,O
that,1815,O
we,1815,O
have,1815,O
demonstrated,1815,O
in,1815,O
cell,1815,O
cultures,1815,O
may,1815,O
be,1815,O
a,1815,O
manifestation,1815,O
of,1815,O
severe,1815,O
replication,1815,O
stalling,1815,O
.,1815,O
One,1816,O
patient,1816,B-OrganismTaxon
with,1816,O
a,1816,O
severe,1816,O
cellular,1816,O
and,1816,O
clinical,1816,O
phenotype,1816,O
was,1816,O
a,1816,O
compound,1816,O
heterozygote,1816,O
with,1816,O
POLG1,1816,B-GeneOrGeneProduct
mutations,1816,O
in,1816,O
the,1816,O
polymerase,1816,O
and,1816,O
exonuclease,1816,O
domain,1816,O
intrans,1816,O
.,1816,O
This,1817,O
suggests,1817,O
that,1817,O
POLG1,1817,B-GeneOrGeneProduct
requires,1817,O
both,1817,O
polymerase,1817,O
and,1817,O
3'-5,1817,O
',1817,O
exonuclease,1817,O
activity,1817,O
in,1817,O
the,1817,O
same,1817,O
molecule,1817,O
.,1817,O
This,1818,O
is,1818,O
consistent,1818,O
with,1818,O
current,1818,O
functional,1818,O
models,1818,O
for,1818,O
eukaryotic,1818,O
DNA,1818,O
polymerases,1818,O
",",1818,O
which,1818,O
alternate,1818,O
between,1818,O
polymerizing,1818,O
and,1818,O
editing,1818,O
modes,1818,O
",",1818,O
as,1818,O
determined,1818,O
by,1818,O
competition,1818,O
between,1818,O
these,1818,O
two,1818,O
active,1818,O
sites,1818,O
for,1818,O
the,1818,O
3,1818,O
',1818,O
end,1818,O
of,1818,O
the,1818,O
DNA,1818,O
.,1818,O
Protective,1819,O
effects,1819,O
of,1819,O
antithrombin,1819,B-ChemicalEntity
on,1819,O
puromycin,1819,B-ChemicalEntity
aminonucleoside,1819,I-ChemicalEntity
nephrosis,1819,B-DiseaseOrPhenotypicFeature
in,1819,O
rats,1819,B-OrganismTaxon
.,1819,O
We,1820,O
investigated,1820,O
the,1820,O
effects,1820,O
of,1820,O
antithrombin,1820,B-ChemicalEntity
",",1820,O
a,1820,O
plasma,1820,O
inhibitor,1820,O
of,1820,O
coagulation,1820,O
factors,1820,O
",",1820,O
in,1820,O
rats,1820,B-OrganismTaxon
with,1820,O
puromycin,1820,B-ChemicalEntity
aminonucleoside-induced,1820,O
nephrosis,1820,B-DiseaseOrPhenotypicFeature
",",1820,O
which,1820,O
is,1820,O
an,1820,O
experimental,1820,O
model,1820,O
of,1820,O
human,1820,B-OrganismTaxon
nephrotic,1820,B-DiseaseOrPhenotypicFeature
syndrome,1820,I-DiseaseOrPhenotypicFeature
.,1820,O
Antithrombin,1821,B-ChemicalEntity
(,1821,O
50,1821,O
or,1821,O
500,1821,O
IU/kg/i.v,1821,O
.,1821,O
),1821,O
was,1822,O
administered,1822,O
to,1822,O
rats,1822,B-OrganismTaxon
once,1822,O
a,1822,O
day,1822,O
for,1822,O
10,1822,O
days,1822,O
immediately,1822,O
after,1822,O
the,1822,O
injection,1822,O
of,1822,O
puromycin,1822,B-ChemicalEntity
aminonucleoside,1822,I-ChemicalEntity
(,1822,O
50,1822,O
mg/kg/i.v,1822,O
.,1822,O
),1822,O
.,1822,O
Treatment,1823,O
with,1823,O
antithrombin,1823,B-ChemicalEntity
attenuated,1823,O
the,1823,O
puromycin,1823,B-ChemicalEntity
aminonucleoside-induced,1823,O
hematological,1823,B-DiseaseOrPhenotypicFeature
abnormalities,1823,I-DiseaseOrPhenotypicFeature
.,1823,O
Puromycin,1824,B-ChemicalEntity
aminonucleoside-induced,1824,O
renal,1824,B-DiseaseOrPhenotypicFeature
dysfunction,1824,I-DiseaseOrPhenotypicFeature
and,1824,O
hyperlipidemia,1824,B-DiseaseOrPhenotypicFeature
were,1824,O
also,1824,O
suppressed,1824,O
.,1824,O
Histopathological,1825,O
examination,1825,O
revealed,1825,O
severe,1825,O
renal,1825,B-DiseaseOrPhenotypicFeature
damage,1825,I-DiseaseOrPhenotypicFeature
such,1825,O
as,1825,O
proteinaceous,1825,O
casts,1825,O
in,1825,O
tubuli,1825,O
and,1825,O
tubular,1825,O
expansion,1825,O
in,1825,O
the,1825,O
kidney,1825,O
of,1825,O
control,1825,O
rats,1825,B-OrganismTaxon
",",1825,O
while,1825,O
an,1825,O
improvement,1825,O
of,1825,O
the,1825,O
damage,1825,O
was,1825,O
seen,1825,O
in,1825,O
antithrombin-treated,1825,B-ChemicalEntity
rats,1825,B-OrganismTaxon
.,1825,O
In,1826,O
addition,1826,O
",",1826,O
antithrombin,1826,B-ChemicalEntity
treatment,1826,O
markedly,1826,O
suppressed,1826,O
puromycin,1826,B-ChemicalEntity
aminonucleoside-induced,1826,O
apoptosis,1826,O
of,1826,O
renal,1826,O
tubular,1826,O
epithelial,1826,O
cells,1826,O
.,1826,O
Furthermore,1827,O
",",1827,O
puromycin,1827,B-ChemicalEntity
aminonucleoside-induced,1827,O
increases,1827,O
in,1827,O
renal,1827,O
cytokine,1827,O
content,1827,O
were,1827,O
also,1827,O
decreased,1827,O
.,1827,O
These,1828,O
findings,1828,O
suggest,1828,O
that,1828,O
thrombin,1828,B-GeneOrGeneProduct
plays,1828,O
an,1828,O
important,1828,O
role,1828,O
in,1828,O
the,1828,O
pathogenesis,1828,O
of,1828,O
puromycin,1828,B-ChemicalEntity
aminonucleoside-induced,1828,O
nephrotic,1828,B-DiseaseOrPhenotypicFeature
syndrome,1828,I-DiseaseOrPhenotypicFeature
.,1828,O
Treatment,1829,O
with,1829,O
antithrombin,1829,B-ChemicalEntity
may,1829,O
be,1829,O
clinically,1829,O
effective,1829,O
in,1829,O
patients,1829,B-OrganismTaxon
with,1829,O
nephrotic,1829,B-DiseaseOrPhenotypicFeature
syndrome,1829,I-DiseaseOrPhenotypicFeature
.,1829,O
Omitting,1830,O
fentanyl,1830,B-ChemicalEntity
reduces,1830,O
nausea,1830,B-DiseaseOrPhenotypicFeature
and,1830,O
vomiting,1830,B-DiseaseOrPhenotypicFeature
",",1830,O
without,1830,O
increasing,1830,O
pain,1830,B-DiseaseOrPhenotypicFeature
",",1830,O
after,1830,O
sevoflurane,1830,B-ChemicalEntity
for,1830,O
day,1830,O
surgery,1830,O
.,1830,O
BACKGROUND,1831,O
AND,1831,O
OBJECTIVE,1831,O
:,1831,O
Despite,1831,O
advantages,1831,O
of,1831,O
induction,1831,O
and,1831,O
maintenance,1831,O
of,1831,O
anaesthesia,1831,O
with,1831,O
sevoflurane,1831,B-ChemicalEntity
",",1831,O
postoperative,1831,B-DiseaseOrPhenotypicFeature
nausea,1831,I-DiseaseOrPhenotypicFeature
and,1831,I-DiseaseOrPhenotypicFeature
vomiting,1831,I-DiseaseOrPhenotypicFeature
occurs,1831,O
frequently,1831,O
.,1831,O
Fentanyl,1832,B-ChemicalEntity
is,1832,O
a,1832,O
commonly,1832,O
used,1832,O
supplement,1832,O
that,1832,O
may,1832,O
contribute,1832,O
to,1832,O
this,1832,O
",",1832,O
although,1832,O
it,1832,O
may,1832,O
also,1832,O
improve,1832,O
analgesia,1832,O
.,1832,O
METHODS,1833,O
:,1833,O
This,1833,O
double-blind,1833,O
study,1833,O
examined,1833,O
the,1833,O
incidence,1833,O
and,1833,O
severity,1833,O
of,1833,O
postoperative,1833,B-DiseaseOrPhenotypicFeature
nausea,1833,I-DiseaseOrPhenotypicFeature
and,1833,I-DiseaseOrPhenotypicFeature
vomiting,1833,I-DiseaseOrPhenotypicFeature
and,1833,I-DiseaseOrPhenotypicFeature
pain,1833,I-DiseaseOrPhenotypicFeature
in,1833,O
the,1833,O
first,1833,O
24,1833,O
h,1833,O
after,1833,O
sevoflurane,1833,B-ChemicalEntity
anaesthesia,1833,O
in,1833,O
216,1833,O
adult,1833,O
day,1833,O
surgery,1833,O
patients,1833,B-OrganismTaxon
.,1833,O
Patients,1834,B-OrganismTaxon
were,1834,O
randomly,1834,O
allocated,1834,O
to,1834,O
either,1834,O
receive,1834,O
or,1834,O
not,1834,O
receive,1834,O
1,1834,O
1,1834,O
fentanyl,1834,B-ChemicalEntity
",",1834,O
while,1834,O
a,1834,O
third,1834,O
group,1834,O
received,1834,O
dexamethasone,1834,B-ChemicalEntity
in,1834,O
addition,1834,O
to,1834,O
fentanyl,1834,B-ChemicalEntity
.,1834,O
RESULTS,1835,O
:,1835,O
Omission,1835,O
of,1835,O
fentanyl,1835,B-ChemicalEntity
did,1835,O
not,1835,O
reduce,1835,O
the,1835,O
overall,1835,O
incidence,1835,O
of,1835,O
postoperative,1835,B-DiseaseOrPhenotypicFeature
nausea,1835,I-DiseaseOrPhenotypicFeature
and,1835,I-DiseaseOrPhenotypicFeature
vomiting,1835,I-DiseaseOrPhenotypicFeature
",",1835,O
but,1835,O
did,1835,O
reduce,1835,O
the,1835,O
incidence,1835,O
of,1835,O
vomiting,1835,B-DiseaseOrPhenotypicFeature
and/or,1835,O
moderate,1835,O
to,1835,O
severe,1835,O
nausea,1835,B-DiseaseOrPhenotypicFeature
prior,1835,O
to,1835,O
discharge,1835,O
from,1835,O
20,1835,O
%,1835,O
and,1835,O
17,1835,O
%,1835,O
with,1835,O
fentanyl,1835,B-ChemicalEntity
and,1835,O
fentanyl-dexamethasone,1835,B-ChemicalEntity
",",1835,O
respectively,1835,O
",",1835,O
to,1835,O
5,1835,O
%,1835,O
(,1835,O
P,1835,O
=,1835,O
0.013,1835,O
),1835,O
.,1835,O
Antiemetic,1836,O
requirements,1836,O
were,1836,O
reduced,1836,O
from,1836,O
24,1836,O
%,1836,O
and,1836,O
31,1836,O
%,1836,O
to,1836,O
7,1836,O
%,1836,O
(,1836,O
P,1836,O
=,1836,O
0.0012,1836,O
),1836,O
.,1836,O
Dexamethasone,1837,B-ChemicalEntity
had,1837,O
no,1837,O
significant,1837,O
effect,1837,O
on,1837,O
the,1837,O
incidence,1837,O
or,1837,O
severity,1837,O
of,1837,O
postoperative,1837,B-DiseaseOrPhenotypicFeature
nausea,1837,I-DiseaseOrPhenotypicFeature
and,1837,I-DiseaseOrPhenotypicFeature
vomiting,1837,I-DiseaseOrPhenotypicFeature
.,1837,O
Combining,1838,O
the,1838,O
two,1838,O
fentanyl,1838,B-ChemicalEntity
groups,1838,O
revealed,1838,O
further,1838,O
significant,1838,O
benefits,1838,O
from,1838,O
the,1838,O
avoidance,1838,O
of,1838,O
opioids,1838,O
",",1838,O
reducing,1838,O
postoperative,1838,B-DiseaseOrPhenotypicFeature
nausea,1838,I-DiseaseOrPhenotypicFeature
and,1838,I-DiseaseOrPhenotypicFeature
vomiting,1838,I-DiseaseOrPhenotypicFeature
and,1838,O
nausea,1838,B-DiseaseOrPhenotypicFeature
prior,1838,O
to,1838,O
discharge,1838,O
from,1838,O
35,1838,O
%,1838,O
and,1838,O
33,1838,O
%,1838,O
to,1838,O
22,1838,O
%,1838,O
and,1838,O
19,1838,O
%,1838,O
(,1838,O
P,1838,O
=,1838,O
0.049,1838,O
and,1838,O
P,1838,O
=,1838,O
0.035,1838,O
),1838,O
",",1838,O
respectively,1838,O
",",1838,O
while,1838,O
nausea,1838,B-DiseaseOrPhenotypicFeature
in,1838,O
the,1838,O
first,1838,O
24,1838,O
h,1838,O
was,1838,O
decreased,1838,O
from,1838,O
42,1838,O
%,1838,O
to,1838,O
27,1838,O
%,1838,O
(,1838,O
P,1838,O
=,1838,O
0.034,1838,O
),1838,O
.,1838,O
Pain,1839,B-DiseaseOrPhenotypicFeature
severity,1839,O
and,1839,O
analgesic,1839,O
requirements,1839,O
were,1839,O
unaffected,1839,O
by,1839,O
the,1839,O
omission,1839,O
of,1839,O
fentanyl,1839,B-ChemicalEntity
.,1839,O
Fentanyl,1840,B-ChemicalEntity
did,1840,O
reduce,1840,O
minor,1840,O
intraoperative,1840,O
movement,1840,O
but,1840,O
had,1840,O
no,1840,O
sevoflurane-sparing,1840,B-ChemicalEntity
effect,1840,O
and,1840,O
increased,1840,O
respiratory,1840,B-DiseaseOrPhenotypicFeature
depression,1840,I-DiseaseOrPhenotypicFeature
",",1840,O
hypotension,1840,B-DiseaseOrPhenotypicFeature
and,1840,O
bradycardia,1840,B-DiseaseOrPhenotypicFeature
.,1840,O
CONCLUSION,1841,O
:,1841,O
As,1841,O
fentanyl,1841,B-ChemicalEntity
exacerbated,1841,O
postoperative,1841,B-DiseaseOrPhenotypicFeature
nausea,1841,I-DiseaseOrPhenotypicFeature
and,1841,I-DiseaseOrPhenotypicFeature
vomiting,1841,I-DiseaseOrPhenotypicFeature
without,1841,O
an,1841,O
improvement,1841,O
in,1841,O
postoperative,1841,B-DiseaseOrPhenotypicFeature
pain,1841,I-DiseaseOrPhenotypicFeature
and,1841,O
also,1841,O
had,1841,O
adverse,1841,O
cardiorespiratory,1841,O
effects,1841,O
",",1841,O
it,1841,O
appears,1841,O
to,1841,O
be,1841,O
an,1841,O
unnecessary,1841,O
and,1841,O
possibly,1841,O
detrimental,1841,O
supplement,1841,O
to,1841,O
sevoflurane,1841,B-ChemicalEntity
in,1841,O
day,1841,O
surgery,1841,O
.,1841,O
Curcumin,1842,B-ChemicalEntity
decreases,1842,O
specificity,1842,B-GeneOrGeneProduct
protein,1842,I-GeneOrGeneProduct
expression,1842,O
in,1842,O
bladder,1842,B-DiseaseOrPhenotypicFeature
cancer,1842,I-DiseaseOrPhenotypicFeature
cells,1842,O
.,1842,O
Curcumin,1843,B-ChemicalEntity
is,1843,O
the,1843,O
active,1843,O
component,1843,O
of,1843,O
tumeric,1843,O
",",1843,O
and,1843,O
this,1843,O
polyphenolic,1843,O
compound,1843,O
has,1843,O
been,1843,O
extensively,1843,O
investigated,1843,O
as,1843,O
an,1843,O
anticancer,1843,O
drug,1843,O
that,1843,O
modulates,1843,O
multiple,1843,O
pathways,1843,O
and,1843,O
genes,1843,O
.,1843,O
In,1844,O
this,1844,O
study,1844,O
",",1844,O
10,1844,O
to,1844,O
25,1844,O
micromol/L,1844,O
curcumin,1844,B-ChemicalEntity
inhibited,1844,O
253JB-V,1844,B-CellLine
and,1844,O
KU7,1844,B-CellLine
bladder,1844,B-DiseaseOrPhenotypicFeature
cancer,1844,I-DiseaseOrPhenotypicFeature
cell,1844,O
growth,1844,O
",",1844,O
and,1844,O
this,1844,O
was,1844,O
accompanied,1844,O
by,1844,O
induction,1844,O
of,1844,O
apoptosis,1844,O
and,1844,O
decreased,1844,O
expression,1844,O
of,1844,O
the,1844,O
proapoptotic,1844,B-GeneOrGeneProduct
protein,1844,I-GeneOrGeneProduct
survivin,1844,B-GeneOrGeneProduct
and,1844,O
the,1844,O
angiogenic,1844,B-GeneOrGeneProduct
proteins,1844,I-GeneOrGeneProduct
vascular,1844,B-GeneOrGeneProduct
endothelial,1844,I-GeneOrGeneProduct
growth,1844,I-GeneOrGeneProduct
factor,1844,I-GeneOrGeneProduct
(,1844,O
VEGF,1844,B-GeneOrGeneProduct
),1844,O
and,1844,O
VEGF,1844,B-GeneOrGeneProduct
receptor,1844,I-GeneOrGeneProduct
1,1844,I-GeneOrGeneProduct
(,1844,O
VEGFR1,1844,B-GeneOrGeneProduct
),1844,O
.,1844,O
Because,1845,O
expression,1845,O
of,1845,O
survivin,1845,B-GeneOrGeneProduct
",",1845,O
VEGF,1845,B-GeneOrGeneProduct
",",1845,O
and,1845,O
VEGFR1,1845,B-GeneOrGeneProduct
are,1845,O
dependent,1845,O
on,1845,O
specificity,1845,B-GeneOrGeneProduct
protein,1845,I-GeneOrGeneProduct
(,1845,I-GeneOrGeneProduct
Sp,1845,I-GeneOrGeneProduct
),1845,I-GeneOrGeneProduct
transcription,1845,I-GeneOrGeneProduct
factors,1845,I-GeneOrGeneProduct
",",1845,O
we,1845,O
also,1845,O
investigated,1845,O
the,1845,O
effects,1845,O
of,1845,O
curcumin,1845,B-ChemicalEntity
on,1845,O
Sp,1845,B-GeneOrGeneProduct
protein,1845,O
expression,1845,O
as,1845,O
an,1845,O
underlying,1845,O
mechanism,1845,O
for,1845,O
the,1845,O
apoptotic,1845,O
and,1845,O
antiangiogenic,1845,O
activity,1845,O
of,1845,O
this,1845,O
compound,1845,O
.,1845,O
The,1846,O
results,1846,O
show,1846,O
that,1846,O
curcumin,1846,B-ChemicalEntity
induced,1846,O
proteasome-dependent,1846,B-GeneOrGeneProduct
down-regulation,1846,O
of,1846,O
Sp1,1846,B-GeneOrGeneProduct
",",1846,O
Sp3,1846,B-GeneOrGeneProduct
",",1846,O
and,1846,O
Sp4,1846,B-GeneOrGeneProduct
in,1846,O
253JB-V,1846,B-CellLine
and,1846,O
KU7,1846,B-CellLine
cells,1846,O
.,1846,O
Moreover,1847,O
",",1847,O
using,1847,O
RNA,1847,O
interference,1847,O
with,1847,O
small,1847,O
inhibitory,1847,O
RNAs,1847,O
for,1847,O
Sp1,1847,B-GeneOrGeneProduct
",",1847,O
Sp3,1847,B-GeneOrGeneProduct
",",1847,O
and,1847,O
Sp4,1847,B-GeneOrGeneProduct
",",1847,O
we,1847,O
observed,1847,O
that,1847,O
curcumin-dependent,1847,B-ChemicalEntity
inhibition,1847,O
of,1847,O
nuclear,1847,B-GeneOrGeneProduct
factor,1847,I-GeneOrGeneProduct
kappaB,1847,I-GeneOrGeneProduct
(,1847,O
NF-kappaB,1847,B-GeneOrGeneProduct
),1847,O
-dependent,1847,O
genes,1847,O
",",1847,O
such,1847,O
as,1847,O
bcl-2,1847,B-GeneOrGeneProduct
",",1847,O
survivin,1847,B-GeneOrGeneProduct
",",1847,O
and,1847,O
cyclin,1847,B-GeneOrGeneProduct
D1,1847,I-GeneOrGeneProduct
",",1847,O
was,1847,O
also,1847,O
due,1847,O
",",1847,O
in,1847,O
part,1847,O
",",1847,O
to,1847,O
loss,1847,O
of,1847,O
Sp,1847,B-GeneOrGeneProduct
proteins,1847,O
.,1847,O
Curcumin,1848,B-ChemicalEntity
also,1848,O
decreased,1848,O
bladder,1848,B-DiseaseOrPhenotypicFeature
tumor,1848,I-DiseaseOrPhenotypicFeature
growth,1848,O
in,1848,O
athymic,1848,O
nude,1848,O
mice,1848,B-OrganismTaxon
bearing,1848,O
KU7,1848,B-CellLine
cells,1848,O
as,1848,O
xenografts,1848,O
and,1848,O
this,1848,O
was,1848,O
accompanied,1848,O
by,1848,O
decreased,1848,O
Sp1,1848,B-GeneOrGeneProduct
",",1848,O
Sp3,1848,B-GeneOrGeneProduct
",",1848,O
and,1848,O
Sp4,1848,B-GeneOrGeneProduct
protein,1848,O
levels,1848,O
in,1848,O
tumors,1848,B-DiseaseOrPhenotypicFeature
.,1848,O
These,1849,O
results,1849,O
show,1849,O
for,1849,O
the,1849,O
first,1849,O
time,1849,O
that,1849,O
one,1849,O
of,1849,O
the,1849,O
underlying,1849,O
mechanisms,1849,O
of,1849,O
action,1849,O
of,1849,O
curcumin,1849,B-ChemicalEntity
as,1849,O
a,1849,O
cancer,1849,B-DiseaseOrPhenotypicFeature
chemotherapeutic,1849,O
agent,1849,O
is,1849,O
due,1849,O
",",1849,O
in,1849,O
part,1849,O
",",1849,O
to,1849,O
decreased,1849,O
expression,1849,O
of,1849,O
Sp,1849,B-GeneOrGeneProduct
transcription,1849,I-GeneOrGeneProduct
factors,1849,I-GeneOrGeneProduct
in,1849,O
bladder,1849,B-DiseaseOrPhenotypicFeature
cancer,1849,I-DiseaseOrPhenotypicFeature
cells,1849,O
.,1849,O
mToR,1850,B-ChemicalEntity
inhibitors-induced,1850,O
proteinuria,1850,B-DiseaseOrPhenotypicFeature
:,1850,O
mechanisms,1850,O
",",1850,O
significance,1850,O
",",1850,O
and,1850,O
management,1850,O
.,1850,O
Massive,1851,O
urinary,1851,O
protein,1851,O
excretion,1851,O
has,1851,O
been,1851,O
observed,1851,O
after,1851,O
conversion,1851,O
from,1851,O
calcineurin,1851,B-ChemicalEntity
inhibitors,1851,I-ChemicalEntity
to,1851,O
mammalian,1851,B-ChemicalEntity
target,1851,I-ChemicalEntity
of,1851,I-ChemicalEntity
rapamycin,1851,I-ChemicalEntity
(,1851,I-ChemicalEntity
mToR,1851,I-ChemicalEntity
),1851,I-ChemicalEntity
inhibitors,1851,I-ChemicalEntity
",",1851,O
especially,1851,O
sirolimus,1851,B-ChemicalEntity
",",1851,O
in,1851,O
renal,1851,O
transplant,1851,O
recipients,1851,O
with,1851,O
chronic,1851,B-DiseaseOrPhenotypicFeature
allograft,1851,I-DiseaseOrPhenotypicFeature
nephropathy,1851,I-DiseaseOrPhenotypicFeature
.,1851,O
Because,1852,O
proteinuria,1852,B-DiseaseOrPhenotypicFeature
is,1852,O
a,1852,O
major,1852,O
predictive,1852,O
factor,1852,O
of,1852,O
poor,1852,O
transplantation,1852,O
outcome,1852,O
",",1852,O
many,1852,O
studies,1852,O
focused,1852,O
on,1852,O
this,1852,O
adverse,1852,O
event,1852,O
during,1852,O
the,1852,O
past,1852,O
years,1852,O
.,1852,O
Whether,1853,O
proteinuria,1853,B-DiseaseOrPhenotypicFeature
was,1853,O
due,1853,O
to,1853,O
sirolimus,1853,B-ChemicalEntity
or,1853,O
only,1853,O
a,1853,O
consequence,1853,O
of,1853,O
calcineurin,1853,B-ChemicalEntity
inhibitors,1853,I-ChemicalEntity
withdrawal,1853,O
remained,1853,O
unsolved,1853,O
until,1853,O
high,1853,O
range,1853,O
proteinuria,1853,B-DiseaseOrPhenotypicFeature
has,1853,O
been,1853,O
observed,1853,O
during,1853,O
sirolimus,1853,B-ChemicalEntity
therapy,1853,O
in,1853,O
islet,1853,O
transplantation,1853,O
and,1853,O
in,1853,O
patients,1853,B-OrganismTaxon
who,1853,O
received,1853,O
sirolimus,1853,B-ChemicalEntity
de,1853,O
novo,1853,O
.,1853,O
Podocyte,1854,O
injury,1854,O
and,1854,O
focal,1854,O
segmental,1854,O
glomerulosclerosis,1854,B-DiseaseOrPhenotypicFeature
have,1854,O
been,1854,O
related,1854,O
to,1854,O
mToR,1854,B-GeneOrGeneProduct
inhibition,1854,O
in,1854,O
some,1854,O
patients,1854,B-OrganismTaxon
",",1854,O
but,1854,O
the,1854,O
pathways,1854,O
underlying,1854,O
these,1854,O
lesions,1854,O
remain,1854,O
hypothetic,1854,O
.,1854,O
We,1855,O
discuss,1855,O
herein,1855,O
the,1855,O
possible,1855,O
mechanisms,1855,O
and,1855,O
the,1855,O
significance,1855,O
of,1855,O
mToR,1855,B-GeneOrGeneProduct
blockade-induced,1855,O
proteinuria,1855,B-DiseaseOrPhenotypicFeature
.,1855,O
Detailed,1856,O
spectral,1856,O
profile,1856,O
analysis,1856,O
of,1856,O
penicillin-induced,1856,B-ChemicalEntity
epileptiform,1856,B-DiseaseOrPhenotypicFeature
activity,1856,I-DiseaseOrPhenotypicFeature
in,1856,O
anesthetized,1856,O
rats,1856,B-OrganismTaxon
.,1856,O
Penicillin,1857,B-ChemicalEntity
model,1857,O
is,1857,O
a,1857,O
widely,1857,O
used,1857,O
experimental,1857,O
model,1857,O
for,1857,O
epilepsy,1857,B-DiseaseOrPhenotypicFeature
research,1857,O
.,1857,O
In,1858,O
the,1858,O
present,1858,O
study,1858,O
we,1858,O
aimed,1858,O
to,1858,O
portray,1858,O
a,1858,O
detailed,1858,O
spectral,1858,O
analysis,1858,O
of,1858,O
penicillin-induced,1858,B-ChemicalEntity
epileptiform,1858,B-DiseaseOrPhenotypicFeature
activity,1858,I-DiseaseOrPhenotypicFeature
in,1858,O
comparison,1858,O
with,1858,O
basal,1858,O
brain,1858,O
activity,1858,O
in,1858,O
anesthetized,1858,O
Wistar,1858,O
rats,1858,B-OrganismTaxon
.,1858,O
Male,1859,O
Wistar,1859,O
rats,1859,B-OrganismTaxon
were,1859,O
anesthetized,1859,O
with,1859,O
i.p,1859,O
.,1859,O
urethane,1860,B-ChemicalEntity
and,1860,O
connected,1860,O
to,1860,O
an,1860,O
electrocorticogram,1860,O
setup,1860,O
.,1860,O
After,1861,O
a,1861,O
short,1861,O
period,1861,O
of,1861,O
basal,1861,O
activity,1861,O
recording,1861,O
",",1861,O
epileptic,1861,B-DiseaseOrPhenotypicFeature
focus,1861,O
was,1861,O
induced,1861,O
by,1861,O
injecting,1861,O
400IU/2,1861,O
microl,1861,O
penicillin-G,1861,B-ChemicalEntity
potassium,1861,I-ChemicalEntity
into,1861,O
the,1861,O
left,1861,O
lateral,1861,O
ventricle,1861,O
while,1861,O
the,1861,O
cortical,1861,O
activity,1861,O
was,1861,O
continuously,1861,O
recorded,1861,O
.,1861,O
Basal,1862,O
activity,1862,O
",",1862,O
latent,1862,O
period,1862,O
and,1862,O
the,1862,O
penicillin-induced,1862,B-ChemicalEntity
epileptiform,1862,B-DiseaseOrPhenotypicFeature
activity,1862,I-DiseaseOrPhenotypicFeature
periods,1862,O
were,1862,O
then,1862,O
analyzed,1862,O
using,1862,O
both,1862,O
conventional,1862,O
methods,1862,O
and,1862,O
spectral,1862,O
analysis,1862,O
.,1862,O
Spectral,1863,O
analyses,1863,O
were,1863,O
conducted,1863,O
by,1863,O
dividing,1863,O
the,1863,O
whole,1863,O
spectrum,1863,O
into,1863,O
different,1863,O
frequency,1863,O
bands,1863,O
including,1863,O
delta,1863,O
",",1863,O
theta,1863,O
(,1863,O
slow,1863,O
and,1863,O
fast,1863,O
),1863,O
",",1863,O
alpha-sigma,1863,O
",",1863,O
beta,1863,O
(,1863,O
1,1863,O
and,1863,O
2,1863,O
),1863,O
and,1863,O
gamma,1863,O
(,1863,O
1,1863,O
and,1863,O
2,1863,O
),1863,O
bands,1863,O
.,1863,O
Our,1864,O
results,1864,O
show,1864,O
that,1864,O
the,1864,O
most,1864,O
affected,1864,O
frequency,1864,O
bands,1864,O
were,1864,O
delta,1864,O
",",1864,O
theta,1864,O
",",1864,O
beta-2,1864,O
and,1864,O
gamma-2,1864,O
bands,1864,O
during,1864,O
the,1864,O
epileptiform,1864,B-DiseaseOrPhenotypicFeature
activity,1864,I-DiseaseOrPhenotypicFeature
and,1864,O
there,1864,O
were,1864,O
marked,1864,O
differences,1864,O
in,1864,O
terms,1864,O
of,1864,O
spectral,1864,O
densities,1864,O
between,1864,O
three,1864,O
investigated,1864,O
episodes,1864,O
(,1864,O
basal,1864,O
activity,1864,O
",",1864,O
latent,1864,O
period,1864,O
and,1864,O
epileptiform,1864,B-DiseaseOrPhenotypicFeature
activity,1864,I-DiseaseOrPhenotypicFeature
),1864,O
.,1864,O
Our,1865,O
results,1865,O
may,1865,O
help,1865,O
to,1865,O
analyze,1865,O
novel,1865,O
data,1865,O
obtained,1865,O
using,1865,O
similar,1865,O
experimental,1865,O
models,1865,O
and,1865,O
the,1865,O
simple,1865,O
analysis,1865,O
method,1865,O
described,1865,O
here,1865,O
can,1865,O
be,1865,O
used,1865,O
in,1865,O
similar,1865,O
studies,1865,O
to,1865,O
investigate,1865,O
the,1865,O
basic,1865,O
neuronal,1865,O
mechanism,1865,O
of,1865,O
this,1865,O
or,1865,O
other,1865,O
types,1865,O
of,1865,O
experimental,1865,O
epilepsies,1865,B-DiseaseOrPhenotypicFeature
.,1865,O
GATA4,1866,B-GeneOrGeneProduct
mutations,1866,O
in,1866,O
486,1866,O
Chinese,1866,O
patients,1866,B-OrganismTaxon
with,1866,O
congenital,1866,B-DiseaseOrPhenotypicFeature
heart,1866,I-DiseaseOrPhenotypicFeature
disease,1866,I-DiseaseOrPhenotypicFeature
.,1866,O
Recent,1867,O
studies,1867,O
have,1867,O
reported,1867,O
germline,1867,O
mutations,1867,O
in,1867,O
GATA4,1867,B-GeneOrGeneProduct
gene,1867,O
in,1867,O
some,1867,O
types,1867,O
of,1867,O
congenital,1867,B-DiseaseOrPhenotypicFeature
heart,1867,I-DiseaseOrPhenotypicFeature
disease,1867,I-DiseaseOrPhenotypicFeature
(,1867,O
CHD,1867,B-DiseaseOrPhenotypicFeature
),1867,O
.,1867,O
However,1868,O
",",1868,O
the,1868,O
prevalence,1868,O
of,1868,O
GATA4,1868,B-GeneOrGeneProduct
mutations,1868,O
in,1868,O
CHD,1868,B-DiseaseOrPhenotypicFeature
and,1868,O
the,1868,O
correlation,1868,O
between,1868,O
the,1868,O
GATA4,1868,B-GeneOrGeneProduct
genotype,1868,O
and,1868,O
CHD,1868,B-DiseaseOrPhenotypicFeature
phenotype,1868,O
have,1868,O
not,1868,O
been,1868,O
extensively,1868,O
studied,1868,O
.,1868,O
We,1869,O
screened,1869,O
germline,1869,O
mutations,1869,O
in,1869,O
the,1869,O
coding,1869,O
exons,1869,O
and,1869,O
the,1869,O
flanking,1869,O
intron,1869,O
sequences,1869,O
of,1869,O
the,1869,O
GATA4,1869,B-GeneOrGeneProduct
gene,1869,O
in,1869,O
486,1869,O
CHD,1869,B-DiseaseOrPhenotypicFeature
patients,1869,B-OrganismTaxon
by,1869,O
denaturing,1869,O
high-performance,1869,O
liquid,1869,O
chromatography,1869,O
(,1869,O
DHPLC,1869,O
),1869,O
",",1869,O
and,1869,O
confirmed,1869,O
the,1869,O
mutations,1869,O
by,1869,O
sequencing,1869,O
.,1869,O
Nine,1870,O
distinct,1870,O
mutations,1870,O
including,1870,O
one,1870,O
small,1870,O
deletion,1870,O
mutation,1870,O
(,1870,O
46delS,1870,B-SequenceVariant
),1870,O
",",1870,O
two,1870,O
small,1870,O
insertion,1870,O
mutations,1870,O
(,1870,O
118-119insA,1870,B-SequenceVariant
and,1870,O
125-126insAA,1870,B-SequenceVariant
),1870,O
",",1870,O
and,1870,O
six,1870,O
non-synonymous,1870,O
mutations,1870,O
(,1870,O
A6V,1870,B-SequenceVariant
",",1870,O
P163S,1870,B-SequenceVariant
",",1870,O
E359K,1870,B-SequenceVariant
",",1870,O
P407Q,1870,B-SequenceVariant
",",1870,O
S429T,1870,B-SequenceVariant
and,1870,O
A442V,1870,B-SequenceVariant
),1870,O
were,1870,O
identified,1870,O
in,1870,O
12,1870,O
of,1870,O
the,1870,O
486,1870,O
patients,1870,B-OrganismTaxon
(,1870,O
nine,1870,O
with,1870,O
ventricular,1870,B-DiseaseOrPhenotypicFeature
septal,1870,I-DiseaseOrPhenotypicFeature
defect,1870,I-DiseaseOrPhenotypicFeature
",",1870,O
two,1870,O
with,1870,O
Tetralogy,1870,B-DiseaseOrPhenotypicFeature
of,1870,I-DiseaseOrPhenotypicFeature
Fallot,1870,I-DiseaseOrPhenotypicFeature
",",1870,O
and,1870,O
one,1870,O
with,1870,O
endocardial,1870,B-DiseaseOrPhenotypicFeature
cushion,1870,I-DiseaseOrPhenotypicFeature
defect,1870,I-DiseaseOrPhenotypicFeature
),1870,O
.,1870,O
Of,1871,O
them,1871,O
",",1871,O
two,1871,O
patients,1871,B-OrganismTaxon
carrying,1871,O
E359K,1871,B-SequenceVariant
mutation,1871,O
were,1871,O
from,1871,O
two,1871,O
generations,1871,O
in,1871,O
one,1871,O
family,1871,O
with,1871,O
ventricular,1871,B-DiseaseOrPhenotypicFeature
septal,1871,I-DiseaseOrPhenotypicFeature
defect,1871,I-DiseaseOrPhenotypicFeature
(,1871,O
VSD,1871,B-DiseaseOrPhenotypicFeature
),1871,O
.,1871,O
Interestingly,1872,O
",",1872,O
a,1872,O
nucleotide,1872,O
insertion,1872,O
of,1872,O
c.1146+25insA,1872,B-SequenceVariant
in,1872,O
exon,1872,O
6,1872,O
was,1872,O
detected,1872,O
in,1872,O
five,1872,O
VSD,1872,B-DiseaseOrPhenotypicFeature
patients,1872,B-OrganismTaxon
",",1872,O
but,1872,O
not,1872,O
in,1872,O
486,1872,O
normal,1872,O
healthy,1872,O
controls,1872,O
.,1872,O
Our,1873,O
findings,1873,O
are,1873,O
useful,1873,O
in,1873,O
understanding,1873,O
the,1873,O
prevalence,1873,O
of,1873,O
GATA4,1873,B-GeneOrGeneProduct
mutations,1873,O
and,1873,O
the,1873,O
correlation,1873,O
between,1873,O
the,1873,O
GATA4,1873,B-GeneOrGeneProduct
genotype,1873,O
and,1873,O
the,1873,O
CHD,1873,B-DiseaseOrPhenotypicFeature
phenotype,1873,O
in,1873,O
Chinese,1873,O
patients,1873,B-OrganismTaxon
.,1873,O
High,1874,O
fat,1874,B-ChemicalEntity
diet-fed,1874,O
obese,1874,B-DiseaseOrPhenotypicFeature
rats,1874,B-OrganismTaxon
are,1874,O
highly,1874,O
sensitive,1874,O
to,1874,O
doxorubicin-induced,1874,B-ChemicalEntity
cardiotoxicity,1874,B-DiseaseOrPhenotypicFeature
.,1874,O
Often,1875,O
",",1875,O
chemotherapy,1875,O
by,1875,O
doxorubicin,1875,B-ChemicalEntity
(,1875,O
Adriamycin,1875,B-ChemicalEntity
),1875,O
is,1875,O
limited,1875,O
due,1875,O
to,1875,O
life,1875,O
threatening,1875,O
cardiotoxicity,1875,B-DiseaseOrPhenotypicFeature
in,1875,O
patients,1875,B-OrganismTaxon
during,1875,O
and,1875,O
posttherapy,1875,O
.,1875,O
Recently,1876,O
",",1876,O
we,1876,O
have,1876,O
shown,1876,O
that,1876,O
moderate,1876,O
diet,1876,O
restriction,1876,O
remarkably,1876,O
protects,1876,O
against,1876,O
doxorubicin-induced,1876,B-ChemicalEntity
cardiotoxicity,1876,B-DiseaseOrPhenotypicFeature
.,1876,O
This,1877,O
cardioprotection,1877,O
is,1877,O
accompanied,1877,O
by,1877,O
decreased,1877,O
cardiac,1877,O
oxidative,1877,O
stress,1877,O
and,1877,O
triglycerides,1877,B-ChemicalEntity
and,1877,O
increased,1877,O
cardiac,1877,O
fatty-acid,1877,B-ChemicalEntity
oxidation,1877,O
",",1877,O
ATP,1877,B-ChemicalEntity
synthesis,1877,O
",",1877,O
and,1877,O
upregulated,1877,O
JAK/STAT3,1877,B-GeneOrGeneProduct
pathway,1877,O
.,1877,O
In,1878,O
the,1878,O
current,1878,O
study,1878,O
",",1878,O
we,1878,O
investigated,1878,O
whether,1878,O
a,1878,O
physiological,1878,O
intervention,1878,O
by,1878,O
feeding,1878,O
40,1878,O
%,1878,O
high,1878,O
fat,1878,B-ChemicalEntity
diet,1878,O
(,1878,O
HFD,1878,O
),1878,O
",",1878,O
which,1878,O
induces,1878,O
obesity,1878,B-DiseaseOrPhenotypicFeature
in,1878,O
male,1878,O
Sprague-Dawley,1878,O
rats,1878,B-OrganismTaxon
(,1878,O
250-275,1878,O
g,1878,O
),1878,O
",",1878,O
sensitizes,1878,O
to,1878,O
doxorubicin-induced,1878,B-ChemicalEntity
cardiotoxicity,1878,B-DiseaseOrPhenotypicFeature
.,1878,O
A,1879,O
LD,1879,O
(,1879,O
10,1879,O
),1879,O
dose,1879,O
(,1879,O
8,1879,O
mg,1879,O
doxorubicin/kg,1879,B-ChemicalEntity
",",1879,O
ip,1879,O
),1879,O
administered,1879,O
on,1879,O
day,1879,O
43,1879,O
of,1879,O
the,1879,O
HFD,1879,O
feeding,1879,O
regimen,1879,O
led,1879,O
to,1879,O
higher,1879,O
cardiotoxicity,1879,B-DiseaseOrPhenotypicFeature
",",1879,O
cardiac,1879,B-DiseaseOrPhenotypicFeature
dysfunction,1879,I-DiseaseOrPhenotypicFeature
",",1879,O
lipid,1879,B-ChemicalEntity
peroxidation,1879,O
",",1879,O
and,1879,O
80,1879,O
%,1879,O
mortality,1879,O
in,1879,O
the,1879,O
obese,1879,B-DiseaseOrPhenotypicFeature
(,1879,O
OB,1879,B-DiseaseOrPhenotypicFeature
),1879,O
rats,1879,B-OrganismTaxon
in,1879,O
the,1879,O
absence,1879,O
of,1879,O
any,1879,O
significant,1879,O
renal,1879,B-DiseaseOrPhenotypicFeature
or,1879,I-DiseaseOrPhenotypicFeature
hepatic,1879,I-DiseaseOrPhenotypicFeature
toxicity,1879,I-DiseaseOrPhenotypicFeature
.,1879,O
Doxorubicin,1880,B-ChemicalEntity
toxicokinetics,1880,O
studies,1880,O
revealed,1880,O
no,1880,O
change,1880,O
in,1880,O
accumulation,1880,O
of,1880,O
doxorubicin,1880,B-ChemicalEntity
and,1880,O
doxorubicinol,1880,B-ChemicalEntity
(,1880,O
toxic,1880,O
metabolite,1880,O
),1880,O
in,1880,O
the,1880,O
normal,1880,O
diet-fed,1880,O
(,1880,O
ND,1880,O
),1880,O
and,1880,O
OB,1880,B-DiseaseOrPhenotypicFeature
hearts,1880,O
.,1880,O
Mechanistic,1881,O
studies,1881,O
revealed,1881,O
that,1881,O
OB,1881,B-DiseaseOrPhenotypicFeature
rats,1881,B-OrganismTaxon
are,1881,O
sensitized,1881,O
due,1881,O
to,1881,O
:,1881,O
(,1881,O
1,1881,O
),1881,O
higher,1881,O
oxyradical,1881,O
stress,1881,O
leading,1881,O
to,1881,O
upregulation,1881,O
of,1881,O
uncoupling,1881,B-GeneOrGeneProduct
proteins,1881,I-GeneOrGeneProduct
2,1881,I-GeneOrGeneProduct
and,1881,I-GeneOrGeneProduct
3,1881,I-GeneOrGeneProduct
",",1881,O
(,1881,O
2,1881,O
),1881,O
downregulation,1881,O
of,1881,O
cardiac,1881,O
peroxisome,1881,B-GeneOrGeneProduct
proliferators,1881,I-GeneOrGeneProduct
activated,1881,I-GeneOrGeneProduct
receptor-alpha,1881,I-GeneOrGeneProduct
",",1881,O
(,1881,O
3,1881,O
),1881,O
decreased,1881,O
plasma,1881,O
adiponectin,1881,B-GeneOrGeneProduct
levels,1881,O
",",1881,O
(,1881,O
4,1881,O
),1881,O
decreased,1881,O
cardiac,1881,O
fatty-acid,1881,B-ChemicalEntity
oxidation,1881,O
(,1881,O
666.9+/-14.0,1881,O
nmol/min/g,1881,O
heart,1881,O
in,1881,O
ND,1881,O
versus,1881,O
400.2+/-11.8,1881,O
nmol/min/g,1881,O
heart,1881,O
in,1881,O
OB,1881,B-DiseaseOrPhenotypicFeature
),1881,O
",",1881,O
(,1881,O
5,1881,O
),1881,O
decreased,1881,O
mitochondrial,1881,O
AMP-alpha2,1881,B-GeneOrGeneProduct
protein,1881,I-GeneOrGeneProduct
kinase,1881,I-GeneOrGeneProduct
",",1881,O
and,1881,O
(,1881,O
6,1881,O
),1881,O
86,1881,O
%,1881,O
drop,1881,O
in,1881,O
cardiac,1881,O
ATP,1881,B-ChemicalEntity
levels,1881,O
accompanied,1881,O
by,1881,O
decreased,1881,O
ATP/ADP,1881,B-ChemicalEntity
ratio,1881,O
after,1881,O
doxorubicin,1881,B-ChemicalEntity
administration,1881,O
.,1881,O
Decreased,1882,O
cardiac,1882,O
erythropoietin,1882,B-GeneOrGeneProduct
and,1882,O
increased,1882,O
SOCS3,1882,B-GeneOrGeneProduct
further,1882,O
downregulated,1882,O
the,1882,O
cardioprotective,1882,O
JAK/STAT3,1882,B-GeneOrGeneProduct
pathway,1882,O
.,1882,O
In,1883,O
conclusion,1883,O
",",1883,O
HFD-induced,1883,O
obese,1883,B-DiseaseOrPhenotypicFeature
rats,1883,B-OrganismTaxon
are,1883,O
highly,1883,O
sensitized,1883,O
to,1883,O
doxorubicin-induced,1883,B-ChemicalEntity
cardiotoxicity,1883,B-DiseaseOrPhenotypicFeature
by,1883,O
substantially,1883,O
downregulating,1883,O
cardiac,1883,O
mitochondrial,1883,O
ATP,1883,B-ChemicalEntity
generation,1883,O
",",1883,O
increasing,1883,O
oxidative,1883,O
stress,1883,O
and,1883,O
downregulating,1883,O
the,1883,O
JAK/STAT3,1883,B-GeneOrGeneProduct
pathway,1883,O
.,1883,O
Expanding,1884,O
clinical,1884,O
spectrum,1884,O
of,1884,O
non-autoimmune,1884,B-DiseaseOrPhenotypicFeature
hyperthyroidism,1884,I-DiseaseOrPhenotypicFeature
due,1884,O
to,1884,O
an,1884,O
activating,1884,O
germline,1884,O
mutation,1884,O
",",1884,O
p.M453T,1884,B-SequenceVariant
",",1884,O
in,1884,O
the,1884,O
thyrotropin,1884,B-GeneOrGeneProduct
receptor,1884,I-GeneOrGeneProduct
gene,1884,O
.,1884,O
OBJECTIVE,1885,O
:,1885,O
To,1885,O
describe,1885,O
clinical,1885,O
and,1885,O
genetic,1885,O
features,1885,O
of,1885,O
a,1885,O
Thai,1885,O
family,1885,O
with,1885,O
non-autoimmune,1885,B-DiseaseOrPhenotypicFeature
hyperthyroidism,1885,I-DiseaseOrPhenotypicFeature
(,1885,O
NAH,1885,B-DiseaseOrPhenotypicFeature
),1885,O
caused,1885,O
by,1885,O
an,1885,O
activating,1885,O
germline,1885,O
mutation,1885,O
in,1885,O
the,1885,O
thyrotropin,1885,B-GeneOrGeneProduct
receptor,1885,I-GeneOrGeneProduct
(,1885,O
TSHR,1885,B-GeneOrGeneProduct
),1885,O
gene,1885,O
.,1885,O
PATIENTS,1886,B-OrganismTaxon
:,1886,O
Three,1886,O
affected,1886,O
individuals,1886,O
from,1886,O
the,1886,O
same,1886,O
family,1886,O
(,1886,O
a,1886,O
father,1886,O
and,1886,O
his,1886,O
two,1886,O
children,1886,O
),1886,O
were,1886,O
studied,1886,O
.,1886,O
Clinical,1887,O
and,1887,O
imaging,1887,O
findings,1887,O
were,1887,O
reviewed,1887,O
and,1887,O
compared,1887,O
.,1887,O
GENETIC,1888,O
ANALYSIS,1888,O
:,1888,O
Genomic,1888,O
DNA,1888,O
was,1888,O
extracted,1888,O
from,1888,O
peripheral,1888,O
blood,1888,O
leukocytes,1888,O
and,1888,O
mutation,1888,O
analysis,1888,O
of,1888,O
the,1888,O
entire,1888,O
coding,1888,O
sequence,1888,O
of,1888,O
the,1888,O
TSHR,1888,B-GeneOrGeneProduct
gene,1888,O
was,1888,O
performed,1888,O
in,1888,O
both,1888,O
children,1888,O
and,1888,O
their,1888,O
parents,1888,O
by,1888,O
direct,1888,O
DNA,1888,O
sequencing,1888,O
.,1888,O
RESULTS,1889,O
:,1889,O
A,1889,O
heterozygous,1889,O
germline,1889,O
T,1889,B-SequenceVariant
to,1889,I-SequenceVariant
C,1889,I-SequenceVariant
transition,1889,O
in,1889,O
exon,1889,O
10,1889,O
of,1889,O
the,1889,O
TSHR,1889,B-GeneOrGeneProduct
gene,1889,O
(,1889,O
c.1358T,1889,B-SequenceVariant
--,1889,I-SequenceVariant
>,1889,I-SequenceVariant
C,1889,I-SequenceVariant
),1889,O
resulting,1889,O
in,1889,O
the,1889,O
substitution,1889,O
of,1889,O
methionine,1889,B-SequenceVariant
(,1889,I-SequenceVariant
ATG,1889,I-SequenceVariant
),1889,I-SequenceVariant
by,1889,I-SequenceVariant
threonine,1889,I-SequenceVariant
(,1889,I-SequenceVariant
ACG,1889,I-SequenceVariant
),1889,I-SequenceVariant
at,1889,I-SequenceVariant
codon,1889,I-SequenceVariant
453,1889,I-SequenceVariant
(,1889,O
p.M453T,1889,B-SequenceVariant
),1889,O
was,1889,O
identified,1889,O
in,1889,O
the,1889,O
father,1889,O
and,1889,O
his,1889,O
two,1889,O
children,1889,O
.,1889,O
They,1890,O
presented,1890,O
with,1890,O
different,1890,O
clinical,1890,O
severity,1890,O
and,1890,O
variable,1890,O
age,1890,O
of,1890,O
onset,1890,O
.,1890,O
In,1891,O
addition,1891,O
to,1891,O
hyperthyroidism,1891,B-DiseaseOrPhenotypicFeature
",",1891,O
ventriculomegaly,1891,B-DiseaseOrPhenotypicFeature
and,1891,O
bilateral,1891,O
shortening,1891,O
of,1891,O
the,1891,O
fifth,1891,O
metacarpal,1891,O
bones,1891,O
and,1891,O
the,1891,O
middle,1891,O
phalanges,1891,O
of,1891,O
the,1891,O
fifth,1891,O
fingers,1891,O
were,1891,O
consistently,1891,O
found,1891,O
in,1891,O
all,1891,O
affected,1891,O
individuals,1891,O
.,1891,O
CONCLUSIONS,1892,O
:,1892,O
Ventriculomegaly,1892,B-DiseaseOrPhenotypicFeature
and,1892,O
bilateral,1892,O
shortening,1892,O
of,1892,O
the,1892,O
fifth,1892,O
metacarpal,1892,O
bones,1892,O
and,1892,O
the,1892,O
middle,1892,O
phalanges,1892,O
of,1892,O
the,1892,O
fifth,1892,O
fingers,1892,O
might,1892,O
be,1892,O
characteristic,1892,O
features,1892,O
of,1892,O
NAH,1892,B-DiseaseOrPhenotypicFeature
because,1892,O
of,1892,O
an,1892,O
activating,1892,O
TSHR,1892,B-GeneOrGeneProduct
germline,1892,O
mutation,1892,O
.,1892,O
In,1893,O
addition,1893,O
",",1893,O
the,1893,O
shortening,1893,O
of,1893,O
the,1893,O
middle,1893,O
phalanges,1893,O
of,1893,O
the,1893,O
fifth,1893,O
fingers,1893,O
has,1893,O
never,1893,O
been,1893,O
previously,1893,O
described,1893,O
",",1893,O
expanding,1893,O
the,1893,O
phenotypic,1893,O
spectrum,1893,O
of,1893,O
the,1893,O
disease,1893,O
.,1893,O
Integrated,1894,O
genomic,1894,O
and,1894,O
expression,1894,O
profiling,1894,O
in,1894,O
mantle,1894,B-DiseaseOrPhenotypicFeature
cell,1894,I-DiseaseOrPhenotypicFeature
lymphoma,1894,I-DiseaseOrPhenotypicFeature
:,1894,O
identification,1894,O
of,1894,O
gene-dosage,1894,O
regulated,1894,O
candidate,1894,O
genes,1894,O
.,1894,O
Mantle,1895,B-DiseaseOrPhenotypicFeature
cell,1895,I-DiseaseOrPhenotypicFeature
lymphoma,1895,I-DiseaseOrPhenotypicFeature
(,1895,O
MCL,1895,B-DiseaseOrPhenotypicFeature
),1895,O
is,1895,O
characterized,1895,O
by,1895,O
the,1895,O
t,1895,O
(,1895,O
11,1895,O
;,1895,O
14,1895,O
),1895,O
(,1895,O
q13,1895,O
;,1895,O
q32,1895,O
),1895,O
translocation,1895,O
and,1895,O
several,1895,O
other,1895,O
cytogenetic,1895,O
aberrations,1895,O
",",1895,O
including,1895,O
heterozygous,1895,O
loss,1895,O
of,1895,O
chromosomal,1895,O
arms,1895,O
1p,1895,O
",",1895,O
6q,1895,O
",",1895,O
11q,1895,O
and,1895,O
13q,1895,O
and/or,1895,O
gains,1895,O
of,1895,O
3q,1895,O
and,1895,O
8q,1895,O
.,1895,O
The,1896,O
common,1896,O
intervals,1896,O
of,1896,O
chromosomal,1896,O
imbalance,1896,O
have,1896,O
been,1896,O
narrowed,1896,O
down,1896,O
using,1896,O
array-comparative,1896,O
genomic,1896,O
hybridization,1896,O
(,1896,O
CGH,1896,O
),1896,O
.,1896,O
However,1897,O
",",1897,O
the,1897,O
chromosomal,1897,O
intervals,1897,O
still,1897,O
contain,1897,O
many,1897,O
genes,1897,O
potentially,1897,O
involved,1897,O
in,1897,O
MCL,1897,B-DiseaseOrPhenotypicFeature
pathogeny,1897,O
.,1897,O
Combined,1898,O
analysis,1898,O
of,1898,O
tiling-resolution,1898,O
array-CGH,1898,O
with,1898,O
gene,1898,O
expression,1898,O
profiling,1898,O
on,1898,O
11,1898,O
MCL,1898,B-DiseaseOrPhenotypicFeature
tumours,1898,I-DiseaseOrPhenotypicFeature
enabled,1898,O
the,1898,O
identification,1898,O
of,1898,O
genomic,1898,O
alterations,1898,O
and,1898,O
their,1898,O
corresponding,1898,O
gene,1898,O
expression,1898,O
profiles,1898,O
.,1898,O
Only,1899,O
subsets,1899,O
of,1899,O
genes,1899,O
located,1899,O
within,1899,O
given,1899,O
cytogenetic,1899,O
anomaly-intervals,1899,O
showed,1899,O
a,1899,O
concomitant,1899,O
change,1899,O
in,1899,O
mRNA,1899,O
expression,1899,O
level,1899,O
.,1899,O
The,1900,O
genes,1900,O
that,1900,O
showed,1900,O
consistent,1900,O
correlation,1900,O
between,1900,O
DNA,1900,O
copy,1900,O
number,1900,O
and,1900,O
RNA,1900,O
expression,1900,O
levels,1900,O
are,1900,O
likely,1900,O
to,1900,O
be,1900,O
important,1900,O
in,1900,O
MCL,1900,B-DiseaseOrPhenotypicFeature
pathology,1900,O
.,1900,O
Besides,1901,O
several,1901,O
'anonymous,1901,O
genes,1901,O
',1901,O
",",1901,O
we,1901,O
also,1901,O
identified,1901,O
various,1901,O
fully,1901,O
annotated,1901,O
genes,1901,O
",",1901,O
whose,1901,O
gene,1901,O
products,1901,O
are,1901,O
involved,1901,O
in,1901,O
cyclic,1901,B-ChemicalEntity
adenosine,1901,I-ChemicalEntity
monophosphate-regulated,1901,O
pathways,1901,O
(,1901,O
PRKACB,1901,B-GeneOrGeneProduct
),1901,O
",",1901,O
DNA,1901,O
damage,1901,O
repair,1901,O
",",1901,O
maintenance,1901,O
of,1901,O
chromosome,1901,O
stability,1901,O
and,1901,O
prevention,1901,O
of,1901,O
rereplication,1901,O
(,1901,O
ATM,1901,B-GeneOrGeneProduct
",",1901,O
ERCC5,1901,B-GeneOrGeneProduct
",",1901,O
FBXO5,1901,B-GeneOrGeneProduct
),1901,O
",",1901,O
energy,1901,O
metabolism,1901,O
(,1901,O
such,1901,O
as,1901,O
genes,1901,O
that,1901,O
are,1901,O
involved,1901,O
in,1901,O
the,1901,O
synthesis,1901,O
of,1901,O
proteins,1901,O
encoded,1901,O
by,1901,O
the,1901,O
mitochondrial,1901,O
genome,1901,O
),1901,O
and,1901,O
signal,1901,O
transduction,1901,O
(,1901,O
ARHGAP29,1901,B-GeneOrGeneProduct
),1901,O
.,1901,O
Deregulation,1902,O
of,1902,O
these,1902,O
gene,1902,O
products,1902,O
may,1902,O
interfere,1902,O
with,1902,O
the,1902,O
signalling,1902,O
pathways,1902,O
that,1902,O
are,1902,O
involved,1902,O
in,1902,O
MCL,1902,B-DiseaseOrPhenotypicFeature
tumour,1902,I-DiseaseOrPhenotypicFeature
development,1902,O
and,1902,O
maintenance,1902,O
.,1902,O
Simvastatin-ezetimibe-induced,1903,B-ChemicalEntity
hepatic,1903,B-DiseaseOrPhenotypicFeature
failure,1903,I-DiseaseOrPhenotypicFeature
necessitating,1903,O
liver,1903,O
transplantation,1903,O
.,1903,O
Abstract,1904,O
Serum,1904,B-ChemicalEntity
aminotransferase,1904,I-ChemicalEntity
elevations,1904,O
are,1904,O
a,1904,O
commonly,1904,O
known,1904,O
adverse,1904,O
effect,1904,O
of,1904,O
3-hydroxy-3-methylglutaryl,1904,B-GeneOrGeneProduct
coenzyme,1904,I-GeneOrGeneProduct
A,1904,I-GeneOrGeneProduct
reductase,1904,I-GeneOrGeneProduct
inhibitor,1904,O
(,1904,O
statin,1904,B-ChemicalEntity
),1904,O
therapy,1904,O
.,1904,O
However,1905,O
",",1905,O
hepatotoxic,1905,B-DiseaseOrPhenotypicFeature
events,1905,O
have,1905,O
not,1905,O
been,1905,O
widely,1905,O
published,1905,O
with,1905,O
ezetimibe,1905,B-ChemicalEntity
or,1905,O
the,1905,O
combination,1905,O
agent,1905,O
simvastatin-ezetimibe,1905,B-ChemicalEntity
.,1905,O
We,1906,O
describe,1906,O
a,1906,O
70-year-old,1906,O
Hispanic,1906,O
woman,1906,B-OrganismTaxon
who,1906,O
developed,1906,O
fulminant,1906,B-DiseaseOrPhenotypicFeature
hepatic,1906,I-DiseaseOrPhenotypicFeature
failure,1906,I-DiseaseOrPhenotypicFeature
necessitating,1906,O
liver,1906,O
transplantation,1906,O
10,1906,O
weeks,1906,O
after,1906,O
conversion,1906,O
from,1906,O
simvastatin,1906,B-ChemicalEntity
40,1906,O
mg/day,1906,O
to,1906,O
simvastatin,1906,B-ChemicalEntity
10,1906,O
mg-ezetimibe,1906,O
40,1906,O
mg/day,1906,O
.,1906,O
The,1907,O
patient,1907,B-OrganismTaxon
's,1907,O
lipid,1907,B-ChemicalEntity
panel,1907,O
had,1907,O
been,1907,O
maintained,1907,O
with,1907,O
simvastatin,1907,B-ChemicalEntity
for,1907,O
18,1907,O
months,1907,O
before,1907,O
the,1907,O
conversion,1907,O
without,1907,O
evidence,1907,O
of,1907,O
hepatotoxicity,1907,B-DiseaseOrPhenotypicFeature
.,1907,O
A,1908,O
routine,1908,O
laboratory,1908,O
work-up,1908,O
10,1908,O
weeks,1908,O
after,1908,O
conversion,1908,O
revealed,1908,O
elevated,1908,O
serum,1908,B-ChemicalEntity
aminotransferase,1908,I-ChemicalEntity
levels,1908,O
.,1908,O
Simvastatinezetimibe,1909,B-ChemicalEntity
and,1909,O
escitalopram,1909,B-ChemicalEntity
(,1909,O
which,1909,O
she,1909,O
was,1909,O
taking,1909,O
for,1909,O
depression,1909,B-DiseaseOrPhenotypicFeature
),1909,O
were,1909,O
discontinued,1909,O
",",1909,O
and,1909,O
other,1909,O
potential,1909,O
causes,1909,O
of,1909,O
hepatotoxicity,1909,B-DiseaseOrPhenotypicFeature
were,1909,O
excluded,1909,O
.,1909,O
A,1910,O
repeat,1910,O
work-up,1910,O
revealed,1910,O
further,1910,O
elevations,1910,O
in,1910,O
aminotransferase,1910,B-ChemicalEntity
levels,1910,O
",",1910,O
and,1910,O
liver,1910,O
biopsy,1910,O
revealed,1910,O
evidence,1910,O
of,1910,O
moderate-to-severe,1910,O
drug,1910,B-DiseaseOrPhenotypicFeature
toxicity,1910,I-DiseaseOrPhenotypicFeature
.,1910,O
She,1911,O
underwent,1911,O
liver,1911,O
transplantation,1911,O
with,1911,O
an,1911,O
uneventful,1911,O
postoperative,1911,O
course,1911,O
.,1911,O
Her,1912,O
aminotransferase,1912,B-ChemicalEntity
levels,1912,O
returned,1912,O
to,1912,O
normal,1912,O
by,1912,O
postoperative,1912,O
day,1912,O
23,1912,O
",",1912,O
and,1912,O
her,1912,O
2-year,1912,O
follow-up,1912,O
showed,1912,O
no,1912,O
adverse,1912,O
events,1912,O
.,1912,O
Ezetimibe,1913,B-ChemicalEntity
undergoes,1913,O
extensive,1913,O
glucuronidation,1913,O
by,1913,O
uridine,1913,B-GeneOrGeneProduct
diphosphate,1913,I-GeneOrGeneProduct
glucoronosyltransferases,1913,I-GeneOrGeneProduct
(,1913,O
UGT,1913,B-GeneOrGeneProduct
),1913,O
in,1913,O
the,1913,O
intestine,1913,O
and,1913,O
liver,1913,O
and,1913,O
may,1913,O
have,1913,O
inhibited,1913,O
the,1913,O
glucuronidation,1913,O
of,1913,O
simvastatin,1913,B-ChemicalEntity
hydroxy,1913,I-ChemicalEntity
acid,1913,I-ChemicalEntity
",",1913,O
resulting,1913,O
in,1913,O
increased,1913,O
simvastatin,1913,B-ChemicalEntity
exposure,1913,O
and,1913,O
subsequent,1913,O
hepatotoxicity,1913,B-DiseaseOrPhenotypicFeature
.,1913,O
To,1914,O
our,1914,O
knowledge,1914,O
",",1914,O
this,1914,O
is,1914,O
the,1914,O
first,1914,O
case,1914,O
report,1914,O
of,1914,O
simvastatin-ezetimibe-induced,1914,B-ChemicalEntity
liver,1914,B-DiseaseOrPhenotypicFeature
failure,1914,I-DiseaseOrPhenotypicFeature
that,1914,O
resulted,1914,O
in,1914,O
liver,1914,O
transplantation,1914,O
.,1914,O
We,1915,O
postulate,1915,O
that,1915,O
the,1915,O
mechanism,1915,O
of,1915,O
the,1915,O
simvastatinezetimibe-induced,1915,B-ChemicalEntity
hepatotoxicity,1915,B-DiseaseOrPhenotypicFeature
is,1915,O
the,1915,O
increased,1915,O
simvastatin,1915,B-ChemicalEntity
exposure,1915,O
by,1915,O
ezetimibe,1915,B-ChemicalEntity
inhibition,1915,O
of,1915,O
UGT,1915,B-GeneOrGeneProduct
enzymes,1915,O
.,1915,O
Clinicians,1916,O
should,1916,O
be,1916,O
aware,1916,O
of,1916,O
potential,1916,O
hepatotoxicity,1916,B-DiseaseOrPhenotypicFeature
with,1916,O
simvastatin-ezetimibe,1916,B-ChemicalEntity
especially,1916,O
in,1916,O
elderly,1916,O
patients,1916,B-OrganismTaxon
and,1916,O
should,1916,O
carefully,1916,O
monitor,1916,O
serum,1916,B-ChemicalEntity
aminotransferase,1916,I-ChemicalEntity
levels,1916,O
when,1916,O
starting,1916,O
therapy,1916,O
and,1916,O
titrating,1916,O
the,1916,O
dosage,1916,O
.,1916,O
Massive,1917,O
proteinuria,1917,B-DiseaseOrPhenotypicFeature
and,1917,O
acute,1917,B-DiseaseOrPhenotypicFeature
renal,1917,I-DiseaseOrPhenotypicFeature
failure,1917,I-DiseaseOrPhenotypicFeature
after,1917,O
oral,1917,O
bisphosphonate,1917,B-ChemicalEntity
(,1917,O
alendronate,1917,B-ChemicalEntity
),1917,O
administration,1917,O
in,1917,O
a,1917,O
patient,1917,B-OrganismTaxon
with,1917,O
focal,1917,B-DiseaseOrPhenotypicFeature
segmental,1917,I-DiseaseOrPhenotypicFeature
glomerulosclerosis,1917,I-DiseaseOrPhenotypicFeature
.,1917,O
A,1918,O
61-year-old,1918,O
Japanese,1918,O
man,1918,B-OrganismTaxon
with,1918,O
nephrotic,1918,B-DiseaseOrPhenotypicFeature
syndrome,1918,I-DiseaseOrPhenotypicFeature
due,1918,O
to,1918,O
focal,1918,B-DiseaseOrPhenotypicFeature
segmental,1918,I-DiseaseOrPhenotypicFeature
glomerulosclerosis,1918,I-DiseaseOrPhenotypicFeature
was,1918,O
initially,1918,O
responding,1918,O
well,1918,O
to,1918,O
steroid,1918,B-ChemicalEntity
therapy,1918,O
.,1918,O
The,1919,O
amount,1919,O
of,1919,O
daily,1919,O
urinary,1919,O
protein,1919,O
decreased,1919,O
from,1919,O
15.6,1919,O
to,1919,O
2.8,1919,O
g.,1919,O
Within,1919,O
14,1919,O
days,1919,O
of,1919,O
the,1919,O
oral,1919,O
bisphosphonate,1919,B-ChemicalEntity
(,1919,O
alendronate,1919,B-ChemicalEntity
sodium,1919,I-ChemicalEntity
),1919,O
administration,1919,O
",",1919,O
the,1919,O
amount,1919,O
of,1919,O
daily,1919,O
urinary,1919,O
protein,1919,O
increased,1919,O
rapidly,1919,O
up,1919,O
to,1919,O
12.8,1919,O
g,1919,O
with,1919,O
acute,1919,B-DiseaseOrPhenotypicFeature
renal,1919,I-DiseaseOrPhenotypicFeature
failure,1919,I-DiseaseOrPhenotypicFeature
.,1919,O
After,1920,O
discontinuing,1920,O
the,1920,O
oral,1920,O
alendronate,1920,B-ChemicalEntity
",",1920,O
the,1920,O
patient,1920,B-OrganismTaxon
underwent,1920,O
six,1920,O
cycles,1920,O
of,1920,O
hemodialysis,1920,O
and,1920,O
four,1920,O
cycles,1920,O
of,1920,O
LDL,1920,O
apheresis,1920,O
.,1920,O
Urinary,1921,O
volume,1921,O
and,1921,O
serum,1921,O
creatinine,1921,B-ChemicalEntity
levels,1921,O
recovered,1921,O
to,1921,O
the,1921,O
normal,1921,O
range,1921,O
",",1921,O
with,1921,O
urinary,1921,O
protein,1921,O
disappearing,1921,O
completely,1921,O
within,1921,O
40,1921,O
days,1921,O
.,1921,O
This,1922,O
report,1922,O
demonstrates,1922,O
that,1922,O
not,1922,O
only,1922,O
intravenous,1922,O
",",1922,O
but,1922,O
also,1922,O
oral,1922,O
bisphosphonates,1922,B-ChemicalEntity
can,1922,O
aggravate,1922,O
proteinuria,1922,B-DiseaseOrPhenotypicFeature
and,1922,O
acute,1922,B-DiseaseOrPhenotypicFeature
renal,1922,I-DiseaseOrPhenotypicFeature
failure,1922,I-DiseaseOrPhenotypicFeature
.,1922,O
Serum-,1923,B-GeneOrGeneProduct
and,1923,I-GeneOrGeneProduct
glucocorticoid-inducible,1923,I-GeneOrGeneProduct
kinase,1923,I-GeneOrGeneProduct
1,1923,I-GeneOrGeneProduct
in,1923,O
doxorubicin-induced,1923,B-ChemicalEntity
nephrotic,1923,B-DiseaseOrPhenotypicFeature
syndrome,1923,I-DiseaseOrPhenotypicFeature
.,1923,O
Doxorubicin-induced,1924,B-ChemicalEntity
nephropathy,1924,B-DiseaseOrPhenotypicFeature
leads,1924,O
to,1924,O
epithelial,1924,O
sodium,1924,B-ChemicalEntity
channel,1924,O
(,1924,O
ENaC,1924,O
),1924,O
-dependent,1924,O
volume,1924,B-DiseaseOrPhenotypicFeature
retention,1924,I-DiseaseOrPhenotypicFeature
and,1924,O
renal,1924,B-DiseaseOrPhenotypicFeature
fibrosis,1924,I-DiseaseOrPhenotypicFeature
.,1924,O
The,1925,O
aldosterone-sensitive,1925,B-ChemicalEntity
serum-,1925,B-GeneOrGeneProduct
and,1925,I-GeneOrGeneProduct
glucocorticoid-inducible,1925,I-GeneOrGeneProduct
kinase,1925,I-GeneOrGeneProduct
SGK1,1925,B-GeneOrGeneProduct
has,1925,O
been,1925,O
shown,1925,O
to,1925,O
participate,1925,O
in,1925,O
the,1925,O
stimulation,1925,O
of,1925,O
ENaC,1925,O
and,1925,O
to,1925,O
mediate,1925,O
renal,1925,B-DiseaseOrPhenotypicFeature
fibrosis,1925,I-DiseaseOrPhenotypicFeature
following,1925,O
mineralocorticoid,1925,B-ChemicalEntity
and,1925,O
salt,1925,B-ChemicalEntity
excess,1925,O
.,1925,O
The,1926,O
present,1926,O
study,1926,O
was,1926,O
performed,1926,O
to,1926,O
elucidate,1926,O
the,1926,O
role,1926,O
of,1926,O
SGK1,1926,B-GeneOrGeneProduct
in,1926,O
the,1926,O
volume,1926,B-DiseaseOrPhenotypicFeature
retention,1926,I-DiseaseOrPhenotypicFeature
and,1926,O
fibrosis,1926,B-DiseaseOrPhenotypicFeature
during,1926,O
nephrotic,1926,B-DiseaseOrPhenotypicFeature
syndrome,1926,I-DiseaseOrPhenotypicFeature
.,1926,O
To,1927,O
this,1927,O
end,1927,O
",",1927,O
doxorubicin,1927,B-ChemicalEntity
(,1927,O
15,1927,O
mug/g,1927,O
body,1927,O
wt,1927,O
),1927,O
was,1927,O
injected,1927,O
intravenously,1927,O
into,1927,O
gene-targeted,1927,O
mice,1927,B-OrganismTaxon
lacking,1927,O
SGK1,1927,B-GeneOrGeneProduct
(,1927,O
sgk1,1927,B-GeneOrGeneProduct
(,1927,O
-/-,1927,O
),1927,O
),1927,O
and,1927,O
their,1927,O
wild-type,1927,O
littermates,1927,O
(,1927,O
sgk1,1927,B-GeneOrGeneProduct
(,1927,O
+/+,1927,O
),1927,O
),1927,O
.,1927,O
Doxorubicin,1928,B-ChemicalEntity
treatment,1928,O
resulted,1928,O
in,1928,O
heavy,1928,O
proteinuria,1928,B-DiseaseOrPhenotypicFeature
(,1928,O
>,1928,O
100,1928,O
mg,1928,O
protein/mg,1928,O
crea,1928,B-ChemicalEntity
),1928,O
in,1928,O
15/44,1928,O
of,1928,O
sgk1,1928,B-GeneOrGeneProduct
(,1928,O
+/+,1928,O
),1928,O
and,1928,O
15/44,1928,O
of,1928,O
sgk1,1928,B-GeneOrGeneProduct
(,1928,O
-/-,1928,O
),1928,O
mice,1928,B-OrganismTaxon
leading,1928,O
to,1928,O
severe,1928,O
nephrotic,1928,B-DiseaseOrPhenotypicFeature
syndrome,1928,I-DiseaseOrPhenotypicFeature
with,1928,O
ascites,1928,B-DiseaseOrPhenotypicFeature
",",1928,O
lipidemia,1928,B-DiseaseOrPhenotypicFeature
",",1928,O
and,1928,O
hypoalbuminemia,1928,B-DiseaseOrPhenotypicFeature
in,1928,O
both,1928,O
genotypes,1928,O
.,1928,O
Plasma,1929,O
aldosterone,1929,B-ChemicalEntity
levels,1929,O
increased,1929,O
in,1929,O
nephrotic,1929,B-DiseaseOrPhenotypicFeature
mice,1929,B-OrganismTaxon
of,1929,O
both,1929,O
genotypes,1929,O
and,1929,O
was,1929,O
followed,1929,O
by,1929,O
increased,1929,O
SGK1,1929,B-GeneOrGeneProduct
protein,1929,O
expression,1929,O
in,1929,O
sgk1,1929,B-GeneOrGeneProduct
(,1929,O
+/+,1929,O
),1929,O
mice,1929,B-OrganismTaxon
.,1929,O
Urinary,1930,O
sodium,1930,B-ChemicalEntity
excretion,1930,O
reached,1930,O
signficantly,1930,O
lower,1930,O
values,1930,O
in,1930,O
sgk1,1930,B-GeneOrGeneProduct
(,1930,O
+/+,1930,O
),1930,O
mice,1930,B-OrganismTaxon
(,1930,O
15,1930,O
+/-,1930,O
5,1930,O
mumol/mg,1930,O
crea,1930,B-ChemicalEntity
),1930,O
than,1930,O
in,1930,O
sgk1,1930,B-GeneOrGeneProduct
(,1930,O
-/-,1930,O
),1930,O
mice,1930,B-OrganismTaxon
(,1930,O
35,1930,O
+/-,1930,O
5,1930,O
mumol/mg,1930,O
crea,1930,B-ChemicalEntity
),1930,O
and,1930,O
was,1930,O
associated,1930,O
with,1930,O
a,1930,O
significantly,1930,O
higher,1930,O
body,1930,O
weight,1930,B-DiseaseOrPhenotypicFeature
gain,1930,I-DiseaseOrPhenotypicFeature
in,1930,O
sgk1,1930,B-GeneOrGeneProduct
(,1930,O
+/+,1930,O
),1930,O
compared,1930,O
with,1930,O
sgk1,1930,B-GeneOrGeneProduct
(,1930,O
-/-,1930,O
),1930,O
mice,1930,B-OrganismTaxon
(,1930,O
+6.6,1930,O
+/-,1930,O
0.7,1930,O
vs.,1930,O
+4.1,1930,O
+/-,1930,O
0.8,1930,O
g,1930,O
),1930,O
.,1930,O
During,1931,O
the,1931,O
course,1931,O
of,1931,O
nephrotic,1931,B-DiseaseOrPhenotypicFeature
syndrome,1931,I-DiseaseOrPhenotypicFeature
",",1931,O
serum,1931,O
urea,1931,B-ChemicalEntity
concentrations,1931,O
increased,1931,O
significantly,1931,O
faster,1931,O
in,1931,O
sgk1,1931,B-GeneOrGeneProduct
(,1931,O
-/-,1931,O
),1931,O
mice,1931,B-OrganismTaxon
than,1931,O
in,1931,O
sgk1,1931,B-GeneOrGeneProduct
(,1931,O
+/+,1931,O
),1931,O
mice,1931,B-OrganismTaxon
leading,1931,O
to,1931,O
uremia,1931,B-DiseaseOrPhenotypicFeature
and,1931,O
a,1931,O
reduced,1931,O
median,1931,O
survival,1931,O
in,1931,O
sgk1,1931,B-GeneOrGeneProduct
(,1931,O
-/-,1931,O
),1931,O
mice,1931,B-OrganismTaxon
(,1931,O
29,1931,O
vs.,1931,O
40,1931,O
days,1931,O
in,1931,O
sgk1,1931,B-GeneOrGeneProduct
(,1931,O
+/+,1931,O
),1931,O
mice,1931,B-OrganismTaxon
),1931,O
.,1931,O
In,1932,O
conclusion,1932,O
",",1932,O
gene-targeted,1932,O
mice,1932,B-OrganismTaxon
lacking,1932,O
SGK1,1932,B-GeneOrGeneProduct
showed,1932,O
blunted,1932,O
volume,1932,B-DiseaseOrPhenotypicFeature
retention,1932,I-DiseaseOrPhenotypicFeature
",",1932,O
yet,1932,O
were,1932,O
not,1932,O
protected,1932,O
against,1932,O
renal,1932,B-DiseaseOrPhenotypicFeature
fibrosis,1932,I-DiseaseOrPhenotypicFeature
during,1932,O
experimental,1932,O
nephrotic,1932,B-DiseaseOrPhenotypicFeature
syndrome,1932,I-DiseaseOrPhenotypicFeature
.,1932,O
Novel,1933,O
suppressors,1933,O
of,1933,O
alpha-synuclein,1933,B-GeneOrGeneProduct
toxicity,1933,B-DiseaseOrPhenotypicFeature
identified,1933,O
using,1933,O
yeast,1933,B-OrganismTaxon
.,1933,O
The,1934,O
mechanism,1934,O
by,1934,O
which,1934,O
the,1934,O
Parkinson,1934,B-DiseaseOrPhenotypicFeature
's,1934,I-DiseaseOrPhenotypicFeature
disease-related,1934,O
protein,1934,O
alpha-synuclein,1934,B-GeneOrGeneProduct
(,1934,O
alpha-syn,1934,B-GeneOrGeneProduct
),1934,O
causes,1934,O
neurodegeneration,1934,B-DiseaseOrPhenotypicFeature
has,1934,O
not,1934,O
been,1934,O
elucidated,1934,O
.,1934,O
To,1935,O
determine,1935,O
the,1935,O
genes,1935,O
that,1935,O
protect,1935,O
cells,1935,O
from,1935,O
alpha-syn,1935,B-GeneOrGeneProduct
",",1935,O
we,1935,O
used,1935,O
a,1935,O
genetic,1935,O
screen,1935,O
to,1935,O
identify,1935,O
suppressors,1935,O
of,1935,O
the,1935,O
super,1935,O
sensitivity,1935,O
of,1935,O
the,1935,O
yeast,1935,B-OrganismTaxon
Saccharomyces,1935,B-OrganismTaxon
cerevisiae,1935,I-OrganismTaxon
expressing,1935,O
alpha-syn,1935,B-GeneOrGeneProduct
to,1935,O
killing,1935,O
by,1935,O
hydrogen,1935,B-ChemicalEntity
peroxide,1935,I-ChemicalEntity
.,1935,O
Forty,1936,O
genes,1936,O
in,1936,O
ubiquitin-dependent,1936,B-GeneOrGeneProduct
protein,1936,O
catabolism,1936,O
",",1936,O
protein,1936,O
biosynthesis,1936,O
",",1936,O
vesicle,1936,O
trafficking,1936,O
and,1936,O
the,1936,O
response,1936,O
to,1936,O
stress,1936,O
were,1936,O
identified,1936,O
.,1936,O
Five,1937,O
of,1937,O
the,1937,O
forty,1937,O
genes,1937,O
--,1937,O
ENT3,1937,B-GeneOrGeneProduct
",",1937,O
IDP3,1937,B-GeneOrGeneProduct
",",1937,O
JEM1,1937,B-GeneOrGeneProduct
",",1937,O
ARG2,1937,B-GeneOrGeneProduct
and,1937,O
HSP82,1937,B-GeneOrGeneProduct
--,1937,O
ranked,1937,O
highest,1937,O
in,1937,O
their,1937,O
ability,1937,O
to,1937,O
block,1937,O
alpha-syn-induced,1937,B-GeneOrGeneProduct
reactive,1937,B-ChemicalEntity
oxygen,1937,I-ChemicalEntity
species,1937,I-ChemicalEntity
accumulation,1937,O
",",1937,O
and,1937,O
these,1937,O
five,1937,O
genes,1937,O
were,1937,O
characterized,1937,O
in,1937,O
more,1937,O
detail,1937,O
.,1937,O
The,1938,O
deletion,1938,O
of,1938,O
any,1938,O
of,1938,O
these,1938,O
five,1938,O
genes,1938,O
enhanced,1938,O
the,1938,O
toxicity,1938,B-DiseaseOrPhenotypicFeature
of,1938,O
alpha-syn,1938,B-GeneOrGeneProduct
as,1938,O
judged,1938,O
by,1938,O
growth,1938,O
defects,1938,O
compared,1938,O
with,1938,O
wild-type,1938,O
cells,1938,O
expressing,1938,O
alpha-syn,1938,B-GeneOrGeneProduct
",",1938,O
which,1938,O
indicates,1938,O
that,1938,O
these,1938,O
genes,1938,O
protect,1938,O
cells,1938,O
from,1938,O
alpha-syn,1938,B-GeneOrGeneProduct
.,1938,O
Strikingly,1939,O
",",1939,O
four,1939,O
of,1939,O
the,1939,O
five,1939,O
genes,1939,O
are,1939,O
specific,1939,O
for,1939,O
alpha-syn,1939,B-GeneOrGeneProduct
in,1939,O
that,1939,O
they,1939,O
fail,1939,O
to,1939,O
protect,1939,O
cells,1939,O
from,1939,O
the,1939,O
toxicity,1939,B-DiseaseOrPhenotypicFeature
of,1939,O
the,1939,O
two,1939,O
inherited,1939,O
mutants,1939,O
A30P,1939,B-SequenceVariant
or,1939,O
A53T,1939,B-SequenceVariant
.,1939,O
This,1940,O
finding,1940,O
suggests,1940,O
that,1940,O
alpha-syn,1940,B-GeneOrGeneProduct
causes,1940,O
toxicity,1940,B-DiseaseOrPhenotypicFeature
to,1940,O
cells,1940,O
through,1940,O
a,1940,O
different,1940,O
pathway,1940,O
than,1940,O
these,1940,O
two,1940,O
inherited,1940,O
mutants,1940,O
.,1940,O
Lastly,1941,O
",",1941,O
overexpression,1941,O
of,1941,O
Ent3p,1941,B-GeneOrGeneProduct
",",1941,O
which,1941,O
is,1941,O
a,1941,O
clathrin,1941,B-ChemicalEntity
adapter,1941,O
protein,1941,O
involved,1941,O
in,1941,O
protein,1941,O
transport,1941,O
between,1941,O
the,1941,O
Golgi,1941,O
and,1941,O
the,1941,O
vacuole,1941,O
",",1941,O
causes,1941,O
alpha-syn,1941,B-GeneOrGeneProduct
to,1941,O
redistribute,1941,O
from,1941,O
the,1941,O
plasma,1941,O
membrane,1941,O
into,1941,O
cytoplasmic,1941,O
vesicular,1941,O
structures,1941,O
.,1941,O
Our,1942,O
interpretation,1942,O
is,1942,O
that,1942,O
Ent3p,1942,B-GeneOrGeneProduct
mediates,1942,O
the,1942,O
transport,1942,O
of,1942,O
alpha-syn,1942,B-GeneOrGeneProduct
to,1942,O
the,1942,O
vacuole,1942,O
for,1942,O
proteolytic,1942,O
degradation,1942,O
.,1942,O
A,1943,O
similar,1943,O
clathrin,1943,B-ChemicalEntity
adaptor,1943,O
protein,1943,O
",",1943,O
epsinR,1943,B-GeneOrGeneProduct
",",1943,O
exists,1943,O
in,1943,O
humans,1943,B-OrganismTaxon
.,1943,O
Identification,1944,O
of,1944,O
a,1944,O
gain-of-function,1944,O
mutation,1944,O
of,1944,O
the,1944,O
prolactin,1944,B-GeneOrGeneProduct
receptor,1944,I-GeneOrGeneProduct
in,1944,O
women,1944,B-OrganismTaxon
with,1944,O
benign,1944,B-DiseaseOrPhenotypicFeature
breast,1944,I-DiseaseOrPhenotypicFeature
tumors,1944,I-DiseaseOrPhenotypicFeature
.,1944,O
There,1945,O
is,1945,O
currently,1945,O
no,1945,O
known,1945,O
genetic,1945,B-DiseaseOrPhenotypicFeature
disease,1945,I-DiseaseOrPhenotypicFeature
linked,1945,O
to,1945,O
prolactin,1945,B-GeneOrGeneProduct
(,1945,O
Prl,1945,B-GeneOrGeneProduct
),1945,O
or,1945,O
its,1945,O
receptor,1945,O
(,1945,O
PrlR,1945,B-GeneOrGeneProduct
),1945,O
in,1945,O
humans,1945,B-OrganismTaxon
.,1945,O
Given,1946,O
the,1946,O
essential,1946,O
role,1946,O
of,1946,O
this,1946,O
hormonal,1946,O
system,1946,O
in,1946,O
breast,1946,O
physiology,1946,O
",",1946,O
we,1946,O
reasoned,1946,O
that,1946,O
genetic,1946,O
anomalies,1946,O
of,1946,O
Prl/PrlR,1946,B-GeneOrGeneProduct
genes,1946,O
may,1946,O
be,1946,O
related,1946,O
to,1946,O
the,1946,O
occurrence,1946,O
of,1946,O
breast,1946,B-DiseaseOrPhenotypicFeature
diseases,1946,I-DiseaseOrPhenotypicFeature
with,1946,O
high,1946,O
proliferative,1946,O
potential,1946,O
.,1946,O
Multiple,1947,B-DiseaseOrPhenotypicFeature
fibroadenomas,1947,I-DiseaseOrPhenotypicFeature
(,1947,O
MFA,1947,B-DiseaseOrPhenotypicFeature
),1947,O
are,1947,O
benign,1947,B-DiseaseOrPhenotypicFeature
breast,1947,I-DiseaseOrPhenotypicFeature
tumors,1947,I-DiseaseOrPhenotypicFeature
which,1947,O
appear,1947,O
most,1947,O
frequently,1947,O
in,1947,O
young,1947,O
women,1947,B-OrganismTaxon
",",1947,O
including,1947,O
at,1947,O
puberty,1947,O
",",1947,O
when,1947,O
Prl,1947,B-GeneOrGeneProduct
has,1947,O
well-recognized,1947,O
proliferative,1947,O
actions,1947,O
on,1947,O
the,1947,O
breast,1947,O
.,1947,O
In,1948,O
a,1948,O
prospective,1948,O
study,1948,O
involving,1948,O
74,1948,O
MFA,1948,B-DiseaseOrPhenotypicFeature
patients,1948,B-OrganismTaxon
and,1948,O
170,1948,O
control,1948,O
subjects,1948,O
",",1948,O
we,1948,O
identified,1948,O
four,1948,O
patients,1948,B-OrganismTaxon
harboring,1948,O
a,1948,O
heterozygous,1948,O
single,1948,O
nucleotide,1948,O
polymorphism,1948,O
in,1948,O
exon,1948,O
6,1948,O
of,1948,O
the,1948,O
PrlR,1948,B-GeneOrGeneProduct
gene,1948,O
",",1948,O
encoding,1948,O
Ile,1948,B-SequenceVariant
(,1948,I-SequenceVariant
146,1948,I-SequenceVariant
),1948,I-SequenceVariant
--,1948,I-SequenceVariant
>,1948,I-SequenceVariant
Leu,1948,I-SequenceVariant
substitution,1948,O
in,1948,O
its,1948,O
extracellular,1948,O
domain,1948,O
.,1948,O
This,1949,O
sole,1949,O
substitution,1949,O
was,1949,O
sufficient,1949,O
to,1949,O
confer,1949,O
constitutive,1949,O
activity,1949,O
to,1949,O
the,1949,O
receptor,1949,O
variant,1949,O
(,1949,O
PrlR,1949,B-GeneOrGeneProduct
(,1949,O
I146L,1949,B-SequenceVariant
),1949,O
),1949,O
",",1949,O
as,1949,O
assessed,1949,O
in,1949,O
three,1949,O
reconstituted,1949,O
cell,1949,O
models,1949,O
(,1949,O
Ba/F3,1949,B-CellLine
",",1949,O
HEK293,1949,B-CellLine
and,1949,O
MCF-7,1949,B-CellLine
cells,1949,O
),1949,O
by,1949,O
Prl-independent,1949,B-GeneOrGeneProduct
(,1949,O
i,1949,O
),1949,O
PrlR,1949,B-GeneOrGeneProduct
tyrosine,1949,O
phosphorylation,1949,O
",",1949,O
(,1949,O
ii,1949,O
),1949,O
activation,1949,O
of,1949,O
signal,1949,B-GeneOrGeneProduct
transducer,1949,I-GeneOrGeneProduct
and,1949,I-GeneOrGeneProduct
activator,1949,I-GeneOrGeneProduct
of,1949,I-GeneOrGeneProduct
transcription,1949,I-GeneOrGeneProduct
5,1949,I-GeneOrGeneProduct
(,1949,O
STAT5,1949,B-GeneOrGeneProduct
),1949,O
signaling,1949,O
",",1949,O
(,1949,O
iii,1949,O
),1949,O
transcriptional,1949,O
activity,1949,O
toward,1949,O
a,1949,O
Prl-responsive,1949,B-GeneOrGeneProduct
reporter,1949,O
gene,1949,O
",",1949,O
and,1949,O
(,1949,O
iv,1949,O
),1949,O
cell,1949,O
proliferation,1949,O
and,1949,O
protection,1949,O
from,1949,O
cell,1949,O
death,1949,O
.,1949,O
Constitutive,1950,O
activity,1950,O
of,1950,O
PrlR,1950,B-GeneOrGeneProduct
(,1950,O
I146L,1950,B-SequenceVariant
),1950,O
in,1950,O
the,1950,O
breast,1950,O
sample,1950,O
from,1950,O
a,1950,O
patient,1950,B-OrganismTaxon
was,1950,O
supported,1950,O
by,1950,O
increased,1950,O
STAT5,1950,B-GeneOrGeneProduct
signaling,1950,O
.,1950,O
This,1951,O
is,1951,O
a,1951,O
unique,1951,O
description,1951,O
of,1951,O
a,1951,O
functional,1951,O
mutation,1951,O
of,1951,O
the,1951,O
PrlR,1951,B-GeneOrGeneProduct
associated,1951,O
with,1951,O
a,1951,O
human,1951,B-OrganismTaxon
disease,1951,O
.,1951,O
Hallmarks,1952,O
of,1952,O
constitutive,1952,O
activity,1952,O
were,1952,O
all,1952,O
reversed,1952,O
by,1952,O
a,1952,O
specific,1952,O
PrlR,1952,B-ChemicalEntity
antagonist,1952,I-ChemicalEntity
",",1952,O
which,1952,O
opens,1952,O
potential,1952,O
therapeutic,1952,O
approaches,1952,O
for,1952,O
MFA,1952,B-DiseaseOrPhenotypicFeature
",",1952,O
or,1952,O
any,1952,O
other,1952,O
disease,1952,O
that,1952,O
could,1952,O
be,1952,O
associated,1952,O
with,1952,O
this,1952,O
mutation,1952,O
in,1952,O
future,1952,O
.,1952,O
Is,1953,O
the,1953,O
European,1953,O
spatial,1953,O
distribution,1953,O
of,1953,O
the,1953,O
HIV-1-resistant,1953,B-OrganismTaxon
CCR5-Delta32,1953,B-GeneOrGeneProduct
allele,1953,O
formed,1953,O
by,1953,O
a,1953,O
breakdown,1953,O
of,1953,O
the,1953,O
pathocenosis,1953,O
due,1953,O
to,1953,O
the,1953,O
historical,1953,O
Roman,1953,O
expansion,1953,O
?,1953,O
We,1954,O
studied,1954,O
the,1954,O
possible,1954,O
effects,1954,O
of,1954,O
the,1954,O
expansion,1954,O
of,1954,O
ancient,1954,O
Mediterranean,1954,O
civilizations,1954,O
during,1954,O
the,1954,O
five,1954,O
centuries,1954,O
before,1954,O
and,1954,O
after,1954,O
Christ,1954,O
on,1954,O
the,1954,O
European,1954,O
distribution,1954,O
of,1954,O
the,1954,O
mutant,1954,O
allele,1954,O
for,1954,O
the,1954,O
chemokine,1954,B-GeneOrGeneProduct
receptor,1954,I-GeneOrGeneProduct
gene,1954,O
CCR5,1954,B-GeneOrGeneProduct
which,1954,O
has,1954,O
a,1954,O
32-bp,1954,B-SequenceVariant
deletion,1954,I-SequenceVariant
(,1954,O
CCR5-Delta32,1954,B-GeneOrGeneProduct
),1954,O
.,1954,O
There,1955,O
is,1955,O
a,1955,O
strong,1955,O
evidence,1955,O
for,1955,O
the,1955,O
unitary,1955,O
origin,1955,O
of,1955,O
the,1955,O
CCR5-Delta32,1955,B-GeneOrGeneProduct
mutation,1955,O
",",1955,O
this,1955,O
it,1955,O
is,1955,O
found,1955,O
principally,1955,O
in,1955,O
Europe,1955,O
and,1955,O
Western,1955,O
Asia,1955,O
",",1955,O
with,1955,O
generally,1955,O
a,1955,O
north-south,1955,O
downhill,1955,O
cline,1955,O
frequency,1955,O
.,1955,O
Homozygous,1956,O
carriers,1956,O
of,1956,O
this,1956,O
mutation,1956,O
show,1956,O
a,1956,O
resistance,1956,O
to,1956,O
HIV-1,1956,B-DiseaseOrPhenotypicFeature
infection,1956,I-DiseaseOrPhenotypicFeature
and,1956,O
a,1956,O
slower,1956,O
progression,1956,O
towards,1956,O
AIDS,1956,B-DiseaseOrPhenotypicFeature
.,1956,O
However,1957,O
",",1957,O
HIV,1957,B-OrganismTaxon
has,1957,O
clearly,1957,O
emerged,1957,O
too,1957,O
recently,1957,O
to,1957,O
have,1957,O
been,1957,O
the,1957,O
selective,1957,O
force,1957,O
on,1957,O
CCR5,1957,B-GeneOrGeneProduct
.,1957,O
Our,1958,O
analyses,1958,O
showed,1958,O
strong,1958,O
negative,1958,O
correlations,1958,O
in,1958,O
Europe,1958,O
between,1958,O
the,1958,O
allele,1958,O
frequency,1958,O
and,1958,O
two,1958,O
historical,1958,O
parameters,1958,O
",",1958,O
i.e,1958,O
.,1958,O
the,1959,O
first,1959,O
colonization,1959,O
dates,1959,O
by,1959,O
the,1959,O
great,1959,O
ancient,1959,O
Mediterranean,1959,O
civilizations,1959,O
",",1959,O
and,1959,O
the,1959,O
distances,1959,O
from,1959,O
the,1959,O
Northern,1959,O
frontiers,1959,O
of,1959,O
the,1959,O
Roman,1959,O
Empire,1959,O
in,1959,O
its,1959,O
greatest,1959,O
expansion,1959,O
.,1959,O
Moreover,1960,O
",",1960,O
other,1960,O
studies,1960,O
have,1960,O
shown,1960,O
that,1960,O
the,1960,O
deletion,1960,O
frequencies,1960,O
in,1960,O
both,1960,O
German,1960,O
Bronze,1960,O
Age,1960,O
and,1960,O
Swedish,1960,O
Neolithic,1960,O
populations,1960,O
were,1960,O
similar,1960,O
to,1960,O
those,1960,O
found,1960,O
in,1960,O
the,1960,O
corresponding,1960,O
modern,1960,O
populations,1960,O
",",1960,O
and,1960,O
this,1960,O
deletion,1960,O
has,1960,O
been,1960,O
found,1960,O
in,1960,O
ancient,1960,O
DNA,1960,O
of,1960,O
around,1960,O
7000,1960,O
years,1960,O
ago,1960,O
",",1960,O
suggesting,1960,O
that,1960,O
in,1960,O
the,1960,O
past,1960,O
",",1960,O
the,1960,O
deletion,1960,O
frequency,1960,O
could,1960,O
have,1960,O
been,1960,O
relatively,1960,O
high,1960,O
in,1960,O
European,1960,O
populations,1960,O
.,1960,O
In,1961,O
addition,1961,O
",",1961,O
in,1961,O
West,1961,B-OrganismTaxon
Nile,1961,I-OrganismTaxon
virus,1961,I-OrganismTaxon
pathogenesis,1961,O
",",1961,O
CCR5,1961,B-GeneOrGeneProduct
plays,1961,O
an,1961,O
antimicrobial,1961,O
role,1961,O
showing,1961,O
that,1961,O
host,1961,O
genetic,1961,O
factors,1961,O
are,1961,O
highly,1961,O
pathogen-specific,1961,O
.,1961,O
Our,1962,O
results,1962,O
added,1962,O
to,1962,O
all,1962,O
these,1962,O
previous,1962,O
data,1962,O
suggest,1962,O
that,1962,O
the,1962,O
actual,1962,O
European,1962,O
allele,1962,O
frequency,1962,O
distribution,1962,O
might,1962,O
not,1962,O
be,1962,O
due,1962,O
to,1962,O
genes,1962,O
spreading,1962,O
",",1962,O
but,1962,O
to,1962,O
a,1962,O
negative,1962,O
selection,1962,O
resulting,1962,O
in,1962,O
the,1962,O
spread,1962,O
of,1962,O
pathogens,1962,O
principally,1962,O
during,1962,O
Roman,1962,O
expansion,1962,O
.,1962,O
Indeed,1963,O
",",1963,O
as,1963,O
gene,1963,O
flows,1963,O
from,1963,O
colonizers,1963,O
to,1963,O
European,1963,O
native,1963,O
populations,1963,O
were,1963,O
extremely,1963,O
low,1963,O
",",1963,O
the,1963,O
mutational,1963,O
changes,1963,O
might,1963,O
be,1963,O
associated,1963,O
with,1963,O
vulnerability,1963,O
to,1963,O
imported,1963,O
infections,1963,B-DiseaseOrPhenotypicFeature
.,1963,O
To,1964,O
date,1964,O
",",1964,O
the,1964,O
nature,1964,O
of,1964,O
the,1964,O
parasites,1964,O
remains,1964,O
unknown,1964,O
;,1964,O
however,1964,O
",",1964,O
zoonoses,1964,O
could,1964,O
be,1964,O
incriminated,1964,O
.,1964,O
A,1965,O
case,1965,O
of,1965,O
Bernard-Soulier,1965,B-DiseaseOrPhenotypicFeature
Syndrome,1965,I-DiseaseOrPhenotypicFeature
due,1965,O
to,1965,O
a,1965,O
homozygous,1965,O
four,1965,O
bases,1965,O
deletion,1965,B-SequenceVariant
(,1965,I-SequenceVariant
TGAG,1965,I-SequenceVariant
),1965,I-SequenceVariant
of,1965,O
GPIbalpha,1965,B-GeneOrGeneProduct
gene,1965,O
:,1965,O
lack,1965,O
of,1965,O
GPIbalpha,1965,B-GeneOrGeneProduct
but,1965,O
absence,1965,O
of,1965,O
bleeding,1965,B-DiseaseOrPhenotypicFeature
.,1965,O
More,1966,O
than,1966,O
20,1966,O
DNA,1966,O
mutations,1966,O
with,1966,O
different,1966,O
inheritance,1966,O
pattern,1966,O
have,1966,O
been,1966,O
described,1966,O
in,1966,O
patients,1966,B-OrganismTaxon
with,1966,O
Bernard-Soulier,1966,B-DiseaseOrPhenotypicFeature
Syndrome,1966,I-DiseaseOrPhenotypicFeature
(,1966,O
BSS,1966,B-DiseaseOrPhenotypicFeature
),1966,O
",",1966,O
leading,1966,O
to,1966,O
abnormal,1966,O
or,1966,O
absent,1966,O
synthesis,1966,O
and/or,1966,O
expression,1966,O
of,1966,O
GPIbalpha,1966,B-GeneOrGeneProduct
.,1966,O
Clinical,1967,O
phenotype,1967,O
shows,1967,O
considerable,1967,O
variation,1967,O
between,1967,O
individuals,1967,O
",",1967,O
such,1967,O
as,1967,O
bleeding,1967,B-DiseaseOrPhenotypicFeature
",",1967,O
platelet,1967,O
count,1967,O
and,1967,O
the,1967,O
percentage,1967,O
of,1967,O
large,1967,O
platelets,1967,O
.,1967,O
We,1968,O
describe,1968,O
in,1968,O
a,1968,O
BSS,1968,B-DiseaseOrPhenotypicFeature
patient,1968,B-OrganismTaxon
the,1968,O
first,1968,O
case,1968,O
of,1968,O
homozygous,1968,O
four,1968,O
bases,1968,O
deletion,1968,B-SequenceVariant
(,1968,I-SequenceVariant
TGAG,1968,I-SequenceVariant
),1968,I-SequenceVariant
in,1968,O
the,1968,O
gpIbalpha,1968,B-GeneOrGeneProduct
gene,1968,O
coding,1968,O
sequence,1968,O
",",1968,O
leading,1968,O
to,1968,O
a,1968,O
premature,1968,O
stop,1968,O
codon,1968,O
.,1968,O
In,1969,O
the,1969,O
propositus,1969,O
",",1969,O
blood,1969,O
smears,1969,O
revealed,1969,O
giant,1969,O
platelets,1969,O
(,1969,O
30,1969,O
x,1969,O
10,1969,O
(,1969,O
9,1969,O
),1969,O
platelets/L,1969,O
),1969,O
",",1969,O
and,1969,O
platelet,1969,O
agglutination,1969,O
to,1969,O
ristocetin,1969,B-ChemicalEntity
was,1969,O
absent,1969,O
.,1969,O
Propositus,1970,O
',1970,O
parents,1970,O
are,1970,O
consanguineous,1970,O
.,1970,O
His,1971,O
father,1971,O
and,1971,O
paternal,1971,O
grandmother,1971,O
showed,1971,O
a,1971,O
mild,1971,O
thrombocytopenia,1971,B-DiseaseOrPhenotypicFeature
(,1971,O
108,1971,O
x,1971,O
10,1971,O
(,1971,O
9,1971,O
),1971,O
/L,1971,O
and,1971,O
120,1971,O
x,1971,O
10,1971,O
(,1971,O
9,1971,O
),1971,O
/L,1971,O
platelets,1971,O
respectively,1971,O
),1971,O
while,1971,O
mothers,1971,O
and,1971,O
sister,1971,O
's,1971,O
referred,1971,O
normal,1971,O
platelet,1971,O
counts,1971,O
.,1971,O
The,1972,O
surface,1972,O
expression,1972,O
of,1972,O
GPIbalpha,1972,B-GeneOrGeneProduct
was,1972,O
practically,1972,O
undetectable,1972,O
by,1972,O
flow-cytometry,1972,O
and,1972,O
western,1972,O
blot,1972,O
in,1972,O
the,1972,O
patient,1972,B-OrganismTaxon
and,1972,O
was,1972,O
reduced,1972,O
in,1972,O
the,1972,O
father,1972,O
.,1972,O
Proband,1973,O
's,1973,O
DNA,1973,O
analysis,1973,O
revealed,1973,O
a,1973,O
homozygous,1973,O
four-base-pair,1973,O
deletion,1973,B-SequenceVariant
(,1973,I-SequenceVariant
TGAG,1973,I-SequenceVariant
),1973,I-SequenceVariant
",",1973,O
starting,1973,O
from,1973,O
the,1973,O
last,1973,O
base,1973,O
of,1973,O
the,1973,O
codon,1973,O
for,1973,O
Ser39,1973,O
",",1973,O
leading,1973,O
to,1973,O
a,1973,O
coding,1973,O
frame,1973,O
shift,1973,O
with,1973,O
a,1973,O
new,1973,O
termination,1973,O
codon,1973,O
after,1973,O
11,1973,O
novel,1973,O
amino,1973,O
acids,1973,O
.,1973,O
The,1974,O
same,1974,O
mutation,1974,O
was,1974,O
seen,1974,O
in,1974,O
heterozygosis,1974,O
in,1974,O
both,1974,O
parents,1974,O
.,1974,O
This,1975,O
is,1975,O
the,1975,O
first,1975,O
report,1975,O
of,1975,O
GPIbalpha,1975,B-GeneOrGeneProduct
TGAG,1975,B-SequenceVariant
deletion,1975,I-SequenceVariant
in,1975,O
homozygous,1975,O
state,1975,O
even,1975,O
if,1975,O
the,1975,O
defect,1975,O
has,1975,O
already,1975,O
been,1975,O
described,1975,O
in,1975,O
a,1975,O
case,1975,O
of,1975,O
compound,1975,O
heterozygosis,1975,O
.,1975,O
Surprisingly,1976,O
",",1976,O
the,1976,O
propositus,1976,O
does,1976,O
not,1976,O
report,1976,O
any,1976,O
spontaneous,1976,O
bleeding,1976,B-DiseaseOrPhenotypicFeature
tendency,1976,I-DiseaseOrPhenotypicFeature
.,1976,O
Isoproterenol,1977,B-ChemicalEntity
induces,1977,O
primary,1977,O
loss,1977,O
of,1977,O
dystrophin,1977,B-GeneOrGeneProduct
in,1977,O
rat,1977,B-OrganismTaxon
hearts,1977,O
:,1977,O
correlation,1977,O
with,1977,O
myocardial,1977,B-DiseaseOrPhenotypicFeature
injury,1977,I-DiseaseOrPhenotypicFeature
.,1977,O
The,1978,O
mechanism,1978,O
of,1978,O
isoproterenol-induced,1978,B-ChemicalEntity
myocardial,1978,B-DiseaseOrPhenotypicFeature
damage,1978,I-DiseaseOrPhenotypicFeature
is,1978,O
unknown,1978,O
",",1978,O
but,1978,O
a,1978,O
mismatch,1978,O
of,1978,O
oxygen,1978,B-ChemicalEntity
supply,1978,O
vs.,1978,O
demand,1978,O
following,1978,O
coronary,1978,O
hypotension,1978,B-DiseaseOrPhenotypicFeature
and,1978,O
myocardial,1978,B-DiseaseOrPhenotypicFeature
hyperactivity,1978,I-DiseaseOrPhenotypicFeature
is,1978,O
the,1978,O
best,1978,O
explanation,1978,O
for,1978,O
the,1978,O
complex,1978,O
morphological,1978,O
alterations,1978,O
observed,1978,O
.,1978,O
Severe,1979,O
alterations,1979,O
in,1979,O
the,1979,O
structural,1979,O
integrity,1979,O
of,1979,O
the,1979,O
sarcolemma,1979,O
of,1979,O
cardiomyocytes,1979,O
have,1979,O
been,1979,O
demonstrated,1979,O
to,1979,O
be,1979,O
caused,1979,O
by,1979,O
isoproterenol,1979,B-ChemicalEntity
.,1979,O
Taking,1980,O
into,1980,O
account,1980,O
that,1980,O
the,1980,O
sarcolemmal,1980,O
integrity,1980,O
is,1980,O
stabilized,1980,O
by,1980,O
the,1980,O
dystrophin-glycoprotein,1980,B-GeneOrGeneProduct
complex,1980,O
(,1980,O
DGC,1980,O
),1980,O
that,1980,O
connects,1980,O
actin,1980,B-GeneOrGeneProduct
and,1980,O
laminin,1980,B-GeneOrGeneProduct
in,1980,O
contractile,1980,O
machinery,1980,O
and,1980,O
extracellular,1980,O
matrix,1980,O
and,1980,O
by,1980,O
integrins,1980,O
",",1980,O
this,1980,O
study,1980,O
tests,1980,O
the,1980,O
hypothesis,1980,O
that,1980,O
isoproterenol,1980,B-ChemicalEntity
affects,1980,O
sarcolemmal,1980,O
stability,1980,O
through,1980,O
changes,1980,O
in,1980,O
the,1980,O
DGC,1980,O
and,1980,O
integrins,1980,O
.,1980,O
We,1981,O
found,1981,O
different,1981,O
sensitivity,1981,O
of,1981,O
the,1981,O
DGC,1981,O
and,1981,O
integrin,1981,O
to,1981,O
isoproterenol,1981,B-ChemicalEntity
subcutaneous,1981,O
administration,1981,O
.,1981,O
Immunofluorescent,1982,O
staining,1982,O
revealed,1982,O
that,1982,O
dystrophin,1982,B-GeneOrGeneProduct
is,1982,O
the,1982,O
most,1982,O
sensitive,1982,O
among,1982,O
the,1982,O
structures,1982,O
connecting,1982,O
the,1982,O
actin,1982,B-GeneOrGeneProduct
in,1982,O
the,1982,O
cardiomyocyte,1982,O
cytoskeleton,1982,O
and,1982,O
the,1982,O
extracellular,1982,O
matrix,1982,O
.,1982,O
The,1983,O
sarcomeric,1983,O
actin,1983,B-GeneOrGeneProduct
dissolution,1983,O
occurred,1983,O
after,1983,O
the,1983,O
reduction,1983,O
or,1983,O
loss,1983,O
of,1983,O
dystrophin,1983,B-GeneOrGeneProduct
.,1983,O
Subsequently,1984,O
",",1984,O
after,1984,O
lysis,1984,O
of,1984,O
myofilaments,1984,O
",",1984,O
gamma-sarcoglycan,1984,B-GeneOrGeneProduct
",",1984,O
beta-dystroglycan,1984,B-GeneOrGeneProduct
",",1984,O
beta1-integrin,1984,B-GeneOrGeneProduct
",",1984,O
and,1984,O
laminin,1984,B-GeneOrGeneProduct
alpha-2,1984,I-GeneOrGeneProduct
expressions,1984,O
were,1984,O
reduced,1984,O
followed,1984,O
by,1984,O
their,1984,O
breakdown,1984,O
",",1984,O
as,1984,O
epiphenomena,1984,O
of,1984,O
the,1984,O
myocytolytic,1984,O
process,1984,O
.,1984,O
In,1985,O
conclusion,1985,O
",",1985,O
administration,1985,O
of,1985,O
isoproterenol,1985,B-ChemicalEntity
to,1985,O
rats,1985,B-OrganismTaxon
results,1985,O
in,1985,O
primary,1985,O
loss,1985,O
of,1985,O
dystrophin,1985,B-GeneOrGeneProduct
",",1985,O
the,1985,O
most,1985,O
sensitive,1985,O
among,1985,O
the,1985,O
structural,1985,O
proteins,1985,O
that,1985,O
form,1985,O
the,1985,O
DGC,1985,O
that,1985,O
connects,1985,O
the,1985,O
extracellular,1985,O
matrix,1985,O
and,1985,O
the,1985,O
cytoskeleton,1985,O
in,1985,O
cardiomyocyte,1985,O
.,1985,O
These,1986,O
changes,1986,O
",",1986,O
related,1986,O
to,1986,O
ischaemic,1986,B-DiseaseOrPhenotypicFeature
injury,1986,I-DiseaseOrPhenotypicFeature
",",1986,O
explain,1986,O
the,1986,O
severe,1986,O
alterations,1986,O
in,1986,O
the,1986,O
structural,1986,O
integrity,1986,O
of,1986,O
the,1986,O
sarcolemma,1986,O
of,1986,O
cardiomyocytes,1986,O
and,1986,O
hence,1986,O
severe,1986,O
and,1986,O
irreversible,1986,O
injury,1986,O
induced,1986,O
by,1986,O
isoproterenol,1986,B-ChemicalEntity
.,1986,O
Alpha-lipoic,1987,B-ChemicalEntity
acid,1987,I-ChemicalEntity
prevents,1987,O
mitochondrial,1987,B-DiseaseOrPhenotypicFeature
damage,1987,I-DiseaseOrPhenotypicFeature
and,1987,O
neurotoxicity,1987,B-DiseaseOrPhenotypicFeature
in,1987,O
experimental,1987,O
chemotherapy,1987,O
neuropathy,1987,B-DiseaseOrPhenotypicFeature
.,1987,O
The,1988,O
study,1988,O
investigates,1988,O
if,1988,O
alpha-lipoic,1988,B-ChemicalEntity
acid,1988,I-ChemicalEntity
is,1988,O
neuroprotective,1988,O
against,1988,O
chemotherapy,1988,O
induced,1988,O
neurotoxicity,1988,B-DiseaseOrPhenotypicFeature
",",1988,O
if,1988,O
mitochondrial,1988,B-DiseaseOrPhenotypicFeature
damage,1988,I-DiseaseOrPhenotypicFeature
plays,1988,O
a,1988,O
critical,1988,O
role,1988,O
in,1988,O
toxic,1988,B-DiseaseOrPhenotypicFeature
neurodegenerative,1988,I-DiseaseOrPhenotypicFeature
cascade,1988,I-DiseaseOrPhenotypicFeature
",",1988,O
and,1988,O
if,1988,O
neuroprotective,1988,O
effects,1988,O
of,1988,O
alpha-lipoic,1988,B-ChemicalEntity
acid,1988,I-ChemicalEntity
depend,1988,O
on,1988,O
mitochondria,1988,O
protection,1988,O
.,1988,O
We,1989,O
used,1989,O
an,1989,O
in,1989,O
vitro,1989,O
model,1989,O
of,1989,O
chemotherapy,1989,O
induced,1989,O
peripheral,1989,B-DiseaseOrPhenotypicFeature
neuropathy,1989,I-DiseaseOrPhenotypicFeature
that,1989,O
closely,1989,O
mimic,1989,O
the,1989,O
in,1989,O
vivo,1989,O
condition,1989,O
by,1989,O
exposing,1989,O
primary,1989,O
cultures,1989,O
of,1989,O
dorsal,1989,O
root,1989,O
ganglion,1989,O
(,1989,O
DRG,1989,O
),1989,O
sensory,1989,O
neurons,1989,O
to,1989,O
paclitaxel,1989,B-ChemicalEntity
and,1989,O
cisplatin,1989,B-ChemicalEntity
",",1989,O
two,1989,O
widely,1989,O
used,1989,O
and,1989,O
highly,1989,O
effective,1989,O
chemotherapeutic,1989,O
drugs,1989,O
.,1989,O
This,1990,O
approach,1990,O
allowed,1990,O
investigating,1990,O
the,1990,O
efficacy,1990,O
of,1990,O
alpha-lipoic,1990,B-ChemicalEntity
acid,1990,I-ChemicalEntity
in,1990,O
preventing,1990,O
axonal,1990,B-DiseaseOrPhenotypicFeature
damage,1990,I-DiseaseOrPhenotypicFeature
and,1990,O
apoptosis,1990,O
and,1990,O
the,1990,O
function,1990,O
and,1990,O
ultrastructural,1990,O
morphology,1990,O
of,1990,O
mitochondria,1990,O
after,1990,O
exposure,1990,O
to,1990,O
toxic,1990,O
agents,1990,O
and,1990,O
alpha-lipoic,1990,B-ChemicalEntity
acid,1990,I-ChemicalEntity
.,1990,O
Our,1991,O
results,1991,O
demonstrate,1991,O
that,1991,O
both,1991,O
cisplatin,1991,B-ChemicalEntity
and,1991,O
paclitaxel,1991,B-ChemicalEntity
cause,1991,O
early,1991,O
mitochondrial,1991,B-DiseaseOrPhenotypicFeature
impairment,1991,I-DiseaseOrPhenotypicFeature
with,1991,O
loss,1991,O
of,1991,O
membrane,1991,O
potential,1991,O
and,1991,O
induction,1991,O
of,1991,O
autophagic,1991,O
vacuoles,1991,O
in,1991,O
neurons,1991,O
.,1991,O
Alpha-lipoic,1992,B-ChemicalEntity
acid,1992,I-ChemicalEntity
exerts,1992,O
neuroprotective,1992,O
effects,1992,O
against,1992,O
chemotherapy,1992,O
induced,1992,O
neurotoxicity,1992,B-DiseaseOrPhenotypicFeature
in,1992,O
sensory,1992,O
neurons,1992,O
:,1992,O
it,1992,O
rescues,1992,O
the,1992,O
mitochondrial,1992,B-DiseaseOrPhenotypicFeature
toxicity,1992,I-DiseaseOrPhenotypicFeature
and,1992,O
induces,1992,O
the,1992,O
expression,1992,O
of,1992,O
frataxin,1992,B-GeneOrGeneProduct
",",1992,O
an,1992,O
essential,1992,O
mitochondrial,1992,O
protein,1992,O
with,1992,O
anti-oxidant,1992,O
and,1992,O
chaperone,1992,O
properties,1992,O
.,1992,O
In,1993,O
conclusion,1993,O
mitochondrial,1993,B-DiseaseOrPhenotypicFeature
toxicity,1993,I-DiseaseOrPhenotypicFeature
is,1993,O
an,1993,O
early,1993,O
common,1993,O
event,1993,O
both,1993,O
in,1993,O
paclitaxel,1993,B-ChemicalEntity
and,1993,O
cisplatin,1993,B-ChemicalEntity
induced,1993,O
neurotoxicity,1993,B-DiseaseOrPhenotypicFeature
.,1993,O
Alpha-lipoic,1994,B-ChemicalEntity
acid,1994,I-ChemicalEntity
protects,1994,O
sensory,1994,O
neurons,1994,O
through,1994,O
its,1994,O
anti-oxidant,1994,O
and,1994,O
mitochondrial,1994,O
regulatory,1994,O
functions,1994,O
",",1994,O
possibly,1994,O
inducing,1994,O
the,1994,O
expression,1994,O
of,1994,O
frataxin,1994,B-GeneOrGeneProduct
.,1994,O
These,1995,O
findings,1995,O
suggest,1995,O
that,1995,O
alpha-lipoic,1995,B-ChemicalEntity
acid,1995,I-ChemicalEntity
might,1995,O
reduce,1995,O
the,1995,O
risk,1995,O
of,1995,O
developing,1995,O
peripheral,1995,B-DiseaseOrPhenotypicFeature
nerve,1995,I-DiseaseOrPhenotypicFeature
toxicity,1995,I-DiseaseOrPhenotypicFeature
in,1995,O
patients,1995,B-OrganismTaxon
undergoing,1995,O
chemotherapy,1995,O
and,1995,O
encourage,1995,O
further,1995,O
confirmatory,1995,O
clinical,1995,O
trials,1995,O
.,1995,O
A,1996,O
novel,1996,O
point,1996,O
mutation,1996,O
in,1996,O
the,1996,O
amino,1996,O
terminal,1996,O
domain,1996,O
of,1996,O
the,1996,O
human,1996,B-OrganismTaxon
glucocorticoid,1996,B-GeneOrGeneProduct
receptor,1996,I-GeneOrGeneProduct
(,1996,O
hGR,1996,B-GeneOrGeneProduct
),1996,O
gene,1996,O
enhancing,1996,O
hGR-mediated,1996,B-GeneOrGeneProduct
gene,1996,O
expression,1996,O
.,1996,O
CONTEXT,1997,O
:,1997,O
Interindividual,1997,O
variations,1997,O
in,1997,O
glucocorticoid,1997,B-ChemicalEntity
sensitivity,1997,O
have,1997,O
been,1997,O
associated,1997,O
with,1997,O
manifestations,1997,O
of,1997,O
cortisol,1997,B-ChemicalEntity
excess,1997,O
or,1997,O
deficiency,1997,O
and,1997,O
may,1997,O
be,1997,O
partly,1997,O
explained,1997,O
by,1997,O
polymorphisms,1997,O
in,1997,O
the,1997,O
human,1997,B-OrganismTaxon
glucocorticoid,1997,B-GeneOrGeneProduct
receptor,1997,I-GeneOrGeneProduct
(,1997,O
hGR,1997,B-GeneOrGeneProduct
),1997,O
gene,1997,O
.,1997,O
We,1998,O
studied,1998,O
a,1998,O
43-yr-old,1998,O
female,1998,O
",",1998,O
who,1998,O
presented,1998,O
with,1998,O
manifestations,1998,O
consistent,1998,O
with,1998,O
tissue-selective,1998,O
glucocorticoid,1998,B-ChemicalEntity
hypersensitivity,1998,B-DiseaseOrPhenotypicFeature
.,1998,O
We,1999,O
detected,1999,O
a,1999,O
novel,1999,O
",",1999,O
single,1999,O
",",1999,O
heterozygous,1999,O
nucleotide,1999,O
(,1999,B-SequenceVariant
G,1999,I-SequenceVariant
--,1999,I-SequenceVariant
>,1999,I-SequenceVariant
C,1999,I-SequenceVariant
),1999,I-SequenceVariant
substitution,1999,I-SequenceVariant
at,1999,I-SequenceVariant
position,1999,I-SequenceVariant
1201,1999,I-SequenceVariant
(,1999,O
exon,1999,O
2,1999,O
),1999,O
of,1999,O
the,1999,O
hGR,1999,B-GeneOrGeneProduct
gene,1999,O
",",1999,O
which,1999,O
resulted,1999,O
in,1999,O
aspartic,1999,B-SequenceVariant
acid,1999,I-SequenceVariant
to,1999,I-SequenceVariant
histidine,1999,I-SequenceVariant
substitution,1999,I-SequenceVariant
at,1999,I-SequenceVariant
amino,1999,I-SequenceVariant
acid,1999,I-SequenceVariant
position,1999,I-SequenceVariant
401,1999,I-SequenceVariant
in,1999,O
the,1999,O
amino-terminal,1999,O
domain,1999,O
of,1999,O
the,1999,O
hGRalpha,1999,B-GeneOrGeneProduct
.,1999,O
We,2000,O
investigated,2000,O
the,2000,O
molecular,2000,O
mechanisms,2000,O
of,2000,O
action,2000,O
of,2000,O
the,2000,O
natural,2000,O
mutant,2000,O
receptor,2000,O
hGRalphaD401H,2000,B-GeneOrGeneProduct
.,2000,O
METHODS-RESULTS,2001,O
:,2001,O
Compared,2001,O
with,2001,O
the,2001,O
wild-type,2001,O
hGRalpha,2001,B-GeneOrGeneProduct
",",2001,O
the,2001,O
mutant,2001,O
receptor,2001,O
hGRalphaD401H,2001,B-GeneOrGeneProduct
demonstrated,2001,O
a,2001,O
2.4-fold,2001,O
increase,2001,O
in,2001,O
its,2001,O
ability,2001,O
to,2001,O
transactivate,2001,O
the,2001,O
glucocorticoid-inducible,2001,B-ChemicalEntity
mouse,2001,B-OrganismTaxon
mammary,2001,I-OrganismTaxon
tumor,2001,I-OrganismTaxon
virus,2001,I-OrganismTaxon
promoter,2001,O
in,2001,O
response,2001,O
to,2001,O
dexamethasone,2001,B-ChemicalEntity
but,2001,O
had,2001,O
similar,2001,O
affinity,2001,O
for,2001,O
the,2001,O
ligand,2001,O
(,2001,O
dissociation,2001,O
constant,2001,O
=,2001,O
6.2,2001,O
+/-,2001,O
0.6,2001,O
vs.,2001,O
6.1,2001,O
+/-,2001,O
0.6,2001,O
nm,2001,O
),2001,O
and,2001,O
time,2001,O
to,2001,O
nuclear,2001,O
translocation,2001,O
(,2001,O
14.75,2001,O
+/-,2001,O
0.25,2001,O
vs.,2001,O
14.25,2001,O
+/-,2001,O
1.13,2001,O
min,2001,O
),2001,O
.,2001,O
The,2002,O
mutant,2002,O
receptor,2002,O
hGRalphaD401H,2002,B-GeneOrGeneProduct
did,2002,O
not,2002,O
exert,2002,O
a,2002,O
dominant,2002,O
positive,2002,O
or,2002,O
negative,2002,O
effect,2002,O
upon,2002,O
the,2002,O
wild-type,2002,O
receptor,2002,O
",",2002,O
it,2002,O
preserved,2002,O
its,2002,O
ability,2002,O
to,2002,O
bind,2002,O
to,2002,O
glucocorticoid,2002,B-ChemicalEntity
response,2002,O
elements,2002,O
",",2002,O
and,2002,O
displayed,2002,O
a,2002,O
normal,2002,O
interaction,2002,O
with,2002,O
the,2002,O
glucocorticoid,2002,B-GeneOrGeneProduct
receptor-interacting,2002,I-GeneOrGeneProduct
protein,2002,I-GeneOrGeneProduct
1,2002,I-GeneOrGeneProduct
coactivator,2002,O
.,2002,O
CONCLUSIONS,2003,O
:,2003,O
The,2003,O
mutant,2003,O
receptor,2003,O
hGRalphaD401H,2003,B-GeneOrGeneProduct
enhances,2003,O
the,2003,O
transcriptional,2003,O
activity,2003,O
of,2003,O
glucocorticoid-responsive,2003,B-GeneOrGeneProduct
genes,2003,I-GeneOrGeneProduct
.,2003,O
The,2004,O
presence,2004,O
of,2004,O
the,2004,O
D401H,2004,B-SequenceVariant
mutation,2004,O
may,2004,O
predispose,2004,O
subjects,2004,O
to,2004,O
obesity,2004,B-DiseaseOrPhenotypicFeature
",",2004,O
hypertension,2004,B-DiseaseOrPhenotypicFeature
",",2004,O
and,2004,O
other,2004,O
manifestations,2004,O
of,2004,O
the,2004,O
metabolic,2004,B-DiseaseOrPhenotypicFeature
syndrome,2004,I-DiseaseOrPhenotypicFeature
.,2004,O
R58fs,2005,B-SequenceVariant
mutation,2005,O
in,2005,O
the,2005,O
HGD,2005,B-GeneOrGeneProduct
gene,2005,O
in,2005,O
a,2005,O
family,2005,O
with,2005,O
alkaptonuria,2005,B-DiseaseOrPhenotypicFeature
in,2005,O
the,2005,O
UAE,2005,O
.,2005,O
This,2006,O
study,2006,O
was,2006,O
conducted,2006,O
to,2006,O
determine,2006,O
the,2006,O
prevalence,2006,O
of,2006,O
alkaptonuria,2006,B-DiseaseOrPhenotypicFeature
in,2006,O
the,2006,O
UAE,2006,O
population,2006,O
and,2006,O
to,2006,O
identify,2006,O
the,2006,O
genotype,2006,O
of,2006,O
affected,2006,O
individuals,2006,O
.,2006,O
In,2007,O
a,2007,O
3,2007,O
stage,2007,O
sampling,2007,O
technique,2007,O
2981,2007,O
pupils,2007,O
from,2007,O
Government,2007,O
schools,2007,O
in,2007,O
Al,2007,O
Ain,2007,O
and,2007,O
private,2007,O
schools,2007,O
in,2007,O
Dubai,2007,O
were,2007,O
selected,2007,O
to,2007,O
take,2007,O
part,2007,O
in,2007,O
the,2007,O
study,2007,O
",",2007,O
of,2007,O
whom,2007,O
2857,2007,O
provided,2007,O
urine,2007,O
samples,2007,O
.,2007,O
Urine,2008,O
collected,2008,O
was,2008,O
analysed,2008,O
for,2008,O
homogentisic,2008,B-ChemicalEntity
acid,2008,I-ChemicalEntity
by,2008,O
gas,2008,O
chromatography-mass,2008,O
spectrometry,2008,O
.,2008,O
Genomic,2009,O
DNA,2009,O
was,2009,O
isolated,2009,O
from,2009,O
the,2009,O
white,2009,O
blood,2009,O
cells,2009,O
of,2009,O
all,2009,O
family,2009,O
members,2009,O
of,2009,O
the,2009,O
affected,2009,O
case,2009,O
following,2009,O
standard,2009,O
established,2009,O
protocols,2009,O
.,2009,O
Specific,2010,O
PRC,2010,O
primers,2010,O
were,2010,O
designed,2010,O
to,2010,O
amplify,2010,O
all,2010,O
14,2010,O
exons,2010,O
of,2010,O
the,2010,O
HGD,2010,B-GeneOrGeneProduct
gene,2010,O
with,2010,O
the,2010,O
flanking,2010,O
intronic,2010,O
sequences,2010,O
including,2010,O
the,2010,O
splice,2010,O
site,2010,O
sequences,2010,O
.,2010,O
2857,2011,O
children,2011,O
returned,2011,O
a,2011,O
viable,2011,O
urine,2011,O
sample,2011,O
",",2011,O
of,2011,O
which,2011,O
one,2011,O
was,2011,O
highly,2011,O
positive,2011,O
for,2011,O
homogentisic,2011,B-ChemicalEntity
acid,2011,I-ChemicalEntity
.,2011,O
All,2012,O
12,2012,O
members,2012,O
of,2012,O
this,2012,O
girl,2012,O
's,2012,O
family,2012,O
were,2012,O
studied,2012,O
and,2012,O
one,2012,O
",",2012,O
a,2012,O
22,2012,O
year,2012,O
old,2012,O
brother,2012,O
",",2012,O
was,2012,O
found,2012,O
to,2012,O
excrete,2012,O
HGA,2012,B-ChemicalEntity
.,2012,O
Another,2013,O
",",2013,O
a,2013,O
sister,2013,O
who,2013,O
had,2013,O
not,2013,O
provided,2013,O
a,2013,O
urine,2013,O
sample,2013,O
",",2013,O
was,2013,O
discovered,2013,O
by,2013,O
genetic,2013,O
testing,2013,O
.,2013,O
There,2014,O
were,2014,O
no,2014,O
complaints,2014,O
of,2014,O
joint,2014,B-DiseaseOrPhenotypicFeature
pain,2014,I-DiseaseOrPhenotypicFeature
or,2014,O
other,2014,O
symptoms,2014,O
in,2014,O
any,2014,O
member,2014,O
of,2014,O
this,2014,O
family,2014,O
.,2014,O
Parents,2015,O
were,2015,O
first,2015,O
cousins,2015,O
.,2015,O
We,2016,O
found,2016,O
a,2016,O
single,2016,O
nucleotide,2016,O
deletion,2016,O
c.342delA,2016,B-SequenceVariant
",",2016,O
located,2016,O
in,2016,O
exon,2016,O
3,2016,O
",",2016,O
which,2016,O
resulted,2016,O
in,2016,O
a,2016,O
frameshift,2016,O
at,2016,O
amino,2016,O
acid,2016,O
position,2016,O
58,2016,O
(,2016,O
p.Arg58fs,2016,B-SequenceVariant
or,2016,O
p.R58fs,2016,B-SequenceVariant
),2016,O
.,2016,O
Alkaptonuria,2017,B-DiseaseOrPhenotypicFeature
may,2017,O
be,2017,O
more,2017,O
common,2017,O
than,2017,O
it,2017,O
is,2017,O
thought,2017,O
to,2017,O
be,2017,O
with,2017,O
an,2017,O
allele,2017,O
prevalence,2017,O
estimated,2017,O
at,2017,O
0.0107,2017,O
(,2017,O
95,2017,O
%,2017,O
CI,2017,O
0.000392-0.03473,2017,O
),2017,O
.,2017,O
The,2018,O
R58fs,2018,B-SequenceVariant
mutation,2018,O
is,2018,O
old,2018,O
",",2018,O
perhaps,2018,O
having,2018,O
occurred,2018,O
several,2018,O
thousand,2018,O
years,2018,O
ago,2018,O
",",2018,O
and,2018,O
has,2018,O
spread,2018,O
over,2018,O
a,2018,O
large,2018,O
geographical,2018,O
area,2018,O
.,2018,O
Risk,2019,O
of,2019,O
coronary,2019,B-DiseaseOrPhenotypicFeature
artery,2019,I-DiseaseOrPhenotypicFeature
disease,2019,I-DiseaseOrPhenotypicFeature
associated,2019,O
with,2019,O
initial,2019,O
sulphonylurea,2019,B-ChemicalEntity
treatment,2019,O
of,2019,O
patients,2019,B-OrganismTaxon
with,2019,O
type,2019,B-DiseaseOrPhenotypicFeature
2,2019,I-DiseaseOrPhenotypicFeature
diabetes,2019,I-DiseaseOrPhenotypicFeature
:,2019,O
a,2019,O
matched,2019,O
case-control,2019,O
study,2019,O
.,2019,O
AIMS,2020,O
:,2020,O
This,2020,O
study,2020,O
sought,2020,O
to,2020,O
assess,2020,O
the,2020,O
risk,2020,O
of,2020,O
developing,2020,O
coronary,2020,B-DiseaseOrPhenotypicFeature
artery,2020,I-DiseaseOrPhenotypicFeature
disease,2020,I-DiseaseOrPhenotypicFeature
(,2020,O
CAD,2020,B-DiseaseOrPhenotypicFeature
),2020,O
associated,2020,O
with,2020,O
initial,2020,O
treatment,2020,O
of,2020,O
type,2020,B-DiseaseOrPhenotypicFeature
2,2020,I-DiseaseOrPhenotypicFeature
diabetes,2020,I-DiseaseOrPhenotypicFeature
with,2020,O
different,2020,O
sulphonylureas,2020,B-ChemicalEntity
.,2020,O
METHODS,2021,O
:,2021,O
In,2021,O
type,2021,B-DiseaseOrPhenotypicFeature
2,2021,I-DiseaseOrPhenotypicFeature
diabetic,2021,I-DiseaseOrPhenotypicFeature
patients,2021,B-OrganismTaxon
",",2021,O
cases,2021,O
who,2021,O
developed,2021,O
CAD,2021,B-DiseaseOrPhenotypicFeature
were,2021,O
compared,2021,O
retrospectively,2021,O
with,2021,O
controls,2021,O
that,2021,O
did,2021,O
not,2021,O
.,2021,O
The,2022,O
20-year,2022,O
risk,2022,O
of,2022,O
CAD,2022,B-DiseaseOrPhenotypicFeature
at,2022,O
diagnosis,2022,O
of,2022,O
diabetes,2022,B-DiseaseOrPhenotypicFeature
",",2022,O
using,2022,O
the,2022,O
UKPDS,2022,O
risk,2022,O
engine,2022,O
",",2022,O
was,2022,O
used,2022,O
to,2022,O
match,2022,O
cases,2022,O
with,2022,O
controls,2022,O
.,2022,O
RESULTS,2023,O
:,2023,O
The,2023,O
76,2023,O
cases,2023,O
of,2023,O
CAD,2023,B-DiseaseOrPhenotypicFeature
were,2023,O
compared,2023,O
with,2023,O
152,2023,O
controls,2023,O
.,2023,O
The,2024,O
hazard,2024,O
of,2024,O
developing,2024,O
CAD,2024,B-DiseaseOrPhenotypicFeature
(,2024,O
95,2024,O
%,2024,O
CI,2024,O
),2024,O
associated,2024,O
with,2024,O
initial,2024,O
treatment,2024,O
increased,2024,O
by,2024,O
2.4-fold,2024,O
(,2024,O
1.3-4.3,2024,O
",",2024,O
P=0.004,2024,O
),2024,O
with,2024,O
glibenclamide,2024,B-ChemicalEntity
;,2024,O
2-fold,2024,O
(,2024,O
0.9-4.6,2024,O
",",2024,O
P=0.099,2024,O
),2024,O
with,2024,O
glipizide,2024,B-ChemicalEntity
;,2024,O
2.9-fold,2024,O
(,2024,O
1.6-5.1,2024,O
",",2024,O
P=0.000,2024,O
),2024,O
with,2024,O
either,2024,O
",",2024,O
and,2024,O
was,2024,O
unchanged,2024,O
with,2024,O
metformin,2024,B-ChemicalEntity
.,2024,O
The,2025,O
hazard,2025,O
decreased,2025,O
0.3-fold,2025,O
(,2025,O
0.7-1.7,2025,O
",",2025,O
P=0.385,2025,O
),2025,O
with,2025,O
glimepiride,2025,B-ChemicalEntity
",",2025,O
0.4-fold,2025,O
(,2025,O
0.7-1.3,2025,O
",",2025,O
P=0.192,2025,O
),2025,O
with,2025,O
gliclazide,2025,B-ChemicalEntity
",",2025,O
and,2025,O
0.4-fold,2025,O
(,2025,O
0.7-1.1,2025,O
",",2025,O
P=0.09,2025,O
),2025,O
with,2025,O
either,2025,O
.,2025,O
CONCLUSIONS,2026,O
:,2026,O
Initiating,2026,O
treatment,2026,O
of,2026,O
type,2026,B-DiseaseOrPhenotypicFeature
2,2026,I-DiseaseOrPhenotypicFeature
diabetes,2026,I-DiseaseOrPhenotypicFeature
with,2026,O
glibenclamide,2026,B-ChemicalEntity
or,2026,O
glipizide,2026,B-ChemicalEntity
is,2026,O
associated,2026,O
with,2026,O
increased,2026,O
risk,2026,O
of,2026,O
CAD,2026,B-DiseaseOrPhenotypicFeature
in,2026,O
comparison,2026,O
to,2026,O
gliclazide,2026,B-ChemicalEntity
or,2026,O
glimepiride,2026,B-ChemicalEntity
.,2026,O
If,2027,O
confirmed,2027,O
",",2027,O
this,2027,O
may,2027,O
be,2027,O
important,2027,O
because,2027,O
most,2027,O
Indian,2027,O
patients,2027,B-OrganismTaxon
receive,2027,O
the,2027,O
cheaper,2027,O
older,2027,O
sulphonylureas,2027,B-ChemicalEntity
",",2027,O
and,2027,O
present,2027,O
guidelines,2027,O
do,2027,O
not,2027,O
distinguish,2027,O
between,2027,O
individual,2027,O
agents,2027,O
.,2027,O
Reduced,2028,O
progression,2028,O
of,2028,O
adriamycin,2028,B-ChemicalEntity
nephropathy,2028,B-DiseaseOrPhenotypicFeature
in,2028,O
spontaneously,2028,O
hypertensive,2028,B-DiseaseOrPhenotypicFeature
rats,2028,B-OrganismTaxon
treated,2028,O
by,2028,O
losartan,2028,B-ChemicalEntity
.,2028,O
BACKGROUND,2029,O
:,2029,O
The,2029,O
aim,2029,O
of,2029,O
the,2029,O
study,2029,O
was,2029,O
to,2029,O
investigate,2029,O
the,2029,O
antihypertensive,2029,O
effects,2029,O
of,2029,O
angiotensin,2029,B-GeneOrGeneProduct
II,2029,I-GeneOrGeneProduct
type-1,2029,I-GeneOrGeneProduct
receptor,2029,I-GeneOrGeneProduct
blocker,2029,O
",",2029,O
losartan,2029,B-ChemicalEntity
",",2029,O
and,2029,O
its,2029,O
potential,2029,O
in,2029,O
slowing,2029,O
down,2029,O
renal,2029,B-DiseaseOrPhenotypicFeature
disease,2029,I-DiseaseOrPhenotypicFeature
progression,2029,O
in,2029,O
spontaneously,2029,O
hypertensive,2029,B-DiseaseOrPhenotypicFeature
rats,2029,B-OrganismTaxon
(,2029,O
SHR,2029,O
),2029,O
with,2029,O
adriamycin,2029,B-ChemicalEntity
(,2029,O
ADR,2029,B-ChemicalEntity
),2029,O
nephropathy,2029,B-DiseaseOrPhenotypicFeature
.,2029,O
METHODS,2030,O
:,2030,O
Six-month-old,2030,O
female,2030,O
SHR,2030,O
were,2030,O
randomly,2030,O
selected,2030,O
in,2030,O
six,2030,O
groups,2030,O
.,2030,O
Two,2031,O
control,2031,O
groups,2031,O
(,2031,O
SH,2031,O
(,2031,O
6,2031,O
),2031,O
",",2031,O
SH,2031,O
(,2031,O
12,2031,O
),2031,O
),2031,O
received,2031,O
vehicle,2031,O
.,2031,O
Groups,2032,O
ADR,2032,B-ChemicalEntity
(,2032,O
6,2032,O
),2032,O
",",2032,O
ADR+LOS,2032,B-ChemicalEntity
(,2032,O
6,2032,O
),2032,O
and,2032,O
ADR,2032,B-ChemicalEntity
(,2032,O
12,2032,O
),2032,O
",",2032,O
and,2032,O
ADR+LOS,2032,B-ChemicalEntity
(,2032,O
12,2032,O
),2032,O
received,2032,O
ADR,2032,B-ChemicalEntity
(,2032,O
2,2032,O
mg/kg/b.w,2032,O
.,2032,O
i.v,2033,O
.,2033,O
),2033,O
twice,2034,O
in,2034,O
a,2034,O
3-week,2034,O
interval,2034,O
.,2034,O
Group,2035,O
ADR+LOS,2035,B-ChemicalEntity
(,2035,O
6,2035,O
),2035,O
received,2035,O
losartan,2035,B-ChemicalEntity
(,2035,O
10,2035,O
mg/kg/b.w./day,2035,O
by,2035,O
gavages,2035,O
),2035,O
for,2035,O
6,2035,O
weeks,2035,O
and,2035,O
group,2035,O
ADR+LOS,2035,B-ChemicalEntity
(,2035,O
12,2035,O
),2035,O
for,2035,O
12,2035,O
weeks,2035,O
after,2035,O
second,2035,O
injection,2035,O
of,2035,O
ADR,2035,B-ChemicalEntity
.,2035,O
Animals,2036,O
were,2036,O
killed,2036,O
after,2036,O
6,2036,O
or,2036,O
12,2036,O
weeks,2036,O
",",2036,O
respectively,2036,O
.,2036,O
Haemodynamic,2037,O
measurements,2037,O
were,2037,O
performed,2037,O
on,2037,O
anaesthetized,2037,O
animals,2037,O
",",2037,O
blood,2037,O
and,2037,O
urine,2037,O
samples,2037,O
were,2037,O
taken,2037,O
for,2037,O
biochemical,2037,O
analysis,2037,O
and,2037,O
the,2037,O
left,2037,O
kidney,2037,O
was,2037,O
processed,2037,O
for,2037,O
morphological,2037,O
studies,2037,O
.,2037,O
RESULTS,2038,O
:,2038,O
Short-term,2038,O
losartan,2038,B-ChemicalEntity
treatment,2038,O
",",2038,O
besides,2038,O
antihypertensive,2038,O
effect,2038,O
",",2038,O
improved,2038,O
glomerular,2038,O
filtration,2038,O
rate,2038,O
and,2038,O
ameliorated,2038,O
glomerulosclerosis,2038,B-DiseaseOrPhenotypicFeature
resulting,2038,O
in,2038,O
decreased,2038,O
proteinuria,2038,B-DiseaseOrPhenotypicFeature
.,2038,O
Prolonged,2039,O
treatment,2039,O
with,2039,O
losartan,2039,B-ChemicalEntity
showed,2039,O
further,2039,O
reduction,2039,O
of,2039,O
glomerulosclerosis,2039,B-DiseaseOrPhenotypicFeature
associated,2039,O
with,2039,O
reduced,2039,O
progression,2039,O
of,2039,O
tubular,2039,O
atrophy,2039,B-DiseaseOrPhenotypicFeature
and,2039,O
interstitial,2039,B-DiseaseOrPhenotypicFeature
fibrosis,2039,I-DiseaseOrPhenotypicFeature
",",2039,O
thus,2039,O
preventing,2039,O
heavy,2039,O
proteinuria,2039,B-DiseaseOrPhenotypicFeature
and,2039,O
chronic,2039,B-DiseaseOrPhenotypicFeature
renal,2039,I-DiseaseOrPhenotypicFeature
failure,2039,I-DiseaseOrPhenotypicFeature
.,2039,O
Losartan,2040,B-ChemicalEntity
reduced,2040,O
uraemia,2040,B-DiseaseOrPhenotypicFeature
and,2040,O
increased,2040,O
urea,2040,B-ChemicalEntity
clearance,2040,O
in,2040,O
advanced,2040,O
ADR,2040,B-ChemicalEntity
nephropathy,2040,B-DiseaseOrPhenotypicFeature
in,2040,O
SHR,2040,O
.,2040,O
Histological,2041,O
examination,2041,O
showed,2041,O
that,2041,O
losartan,2041,B-ChemicalEntity
could,2041,O
prevent,2041,O
tubular,2041,O
atrophy,2041,B-DiseaseOrPhenotypicFeature
",",2041,O
interstitial,2041,O
infiltration,2041,O
and,2041,O
fibrosis,2041,B-DiseaseOrPhenotypicFeature
in,2041,O
ADR,2041,B-ChemicalEntity
nephropathy,2041,B-DiseaseOrPhenotypicFeature
.,2041,O
CONCLUSION,2042,O
:,2042,O
Losartan,2042,B-ChemicalEntity
reduces,2042,O
the,2042,O
rate,2042,O
of,2042,O
progression,2042,O
of,2042,O
ADR-induced,2042,B-ChemicalEntity
focal,2042,B-DiseaseOrPhenotypicFeature
segmental,2042,I-DiseaseOrPhenotypicFeature
glomerulosclerosis,2042,I-DiseaseOrPhenotypicFeature
to,2042,O
end-stage,2042,B-DiseaseOrPhenotypicFeature
renal,2042,I-DiseaseOrPhenotypicFeature
disease,2042,I-DiseaseOrPhenotypicFeature
in,2042,O
SHR,2042,O
.,2042,O
Mutations,2043,O
in,2043,O
phospholipase,2043,B-GeneOrGeneProduct
C,2043,I-GeneOrGeneProduct
epsilon,2043,I-GeneOrGeneProduct
1,2043,I-GeneOrGeneProduct
are,2043,O
not,2043,O
sufficient,2043,O
to,2043,O
cause,2043,O
diffuse,2043,B-DiseaseOrPhenotypicFeature
mesangial,2043,I-DiseaseOrPhenotypicFeature
sclerosis,2043,I-DiseaseOrPhenotypicFeature
.,2043,O
Diffuse,2044,B-DiseaseOrPhenotypicFeature
mesangial,2044,I-DiseaseOrPhenotypicFeature
sclerosis,2044,I-DiseaseOrPhenotypicFeature
occurs,2044,O
as,2044,O
an,2044,O
isolated,2044,O
abnormality,2044,O
or,2044,O
as,2044,O
a,2044,O
part,2044,O
of,2044,O
a,2044,O
syndrome,2044,O
.,2044,O
Recently,2045,O
",",2045,O
mutations,2045,O
in,2045,O
phospholipase,2045,B-GeneOrGeneProduct
C,2045,I-GeneOrGeneProduct
epsilon,2045,I-GeneOrGeneProduct
1,2045,I-GeneOrGeneProduct
(,2045,O
PLCE1,2045,B-GeneOrGeneProduct
),2045,O
were,2045,O
found,2045,O
to,2045,O
cause,2045,O
a,2045,O
nonsyndromic,2045,O
",",2045,O
autosomal,2045,O
recessive,2045,O
form,2045,O
of,2045,O
this,2045,O
disease,2045,O
.,2045,O
Here,2046,O
we,2046,O
describe,2046,O
three,2046,O
children,2046,O
from,2046,O
one,2046,O
consanguineous,2046,O
kindred,2046,O
of,2046,O
Pakistani,2046,O
origin,2046,O
with,2046,O
diffuse,2046,B-DiseaseOrPhenotypicFeature
mesangial,2046,I-DiseaseOrPhenotypicFeature
sclerosis,2046,I-DiseaseOrPhenotypicFeature
who,2046,O
presented,2046,O
with,2046,O
congenital,2046,B-DiseaseOrPhenotypicFeature
or,2046,I-DiseaseOrPhenotypicFeature
infantile,2046,I-DiseaseOrPhenotypicFeature
nephrotic,2046,I-DiseaseOrPhenotypicFeature
syndrome,2046,I-DiseaseOrPhenotypicFeature
.,2046,O
Homozygous,2047,O
mutations,2047,O
in,2047,O
PLCE1,2047,B-GeneOrGeneProduct
(,2047,O
also,2047,O
known,2047,O
as,2047,O
KIAA1516,2047,B-GeneOrGeneProduct
",",2047,O
PLCE,2047,B-GeneOrGeneProduct
",",2047,O
or,2047,O
NPHS3,2047,B-GeneOrGeneProduct
),2047,O
were,2047,O
identified,2047,O
following,2047,O
genome-wide,2047,O
mapping,2047,O
of,2047,O
single-nucleotide,2047,O
polymorphisms,2047,O
.,2047,O
All,2048,O
affected,2048,O
children,2048,O
were,2048,O
homozygous,2048,O
for,2048,O
a,2048,O
four-basepair,2048,B-SequenceVariant
deletion,2048,I-SequenceVariant
in,2048,O
exon,2048,O
3,2048,O
",",2048,O
which,2048,O
created,2048,O
a,2048,O
premature,2048,O
translational,2048,O
stop,2048,O
codon,2048,O
.,2048,O
Analysis,2049,O
of,2049,O
the,2049,O
asymptomatic,2049,O
father,2049,O
of,2049,O
two,2049,O
of,2049,O
the,2049,O
children,2049,O
revealed,2049,O
that,2049,O
he,2049,O
was,2049,O
also,2049,O
homozygous,2049,O
for,2049,O
the,2049,O
same,2049,O
mutation,2049,O
.,2049,O
We,2050,O
conclude,2050,O
this,2050,O
nonpenetrance,2050,O
may,2050,O
be,2050,O
due,2050,O
to,2050,O
compensatory,2050,O
mutations,2050,O
at,2050,O
a,2050,O
second,2050,O
locus,2050,O
and,2050,O
that,2050,O
mutation,2050,O
within,2050,O
PLCE1,2050,B-GeneOrGeneProduct
is,2050,O
not,2050,O
always,2050,O
sufficient,2050,O
to,2050,O
cause,2050,O
diffuse,2050,B-DiseaseOrPhenotypicFeature
mesangial,2050,I-DiseaseOrPhenotypicFeature
sclerosis,2050,I-DiseaseOrPhenotypicFeature
.,2050,O
Neurofibromin,2051,B-GeneOrGeneProduct
1,2051,I-GeneOrGeneProduct
(,2051,O
NF1,2051,B-GeneOrGeneProduct
),2051,O
defects,2051,O
are,2051,O
common,2051,O
in,2051,O
human,2051,B-OrganismTaxon
ovarian,2051,B-DiseaseOrPhenotypicFeature
serous,2051,I-DiseaseOrPhenotypicFeature
carcinomas,2051,I-DiseaseOrPhenotypicFeature
and,2051,O
co-occur,2051,O
with,2051,O
TP53,2051,B-GeneOrGeneProduct
mutations,2051,O
.,2051,O
Ovarian,2052,B-DiseaseOrPhenotypicFeature
serous,2052,I-DiseaseOrPhenotypicFeature
carcinoma,2052,I-DiseaseOrPhenotypicFeature
(,2052,O
OSC,2052,B-DiseaseOrPhenotypicFeature
),2052,O
is,2052,O
the,2052,O
most,2052,O
common,2052,O
and,2052,O
lethal,2052,O
histologic,2052,O
type,2052,O
of,2052,O
ovarian,2052,B-DiseaseOrPhenotypicFeature
epithelial,2052,I-DiseaseOrPhenotypicFeature
malignancy,2052,I-DiseaseOrPhenotypicFeature
.,2052,O
Mutations,2053,O
of,2053,O
TP53,2053,B-GeneOrGeneProduct
and,2053,O
dysfunction,2053,O
of,2053,O
the,2053,O
Brca1,2053,B-GeneOrGeneProduct
and/or,2053,O
Brca2,2053,B-GeneOrGeneProduct
tumor-suppressor,2053,B-DiseaseOrPhenotypicFeature
proteins,2053,O
have,2053,O
been,2053,O
implicated,2053,O
in,2053,O
the,2053,O
molecular,2053,O
pathogenesis,2053,O
of,2053,O
a,2053,O
large,2053,O
fraction,2053,O
of,2053,O
OSCs,2053,B-DiseaseOrPhenotypicFeature
",",2053,O
but,2053,O
frequent,2053,O
somatic,2053,O
mutations,2053,O
in,2053,O
other,2053,O
well-established,2053,O
tumor-suppressor,2053,B-DiseaseOrPhenotypicFeature
genes,2053,O
have,2053,O
not,2053,O
been,2053,O
identified,2053,O
.,2053,O
Using,2054,O
a,2054,O
genome-wide,2054,O
screen,2054,O
of,2054,O
DNA,2054,O
copy,2054,O
number,2054,O
alterations,2054,O
in,2054,O
36,2054,O
primary,2054,O
OSCs,2054,B-DiseaseOrPhenotypicFeature
",",2054,O
we,2054,O
identified,2054,O
two,2054,O
tumors,2054,B-DiseaseOrPhenotypicFeature
with,2054,O
apparent,2054,O
homozygous,2054,O
deletions,2054,O
of,2054,O
the,2054,O
NF1,2054,B-GeneOrGeneProduct
gene,2054,O
.,2054,O
Subsequently,2055,O
",",2055,O
18,2055,O
ovarian,2055,B-DiseaseOrPhenotypicFeature
carcinoma-derived,2055,O
cell,2055,O
lines,2055,O
and,2055,O
41,2055,O
primary,2055,O
OSCs,2055,B-DiseaseOrPhenotypicFeature
were,2055,O
evaluated,2055,O
for,2055,O
NF1,2055,B-GeneOrGeneProduct
alterations,2055,O
.,2055,O
Markedly,2056,O
reduced,2056,O
or,2056,O
absent,2056,O
expression,2056,O
of,2056,O
Nf1,2056,B-GeneOrGeneProduct
protein,2056,O
was,2056,O
observed,2056,O
in,2056,O
6,2056,O
of,2056,O
the,2056,O
18,2056,O
cell,2056,O
lines,2056,O
",",2056,O
and,2056,O
using,2056,O
the,2056,O
protein,2056,O
truncation,2056,O
test,2056,O
and,2056,O
sequencing,2056,O
of,2056,O
cDNA,2056,O
and,2056,O
genomic,2056,O
DNA,2056,O
",",2056,O
NF1,2056,B-GeneOrGeneProduct
mutations,2056,O
resulting,2056,O
in,2056,O
deletion,2056,O
of,2056,O
exons,2056,O
and/or,2056,O
aberrant,2056,O
splicing,2056,O
of,2056,O
NF1,2056,B-GeneOrGeneProduct
transcripts,2056,O
were,2056,O
detected,2056,O
in,2056,O
5,2056,O
of,2056,O
the,2056,O
6,2056,O
cell,2056,O
lines,2056,O
with,2056,O
loss,2056,O
of,2056,O
NF1,2056,B-GeneOrGeneProduct
expression,2056,O
.,2056,O
Similarly,2057,O
",",2057,O
NF1,2057,B-GeneOrGeneProduct
alterations,2057,O
including,2057,O
homozygous,2057,O
deletions,2057,O
and,2057,O
splicing,2057,O
mutations,2057,O
were,2057,O
identified,2057,O
in,2057,O
9,2057,O
(,2057,O
22,2057,O
%,2057,O
),2057,O
of,2057,O
41,2057,O
primary,2057,O
OSCs,2057,B-DiseaseOrPhenotypicFeature
.,2057,O
As,2058,O
expected,2058,O
",",2058,O
tumors,2058,B-DiseaseOrPhenotypicFeature
and,2058,O
cell,2058,O
lines,2058,O
with,2058,O
NF1,2058,B-GeneOrGeneProduct
defects,2058,O
lacked,2058,O
mutations,2058,O
in,2058,O
KRAS,2058,B-GeneOrGeneProduct
or,2058,O
BRAF,2058,B-GeneOrGeneProduct
but,2058,O
showed,2058,O
Ras,2058,B-GeneOrGeneProduct
pathway,2058,O
activation,2058,O
based,2058,O
on,2058,O
immunohistochemical,2058,O
detection,2058,O
of,2058,O
phosphorylated,2058,O
MAPK,2058,B-GeneOrGeneProduct
(,2058,O
primary,2058,O
tumors,2058,B-DiseaseOrPhenotypicFeature
),2058,O
or,2058,O
increased,2058,O
levels,2058,O
of,2058,O
GTP-bound,2058,B-ChemicalEntity
Ras,2058,B-GeneOrGeneProduct
(,2058,O
cell,2058,O
lines,2058,O
),2058,O
.,2058,O
The,2059,O
TP53,2059,B-GeneOrGeneProduct
tumor-suppressor,2059,B-DiseaseOrPhenotypicFeature
gene,2059,O
was,2059,O
mutated,2059,O
in,2059,O
all,2059,O
OSCs,2059,B-DiseaseOrPhenotypicFeature
with,2059,O
documented,2059,O
NF1,2059,B-GeneOrGeneProduct
mutation,2059,O
",",2059,O
suggesting,2059,O
that,2059,O
the,2059,O
pathways,2059,O
regulated,2059,O
by,2059,O
these,2059,O
two,2059,O
tumor-suppressor,2059,B-DiseaseOrPhenotypicFeature
proteins,2059,O
often,2059,O
cooperate,2059,O
in,2059,O
the,2059,O
development,2059,O
of,2059,O
ovarian,2059,B-DiseaseOrPhenotypicFeature
carcinomas,2059,I-DiseaseOrPhenotypicFeature
with,2059,O
serous,2059,O
differentiation,2059,O
.,2059,O
Effect,2060,O
of,2060,O
green,2060,B-ChemicalEntity
tea,2060,I-ChemicalEntity
and,2060,O
vitamin,2060,B-ChemicalEntity
E,2060,I-ChemicalEntity
combination,2060,O
in,2060,O
isoproterenol,2060,B-ChemicalEntity
induced,2060,O
myocardial,2060,B-DiseaseOrPhenotypicFeature
infarction,2060,I-DiseaseOrPhenotypicFeature
in,2060,O
rats,2060,B-OrganismTaxon
.,2060,O
The,2061,O
present,2061,O
study,2061,O
was,2061,O
aimed,2061,O
to,2061,O
investigate,2061,O
the,2061,O
combined,2061,O
effects,2061,O
of,2061,O
green,2061,B-ChemicalEntity
tea,2061,I-ChemicalEntity
and,2061,O
vitamin,2061,B-ChemicalEntity
E,2061,I-ChemicalEntity
on,2061,O
heart,2061,O
weight,2061,O
",",2061,O
body,2061,O
weight,2061,O
",",2061,O
serum,2061,O
marker,2061,O
enzymes,2061,O
",",2061,O
lipid,2061,B-ChemicalEntity
peroxidation,2061,O
",",2061,O
endogenous,2061,O
antioxidants,2061,B-ChemicalEntity
and,2061,O
membrane,2061,O
bound,2061,O
ATPases,2061,O
in,2061,O
isoproterenol,2061,B-ChemicalEntity
(,2061,O
ISO,2061,B-ChemicalEntity
),2061,O
-induced,2061,O
myocardial,2061,B-DiseaseOrPhenotypicFeature
infarction,2061,I-DiseaseOrPhenotypicFeature
in,2061,O
rats,2061,B-OrganismTaxon
.,2061,O
Adult,2062,O
male,2062,O
albino,2062,O
rats,2062,B-OrganismTaxon
",",2062,O
treated,2062,O
with,2062,O
ISO,2062,B-ChemicalEntity
(,2062,O
200,2062,O
mg/kg,2062,O
",",2062,O
s.c.,2062,O
),2062,O
for,2062,O
2,2062,O
days,2062,O
at,2062,O
an,2062,O
interval,2062,O
of,2062,O
24,2062,O
h,2062,O
caused,2062,O
a,2062,O
significant,2062,O
(,2062,O
P,2062,O
<,2062,O
0.05,2062,O
),2062,O
elevation,2062,O
of,2062,O
heart,2062,O
weight,2062,O
",",2062,O
serum,2062,O
marker,2062,O
enzymes,2062,O
",",2062,O
lipid,2062,B-ChemicalEntity
peroxidation,2062,O
and,2062,O
Ca+2,2062,B-ChemicalEntity
ATPase,2062,I-ChemicalEntity
level,2062,O
whereas,2062,O
there,2062,O
was,2062,O
a,2062,O
significant,2062,O
(,2062,O
P,2062,O
<,2062,O
0.05,2062,O
),2062,O
decrease,2062,O
in,2062,O
body,2062,O
weight,2062,O
",",2062,O
endogenous,2062,O
antioxidants,2062,B-ChemicalEntity
",",2062,O
Na+/,2062,B-ChemicalEntity
K+,2062,I-ChemicalEntity
ATPase,2062,I-ChemicalEntity
and,2062,O
Mg+2,2062,B-ChemicalEntity
ATPase,2062,I-ChemicalEntity
levels,2062,O
.,2062,O
Administration,2063,O
of,2063,O
green,2063,B-ChemicalEntity
tea,2063,I-ChemicalEntity
(,2063,O
100,2063,O
mg/kg/day,2063,O
",",2063,O
p.o,2063,O
.,2063,O
),2063,O
and,2064,O
vitamin,2064,B-ChemicalEntity
E,2064,I-ChemicalEntity
(,2064,O
100,2064,O
mg/kg/day,2064,O
",",2064,O
p.o,2064,O
.,2064,O
),2064,O
together,2065,O
for,2065,O
30,2065,O
consecutive,2065,O
days,2065,O
and,2065,O
challenged,2065,O
with,2065,O
ISO,2065,B-ChemicalEntity
on,2065,O
the,2065,O
day,2065,O
29th,2065,O
and,2065,O
30th,2065,O
",",2065,O
showed,2065,O
a,2065,O
significant,2065,O
(,2065,O
P,2065,O
<,2065,O
0.05,2065,O
),2065,O
decrease,2065,O
in,2065,O
heart,2065,O
weight,2065,O
",",2065,O
serum,2065,O
marker,2065,O
enzymes,2065,O
",",2065,O
lipid,2065,B-ChemicalEntity
peroxidation,2065,O
",",2065,O
Ca+2,2065,B-ChemicalEntity
ATPase,2065,I-ChemicalEntity
and,2065,O
a,2065,O
significant,2065,O
increase,2065,O
in,2065,O
the,2065,O
body,2065,O
weight,2065,O
",",2065,O
endogenous,2065,O
antioxidants,2065,B-ChemicalEntity
",",2065,O
Na+/K+,2065,B-ChemicalEntity
ATPase,2065,I-ChemicalEntity
and,2065,O
Mg+2,2065,B-ChemicalEntity
ATPase,2065,I-ChemicalEntity
when,2065,O
compared,2065,O
with,2065,O
ISO,2065,B-ChemicalEntity
treated,2065,O
group,2065,O
and,2065,O
green,2065,B-ChemicalEntity
tea,2065,I-ChemicalEntity
or,2065,O
vitamin,2065,B-ChemicalEntity
E,2065,I-ChemicalEntity
alone,2065,O
treated,2065,O
groups,2065,O
.,2065,O
These,2066,O
findings,2066,O
indicate,2066,O
the,2066,O
synergistic,2066,O
protective,2066,O
effect,2066,O
of,2066,O
green,2066,B-ChemicalEntity
tea,2066,I-ChemicalEntity
and,2066,O
vitamin,2066,B-ChemicalEntity
E,2066,I-ChemicalEntity
during,2066,O
ISO,2066,B-ChemicalEntity
induced,2066,O
myocardial,2066,B-DiseaseOrPhenotypicFeature
infarction,2066,I-DiseaseOrPhenotypicFeature
in,2066,O
rats,2066,B-OrganismTaxon
.,2066,O
Hemodynamic,2067,O
parameters,2067,O
and,2067,O
heart,2067,O
rate,2067,O
variability,2067,O
during,2067,O
a,2067,O
tilt,2067,O
test,2067,O
in,2067,O
relation,2067,O
to,2067,O
gene,2067,O
polymorphism,2067,O
of,2067,O
renin-angiotensin,2067,B-GeneOrGeneProduct
and,2067,O
serotonin,2067,B-ChemicalEntity
system,2067,O
.,2067,O
PURPOSE,2068,O
:,2068,O
The,2068,O
aim,2068,O
of,2068,O
the,2068,O
study,2068,O
was,2068,O
to,2068,O
evaluate,2068,O
the,2068,O
renin-angiotensin,2068,B-GeneOrGeneProduct
system,2068,O
and,2068,O
serotonin,2068,B-GeneOrGeneProduct
transporter,2068,I-GeneOrGeneProduct
gene,2068,O
polymorphisms,2068,O
in,2068,O
relation,2068,O
to,2068,O
hemodynamic,2068,O
parameters,2068,O
and,2068,O
heart,2068,O
rate,2068,O
variability,2068,O
during,2068,O
a,2068,O
head-up,2068,O
tilt,2068,O
test,2068,O
(,2068,O
HUT,2068,O
),2068,O
in,2068,O
patients,2068,B-OrganismTaxon
with,2068,O
vasovagal,2068,B-DiseaseOrPhenotypicFeature
syncope,2068,I-DiseaseOrPhenotypicFeature
.,2068,O
METHODS,2069,O
:,2069,O
DNA,2069,O
was,2069,O
collected,2069,O
from,2069,O
191,2069,O
patients,2069,B-OrganismTaxon
(,2069,O
mean,2069,O
age,2069,O
44+/-18,2069,O
years,2069,O
",",2069,O
61,2069,O
men,2069,B-OrganismTaxon
",",2069,O
130,2069,O
women,2069,B-OrganismTaxon
),2069,O
.,2069,O
The,2070,O
following,2070,O
gene,2070,O
polymorphisms,2070,O
were,2070,O
determined,2070,O
in,2070,O
genomic,2070,O
DNA,2070,O
:,2070,O
angiotensin-converting,2070,B-GeneOrGeneProduct
enzyme,2070,I-GeneOrGeneProduct
insertion/deletion,2070,O
polymorphism,2070,O
(,2070,O
I/D,2070,O
ACE,2070,B-GeneOrGeneProduct
),2070,O
",",2070,O
angiotensinogen,2070,B-GeneOrGeneProduct
gene,2070,O
polymorphism,2070,O
(,2070,O
M,2070,B-SequenceVariant
235,2070,I-SequenceVariant
),2070,O
",",2070,O
angiotensin,2070,B-GeneOrGeneProduct
II,2070,I-GeneOrGeneProduct
receptor,2070,I-GeneOrGeneProduct
type,2070,I-GeneOrGeneProduct
1,2070,I-GeneOrGeneProduct
(,2070,O
ATR1,2070,B-GeneOrGeneProduct
),2070,O
polymorphism,2070,O
(,2070,O
A,2070,B-SequenceVariant
11666C,2070,I-SequenceVariant
),2070,O
",",2070,O
and,2070,O
polymorphism,2070,O
of,2070,O
serotonin,2070,B-GeneOrGeneProduct
transporter,2070,I-GeneOrGeneProduct
gene,2070,O
(,2070,O
5HTTLPR,2070,B-GeneOrGeneProduct
),2070,O
.Heart,2070,O
rate,2070,O
variability,2070,O
during,2070,O
HUT,2070,O
was,2070,O
assessed,2070,O
in,2070,O
5-minute,2070,O
intervals,2070,O
by,2070,O
low,2070,O
frequency,2070,O
",",2070,O
high,2070,O
frequency,2070,O
",",2070,O
standard,2070,O
deviation,2070,O
of,2070,O
the,2070,O
normal-to-normal,2070,O
(,2070,O
SDNN,2070,O
),2070,O
",",2070,O
and,2070,O
root,2070,O
mean,2070,O
square,2070,O
successive,2070,O
difference,2070,O
parameters,2070,O
.,2070,O
RESULTS,2071,O
:,2071,O
AA,2071,O
genotype,2071,O
of,2071,O
A,2071,B-SequenceVariant
1166C,2071,I-SequenceVariant
polymorphism,2071,O
was,2071,O
associated,2071,O
with,2071,O
lower,2071,O
minimal,2071,O
systolic,2071,O
blood,2071,O
pressure,2071,O
(,2071,O
SBP,2071,O
),2071,O
and,2071,O
diastolic,2071,O
blood,2071,O
pressure,2071,O
(,2071,O
DBP,2071,O
),2071,O
during,2071,O
HUT,2071,O
compared,2071,O
with,2071,O
other,2071,O
genotypes,2071,O
(,2071,O
minimal,2071,O
SBP,2071,O
:,2071,O
AA,2071,O
"59.6+/-21,8",2071,O
",",2071,O
AC,2071,O
79.9+/-22.7,2071,O
",",2071,O
CC,2071,O
65.4+/-22.7,2071,O
mmHg,2071,O
",",2071,O
P=0.007,2071,O
),2071,O
",",2071,O
(,2071,O
minimal,2071,O
DBP,2071,O
:,2071,O
AA,2071,O
36.4+/-22.7,2071,O
",",2071,O
AC,2071,O
52.3+/-22.9,2071,O
",",2071,O
CC,2071,O
45.4+/-19.5,2071,O
mmHg,2071,O
",",2071,O
P=0.007,2071,O
),2071,O
.AA,2071,O
genotype,2071,O
was,2071,O
also,2071,O
associated,2071,O
with,2071,O
higher,2071,O
SDNN,2071,O
compared,2071,O
to,2071,O
other,2071,O
genotypes,2071,O
in,2071,O
the,2071,O
early,2071,O
phase,2071,O
of,2071,O
HUT,2071,O
(,2071,O
SDNN,2071,O
in,2071,O
5,2071,O
minutes,2071,O
of,2071,O
tilt,2071,O
:,2071,O
AA,2071,O
59.7+/-24.6,2071,O
",",2071,O
AC,2071,O
50.6+/-20.6,2071,O
",",2071,O
CC,2071,O
46.0+/-13.2,2071,O
",",2071,O
P=0.01,2071,O
),2071,O
and,2071,O
at,2071,O
syncope,2071,B-DiseaseOrPhenotypicFeature
occurrence,2071,O
(,2071,O
SDNN,2071,O
:,2071,O
AA,2071,O
71.0+/-20.9,2071,O
",",2071,O
AC,2071,O
58.2+/-17.9,2071,O
",",2071,O
CC,2071,O
58+/-10,2071,O
",",2071,O
P=0.04,2071,O
),2071,O
CONCLUSION,2071,O
:,2071,O
AA,2071,O
genotype,2071,O
of,2071,O
A,2071,B-SequenceVariant
1166C,2071,I-SequenceVariant
polymorphism,2071,O
in,2071,O
the,2071,O
ATR1,2071,B-GeneOrGeneProduct
gene,2071,O
may,2071,O
be,2071,O
associated,2071,O
with,2071,O
hypotension,2071,B-DiseaseOrPhenotypicFeature
and,2071,O
decline,2071,O
in,2071,O
sympathetic,2071,O
tone,2071,O
during,2071,O
HUT,2071,O
.,2071,O
Its,2072,O
role,2072,O
in,2072,O
genetic,2072,O
predisposition,2072,O
to,2072,O
vasovagal,2072,B-DiseaseOrPhenotypicFeature
syncope,2072,I-DiseaseOrPhenotypicFeature
can,2072,O
not,2072,O
be,2072,O
excluded,2072,O
.,2072,O
Combination,2073,O
of,2073,O
polymorphisms,2073,O
within,2073,O
5,2073,O
',2073,O
and,2073,O
3,2073,O
',2073,O
untranslated,2073,O
regions,2073,O
of,2073,O
thymidylate,2073,B-GeneOrGeneProduct
synthase,2073,I-GeneOrGeneProduct
gene,2073,O
modulates,2073,O
survival,2073,O
in,2073,O
5,2073,B-ChemicalEntity
fluorouracil-treated,2073,O
colorectal,2073,B-DiseaseOrPhenotypicFeature
cancer,2073,I-DiseaseOrPhenotypicFeature
patients,2073,B-OrganismTaxon
.,2073,O
In,2074,O
the,2074,O
present,2074,O
study,2074,O
we,2074,O
explored,2074,O
the,2074,O
effect,2074,O
of,2074,O
three,2074,O
polymorphisms,2074,O
of,2074,O
the,2074,O
TS,2074,B-GeneOrGeneProduct
gene,2074,O
on,2074,O
overall,2074,O
and,2074,O
progression-,2074,O
free,2074,O
survival,2074,O
of,2074,O
colorectal,2074,B-DiseaseOrPhenotypicFeature
cancer,2074,I-DiseaseOrPhenotypicFeature
(,2074,O
CRC,2074,B-DiseaseOrPhenotypicFeature
),2074,O
patients,2074,B-OrganismTaxon
subjected,2074,O
to,2074,O
5FU,2074,B-ChemicalEntity
chemotherapy,2074,O
.,2074,O
A,2075,O
28,2075,B-SequenceVariant
bp,2075,I-SequenceVariant
variable,2075,I-SequenceVariant
number,2075,I-SequenceVariant
of,2075,I-SequenceVariant
tandem,2075,I-SequenceVariant
repeats,2075,I-SequenceVariant
(,2075,O
VNTR,2075,O
),2075,O
",",2075,O
a,2075,O
G/C,2075,B-SequenceVariant
single,2075,O
nucleotide,2075,O
polymorphism,2075,O
(,2075,O
SNP,2075,O
),2075,O
",",2075,O
and,2075,O
a,2075,O
deletion,2075,B-SequenceVariant
of,2075,I-SequenceVariant
6,2075,I-SequenceVariant
bp,2075,I-SequenceVariant
at,2075,I-SequenceVariant
position,2075,I-SequenceVariant
1494,2075,I-SequenceVariant
were,2075,O
studied,2075,O
.,2075,O
The,2076,O
possible,2076,O
combined,2076,O
effect,2076,O
of,2076,O
these,2076,O
DNA,2076,O
polymorphisms,2076,O
on,2076,O
the,2076,O
clinical,2076,O
outcome,2076,O
of,2076,O
patients,2076,B-OrganismTaxon
was,2076,O
also,2076,O
evaluated,2076,O
.,2076,O
A,2077,O
retrospective,2077,O
study,2077,O
was,2077,O
carried,2077,O
out,2077,O
on,2077,O
paraffin-embedded,2077,B-ChemicalEntity
sections,2077,O
from,2077,O
113,2077,O
patients,2077,B-OrganismTaxon
diagnosed,2077,O
of,2077,O
advanced,2077,O
CRC,2077,B-DiseaseOrPhenotypicFeature
.,2077,O
TS,2078,B-GeneOrGeneProduct
genotyping,2078,O
methods,2078,O
were,2078,O
polymerase,2078,O
chain,2078,O
reaction,2078,O
(,2078,O
PCR,2078,O
),2078,O
for,2078,O
VNTR,2078,O
and,2078,O
PCR,2078,O
",",2078,O
followed,2078,O
by,2078,O
restriction,2078,O
length,2078,O
fragment,2078,O
polymorphism,2078,O
(,2078,O
PCR-RFLP,2078,O
),2078,O
for,2078,O
SNP,2078,O
and,2078,O
ins/del,2078,B-SequenceVariant
6,2078,I-SequenceVariant
bp,2078,I-SequenceVariant
.,2078,O
To,2079,O
study,2079,O
the,2079,O
combined,2079,O
effect,2079,O
of,2079,O
TS,2079,B-GeneOrGeneProduct
polymorphisms,2079,O
",",2079,O
four,2079,O
categories,2079,O
were,2079,O
defined,2079,O
accordingly,2079,O
to,2079,O
the,2079,O
level,2079,O
of,2079,O
expression,2079,O
attributed,2079,O
to,2079,O
SNP,2079,O
and,2079,O
ins/del,2079,B-SequenceVariant
6,2079,I-SequenceVariant
bp,2079,I-SequenceVariant
genotypes,2079,O
:,2079,O
C_allele,2079,O
6-,2079,O
",",2079,O
C_6+/6+,2079,O
",",2079,O
G_allele6-,2079,O
and,2079,O
G_6+/6+,2079,O
.,2079,O
VNTR,2080,O
and,2080,O
ins/del,2080,B-SequenceVariant
6,2080,I-SequenceVariant
bp,2080,I-SequenceVariant
genotypes,2080,O
varied,2080,O
with,2080,O
tumour,2080,B-DiseaseOrPhenotypicFeature
anatomical,2080,O
site,2080,O
:,2080,O
2R/2R,2080,O
genotype,2080,O
was,2080,O
rare,2080,O
in,2080,O
left-sided,2080,O
tumours,2080,B-DiseaseOrPhenotypicFeature
(,2080,O
7.0,2080,O
%,2080,O
vs.,2080,O
26.3,2080,O
%,2080,O
of,2080,O
right-sided,2080,O
and,2080,O
24.1,2080,O
%,2080,O
of,2080,O
rectal,2080,B-DiseaseOrPhenotypicFeature
cancers,2080,I-DiseaseOrPhenotypicFeature
;,2080,O
P,2080,O
<,2080,O
0.01,2080,O
),2080,O
",",2080,O
where,2080,O
the,2080,O
variant,2080,O
allele,2080,O
6-,2080,O
was,2080,O
very,2080,O
frequent,2080,O
(,2080,O
69.0,2080,O
%,2080,O
),2080,O
.,2080,O
Instead,2081,O
",",2081,O
most,2081,O
patients,2081,B-OrganismTaxon
with,2081,O
right-sided,2081,O
tumours,2081,B-DiseaseOrPhenotypicFeature
were,2081,O
wild-type,2081,O
homozygous,2081,O
6+/6+,2081,O
(,2081,O
63.9,2081,O
%,2081,O
),2081,O
(,2081,O
P,2081,O
<,2081,O
0.01,2081,O
),2081,O
.,2081,O
Heterozygous,2082,O
6+/6-,2082,O
genotype,2082,O
was,2082,O
more,2082,O
frequent,2082,O
among,2082,O
tumours,2082,B-DiseaseOrPhenotypicFeature
classified,2082,O
as,2082,O
C,2082,O
(,2082,O
50.0,2082,O
%,2082,O
),2082,O
and,2082,O
D,2082,O
(,2082,O
76.5,2082,O
%,2082,O
),2082,O
Dukes,2082,O
stages,2082,O
(,2082,O
P=0.05,2082,O
),2082,O
.,2082,O
None,2083,O
of,2083,O
the,2083,O
studied,2083,O
polymorphisms,2083,O
alone,2083,O
affected,2083,O
overall,2083,O
or,2083,O
progression-free,2083,O
survival,2083,O
(,2083,O
PFS,2083,O
),2083,O
.,2083,O
C_6+/6+,2084,O
and,2084,O
G_6+/6+,2084,O
combined,2084,O
genotypes,2084,O
were,2084,O
respectively,2084,O
associated,2084,O
to,2084,O
the,2084,O
best,2084,O
and,2084,O
worst,2084,O
PFS,2084,O
(,2084,O
P=0.03,2084,O
when,2084,O
compared,2084,O
with,2084,O
each,2084,O
other,2084,O
),2084,O
",",2084,O
while,2084,O
combinations,2084,O
carrying,2084,O
the,2084,O
allele,2084,O
6-,2084,O
determined,2084,O
an,2084,O
intermediate,2084,O
evolution,2084,O
that,2084,O
might,2084,O
be,2084,O
indicative,2084,O
of,2084,O
a,2084,O
variable,2084,O
response,2084,O
to,2084,O
chemotherapy,2084,O
.,2084,O
The,2085,O
rate,2085,O
of,2085,O
Dukes,2085,O
B,2085,O
stage,2085,O
tumours,2085,B-DiseaseOrPhenotypicFeature
was,2085,O
unexpectedly,2085,O
high,2085,O
(,2085,O
59.1,2085,O
%,2085,O
),2085,O
among,2085,O
patients,2085,B-OrganismTaxon
with,2085,O
the,2085,O
unfavourable,2085,O
G_6+/6+,2085,O
combination,2085,O
.,2085,O
In,2086,O
our,2086,O
study,2086,O
the,2086,O
combination,2086,O
of,2086,O
high,2086,O
TS,2086,B-GeneOrGeneProduct
expression,2086,O
genotypes,2086,O
G_6+/6+,2086,O
identifies,2086,O
a,2086,O
group,2086,O
of,2086,O
high,2086,O
risk,2086,O
within,2086,O
CRC,2086,B-DiseaseOrPhenotypicFeature
patients,2086,B-OrganismTaxon
treated,2086,O
with,2086,O
5FU,2086,B-ChemicalEntity
.,2086,O
Study,2087,O
of,2087,O
a,2087,O
Taiwanese,2087,O
family,2087,O
with,2087,O
oculopharyngeal,2087,B-DiseaseOrPhenotypicFeature
muscular,2087,I-DiseaseOrPhenotypicFeature
dystrophy,2087,I-DiseaseOrPhenotypicFeature
.,2087,O
BACKGROUND,2088,O
:,2088,O
Oculopharyngeal,2088,B-DiseaseOrPhenotypicFeature
muscular,2088,I-DiseaseOrPhenotypicFeature
dystrophy,2088,I-DiseaseOrPhenotypicFeature
(,2088,O
OPMD,2088,B-DiseaseOrPhenotypicFeature
),2088,O
is,2088,O
a,2088,O
late,2088,O
onset,2088,O
autosomal,2088,B-DiseaseOrPhenotypicFeature
dominant,2088,I-DiseaseOrPhenotypicFeature
muscle,2088,I-DiseaseOrPhenotypicFeature
disorder,2088,I-DiseaseOrPhenotypicFeature
.,2088,O
OPMD,2089,B-DiseaseOrPhenotypicFeature
is,2089,O
caused,2089,O
by,2089,O
a,2089,O
short,2089,O
trinucleotide,2089,O
repeat,2089,O
expansion,2089,O
encoding,2089,O
an,2089,O
expanded,2089,O
polyalanine,2089,B-ChemicalEntity
tract,2089,O
in,2089,O
the,2089,O
polyadenylate,2089,B-GeneOrGeneProduct
binding-protein,2089,I-GeneOrGeneProduct
nuclear,2089,I-GeneOrGeneProduct
1,2089,I-GeneOrGeneProduct
(,2089,O
PABPN1,2089,B-GeneOrGeneProduct
),2089,O
gene,2089,O
.,2089,O
We,2090,O
identified,2090,O
and,2090,O
characterized,2090,O
a,2090,O
PABPN1,2090,B-GeneOrGeneProduct
mutation,2090,O
in,2090,O
a,2090,O
Taiwanese,2090,O
family,2090,O
with,2090,O
OPMD,2090,B-DiseaseOrPhenotypicFeature
.,2090,O
METHODS,2091,O
:,2091,O
The,2091,O
phenotypic,2091,O
and,2091,O
genotypic,2091,O
characteristics,2091,O
of,2091,O
all,2091,O
subjects,2091,O
were,2091,O
evaluated,2091,O
in,2091,O
a,2091,O
Taiwanese,2091,O
OPMD,2091,B-DiseaseOrPhenotypicFeature
family,2091,O
.,2091,O
Genetic,2092,O
alterations,2092,O
in,2092,O
the,2092,O
PABPN1,2092,B-GeneOrGeneProduct
gene,2092,O
were,2092,O
identified,2092,O
using,2092,O
PCR,2092,O
and,2092,O
DNA,2092,O
sequencing,2092,O
.,2092,O
RESULTS,2093,O
:,2093,O
Ten,2093,O
subjects,2093,O
with,2093,O
OPMD,2093,B-DiseaseOrPhenotypicFeature
(,2093,O
6,2093,O
symptomatic,2093,O
and,2093,O
4,2093,O
asymptomatic,2093,O
),2093,O
within,2093,O
the,2093,O
Taiwanese,2093,O
family,2093,O
carried,2093,O
a,2093,O
novel,2093,O
mutation,2093,O
in,2093,O
the,2093,O
PABPN1,2093,B-GeneOrGeneProduct
gene,2093,O
.,2093,O
The,2094,O
normal,2094,O
(,2094,B-SequenceVariant
GCG,2094,I-SequenceVariant
),2094,I-SequenceVariant
6,2094,I-SequenceVariant
(,2094,I-SequenceVariant
GCA,2094,I-SequenceVariant
),2094,I-SequenceVariant
3GCG,2094,I-SequenceVariant
sequence,2094,I-SequenceVariant
was,2094,I-SequenceVariant
replaced,2094,I-SequenceVariant
by,2094,I-SequenceVariant
(,2094,I-SequenceVariant
GCG,2094,I-SequenceVariant
),2094,I-SequenceVariant
6,2094,I-SequenceVariant
(,2094,I-SequenceVariant
GCA,2094,I-SequenceVariant
),2094,I-SequenceVariant
(,2094,I-SequenceVariant
GCG,2094,I-SequenceVariant
),2094,I-SequenceVariant
4,2094,I-SequenceVariant
(,2094,I-SequenceVariant
GCA,2094,I-SequenceVariant
),2094,I-SequenceVariant
3GCG,2094,I-SequenceVariant
due,2094,O
to,2094,O
an,2094,O
insertion,2094,B-SequenceVariant
of,2094,I-SequenceVariant
(,2094,I-SequenceVariant
GCG,2094,I-SequenceVariant
),2094,I-SequenceVariant
4GCA,2094,I-SequenceVariant
into,2094,O
the,2094,O
normal,2094,O
allele,2094,O
in,2094,O
the,2094,O
Taiwanese,2094,O
OPMD,2094,B-DiseaseOrPhenotypicFeature
subjects,2094,O
.,2094,O
CONCLUSIONS,2095,O
:,2095,O
In,2095,O
contrast,2095,O
to,2095,O
a,2095,O
single,2095,O
GCG,2095,O
expansion,2095,O
in,2095,O
most,2095,O
of,2095,O
OPMD,2095,B-DiseaseOrPhenotypicFeature
patients,2095,B-OrganismTaxon
in,2095,O
the,2095,O
literature,2095,O
",",2095,O
an,2095,O
insertion,2095,B-SequenceVariant
of,2095,I-SequenceVariant
(,2095,I-SequenceVariant
GCG,2095,I-SequenceVariant
),2095,I-SequenceVariant
4GCA,2095,I-SequenceVariant
in,2095,O
the,2095,O
PABPN1,2095,B-GeneOrGeneProduct
gene,2095,O
was,2095,O
found,2095,O
in,2095,O
the,2095,O
Taiwanese,2095,O
OPMD,2095,B-DiseaseOrPhenotypicFeature
subjects,2095,O
.,2095,O
The,2096,O
identification,2096,O
of,2096,O
this,2096,O
mutation,2096,O
appears,2096,O
to,2096,O
support,2096,O
the,2096,O
molecular,2096,O
mechanism,2096,O
of,2096,O
unequal,2096,O
cross-over,2096,O
of,2096,O
two,2096,O
PABPN1,2096,B-GeneOrGeneProduct
alleles,2096,O
.,2096,O
The,2097,O
biological,2097,O
properties,2097,O
of,2097,O
the,2097,O
optical,2097,O
isomers,2097,O
of,2097,O
propranolol,2097,B-ChemicalEntity
and,2097,O
their,2097,O
effects,2097,O
on,2097,O
cardiac,2097,B-DiseaseOrPhenotypicFeature
arrhythmias,2097,I-DiseaseOrPhenotypicFeature
.,2097,O
1,2098,O
.,2098,O
The,2099,O
optical,2099,O
isomers,2099,O
of,2099,O
propranolol,2099,B-ChemicalEntity
have,2099,O
been,2099,O
compared,2099,O
for,2099,O
their,2099,O
beta-blocking,2099,O
and,2099,O
antiarrhythmic,2099,O
activities.2,2099,O
.,2099,O
In,2100,O
blocking,2100,O
the,2100,O
positive,2100,O
inotropic,2100,O
and,2100,O
chronotropic,2100,O
responses,2100,O
to,2100,O
isoprenaline,2100,B-ChemicalEntity
",",2100,O
(,2100,O
+,2100,O
),2100,O
-propranolol,2100,O
had,2100,O
less,2100,O
than,2100,O
one,2100,O
hundredth,2100,O
the,2100,O
potency,2100,O
of,2100,O
(,2100,O
-,2100,O
),2100,O
-propranolol,2100,O
.,2100,O
At,2101,O
dose,2101,O
levels,2101,O
of,2101,O
(,2101,O
+,2101,O
),2101,O
-propranolol,2101,O
which,2101,O
attenuated,2101,O
the,2101,O
responses,2101,O
to,2101,O
isoprenaline,2101,B-ChemicalEntity
",",2101,O
there,2101,O
was,2101,O
a,2101,O
significant,2101,O
prolongation,2101,O
of,2101,O
the,2101,O
PR,2101,O
interval,2101,O
of,2101,O
the,2101,O
electrocardiogram.3,2101,O
.,2101,O
The,2102,O
metabolic,2102,O
responses,2102,O
to,2102,O
isoprenaline,2102,B-ChemicalEntity
in,2102,O
dogs,2102,B-OrganismTaxon
(,2102,O
an,2102,O
increase,2102,O
in,2102,O
circulating,2102,O
glucose,2102,B-ChemicalEntity
",",2102,O
lactate,2102,B-ChemicalEntity
and,2102,O
free,2102,O
fatty,2102,B-ChemicalEntity
acids,2102,I-ChemicalEntity
),2102,O
were,2102,O
all,2102,O
blocked,2102,O
by,2102,O
(,2102,O
-,2102,O
),2102,O
-propranolol,2102,O
.,2102,O
(,2103,O
+,2103,O
),2103,O
-Propranolol,2103,O
had,2103,O
no,2103,O
effect,2103,O
on,2103,O
fatty,2103,B-ChemicalEntity
acid,2103,I-ChemicalEntity
mobilization,2103,O
but,2103,O
significantly,2103,O
reduced,2103,O
the,2103,O
increments,2103,O
in,2103,O
both,2103,O
lactate,2103,B-ChemicalEntity
and,2103,O
glucose.4,2103,B-ChemicalEntity
.,2103,O
Both,2104,O
isomers,2104,O
of,2104,O
propranolol,2104,B-ChemicalEntity
possessed,2104,O
similar,2104,O
depressant,2104,O
potency,2104,O
on,2104,O
isolated,2104,O
atrial,2104,O
muscle,2104,O
taken,2104,O
from,2104,O
guinea-pigs.5,2104,B-OrganismTaxon
.,2104,O
The,2105,O
isomers,2105,O
of,2105,O
propranolol,2105,B-ChemicalEntity
exhibited,2105,O
similar,2105,O
local,2105,O
anaesthetic,2105,O
potencies,2105,O
on,2105,O
an,2105,O
isolated,2105,O
frog,2105,O
nerve,2105,O
preparation,2105,O
at,2105,O
a,2105,O
level,2105,O
approximately,2105,O
three,2105,O
times,2105,O
that,2105,O
of,2105,O
procaine,2105,B-ChemicalEntity
.,2105,O
The,2106,O
racemic,2106,O
compound,2106,O
was,2106,O
significantly,2106,O
less,2106,O
potent,2106,O
than,2106,O
either,2106,O
isomer.6,2106,O
.,2106,O
Both,2107,O
isomers,2107,O
of,2107,O
propranolol,2107,B-ChemicalEntity
were,2107,O
capable,2107,O
of,2107,O
preventing,2107,O
adrenaline-induced,2107,B-ChemicalEntity
cardiac,2107,B-DiseaseOrPhenotypicFeature
arrhythmias,2107,I-DiseaseOrPhenotypicFeature
in,2107,O
cats,2107,B-OrganismTaxon
anaesthetized,2107,O
with,2107,O
halothane,2107,B-ChemicalEntity
",",2107,O
but,2107,O
the,2107,O
mean,2107,O
dose,2107,O
of,2107,O
(,2107,O
-,2107,O
),2107,O
-propranolol,2107,O
was,2107,O
0.09+/-0.02,2107,O
mg/kg,2107,O
whereas,2107,O
that,2107,O
of,2107,O
(,2107,O
+,2107,O
),2107,O
-propranolol,2107,O
was,2107,O
4.2+/-1.2,2107,O
mg/kg,2107,O
.,2107,O
At,2108,O
the,2108,O
effective,2108,O
dose,2108,O
level,2108,O
of,2108,O
(,2108,O
+,2108,O
),2108,O
-propranolol,2108,O
there,2108,O
was,2108,O
a,2108,O
significant,2108,O
prolongation,2108,O
of,2108,O
the,2108,O
PR,2108,O
interval,2108,O
of,2108,O
the,2108,O
electrocardiogram,2108,O
.,2108,O
Blockade,2109,O
of,2109,O
arrhythmias,2109,B-DiseaseOrPhenotypicFeature
with,2109,O
both,2109,O
isomers,2109,O
was,2109,O
surmountable,2109,O
by,2109,O
increasing,2109,O
the,2109,O
dose,2109,O
of,2109,O
adrenaline.7,2109,B-ChemicalEntity
.,2109,O
Both,2110,O
isomers,2110,O
of,2110,O
propranolol,2110,B-ChemicalEntity
were,2110,O
also,2110,O
capable,2110,O
of,2110,O
reversing,2110,O
ventricular,2110,B-DiseaseOrPhenotypicFeature
tachycardia,2110,I-DiseaseOrPhenotypicFeature
caused,2110,O
by,2110,O
ouabain,2110,B-ChemicalEntity
in,2110,O
anaesthetized,2110,O
cats,2110,B-OrganismTaxon
and,2110,O
dogs,2110,B-OrganismTaxon
.,2110,O
The,2111,O
dose,2111,O
of,2111,O
(,2111,O
-,2111,O
),2111,O
-propranolol,2111,O
was,2111,O
significantly,2111,O
smaller,2111,O
than,2111,O
that,2111,O
of,2111,O
(,2111,O
+,2111,O
),2111,O
-propranolol,2111,O
in,2111,O
both,2111,O
species,2111,O
but,2111,O
much,2111,O
higher,2111,O
than,2111,O
that,2111,O
required,2111,O
to,2111,O
produce,2111,O
evidence,2111,O
of,2111,O
beta-blockade.8,2111,O
.,2111,O
The,2112,O
implications,2112,O
of,2112,O
these,2112,O
results,2112,O
are,2112,O
discussed,2112,O
.,2112,O
A,2113,O
recessive,2113,B-DiseaseOrPhenotypicFeature
skeletal,2113,I-DiseaseOrPhenotypicFeature
dysplasia,2113,I-DiseaseOrPhenotypicFeature
",",2113,O
SEMD,2113,B-DiseaseOrPhenotypicFeature
aggrecan,2113,B-GeneOrGeneProduct
type,2113,O
",",2113,O
results,2113,O
from,2113,O
a,2113,O
missense,2113,O
mutation,2113,O
affecting,2113,O
the,2113,O
C-type,2113,O
lectin,2113,O
domain,2113,O
of,2113,O
aggrecan,2113,B-GeneOrGeneProduct
.,2113,O
Analysis,2114,O
of,2114,O
a,2114,O
nuclear,2114,O
family,2114,O
with,2114,O
three,2114,O
affected,2114,O
offspring,2114,O
identified,2114,O
an,2114,O
autosomal-recessive,2114,O
form,2114,O
of,2114,O
spondyloepimetaphyseal,2114,B-DiseaseOrPhenotypicFeature
dysplasia,2114,I-DiseaseOrPhenotypicFeature
characterized,2114,O
by,2114,O
severe,2114,O
short,2114,B-DiseaseOrPhenotypicFeature
stature,2114,I-DiseaseOrPhenotypicFeature
and,2114,O
a,2114,O
unique,2114,O
constellation,2114,O
of,2114,O
radiographic,2114,O
findings,2114,O
.,2114,O
Homozygosity,2115,O
for,2115,O
a,2115,O
haplotype,2115,O
that,2115,O
was,2115,O
identical,2115,O
by,2115,O
descent,2115,O
between,2115,O
two,2115,O
of,2115,O
the,2115,O
affected,2115,O
individuals,2115,O
identified,2115,O
a,2115,O
locus,2115,O
for,2115,O
the,2115,O
disease,2115,O
gene,2115,O
within,2115,O
a,2115,O
17.4,2115,O
Mb,2115,O
interval,2115,O
on,2115,O
chromosome,2115,O
15,2115,O
",",2115,O
a,2115,O
region,2115,O
containing,2115,O
296,2115,O
genes,2115,O
.,2115,O
These,2116,O
genes,2116,O
were,2116,O
assessed,2116,O
and,2116,O
ranked,2116,O
by,2116,O
cartilage,2116,O
selectivity,2116,O
with,2116,O
whole-genome,2116,O
microarray,2116,O
data,2116,O
",",2116,O
revealing,2116,O
only,2116,O
two,2116,O
genes,2116,O
",",2116,O
encoding,2116,O
aggrecan,2116,B-GeneOrGeneProduct
and,2116,O
chondroitin,2116,B-GeneOrGeneProduct
sulfate,2116,I-GeneOrGeneProduct
proteoglycan,2116,I-GeneOrGeneProduct
4,2116,I-GeneOrGeneProduct
",",2116,O
that,2116,O
were,2116,O
selectively,2116,O
expressed,2116,O
in,2116,O
cartilage,2116,O
.,2116,O
Sequence,2117,O
analysis,2117,O
of,2117,O
aggrecan,2117,B-GeneOrGeneProduct
complementary,2117,O
DNA,2117,O
from,2117,O
an,2117,O
affected,2117,O
individual,2117,O
revealed,2117,O
homozygosity,2117,O
for,2117,O
a,2117,O
missense,2117,O
mutation,2117,O
(,2117,O
c.6799G,2117,B-SequenceVariant
--,2117,I-SequenceVariant
>,2117,I-SequenceVariant
A,2117,I-SequenceVariant
),2117,O
that,2117,O
predicts,2117,O
a,2117,O
p.D2267N,2117,B-SequenceVariant
amino,2117,O
acid,2117,O
substitution,2117,O
in,2117,O
the,2117,O
C-type,2117,O
lectin,2117,O
domain,2117,O
within,2117,O
the,2117,O
G3,2117,O
domain,2117,O
of,2117,O
aggrecan,2117,B-GeneOrGeneProduct
.,2117,O
The,2118,O
D2267,2118,B-SequenceVariant
residue,2118,O
is,2118,O
predicted,2118,O
to,2118,O
coordinate,2118,O
binding,2118,O
of,2118,O
a,2118,O
calcium,2118,B-ChemicalEntity
ion,2118,O
",",2118,O
which,2118,O
influences,2118,O
the,2118,O
conformational,2118,O
binding,2118,O
loops,2118,O
of,2118,O
the,2118,O
C-type,2118,O
lectin,2118,O
domain,2118,O
that,2118,O
mediate,2118,O
interactions,2118,O
with,2118,O
tenascins,2118,O
and,2118,O
other,2118,O
extracellular-matrix,2118,O
proteins,2118,O
.,2118,O
Expression,2119,O
of,2119,O
the,2119,O
normal,2119,O
and,2119,O
mutant,2119,O
G3,2119,O
domains,2119,O
in,2119,O
mammalian,2119,O
cells,2119,O
showed,2119,O
that,2119,O
the,2119,O
mutation,2119,O
created,2119,O
a,2119,O
functional,2119,O
N-glycosylation,2119,O
site,2119,O
but,2119,O
did,2119,O
not,2119,O
adversely,2119,O
affect,2119,O
protein,2119,O
trafficking,2119,O
and,2119,O
secretion,2119,O
.,2119,O
Surface-plasmon-resonance,2120,O
studies,2120,O
showed,2120,O
that,2120,O
the,2120,O
mutation,2120,O
influenced,2120,O
the,2120,O
binding,2120,O
and,2120,O
kinetics,2120,O
of,2120,O
the,2120,O
interactions,2120,O
between,2120,O
the,2120,O
aggrecan,2120,B-GeneOrGeneProduct
G3,2120,O
domain,2120,O
and,2120,O
tenascin-C,2120,B-GeneOrGeneProduct
.,2120,O
These,2121,O
findings,2121,O
identify,2121,O
an,2121,O
autosomal-recessive,2121,B-DiseaseOrPhenotypicFeature
skeletal,2121,I-DiseaseOrPhenotypicFeature
dysplasia,2121,I-DiseaseOrPhenotypicFeature
and,2121,O
a,2121,O
significant,2121,O
role,2121,O
for,2121,O
the,2121,O
aggrecan,2121,B-GeneOrGeneProduct
C-type,2121,O
lectin,2121,O
domain,2121,O
in,2121,O
regulating,2121,O
endochondral,2121,O
ossification,2121,O
and,2121,O
",",2121,O
thereby,2121,O
",",2121,O
height,2121,O
.,2121,O
P2RX7,2122,B-GeneOrGeneProduct
:,2122,O
A,2122,O
bipolar,2122,B-DiseaseOrPhenotypicFeature
and,2122,I-DiseaseOrPhenotypicFeature
unipolar,2122,I-DiseaseOrPhenotypicFeature
disorder,2122,I-DiseaseOrPhenotypicFeature
candidate,2122,O
susceptibility,2122,O
gene,2122,O
?,2122,O
The,2123,O
chromosomal,2123,O
region,2123,O
12q24,2123,O
has,2123,O
been,2123,O
previously,2123,O
implicated,2123,O
by,2123,O
linkage,2123,O
studies,2123,O
of,2123,O
both,2123,O
bipolar,2123,B-DiseaseOrPhenotypicFeature
disorder,2123,I-DiseaseOrPhenotypicFeature
and,2123,O
unipolar,2123,B-DiseaseOrPhenotypicFeature
mood,2123,I-DiseaseOrPhenotypicFeature
disorder,2123,I-DiseaseOrPhenotypicFeature
and,2123,O
we,2123,O
have,2123,O
reported,2123,O
two,2123,O
pedigrees,2123,O
segregating,2123,O
both,2123,O
bipolar,2123,B-DiseaseOrPhenotypicFeature
disorder,2123,I-DiseaseOrPhenotypicFeature
and,2123,O
Darier,2123,B-DiseaseOrPhenotypicFeature
's,2123,I-DiseaseOrPhenotypicFeature
disease,2123,I-DiseaseOrPhenotypicFeature
that,2123,O
show,2123,O
linkage,2123,O
across,2123,O
this,2123,O
region,2123,O
.,2123,O
The,2124,O
gene,2124,O
P2RX7,2124,B-GeneOrGeneProduct
is,2124,O
located,2124,O
in,2124,O
this,2124,O
chromosomal,2124,O
region,2124,O
and,2124,O
has,2124,O
been,2124,O
recently,2124,O
reported,2124,O
as,2124,O
a,2124,O
susceptibility,2124,O
gene,2124,O
for,2124,O
bipolar,2124,B-DiseaseOrPhenotypicFeature
disorder,2124,I-DiseaseOrPhenotypicFeature
and,2124,O
unipolar,2124,B-DiseaseOrPhenotypicFeature
depression,2124,I-DiseaseOrPhenotypicFeature
.,2124,O
The,2125,O
non-synonymous,2125,O
SNP,2125,O
rs2230912,2125,B-SequenceVariant
(,2125,O
resulting,2125,O
in,2125,O
amino-acid,2125,O
polymorphism,2125,O
Q460R,2125,B-SequenceVariant
),2125,O
showed,2125,O
the,2125,O
strongest,2125,O
association,2125,O
and,2125,O
has,2125,O
been,2125,O
postulated,2125,O
to,2125,O
be,2125,O
pathogenically,2125,O
relevant,2125,O
.,2125,O
We,2126,O
have,2126,O
investigated,2126,O
this,2126,O
gene,2126,O
in,2126,O
a,2126,O
large,2126,O
UK,2126,O
case-control,2126,O
sample,2126,O
(,2126,O
bipolar,2126,B-DiseaseOrPhenotypicFeature
I,2126,I-DiseaseOrPhenotypicFeature
disorder,2126,I-DiseaseOrPhenotypicFeature
N,2126,O
=,2126,O
687,2126,O
",",2126,O
unipolar,2126,B-DiseaseOrPhenotypicFeature
recurrent,2126,I-DiseaseOrPhenotypicFeature
major,2126,I-DiseaseOrPhenotypicFeature
depression,2126,I-DiseaseOrPhenotypicFeature
N,2126,O
=,2126,O
"1,036",2126,O
",",2126,O
controls,2126,O
N,2126,O
=,2126,O
"1,204",2126,O
),2126,O
.,2126,O
Neither,2127,O
rs2230912,2127,B-SequenceVariant
nor,2127,O
any,2127,O
of,2127,O
8,2127,O
other,2127,O
SNPs,2127,O
genotyped,2127,O
across,2127,O
P2RX7,2127,B-GeneOrGeneProduct
was,2127,O
found,2127,O
to,2127,O
be,2127,O
associated,2127,O
with,2127,O
mood,2127,B-DiseaseOrPhenotypicFeature
disorder,2127,I-DiseaseOrPhenotypicFeature
in,2127,O
general,2127,O
",",2127,O
nor,2127,O
specifically,2127,O
with,2127,O
bipolar,2127,B-DiseaseOrPhenotypicFeature
or,2127,I-DiseaseOrPhenotypicFeature
unipolar,2127,I-DiseaseOrPhenotypicFeature
disorder,2127,I-DiseaseOrPhenotypicFeature
.,2127,O
Further,2128,O
",",2128,O
sequencing,2128,O
of,2128,O
our,2128,O
two,2128,O
chromosome,2128,O
12-linked,2128,O
bipolar-Darier,2128,O
families,2128,O
showed,2128,O
no,2128,O
evidence,2128,O
of,2128,O
rare,2128,O
variants,2128,O
at,2128,O
P2RX7,2128,B-GeneOrGeneProduct
that,2128,O
could,2128,O
explain,2128,O
the,2128,O
linkage,2128,O
.,2128,O
Our,2129,O
data,2129,O
do,2129,O
not,2129,O
provide,2129,O
support,2129,O
for,2129,O
rs2230912,2129,B-SequenceVariant
or,2129,O
the,2129,O
other,2129,O
polymorphisms,2129,O
studied,2129,O
within,2129,O
the,2129,O
P2RX7,2129,B-GeneOrGeneProduct
locus,2129,O
",",2129,O
being,2129,O
involved,2129,O
in,2129,O
susceptibility,2129,O
to,2129,O
mood,2129,B-DiseaseOrPhenotypicFeature
disorders,2129,I-DiseaseOrPhenotypicFeature
.,2129,O
Phosphatidylinositol,2130,B-GeneOrGeneProduct
3-kinase,2130,I-GeneOrGeneProduct
p85alpha,2130,B-GeneOrGeneProduct
regulatory,2130,O
subunit,2130,O
gene,2130,O
Met326Ile,2130,B-SequenceVariant
polymorphism,2130,O
in,2130,O
women,2130,B-OrganismTaxon
with,2130,O
polycystic,2130,B-DiseaseOrPhenotypicFeature
ovary,2130,I-DiseaseOrPhenotypicFeature
syndrome,2130,I-DiseaseOrPhenotypicFeature
.,2130,O
BACKGROUND,2131,O
:,2131,O
Insulin,2131,B-DiseaseOrPhenotypicFeature
resistance,2131,I-DiseaseOrPhenotypicFeature
is,2131,O
a,2131,O
core,2131,O
feature,2131,O
of,2131,O
polycystic,2131,B-DiseaseOrPhenotypicFeature
ovary,2131,I-DiseaseOrPhenotypicFeature
syndrome,2131,I-DiseaseOrPhenotypicFeature
(,2131,O
PCOS,2131,B-DiseaseOrPhenotypicFeature
),2131,O
.,2131,O
Phosphatidylinositol,2132,B-GeneOrGeneProduct
(,2132,I-GeneOrGeneProduct
PI,2132,I-GeneOrGeneProduct
),2132,I-GeneOrGeneProduct
3-kinase,2132,I-GeneOrGeneProduct
is,2132,O
an,2132,O
important,2132,O
enzyme,2132,O
in,2132,O
the,2132,O
early,2132,O
insulin,2132,B-GeneOrGeneProduct
signaling,2132,O
cascade,2132,O
and,2132,O
plays,2132,O
a,2132,O
key,2132,O
role,2132,O
in,2132,O
insulin-mediated,2132,B-GeneOrGeneProduct
glucose,2132,B-ChemicalEntity
transport,2132,O
.,2132,O
In,2133,O
its,2133,O
regulatory,2133,O
subunit,2133,O
",",2133,O
p85alpha,2133,B-GeneOrGeneProduct
",",2133,O
there,2133,O
is,2133,O
a,2133,O
common,2133,O
amino,2133,O
acid,2133,O
substitution,2133,O
(,2133,O
the,2133,O
Met326Ile,2133,B-SequenceVariant
polymorphism,2133,O
),2133,O
",",2133,O
and,2133,O
this,2133,O
amino,2133,O
acid,2133,O
may,2133,O
be,2133,O
crucial,2133,O
for,2133,O
the,2133,O
function,2133,O
of,2133,O
the,2133,O
p85alpha,2133,B-GeneOrGeneProduct
regulatory,2133,O
subunit,2133,O
and,2133,O
PI3-kinase,2133,B-GeneOrGeneProduct
.,2133,O
METHODS,2134,O
:,2134,O
Analysis,2134,O
of,2134,O
the,2134,O
Met326Ile,2134,B-SequenceVariant
polymorphism,2134,O
was,2134,O
carried,2134,O
out,2134,O
on,2134,O
DNA,2134,O
samples,2134,O
from,2134,O
256,2134,O
PCOS,2134,B-DiseaseOrPhenotypicFeature
patients,2134,B-OrganismTaxon
and,2134,O
283,2134,O
controls,2134,O
.,2134,O
Clinical,2135,O
and,2135,O
biochemical,2135,O
profiles,2135,O
of,2135,O
participants,2135,O
were,2135,O
also,2135,O
compared,2135,O
.,2135,O
RESULTS,2136,O
:,2136,O
The,2136,O
genotype,2136,O
distribution,2136,O
of,2136,O
the,2136,O
Met326Ile,2136,B-SequenceVariant
polymorphism,2136,O
in,2136,O
the,2136,O
PCOS,2136,B-DiseaseOrPhenotypicFeature
group,2136,O
was,2136,O
not,2136,O
different,2136,O
from,2136,O
that,2136,O
of,2136,O
the,2136,O
controls,2136,O
(,2136,O
Met326Met/Met326Ile/Ile326Ile,2136,B-SequenceVariant
rates,2136,O
were,2136,O
73.4,2136,O
%,2136,O
/23.4,2136,O
%,2136,O
/3.2,2136,O
%,2136,O
and,2136,O
70.3,2136,O
%,2136,O
/26.1,2136,O
%,2136,O
/3.6,2136,O
%,2136,O
for,2136,O
the,2136,O
PCOS,2136,B-DiseaseOrPhenotypicFeature
and,2136,O
control,2136,O
groups,2136,O
",",2136,O
respectively,2136,O
",",2136,O
P,2136,O
=,2136,O
0.72,2136,O
),2136,O
.,2136,O
The,2137,O
PCOS,2137,B-DiseaseOrPhenotypicFeature
group,2137,O
was,2137,O
divided,2137,O
into,2137,O
two,2137,O
subgroups,2137,O
according,2137,O
to,2137,O
the,2137,O
presence,2137,O
of,2137,O
the,2137,O
variant,2137,O
326Ile,2137,B-SequenceVariant
allele,2137,O
.,2137,O
Compared,2138,O
with,2138,O
those,2138,O
carrying,2138,O
at,2138,O
least,2138,O
one,2138,O
variant,2138,O
326Ile,2138,B-SequenceVariant
allele,2138,O
",",2138,O
carriers,2138,O
with,2138,O
the,2138,O
Met326Met,2138,B-SequenceVariant
genotype,2138,O
had,2138,O
higher,2138,O
serum,2138,O
17-hydroxyprogesterone,2138,B-ChemicalEntity
(,2138,O
17-OHP,2138,B-ChemicalEntity
),2138,O
{,2138,O
1.1,2138,O
[,2138,O
95,2138,O
%,2138,O
confidence,2138,O
interval,2138,O
(,2138,O
CI,2138,O
),2138,O
1.1-1.3,2138,O
],2138,O
ng/ml,2138,O
in,2138,O
those,2138,O
with,2138,O
the,2138,O
Met326Met,2138,B-SequenceVariant
genotype,2138,O
versus,2138,O
0.8,2138,O
(,2138,O
95,2138,O
%,2138,O
CI,2138,O
0.7-1.0,2138,O
),2138,O
ng/ml,2138,O
in,2138,O
those,2138,O
with,2138,O
Ile326Ile,2138,B-SequenceVariant
and,2138,O
Met326Ile,2138,B-SequenceVariant
genotypes,2138,O
",",2138,O
P,2138,O
=,2138,O
0.0073,2138,O
},2138,O
and,2138,O
free,2138,O
testosterone,2138,B-ChemicalEntity
levels,2138,O
[,2138,O
1.2,2138,O
(,2138,O
95,2138,O
%,2138,O
CI,2138,O
1.1-1.4,2138,O
),2138,O
pg/ml,2138,O
for,2138,O
Met326Met,2138,B-SequenceVariant
genotype,2138,O
versus,2138,O
0.9,2138,O
(,2138,O
95,2138,O
%,2138,O
CI,2138,O
0.6-1.3,2138,O
),2138,O
pg/ml,2138,O
for,2138,O
Ile326Ile,2138,B-SequenceVariant
and,2138,O
Met326Ile,2138,B-SequenceVariant
genotypes,2138,O
",",2138,O
P,2138,O
=,2138,O
0.038,2138,O
],2138,O
.,2138,O
CONCLUSIONS,2139,O
:,2139,O
Our,2139,O
results,2139,O
suggest,2139,O
that,2139,O
the,2139,O
PI3-kinase,2139,B-GeneOrGeneProduct
gene,2139,O
Met326Ile,2139,B-SequenceVariant
polymorphism,2139,O
may,2139,O
not,2139,O
be,2139,O
a,2139,O
major,2139,O
determinant,2139,O
for,2139,O
the,2139,O
development,2139,O
of,2139,O
PCOS,2139,B-DiseaseOrPhenotypicFeature
",",2139,O
but,2139,O
it,2139,O
may,2139,O
modulate,2139,O
the,2139,O
concentrations,2139,O
of,2139,O
serum,2139,O
17-OHP,2139,B-ChemicalEntity
or,2139,O
free,2139,O
testosterone,2139,B-ChemicalEntity
in,2139,O
PCOS,2139,B-DiseaseOrPhenotypicFeature
patients,2139,B-OrganismTaxon
.,2139,O
Comparison,2140,O
of,2140,O
unilateral,2140,O
pallidotomy,2140,O
and,2140,O
subthalamotomy,2140,O
findings,2140,O
in,2140,O
advanced,2140,O
idiopathic,2140,B-DiseaseOrPhenotypicFeature
Parkinson,2140,I-DiseaseOrPhenotypicFeature
's,2140,I-DiseaseOrPhenotypicFeature
disease,2140,I-DiseaseOrPhenotypicFeature
.,2140,O
A,2141,O
prospective,2141,O
",",2141,O
randomized,2141,O
",",2141,O
double-blind,2141,O
pilot,2141,O
study,2141,O
to,2141,O
compare,2141,O
the,2141,O
results,2141,O
of,2141,O
stereotactic,2141,O
unilateral,2141,O
pallidotomy,2141,O
and,2141,O
subthalamotomy,2141,O
in,2141,O
advanced,2141,O
idiopathic,2141,B-DiseaseOrPhenotypicFeature
Parkinson,2141,I-DiseaseOrPhenotypicFeature
's,2141,I-DiseaseOrPhenotypicFeature
disease,2141,I-DiseaseOrPhenotypicFeature
(,2141,O
PD,2141,B-DiseaseOrPhenotypicFeature
),2141,O
refractory,2141,O
to,2141,O
medical,2141,O
treatment,2141,O
was,2141,O
designed,2141,O
.,2141,O
Ten,2142,O
consecutive,2142,O
patients,2142,B-OrganismTaxon
(,2142,O
mean,2142,O
age,2142,O
",",2142,O
58.4,2142,O
+/-,2142,O
6.8,2142,O
years,2142,O
;,2142,O
7,2142,O
men,2142,B-OrganismTaxon
",",2142,O
3,2142,O
women,2142,B-OrganismTaxon
),2142,O
with,2142,O
similar,2142,O
characteristics,2142,O
at,2142,O
the,2142,O
duration,2142,O
of,2142,O
disease,2142,O
(,2142,O
mean,2142,O
disease,2142,O
time,2142,O
",",2142,O
8.4,2142,O
+/-,2142,O
3.5,2142,O
years,2142,O
),2142,O
",",2142,O
disabling,2142,O
motor,2142,O
fluctuations,2142,O
(,2142,O
Hoehn,2142,O
_,2142,O
Yahr,2142,O
stage,2142,O
3-5,2142,O
in,2142,O
off-drug,2142,O
phases,2142,O
),2142,O
and,2142,O
levodopa-induced,2142,B-ChemicalEntity
dyskinesias,2142,B-DiseaseOrPhenotypicFeature
were,2142,O
selected,2142,O
.,2142,O
All,2143,O
patients,2143,B-OrganismTaxon
had,2143,O
bilateral,2143,O
symptoms,2143,O
and,2143,O
their,2143,O
levodopa,2143,B-ChemicalEntity
equivalent,2143,O
dosing,2143,O
were,2143,O
analysed,2143,O
.,2143,O
Six,2144,O
patients,2144,B-OrganismTaxon
were,2144,O
operated,2144,O
on,2144,O
in,2144,O
the,2144,O
globus,2144,O
pallidus,2144,O
interna,2144,O
(,2144,O
GPi,2144,O
),2144,O
and,2144,O
four,2144,O
in,2144,O
the,2144,O
subthalamic,2144,O
nucleus,2144,O
(,2144,O
STN,2144,O
),2144,O
.,2144,O
Clinical,2145,O
evaluation,2145,O
included,2145,O
the,2145,O
use,2145,O
of,2145,O
the,2145,O
Unified,2145,O
Parkinson,2145,B-DiseaseOrPhenotypicFeature
's,2145,I-DiseaseOrPhenotypicFeature
Disease,2145,I-DiseaseOrPhenotypicFeature
Rating,2145,O
Scale,2145,O
(,2145,O
UPDRS,2145,O
),2145,O
",",2145,O
Hoehn_Yahr,2145,O
score,2145,O
and,2145,O
Schwab,2145,O
England,2145,O
activities,2145,O
of,2145,O
daily,2145,O
living,2145,O
(,2145,O
ADL,2145,O
),2145,O
score,2145,O
in,2145,O
'on'-,2145,O
and,2145,O
'off'-drug,2145,O
conditions,2145,O
before,2145,O
surgery,2145,O
and,2145,O
6,2145,O
months,2145,O
after,2145,O
surgery,2145,O
.,2145,O
There,2146,O
was,2146,O
statistically,2146,O
significant,2146,O
improvement,2146,O
in,2146,O
all,2146,O
contralateral,2146,O
major,2146,O
parkinsonian,2146,B-DiseaseOrPhenotypicFeature
motor,2146,O
signs,2146,O
in,2146,O
all,2146,O
patients,2146,B-OrganismTaxon
followed,2146,O
for,2146,O
6,2146,O
months,2146,O
.,2146,O
Levodopa,2147,B-ChemicalEntity
equivalent,2147,O
daily,2147,O
intake,2147,O
was,2147,O
significantly,2147,O
reduced,2147,O
in,2147,O
the,2147,O
STN,2147,O
group,2147,O
.,2147,O
Changes,2148,O
in,2148,O
UPDRS,2148,O
",",2148,O
Hoehn,2148,O
_,2148,O
Yahr,2148,O
and,2148,O
Schwab,2148,O
England,2148,O
ADL,2148,O
scores,2148,O
were,2148,O
similar,2148,O
in,2148,O
both,2148,O
groups,2148,O
.,2148,O
Cognitive,2149,O
functions,2149,O
were,2149,O
unchanged,2149,O
in,2149,O
both,2149,O
groups,2149,O
.,2149,O
Complications,2150,O
were,2150,O
observed,2150,O
in,2150,O
two,2150,O
patients,2150,B-OrganismTaxon
:,2150,O
one,2150,O
had,2150,O
a,2150,O
left,2150,O
homonymous,2150,B-DiseaseOrPhenotypicFeature
hemianopsia,2150,I-DiseaseOrPhenotypicFeature
after,2150,O
pallidotomy,2150,O
and,2150,O
another,2150,O
one,2150,O
developed,2150,O
left,2150,O
hemiballistic,2150,O
movements,2150,O
3,2150,O
days,2150,O
after,2150,O
subthalamotomy,2150,O
which,2150,O
partly,2150,O
improved,2150,O
within,2150,O
1,2150,O
month,2150,O
with,2150,O
Valproate,2150,B-ChemicalEntity
1000,2150,O
mg/day,2150,O
.,2150,O
The,2151,O
findings,2151,O
of,2151,O
this,2151,O
study,2151,O
suggest,2151,O
that,2151,O
lesions,2151,O
of,2151,O
the,2151,O
unilateral,2151,O
STN,2151,O
and,2151,O
GPi,2151,O
are,2151,O
equally,2151,O
effective,2151,O
treatment,2151,O
for,2151,O
patients,2151,B-OrganismTaxon
with,2151,O
advanced,2151,O
PD,2151,B-DiseaseOrPhenotypicFeature
refractory,2151,O
to,2151,O
medical,2151,O
treatment,2151,O
.,2151,O
Neuregulin-1,2152,B-GeneOrGeneProduct
beta,2152,I-GeneOrGeneProduct
and,2152,O
neuregulin-1,2152,B-GeneOrGeneProduct
alpha,2152,I-GeneOrGeneProduct
differentially,2152,O
affect,2152,O
the,2152,O
migration,2152,O
and,2152,O
invasion,2152,O
of,2152,O
malignant,2152,B-DiseaseOrPhenotypicFeature
peripheral,2152,I-DiseaseOrPhenotypicFeature
nerve,2152,I-DiseaseOrPhenotypicFeature
sheath,2152,I-DiseaseOrPhenotypicFeature
tumor,2152,I-DiseaseOrPhenotypicFeature
cells,2152,O
.,2152,O
Malignant,2153,B-DiseaseOrPhenotypicFeature
peripheral,2153,I-DiseaseOrPhenotypicFeature
nerve,2153,I-DiseaseOrPhenotypicFeature
sheath,2153,I-DiseaseOrPhenotypicFeature
tumors,2153,I-DiseaseOrPhenotypicFeature
(,2153,O
MPNSTs,2153,B-DiseaseOrPhenotypicFeature
),2153,O
are,2153,O
the,2153,O
most,2153,O
common,2153,O
malignancy,2153,B-DiseaseOrPhenotypicFeature
associated,2153,O
with,2153,O
neurofibromatosis,2153,B-GeneOrGeneProduct
Type,2153,I-GeneOrGeneProduct
1,2153,I-GeneOrGeneProduct
(,2153,O
NF1,2153,B-GeneOrGeneProduct
),2153,O
.,2153,O
These,2154,O
Schwann,2154,O
cell,2154,O
lineage-derived,2154,O
sarcomas,2154,B-DiseaseOrPhenotypicFeature
aggressively,2154,O
invade,2154,O
adjacent,2154,O
nerve,2154,O
and,2154,O
soft,2154,O
tissue,2154,O
",",2154,O
frequently,2154,O
precluding,2154,O
surgical,2154,O
resection,2154,O
.,2154,O
Little,2155,O
is,2155,O
known,2155,O
regarding,2155,O
the,2155,O
mechanisms,2155,O
underlying,2155,O
this,2155,O
invasive,2155,O
behavior,2155,O
.,2155,O
We,2156,O
have,2156,O
shown,2156,O
that,2156,O
MPNSTs,2156,B-DiseaseOrPhenotypicFeature
express,2156,O
neuregulin-1,2156,B-GeneOrGeneProduct
(,2156,I-GeneOrGeneProduct
NRG-1,2156,I-GeneOrGeneProduct
),2156,I-GeneOrGeneProduct
beta,2156,I-GeneOrGeneProduct
isoforms,2156,O
",",2156,O
which,2156,O
promote,2156,O
Schwann,2156,O
cell,2156,O
migration,2156,O
during,2156,O
development,2156,O
",",2156,O
and,2156,O
NRG-1,2156,B-GeneOrGeneProduct
alpha,2156,I-GeneOrGeneProduct
isoforms,2156,O
",",2156,O
whose,2156,O
effects,2156,O
on,2156,O
Schwann,2156,O
cells,2156,O
are,2156,O
poorly,2156,O
understood,2156,O
.,2156,O
Hypothesizing,2157,O
that,2157,O
NRG-1,2157,B-GeneOrGeneProduct
beta,2157,I-GeneOrGeneProduct
and/or,2157,O
NRG-1,2157,B-GeneOrGeneProduct
alpha,2157,I-GeneOrGeneProduct
promote,2157,O
MPNST,2157,B-DiseaseOrPhenotypicFeature
invasion,2157,O
",",2157,O
we,2157,O
found,2157,O
that,2157,O
NRG-1,2157,B-GeneOrGeneProduct
beta,2157,I-GeneOrGeneProduct
promoted,2157,O
MPNST,2157,B-DiseaseOrPhenotypicFeature
migration,2157,O
in,2157,O
a,2157,O
substrate-specific,2157,O
manner,2157,O
",",2157,O
markedly,2157,O
enhancing,2157,O
migration,2157,O
on,2157,O
laminin,2157,B-GeneOrGeneProduct
but,2157,O
not,2157,O
on,2157,O
collagen,2157,B-GeneOrGeneProduct
type,2157,I-GeneOrGeneProduct
I,2157,I-GeneOrGeneProduct
or,2157,O
fibronectin,2157,B-GeneOrGeneProduct
.,2157,O
The,2158,O
NRG-1,2158,B-GeneOrGeneProduct
receptors,2158,O
erbB3,2158,B-GeneOrGeneProduct
and,2158,O
erbB4,2158,B-GeneOrGeneProduct
were,2158,O
present,2158,O
in,2158,O
MPNST,2158,B-DiseaseOrPhenotypicFeature
invadopodia,2158,O
(,2158,O
processes,2158,O
mediating,2158,O
invasion,2158,O
),2158,O
",",2158,O
partially,2158,O
colocalized,2158,O
with,2158,O
focal,2158,B-GeneOrGeneProduct
adhesion,2158,I-GeneOrGeneProduct
kinase,2158,I-GeneOrGeneProduct
and,2158,O
the,2158,O
laminin,2158,B-GeneOrGeneProduct
receptor,2158,I-GeneOrGeneProduct
beta,2158,B-GeneOrGeneProduct
(,2158,I-GeneOrGeneProduct
1,2158,I-GeneOrGeneProduct
),2158,I-GeneOrGeneProduct
-integrin,2158,I-GeneOrGeneProduct
and,2158,O
coimmunoprecipitated,2158,O
with,2158,O
beta,2158,B-GeneOrGeneProduct
(,2158,I-GeneOrGeneProduct
1,2158,I-GeneOrGeneProduct
),2158,I-GeneOrGeneProduct
-integrin,2158,I-GeneOrGeneProduct
.,2158,O
NRG-1,2159,B-GeneOrGeneProduct
beta,2159,I-GeneOrGeneProduct
stimulated,2159,O
human,2159,B-OrganismTaxon
and,2159,O
murine,2159,B-OrganismTaxon
MPNST,2159,B-DiseaseOrPhenotypicFeature
cell,2159,O
migration,2159,O
and,2159,O
invasion,2159,O
in,2159,O
a,2159,O
concentration-dependent,2159,O
manner,2159,O
in,2159,O
three-dimensional,2159,O
migration,2159,O
assays,2159,O
",",2159,O
acting,2159,O
as,2159,O
a,2159,O
chemotactic,2159,O
factor,2159,O
.,2159,O
Both,2160,O
baseline,2160,O
and,2160,O
NRG-1,2160,B-GeneOrGeneProduct
beta-induced,2160,O
migration,2160,O
were,2160,O
erbB-dependent,2160,B-GeneOrGeneProduct
and,2160,O
required,2160,O
the,2160,O
action,2160,O
of,2160,O
MEK,2160,B-GeneOrGeneProduct
1/2,2160,I-GeneOrGeneProduct
",",2160,O
SAPK/JNK,2160,B-GeneOrGeneProduct
",",2160,O
PI-3,2160,B-GeneOrGeneProduct
kinase,2160,I-GeneOrGeneProduct
",",2160,O
Src,2160,B-GeneOrGeneProduct
family,2160,I-GeneOrGeneProduct
kinases,2160,I-GeneOrGeneProduct
and,2160,O
ROCK-I/II,2160,B-GeneOrGeneProduct
.,2160,O
In,2161,O
contrast,2161,O
",",2161,O
NRG-1,2161,B-GeneOrGeneProduct
alpha,2161,I-GeneOrGeneProduct
had,2161,O
no,2161,O
effect,2161,O
on,2161,O
the,2161,O
migration,2161,O
and,2161,O
invasion,2161,O
of,2161,O
some,2161,O
MPNST,2161,B-DiseaseOrPhenotypicFeature
lines,2161,O
and,2161,O
inhibited,2161,O
the,2161,O
migration,2161,O
of,2161,O
others,2161,O
.,2161,O
While,2162,O
NRG-1,2162,B-GeneOrGeneProduct
beta,2162,I-GeneOrGeneProduct
potently,2162,O
and,2162,O
persistently,2162,O
activated,2162,O
Erk,2162,B-GeneOrGeneProduct
1/2,2162,I-GeneOrGeneProduct
",",2162,O
SAPK/JNK,2162,B-GeneOrGeneProduct
",",2162,O
Akt,2162,B-GeneOrGeneProduct
and,2162,O
Src,2162,B-GeneOrGeneProduct
family,2162,I-GeneOrGeneProduct
kinases,2162,I-GeneOrGeneProduct
",",2162,O
NRG-1,2162,B-GeneOrGeneProduct
alpha,2162,I-GeneOrGeneProduct
did,2162,O
not,2162,O
activate,2162,O
Akt,2162,B-GeneOrGeneProduct
and,2162,O
activated,2162,O
these,2162,O
other,2162,O
kinases,2162,O
with,2162,O
kinetics,2162,O
distinct,2162,O
from,2162,O
those,2162,O
evident,2162,O
in,2162,O
NRG-1,2162,B-GeneOrGeneProduct
beta-stimulated,2162,O
cells,2162,O
.,2162,O
These,2163,O
findings,2163,O
suggest,2163,O
that,2163,O
NRG-1,2163,B-GeneOrGeneProduct
beta,2163,I-GeneOrGeneProduct
enhances,2163,O
MPNST,2163,B-DiseaseOrPhenotypicFeature
migration,2163,O
and,2163,O
that,2163,O
NRG-1,2163,B-GeneOrGeneProduct
beta,2163,I-GeneOrGeneProduct
and,2163,O
NRG-1,2163,B-GeneOrGeneProduct
alpha,2163,I-GeneOrGeneProduct
differentially,2163,O
modulate,2163,O
this,2163,O
process,2163,O
.,2163,O
Rapid,2164,O
reversal,2164,O
of,2164,O
anticoagulation,2164,O
reduces,2164,O
hemorrhage,2164,B-DiseaseOrPhenotypicFeature
volume,2164,O
in,2164,O
a,2164,O
mouse,2164,B-OrganismTaxon
model,2164,O
of,2164,O
warfarin-associated,2164,B-ChemicalEntity
intracerebral,2164,B-DiseaseOrPhenotypicFeature
hemorrhage,2164,I-DiseaseOrPhenotypicFeature
.,2164,O
Warfarin-associated,2165,B-ChemicalEntity
intracerebral,2165,B-DiseaseOrPhenotypicFeature
hemorrhage,2165,I-DiseaseOrPhenotypicFeature
(,2165,O
W-ICH,2165,B-ChemicalEntity
),2165,O
is,2165,O
a,2165,O
severe,2165,O
type,2165,O
of,2165,O
stroke,2165,B-DiseaseOrPhenotypicFeature
.,2165,O
There,2166,O
is,2166,O
no,2166,O
consensus,2166,O
on,2166,O
the,2166,O
optimal,2166,O
treatment,2166,O
for,2166,O
W-ICH,2166,B-ChemicalEntity
.,2166,O
Using,2167,O
a,2167,O
mouse,2167,B-OrganismTaxon
model,2167,O
",",2167,O
we,2167,O
tested,2167,O
whether,2167,O
the,2167,O
rapid,2167,O
reversal,2167,O
of,2167,O
anticoagulation,2167,O
using,2167,O
human,2167,B-OrganismTaxon
prothrombin,2167,B-ChemicalEntity
complex,2167,I-ChemicalEntity
concentrate,2167,I-ChemicalEntity
(,2167,O
PCC,2167,B-ChemicalEntity
),2167,O
can,2167,O
reduce,2167,O
hemorrhagic,2167,O
blood,2167,O
volume,2167,O
.,2167,O
Male,2168,O
CD-1,2168,O
mice,2168,B-OrganismTaxon
were,2168,O
treated,2168,O
with,2168,O
warfarin,2168,B-ChemicalEntity
(,2168,O
2,2168,O
mg/kg,2168,O
over,2168,O
24,2168,O
h,2168,O
),2168,O
",",2168,O
resulting,2168,O
in,2168,O
a,2168,O
mean,2168,O
(,2168,O
+/-s.d,2168,O
.,2168,O
),2168,O
International,2169,O
Normalized,2169,O
Ratio,2169,O
of,2169,O
3.5+/-0.9,2169,O
.,2169,O
First,2170,O
",",2170,O
we,2170,O
showed,2170,O
that,2170,O
an,2170,O
intravenous,2170,O
administration,2170,O
of,2170,O
human,2170,B-OrganismTaxon
PCC,2170,B-ChemicalEntity
rapidly,2170,O
reversed,2170,O
anticoagulation,2170,O
in,2170,O
mice,2170,B-OrganismTaxon
.,2170,O
Second,2171,O
",",2171,O
a,2171,O
stereotactic,2171,O
injection,2171,O
of,2171,O
collagenase,2171,B-ChemicalEntity
was,2171,O
administered,2171,O
to,2171,O
induce,2171,O
hemorrhage,2171,B-DiseaseOrPhenotypicFeature
in,2171,O
the,2171,O
right,2171,O
striatum,2171,O
.,2171,O
Forty-five,2172,O
minutes,2172,O
later,2172,O
",",2172,O
the,2172,O
animals,2172,O
were,2172,O
randomly,2172,O
treated,2172,O
with,2172,O
PCC,2172,B-ChemicalEntity
(,2172,O
100,2172,O
U/kg,2172,O
),2172,O
or,2172,O
saline,2172,O
i.v,2172,O
.,2172,O
(,2173,O
n=12,2173,O
per,2173,O
group,2173,O
),2173,O
.,2173,O
Twenty-four,2174,O
hours,2174,O
after,2174,O
hemorrhage,2174,B-DiseaseOrPhenotypicFeature
induction,2174,O
",",2174,O
hemorrhagic,2174,O
blood,2174,O
volume,2174,O
was,2174,O
quantified,2174,O
using,2174,O
a,2174,O
photometric,2174,O
hemoglobin,2174,O
assay,2174,O
.,2174,O
The,2175,O
mean,2175,O
hemorrhagic,2175,O
blood,2175,O
volume,2175,O
was,2175,O
reduced,2175,O
in,2175,O
PCC-treated,2175,B-ChemicalEntity
animals,2175,O
(,2175,O
6.5+/-3.1,2175,O
microL,2175,O
),2175,O
compared,2175,O
with,2175,O
saline,2175,O
controls,2175,O
(,2175,O
15.3+/-11.2,2175,O
microL,2175,O
",",2175,O
P=0.015,2175,O
),2175,O
.,2175,O
In,2176,O
the,2176,O
saline,2176,O
group,2176,O
",",2176,O
45,2176,O
%,2176,O
of,2176,O
the,2176,O
mice,2176,B-OrganismTaxon
developed,2176,O
large,2176,O
hematomas,2176,B-DiseaseOrPhenotypicFeature
(,2176,O
i.e.,2176,O
",",2176,O
>,2176,O
15,2176,O
microL,2176,O
),2176,O
.,2176,O
In,2177,O
contrast,2177,O
",",2177,O
such,2177,O
extensive,2177,O
lesions,2177,O
were,2177,O
never,2177,O
found,2177,O
in,2177,O
the,2177,O
PCC,2177,B-ChemicalEntity
group,2177,O
.,2177,O
We,2178,O
provide,2178,O
experimental,2178,O
data,2178,O
suggesting,2178,O
PCC,2178,B-ChemicalEntity
to,2178,O
be,2178,O
an,2178,O
effective,2178,O
acute,2178,O
treatment,2178,O
for,2178,O
W-ICH,2178,B-ChemicalEntity
in,2178,O
terms,2178,O
of,2178,O
reducing,2178,O
hemorrhagic,2178,O
blood,2178,O
volume,2178,O
.,2178,O
Future,2179,O
studies,2179,O
are,2179,O
needed,2179,O
to,2179,O
assess,2179,O
the,2179,O
therapeutic,2179,O
potential,2179,O
emerging,2179,O
from,2179,O
our,2179,O
finding,2179,O
for,2179,O
human,2179,B-OrganismTaxon
W-ICH,2179,B-ChemicalEntity
.,2179,O
Reversible,2180,O
inferior,2180,B-DiseaseOrPhenotypicFeature
colliculus,2180,I-DiseaseOrPhenotypicFeature
lesion,2180,I-DiseaseOrPhenotypicFeature
in,2180,O
metronidazole-induced,2180,B-ChemicalEntity
encephalopathy,2180,B-DiseaseOrPhenotypicFeature
:,2180,O
magnetic,2180,O
resonance,2180,O
findings,2180,O
on,2180,O
diffusion-weighted,2180,O
and,2180,O
fluid,2180,O
attenuated,2180,O
inversion,2180,O
recovery,2180,O
imaging,2180,O
.,2180,O
OBJECTIVE,2181,O
:,2181,O
This,2181,O
is,2181,O
to,2181,O
present,2181,O
reversible,2181,O
inferior,2181,B-DiseaseOrPhenotypicFeature
colliculus,2181,I-DiseaseOrPhenotypicFeature
lesions,2181,I-DiseaseOrPhenotypicFeature
in,2181,O
metronidazole-induced,2181,B-ChemicalEntity
encephalopathy,2181,B-DiseaseOrPhenotypicFeature
",",2181,O
to,2181,O
focus,2181,O
on,2181,O
the,2181,O
diffusion-weighted,2181,O
imaging,2181,O
(,2181,O
DWI,2181,O
),2181,O
and,2181,O
fluid,2181,O
attenuated,2181,O
inversion,2181,O
recovery,2181,O
(,2181,O
FLAIR,2181,O
),2181,O
imaging,2181,O
.,2181,O
MATERIALS,2182,O
AND,2182,O
METHODS,2182,O
:,2182,O
From,2182,O
November,2182,O
2005,2182,O
to,2182,O
September,2182,O
2007,2182,O
",",2182,O
8,2182,O
patients,2182,B-OrganismTaxon
(,2182,O
5,2182,O
men,2182,B-OrganismTaxon
and,2182,O
3,2182,O
women,2182,B-OrganismTaxon
),2182,O
were,2182,O
diagnosed,2182,O
as,2182,O
having,2182,O
metronidazole-induced,2182,B-ChemicalEntity
encephalopathy,2182,B-DiseaseOrPhenotypicFeature
(,2182,O
age,2182,O
range,2182,O
;,2182,O
43-78,2182,O
years,2182,O
),2182,O
.,2182,O
They,2183,O
had,2183,O
been,2183,O
taking,2183,O
metronidazole,2183,B-ChemicalEntity
(,2183,O
total,2183,O
dosage,2183,O
",",2183,O
45-120,2183,O
g,2183,O
;,2183,O
duration,2183,O
",",2183,O
30,2183,O
days,2183,O
to,2183,O
2,2183,O
months,2183,O
),2183,O
to,2183,O
treat,2183,O
the,2183,O
infection,2183,B-DiseaseOrPhenotypicFeature
in,2183,O
various,2183,O
organs,2183,O
.,2183,O
Initial,2184,O
brain,2184,O
magnetic,2184,O
resonance,2184,O
imaging,2184,O
(,2184,O
MRI,2184,O
),2184,O
were,2184,O
obtained,2184,O
after,2184,O
the,2184,O
hospitalization,2184,O
",",2184,O
including,2184,O
DWI,2184,O
(,2184,O
8/8,2184,O
),2184,O
",",2184,O
apparent,2184,O
diffusion,2184,O
coefficient,2184,O
(,2184,O
ADC,2184,O
),2184,O
map,2184,O
(,2184,O
4/8,2184,O
),2184,O
",",2184,O
FLAIR,2184,O
(,2184,O
7/8,2184,O
),2184,O
",",2184,O
and,2184,O
T2-weighted,2184,O
image,2184,O
(,2184,O
8/8,2184,O
),2184,O
.,2184,O
Follow-up,2185,O
MRIs,2185,O
were,2185,O
performed,2185,O
on,2185,O
5,2185,O
patients,2185,B-OrganismTaxon
from,2185,O
third,2185,O
to,2185,O
14th,2185,O
days,2185,O
after,2185,O
discontinuation,2185,O
of,2185,O
metronidazole,2185,B-ChemicalEntity
administration,2185,O
.,2185,O
Findings,2186,O
of,2186,O
initial,2186,O
and,2186,O
follow-up,2186,O
MRIs,2186,O
were,2186,O
retrospectively,2186,O
evaluated,2186,O
by,2186,O
2,2186,O
neuroradiologists,2186,O
by,2186,O
consensus,2186,O
",",2186,O
to,2186,O
analyze,2186,O
the,2186,O
presence,2186,O
of,2186,O
abnormal,2186,O
signal,2186,O
intensities,2186,O
",",2186,O
their,2186,O
locations,2186,O
",",2186,O
and,2186,O
signal,2186,O
changes,2186,O
on,2186,O
follow-up,2186,O
images,2186,O
.,2186,O
RESULTS,2187,O
:,2187,O
Initial,2187,O
MRIs,2187,O
showed,2187,O
abnormal,2187,O
high,2187,O
signal,2187,O
intensities,2187,O
on,2187,O
DWI,2187,O
and,2187,O
FLAIR,2187,O
(,2187,O
or,2187,O
T2-weighted,2187,O
image,2187,O
),2187,O
at,2187,O
the,2187,O
dentate,2187,O
nucleus,2187,O
(,2187,O
8/8,2187,O
),2187,O
",",2187,O
inferior,2187,O
colliculus,2187,O
(,2187,O
6/8,2187,O
),2187,O
",",2187,O
corpus,2187,O
callosum,2187,O
(,2187,O
2/8,2187,O
),2187,O
",",2187,O
pons,2187,O
(,2187,O
2/8,2187,O
),2187,O
",",2187,O
medulla,2187,O
(,2187,O
1/8,2187,O
),2187,O
",",2187,O
and,2187,O
bilateral,2187,O
cerebral,2187,O
white,2187,O
matter,2187,O
(,2187,O
1/8,2187,O
),2187,O
.,2187,O
High-signal,2188,O
intensity,2188,O
lesions,2188,O
on,2188,O
DWI,2188,O
tended,2188,O
to,2188,O
show,2188,O
low,2188,O
signal,2188,O
intensity,2188,O
on,2188,O
ADC,2188,O
map,2188,O
(,2188,O
3/4,2188,O
),2188,O
",",2188,O
but,2188,O
in,2188,O
one,2188,O
patient,2188,B-OrganismTaxon
",",2188,O
high,2188,O
signal,2188,O
intensity,2188,O
was,2188,O
shown,2188,O
at,2188,O
bilateral,2188,O
dentate,2188,O
nuclei,2188,O
on,2188,O
not,2188,O
only,2188,O
DWI,2188,O
but,2188,O
also,2188,O
ADC,2188,O
map,2188,O
.,2188,O
All,2189,O
the,2189,O
lesions,2189,O
in,2189,O
dentate,2189,O
",",2189,O
inferior,2189,O
colliculus,2189,O
",",2189,O
pons,2189,O
",",2189,O
and,2189,O
medullas,2189,O
had,2189,O
been,2189,O
resolved,2189,O
completely,2189,O
on,2189,O
follow-up,2189,O
MRIs,2189,O
in,2189,O
5,2189,O
patients,2189,B-OrganismTaxon
",",2189,O
but,2189,O
in,2189,O
1,2189,O
patient,2189,B-OrganismTaxon
of,2189,O
them,2189,O
",",2189,O
corpus,2189,O
callosal,2189,B-DiseaseOrPhenotypicFeature
lesion,2189,I-DiseaseOrPhenotypicFeature
persisted,2189,O
.,2189,O
CONCLUSIONS,2190,O
:,2190,O
Reversible,2190,O
inferior,2190,B-DiseaseOrPhenotypicFeature
colliculus,2190,I-DiseaseOrPhenotypicFeature
lesions,2190,I-DiseaseOrPhenotypicFeature
could,2190,O
be,2190,O
considered,2190,O
as,2190,O
the,2190,O
characteristic,2190,O
for,2190,O
metronidazole-induced,2190,B-ChemicalEntity
encephalopathy,2190,B-DiseaseOrPhenotypicFeature
",",2190,O
next,2190,O
to,2190,O
the,2190,O
dentate,2190,O
nucleus,2190,O
involvement,2190,O
.,2190,O
Macular,2191,B-DiseaseOrPhenotypicFeature
corneal,2191,I-DiseaseOrPhenotypicFeature
dystrophy,2191,I-DiseaseOrPhenotypicFeature
in,2191,O
a,2191,O
Chinese,2191,O
family,2191,O
related,2191,O
with,2191,O
novel,2191,O
mutations,2191,O
of,2191,O
CHST6,2191,B-GeneOrGeneProduct
.,2191,O
PURPOSE,2192,O
:,2192,O
To,2192,O
identify,2192,O
mutations,2192,O
in,2192,O
the,2192,O
carbohydrate,2192,B-GeneOrGeneProduct
sulfotransferase,2192,I-GeneOrGeneProduct
gene,2192,I-GeneOrGeneProduct
(,2192,O
CHST6,2192,B-GeneOrGeneProduct
),2192,O
for,2192,O
a,2192,O
Chinese,2192,O
family,2192,O
with,2192,O
macular,2192,B-DiseaseOrPhenotypicFeature
corneal,2192,I-DiseaseOrPhenotypicFeature
dystrophy,2192,I-DiseaseOrPhenotypicFeature
(,2192,O
MCD,2192,B-DiseaseOrPhenotypicFeature
),2192,O
and,2192,O
to,2192,O
investigate,2192,O
the,2192,O
histopathological,2192,O
changes,2192,O
in,2192,O
the,2192,O
affected,2192,O
cornea,2192,O
.,2192,O
METHODS,2193,O
:,2193,O
A,2193,O
corneal,2193,O
button,2193,O
of,2193,O
the,2193,O
proband,2193,O
was,2193,O
obtained,2193,O
by,2193,O
penetrating,2193,O
keratoplasty,2193,O
.,2193,O
The,2194,O
half,2194,O
button,2194,O
and,2194,O
ultrathin,2194,O
sections,2194,O
from,2194,O
the,2194,O
other,2194,O
half,2194,O
button,2194,O
were,2194,O
examined,2194,O
with,2194,O
special,2194,O
stains,2194,O
under,2194,O
a,2194,O
light,2194,O
microscope,2194,O
(,2194,O
LM,2194,O
),2194,O
and,2194,O
an,2194,O
electron,2194,O
microscope,2194,O
(,2194,O
EM,2194,O
),2194,O
separately,2194,O
.,2194,O
Genomic,2195,O
DNA,2195,O
was,2195,O
extracted,2195,O
from,2195,O
peripheral,2195,O
blood,2195,O
of,2195,O
11,2195,O
family,2195,O
members,2195,O
",",2195,O
and,2195,O
the,2195,O
coding,2195,O
region,2195,O
of,2195,O
CHST6,2195,B-GeneOrGeneProduct
was,2195,O
amplified,2195,O
by,2195,O
the,2195,O
polymerase,2195,O
chain,2195,O
reaction,2195,O
(,2195,O
PCR,2195,O
),2195,O
method,2195,O
.,2195,O
The,2196,O
PCR,2196,O
products,2196,O
were,2196,O
analyzed,2196,O
by,2196,O
direct,2196,O
sequencing,2196,O
and,2196,O
restriction,2196,O
enzyme,2196,O
digestion,2196,O
.,2196,O
RESULTS,2197,O
:,2197,O
The,2197,O
positive,2197,O
reaction,2197,O
to,2197,O
colloidal,2197,O
iron,2197,B-ChemicalEntity
stain,2197,O
(,2197,O
extracellular,2197,O
blue,2197,O
accumulations,2197,O
in,2197,O
the,2197,O
stroma,2197,O
),2197,O
was,2197,O
detected,2197,O
under,2197,O
light,2197,O
microscopy,2197,O
.,2197,O
Transmission,2198,O
electron,2198,O
microscopy,2198,O
revealed,2198,O
the,2198,O
enlargement,2198,O
of,2198,O
smooth,2198,O
endoplasmic,2198,O
reticulum,2198,O
and,2198,O
the,2198,O
presence,2198,O
of,2198,O
intracytoplasmic,2198,O
vacuoles,2198,O
.,2198,O
The,2199,O
compound,2199,O
heterozygous,2199,O
mutations,2199,O
",",2199,O
c.892C,2199,B-SequenceVariant
>,2199,I-SequenceVariant
T,2199,I-SequenceVariant
and,2199,O
c.1072T,2199,B-SequenceVariant
>,2199,I-SequenceVariant
C,2199,I-SequenceVariant
",",2199,O
were,2199,O
identified,2199,O
in,2199,O
exon,2199,O
3,2199,O
of,2199,O
CHST6,2199,B-GeneOrGeneProduct
in,2199,O
three,2199,O
patients,2199,B-OrganismTaxon
.,2199,O
The,2200,O
two,2200,O
transversions,2200,O
resulted,2200,O
in,2200,O
the,2200,O
substitution,2200,O
of,2200,O
a,2200,O
stop,2200,B-SequenceVariant
codon,2200,I-SequenceVariant
for,2200,I-SequenceVariant
glutamine,2200,I-SequenceVariant
at,2200,I-SequenceVariant
codon,2200,I-SequenceVariant
298,2200,I-SequenceVariant
(,2200,O
p.Q298X,2200,B-SequenceVariant
),2200,O
and,2200,O
a,2200,O
missense,2200,O
mutation,2200,O
at,2200,O
codon,2200,B-SequenceVariant
358,2200,I-SequenceVariant
",",2200,I-SequenceVariant
tyrosine,2200,I-SequenceVariant
to,2200,I-SequenceVariant
histidine,2200,I-SequenceVariant
(,2200,O
p.Y358H,2200,B-SequenceVariant
),2200,O
.,2200,O
The,2201,O
six,2201,O
unaffected,2201,O
family,2201,O
individuals,2201,O
carried,2201,O
alternative,2201,O
heterozygous,2201,O
mutations,2201,O
.,2201,O
These,2202,O
two,2202,O
mutations,2202,O
were,2202,O
not,2202,O
detected,2202,O
in,2202,O
any,2202,O
of,2202,O
the,2202,O
100,2202,O
control,2202,O
subjects,2202,O
.,2202,O
CONCLUSIONS,2203,O
:,2203,O
Those,2203,O
novel,2203,O
compound,2203,O
heterozygous,2203,O
mutations,2203,O
were,2203,O
thought,2203,O
to,2203,O
contribute,2203,O
to,2203,O
the,2203,O
loss,2203,O
of,2203,O
CHST6,2203,B-GeneOrGeneProduct
function,2203,O
",",2203,O
which,2203,O
induced,2203,O
the,2203,O
abnormal,2203,O
metabolism,2203,O
of,2203,O
keratan,2203,B-ChemicalEntity
sulfate,2203,I-ChemicalEntity
(,2203,O
KS,2203,B-ChemicalEntity
),2203,O
that,2203,O
deposited,2203,O
in,2203,O
the,2203,O
corneal,2203,O
stroma,2203,O
.,2203,O
It,2204,O
could,2204,O
be,2204,O
proved,2204,O
by,2204,O
the,2204,O
observation,2204,O
of,2204,O
a,2204,O
positive,2204,O
stain,2204,O
reaction,2204,O
and,2204,O
the,2204,O
enlarged,2204,O
collagen,2204,B-GeneOrGeneProduct
fibers,2204,O
as,2204,O
well,2204,O
as,2204,O
hyperplastic,2204,O
fibroblasts,2204,O
under,2204,O
microscopes,2204,O
.,2204,O
Identification,2205,O
and,2205,O
molecular,2205,O
characterization,2205,O
of,2205,O
six,2205,O
novel,2205,O
mutations,2205,O
in,2205,O
the,2205,O
UDP-N-acetylglucosamine-1-phosphotransferase,2205,B-GeneOrGeneProduct
gamma,2205,I-GeneOrGeneProduct
subunit,2205,I-GeneOrGeneProduct
(,2205,O
GNPTG,2205,B-GeneOrGeneProduct
),2205,O
gene,2205,O
in,2205,O
patients,2205,B-OrganismTaxon
with,2205,O
mucolipidosis,2205,B-DiseaseOrPhenotypicFeature
III,2205,I-DiseaseOrPhenotypicFeature
gamma,2205,I-DiseaseOrPhenotypicFeature
.,2205,O
Mucolipidosis,2206,B-DiseaseOrPhenotypicFeature
type,2206,I-DiseaseOrPhenotypicFeature
III,2206,I-DiseaseOrPhenotypicFeature
(,2206,O
MLIII,2206,B-DiseaseOrPhenotypicFeature
),2206,O
is,2206,O
an,2206,O
autosomal,2206,B-DiseaseOrPhenotypicFeature
recessive,2206,I-DiseaseOrPhenotypicFeature
disorder,2206,I-DiseaseOrPhenotypicFeature
affecting,2206,O
lysosomal,2206,O
hydrolase,2206,O
trafficking,2206,O
.,2206,O
In,2207,O
a,2207,O
study,2207,O
of,2207,O
10,2207,O
patients,2207,B-OrganismTaxon
from,2207,O
seven,2207,O
families,2207,O
with,2207,O
a,2207,O
clinical,2207,O
phenotype,2207,O
and,2207,O
enzymatic,2207,O
diagnosis,2207,O
of,2207,O
MLIII,2207,B-DiseaseOrPhenotypicFeature
",",2207,O
six,2207,O
novel,2207,O
GNPTG,2207,B-GeneOrGeneProduct
gene,2207,O
mutations,2207,O
were,2207,O
identified,2207,O
.,2207,O
These,2208,O
included,2208,O
missense,2208,O
(,2208,O
p.T286M,2208,B-SequenceVariant
),2208,O
and,2208,O
nonsense,2208,O
(,2208,O
p.W111X,2208,B-SequenceVariant
),2208,O
mutations,2208,O
and,2208,O
a,2208,O
transition,2208,O
in,2208,O
the,2208,O
obligate,2208,O
AG-dinucleotide,2208,B-SequenceVariant
of,2208,O
the,2208,O
intron,2208,O
8,2208,O
acceptor,2208,O
splice,2208,O
site,2208,O
(,2208,O
c.610-2A,2208,B-SequenceVariant
>,2208,I-SequenceVariant
G,2208,I-SequenceVariant
),2208,O
.,2208,O
Three,2209,O
microdeletions,2209,O
were,2209,O
also,2209,O
identified,2209,O
",",2209,O
two,2209,O
of,2209,O
which,2209,O
(,2209,O
c.611delG,2209,B-SequenceVariant
and,2209,O
c.640_667del28,2209,B-SequenceVariant
),2209,O
were,2209,O
located,2209,O
within,2209,O
the,2209,O
coding,2209,O
region,2209,O
whereas,2209,O
one,2209,O
(,2209,O
c.609+28_610-16del,2209,B-SequenceVariant
),2209,O
was,2209,O
located,2209,O
entirely,2209,O
within,2209,O
intron,2209,O
8,2209,O
.,2209,O
RT-PCR,2210,O
analysis,2210,O
of,2210,O
the,2210,O
c.610-2A,2210,B-SequenceVariant
>,2210,I-SequenceVariant
G,2210,I-SequenceVariant
transition,2210,O
demonstrated,2210,O
that,2210,O
the,2210,O
change,2210,O
altered,2210,O
splicing,2210,O
",",2210,O
leading,2210,O
to,2210,O
the,2210,O
production,2210,O
of,2210,O
two,2210,O
distinct,2210,O
aberrantly,2210,O
spliced,2210,O
forms,2210,O
",",2210,O
viz,2210,O
.,2210,O
the,2211,O
skipping,2211,O
of,2211,O
exon,2211,O
9,2211,O
(,2211,O
p.G204_K247del,2211,B-SequenceVariant
),2211,O
or,2211,O
the,2211,O
retention,2211,O
of,2211,O
introns,2211,O
8,2211,O
and,2211,O
9,2211,O
(,2211,O
p.G204VfsX28,2211,B-SequenceVariant
),2211,O
.,2211,O
RT-PCR,2212,O
analysis,2212,O
",",2212,O
performed,2212,O
on,2212,O
a,2212,O
patient,2212,B-OrganismTaxon
homozygous,2212,O
for,2212,O
the,2212,O
intronic,2212,O
deletion,2212,O
(,2212,O
c.609+28_610-16del,2212,B-SequenceVariant
),2212,O
",",2212,O
failed,2212,O
to,2212,O
detect,2212,O
any,2212,O
GNPTG,2212,B-GeneOrGeneProduct
RNA,2212,O
transcripts,2212,O
.,2212,O
To,2213,O
determine,2213,O
whether,2213,O
c.609+28_610-16del,2213,B-SequenceVariant
allele-derived,2213,O
transcripts,2213,O
were,2213,O
subject,2213,O
to,2213,O
nonsense-mediated,2213,O
mRNA,2213,O
decay,2213,O
(,2213,O
NMD,2213,O
),2213,O
",",2213,O
patient,2213,B-OrganismTaxon
fibroblasts,2213,O
were,2213,O
incubated,2213,O
with,2213,O
the,2213,O
protein,2213,O
synthesis,2213,O
inhibitor,2213,O
anisomycin,2213,B-ChemicalEntity
.,2213,O
An,2214,O
RT-PCR,2214,O
fragment,2214,O
retaining,2214,O
43,2214,O
bp,2214,O
of,2214,O
intron,2214,O
8,2214,O
was,2214,O
consistently,2214,O
detected,2214,O
suggesting,2214,O
that,2214,O
the,2214,O
33-bp,2214,B-SequenceVariant
genomic,2214,I-SequenceVariant
deletion,2214,I-SequenceVariant
had,2214,O
elicited,2214,O
NMD,2214,O
.,2214,O
Quantitative,2215,O
real-time,2215,O
PCR,2215,O
and,2215,O
GNPTG,2215,B-GeneOrGeneProduct
western,2215,O
blot,2215,O
analysis,2215,O
confirmed,2215,O
that,2215,O
the,2215,O
homozygous,2215,O
microdeletion,2215,O
p.G204VfsX17,2215,B-SequenceVariant
had,2215,O
elicited,2215,O
NMD,2215,O
resulting,2215,O
in,2215,O
failure,2215,O
to,2215,O
synthesize,2215,O
GNPTG,2215,B-GeneOrGeneProduct
protein,2215,O
.,2215,O
Analysis,2216,O
of,2216,O
the,2216,O
sequences,2216,O
surrounding,2216,O
the,2216,O
microdeletion,2216,O
breakpoints,2216,O
revealed,2216,O
either,2216,O
intrinsic,2216,O
repetitivity,2216,O
of,2216,O
the,2216,O
deleted,2216,O
region,2216,O
or,2216,O
short,2216,O
direct,2216,O
repeats,2216,O
adjacent,2216,O
to,2216,O
the,2216,O
breakpoint,2216,O
junctions,2216,O
.,2216,O
This,2217,O
is,2217,O
consistent,2217,O
with,2217,O
these,2217,O
repeats,2217,O
having,2217,O
mediated,2217,O
the,2217,O
microdeletions,2217,O
via,2217,O
replication,2217,O
slippage,2217,O
and,2217,O
supports,2217,O
the,2217,O
view,2217,O
that,2217,O
the,2217,O
mutational,2217,O
spectrum,2217,O
of,2217,O
the,2217,O
GNPTG,2217,B-GeneOrGeneProduct
gene,2217,O
is,2217,O
strongly,2217,O
influenced,2217,O
by,2217,O
the,2217,O
properties,2217,O
of,2217,O
the,2217,O
local,2217,O
DNA,2217,O
sequence,2217,O
environment,2217,O
.,2217,O
Cardioprotective,2218,O
effect,2218,O
of,2218,O
salvianolic,2218,B-ChemicalEntity
acid,2218,I-ChemicalEntity
A,2218,I-ChemicalEntity
on,2218,O
isoproterenol-induced,2218,B-ChemicalEntity
myocardial,2218,B-DiseaseOrPhenotypicFeature
infarction,2218,I-DiseaseOrPhenotypicFeature
in,2218,O
rats,2218,B-OrganismTaxon
.,2218,O
The,2219,O
present,2219,O
study,2219,O
was,2219,O
designed,2219,O
to,2219,O
evaluate,2219,O
the,2219,O
cardioprotective,2219,O
potential,2219,O
of,2219,O
salvianolic,2219,B-ChemicalEntity
acid,2219,I-ChemicalEntity
A,2219,I-ChemicalEntity
on,2219,O
isoproterenol-induced,2219,B-ChemicalEntity
myocardial,2219,B-DiseaseOrPhenotypicFeature
infarction,2219,I-DiseaseOrPhenotypicFeature
in,2219,O
rats,2219,B-OrganismTaxon
.,2219,O
Hemodynamic,2220,O
parameters,2220,O
and,2220,O
lead,2220,O
II,2220,O
electrocardiograph,2220,O
were,2220,O
monitored,2220,O
and,2220,O
recorded,2220,O
continuously,2220,O
.,2220,O
Cardiac,2221,O
marker,2221,O
enzymes,2221,O
and,2221,O
antioxidative,2221,O
parameters,2221,O
in,2221,O
serum,2221,O
and,2221,O
heart,2221,O
tissues,2221,O
were,2221,O
measured,2221,O
.,2221,O
Assay,2222,O
for,2222,O
mitochondrial,2222,O
respiratory,2222,O
function,2222,O
and,2222,O
histopathological,2222,O
examination,2222,O
of,2222,O
heart,2222,O
tissues,2222,O
were,2222,O
performed,2222,O
.,2222,O
Isoproterenol-treated,2223,B-ChemicalEntity
rats,2223,B-OrganismTaxon
showed,2223,O
significant,2223,O
increases,2223,O
in,2223,O
the,2223,O
levels,2223,O
of,2223,O
lactate,2223,B-GeneOrGeneProduct
dehydrogenase,2223,I-GeneOrGeneProduct
",",2223,O
aspartate,2223,B-GeneOrGeneProduct
transaminase,2223,I-GeneOrGeneProduct
",",2223,O
creatine,2223,B-GeneOrGeneProduct
kinase,2223,I-GeneOrGeneProduct
and,2223,O
malondialdehyde,2223,B-ChemicalEntity
and,2223,O
significant,2223,O
decreases,2223,O
in,2223,O
the,2223,O
activities,2223,O
of,2223,O
superoxide,2223,B-GeneOrGeneProduct
dismutase,2223,I-GeneOrGeneProduct
",",2223,O
catalase,2223,B-GeneOrGeneProduct
and,2223,O
glutathione,2223,B-GeneOrGeneProduct
peroxidase,2223,I-GeneOrGeneProduct
in,2223,O
serum,2223,O
and,2223,O
heart,2223,O
.,2223,O
These,2224,O
rats,2224,B-OrganismTaxon
also,2224,O
showed,2224,O
declines,2224,O
in,2224,O
left,2224,O
ventricular,2224,O
systolic,2224,O
pressure,2224,O
",",2224,O
maximum,2224,O
and,2224,O
minimum,2224,O
rate,2224,O
of,2224,O
developed,2224,O
left,2224,O
ventricular,2224,O
pressure,2224,O
",",2224,O
and,2224,O
elevation,2224,O
of,2224,O
left,2224,O
ventricular,2224,O
end-diastolic,2224,O
pressure,2224,O
and,2224,O
ST-segment,2224,O
.,2224,O
In,2225,O
addition,2225,O
",",2225,O
mitochondrial,2225,B-DiseaseOrPhenotypicFeature
respiratory,2225,I-DiseaseOrPhenotypicFeature
dysfunction,2225,I-DiseaseOrPhenotypicFeature
characterized,2225,O
by,2225,O
decreased,2225,O
respiratory,2225,O
control,2225,O
ratio,2225,O
and,2225,O
ADP/O,2225,B-ChemicalEntity
was,2225,O
observed,2225,O
in,2225,O
isoproterenol-treated,2225,B-ChemicalEntity
rats,2225,B-OrganismTaxon
.,2225,O
Administration,2226,O
of,2226,O
salvianolic,2226,B-ChemicalEntity
acid,2226,I-ChemicalEntity
A,2226,I-ChemicalEntity
for,2226,O
a,2226,O
period,2226,O
of,2226,O
8,2226,O
days,2226,O
significantly,2226,O
attenuated,2226,O
isoproterenol-induced,2226,B-ChemicalEntity
cardiac,2226,B-DiseaseOrPhenotypicFeature
dysfunction,2226,I-DiseaseOrPhenotypicFeature
and,2226,O
myocardial,2226,B-DiseaseOrPhenotypicFeature
injury,2226,I-DiseaseOrPhenotypicFeature
and,2226,O
improved,2226,O
mitochondrial,2226,O
respiratory,2226,O
function,2226,O
.,2226,O
The,2227,O
protective,2227,O
role,2227,O
of,2227,O
salvianolic,2227,B-ChemicalEntity
acid,2227,I-ChemicalEntity
A,2227,I-ChemicalEntity
against,2227,O
isoproterenol-induced,2227,B-ChemicalEntity
myocardial,2227,B-DiseaseOrPhenotypicFeature
damage,2227,I-DiseaseOrPhenotypicFeature
was,2227,O
further,2227,O
confirmed,2227,O
by,2227,O
histopathological,2227,O
examination,2227,O
.,2227,O
The,2228,O
results,2228,O
of,2228,O
our,2228,O
study,2228,O
suggest,2228,O
that,2228,O
salvianolic,2228,B-ChemicalEntity
acid,2228,I-ChemicalEntity
A,2228,I-ChemicalEntity
possessing,2228,O
antioxidant,2228,O
activity,2228,O
has,2228,O
a,2228,O
significant,2228,O
protective,2228,O
effect,2228,O
against,2228,O
isoproterenol-induced,2228,B-ChemicalEntity
myocardial,2228,B-DiseaseOrPhenotypicFeature
infarction,2228,I-DiseaseOrPhenotypicFeature
.,2228,O
Melanocortin-4,2229,B-GeneOrGeneProduct
receptor,2229,I-GeneOrGeneProduct
activation,2229,O
inhibits,2229,O
c-Jun,2229,B-GeneOrGeneProduct
N-terminal,2229,I-GeneOrGeneProduct
kinase,2229,I-GeneOrGeneProduct
activity,2229,O
and,2229,O
promotes,2229,O
insulin,2229,B-GeneOrGeneProduct
signaling,2229,O
.,2229,O
The,2230,O
melanocortin,2230,B-GeneOrGeneProduct
system,2230,O
is,2230,O
crucial,2230,O
to,2230,O
regulation,2230,O
of,2230,O
energy,2230,O
homeostasis,2230,O
.,2230,O
The,2231,O
melanocortin,2231,B-GeneOrGeneProduct
receptor,2231,I-GeneOrGeneProduct
type,2231,I-GeneOrGeneProduct
4,2231,I-GeneOrGeneProduct
(,2231,O
MC4R,2231,B-GeneOrGeneProduct
),2231,O
modulates,2231,O
insulin,2231,B-GeneOrGeneProduct
signaling,2231,O
via,2231,O
effects,2231,O
on,2231,O
c-Jun,2231,B-GeneOrGeneProduct
N-terminal,2231,I-GeneOrGeneProduct
kinase,2231,I-GeneOrGeneProduct
(,2231,O
JNK,2231,B-GeneOrGeneProduct
),2231,O
.,2231,O
The,2232,O
melanocortin,2232,B-GeneOrGeneProduct
agonist,2232,O
NDP-MSH,2232,B-ChemicalEntity
dose-dependently,2232,O
inhibited,2232,O
JNK,2232,B-GeneOrGeneProduct
activity,2232,O
in,2232,O
HEK293,2232,B-CellLine
cells,2232,O
stably,2232,O
expressing,2232,O
the,2232,O
human,2232,B-OrganismTaxon
MC4R,2232,B-GeneOrGeneProduct
;,2232,O
effects,2232,O
were,2232,O
reversed,2232,O
by,2232,O
melanocortin,2232,B-GeneOrGeneProduct
receptor,2232,I-GeneOrGeneProduct
antagonist,2232,O
.,2232,O
NDP-MSH,2233,B-ChemicalEntity
time-,2233,O
and,2233,O
dose-dependently,2233,O
inhibited,2233,O
IRS-1,2233,B-GeneOrGeneProduct
(,2233,O
ser307,2233,O
),2233,O
phosphorylation,2233,O
",",2233,O
effects,2233,O
also,2233,O
reversed,2233,O
by,2233,O
a,2233,O
specific,2233,O
melanocortin,2233,B-GeneOrGeneProduct
receptor,2233,I-GeneOrGeneProduct
antagonist,2233,O
.,2233,O
NDP-MSH,2234,B-ChemicalEntity
augmented,2234,O
insulin-stimulated,2234,B-GeneOrGeneProduct
AKT,2234,B-GeneOrGeneProduct
phosphorylation,2234,O
in,2234,O
vitro,2234,O
.,2234,O
The,2235,O
melanocortin,2235,B-GeneOrGeneProduct
agonist,2235,O
melanotan,2235,B-ChemicalEntity
II,2235,I-ChemicalEntity
increased,2235,O
insulin-stimulated,2235,B-GeneOrGeneProduct
AKT,2235,B-GeneOrGeneProduct
phosphorylation,2235,O
in,2235,O
the,2235,O
rat,2235,B-OrganismTaxon
hypothalamus,2235,O
in,2235,O
vivo,2235,O
.,2235,O
NDP-MSH,2236,B-ChemicalEntity
increased,2236,O
insulin-stimulated,2236,B-GeneOrGeneProduct
glucose,2236,B-ChemicalEntity
uptake,2236,O
in,2236,O
hypothalamic,2236,O
GT1-1,2236,B-CellLine
cells,2236,O
.,2236,O
The,2237,O
current,2237,O
study,2237,O
shows,2237,O
that,2237,O
the,2237,O
melanocortinergic,2237,O
system,2237,O
interacts,2237,O
with,2237,O
insulin,2237,B-GeneOrGeneProduct
signaling,2237,O
via,2237,O
novel,2237,O
effects,2237,O
on,2237,O
JNK,2237,B-GeneOrGeneProduct
activity,2237,O
.,2237,O
Hypomorphic,2238,O
mutations,2238,O
in,2238,O
meckelin,2238,B-GeneOrGeneProduct
(,2238,O
MKS3/TMEM67,2238,B-GeneOrGeneProduct
),2238,O
cause,2238,O
nephronophthisis,2238,B-DiseaseOrPhenotypicFeature
with,2238,I-DiseaseOrPhenotypicFeature
liver,2238,I-DiseaseOrPhenotypicFeature
fibrosis,2238,I-DiseaseOrPhenotypicFeature
(,2238,O
NPHP11,2238,B-DiseaseOrPhenotypicFeature
),2238,O
.,2238,O
BACKGROUND,2239,O
:,2239,O
Nephronophthisis,2239,B-DiseaseOrPhenotypicFeature
(,2239,O
NPHP,2239,B-DiseaseOrPhenotypicFeature
),2239,O
",",2239,O
a,2239,O
rare,2239,O
recessive,2239,O
cystic,2239,B-DiseaseOrPhenotypicFeature
kidney,2239,I-DiseaseOrPhenotypicFeature
disease,2239,I-DiseaseOrPhenotypicFeature
",",2239,O
is,2239,O
the,2239,O
most,2239,O
frequent,2239,O
genetic,2239,O
cause,2239,O
of,2239,O
chronic,2239,B-DiseaseOrPhenotypicFeature
renal,2239,I-DiseaseOrPhenotypicFeature
failure,2239,I-DiseaseOrPhenotypicFeature
in,2239,O
children,2239,O
and,2239,O
young,2239,O
adults,2239,O
.,2239,O
Mutations,2240,O
in,2240,O
nine,2240,O
genes,2240,O
(,2240,O
NPHP1-9,2240,B-GeneOrGeneProduct
),2240,O
have,2240,O
been,2240,O
identified,2240,O
.,2240,O
NPHP,2241,B-DiseaseOrPhenotypicFeature
can,2241,O
be,2241,O
associated,2241,O
with,2241,O
retinal,2241,B-DiseaseOrPhenotypicFeature
degeneration,2241,I-DiseaseOrPhenotypicFeature
(,2241,O
Senior-Loken,2241,B-DiseaseOrPhenotypicFeature
syndrome,2241,I-DiseaseOrPhenotypicFeature
),2241,O
",",2241,O
brainstem,2241,O
and,2241,O
cerebellar,2241,B-DiseaseOrPhenotypicFeature
anomalies,2241,I-DiseaseOrPhenotypicFeature
(,2241,O
Joubert,2241,B-DiseaseOrPhenotypicFeature
syndrome,2241,I-DiseaseOrPhenotypicFeature
),2241,O
",",2241,O
or,2241,O
liver,2241,B-DiseaseOrPhenotypicFeature
fibrosis,2241,I-DiseaseOrPhenotypicFeature
.,2241,O
METHODS,2242,O
:,2242,O
To,2242,O
identify,2242,O
a,2242,O
causative,2242,O
gene,2242,O
for,2242,O
the,2242,O
subset,2242,O
of,2242,O
patients,2242,B-OrganismTaxon
with,2242,O
associated,2242,O
liver,2242,B-DiseaseOrPhenotypicFeature
fibrosis,2242,I-DiseaseOrPhenotypicFeature
",",2242,O
the,2242,O
authors,2242,O
performed,2242,O
a,2242,O
genome,2242,O
wide,2242,O
linkage,2242,O
search,2242,O
in,2242,O
a,2242,O
consanguineous,2242,O
family,2242,O
with,2242,O
three,2242,O
affected,2242,O
patients,2242,B-OrganismTaxon
using,2242,O
50K,2242,O
SNP,2242,O
microarrays,2242,O
and,2242,O
homozygosity,2242,O
mapping,2242,O
.,2242,O
RESULTS,2243,O
:,2243,O
The,2243,O
authors,2243,O
obtained,2243,O
a,2243,O
significant,2243,O
maximum,2243,O
parametric,2243,O
LOD,2243,O
(,2243,O
logarithm,2243,O
of,2243,O
odds,2243,O
),2243,O
score,2243,O
of,2243,O
Z,2243,O
(,2243,O
max,2243,O
),2243,O
=,2243,O
3.72,2243,O
on,2243,O
chromosome,2243,O
8q22,2243,O
and,2243,O
identified,2243,O
a,2243,O
homozygous,2243,O
missense,2243,O
mutation,2243,O
in,2243,O
the,2243,O
gene,2243,O
MKS3/TMEM67,2243,B-GeneOrGeneProduct
.,2243,O
When,2244,O
examining,2244,O
a,2244,O
worldwide,2244,O
cohort,2244,O
of,2244,O
62,2244,O
independent,2244,O
patients,2244,B-OrganismTaxon
with,2244,O
NPHP,2244,B-DiseaseOrPhenotypicFeature
and,2244,O
associated,2244,O
liver,2244,B-DiseaseOrPhenotypicFeature
fibrosis,2244,I-DiseaseOrPhenotypicFeature
we,2244,O
identified,2244,O
altogether,2244,O
four,2244,O
novel,2244,O
mutations,2244,O
(,2244,O
p.W290L,2244,B-SequenceVariant
",",2244,O
p.C615R,2244,B-SequenceVariant
",",2244,O
p.G821S,2244,B-SequenceVariant
",",2244,O
and,2244,O
p.G821R,2244,B-SequenceVariant
),2244,O
in,2244,O
five,2244,O
of,2244,O
them,2244,O
.,2244,O
Mutations,2245,O
of,2245,O
MKS3/TMEM67,2245,B-GeneOrGeneProduct
",",2245,O
found,2245,O
recently,2245,O
in,2245,O
Meckel-Gruber,2245,B-DiseaseOrPhenotypicFeature
syndrome,2245,I-DiseaseOrPhenotypicFeature
(,2245,I-DiseaseOrPhenotypicFeature
MKS,2245,I-DiseaseOrPhenotypicFeature
),2245,I-DiseaseOrPhenotypicFeature
type,2245,I-DiseaseOrPhenotypicFeature
3,2245,I-DiseaseOrPhenotypicFeature
and,2245,O
Joubert,2245,B-DiseaseOrPhenotypicFeature
syndrome,2245,I-DiseaseOrPhenotypicFeature
(,2245,I-DiseaseOrPhenotypicFeature
JBTS,2245,I-DiseaseOrPhenotypicFeature
),2245,I-DiseaseOrPhenotypicFeature
type,2245,I-DiseaseOrPhenotypicFeature
6,2245,I-DiseaseOrPhenotypicFeature
",",2245,O
are,2245,O
predominantly,2245,O
truncating,2245,O
mutations,2245,O
.,2245,O
In,2246,O
contrast,2246,O
",",2246,O
the,2246,O
mutations,2246,O
detected,2246,O
here,2246,O
in,2246,O
patients,2246,B-OrganismTaxon
with,2246,O
NPHP,2246,B-DiseaseOrPhenotypicFeature
and,2246,O
associated,2246,O
liver,2246,B-DiseaseOrPhenotypicFeature
fibrosis,2246,I-DiseaseOrPhenotypicFeature
are,2246,O
exclusively,2246,O
missense,2246,O
mutations,2246,O
.,2246,O
This,2247,O
suggests,2247,O
that,2247,O
they,2247,O
may,2247,O
represent,2247,O
hypomorphic,2247,O
alleles,2247,O
",",2247,O
leading,2247,O
to,2247,O
a,2247,O
milder,2247,O
phenotype,2247,O
compared,2247,O
with,2247,O
the,2247,O
more,2247,O
severe,2247,O
MKS,2247,B-DiseaseOrPhenotypicFeature
or,2247,O
JBTS,2247,B-DiseaseOrPhenotypicFeature
phenotype,2247,O
.,2247,O
Additionally,2248,O
",",2248,O
mutation,2248,O
analysis,2248,O
for,2248,O
MKS3/TMEM67,2248,B-GeneOrGeneProduct
in,2248,O
120,2248,O
patients,2248,B-OrganismTaxon
with,2248,O
JBTS,2248,B-DiseaseOrPhenotypicFeature
yielded,2248,O
seven,2248,O
different,2248,O
(,2248,O
four,2248,O
novel,2248,O
),2248,O
mutations,2248,O
in,2248,O
five,2248,O
patients,2248,B-OrganismTaxon
",",2248,O
four,2248,O
of,2248,O
whom,2248,O
also,2248,O
presented,2248,O
with,2248,O
congenital,2248,O
liver,2248,B-DiseaseOrPhenotypicFeature
fibrosis,2248,I-DiseaseOrPhenotypicFeature
.,2248,O
CONCLUSIONS,2249,O
:,2249,O
Hypomorphic,2249,O
MKS3/TMEM67,2249,B-GeneOrGeneProduct
mutations,2249,O
cause,2249,O
NPHP,2249,B-DiseaseOrPhenotypicFeature
with,2249,I-DiseaseOrPhenotypicFeature
liver,2249,I-DiseaseOrPhenotypicFeature
fibrosis,2249,I-DiseaseOrPhenotypicFeature
(,2249,O
NPHP11,2249,B-DiseaseOrPhenotypicFeature
),2249,O
.,2249,O
This,2250,O
is,2250,O
the,2250,O
first,2250,O
report,2250,O
of,2250,O
MKS3,2250,B-GeneOrGeneProduct
mutations,2250,O
in,2250,O
patients,2250,B-OrganismTaxon
with,2250,O
no,2250,O
vermian,2250,O
agenesis,2250,O
and,2250,O
without,2250,O
neurological,2250,O
signs,2250,O
.,2250,O
Thus,2251,O
NPHP,2251,B-DiseaseOrPhenotypicFeature
",",2251,O
JBTS,2251,B-DiseaseOrPhenotypicFeature
",",2251,O
and,2251,O
MKS,2251,B-DiseaseOrPhenotypicFeature
represent,2251,O
allelic,2251,B-DiseaseOrPhenotypicFeature
disorders,2251,I-DiseaseOrPhenotypicFeature
.,2251,O
Serotonin,2252,B-GeneOrGeneProduct
transporter,2252,I-GeneOrGeneProduct
gene,2252,O
polymorphic,2252,O
element,2252,O
5-HTTLPR,2252,B-GeneOrGeneProduct
increases,2252,O
the,2252,O
risk,2252,O
of,2252,O
sporadic,2252,O
Parkinson,2252,B-DiseaseOrPhenotypicFeature
's,2252,I-DiseaseOrPhenotypicFeature
disease,2252,I-DiseaseOrPhenotypicFeature
in,2252,O
Italy,2252,O
.,2252,O
Parkinson,2253,B-DiseaseOrPhenotypicFeature
's,2253,I-DiseaseOrPhenotypicFeature
disease,2253,I-DiseaseOrPhenotypicFeature
(,2253,O
PD,2253,B-DiseaseOrPhenotypicFeature
),2253,O
is,2253,O
a,2253,O
neurodegenerative,2253,B-DiseaseOrPhenotypicFeature
disorder,2253,I-DiseaseOrPhenotypicFeature
causing,2253,O
muscular,2253,B-DiseaseOrPhenotypicFeature
rigidity,2253,I-DiseaseOrPhenotypicFeature
",",2253,O
resting,2253,B-DiseaseOrPhenotypicFeature
tremor,2253,I-DiseaseOrPhenotypicFeature
and,2253,O
bradykinesia,2253,B-DiseaseOrPhenotypicFeature
.,2253,O
We,2254,O
conducted,2254,O
an,2254,O
association,2254,O
study,2254,O
assessing,2254,O
how,2254,O
PD,2254,B-DiseaseOrPhenotypicFeature
risk,2254,O
in,2254,O
Italy,2254,O
was,2254,O
influenced,2254,O
by,2254,O
the,2254,O
serotonin,2254,B-GeneOrGeneProduct
transporter,2254,I-GeneOrGeneProduct
gene,2254,O
(,2254,O
SLC6A4,2254,B-GeneOrGeneProduct
),2254,O
polymorphic,2254,O
region,2254,O
5-HTTLPR,2254,B-GeneOrGeneProduct
",",2254,O
consisting,2254,O
of,2254,O
an,2254,O
insertion/deletion,2254,B-SequenceVariant
(,2254,I-SequenceVariant
long,2254,I-SequenceVariant
allele-L/short,2254,I-SequenceVariant
allele-S,2254,I-SequenceVariant
),2254,I-SequenceVariant
of,2254,I-SequenceVariant
43,2254,I-SequenceVariant
bp,2254,I-SequenceVariant
in,2254,O
the,2254,O
SLC6A4,2254,B-GeneOrGeneProduct
promoter,2254,O
region,2254,O
.,2254,O
The,2255,O
SLC6A4,2255,B-GeneOrGeneProduct
promoter,2255,O
single,2255,O
nucleotide,2255,O
polymorphism,2255,O
rs25531,2255,B-SequenceVariant
(,2255,O
A,2255,B-SequenceVariant
--,2255,I-SequenceVariant
>,2255,I-SequenceVariant
G,2255,I-SequenceVariant
),2255,O
was,2255,O
evaluated,2255,O
too,2255,O
.,2255,O
We,2256,O
collected,2256,O
837,2256,O
independent,2256,O
subjects,2256,O
(,2256,O
393,2256,O
PD,2256,B-DiseaseOrPhenotypicFeature
",",2256,O
444,2256,O
controls,2256,O
),2256,O
.,2256,O
An,2257,O
association,2257,O
between,2257,O
the,2257,O
5-HTTLPR,2257,B-GeneOrGeneProduct
polymorphism,2257,O
and,2257,O
risk,2257,O
of,2257,O
PD,2257,B-DiseaseOrPhenotypicFeature
(,2257,O
S/S,2257,O
genotype,2257,O
OR,2257,O
[,2257,O
95,2257,O
%,2257,O
CI,2257,O
],2257,O
:,2257,O
1.7,2257,O
[,2257,O
1.2-2.5,2257,O
],2257,O
",",2257,O
p,2257,O
=,2257,O
0.002,2257,O
),2257,O
was,2257,O
found,2257,O
.,2257,O
The,2258,O
rs25531,2258,B-SequenceVariant
and,2258,O
the,2258,O
haplotype,2258,O
5-HTTLPR/rs25531,2258,B-GeneOrGeneProduct
did,2258,O
not,2258,O
associate,2258,O
with,2258,O
risk,2258,O
of,2258,O
PD,2258,B-DiseaseOrPhenotypicFeature
.,2258,O
Our,2259,O
data,2259,O
indicate,2259,O
that,2259,O
the,2259,O
5-HTTLPR,2259,B-GeneOrGeneProduct
polymorphic,2259,O
element,2259,O
within,2259,O
the,2259,O
SLC6A4,2259,B-GeneOrGeneProduct
promoter,2259,O
may,2259,O
govern,2259,O
the,2259,O
genetic,2259,O
risk,2259,O
of,2259,O
PD,2259,B-DiseaseOrPhenotypicFeature
in,2259,O
Italians,2259,O
.,2259,O
TAK1,2260,B-GeneOrGeneProduct
is,2260,O
an,2260,O
essential,2260,O
regulator,2260,O
of,2260,O
BMP,2260,B-GeneOrGeneProduct
signalling,2260,O
in,2260,O
cartilage,2260,O
.,2260,O
TGFbeta,2261,B-GeneOrGeneProduct
activated,2261,I-GeneOrGeneProduct
kinase,2261,I-GeneOrGeneProduct
1,2261,I-GeneOrGeneProduct
(,2261,O
TAK1,2261,B-GeneOrGeneProduct
),2261,O
",",2261,O
a,2261,O
member,2261,O
of,2261,O
the,2261,O
MAPKKK,2261,B-GeneOrGeneProduct
family,2261,O
",",2261,O
controls,2261,O
diverse,2261,O
functions,2261,O
ranging,2261,O
from,2261,O
innate,2261,O
and,2261,O
adaptive,2261,O
immune,2261,O
system,2261,O
activation,2261,O
to,2261,O
vascular,2261,O
development,2261,O
and,2261,O
apoptosis,2261,O
.,2261,O
To,2262,O
analyse,2262,O
the,2262,O
in,2262,O
vivo,2262,O
function,2262,O
of,2262,O
TAK1,2262,B-GeneOrGeneProduct
in,2262,O
cartilage,2262,O
",",2262,O
we,2262,O
generated,2262,O
mice,2262,B-OrganismTaxon
with,2262,O
a,2262,O
conditional,2262,O
deletion,2262,O
of,2262,O
Tak1,2262,B-GeneOrGeneProduct
driven,2262,O
by,2262,O
the,2262,O
collagen,2262,B-GeneOrGeneProduct
2,2262,I-GeneOrGeneProduct
promoter,2262,O
.,2262,O
Tak1,2263,B-GeneOrGeneProduct
(,2263,O
col2,2263,B-GeneOrGeneProduct
),2263,O
mice,2263,B-OrganismTaxon
displayed,2263,O
severe,2263,O
chondrodysplasia,2263,B-DiseaseOrPhenotypicFeature
with,2263,O
runting,2263,O
",",2263,O
impaired,2263,O
formation,2263,O
of,2263,O
secondary,2263,O
centres,2263,O
of,2263,O
ossification,2263,O
",",2263,O
and,2263,O
joint,2263,B-DiseaseOrPhenotypicFeature
abnormalities,2263,I-DiseaseOrPhenotypicFeature
including,2263,O
elbow,2263,B-DiseaseOrPhenotypicFeature
dislocation,2263,I-DiseaseOrPhenotypicFeature
and,2263,O
tarsal,2263,B-DiseaseOrPhenotypicFeature
fusion,2263,I-DiseaseOrPhenotypicFeature
.,2263,O
This,2264,O
phenotype,2264,O
resembled,2264,O
that,2264,O
of,2264,O
bone,2264,B-GeneOrGeneProduct
morphogenetic,2264,I-GeneOrGeneProduct
protein,2264,I-GeneOrGeneProduct
receptor,2264,I-GeneOrGeneProduct
(,2264,I-GeneOrGeneProduct
BMPR,2264,I-GeneOrGeneProduct
),2264,I-GeneOrGeneProduct
1,2264,I-GeneOrGeneProduct
and,2264,O
Gdf5-deficient,2264,B-GeneOrGeneProduct
mice,2264,B-OrganismTaxon
.,2264,O
BMPR,2265,B-GeneOrGeneProduct
signalling,2265,O
was,2265,O
markedly,2265,O
impaired,2265,O
in,2265,O
TAK1-deficient,2265,B-GeneOrGeneProduct
chondrocytes,2265,O
as,2265,O
evidenced,2265,O
by,2265,O
reduced,2265,O
expression,2265,O
of,2265,O
known,2265,O
BMP,2265,B-GeneOrGeneProduct
target,2265,O
genes,2265,O
as,2265,O
well,2265,O
as,2265,O
reduced,2265,O
phosphorylation,2265,O
of,2265,O
Smad1/5/8,2265,B-GeneOrGeneProduct
and,2265,O
p38/Jnk/Erk,2265,B-GeneOrGeneProduct
MAP,2265,B-GeneOrGeneProduct
kinases,2265,I-GeneOrGeneProduct
.,2265,O
TAK1,2266,B-GeneOrGeneProduct
mediates,2266,O
Smad1,2266,B-GeneOrGeneProduct
phosphorylation,2266,O
at,2266,O
C-terminal,2266,O
serine,2266,O
residues,2266,O
.,2266,O
These,2267,O
findings,2267,O
provide,2267,O
the,2267,O
first,2267,O
in,2267,O
vivo,2267,O
evidence,2267,O
in,2267,O
a,2267,O
mammalian,2267,O
system,2267,O
that,2267,O
TAK1,2267,B-GeneOrGeneProduct
is,2267,O
required,2267,O
for,2267,O
BMP,2267,B-GeneOrGeneProduct
signalling,2267,O
and,2267,O
functions,2267,O
as,2267,O
an,2267,O
upstream,2267,O
activating,2267,O
kinase,2267,O
for,2267,O
Smad1/5/8,2267,B-GeneOrGeneProduct
in,2267,O
addition,2267,O
to,2267,O
its,2267,O
known,2267,O
role,2267,O
in,2267,O
regulating,2267,O
MAP,2267,B-GeneOrGeneProduct
kinase,2267,I-GeneOrGeneProduct
pathways,2267,O
.,2267,O
Our,2268,O
experiments,2268,O
reveal,2268,O
an,2268,O
essential,2268,O
role,2268,O
for,2268,O
TAK1,2268,B-GeneOrGeneProduct
in,2268,O
the,2268,O
morphogenesis,2268,O
",",2268,O
growth,2268,O
",",2268,O
and,2268,O
maintenance,2268,O
of,2268,O
cartilage,2268,O
.,2268,O
Efficacy,2269,O
of,2269,O
everolimus,2269,B-ChemicalEntity
(,2269,O
RAD001,2269,B-ChemicalEntity
),2269,O
in,2269,O
patients,2269,B-OrganismTaxon
with,2269,O
advanced,2269,O
NSCLC,2269,B-DiseaseOrPhenotypicFeature
previously,2269,O
treated,2269,O
with,2269,O
chemotherapy,2269,O
alone,2269,O
or,2269,O
with,2269,O
chemotherapy,2269,O
and,2269,O
EGFR,2269,B-GeneOrGeneProduct
inhibitors,2269,O
.,2269,O
BACKGROUND,2270,O
:,2270,O
Treatment,2270,O
options,2270,O
are,2270,O
scarce,2270,O
in,2270,O
pretreated,2270,O
advanced,2270,O
non-small-cell,2270,B-DiseaseOrPhenotypicFeature
lung,2270,I-DiseaseOrPhenotypicFeature
cancer,2270,I-DiseaseOrPhenotypicFeature
(,2270,O
NSCLC,2270,B-DiseaseOrPhenotypicFeature
),2270,O
patients,2270,B-OrganismTaxon
.,2270,O
RAD001,2271,B-ChemicalEntity
",",2271,O
an,2271,O
oral,2271,O
inhibitor,2271,O
of,2271,O
the,2271,O
mammalian,2271,B-GeneOrGeneProduct
target,2271,I-GeneOrGeneProduct
of,2271,I-GeneOrGeneProduct
rapamycin,2271,I-GeneOrGeneProduct
(,2271,O
mTOR,2271,B-GeneOrGeneProduct
),2271,O
",",2271,O
has,2271,O
shown,2271,O
phase,2271,O
I,2271,O
efficacy,2271,O
in,2271,O
NSCLC,2271,B-DiseaseOrPhenotypicFeature
.,2271,O
METHODS,2272,O
:,2272,O
Stage,2272,O
IIIb,2272,O
or,2272,O
IV,2272,O
NSCLC,2272,B-DiseaseOrPhenotypicFeature
patients,2272,B-OrganismTaxon
",",2272,O
with,2272,O
two,2272,O
or,2272,O
fewer,2272,O
prior,2272,O
chemotherapy,2272,O
regimens,2272,O
",",2272,O
one,2272,O
platinum,2272,B-ChemicalEntity
based,2272,O
(,2272,O
stratum,2272,O
1,2272,O
),2272,O
or,2272,O
both,2272,O
chemotherapy,2272,O
and,2272,O
epidermal,2272,B-GeneOrGeneProduct
growth,2272,I-GeneOrGeneProduct
factor,2272,I-GeneOrGeneProduct
receptor,2272,I-GeneOrGeneProduct
tyrosine,2272,I-GeneOrGeneProduct
kinase,2272,I-GeneOrGeneProduct
inhibitors,2272,O
(,2272,O
stratum,2272,O
2,2272,O
),2272,O
",",2272,O
received,2272,O
RAD001,2272,B-ChemicalEntity
10,2272,O
mg/day,2272,O
until,2272,O
progression,2272,O
or,2272,O
unacceptable,2272,O
toxicity,2272,B-DiseaseOrPhenotypicFeature
.,2272,O
Primary,2273,O
objective,2273,O
was,2273,O
overall,2273,O
response,2273,O
rate,2273,O
(,2273,O
ORR,2273,O
),2273,O
.,2273,O
Analyses,2274,O
of,2274,O
markers,2274,O
associated,2274,O
with,2274,O
the,2274,O
mTOR,2274,B-GeneOrGeneProduct
pathway,2274,O
were,2274,O
carried,2274,O
out,2274,O
on,2274,O
archival,2274,O
tumor,2274,B-DiseaseOrPhenotypicFeature
from,2274,O
a,2274,O
subgroup,2274,O
using,2274,O
immunohistochemistry,2274,O
(,2274,O
IHC,2274,O
),2274,O
and,2274,O
direct,2274,O
mutation,2274,O
sequencing,2274,O
.,2274,O
RESULTS,2275,O
:,2275,O
Eighty-five,2275,O
patients,2275,B-OrganismTaxon
were,2275,O
enrolled,2275,O
",",2275,O
42,2275,O
in,2275,O
stratum,2275,O
1,2275,O
and,2275,O
43,2275,O
in,2275,O
stratum,2275,O
.,2275,O
ORR,2276,O
was,2276,O
4.7,2276,O
%,2276,O
(,2276,O
7.1,2276,O
%,2276,O
stratum,2276,O
1,2276,O
;,2276,O
2.3,2276,O
%,2276,O
stratum,2276,O
2,2276,O
),2276,O
.,2276,O
Overall,2277,O
disease,2277,O
control,2277,O
rate,2277,O
was,2277,O
47.1,2277,O
%,2277,O
.,2277,O
Median,2278,O
progression-free,2278,O
survivals,2278,O
(,2278,O
PFSs,2278,O
),2278,O
were,2278,O
2.6,2278,O
(,2278,O
stratum,2278,O
1,2278,O
),2278,O
and,2278,O
2.7,2278,O
months,2278,O
(,2278,O
stratum,2278,O
2,2278,O
),2278,O
.,2278,O
Common,2279,O
>,2279,O
or,2279,O
=grade,2279,O
3,2279,O
events,2279,O
were,2279,O
fatigue,2279,B-DiseaseOrPhenotypicFeature
",",2279,O
dyspnea,2279,B-DiseaseOrPhenotypicFeature
",",2279,O
stomatitis,2279,B-DiseaseOrPhenotypicFeature
",",2279,O
anemia,2279,B-DiseaseOrPhenotypicFeature
",",2279,O
and,2279,O
thrombocytopenia,2279,B-DiseaseOrPhenotypicFeature
.,2279,O
Pneumonitis,2280,B-DiseaseOrPhenotypicFeature
",",2280,O
probably,2280,O
or,2280,O
possibly,2280,O
related,2280,O
",",2280,O
mainly,2280,O
grade,2280,O
1/2,2280,O
",",2280,O
occurred,2280,O
in,2280,O
25,2280,O
%,2280,O
.,2280,O
Cox,2281,O
regression,2281,O
analysis,2281,O
of,2281,O
IHC,2281,O
scores,2281,O
found,2281,O
that,2281,O
only,2281,O
phospho,2281,O
AKT,2281,B-GeneOrGeneProduct
(,2281,O
pAKT,2281,B-GeneOrGeneProduct
),2281,O
was,2281,O
a,2281,O
significant,2281,O
independent,2281,O
predictor,2281,O
of,2281,O
worse,2281,O
PFS,2281,O
.,2281,O
CONCLUSIONS,2282,O
:,2282,O
RAD001,2282,B-ChemicalEntity
10,2282,O
mg/day,2282,O
was,2282,O
well,2282,O
tolerated,2282,O
",",2282,O
showing,2282,O
modest,2282,O
clinical,2282,O
activity,2282,O
in,2282,O
pretreated,2282,O
NSCLC,2282,B-DiseaseOrPhenotypicFeature
.,2282,O
Evaluation,2283,O
of,2283,O
RAD001,2283,B-ChemicalEntity
plus,2283,O
standard,2283,O
therapy,2283,O
for,2283,O
metastatic,2283,O
NSCLC,2283,B-DiseaseOrPhenotypicFeature
continues,2283,O
.,2283,O
Matriptase-2,2284,B-GeneOrGeneProduct
mutations,2284,O
in,2284,O
iron-refractory,2284,B-ChemicalEntity
iron,2284,B-DiseaseOrPhenotypicFeature
deficiency,2284,I-DiseaseOrPhenotypicFeature
anemia,2284,I-DiseaseOrPhenotypicFeature
patients,2284,B-OrganismTaxon
provide,2284,O
new,2284,O
insights,2284,O
into,2284,O
protease,2284,O
activation,2284,O
mechanisms,2284,O
.,2284,O
Mutations,2285,O
leading,2285,O
to,2285,O
abrogation,2285,O
of,2285,O
matriptase-2,2285,B-GeneOrGeneProduct
proteolytic,2285,O
activity,2285,O
in,2285,O
humans,2285,B-OrganismTaxon
are,2285,O
associated,2285,O
with,2285,O
an,2285,O
iron-refractory,2285,B-DiseaseOrPhenotypicFeature
iron,2285,I-DiseaseOrPhenotypicFeature
deficiency,2285,I-DiseaseOrPhenotypicFeature
anemia,2285,I-DiseaseOrPhenotypicFeature
(,2285,O
IRIDA,2285,B-DiseaseOrPhenotypicFeature
),2285,O
due,2285,O
to,2285,O
elevated,2285,O
hepcidin,2285,B-GeneOrGeneProduct
levels,2285,O
.,2285,O
Here,2286,O
we,2286,O
describe,2286,O
two,2286,O
novel,2286,O
heterozygous,2286,O
mutations,2286,O
within,2286,O
the,2286,O
matriptase-2,2286,B-GeneOrGeneProduct
(,2286,O
TMPRSS6,2286,B-GeneOrGeneProduct
),2286,O
gene,2286,O
of,2286,O
monozygotic,2286,O
twin,2286,O
girls,2286,O
exhibiting,2286,O
an,2286,O
IRIDA,2286,B-DiseaseOrPhenotypicFeature
phenotype,2286,O
.,2286,O
The,2287,O
first,2287,O
is,2287,O
the,2287,O
frameshift,2287,O
mutation,2287,O
(,2287,O
P686fs,2287,B-SequenceVariant
),2287,O
caused,2287,O
by,2287,O
the,2287,O
insertion,2287,B-SequenceVariant
of,2287,I-SequenceVariant
the,2287,I-SequenceVariant
four,2287,I-SequenceVariant
nucleotides,2287,I-SequenceVariant
CCCC,2287,I-SequenceVariant
in,2287,O
exon,2287,O
16,2287,O
(,2287,O
2172_2173insCCCC,2287,B-SequenceVariant
),2287,O
that,2287,O
is,2287,O
predicted,2287,O
to,2287,O
terminate,2287,O
translation,2287,O
before,2287,O
the,2287,O
catalytic,2287,O
serine,2287,O
.,2287,O
The,2288,O
second,2288,O
mutation,2288,O
is,2288,O
the,2288,O
di-nucleotide,2288,O
substitution,2288,O
c.467C,2288,B-SequenceVariant
>,2288,I-SequenceVariant
A,2288,I-SequenceVariant
and,2288,O
c.468C,2288,B-SequenceVariant
>,2288,I-SequenceVariant
T,2288,I-SequenceVariant
in,2288,O
exon,2288,O
3,2288,O
that,2288,O
causes,2288,O
the,2288,O
missense,2288,O
mutation,2288,O
A118D,2288,B-SequenceVariant
in,2288,O
the,2288,O
SEA,2288,O
domain,2288,O
of,2288,O
the,2288,O
extracellular,2288,O
stem,2288,O
region,2288,O
of,2288,O
matriptase-2,2288,B-GeneOrGeneProduct
.,2288,O
Functional,2289,O
analysis,2289,O
of,2289,O
both,2289,O
variant,2289,O
matriptase-2,2289,B-GeneOrGeneProduct
proteases,2289,O
has,2289,O
revealed,2289,O
that,2289,O
they,2289,O
lead,2289,O
to,2289,O
ineffective,2289,O
suppression,2289,O
of,2289,O
hepcidin,2289,B-GeneOrGeneProduct
transcription,2289,O
.,2289,O
We,2290,O
also,2290,O
demonstrate,2290,O
that,2290,O
the,2290,O
A118D,2290,B-SequenceVariant
SEA,2290,O
domain,2290,O
mutation,2290,O
causes,2290,O
an,2290,O
intra-molecular,2290,O
structural,2290,O
imbalance,2290,O
that,2290,O
impairs,2290,O
matriptase-2,2290,B-GeneOrGeneProduct
activation,2290,O
.,2290,O
Collectively,2291,O
",",2291,O
these,2291,O
results,2291,O
extend,2291,O
the,2291,O
pattern,2291,O
of,2291,O
TMPRSS6,2291,B-GeneOrGeneProduct
mutations,2291,O
associated,2291,O
with,2291,O
IRIDA,2291,B-DiseaseOrPhenotypicFeature
and,2291,O
functionally,2291,O
demonstrate,2291,O
that,2291,O
mutations,2291,O
affecting,2291,O
protease,2291,O
regions,2291,O
other,2291,O
than,2291,O
the,2291,O
catalytic,2291,O
domain,2291,O
may,2291,O
have,2291,O
a,2291,O
profound,2291,O
impact,2291,O
in,2291,O
the,2291,O
regulatory,2291,O
role,2291,O
of,2291,O
matriptase-2,2291,B-GeneOrGeneProduct
during,2291,O
iron,2291,B-DiseaseOrPhenotypicFeature
deficiency,2291,I-DiseaseOrPhenotypicFeature
.,2291,O
Learning,2292,B-DiseaseOrPhenotypicFeature
and,2292,I-DiseaseOrPhenotypicFeature
memory,2292,I-DiseaseOrPhenotypicFeature
deficits,2292,I-DiseaseOrPhenotypicFeature
in,2292,O
ecstasy,2292,B-ChemicalEntity
users,2292,O
and,2292,O
their,2292,O
neural,2292,O
correlates,2292,O
during,2292,O
a,2292,O
face-learning,2292,O
task,2292,O
.,2292,O
It,2293,O
has,2293,O
been,2293,O
consistently,2293,O
shown,2293,O
that,2293,O
ecstasy,2293,B-ChemicalEntity
users,2293,O
display,2293,O
impairments,2293,B-DiseaseOrPhenotypicFeature
in,2293,I-DiseaseOrPhenotypicFeature
learning,2293,I-DiseaseOrPhenotypicFeature
and,2293,I-DiseaseOrPhenotypicFeature
memory,2293,I-DiseaseOrPhenotypicFeature
performance,2293,O
.,2293,O
In,2294,O
addition,2294,O
",",2294,O
working,2294,O
memory,2294,O
processing,2294,O
in,2294,O
ecstasy,2294,B-ChemicalEntity
users,2294,O
has,2294,O
been,2294,O
shown,2294,O
to,2294,O
be,2294,O
associated,2294,O
with,2294,O
neural,2294,O
alterations,2294,O
in,2294,O
hippocampal,2294,O
and/or,2294,O
cortical,2294,O
regions,2294,O
as,2294,O
measured,2294,O
by,2294,O
functional,2294,O
magnetic,2294,O
resonance,2294,O
imaging,2294,O
(,2294,O
fMRI,2294,O
),2294,O
.,2294,O
Using,2295,O
functional,2295,O
imaging,2295,O
and,2295,O
a,2295,O
face-learning,2295,O
task,2295,O
",",2295,O
we,2295,O
investigated,2295,O
neural,2295,O
correlates,2295,O
of,2295,O
encoding,2295,O
and,2295,O
recalling,2295,O
face-name,2295,O
associations,2295,O
in,2295,O
20,2295,O
recreational,2295,O
drug,2295,O
users,2295,O
whose,2295,O
predominant,2295,O
drug,2295,O
use,2295,O
was,2295,O
ecstasy,2295,B-ChemicalEntity
and,2295,O
20,2295,O
controls,2295,O
.,2295,O
To,2296,O
address,2296,O
the,2296,O
potential,2296,O
confounding,2296,O
effects,2296,O
of,2296,O
the,2296,O
cannabis,2296,B-ChemicalEntity
use,2296,O
of,2296,O
the,2296,O
ecstasy,2296,B-ChemicalEntity
using,2296,O
group,2296,O
",",2296,O
a,2296,O
second,2296,O
analysis,2296,O
included,2296,O
14,2296,O
previously,2296,O
tested,2296,O
cannabis,2296,B-ChemicalEntity
users,2296,O
(,2296,O
Nestor,2296,O
",",2296,O
L.,2296,O
",",2296,O
Roberts,2296,O
",",2296,O
G.,2296,O
",",2296,O
Garavan,2296,O
",",2296,O
H.,2296,O
",",2296,O
Hester,2296,O
",",2296,O
R.,2296,O
",",2296,O
2008,2296,O
.,2296,O
Deficits,2297,B-DiseaseOrPhenotypicFeature
in,2297,I-DiseaseOrPhenotypicFeature
learning,2297,I-DiseaseOrPhenotypicFeature
and,2297,I-DiseaseOrPhenotypicFeature
memory,2297,I-DiseaseOrPhenotypicFeature
:,2297,O
parahippocampal,2297,O
hyperactivity,2297,B-DiseaseOrPhenotypicFeature
and,2297,O
frontocortical,2297,O
hypoactivity,2297,O
in,2297,O
cannabis,2297,B-ChemicalEntity
users,2297,O
.,2297,O
Neuroimage,2298,O
40,2298,O
",",2298,O
1328-1339,2298,O
),2298,O
.,2298,O
Ecstasy,2299,B-ChemicalEntity
users,2299,O
performed,2299,O
significantly,2299,O
worse,2299,O
in,2299,O
learning,2299,O
and,2299,O
memory,2299,O
compared,2299,O
to,2299,O
controls,2299,O
and,2299,O
cannabis,2299,B-ChemicalEntity
users,2299,O
.,2299,O
A,2300,O
conjunction,2300,O
analysis,2300,O
of,2300,O
the,2300,O
encode,2300,O
and,2300,O
recall,2300,O
phases,2300,O
of,2300,O
the,2300,O
task,2300,O
revealed,2300,O
ecstasy-specific,2300,B-ChemicalEntity
hyperactivity,2300,B-DiseaseOrPhenotypicFeature
in,2300,O
bilateral,2300,O
frontal,2300,O
regions,2300,O
",",2300,O
left,2300,O
temporal,2300,O
",",2300,O
right,2300,O
parietal,2300,O
",",2300,O
bilateral,2300,O
temporal,2300,O
",",2300,O
and,2300,O
bilateral,2300,O
occipital,2300,O
brain,2300,O
regions,2300,O
.,2300,O
Ecstasy-specific,2301,B-ChemicalEntity
hypoactivity,2301,O
was,2301,O
evident,2301,O
in,2301,O
the,2301,O
right,2301,O
dorsal,2301,O
anterior,2301,O
cingulated,2301,O
cortex,2301,O
(,2301,O
ACC,2301,O
),2301,O
and,2301,O
left,2301,O
posterior,2301,O
cingulated,2301,O
cortex,2301,O
.,2301,O
In,2302,O
both,2302,O
ecstasy,2302,B-ChemicalEntity
and,2302,O
cannabis,2302,B-ChemicalEntity
groups,2302,O
brain,2302,O
activation,2302,O
was,2302,O
decreased,2302,O
in,2302,O
the,2302,O
right,2302,O
medial,2302,O
frontal,2302,O
gyrus,2302,O
",",2302,O
left,2302,O
parahippocampal,2302,O
gyrus,2302,O
",",2302,O
left,2302,O
dorsal,2302,O
cingulate,2302,O
gyrus,2302,O
",",2302,O
and,2302,O
left,2302,O
caudate,2302,O
.,2302,O
These,2303,O
results,2303,O
elucidated,2303,O
ecstasy-related,2303,B-ChemicalEntity
deficits,2303,O
",",2303,O
only,2303,O
some,2303,O
of,2303,O
which,2303,O
might,2303,O
be,2303,O
attributed,2303,O
to,2303,O
cannabis,2303,B-ChemicalEntity
use,2303,O
.,2303,O
These,2304,O
ecstasy-specific,2304,B-ChemicalEntity
effects,2304,O
may,2304,O
be,2304,O
related,2304,O
to,2304,O
the,2304,O
vulnerability,2304,O
of,2304,O
isocortical,2304,O
and,2304,O
allocortical,2304,O
regions,2304,O
to,2304,O
the,2304,O
neurotoxic,2304,B-DiseaseOrPhenotypicFeature
effects,2304,O
of,2304,O
ecstasy,2304,B-ChemicalEntity
.,2304,O
Acute,2305,B-DiseaseOrPhenotypicFeature
renal,2305,I-DiseaseOrPhenotypicFeature
failure,2305,I-DiseaseOrPhenotypicFeature
in,2305,O
patients,2305,B-OrganismTaxon
with,2305,O
AIDS,2305,B-DiseaseOrPhenotypicFeature
on,2305,O
tenofovir,2305,B-ChemicalEntity
while,2305,O
receiving,2305,O
prolonged,2305,O
vancomycin,2305,B-ChemicalEntity
course,2305,O
for,2305,O
osteomyelitis,2305,B-DiseaseOrPhenotypicFeature
.,2305,O
Renal,2306,B-DiseaseOrPhenotypicFeature
failure,2306,I-DiseaseOrPhenotypicFeature
developed,2306,O
after,2306,O
a,2306,O
prolonged,2306,O
course,2306,O
of,2306,O
vancomycin,2306,B-ChemicalEntity
therapy,2306,O
in,2306,O
2,2306,O
patients,2306,B-OrganismTaxon
who,2306,O
were,2306,O
receiving,2306,O
tenofovir,2306,B-ChemicalEntity
disoproxil,2306,I-ChemicalEntity
fumarate,2306,I-ChemicalEntity
as,2306,O
part,2306,O
of,2306,O
an,2306,O
antiretroviral,2306,O
regimen,2306,O
.,2306,O
Tenofovir,2307,B-ChemicalEntity
has,2307,O
been,2307,O
implicated,2307,O
in,2307,O
the,2307,O
development,2307,O
of,2307,O
Fanconi,2307,B-DiseaseOrPhenotypicFeature
syndrome,2307,I-DiseaseOrPhenotypicFeature
and,2307,O
renal,2307,B-DiseaseOrPhenotypicFeature
insufficiency,2307,I-DiseaseOrPhenotypicFeature
because,2307,O
of,2307,O
its,2307,O
effects,2307,O
on,2307,O
the,2307,O
proximal,2307,O
renal,2307,O
tubule,2307,O
.,2307,O
Vancomycin,2308,B-ChemicalEntity
nephrotoxicity,2308,B-DiseaseOrPhenotypicFeature
is,2308,O
infrequent,2308,O
but,2308,O
may,2308,O
result,2308,O
from,2308,O
coadministration,2308,O
with,2308,O
a,2308,O
nephrotoxic,2308,B-DiseaseOrPhenotypicFeature
agent,2308,O
.,2308,O
Clinicians,2309,O
should,2309,O
be,2309,O
aware,2309,O
that,2309,O
tenofovir,2309,B-ChemicalEntity
may,2309,O
raise,2309,O
the,2309,O
risk,2309,O
of,2309,O
renal,2309,B-DiseaseOrPhenotypicFeature
failure,2309,I-DiseaseOrPhenotypicFeature
during,2309,O
prolonged,2309,O
administration,2309,O
of,2309,O
vancomycin,2309,B-ChemicalEntity
.,2309,O
Protein,2310,B-GeneOrGeneProduct
kinase,2310,I-GeneOrGeneProduct
C,2310,I-GeneOrGeneProduct
alpha-dependent,2310,O
signaling,2310,O
mediates,2310,O
endometrial,2310,B-DiseaseOrPhenotypicFeature
cancer,2310,I-DiseaseOrPhenotypicFeature
cell,2310,O
growth,2310,O
and,2310,O
tumorigenesis,2310,B-DiseaseOrPhenotypicFeature
.,2310,O
Endometrial,2311,B-DiseaseOrPhenotypicFeature
cancer,2311,I-DiseaseOrPhenotypicFeature
is,2311,O
the,2311,O
most,2311,O
common,2311,O
invasive,2311,O
gynecologic,2311,B-DiseaseOrPhenotypicFeature
malignancy,2311,I-DiseaseOrPhenotypicFeature
",",2311,O
yet,2311,O
molecular,2311,O
mechanisms,2311,O
and,2311,O
signaling,2311,O
pathways,2311,O
underlying,2311,O
its,2311,O
etiology,2311,O
and,2311,O
pathophysiology,2311,O
remain,2311,O
poorly,2311,O
characterized,2311,O
.,2311,O
We,2312,O
sought,2312,O
to,2312,O
define,2312,O
a,2312,O
functional,2312,O
role,2312,O
for,2312,O
the,2312,O
protein,2312,B-GeneOrGeneProduct
kinase,2312,I-GeneOrGeneProduct
C,2312,I-GeneOrGeneProduct
(,2312,O
PKC,2312,B-GeneOrGeneProduct
),2312,O
isoform,2312,O
",",2312,O
PKCalpha,2312,B-GeneOrGeneProduct
",",2312,O
in,2312,O
an,2312,O
established,2312,O
cell,2312,O
model,2312,O
of,2312,O
endometrial,2312,B-DiseaseOrPhenotypicFeature
adenocarcinoma,2312,I-DiseaseOrPhenotypicFeature
.,2312,O
Ishikawa,2313,B-CellLine
cells,2313,O
depleted,2313,O
of,2313,O
PKCalpha,2313,B-GeneOrGeneProduct
protein,2313,O
grew,2313,O
slower,2313,O
",",2313,O
formed,2313,O
fewer,2313,O
colonies,2313,O
in,2313,O
anchorage-independent,2313,O
growth,2313,O
assays,2313,O
and,2313,O
exhibited,2313,O
impaired,2313,O
xenograft,2313,O
tumor,2313,B-DiseaseOrPhenotypicFeature
formation,2313,O
in,2313,O
nude,2313,O
mice,2313,B-OrganismTaxon
.,2313,O
Consistent,2314,O
with,2314,O
impaired,2314,O
growth,2314,O
",",2314,O
PKCalpha,2314,B-GeneOrGeneProduct
knockdown,2314,O
increased,2314,O
levels,2314,O
of,2314,O
the,2314,O
cyclin-dependent,2314,B-GeneOrGeneProduct
kinase,2314,I-GeneOrGeneProduct
(,2314,O
CDK,2314,B-GeneOrGeneProduct
),2314,O
inhibitors,2314,O
p21,2314,B-GeneOrGeneProduct
(,2314,O
Cip1/WAF1,2314,B-GeneOrGeneProduct
),2314,O
(,2314,O
p21,2314,B-GeneOrGeneProduct
),2314,O
and,2314,O
p27,2314,B-GeneOrGeneProduct
(,2314,O
Kip1,2314,B-GeneOrGeneProduct
),2314,O
(,2314,O
p27,2314,B-GeneOrGeneProduct
),2314,O
.,2314,O
Despite,2315,O
the,2315,O
absence,2315,O
of,2315,O
functional,2315,O
phosphatase,2315,B-GeneOrGeneProduct
and,2315,I-GeneOrGeneProduct
tensin,2315,I-GeneOrGeneProduct
homolog,2315,I-GeneOrGeneProduct
(,2315,O
PTEN,2315,B-GeneOrGeneProduct
),2315,O
protein,2315,O
in,2315,O
Ishikawa,2315,B-CellLine
cells,2315,O
",",2315,O
PKCalpha,2315,B-GeneOrGeneProduct
knockdown,2315,O
reduced,2315,O
Akt,2315,B-GeneOrGeneProduct
phosphorylation,2315,O
at,2315,O
serine,2315,O
473,2315,O
and,2315,O
concomitantly,2315,O
inhibited,2315,O
phosphorylation,2315,O
of,2315,O
the,2315,O
Akt,2315,B-GeneOrGeneProduct
target,2315,O
",",2315,O
glycogen,2315,B-GeneOrGeneProduct
synthase,2315,I-GeneOrGeneProduct
kinase-3beta,2315,I-GeneOrGeneProduct
(,2315,O
GSK-3beta,2315,B-GeneOrGeneProduct
),2315,O
.,2315,O
PKCalpha,2316,B-GeneOrGeneProduct
knockdown,2316,O
also,2316,O
resulted,2316,O
in,2316,O
decreased,2316,O
basal,2316,O
ERK,2316,B-GeneOrGeneProduct
phosphorylation,2316,O
and,2316,O
attenuated,2316,O
ERK,2316,B-GeneOrGeneProduct
activation,2316,O
following,2316,O
EGF,2316,B-GeneOrGeneProduct
stimulation,2316,O
.,2316,O
p21,2317,B-GeneOrGeneProduct
and,2317,O
p27,2317,B-GeneOrGeneProduct
expression,2317,O
was,2317,O
not,2317,O
increased,2317,O
by,2317,O
treatment,2317,O
of,2317,O
Ishikawa,2317,B-CellLine
cells,2317,O
with,2317,O
ERK,2317,B-GeneOrGeneProduct
and,2317,O
Akt,2317,B-GeneOrGeneProduct
inhibitors,2317,O
",",2317,O
suggesting,2317,O
that,2317,O
PKCalpha,2317,B-GeneOrGeneProduct
regulates,2317,O
CDK,2317,B-GeneOrGeneProduct
expression,2317,O
independently,2317,O
of,2317,O
Akt,2317,B-GeneOrGeneProduct
and,2317,O
ERK,2317,B-GeneOrGeneProduct
.,2317,O
Immunohistochemical,2318,O
analysis,2318,O
of,2318,O
Grade,2318,O
1,2318,O
endometrioid,2318,B-DiseaseOrPhenotypicFeature
adenocarcinoma,2318,I-DiseaseOrPhenotypicFeature
revealed,2318,O
aberrant,2318,O
PKCalpha,2318,B-GeneOrGeneProduct
expression,2318,O
",",2318,O
with,2318,O
foci,2318,O
of,2318,O
elevated,2318,O
PKCalpha,2318,B-GeneOrGeneProduct
staining,2318,O
",",2318,O
not,2318,O
observed,2318,O
in,2318,O
normal,2318,O
endometrium,2318,O
.,2318,O
These,2319,O
studies,2319,O
demonstrate,2319,O
a,2319,O
critical,2319,O
role,2319,O
for,2319,O
PKCalpha,2319,B-GeneOrGeneProduct
signaling,2319,O
in,2319,O
endometrial,2319,O
tumorigenesis,2319,B-DiseaseOrPhenotypicFeature
by,2319,O
regulating,2319,O
expression,2319,O
of,2319,O
CDK,2319,B-GeneOrGeneProduct
inhibitors,2319,O
p21,2319,B-GeneOrGeneProduct
and,2319,O
p27,2319,B-GeneOrGeneProduct
and,2319,O
activation,2319,O
of,2319,O
Akt,2319,B-GeneOrGeneProduct
and,2319,O
ERK-dependent,2319,B-GeneOrGeneProduct
proliferative,2319,O
pathways,2319,O
.,2319,O
Thus,2320,O
",",2320,O
targeting,2320,O
PKCalpha,2320,B-GeneOrGeneProduct
may,2320,O
provide,2320,O
novel,2320,O
therapeutic,2320,O
options,2320,O
in,2320,O
endometrial,2320,B-DiseaseOrPhenotypicFeature
tumors,2320,I-DiseaseOrPhenotypicFeature
.,2320,O
Mice,2321,B-OrganismTaxon
lacking,2321,O
mPGES-1,2321,B-GeneOrGeneProduct
are,2321,O
resistant,2321,O
to,2321,O
lithium-induced,2321,B-ChemicalEntity
polyuria,2321,B-DiseaseOrPhenotypicFeature
.,2321,O
Cyclooxygenase-2,2322,B-GeneOrGeneProduct
activity,2322,O
is,2322,O
required,2322,O
for,2322,O
the,2322,O
development,2322,O
of,2322,O
lithium-induced,2322,B-ChemicalEntity
polyuria,2322,B-DiseaseOrPhenotypicFeature
.,2322,O
However,2323,O
",",2323,O
the,2323,O
involvement,2323,O
of,2323,O
a,2323,O
specific,2323,O
",",2323,O
terminal,2323,O
prostaglandin,2323,B-ChemicalEntity
(,2323,O
PG,2323,B-ChemicalEntity
),2323,O
isomerase,2323,O
has,2323,O
not,2323,O
been,2323,O
evaluated,2323,O
.,2323,O
The,2324,O
present,2324,O
study,2324,O
was,2324,O
undertaken,2324,O
to,2324,O
assess,2324,O
lithium-induced,2324,B-ChemicalEntity
polyuria,2324,B-DiseaseOrPhenotypicFeature
in,2324,O
mice,2324,B-OrganismTaxon
deficient,2324,O
in,2324,O
microsomal,2324,B-GeneOrGeneProduct
prostaglandin,2324,I-GeneOrGeneProduct
E,2324,I-GeneOrGeneProduct
synthase-1,2324,I-GeneOrGeneProduct
(,2324,O
mPGES-1,2324,B-GeneOrGeneProduct
),2324,O
.,2324,O
A,2325,O
2-wk,2325,O
administration,2325,O
of,2325,O
LiCl,2325,B-ChemicalEntity
(,2325,O
4,2325,O
mmol.kg,2325,O
(,2325,O
-1,2325,O
),2325,O
.day,2325,O
(,2325,O
-1,2325,O
),2325,O
ip,2325,O
),2325,O
in,2325,O
mPGES-1,2325,B-GeneOrGeneProduct
+/+,2325,O
mice,2325,B-OrganismTaxon
led,2325,O
to,2325,O
a,2325,O
marked,2325,O
polyuria,2325,B-DiseaseOrPhenotypicFeature
with,2325,O
hyposmotic,2325,O
urine,2325,O
.,2325,O
This,2326,O
was,2326,O
associated,2326,O
with,2326,O
elevated,2326,O
renal,2326,O
mPGES-1,2326,B-GeneOrGeneProduct
protein,2326,O
expression,2326,O
and,2326,O
increased,2326,O
urine,2326,O
PGE,2326,B-ChemicalEntity
(,2326,I-ChemicalEntity
2,2326,I-ChemicalEntity
),2326,I-ChemicalEntity
excretion,2326,O
.,2326,O
In,2327,O
contrast,2327,O
",",2327,O
mPGES-1,2327,B-GeneOrGeneProduct
-/-,2327,O
mice,2327,B-OrganismTaxon
were,2327,O
largely,2327,O
resistant,2327,O
to,2327,O
lithium-induced,2327,B-ChemicalEntity
polyuria,2327,B-DiseaseOrPhenotypicFeature
and,2327,O
a,2327,O
urine,2327,O
concentrating,2327,O
defect,2327,O
",",2327,O
accompanied,2327,O
by,2327,O
nearly,2327,O
complete,2327,O
blockade,2327,O
of,2327,O
high,2327,O
urine,2327,O
PGE,2327,B-ChemicalEntity
(,2327,I-ChemicalEntity
2,2327,I-ChemicalEntity
),2327,I-ChemicalEntity
and,2327,O
cAMP,2327,B-ChemicalEntity
output,2327,O
.,2327,O
Immunoblotting,2328,O
",",2328,O
immunohistochemistry,2328,O
",",2328,O
and,2328,O
quantitative,2328,O
(,2328,O
q,2328,O
),2328,O
RT-PCR,2328,O
consistently,2328,O
detected,2328,O
a,2328,O
significant,2328,O
decrease,2328,O
in,2328,O
aquaporin-2,2328,B-GeneOrGeneProduct
(,2328,O
AQP2,2328,B-GeneOrGeneProduct
),2328,O
protein,2328,O
expression,2328,O
in,2328,O
both,2328,O
the,2328,O
renal,2328,O
cortex,2328,O
and,2328,O
medulla,2328,O
of,2328,O
lithium-treated,2328,B-ChemicalEntity
+/+,2328,O
mice,2328,B-OrganismTaxon
.,2328,O
This,2329,O
decrease,2329,O
was,2329,O
significantly,2329,O
attenuated,2329,O
in,2329,O
the,2329,O
-/-,2329,O
mice,2329,B-OrganismTaxon
.,2329,O
qRT-PCR,2330,O
detected,2330,O
similar,2330,O
patterns,2330,O
of,2330,O
changes,2330,O
in,2330,O
AQP2,2330,B-GeneOrGeneProduct
mRNA,2330,O
in,2330,O
the,2330,O
medulla,2330,O
but,2330,O
not,2330,O
in,2330,O
the,2330,O
cortex,2330,O
.,2330,O
Similarly,2331,O
",",2331,O
the,2331,O
total,2331,O
protein,2331,O
abundance,2331,O
of,2331,O
the,2331,O
Na-K-2Cl,2331,B-GeneOrGeneProduct
cotransporter,2331,I-GeneOrGeneProduct
(,2331,O
NKCC2,2331,B-GeneOrGeneProduct
),2331,O
in,2331,O
the,2331,O
medulla,2331,O
but,2331,O
not,2331,O
in,2331,O
the,2331,O
cortex,2331,O
of,2331,O
the,2331,O
+/+,2331,O
mice,2331,B-OrganismTaxon
was,2331,O
significantly,2331,O
reduced,2331,O
by,2331,O
lithium,2331,B-ChemicalEntity
treatment,2331,O
.,2331,O
In,2332,O
contrast,2332,O
",",2332,O
the,2332,O
dowregulation,2332,O
of,2332,O
renal,2332,O
medullary,2332,O
NKCC2,2332,B-GeneOrGeneProduct
expression,2332,O
was,2332,O
significantly,2332,O
attenuated,2332,O
in,2332,O
the,2332,O
-/-,2332,O
mice,2332,B-OrganismTaxon
.,2332,O
We,2333,O
conclude,2333,O
that,2333,O
mPGES-1-derived,2333,B-GeneOrGeneProduct
PGE,2333,B-ChemicalEntity
(,2333,I-ChemicalEntity
2,2333,I-ChemicalEntity
),2333,I-ChemicalEntity
mediates,2333,O
lithium-induced,2333,B-ChemicalEntity
polyuria,2333,B-DiseaseOrPhenotypicFeature
likely,2333,O
via,2333,O
inhibition,2333,O
of,2333,O
AQP2,2333,B-GeneOrGeneProduct
and,2333,O
NKCC2,2333,B-GeneOrGeneProduct
expression,2333,O
.,2333,O
Single,2334,O
nucleotide,2334,O
polymorphism,2334,O
in,2334,O
ABCG2,2334,B-GeneOrGeneProduct
is,2334,O
associated,2334,O
with,2334,O
irinotecan-induced,2334,B-ChemicalEntity
severe,2334,O
myelosuppression,2334,B-DiseaseOrPhenotypicFeature
.,2334,O
Irinotecan,2335,B-ChemicalEntity
is,2335,O
an,2335,O
anti-neoplastic,2335,O
agent,2335,O
that,2335,O
is,2335,O
widely,2335,O
used,2335,O
for,2335,O
treating,2335,O
colorectal,2335,B-DiseaseOrPhenotypicFeature
and,2335,I-DiseaseOrPhenotypicFeature
lung,2335,I-DiseaseOrPhenotypicFeature
cancers,2335,I-DiseaseOrPhenotypicFeature
",",2335,O
but,2335,O
often,2335,O
causes,2335,O
toxicities,2335,B-DiseaseOrPhenotypicFeature
such,2335,O
as,2335,O
severe,2335,O
myelosuppression,2335,B-DiseaseOrPhenotypicFeature
and,2335,O
diarrhea,2335,B-DiseaseOrPhenotypicFeature
.,2335,O
In,2336,O
this,2336,O
study,2336,O
",",2336,O
we,2336,O
performed,2336,O
a,2336,O
two-stage,2336,O
case-control,2336,O
association,2336,O
study,2336,O
for,2336,O
irinotecan-induced,2336,B-ChemicalEntity
severe,2336,O
myelosuppression,2336,B-DiseaseOrPhenotypicFeature
(,2336,O
grades,2336,O
3,2336,O
and,2336,O
4,2336,O
),2336,O
.,2336,O
In,2337,O
the,2337,O
first,2337,O
stage,2337,O
",",2337,O
23,2337,O
patients,2337,B-OrganismTaxon
who,2337,O
developed,2337,O
severe,2337,O
myelosuppression,2337,B-DiseaseOrPhenotypicFeature
and,2337,O
58,2337,O
patients,2337,B-OrganismTaxon
who,2337,O
did,2337,O
not,2337,O
develop,2337,O
any,2337,O
toxicity,2337,B-DiseaseOrPhenotypicFeature
were,2337,O
examined,2337,O
for,2337,O
170,2337,O
single,2337,O
nucleotide,2337,O
polymorphisms,2337,O
(,2337,O
SNPs,2337,O
),2337,O
in,2337,O
14,2337,O
genes,2337,O
involved,2337,O
in,2337,O
the,2337,O
metabolism,2337,O
and,2337,O
transport,2337,O
of,2337,O
irinotecan,2337,B-ChemicalEntity
.,2337,O
A,2338,O
total,2338,O
of,2338,O
five,2338,O
SNPs,2338,O
were,2338,O
identified,2338,O
to,2338,O
show,2338,O
the,2338,O
possible,2338,O
association,2338,O
with,2338,O
severe,2338,O
myelosuppression,2338,B-DiseaseOrPhenotypicFeature
(,2338,O
P,2338,O
(,2338,O
Fisher,2338,O
),2338,O
<,2338,O
0.01,2338,O
),2338,O
and,2338,O
were,2338,O
further,2338,O
examined,2338,O
in,2338,O
7,2338,O
cases,2338,O
and,2338,O
20,2338,O
controls,2338,O
in,2338,O
the,2338,O
second,2338,O
stage,2338,O
of,2338,O
the,2338,O
study,2338,O
.,2338,O
An,2339,O
intronic,2339,O
SNP,2339,O
",",2339,O
rs2622604,2339,B-SequenceVariant
",",2339,O
in,2339,O
ABCG2,2339,B-GeneOrGeneProduct
showed,2339,O
P,2339,O
(,2339,O
Fisher,2339,O
),2339,O
=0.0419,2339,O
in,2339,O
the,2339,O
second,2339,O
stage,2339,O
and,2339,O
indicated,2339,O
a,2339,O
significant,2339,O
association,2339,O
with,2339,O
severe,2339,O
myelosuppression,2339,B-DiseaseOrPhenotypicFeature
in,2339,O
the,2339,O
combined,2339,O
study,2339,O
(,2339,O
P,2339,O
(,2339,O
Fisher,2339,O
),2339,O
=0.000237,2339,O
;,2339,O
P,2339,O
(,2339,O
Corrected,2339,O
),2339,O
=0.036,2339,O
),2339,O
.,2339,O
Although,2340,O
only,2340,O
limited,2340,O
subjects,2340,O
were,2340,O
investigated,2340,O
",",2340,O
our,2340,O
results,2340,O
suggested,2340,O
that,2340,O
a,2340,O
genetic,2340,O
polymorphism,2340,O
in,2340,O
ABCG2,2340,B-GeneOrGeneProduct
might,2340,O
alter,2340,O
the,2340,O
transport,2340,O
activity,2340,O
for,2340,O
the,2340,O
drug,2340,O
and,2340,O
elevate,2340,O
the,2340,O
systemic,2340,O
circulation,2340,O
level,2340,O
of,2340,O
irinotecan,2340,B-ChemicalEntity
",",2340,O
leading,2340,O
to,2340,O
severe,2340,O
myelosuppression,2340,B-DiseaseOrPhenotypicFeature
.,2340,O
Seizures,2341,B-DiseaseOrPhenotypicFeature
associated,2341,O
with,2341,O
levofloxacin,2341,B-ChemicalEntity
:,2341,O
case,2341,O
presentation,2341,O
and,2341,O
literature,2341,O
review,2341,O
.,2341,O
PURPOSE,2342,O
:,2342,O
We,2342,O
present,2342,O
a,2342,O
case,2342,O
of,2342,O
a,2342,O
patient,2342,B-OrganismTaxon
who,2342,O
developed,2342,O
seizures,2342,B-DiseaseOrPhenotypicFeature
shortly,2342,O
after,2342,O
initiating,2342,O
treatment,2342,O
with,2342,O
levofloxacin,2342,B-ChemicalEntity
and,2342,O
to,2342,O
discuss,2342,O
the,2342,O
potential,2342,O
drug-drug,2342,O
interactions,2342,O
related,2342,O
to,2342,O
the,2342,O
inhibition,2342,O
of,2342,O
cytochrome,2342,B-GeneOrGeneProduct
P450,2342,I-GeneOrGeneProduct
(,2342,I-GeneOrGeneProduct
CYP,2342,I-GeneOrGeneProduct
),2342,I-GeneOrGeneProduct
1A2,2342,I-GeneOrGeneProduct
in,2342,O
this,2342,O
case,2342,O
",",2342,O
as,2342,O
well,2342,O
as,2342,O
in,2342,O
other,2342,O
cases,2342,O
",",2342,O
of,2342,O
levofloxacin-induced,2342,B-ChemicalEntity
seizures,2342,B-DiseaseOrPhenotypicFeature
.,2342,O
METHODS,2343,O
:,2343,O
Several,2343,O
biomedical,2343,O
databases,2343,O
were,2343,O
searched,2343,O
including,2343,O
MEDLINE,2343,O
",",2343,O
Cochrane,2343,O
and,2343,O
Ovid,2343,O
.,2343,O
The,2344,O
main,2344,O
search,2344,O
terms,2344,O
utilized,2344,O
were,2344,O
case,2344,O
report,2344,O
and,2344,O
levofloxacin,2344,B-ChemicalEntity
.,2344,O
The,2345,O
search,2345,O
was,2345,O
limited,2345,O
to,2345,O
studies,2345,O
published,2345,O
in,2345,O
English,2345,O
.,2345,O
RESULTS,2346,O
:,2346,O
Six,2346,O
cases,2346,O
of,2346,O
levofloxacin-induced,2346,B-ChemicalEntity
seizures,2346,B-DiseaseOrPhenotypicFeature
have,2346,O
been,2346,O
reported,2346,O
in,2346,O
the,2346,O
literature,2346,O
.,2346,O
Drug-drug,2347,O
interactions,2347,O
related,2347,O
to,2347,O
the,2347,O
inhibition,2347,O
of,2347,O
CYP1A2,2347,B-GeneOrGeneProduct
by,2347,O
levofloxacin,2347,B-ChemicalEntity
are,2347,O
likely,2347,O
involved,2347,O
in,2347,O
the,2347,O
clinical,2347,O
outcome,2347,O
of,2347,O
these,2347,O
cases,2347,O
.,2347,O
CONCLUSIONS,2348,O
:,2348,O
Clinicians,2348,O
are,2348,O
exhorted,2348,O
to,2348,O
pay,2348,O
close,2348,O
attention,2348,O
when,2348,O
initiating,2348,O
levofloxacin,2348,B-ChemicalEntity
therapy,2348,O
in,2348,O
patients,2348,B-OrganismTaxon
taking,2348,O
medications,2348,O
with,2348,O
epileptogenic,2348,O
properties,2348,O
that,2348,O
are,2348,O
CYP1A2,2348,B-GeneOrGeneProduct
substrates,2348,O
.,2348,O
Dextran-etodolac,2349,B-ChemicalEntity
conjugates,2349,O
:,2349,O
synthesis,2349,O
",",2349,O
in,2349,O
vitro,2349,O
and,2349,O
in,2349,O
vivo,2349,O
evaluation,2349,O
.,2349,O
Etodolac,2350,B-ChemicalEntity
(,2350,O
E,2350,B-ChemicalEntity
),2350,O
",",2350,O
is,2350,O
a,2350,O
non-narcotic,2350,O
analgesic,2350,O
and,2350,O
antiinflammatory,2350,B-ChemicalEntity
drug,2350,I-ChemicalEntity
.,2350,O
A,2351,O
biodegradable,2351,O
polymer,2351,O
dextran,2351,B-ChemicalEntity
has,2351,O
been,2351,O
utilized,2351,O
as,2351,O
a,2351,O
carrier,2351,O
for,2351,O
synthesis,2351,O
of,2351,O
etodolac-dextran,2351,B-ChemicalEntity
conjugates,2351,O
(,2351,O
ED,2351,B-ChemicalEntity
),2351,O
to,2351,O
improve,2351,O
its,2351,O
aqueous,2351,O
solubility,2351,O
and,2351,O
reduce,2351,O
gastrointestinal,2351,O
side,2351,O
effects,2351,O
.,2351,O
An,2352,O
activated,2352,O
moiety,2352,O
",",2352,O
i.e,2352,O
.,2352,O
N-acylimidazole,2353,B-ChemicalEntity
derivative,2353,O
of,2353,O
etodolac,2353,B-ChemicalEntity
(,2353,O
EAI,2353,B-ChemicalEntity
),2353,O
",",2353,O
was,2353,O
condensed,2353,O
with,2353,O
the,2353,O
polysaccharide,2353,O
polymer,2353,O
dextran,2353,B-ChemicalEntity
of,2353,O
different,2353,O
molecular,2353,O
weights,2353,O
(,2353,O
40000,2353,O
",",2353,O
60000,2353,O
",",2353,O
110000,2353,O
and,2353,O
200000,2353,O
),2353,O
.,2353,O
IR,2354,O
spectral,2354,O
data,2354,O
confirmed,2354,O
formation,2354,O
of,2354,O
ester,2354,B-ChemicalEntity
bonding,2354,O
in,2354,O
the,2354,O
conjugates,2354,O
.,2354,O
Etodolac,2355,B-ChemicalEntity
contents,2355,O
were,2355,O
evaluated,2355,O
by,2355,O
UV-spectrophotometric,2355,O
analysis,2355,O
.,2355,O
The,2356,O
molecular,2356,O
weights,2356,O
were,2356,O
determined,2356,O
by,2356,O
measuring,2356,O
viscosity,2356,O
using,2356,O
the,2356,O
Mark-Howink-Sakurada,2356,O
equation,2356,O
.,2356,O
In,2357,O
vitro,2357,O
hydrolysis,2357,O
of,2357,O
ED,2357,B-ChemicalEntity
was,2357,O
done,2357,O
in,2357,O
aqueous,2357,O
buffers,2357,O
(,2357,O
pH,2357,O
1.2,2357,O
",",2357,O
7.4,2357,O
",",2357,O
9,2357,O
),2357,O
and,2357,O
in,2357,O
80,2357,O
%,2357,O
(,2357,O
v/v,2357,O
),2357,O
human,2357,B-OrganismTaxon
plasma,2357,O
(,2357,O
pH,2357,O
7.4,2357,O
),2357,O
.,2357,O
At,2358,O
pH,2358,O
9,2358,O
",",2358,O
a,2358,O
higher,2358,O
rate,2358,O
of,2358,O
etodolac,2358,B-ChemicalEntity
release,2358,O
from,2358,O
ED,2358,B-ChemicalEntity
was,2358,O
observed,2358,O
as,2358,O
compared,2358,O
to,2358,O
aqueous,2358,O
buffer,2358,O
of,2358,O
pH,2358,O
7.4,2358,O
and,2358,O
80,2358,O
%,2358,O
human,2358,B-OrganismTaxon
plasma,2358,O
(,2358,O
pH,2358,O
7.4,2358,O
),2358,O
",",2358,O
following,2358,O
first-order,2358,O
kinetics,2358,O
.,2358,O
In,2359,O
vivo,2359,O
investigations,2359,O
were,2359,O
performed,2359,O
in,2359,O
animals,2359,O
.,2359,O
Acute,2360,O
analgesic,2360,O
and,2360,O
antiinflammatory,2360,O
activities,2360,O
were,2360,O
ascertained,2360,O
using,2360,O
acetic,2360,B-ChemicalEntity
acid,2360,I-ChemicalEntity
induced,2360,O
writhing,2360,O
model,2360,O
(,2360,O
mice,2360,B-OrganismTaxon
),2360,O
and,2360,O
carrageenan-induced,2360,B-ChemicalEntity
rat,2360,B-OrganismTaxon
paw,2360,O
edema,2360,B-DiseaseOrPhenotypicFeature
model,2360,O
",",2360,O
respectively,2360,O
.,2360,O
In,2361,O
comparison,2361,O
to,2361,O
control,2361,O
",",2361,O
E,2361,B-ChemicalEntity
and,2361,O
ED1-ED4,2361,O
showed,2361,O
highly,2361,O
significant,2361,O
analgesic,2361,O
and,2361,O
antiinflammatory,2361,O
activities,2361,O
(,2361,O
p,2361,O
<,2361,O
0.001,2361,O
),2361,O
.,2361,O
Biological,2362,O
evaluation,2362,O
suggested,2362,O
that,2362,O
conjugates,2362,O
(,2362,O
ED1-ED4,2362,O
),2362,O
retained,2362,O
comparable,2362,O
analgesic,2362,O
and,2362,O
antiinflammatory,2362,O
activities,2362,O
with,2362,O
remarkably,2362,O
reduced,2362,O
ulcerogenicity,2362,O
as,2362,O
compared,2362,O
to,2362,O
their,2362,O
parent,2362,O
drug,2362,O
--,2362,O
etodolac,2362,B-ChemicalEntity
.,2362,O
The,2363,O
antiarrhythmic,2363,O
effect,2363,O
and,2363,O
possible,2363,O
ionic,2363,O
mechanisms,2363,O
of,2363,O
pilocarpine,2363,B-ChemicalEntity
on,2363,O
animal,2363,O
models,2363,O
.,2363,O
This,2364,O
study,2364,O
was,2364,O
designed,2364,O
to,2364,O
evaluate,2364,O
the,2364,O
effects,2364,O
of,2364,O
pilocarpine,2364,B-ChemicalEntity
and,2364,O
explore,2364,O
the,2364,O
underlying,2364,O
ionic,2364,O
mechanism,2364,O
",",2364,O
using,2364,O
both,2364,O
aconitine-induced,2364,B-ChemicalEntity
rat,2364,B-OrganismTaxon
and,2364,O
ouabain-induced,2364,B-ChemicalEntity
guinea,2364,B-OrganismTaxon
pig,2364,I-OrganismTaxon
arrhythmia,2364,B-DiseaseOrPhenotypicFeature
models,2364,O
.,2364,O
Confocal,2365,O
microscopy,2365,O
was,2365,O
used,2365,O
to,2365,O
measure,2365,O
intracellular,2365,O
free-calcium,2365,O
concentrations,2365,O
(,2365,O
[,2365,O
Ca,2365,B-ChemicalEntity
(,2365,I-ChemicalEntity
2+,2365,I-ChemicalEntity
),2365,I-ChemicalEntity
],2365,O
(,2365,O
i,2365,O
),2365,O
),2365,O
in,2365,O
isolated,2365,O
myocytes,2365,O
.,2365,O
The,2366,O
current,2366,O
data,2366,O
showed,2366,O
that,2366,O
pilocarpine,2366,B-ChemicalEntity
significantly,2366,O
delayed,2366,O
onset,2366,O
of,2366,O
arrhythmias,2366,B-DiseaseOrPhenotypicFeature
",",2366,O
decreased,2366,O
the,2366,O
time,2366,O
course,2366,O
of,2366,O
ventricular,2366,B-DiseaseOrPhenotypicFeature
tachycardia,2366,I-DiseaseOrPhenotypicFeature
and,2366,I-DiseaseOrPhenotypicFeature
fibrillation,2366,I-DiseaseOrPhenotypicFeature
",",2366,O
reduced,2366,O
arrhythmia,2366,B-DiseaseOrPhenotypicFeature
score,2366,O
",",2366,O
and,2366,O
increased,2366,O
the,2366,O
survival,2366,O
time,2366,O
of,2366,O
arrhythmic,2366,B-DiseaseOrPhenotypicFeature
rats,2366,B-OrganismTaxon
and,2366,O
guinea,2366,B-OrganismTaxon
pigs,2366,I-OrganismTaxon
.,2366,O
[,2367,O
Ca,2367,B-ChemicalEntity
(,2367,I-ChemicalEntity
2+,2367,I-ChemicalEntity
),2367,I-ChemicalEntity
],2367,O
(,2367,O
i,2367,O
),2367,O
overload,2367,O
induced,2367,O
by,2367,O
aconitine,2367,B-ChemicalEntity
or,2367,O
ouabain,2367,B-ChemicalEntity
was,2367,O
reduced,2367,O
in,2367,O
isolated,2367,O
myocytes,2367,O
pretreated,2367,O
with,2367,O
pilocarpine,2367,B-ChemicalEntity
.,2367,O
Moreover,2368,O
",",2368,O
M,2368,B-GeneOrGeneProduct
(,2368,I-GeneOrGeneProduct
3,2368,I-GeneOrGeneProduct
),2368,I-GeneOrGeneProduct
-muscarinic,2368,I-GeneOrGeneProduct
acetylcholine,2368,I-GeneOrGeneProduct
receptor,2368,I-GeneOrGeneProduct
(,2368,O
mAChR,2368,B-GeneOrGeneProduct
),2368,O
antagonist,2368,O
4-DAMP,2368,B-ChemicalEntity
(,2368,O
4-diphenylacetoxy-N-methylpiperidine-methiodide,2368,B-ChemicalEntity
),2368,O
partially,2368,O
abolished,2368,O
the,2368,O
beneficial,2368,O
effects,2368,O
of,2368,O
pilocarpine,2368,B-ChemicalEntity
.,2368,O
These,2369,O
data,2369,O
suggest,2369,O
that,2369,O
pilocarpine,2369,B-ChemicalEntity
produced,2369,O
antiarrhythmic,2369,O
actions,2369,O
on,2369,O
arrhythmic,2369,B-DiseaseOrPhenotypicFeature
rat,2369,B-OrganismTaxon
and,2369,O
guinea,2369,B-OrganismTaxon
pig,2369,I-OrganismTaxon
models,2369,O
induced,2369,O
by,2369,O
aconitine,2369,B-ChemicalEntity
or,2369,O
ouabain,2369,B-ChemicalEntity
via,2369,O
stimulating,2369,O
the,2369,O
cardiac,2369,O
M,2369,B-GeneOrGeneProduct
(,2369,I-GeneOrGeneProduct
3,2369,I-GeneOrGeneProduct
),2369,I-GeneOrGeneProduct
-mAChR,2369,I-GeneOrGeneProduct
.,2369,O
The,2370,O
mechanism,2370,O
may,2370,O
be,2370,O
related,2370,O
to,2370,O
the,2370,O
improvement,2370,O
of,2370,O
Ca,2370,B-ChemicalEntity
(,2370,I-ChemicalEntity
2+,2370,I-ChemicalEntity
),2370,I-ChemicalEntity
handling,2370,O
.,2370,O
Prolonged,2371,O
hypothermia,2371,B-DiseaseOrPhenotypicFeature
as,2371,O
a,2371,O
bridge,2371,O
to,2371,O
recovery,2371,O
for,2371,O
cerebral,2371,B-DiseaseOrPhenotypicFeature
edema,2371,I-DiseaseOrPhenotypicFeature
and,2371,O
intracranial,2371,B-DiseaseOrPhenotypicFeature
hypertension,2371,I-DiseaseOrPhenotypicFeature
associated,2371,O
with,2371,O
fulminant,2371,B-DiseaseOrPhenotypicFeature
hepatic,2371,I-DiseaseOrPhenotypicFeature
failure,2371,I-DiseaseOrPhenotypicFeature
.,2371,O
BACKGROUND,2372,O
:,2372,O
To,2372,O
review,2372,O
evidence-based,2372,O
treatment,2372,O
options,2372,O
in,2372,O
patients,2372,B-OrganismTaxon
with,2372,O
cerebral,2372,B-DiseaseOrPhenotypicFeature
edema,2372,I-DiseaseOrPhenotypicFeature
complicating,2372,O
fulminant,2372,B-DiseaseOrPhenotypicFeature
hepatic,2372,I-DiseaseOrPhenotypicFeature
failure,2372,I-DiseaseOrPhenotypicFeature
(,2372,O
FHF,2372,B-DiseaseOrPhenotypicFeature
),2372,O
and,2372,O
discuss,2372,O
the,2372,O
potential,2372,O
applications,2372,O
of,2372,O
hypothermia,2372,B-DiseaseOrPhenotypicFeature
.,2372,O
METHOD,2373,O
:,2373,O
Case-based,2373,O
observations,2373,O
from,2373,O
a,2373,O
medical,2373,O
intensive,2373,O
care,2373,O
unit,2373,O
(,2373,O
MICU,2373,O
),2373,O
in,2373,O
a,2373,O
tertiary,2373,O
care,2373,O
facility,2373,O
in,2373,O
a,2373,O
27-year-old,2373,O
female,2373,O
with,2373,O
FHF,2373,B-DiseaseOrPhenotypicFeature
from,2373,O
acetaminophen,2373,B-ChemicalEntity
and,2373,O
resultant,2373,O
cerebral,2373,B-DiseaseOrPhenotypicFeature
edema,2373,I-DiseaseOrPhenotypicFeature
.,2373,O
RESULTS,2374,O
:,2374,O
Our,2374,O
patient,2374,B-OrganismTaxon
was,2374,O
admitted,2374,O
to,2374,O
the,2374,O
MICU,2374,O
after,2374,O
being,2374,O
found,2374,O
unresponsive,2374,O
with,2374,O
presumed,2374,O
toxicity,2374,B-DiseaseOrPhenotypicFeature
from,2374,O
acetaminophen,2374,B-ChemicalEntity
which,2374,O
was,2374,O
ingested,2374,O
over,2374,O
a,2374,O
2-day,2374,O
period,2374,O
.,2374,O
The,2375,O
patient,2375,B-OrganismTaxon
had,2375,O
depressed,2375,B-DiseaseOrPhenotypicFeature
of,2375,O
mental,2375,O
status,2375,O
lasting,2375,O
at,2375,O
least,2375,O
24,2375,O
h,2375,O
prior,2375,O
to,2375,O
admission,2375,O
.,2375,O
Initial,2376,O
evaluation,2376,O
confirmed,2376,O
FHF,2376,B-DiseaseOrPhenotypicFeature
from,2376,O
acetaminophen,2376,B-ChemicalEntity
and,2376,O
cerebral,2376,B-DiseaseOrPhenotypicFeature
edema,2376,I-DiseaseOrPhenotypicFeature
.,2376,O
The,2377,O
patient,2377,B-OrganismTaxon
was,2377,O
treated,2377,O
with,2377,O
hyperosmolar,2377,O
therapy,2377,O
",",2377,O
hyperventilation,2377,B-DiseaseOrPhenotypicFeature
",",2377,O
sedation,2377,O
",",2377,O
and,2377,O
chemical,2377,O
paralysis,2377,B-DiseaseOrPhenotypicFeature
.,2377,O
Her,2378,O
intracranial,2378,O
pressure,2378,O
remained,2378,O
elevated,2378,O
despite,2378,O
maximal,2378,O
medical,2378,O
therapy,2378,O
.,2378,O
We,2379,O
then,2379,O
initiated,2379,O
therapeutic,2379,O
hypothermia,2379,B-DiseaseOrPhenotypicFeature
which,2379,O
was,2379,O
continued,2379,O
for,2379,O
5,2379,O
days,2379,O
.,2379,O
At,2380,O
re-warming,2380,O
",",2380,O
patient,2380,B-OrganismTaxon
had,2380,O
resolution,2380,O
of,2380,O
her,2380,O
cerebral,2380,B-DiseaseOrPhenotypicFeature
edema,2380,I-DiseaseOrPhenotypicFeature
and,2380,O
intracranial,2380,B-DiseaseOrPhenotypicFeature
hypertension,2380,I-DiseaseOrPhenotypicFeature
.,2380,O
At,2381,O
discharge,2381,O
",",2381,O
she,2381,O
had,2381,O
complete,2381,O
recovery,2381,O
of,2381,O
neurological,2381,O
and,2381,O
hepatic,2381,O
functions,2381,O
.,2381,O
CONCLUSION,2382,O
:,2382,O
In,2382,O
patients,2382,B-OrganismTaxon
with,2382,O
FHF,2382,B-DiseaseOrPhenotypicFeature
and,2382,O
cerebral,2382,B-DiseaseOrPhenotypicFeature
edema,2382,I-DiseaseOrPhenotypicFeature
from,2382,O
acetaminophen,2382,B-ChemicalEntity
overdose,2382,O
",",2382,O
prolonged,2382,O
therapeutic,2382,O
hypothermia,2382,B-DiseaseOrPhenotypicFeature
could,2382,O
potentially,2382,O
be,2382,O
used,2382,O
as,2382,O
a,2382,O
life,2382,O
saving,2382,O
therapy,2382,O
and,2382,O
a,2382,O
bridge,2382,O
to,2382,O
hepatic,2382,O
and,2382,O
neurological,2382,O
recovery,2382,O
.,2382,O
A,2383,O
clinical,2383,O
trial,2383,O
of,2383,O
hypothermia,2383,B-DiseaseOrPhenotypicFeature
in,2383,O
patients,2383,B-OrganismTaxon
with,2383,O
this,2383,O
condition,2383,O
is,2383,O
warranted,2383,O
.,2383,O
Novel,2384,O
CACNA1S,2384,B-GeneOrGeneProduct
mutation,2384,O
causes,2384,O
autosomal,2384,O
dominant,2384,O
hypokalemic,2384,B-DiseaseOrPhenotypicFeature
periodic,2384,I-DiseaseOrPhenotypicFeature
paralysis,2384,I-DiseaseOrPhenotypicFeature
in,2384,O
a,2384,O
South,2384,O
American,2384,O
family,2384,O
.,2384,O
Hypokalaemic,2385,B-DiseaseOrPhenotypicFeature
periodic,2385,I-DiseaseOrPhenotypicFeature
paralysis,2385,I-DiseaseOrPhenotypicFeature
(,2385,O
HypoPP,2385,B-DiseaseOrPhenotypicFeature
),2385,O
is,2385,O
an,2385,O
autosomal,2385,B-DiseaseOrPhenotypicFeature
dominant,2385,I-DiseaseOrPhenotypicFeature
disorder,2385,I-DiseaseOrPhenotypicFeature
",",2385,O
which,2385,O
is,2385,O
characterized,2385,O
by,2385,O
periodic,2385,O
attacks,2385,O
of,2385,O
muscle,2385,B-DiseaseOrPhenotypicFeature
weakness,2385,I-DiseaseOrPhenotypicFeature
associated,2385,O
with,2385,O
a,2385,O
decrease,2385,O
in,2385,O
the,2385,O
serum,2385,O
potassium,2385,B-ChemicalEntity
level,2385,O
.,2385,O
A,2386,O
major,2386,O
disease-causing,2386,O
gene,2386,O
for,2386,O
HypoPP,2386,B-DiseaseOrPhenotypicFeature
has,2386,O
been,2386,O
identified,2386,O
as,2386,O
CACNA1S,2386,B-GeneOrGeneProduct
",",2386,O
which,2386,O
encodes,2386,O
the,2386,O
skeletal,2386,B-GeneOrGeneProduct
muscle,2386,I-GeneOrGeneProduct
calcium,2386,I-GeneOrGeneProduct
channel,2386,I-GeneOrGeneProduct
alpha-subunit,2386,I-GeneOrGeneProduct
with,2386,O
four,2386,O
transmembrane,2386,O
domains,2386,O
(,2386,O
I-IV,2386,O
),2386,O
",",2386,O
each,2386,O
with,2386,O
six,2386,O
transmembrane,2386,O
segments,2386,O
(,2386,O
S1-S6,2386,O
),2386,O
.,2386,O
To,2387,O
date,2387,O
",",2387,O
all,2387,O
CACNA1S,2387,B-GeneOrGeneProduct
mutations,2387,O
identified,2387,O
in,2387,O
HypoPP,2387,B-DiseaseOrPhenotypicFeature
patients,2387,B-OrganismTaxon
are,2387,O
located,2387,O
within,2387,O
the,2387,O
voltage-sensor,2387,O
S4,2387,O
segment,2387,O
.,2387,O
In,2388,O
this,2388,O
study,2388,O
we,2388,O
report,2388,O
a,2388,O
novel,2388,O
CACNA1S,2388,B-GeneOrGeneProduct
mutation,2388,O
in,2388,O
a,2388,O
new,2388,O
region,2388,O
of,2388,O
the,2388,O
protein,2388,O
",",2388,O
the,2388,O
S3,2388,O
segment,2388,O
of,2388,O
domain,2388,O
III,2388,O
.,2388,O
We,2389,O
characterized,2389,O
a,2389,O
four-generation,2389,O
South,2389,O
American,2389,O
family,2389,O
with,2389,O
HypoPP,2389,B-DiseaseOrPhenotypicFeature
.,2389,O
Genetic,2390,O
analysis,2390,O
identified,2390,O
a,2390,O
novel,2390,O
V876E,2390,B-SequenceVariant
mutation,2390,O
in,2390,O
all,2390,O
HypoPP,2390,B-DiseaseOrPhenotypicFeature
patients,2390,B-OrganismTaxon
in,2390,O
the,2390,O
family,2390,O
",",2390,O
but,2390,O
not,2390,O
in,2390,O
normal,2390,O
family,2390,O
members,2390,O
or,2390,O
160,2390,O
control,2390,O
people,2390,O
.,2390,O
Clinical,2391,O
analysis,2391,O
indicates,2391,O
that,2391,O
mutation,2391,O
V876E,2391,B-SequenceVariant
is,2391,O
associated,2391,O
with,2391,O
a,2391,O
severe,2391,O
outcome,2391,O
as,2391,O
characterized,2391,O
by,2391,O
a,2391,O
very,2391,O
early,2391,O
age,2391,O
of,2391,O
onset,2391,O
",",2391,O
complete,2391,O
penetrance,2391,O
and,2391,O
a,2391,O
severe,2391,O
prognosis,2391,O
including,2391,O
death,2391,B-DiseaseOrPhenotypicFeature
.,2391,O
These,2392,O
results,2392,O
identify,2392,O
a,2392,O
new,2392,O
mutation,2392,O
in,2392,O
CACNA1S,2392,B-GeneOrGeneProduct
and,2392,O
expand,2392,O
the,2392,O
spectrum,2392,O
of,2392,O
CACNA1S,2392,B-GeneOrGeneProduct
mutations,2392,O
associated,2392,O
with,2392,O
HypoPP,2392,B-DiseaseOrPhenotypicFeature
.,2392,O
Independent,2393,O
and,2393,O
cooperative,2393,O
roles,2393,O
of,2393,O
tumor,2393,B-GeneOrGeneProduct
necrosis,2393,I-GeneOrGeneProduct
factor-alpha,2393,I-GeneOrGeneProduct
",",2393,O
nuclear,2393,B-GeneOrGeneProduct
factor-kappaB,2393,I-GeneOrGeneProduct
",",2393,O
and,2393,O
bone,2393,B-GeneOrGeneProduct
morphogenetic,2393,I-GeneOrGeneProduct
protein-2,2393,I-GeneOrGeneProduct
in,2393,O
regulation,2393,O
of,2393,O
metastasis,2393,B-DiseaseOrPhenotypicFeature
and,2393,O
osteomimicry,2393,O
of,2393,O
prostate,2393,B-DiseaseOrPhenotypicFeature
cancer,2393,I-DiseaseOrPhenotypicFeature
cells,2393,O
and,2393,O
differentiation,2393,O
and,2393,O
mineralization,2393,O
of,2393,O
MC3T3-E1,2393,B-CellLine
osteoblast-like,2393,O
cells,2393,O
.,2393,O
The,2394,O
molecular,2394,O
mechanisms,2394,O
involved,2394,O
in,2394,O
prostate,2394,B-DiseaseOrPhenotypicFeature
cancer,2394,I-DiseaseOrPhenotypicFeature
(,2394,I-DiseaseOrPhenotypicFeature
PC,2394,I-DiseaseOrPhenotypicFeature
),2394,I-DiseaseOrPhenotypicFeature
metastasis,2394,I-DiseaseOrPhenotypicFeature
and,2394,O
bone,2394,O
remodeling,2394,O
are,2394,O
poorly,2394,O
understood,2394,O
.,2394,O
We,2395,O
recently,2395,O
reported,2395,O
that,2395,O
phosphoinositide,2395,B-GeneOrGeneProduct
3-kinase,2395,I-GeneOrGeneProduct
(,2395,I-GeneOrGeneProduct
PI3K,2395,I-GeneOrGeneProduct
),2395,I-GeneOrGeneProduct
/protein,2395,I-GeneOrGeneProduct
kinase,2395,I-GeneOrGeneProduct
B,2395,I-GeneOrGeneProduct
(,2395,O
Akt,2395,B-GeneOrGeneProduct
),2395,O
mediates,2395,O
transcriptional,2395,O
regulation,2395,O
and,2395,O
activation,2395,O
of,2395,O
bone,2395,B-GeneOrGeneProduct
morphogenetic,2395,I-GeneOrGeneProduct
protein,2395,I-GeneOrGeneProduct
(,2395,I-GeneOrGeneProduct
BMP,2395,I-GeneOrGeneProduct
),2395,I-GeneOrGeneProduct
-2,2395,I-GeneOrGeneProduct
signaling,2395,O
by,2395,O
nuclear,2395,B-GeneOrGeneProduct
factor,2395,I-GeneOrGeneProduct
(,2395,I-GeneOrGeneProduct
NF,2395,I-GeneOrGeneProduct
),2395,I-GeneOrGeneProduct
-kappaB,2395,I-GeneOrGeneProduct
in,2395,O
bone,2395,O
metastatic,2395,O
prostate,2395,B-DiseaseOrPhenotypicFeature
cancer,2395,I-DiseaseOrPhenotypicFeature
cells,2395,O
.,2395,O
In,2396,O
the,2396,O
present,2396,O
study,2396,O
",",2396,O
we,2396,O
demonstrate,2396,O
that,2396,O
NF-kappaB,2396,B-GeneOrGeneProduct
",",2396,O
whether,2396,O
activated,2396,O
by,2396,O
recombinant,2396,O
human,2396,B-OrganismTaxon
tumor,2396,B-GeneOrGeneProduct
necrosis,2396,I-GeneOrGeneProduct
factor,2396,I-GeneOrGeneProduct
(,2396,I-GeneOrGeneProduct
TNF,2396,I-GeneOrGeneProduct
),2396,I-GeneOrGeneProduct
-alpha,2396,I-GeneOrGeneProduct
or,2396,O
by,2396,O
ectopic,2396,O
expression,2396,O
of,2396,O
the,2396,O
p65,2396,B-GeneOrGeneProduct
subunit,2396,O
",",2396,O
is,2396,O
involved,2396,O
in,2396,O
extracellular,2396,O
matrix,2396,O
adhesion,2396,O
and,2396,O
invasion,2396,O
of,2396,O
osteotropic,2396,O
PC-3,2396,B-CellLine
and,2396,O
C4-2B,2396,B-CellLine
",",2396,O
but,2396,O
not,2396,O
LNCaP,2396,B-CellLine
",",2396,O
cells,2396,O
.,2396,O
The,2397,O
enhanced,2397,O
metastatic,2397,O
potential,2397,O
was,2397,O
associated,2397,O
with,2397,O
transcriptional,2397,O
upregulation,2397,O
of,2397,O
osteopontin,2397,B-GeneOrGeneProduct
",",2397,O
osteocalcin,2397,B-GeneOrGeneProduct
",",2397,O
and,2397,O
collagen,2397,B-GeneOrGeneProduct
IA1,2397,I-GeneOrGeneProduct
in,2397,O
osteotropic,2397,O
PC,2397,B-DiseaseOrPhenotypicFeature
cells,2397,O
",",2397,O
suggesting,2397,O
their,2397,O
role,2397,O
in,2397,O
osteomimicry,2397,O
of,2397,O
PC,2397,B-DiseaseOrPhenotypicFeature
cells,2397,O
.,2397,O
Unlike,2398,O
BMP-4,2398,B-GeneOrGeneProduct
",",2398,O
BMP-2,2398,B-GeneOrGeneProduct
protein,2398,O
enhanced,2398,O
the,2398,O
invasive,2398,O
properties,2398,O
of,2398,O
C4-2B,2398,B-CellLine
cells,2398,O
",",2398,O
but,2398,O
not,2398,O
in,2398,O
LNCaP,2398,B-CellLine
cells,2398,O
.,2398,O
Also,2399,O
",",2399,O
this,2399,O
effect,2399,O
was,2399,O
nullified,2399,O
by,2399,O
Noggin,2399,B-GeneOrGeneProduct
.,2399,O
In,2400,O
addition,2400,O
",",2400,O
BMP-2,2400,B-GeneOrGeneProduct
mediates,2400,O
TNF-alpha-induced,2400,B-GeneOrGeneProduct
invasion,2400,O
of,2400,O
C4-2B,2400,B-CellLine
cells,2400,O
in,2400,O
a,2400,O
NF-kappaB-dependent,2400,B-GeneOrGeneProduct
fashion,2400,O
.,2400,O
TNF-alpha,2401,B-GeneOrGeneProduct
or,2401,O
conditioned,2401,O
media,2401,O
(,2401,O
CM,2401,O
),2401,O
of,2401,O
TNF-alpha-stimulated,2401,B-GeneOrGeneProduct
C4-2B,2401,B-CellLine
cells,2401,O
upregulated,2401,O
BMP-2,2401,B-GeneOrGeneProduct
and,2401,O
BMP-dependent,2401,B-GeneOrGeneProduct
Smad,2401,B-GeneOrGeneProduct
transcripts,2401,O
and,2401,O
inhibited,2401,O
receptor,2401,B-GeneOrGeneProduct
activator,2401,I-GeneOrGeneProduct
of,2401,I-GeneOrGeneProduct
NF-kappaB,2401,I-GeneOrGeneProduct
ligand,2401,I-GeneOrGeneProduct
transcripts,2401,O
in,2401,O
RAW,2401,B-CellLine
264.7,2401,I-CellLine
preosteoclast,2401,O
cells,2401,O
",",2401,O
respectively,2401,O
",",2401,O
implying,2401,O
that,2401,O
this,2401,O
factor,2401,O
may,2401,O
contribute,2401,O
to,2401,O
suppression,2401,O
of,2401,O
osteoclastogenesis,2401,O
via,2401,O
direct,2401,O
and,2401,O
paracrine,2401,O
mechanisms,2401,O
.,2401,O
In,2402,O
contrast,2402,O
",",2402,O
CM,2402,O
of,2402,O
TNF-alpha-stimulate,2402,B-GeneOrGeneProduct
or,2402,O
BMP2-stimulated,2402,B-GeneOrGeneProduct
C4-2B,2402,B-CellLine
cells,2402,O
induced,2402,O
in,2402,O
vitro,2402,O
mineralization,2402,O
of,2402,O
MC3T3-E1,2402,B-CellLine
osteoblast,2402,O
cells,2402,O
in,2402,O
a,2402,O
BMP-2-dependent,2402,B-GeneOrGeneProduct
and,2402,O
NF-kappaB-dependent,2402,B-GeneOrGeneProduct
manner,2402,O
",",2402,O
respectively,2402,O
.,2402,O
Taken,2403,O
together,2403,O
",",2403,O
the,2403,O
results,2403,O
suggest,2403,O
that,2403,O
mutual,2403,O
interactions,2403,O
between,2403,O
these,2403,O
factors,2403,O
may,2403,O
be,2403,O
pivotal,2403,O
not,2403,O
only,2403,O
in,2403,O
enhancing,2403,O
the,2403,O
osteomimicry,2403,O
and,2403,O
metastatic,2403,O
potential,2403,O
of,2403,O
PC,2403,B-DiseaseOrPhenotypicFeature
cells,2403,O
",",2403,O
but,2403,O
also,2403,O
in,2403,O
bone,2403,O
remodeling,2403,O
and,2403,O
in,2403,O
shifting,2403,O
the,2403,O
balance,2403,O
from,2403,O
osteoclastogenesis,2403,O
towards,2403,O
osteoblastogenesis,2403,O
.,2403,O
H3,2404,B-GeneOrGeneProduct
histamine,2404,I-GeneOrGeneProduct
receptor-mediated,2404,O
activation,2404,O
of,2404,O
protein,2404,B-GeneOrGeneProduct
kinase,2404,I-GeneOrGeneProduct
Calpha,2404,I-GeneOrGeneProduct
inhibits,2404,O
the,2404,O
growth,2404,O
of,2404,O
cholangiocarcinoma,2404,B-DiseaseOrPhenotypicFeature
in,2404,O
vitro,2404,O
and,2404,O
in,2404,O
vivo,2404,O
.,2404,O
Histamine,2405,B-ChemicalEntity
regulates,2405,O
functions,2405,O
via,2405,O
four,2405,O
receptors,2405,O
(,2405,O
HRH1,2405,B-GeneOrGeneProduct
",",2405,O
HRH2,2405,B-GeneOrGeneProduct
",",2405,O
HRH3,2405,B-GeneOrGeneProduct
",",2405,O
and,2405,O
HRH4,2405,B-GeneOrGeneProduct
),2405,O
.,2405,O
The,2406,O
d-myo-inositol,2406,B-ChemicalEntity
"1,4,5-trisphosphate",2406,I-ChemicalEntity
(,2406,O
IP,2406,B-ChemicalEntity
(,2406,I-ChemicalEntity
3,2406,I-ChemicalEntity
),2406,I-ChemicalEntity
),2406,O
/Ca,2406,O
(,2406,I-ChemicalEntity
2+,2406,I-ChemicalEntity
),2406,I-ChemicalEntity
/protein,2406,O
kinase,2406,I-GeneOrGeneProduct
C,2406,I-GeneOrGeneProduct
(,2406,O
PKC,2406,B-GeneOrGeneProduct
),2406,O
/mitogen-activated,2406,O
protein,2406,I-GeneOrGeneProduct
kinase,2406,I-GeneOrGeneProduct
pathway,2406,O
regulates,2406,O
cholangiocarcinoma,2406,B-DiseaseOrPhenotypicFeature
growth,2406,O
.,2406,O
We,2407,O
evaluated,2407,O
the,2407,O
role,2407,O
of,2407,O
HRH3,2407,B-GeneOrGeneProduct
in,2407,O
the,2407,O
regulation,2407,O
of,2407,O
cholangiocarcinoma,2407,B-DiseaseOrPhenotypicFeature
growth,2407,O
.,2407,O
Expression,2408,O
of,2408,O
HRH3,2408,B-GeneOrGeneProduct
in,2408,O
intrahepatic,2408,O
and,2408,O
extrahepatic,2408,O
cell,2408,O
lines,2408,O
",",2408,O
normal,2408,O
cholangiocytes,2408,O
",",2408,O
and,2408,O
human,2408,B-OrganismTaxon
tissue,2408,O
arrays,2408,O
was,2408,O
measured,2408,O
.,2408,O
In,2409,O
Mz-ChA-1,2409,B-CellLine
cells,2409,O
stimulated,2409,O
with,2409,O
(,2409,B-ChemicalEntity
R,2409,I-ChemicalEntity
),2409,I-ChemicalEntity
-,2409,I-ChemicalEntity
(,2409,I-ChemicalEntity
alpha,2409,I-ChemicalEntity
),2409,I-ChemicalEntity
-,2409,I-ChemicalEntity
(,2409,I-ChemicalEntity
-,2409,I-ChemicalEntity
),2409,I-ChemicalEntity
-methylhistamine,2409,I-ChemicalEntity
dihydrobromide,2409,I-ChemicalEntity
(,2409,O
RAMH,2409,B-ChemicalEntity
),2409,O
",",2409,O
we,2409,O
measured,2409,O
(,2409,O
a,2409,O
),2409,O
cell,2409,O
growth,2409,O
",",2409,O
(,2409,O
b,2409,O
),2409,O
IP,2409,B-ChemicalEntity
(,2409,I-ChemicalEntity
3,2409,I-ChemicalEntity
),2409,I-ChemicalEntity
and,2409,O
cyclic,2409,B-ChemicalEntity
AMP,2409,I-ChemicalEntity
levels,2409,O
",",2409,O
and,2409,O
(,2409,O
c,2409,O
),2409,O
phosphorylation,2409,O
of,2409,O
PKC,2409,B-GeneOrGeneProduct
and,2409,O
mitogen-activated,2409,B-GeneOrGeneProduct
protein,2409,I-GeneOrGeneProduct
kinase,2409,I-GeneOrGeneProduct
isoforms,2409,O
.,2409,O
Localization,2410,O
of,2410,O
PKCalpha,2410,B-GeneOrGeneProduct
was,2410,O
visualized,2410,O
by,2410,O
immunofluorescence,2410,O
in,2410,O
cell,2410,O
smears,2410,O
and,2410,O
immunoblotting,2410,O
for,2410,O
PKCalpha,2410,B-GeneOrGeneProduct
in,2410,O
cytosol,2410,O
and,2410,O
membrane,2410,O
fractions,2410,O
.,2410,O
Following,2411,O
knockdown,2411,O
of,2411,O
PKCalpha,2411,B-GeneOrGeneProduct
",",2411,O
Mz-ChA-1,2411,B-CellLine
cells,2411,O
were,2411,O
stimulated,2411,O
with,2411,O
RAMH,2411,B-ChemicalEntity
before,2411,O
evaluating,2411,O
cell,2411,O
growth,2411,O
and,2411,O
extracellular,2411,B-GeneOrGeneProduct
signal-regulated,2411,I-GeneOrGeneProduct
kinase,2411,I-GeneOrGeneProduct
(,2411,I-GeneOrGeneProduct
ERK,2411,I-GeneOrGeneProduct
),2411,I-GeneOrGeneProduct
-1/2,2411,I-GeneOrGeneProduct
phosphorylation,2411,O
.,2411,O
In,2412,O
vivo,2412,O
experiments,2412,O
were,2412,O
done,2412,O
in,2412,O
BALB/c,2412,B-CellLine
nude,2412,O
mice,2412,B-OrganismTaxon
.,2412,O
Mice,2413,B-OrganismTaxon
were,2413,O
treated,2413,O
with,2413,O
saline,2413,O
or,2413,O
RAMH,2413,B-ChemicalEntity
for,2413,O
44,2413,O
days,2413,O
and,2413,O
tumor,2413,B-DiseaseOrPhenotypicFeature
volume,2413,O
was,2413,O
measured,2413,O
.,2413,O
Tumors,2414,B-DiseaseOrPhenotypicFeature
were,2414,O
excised,2414,O
and,2414,O
evaluated,2414,O
for,2414,O
proliferation,2414,O
",",2414,O
apoptosis,2414,O
",",2414,O
and,2414,O
expression,2414,O
of,2414,O
PKCalpha,2414,B-GeneOrGeneProduct
",",2414,O
vascular,2414,B-GeneOrGeneProduct
endothelial,2414,I-GeneOrGeneProduct
growth,2414,I-GeneOrGeneProduct
factor,2414,I-GeneOrGeneProduct
(,2414,I-GeneOrGeneProduct
VEGF,2414,I-GeneOrGeneProduct
),2414,I-GeneOrGeneProduct
-A,2414,I-GeneOrGeneProduct
",",2414,O
VEGF-C,2414,B-GeneOrGeneProduct
",",2414,O
VEGF,2414,B-GeneOrGeneProduct
receptor,2414,I-GeneOrGeneProduct
2,2414,I-GeneOrGeneProduct
",",2414,O
and,2414,O
VEGF,2414,B-GeneOrGeneProduct
receptor,2414,I-GeneOrGeneProduct
3,2414,I-GeneOrGeneProduct
.,2414,O
HRH3,2415,B-GeneOrGeneProduct
expression,2415,O
was,2415,O
found,2415,O
in,2415,O
all,2415,O
cells,2415,O
.,2415,O
RAMH,2416,B-ChemicalEntity
inhibited,2416,O
the,2416,O
growth,2416,O
of,2416,O
cholangiocarcinoma,2416,B-DiseaseOrPhenotypicFeature
cells,2416,O
.,2416,O
RAMH,2417,B-ChemicalEntity
increased,2417,O
IP,2417,B-ChemicalEntity
(,2417,I-ChemicalEntity
3,2417,I-ChemicalEntity
),2417,I-ChemicalEntity
levels,2417,O
and,2417,O
PKCalpha,2417,B-GeneOrGeneProduct
phosphorylation,2417,O
and,2417,O
decreased,2417,O
ERK1/2,2417,B-GeneOrGeneProduct
phosphorylation,2417,O
.,2417,O
RAMH,2418,B-ChemicalEntity
induced,2418,O
a,2418,O
shift,2418,O
in,2418,O
the,2418,O
localization,2418,O
of,2418,O
PKCalpha,2418,B-GeneOrGeneProduct
expression,2418,O
from,2418,O
the,2418,O
cytosolic,2418,O
domain,2418,O
into,2418,O
the,2418,O
membrane,2418,O
region,2418,O
of,2418,O
Mz-ChA-1,2418,B-CellLine
cells,2418,O
.,2418,O
Silencing,2419,O
of,2419,O
PKCalpha,2419,B-GeneOrGeneProduct
prevented,2419,O
RAMH,2419,B-ChemicalEntity
inhibition,2419,O
of,2419,O
Mz-ChA-1,2419,B-CellLine
cell,2419,O
growth,2419,O
and,2419,O
ablated,2419,O
RAMH,2419,B-ChemicalEntity
effects,2419,O
on,2419,O
ERK1/2,2419,B-GeneOrGeneProduct
phosphorylation,2419,O
.,2419,O
In,2420,O
vivo,2420,O
",",2420,O
RAMH,2420,B-ChemicalEntity
decreased,2420,O
tumor,2420,B-DiseaseOrPhenotypicFeature
growth,2420,O
and,2420,O
expression,2420,O
of,2420,O
VEGF,2420,B-GeneOrGeneProduct
and,2420,O
its,2420,O
receptors,2420,O
;,2420,O
PKCalpha,2420,B-GeneOrGeneProduct
expression,2420,O
was,2420,O
increased,2420,O
.,2420,O
RAMH,2421,B-ChemicalEntity
inhibits,2421,O
cholangiocarcinoma,2421,B-DiseaseOrPhenotypicFeature
growth,2421,O
by,2421,O
PKCalpha-dependent,2421,B-GeneOrGeneProduct
ERK1/2,2421,B-GeneOrGeneProduct
dephosphorylation,2421,O
.,2421,O
Modulation,2422,O
of,2422,O
PKCalpha,2422,B-GeneOrGeneProduct
by,2422,O
histamine,2422,B-GeneOrGeneProduct
receptors,2422,I-GeneOrGeneProduct
may,2422,O
be,2422,O
important,2422,O
in,2422,O
regulating,2422,O
cholangiocarcinoma,2422,B-DiseaseOrPhenotypicFeature
growth,2422,O
.,2422,O
Smoking,2423,O
of,2423,O
crack,2423,B-ChemicalEntity
cocaine,2423,I-ChemicalEntity
as,2423,O
a,2423,O
risk,2423,O
factor,2423,O
for,2423,O
HIV,2423,B-DiseaseOrPhenotypicFeature
infection,2423,I-DiseaseOrPhenotypicFeature
among,2423,O
people,2423,O
who,2423,O
use,2423,O
injection,2423,O
drugs,2423,O
.,2423,O
BACKGROUND,2424,O
:,2424,O
Little,2424,O
is,2424,O
known,2424,O
about,2424,O
the,2424,O
possible,2424,O
role,2424,O
that,2424,O
smoking,2424,O
crack,2424,B-ChemicalEntity
cocaine,2424,I-ChemicalEntity
has,2424,O
on,2424,O
the,2424,O
incidence,2424,O
of,2424,O
HIV,2424,B-DiseaseOrPhenotypicFeature
infection,2424,I-DiseaseOrPhenotypicFeature
.,2424,O
Given,2425,O
the,2425,O
increasing,2425,O
use,2425,O
of,2425,O
crack,2425,B-ChemicalEntity
cocaine,2425,I-ChemicalEntity
",",2425,O
we,2425,O
sought,2425,O
to,2425,O
examine,2425,O
whether,2425,O
use,2425,O
of,2425,O
this,2425,O
illicit,2425,O
drug,2425,O
has,2425,O
become,2425,O
a,2425,O
risk,2425,O
factor,2425,O
for,2425,O
HIV,2425,B-DiseaseOrPhenotypicFeature
infection,2425,I-DiseaseOrPhenotypicFeature
.,2425,O
METHODS,2426,O
:,2426,O
We,2426,O
included,2426,O
data,2426,O
from,2426,O
people,2426,O
participating,2426,O
in,2426,O
the,2426,O
Vancouver,2426,O
Injection,2426,O
Drug,2426,O
Users,2426,O
Study,2426,O
who,2426,O
reported,2426,O
injecting,2426,O
illicit,2426,O
drugs,2426,O
at,2426,O
least,2426,O
once,2426,O
in,2426,O
the,2426,O
month,2426,O
before,2426,O
enrolment,2426,O
",",2426,O
lived,2426,O
in,2426,O
the,2426,O
greater,2426,O
Vancouver,2426,O
area,2426,O
",",2426,O
were,2426,O
HIV-negative,2426,B-DiseaseOrPhenotypicFeature
at,2426,O
enrolment,2426,O
and,2426,O
completed,2426,O
at,2426,O
least,2426,O
1,2426,O
follow-up,2426,O
study,2426,O
visit,2426,O
.,2426,O
To,2427,O
determine,2427,O
whether,2427,O
the,2427,O
risk,2427,O
of,2427,O
HIV,2427,B-DiseaseOrPhenotypicFeature
seroconversion,2427,I-DiseaseOrPhenotypicFeature
among,2427,O
daily,2427,O
smokers,2427,O
of,2427,O
crack,2427,B-ChemicalEntity
cocaine,2427,I-ChemicalEntity
changed,2427,O
over,2427,O
time,2427,O
",",2427,O
we,2427,O
used,2427,O
Cox,2427,O
proportional,2427,O
hazards,2427,O
regression,2427,O
and,2427,O
divided,2427,O
the,2427,O
study,2427,O
into,2427,O
3,2427,O
periods,2427,O
:,2427,O
May,2427,O
1,2427,O
",",2427,O
1996-Nov.,2427,O
30,2427,O
",",2427,O
1999,2427,O
(,2427,O
period,2427,O
1,2427,O
),2427,O
",",2427,O
Dec.,2427,O
1,2427,O
",",2427,O
1999-Nov.,2427,O
30,2427,O
",",2427,O
2002,2427,O
(,2427,O
period,2427,O
2,2427,O
),2427,O
",",2427,O
and,2427,O
Dec.,2427,O
1,2427,O
",",2427,O
2002-Dec.,2427,O
30,2427,O
",",2427,O
2005,2427,O
(,2427,O
period,2427,O
3,2427,O
),2427,O
.,2427,O
RESULTS,2428,O
:,2428,O
Overall,2428,O
",",2428,O
1048,2428,O
eligible,2428,O
injection,2428,O
drug,2428,O
users,2428,O
were,2428,O
included,2428,O
in,2428,O
our,2428,O
study,2428,O
.,2428,O
Of,2429,O
these,2429,O
",",2429,O
137,2429,O
acquired,2429,O
HIV,2429,B-DiseaseOrPhenotypicFeature
infection,2429,I-DiseaseOrPhenotypicFeature
during,2429,O
follow-up,2429,O
.,2429,O
The,2430,O
mean,2430,O
proportion,2430,O
of,2430,O
participants,2430,O
who,2430,O
reported,2430,O
daily,2430,O
smoking,2430,O
of,2430,O
crack,2430,B-ChemicalEntity
cocaine,2430,I-ChemicalEntity
increased,2430,O
from,2430,O
11.6,2430,O
%,2430,O
in,2430,O
period,2430,O
1,2430,O
to,2430,O
39.7,2430,O
%,2430,O
in,2430,O
period,2430,O
3,2430,O
.,2430,O
After,2431,O
adjusting,2431,O
for,2431,O
potential,2431,O
confounders,2431,O
",",2431,O
we,2431,O
found,2431,O
that,2431,O
the,2431,O
risk,2431,O
of,2431,O
HIV,2431,B-DiseaseOrPhenotypicFeature
seroconversion,2431,I-DiseaseOrPhenotypicFeature
among,2431,O
participants,2431,O
who,2431,O
were,2431,O
daily,2431,O
smokers,2431,O
of,2431,O
crack,2431,B-ChemicalEntity
cocaine,2431,I-ChemicalEntity
increased,2431,O
over,2431,O
time,2431,O
(,2431,O
period,2431,O
1,2431,O
:,2431,O
hazard,2431,O
ratio,2431,O
[,2431,O
HR,2431,O
],2431,O
1.03,2431,O
",",2431,O
95,2431,O
%,2431,O
confidence,2431,O
interval,2431,O
[,2431,O
CI,2431,O
],2431,O
0.57-1.85,2431,O
;,2431,O
period,2431,O
2,2431,O
:,2431,O
HR,2431,O
1.68,2431,O
",",2431,O
95,2431,O
%,2431,O
CI,2431,O
1.01-2.80,2431,O
;,2431,O
and,2431,O
period,2431,O
3,2431,O
:,2431,O
HR,2431,O
2.74,2431,O
",",2431,O
95,2431,O
%,2431,O
CI,2431,O
1.06-7.11,2431,O
),2431,O
.,2431,O
INTERPRETATION,2432,O
:,2432,O
Smoking,2432,O
of,2432,O
crack,2432,B-ChemicalEntity
cocaine,2432,I-ChemicalEntity
was,2432,O
found,2432,O
to,2432,O
be,2432,O
an,2432,O
independent,2432,O
risk,2432,O
factor,2432,O
for,2432,O
HIV,2432,B-DiseaseOrPhenotypicFeature
seroconversion,2432,I-DiseaseOrPhenotypicFeature
among,2432,O
people,2432,O
who,2432,O
were,2432,O
injection,2432,O
drug,2432,O
users,2432,O
.,2432,O
This,2433,O
finding,2433,O
points,2433,O
to,2433,O
the,2433,O
urgent,2433,O
need,2433,O
for,2433,O
evidence-based,2433,O
public,2433,O
health,2433,O
initiatives,2433,O
targeted,2433,O
at,2433,O
people,2433,O
who,2433,O
smoke,2433,O
crack,2433,B-ChemicalEntity
cocaine,2433,I-ChemicalEntity
.,2433,O
hOGG1,2434,B-GeneOrGeneProduct
Ser326Cys,2434,B-SequenceVariant
polymorphism,2434,O
and,2434,O
risk,2434,O
of,2434,O
lung,2434,B-DiseaseOrPhenotypicFeature
cancer,2434,I-DiseaseOrPhenotypicFeature
by,2434,O
histological,2434,O
type,2434,O
.,2434,O
Human,2435,B-OrganismTaxon
8-oxoguanine,2435,B-GeneOrGeneProduct
DNA,2435,I-GeneOrGeneProduct
glycosylase,2435,I-GeneOrGeneProduct
1,2435,I-GeneOrGeneProduct
(,2435,O
hOGG1,2435,B-GeneOrGeneProduct
),2435,O
has,2435,O
a,2435,O
major,2435,O
role,2435,O
in,2435,O
the,2435,O
repair,2435,O
of,2435,O
8-hydroxyguanine,2435,B-ChemicalEntity
",",2435,O
a,2435,O
major,2435,O
promutagenic,2435,O
DNA,2435,O
lesion,2435,O
.,2435,O
The,2436,O
genetic,2436,O
polymorphism,2436,O
rs1052133,2436,B-SequenceVariant
",",2436,O
which,2436,O
leads,2436,O
to,2436,O
substitution,2436,O
of,2436,O
the,2436,O
amino,2436,O
acid,2436,O
at,2436,O
codon,2436,O
326,2436,B-SequenceVariant
from,2436,I-SequenceVariant
Ser,2436,I-SequenceVariant
to,2436,I-SequenceVariant
Cys,2436,I-SequenceVariant
",",2436,O
shows,2436,O
functional,2436,O
differences,2436,O
",",2436,O
namely,2436,O
a,2436,O
decrease,2436,O
in,2436,O
enzyme,2436,O
activity,2436,O
in,2436,O
hOGG1-Cys326,2436,B-GeneOrGeneProduct
.,2436,O
Although,2437,O
several,2437,O
studies,2437,O
have,2437,O
investigated,2437,O
the,2437,O
association,2437,O
between,2437,O
rs1052133,2437,B-SequenceVariant
and,2437,O
lung,2437,B-DiseaseOrPhenotypicFeature
cancer,2437,I-DiseaseOrPhenotypicFeature
susceptibility,2437,O
",",2437,O
the,2437,O
effect,2437,O
of,2437,O
this,2437,O
locus,2437,O
on,2437,O
lung,2437,B-DiseaseOrPhenotypicFeature
cancer,2437,I-DiseaseOrPhenotypicFeature
according,2437,O
to,2437,O
histology,2437,O
remains,2437,O
unclear,2437,O
.,2437,O
We,2438,O
therefore,2438,O
conducted,2438,O
a,2438,O
case-control,2438,O
study,2438,O
with,2438,O
515,2438,O
incident,2438,O
lung,2438,B-DiseaseOrPhenotypicFeature
cancer,2438,I-DiseaseOrPhenotypicFeature
cases,2438,O
and,2438,O
1030,2438,O
age-,2438,O
and,2438,O
sex-matched,2438,O
controls,2438,O
without,2438,O
cancer,2438,B-DiseaseOrPhenotypicFeature
",",2438,O
and,2438,O
further,2438,O
conducted,2438,O
a,2438,O
meta-analysis,2438,O
.,2438,O
In,2439,O
overall,2439,O
analysis,2439,O
",",2439,O
the,2439,O
homozygous,2439,O
Cys/Cys,2439,O
genotype,2439,O
showed,2439,O
a,2439,O
significant,2439,O
association,2439,O
with,2439,O
lung,2439,B-DiseaseOrPhenotypicFeature
cancer,2439,I-DiseaseOrPhenotypicFeature
compared,2439,O
to,2439,O
Ser,2439,O
allele,2439,O
carrier,2439,O
status,2439,O
(,2439,O
odds,2439,O
ratio,2439,O
(,2439,O
OR,2439,O
),2439,O
=1.31,2439,O
",",2439,O
95,2439,O
%,2439,O
confidence,2439,O
interval,2439,O
(,2439,O
CI,2439,O
),2439,O
=1.02-1.69,2439,O
),2439,O
.,2439,O
By,2440,O
histology-based,2440,O
analysis,2440,O
",",2440,O
the,2440,O
Cys/Cys,2440,O
genotype,2440,O
showed,2440,O
a,2440,O
significantly,2440,O
positive,2440,O
association,2440,O
with,2440,O
small-cell,2440,B-DiseaseOrPhenotypicFeature
carcinoma,2440,I-DiseaseOrPhenotypicFeature
(,2440,O
OR=2.40,2440,O
",",2440,O
95,2440,O
%,2440,O
CI=1.32-4.49,2440,O
),2440,O
and,2440,O
marginally,2440,O
significant,2440,O
association,2440,O
with,2440,O
adenocarcinoma,2440,B-DiseaseOrPhenotypicFeature
(,2440,O
OR=1.32,2440,O
",",2440,O
95,2440,O
%,2440,O
CI=0.98-1.77,2440,O
),2440,O
.,2440,O
A,2441,O
meta-analysis,2441,O
of,2441,O
previous,2441,O
and,2441,O
our,2441,O
present,2441,O
study,2441,O
revealed,2441,O
that,2441,O
this,2441,O
polymorphism,2441,O
is,2441,O
positively,2441,O
associated,2441,O
with,2441,O
adenocarcinoma,2441,B-DiseaseOrPhenotypicFeature
",",2441,O
although,2441,O
suggestive,2441,O
associations,2441,O
were,2441,O
also,2441,O
found,2441,O
for,2441,O
squamous-,2441,B-DiseaseOrPhenotypicFeature
and,2441,I-DiseaseOrPhenotypicFeature
small-cell,2441,I-DiseaseOrPhenotypicFeature
lung,2441,I-DiseaseOrPhenotypicFeature
cancers,2441,I-DiseaseOrPhenotypicFeature
.,2441,O
These,2442,O
results,2442,O
indicate,2442,O
that,2442,O
rs1052133,2442,B-SequenceVariant
contributes,2442,O
to,2442,O
the,2442,O
risk,2442,O
of,2442,O
adenocarcinoma,2442,B-DiseaseOrPhenotypicFeature
of,2442,I-DiseaseOrPhenotypicFeature
lung,2442,I-DiseaseOrPhenotypicFeature
.,2442,O
Differential,2443,O
impact,2443,O
of,2443,O
immune,2443,O
escape,2443,O
mutations,2443,O
G145R,2443,B-SequenceVariant
and,2443,O
P120T,2443,B-SequenceVariant
on,2443,O
the,2443,O
replication,2443,O
of,2443,O
lamivudine-resistant,2443,B-ChemicalEntity
hepatitis,2443,B-ChemicalEntity
B,2443,I-ChemicalEntity
virus,2443,I-ChemicalEntity
e,2443,I-ChemicalEntity
antigen-positive,2443,O
and,2443,O
-negative,2443,O
strains,2443,O
.,2443,O
Immune,2444,O
escape,2444,O
variants,2444,O
of,2444,O
the,2444,O
hepatitis,2444,B-OrganismTaxon
B,2444,I-OrganismTaxon
virus,2444,I-OrganismTaxon
(,2444,O
HBV,2444,B-OrganismTaxon
),2444,O
represent,2444,O
an,2444,O
emerging,2444,O
clinical,2444,O
challenge,2444,O
",",2444,O
because,2444,O
they,2444,O
can,2444,O
be,2444,O
associated,2444,O
with,2444,O
vaccine,2444,O
escape,2444,O
",",2444,O
HBV,2444,B-OrganismTaxon
reactivation,2444,O
",",2444,O
and,2444,O
failure,2444,O
of,2444,O
diagnostic,2444,O
tests,2444,O
.,2444,O
Recent,2445,O
data,2445,O
suggest,2445,O
a,2445,O
preferential,2445,O
selection,2445,O
of,2445,O
immune,2445,O
escape,2445,O
mutants,2445,O
in,2445,O
distinct,2445,O
peripheral,2445,O
blood,2445,O
leukocyte,2445,O
compartments,2445,O
of,2445,O
infected,2445,O
individuals,2445,O
.,2445,O
We,2446,O
therefore,2446,O
systematically,2446,O
analyzed,2446,O
the,2446,O
functional,2446,O
impact,2446,O
of,2446,O
the,2446,O
most,2446,O
prevalent,2446,O
immune,2446,O
escape,2446,O
variants,2446,O
",",2446,O
the,2446,O
sG145R,2446,O
and,2446,O
sP120T,2446,O
mutants,2446,O
",",2446,O
on,2446,O
the,2446,O
viral,2446,O
replication,2446,O
efficacy,2446,O
and,2446,O
antiviral,2446,O
drug,2446,O
susceptibility,2446,O
of,2446,O
common,2446,O
treatment-associated,2446,O
mutants,2446,O
with,2446,O
resistance,2446,O
to,2446,O
lamivudine,2446,B-ChemicalEntity
(,2446,O
LAM,2446,B-ChemicalEntity
),2446,O
and/or,2446,O
HBeAg,2446,B-ChemicalEntity
negativity,2446,O
.,2446,O
Replication-competent,2447,O
HBV,2447,B-OrganismTaxon
strains,2447,O
with,2447,O
sG145R,2447,O
or,2447,O
sP120T,2447,O
and,2447,O
LAM,2447,B-ChemicalEntity
resistance,2447,O
(,2447,O
rtM204I,2447,O
or,2447,O
rtL180M/rtM204V,2447,O
),2447,O
were,2447,O
generated,2447,O
on,2447,O
an,2447,O
HBeAg-positive,2447,B-ChemicalEntity
and,2447,O
an,2447,O
HBeAg-negative,2447,B-ChemicalEntity
background,2447,O
with,2447,O
precore,2447,B-GeneOrGeneProduct
(,2447,O
PC,2447,B-GeneOrGeneProduct
),2447,O
and,2447,O
basal,2447,O
core,2447,O
promoter,2447,O
(,2447,O
BCP,2447,O
),2447,O
mutants,2447,O
.,2447,O
The,2448,O
sG145R,2448,O
mutation,2448,O
strongly,2448,O
reduced,2448,O
HBsAg,2448,B-ChemicalEntity
levels,2448,O
and,2448,O
was,2448,O
able,2448,O
to,2448,O
fully,2448,O
restore,2448,O
the,2448,O
impaired,2448,O
replication,2448,O
of,2448,O
LAM-resistant,2448,B-ChemicalEntity
HBV,2448,B-OrganismTaxon
mutants,2448,O
to,2448,O
the,2448,O
levels,2448,O
of,2448,O
wild-type,2448,O
HBV,2448,B-OrganismTaxon
",",2448,O
and,2448,O
PC,2448,B-GeneOrGeneProduct
or,2448,O
BCP,2448,O
mutations,2448,O
further,2448,O
enhanced,2448,O
viral,2448,O
replication,2448,O
.,2448,O
Although,2449,O
the,2449,O
sP120T,2449,O
substitution,2449,O
also,2449,O
impaired,2449,O
HBsAg,2449,B-ChemicalEntity
secretion,2449,O
",",2449,O
it,2449,O
did,2449,O
not,2449,O
enhance,2449,O
the,2449,O
replication,2449,O
of,2449,O
LAM-resistant,2449,B-ChemicalEntity
clones,2449,O
.,2449,O
However,2450,O
",",2450,O
the,2450,O
concomitant,2450,O
occurrence,2450,O
of,2450,O
HBeAg,2450,B-ChemicalEntity
negativity,2450,O
(,2450,O
PC/BCP,2450,B-GeneOrGeneProduct
),2450,O
",",2450,O
sP120T,2450,O
",",2450,O
and,2450,O
LAM,2450,B-ChemicalEntity
resistance,2450,O
resulted,2450,O
in,2450,O
the,2450,O
restoration,2450,O
of,2450,O
replication,2450,O
to,2450,O
levels,2450,O
of,2450,O
wild-type,2450,O
HBV,2450,B-OrganismTaxon
.,2450,O
In,2451,O
all,2451,O
clones,2451,O
with,2451,O
combined,2451,O
immune,2451,O
escape,2451,O
and,2451,O
LAM,2451,B-ChemicalEntity
resistance,2451,O
mutations,2451,O
",",2451,O
the,2451,O
nucleotide,2451,O
analogues,2451,O
adefovir,2451,B-ChemicalEntity
and,2451,O
tenofovir,2451,B-ChemicalEntity
remained,2451,O
effective,2451,O
in,2451,O
suppressing,2451,O
viral,2451,O
replication,2451,O
in,2451,O
vitro,2451,O
.,2451,O
These,2452,O
findings,2452,O
reveal,2452,O
the,2452,O
differential,2452,O
impact,2452,O
of,2452,O
immune,2452,O
escape,2452,O
variants,2452,O
on,2452,O
the,2452,O
replication,2452,O
and,2452,O
drug,2452,O
susceptibility,2452,O
of,2452,O
complex,2452,O
HBV,2452,B-OrganismTaxon
mutants,2452,O
",",2452,O
supporting,2452,O
the,2452,O
need,2452,O
of,2452,O
close,2452,O
surveillance,2452,O
and,2452,O
treatment,2452,O
adjustment,2452,O
in,2452,O
response,2452,O
to,2452,O
the,2452,O
selection,2452,O
of,2452,O
distinct,2452,O
mutational,2452,O
patterns,2452,O
.,2452,O
Clopidogrel,2453,B-ChemicalEntity
pharmacogenomics,2453,O
and,2453,O
risk,2453,O
of,2453,O
inadequate,2453,O
platelet,2453,O
inhibition,2453,O
:,2453,O
US,2453,O
FDA,2453,O
recommendations,2453,O
.,2453,O
Antiplatelet,2454,O
therapy,2454,O
with,2454,O
clopidogrel,2454,B-ChemicalEntity
is,2454,O
the,2454,O
current,2454,O
standard,2454,O
of,2454,O
care,2454,O
for,2454,O
coronary,2454,B-DiseaseOrPhenotypicFeature
artery,2454,I-DiseaseOrPhenotypicFeature
disease,2454,I-DiseaseOrPhenotypicFeature
patients,2454,B-OrganismTaxon
undergoing,2454,O
a,2454,O
percutaneous,2454,O
coronary,2454,O
intervention,2454,O
.,2454,O
However,2455,O
",",2455,O
approximately,2455,O
25,2455,O
%,2455,O
of,2455,O
patients,2455,B-OrganismTaxon
experience,2455,O
a,2455,O
subtherapeutic,2455,O
antiplatelet,2455,O
response,2455,O
.,2455,O
Clopidogrel,2456,B-ChemicalEntity
is,2456,O
a,2456,O
prodrug,2456,O
that,2456,O
undergoes,2456,O
hepatic,2456,O
biotransformation,2456,O
by,2456,O
CYP2C19,2456,B-GeneOrGeneProduct
into,2456,O
its,2456,O
active,2456,O
metabolite,2456,O
.,2456,O
Several,2457,O
studies,2457,O
have,2457,O
reported,2457,O
that,2457,O
",",2457,O
compared,2457,O
with,2457,O
wild-type,2457,O
individuals,2457,O
",",2457,O
CYP2C19,2457,B-GeneOrGeneProduct
variant,2457,O
allele,2457,O
carriers,2457,O
exhibit,2457,O
a,2457,O
significantly,2457,O
lower,2457,O
capacity,2457,O
to,2457,O
metabolize,2457,O
clopidogrel,2457,B-ChemicalEntity
into,2457,O
its,2457,O
active,2457,O
metabolite,2457,O
and,2457,O
inhibit,2457,O
platelet,2457,O
activation,2457,O
",",2457,O
and,2457,O
are,2457,O
therefore,2457,O
at,2457,O
significantly,2457,O
higher,2457,O
risk,2457,O
of,2457,O
adverse,2457,O
cardiovascular,2457,O
events,2457,O
.,2457,O
Consequently,2458,O
",",2458,O
the,2458,O
US,2458,O
FDA,2458,O
has,2458,O
recently,2458,O
changed,2458,O
clopidogrel,2458,B-ChemicalEntity
's,2458,O
prescribing,2458,O
information,2458,O
to,2458,O
highlight,2458,O
the,2458,O
impact,2458,O
of,2458,O
CYP2C19,2458,B-GeneOrGeneProduct
genotype,2458,O
on,2458,O
clopidogrel,2458,B-ChemicalEntity
pharmacokinetics,2458,O
",",2458,O
pharmacodynamics,2458,O
and,2458,O
clinical,2458,O
response,2458,O
.,2458,O
Future,2459,O
studies,2459,O
remain,2459,O
necessary,2459,O
to,2459,O
develop,2459,O
effective,2459,O
personalized,2459,O
therapeutic,2459,O
strategies,2459,O
for,2459,O
CYP2C19,2459,B-GeneOrGeneProduct
variant,2459,O
allele,2459,O
carriers,2459,O
and,2459,O
other,2459,O
individuals,2459,O
at,2459,O
risk,2459,O
for,2459,O
clopidogrel,2459,B-ChemicalEntity
nonresponsiveness,2459,O
.,2459,O
FGFR4,2460,B-GeneOrGeneProduct
Gly388Arg,2460,B-SequenceVariant
polymorphism,2460,O
and,2460,O
prostate,2460,B-DiseaseOrPhenotypicFeature
cancer,2460,I-DiseaseOrPhenotypicFeature
risk,2460,O
in,2460,O
Scottish,2460,O
men,2460,B-OrganismTaxon
.,2460,O
Fibroblast,2461,B-GeneOrGeneProduct
growth,2461,I-GeneOrGeneProduct
factor,2461,I-GeneOrGeneProduct
receptor,2461,I-GeneOrGeneProduct
4,2461,I-GeneOrGeneProduct
(,2461,O
FGFR4,2461,B-GeneOrGeneProduct
),2461,O
",",2461,O
a,2461,O
member,2461,O
of,2461,O
the,2461,O
fibroblast,2461,B-GeneOrGeneProduct
growth,2461,I-GeneOrGeneProduct
receptor,2461,I-GeneOrGeneProduct
family,2461,O
",",2461,O
was,2461,O
recently,2461,O
reported,2461,O
to,2461,O
be,2461,O
more,2461,O
abundantly,2461,O
expressed,2461,O
in,2461,O
malignant,2461,O
than,2461,O
benign,2461,O
prostate,2461,O
cells,2461,O
.,2461,O
A,2462,O
single,2462,O
nucleotide,2462,O
polymorphism,2462,O
at,2462,O
position,2462,O
388,2462,O
of,2462,O
the,2462,O
FGFR4,2462,B-GeneOrGeneProduct
amino-acid,2462,O
sequence,2462,O
results,2462,O
in,2462,O
the,2462,O
substitution,2462,O
of,2462,O
glycine,2462,B-SequenceVariant
(,2462,I-SequenceVariant
Gly,2462,I-SequenceVariant
),2462,I-SequenceVariant
with,2462,I-SequenceVariant
arginine,2462,I-SequenceVariant
(,2462,I-SequenceVariant
Arg,2462,I-SequenceVariant
),2462,I-SequenceVariant
and,2462,O
higher,2462,O
frequency,2462,O
of,2462,O
the,2462,O
ArgArg,2462,O
genotype,2462,O
was,2462,O
previously,2462,O
found,2462,O
in,2462,O
prostate,2462,B-DiseaseOrPhenotypicFeature
cancer,2462,I-DiseaseOrPhenotypicFeature
patients,2462,B-OrganismTaxon
.,2462,O
DNA,2463,O
was,2463,O
extracted,2463,O
from,2463,O
the,2463,O
blood,2463,O
drawn,2463,O
from,2463,O
399,2463,O
prostate,2463,B-DiseaseOrPhenotypicFeature
cancer,2463,I-DiseaseOrPhenotypicFeature
patients,2463,B-OrganismTaxon
",",2463,O
150,2463,O
BPH,2463,B-DiseaseOrPhenotypicFeature
patients,2463,B-OrganismTaxon
and,2463,O
294,2463,O
healthy,2463,O
community,2463,O
controls,2463,O
.,2463,O
Polymerase,2464,O
chain,2464,O
reaction,2464,O
was,2464,O
carried,2464,O
out,2464,O
and,2464,O
single,2464,O
nucleotide,2464,O
polymorphisms,2464,O
of,2464,O
FGFR4,2464,B-GeneOrGeneProduct
were,2464,O
identified,2464,O
by,2464,O
restriction,2464,O
enzyme,2464,O
digestion,2464,O
.,2464,O
No,2465,O
overall,2465,O
association,2465,O
is,2465,O
detectable,2465,O
between,2465,O
the,2465,O
Arg,2465,O
allele,2465,O
and,2465,O
increased,2465,O
prostate,2465,B-DiseaseOrPhenotypicFeature
cancer,2465,I-DiseaseOrPhenotypicFeature
risk,2465,O
.,2465,O
Subgroup,2466,O
analysis,2466,O
shows,2466,O
a,2466,O
higher,2466,O
incidence,2466,O
of,2466,O
the,2466,O
heterozygous,2466,O
ArgGly,2466,O
genotype,2466,O
in,2466,O
cancer,2466,B-DiseaseOrPhenotypicFeature
cases,2466,O
than,2466,O
in,2466,O
the,2466,O
combined,2466,O
group,2466,O
of,2466,O
BPH,2466,B-DiseaseOrPhenotypicFeature
and,2466,O
controls,2466,O
(,2466,O
P,2466,O
<,2466,O
0.05,2466,O
),2466,O
;,2466,O
this,2466,O
difference,2466,O
is,2466,O
statistically,2466,O
significant,2466,O
between,2466,O
cancer,2466,B-DiseaseOrPhenotypicFeature
and,2466,O
BPH,2466,B-DiseaseOrPhenotypicFeature
patients,2466,B-OrganismTaxon
but,2466,O
not,2466,O
between,2466,O
cancer,2466,B-DiseaseOrPhenotypicFeature
cases,2466,O
and,2466,O
community,2466,O
controls,2466,O
.,2466,O
The,2467,O
single,2467,O
nucleotide,2467,O
polymorphism,2467,O
Gly,2467,B-SequenceVariant
(,2467,I-SequenceVariant
388,2467,I-SequenceVariant
),2467,I-SequenceVariant
Arg,2467,I-SequenceVariant
in,2467,O
FGFR4,2467,B-GeneOrGeneProduct
is,2467,O
not,2467,O
associated,2467,O
with,2467,O
increased,2467,O
risk,2467,O
of,2467,O
prostate,2467,B-DiseaseOrPhenotypicFeature
cancer,2467,I-DiseaseOrPhenotypicFeature
in,2467,O
Scottish,2467,O
men,2467,B-OrganismTaxon
.,2467,O
This,2468,O
observation,2468,O
is,2468,O
in,2468,O
contrast,2468,O
with,2468,O
results,2468,O
from,2468,O
two,2468,O
previous,2468,O
studies,2468,O
conducted,2468,O
in,2468,O
the,2468,O
USA,2468,O
and,2468,O
Japan,2468,O
.,2468,O
Nimodipine,2469,B-ChemicalEntity
prevents,2469,O
memory,2469,B-DiseaseOrPhenotypicFeature
impairment,2469,I-DiseaseOrPhenotypicFeature
caused,2469,O
by,2469,O
nitroglycerin-induced,2469,B-ChemicalEntity
hypotension,2469,B-DiseaseOrPhenotypicFeature
in,2469,O
adult,2469,O
mice,2469,B-OrganismTaxon
.,2469,O
BACKGROUND,2470,O
:,2470,O
Hypotension,2470,B-DiseaseOrPhenotypicFeature
and,2470,O
a,2470,O
resultant,2470,O
decrease,2470,O
in,2470,O
cerebral,2470,O
blood,2470,O
flow,2470,O
have,2470,O
been,2470,O
implicated,2470,O
in,2470,O
the,2470,O
development,2470,O
of,2470,O
cognitive,2470,B-DiseaseOrPhenotypicFeature
dysfunction,2470,I-DiseaseOrPhenotypicFeature
.,2470,O
We,2471,O
tested,2471,O
the,2471,O
hypothesis,2471,O
that,2471,O
nimodipine,2471,B-ChemicalEntity
(,2471,O
NIMO,2471,B-ChemicalEntity
),2471,O
administered,2471,O
at,2471,O
the,2471,O
onset,2471,O
of,2471,O
nitroglycerin,2471,B-ChemicalEntity
(,2471,O
NTG,2471,B-ChemicalEntity
),2471,O
-induced,2471,O
hypotension,2471,B-DiseaseOrPhenotypicFeature
would,2471,O
preserve,2471,O
long-term,2471,O
associative,2471,O
memory,2471,O
.,2471,O
METHODS,2472,O
:,2472,O
The,2472,O
passive,2472,O
avoidance,2472,O
(,2472,O
PA,2472,O
),2472,O
paradigm,2472,O
was,2472,O
used,2472,O
to,2472,O
assess,2472,O
memory,2472,O
retention,2472,O
.,2472,O
For,2473,O
PA,2473,O
training,2473,O
",",2473,O
latencies,2473,O
(,2473,O
seconds,2473,O
),2473,O
were,2473,O
recorded,2473,O
for,2473,O
entry,2473,O
from,2473,O
a,2473,O
suspended,2473,O
platform,2473,O
into,2473,O
a,2473,O
Plexiglas,2473,O
tube,2473,O
where,2473,O
a,2473,O
shock,2473,O
was,2473,O
automatically,2473,O
delivered,2473,O
.,2473,O
Latencies,2474,O
were,2474,O
recorded,2474,O
48,2474,O
h,2474,O
later,2474,O
for,2474,O
a,2474,O
testing,2474,O
trial,2474,O
.,2474,O
Ninety-six,2475,O
Swiss-Webster,2475,O
mice,2475,B-OrganismTaxon
(,2475,O
30-35,2475,O
g,2475,O
",",2475,O
6-8,2475,O
wk,2475,O
),2475,O
",",2475,O
were,2475,O
randomized,2475,O
into,2475,O
6,2475,O
groups,2475,O
1,2475,O
),2475,O
saline,2475,O
(,2475,O
control,2475,O
),2475,O
",",2475,O
2,2475,O
),2475,O
NTG,2475,B-ChemicalEntity
immediately,2475,O
after,2475,O
learning,2475,O
",",2475,O
3,2475,O
),2475,O
NTG,2475,B-ChemicalEntity
3,2475,O
h,2475,O
after,2475,O
learning,2475,O
",",2475,O
4,2475,O
),2475,O
NTG,2475,B-ChemicalEntity
and,2475,O
NIMO,2475,B-ChemicalEntity
",",2475,O
5,2475,O
),2475,O
vehicle,2475,O
",",2475,O
and,2475,O
6,2475,O
),2475,O
NIMO,2475,B-ChemicalEntity
alone,2475,O
.,2475,O
The,2476,O
extent,2476,O
of,2476,O
hypotension,2476,B-DiseaseOrPhenotypicFeature
and,2476,O
changes,2476,O
in,2476,O
brain,2476,O
tissue,2476,O
oxygenation,2476,O
(,2476,O
PbtO,2476,O
(,2476,O
2,2476,O
),2476,O
),2476,O
and,2476,O
in,2476,O
cerebral,2476,O
blood,2476,O
flow,2476,O
were,2476,O
studied,2476,O
in,2476,O
a,2476,O
separate,2476,O
group,2476,O
of,2476,O
animals,2476,O
.,2476,O
RESULTS,2477,O
:,2477,O
All,2477,O
groups,2477,O
exhibited,2477,O
similar,2477,O
training,2477,O
latencies,2477,O
(,2477,O
17.0,2477,O
+/-,2477,O
4.6,2477,O
s,2477,O
),2477,O
.,2477,O
Mice,2478,B-OrganismTaxon
subjected,2478,O
to,2478,O
hypotensive,2478,B-DiseaseOrPhenotypicFeature
episodes,2478,O
showed,2478,O
a,2478,O
significant,2478,O
decrease,2478,O
in,2478,O
latency,2478,O
time,2478,O
(,2478,O
178,2478,O
+/-,2478,O
156,2478,O
s,2478,O
),2478,O
compared,2478,O
with,2478,O
those,2478,O
injected,2478,O
with,2478,O
saline,2478,O
",",2478,O
NTG,2478,B-ChemicalEntity
+,2478,O
NIMO,2478,B-ChemicalEntity
",",2478,O
or,2478,O
delayed,2478,O
NTG,2478,B-ChemicalEntity
(,2478,O
580,2478,O
+/-,2478,O
81,2478,O
s,2478,O
",",2478,O
557,2478,O
+/-,2478,O
67,2478,O
s,2478,O
",",2478,O
and,2478,O
493,2478,O
+/-,2478,O
146,2478,O
s,2478,O
",",2478,O
respectively,2478,O
),2478,O
.,2478,O
A,2479,O
Kruskal-Wallis,2479,O
1-way,2479,O
analysis,2479,O
of,2479,O
variance,2479,O
indicated,2479,O
a,2479,O
significant,2479,O
difference,2479,O
among,2479,O
the,2479,O
4,2479,O
treatment,2479,O
groups,2479,O
(,2479,O
H,2479,O
=,2479,O
15.34,2479,O
;,2479,O
P,2479,O
<,2479,O
0.001,2479,O
),2479,O
.,2479,O
In,2480,O
a,2480,O
separate,2480,O
group,2480,O
of,2480,O
mice,2480,B-OrganismTaxon
not,2480,O
subjected,2480,O
to,2480,O
behavioral,2480,O
studies,2480,O
",",2480,O
the,2480,O
same,2480,O
dose,2480,O
of,2480,O
NTG,2480,B-ChemicalEntity
(,2480,O
n,2480,O
=,2480,O
3,2480,O
),2480,O
and,2480,O
NTG,2480,B-ChemicalEntity
+,2480,O
NIMO,2480,B-ChemicalEntity
(,2480,O
n,2480,O
=,2480,O
3,2480,O
),2480,O
caused,2480,O
mean,2480,O
arterial,2480,O
blood,2480,O
pressure,2480,O
to,2480,O
decrease,2480,O
from,2480,O
85.9,2480,O
+/-,2480,O
3.8,2480,O
mm,2480,O
Hg,2480,O
sem,2480,O
to,2480,O
31.6,2480,O
+/-,2480,O
0.8,2480,O
mm,2480,O
Hg,2480,O
sem,2480,O
and,2480,O
from,2480,O
86.2,2480,O
+/-,2480,O
3.7,2480,O
mm,2480,O
Hg,2480,O
sem,2480,O
to,2480,O
32.6,2480,O
+/-,2480,O
0.2,2480,O
mm,2480,O
Hg,2480,O
sem,2480,O
",",2480,O
respectively,2480,O
.,2480,O
Mean,2481,O
arterial,2481,O
blood,2481,O
pressure,2481,O
in,2481,O
mice,2481,B-OrganismTaxon
treated,2481,O
with,2481,O
NIMO,2481,B-ChemicalEntity
alone,2481,O
decreased,2481,O
from,2481,O
88.1,2481,O
+/-,2481,O
3.8,2481,O
mm,2481,O
Hg,2481,O
to,2481,O
80.0,2481,O
+/-,2481,O
2.9,2481,O
mm,2481,O
Hg,2481,O
.,2481,O
The,2482,O
intergroup,2482,O
difference,2482,O
was,2482,O
statistically,2482,O
significant,2482,O
(,2482,O
P,2482,O
<,2482,O
0.05,2482,O
),2482,O
.,2482,O
PbtO,2483,O
(,2483,O
2,2483,O
),2483,O
decreased,2483,O
from,2483,O
51.7,2483,O
+/-,2483,O
4.5,2483,O
mm,2483,O
Hg,2483,O
sem,2483,O
to,2483,O
33.8,2483,O
+/-,2483,O
5.2,2483,O
mm,2483,O
Hg,2483,O
sem,2483,O
in,2483,O
the,2483,O
NTG,2483,B-ChemicalEntity
group,2483,O
and,2483,O
from,2483,O
38.6,2483,O
+/-,2483,O
6.1,2483,O
mm,2483,O
Hg,2483,O
sem,2483,O
to,2483,O
25.4,2483,O
+/-,2483,O
2.0,2483,O
mm,2483,O
Hg,2483,O
sem,2483,O
in,2483,O
the,2483,O
NTG,2483,B-ChemicalEntity
+,2483,O
NIMO,2483,B-ChemicalEntity
groups,2483,O
",",2483,O
respectively,2483,O
.,2483,O
There,2484,O
were,2484,O
no,2484,O
significant,2484,O
differences,2484,O
among,2484,O
groups,2484,O
.,2484,O
CONCLUSION,2485,O
:,2485,O
In,2485,O
a,2485,O
PA,2485,O
retention,2485,O
paradigm,2485,O
",",2485,O
the,2485,O
injection,2485,O
of,2485,O
NTG,2485,B-ChemicalEntity
immediately,2485,O
after,2485,O
learning,2485,O
produced,2485,O
a,2485,O
significant,2485,O
impairment,2485,O
of,2485,O
long-term,2485,O
associative,2485,O
memory,2485,O
in,2485,O
mice,2485,B-OrganismTaxon
",",2485,O
whereas,2485,O
delayed,2485,O
induced,2485,O
hypotension,2485,B-DiseaseOrPhenotypicFeature
had,2485,O
no,2485,O
effect,2485,O
.,2485,O
NIMO,2486,B-ChemicalEntity
attenuated,2486,O
the,2486,O
disruption,2486,O
in,2486,O
consolidation,2486,O
of,2486,O
long-term,2486,O
memory,2486,O
caused,2486,O
by,2486,O
NTG,2486,B-ChemicalEntity
but,2486,O
did,2486,O
not,2486,O
improve,2486,O
latency,2486,O
in,2486,O
the,2486,O
absence,2486,O
of,2486,O
hypotension,2486,B-DiseaseOrPhenotypicFeature
.,2486,O
The,2487,O
observed,2487,O
effect,2487,O
of,2487,O
NIMO,2487,B-ChemicalEntity
may,2487,O
have,2487,O
been,2487,O
attributable,2487,O
to,2487,O
the,2487,O
preservation,2487,O
of,2487,O
calcium,2487,B-ChemicalEntity
homeostasis,2487,O
during,2487,O
hypotension,2487,B-DiseaseOrPhenotypicFeature
",",2487,O
because,2487,O
there,2487,O
were,2487,O
no,2487,O
differences,2487,O
in,2487,O
the,2487,O
PbtO,2487,O
(,2487,O
2,2487,O
),2487,O
indices,2487,O
among,2487,O
groups,2487,O
.,2487,O
High-dose,2488,O
tranexamic,2488,B-ChemicalEntity
Acid,2488,I-ChemicalEntity
is,2488,O
associated,2488,O
with,2488,O
nonischemic,2488,O
clinical,2488,O
seizures,2488,B-DiseaseOrPhenotypicFeature
in,2488,O
cardiac,2488,O
surgical,2488,O
patients,2488,B-OrganismTaxon
.,2488,O
BACKGROUND,2489,O
:,2489,O
In,2489,O
2,2489,O
separate,2489,O
centers,2489,O
",",2489,O
we,2489,O
observed,2489,O
a,2489,O
notable,2489,O
increase,2489,O
in,2489,O
the,2489,O
incidence,2489,O
of,2489,O
postoperative,2489,O
convulsive,2489,B-DiseaseOrPhenotypicFeature
seizures,2489,I-DiseaseOrPhenotypicFeature
from,2489,O
1.3,2489,O
%,2489,O
to,2489,O
3.8,2489,O
%,2489,O
in,2489,O
patients,2489,B-OrganismTaxon
having,2489,O
undergone,2489,O
major,2489,O
cardiac,2489,O
surgical,2489,O
procedures,2489,O
.,2489,O
These,2490,O
events,2490,O
were,2490,O
temporally,2490,O
coincident,2490,O
with,2490,O
the,2490,O
initial,2490,O
use,2490,O
of,2490,O
high-dose,2490,O
tranexamic,2490,B-ChemicalEntity
acid,2490,I-ChemicalEntity
(,2490,O
TXA,2490,B-ChemicalEntity
),2490,O
therapy,2490,O
after,2490,O
withdrawal,2490,O
of,2490,O
aprotinin,2490,O
from,2490,O
general,2490,O
clinical,2490,O
usage,2490,O
.,2490,O
The,2491,O
purpose,2491,O
of,2491,O
this,2491,O
review,2491,O
was,2491,O
to,2491,O
perform,2491,O
a,2491,O
retrospective,2491,O
analysis,2491,O
to,2491,O
examine,2491,O
whether,2491,O
there,2491,O
was,2491,O
a,2491,O
relation,2491,O
between,2491,O
TXA,2491,B-ChemicalEntity
usage,2491,O
and,2491,O
seizures,2491,B-DiseaseOrPhenotypicFeature
after,2491,O
cardiac,2491,O
surgery,2491,O
.,2491,O
METHODS,2492,O
:,2492,O
An,2492,O
in-depth,2492,O
chart,2492,O
review,2492,O
was,2492,O
undertaken,2492,O
in,2492,O
all,2492,O
24,2492,O
patients,2492,B-OrganismTaxon
who,2492,O
developed,2492,O
perioperative,2492,O
seizures,2492,B-DiseaseOrPhenotypicFeature
.,2492,O
Electroencephalographic,2493,O
activity,2493,O
was,2493,O
recorded,2493,O
in,2493,O
11,2493,O
of,2493,O
these,2493,O
patients,2493,B-OrganismTaxon
",",2493,O
and,2493,O
all,2493,O
patients,2493,B-OrganismTaxon
had,2493,O
a,2493,O
formal,2493,O
neurological,2493,O
evaluation,2493,O
and,2493,O
brain,2493,O
imaging,2493,O
studies,2493,O
.,2493,O
RESULTS,2494,O
:,2494,O
Twenty-one,2494,O
of,2494,O
the,2494,O
24,2494,O
patients,2494,B-OrganismTaxon
did,2494,O
not,2494,O
have,2494,O
evidence,2494,O
of,2494,O
new,2494,O
cerebral,2494,B-DiseaseOrPhenotypicFeature
ischemic,2494,I-DiseaseOrPhenotypicFeature
injury,2494,I-DiseaseOrPhenotypicFeature
",",2494,O
but,2494,O
seizures,2494,B-DiseaseOrPhenotypicFeature
were,2494,O
likely,2494,O
due,2494,O
to,2494,O
ischemic,2494,B-DiseaseOrPhenotypicFeature
brain,2494,I-DiseaseOrPhenotypicFeature
injury,2494,I-DiseaseOrPhenotypicFeature
in,2494,O
3,2494,O
patients,2494,B-OrganismTaxon
.,2494,O
All,2495,O
patients,2495,B-OrganismTaxon
with,2495,O
seizures,2495,B-DiseaseOrPhenotypicFeature
did,2495,O
not,2495,O
have,2495,O
permanent,2495,O
neurological,2495,B-DiseaseOrPhenotypicFeature
abnormalities,2495,I-DiseaseOrPhenotypicFeature
.,2495,O
All,2496,O
24,2496,O
patients,2496,B-OrganismTaxon
with,2496,O
seizures,2496,B-DiseaseOrPhenotypicFeature
received,2496,O
high,2496,O
doses,2496,O
of,2496,O
TXA,2496,B-ChemicalEntity
intraoperatively,2496,O
ranging,2496,O
from,2496,O
61,2496,O
to,2496,O
259,2496,O
mg/kg,2496,O
",",2496,O
had,2496,O
a,2496,O
mean,2496,O
age,2496,O
of,2496,O
69.9,2496,O
years,2496,O
",",2496,O
and,2496,O
21,2496,O
of,2496,O
24,2496,O
had,2496,O
undergone,2496,O
open,2496,O
chamber,2496,O
rather,2496,O
than,2496,O
coronary,2496,O
bypass,2496,O
procedures,2496,O
.,2496,O
All,2497,O
but,2497,O
one,2497,O
patient,2497,B-OrganismTaxon
were,2497,O
managed,2497,O
using,2497,O
cardiopulmonary,2497,O
bypass,2497,O
.,2497,O
No,2498,O
evidence,2498,O
of,2498,O
brain,2498,B-DiseaseOrPhenotypicFeature
ischemic,2498,I-DiseaseOrPhenotypicFeature
",",2498,O
metabolic,2498,O
",",2498,O
or,2498,O
hyperthermia-induced,2498,B-DiseaseOrPhenotypicFeature
causes,2498,O
for,2498,O
their,2498,O
seizures,2498,B-DiseaseOrPhenotypicFeature
was,2498,O
apparent,2498,O
.,2498,O
CONCLUSION,2499,O
:,2499,O
Our,2499,O
results,2499,O
suggest,2499,O
that,2499,O
use,2499,O
of,2499,O
high-dose,2499,O
TXA,2499,B-ChemicalEntity
in,2499,O
older,2499,O
patients,2499,B-OrganismTaxon
in,2499,O
conjunction,2499,O
with,2499,O
cardiopulmonary,2499,O
bypass,2499,O
and,2499,O
open-chamber,2499,O
cardiac,2499,O
surgery,2499,O
is,2499,O
associated,2499,O
with,2499,O
clinical,2499,O
seizures,2499,B-DiseaseOrPhenotypicFeature
in,2499,O
susceptible,2499,O
patients,2499,B-OrganismTaxon
.,2499,O
A,2500,O
potential,2500,O
regulatory,2500,O
single,2500,O
nucleotide,2500,O
polymorphism,2500,O
in,2500,O
the,2500,O
promoter,2500,O
of,2500,O
the,2500,O
Klotho,2500,B-GeneOrGeneProduct
gene,2500,O
may,2500,O
be,2500,O
associated,2500,O
with,2500,O
essential,2500,B-DiseaseOrPhenotypicFeature
hypertension,2500,I-DiseaseOrPhenotypicFeature
in,2500,O
the,2500,O
Chinese,2500,O
Han,2500,O
population,2500,O
.,2500,O
BACKGROUND,2501,O
:,2501,O
Mice,2501,B-OrganismTaxon
with,2501,O
defects,2501,O
in,2501,O
the,2501,O
Klotho,2501,B-GeneOrGeneProduct
gene,2501,O
exhibit,2501,O
multiple,2501,O
aging,2501,O
phenotypes,2501,O
including,2501,O
arteriosclerosis,2501,B-DiseaseOrPhenotypicFeature
.,2501,O
We,2502,O
hypothesised,2502,O
that,2502,O
the,2502,O
G-395A,2502,B-SequenceVariant
polymorphism,2502,O
in,2502,O
the,2502,O
promoter,2502,O
region,2502,O
of,2502,O
the,2502,O
human,2502,B-OrganismTaxon
Klotho,2502,B-GeneOrGeneProduct
gene,2502,O
may,2502,O
contribute,2502,O
to,2502,O
the,2502,O
prevalence,2502,O
of,2502,O
Essential,2502,B-DiseaseOrPhenotypicFeature
Hypertension,2502,I-DiseaseOrPhenotypicFeature
(,2502,O
EH,2502,B-DiseaseOrPhenotypicFeature
),2502,O
.,2502,O
METHODS,2503,O
:,2503,O
We,2503,O
investigate,2503,O
whether,2503,O
the,2503,O
G-395A,2503,B-SequenceVariant
polymorphism,2503,O
of,2503,O
Klotho,2503,B-GeneOrGeneProduct
is,2503,O
associated,2503,O
with,2503,O
EH,2503,B-DiseaseOrPhenotypicFeature
in,2503,O
a,2503,O
population,2503,O
consisting,2503,O
of,2503,O
215,2503,O
patients,2503,B-OrganismTaxon
with,2503,O
EH,2503,B-DiseaseOrPhenotypicFeature
and,2503,O
220,2503,O
non-hypertensive,2503,O
subjects,2503,O
.,2503,O
We,2504,O
also,2504,O
tested,2504,O
whether,2504,O
a,2504,O
G/A,2504,B-SequenceVariant
substitution,2504,O
at,2504,O
the,2504,O
G-395A,2504,B-SequenceVariant
site,2504,O
affected,2504,O
the,2504,O
transcription,2504,O
level,2504,O
in,2504,O
vitro,2504,O
through,2504,O
the,2504,O
dual-luciferase,2504,O
reporter,2504,O
assay,2504,O
.,2504,O
RESULTS,2505,O
:,2505,O
Differences,2505,O
in,2505,O
the,2505,O
genotype,2505,O
distributions,2505,O
of,2505,O
the,2505,O
G-395A,2505,B-SequenceVariant
polymorphism,2505,O
between,2505,O
the,2505,O
EH,2505,B-DiseaseOrPhenotypicFeature
and,2505,O
non-hypertension,2505,O
groups,2505,O
are,2505,O
statistically,2505,O
significant,2505,O
(,2505,O
P=0.032,2505,O
),2505,O
.,2505,O
There,2506,O
are,2506,O
differential,2506,O
effects,2506,O
of,2506,O
age,2506,O
",",2506,O
gender,2506,O
and,2506,O
smoking,2506,O
status,2506,O
on,2506,O
the,2506,O
association,2506,O
of,2506,O
the,2506,O
G-395A,2506,B-SequenceVariant
polymorphism,2506,O
with,2506,O
EH,2506,B-DiseaseOrPhenotypicFeature
;,2506,O
the,2506,O
G-395A,2506,B-SequenceVariant
polymorphism,2506,O
is,2506,O
significantly,2506,O
associated,2506,O
with,2506,O
EH,2506,B-DiseaseOrPhenotypicFeature
in,2506,O
subjects,2506,O
over,2506,O
60years,2506,O
old,2506,O
",",2506,O
in,2506,O
females,2506,O
and,2506,O
in,2506,O
nonsmokers,2506,O
.,2506,O
A,2507,O
multiple,2507,O
logistic,2507,O
regression,2507,O
analysis,2507,O
indicated,2507,O
that,2507,O
the,2507,O
odds,2507,O
ratio,2507,O
for,2507,O
EH,2507,B-DiseaseOrPhenotypicFeature
in,2507,O
the,2507,O
-395A,2507,B-SequenceVariant
allele,2507,O
carriers,2507,O
as,2507,O
compared,2507,O
with,2507,O
the,2507,O
control,2507,O
group,2507,O
was,2507,O
0.593,2507,O
(,2507,O
P=0.024,2507,O
),2507,O
after,2507,O
adjusting,2507,O
for,2507,O
current,2507,O
traditional,2507,O
risk,2507,O
factors,2507,O
.,2507,O
The,2508,O
dual-luciferase,2508,O
reporter,2508,O
assay,2508,O
revealed,2508,O
that,2508,O
the,2508,O
-395A,2508,B-SequenceVariant
carrier,2508,O
of,2508,O
a,2508,O
498-bp,2508,O
DNA,2508,O
fragment,2508,O
(,2508,O
containing,2508,O
the,2508,O
G-395A,2508,B-SequenceVariant
site,2508,O
),2508,O
upstream,2508,O
of,2508,O
the,2508,O
Klotho,2508,B-GeneOrGeneProduct
gene,2508,O
has,2508,O
higher,2508,O
relative,2508,O
luciferase,2508,O
activity,2508,O
than,2508,O
the,2508,O
-395G,2508,B-SequenceVariant
carrier,2508,O
.,2508,O
CONCLUSIONS,2509,O
:,2509,O
The,2509,O
G-395A,2509,B-SequenceVariant
polymorphism,2509,O
of,2509,O
the,2509,O
human,2509,B-OrganismTaxon
Klotho,2509,B-GeneOrGeneProduct
gene,2509,O
is,2509,O
associated,2509,O
with,2509,O
EH,2509,B-DiseaseOrPhenotypicFeature
and,2509,O
may,2509,O
be,2509,O
a,2509,O
potential,2509,O
regulatory,2509,O
site,2509,O
.,2509,O
Chemokine,2510,O
CCL2,2510,B-GeneOrGeneProduct
and,2510,O
its,2510,O
receptor,2510,O
CCR2,2510,B-GeneOrGeneProduct
are,2510,O
increased,2510,O
in,2510,O
the,2510,O
hippocampus,2510,O
following,2510,O
pilocarpine-induced,2510,B-ChemicalEntity
status,2510,B-DiseaseOrPhenotypicFeature
epilepticus,2510,I-DiseaseOrPhenotypicFeature
.,2510,O
BACKGROUND,2511,O
:,2511,O
Neuroinflammation,2511,B-DiseaseOrPhenotypicFeature
occurs,2511,O
after,2511,O
seizures,2511,B-DiseaseOrPhenotypicFeature
and,2511,O
is,2511,O
implicated,2511,O
in,2511,O
epileptogenesis,2511,O
.,2511,O
CCR2,2512,B-GeneOrGeneProduct
is,2512,O
a,2512,O
chemokine,2512,B-GeneOrGeneProduct
receptor,2512,I-GeneOrGeneProduct
for,2512,O
CCL2,2512,B-GeneOrGeneProduct
and,2512,O
their,2512,O
interaction,2512,O
mediates,2512,O
monocyte,2512,O
infiltration,2512,O
in,2512,O
the,2512,O
neuroinflammatory,2512,B-DiseaseOrPhenotypicFeature
cascade,2512,O
triggered,2512,O
in,2512,O
different,2512,O
brain,2512,O
pathologies,2512,O
.,2512,O
In,2513,O
this,2513,O
work,2513,O
CCR2,2513,B-GeneOrGeneProduct
and,2513,O
CCL2,2513,B-GeneOrGeneProduct
expression,2513,O
were,2513,O
examined,2513,O
following,2513,O
status,2513,B-DiseaseOrPhenotypicFeature
epilepticus,2513,I-DiseaseOrPhenotypicFeature
(,2513,O
SE,2513,B-DiseaseOrPhenotypicFeature
),2513,O
induced,2513,O
by,2513,O
pilocarpine,2513,B-ChemicalEntity
injection,2513,O
.,2513,O
METHODS,2514,O
:,2514,O
SE,2514,B-DiseaseOrPhenotypicFeature
was,2514,O
induced,2514,O
by,2514,O
pilocarpine,2514,B-ChemicalEntity
injection,2514,O
.,2514,O
Control,2515,O
rats,2515,B-OrganismTaxon
were,2515,O
injected,2515,O
with,2515,O
saline,2515,O
instead,2515,O
of,2515,O
pilocarpine,2515,B-ChemicalEntity
.,2515,O
Five,2516,O
days,2516,O
after,2516,O
SE,2516,B-DiseaseOrPhenotypicFeature
",",2516,O
CCR2,2516,B-GeneOrGeneProduct
staining,2516,O
in,2516,O
neurons,2516,O
and,2516,O
glial,2516,O
cells,2516,O
was,2516,O
examined,2516,O
using,2516,O
imunohistochemical,2516,O
analyses,2516,O
.,2516,O
The,2517,O
number,2517,O
of,2517,O
CCR2,2517,B-GeneOrGeneProduct
positive,2517,O
cells,2517,O
was,2517,O
determined,2517,O
using,2517,O
stereology,2517,O
probes,2517,O
in,2517,O
the,2517,O
hippocampus,2517,O
.,2517,O
CCL2,2518,B-GeneOrGeneProduct
expression,2518,O
in,2518,O
the,2518,O
hippocampus,2518,O
was,2518,O
examined,2518,O
by,2518,O
molecular,2518,O
assay,2518,O
.,2518,O
RESULTS,2519,O
:,2519,O
Increased,2519,O
CCR2,2519,B-GeneOrGeneProduct
was,2519,O
observed,2519,O
in,2519,O
the,2519,O
hippocampus,2519,O
after,2519,O
SE,2519,B-DiseaseOrPhenotypicFeature
.,2519,O
Seizures,2520,B-DiseaseOrPhenotypicFeature
also,2520,O
resulted,2520,O
in,2520,O
alterations,2520,O
to,2520,O
the,2520,O
cell,2520,O
types,2520,O
expressing,2520,O
CCR2,2520,B-GeneOrGeneProduct
.,2520,O
Increased,2521,O
numbers,2521,O
of,2521,O
neurons,2521,O
that,2521,O
expressed,2521,O
CCR2,2521,B-GeneOrGeneProduct
was,2521,O
observed,2521,O
following,2521,O
SE,2521,B-DiseaseOrPhenotypicFeature
.,2521,O
Microglial,2522,O
cells,2522,O
were,2522,O
more,2522,O
closely,2522,O
apposed,2522,O
to,2522,O
the,2522,O
CCR2-labeled,2522,B-GeneOrGeneProduct
cells,2522,O
in,2522,O
SE,2522,B-DiseaseOrPhenotypicFeature
rats,2522,B-OrganismTaxon
.,2522,O
In,2523,O
addition,2523,O
",",2523,O
rats,2523,B-OrganismTaxon
that,2523,O
experienced,2523,O
SE,2523,B-DiseaseOrPhenotypicFeature
exhibited,2523,O
CCR2-labeling,2523,B-GeneOrGeneProduct
in,2523,O
populations,2523,O
of,2523,O
hypertrophied,2523,O
astrocytes,2523,O
",",2523,O
especially,2523,O
in,2523,O
CA1,2523,O
and,2523,O
dentate,2523,O
gyrus,2523,O
.,2523,O
These,2524,O
CCR2+,2524,B-GeneOrGeneProduct
astroctytes,2524,O
were,2524,O
not,2524,O
observed,2524,O
in,2524,O
control,2524,O
rats,2524,B-OrganismTaxon
.,2524,O
Examination,2525,O
of,2525,O
CCL2,2525,B-GeneOrGeneProduct
expression,2525,O
showed,2525,O
that,2525,O
it,2525,O
was,2525,O
elevated,2525,O
in,2525,O
the,2525,O
hippocampus,2525,O
following,2525,O
SE,2525,B-DiseaseOrPhenotypicFeature
.,2525,O
CONCLUSION,2526,O
:,2526,O
The,2526,O
data,2526,O
show,2526,O
that,2526,O
CCR2,2526,B-GeneOrGeneProduct
and,2526,O
CCL2,2526,B-GeneOrGeneProduct
are,2526,O
up-regulated,2526,O
in,2526,O
the,2526,O
hippocampus,2526,O
after,2526,O
pilocarpine-induced,2526,B-ChemicalEntity
SE,2526,B-DiseaseOrPhenotypicFeature
.,2526,O
Seizures,2527,B-DiseaseOrPhenotypicFeature
also,2527,O
result,2527,O
in,2527,O
changes,2527,O
to,2527,O
CCR2,2527,B-GeneOrGeneProduct
receptor,2527,O
expression,2527,O
in,2527,O
neurons,2527,O
and,2527,O
astrocytes,2527,O
.,2527,O
These,2528,O
changes,2528,O
might,2528,O
be,2528,O
involved,2528,O
in,2528,O
detrimental,2528,O
neuroplasticity,2528,O
and,2528,O
neuroinflammatory,2528,B-DiseaseOrPhenotypicFeature
changes,2528,O
that,2528,O
occur,2528,O
following,2528,O
seizures,2528,B-DiseaseOrPhenotypicFeature
.,2528,O
Metallothionein,2529,B-ChemicalEntity
induction,2529,O
reduces,2529,O
caspase-3,2529,B-GeneOrGeneProduct
activity,2529,O
and,2529,O
TNFalpha,2529,B-GeneOrGeneProduct
levels,2529,O
with,2529,O
preservation,2529,O
of,2529,O
cognitive,2529,O
function,2529,O
and,2529,O
intact,2529,O
hippocampal,2529,O
neurons,2529,O
in,2529,O
carmustine-treated,2529,B-ChemicalEntity
rats,2529,B-OrganismTaxon
.,2529,O
Hippocampal,2530,O
integrity,2530,O
is,2530,O
essential,2530,O
for,2530,O
cognitive,2530,O
functions,2530,O
.,2530,O
On,2531,O
the,2531,O
other,2531,O
hand,2531,O
",",2531,O
induction,2531,O
of,2531,O
metallothionein,2531,B-ChemicalEntity
(,2531,O
MT,2531,B-ChemicalEntity
),2531,O
by,2531,O
ZnSO,2531,B-ChemicalEntity
(,2531,I-ChemicalEntity
4,2531,I-ChemicalEntity
),2531,I-ChemicalEntity
and,2531,O
its,2531,O
role,2531,O
in,2531,O
neuroprotection,2531,O
has,2531,O
been,2531,O
documented,2531,O
.,2531,O
The,2532,O
present,2532,O
study,2532,O
aimed,2532,O
to,2532,O
explore,2532,O
the,2532,O
effect,2532,O
of,2532,O
MT,2532,B-ChemicalEntity
induction,2532,O
on,2532,O
carmustine,2532,B-ChemicalEntity
(,2532,O
BCNU,2532,B-ChemicalEntity
),2532,O
-induced,2532,O
hippocampal,2532,O
cognitive,2532,B-DiseaseOrPhenotypicFeature
dysfunction,2532,I-DiseaseOrPhenotypicFeature
in,2532,O
rats,2532,B-OrganismTaxon
.,2532,O
A,2533,O
total,2533,O
of,2533,O
60,2533,O
male,2533,O
Wistar,2533,O
albino,2533,O
rats,2533,B-OrganismTaxon
were,2533,O
randomly,2533,O
divided,2533,O
into,2533,O
four,2533,O
groups,2533,O
(,2533,O
15/group,2533,O
),2533,O
:,2533,O
The,2533,O
control,2533,O
group,2533,O
injected,2533,O
with,2533,O
single,2533,O
doses,2533,O
of,2533,O
normal,2533,O
saline,2533,O
(,2533,O
i.c.v,2533,O
),2533,O
followed,2533,O
24,2533,O
h,2533,O
later,2533,O
by,2533,O
BCNU,2533,B-ChemicalEntity
solvent,2533,O
(,2533,O
i.v,2533,O
),2533,O
.,2533,O
The,2534,O
second,2534,O
group,2534,O
administered,2534,O
ZnSO,2534,B-ChemicalEntity
(,2534,I-ChemicalEntity
4,2534,I-ChemicalEntity
),2534,I-ChemicalEntity
(,2534,O
0.1,2534,O
micromol/10,2534,O
microl,2534,O
normal,2534,O
saline,2534,O
",",2534,O
i.c.v,2534,O
",",2534,O
once,2534,O
),2534,O
then,2534,O
BCNU,2534,B-ChemicalEntity
solvent,2534,O
(,2534,O
i.v,2534,O
),2534,O
after,2534,O
24,2534,O
h.,2534,O
Third,2534,O
group,2534,O
received,2534,O
BCNU,2534,B-ChemicalEntity
(,2534,O
20,2534,O
mg/kg,2534,O
",",2534,O
i.v,2534,O
",",2534,O
once,2534,O
),2534,O
24,2534,O
h,2534,O
after,2534,O
injection,2534,O
with,2534,O
normal,2534,O
saline,2534,O
(,2534,O
i.c.v,2534,O
),2534,O
.,2534,O
Fourth,2535,O
group,2535,O
received,2535,O
a,2535,O
single,2535,O
dose,2535,O
of,2535,O
ZnSO,2535,B-ChemicalEntity
(,2535,I-ChemicalEntity
4,2535,I-ChemicalEntity
),2535,I-ChemicalEntity
(,2535,O
0.1,2535,O
micromol/10,2535,O
microl,2535,O
normal,2535,O
saline,2535,O
",",2535,O
i.c.v,2535,O
),2535,O
then,2535,O
BCNU,2535,B-ChemicalEntity
(,2535,O
20,2535,O
mg/kg,2535,O
",",2535,O
i.v,2535,O
",",2535,O
once,2535,O
),2535,O
after,2535,O
24,2535,O
h.,2535,O
The,2535,O
obtained,2535,O
data,2535,O
revealed,2535,O
that,2535,O
BCNU,2535,B-ChemicalEntity
administration,2535,O
resulted,2535,O
in,2535,O
deterioration,2535,B-DiseaseOrPhenotypicFeature
of,2535,I-DiseaseOrPhenotypicFeature
learning,2535,I-DiseaseOrPhenotypicFeature
and,2535,I-DiseaseOrPhenotypicFeature
short-term,2535,I-DiseaseOrPhenotypicFeature
memory,2535,I-DiseaseOrPhenotypicFeature
(,2535,O
STM,2535,O
),2535,O
",",2535,O
as,2535,O
measured,2535,O
by,2535,O
using,2535,O
radial,2535,O
arm,2535,O
water,2535,O
maze,2535,O
",",2535,O
accompanied,2535,O
with,2535,O
decreased,2535,O
hippocampal,2535,O
glutathione,2535,B-GeneOrGeneProduct
reductase,2535,I-GeneOrGeneProduct
(,2535,O
GR,2535,B-GeneOrGeneProduct
),2535,O
activity,2535,O
and,2535,O
reduced,2535,O
glutathione,2535,B-ChemicalEntity
(,2535,O
GSH,2535,B-ChemicalEntity
),2535,O
content,2535,O
.,2535,O
Also,2536,O
",",2536,O
BCNU,2536,B-ChemicalEntity
administration,2536,O
increased,2536,O
serum,2536,O
tumor,2536,B-GeneOrGeneProduct
necrosis,2536,I-GeneOrGeneProduct
factor-alpha,2536,I-GeneOrGeneProduct
(,2536,O
TNFalpha,2536,B-GeneOrGeneProduct
),2536,O
",",2536,O
hippocampal,2536,O
MT,2536,B-ChemicalEntity
and,2536,O
malondialdehyde,2536,B-ChemicalEntity
(,2536,O
MDA,2536,B-ChemicalEntity
),2536,O
contents,2536,O
as,2536,O
well,2536,O
as,2536,O
caspase-3,2536,B-GeneOrGeneProduct
activity,2536,O
in,2536,O
addition,2536,O
to,2536,O
histological,2536,O
alterations,2536,O
.,2536,O
ZnSO,2537,B-ChemicalEntity
(,2537,I-ChemicalEntity
4,2537,I-ChemicalEntity
),2537,I-ChemicalEntity
pretreatment,2537,O
counteracted,2537,O
BCNU-induced,2537,B-ChemicalEntity
inhibition,2537,O
of,2537,O
GR,2537,B-GeneOrGeneProduct
and,2537,O
depletion,2537,O
of,2537,O
GSH,2537,B-ChemicalEntity
and,2537,O
resulted,2537,O
in,2537,O
significant,2537,O
reduction,2537,O
in,2537,O
the,2537,O
levels,2537,O
of,2537,O
MDA,2537,B-ChemicalEntity
and,2537,O
TNFalpha,2537,B-GeneOrGeneProduct
as,2537,O
well,2537,O
as,2537,O
the,2537,O
activity,2537,O
of,2537,O
caspase-3,2537,B-GeneOrGeneProduct
.,2537,O
The,2538,O
histological,2538,O
features,2538,O
were,2538,O
improved,2538,O
in,2538,O
hippocampus,2538,O
of,2538,O
rats,2538,B-OrganismTaxon
treated,2538,O
with,2538,O
ZnSO,2538,B-ChemicalEntity
(,2538,I-ChemicalEntity
4,2538,I-ChemicalEntity
),2538,I-ChemicalEntity
+,2538,O
BCNU,2538,B-ChemicalEntity
compared,2538,O
to,2538,O
only,2538,O
BCNU-treated,2538,B-ChemicalEntity
animals,2538,O
.,2538,O
In,2539,O
conclusion,2539,O
",",2539,O
MT,2539,B-ChemicalEntity
induction,2539,O
halts,2539,O
BCNU-induced,2539,B-ChemicalEntity
hippocampal,2539,O
toxicity,2539,B-DiseaseOrPhenotypicFeature
as,2539,O
it,2539,O
prevented,2539,O
GR,2539,B-GeneOrGeneProduct
inhibition,2539,O
and,2539,O
GSH,2539,B-ChemicalEntity
depletion,2539,O
and,2539,O
counteracted,2539,O
the,2539,O
increased,2539,O
levels,2539,O
of,2539,O
TNFalpha,2539,B-GeneOrGeneProduct
",",2539,O
MDA,2539,B-ChemicalEntity
and,2539,O
caspase-3,2539,B-GeneOrGeneProduct
activity,2539,O
with,2539,O
subsequent,2539,O
preservation,2539,O
of,2539,O
cognition,2539,O
.,2539,O
Promoter,2540,O
insertion/deletion,2540,O
in,2540,O
the,2540,O
IRF5,2540,B-GeneOrGeneProduct
gene,2540,O
is,2540,O
highly,2540,O
associated,2540,O
with,2540,O
susceptibility,2540,O
to,2540,O
systemic,2540,B-DiseaseOrPhenotypicFeature
lupus,2540,I-DiseaseOrPhenotypicFeature
erythematosus,2540,I-DiseaseOrPhenotypicFeature
in,2540,O
distinct,2540,O
populations,2540,O
",",2540,O
but,2540,O
exerts,2540,O
a,2540,O
modest,2540,O
effect,2540,O
on,2540,O
gene,2540,O
expression,2540,O
in,2540,O
peripheral,2540,O
blood,2540,O
mononuclear,2540,O
cells,2540,O
.,2540,O
OBJECTIVE,2541,O
:,2541,O
We,2541,O
examined,2541,O
the,2541,O
genetic,2541,O
association,2541,O
of,2541,O
the,2541,O
promoter,2541,O
insertion/deletion,2541,O
(,2541,O
indel,2541,O
),2541,O
in,2541,O
IRF5,2541,B-GeneOrGeneProduct
gene,2541,O
with,2541,O
systemic,2541,B-DiseaseOrPhenotypicFeature
lupus,2541,I-DiseaseOrPhenotypicFeature
erythematosus,2541,I-DiseaseOrPhenotypicFeature
(,2541,O
SLE,2541,B-DiseaseOrPhenotypicFeature
),2541,O
in,2541,O
distinct,2541,O
populations,2541,O
and,2541,O
assessed,2541,O
its,2541,O
role,2541,O
in,2541,O
gene,2541,O
expression,2541,O
.,2541,O
METHODS,2542,O
:,2542,O
Four,2542,O
IRF5,2542,B-GeneOrGeneProduct
polymorphisms,2542,O
were,2542,O
genotyped,2542,O
in,2542,O
1488,2542,O
SLE,2542,B-DiseaseOrPhenotypicFeature
patients,2542,B-OrganismTaxon
and,2542,O
1466,2542,O
controls,2542,O
.,2542,O
Gene,2543,O
expression,2543,O
was,2543,O
analyzed,2543,O
by,2543,O
quantitative,2543,O
real-time,2543,O
PCR,2543,O
using,2543,O
RNA,2543,O
from,2543,O
peripheral,2543,O
blood,2543,O
mononuclear,2543,O
cells,2543,O
(,2543,O
PBMC,2543,O
),2543,O
.,2543,O
RESULTS,2544,O
:,2544,O
The,2544,O
promoter,2544,O
indel,2544,O
and,2544,O
rs2070197,2544,B-SequenceVariant
had,2544,O
independent,2544,O
genetic,2544,O
effects,2544,O
",",2544,O
which,2544,O
accounted,2544,O
for,2544,O
the,2544,O
association,2544,O
of,2544,O
rs2004640,2544,B-SequenceVariant
and,2544,O
rs10954213,2544,B-SequenceVariant
.,2544,O
Gene,2545,O
expression,2545,O
analysis,2545,O
revealed,2545,O
that,2545,O
rs10954213,2545,B-SequenceVariant
exerted,2545,O
the,2545,O
greatest,2545,O
influence,2545,O
on,2545,O
IRF5,2545,B-GeneOrGeneProduct
transcript,2545,O
levels,2545,O
.,2545,O
CONCLUSION,2546,O
:,2546,O
We,2546,O
corroborated,2546,O
the,2546,O
association,2546,O
of,2546,O
the,2546,O
promoter,2546,O
indel,2546,O
with,2546,O
SLE,2546,B-DiseaseOrPhenotypicFeature
in,2546,O
5,2546,O
different,2546,O
populations,2546,O
and,2546,O
revealed,2546,O
that,2546,O
rs10954213,2546,B-SequenceVariant
is,2546,O
the,2546,O
main,2546,O
single-nucleotide,2546,O
polymorphism,2546,O
responsible,2546,O
for,2546,O
altered,2546,O
IRF5,2546,B-GeneOrGeneProduct
expression,2546,O
in,2546,O
PBMC,2546,O
.,2546,O
Normalizing,2547,O
effects,2547,O
of,2547,O
modafinil,2547,B-ChemicalEntity
on,2547,O
sleep,2547,O
in,2547,O
chronic,2547,O
cocaine,2547,B-ChemicalEntity
users,2547,O
.,2547,O
OBJECTIVE,2548,O
:,2548,O
The,2548,O
purpose,2548,O
of,2548,O
the,2548,O
present,2548,O
study,2548,O
was,2548,O
to,2548,O
determine,2548,O
the,2548,O
effect,2548,O
of,2548,O
morning-dosed,2548,O
modafinil,2548,B-ChemicalEntity
on,2548,O
sleep,2548,O
and,2548,O
daytime,2548,B-DiseaseOrPhenotypicFeature
sleepiness,2548,I-DiseaseOrPhenotypicFeature
in,2548,O
chronic,2548,O
cocaine,2548,B-ChemicalEntity
users,2548,O
.,2548,O
METHOD,2549,O
:,2549,O
Twenty,2549,O
cocaine-dependent,2549,B-ChemicalEntity
participants,2549,O
were,2549,O
randomly,2549,O
assigned,2549,O
to,2549,O
receive,2549,O
modafinil,2549,B-ChemicalEntity
",",2549,O
400,2549,O
mg,2549,O
(,2549,O
N=10,2549,O
),2549,O
",",2549,O
or,2549,O
placebo,2549,O
(,2549,O
N=10,2549,O
),2549,O
every,2549,O
morning,2549,O
at,2549,O
7:30,2549,O
a.m.,2549,O
for,2549,O
16,2549,O
days,2549,O
in,2549,O
an,2549,O
inpatient,2549,B-OrganismTaxon
",",2549,O
double-blind,2549,O
randomized,2549,O
trial,2549,O
.,2549,O
Participants,2550,O
underwent,2550,O
polysomnographic,2550,O
sleep,2550,O
recordings,2550,O
on,2550,O
days,2550,O
1,2550,O
to,2550,O
3,2550,O
",",2550,O
7,2550,O
to,2550,O
9,2550,O
",",2550,O
and,2550,O
14,2550,O
to,2550,O
16,2550,O
(,2550,O
first,2550,O
",",2550,O
second,2550,O
",",2550,O
and,2550,O
third,2550,O
weeks,2550,O
of,2550,O
abstinence,2550,O
),2550,O
.,2550,O
The,2551,O
Multiple,2551,O
Sleep,2551,O
Latency,2551,O
Test,2551,O
was,2551,O
performed,2551,O
at,2551,O
11:30,2551,O
a.m.,2551,O
",",2551,O
2:00,2551,O
p.m.,2551,O
",",2551,O
and,2551,O
4:30,2551,O
p.m.,2551,O
on,2551,O
days,2551,O
2,2551,O
",",2551,O
8,2551,O
",",2551,O
and,2551,O
15,2551,O
.,2551,O
For,2552,O
comparison,2552,O
of,2552,O
sleep,2552,O
architecture,2552,O
variables,2552,O
",",2552,O
12,2552,O
healthy,2552,O
comparison,2552,O
participants,2552,O
underwent,2552,O
a,2552,O
single,2552,O
night,2552,O
of,2552,O
experimental,2552,O
polysomnography,2552,O
that,2552,O
followed,2552,O
1,2552,O
night,2552,O
of,2552,O
accommodation,2552,O
polysomnography,2552,O
.,2552,O
RESULTS,2553,O
:,2553,O
Progressive,2553,O
abstinence,2553,O
from,2553,O
cocaine,2553,B-ChemicalEntity
was,2553,O
associated,2553,O
with,2553,O
worsening,2553,O
of,2553,O
all,2553,O
measured,2553,O
polysomnographic,2553,O
sleep,2553,O
outcomes,2553,O
.,2553,O
Compared,2554,O
with,2554,O
placebo,2554,O
",",2554,O
modafinil,2554,B-ChemicalEntity
decreased,2554,O
nighttime,2554,O
sleep,2554,O
latency,2554,O
and,2554,O
increased,2554,O
slow-wave,2554,O
sleep,2554,O
time,2554,O
in,2554,O
cocaine-dependent,2554,B-ChemicalEntity
participants,2554,O
.,2554,O
The,2555,O
effect,2555,O
of,2555,O
modafinil,2555,B-ChemicalEntity
interacted,2555,O
with,2555,O
the,2555,O
abstinence,2555,O
week,2555,O
and,2555,O
was,2555,O
associated,2555,O
with,2555,O
longer,2555,O
total,2555,O
sleep,2555,O
time,2555,O
and,2555,O
shorter,2555,O
REM,2555,O
sleep,2555,O
latency,2555,O
in,2555,O
the,2555,O
third,2555,O
week,2555,O
of,2555,O
abstinence,2555,O
.,2555,O
Comparison,2556,O
of,2556,O
slow-wave,2556,O
sleep,2556,O
time,2556,O
",",2556,O
total,2556,O
sleep,2556,O
time,2556,O
",",2556,O
and,2556,O
sleep,2556,O
latency,2556,O
in,2556,O
cocaine-dependent,2556,B-ChemicalEntity
and,2556,O
healthy,2556,O
participants,2556,O
revealed,2556,O
a,2556,O
normalizing,2556,O
effect,2556,O
of,2556,O
modafinil,2556,B-ChemicalEntity
in,2556,O
cocaine-dependent,2556,B-ChemicalEntity
participants,2556,O
.,2556,O
Modafinil,2557,B-ChemicalEntity
was,2557,O
associated,2557,O
with,2557,O
increased,2557,O
daytime,2557,O
sleep,2557,O
latency,2557,O
",",2557,O
as,2557,O
measured,2557,O
by,2557,O
the,2557,O
Multiple,2557,O
Sleep,2557,O
Latency,2557,O
Test,2557,O
",",2557,O
and,2557,O
a,2557,O
nearly,2557,O
significant,2557,O
decrease,2557,O
in,2557,O
subjective,2557,O
daytime,2557,B-DiseaseOrPhenotypicFeature
sleepiness,2557,I-DiseaseOrPhenotypicFeature
.,2557,O
CONCLUSIONS,2558,O
:,2558,O
Morning-dosed,2558,O
modafinil,2558,B-ChemicalEntity
promotes,2558,O
nocturnal,2558,O
sleep,2558,O
",",2558,O
normalizes,2558,O
sleep,2558,O
architecture,2558,O
",",2558,O
and,2558,O
decreases,2558,O
daytime,2558,B-DiseaseOrPhenotypicFeature
sleepiness,2558,I-DiseaseOrPhenotypicFeature
in,2558,O
abstinent,2558,O
cocaine,2558,B-ChemicalEntity
users,2558,O
.,2558,O
These,2559,O
effects,2559,O
may,2559,O
be,2559,O
relevant,2559,O
in,2559,O
the,2559,O
treatment,2559,O
of,2559,O
cocaine,2559,B-ChemicalEntity
dependence,2559,O
.,2559,O
The,2560,O
six-nucleotide,2560,O
deletion/insertion,2560,O
variant,2560,O
in,2560,O
the,2560,O
CASP8,2560,B-GeneOrGeneProduct
promoter,2560,O
region,2560,O
is,2560,O
inversely,2560,O
associated,2560,O
with,2560,O
risk,2560,O
of,2560,O
squamous,2560,B-DiseaseOrPhenotypicFeature
cell,2560,I-DiseaseOrPhenotypicFeature
carcinoma,2560,I-DiseaseOrPhenotypicFeature
of,2560,I-DiseaseOrPhenotypicFeature
the,2560,I-DiseaseOrPhenotypicFeature
head,2560,I-DiseaseOrPhenotypicFeature
and,2560,I-DiseaseOrPhenotypicFeature
neck,2560,I-DiseaseOrPhenotypicFeature
.,2560,O
Caspase,2561,B-GeneOrGeneProduct
8,2561,I-GeneOrGeneProduct
(,2561,O
CASP8,2561,B-GeneOrGeneProduct
),2561,O
is,2561,O
an,2561,O
apoptosis-related,2561,O
cysteine,2561,O
peptidase,2561,O
involved,2561,O
in,2561,O
the,2561,O
death,2561,O
receptor,2561,O
pathway,2561,O
and,2561,O
likely,2561,O
in,2561,O
the,2561,O
mitochondrial,2561,O
pathway,2561,O
.,2561,O
A,2562,O
CASP8,2562,B-GeneOrGeneProduct
promoter,2562,O
region,2562,O
six-nucleotide,2562,O
deletion/insertion,2562,O
(,2562,O
-652,2562,B-SequenceVariant
6N,2562,I-SequenceVariant
ins/del,2562,I-SequenceVariant
),2562,O
variant,2562,O
and,2562,O
a,2562,O
coding,2562,O
region,2562,O
D302H,2562,B-SequenceVariant
polymorphism,2562,O
are,2562,O
reportedly,2562,O
important,2562,O
in,2562,O
cancer,2562,B-DiseaseOrPhenotypicFeature
development,2562,O
",",2562,O
but,2562,O
no,2562,O
reported,2562,O
study,2562,O
has,2562,O
assessed,2562,O
the,2562,O
associations,2562,O
of,2562,O
these,2562,O
genetic,2562,O
variations,2562,O
with,2562,O
risk,2562,O
of,2562,O
head,2562,B-DiseaseOrPhenotypicFeature
and,2562,I-DiseaseOrPhenotypicFeature
neck,2562,I-DiseaseOrPhenotypicFeature
cancer,2562,I-DiseaseOrPhenotypicFeature
.,2562,O
In,2563,O
a,2563,O
hospital-based,2563,O
study,2563,O
of,2563,O
non-Hispanic,2563,O
whites,2563,O
",",2563,O
we,2563,O
genotyped,2563,O
CASP8,2563,B-GeneOrGeneProduct
-652,2563,B-SequenceVariant
6N,2563,I-SequenceVariant
del,2563,I-SequenceVariant
and,2563,O
302H,2563,B-SequenceVariant
variants,2563,O
in,2563,O
"1,023",2563,O
patients,2563,B-OrganismTaxon
with,2563,O
squamous,2563,B-DiseaseOrPhenotypicFeature
cell,2563,I-DiseaseOrPhenotypicFeature
carcinoma,2563,I-DiseaseOrPhenotypicFeature
of,2563,I-DiseaseOrPhenotypicFeature
the,2563,I-DiseaseOrPhenotypicFeature
head,2563,I-DiseaseOrPhenotypicFeature
and,2563,I-DiseaseOrPhenotypicFeature
neck,2563,I-DiseaseOrPhenotypicFeature
(,2563,O
SCCHN,2563,B-DiseaseOrPhenotypicFeature
),2563,O
and,2563,O
"1,052",2563,O
cancer-free,2563,O
controls,2563,O
.,2563,O
Crude,2564,O
and,2564,O
adjusted,2564,O
odds,2564,O
ratios,2564,O
(,2564,O
OR,2564,O
),2564,O
and,2564,O
95,2564,O
%,2564,O
confidence,2564,O
intervals,2564,O
(,2564,O
CI,2564,O
),2564,O
were,2564,O
estimated,2564,O
using,2564,O
unconditional,2564,O
logistic,2564,O
regression,2564,O
models,2564,O
.,2564,O
The,2565,O
CASP8,2565,B-GeneOrGeneProduct
-652,2565,B-SequenceVariant
6N,2565,I-SequenceVariant
del,2565,I-SequenceVariant
variant,2565,O
genotypes,2565,O
or,2565,O
haplotypes,2565,O
were,2565,O
inversely,2565,O
associated,2565,O
with,2565,O
SCCHN,2565,B-DiseaseOrPhenotypicFeature
risk,2565,O
(,2565,O
adjusted,2565,O
OR,2565,O
",",2565,O
0.70,2565,O
;,2565,O
95,2565,O
%,2565,O
CI,2565,O
",",2565,O
0.57-0.85,2565,O
for,2565,O
the,2565,O
ins/del,2565,O
+,2565,O
del/del,2565,O
genotypes,2565,O
compared,2565,O
with,2565,O
the,2565,O
ins/ins,2565,O
genotype,2565,O
;,2565,O
adjusted,2565,O
OR,2565,O
",",2565,O
0.73,2565,O
;,2565,O
95,2565,O
%,2565,O
CI,2565,O
",",2565,O
0.55-0.97,2565,O
for,2565,O
the,2565,O
del-D,2565,O
haplotype,2565,O
compared,2565,O
with,2565,O
the,2565,O
ins-D,2565,O
haplotype,2565,O
),2565,O
.,2565,O
Furthermore,2566,O
",",2566,O
the,2566,O
number,2566,O
of,2566,O
the,2566,O
CASP8,2566,B-GeneOrGeneProduct
-652,2566,B-SequenceVariant
6N,2566,I-SequenceVariant
del,2566,I-SequenceVariant
(,2566,O
but,2566,O
not,2566,O
302H,2566,B-SequenceVariant
),2566,O
variant,2566,O
allele,2566,O
tended,2566,O
to,2566,O
correlate,2566,O
with,2566,O
increased,2566,O
levels,2566,O
of,2566,O
camptothecin-induced,2566,B-ChemicalEntity
p53-mediated,2566,B-GeneOrGeneProduct
apoptosis,2566,O
in,2566,O
T,2566,O
lymphocytes,2566,O
from,2566,O
170,2566,O
cancer-free,2566,O
controls,2566,O
.,2566,O
We,2567,O
concluded,2567,O
that,2567,O
the,2567,O
CASP8,2567,B-GeneOrGeneProduct
-652,2567,B-SequenceVariant
6N,2567,I-SequenceVariant
del,2567,I-SequenceVariant
variant,2567,O
allele,2567,O
may,2567,O
contribute,2567,O
to,2567,O
the,2567,O
risk,2567,O
of,2567,O
developing,2567,O
SCCHN,2567,B-DiseaseOrPhenotypicFeature
in,2567,O
non-Hispanic,2567,O
white,2567,O
populations,2567,O
.,2567,O
Further,2568,O
validation,2568,O
by,2568,O
population-based,2568,O
case-control,2568,O
studies,2568,O
and,2568,O
rigorous,2568,O
mechanistic,2568,O
studies,2568,O
is,2568,O
warranted,2568,O
.,2568,O
Activated,2569,O
Ras,2569,B-GeneOrGeneProduct
alters,2569,O
lens,2569,O
and,2569,O
corneal,2569,O
development,2569,O
through,2569,O
induction,2569,O
of,2569,O
distinct,2569,O
downstream,2569,O
targets,2569,O
.,2569,O
BACKGROUND,2570,O
:,2570,O
Mammalian,2570,O
Ras,2570,B-GeneOrGeneProduct
genes,2570,O
regulate,2570,O
diverse,2570,O
cellular,2570,O
processes,2570,O
including,2570,O
proliferation,2570,O
and,2570,O
differentiation,2570,O
and,2570,O
are,2570,O
frequently,2570,O
mutated,2570,O
in,2570,O
human,2570,B-OrganismTaxon
cancers,2570,B-DiseaseOrPhenotypicFeature
.,2570,O
Tumor,2571,B-DiseaseOrPhenotypicFeature
development,2571,O
in,2571,O
response,2571,O
to,2571,O
Ras,2571,B-GeneOrGeneProduct
activation,2571,O
varies,2571,O
between,2571,O
different,2571,O
tissues,2571,O
and,2571,O
the,2571,O
molecular,2571,O
basis,2571,O
for,2571,O
these,2571,O
variations,2571,O
are,2571,O
poorly,2571,O
understood,2571,O
.,2571,O
The,2572,O
murine,2572,B-OrganismTaxon
lens,2572,O
and,2572,O
cornea,2572,O
have,2572,O
a,2572,O
common,2572,O
embryonic,2572,O
origin,2572,O
and,2572,O
arise,2572,O
from,2572,O
adjacent,2572,O
regions,2572,O
of,2572,O
the,2572,O
surface,2572,O
ectoderm,2572,O
.,2572,O
Activation,2573,O
of,2573,O
the,2573,O
fibroblast,2573,B-GeneOrGeneProduct
growth,2573,I-GeneOrGeneProduct
factor,2573,I-GeneOrGeneProduct
(,2573,O
FGF,2573,B-GeneOrGeneProduct
),2573,O
signaling,2573,O
pathway,2573,O
induces,2573,O
the,2573,O
corneal,2573,O
epithelial,2573,O
cells,2573,O
to,2573,O
proliferate,2573,O
and,2573,O
the,2573,O
lens,2573,O
epithelial,2573,O
cells,2573,O
to,2573,O
exit,2573,O
the,2573,O
cell,2573,O
cycle,2573,O
.,2573,O
The,2574,O
molecular,2574,O
mechanisms,2574,O
that,2574,O
regulate,2574,O
the,2574,O
differential,2574,O
responses,2574,O
of,2574,O
these,2574,O
two,2574,O
related,2574,O
tissues,2574,O
have,2574,O
not,2574,O
been,2574,O
defined,2574,O
.,2574,O
We,2575,O
have,2575,O
generated,2575,O
transgenic,2575,O
mice,2575,B-OrganismTaxon
that,2575,O
express,2575,O
a,2575,O
constitutively,2575,O
active,2575,O
version,2575,O
of,2575,O
human,2575,B-OrganismTaxon
H-Ras,2575,B-GeneOrGeneProduct
in,2575,O
their,2575,O
lenses,2575,O
and,2575,O
corneas,2575,O
.,2575,O
RESULTS,2576,O
:,2576,O
Ras,2576,B-GeneOrGeneProduct
transgenic,2576,O
lenses,2576,O
and,2576,O
corneal,2576,O
epithelial,2576,O
cells,2576,O
showed,2576,O
increased,2576,O
proliferation,2576,O
with,2576,O
concomitant,2576,O
increases,2576,O
in,2576,O
cyclin,2576,B-GeneOrGeneProduct
D1,2576,I-GeneOrGeneProduct
and,2576,I-GeneOrGeneProduct
D2,2576,I-GeneOrGeneProduct
expression,2576,O
.,2576,O
This,2577,O
initial,2577,O
increase,2577,O
in,2577,O
proliferation,2577,O
is,2577,O
sustained,2577,O
in,2577,O
the,2577,O
cornea,2577,O
but,2577,O
not,2577,O
in,2577,O
the,2577,O
lens,2577,O
epithelial,2577,O
cells,2577,O
.,2577,O
Coincidentally,2578,O
",",2578,O
cdk,2578,B-GeneOrGeneProduct
inhibitors,2578,O
p27Kip1,2578,B-GeneOrGeneProduct
and,2578,O
p57Kip2,2578,B-GeneOrGeneProduct
were,2578,O
upregulated,2578,O
in,2578,O
the,2578,O
Ras,2578,B-GeneOrGeneProduct
transgenic,2578,O
lenses,2578,O
but,2578,O
not,2578,O
in,2578,O
the,2578,O
corneas,2578,O
.,2578,O
Phospho-Erk1,2579,O
and,2579,O
Erk2,2579,B-GeneOrGeneProduct
levels,2579,O
were,2579,O
elevated,2579,O
in,2579,O
the,2579,O
lens,2579,O
but,2579,O
not,2579,O
in,2579,O
the,2579,O
cornea,2579,O
and,2579,O
Spry,2579,B-GeneOrGeneProduct
1,2579,I-GeneOrGeneProduct
and,2579,O
Spry,2579,B-GeneOrGeneProduct
2,2579,I-GeneOrGeneProduct
",",2579,O
negative,2579,O
regulators,2579,O
of,2579,O
Ras-Raf-Erk,2579,B-GeneOrGeneProduct
signaling,2579,O
",",2579,O
were,2579,O
upregulated,2579,O
more,2579,O
in,2579,O
the,2579,O
corneal,2579,O
than,2579,O
in,2579,O
the,2579,O
lens,2579,O
epithelial,2579,O
cells,2579,O
.,2579,O
Both,2580,O
lens,2580,O
and,2580,O
corneal,2580,O
differentiation,2580,O
programs,2580,O
were,2580,O
sensitive,2580,O
to,2580,O
Ras,2580,B-GeneOrGeneProduct
activation,2580,O
.,2580,O
Ras,2581,B-GeneOrGeneProduct
transgenic,2581,O
embryos,2581,O
showed,2581,O
a,2581,O
distinctive,2581,O
alteration,2581,O
in,2581,O
the,2581,O
architecture,2581,O
of,2581,O
the,2581,O
lens,2581,O
pit,2581,O
.,2581,O
Ras,2582,B-GeneOrGeneProduct
activation,2582,O
",",2582,O
though,2582,O
sufficient,2582,O
for,2582,O
upregulation,2582,O
of,2582,O
Prox1,2582,B-GeneOrGeneProduct
",",2582,O
a,2582,O
transcription,2582,O
factor,2582,O
critical,2582,O
for,2582,O
cell,2582,O
cycle,2582,O
exit,2582,O
and,2582,O
initiation,2582,O
of,2582,O
fiber,2582,O
differentiation,2582,O
",",2582,O
is,2582,O
not,2582,O
sufficient,2582,O
for,2582,O
induction,2582,O
of,2582,O
terminal,2582,O
fiber,2582,O
differentiation,2582,O
.,2582,O
Expression,2583,O
of,2583,O
Keratin,2583,B-GeneOrGeneProduct
12,2583,I-GeneOrGeneProduct
",",2583,O
a,2583,O
marker,2583,O
of,2583,O
corneal,2583,O
epithelial,2583,O
differentiation,2583,O
",",2583,O
was,2583,O
reduced,2583,O
in,2583,O
the,2583,O
Ras,2583,B-GeneOrGeneProduct
transgenic,2583,O
corneas,2583,O
.,2583,O
CONCLUSIONS,2584,O
:,2584,O
Collectively,2584,O
",",2584,O
these,2584,O
results,2584,O
suggest,2584,O
that,2584,O
Ras,2584,B-GeneOrGeneProduct
activation,2584,O
a,2584,O
),2584,O
induces,2584,O
distinct,2584,O
sets,2584,O
of,2584,O
downstream,2584,O
targets,2584,O
in,2584,O
the,2584,O
lens,2584,O
and,2584,O
cornea,2584,O
resulting,2584,O
in,2584,O
distinct,2584,O
cellular,2584,O
responses,2584,O
and,2584,O
b,2584,O
),2584,O
is,2584,O
sufficient,2584,O
for,2584,O
initiation,2584,O
but,2584,O
not,2584,O
completion,2584,O
of,2584,O
lens,2584,O
fiber,2584,O
differentiation,2584,O
.,2584,O
Association,2585,O
of,2585,O
adipocyte,2585,O
genes,2585,O
with,2585,O
ASP,2585,B-GeneOrGeneProduct
expression,2585,O
:,2585,O
a,2585,O
microarray,2585,O
analysis,2585,O
of,2585,O
subcutaneous,2585,O
and,2585,O
omental,2585,O
adipose,2585,O
tissue,2585,O
in,2585,O
morbidly,2585,O
obese,2585,B-DiseaseOrPhenotypicFeature
subjects,2585,O
.,2585,O
BACKGROUND,2586,O
:,2586,O
Prevalence,2586,O
of,2586,O
obesity,2586,B-DiseaseOrPhenotypicFeature
is,2586,O
increasing,2586,O
to,2586,O
pandemic,2586,O
proportions,2586,O
.,2586,O
However,2587,O
",",2587,O
obese,2587,B-DiseaseOrPhenotypicFeature
subjects,2587,O
differ,2587,O
in,2587,O
insulin,2587,B-DiseaseOrPhenotypicFeature
resistance,2587,I-DiseaseOrPhenotypicFeature
",",2587,O
adipokine,2587,B-GeneOrGeneProduct
production,2587,O
and,2587,O
co-morbidities,2587,O
.,2587,O
Based,2588,O
on,2588,O
fasting,2588,O
plasma,2588,O
analysis,2588,O
",",2588,O
obese,2588,B-DiseaseOrPhenotypicFeature
subjects,2588,O
were,2588,O
grouped,2588,O
as,2588,O
Low,2588,O
Acylation,2588,B-GeneOrGeneProduct
Stimulating,2588,I-GeneOrGeneProduct
protein,2588,I-GeneOrGeneProduct
(,2588,O
ASP,2588,B-GeneOrGeneProduct
),2588,O
and,2588,O
Triglyceride,2588,B-ChemicalEntity
(,2588,O
TG,2588,B-ChemicalEntity
),2588,O
(,2588,O
LAT,2588,O
),2588,O
vs,2588,O
High,2588,O
ASP,2588,B-GeneOrGeneProduct
and,2588,O
TG,2588,B-ChemicalEntity
(,2588,O
HAT,2588,O
),2588,O
.,2588,O
Subcutaneous,2589,O
(,2589,O
SC,2589,O
),2589,O
and,2589,O
omental,2589,O
(,2589,O
OM,2589,O
),2589,O
adipose,2589,O
tissues,2589,O
(,2589,O
n,2589,O
=,2589,O
21,2589,O
),2589,O
were,2589,O
analysed,2589,O
by,2589,O
microarray,2589,O
",",2589,O
and,2589,O
biologic,2589,O
pathways,2589,O
in,2589,O
lipid,2589,B-ChemicalEntity
metabolism,2589,O
and,2589,O
inflammation,2589,B-DiseaseOrPhenotypicFeature
were,2589,O
specifically,2589,O
examined,2589,O
.,2589,O
METHODS,2590,O
:,2590,O
LAT,2590,O
and,2590,O
HAT,2590,O
groups,2590,O
were,2590,O
matched,2590,O
in,2590,O
age,2590,O
",",2590,O
obesity,2590,B-DiseaseOrPhenotypicFeature
",",2590,O
insulin,2590,B-GeneOrGeneProduct
",",2590,O
and,2590,O
glucose,2590,B-ChemicalEntity
",",2590,O
and,2590,O
had,2590,O
similar,2590,O
expression,2590,O
of,2590,O
insulin-related,2590,B-GeneOrGeneProduct
genes,2590,O
(,2590,O
InsR,2590,B-GeneOrGeneProduct
",",2590,O
IRS-1,2590,B-GeneOrGeneProduct
),2590,O
.,2590,O
ASP,2591,B-GeneOrGeneProduct
related,2591,O
genes,2591,O
tended,2591,O
to,2591,O
be,2591,O
increased,2591,O
in,2591,O
the,2591,O
HAT,2591,O
group,2591,O
and,2591,O
were,2591,O
correlated,2591,O
(,2591,O
factor,2591,B-GeneOrGeneProduct
B,2591,I-GeneOrGeneProduct
",",2591,O
adipsin,2591,B-GeneOrGeneProduct
",",2591,O
complement,2591,B-GeneOrGeneProduct
C3,2591,I-GeneOrGeneProduct
",",2591,O
p,2591,O
<,2591,O
0.01,2591,O
each,2591,O
),2591,O
.,2591,O
Differences,2592,O
between,2592,O
LAT,2592,O
and,2592,O
HAT,2592,O
group,2592,O
were,2592,O
almost,2592,O
exclusively,2592,O
in,2592,O
SC,2592,O
tissue,2592,O
",",2592,O
with,2592,O
little,2592,O
difference,2592,O
in,2592,O
OM,2592,O
tissue,2592,O
.,2592,O
Increased,2593,O
C5L2,2593,B-GeneOrGeneProduct
(,2593,O
p,2593,O
<,2593,O
0.01,2593,O
),2593,O
",",2593,O
an,2593,O
ASP,2593,B-GeneOrGeneProduct
receptor,2593,I-GeneOrGeneProduct
",",2593,O
in,2593,O
HAT,2593,O
suggests,2593,O
a,2593,O
compensatory,2593,O
ASP,2593,B-GeneOrGeneProduct
pathway,2593,O
",",2593,O
associated,2593,O
with,2593,O
increased,2593,O
TG,2593,B-ChemicalEntity
storage,2593,O
.,2593,O
RESULTS,2594,O
:,2594,O
HAT,2594,O
adipose,2594,O
tissue,2594,O
demonstrated,2594,O
increased,2594,O
lipid,2594,B-ChemicalEntity
related,2594,O
genes,2594,O
for,2594,O
storage,2594,O
(,2594,O
CD36,2594,B-GeneOrGeneProduct
",",2594,O
DGAT1,2594,B-GeneOrGeneProduct
",",2594,O
DGAT2,2594,B-GeneOrGeneProduct
",",2594,O
SCD1,2594,B-GeneOrGeneProduct
",",2594,O
FASN,2594,B-GeneOrGeneProduct
",",2594,O
and,2594,O
LPL,2594,B-GeneOrGeneProduct
),2594,O
",",2594,O
lipolysis,2594,O
(,2594,O
HSL,2594,B-GeneOrGeneProduct
",",2594,O
CES1,2594,B-GeneOrGeneProduct
",",2594,O
perilipin,2594,B-GeneOrGeneProduct
),2594,O
",",2594,O
fatty,2594,B-GeneOrGeneProduct
acid,2594,I-GeneOrGeneProduct
binding,2594,I-GeneOrGeneProduct
proteins,2594,I-GeneOrGeneProduct
(,2594,O
FABP1,2594,B-GeneOrGeneProduct
",",2594,O
FABP3,2594,B-GeneOrGeneProduct
),2594,O
and,2594,O
adipocyte,2594,O
differentiation,2594,O
markers,2594,O
(,2594,O
CEBPalpha,2594,B-GeneOrGeneProduct
",",2594,O
CEBPbeta,2594,B-GeneOrGeneProduct
",",2594,O
PPARgamma,2594,B-GeneOrGeneProduct
),2594,O
.,2594,O
By,2595,O
contrast,2595,O
",",2595,O
oxidation,2595,O
related,2595,O
genes,2595,O
were,2595,O
decreased,2595,O
(,2595,O
AMPK,2595,B-GeneOrGeneProduct
",",2595,O
UCP1,2595,B-GeneOrGeneProduct
",",2595,O
CPT1,2595,B-GeneOrGeneProduct
",",2595,O
FABP7,2595,B-GeneOrGeneProduct
),2595,O
.,2595,O
HAT,2596,O
subjects,2596,O
had,2596,O
increased,2596,O
anti-inflammatory,2596,O
genes,2596,O
TGFB1,2596,B-GeneOrGeneProduct
",",2596,O
TIMP1,2596,B-GeneOrGeneProduct
",",2596,O
TIMP3,2596,B-GeneOrGeneProduct
",",2596,O
and,2596,O
TIMP4,2596,B-GeneOrGeneProduct
while,2596,O
proinflammatory,2596,B-DiseaseOrPhenotypicFeature
PIG7,2596,B-GeneOrGeneProduct
and,2596,O
MMP2,2596,B-GeneOrGeneProduct
were,2596,O
also,2596,O
significantly,2596,O
increased,2596,O
;,2596,O
all,2596,O
genes,2596,O
",",2596,O
p,2596,O
<,2596,O
0.025,2596,O
.,2596,O
CONCLUSION,2597,O
:,2597,O
Taken,2597,O
together,2597,O
",",2597,O
the,2597,O
profile,2597,O
of,2597,O
C5L2,2597,B-GeneOrGeneProduct
receptor,2597,O
",",2597,O
ASP,2597,B-GeneOrGeneProduct
gene,2597,O
expression,2597,O
and,2597,O
metabolic,2597,O
factors,2597,O
in,2597,O
adipose,2597,O
tissue,2597,O
from,2597,O
morbidly,2597,O
obese,2597,B-DiseaseOrPhenotypicFeature
HAT,2597,O
subjects,2597,O
suggests,2597,O
a,2597,O
compensatory,2597,O
response,2597,O
associated,2597,O
with,2597,O
the,2597,O
increased,2597,O
plasma,2597,O
ASP,2597,B-GeneOrGeneProduct
and,2597,O
TG,2597,B-ChemicalEntity
.,2597,O
Fatal,2598,O
carbamazepine,2598,B-ChemicalEntity
induced,2598,O
fulminant,2598,O
eosinophilic,2598,O
(,2598,O
hypersensitivity,2598,B-DiseaseOrPhenotypicFeature
),2598,O
myocarditis,2598,B-DiseaseOrPhenotypicFeature
:,2598,O
emphasis,2598,O
on,2598,O
anatomical,2598,O
and,2598,O
histological,2598,O
characteristics,2598,O
",",2598,O
mechanisms,2598,O
and,2598,O
genetics,2598,O
of,2598,O
drug,2598,B-DiseaseOrPhenotypicFeature
hypersensitivity,2598,I-DiseaseOrPhenotypicFeature
and,2598,O
differential,2598,O
diagnosis,2598,O
.,2598,O
The,2599,O
most,2599,O
severe,2599,O
adverse,2599,O
reactions,2599,O
to,2599,O
carbamazepine,2599,B-ChemicalEntity
have,2599,O
been,2599,O
observed,2599,O
in,2599,O
the,2599,O
haemopoietic,2599,O
system,2599,O
",",2599,O
the,2599,O
liver,2599,O
and,2599,O
the,2599,O
cardiovascular,2599,O
system,2599,O
.,2599,O
A,2600,O
frequently,2600,O
fatal,2600,O
",",2600,O
although,2600,O
exceptionally,2600,O
rare,2600,O
side,2600,O
effect,2600,O
of,2600,O
carbamazepine,2600,B-ChemicalEntity
is,2600,O
necrotizing,2600,O
eosinophilic,2600,O
(,2600,O
hypersensitivity,2600,B-DiseaseOrPhenotypicFeature
),2600,O
myocarditis,2600,B-DiseaseOrPhenotypicFeature
.,2600,O
We,2601,O
report,2601,O
a,2601,O
case,2601,O
of,2601,O
hypersensitivity,2601,B-DiseaseOrPhenotypicFeature
myocarditis,2601,B-DiseaseOrPhenotypicFeature
secondary,2601,O
to,2601,O
administration,2601,O
of,2601,O
carbamazepine,2601,B-ChemicalEntity
.,2601,O
Acute,2602,O
hypersensitivity,2602,B-DiseaseOrPhenotypicFeature
myocarditis,2602,B-DiseaseOrPhenotypicFeature
was,2602,O
not,2602,O
suspected,2602,O
clinically,2602,O
",",2602,O
and,2602,O
the,2602,O
diagnosis,2602,O
was,2602,O
made,2602,O
post-mortem,2602,O
.,2602,O
Histology,2603,O
revealed,2603,O
diffuse,2603,O
infiltration,2603,O
of,2603,O
the,2603,O
myocardium,2603,O
by,2603,O
eosinophils,2603,O
and,2603,O
lymphocytes,2603,O
with,2603,O
myocyte,2603,O
damage,2603,O
.,2603,O
Clinically,2604,O
",",2604,O
death,2604,B-DiseaseOrPhenotypicFeature
was,2604,O
due,2604,O
to,2604,O
cardiogenic,2604,B-DiseaseOrPhenotypicFeature
shock,2604,I-DiseaseOrPhenotypicFeature
.,2604,O
To,2605,O
best,2605,O
of,2605,O
our,2605,O
knowledge,2605,O
this,2605,O
is,2605,O
the,2605,O
second,2605,O
case,2605,O
of,2605,O
fatal,2605,O
carbamazepine,2605,B-ChemicalEntity
induced,2605,O
myocarditis,2605,B-DiseaseOrPhenotypicFeature
reported,2605,O
in,2605,O
English,2605,O
literature,2605,O
.,2605,O
Zebrafish,2606,B-OrganismTaxon
chordin-like,2606,B-GeneOrGeneProduct
and,2606,O
chordin,2606,B-GeneOrGeneProduct
are,2606,O
functionally,2606,O
redundant,2606,O
in,2606,O
regulating,2606,O
patterning,2606,O
of,2606,O
the,2606,O
dorsoventral,2606,O
axis,2606,O
.,2606,O
Chordin,2607,B-GeneOrGeneProduct
is,2607,O
the,2607,O
prototype,2607,O
of,2607,O
a,2607,O
group,2607,O
of,2607,O
cysteine-rich,2607,B-GeneOrGeneProduct
domain-containing,2607,I-GeneOrGeneProduct
proteins,2607,I-GeneOrGeneProduct
that,2607,O
bind,2607,O
and,2607,O
modulate,2607,O
signaling,2607,O
of,2607,O
various,2607,O
TGFbeta-like,2607,B-GeneOrGeneProduct
ligands,2607,O
.,2607,O
Chordin-like,2608,B-GeneOrGeneProduct
1,2608,I-GeneOrGeneProduct
and,2608,I-GeneOrGeneProduct
2,2608,I-GeneOrGeneProduct
(,2608,O
CHL1,2608,B-GeneOrGeneProduct
and,2608,I-GeneOrGeneProduct
2,2608,I-GeneOrGeneProduct
),2608,O
are,2608,O
two,2608,O
members,2608,O
of,2608,O
this,2608,O
group,2608,O
that,2608,O
have,2608,O
been,2608,O
described,2608,O
in,2608,O
human,2608,B-OrganismTaxon
",",2608,O
mouse,2608,B-OrganismTaxon
",",2608,O
and,2608,O
chick,2608,B-OrganismTaxon
.,2608,O
However,2609,O
",",2609,O
in,2609,O
vivo,2609,O
roles,2609,O
for,2609,O
CHL1,2609,B-GeneOrGeneProduct
and,2609,I-GeneOrGeneProduct
2,2609,I-GeneOrGeneProduct
in,2609,O
early,2609,O
development,2609,O
are,2609,O
unknown,2609,O
due,2609,O
to,2609,O
lack,2609,O
of,2609,O
loss-of-function,2609,O
analysis,2609,O
.,2609,O
Here,2610,O
we,2610,O
identify,2610,O
and,2610,O
characterize,2610,O
zebrafish,2610,B-OrganismTaxon
",",2610,O
Danio,2610,B-OrganismTaxon
rerio,2610,I-OrganismTaxon
",",2610,O
CHL,2610,B-GeneOrGeneProduct
(,2610,O
Chl,2610,B-GeneOrGeneProduct
),2610,O
.,2610,O
The,2611,O
chl,2611,B-GeneOrGeneProduct
gene,2611,O
is,2611,O
on,2611,O
a,2611,O
region,2611,O
of,2611,O
chromosome,2611,O
21,2611,O
syntenic,2611,O
with,2611,O
the,2611,O
area,2611,O
of,2611,O
murine,2611,B-OrganismTaxon
chromosome,2611,O
7,2611,O
bearing,2611,O
the,2611,O
CHL2,2611,B-GeneOrGeneProduct
gene,2611,O
.,2611,O
Inability,2612,O
to,2612,O
identify,2612,O
a,2612,O
separate,2612,O
zebrafish,2612,B-OrganismTaxon
gene,2612,O
corresponding,2612,O
to,2612,O
the,2612,O
mammalian,2612,O
CHL1,2612,B-GeneOrGeneProduct
gene,2612,O
suggests,2612,O
that,2612,O
Chl,2612,B-GeneOrGeneProduct
may,2612,O
serve,2612,O
roles,2612,O
in,2612,O
zebrafish,2612,B-OrganismTaxon
distributed,2612,O
between,2612,O
CHL1,2612,B-GeneOrGeneProduct
and,2612,O
CHL2,2612,B-GeneOrGeneProduct
in,2612,O
other,2612,O
species,2612,O
.,2612,O
Chl,2613,B-GeneOrGeneProduct
is,2613,O
a,2613,O
maternal,2613,O
factor,2613,O
that,2613,O
is,2613,O
also,2613,O
zygotically,2613,O
expressed,2613,O
later,2613,O
in,2613,O
development,2613,O
and,2613,O
has,2613,O
spatiotemporal,2613,O
expression,2613,O
patterns,2613,O
that,2613,O
differ,2613,O
from,2613,O
but,2613,O
overlap,2613,O
those,2613,O
of,2613,O
zebrafish,2613,B-OrganismTaxon
chordin,2613,B-GeneOrGeneProduct
(,2613,O
Chd,2613,B-GeneOrGeneProduct
),2613,O
",",2613,O
suggesting,2613,O
differences,2613,O
but,2613,O
also,2613,O
possible,2613,O
overlap,2613,O
in,2613,O
developmental,2613,O
roles,2613,O
of,2613,O
the,2613,O
two,2613,O
proteins,2613,O
.,2613,O
Chl,2614,B-GeneOrGeneProduct
",",2614,O
like,2614,O
Chd,2614,B-GeneOrGeneProduct
",",2614,O
dorsalizes,2614,O
embryos,2614,O
upon,2614,O
overexpression,2614,O
and,2614,O
is,2614,O
cleaved,2614,O
by,2614,O
BMP1,2614,B-GeneOrGeneProduct
",",2614,O
which,2614,O
antagonizes,2614,O
this,2614,O
activity,2614,O
.,2614,O
Loss-of-function,2615,O
experiments,2615,O
demonstrate,2615,O
that,2615,O
Chl,2615,B-GeneOrGeneProduct
serves,2615,O
as,2615,O
a,2615,O
BMP,2615,B-GeneOrGeneProduct
antagonist,2615,O
with,2615,O
functions,2615,O
that,2615,O
overlap,2615,O
and,2615,O
are,2615,O
redundant,2615,O
with,2615,O
those,2615,O
of,2615,O
Chd,2615,B-GeneOrGeneProduct
in,2615,O
forming,2615,O
the,2615,O
dorsoventral,2615,O
axis,2615,O
.,2615,O
A,2616,O
cross-sectional,2616,O
evaluation,2616,O
of,2616,O
the,2616,O
effect,2616,O
of,2616,O
risperidone,2616,B-ChemicalEntity
and,2616,O
selective,2616,B-ChemicalEntity
serotonin,2616,I-ChemicalEntity
reuptake,2616,I-ChemicalEntity
inhibitors,2616,I-ChemicalEntity
on,2616,O
bone,2616,O
mineral,2616,O
density,2616,O
in,2616,O
boys,2616,O
.,2616,O
OBJECTIVE,2617,O
:,2617,O
The,2617,O
aim,2617,O
of,2617,O
the,2617,O
present,2617,O
study,2617,O
was,2617,O
to,2617,O
investigate,2617,O
the,2617,O
effect,2617,O
of,2617,O
risperidone-induced,2617,B-ChemicalEntity
hyperprolactinemia,2617,B-DiseaseOrPhenotypicFeature
on,2617,O
trabecular,2617,O
bone,2617,O
mineral,2617,O
density,2617,O
(,2617,O
BMD,2617,O
),2617,O
in,2617,O
children,2617,O
and,2617,O
adolescents,2617,O
.,2617,O
METHOD,2618,O
:,2618,O
Medically,2618,O
healthy,2618,O
7-,2618,O
to,2618,O
17-year-old,2618,O
males,2618,O
chronically,2618,O
treated,2618,O
",",2618,O
in,2618,O
a,2618,O
naturalistic,2618,O
setting,2618,O
",",2618,O
with,2618,O
risperidone,2618,B-ChemicalEntity
were,2618,O
recruited,2618,O
for,2618,O
this,2618,O
cross-sectional,2618,O
study,2618,O
through,2618,O
child,2618,O
psychiatry,2618,O
outpatient,2618,B-OrganismTaxon
clinics,2618,O
between,2618,O
November,2618,O
2005,2618,O
and,2618,O
June,2618,O
2007,2618,O
.,2618,O
Anthropometric,2619,O
measurements,2619,O
and,2619,O
laboratory,2619,O
testing,2619,O
were,2619,O
conducted,2619,O
.,2619,O
The,2620,O
clinical,2620,O
diagnoses,2620,O
were,2620,O
based,2620,O
on,2620,O
chart,2620,O
review,2620,O
",",2620,O
and,2620,O
developmental,2620,O
and,2620,O
treatment,2620,O
history,2620,O
was,2620,O
obtained,2620,O
from,2620,O
the,2620,O
medical,2620,O
record,2620,O
.,2620,O
Volumetric,2621,O
BMD,2621,O
of,2621,O
the,2621,O
ultradistal,2621,O
radius,2621,O
was,2621,O
measured,2621,O
using,2621,O
peripheral,2621,O
quantitative,2621,O
computed,2621,O
tomography,2621,O
",",2621,O
and,2621,O
areal,2621,O
BMD,2621,O
of,2621,O
the,2621,O
lumbar,2621,O
spine,2621,O
was,2621,O
estimated,2621,O
using,2621,O
dual-energy,2621,O
x-ray,2621,O
absorptiometry,2621,O
.,2621,O
RESULTS,2622,O
:,2622,O
Hyperprolactinemia,2622,B-DiseaseOrPhenotypicFeature
was,2622,O
present,2622,O
in,2622,O
49,2622,O
%,2622,O
of,2622,O
83,2622,O
boys,2622,O
(,2622,O
n,2622,O
=,2622,O
41,2622,O
),2622,O
treated,2622,O
with,2622,O
risperidone,2622,B-ChemicalEntity
for,2622,O
a,2622,O
mean,2622,O
of,2622,O
2.9,2622,O
years,2622,O
.,2622,O
Serum,2623,O
testosterone,2623,B-ChemicalEntity
concentration,2623,O
increased,2623,O
with,2623,O
pubertal,2623,O
status,2623,O
but,2623,O
was,2623,O
not,2623,O
affected,2623,O
by,2623,O
hyperprolactinemia,2623,B-DiseaseOrPhenotypicFeature
.,2623,O
As,2624,O
expected,2624,O
",",2624,O
bone,2624,O
mineral,2624,O
content,2624,O
and,2624,O
BMD,2624,O
increased,2624,O
with,2624,O
sexual,2624,O
maturity,2624,O
.,2624,O
After,2625,O
adjusting,2625,O
for,2625,O
the,2625,O
stage,2625,O
of,2625,O
sexual,2625,O
development,2625,O
and,2625,O
height,2625,O
and,2625,O
BMI,2625,O
z,2625,O
scores,2625,O
",",2625,O
serum,2625,O
prolactin,2625,B-GeneOrGeneProduct
was,2625,O
negatively,2625,O
associated,2625,O
with,2625,O
trabecular,2625,O
volumetric,2625,O
BMD,2625,O
at,2625,O
the,2625,O
ultradistal,2625,O
radius,2625,O
(,2625,O
P,2625,O
<,2625,O
.03,2625,O
),2625,O
.,2625,O
Controlling,2626,O
for,2626,O
relevant,2626,O
covariates,2626,O
",",2626,O
we,2626,O
also,2626,O
found,2626,O
treatment,2626,O
with,2626,O
selective,2626,B-ChemicalEntity
serotonin,2626,I-ChemicalEntity
reuptake,2626,I-ChemicalEntity
inhibitors,2626,I-ChemicalEntity
(,2626,O
SSRIs,2626,B-ChemicalEntity
),2626,O
to,2626,O
be,2626,O
associated,2626,O
with,2626,O
lower,2626,O
trabecular,2626,O
BMD,2626,O
at,2626,O
the,2626,O
radius,2626,O
(,2626,O
P,2626,O
=,2626,O
.03,2626,O
),2626,O
and,2626,O
BMD,2626,O
z,2626,O
score,2626,O
at,2626,O
the,2626,O
lumbar,2626,O
spine,2626,O
(,2626,O
P,2626,O
<,2626,O
.05,2626,O
),2626,O
.,2626,O
These,2627,O
findings,2627,O
became,2627,O
more,2627,O
marked,2627,O
when,2627,O
the,2627,O
analysis,2627,O
was,2627,O
restricted,2627,O
to,2627,O
non-Hispanic,2627,O
white,2627,O
patients,2627,B-OrganismTaxon
.,2627,O
Of,2628,O
13,2628,O
documented,2628,O
fractures,2628,B-DiseaseOrPhenotypicFeature
",",2628,O
3,2628,O
occurred,2628,O
after,2628,O
risperidone,2628,B-ChemicalEntity
and,2628,O
SSRIs,2628,B-ChemicalEntity
were,2628,O
started,2628,O
",",2628,O
and,2628,O
none,2628,O
occurred,2628,O
in,2628,O
patients,2628,B-OrganismTaxon
with,2628,O
hyperprolactinemia,2628,B-DiseaseOrPhenotypicFeature
.,2628,O
CONCLUSIONS,2629,O
:,2629,O
This,2629,O
is,2629,O
the,2629,O
first,2629,O
study,2629,O
to,2629,O
link,2629,O
risperidone-induced,2629,B-ChemicalEntity
hyperprolactinemia,2629,B-DiseaseOrPhenotypicFeature
and,2629,O
SSRI,2629,B-ChemicalEntity
treatment,2629,O
to,2629,O
lower,2629,O
BMD,2629,O
in,2629,O
children,2629,O
and,2629,O
adolescents,2629,O
.,2629,O
Future,2630,O
research,2630,O
should,2630,O
evaluate,2630,O
the,2630,O
longitudinal,2630,O
course,2630,O
of,2630,O
this,2630,O
adverse,2630,O
event,2630,O
to,2630,O
determine,2630,O
its,2630,O
temporal,2630,O
stability,2630,O
and,2630,O
whether,2630,O
a,2630,O
higher,2630,O
fracture,2630,B-DiseaseOrPhenotypicFeature
rate,2630,O
ensues,2630,O
.,2630,O
A,2631,O
novel,2631,O
point,2631,O
mutation,2631,O
in,2631,O
helix,2631,O
10,2631,O
of,2631,O
the,2631,O
human,2631,B-OrganismTaxon
glucocorticoid,2631,B-GeneOrGeneProduct
receptor,2631,I-GeneOrGeneProduct
causes,2631,O
generalized,2631,O
glucocorticoid,2631,B-DiseaseOrPhenotypicFeature
resistance,2631,I-DiseaseOrPhenotypicFeature
by,2631,O
disrupting,2631,O
the,2631,O
structure,2631,O
of,2631,O
the,2631,O
ligand-binding,2631,O
domain,2631,O
.,2631,O
CONTEXT,2632,O
:,2632,O
Generalized,2632,O
glucocorticoid,2632,B-DiseaseOrPhenotypicFeature
resistance,2632,I-DiseaseOrPhenotypicFeature
syndrome,2632,O
is,2632,O
a,2632,O
rare,2632,O
familial,2632,O
or,2632,O
sporadic,2632,O
condition,2632,O
characterized,2632,O
by,2632,O
partial,2632,O
insensitivity,2632,O
to,2632,O
glucocorticoids,2632,B-ChemicalEntity
",",2632,O
caused,2632,O
by,2632,O
mutations,2632,O
in,2632,O
the,2632,O
glucocorticoid,2632,B-GeneOrGeneProduct
receptor,2632,I-GeneOrGeneProduct
(,2632,O
GR,2632,B-GeneOrGeneProduct
),2632,O
gene,2632,O
.,2632,O
Most,2633,O
of,2633,O
the,2633,O
reported,2633,O
cases,2633,O
are,2633,O
adults,2633,O
",",2633,O
demonstrating,2633,O
symptoms,2633,O
associated,2633,O
with,2633,O
mineralocorticoid,2633,B-ChemicalEntity
and/or,2633,O
adrenal,2633,O
androgen,2633,B-ChemicalEntity
excess,2633,O
caused,2633,O
by,2633,O
compensatively,2633,O
increased,2633,O
secretion,2633,O
of,2633,O
the,2633,O
adrenocorticotropic,2633,O
hormone,2633,O
.,2633,O
PATIENT,2634,B-OrganismTaxon
:,2634,O
We,2634,O
identified,2634,O
a,2634,O
new,2634,O
2-yr-old,2634,O
female,2634,O
case,2634,O
of,2634,O
generalized,2634,O
glucocorticoid,2634,B-DiseaseOrPhenotypicFeature
resistance,2634,I-DiseaseOrPhenotypicFeature
syndrome,2634,O
.,2634,O
The,2635,O
patient,2635,B-OrganismTaxon
(,2635,O
TJ,2635,O
),2635,O
presented,2635,O
with,2635,O
a,2635,O
generalized,2635,O
seizure,2635,B-DiseaseOrPhenotypicFeature
associated,2635,O
with,2635,O
hypoglycemia,2635,B-DiseaseOrPhenotypicFeature
and,2635,O
hypokalemia,2635,B-DiseaseOrPhenotypicFeature
.,2635,O
She,2636,O
also,2636,O
had,2636,O
hypertension,2636,B-DiseaseOrPhenotypicFeature
and,2636,O
premature,2636,B-DiseaseOrPhenotypicFeature
pubarche,2636,I-DiseaseOrPhenotypicFeature
",",2636,O
whereas,2636,O
dexamethasone,2636,B-ChemicalEntity
effectively,2636,O
suppressed,2636,O
these,2636,O
clinical,2636,O
manifestations,2636,O
.,2636,O
RESULTS,2637,O
:,2637,O
The,2637,O
patient,2637,B-OrganismTaxon
's,2637,O
GR,2637,B-GeneOrGeneProduct
gene,2637,O
had,2637,O
a,2637,O
heterozygotic,2637,O
mutation,2637,O
(,2637,B-SequenceVariant
G,2637,I-SequenceVariant
--,2637,I-SequenceVariant
>,2637,I-SequenceVariant
A,2637,I-SequenceVariant
),2637,I-SequenceVariant
at,2637,I-SequenceVariant
nucleotide,2637,I-SequenceVariant
position,2637,I-SequenceVariant
2141,2637,I-SequenceVariant
(,2637,O
exon,2637,O
8,2637,O
),2637,O
",",2637,O
which,2637,O
resulted,2637,O
in,2637,O
substitution,2637,O
of,2637,O
arginine,2637,B-SequenceVariant
by,2637,I-SequenceVariant
glutamine,2637,I-SequenceVariant
at,2637,I-SequenceVariant
amino,2637,I-SequenceVariant
acid,2637,I-SequenceVariant
position,2637,I-SequenceVariant
714,2637,I-SequenceVariant
in,2637,O
the,2637,O
ligand-binding,2637,O
domain,2637,O
(,2637,O
LBD,2637,O
),2637,O
of,2637,O
the,2637,O
GR,2637,B-GeneOrGeneProduct
alpha,2637,I-GeneOrGeneProduct
.,2637,O
Molecular,2638,O
analysis,2638,O
revealed,2638,O
that,2638,O
the,2638,O
mutant,2638,O
receptor,2638,O
had,2638,O
significantly,2638,O
impaired,2638,O
transactivation,2638,O
activity,2638,O
with,2638,O
a,2638,O
2-fold,2638,O
reduction,2638,O
in,2638,O
affinity,2638,O
to,2638,O
ligand,2638,O
.,2638,O
It,2639,O
showed,2639,O
attenuated,2639,O
transactivation,2639,O
of,2639,O
the,2639,O
activation,2639,O
function,2639,O
(,2639,O
AF,2639,O
),2639,O
-2,2639,O
and,2639,O
reduced,2639,O
binding,2639,O
to,2639,O
a,2639,O
p160,2639,B-GeneOrGeneProduct
nuclear,2639,I-GeneOrGeneProduct
receptor,2639,I-GeneOrGeneProduct
coactivator,2639,I-GeneOrGeneProduct
.,2639,O
Computer-based,2640,O
structural,2640,O
analysis,2640,O
revealed,2640,O
that,2640,O
replacement,2640,O
of,2640,O
arginine,2640,B-SequenceVariant
by,2640,I-SequenceVariant
glutamine,2640,I-SequenceVariant
at,2640,I-SequenceVariant
position,2640,I-SequenceVariant
714,2640,I-SequenceVariant
transmitted,2640,O
a,2640,O
conformational,2640,O
change,2640,O
to,2640,O
the,2640,O
LBD,2640,O
and,2640,O
the,2640,O
AF-2,2640,O
transactivation,2640,O
surface,2640,O
",",2640,O
resulting,2640,O
in,2640,O
a,2640,O
decreased,2640,O
binding,2640,O
affinity,2640,O
to,2640,O
ligand,2640,O
and,2640,O
to,2640,O
the,2640,O
LXXLL,2640,O
coactivator,2640,O
motif,2640,O
.,2640,O
CONCLUSIONS,2641,O
:,2641,O
Dexamethasone,2641,B-ChemicalEntity
treatment,2641,O
is,2641,O
effective,2641,O
in,2641,O
controlling,2641,O
the,2641,O
premature,2641,B-DiseaseOrPhenotypicFeature
pubarche,2641,I-DiseaseOrPhenotypicFeature
",",2641,O
hypoglycemia,2641,B-DiseaseOrPhenotypicFeature
",",2641,O
hypertension,2641,B-DiseaseOrPhenotypicFeature
",",2641,O
and,2641,O
hypokalemia,2641,B-DiseaseOrPhenotypicFeature
in,2641,O
this,2641,O
child,2641,O
case,2641,O
",",2641,O
wherein,2641,O
arginine,2641,B-SequenceVariant
714,2641,I-SequenceVariant
plays,2641,O
a,2641,O
key,2641,O
role,2641,O
in,2641,O
the,2641,O
proper,2641,O
formation,2641,O
of,2641,O
the,2641,O
ligand-binding,2641,O
pocket,2641,O
and,2641,O
the,2641,O
AF-2,2641,O
surface,2641,O
of,2641,O
the,2641,O
GR,2641,B-GeneOrGeneProduct
alpha,2641,I-GeneOrGeneProduct
LBD,2641,O
.,2641,O
Mutation,2642,O
analysis,2642,O
in,2642,O
a,2642,O
Chinese,2642,O
family,2642,O
with,2642,O
multiple,2642,B-DiseaseOrPhenotypicFeature
endocrine,2642,I-DiseaseOrPhenotypicFeature
neoplasia,2642,I-DiseaseOrPhenotypicFeature
type,2642,I-DiseaseOrPhenotypicFeature
1,2642,I-DiseaseOrPhenotypicFeature
.,2642,O
BACKGROUND,2643,O
:,2643,O
Multiple,2643,B-DiseaseOrPhenotypicFeature
endocrine,2643,I-DiseaseOrPhenotypicFeature
neoplasia,2643,I-DiseaseOrPhenotypicFeature
type,2643,I-DiseaseOrPhenotypicFeature
1,2643,I-DiseaseOrPhenotypicFeature
(,2643,O
MEN1,2643,B-DiseaseOrPhenotypicFeature
),2643,O
is,2643,O
an,2643,O
autosomal,2643,B-DiseaseOrPhenotypicFeature
dominant,2643,I-DiseaseOrPhenotypicFeature
cancer,2643,I-DiseaseOrPhenotypicFeature
syndrome,2643,I-DiseaseOrPhenotypicFeature
which,2643,O
is,2643,O
caused,2643,O
by,2643,O
germline,2643,O
mutations,2643,O
of,2643,O
the,2643,O
tumor,2643,B-DiseaseOrPhenotypicFeature
suppressor,2643,O
gene,2643,O
MEN1,2643,B-GeneOrGeneProduct
.,2643,O
This,2644,O
study,2644,O
aimed,2644,O
to,2644,O
identify,2644,O
mutations,2644,O
in,2644,O
a,2644,O
Chinese,2644,O
pedigree,2644,O
with,2644,O
MEN1,2644,B-DiseaseOrPhenotypicFeature
.,2644,O
METHODS,2645,O
:,2645,O
A,2645,O
large,2645,O
Chinese,2645,O
family,2645,O
with,2645,O
MEN1,2645,B-DiseaseOrPhenotypicFeature
was,2645,O
collected,2645,O
.,2645,O
All,2646,O
of,2646,O
the,2646,O
coded,2646,O
regions,2646,O
and,2646,O
their,2646,O
adjacent,2646,O
sequences,2646,O
of,2646,O
the,2646,O
MEN1,2646,B-GeneOrGeneProduct
gene,2646,O
were,2646,O
amplified,2646,O
and,2646,O
sequenced,2646,O
.,2646,O
RESULTS,2647,O
:,2647,O
In,2647,O
this,2647,O
family,2647,O
",",2647,O
a,2647,O
heterozygous,2647,O
cytosine,2647,B-SequenceVariant
insertion,2647,I-SequenceVariant
in,2647,O
exon,2647,O
10,2647,O
(,2647,O
c.1546_1547insC,2647,B-SequenceVariant
),2647,O
inducing,2647,O
a,2647,O
frame,2647,O
shift,2647,O
mutation,2647,O
of,2647,O
MEN1,2647,B-GeneOrGeneProduct
was,2647,O
found,2647,O
in,2647,O
the,2647,O
proband,2647,O
and,2647,O
the,2647,O
other,2647,O
two,2647,O
suffering,2647,O
members,2647,O
of,2647,O
his,2647,O
family,2647,O
.,2647,O
This,2648,O
mutation,2648,O
was,2648,O
linked,2648,O
to,2648,O
a,2648,O
novel,2648,O
single,2648,O
nucleotide,2648,O
polymorphism,2648,O
(,2648,O
SNP,2648,O
),2648,O
in,2648,O
intron,2648,O
3,2648,O
(,2648,O
IVS3,2648,B-SequenceVariant
+,2648,I-SequenceVariant
18C,2648,I-SequenceVariant
>,2648,I-SequenceVariant
T,2648,I-SequenceVariant
),2648,O
.,2648,O
CONCLUSIONS,2649,O
:,2649,O
The,2649,O
mutation,2649,O
in,2649,O
exon,2649,O
10,2649,O
of,2649,O
MEN1,2649,B-GeneOrGeneProduct
gene,2649,O
might,2649,O
induce,2649,O
development,2649,O
of,2649,O
parathyroid,2649,B-DiseaseOrPhenotypicFeature
hyperplasia,2649,I-DiseaseOrPhenotypicFeature
and,2649,O
pituitary,2649,B-DiseaseOrPhenotypicFeature
adenoma,2649,I-DiseaseOrPhenotypicFeature
and,2649,O
cosegregate,2649,O
with,2649,O
MEN1,2649,B-DiseaseOrPhenotypicFeature
syndrome,2649,I-DiseaseOrPhenotypicFeature
.,2649,O
The,2650,O
significance,2650,O
of,2650,O
the,2650,O
new,2650,O
found,2650,O
IVS3,2650,B-SequenceVariant
+,2650,I-SequenceVariant
18C,2650,I-SequenceVariant
>,2650,I-SequenceVariant
T,2650,I-SequenceVariant
of,2650,O
MEN1,2650,B-GeneOrGeneProduct
needs,2650,O
a,2650,O
further,2650,O
investigation,2650,O
.,2650,O
The,2651,O
human,2651,B-OrganismTaxon
AHR,2651,B-GeneOrGeneProduct
:,2651,O
identification,2651,O
of,2651,O
single,2651,O
nucleotide,2651,O
polymorphisms,2651,O
from,2651,O
six,2651,O
ethnic,2651,O
populations,2651,O
.,2651,O
BACKGROUND,2652,O
:,2652,O
The,2652,O
effects,2652,O
of,2652,O
"2,3,7,8-tetrachlorodibenzo-p-dioxin",2652,B-ChemicalEntity
and,2652,O
related,2652,O
dioxin-like,2652,B-ChemicalEntity
chemicals,2652,O
are,2652,O
mediated,2652,O
through,2652,O
binding-dependent,2652,O
activation,2652,O
of,2652,O
the,2652,O
cytosolic,2652,O
aryl,2652,B-GeneOrGeneProduct
hydrocarbon,2652,I-GeneOrGeneProduct
receptor,2652,I-GeneOrGeneProduct
(,2652,O
AHR,2652,B-GeneOrGeneProduct
),2652,O
.,2652,O
The,2653,O
human,2653,B-OrganismTaxon
AHR,2653,B-GeneOrGeneProduct
is,2653,O
a,2653,O
low-affinity,2653,O
receptor,2653,O
relative,2653,O
to,2653,O
most,2653,O
rodents,2653,O
",",2653,O
but,2653,O
some,2653,O
reports,2653,O
suggest,2653,O
that,2653,O
there,2653,O
may,2653,O
be,2653,O
individuals,2653,O
with,2653,O
polymorphic,2653,O
high-affinity,2653,O
receptors,2653,O
",",2653,O
thereby,2653,O
possibly,2653,O
increasing,2653,O
the,2653,O
sensitivity,2653,O
to,2653,O
dioxins,2653,B-ChemicalEntity
in,2653,O
such,2653,O
people,2653,O
.,2653,O
METHODS,2654,O
:,2654,O
Although,2654,O
no,2654,O
polymorphisms,2654,O
have,2654,O
been,2654,O
reported,2654,O
in,2654,O
the,2654,O
ligand,2654,O
binding,2654,O
region,2654,O
of,2654,O
the,2654,O
AHR,2654,B-GeneOrGeneProduct
in,2654,O
the,2654,O
over,2654,O
100,2654,O
reported,2654,O
sequences,2654,O
",",2654,O
we,2654,O
sequenced,2654,O
108,2654,O
additional,2654,O
human,2654,B-OrganismTaxon
AHR,2654,B-GeneOrGeneProduct
genes,2654,O
in,2654,O
an,2654,O
effort,2654,O
to,2654,O
further,2654,O
identify,2654,O
single,2654,O
single,2654,O
nucleotide,2654,O
polymorphisms,2654,O
(,2654,O
SNPs,2654,O
),2654,O
within,2654,O
the,2654,O
open,2654,O
reading,2654,O
frames,2654,O
of,2654,O
the,2654,O
AHR,2654,B-GeneOrGeneProduct
locus,2654,O
.,2654,O
The,2655,O
DNA,2655,O
was,2655,O
sequenced,2655,O
from,2655,O
six,2655,O
ethnic,2655,O
populations,2655,O
that,2655,O
included,2655,O
Japanese,2655,O
",",2655,O
Chinese,2655,O
",",2655,O
European/Caucasian,2655,O
",",2655,O
African-American,2655,O
",",2655,O
South,2655,O
East,2655,O
Asian,2655,O
",",2655,O
and,2655,O
Hispanic,2655,O
.,2655,O
RESULTS,2656,O
:,2656,O
Six,2656,O
exonic,2656,O
SNPs,2656,O
were,2656,O
identified,2656,O
;,2656,O
four,2656,O
had,2656,O
been,2656,O
described,2656,O
as,2656,O
previously,2656,O
reported,2656,O
and,2656,O
two,2656,O
seem,2656,O
to,2656,O
be,2656,O
novel,2656,O
.,2656,O
Four,2657,O
of,2657,O
the,2657,O
SNPs,2657,O
identified,2657,O
lead,2657,O
to,2657,O
amino,2657,O
acid,2657,O
changes,2657,O
in,2657,O
the,2657,O
AHR,2657,B-GeneOrGeneProduct
protein,2657,O
and,2657,O
two,2657,O
of,2657,O
the,2657,O
SNPs,2657,O
lead,2657,O
to,2657,O
synonymous,2657,O
substitutions,2657,O
.,2657,O
An,2658,O
additional,2658,O
four,2658,O
SNPs,2658,O
have,2658,O
been,2658,O
reported,2658,O
elsewhere,2658,O
that,2658,O
were,2658,O
not,2658,O
identified,2658,O
in,2658,O
the,2658,O
current,2658,O
analysis,2658,O
.,2658,O
With,2659,O
these,2659,O
new,2659,O
sequences,2659,O
",",2659,O
more,2659,O
than,2659,O
200,2659,O
human,2659,B-OrganismTaxon
AHR,2659,B-GeneOrGeneProduct
gene,2659,O
sequences,2659,O
have,2659,O
been,2659,O
analyzed,2659,O
for,2659,O
SNPs,2659,O
.,2659,O
CONCLUSION,2660,O
:,2660,O
The,2660,O
results,2660,O
indicate,2660,O
a,2660,O
very,2660,O
limited,2660,O
presence,2660,O
of,2660,O
polymorphisms,2660,O
in,2660,O
the,2660,O
core,2660,O
ligand,2660,O
binding,2660,O
region,2660,O
of,2660,O
the,2660,O
human,2660,B-OrganismTaxon
AHR,2660,B-GeneOrGeneProduct
.,2660,O
Other,2661,O
regions,2661,O
",",2661,O
such,2661,O
as,2661,O
the,2661,O
transactivation,2661,O
domain,2661,O
",",2661,O
seem,2661,O
to,2661,O
be,2661,O
slightly,2661,O
more,2661,O
polymorphic,2661,O
in,2661,O
the,2661,O
human,2661,B-OrganismTaxon
population,2661,O
and,2661,O
the,2661,O
impact,2661,O
on,2661,O
functionality,2661,O
should,2661,O
be,2661,O
further,2661,O
examined,2661,O
.,2661,O
Vitamin,2662,B-ChemicalEntity
E,2662,I-ChemicalEntity
reduces,2662,O
cardiovascular,2662,B-DiseaseOrPhenotypicFeature
disease,2662,I-DiseaseOrPhenotypicFeature
in,2662,O
individuals,2662,O
with,2662,O
diabetes,2662,B-DiseaseOrPhenotypicFeature
mellitus,2662,I-DiseaseOrPhenotypicFeature
and,2662,O
the,2662,O
haptoglobin,2662,B-GeneOrGeneProduct
2-2,2662,O
genotype,2662,O
.,2662,O
AIMS,2663,O
:,2663,O
Individuals,2663,O
with,2663,O
both,2663,O
diabetes,2663,B-DiseaseOrPhenotypicFeature
mellitus,2663,I-DiseaseOrPhenotypicFeature
(,2663,O
DM,2663,B-DiseaseOrPhenotypicFeature
),2663,O
and,2663,O
the,2663,O
Haptoglobin,2663,B-GeneOrGeneProduct
(,2663,O
Hp,2663,B-GeneOrGeneProduct
),2663,O
2-2,2663,O
genotype,2663,O
are,2663,O
at,2663,O
increased,2663,O
risk,2663,O
of,2663,O
cardiovascular,2663,B-DiseaseOrPhenotypicFeature
disease,2663,I-DiseaseOrPhenotypicFeature
.,2663,O
As,2664,O
the,2664,O
antioxidant,2664,O
function,2664,O
of,2664,O
the,2664,O
Hp,2664,B-GeneOrGeneProduct
2-2,2664,O
protein,2664,O
is,2664,O
impaired,2664,O
",",2664,O
we,2664,O
sought,2664,O
to,2664,O
test,2664,O
the,2664,O
pharmacogenomic,2664,O
hypothesis,2664,O
that,2664,O
antioxidant,2664,B-ChemicalEntity
vitamin,2664,B-ChemicalEntity
E,2664,I-ChemicalEntity
supplementation,2664,O
would,2664,O
provide,2664,O
cardiovascular,2664,O
protection,2664,O
to,2664,O
Hp,2664,B-GeneOrGeneProduct
2-2,2664,O
DM,2664,B-DiseaseOrPhenotypicFeature
individuals,2664,O
.,2664,O
MATERIALS,2665,O
&,2665,O
METHODS,2665,O
:,2665,O
We,2665,O
determined,2665,O
the,2665,O
Hp,2665,B-GeneOrGeneProduct
genotype,2665,O
on,2665,O
DM,2665,B-DiseaseOrPhenotypicFeature
participants,2665,O
from,2665,O
two,2665,O
trials,2665,O
(,2665,O
HOPE,2665,O
and,2665,O
ICARE,2665,O
),2665,O
and,2665,O
assessed,2665,O
the,2665,O
effect,2665,O
of,2665,O
vitamin,2665,B-ChemicalEntity
E,2665,I-ChemicalEntity
by,2665,O
Hp,2665,B-GeneOrGeneProduct
genotype,2665,O
on,2665,O
their,2665,O
common,2665,O
prespecified,2665,O
outcome,2665,O
",",2665,O
the,2665,O
composite,2665,O
of,2665,O
stroke,2665,B-DiseaseOrPhenotypicFeature
",",2665,O
myocardial,2665,B-DiseaseOrPhenotypicFeature
infarction,2665,I-DiseaseOrPhenotypicFeature
and,2665,O
cardiovascular,2665,B-DiseaseOrPhenotypicFeature
death,2665,I-DiseaseOrPhenotypicFeature
.,2665,O
Data,2666,O
was,2666,O
analyzed,2666,O
with,2666,O
a,2666,O
fixed-effect,2666,O
model,2666,O
.,2666,O
These,2667,O
results,2667,O
were,2667,O
input,2667,O
into,2667,O
a,2667,O
simulation,2667,O
model,2667,O
",",2667,O
the,2667,O
Evidence,2667,O
Based,2667,O
Medicine,2667,O
Integrator,2667,O
",",2667,O
in,2667,O
order,2667,O
to,2667,O
estimate,2667,O
their,2667,O
long-term,2667,O
implications,2667,O
in,2667,O
a,2667,O
real-world,2667,O
population,2667,O
from,2667,O
Kaiser,2667,O
Permanente,2667,O
(,2667,O
CA,2667,O
",",2667,O
USA,2667,O
),2667,O
.,2667,O
RESULTS,2668,O
:,2668,O
Meta-analysis,2668,O
of,2668,O
the,2668,O
two,2668,O
trials,2668,O
demonstrated,2668,O
a,2668,O
significant,2668,O
overall,2668,O
reduction,2668,O
in,2668,O
the,2668,O
composite,2668,O
end,2668,O
point,2668,O
in,2668,O
Hp,2668,B-GeneOrGeneProduct
2-2,2668,O
DM,2668,B-DiseaseOrPhenotypicFeature
individuals,2668,O
with,2668,O
vitamin,2668,B-ChemicalEntity
E,2668,I-ChemicalEntity
(,2668,O
odds,2668,O
ratio,2668,O
:,2668,O
0.58,2668,O
;,2668,O
95,2668,O
%,2668,O
CI,2668,O
:,2668,O
0.40-0.86,2668,O
;,2668,O
p,2668,O
=,2668,O
0.006,2668,O
),2668,O
.,2668,O
There,2669,O
was,2669,O
a,2669,O
statistically,2669,O
significant,2669,O
interaction,2669,O
between,2669,O
the,2669,O
Hp,2669,B-GeneOrGeneProduct
genotype,2669,O
and,2669,O
vitamin,2669,B-ChemicalEntity
E,2669,I-ChemicalEntity
on,2669,O
the,2669,O
composite,2669,O
end,2669,O
point,2669,O
.,2669,O
In,2670,O
these,2670,O
trials,2670,O
",",2670,O
Hp,2670,B-GeneOrGeneProduct
typing,2670,O
of,2670,O
69,2670,O
DM,2670,B-DiseaseOrPhenotypicFeature
individuals,2670,O
and,2670,O
treating,2670,O
those,2670,O
with,2670,O
the,2670,O
Hp,2670,B-GeneOrGeneProduct
2-2,2670,O
with,2670,O
vitamin,2670,B-ChemicalEntity
E,2670,I-ChemicalEntity
prevented,2670,O
one,2670,O
myocardial,2670,B-DiseaseOrPhenotypicFeature
infarct,2670,I-DiseaseOrPhenotypicFeature
",",2670,O
stroke,2670,B-DiseaseOrPhenotypicFeature
or,2670,O
cardiovascular,2670,B-DiseaseOrPhenotypicFeature
death,2670,I-DiseaseOrPhenotypicFeature
.,2670,O
Lifelong,2671,O
administration,2671,O
of,2671,O
vitamin,2671,B-ChemicalEntity
E,2671,I-ChemicalEntity
to,2671,O
Hp,2671,B-GeneOrGeneProduct
2-2,2671,O
DM,2671,B-DiseaseOrPhenotypicFeature
individuals,2671,O
in,2671,O
the,2671,O
Kaiser,2671,O
population,2671,O
would,2671,O
increase,2671,O
their,2671,O
life,2671,O
expectancy,2671,O
by,2671,O
3,2671,O
years,2671,O
.,2671,O
CONCLUSION,2672,O
:,2672,O
A,2672,O
pharmacogenomic,2672,O
strategy,2672,O
of,2672,O
screening,2672,O
DM,2672,B-DiseaseOrPhenotypicFeature
individuals,2672,O
for,2672,O
the,2672,O
Hp,2672,B-GeneOrGeneProduct
genotype,2672,O
and,2672,O
treating,2672,O
those,2672,O
with,2672,O
Hp,2672,B-GeneOrGeneProduct
2-2,2672,O
with,2672,O
vitamin,2672,B-ChemicalEntity
E,2672,I-ChemicalEntity
appears,2672,O
to,2672,O
be,2672,O
highly,2672,O
clinically,2672,O
effective,2672,O
.,2672,O
Effect,2673,O
of,2673,O
the,2673,O
abrogation,2673,O
of,2673,O
TGF-beta1,2673,B-GeneOrGeneProduct
by,2673,O
antisense,2673,O
oligonucleotides,2673,B-ChemicalEntity
on,2673,O
the,2673,O
expression,2673,O
of,2673,O
TGF-beta-isoforms,2673,B-GeneOrGeneProduct
and,2673,I-GeneOrGeneProduct
their,2673,I-GeneOrGeneProduct
receptors,2673,I-GeneOrGeneProduct
I,2673,I-GeneOrGeneProduct
and,2673,I-GeneOrGeneProduct
II,2673,I-GeneOrGeneProduct
in,2673,O
isolated,2673,O
fibroblasts,2673,O
from,2673,O
keloid,2673,B-DiseaseOrPhenotypicFeature
scars,2673,I-DiseaseOrPhenotypicFeature
.,2673,O
Disequilibrium,2674,O
of,2674,O
dermal,2674,O
wound,2674,O
repair,2674,O
can,2674,O
result,2674,O
in,2674,O
continued,2674,O
accumulation,2674,O
of,2674,O
ECM,2674,O
and,2674,O
excessive,2674,O
scar,2674,O
formation,2674,O
.,2674,O
In,2675,O
susceptible,2675,O
genetically,2675,O
predisposed,2675,O
individuals,2675,O
",",2675,O
keloid,2675,B-DiseaseOrPhenotypicFeature
formation,2675,O
can,2675,O
be,2675,O
observed,2675,O
.,2675,O
Keloid,2676,B-DiseaseOrPhenotypicFeature
disease,2676,I-DiseaseOrPhenotypicFeature
represents,2676,O
a,2676,O
benign,2676,O
dermal,2676,O
fibroproliferative,2676,O
tumor,2676,B-DiseaseOrPhenotypicFeature
that,2676,O
is,2676,O
unique,2676,O
to,2676,O
humans,2676,B-OrganismTaxon
.,2676,O
TGF-beta,2677,B-GeneOrGeneProduct
is,2677,O
known,2677,O
to,2677,O
play,2677,O
a,2677,O
key,2677,O
role,2677,O
in,2677,O
the,2677,O
pathogenesis,2677,O
of,2677,O
this,2677,O
disease,2677,O
which,2677,O
is,2677,O
still,2677,O
not,2677,O
fully,2677,O
understood,2677,O
.,2677,O
The,2678,O
isoforms,2678,O
TGF-beta1,2678,B-GeneOrGeneProduct
and,2678,O
TGF-beta2,2678,B-GeneOrGeneProduct
have,2678,O
profibrotic,2678,O
properties,2678,O
",",2678,O
whereas,2678,O
TGF-beta3,2678,B-GeneOrGeneProduct
may,2678,O
have,2678,O
antifibrotic,2678,O
functions,2678,O
.,2678,O
TGF-beta,2679,B-GeneOrGeneProduct
exerts,2679,O
its,2679,O
influence,2679,O
by,2679,O
binding,2679,O
to,2679,O
type,2679,B-GeneOrGeneProduct
I,2679,I-GeneOrGeneProduct
and,2679,I-GeneOrGeneProduct
type,2679,I-GeneOrGeneProduct
II,2679,I-GeneOrGeneProduct
TGF-beta,2679,I-GeneOrGeneProduct
receptors,2679,I-GeneOrGeneProduct
",",2679,O
thereby,2679,O
forming,2679,O
a,2679,O
complex,2679,O
and,2679,O
activating,2679,O
specific,2679,O
downstream,2679,O
effector,2679,O
molecules,2679,O
.,2679,O
The,2680,O
aim,2680,O
of,2680,O
this,2680,O
study,2680,O
was,2680,O
to,2680,O
investigate,2680,O
the,2680,O
effect,2680,O
of,2680,O
TGF-beta1,2680,B-GeneOrGeneProduct
targeting,2680,O
by,2680,O
antisense,2680,O
oligonucleotides,2680,B-ChemicalEntity
on,2680,O
the,2680,O
RNA,2680,O
synthesis,2680,O
and,2680,O
protein,2680,O
expression,2680,O
of,2680,O
TGF-beta,2680,B-GeneOrGeneProduct
isoforms,2680,O
and,2680,O
their,2680,O
receptors,2680,O
in,2680,O
keloid-derived,2680,B-DiseaseOrPhenotypicFeature
fibroblasts,2680,O
.,2680,O
In,2681,O
tissue,2681,O
samples,2681,O
with,2681,O
normal,2681,O
fibroblasts,2681,O
(,2681,O
NFs,2681,O
),2681,O
serving,2681,O
as,2681,O
control,2681,O
samples,2681,O
",",2681,O
expression,2681,O
of,2681,O
TGF-beta1,2681,B-GeneOrGeneProduct
and,2681,I-GeneOrGeneProduct
-beta2,2681,I-GeneOrGeneProduct
was,2681,O
decreased,2681,O
when,2681,O
compared,2681,O
to,2681,O
keloid,2681,B-DiseaseOrPhenotypicFeature
fibroblasts,2681,O
(,2681,O
KFs,2681,O
),2681,O
",",2681,O
while,2681,O
expression,2681,O
of,2681,O
TGF-beta3,2681,B-GeneOrGeneProduct
and,2681,O
of,2681,O
TGF-betaRII,2681,B-GeneOrGeneProduct
was,2681,O
significantly,2681,O
higher,2681,O
in,2681,O
NFs,2681,O
.,2681,O
In,2682,O
the,2682,O
ELISA,2682,O
assay,2682,O
",",2682,O
abrogation,2682,O
of,2682,O
TGF-beta1,2682,B-GeneOrGeneProduct
led,2682,O
to,2682,O
a,2682,O
significant,2682,O
decrease,2682,O
in,2682,O
TGF-beta1,2682,B-GeneOrGeneProduct
and,2682,I-GeneOrGeneProduct
-beta2,2682,I-GeneOrGeneProduct
(,2682,O
p,2682,O
<,2682,O
0.05,2682,O
),2682,O
.,2682,O
Expression,2683,O
of,2683,O
TGF-beta2,2683,B-GeneOrGeneProduct
mRNA,2683,O
was,2683,O
reduced,2683,O
.,2683,O
Expression,2684,O
of,2684,O
TGF-beta3,2684,B-GeneOrGeneProduct
mRNA,2684,O
revealed,2684,O
contrary,2684,O
patterns,2684,O
in,2684,O
KFs,2684,O
from,2684,O
different,2684,O
patients,2684,B-OrganismTaxon
while,2684,O
expression,2684,O
of,2684,O
TGF-betaRI,2684,B-GeneOrGeneProduct
was,2684,O
found,2684,O
to,2684,O
be,2684,O
equal,2684,O
during,2684,O
the,2684,O
measurement,2684,O
period,2684,O
.,2684,O
TGF-betaRII,2685,B-GeneOrGeneProduct
mRNA,2685,O
expression,2685,O
was,2685,O
increased,2685,O
after,2685,O
48,2685,O
and,2685,O
72,2685,O
h,2685,O
respectively,2685,O
.,2685,O
There,2686,O
is,2686,O
growing,2686,O
evidence,2686,O
for,2686,O
a,2686,O
regulatory,2686,O
mechanism,2686,O
between,2686,O
TGF-beta1,2686,B-GeneOrGeneProduct
and,2686,O
its,2686,O
receptors,2686,O
.,2686,O
Our,2687,O
findings,2687,O
support,2687,O
this,2687,O
theory,2687,O
by,2687,O
suggesting,2687,O
interrelations,2687,O
between,2687,O
the,2687,O
different,2687,O
TGF-beta,2687,B-GeneOrGeneProduct
isoforms,2687,O
and,2687,O
their,2687,O
receptors,2687,O
.,2687,O
Abnormal,2688,O
response,2688,O
of,2688,O
KFs,2688,O
to,2688,O
TGF-betamight,2688,O
reflect,2688,O
a,2688,O
modification,2688,O
in,2688,O
the,2688,O
regulatory,2688,O
pathway,2688,O
that,2688,O
occurs,2688,O
at,2688,O
the,2688,O
receptor,2688,O
level,2688,O
or,2688,O
during,2688,O
intracellular,2688,O
trans-duction,2688,O
.,2688,O
Improving,2689,O
the,2689,O
understanding,2689,O
of,2689,O
TGF-beta,2689,B-GeneOrGeneProduct
in,2689,O
keloid,2689,B-DiseaseOrPhenotypicFeature
disease,2689,I-DiseaseOrPhenotypicFeature
could,2689,O
lead,2689,O
to,2689,O
the,2689,O
development,2689,O
of,2689,O
clinically,2689,O
useful,2689,O
therapeutic,2689,O
modalities,2689,O
for,2689,O
treatment,2689,O
of,2689,O
keloid,2689,B-DiseaseOrPhenotypicFeature
disease,2689,I-DiseaseOrPhenotypicFeature
or,2689,O
even,2689,O
allow,2689,O
identification,2689,O
of,2689,O
preventive,2689,O
strategies,2689,O
.,2689,O
Antithrombotic,2690,B-ChemicalEntity
drug,2690,I-ChemicalEntity
use,2690,O
",",2690,O
cerebral,2690,B-DiseaseOrPhenotypicFeature
microbleeds,2690,I-DiseaseOrPhenotypicFeature
",",2690,O
and,2690,O
intracerebral,2690,B-DiseaseOrPhenotypicFeature
hemorrhage,2690,I-DiseaseOrPhenotypicFeature
:,2690,O
a,2690,O
systematic,2690,O
review,2690,O
of,2690,O
published,2690,O
and,2690,O
unpublished,2690,O
studies,2690,O
.,2690,O
BACKGROUND,2691,O
AND,2691,O
PURPOSE,2691,O
:,2691,O
Cerebral,2691,B-DiseaseOrPhenotypicFeature
microbleeds,2691,I-DiseaseOrPhenotypicFeature
(,2691,O
MB,2691,B-DiseaseOrPhenotypicFeature
),2691,O
are,2691,O
potential,2691,O
risk,2691,O
factors,2691,O
for,2691,O
intracerebral,2691,B-DiseaseOrPhenotypicFeature
hemorrhage,2691,I-DiseaseOrPhenotypicFeature
(,2691,O
ICH,2691,B-DiseaseOrPhenotypicFeature
),2691,O
",",2691,O
but,2691,O
it,2691,O
is,2691,O
unclear,2691,O
if,2691,O
they,2691,O
are,2691,O
a,2691,O
contraindication,2691,O
to,2691,O
using,2691,O
antithrombotic,2691,B-ChemicalEntity
drugs,2691,I-ChemicalEntity
.,2691,O
Insights,2692,O
could,2692,O
be,2692,O
gained,2692,O
by,2692,O
pooling,2692,O
data,2692,O
on,2692,O
MB,2692,B-DiseaseOrPhenotypicFeature
frequency,2692,O
stratified,2692,O
by,2692,O
antithrombotic,2692,O
use,2692,O
in,2692,O
cohorts,2692,O
with,2692,O
ICH,2692,B-DiseaseOrPhenotypicFeature
and,2692,O
ischemic,2692,B-DiseaseOrPhenotypicFeature
stroke,2692,I-DiseaseOrPhenotypicFeature
(,2692,O
IS,2692,B-DiseaseOrPhenotypicFeature
),2692,O
/transient,2692,O
ischemic,2692,I-DiseaseOrPhenotypicFeature
attack,2692,I-DiseaseOrPhenotypicFeature
(,2692,O
TIA,2692,B-DiseaseOrPhenotypicFeature
),2692,O
.,2692,O
METHODS,2693,O
:,2693,O
We,2693,O
performed,2693,O
a,2693,O
systematic,2693,O
review,2693,O
of,2693,O
published,2693,O
and,2693,O
unpublished,2693,O
data,2693,O
from,2693,O
cohorts,2693,O
with,2693,O
stroke,2693,B-DiseaseOrPhenotypicFeature
or,2693,O
TIA,2693,B-DiseaseOrPhenotypicFeature
to,2693,O
compare,2693,O
the,2693,O
presence,2693,O
of,2693,O
MB,2693,B-DiseaseOrPhenotypicFeature
in,2693,O
:,2693,O
(,2693,O
1,2693,O
),2693,O
antithrombotic,2693,O
users,2693,O
vs,2693,O
nonantithrombotic,2693,O
users,2693,O
with,2693,O
ICH,2693,B-DiseaseOrPhenotypicFeature
;,2693,O
(,2693,O
2,2693,O
),2693,O
antithrombotic,2693,O
users,2693,O
vs,2693,O
nonusers,2693,O
with,2693,O
IS/TIA,2693,B-DiseaseOrPhenotypicFeature
;,2693,O
and,2693,O
(,2693,O
3,2693,O
),2693,O
ICH,2693,B-DiseaseOrPhenotypicFeature
vs,2693,O
ischemic,2693,B-DiseaseOrPhenotypicFeature
events,2693,O
stratified,2693,O
by,2693,O
antithrombotic,2693,O
use,2693,O
.,2693,O
We,2694,O
also,2694,O
analyzed,2694,O
published,2694,O
and,2694,O
unpublished,2694,O
follow-up,2694,O
data,2694,O
to,2694,O
determine,2694,O
the,2694,O
risk,2694,O
of,2694,O
ICH,2694,B-DiseaseOrPhenotypicFeature
in,2694,O
antithrombotic,2694,O
users,2694,O
with,2694,O
MB,2694,B-DiseaseOrPhenotypicFeature
.,2694,O
RESULTS,2695,O
:,2695,O
In,2695,O
a,2695,O
pooled,2695,O
analysis,2695,O
of,2695,O
1460,2695,O
ICH,2695,B-DiseaseOrPhenotypicFeature
and,2695,O
3817,2695,O
IS/TIA,2695,B-DiseaseOrPhenotypicFeature
",",2695,O
MB,2695,B-DiseaseOrPhenotypicFeature
were,2695,O
more,2695,O
frequent,2695,O
in,2695,O
ICH,2695,B-DiseaseOrPhenotypicFeature
vs,2695,O
IS/TIA,2695,B-DiseaseOrPhenotypicFeature
in,2695,O
all,2695,O
treatment,2695,O
groups,2695,O
",",2695,O
but,2695,O
the,2695,O
excess,2695,O
increased,2695,O
from,2695,O
2.8,2695,O
(,2695,O
odds,2695,O
ratio,2695,O
;,2695,O
range,2695,O
",",2695,O
2.3-3.5,2695,O
),2695,O
in,2695,O
nonantithrombotic,2695,O
users,2695,O
to,2695,O
5.7,2695,O
(,2695,O
range,2695,O
",",2695,O
3.4-9.7,2695,O
),2695,O
in,2695,O
antiplatelet,2695,O
users,2695,O
and,2695,O
8.0,2695,O
(,2695,O
range,2695,O
",",2695,O
3.5-17.8,2695,O
),2695,O
in,2695,O
warfarin,2695,B-ChemicalEntity
users,2695,O
(,2695,O
P,2695,O
difference=0.01,2695,O
),2695,O
.,2695,O
There,2696,O
was,2696,O
also,2696,O
an,2696,O
excess,2696,O
of,2696,O
MB,2696,B-DiseaseOrPhenotypicFeature
in,2696,O
warfarin,2696,B-ChemicalEntity
users,2696,O
vs,2696,O
nonusers,2696,O
with,2696,O
ICH,2696,B-DiseaseOrPhenotypicFeature
(,2696,O
OR,2696,O
",",2696,O
2.7,2696,O
;,2696,O
95,2696,O
%,2696,O
CI,2696,O
",",2696,O
1.6-4.4,2696,O
;,2696,O
P,2696,O
<,2696,O
0.001,2696,O
),2696,O
but,2696,O
none,2696,O
in,2696,O
warfarin,2696,B-ChemicalEntity
users,2696,O
with,2696,O
IS/TIA,2696,B-DiseaseOrPhenotypicFeature
(,2696,O
OR,2696,O
",",2696,O
1.3,2696,O
;,2696,O
95,2696,O
%,2696,O
CI,2696,O
",",2696,O
0.9-1.7,2696,O
;,2696,O
P=0.33,2696,O
;,2696,O
P,2696,O
difference=0.01,2696,O
),2696,O
.,2696,O
There,2697,O
was,2697,O
a,2697,O
smaller,2697,O
excess,2697,O
of,2697,O
MB,2697,B-DiseaseOrPhenotypicFeature
in,2697,O
antiplatelet,2697,O
users,2697,O
vs,2697,O
nonusers,2697,O
with,2697,O
ICH,2697,B-DiseaseOrPhenotypicFeature
(,2697,O
OR,2697,O
",",2697,O
1.7,2697,O
;,2697,O
95,2697,O
%,2697,O
CI,2697,O
",",2697,O
1.3-2.3,2697,O
;,2697,O
P,2697,O
<,2697,O
0.001,2697,O
),2697,O
",",2697,O
but,2697,O
findings,2697,O
were,2697,O
similar,2697,O
for,2697,O
antiplatelet,2697,O
users,2697,O
with,2697,O
IS/TIA,2697,B-DiseaseOrPhenotypicFeature
(,2697,O
OR,2697,O
",",2697,O
1.4,2697,O
;,2697,O
95,2697,O
%,2697,O
CI,2697,O
",",2697,O
1.2-1.7,2697,O
;,2697,O
P,2697,O
<,2697,O
0.001,2697,O
;,2697,O
P,2697,O
difference=0.25,2697,O
),2697,O
.,2697,O
In,2698,O
pooled,2698,O
follow-up,2698,O
data,2698,O
for,2698,O
768,2698,O
antithrombotic,2698,O
users,2698,O
",",2698,O
presence,2698,O
of,2698,O
MB,2698,B-DiseaseOrPhenotypicFeature
at,2698,O
baseline,2698,O
was,2698,O
associated,2698,O
with,2698,O
a,2698,O
substantially,2698,O
increased,2698,O
risk,2698,O
of,2698,O
subsequent,2698,O
ICH,2698,B-DiseaseOrPhenotypicFeature
(,2698,O
OR,2698,O
",",2698,O
12.1,2698,O
;,2698,O
95,2698,O
%,2698,O
CI,2698,O
",",2698,O
3.4-42.5,2698,O
;,2698,O
P,2698,O
<,2698,O
0.001,2698,O
),2698,O
.,2698,O
CONCLUSIONS,2699,O
:,2699,O
The,2699,O
excess,2699,O
of,2699,O
MB,2699,B-DiseaseOrPhenotypicFeature
in,2699,O
warfarin,2699,B-ChemicalEntity
users,2699,O
with,2699,O
ICH,2699,B-DiseaseOrPhenotypicFeature
compared,2699,O
to,2699,O
other,2699,O
groups,2699,O
suggests,2699,O
that,2699,O
MB,2699,B-DiseaseOrPhenotypicFeature
increase,2699,O
the,2699,O
risk,2699,O
of,2699,O
warfarin-associated,2699,B-ChemicalEntity
ICH,2699,B-DiseaseOrPhenotypicFeature
.,2699,O
Limited,2700,O
prospective,2700,O
data,2700,O
corroborate,2700,O
these,2700,O
findings,2700,O
",",2700,O
but,2700,O
larger,2700,O
prospective,2700,O
studies,2700,O
are,2700,O
urgently,2700,O
required,2700,O
.,2700,O
Studies,2701,O
of,2701,O
synergy,2701,O
between,2701,O
morphine,2701,B-ChemicalEntity
and,2701,O
a,2701,O
novel,2701,O
sodium,2701,B-ChemicalEntity
channel,2701,I-ChemicalEntity
blocker,2701,I-ChemicalEntity
",",2701,O
CNSB002,2701,B-ChemicalEntity
",",2701,O
in,2701,O
rat,2701,B-OrganismTaxon
models,2701,O
of,2701,O
inflammatory,2701,B-DiseaseOrPhenotypicFeature
and,2701,O
neuropathic,2701,B-DiseaseOrPhenotypicFeature
pain,2701,I-DiseaseOrPhenotypicFeature
.,2701,O
OBJECTIVE,2702,O
:,2702,O
This,2702,O
study,2702,O
determined,2702,O
the,2702,O
antihyperalgesic,2702,O
effect,2702,O
of,2702,O
CNSB002,2702,B-ChemicalEntity
",",2702,O
a,2702,O
sodium,2702,B-ChemicalEntity
channel,2702,I-ChemicalEntity
blocker,2702,I-ChemicalEntity
with,2702,O
antioxidant,2702,O
properties,2702,O
given,2702,O
alone,2702,O
and,2702,O
in,2702,O
combinations,2702,O
with,2702,O
morphine,2702,B-ChemicalEntity
in,2702,O
rat,2702,B-OrganismTaxon
models,2702,O
of,2702,O
inflammatory,2702,B-DiseaseOrPhenotypicFeature
and,2702,O
neuropathic,2702,B-DiseaseOrPhenotypicFeature
pain,2702,I-DiseaseOrPhenotypicFeature
.,2702,O
DESIGN,2703,O
:,2703,O
Dose,2703,O
response,2703,O
curves,2703,O
for,2703,O
nonsedating,2703,O
doses,2703,O
of,2703,O
morphine,2703,B-ChemicalEntity
and,2703,O
CNSB002,2703,B-ChemicalEntity
given,2703,O
intraperitoneally,2703,O
alone,2703,O
and,2703,O
together,2703,O
in,2703,O
combinations,2703,O
were,2703,O
constructed,2703,O
for,2703,O
antihyperalgesic,2703,O
effect,2703,O
using,2703,O
paw,2703,O
withdrawal,2703,O
from,2703,O
noxious,2703,O
heat,2703,O
in,2703,O
two,2703,O
rat,2703,B-OrganismTaxon
pain,2703,B-DiseaseOrPhenotypicFeature
models,2703,O
:,2703,O
carrageenan-induced,2703,B-ChemicalEntity
paw,2703,O
inflammation,2703,B-DiseaseOrPhenotypicFeature
and,2703,O
streptozotocin,2703,B-ChemicalEntity
(,2703,O
STZ,2703,B-ChemicalEntity
),2703,O
-induced,2703,O
diabetic,2703,B-DiseaseOrPhenotypicFeature
neuropathy,2703,I-DiseaseOrPhenotypicFeature
.,2703,O
RESULTS,2704,O
:,2704,O
The,2704,O
maximum,2704,O
nonsedating,2704,O
doses,2704,O
were,2704,O
:,2704,O
morphine,2704,B-ChemicalEntity
",",2704,O
3.2,2704,O
mg/kg,2704,O
;,2704,O
CNSB002,2704,B-ChemicalEntity
10.0,2704,O
mg/kg,2704,O
;,2704,O
5.0,2704,O
mg/kg,2704,O
CNSB002,2704,B-ChemicalEntity
with,2704,O
morphine,2704,B-ChemicalEntity
3.2,2704,O
mg/kg,2704,O
in,2704,O
combination,2704,O
.,2704,O
The,2705,O
doses,2705,O
calculated,2705,O
to,2705,O
cause,2705,O
50,2705,O
%,2705,O
reversal,2705,O
of,2705,O
hyperalgesia,2705,B-DiseaseOrPhenotypicFeature
(,2705,O
ED50,2705,O
),2705,O
were,2705,O
7.54,2705,O
(,2705,O
1.81,2705,O
),2705,O
and,2705,O
4.83,2705,O
(,2705,O
1.54,2705,O
),2705,O
in,2705,O
the,2705,O
carrageenan,2705,B-ChemicalEntity
model,2705,O
and,2705,O
44.18,2705,O
(,2705,O
1.37,2705,O
),2705,O
and,2705,O
9.14,2705,O
(,2705,O
1.24,2705,O
),2705,O
in,2705,O
the,2705,O
STZ-induced,2705,B-ChemicalEntity
neuropathy,2705,B-DiseaseOrPhenotypicFeature
model,2705,O
for,2705,O
CNSB002,2705,B-ChemicalEntity
and,2705,O
morphine,2705,B-ChemicalEntity
",",2705,O
respectively,2705,O
(,2705,O
mg/kg,2705,O
;,2705,O
mean,2705,O
",",2705,O
SEM,2705,O
),2705,O
.,2705,O
These,2706,O
values,2706,O
were,2706,O
greater,2706,O
than,2706,O
the,2706,O
maximum,2706,O
nonsedating,2706,O
doses,2706,O
.,2706,O
The,2707,O
ED50,2707,O
values,2707,O
for,2707,O
morphine,2707,B-ChemicalEntity
when,2707,O
given,2707,O
in,2707,O
combination,2707,O
with,2707,O
CNSB002,2707,B-ChemicalEntity
(,2707,O
5,2707,O
mg/kg,2707,O
),2707,O
were,2707,O
less,2707,O
than,2707,O
the,2707,O
maximum,2707,O
nonsedating,2707,O
dose,2707,O
:,2707,O
0.56,2707,O
(,2707,O
1.55,2707,O
),2707,O
in,2707,O
the,2707,O
carrageenan,2707,B-ChemicalEntity
model,2707,O
and,2707,O
1.37,2707,O
(,2707,O
1.23,2707,O
),2707,O
in,2707,O
the,2707,O
neuropathy,2707,B-DiseaseOrPhenotypicFeature
model,2707,O
(,2707,O
mg/kg,2707,O
;,2707,O
mean,2707,O
",",2707,O
SEM,2707,O
),2707,O
.,2707,O
The,2708,O
antinociception,2708,O
after,2708,O
morphine,2708,B-ChemicalEntity
(,2708,O
3.2,2708,O
mg/kg,2708,O
),2708,O
was,2708,O
increased,2708,O
by,2708,O
co-administration,2708,O
with,2708,O
CNSB002,2708,B-ChemicalEntity
from,2708,O
28.0,2708,O
and,2708,O
31.7,2708,O
%,2708,O
to,2708,O
114.6,2708,O
and,2708,O
56.9,2708,O
%,2708,O
reversal,2708,O
of,2708,O
hyperalgesia,2708,B-DiseaseOrPhenotypicFeature
in,2708,O
the,2708,O
inflammatory,2708,B-DiseaseOrPhenotypicFeature
and,2708,O
neuropathic,2708,B-DiseaseOrPhenotypicFeature
models,2708,O
",",2708,O
respectively,2708,O
(,2708,O
P,2708,O
<,2708,O
0.01,2708,O
;,2708,O
one-way,2708,O
analysis,2708,O
of,2708,O
variance-significantly,2708,O
greater,2708,O
than,2708,O
either,2708,O
drug,2708,O
given,2708,O
alone,2708,O
),2708,O
.,2708,O
CONCLUSIONS,2709,O
:,2709,O
The,2709,O
maximum,2709,O
antihyperalgesic,2709,O
effect,2709,O
achievable,2709,O
with,2709,O
nonsedating,2709,O
doses,2709,O
of,2709,O
morphine,2709,B-ChemicalEntity
may,2709,O
be,2709,O
increased,2709,O
significantly,2709,O
when,2709,O
the,2709,O
drug,2709,O
is,2709,O
used,2709,O
in,2709,O
combination,2709,O
with,2709,O
CNSB002,2709,B-ChemicalEntity
.,2709,O
Cocaine,2710,B-ChemicalEntity
causes,2710,O
memory,2710,B-DiseaseOrPhenotypicFeature
and,2710,I-DiseaseOrPhenotypicFeature
learning,2710,I-DiseaseOrPhenotypicFeature
impairments,2710,I-DiseaseOrPhenotypicFeature
in,2710,O
rats,2710,B-OrganismTaxon
:,2710,O
involvement,2710,O
of,2710,O
nuclear,2710,B-GeneOrGeneProduct
factor,2710,I-GeneOrGeneProduct
kappa,2710,I-GeneOrGeneProduct
B,2710,I-GeneOrGeneProduct
and,2710,O
oxidative,2710,O
stress,2710,O
",",2710,O
and,2710,O
prevention,2710,O
by,2710,O
topiramate,2710,B-ChemicalEntity
.,2710,O
Different,2711,O
mechanisms,2711,O
have,2711,O
been,2711,O
suggested,2711,O
for,2711,O
cocaine,2711,B-ChemicalEntity
toxicity,2711,B-DiseaseOrPhenotypicFeature
including,2711,O
an,2711,O
increase,2711,O
in,2711,O
oxidative,2711,O
stress,2711,O
but,2711,O
the,2711,O
association,2711,O
between,2711,O
oxidative,2711,O
status,2711,O
in,2711,O
the,2711,O
brain,2711,O
and,2711,O
cocaine,2711,B-ChemicalEntity
induced-behaviour,2711,O
is,2711,O
poorly,2711,O
understood,2711,O
.,2711,O
Nuclear,2712,B-GeneOrGeneProduct
factor,2712,I-GeneOrGeneProduct
kappa,2712,I-GeneOrGeneProduct
B,2712,I-GeneOrGeneProduct
(,2712,O
NFkappaB,2712,B-GeneOrGeneProduct
),2712,O
is,2712,O
a,2712,O
sensor,2712,O
of,2712,O
oxidative,2712,O
stress,2712,O
and,2712,O
participates,2712,O
in,2712,O
memory,2712,O
formation,2712,O
that,2712,O
could,2712,O
be,2712,O
involved,2712,O
in,2712,O
drug,2712,O
toxicity,2712,B-DiseaseOrPhenotypicFeature
and,2712,O
addiction,2712,O
mechanisms,2712,O
.,2712,O
Therefore,2713,O
NFkappaB,2713,B-GeneOrGeneProduct
activity,2713,O
",",2713,O
oxidative,2713,O
stress,2713,O
",",2713,O
neuronal,2713,B-GeneOrGeneProduct
nitric,2713,I-GeneOrGeneProduct
oxide,2713,I-GeneOrGeneProduct
synthase,2713,I-GeneOrGeneProduct
(,2713,O
nNOS,2713,B-GeneOrGeneProduct
),2713,O
activity,2713,O
",",2713,O
spatial,2713,O
learning,2713,O
and,2713,O
memory,2713,O
as,2713,O
well,2713,O
as,2713,O
the,2713,O
effect,2713,O
of,2713,O
topiramate,2713,B-ChemicalEntity
",",2713,O
a,2713,O
previously,2713,O
proposed,2713,O
therapy,2713,O
for,2713,O
cocaine,2713,B-DiseaseOrPhenotypicFeature
addiction,2713,I-DiseaseOrPhenotypicFeature
",",2713,O
were,2713,O
evaluated,2713,O
in,2713,O
an,2713,O
experimental,2713,O
model,2713,O
of,2713,O
cocaine,2713,B-ChemicalEntity
administration,2713,O
in,2713,O
rats,2713,B-OrganismTaxon
.,2713,O
NFkappaB,2714,B-GeneOrGeneProduct
activity,2714,O
was,2714,O
decreased,2714,O
in,2714,O
the,2714,O
frontal,2714,O
cortex,2714,O
of,2714,O
cocaine,2714,B-ChemicalEntity
treated,2714,O
rats,2714,B-OrganismTaxon
",",2714,O
as,2714,O
well,2714,O
as,2714,O
GSH,2714,B-ChemicalEntity
concentration,2714,O
and,2714,O
glutathione,2714,B-GeneOrGeneProduct
peroxidase,2714,I-GeneOrGeneProduct
activity,2714,O
in,2714,O
the,2714,O
hippocampus,2714,O
",",2714,O
whereas,2714,O
nNOS,2714,B-GeneOrGeneProduct
activity,2714,O
in,2714,O
the,2714,O
hippocampus,2714,O
was,2714,O
increased,2714,O
.,2714,O
Memory,2715,O
retrieval,2715,O
of,2715,O
experiences,2715,O
acquired,2715,O
prior,2715,O
to,2715,O
cocaine,2715,B-ChemicalEntity
administration,2715,O
was,2715,O
impaired,2715,O
and,2715,O
negatively,2715,O
correlated,2715,O
with,2715,O
NFkappaB,2715,B-GeneOrGeneProduct
activity,2715,O
in,2715,O
the,2715,O
frontal,2715,O
cortex,2715,O
.,2715,O
In,2716,O
contrast,2716,O
",",2716,O
learning,2716,O
of,2716,O
new,2716,O
tasks,2716,O
was,2716,O
enhanced,2716,O
and,2716,O
correlated,2716,O
with,2716,O
the,2716,O
increase,2716,O
of,2716,O
nNOS,2716,B-GeneOrGeneProduct
activity,2716,O
and,2716,O
the,2716,O
decrease,2716,O
of,2716,O
glutathione,2716,B-GeneOrGeneProduct
peroxidase,2716,I-GeneOrGeneProduct
.,2716,O
These,2717,O
results,2717,O
provide,2717,O
evidence,2717,O
for,2717,O
a,2717,O
possible,2717,O
mechanistic,2717,O
role,2717,O
of,2717,O
oxidative,2717,O
and,2717,O
nitrosative,2717,O
stress,2717,O
and,2717,O
NFkappaB,2717,B-GeneOrGeneProduct
in,2717,O
the,2717,O
alterations,2717,O
induced,2717,O
by,2717,O
cocaine,2717,B-ChemicalEntity
.,2717,O
Topiramate,2718,B-ChemicalEntity
prevented,2718,O
all,2718,O
the,2718,O
alterations,2718,O
observed,2718,O
",",2718,O
showing,2718,O
novel,2718,O
neuroprotective,2718,O
properties,2718,O
.,2718,O
Coenzyme,2719,B-ChemicalEntity
Q10,2719,I-ChemicalEntity
treatment,2719,O
ameliorates,2719,O
acute,2719,O
cisplatin,2719,B-ChemicalEntity
nephrotoxicity,2719,B-DiseaseOrPhenotypicFeature
in,2719,O
mice,2719,B-OrganismTaxon
.,2719,O
The,2720,O
nephroprotective,2720,O
effect,2720,O
of,2720,O
coenzyme,2720,B-ChemicalEntity
Q10,2720,I-ChemicalEntity
was,2720,O
investigated,2720,O
in,2720,O
mice,2720,B-OrganismTaxon
with,2720,O
acute,2720,B-DiseaseOrPhenotypicFeature
renal,2720,I-DiseaseOrPhenotypicFeature
injury,2720,I-DiseaseOrPhenotypicFeature
induced,2720,O
by,2720,O
a,2720,O
single,2720,O
i.p,2720,O
.,2720,O
injection,2721,O
of,2721,O
cisplatin,2721,B-ChemicalEntity
(,2721,O
5,2721,O
mg/kg,2721,O
),2721,O
.,2721,O
Coenzyme,2722,B-ChemicalEntity
Q10,2722,I-ChemicalEntity
treatment,2722,O
(,2722,O
10,2722,O
mg/kg/day,2722,O
",",2722,O
i.p,2722,O
.,2722,O
),2722,O
was,2723,O
applied,2723,O
for,2723,O
6,2723,O
consecutive,2723,O
days,2723,O
",",2723,O
starting,2723,O
1,2723,O
day,2723,O
before,2723,O
cisplatin,2723,B-ChemicalEntity
administration,2723,O
.,2723,O
Coenzyme,2724,B-ChemicalEntity
Q10,2724,I-ChemicalEntity
significantly,2724,O
reduced,2724,O
blood,2724,B-ChemicalEntity
urea,2724,I-ChemicalEntity
nitrogen,2724,I-ChemicalEntity
and,2724,O
serum,2724,O
creatinine,2724,B-ChemicalEntity
levels,2724,O
which,2724,O
were,2724,O
increased,2724,O
by,2724,O
cisplatin,2724,B-ChemicalEntity
.,2724,O
Coenzyme,2725,B-ChemicalEntity
Q10,2725,I-ChemicalEntity
significantly,2725,O
compensated,2725,O
deficits,2725,O
in,2725,O
the,2725,O
antioxidant,2725,O
defense,2725,O
mechanisms,2725,O
(,2725,O
reduced,2725,O
glutathione,2725,B-ChemicalEntity
level,2725,O
and,2725,O
superoxide,2725,B-GeneOrGeneProduct
dismutase,2725,I-GeneOrGeneProduct
activity,2725,O
),2725,O
",",2725,O
suppressed,2725,O
lipid,2725,B-ChemicalEntity
peroxidation,2725,O
",",2725,O
decreased,2725,O
the,2725,O
elevations,2725,O
of,2725,O
tumor,2725,B-GeneOrGeneProduct
necrosis,2725,I-GeneOrGeneProduct
factor-alpha,2725,I-GeneOrGeneProduct
",",2725,O
nitric,2725,B-ChemicalEntity
oxide,2725,I-ChemicalEntity
and,2725,O
platinum,2725,B-ChemicalEntity
ion,2725,O
concentration,2725,O
",",2725,O
and,2725,O
attenuated,2725,O
the,2725,O
reductions,2725,O
of,2725,O
selenium,2725,B-ChemicalEntity
and,2725,O
zinc,2725,B-ChemicalEntity
ions,2725,O
in,2725,O
renal,2725,O
tissue,2725,O
resulted,2725,O
from,2725,O
cisplatin,2725,B-ChemicalEntity
administration,2725,O
.,2725,O
Also,2726,O
",",2726,O
histopathological,2726,O
renal,2726,B-DiseaseOrPhenotypicFeature
tissue,2726,I-DiseaseOrPhenotypicFeature
damage,2726,I-DiseaseOrPhenotypicFeature
mediated,2726,O
by,2726,O
cisplatin,2726,B-ChemicalEntity
was,2726,O
ameliorated,2726,O
by,2726,O
coenzyme,2726,B-ChemicalEntity
Q10,2726,I-ChemicalEntity
treatment,2726,O
.,2726,O
Immunohistochemical,2727,O
analysis,2727,O
revealed,2727,O
that,2727,O
coenzyme,2727,B-ChemicalEntity
Q10,2727,I-ChemicalEntity
significantly,2727,O
decreased,2727,O
the,2727,O
cisplatin-induced,2727,B-ChemicalEntity
overexpression,2727,O
of,2727,O
inducible,2727,O
nitric,2727,B-GeneOrGeneProduct
oxide,2727,I-GeneOrGeneProduct
synthase,2727,I-GeneOrGeneProduct
",",2727,O
nuclear,2727,B-GeneOrGeneProduct
factor-kappaB,2727,I-GeneOrGeneProduct
",",2727,O
caspase-3,2727,B-GeneOrGeneProduct
and,2727,O
p53,2727,B-GeneOrGeneProduct
in,2727,O
renal,2727,O
tissue,2727,O
.,2727,O
It,2728,O
was,2728,O
concluded,2728,O
that,2728,O
coenzyme,2728,B-ChemicalEntity
Q10,2728,I-ChemicalEntity
represents,2728,O
a,2728,O
potential,2728,O
therapeutic,2728,O
option,2728,O
to,2728,O
protect,2728,O
against,2728,O
acute,2728,O
cisplatin,2728,B-ChemicalEntity
nephrotoxicity,2728,B-DiseaseOrPhenotypicFeature
commonly,2728,O
encountered,2728,O
in,2728,O
clinical,2728,O
practice,2728,O
.,2728,O
Efficacy,2729,O
and,2729,O
safety,2729,O
of,2729,O
asenapine,2729,B-ChemicalEntity
in,2729,O
a,2729,O
placebo-,2729,O
and,2729,O
haloperidol-controlled,2729,B-ChemicalEntity
trial,2729,O
in,2729,O
patients,2729,B-OrganismTaxon
with,2729,O
acute,2729,O
exacerbation,2729,O
of,2729,O
schizophrenia,2729,B-DiseaseOrPhenotypicFeature
.,2729,O
Asenapine,2730,B-ChemicalEntity
is,2730,O
approved,2730,O
by,2730,O
the,2730,O
Food,2730,O
and,2730,O
Drugs,2730,O
Administration,2730,O
in,2730,O
adults,2730,O
for,2730,O
acute,2730,O
treatment,2730,O
of,2730,O
schizophrenia,2730,B-DiseaseOrPhenotypicFeature
or,2730,O
of,2730,O
manic,2730,B-DiseaseOrPhenotypicFeature
or,2730,O
mixed,2730,O
episodes,2730,O
associated,2730,O
with,2730,O
bipolar,2730,B-DiseaseOrPhenotypicFeature
I,2730,I-DiseaseOrPhenotypicFeature
disorder,2730,I-DiseaseOrPhenotypicFeature
with,2730,O
or,2730,O
without,2730,O
psychotic,2730,B-DiseaseOrPhenotypicFeature
features,2730,O
.,2730,O
In,2731,O
a,2731,O
double-blind,2731,O
6-week,2731,O
trial,2731,O
",",2731,O
458,2731,O
patients,2731,B-OrganismTaxon
with,2731,O
acute,2731,O
schizophrenia,2731,B-DiseaseOrPhenotypicFeature
were,2731,O
randomly,2731,O
assigned,2731,O
to,2731,O
fixed-dose,2731,O
treatment,2731,O
with,2731,O
asenapine,2731,B-ChemicalEntity
at,2731,O
5,2731,O
mg,2731,O
twice,2731,O
daily,2731,O
(,2731,O
BID,2731,O
),2731,O
",",2731,O
asenapine,2731,B-ChemicalEntity
at,2731,O
10,2731,O
mg,2731,O
BID,2731,O
",",2731,O
placebo,2731,O
",",2731,O
or,2731,O
haloperidol,2731,B-ChemicalEntity
at,2731,O
4,2731,O
mg,2731,O
BID,2731,O
(,2731,O
to,2731,O
verify,2731,O
assay,2731,O
sensitivity,2731,O
),2731,O
.,2731,O
With,2732,O
last,2732,O
observations,2732,O
carried,2732,O
forward,2732,O
(,2732,O
LOCF,2732,O
),2732,O
",",2732,O
mean,2732,O
Positive,2732,O
and,2732,O
Negative,2732,O
Syndrome,2732,O
Scale,2732,O
total,2732,O
score,2732,O
reductions,2732,O
from,2732,O
baseline,2732,O
to,2732,O
endpoint,2732,O
were,2732,O
significantly,2732,O
greater,2732,O
with,2732,O
asenapine,2732,B-ChemicalEntity
at,2732,O
5,2732,O
mg,2732,O
BID,2732,O
(,2732,O
-16.2,2732,O
),2732,O
and,2732,O
haloperidol,2732,B-ChemicalEntity
(,2732,O
-15.4,2732,O
),2732,O
than,2732,O
placebo,2732,O
(,2732,O
-10.7,2732,O
;,2732,O
both,2732,O
P,2732,O
<,2732,O
0.05,2732,O
),2732,O
;,2732,O
using,2732,O
mixed,2732,O
model,2732,O
for,2732,O
repeated,2732,O
measures,2732,O
(,2732,O
MMRM,2732,O
),2732,O
",",2732,O
changes,2732,O
at,2732,O
day,2732,O
42,2732,O
were,2732,O
significantly,2732,O
greater,2732,O
with,2732,O
asenapine,2732,B-ChemicalEntity
at,2732,O
5,2732,O
and,2732,O
10,2732,O
mg,2732,O
BID,2732,O
(,2732,O
-21.3,2732,O
and,2732,O
-19.4,2732,O
",",2732,O
respectively,2732,O
),2732,O
and,2732,O
haloperidol,2732,B-ChemicalEntity
(,2732,O
-20.0,2732,O
),2732,O
than,2732,O
placebo,2732,O
(,2732,O
-14.6,2732,O
;,2732,O
all,2732,O
P,2732,O
<,2732,O
0.05,2732,O
),2732,O
.,2732,O
On,2733,O
the,2733,O
Positive,2733,O
and,2733,O
Negative,2733,O
Syndrome,2733,O
Scale,2733,O
positive,2733,O
subscale,2733,O
",",2733,O
all,2733,O
treatments,2733,O
were,2733,O
superior,2733,O
to,2733,O
placebo,2733,O
with,2733,O
LOCF,2733,O
and,2733,O
MMRM,2733,O
;,2733,O
asenapine,2733,B-ChemicalEntity
at,2733,O
5,2733,O
mg,2733,O
BID,2733,O
was,2733,O
superior,2733,O
to,2733,O
placebo,2733,O
on,2733,O
the,2733,O
negative,2733,O
subscale,2733,O
with,2733,O
MMRM,2733,O
and,2733,O
on,2733,O
the,2733,O
general,2733,O
psychopathology,2733,O
subscale,2733,O
with,2733,O
LOCF,2733,O
and,2733,O
MMRM,2733,O
.,2733,O
Treatment-related,2734,O
adverse,2734,O
events,2734,O
(,2734,O
AEs,2734,O
),2734,O
occurred,2734,O
in,2734,O
44,2734,O
%,2734,O
and,2734,O
52,2734,O
%,2734,O
",",2734,O
57,2734,O
%,2734,O
",",2734,O
and,2734,O
41,2734,O
%,2734,O
of,2734,O
the,2734,O
asenapine,2734,B-ChemicalEntity
at,2734,O
5,2734,O
and,2734,O
10,2734,O
mg,2734,O
BID,2734,O
",",2734,O
haloperidol,2734,B-ChemicalEntity
",",2734,O
and,2734,O
placebo,2734,O
groups,2734,O
",",2734,O
respectively,2734,O
.,2734,O
Extrapyramidal,2735,B-DiseaseOrPhenotypicFeature
symptoms,2735,I-DiseaseOrPhenotypicFeature
reported,2735,O
as,2735,O
AEs,2735,O
occurred,2735,O
in,2735,O
15,2735,O
%,2735,O
and,2735,O
18,2735,O
%,2735,O
",",2735,O
34,2735,O
%,2735,O
",",2735,O
and,2735,O
10,2735,O
%,2735,O
of,2735,O
the,2735,O
asenapine,2735,B-ChemicalEntity
at,2735,O
5,2735,O
and,2735,O
10,2735,O
mg,2735,O
BID,2735,O
",",2735,O
haloperidol,2735,B-ChemicalEntity
",",2735,O
and,2735,O
placebo,2735,O
groups,2735,O
",",2735,O
respectively,2735,O
.,2735,O
Across,2736,O
all,2736,O
groups,2736,O
",",2736,O
no,2736,O
more,2736,O
than,2736,O
5,2736,O
%,2736,O
of,2736,O
patients,2736,B-OrganismTaxon
had,2736,O
clinically,2736,O
significant,2736,O
weight,2736,O
change,2736,O
.,2736,O
Post,2737,O
hoc,2737,O
analyses,2737,O
indicated,2737,O
that,2737,O
efficacy,2737,O
was,2737,O
similar,2737,O
with,2737,O
asenapine,2737,B-ChemicalEntity
and,2737,O
haloperidol,2737,B-ChemicalEntity
;,2737,O
greater,2737,O
contrasts,2737,O
were,2737,O
seen,2737,O
in,2737,O
AEs,2737,O
",",2737,O
especially,2737,O
extrapyramidal,2737,B-DiseaseOrPhenotypicFeature
symptoms,2737,I-DiseaseOrPhenotypicFeature
.,2737,O
Association,2738,O
study,2738,O
of,2738,O
complement,2738,B-GeneOrGeneProduct
factor,2738,I-GeneOrGeneProduct
H,2738,I-GeneOrGeneProduct
",",2738,O
C2,2738,B-GeneOrGeneProduct
",",2738,O
CFB,2738,B-GeneOrGeneProduct
",",2738,O
and,2738,O
C3,2738,B-GeneOrGeneProduct
and,2738,O
age-related,2738,B-DiseaseOrPhenotypicFeature
macular,2738,I-DiseaseOrPhenotypicFeature
degeneration,2738,I-DiseaseOrPhenotypicFeature
in,2738,O
a,2738,O
Han,2738,O
Chinese,2738,O
population,2738,O
.,2738,O
PURPOSE,2739,O
:,2739,O
Genes,2739,O
in,2739,O
the,2739,O
complement,2739,O
pathway,2739,O
",",2739,O
including,2739,O
complement,2739,B-GeneOrGeneProduct
factor,2739,I-GeneOrGeneProduct
H,2739,I-GeneOrGeneProduct
(,2739,O
CFH,2739,B-GeneOrGeneProduct
),2739,O
",",2739,O
C2/BF,2739,B-GeneOrGeneProduct
",",2739,O
and,2739,O
C3,2739,B-GeneOrGeneProduct
",",2739,O
have,2739,O
been,2739,O
reported,2739,O
to,2739,O
be,2739,O
associated,2739,O
with,2739,O
age-related,2739,B-DiseaseOrPhenotypicFeature
macular,2739,I-DiseaseOrPhenotypicFeature
degeneration,2739,I-DiseaseOrPhenotypicFeature
(,2739,O
AMD,2739,B-DiseaseOrPhenotypicFeature
),2739,O
.,2739,O
Genetic,2740,O
variants,2740,O
",",2740,O
single-nucleotide,2740,O
polymorphisms,2740,O
(,2740,O
SNPs,2740,O
),2740,O
",",2740,O
in,2740,O
these,2740,O
genes,2740,O
were,2740,O
geno-typed,2740,O
for,2740,O
a,2740,O
case-control,2740,O
association,2740,O
study,2740,O
in,2740,O
a,2740,O
mainland,2740,O
Han,2740,O
Chinese,2740,O
population,2740,O
.,2740,O
METHODS,2741,O
:,2741,O
One,2741,O
hundred,2741,O
and,2741,O
fifty-eight,2741,O
patients,2741,B-OrganismTaxon
with,2741,O
wet,2741,O
AMD,2741,B-DiseaseOrPhenotypicFeature
",",2741,O
80,2741,O
patients,2741,B-OrganismTaxon
with,2741,O
soft,2741,O
drusen,2741,B-DiseaseOrPhenotypicFeature
",",2741,O
and,2741,O
220,2741,O
matched,2741,O
control,2741,O
subjects,2741,O
were,2741,O
recruited,2741,O
among,2741,O
Han,2741,O
Chinese,2741,O
in,2741,O
mainland,2741,O
China,2741,O
.,2741,O
Seven,2742,O
SNPs,2742,O
in,2742,O
CFH,2742,B-GeneOrGeneProduct
and,2742,O
two,2742,O
SNPs,2742,O
in,2742,O
C2,2742,B-GeneOrGeneProduct
",",2742,O
CFB,2742,B-GeneOrGeneProduct
',2742,O
",",2742,O
and,2742,O
C3,2742,B-GeneOrGeneProduct
were,2742,O
genotyped,2742,O
using,2742,O
the,2742,O
ABI,2742,O
SNaPshot,2742,O
method,2742,O
.,2742,O
A,2743,O
deletion,2743,O
of,2743,O
"84,682",2743,O
base,2743,O
pairs,2743,O
covering,2743,O
the,2743,O
CFHR1,2743,B-GeneOrGeneProduct
and,2743,O
CFHR3,2743,B-GeneOrGeneProduct
genes,2743,O
was,2743,O
detected,2743,O
by,2743,O
direct,2743,O
polymerase,2743,O
chain,2743,O
reaction,2743,O
and,2743,O
gel,2743,O
electrophoresis,2743,O
.,2743,O
RESULTS,2744,O
:,2744,O
Four,2744,O
SNPs,2744,O
",",2744,O
including,2744,O
rs3753394,2744,B-SequenceVariant
(,2744,O
P,2744,O
=,2744,O
0.0276,2744,O
),2744,O
",",2744,O
rs800292,2744,B-SequenceVariant
(,2744,O
P,2744,O
=,2744,O
0.0266,2744,O
),2744,O
",",2744,O
rs1061170,2744,B-SequenceVariant
(,2744,O
P,2744,O
=,2744,O
0.00514,2744,O
),2744,O
",",2744,O
and,2744,O
rs1329428,2744,B-SequenceVariant
(,2744,O
P,2744,O
=,2744,O
0.0089,2744,O
),2744,O
",",2744,O
in,2744,O
CFH,2744,B-GeneOrGeneProduct
showed,2744,O
a,2744,O
significant,2744,O
association,2744,O
with,2744,O
wet,2744,O
AMD,2744,B-DiseaseOrPhenotypicFeature
in,2744,O
the,2744,O
cohort,2744,O
of,2744,O
this,2744,O
study,2744,O
.,2744,O
A,2745,O
haplotype,2745,O
containing,2745,O
these,2745,O
four,2745,O
SNPs,2745,O
(,2745,O
CATA,2745,O
),2745,O
significantly,2745,O
increased,2745,O
protection,2745,O
of,2745,O
wet,2745,O
AMD,2745,B-DiseaseOrPhenotypicFeature
with,2745,O
a,2745,O
P,2745,O
value,2745,O
of,2745,O
0.0005,2745,O
and,2745,O
an,2745,O
odds,2745,O
ratio,2745,O
of,2745,O
0.29,2745,O
(,2745,O
95,2745,O
%,2745,O
confidence,2745,O
interval,2745,O
:,2745,O
0.15-0.60,2745,O
),2745,O
.,2745,O
Unlike,2746,O
in,2746,O
other,2746,O
populations,2746,O
",",2746,O
rs2274700,2746,B-SequenceVariant
and,2746,O
rs1410996,2746,B-SequenceVariant
did,2746,O
not,2746,O
show,2746,O
a,2746,O
significant,2746,O
association,2746,O
with,2746,O
AMD,2746,B-DiseaseOrPhenotypicFeature
in,2746,O
the,2746,O
Chinese,2746,O
population,2746,O
of,2746,O
this,2746,O
study,2746,O
.,2746,O
None,2747,O
of,2747,O
the,2747,O
SNPs,2747,O
in,2747,O
CFH,2747,B-GeneOrGeneProduct
showed,2747,O
a,2747,O
significant,2747,O
association,2747,O
with,2747,O
drusen,2747,B-DiseaseOrPhenotypicFeature
",",2747,O
and,2747,O
none,2747,O
of,2747,O
the,2747,O
SNPs,2747,O
in,2747,O
CFH,2747,B-GeneOrGeneProduct
",",2747,O
C2,2747,B-GeneOrGeneProduct
",",2747,O
CFB,2747,B-GeneOrGeneProduct
",",2747,O
and,2747,O
C3,2747,B-GeneOrGeneProduct
showed,2747,O
a,2747,O
significant,2747,O
association,2747,O
with,2747,O
either,2747,O
wet,2747,O
AMD,2747,B-DiseaseOrPhenotypicFeature
or,2747,O
drusen,2747,B-DiseaseOrPhenotypicFeature
in,2747,O
the,2747,O
cohort,2747,O
of,2747,O
this,2747,O
study,2747,O
.,2747,O
The,2748,O
CFHR1,2748,B-GeneOrGeneProduct
and,2748,O
CFHR3,2748,B-GeneOrGeneProduct
deletion,2748,O
was,2748,O
not,2748,O
polymorphic,2748,O
in,2748,O
the,2748,O
Chinese,2748,O
population,2748,O
and,2748,O
was,2748,O
not,2748,O
associated,2748,O
with,2748,O
wet,2748,O
AMD,2748,B-DiseaseOrPhenotypicFeature
or,2748,O
drusen,2748,B-DiseaseOrPhenotypicFeature
.,2748,O
CONCLUSION,2749,O
:,2749,O
This,2749,O
study,2749,O
showed,2749,O
that,2749,O
SNPs,2749,O
rs3753394,2749,B-SequenceVariant
(,2749,O
P,2749,O
=,2749,O
0.0276,2749,O
),2749,O
",",2749,O
rs800292,2749,B-SequenceVariant
(,2749,O
P,2749,O
=,2749,O
0.0266,2749,O
),2749,O
",",2749,O
rs1061170,2749,B-SequenceVariant
(,2749,O
P,2749,O
=,2749,O
0.00514,2749,O
),2749,O
",",2749,O
and,2749,O
rs1329428,2749,B-SequenceVariant
(,2749,O
P,2749,O
=,2749,O
0.0089,2749,O
),2749,O
",",2749,O
but,2749,O
not,2749,O
rs7535263,2749,B-SequenceVariant
",",2749,O
rs1410996,2749,B-SequenceVariant
",",2749,O
or,2749,O
rs2274700,2749,B-SequenceVariant
",",2749,O
in,2749,O
CFH,2749,B-GeneOrGeneProduct
were,2749,O
significantly,2749,O
associated,2749,O
with,2749,O
wet,2749,O
AMD,2749,B-DiseaseOrPhenotypicFeature
in,2749,O
a,2749,O
mainland,2749,O
Han,2749,O
Chinese,2749,O
population,2749,O
.,2749,O
This,2750,O
study,2750,O
showed,2750,O
that,2750,O
CFH,2750,B-GeneOrGeneProduct
was,2750,O
more,2750,O
likely,2750,O
to,2750,O
be,2750,O
AMD,2750,B-DiseaseOrPhenotypicFeature
susceptibility,2750,O
gene,2750,O
at,2750,O
Chr.1q31,2750,O
based,2750,O
on,2750,O
the,2750,O
finding,2750,O
that,2750,O
the,2750,O
CFHR1,2750,B-GeneOrGeneProduct
and,2750,O
CFHR3,2750,B-GeneOrGeneProduct
deletion,2750,O
was,2750,O
not,2750,O
polymorphic,2750,O
in,2750,O
the,2750,O
cohort,2750,O
of,2750,O
this,2750,O
study,2750,O
",",2750,O
and,2750,O
none,2750,O
of,2750,O
the,2750,O
SNPs,2750,O
that,2750,O
were,2750,O
significantly,2750,O
associated,2750,O
with,2750,O
AMD,2750,B-DiseaseOrPhenotypicFeature
in,2750,O
a,2750,O
white,2750,O
population,2750,O
in,2750,O
C2,2750,B-GeneOrGeneProduct
",",2750,O
CFB,2750,B-GeneOrGeneProduct
",",2750,O
and,2750,O
C3,2750,B-GeneOrGeneProduct
genes,2750,O
showed,2750,O
a,2750,O
significant,2750,O
association,2750,O
with,2750,O
AMD,2750,B-DiseaseOrPhenotypicFeature
.,2750,O
Salvage,2751,O
therapy,2751,O
with,2751,O
nelarabine,2751,B-ChemicalEntity
",",2751,O
etoposide,2751,B-ChemicalEntity
",",2751,O
and,2751,O
cyclophosphamide,2751,B-ChemicalEntity
in,2751,O
relapsed/refractory,2751,O
paediatric,2751,O
T-cell,2751,B-DiseaseOrPhenotypicFeature
lymphoblastic,2751,I-DiseaseOrPhenotypicFeature
leukaemia,2751,I-DiseaseOrPhenotypicFeature
and,2751,I-DiseaseOrPhenotypicFeature
lymphoma,2751,I-DiseaseOrPhenotypicFeature
.,2751,O
A,2752,O
combination,2752,O
of,2752,O
5,2752,O
d,2752,O
of,2752,O
nelarabine,2752,B-ChemicalEntity
(,2752,O
AraG,2752,B-ChemicalEntity
),2752,O
with,2752,O
5,2752,O
d,2752,O
of,2752,O
etoposide,2752,B-ChemicalEntity
(,2752,O
VP,2752,B-ChemicalEntity
),2752,O
and,2752,O
cyclophosphamide,2752,B-ChemicalEntity
(,2752,O
CPM,2752,B-ChemicalEntity
),2752,O
and,2752,O
prophylactic,2752,O
intrathecal,2752,O
chemotherapy,2752,O
was,2752,O
used,2752,O
as,2752,O
salvage,2752,O
therapy,2752,O
in,2752,O
seven,2752,O
children,2752,O
with,2752,O
refractory,2752,O
or,2752,O
relapsed,2752,O
T-cell,2752,B-DiseaseOrPhenotypicFeature
leukaemia,2752,I-DiseaseOrPhenotypicFeature
or,2752,I-DiseaseOrPhenotypicFeature
lymphoma,2752,I-DiseaseOrPhenotypicFeature
.,2752,O
The,2753,O
most,2753,O
common,2753,O
side,2753,O
effects,2753,O
attributable,2753,O
to,2753,O
the,2753,O
AraG,2753,B-ChemicalEntity
included,2753,O
Grade,2753,O
2,2753,O
and,2753,O
3,2753,O
sensory,2753,O
and,2753,O
motor,2753,O
neuropathy,2753,B-DiseaseOrPhenotypicFeature
and,2753,O
musculoskeletal,2753,B-DiseaseOrPhenotypicFeature
pain,2753,I-DiseaseOrPhenotypicFeature
.,2753,O
Haematological,2754,B-DiseaseOrPhenotypicFeature
toxicity,2754,I-DiseaseOrPhenotypicFeature
was,2754,O
greater,2754,O
for,2754,O
the,2754,O
combination,2754,O
than,2754,O
AraG,2754,B-ChemicalEntity
alone,2754,O
",",2754,O
although,2754,O
median,2754,O
time,2754,O
to,2754,O
neutrophil,2754,O
and,2754,O
platelet,2754,O
recovery,2754,O
was,2754,O
consistent,2754,O
with,2754,O
other,2754,O
salvage,2754,O
therapies,2754,O
.,2754,O
All,2755,O
patients,2755,B-OrganismTaxon
had,2755,O
some,2755,O
response,2755,O
to,2755,O
the,2755,O
combined,2755,O
therapy,2755,O
and,2755,O
five,2755,O
of,2755,O
the,2755,O
seven,2755,O
went,2755,O
into,2755,O
complete,2755,O
remission,2755,O
after,2755,O
one,2755,O
or,2755,O
two,2755,O
courses,2755,O
of,2755,O
AraG/VP/CPM,2755,B-ChemicalEntity
.,2755,O
Our,2756,O
experience,2756,O
supports,2756,O
the,2756,O
safety,2756,O
of,2756,O
giving,2756,O
AraG,2756,B-ChemicalEntity
as,2756,O
salvage,2756,O
therapy,2756,O
in,2756,O
synchrony,2756,O
with,2756,O
etoposide,2756,B-ChemicalEntity
and,2756,O
cyclophosphamide,2756,B-ChemicalEntity
",",2756,O
although,2756,O
neurological,2756,B-DiseaseOrPhenotypicFeature
toxicity,2756,I-DiseaseOrPhenotypicFeature
must,2756,O
be,2756,O
closely,2756,O
monitored,2756,O
.,2756,O
Dopamine,2757,B-ChemicalEntity
is,2757,O
not,2757,O
essential,2757,O
for,2757,O
the,2757,O
development,2757,O
of,2757,O
methamphetamine-induced,2757,B-ChemicalEntity
neurotoxicity,2757,B-DiseaseOrPhenotypicFeature
.,2757,O
It,2758,O
is,2758,O
widely,2758,O
believed,2758,O
that,2758,O
dopamine,2758,B-ChemicalEntity
(,2758,O
DA,2758,B-ChemicalEntity
),2758,O
mediates,2758,O
methamphetamine,2758,B-ChemicalEntity
(,2758,O
METH,2758,B-ChemicalEntity
),2758,O
-induced,2758,O
toxicity,2758,B-DiseaseOrPhenotypicFeature
to,2758,O
brain,2758,O
dopaminergic,2758,O
neurons,2758,O
",",2758,O
because,2758,O
drugs,2758,O
that,2758,O
interfere,2758,O
with,2758,O
DA,2758,B-ChemicalEntity
neurotransmission,2758,O
decrease,2758,O
toxicity,2758,B-DiseaseOrPhenotypicFeature
",",2758,O
whereas,2758,O
drugs,2758,O
that,2758,O
increase,2758,O
DA,2758,B-ChemicalEntity
neurotransmission,2758,O
enhance,2758,O
toxicity,2758,B-DiseaseOrPhenotypicFeature
.,2758,O
However,2759,O
",",2759,O
temperature,2759,O
effects,2759,O
of,2759,O
drugs,2759,O
that,2759,O
have,2759,O
been,2759,O
used,2759,O
to,2759,O
manipulate,2759,O
brain,2759,O
DA,2759,B-ChemicalEntity
neurotransmission,2759,O
confound,2759,O
interpretation,2759,O
of,2759,O
the,2759,O
data,2759,O
.,2759,O
Here,2760,O
we,2760,O
show,2760,O
that,2760,O
the,2760,O
recently,2760,O
reported,2760,O
ability,2760,O
of,2760,O
L-dihydroxyphenylalanine,2760,B-ChemicalEntity
to,2760,O
reverse,2760,O
the,2760,O
protective,2760,O
effect,2760,O
of,2760,O
alpha-methyl-para-tyrosine,2760,B-ChemicalEntity
on,2760,O
METH-induced,2760,B-ChemicalEntity
DA,2760,B-ChemicalEntity
neurotoxicity,2760,B-DiseaseOrPhenotypicFeature
is,2760,O
also,2760,O
confounded,2760,O
by,2760,O
drug,2760,O
effects,2760,O
on,2760,O
body,2760,O
temperature,2760,O
.,2760,O
Further,2761,O
",",2761,O
we,2761,O
show,2761,O
that,2761,O
mice,2761,B-OrganismTaxon
genetically,2761,O
engineered,2761,O
to,2761,O
be,2761,O
deficient,2761,O
in,2761,O
brain,2761,O
DA,2761,B-ChemicalEntity
develop,2761,O
METH,2761,B-ChemicalEntity
neurotoxicity,2761,B-DiseaseOrPhenotypicFeature
",",2761,O
as,2761,O
long,2761,O
as,2761,O
the,2761,O
thermic,2761,O
effects,2761,O
of,2761,O
METH,2761,B-ChemicalEntity
are,2761,O
preserved,2761,O
.,2761,O
In,2762,O
addition,2762,O
",",2762,O
we,2762,O
demonstrate,2762,O
that,2762,O
mice,2762,B-OrganismTaxon
genetically,2762,O
engineered,2762,O
to,2762,O
have,2762,O
unilateral,2762,O
brain,2762,O
DA,2762,B-ChemicalEntity
deficits,2762,O
develop,2762,O
METH-induced,2762,B-ChemicalEntity
dopaminergic,2762,B-DiseaseOrPhenotypicFeature
deficits,2762,I-DiseaseOrPhenotypicFeature
that,2762,O
are,2762,O
of,2762,O
comparable,2762,O
magnitude,2762,O
on,2762,O
both,2762,O
sides,2762,O
of,2762,O
the,2762,O
brain,2762,O
.,2762,O
Taken,2763,O
together,2763,O
",",2763,O
these,2763,O
findings,2763,O
demonstrate,2763,O
that,2763,O
DA,2763,B-ChemicalEntity
is,2763,O
not,2763,O
essential,2763,O
for,2763,O
the,2763,O
development,2763,O
of,2763,O
METH-induced,2763,B-ChemicalEntity
dopaminergic,2763,O
neurotoxicity,2763,B-DiseaseOrPhenotypicFeature
and,2763,O
suggest,2763,O
that,2763,O
mechanisms,2763,O
independent,2763,O
of,2763,O
DA,2763,B-ChemicalEntity
warrant,2763,O
more,2763,O
intense,2763,O
investigation,2763,O
.,2763,O
Association,2764,O
of,2764,O
obesity,2764,B-DiseaseOrPhenotypicFeature
risk,2764,O
SNPs,2764,O
in,2764,O
PCSK1,2764,B-GeneOrGeneProduct
with,2764,O
insulin,2764,B-GeneOrGeneProduct
sensitivity,2764,O
and,2764,O
proinsulin,2764,B-ChemicalEntity
conversion,2764,O
.,2764,O
BACKGROUND,2765,O
:,2765,O
Prohormone,2765,B-GeneOrGeneProduct
convertase,2765,I-GeneOrGeneProduct
1,2765,I-GeneOrGeneProduct
is,2765,O
involved,2765,O
in,2765,O
maturation,2765,O
of,2765,O
peptides,2765,O
.,2765,O
Rare,2766,O
mutations,2766,O
in,2766,O
gene,2766,O
PCSK1,2766,B-GeneOrGeneProduct
",",2766,O
encoding,2766,O
this,2766,O
enzyme,2766,O
",",2766,O
cause,2766,O
childhood,2766,O
obesity,2766,B-DiseaseOrPhenotypicFeature
and,2766,O
abnormal,2766,B-DiseaseOrPhenotypicFeature
glucose,2766,I-DiseaseOrPhenotypicFeature
homeostasis,2766,I-DiseaseOrPhenotypicFeature
with,2766,O
elevated,2766,O
proinsulin,2766,B-ChemicalEntity
concentrations,2766,O
.,2766,O
Common,2767,O
single,2767,O
nucleotide,2767,O
polymorphisms,2767,O
(,2767,O
SNPs,2767,O
),2767,O
within,2767,O
this,2767,O
gene,2767,O
",",2767,O
rs6232,2767,B-SequenceVariant
and,2767,O
rs6235,2767,B-SequenceVariant
",",2767,O
are,2767,O
associated,2767,O
with,2767,O
obesity,2767,B-DiseaseOrPhenotypicFeature
.,2767,O
We,2768,O
studied,2768,O
whether,2768,O
these,2768,O
SNPs,2768,O
influence,2768,O
the,2768,O
prediabetic,2768,O
traits,2768,O
insulin,2768,B-DiseaseOrPhenotypicFeature
resistance,2768,I-DiseaseOrPhenotypicFeature
",",2768,O
beta-cell,2768,B-DiseaseOrPhenotypicFeature
dysfunction,2768,I-DiseaseOrPhenotypicFeature
",",2768,O
or,2768,O
glucose,2768,B-DiseaseOrPhenotypicFeature
intolerance,2768,I-DiseaseOrPhenotypicFeature
.,2768,O
METHODS,2769,O
:,2769,O
We,2769,O
genotyped,2769,O
1498,2769,O
German,2769,O
subjects,2769,O
for,2769,O
SNPs,2769,O
rs6232,2769,B-SequenceVariant
and,2769,O
rs6235,2769,B-SequenceVariant
within,2769,O
PCSK1,2769,B-GeneOrGeneProduct
.,2769,O
The,2770,O
subjects,2770,O
were,2770,O
metabolically,2770,O
characterized,2770,O
by,2770,O
oral,2770,O
glucose,2770,B-ChemicalEntity
tolerance,2770,O
test,2770,O
with,2770,O
glucose,2770,B-ChemicalEntity
",",2770,O
insulin,2770,B-GeneOrGeneProduct
",",2770,O
proinsulin,2770,B-ChemicalEntity
",",2770,O
and,2770,O
C-peptide,2770,B-ChemicalEntity
measurements,2770,O
.,2770,O
A,2771,O
subgroup,2771,O
of,2771,O
512,2771,O
subjects,2771,O
underwent,2771,O
a,2771,O
hyperinsulinemic-euglycemic,2771,B-DiseaseOrPhenotypicFeature
clamp,2771,O
.,2771,O
RESULTS,2772,O
:,2772,O
The,2772,O
minor,2772,O
allele,2772,O
frequencies,2772,O
were,2772,O
25.8,2772,O
%,2772,O
for,2772,O
SNP,2772,O
rs6235,2772,B-SequenceVariant
and,2772,O
6.0,2772,O
%,2772,O
for,2772,O
rs6232,2772,B-SequenceVariant
.,2772,O
After,2773,O
adjustment,2773,O
for,2773,O
sex,2773,O
and,2773,O
age,2773,O
",",2773,O
we,2773,O
found,2773,O
no,2773,O
association,2773,O
of,2773,O
SNPs,2773,O
rs6235,2773,B-SequenceVariant
and,2773,O
rs6232,2773,B-SequenceVariant
with,2773,O
BMI,2773,O
or,2773,O
other,2773,O
weight-related,2773,O
traits,2773,O
(,2773,O
all,2773,O
p,2773,O
>,2773,O
or=,2773,O
0.07,2773,O
),2773,O
.,2773,O
Both,2774,O
minor,2774,O
alleles,2774,O
",",2774,O
adjusted,2774,O
for,2774,O
sex,2774,O
",",2774,O
age,2774,O
",",2774,O
BMI,2774,O
and,2774,O
insulin,2774,B-GeneOrGeneProduct
sensitivity,2774,O
were,2774,O
associated,2774,O
with,2774,O
elevated,2774,O
AUCproinsulin,2774,O
and,2774,O
AUCproinsulin/AUCinsulin,2774,O
(,2774,O
rs6235,2774,B-SequenceVariant
:,2774,O
p,2774,O
(,2774,O
additive,2774,O
),2774,O
model,2774,O
<,2774,O
or=,2774,O
0.009,2774,O
",",2774,O
effect,2774,O
sizes,2774,O
8/8,2774,O
%,2774,O
",",2774,O
rs6232,2774,B-SequenceVariant
:,2774,O
pdominant,2774,O
model,2774,O
<,2774,O
or=,2774,O
0.01,2774,O
",",2774,O
effect,2774,O
sizes,2774,O
10/21,2774,O
%,2774,O
),2774,O
.,2774,O
Insulin,2775,B-GeneOrGeneProduct
secretion,2775,O
was,2775,O
not,2775,O
affected,2775,O
by,2775,O
the,2775,O
variants,2775,O
(,2775,O
different,2775,O
secretion,2775,O
parameters,2775,O
",",2775,O
all,2775,O
p,2775,O
>,2775,O
or=,2775,O
0.08,2775,O
),2775,O
.,2775,O
The,2776,O
minor,2776,O
allele,2776,O
of,2776,O
SNP,2776,O
rs6232,2776,B-SequenceVariant
was,2776,O
additionally,2776,O
associated,2776,O
with,2776,O
15,2776,O
%,2776,O
higher,2776,O
OGTT-derived,2776,O
and,2776,O
19,2776,O
%,2776,O
higher,2776,O
clamp-derived,2776,O
insulin,2776,B-GeneOrGeneProduct
sensitivity,2776,O
(,2776,O
pdom,2776,O
<,2776,O
or=,2776,O
0.0047,2776,O
),2776,O
",",2776,O
4.5,2776,O
%,2776,O
lower,2776,O
HOMAIR,2776,O
(,2776,O
pdom,2776,O
=,2776,O
0.02,2776,O
),2776,O
and,2776,O
3.5,2776,O
%,2776,O
lower,2776,O
120-min,2776,O
glucose,2776,B-ChemicalEntity
(,2776,O
pdom,2776,O
=,2776,O
0.0003,2776,O
),2776,O
independently,2776,O
of,2776,O
BMI,2776,O
and,2776,O
proinsulin,2776,B-ChemicalEntity
conversion,2776,O
.,2776,O
SNP,2777,O
rs6235,2777,B-SequenceVariant
was,2777,O
not,2777,O
associated,2777,O
with,2777,O
parameters,2777,O
of,2777,O
glucose,2777,O
metabolism,2777,O
.,2777,O
CONCLUSIONS,2778,O
:,2778,O
Like,2778,O
rare,2778,O
mutations,2778,O
in,2778,O
PCSK1,2778,B-GeneOrGeneProduct
",",2778,O
the,2778,O
more,2778,O
common,2778,O
variants,2778,O
tested,2778,O
determine,2778,O
glucose-stimulated,2778,B-ChemicalEntity
proinsulin,2778,B-ChemicalEntity
conversion,2778,O
",",2778,O
but,2778,O
not,2778,O
insulin,2778,B-GeneOrGeneProduct
secretion,2778,O
.,2778,O
In,2779,O
addition,2779,O
",",2779,O
rs6232,2779,B-SequenceVariant
",",2779,O
encoding,2779,O
the,2779,O
amino,2779,O
acid,2779,O
exchange,2779,O
N221D,2779,B-SequenceVariant
",",2779,O
influences,2779,O
insulin,2779,B-GeneOrGeneProduct
sensitivity,2779,O
and,2779,O
glucose,2779,B-ChemicalEntity
homeostasis,2779,O
.,2779,O
Glutamatergic,2780,O
neurotransmission,2780,O
mediated,2780,O
by,2780,O
NMDA,2780,B-GeneOrGeneProduct
receptors,2780,I-GeneOrGeneProduct
in,2780,O
the,2780,O
inferior,2780,O
colliculus,2780,O
can,2780,O
modulate,2780,O
haloperidol-induced,2780,B-ChemicalEntity
catalepsy,2780,B-DiseaseOrPhenotypicFeature
.,2780,O
The,2781,O
inferior,2781,O
colliculus,2781,O
(,2781,O
IC,2781,O
),2781,O
is,2781,O
primarily,2781,O
involved,2781,O
in,2781,O
the,2781,O
processing,2781,O
of,2781,O
auditory,2781,O
information,2781,O
",",2781,O
but,2781,O
it,2781,O
is,2781,O
distinguished,2781,O
from,2781,O
other,2781,O
auditory,2781,O
nuclei,2781,O
in,2781,O
the,2781,O
brainstem,2781,O
by,2781,O
its,2781,O
connections,2781,O
with,2781,O
structures,2781,O
of,2781,O
the,2781,O
motor,2781,O
system,2781,O
.,2781,O
Functional,2782,O
evidence,2782,O
relating,2782,O
the,2782,O
IC,2782,O
to,2782,O
motor,2782,O
behavior,2782,O
derives,2782,O
from,2782,O
experiments,2782,O
showing,2782,O
that,2782,O
activation,2782,O
of,2782,O
the,2782,O
IC,2782,O
by,2782,O
electrical,2782,O
stimulation,2782,O
or,2782,O
excitatory,2782,O
amino,2782,O
acid,2782,O
microinjection,2782,O
causes,2782,O
freezing,2782,O
",",2782,O
escape-like,2782,O
behavior,2782,O
",",2782,O
and,2782,O
immobility,2782,O
.,2782,O
However,2783,O
",",2783,O
the,2783,O
nature,2783,O
of,2783,O
this,2783,O
immobility,2783,O
is,2783,O
still,2783,O
unclear,2783,O
.,2783,O
The,2784,O
present,2784,O
study,2784,O
examined,2784,O
the,2784,O
influence,2784,O
of,2784,O
excitatory,2784,O
amino,2784,O
acid-mediated,2784,O
mechanisms,2784,O
in,2784,O
the,2784,O
IC,2784,O
on,2784,O
the,2784,O
catalepsy,2784,B-DiseaseOrPhenotypicFeature
induced,2784,O
by,2784,O
the,2784,O
dopamine,2784,B-GeneOrGeneProduct
receptor,2784,I-GeneOrGeneProduct
blocker,2784,O
haloperidol,2784,B-ChemicalEntity
administered,2784,O
systemically,2784,O
(,2784,O
1,2784,O
or,2784,O
0.5,2784,O
mg/kg,2784,O
),2784,O
in,2784,O
rats,2784,B-OrganismTaxon
.,2784,O
Haloperidol-induced,2785,B-ChemicalEntity
catalepsy,2785,B-DiseaseOrPhenotypicFeature
was,2785,O
challenged,2785,O
with,2785,O
prior,2785,O
intracollicular,2785,O
microinjections,2785,O
of,2785,O
glutamate,2785,B-GeneOrGeneProduct
NMDA,2785,I-GeneOrGeneProduct
receptor,2785,I-GeneOrGeneProduct
antagonists,2785,O
",",2785,O
MK-801,2785,B-ChemicalEntity
(,2785,O
15,2785,O
or,2785,O
30,2785,O
mmol/0.5,2785,O
microl,2785,O
),2785,O
and,2785,O
AP7,2785,B-ChemicalEntity
(,2785,O
10,2785,O
or,2785,O
20,2785,O
nmol/0.5,2785,O
microl,2785,O
),2785,O
",",2785,O
or,2785,O
of,2785,O
the,2785,O
NMDA,2785,B-GeneOrGeneProduct
receptor,2785,I-GeneOrGeneProduct
agonist,2785,O
N-methyl-d-aspartate,2785,B-ChemicalEntity
(,2785,O
NMDA,2785,B-ChemicalEntity
",",2785,O
20,2785,O
or,2785,O
30,2785,O
nmol/0.5,2785,O
microl,2785,O
),2785,O
.,2785,O
The,2786,O
results,2786,O
showed,2786,O
that,2786,O
intracollicular,2786,O
microinjection,2786,O
of,2786,O
MK-801,2786,B-ChemicalEntity
and,2786,O
AP7,2786,B-ChemicalEntity
previous,2786,O
to,2786,O
systemic,2786,O
injections,2786,O
of,2786,O
haloperidol,2786,B-ChemicalEntity
significantly,2786,O
attenuated,2786,O
the,2786,O
catalepsy,2786,B-DiseaseOrPhenotypicFeature
",",2786,O
as,2786,O
indicated,2786,O
by,2786,O
a,2786,O
reduced,2786,O
latency,2786,O
to,2786,O
step,2786,O
down,2786,O
from,2786,O
a,2786,O
horizontal,2786,O
bar,2786,O
.,2786,O
Accordingly,2787,O
",",2787,O
intracollicular,2787,O
microinjection,2787,O
of,2787,O
NMDA,2787,B-ChemicalEntity
increased,2787,O
the,2787,O
latency,2787,O
to,2787,O
step,2787,O
down,2787,O
the,2787,O
bar,2787,O
.,2787,O
These,2788,O
findings,2788,O
suggest,2788,O
that,2788,O
glutamate-mediated,2788,B-ChemicalEntity
mechanisms,2788,O
in,2788,O
the,2788,O
neural,2788,O
circuits,2788,O
at,2788,O
the,2788,O
IC,2788,O
level,2788,O
influence,2788,O
haloperidol-induced,2788,B-ChemicalEntity
catalepsy,2788,B-DiseaseOrPhenotypicFeature
and,2788,O
participate,2788,O
in,2788,O
the,2788,O
regulation,2788,O
of,2788,O
motor,2788,O
activity,2788,O
.,2788,O
Identification,2789,O
of,2789,O
a,2789,O
frameshift,2789,O
mutation,2789,O
in,2789,O
Osterix,2789,B-GeneOrGeneProduct
in,2789,O
a,2789,O
patient,2789,B-OrganismTaxon
with,2789,O
recessive,2789,B-DiseaseOrPhenotypicFeature
osteogenesis,2789,I-DiseaseOrPhenotypicFeature
imperfecta,2789,I-DiseaseOrPhenotypicFeature
.,2789,O
Osteogenesis,2790,B-DiseaseOrPhenotypicFeature
imperfecta,2790,I-DiseaseOrPhenotypicFeature
",",2790,O
or,2790,O
``,2790,O
brittle,2790,B-DiseaseOrPhenotypicFeature
bone,2790,I-DiseaseOrPhenotypicFeature
disease,2790,I-DiseaseOrPhenotypicFeature
",",2790,O
'',2790,O
is,2790,I-DiseaseOrPhenotypicFeature
a,2790,I-DiseaseOrPhenotypicFeature
type,2790,B-GeneOrGeneProduct
I,2790,I-GeneOrGeneProduct
collagen-related,2790,O
condition,2790,O
associated,2790,O
with,2790,O
osteoporosis,2790,B-DiseaseOrPhenotypicFeature
and,2790,O
increased,2790,O
risk,2790,O
of,2790,O
bone,2790,B-DiseaseOrPhenotypicFeature
fractures,2790,I-DiseaseOrPhenotypicFeature
.,2790,O
Using,2791,O
a,2791,O
combination,2791,O
of,2791,O
homozygosity,2791,O
mapping,2791,O
and,2791,O
candidate,2791,O
gene,2791,O
approach,2791,O
",",2791,O
we,2791,O
have,2791,O
identified,2791,O
a,2791,O
homozygous,2791,O
single,2791,B-SequenceVariant
base,2791,I-SequenceVariant
pair,2791,I-SequenceVariant
deletion,2791,I-SequenceVariant
(,2791,O
c.1052delA,2791,B-SequenceVariant
),2791,O
in,2791,O
SP7/Osterix,2791,B-GeneOrGeneProduct
(,2791,O
OSX,2791,B-GeneOrGeneProduct
),2791,O
in,2791,O
an,2791,O
Egyptian,2791,O
child,2791,O
with,2791,O
recessive,2791,B-DiseaseOrPhenotypicFeature
osteogenesis,2791,I-DiseaseOrPhenotypicFeature
imperfecta,2791,I-DiseaseOrPhenotypicFeature
.,2791,O
The,2792,O
clinical,2792,O
findings,2792,O
from,2792,O
this,2792,O
patient,2792,B-OrganismTaxon
include,2792,O
recurrent,2792,O
fractures,2792,B-DiseaseOrPhenotypicFeature
",",2792,O
mild,2792,O
bone,2792,B-DiseaseOrPhenotypicFeature
deformities,2792,I-DiseaseOrPhenotypicFeature
",",2792,O
delayed,2792,O
tooth,2792,B-DiseaseOrPhenotypicFeature
eruption,2792,I-DiseaseOrPhenotypicFeature
",",2792,O
normal,2792,O
hearing,2792,O
",",2792,O
and,2792,O
white,2792,O
sclera,2792,O
.,2792,O
OSX,2793,B-GeneOrGeneProduct
encodes,2793,O
a,2793,O
transcription,2793,O
factor,2793,O
containing,2793,O
three,2793,O
Cys2-His2,2793,O
zinc-finger,2793,O
DNA-binding,2793,O
domains,2793,O
at,2793,O
its,2793,O
C,2793,O
terminus,2793,O
",",2793,O
which,2793,O
",",2793,O
in,2793,O
mice,2793,B-OrganismTaxon
",",2793,O
has,2793,O
been,2793,O
shown,2793,O
to,2793,O
be,2793,O
essential,2793,O
for,2793,O
bone,2793,O
formation,2793,O
.,2793,O
The,2794,O
frameshift,2794,O
caused,2794,O
by,2794,O
the,2794,O
c.1052delA,2794,B-SequenceVariant
deletion,2794,O
removes,2794,O
the,2794,O
last,2794,O
81,2794,O
amino,2794,O
acids,2794,O
of,2794,O
the,2794,O
protein,2794,O
",",2794,O
including,2794,O
the,2794,O
third,2794,O
zinc-finger,2794,O
motif,2794,O
.,2794,O
This,2795,O
finding,2795,O
adds,2795,O
another,2795,O
locus,2795,O
to,2795,O
the,2795,O
spectrum,2795,O
of,2795,O
genes,2795,O
associated,2795,O
with,2795,O
osteogenesis,2795,B-DiseaseOrPhenotypicFeature
imperfecta,2795,I-DiseaseOrPhenotypicFeature
and,2795,O
reveals,2795,O
that,2795,O
SP7/OSX,2795,B-GeneOrGeneProduct
also,2795,O
plays,2795,O
a,2795,O
key,2795,O
role,2795,O
in,2795,O
human,2795,B-OrganismTaxon
bone,2795,O
development,2795,O
.,2795,O
Molecular,2796,O
diagnosis,2796,O
of,2796,O
46,2796,B-DiseaseOrPhenotypicFeature
",",2796,I-DiseaseOrPhenotypicFeature
XY,2796,I-DiseaseOrPhenotypicFeature
DSD,2796,I-DiseaseOrPhenotypicFeature
and,2796,O
identification,2796,O
of,2796,O
a,2796,O
novel,2796,O
8,2796,B-SequenceVariant
nucleotide,2796,I-SequenceVariant
deletion,2796,I-SequenceVariant
in,2796,O
exon,2796,O
1,2796,O
of,2796,O
the,2796,O
SRD5A2,2796,B-GeneOrGeneProduct
gene,2796,O
.,2796,O
Phenotypic,2797,O
presentation,2797,O
of,2797,O
46,2797,B-DiseaseOrPhenotypicFeature
",",2797,I-DiseaseOrPhenotypicFeature
XY,2797,I-DiseaseOrPhenotypicFeature
DSD,2797,I-DiseaseOrPhenotypicFeature
depends,2797,O
on,2797,O
the,2797,O
underlying,2797,O
defects,2797,O
.,2797,O
Defect,2798,O
in,2798,O
androgen,2798,O
action,2798,O
on,2798,O
the,2798,O
target,2798,O
tissues,2798,O
or,2798,O
production,2798,O
of,2798,O
active,2798,O
metabolite,2798,O
share,2798,O
common,2798,O
morphological,2798,O
features,2798,O
.,2798,O
Molecular,2799,O
study,2799,O
may,2799,O
help,2799,O
differentiating,2799,O
these,2799,O
abnormalities,2799,O
with,2799,O
precision,2799,O
.,2799,O
Mutational,2800,O
analysis,2800,O
of,2800,O
androgen,2800,B-GeneOrGeneProduct
receptor,2800,I-GeneOrGeneProduct
(,2800,O
AR,2800,B-GeneOrGeneProduct
),2800,O
and,2800,O
SRD5A2,2800,B-GeneOrGeneProduct
genes,2800,O
was,2800,O
performed,2800,O
in,2800,O
29,2800,O
patients,2800,B-OrganismTaxon
with,2800,O
46,2800,B-DiseaseOrPhenotypicFeature
",",2800,I-DiseaseOrPhenotypicFeature
XY,2800,I-DiseaseOrPhenotypicFeature
DSD,2800,I-DiseaseOrPhenotypicFeature
",",2800,O
by,2800,O
PCR-SSCP,2800,O
.,2800,O
The,2801,O
amplicons,2801,O
that,2801,O
showed,2801,O
an,2801,O
aberrant,2801,O
migration,2801,O
in,2801,O
SSCP,2801,O
were,2801,O
subjected,2801,O
to,2801,O
sequencing,2801,O
.,2801,O
Interestingly,2802,O
",",2802,O
six,2802,O
patients,2802,B-OrganismTaxon
from,2802,O
4,2802,O
unrelated,2802,O
families,2802,O
(,2802,O
a,2802,O
pair,2802,O
of,2802,O
sibs,2802,O
",",2802,O
uncle/nephew,2802,O
and,2802,O
other,2802,O
two,2802,O
isolated,2802,O
),2802,O
were,2802,O
identified,2802,O
with,2802,O
mutations,2802,O
in,2802,O
SRD5A2,2802,B-GeneOrGeneProduct
gene,2802,O
.,2802,O
In,2803,O
five,2803,O
patients,2803,B-OrganismTaxon
p.R246Q,2803,B-SequenceVariant
missense,2803,O
mutation,2803,O
was,2803,O
detected,2803,O
",",2803,O
of,2803,O
which,2803,O
four,2803,O
were,2803,O
homozygous,2803,O
and,2803,O
one,2803,O
was,2803,O
compound,2803,O
heterozygous,2803,O
:,2803,O
g.80_87delT,2803,B-SequenceVariant
CGCGAAG,2803,I-SequenceVariant
(,2803,O
p.A27fsX132,2803,B-SequenceVariant
),2803,O
and,2803,O
p.R246Q,2803,B-SequenceVariant
.,2803,O
Another,2804,O
patient,2804,B-OrganismTaxon
with,2804,O
isolated,2804,B-DiseaseOrPhenotypicFeature
micropenis,2804,I-DiseaseOrPhenotypicFeature
harbored,2804,O
a,2804,O
heterozygous,2804,O
p.G196S,2804,B-SequenceVariant
missense,2804,O
mutation,2804,O
.,2804,O
No,2805,O
AR,2805,B-GeneOrGeneProduct
gene,2805,O
mutation,2805,O
was,2805,O
detected,2805,O
.,2805,O
In,2806,O
conclusion,2806,O
",",2806,O
our,2806,O
study,2806,O
suggests,2806,O
that,2806,O
p.R246Q,2806,B-SequenceVariant
mutation,2806,O
is,2806,O
common,2806,O
amongst,2806,O
patients,2806,B-OrganismTaxon
with,2806,O
SRD5A2,2806,B-GeneOrGeneProduct
gene,2806,O
defect,2806,O
from,2806,O
the,2806,O
Northern,2806,O
states,2806,O
of,2806,O
India,2806,O
.,2806,O
Also,2807,O
",",2807,O
it,2807,O
records,2807,O
a,2807,O
novel,2807,O
deletion,2807,O
in,2807,O
exon,2807,O
1,2807,O
of,2807,O
SRD5A2,2807,B-GeneOrGeneProduct
gene,2807,O
in,2807,O
a,2807,O
patient,2807,B-OrganismTaxon
with,2807,O
severe,2807,O
hypospadias,2807,B-DiseaseOrPhenotypicFeature
.,2807,O
Permeability,2808,O
",",2808,O
ultrastructural,2808,O
changes,2808,O
",",2808,O
and,2808,O
distribution,2808,O
of,2808,O
novel,2808,O
proteins,2808,O
in,2808,O
the,2808,O
glomerular,2808,O
barrier,2808,O
in,2808,O
early,2808,O
puromycin,2808,B-ChemicalEntity
aminonucleoside,2808,I-ChemicalEntity
nephrosis,2808,B-DiseaseOrPhenotypicFeature
.,2808,O
BACKGROUND/AIMS,2809,O
:,2809,O
It,2809,O
is,2809,O
still,2809,O
unclear,2809,O
what,2809,O
happens,2809,O
in,2809,O
the,2809,O
glomerulus,2809,O
when,2809,O
proteinuria,2809,B-DiseaseOrPhenotypicFeature
starts,2809,O
.,2809,O
Using,2810,O
puromycin,2810,B-ChemicalEntity
aminonucleoside,2810,I-ChemicalEntity
nephrosis,2810,B-DiseaseOrPhenotypicFeature
(,2810,O
PAN,2810,B-DiseaseOrPhenotypicFeature
),2810,O
rats,2810,B-OrganismTaxon
",",2810,O
we,2810,O
studied,2810,O
early,2810,O
ultrastructural,2810,O
and,2810,O
permeability,2810,O
changes,2810,O
in,2810,O
relation,2810,O
to,2810,O
the,2810,O
expression,2810,O
of,2810,O
the,2810,O
podocyte-associated,2810,O
molecules,2810,O
nephrin,2810,B-GeneOrGeneProduct
",",2810,O
a-actinin,2810,B-GeneOrGeneProduct
",",2810,O
dendrin,2810,B-GeneOrGeneProduct
",",2810,O
and,2810,O
plekhh2,2810,B-GeneOrGeneProduct
",",2810,O
the,2810,O
last,2810,O
two,2810,O
of,2810,O
which,2810,O
were,2810,O
only,2810,O
recently,2810,O
discovered,2810,O
in,2810,O
podocytes,2810,O
.,2810,O
METHODS,2811,O
:,2811,O
Using,2811,O
immune,2811,O
stainings,2811,O
",",2811,O
semiquantitative,2811,O
measurement,2811,O
was,2811,O
performed,2811,O
under,2811,O
the,2811,O
electron,2811,O
microscope,2811,O
.,2811,O
Permeability,2812,O
was,2812,O
assessed,2812,O
using,2812,O
isolated,2812,O
kidney,2812,O
perfusion,2812,O
with,2812,O
tracers,2812,O
.,2812,O
Possible,2813,O
effects,2813,O
of,2813,O
ACE,2813,B-GeneOrGeneProduct
inhibition,2813,O
were,2813,O
tested,2813,O
.,2813,O
RESULTS,2814,O
:,2814,O
By,2814,O
day,2814,O
2,2814,O
",",2814,O
some,2814,O
patchy,2814,O
foot,2814,O
process,2814,O
effacement,2814,O
",",2814,O
but,2814,O
no,2814,O
proteinuria,2814,B-DiseaseOrPhenotypicFeature
",",2814,O
appeared,2814,O
.,2814,O
The,2815,O
amount,2815,O
of,2815,O
nephrin,2815,B-GeneOrGeneProduct
was,2815,O
reduced,2815,O
in,2815,O
both,2815,O
diseased,2815,O
and,2815,O
normal,2815,O
areas,2815,O
.,2815,O
The,2816,O
other,2816,O
proteins,2816,O
showed,2816,O
few,2816,O
changes,2816,O
",",2816,O
which,2816,O
were,2816,O
limited,2816,O
to,2816,O
diseased,2816,O
areas,2816,O
.,2816,O
By,2817,O
day,2817,O
4,2817,O
",",2817,O
foot,2817,O
process,2817,O
effacement,2817,O
was,2817,O
complete,2817,O
and,2817,O
proteinuria,2817,B-DiseaseOrPhenotypicFeature
appeared,2817,O
in,2817,O
parallel,2817,O
with,2817,O
signs,2817,O
of,2817,O
size,2817,O
barrier,2817,O
damage,2817,O
.,2817,O
Nephrin,2818,B-GeneOrGeneProduct
decreased,2818,O
further,2818,O
",",2818,O
while,2818,O
dendrin,2818,B-GeneOrGeneProduct
and,2818,O
plekhh2,2818,B-GeneOrGeneProduct
also,2818,O
decreased,2818,O
but,2818,O
a-actinin,2818,B-GeneOrGeneProduct
remained,2818,O
unchanged,2818,O
.,2818,O
ACE,2819,B-GeneOrGeneProduct
inhibition,2819,O
had,2819,O
no,2819,O
significant,2819,O
protective,2819,O
effect,2819,O
.,2819,O
CONCLUSIONS,2820,O
:,2820,O
PAN,2820,B-DiseaseOrPhenotypicFeature
glomeruli,2820,O
already,2820,O
showed,2820,O
significant,2820,O
pathology,2820,O
by,2820,O
day,2820,O
4,2820,O
",",2820,O
despite,2820,O
relatively,2820,O
mild,2820,O
proteinuria,2820,B-DiseaseOrPhenotypicFeature
.,2820,O
This,2821,O
was,2821,O
preceded,2821,O
by,2821,O
altered,2821,O
nephrin,2821,B-GeneOrGeneProduct
expression,2821,O
",",2821,O
supporting,2821,O
its,2821,O
pivotal,2821,O
role,2821,O
in,2821,O
podocyte,2821,O
morphology,2821,O
.,2821,O
The,2822,O
novel,2822,O
proteins,2822,O
dendrin,2822,B-GeneOrGeneProduct
and,2822,O
plekhh2,2822,B-GeneOrGeneProduct
were,2822,O
both,2822,O
reduced,2822,O
",",2822,O
suggesting,2822,O
roles,2822,O
in,2822,O
PAN,2822,B-DiseaseOrPhenotypicFeature
",",2822,O
whereas,2822,O
a-actinin,2822,B-GeneOrGeneProduct
was,2822,O
unchanged,2822,O
.,2822,O
Atypical,2823,O
GH,2823,B-DiseaseOrPhenotypicFeature
insensitivity,2823,I-DiseaseOrPhenotypicFeature
syndrome,2823,I-DiseaseOrPhenotypicFeature
and,2823,O
severe,2823,O
insulin-like,2823,B-DiseaseOrPhenotypicFeature
growth,2823,I-DiseaseOrPhenotypicFeature
factor-I,2823,I-DiseaseOrPhenotypicFeature
deficiency,2823,I-DiseaseOrPhenotypicFeature
resulting,2823,O
from,2823,O
compound,2823,O
heterozygous,2823,O
mutations,2823,O
of,2823,O
the,2823,O
GH,2823,B-GeneOrGeneProduct
receptor,2823,I-GeneOrGeneProduct
",",2823,O
including,2823,O
a,2823,O
novel,2823,O
frameshift,2823,O
mutation,2823,O
affecting,2823,O
the,2823,O
intracellular,2823,O
domain,2823,O
.,2823,O
BACKGROUND/AIMS,2824,O
:,2824,O
GH,2824,B-DiseaseOrPhenotypicFeature
insensitivity,2824,I-DiseaseOrPhenotypicFeature
and,2824,O
IGF,2824,B-DiseaseOrPhenotypicFeature
deficiency,2824,I-DiseaseOrPhenotypicFeature
may,2824,O
result,2824,O
from,2824,O
aberrations,2824,O
of,2824,O
the,2824,O
GH,2824,B-GeneOrGeneProduct
receptor,2824,I-GeneOrGeneProduct
(,2824,O
GHR,2824,B-GeneOrGeneProduct
),2824,O
.,2824,O
We,2825,O
describe,2825,O
a,2825,O
4-year-old,2825,O
child,2825,O
with,2825,O
modest,2825,O
growth,2825,B-DiseaseOrPhenotypicFeature
failure,2825,I-DiseaseOrPhenotypicFeature
and,2825,O
normal,2825,O
serum,2825,O
concentrations,2825,O
of,2825,O
GH-binding,2825,B-GeneOrGeneProduct
protein,2825,I-GeneOrGeneProduct
(,2825,O
GHBP,2825,B-GeneOrGeneProduct
),2825,O
",",2825,O
but,2825,O
clinical,2825,O
evidence,2825,O
of,2825,O
GH,2825,B-DiseaseOrPhenotypicFeature
insensitivity,2825,I-DiseaseOrPhenotypicFeature
.,2825,O
METHOD,2826,O
:,2826,O
Serum,2826,O
and,2826,O
DNA,2826,O
samples,2826,O
from,2826,O
the,2826,O
proband,2826,O
and,2826,O
his,2826,O
parents,2826,O
were,2826,O
analyzed,2826,O
.,2826,O
RESULTS,2827,O
:,2827,O
The,2827,O
child,2827,O
had,2827,O
a,2827,O
height,2827,O
of,2827,O
-4,2827,O
SD,2827,O
",",2827,O
elevated,2827,O
serum,2827,O
GH,2827,B-GeneOrGeneProduct
concentrations,2827,O
",",2827,O
abnormally,2827,O
low,2827,O
serum,2827,O
IGF-I,2827,B-GeneOrGeneProduct
and,2827,O
IGFBP-3,2827,B-GeneOrGeneProduct
concentrations,2827,O
and,2827,O
normal,2827,O
GHBP,2827,B-GeneOrGeneProduct
concentrations,2827,O
.,2827,O
DNA,2828,O
analysis,2828,O
revealed,2828,O
compound,2828,O
heterozygosity,2828,O
for,2828,O
mutations,2828,O
of,2828,O
GHR,2828,B-GeneOrGeneProduct
",",2828,O
including,2828,O
a,2828,O
previously,2828,O
reported,2828,O
R211H,2828,B-SequenceVariant
mutation,2828,O
and,2828,O
a,2828,O
novel,2828,O
duplication,2828,O
of,2828,O
a,2828,O
nucleotide,2828,O
in,2828,O
exon,2828,O
9,2828,O
(,2828,O
899dupC,2828,B-SequenceVariant
),2828,O
",",2828,O
the,2828,O
latter,2828,O
resulting,2828,O
in,2828,O
a,2828,O
frameshift,2828,O
and,2828,O
a,2828,O
premature,2828,O
stop,2828,O
codon,2828,O
.,2828,O
Treatment,2829,O
with,2829,O
recombinant,2829,O
DNA-derived,2829,O
IGF-I,2829,B-GeneOrGeneProduct
resulted,2829,O
in,2829,O
growth,2829,O
acceleration,2829,O
.,2829,O
CONCLUSION,2830,O
:,2830,O
Mutations,2830,O
affecting,2830,O
the,2830,O
intracellular,2830,O
domain,2830,O
of,2830,O
the,2830,O
GHR,2830,B-GeneOrGeneProduct
can,2830,O
result,2830,O
in,2830,O
GH,2830,B-DiseaseOrPhenotypicFeature
insensitivity,2830,I-DiseaseOrPhenotypicFeature
and,2830,O
IGF,2830,B-DiseaseOrPhenotypicFeature
deficiency,2830,I-DiseaseOrPhenotypicFeature
",",2830,O
despite,2830,O
normal,2830,O
serum,2830,O
concentrations,2830,O
of,2830,O
GHBP,2830,B-GeneOrGeneProduct
.,2830,O
The,2831,O
presence,2831,O
of,2831,O
clinical,2831,O
and,2831,O
biochemical,2831,O
evidence,2831,O
of,2831,O
GH,2831,B-GeneOrGeneProduct
resistance,2831,O
is,2831,O
sufficient,2831,O
to,2831,O
consider,2831,O
the,2831,O
possibility,2831,O
of,2831,O
aberrations,2831,O
of,2831,O
the,2831,O
GHR,2831,B-GeneOrGeneProduct
",",2831,O
even,2831,O
in,2831,O
the,2831,O
presence,2831,O
of,2831,O
normal,2831,O
serum,2831,O
GHBP,2831,B-GeneOrGeneProduct
concentrations,2831,O
.,2831,O
Lack,2832,O
of,2832,O
association,2832,O
between,2832,O
ADRA2B-4825,2832,B-GeneOrGeneProduct
gene,2832,I-SequenceVariant
insertion/deletion,2832,I-SequenceVariant
polymorphism,2832,O
and,2832,O
migraine,2832,B-DiseaseOrPhenotypicFeature
in,2832,O
Chinese,2832,O
Han,2832,O
population,2832,O
.,2832,O
OBJECTIVE,2833,O
:,2833,O
The,2833,O
present,2833,O
study,2833,O
aimed,2833,O
to,2833,O
estimate,2833,O
the,2833,O
association,2833,O
between,2833,O
susceptibility,2833,O
to,2833,O
migraine,2833,B-DiseaseOrPhenotypicFeature
and,2833,O
the,2833,O
12-nucleotide,2833,B-SequenceVariant
insertion/deletion,2833,I-SequenceVariant
(,2833,I-SequenceVariant
indel,2833,I-SequenceVariant
),2833,I-SequenceVariant
polymorphism,2833,O
in,2833,O
promoter,2833,O
region,2833,O
of,2833,O
alpha,2833,B-GeneOrGeneProduct
(,2833,I-GeneOrGeneProduct
2B,2833,I-GeneOrGeneProduct
),2833,I-GeneOrGeneProduct
-adrenergic,2833,I-GeneOrGeneProduct
receptor,2833,I-GeneOrGeneProduct
gene,2833,O
(,2833,O
ADRA2B,2833,B-GeneOrGeneProduct
),2833,O
.,2833,O
METHODS,2834,O
:,2834,O
A,2834,O
case-control,2834,O
study,2834,O
was,2834,O
carried,2834,O
out,2834,O
in,2834,O
Chinese,2834,O
Han,2834,O
population,2834,O
",",2834,O
including,2834,O
368,2834,O
cases,2834,O
of,2834,O
migraine,2834,B-DiseaseOrPhenotypicFeature
and,2834,O
517,2834,O
controls,2834,O
.,2834,O
Genomic,2835,O
DNA,2835,O
was,2835,O
extracted,2835,O
from,2835,O
blood,2835,O
samples,2835,O
",",2835,O
and,2835,O
DNA,2835,O
fragments,2835,O
containing,2835,O
the,2835,O
site,2835,O
of,2835,O
polymorphism,2835,O
were,2835,O
amplified,2835,O
by,2835,O
PCR,2835,O
.,2835,O
Data,2836,O
were,2836,O
adjusted,2836,O
for,2836,O
sex,2836,O
",",2836,O
age,2836,O
",",2836,O
migraine,2836,B-DiseaseOrPhenotypicFeature
history,2836,O
and,2836,O
family,2836,O
history,2836,O
",",2836,O
and,2836,O
analyzed,2836,O
using,2836,O
a,2836,O
logistic,2836,O
regression,2836,O
model,2836,O
.,2836,O
RESULTS,2837,O
:,2837,O
There,2837,O
was,2837,O
no,2837,O
association,2837,O
between,2837,O
indel,2837,O
polymorphism,2837,O
and,2837,O
migraine,2837,B-DiseaseOrPhenotypicFeature
",",2837,O
at,2837,O
either,2837,O
the,2837,O
allele,2837,O
or,2837,O
the,2837,O
genotype,2837,O
level,2837,O
.,2837,O
CONCLUSION,2838,O
:,2838,O
These,2838,O
findings,2838,O
do,2838,O
not,2838,O
support,2838,O
a,2838,O
functional,2838,O
significance,2838,O
of,2838,O
ADRA2B,2838,B-GeneOrGeneProduct
indel,2838,B-SequenceVariant
polymorphism,2838,I-SequenceVariant
at,2838,I-SequenceVariant
position,2838,I-SequenceVariant
-4825,2838,I-SequenceVariant
relative,2838,O
to,2838,O
the,2838,O
start,2838,O
codon,2838,O
in,2838,O
the,2838,O
far,2838,O
upstream,2838,O
region,2838,O
of,2838,O
the,2838,O
promoter,2838,O
in,2838,O
the,2838,O
present,2838,O
migraine,2838,B-DiseaseOrPhenotypicFeature
subjects,2838,O
.,2838,O
Curcumin,2839,B-ChemicalEntity
ameliorates,2839,O
cognitive,2839,B-DiseaseOrPhenotypicFeature
dysfunction,2839,I-DiseaseOrPhenotypicFeature
and,2839,O
oxidative,2839,O
damage,2839,O
in,2839,O
phenobarbitone,2839,B-ChemicalEntity
and,2839,O
carbamazepine,2839,B-ChemicalEntity
administered,2839,O
rats,2839,B-OrganismTaxon
.,2839,O
The,2840,O
antiepileptic,2840,B-ChemicalEntity
drugs,2840,I-ChemicalEntity
",",2840,O
phenobarbitone,2840,B-ChemicalEntity
and,2840,O
carbamazepine,2840,B-ChemicalEntity
are,2840,O
well,2840,O
known,2840,O
to,2840,O
cause,2840,O
cognitive,2840,B-DiseaseOrPhenotypicFeature
impairment,2840,I-DiseaseOrPhenotypicFeature
on,2840,O
chronic,2840,O
use,2840,O
.,2840,O
The,2841,O
increase,2841,O
in,2841,O
free,2841,O
radical,2841,O
generation,2841,O
has,2841,O
been,2841,O
implicated,2841,O
as,2841,O
one,2841,O
of,2841,O
the,2841,O
important,2841,O
mechanisms,2841,O
of,2841,O
cognitive,2841,B-DiseaseOrPhenotypicFeature
impairment,2841,I-DiseaseOrPhenotypicFeature
by,2841,O
antiepileptic,2841,B-ChemicalEntity
drugs,2841,I-ChemicalEntity
.,2841,O
Curcumin,2842,B-ChemicalEntity
has,2842,O
shown,2842,O
antioxidant,2842,B-ChemicalEntity
",",2842,O
anti-inflammatory,2842,O
and,2842,O
neuro-protective,2842,O
properties,2842,O
.,2842,O
Therefore,2843,O
",",2843,O
the,2843,O
present,2843,O
study,2843,O
was,2843,O
carried,2843,O
out,2843,O
to,2843,O
investigate,2843,O
the,2843,O
effect,2843,O
of,2843,O
chronic,2843,O
curcumin,2843,B-ChemicalEntity
administration,2843,O
on,2843,O
phenobarbitone-,2843,B-ChemicalEntity
and,2843,O
carbamazepine-induced,2843,B-ChemicalEntity
cognitive,2843,B-DiseaseOrPhenotypicFeature
impairment,2843,I-DiseaseOrPhenotypicFeature
and,2843,O
oxidative,2843,O
stress,2843,O
in,2843,O
rats,2843,B-OrganismTaxon
.,2843,O
Pharmacokinetic,2844,O
interactions,2844,O
of,2844,O
curcumin,2844,B-ChemicalEntity
with,2844,O
phenobarbitone,2844,B-ChemicalEntity
and,2844,O
carbamazepine,2844,B-ChemicalEntity
were,2844,O
also,2844,O
studied,2844,O
.,2844,O
Vehicle/drugs,2845,O
were,2845,O
administered,2845,O
daily,2845,O
for,2845,O
21days,2845,O
to,2845,O
male,2845,O
Wistar,2845,O
rats,2845,B-OrganismTaxon
.,2845,O
Passive,2846,O
avoidance,2846,O
paradigm,2846,O
and,2846,O
elevated,2846,O
plus,2846,O
maze,2846,O
test,2846,O
were,2846,O
used,2846,O
to,2846,O
assess,2846,O
cognitive,2846,O
function,2846,O
.,2846,O
At,2847,O
the,2847,O
end,2847,O
of,2847,O
study,2847,O
period,2847,O
",",2847,O
serum,2847,O
phenobarbitone,2847,B-ChemicalEntity
and,2847,O
carbamazepine,2847,B-ChemicalEntity
",",2847,O
whole,2847,O
brain,2847,O
malondialdehyde,2847,B-ChemicalEntity
and,2847,O
reduced,2847,O
glutathione,2847,B-ChemicalEntity
levels,2847,O
were,2847,O
estimated,2847,O
.,2847,O
The,2848,O
administration,2848,O
of,2848,O
phenobarbitone,2848,B-ChemicalEntity
and,2848,O
carbamazepine,2848,B-ChemicalEntity
for,2848,O
21days,2848,O
caused,2848,O
a,2848,O
significant,2848,O
impairment,2848,B-DiseaseOrPhenotypicFeature
of,2848,I-DiseaseOrPhenotypicFeature
learning,2848,I-DiseaseOrPhenotypicFeature
and,2848,I-DiseaseOrPhenotypicFeature
memory,2848,I-DiseaseOrPhenotypicFeature
as,2848,O
well,2848,O
as,2848,O
an,2848,O
increased,2848,O
oxidative,2848,O
stress,2848,O
.,2848,O
Concomitant,2849,O
curcumin,2849,B-ChemicalEntity
administration,2849,O
prevented,2849,O
the,2849,O
cognitive,2849,B-DiseaseOrPhenotypicFeature
impairment,2849,I-DiseaseOrPhenotypicFeature
and,2849,O
decreased,2849,O
the,2849,O
increased,2849,O
oxidative,2849,O
stress,2849,O
induced,2849,O
by,2849,O
these,2849,O
antiepileptic,2849,B-ChemicalEntity
drugs,2849,I-ChemicalEntity
.,2849,O
Curcumin,2850,B-ChemicalEntity
co-administration,2850,O
did,2850,O
not,2850,O
cause,2850,O
any,2850,O
significant,2850,O
alteration,2850,O
in,2850,O
the,2850,O
serum,2850,O
concentrations,2850,O
of,2850,O
both,2850,O
phenobarbitone,2850,B-ChemicalEntity
as,2850,O
well,2850,O
as,2850,O
carbamazepine,2850,B-ChemicalEntity
.,2850,O
These,2851,O
results,2851,O
show,2851,O
that,2851,O
curcumin,2851,B-ChemicalEntity
has,2851,O
beneficial,2851,O
effect,2851,O
in,2851,O
mitigating,2851,O
the,2851,O
deterioration,2851,B-DiseaseOrPhenotypicFeature
of,2851,I-DiseaseOrPhenotypicFeature
cognitive,2851,I-DiseaseOrPhenotypicFeature
functions,2851,I-DiseaseOrPhenotypicFeature
and,2851,O
oxidative,2851,O
damage,2851,O
in,2851,O
rats,2851,B-OrganismTaxon
treated,2851,O
with,2851,O
phenobarbitone,2851,B-ChemicalEntity
and,2851,O
carbamazepine,2851,B-ChemicalEntity
without,2851,O
significantly,2851,O
altering,2851,O
their,2851,O
serum,2851,O
concentrations,2851,O
.,2851,O
The,2852,O
findings,2852,O
suggest,2852,O
that,2852,O
curcumin,2852,B-ChemicalEntity
can,2852,O
be,2852,O
considered,2852,O
as,2852,O
a,2852,O
potential,2852,O
safe,2852,O
and,2852,O
effective,2852,O
adjuvant,2852,O
to,2852,O
phenobarbitone,2852,B-ChemicalEntity
and,2852,O
carbamazepine,2852,B-ChemicalEntity
therapy,2852,O
in,2852,O
preventing,2852,O
cognitive,2852,B-DiseaseOrPhenotypicFeature
impairment,2852,I-DiseaseOrPhenotypicFeature
associated,2852,O
with,2852,O
these,2852,O
drugs,2852,O
.,2852,O
Effects,2853,O
of,2853,O
active,2853,O
constituents,2853,B-ChemicalEntity
of,2853,I-ChemicalEntity
Crocus,2853,I-ChemicalEntity
sativus,2853,I-ChemicalEntity
L.,2853,I-ChemicalEntity
",",2853,O
crocin,2853,B-ChemicalEntity
on,2853,O
streptozocin-induced,2853,B-ChemicalEntity
model,2853,O
of,2853,O
sporadic,2853,O
Alzheimer,2853,B-DiseaseOrPhenotypicFeature
's,2853,I-DiseaseOrPhenotypicFeature
disease,2853,I-DiseaseOrPhenotypicFeature
in,2853,O
male,2853,O
rats,2853,B-OrganismTaxon
.,2853,O
BACKGROUND,2854,O
:,2854,O
The,2854,O
involvement,2854,O
of,2854,O
water-soluble,2854,O
carotenoids,2854,B-ChemicalEntity
",",2854,O
crocins,2854,B-ChemicalEntity
",",2854,O
as,2854,O
the,2854,O
main,2854,O
and,2854,O
active,2854,O
components,2854,O
of,2854,O
Crocus,2854,B-ChemicalEntity
sativus,2854,I-ChemicalEntity
L.,2854,I-ChemicalEntity
extract,2854,I-ChemicalEntity
in,2854,O
learning,2854,O
and,2854,O
memory,2854,O
processes,2854,O
has,2854,O
been,2854,O
proposed,2854,O
.,2854,O
In,2855,O
the,2855,O
present,2855,O
study,2855,O
",",2855,O
the,2855,O
effect,2855,O
of,2855,O
crocins,2855,B-ChemicalEntity
on,2855,O
sporadic,2855,O
Alzheimer,2855,B-DiseaseOrPhenotypicFeature
's,2855,I-DiseaseOrPhenotypicFeature
disease,2855,I-DiseaseOrPhenotypicFeature
induced,2855,O
by,2855,O
intracerebroventricular,2855,O
(,2855,O
icv,2855,O
),2855,O
streptozocin,2855,B-ChemicalEntity
(,2855,O
STZ,2855,B-ChemicalEntity
),2855,O
in,2855,O
male,2855,O
rats,2855,B-OrganismTaxon
was,2855,O
investigated,2855,O
.,2855,O
METHODS,2856,O
:,2856,O
Male,2856,O
adult,2856,O
Wistar,2856,O
rats,2856,B-OrganismTaxon
(,2856,O
n,2856,O
=,2856,O
90,2856,O
and,2856,O
260-290,2856,O
g,2856,O
),2856,O
were,2856,O
divided,2856,O
into,2856,O
1,2856,O
",",2856,O
control,2856,O
;,2856,O
2,2856,O
and,2856,O
3,2856,O
",",2856,O
crocins,2856,B-ChemicalEntity
(,2856,O
15,2856,O
and,2856,O
30,2856,O
mg/kg,2856,O
),2856,O
;,2856,O
4,2856,O
",",2856,O
STZ,2856,B-ChemicalEntity
;,2856,O
5,2856,O
and,2856,O
6,2856,O
",",2856,O
STZ,2856,B-ChemicalEntity
+,2856,O
crocins,2856,B-ChemicalEntity
(,2856,O
15,2856,O
and,2856,O
30,2856,O
mg/kg,2856,O
),2856,O
groups,2856,O
.,2856,O
In,2857,O
Alzheimer,2857,B-DiseaseOrPhenotypicFeature
's,2857,I-DiseaseOrPhenotypicFeature
disease,2857,I-DiseaseOrPhenotypicFeature
groups,2857,O
",",2857,O
rats,2857,B-OrganismTaxon
were,2857,O
injected,2857,O
with,2857,O
STZ-icv,2857,B-ChemicalEntity
bilaterally,2857,O
(,2857,O
3,2857,O
mg/kg,2857,O
),2857,O
in,2857,O
first,2857,O
day,2857,O
and,2857,O
3,2857,O
days,2857,O
later,2857,O
",",2857,O
a,2857,O
similar,2857,O
STZ-icv,2857,B-ChemicalEntity
application,2857,O
was,2857,O
repeated,2857,O
.,2857,O
In,2858,O
STZ,2858,B-ChemicalEntity
+,2858,O
crocin,2858,B-ChemicalEntity
animal,2858,O
groups,2858,O
",",2858,O
crocin,2858,B-ChemicalEntity
was,2858,O
applied,2858,O
in,2858,O
doses,2858,O
of,2858,O
15,2858,O
and,2858,O
30,2858,O
mg/kg,2858,O
",",2858,O
i.p.,2858,O
",",2858,O
one,2858,O
day,2858,O
pre-surgery,2858,O
and,2858,O
continued,2858,O
for,2858,O
three,2858,O
weeks,2858,O
.,2858,O
Prescription,2859,O
of,2859,O
crocin,2859,B-ChemicalEntity
in,2859,O
each,2859,O
dose,2859,O
was,2859,O
repeated,2859,O
once,2859,O
for,2859,O
two,2859,O
days,2859,O
.,2859,O
However,2860,O
",",2860,O
the,2860,O
learning,2860,O
and,2860,O
memory,2860,O
performance,2860,O
was,2860,O
assessed,2860,O
using,2860,O
passive,2860,O
avoidance,2860,O
paradigm,2860,O
",",2860,O
and,2860,O
for,2860,O
spatial,2860,O
cognition,2860,O
evaluation,2860,O
",",2860,O
Y-maze,2860,O
task,2860,O
was,2860,O
used,2860,O
.,2860,O
RESULTS,2861,O
:,2861,O
It,2861,O
was,2861,O
found,2861,O
out,2861,O
that,2861,O
crocin,2861,B-ChemicalEntity
(,2861,O
30,2861,O
mg/kg,2861,O
),2861,O
-treated,2861,O
STZ-injected,2861,B-ChemicalEntity
rats,2861,B-OrganismTaxon
show,2861,O
higher,2861,O
correct,2861,O
choices,2861,O
and,2861,O
lower,2861,O
errors,2861,O
in,2861,O
Y-maze,2861,O
than,2861,O
vehicle-treated,2861,O
STZ-injected,2861,B-ChemicalEntity
rats,2861,B-OrganismTaxon
.,2861,O
In,2862,O
addition,2862,O
",",2862,O
crocin,2862,B-ChemicalEntity
in,2862,O
the,2862,O
mentioned,2862,O
dose,2862,O
could,2862,O
significantly,2862,O
attenuated,2862,O
learning,2862,B-DiseaseOrPhenotypicFeature
and,2862,I-DiseaseOrPhenotypicFeature
memory,2862,I-DiseaseOrPhenotypicFeature
impairment,2862,I-DiseaseOrPhenotypicFeature
in,2862,O
treated,2862,O
STZ-injected,2862,B-ChemicalEntity
group,2862,O
in,2862,O
passive,2862,O
avoidance,2862,O
test,2862,O
.,2862,O
CONCLUSION,2863,O
:,2863,O
Therefore,2863,O
",",2863,O
these,2863,O
results,2863,O
demonstrate,2863,O
the,2863,O
effectiveness,2863,O
of,2863,O
crocin,2863,B-ChemicalEntity
(,2863,O
30,2863,O
mg/kg,2863,O
),2863,O
in,2863,O
antagonizing,2863,O
the,2863,O
cognitive,2863,B-DiseaseOrPhenotypicFeature
deficits,2863,I-DiseaseOrPhenotypicFeature
caused,2863,O
by,2863,O
STZ-icv,2863,B-ChemicalEntity
in,2863,O
rats,2863,B-OrganismTaxon
and,2863,O
its,2863,O
potential,2863,O
in,2863,O
the,2863,O
treatment,2863,O
of,2863,O
neurodegenerative,2863,B-DiseaseOrPhenotypicFeature
diseases,2863,I-DiseaseOrPhenotypicFeature
such,2863,O
as,2863,O
Alzheimer,2863,B-DiseaseOrPhenotypicFeature
's,2863,I-DiseaseOrPhenotypicFeature
disease,2863,I-DiseaseOrPhenotypicFeature
.,2863,O
Association,2864,O
of,2864,O
DNA,2864,O
polymorphisms,2864,O
within,2864,O
the,2864,O
CYP11B2/CYP11B1,2864,B-GeneOrGeneProduct
locus,2864,O
and,2864,O
postoperative,2864,O
hypertension,2864,B-DiseaseOrPhenotypicFeature
risk,2864,O
in,2864,O
the,2864,O
patients,2864,B-OrganismTaxon
with,2864,O
aldosterone-producing,2864,B-DiseaseOrPhenotypicFeature
adenomas,2864,I-DiseaseOrPhenotypicFeature
.,2864,O
OBJECTIVES,2865,O
:,2865,O
Hypertension,2865,B-DiseaseOrPhenotypicFeature
often,2865,O
persists,2865,O
after,2865,O
adrenalectomy,2865,O
for,2865,O
primary,2865,O
aldosteronism,2865,O
.,2865,O
Traditional,2866,O
factors,2866,O
associated,2866,O
with,2866,O
postoperative,2866,O
hypertension,2866,B-DiseaseOrPhenotypicFeature
were,2866,O
evaluated,2866,O
",",2866,O
but,2866,O
whether,2866,O
genetic,2866,O
determinants,2866,O
were,2866,O
involved,2866,O
remains,2866,O
poorly,2866,O
understood,2866,O
.,2866,O
The,2867,O
aim,2867,O
of,2867,O
this,2867,O
study,2867,O
was,2867,O
to,2867,O
investigate,2867,O
the,2867,O
association,2867,O
of,2867,O
DNA,2867,O
polymorphisms,2867,O
within,2867,O
steroid,2867,B-GeneOrGeneProduct
synthesis,2867,I-GeneOrGeneProduct
genes,2867,I-GeneOrGeneProduct
(,2867,O
CYP11B2,2867,B-GeneOrGeneProduct
",",2867,O
CYP11B1,2867,B-GeneOrGeneProduct
),2867,O
and,2867,O
the,2867,O
postoperative,2867,O
resolution,2867,O
of,2867,O
hypertension,2867,B-DiseaseOrPhenotypicFeature
in,2867,O
Chinese,2867,O
patients,2867,B-OrganismTaxon
undergoing,2867,O
adrenalectomy,2867,O
for,2867,O
aldosterone-producing,2867,B-DiseaseOrPhenotypicFeature
adenomas,2867,I-DiseaseOrPhenotypicFeature
(,2867,O
APA,2867,B-DiseaseOrPhenotypicFeature
),2867,O
.,2867,O
METHODS,2868,O
:,2868,O
Ninety-three,2868,O
patients,2868,B-OrganismTaxon
with,2868,O
APA,2868,B-DiseaseOrPhenotypicFeature
were,2868,O
assessed,2868,O
for,2868,O
postoperative,2868,O
resolution,2868,O
of,2868,O
hypertension,2868,B-DiseaseOrPhenotypicFeature
.,2868,O
All,2869,O
patients,2869,B-OrganismTaxon
were,2869,O
genotyped,2869,O
for,2869,O
rs1799998,2869,B-SequenceVariant
(,2869,O
C-344,2869,B-SequenceVariant
T,2869,I-SequenceVariant
),2869,O
",",2869,O
intron,2869,O
2,2869,O
conversion,2869,O
",",2869,O
rs4539,2869,B-SequenceVariant
(,2869,O
A2718G,2869,B-SequenceVariant
),2869,O
within,2869,O
CYP11B2,2869,B-GeneOrGeneProduct
and,2869,O
rs6410,2869,B-SequenceVariant
(,2869,O
G22,2869,B-SequenceVariant
5A,2869,I-SequenceVariant
),2869,O
",",2869,O
rs6387,2869,B-SequenceVariant
(,2869,O
A2803G,2869,B-SequenceVariant
),2869,O
within,2869,O
CYP11B1,2869,B-GeneOrGeneProduct
.,2869,O
The,2870,O
associations,2870,O
between,2870,O
CYPB11B2/CYP11B1,2870,B-GeneOrGeneProduct
polymorphisms,2870,O
and,2870,O
persistent,2870,O
postoperative,2870,O
hypertension,2870,B-DiseaseOrPhenotypicFeature
were,2870,O
assessed,2870,O
by,2870,O
multivariate,2870,O
analysis,2870,O
.,2870,O
RESULTS,2871,O
:,2871,O
CYP11B2-CYP11B1,2871,B-GeneOrGeneProduct
haplotype,2871,O
was,2871,O
associated,2871,O
with,2871,O
persistent,2871,O
postoperative,2871,O
hypertension,2871,B-DiseaseOrPhenotypicFeature
in,2871,O
Chinese,2871,O
patients,2871,B-OrganismTaxon
undergoing,2871,O
adrenalectomy,2871,O
with,2871,O
APA,2871,B-DiseaseOrPhenotypicFeature
(,2871,O
P,2871,O
=,2871,O
.006,2871,O
),2871,O
.,2871,O
Specifically,2872,O
",",2872,O
the,2872,O
rs4539,2872,B-SequenceVariant
(,2872,O
AA,2872,O
),2872,O
polymorphism,2872,O
was,2872,O
associated,2872,O
with,2872,O
persistent,2872,O
postoperative,2872,O
hypertension,2872,B-DiseaseOrPhenotypicFeature
(,2872,O
P,2872,O
=,2872,O
.002,2872,O
),2872,O
.,2872,O
Multivariate,2873,O
logistic,2873,O
regression,2873,O
revealed,2873,O
the,2873,O
common,2873,O
haplotypes,2873,O
H1,2873,O
(,2873,O
AGACT,2873,O
),2873,O
",",2873,O
H2,2873,O
(,2873,O
AGAWT,2873,O
),2873,O
",",2873,O
and,2873,O
H3,2873,O
(,2873,O
AGAWC,2873,O
),2873,O
were,2873,O
associated,2873,O
with,2873,O
the,2873,O
persistent,2873,O
postoperative,2873,O
hypertension,2873,B-DiseaseOrPhenotypicFeature
(,2873,O
P,2873,O
=,2873,O
.01,2873,O
",",2873,O
0.03,2873,O
",",2873,O
0.005,2873,O
after,2873,O
Bonferroni,2873,O
correction,2873,O
),2873,O
.,2873,O
Additional,2874,O
predictors,2874,O
of,2874,O
persistent,2874,O
postoperative,2874,O
hypertension,2874,B-DiseaseOrPhenotypicFeature
included,2874,O
duration,2874,O
of,2874,O
hypertension,2874,B-DiseaseOrPhenotypicFeature
(,2874,O
P,2874,O
<,2874,O
.0005,2874,O
),2874,O
",",2874,O
family,2874,O
history,2874,O
of,2874,O
hypertension,2874,B-DiseaseOrPhenotypicFeature
(,2874,O
P,2874,O
=,2874,O
.001,2874,O
),2874,O
",",2874,O
and,2874,O
elevated,2874,O
systolic,2874,O
blood,2874,O
pressure,2874,O
(,2874,O
P,2874,O
=,2874,O
.015,2874,O
),2874,O
.,2874,O
CONCLUSIONS,2875,O
:,2875,O
The,2875,O
rs4539,2875,B-SequenceVariant
(,2875,O
AA,2875,O
),2875,O
",",2875,O
H1,2875,O
",",2875,O
H2,2875,O
",",2875,O
and,2875,O
H3,2875,O
are,2875,O
genetic,2875,O
predictors,2875,O
for,2875,O
postoperative,2875,O
persistence,2875,O
of,2875,O
hypertension,2875,B-DiseaseOrPhenotypicFeature
for,2875,O
Chinese,2875,O
patients,2875,B-OrganismTaxon
treated,2875,O
by,2875,O
adrenalectomy,2875,O
with,2875,O
APA,2875,B-DiseaseOrPhenotypicFeature
.,2875,O
DNA,2876,O
polymorphisms,2876,O
at,2876,O
CYP11B2/B1,2876,B-GeneOrGeneProduct
locus,2876,O
may,2876,O
confer,2876,O
susceptibility,2876,O
to,2876,O
postoperative,2876,O
hypertension,2876,B-DiseaseOrPhenotypicFeature
of,2876,O
patients,2876,B-OrganismTaxon
with,2876,O
APA,2876,B-DiseaseOrPhenotypicFeature
.,2876,O
Safety,2877,O
of,2877,O
capecitabine,2877,B-ChemicalEntity
:,2877,O
a,2877,O
review,2877,O
.,2877,O
IMPORTANCE,2878,O
OF,2878,O
THE,2878,O
FIELD,2878,O
:,2878,O
Fluoropyrimidines,2878,B-ChemicalEntity
",",2878,O
in,2878,O
particular,2878,O
5-fluorouracil,2878,B-ChemicalEntity
(,2878,O
5-FU,2878,B-ChemicalEntity
),2878,O
",",2878,O
have,2878,O
been,2878,O
the,2878,O
mainstay,2878,O
of,2878,O
treatment,2878,O
for,2878,O
several,2878,O
solid,2878,O
tumors,2878,B-DiseaseOrPhenotypicFeature
",",2878,O
including,2878,O
colorectal,2878,B-DiseaseOrPhenotypicFeature
",",2878,I-DiseaseOrPhenotypicFeature
breast,2878,I-DiseaseOrPhenotypicFeature
and,2878,I-DiseaseOrPhenotypicFeature
head,2878,I-DiseaseOrPhenotypicFeature
and,2878,I-DiseaseOrPhenotypicFeature
neck,2878,I-DiseaseOrPhenotypicFeature
cancers,2878,I-DiseaseOrPhenotypicFeature
",",2878,O
for,2878,O
>,2878,O
40,2878,O
years,2878,O
.,2878,O
AREAS,2879,O
COVERED,2879,O
IN,2879,O
THIS,2879,O
REVIEW,2879,O
:,2879,O
This,2879,O
article,2879,O
reviews,2879,O
the,2879,O
pharmacology,2879,O
and,2879,O
efficacy,2879,O
of,2879,O
capecitabine,2879,B-ChemicalEntity
with,2879,O
a,2879,O
special,2879,O
emphasis,2879,O
on,2879,O
its,2879,O
safety,2879,O
.,2879,O
WHAT,2880,O
THE,2880,O
READER,2880,O
WILL,2880,O
GAIN,2880,O
:,2880,O
The,2880,O
reader,2880,O
will,2880,O
gain,2880,O
better,2880,O
insight,2880,O
into,2880,O
the,2880,O
safety,2880,O
of,2880,O
capecitabine,2880,B-ChemicalEntity
in,2880,O
special,2880,O
populations,2880,O
such,2880,O
as,2880,O
patients,2880,B-OrganismTaxon
with,2880,O
advanced,2880,O
age,2880,O
",",2880,O
renal,2880,B-DiseaseOrPhenotypicFeature
and,2880,I-DiseaseOrPhenotypicFeature
kidney,2880,I-DiseaseOrPhenotypicFeature
disease,2880,I-DiseaseOrPhenotypicFeature
.,2880,O
We,2881,O
also,2881,O
explore,2881,O
different,2881,O
dosing,2881,O
and,2881,O
schedules,2881,O
of,2881,O
capecitabine,2881,B-ChemicalEntity
administration,2881,O
.,2881,O
TAKE,2882,O
HOME,2882,O
MESSAGE,2882,O
:,2882,O
Capecitabine,2882,B-ChemicalEntity
is,2882,O
an,2882,O
oral,2882,O
prodrug,2882,O
of,2882,O
5-FU,2882,B-ChemicalEntity
and,2882,O
was,2882,O
developed,2882,O
to,2882,O
fulfill,2882,O
the,2882,O
need,2882,O
for,2882,O
a,2882,O
more,2882,O
convenient,2882,O
therapy,2882,O
and,2882,O
provide,2882,O
an,2882,O
improved,2882,O
safety/efficacy,2882,O
profile,2882,O
.,2882,O
It,2883,O
has,2883,O
shown,2883,O
promising,2883,O
results,2883,O
alone,2883,O
or,2883,O
in,2883,O
combination,2883,O
with,2883,O
other,2883,O
chemotherapeutic,2883,O
agents,2883,O
in,2883,O
colorectal,2883,B-DiseaseOrPhenotypicFeature
",",2883,I-DiseaseOrPhenotypicFeature
breast,2883,I-DiseaseOrPhenotypicFeature
",",2883,I-DiseaseOrPhenotypicFeature
pancreaticobiliary,2883,I-DiseaseOrPhenotypicFeature
",",2883,I-DiseaseOrPhenotypicFeature
gastric,2883,I-DiseaseOrPhenotypicFeature
",",2883,I-DiseaseOrPhenotypicFeature
renal,2883,I-DiseaseOrPhenotypicFeature
cell,2883,I-DiseaseOrPhenotypicFeature
and,2883,I-DiseaseOrPhenotypicFeature
head,2883,I-DiseaseOrPhenotypicFeature
and,2883,I-DiseaseOrPhenotypicFeature
neck,2883,I-DiseaseOrPhenotypicFeature
cancers,2883,I-DiseaseOrPhenotypicFeature
.,2883,O
The,2884,O
most,2884,O
commonly,2884,O
reported,2884,O
toxic,2884,O
effects,2884,O
of,2884,O
capecitabine,2884,B-ChemicalEntity
are,2884,O
diarrhea,2884,B-DiseaseOrPhenotypicFeature
",",2884,O
nausea,2884,B-DiseaseOrPhenotypicFeature
",",2884,O
vomiting,2884,B-DiseaseOrPhenotypicFeature
",",2884,O
stomatitis,2884,B-DiseaseOrPhenotypicFeature
and,2884,O
hand-foot,2884,B-DiseaseOrPhenotypicFeature
syndrome,2884,I-DiseaseOrPhenotypicFeature
.,2884,O
Capecitabine,2885,B-ChemicalEntity
has,2885,O
a,2885,O
well-established,2885,O
safety,2885,O
profile,2885,O
and,2885,O
can,2885,O
be,2885,O
given,2885,O
safely,2885,O
to,2885,O
patients,2885,B-OrganismTaxon
with,2885,O
advanced,2885,O
age,2885,O
",",2885,O
hepatic,2885,B-DiseaseOrPhenotypicFeature
and,2885,I-DiseaseOrPhenotypicFeature
renal,2885,I-DiseaseOrPhenotypicFeature
dysfunctions,2885,I-DiseaseOrPhenotypicFeature
.,2885,O
Association,2886,O
study,2886,O
of,2886,O
polymorphisms,2886,O
in,2886,O
the,2886,O
promoter,2886,O
region,2886,O
of,2886,O
DRD4,2886,B-GeneOrGeneProduct
with,2886,O
schizophrenia,2886,B-DiseaseOrPhenotypicFeature
",",2886,O
depression,2886,B-DiseaseOrPhenotypicFeature
",",2886,O
and,2886,O
heroin,2886,B-DiseaseOrPhenotypicFeature
addiction,2886,I-DiseaseOrPhenotypicFeature
.,2886,O
This,2887,O
study,2887,O
investigated,2887,O
the,2887,O
possible,2887,O
association,2887,O
between,2887,O
three,2887,O
functional,2887,O
polymorphisms,2887,O
in,2887,O
the,2887,O
promoter,2887,O
region,2887,O
of,2887,O
the,2887,O
dopamine,2887,B-GeneOrGeneProduct
D4,2887,I-GeneOrGeneProduct
receptor,2887,I-GeneOrGeneProduct
(,2887,O
DRD4,2887,B-GeneOrGeneProduct
),2887,O
gene,2887,O
and,2887,O
schizophrenia,2887,B-DiseaseOrPhenotypicFeature
",",2887,O
depression,2887,B-DiseaseOrPhenotypicFeature
",",2887,O
and,2887,O
heroin,2887,B-DiseaseOrPhenotypicFeature
addiction,2887,I-DiseaseOrPhenotypicFeature
.,2887,O
Genomic,2888,O
DNA,2888,O
was,2888,O
isolated,2888,O
from,2888,O
the,2888,O
venous,2888,O
blood,2888,O
leukocytes,2888,O
of,2888,O
322,2888,O
unrelated,2888,O
patients,2888,B-OrganismTaxon
with,2888,O
schizophrenia,2888,B-DiseaseOrPhenotypicFeature
",",2888,O
156,2888,O
patients,2888,B-OrganismTaxon
with,2888,O
depression,2888,B-DiseaseOrPhenotypicFeature
",",2888,O
300,2888,O
patients,2888,B-OrganismTaxon
with,2888,O
heroin,2888,B-DiseaseOrPhenotypicFeature
addiction,2888,I-DiseaseOrPhenotypicFeature
",",2888,O
and,2888,O
300,2888,O
healthy,2888,O
unrelated,2888,O
individuals,2888,O
.,2888,O
Polymorphisms,2889,O
in,2889,O
the,2889,O
promoter,2889,O
region,2889,O
of,2889,O
DRD4,2889,B-GeneOrGeneProduct
(,2889,O
-120,2889,B-SequenceVariant
bp,2889,I-SequenceVariant
duplication,2889,I-SequenceVariant
",",2889,O
-616C/G,2889,B-SequenceVariant
",",2889,O
and,2889,O
-521C/T,2889,B-SequenceVariant
),2889,O
were,2889,O
genotyped,2889,O
using,2889,O
allele-specific,2889,O
polymerase,2889,O
chain,2889,O
reaction,2889,O
analysis,2889,O
.,2889,O
Genotype,2890,O
and,2890,O
allele,2890,O
were,2890,O
analyzed,2890,O
using,2890,O
SPSS,2890,O
11.5,2890,O
software,2890,O
.,2890,O
Results,2891,O
of,2891,O
this,2891,O
analysis,2891,O
indicated,2891,O
that,2891,O
there,2891,O
is,2891,O
a,2891,O
strong,2891,O
finding,2891,O
of,2891,O
-120,2891,B-SequenceVariant
bp,2891,I-SequenceVariant
duplication,2891,I-SequenceVariant
allele,2891,O
frequencies,2891,O
with,2891,O
schizophrenia,2891,B-DiseaseOrPhenotypicFeature
(,2891,O
p=0.008,2891,O
),2891,O
and,2891,O
weak,2891,O
finding,2891,O
with,2891,O
-1240,2891,B-SequenceVariant
L/S,2891,I-SequenceVariant
and,2891,O
for,2891,O
paranoid,2891,B-DiseaseOrPhenotypicFeature
schizophrenia,2891,I-DiseaseOrPhenotypicFeature
(,2891,O
p=0.022,2891,O
),2891,O
.,2891,O
Interestingly,2892,O
",",2892,O
there,2892,O
is,2892,O
a,2892,O
stronger,2892,O
finding,2892,O
with,2892,O
-521,2892,B-SequenceVariant
C/T,2892,I-SequenceVariant
allele,2892,O
frequencies,2892,O
with,2892,O
heroin,2892,B-DiseaseOrPhenotypicFeature
dependence,2892,I-DiseaseOrPhenotypicFeature
(,2892,O
p=0.0002,2892,O
),2892,O
.,2892,O
These,2893,O
observations,2893,O
strongly,2893,O
suggest,2893,O
that,2893,O
the,2893,O
-120-bp,2893,B-SequenceVariant
duplication,2893,I-SequenceVariant
polymorphism,2893,O
of,2893,O
DRD4,2893,B-GeneOrGeneProduct
is,2893,O
associated,2893,O
with,2893,O
schizophrenia,2893,B-DiseaseOrPhenotypicFeature
and,2893,O
that,2893,O
the,2893,O
-521,2893,B-SequenceVariant
C/T,2893,I-SequenceVariant
polymorphism,2893,O
is,2893,O
associated,2893,O
with,2893,O
heroin,2893,B-DiseaseOrPhenotypicFeature
addiction,2893,I-DiseaseOrPhenotypicFeature
.,2893,O
A,2894,O
novel,2894,O
mutation,2894,O
in,2894,O
GJA8,2894,B-GeneOrGeneProduct
causing,2894,O
congenital,2894,O
cataract-microcornea,2894,B-DiseaseOrPhenotypicFeature
syndrome,2894,I-DiseaseOrPhenotypicFeature
in,2894,O
a,2894,O
Chinese,2894,O
pedigree,2894,O
.,2894,O
PURPOSE,2895,O
:,2895,O
To,2895,O
identify,2895,O
the,2895,O
underlying,2895,O
genetic,2895,B-DiseaseOrPhenotypicFeature
defect,2895,I-DiseaseOrPhenotypicFeature
in,2895,O
a,2895,O
four-generation,2895,O
family,2895,O
of,2895,O
Chinese,2895,O
origin,2895,O
with,2895,O
autosomal,2895,O
dominant,2895,O
congenital,2895,O
cataract-microcornea,2895,B-DiseaseOrPhenotypicFeature
syndrome,2895,I-DiseaseOrPhenotypicFeature
(,2895,O
CCMC,2895,B-DiseaseOrPhenotypicFeature
),2895,O
.,2895,O
METHODS,2896,O
:,2896,O
All,2896,O
individuals,2896,O
in,2896,O
the,2896,O
study,2896,O
underwent,2896,O
a,2896,O
full,2896,O
clinical,2896,O
examination,2896,O
and,2896,O
the,2896,O
details,2896,O
of,2896,O
history,2896,O
were,2896,O
collected,2896,O
.,2896,O
Genomic,2897,O
DNA,2897,O
extracted,2897,O
from,2897,O
peripheral,2897,O
blood,2897,O
was,2897,O
amplified,2897,O
by,2897,O
polymerase,2897,O
chain,2897,O
reaction,2897,O
(,2897,O
PCR,2897,O
),2897,O
method,2897,O
and,2897,O
the,2897,O
exons,2897,O
of,2897,O
all,2897,O
candidate,2897,O
genes,2897,O
were,2897,O
sequenced,2897,O
.,2897,O
RESULTS,2898,O
:,2898,O
Direct,2898,O
sequencing,2898,O
of,2898,O
the,2898,O
encoding,2898,O
regions,2898,O
of,2898,O
the,2898,O
candidate,2898,O
genes,2898,O
revealed,2898,O
a,2898,O
heterozygous,2898,O
mutation,2898,O
c.592C,2898,B-SequenceVariant
--,2898,I-SequenceVariant
>,2898,I-SequenceVariant
T,2898,I-SequenceVariant
in,2898,O
exon,2898,O
2,2898,O
of,2898,O
the,2898,O
gap,2898,B-GeneOrGeneProduct
junction,2898,I-GeneOrGeneProduct
protein,2898,I-GeneOrGeneProduct
",",2898,I-GeneOrGeneProduct
alpha,2898,I-GeneOrGeneProduct
8,2898,I-GeneOrGeneProduct
(,2898,O
GJA8,2898,B-GeneOrGeneProduct
),2898,O
gene,2898,O
.,2898,O
This,2899,O
mutation,2899,O
was,2899,O
responsible,2899,O
for,2899,O
the,2899,O
familial,2899,O
disorder,2899,O
through,2899,O
the,2899,O
substitution,2899,O
of,2899,O
a,2899,O
highly,2899,O
conserved,2899,O
arginine,2899,B-SequenceVariant
to,2899,I-SequenceVariant
tryptophan,2899,I-SequenceVariant
at,2899,I-SequenceVariant
codon,2899,I-SequenceVariant
198,2899,I-SequenceVariant
(,2899,O
p.R198W,2899,B-SequenceVariant
),2899,O
.,2899,O
This,2900,O
change,2900,O
co-segregated,2900,O
with,2900,O
all,2900,O
affected,2900,O
members,2900,O
of,2900,O
the,2900,O
family,2900,O
",",2900,O
but,2900,O
was,2900,O
not,2900,O
detected,2900,O
either,2900,O
in,2900,O
the,2900,O
non-carrier,2900,O
relatives,2900,O
or,2900,O
in,2900,O
the,2900,O
100,2900,O
normal,2900,O
controls,2900,O
.,2900,O
CONCLUSIONS,2901,O
:,2901,O
This,2901,O
report,2901,O
is,2901,O
the,2901,O
first,2901,O
to,2901,O
relate,2901,O
p.R198W,2901,B-SequenceVariant
mutation,2901,O
in,2901,O
GJA8,2901,B-GeneOrGeneProduct
with,2901,O
CCMC,2901,B-DiseaseOrPhenotypicFeature
.,2901,O
The,2902,O
result,2902,O
expands,2902,O
the,2902,O
mutation,2902,O
spectrum,2902,O
of,2902,O
GJA8,2902,B-GeneOrGeneProduct
in,2902,O
associated,2902,O
with,2902,O
congenital,2902,O
cataract,2902,B-DiseaseOrPhenotypicFeature
and,2902,O
microcornea,2902,B-DiseaseOrPhenotypicFeature
",",2902,O
and,2902,O
implies,2902,O
that,2902,O
this,2902,O
gene,2902,O
has,2902,O
direct,2902,O
involvement,2902,O
with,2902,O
the,2902,O
development,2902,O
of,2902,O
the,2902,O
lens,2902,O
as,2902,O
well,2902,O
as,2902,O
the,2902,O
other,2902,O
anterior,2902,O
segment,2902,O
of,2902,O
the,2902,O
eye,2902,O
.,2902,O
Cytostatic,2903,O
and,2903,O
anti-angiogenic,2903,O
effects,2903,O
of,2903,O
temsirolimus,2903,B-ChemicalEntity
in,2903,O
refractory,2903,O
mantle,2903,B-DiseaseOrPhenotypicFeature
cell,2903,I-DiseaseOrPhenotypicFeature
lymphoma,2903,I-DiseaseOrPhenotypicFeature
.,2903,O
Mantle,2904,B-DiseaseOrPhenotypicFeature
cell,2904,I-DiseaseOrPhenotypicFeature
lymphoma,2904,I-DiseaseOrPhenotypicFeature
(,2904,O
MCL,2904,B-DiseaseOrPhenotypicFeature
),2904,O
is,2904,O
a,2904,O
rare,2904,O
and,2904,O
aggressive,2904,O
type,2904,O
of,2904,O
B-cell,2904,B-DiseaseOrPhenotypicFeature
non-Hodgkin,2904,I-DiseaseOrPhenotypicFeature
's,2904,I-DiseaseOrPhenotypicFeature
lymphoma,2904,I-DiseaseOrPhenotypicFeature
.,2904,O
Patients,2905,B-OrganismTaxon
become,2905,O
progressively,2905,O
refractory,2905,O
to,2905,O
conventional,2905,O
chemotherapy,2905,O
",",2905,O
and,2905,O
their,2905,O
prognosis,2905,O
is,2905,O
poor,2905,O
.,2905,O
However,2906,O
",",2906,O
a,2906,O
38,2906,O
%,2906,O
remission,2906,O
rate,2906,O
has,2906,O
been,2906,O
recently,2906,O
reported,2906,O
in,2906,O
refractory,2906,O
MCL,2906,B-DiseaseOrPhenotypicFeature
treated,2906,O
with,2906,O
temsirolimus,2906,B-ChemicalEntity
",",2906,O
a,2906,O
mTOR,2906,B-GeneOrGeneProduct
inhibitor.Here,2906,O
we,2906,O
had,2906,O
the,2906,O
opportunity,2906,O
to,2906,O
study,2906,O
a,2906,O
case,2906,O
of,2906,O
refractory,2906,O
MCL,2906,B-DiseaseOrPhenotypicFeature
who,2906,O
had,2906,O
tumor,2906,B-DiseaseOrPhenotypicFeature
regression,2906,O
two,2906,O
months,2906,O
after,2906,O
temsirolimus,2906,B-ChemicalEntity
treatment,2906,O
",",2906,O
and,2906,O
a,2906,O
progression-free,2906,O
survival,2906,O
of,2906,O
10,2906,O
months,2906,O
.,2906,O
In,2907,O
this,2907,O
case,2907,O
",",2907,O
lymph,2907,O
node,2907,O
biopsies,2907,O
were,2907,O
performed,2907,O
before,2907,O
and,2907,O
six,2907,O
months,2907,O
after,2907,O
temsirolimus,2907,B-ChemicalEntity
therapy,2907,O
.,2907,O
Comparison,2908,O
of,2908,O
the,2908,O
two,2908,O
biopsies,2908,O
showed,2908,O
that,2908,O
temsirolimus,2908,B-ChemicalEntity
inhibited,2908,O
tumor,2908,B-DiseaseOrPhenotypicFeature
cell,2908,O
proliferation,2908,O
through,2908,O
cell,2908,O
cycle,2908,O
arrest,2908,O
",",2908,O
but,2908,O
did,2908,O
not,2908,O
induce,2908,O
any,2908,O
change,2908,O
in,2908,O
the,2908,O
number,2908,O
of,2908,O
apoptotic,2908,O
tumor,2908,B-DiseaseOrPhenotypicFeature
cells,2908,O
.,2908,O
Apart,2909,O
from,2909,O
this,2909,O
cytostatic,2909,O
effect,2909,O
",",2909,O
temsirolimus,2909,B-ChemicalEntity
had,2909,O
an,2909,O
antiangiogenic,2909,O
effect,2909,O
with,2909,O
decrease,2909,O
of,2909,O
tumor,2909,B-DiseaseOrPhenotypicFeature
microvessel,2909,O
density,2909,O
and,2909,O
of,2909,O
VEGF,2909,B-GeneOrGeneProduct
expression,2909,O
.,2909,O
Moreover,2910,O
",",2910,O
numerous,2910,O
patchy,2910,O
",",2910,O
well-limited,2910,O
fibrotic,2910,O
areas,2910,O
",",2910,O
compatible,2910,O
with,2910,O
post-necrotic,2910,O
tissue,2910,O
repair,2910,O
",",2910,O
were,2910,O
found,2910,O
after,2910,O
6-month,2910,O
temsirolimus,2910,B-ChemicalEntity
therapy,2910,O
.,2910,O
Thus,2911,O
",",2911,O
temsirolimus,2911,B-ChemicalEntity
reduced,2911,O
tumor,2911,B-DiseaseOrPhenotypicFeature
burden,2911,O
through,2911,O
associated,2911,O
cytostatic,2911,O
and,2911,O
anti-angiogenic,2911,O
effects.This,2911,O
dual,2911,O
effect,2911,O
of,2911,O
temsirolimus,2911,B-ChemicalEntity
on,2911,O
tumor,2911,B-DiseaseOrPhenotypicFeature
tissue,2911,O
could,2911,O
contribute,2911,O
to,2911,O
its,2911,O
recently,2911,O
reported,2911,O
efficiency,2911,O
in,2911,O
refractory,2911,O
MCL,2911,B-DiseaseOrPhenotypicFeature
resistant,2911,O
to,2911,O
conventional,2911,O
chemotherapy,2911,O
.,2911,O
A,2912,O
novel,2912,O
mutation,2912,O
in,2912,O
the,2912,O
connexin,2912,B-GeneOrGeneProduct
26,2912,I-GeneOrGeneProduct
gene,2912,O
(,2912,O
GJB2,2912,B-GeneOrGeneProduct
),2912,O
in,2912,O
a,2912,O
child,2912,O
with,2912,O
clinical,2912,O
and,2912,O
histological,2912,O
features,2912,O
of,2912,O
keratitis-ichthyosis-deafness,2912,B-DiseaseOrPhenotypicFeature
(,2912,I-DiseaseOrPhenotypicFeature
KID,2912,I-DiseaseOrPhenotypicFeature
),2912,I-DiseaseOrPhenotypicFeature
syndrome,2912,I-DiseaseOrPhenotypicFeature
.,2912,O
BACKGROUND,2913,O
:,2913,O
Keratitis-ichthyosis-deafness,2913,B-DiseaseOrPhenotypicFeature
(,2913,I-DiseaseOrPhenotypicFeature
KID,2913,I-DiseaseOrPhenotypicFeature
),2913,I-DiseaseOrPhenotypicFeature
syndrome,2913,I-DiseaseOrPhenotypicFeature
is,2913,O
a,2913,O
rare,2913,O
congenital,2913,B-DiseaseOrPhenotypicFeature
ectodermal,2913,I-DiseaseOrPhenotypicFeature
disorder,2913,I-DiseaseOrPhenotypicFeature
",",2913,O
caused,2913,O
by,2913,O
heterozygous,2913,O
missense,2913,O
mutation,2913,O
in,2913,O
GJB2,2913,B-GeneOrGeneProduct
",",2913,O
encoding,2913,O
the,2913,O
gap,2913,O
junction,2913,O
protein,2913,O
connexin,2913,B-GeneOrGeneProduct
26,2913,I-GeneOrGeneProduct
.,2913,O
The,2914,O
commonest,2914,O
mutation,2914,O
is,2914,O
the,2914,O
p.Asp50Asn,2914,B-SequenceVariant
mutation,2914,O
",",2914,O
and,2914,O
only,2914,O
a,2914,O
few,2914,O
other,2914,O
mutations,2914,O
have,2914,O
been,2914,O
described,2914,O
to,2914,O
date,2914,O
.,2914,O
AIM,2915,O
:,2915,O
To,2915,O
report,2915,O
the,2915,O
fatal,2915,O
clinical,2915,O
course,2915,O
and,2915,O
characterize,2915,O
the,2915,O
genetic,2915,O
background,2915,O
of,2915,O
a,2915,O
premature,2915,O
male,2915,O
neonate,2915,O
with,2915,O
the,2915,O
clinical,2915,O
and,2915,O
histological,2915,O
features,2915,O
of,2915,O
KID,2915,B-DiseaseOrPhenotypicFeature
syndrome,2915,I-DiseaseOrPhenotypicFeature
.,2915,O
METHODS,2916,O
:,2916,O
Genomic,2916,O
DNA,2916,O
was,2916,O
extracted,2916,O
from,2916,O
peripheral,2916,O
blood,2916,O
and,2916,O
used,2916,O
for,2916,O
PCR,2916,O
amplification,2916,O
of,2916,O
the,2916,O
GJB2,2916,B-GeneOrGeneProduct
gene,2916,O
.,2916,O
Direct,2917,O
sequencing,2917,O
was,2917,O
used,2917,O
for,2917,O
mutation,2917,O
analysis,2917,O
.,2917,O
RESULTS,2918,O
:,2918,O
The,2918,O
clinical,2918,O
features,2918,O
included,2918,O
hearing,2918,B-DiseaseOrPhenotypicFeature
impairment,2918,I-DiseaseOrPhenotypicFeature
",",2918,O
ichthyosiform,2918,B-DiseaseOrPhenotypicFeature
erythroderma,2918,I-DiseaseOrPhenotypicFeature
with,2918,O
hyperkeratotic,2918,O
plaques,2918,O
",",2918,O
palmoplantar,2918,B-DiseaseOrPhenotypicFeature
keratoderma,2918,I-DiseaseOrPhenotypicFeature
",",2918,O
alopecia,2918,B-DiseaseOrPhenotypicFeature
of,2918,I-DiseaseOrPhenotypicFeature
the,2918,I-DiseaseOrPhenotypicFeature
scalp,2918,I-DiseaseOrPhenotypicFeature
and,2918,I-DiseaseOrPhenotypicFeature
eyelashes,2918,I-DiseaseOrPhenotypicFeature
",",2918,O
and,2918,O
a,2918,O
thick,2918,O
vernix,2918,O
caseosa-like,2918,O
covering,2918,O
of,2918,O
the,2918,O
scalp,2918,O
.,2918,O
On,2919,O
histological,2919,O
analysis,2919,O
",",2919,O
features,2919,O
characteristic,2919,O
of,2919,O
KID,2919,B-DiseaseOrPhenotypicFeature
syndrome,2919,I-DiseaseOrPhenotypicFeature
",",2919,O
such,2919,O
as,2919,O
acanthosis,2919,B-DiseaseOrPhenotypicFeature
and,2919,O
papillomatosis,2919,B-DiseaseOrPhenotypicFeature
of,2919,O
the,2919,O
epidermis,2919,O
with,2919,O
basket-weave,2919,O
hyperkeratosis,2919,B-DiseaseOrPhenotypicFeature
",",2919,O
were,2919,O
seen,2919,O
.,2919,O
The,2920,O
skin,2920,O
symptoms,2920,O
were,2920,O
treated,2920,O
successfully,2920,O
with,2920,O
acitretin,2920,B-ChemicalEntity
0.5,2920,O
mg/kg,2920,O
.,2920,O
The,2921,O
boy,2921,O
developed,2921,O
intraventricular,2921,B-DiseaseOrPhenotypicFeature
and,2921,I-DiseaseOrPhenotypicFeature
intracerebral,2921,I-DiseaseOrPhenotypicFeature
haemorrhage,2921,I-DiseaseOrPhenotypicFeature
",",2921,O
leading,2921,O
to,2921,O
hydrocephalus,2921,B-DiseaseOrPhenotypicFeature
.,2921,O
His,2922,O
condition,2922,O
was,2922,O
further,2922,O
complicated,2922,O
by,2922,O
septicaemia,2922,B-DiseaseOrPhenotypicFeature
and,2922,O
meningitis,2922,B-DiseaseOrPhenotypicFeature
caused,2922,O
by,2922,O
infection,2922,B-DiseaseOrPhenotypicFeature
with,2922,O
extended-spectrum,2922,O
beta-lactamase-producing,2922,O
Klebsiella,2922,B-DiseaseOrPhenotypicFeature
pneumoniae,2922,I-DiseaseOrPhenotypicFeature
.,2922,O
Severe,2923,O
respiratory,2923,B-DiseaseOrPhenotypicFeature
failure,2923,I-DiseaseOrPhenotypicFeature
followed,2923,O
",",2923,O
and,2923,O
the,2923,O
child,2923,O
died,2923,O
at,2923,O
46,2923,O
weeks,2923,O
of,2923,O
gestational,2923,O
age,2923,O
(,2923,O
13,2923,O
weeks,2923,O
postnatally,2923,O
),2923,O
.,2923,O
Sequencing,2924,O
of,2924,O
the,2924,O
GJB2,2924,B-GeneOrGeneProduct
gene,2924,O
showed,2924,O
that,2924,O
the,2924,O
child,2924,O
was,2924,O
heterozygous,2924,O
for,2924,O
a,2924,O
novel,2924,O
nucleotide,2924,O
change,2924,O
",",2924,O
c.263C,2924,B-SequenceVariant
>,2924,I-SequenceVariant
T,2924,I-SequenceVariant
",",2924,O
in,2924,O
exon,2924,O
2,2924,O
",",2924,O
leading,2924,O
to,2924,O
a,2924,O
substitution,2924,O
of,2924,O
alanine,2924,B-SequenceVariant
for,2924,I-SequenceVariant
valine,2924,I-SequenceVariant
at,2924,I-SequenceVariant
position,2924,I-SequenceVariant
88,2924,I-SequenceVariant
(,2924,O
p.Ala88Val,2924,B-SequenceVariant
),2924,O
.,2924,O
CONCLUSIONS,2925,O
:,2925,O
This,2925,O
study,2925,O
has,2925,O
identified,2925,O
a,2925,O
new,2925,O
heterozygous,2925,O
de,2925,O
novo,2925,O
mutation,2925,O
in,2925,O
the,2925,O
Cx26,2925,B-GeneOrGeneProduct
gene,2925,O
(,2925,O
c.263C,2925,B-SequenceVariant
>,2925,I-SequenceVariant
T,2925,I-SequenceVariant
;,2925,O
p.Ala88Val,2925,B-SequenceVariant
),2925,O
leading,2925,O
to,2925,O
KID,2925,B-DiseaseOrPhenotypicFeature
syndrome,2925,I-DiseaseOrPhenotypicFeature
.,2925,O
SLURP1,2926,B-GeneOrGeneProduct
mutation-impaired,2926,O
T-cell,2926,O
activation,2926,O
in,2926,O
a,2926,O
family,2926,O
with,2926,O
mal,2926,B-DiseaseOrPhenotypicFeature
de,2926,I-DiseaseOrPhenotypicFeature
Meleda,2926,I-DiseaseOrPhenotypicFeature
.,2926,O
BACKGROUND,2927,O
:,2927,O
Mal,2927,B-DiseaseOrPhenotypicFeature
de,2927,I-DiseaseOrPhenotypicFeature
Meleda,2927,I-DiseaseOrPhenotypicFeature
(,2927,O
MDM,2927,B-DiseaseOrPhenotypicFeature
),2927,O
is,2927,O
palmoplantar,2927,B-DiseaseOrPhenotypicFeature
erythrokeratoderma,2927,I-DiseaseOrPhenotypicFeature
with,2927,O
an,2927,O
autosomal,2927,O
recessive,2927,O
inheritance,2927,O
and,2927,O
is,2927,O
caused,2927,O
by,2927,O
a,2927,O
mutation,2927,O
in,2927,O
the,2927,O
gene,2927,O
encoding,2927,O
SLURP-1,2927,B-GeneOrGeneProduct
(,2927,O
lymphocyte,2927,B-GeneOrGeneProduct
antigen,2927,I-GeneOrGeneProduct
6/urokinase-type,2927,O
plasminogen,2927,I-GeneOrGeneProduct
activator,2927,I-GeneOrGeneProduct
receptor,2927,I-GeneOrGeneProduct
related,2927,I-GeneOrGeneProduct
protein-1,2927,I-GeneOrGeneProduct
),2927,O
.,2927,O
SLURP-1,2928,B-GeneOrGeneProduct
is,2928,O
an,2928,O
allosteric,2928,O
agonist,2928,O
to,2928,O
the,2928,O
nicotinic,2928,B-GeneOrGeneProduct
acetylcholine,2928,I-GeneOrGeneProduct
receptor,2928,I-GeneOrGeneProduct
(,2928,O
nAchR,2928,B-GeneOrGeneProduct
),2928,O
and,2928,O
it,2928,O
regulates,2928,O
epidermal,2928,O
homeostasis,2928,O
.,2928,O
In,2929,O
addition,2929,O
",",2929,O
murine,2929,B-OrganismTaxon
studies,2929,O
have,2929,O
shown,2929,O
that,2929,O
nAchR,2929,B-GeneOrGeneProduct
signalling,2929,O
is,2929,O
important,2929,O
for,2929,O
the,2929,O
regulation,2929,O
of,2929,O
T-cell,2929,O
function,2929,O
.,2929,O
Among,2930,O
the,2930,O
family,2930,O
members,2930,O
",",2930,O
patients,2930,B-OrganismTaxon
with,2930,O
the,2930,O
homozygous,2930,O
SLURP1,2930,B-GeneOrGeneProduct
(,2930,O
previously,2930,O
known,2930,O
as,2930,O
ARS,2930,O
component,2930,O
B,2930,O
),2930,O
mutation,2930,O
are,2930,O
prone,2930,O
to,2930,O
melanoma,2930,B-DiseaseOrPhenotypicFeature
and,2930,O
viral,2930,B-DiseaseOrPhenotypicFeature
infection,2930,I-DiseaseOrPhenotypicFeature
",",2930,O
which,2930,O
might,2930,O
link,2930,O
to,2930,O
defective,2930,O
T-cell,2930,O
function,2930,O
as,2930,O
well,2930,O
as,2930,O
a,2930,O
derangement,2930,O
of,2930,O
epidermal,2930,O
homeostasis,2930,O
.,2930,O
OBJECTIVES,2931,O
:,2931,O
To,2931,O
investigate,2931,O
the,2931,O
association,2931,O
of,2931,O
the,2931,O
SLURP1,2931,B-GeneOrGeneProduct
gene,2931,O
mutation,2931,O
with,2931,O
T-cell,2931,O
activation,2931,O
in,2931,O
a,2931,O
Taiwanese,2931,O
family,2931,O
with,2931,O
MDM,2931,B-DiseaseOrPhenotypicFeature
.,2931,O
To,2932,O
test,2932,O
that,2932,O
SLURP-1,2932,B-GeneOrGeneProduct
is,2932,O
essential,2932,O
for,2932,O
T-cell,2932,O
activation,2932,O
.,2932,O
METHODS,2933,O
:,2933,O
Human,2933,B-OrganismTaxon
peripheral,2933,O
blood,2933,O
mononuclear,2933,O
cells,2933,O
(,2933,O
PBMCs,2933,O
),2933,O
were,2933,O
isolated,2933,O
from,2933,O
a,2933,O
Taiwanese,2933,O
MDM,2933,B-DiseaseOrPhenotypicFeature
family,2933,O
bearing,2933,O
the,2933,O
G,2933,B-SequenceVariant
to,2933,I-SequenceVariant
A,2933,I-SequenceVariant
substitution,2933,I-SequenceVariant
in,2933,I-SequenceVariant
nucleotide,2933,I-SequenceVariant
256,2933,I-SequenceVariant
in,2933,O
the,2933,O
SLURP1,2933,B-GeneOrGeneProduct
gene,2933,O
",",2933,O
corresponding,2933,O
to,2933,O
a,2933,O
glycine,2933,B-SequenceVariant
to,2933,I-SequenceVariant
arginine,2933,I-SequenceVariant
substitution,2933,I-SequenceVariant
at,2933,I-SequenceVariant
amino,2933,I-SequenceVariant
acid,2933,I-SequenceVariant
86,2933,I-SequenceVariant
(,2933,O
G86R,2933,B-SequenceVariant
),2933,O
in,2933,O
the,2933,O
SLURP-1,2933,B-GeneOrGeneProduct
protein,2933,O
.,2933,O
PBMCs,2934,O
from,2934,O
homozygotes,2934,O
and,2934,O
wild-type,2934,O
controls,2934,O
were,2934,O
stimulated,2934,O
with,2934,O
anti-CD3/anti-CD28,2934,O
antibodies,2934,O
and,2934,O
the,2934,O
level,2934,O
of,2934,O
T-cell,2934,O
activation,2934,O
was,2934,O
determined,2934,O
by,2934,O
the,2934,O
stimulation,2934,O
index,2934,O
.,2934,O
RESULTS,2935,O
:,2935,O
PBMCs,2935,O
with,2935,O
the,2935,O
heterozygous,2935,O
and,2935,O
homozygous,2935,O
SLURP-1,2935,B-GeneOrGeneProduct
G86R,2935,B-SequenceVariant
mutation,2935,O
had,2935,O
defective,2935,O
T-cell,2935,O
activation,2935,O
.,2935,O
This,2936,O
was,2936,O
restored,2936,O
by,2936,O
the,2936,O
addition,2936,O
of,2936,O
0,2936,O
5,2936,O
ug,2936,O
mL,2936,O
(,2936,O
-1,2936,O
),2936,O
recombinant,2936,O
human,2936,B-OrganismTaxon
SLURP-1,2936,B-GeneOrGeneProduct
protein,2936,O
.,2936,O
CONCLUSIONS,2937,O
:,2937,O
Patients,2937,B-OrganismTaxon
with,2937,O
MDM,2937,B-DiseaseOrPhenotypicFeature
with,2937,O
the,2937,O
homozygous,2937,O
SLURP-1,2937,B-GeneOrGeneProduct
G86R,2937,B-SequenceVariant
mutation,2937,O
may,2937,O
have,2937,O
an,2937,O
impaired,2937,O
T-cell,2937,O
activation,2937,O
.,2937,O
The,2938,O
presence,2938,O
of,2938,O
wild-type,2938,O
SLURP-1,2938,B-GeneOrGeneProduct
is,2938,O
essential,2938,O
for,2938,O
normal,2938,O
T-cell,2938,O
activation,2938,O
.,2938,O
Alternative,2939,O
splicing,2939,O
at,2939,O
a,2939,O
NAGNAG,2939,O
acceptor,2939,O
site,2939,O
as,2939,O
a,2939,O
novel,2939,O
phenotype,2939,O
modifier,2939,O
.,2939,O
Approximately,2940,O
30,2940,O
%,2940,O
of,2940,O
alleles,2940,O
causing,2940,O
genetic,2940,O
disorders,2940,O
generate,2940,O
premature,2940,O
termination,2940,O
codons,2940,O
(,2940,O
PTCs,2940,O
),2940,O
",",2940,O
which,2940,O
are,2940,O
usually,2940,O
associated,2940,O
with,2940,O
severe,2940,O
phenotypes,2940,O
.,2940,O
However,2941,O
",",2941,O
bypassing,2941,O
the,2941,O
deleterious,2941,O
stop,2941,O
codon,2941,O
can,2941,O
lead,2941,O
to,2941,O
a,2941,O
mild,2941,O
disease,2941,O
outcome,2941,O
.,2941,O
Splicing,2942,O
at,2942,O
NAGNAG,2942,O
tandem,2942,O
splice,2942,O
sites,2942,O
has,2942,O
been,2942,O
reported,2942,O
to,2942,O
result,2942,O
in,2942,O
insertion,2942,O
or,2942,O
deletion,2942,O
(,2942,O
indel,2942,O
),2942,O
of,2942,O
three,2942,O
nucleotides,2942,O
.,2942,O
We,2943,O
identified,2943,O
such,2943,O
a,2943,O
mechanism,2943,O
as,2943,O
the,2943,O
origin,2943,O
of,2943,O
the,2943,O
mild,2943,O
to,2943,O
asymptomatic,2943,O
phenotype,2943,O
observed,2943,O
in,2943,O
cystic,2943,B-DiseaseOrPhenotypicFeature
fibrosis,2943,I-DiseaseOrPhenotypicFeature
patients,2943,B-OrganismTaxon
homozygous,2943,O
for,2943,O
the,2943,O
E831X,2943,B-SequenceVariant
mutation,2943,O
(,2943,O
2623G,2943,B-SequenceVariant
>,2943,I-SequenceVariant
T,2943,I-SequenceVariant
),2943,O
in,2943,O
the,2943,O
CFTR,2943,B-GeneOrGeneProduct
gene,2943,O
.,2943,O
Analyses,2944,O
performed,2944,O
on,2944,O
nasal,2944,O
epithelial,2944,O
cell,2944,O
mRNA,2944,O
detected,2944,O
three,2944,O
distinct,2944,O
isoforms,2944,O
",",2944,O
a,2944,O
considerably,2944,O
more,2944,O
complex,2944,O
situation,2944,O
than,2944,O
expected,2944,O
for,2944,O
a,2944,O
single,2944,O
nucleotide,2944,O
substitution,2944,O
.,2944,O
Structure-function,2945,O
studies,2945,O
and,2945,O
in,2945,O
silico,2945,O
analyses,2945,O
provided,2945,O
the,2945,O
first,2945,O
experimental,2945,O
evidence,2945,O
of,2945,O
an,2945,O
indel,2945,O
of,2945,O
a,2945,O
stop,2945,O
codon,2945,O
by,2945,O
alternative,2945,O
splicing,2945,O
at,2945,O
a,2945,O
NAGNAG,2945,O
acceptor,2945,O
site,2945,O
.,2945,O
In,2946,O
addition,2946,O
to,2946,O
contributing,2946,O
to,2946,O
proteome,2946,O
plasticity,2946,O
",",2946,O
alternative,2946,O
splicing,2946,O
at,2946,O
a,2946,O
NAGNAG,2946,O
tandem,2946,O
site,2946,O
can,2946,O
thus,2946,O
remove,2946,O
a,2946,O
disease-causing,2946,O
UAG,2946,O
stop,2946,O
codon,2946,O
.,2946,O
This,2947,O
molecular,2947,O
study,2947,O
reveals,2947,O
a,2947,O
naturally,2947,O
occurring,2947,O
mechanism,2947,O
where,2947,O
the,2947,O
effect,2947,O
of,2947,O
either,2947,O
modifier,2947,O
genes,2947,O
or,2947,O
epigenetic,2947,O
factors,2947,O
could,2947,O
be,2947,O
suspected,2947,O
.,2947,O
This,2948,O
finding,2948,O
is,2948,O
of,2948,O
importance,2948,O
for,2948,O
genetic,2948,O
counseling,2948,O
as,2948,O
well,2948,O
as,2948,O
for,2948,O
deciding,2948,O
appropriate,2948,O
therapeutic,2948,O
strategies,2948,O
.,2948,O
In,2949,O
vivo,2949,O
characterization,2949,O
of,2949,O
a,2949,O
dual,2949,O
adenosine,2949,B-ChemicalEntity
A2A/A1,2949,I-ChemicalEntity
receptor,2949,I-ChemicalEntity
antagonist,2949,I-ChemicalEntity
in,2949,O
animal,2949,O
models,2949,O
of,2949,O
Parkinson,2949,B-DiseaseOrPhenotypicFeature
's,2949,I-DiseaseOrPhenotypicFeature
disease,2949,I-DiseaseOrPhenotypicFeature
.,2949,O
The,2950,O
in,2950,O
vivo,2950,O
characterization,2950,O
of,2950,O
a,2950,O
dual,2950,O
adenosine,2950,B-ChemicalEntity
A,2950,I-ChemicalEntity
(,2950,I-ChemicalEntity
2A,2950,I-ChemicalEntity
),2950,I-ChemicalEntity
/A,2950,I-ChemicalEntity
(,2950,I-ChemicalEntity
1,2950,I-ChemicalEntity
),2950,I-ChemicalEntity
receptor,2950,I-ChemicalEntity
antagonist,2950,I-ChemicalEntity
in,2950,O
several,2950,O
animal,2950,O
models,2950,O
of,2950,O
Parkinson,2950,B-DiseaseOrPhenotypicFeature
's,2950,I-DiseaseOrPhenotypicFeature
disease,2950,I-DiseaseOrPhenotypicFeature
is,2950,O
described,2950,O
.,2950,O
Discovery,2951,O
and,2951,O
scale-up,2951,O
syntheses,2951,O
of,2951,O
compound,2951,O
1,2951,O
are,2951,O
described,2951,O
in,2951,O
detail,2951,O
",",2951,O
highlighting,2951,O
optimization,2951,O
steps,2951,O
that,2951,O
increased,2951,O
the,2951,O
overall,2951,O
yield,2951,O
of,2951,O
1,2951,O
from,2951,O
10.0,2951,O
%,2951,O
to,2951,O
30.5,2951,O
%,2951,O
.,2951,O
Compound,2952,O
1,2952,O
is,2952,O
a,2952,O
potent,2952,O
A,2952,B-ChemicalEntity
(,2952,I-ChemicalEntity
2A,2952,I-ChemicalEntity
),2952,I-ChemicalEntity
/A,2952,I-ChemicalEntity
(,2952,I-ChemicalEntity
1,2952,I-ChemicalEntity
),2952,I-ChemicalEntity
receptor,2952,I-ChemicalEntity
antagonist,2952,I-ChemicalEntity
in,2952,O
vitro,2952,O
(,2952,O
A,2952,O
(,2952,O
2A,2952,O
),2952,O
K,2952,O
(,2952,O
i,2952,O
),2952,O
=,2952,O
4.1,2952,O
nM,2952,O
;,2952,O
A,2952,O
(,2952,O
1,2952,O
),2952,O
K,2952,O
(,2952,O
i,2952,O
),2952,O
=,2952,O
17.0,2952,O
nM,2952,O
),2952,O
that,2952,O
has,2952,O
excellent,2952,O
activity,2952,O
",",2952,O
after,2952,O
oral,2952,O
administration,2952,O
",",2952,O
across,2952,O
a,2952,O
number,2952,O
of,2952,O
animal,2952,O
models,2952,O
of,2952,O
Parkinson,2952,B-DiseaseOrPhenotypicFeature
's,2952,I-DiseaseOrPhenotypicFeature
disease,2952,I-DiseaseOrPhenotypicFeature
including,2952,O
mouse,2952,B-OrganismTaxon
and,2952,O
rat,2952,B-OrganismTaxon
models,2952,O
of,2952,O
haloperidol-induced,2952,B-ChemicalEntity
catalepsy,2952,B-DiseaseOrPhenotypicFeature
",",2952,O
mouse,2952,B-OrganismTaxon
model,2952,O
of,2952,O
reserpine-induced,2952,B-ChemicalEntity
akinesia,2952,B-DiseaseOrPhenotypicFeature
",",2952,O
rat,2952,B-OrganismTaxon
6-hydroxydopamine,2952,B-ChemicalEntity
(,2952,O
6-OHDA,2952,B-ChemicalEntity
),2952,O
lesion,2952,O
model,2952,O
of,2952,O
drug-induced,2952,O
rotation,2952,O
",",2952,O
and,2952,O
MPTP-treated,2952,B-ChemicalEntity
non-human,2952,O
primate,2952,O
model,2952,O
.,2952,O
The,2953,O
GALT,2953,B-GeneOrGeneProduct
rush,2953,O
:,2953,O
high,2953,O
carrier,2953,O
frequency,2953,O
of,2953,O
an,2953,O
unusual,2953,O
deletion,2953,O
mutation,2953,O
of,2953,O
the,2953,O
GALT,2953,B-GeneOrGeneProduct
gene,2953,O
in,2953,O
the,2953,O
Ashkenazi,2953,O
population,2953,O
.,2953,O
Classic,2954,B-DiseaseOrPhenotypicFeature
galactosemia,2954,I-DiseaseOrPhenotypicFeature
is,2954,O
an,2954,O
autosomal,2954,B-DiseaseOrPhenotypicFeature
recessive,2954,I-DiseaseOrPhenotypicFeature
disorder,2954,I-DiseaseOrPhenotypicFeature
of,2954,I-DiseaseOrPhenotypicFeature
galactose,2954,I-DiseaseOrPhenotypicFeature
metabolism,2954,I-DiseaseOrPhenotypicFeature
manifesting,2954,O
in,2954,O
the,2954,O
first,2954,O
weeks,2954,O
of,2954,O
life,2954,O
following,2954,O
exposure,2954,O
to,2954,O
a,2954,O
milk-based,2954,O
diet,2954,O
.,2954,O
Despite,2955,O
the,2955,O
benefit,2955,O
of,2955,O
avoidance,2955,O
of,2955,O
lactose,2955,B-ChemicalEntity
",",2955,O
many,2955,O
patients,2955,B-OrganismTaxon
suffer,2955,O
from,2955,O
long-term,2955,O
complications,2955,O
including,2955,O
neurological,2955,B-DiseaseOrPhenotypicFeature
deficits,2955,I-DiseaseOrPhenotypicFeature
and,2955,O
ovarian,2955,B-DiseaseOrPhenotypicFeature
failure,2955,I-DiseaseOrPhenotypicFeature
.,2955,O
To,2956,O
date,2956,O
",",2956,O
over,2956,O
230,2956,O
mutations,2956,O
have,2956,O
been,2956,O
described,2956,O
in,2956,O
the,2956,O
GALT,2956,B-GeneOrGeneProduct
gene,2956,O
resulting,2956,O
in,2956,O
galactosemia,2956,B-DiseaseOrPhenotypicFeature
.,2956,O
Recently,2957,O
",",2957,O
an,2957,O
unusual,2957,O
mutation,2957,O
was,2957,O
characterized,2957,O
causing,2957,O
a,2957,O
5.5,2957,B-SequenceVariant
kb,2957,I-SequenceVariant
deletion,2957,I-SequenceVariant
",",2957,O
with,2957,O
a,2957,O
relatively,2957,O
high,2957,O
carrier,2957,O
rate,2957,O
in,2957,O
subjects,2957,O
of,2957,O
Ashkenazi,2957,O
Jewish,2957,O
(,2957,O
AJ,2957,O
),2957,O
descent,2957,O
.,2957,O
The,2958,O
aim,2958,O
of,2958,O
this,2958,O
study,2958,O
was,2958,O
to,2958,O
estimate,2958,O
the,2958,O
carrier,2958,O
frequency,2958,O
of,2958,O
this,2958,O
mutation,2958,O
in,2958,O
the,2958,O
AJ,2958,O
population,2958,O
in,2958,O
Israel,2958,O
.,2958,O
For,2959,O
this,2959,O
purpose,2959,O
we,2959,O
developed,2959,O
a,2959,O
high-throughput,2959,O
methodology,2959,O
to,2959,O
genotype,2959,O
both,2959,O
normal,2959,O
and,2959,O
deleted,2959,O
alleles,2959,O
using,2959,O
a,2959,O
chip-based,2959,O
matrix-assisted,2959,O
laser,2959,O
desorption-time-of-flight,2959,O
(,2959,O
MALDI-TOF,2959,O
),2959,O
mass,2959,O
spectrometer,2959,O
and,2959,O
Multiplex,2959,O
PCR,2959,O
.,2959,O
DNA,2960,O
samples,2960,O
of,2960,O
760,2960,O
anonymous,2960,O
AJ,2960,O
subjects,2960,O
were,2960,O
submitted,2960,O
for,2960,O
analysis,2960,O
",",2960,O
subsequently,2960,O
detecting,2960,O
six,2960,O
individuals,2960,O
heterozygous,2960,O
for,2960,O
the,2960,O
GALT,2960,B-GeneOrGeneProduct
deletion,2960,O
mutation,2960,O
",",2960,O
giving,2960,O
a,2960,O
carrier,2960,O
frequency,2960,O
of,2960,O
1,2960,O
in,2960,O
127,2960,O
(,2960,O
0.79,2960,O
%,2960,O
),2960,O
.,2960,O
Based,2961,O
on,2961,O
these,2961,O
results,2961,O
",",2961,O
we,2961,O
suggest,2961,O
that,2961,O
the,2961,O
method,2961,O
described,2961,O
here,2961,O
provides,2961,O
a,2961,O
basis,2961,O
for,2961,O
genetic,2961,O
screening,2961,O
and,2961,O
prenatal,2961,O
counseling,2961,O
and,2961,O
can,2961,O
potentially,2961,O
reduce,2961,O
the,2961,O
morbidity,2961,O
and,2961,O
mortality,2961,O
associated,2961,O
with,2961,O
delayed,2961,O
diagnosis,2961,O
of,2961,O
galactosemia,2961,B-DiseaseOrPhenotypicFeature
in,2961,O
this,2961,O
patient,2961,B-OrganismTaxon
population,2961,O
.,2961,O
The,2962,O
dopamine,2962,B-GeneOrGeneProduct
b-hydroxylase,2962,I-GeneOrGeneProduct
-1021C/T,2962,B-SequenceVariant
polymorphism,2962,O
is,2962,O
associated,2962,O
with,2962,O
the,2962,O
risk,2962,O
of,2962,O
Alzheimer,2962,B-DiseaseOrPhenotypicFeature
's,2962,I-DiseaseOrPhenotypicFeature
disease,2962,I-DiseaseOrPhenotypicFeature
in,2962,O
the,2962,O
Epistasis,2962,O
Project,2962,O
.,2962,O
BACKGROUND,2963,O
:,2963,O
The,2963,O
loss,2963,O
of,2963,O
noradrenergic,2963,O
neurones,2963,O
of,2963,O
the,2963,O
locus,2963,O
coeruleus,2963,O
is,2963,O
a,2963,O
major,2963,O
feature,2963,O
of,2963,O
Alzheimer,2963,B-DiseaseOrPhenotypicFeature
's,2963,I-DiseaseOrPhenotypicFeature
disease,2963,I-DiseaseOrPhenotypicFeature
(,2963,O
AD,2963,B-DiseaseOrPhenotypicFeature
),2963,O
.,2963,O
Dopamine,2964,B-GeneOrGeneProduct
b-hydroxylase,2964,I-GeneOrGeneProduct
(,2964,O
DBH,2964,B-GeneOrGeneProduct
),2964,O
catalyses,2964,O
the,2964,O
conversion,2964,O
of,2964,O
dopamine,2964,B-ChemicalEntity
to,2964,O
noradrenaline,2964,B-ChemicalEntity
.,2964,O
Interactions,2965,O
have,2965,O
been,2965,O
reported,2965,O
between,2965,O
the,2965,O
low-activity,2965,O
-1021T,2965,B-SequenceVariant
allele,2965,O
(,2965,O
rs1611115,2965,B-SequenceVariant
),2965,O
of,2965,O
DBH,2965,B-GeneOrGeneProduct
and,2965,O
polymorphisms,2965,O
of,2965,O
the,2965,O
pro-inflammatory,2965,O
cytokine,2965,O
genes,2965,O
",",2965,O
IL1A,2965,B-GeneOrGeneProduct
and,2965,O
IL6,2965,B-GeneOrGeneProduct
",",2965,O
contributing,2965,O
to,2965,O
the,2965,O
risk,2965,O
of,2965,O
AD,2965,B-DiseaseOrPhenotypicFeature
.,2965,O
We,2966,O
therefore,2966,O
examined,2966,O
the,2966,O
associations,2966,O
with,2966,O
AD,2966,B-DiseaseOrPhenotypicFeature
of,2966,O
the,2966,O
DBH,2966,B-GeneOrGeneProduct
-1021T,2966,B-SequenceVariant
allele,2966,O
and,2966,O
of,2966,O
the,2966,O
above,2966,O
interactions,2966,O
in,2966,O
the,2966,O
Epistasis,2966,O
Project,2966,O
",",2966,O
with,2966,O
1757,2966,O
cases,2966,O
of,2966,O
AD,2966,B-DiseaseOrPhenotypicFeature
and,2966,O
6294,2966,O
elderly,2966,O
controls,2966,O
.,2966,O
METHODS,2967,O
:,2967,O
We,2967,O
genotyped,2967,O
eight,2967,O
single,2967,O
nucleotide,2967,O
polymorphisms,2967,O
(,2967,O
SNPs,2967,O
),2967,O
in,2967,O
the,2967,O
three,2967,O
genes,2967,O
",",2967,O
DBH,2967,B-GeneOrGeneProduct
",",2967,O
IL1A,2967,B-GeneOrGeneProduct
and,2967,O
IL6,2967,B-GeneOrGeneProduct
.,2967,O
We,2968,O
used,2968,O
logistic,2968,O
regression,2968,O
models,2968,O
and,2968,O
synergy,2968,O
factor,2968,O
analysis,2968,O
to,2968,O
examine,2968,O
potential,2968,O
interactions,2968,O
and,2968,O
associations,2968,O
with,2968,O
AD,2968,B-DiseaseOrPhenotypicFeature
.,2968,O
RESULTS,2969,O
:,2969,O
We,2969,O
found,2969,O
that,2969,O
the,2969,O
presence,2969,O
of,2969,O
the,2969,O
-1021T,2969,B-SequenceVariant
allele,2969,O
was,2969,O
associated,2969,O
with,2969,O
AD,2969,B-DiseaseOrPhenotypicFeature
:,2969,O
odds,2969,O
ratio,2969,O
=,2969,O
1.2,2969,O
(,2969,O
95,2969,O
%,2969,O
confidence,2969,O
interval,2969,O
:,2969,O
1.06-1.4,2969,O
",",2969,O
p,2969,O
=,2969,O
0.005,2969,O
),2969,O
.,2969,O
This,2970,O
association,2970,O
was,2970,O
nearly,2970,O
restricted,2970,O
to,2970,O
men,2970,B-OrganismTaxon
<,2970,O
75,2970,O
years,2970,O
old,2970,O
:,2970,O
odds,2970,O
ratio,2970,O
=,2970,O
2.2,2970,O
(,2970,O
1.4-3.3,2970,O
",",2970,O
0.0004,2970,O
),2970,O
.,2970,O
We,2971,O
also,2971,O
found,2971,O
an,2971,O
interaction,2971,O
between,2971,O
the,2971,O
presence,2971,O
of,2971,O
DBH,2971,B-GeneOrGeneProduct
-1021T,2971,B-SequenceVariant
and,2971,O
the,2971,O
-889TT,2971,B-SequenceVariant
genotype,2971,O
(,2971,O
rs1800587,2971,B-SequenceVariant
),2971,O
of,2971,O
IL1A,2971,B-GeneOrGeneProduct
:,2971,O
synergy,2971,O
factor,2971,O
=,2971,O
1.9,2971,O
(,2971,O
1.2-3.1,2971,O
",",2971,O
0.005,2971,O
),2971,O
.,2971,O
All,2972,O
these,2972,O
results,2972,O
were,2972,O
consistent,2972,O
between,2972,O
North,2972,O
Europe,2972,O
and,2972,O
North,2972,O
Spain,2972,O
.,2972,O
CONCLUSIONS,2973,O
:,2973,O
Extensive,2973,O
",",2973,O
previous,2973,O
evidence,2973,O
(,2973,O
reviewed,2973,O
here,2973,O
),2973,O
indicates,2973,O
an,2973,O
important,2973,O
role,2973,O
for,2973,O
noradrenaline,2973,B-ChemicalEntity
in,2973,O
the,2973,O
control,2973,O
of,2973,O
inflammation,2973,B-DiseaseOrPhenotypicFeature
in,2973,O
the,2973,O
brain,2973,O
.,2973,O
Thus,2974,O
",",2974,O
the,2974,O
-1021T,2974,B-SequenceVariant
allele,2974,O
with,2974,O
presumed,2974,O
low,2974,O
activity,2974,O
may,2974,O
be,2974,O
associated,2974,O
with,2974,O
misregulation,2974,O
of,2974,O
inflammation,2974,B-DiseaseOrPhenotypicFeature
",",2974,O
which,2974,O
could,2974,O
contribute,2974,O
to,2974,O
the,2974,O
onset,2974,O
of,2974,O
AD,2974,B-DiseaseOrPhenotypicFeature
.,2974,O
We,2975,O
suggest,2975,O
that,2975,O
such,2975,O
misregulation,2975,O
is,2975,O
the,2975,O
predominant,2975,O
mechanism,2975,O
of,2975,O
the,2975,O
association,2975,O
we,2975,O
report,2975,O
here,2975,O
.,2975,O
Novel,2976,O
CRELD1,2976,B-GeneOrGeneProduct
gene,2976,O
mutations,2976,O
in,2976,O
patients,2976,B-OrganismTaxon
with,2976,O
atrioventricular,2976,B-DiseaseOrPhenotypicFeature
septal,2976,I-DiseaseOrPhenotypicFeature
defect,2976,I-DiseaseOrPhenotypicFeature
.,2976,O
BACKGROUND,2977,O
:,2977,O
Atrioventricular,2977,B-DiseaseOrPhenotypicFeature
septal,2977,I-DiseaseOrPhenotypicFeature
defects,2977,I-DiseaseOrPhenotypicFeature
(,2977,O
AVSDs,2977,B-DiseaseOrPhenotypicFeature
),2977,O
occur,2977,O
as,2977,O
clinical,2977,O
defects,2977,O
of,2977,O
several,2977,O
different,2977,O
syndromes,2977,O
",",2977,O
as,2977,O
autosomal,2977,B-DiseaseOrPhenotypicFeature
dominant,2977,I-DiseaseOrPhenotypicFeature
defects,2977,I-DiseaseOrPhenotypicFeature
",",2977,O
and,2977,O
as,2977,O
sporadically,2977,O
occurring,2977,O
malformations,2977,B-DiseaseOrPhenotypicFeature
.,2977,O
Consequently,2978,O
",",2978,O
there,2978,O
is,2978,O
genetic,2978,O
heterogeneity,2978,O
",",2978,O
but,2978,O
until,2978,O
recently,2978,O
",",2978,O
little,2978,O
is,2978,O
known,2978,O
about,2978,O
the,2978,O
genes,2978,O
involving,2978,O
in,2978,O
the,2978,O
pathogenesis,2978,O
of,2978,O
AVSD,2978,B-DiseaseOrPhenotypicFeature
.,2978,O
CRELD1,2979,B-GeneOrGeneProduct
gene,2979,O
",",2979,O
a,2979,O
novel,2979,O
cell,2979,O
adhesion,2979,O
molecule,2979,O
",",2979,O
is,2979,O
a,2979,O
candidate,2979,O
gene,2979,O
for,2979,O
AVSD,2979,B-DiseaseOrPhenotypicFeature
.,2979,O
METHODS,2980,O
:,2980,O
This,2980,O
study,2980,O
included,2980,O
133,2980,O
patients,2980,B-OrganismTaxon
with,2980,O
AVSD,2980,B-DiseaseOrPhenotypicFeature
and,2980,O
200,2980,O
healthy,2980,O
controls,2980,O
.,2980,O
Peripheral,2981,O
blood,2981,O
samples,2981,O
were,2981,O
collected,2981,O
and,2981,O
genomic,2981,O
DNA,2981,O
was,2981,O
extracted,2981,O
from,2981,O
the,2981,O
leukocytes,2981,O
.,2981,O
CRELD1,2982,B-GeneOrGeneProduct
was,2982,O
amplified,2982,O
by,2982,O
polymerase,2982,O
chain,2982,O
reaction,2982,O
(,2982,O
PCR,2982,O
),2982,O
with,2982,O
specific,2982,O
primers,2982,O
.,2982,O
The,2983,O
sequences,2983,O
of,2983,O
PCR,2983,O
products,2983,O
were,2983,O
compared,2983,O
between,2983,O
the,2983,O
patients,2983,B-OrganismTaxon
and,2983,O
controls,2983,O
.,2983,O
RESULTS,2984,O
:,2984,O
In,2984,O
a,2984,O
patient,2984,B-OrganismTaxon
",",2984,O
a,2984,O
C-to-G,2984,B-SequenceVariant
transition,2984,I-SequenceVariant
was,2984,I-SequenceVariant
identified,2984,I-SequenceVariant
at,2984,I-SequenceVariant
nucleotide,2984,I-SequenceVariant
857,2984,I-SequenceVariant
in,2984,O
exon,2984,O
8,2984,O
that,2984,O
resulted,2984,O
in,2984,O
a,2984,O
substitution,2984,O
of,2984,O
alanine,2984,B-SequenceVariant
for,2984,I-SequenceVariant
proline,2984,I-SequenceVariant
at,2984,I-SequenceVariant
amino,2984,I-SequenceVariant
acid,2984,I-SequenceVariant
286,2984,I-SequenceVariant
in,2984,O
the,2984,O
first,2984,O
calcium-binding,2984,B-ChemicalEntity
EGF,2984,B-GeneOrGeneProduct
domain,2984,O
.,2984,O
This,2985,O
patient,2985,B-OrganismTaxon
had,2985,O
an,2985,O
isolated,2985,O
partial,2985,O
AVSD,2985,B-DiseaseOrPhenotypicFeature
and,2985,O
the,2985,O
mutation,2985,O
was,2985,O
inherited,2985,O
from,2985,O
her,2985,O
mother,2985,O
.,2985,O
Another,2986,O
mutation,2986,O
was,2986,O
detected,2986,O
in,2986,O
a,2986,O
patient,2986,B-OrganismTaxon
with,2986,O
a,2986,O
partial,2986,O
AVSD,2986,B-DiseaseOrPhenotypicFeature
and,2986,O
evidence,2986,O
of,2986,O
Down,2986,B-DiseaseOrPhenotypicFeature
syndrome,2986,I-DiseaseOrPhenotypicFeature
.,2986,O
The,2987,O
heterozygous,2987,O
c.973G,2987,B-SequenceVariant
>,2987,I-SequenceVariant
A,2987,I-SequenceVariant
transition,2987,O
in,2987,O
exon,2987,O
9,2987,O
resulted,2987,O
in,2987,O
a,2987,O
substitution,2987,O
of,2987,O
lysine,2987,B-SequenceVariant
for,2987,I-SequenceVariant
glutamic,2987,I-SequenceVariant
acid,2987,I-SequenceVariant
at,2987,I-SequenceVariant
amino,2987,I-SequenceVariant
acid,2987,I-SequenceVariant
325,2987,I-SequenceVariant
(,2987,O
E325K,2987,B-SequenceVariant
),2987,O
in,2987,O
the,2987,O
second,2987,O
calcium-binding,2987,B-ChemicalEntity
EGF,2987,B-GeneOrGeneProduct
domain,2987,O
.,2987,O
CONCLUSIONS,2988,O
:,2988,O
Two,2988,O
novel,2988,O
CRELD1,2988,B-GeneOrGeneProduct
mutations,2988,O
were,2988,O
identified,2988,O
in,2988,O
the,2988,O
calcium-binding,2988,B-ChemicalEntity
EGF,2988,B-GeneOrGeneProduct
domain,2988,O
in,2988,O
patients,2988,B-OrganismTaxon
with,2988,O
AVSD,2988,B-DiseaseOrPhenotypicFeature
.,2988,O
CRELD1,2989,B-GeneOrGeneProduct
is,2989,O
likely,2989,O
to,2989,O
be,2989,O
an,2989,O
AVSD-susceptibility,2989,B-DiseaseOrPhenotypicFeature
gene,2989,O
and,2989,O
CRELD1,2989,B-GeneOrGeneProduct
mutations,2989,O
may,2989,O
increase,2989,O
the,2989,O
risk,2989,O
of,2989,O
developing,2989,O
a,2989,O
heart,2989,B-DiseaseOrPhenotypicFeature
defect,2989,I-DiseaseOrPhenotypicFeature
rather,2989,O
than,2989,O
being,2989,O
a,2989,O
direct,2989,O
causative,2989,O
mutation,2989,O
.,2989,O
Impact,2990,O
of,2990,O
CCR5delta32,2990,B-GeneOrGeneProduct
host,2990,O
genetic,2990,O
background,2990,O
and,2990,O
disease,2990,O
progression,2990,O
on,2990,O
HIV-1,2990,B-OrganismTaxon
intrahost,2990,O
evolutionary,2990,O
processes,2990,O
:,2990,O
efficient,2990,O
hypothesis,2990,O
testing,2990,O
through,2990,O
hierarchical,2990,O
phylogenetic,2990,O
models,2990,O
.,2990,O
The,2991,O
interplay,2991,O
between,2991,O
C-C,2991,B-GeneOrGeneProduct
chemokine,2991,I-GeneOrGeneProduct
receptor,2991,I-GeneOrGeneProduct
type,2991,I-GeneOrGeneProduct
5,2991,I-GeneOrGeneProduct
(,2991,O
CCR5,2991,B-GeneOrGeneProduct
),2991,O
host,2991,O
genetic,2991,O
background,2991,O
",",2991,O
disease,2991,O
progression,2991,O
",",2991,O
and,2991,O
intrahost,2991,O
HIV-1,2991,B-OrganismTaxon
evolutionary,2991,O
dynamics,2991,O
remains,2991,O
unclear,2991,O
because,2991,O
differences,2991,O
in,2991,O
viral,2991,O
evolution,2991,O
between,2991,O
hosts,2991,O
limit,2991,O
the,2991,O
ability,2991,O
to,2991,O
draw,2991,O
conclusions,2991,O
across,2991,O
hosts,2991,O
stratified,2991,O
into,2991,O
clinically,2991,O
relevant,2991,O
populations,2991,O
.,2991,O
Similar,2992,O
inference,2992,O
problems,2992,O
are,2992,O
proliferating,2992,O
across,2992,O
many,2992,O
measurably,2992,O
evolving,2992,O
pathogens,2992,O
for,2992,O
which,2992,O
intrahost,2992,O
sequence,2992,O
samples,2992,O
are,2992,O
readily,2992,O
available,2992,O
.,2992,O
To,2993,O
this,2993,O
end,2993,O
",",2993,O
we,2993,O
propose,2993,O
novel,2993,O
hierarchical,2993,O
phylogenetic,2993,O
models,2993,O
(,2993,O
HPMs,2993,O
),2993,O
that,2993,O
incorporate,2993,O
fixed,2993,O
effects,2993,O
to,2993,O
test,2993,O
for,2993,O
differences,2993,O
in,2993,O
dynamics,2993,O
across,2993,O
host,2993,O
populations,2993,O
in,2993,O
a,2993,O
formal,2993,O
statistical,2993,O
framework,2993,O
employing,2993,O
stochastic,2993,O
search,2993,O
variable,2993,O
selection,2993,O
and,2993,O
model,2993,O
averaging,2993,O
.,2993,O
To,2994,O
clarify,2994,O
the,2994,O
role,2994,O
of,2994,O
CCR5,2994,B-GeneOrGeneProduct
host,2994,O
genetic,2994,O
background,2994,O
and,2994,O
disease,2994,O
progression,2994,O
on,2994,O
viral,2994,O
evolutionary,2994,O
patterns,2994,O
",",2994,O
we,2994,O
obtain,2994,O
gp120,2994,B-GeneOrGeneProduct
envelope,2994,O
sequences,2994,O
from,2994,O
clonal,2994,O
HIV-1,2994,B-OrganismTaxon
variants,2994,O
isolated,2994,O
at,2994,O
multiple,2994,O
time,2994,O
points,2994,O
in,2994,O
the,2994,O
course,2994,O
of,2994,O
infection,2994,B-DiseaseOrPhenotypicFeature
from,2994,O
populations,2994,O
of,2994,O
HIV-1-infected,2994,B-DiseaseOrPhenotypicFeature
individuals,2994,O
who,2994,O
only,2994,O
harbored,2994,O
CCR5-using,2994,B-GeneOrGeneProduct
HIV-1,2994,B-OrganismTaxon
variants,2994,O
at,2994,O
all,2994,O
time,2994,O
points,2994,O
.,2994,O
Presence,2995,O
or,2995,O
absence,2995,O
of,2995,O
a,2995,O
CCR5,2995,B-GeneOrGeneProduct
wt/DD32,2995,O
genotype,2995,O
and,2995,O
progressive,2995,O
or,2995,O
long-term,2995,O
nonprogressive,2995,O
course,2995,O
of,2995,O
infection,2995,B-DiseaseOrPhenotypicFeature
stratify,2995,O
the,2995,O
clinical,2995,O
populations,2995,O
in,2995,O
a,2995,O
two-way,2995,O
design,2995,O
.,2995,O
As,2996,O
compared,2996,O
with,2996,O
the,2996,O
standard,2996,O
approach,2996,O
of,2996,O
analyzing,2996,O
sequences,2996,O
from,2996,O
each,2996,O
patient,2996,B-OrganismTaxon
independently,2996,O
",",2996,O
the,2996,O
HPM,2996,O
provides,2996,O
more,2996,O
efficient,2996,O
estimation,2996,O
of,2996,O
evolutionary,2996,O
parameters,2996,O
such,2996,O
as,2996,O
nucleotide,2996,O
substitution,2996,O
rates,2996,O
and,2996,O
d,2996,O
(,2996,O
N,2996,O
),2996,O
/d,2996,O
(,2996,O
S,2996,O
),2996,O
rate,2996,O
ratios,2996,O
",",2996,O
as,2996,O
shown,2996,O
by,2996,O
significant,2996,O
shrinkage,2996,O
of,2996,O
the,2996,O
estimator,2996,O
variance,2996,O
.,2996,O
The,2997,O
fixed,2997,O
effects,2997,O
also,2997,O
correct,2997,O
for,2997,O
nonindependence,2997,O
of,2997,O
data,2997,O
between,2997,O
populations,2997,O
and,2997,O
results,2997,O
in,2997,O
even,2997,O
further,2997,O
shrinkage,2997,O
of,2997,O
individual,2997,O
patient,2997,B-OrganismTaxon
estimates,2997,O
.,2997,O
Model,2998,O
selection,2998,O
suggests,2998,O
an,2998,O
association,2998,O
between,2998,O
nucleotide,2998,O
substitution,2998,O
rate,2998,O
and,2998,O
disease,2998,O
progression,2998,O
",",2998,O
but,2998,O
a,2998,O
role,2998,O
for,2998,O
CCR5,2998,B-GeneOrGeneProduct
genotype,2998,O
remains,2998,O
elusive,2998,O
.,2998,O
Given,2999,O
the,2999,O
absence,2999,O
of,2999,O
clear,2999,O
d,2999,O
(,2999,O
N,2999,O
),2999,O
/d,2999,O
(,2999,O
S,2999,O
),2999,O
differences,2999,O
between,2999,O
patient,2999,B-OrganismTaxon
groups,2999,O
",",2999,O
delayed,2999,O
onset,2999,O
of,2999,O
AIDS,2999,B-DiseaseOrPhenotypicFeature
symptoms,2999,O
appears,2999,O
to,2999,O
be,2999,O
solely,2999,O
associated,2999,O
with,2999,O
lower,2999,O
viral,2999,O
replication,2999,O
rates,2999,O
rather,2999,O
than,2999,O
with,2999,O
differences,2999,O
in,2999,O
selection,2999,O
on,2999,O
amino,2999,O
acid,2999,O
fixation,2999,O
.,2999,O
The,3000,O
M235T,3000,B-SequenceVariant
polymorphism,3000,O
of,3000,O
the,3000,O
angiotensinogen,3000,B-GeneOrGeneProduct
gene,3000,O
in,3000,O
South,3000,O
Indian,3000,O
patients,3000,B-OrganismTaxon
of,3000,O
hypertrophic,3000,B-DiseaseOrPhenotypicFeature
cardiomyopathy,3000,I-DiseaseOrPhenotypicFeature
.,3000,O
INTRODUCTION,3001,O
:,3001,O
Hypertrophic,3001,B-DiseaseOrPhenotypicFeature
cardiomyopathy,3001,I-DiseaseOrPhenotypicFeature
(,3001,O
HCM,3001,B-DiseaseOrPhenotypicFeature
),3001,O
is,3001,O
a,3001,O
complex,3001,O
disorder,3001,O
and,3001,O
genetically,3001,O
transmitted,3001,O
cardiac,3001,B-DiseaseOrPhenotypicFeature
disease,3001,I-DiseaseOrPhenotypicFeature
with,3001,O
a,3001,O
diverse,3001,O
clinical,3001,O
course,3001,O
.,3001,O
The,3002,O
objective,3002,O
of,3002,O
the,3002,O
present,3002,O
study,3002,O
was,3002,O
to,3002,O
examine,3002,O
the,3002,O
association,3002,O
of,3002,O
the,3002,O
T704C,3002,B-SequenceVariant
polymorphism,3002,O
of,3002,O
exon,3002,O
2,3002,O
of,3002,O
the,3002,O
angiotensinogen,3002,B-GeneOrGeneProduct
(,3002,O
AGT,3002,B-GeneOrGeneProduct
),3002,O
gene,3002,O
with,3002,O
HCM,3002,B-DiseaseOrPhenotypicFeature
in,3002,O
a,3002,O
South,3002,O
Indian,3002,O
population,3002,O
from,3002,O
Andhra,3002,O
Pradesh,3002,O
.,3002,O
Subjects,3003,O
and,3003,O
methods,3003,O
.,3003,O
One-hundred,3004,O
and,3004,O
fifty,3004,O
HCM,3004,B-DiseaseOrPhenotypicFeature
(,3004,O
90,3004,O
sporadic,3004,B-DiseaseOrPhenotypicFeature
hypertrophic,3004,I-DiseaseOrPhenotypicFeature
cardiomyopathy,3004,I-DiseaseOrPhenotypicFeature
[,3004,O
SHCM,3004,B-DiseaseOrPhenotypicFeature
],3004,O
and,3004,O
60,3004,O
familial,3004,B-DiseaseOrPhenotypicFeature
hypertrophic,3004,I-DiseaseOrPhenotypicFeature
cardiomyopathy,3004,I-DiseaseOrPhenotypicFeature
[,3004,O
FHCM,3004,B-DiseaseOrPhenotypicFeature
],3004,O
),3004,O
patients,3004,B-OrganismTaxon
and,3004,O
165,3004,O
age-,3004,O
and,3004,O
sex-matched,3004,O
normal,3004,O
healthy,3004,O
controls,3004,O
without,3004,O
known,3004,O
hypertension,3004,B-DiseaseOrPhenotypicFeature
and,3004,O
left,3004,B-DiseaseOrPhenotypicFeature
ventricular,3004,I-DiseaseOrPhenotypicFeature
hypertrophy,3004,I-DiseaseOrPhenotypicFeature
were,3004,O
included,3004,O
in,3004,O
the,3004,O
study,3004,O
.,3004,O
DNA,3005,O
was,3005,O
isolated,3005,O
from,3005,O
peripheral,3005,O
leukocytes,3005,O
and,3005,O
the,3005,O
region,3005,O
of,3005,O
interest,3005,O
in,3005,O
the,3005,O
AGT,3005,B-GeneOrGeneProduct
gene,3005,O
bearing,3005,O
a,3005,O
missense,3005,O
mutation,3005,O
methionine,3005,B-SequenceVariant
to,3005,I-SequenceVariant
threonine,3005,I-SequenceVariant
substitution,3005,I-SequenceVariant
at,3005,I-SequenceVariant
codon,3005,I-SequenceVariant
235,3005,I-SequenceVariant
(,3005,O
M235T,3005,B-SequenceVariant
),3005,O
of,3005,O
exon,3005,O
2,3005,O
",",3005,O
was,3005,O
amplified,3005,O
by,3005,O
polymerase,3005,O
chain,3005,O
reaction,3005,O
(,3005,O
PCR,3005,O
),3005,O
.,3005,O
The,3006,O
PCR,3006,O
products,3006,O
were,3006,O
subjected,3006,O
to,3006,O
restriction,3006,O
digestion,3006,O
with,3006,O
the,3006,O
enzyme,3006,O
SfaNI,3006,B-ChemicalEntity
.,3006,O
RESULTS,3007,O
:,3007,O
Significant,3007,O
differences,3007,O
were,3007,O
detected,3007,O
in,3007,O
genotypic,3007,O
distribution,3007,O
(,3007,O
p,3007,O
=,3007,O
0.04,3007,O
),3007,O
as,3007,O
well,3007,O
as,3007,O
the,3007,O
allelic,3007,O
frequency,3007,O
(,3007,O
p,3007,O
=,3007,O
0.003,3007,O
),3007,O
between,3007,O
the,3007,O
SHCM,3007,B-DiseaseOrPhenotypicFeature
patients,3007,B-OrganismTaxon
and,3007,O
controls,3007,O
.,3007,O
The,3008,O
polymorphism,3008,O
did,3008,O
not,3008,O
show,3008,O
any,3008,O
association,3008,O
with,3008,O
FHCM,3008,B-DiseaseOrPhenotypicFeature
.,3008,O
CONCLUSION,3009,O
:,3009,O
Our,3009,O
results,3009,O
suggest,3009,O
that,3009,O
the,3009,O
T,3009,O
allele,3009,O
of,3009,O
the,3009,O
AGT,3009,B-GeneOrGeneProduct
gene,3009,O
is,3009,O
significantly,3009,O
associated,3009,O
with,3009,O
SHCM,3009,B-DiseaseOrPhenotypicFeature
in,3009,O
a,3009,O
South,3009,O
Indian,3009,O
population,3009,O
from,3009,O
Andhra,3009,O
Pradesh,3009,O
.,3009,O
However,3010,O
",",3010,O
we,3010,O
did,3010,O
not,3010,O
find,3010,O
significant,3010,O
association,3010,O
of,3010,O
this,3010,O
polymorphism,3010,O
with,3010,O
FHCM,3010,B-DiseaseOrPhenotypicFeature
.,3010,O
The,3011,O
role,3011,O
of,3011,O
nitric,3011,B-ChemicalEntity
oxide,3011,I-ChemicalEntity
in,3011,O
convulsions,3011,B-DiseaseOrPhenotypicFeature
induced,3011,O
by,3011,O
lindane,3011,B-ChemicalEntity
in,3011,O
rats,3011,B-OrganismTaxon
.,3011,O
Lindane,3012,B-ChemicalEntity
is,3012,O
an,3012,O
organochloride,3012,B-ChemicalEntity
pesticide,3012,B-ChemicalEntity
and,3012,O
scabicide,3012,B-ChemicalEntity
.,3012,O
It,3013,O
evokes,3013,O
convulsions,3013,B-DiseaseOrPhenotypicFeature
mainly,3013,O
trough,3013,O
the,3013,O
blockage,3013,O
of,3013,O
GABA,3013,B-GeneOrGeneProduct
(,3013,I-GeneOrGeneProduct
A,3013,I-GeneOrGeneProduct
),3013,I-GeneOrGeneProduct
receptors,3013,I-GeneOrGeneProduct
.,3013,O
Nitric,3014,B-ChemicalEntity
oxide,3014,I-ChemicalEntity
(,3014,O
NO,3014,B-ChemicalEntity
),3014,O
",",3014,O
gaseous,3014,O
neurotransmitter,3014,O
",",3014,O
has,3014,O
contradictor,3014,O
role,3014,O
in,3014,O
epileptogenesis,3014,O
due,3014,O
to,3014,O
opposite,3014,O
effects,3014,O
of,3014,O
L-arginine,3014,B-ChemicalEntity
",",3014,O
precursor,3014,O
of,3014,O
NO,3014,B-GeneOrGeneProduct
syntheses,3014,I-GeneOrGeneProduct
(,3014,O
NOS,3014,B-GeneOrGeneProduct
),3014,O
",",3014,O
and,3014,O
L-NAME,3014,B-ChemicalEntity
(,3014,O
NOS,3014,B-GeneOrGeneProduct
inhibitor,3014,O
),3014,O
observed,3014,O
in,3014,O
different,3014,O
epilepsy,3014,B-DiseaseOrPhenotypicFeature
models,3014,O
.,3014,O
The,3015,O
aim,3015,O
of,3015,O
the,3015,O
current,3015,O
study,3015,O
was,3015,O
to,3015,O
determine,3015,O
the,3015,O
effects,3015,O
of,3015,O
NO,3015,B-ChemicalEntity
on,3015,O
the,3015,O
behavioral,3015,O
and,3015,O
EEG,3015,O
characteristics,3015,O
of,3015,O
lindane-induced,3015,B-ChemicalEntity
epilepsy,3015,B-DiseaseOrPhenotypicFeature
in,3015,O
male,3015,O
Wistar,3015,O
albino,3015,O
rats,3015,B-OrganismTaxon
.,3015,O
The,3016,O
administration,3016,O
of,3016,O
L-arginine,3016,B-ChemicalEntity
(,3016,O
600,3016,O
",",3016,O
800,3016,O
and,3016,O
1000,3016,O
mg/kg,3016,O
",",3016,O
i.p,3016,O
.,3016,O
),3016,O
in,3017,O
dose-dependent,3017,O
manner,3017,O
significantly,3017,O
increased,3017,O
convulsion,3017,B-DiseaseOrPhenotypicFeature
incidence,3017,O
and,3017,O
severity,3017,O
and,3017,O
shortened,3017,O
latency,3017,O
time,3017,O
to,3017,O
first,3017,O
convulsion,3017,B-DiseaseOrPhenotypicFeature
elicited,3017,O
by,3017,O
lower,3017,O
lindane,3017,B-ChemicalEntity
dose,3017,O
(,3017,O
4,3017,O
mg/kg,3017,O
",",3017,O
i.p,3017,O
.,3017,O
),3017,O
.,3017,O
On,3018,O
the,3018,O
contrary,3018,O
",",3018,O
pretreatment,3018,O
with,3018,O
L-NAME,3018,B-ChemicalEntity
(,3018,O
500,3018,O
",",3018,O
700,3018,O
and,3018,O
900,3018,O
mg/kg,3018,O
",",3018,O
i.p,3018,O
.,3018,O
),3018,O
decreased,3019,O
convulsion,3019,B-DiseaseOrPhenotypicFeature
incidence,3019,O
and,3019,O
severity,3019,O
and,3019,O
prolonged,3019,O
latency,3019,O
time,3019,O
to,3019,O
convulsion,3019,B-DiseaseOrPhenotypicFeature
following,3019,O
injection,3019,O
with,3019,O
a,3019,O
convulsive,3019,B-DiseaseOrPhenotypicFeature
dose,3019,O
of,3019,O
lindane,3019,B-ChemicalEntity
(,3019,O
8,3019,O
mg/kg,3019,O
",",3019,O
i.p,3019,O
.,3019,O
),3019,O
.,3019,O
EEG,3020,O
analyses,3020,O
showed,3020,O
increase,3020,O
of,3020,O
number,3020,O
and,3020,O
duration,3020,O
of,3020,O
ictal,3020,O
periods,3020,O
in,3020,O
EEG,3020,O
of,3020,O
rats,3020,B-OrganismTaxon
receiving,3020,O
l-arginine,3020,B-ChemicalEntity
prior,3020,O
to,3020,O
lindane,3020,B-ChemicalEntity
and,3020,O
decrease,3020,O
of,3020,O
this,3020,O
number,3020,O
in,3020,O
rats,3020,B-OrganismTaxon
pretreated,3020,O
with,3020,O
L-NAME,3020,B-ChemicalEntity
.,3020,O
These,3021,O
results,3021,O
support,3021,O
the,3021,O
conclusion,3021,O
that,3021,O
NO,3021,B-ChemicalEntity
plays,3021,O
a,3021,O
role,3021,O
of,3021,O
endogenous,3021,O
convulsant,3021,B-DiseaseOrPhenotypicFeature
in,3021,O
rat,3021,B-OrganismTaxon
model,3021,O
of,3021,O
lindane,3021,B-ChemicalEntity
seizures,3021,B-DiseaseOrPhenotypicFeature
.,3021,O
Brat,3022,B-GeneOrGeneProduct
promotes,3022,O
stem,3022,O
cell,3022,O
differentiation,3022,O
via,3022,O
control,3022,O
of,3022,O
a,3022,O
bistable,3022,O
switch,3022,O
that,3022,O
restricts,3022,O
BMP,3022,B-GeneOrGeneProduct
signaling,3022,O
.,3022,O
Drosophila,3023,B-OrganismTaxon
ovarian,3023,O
germline,3023,O
stem,3023,O
cells,3023,O
(,3023,O
GSCs,3023,O
),3023,O
are,3023,O
maintained,3023,O
by,3023,O
Dpp,3023,B-GeneOrGeneProduct
signaling,3023,O
and,3023,O
the,3023,O
Pumilio,3023,B-GeneOrGeneProduct
(,3023,O
Pum,3023,B-GeneOrGeneProduct
),3023,O
and,3023,O
Nanos,3023,B-GeneOrGeneProduct
(,3023,O
Nos,3023,B-GeneOrGeneProduct
),3023,O
translational,3023,O
repressors,3023,O
.,3023,O
Upon,3024,O
division,3024,O
",",3024,O
Dpp,3024,B-GeneOrGeneProduct
signaling,3024,O
is,3024,O
extinguished,3024,O
",",3024,O
and,3024,O
Nos,3024,B-GeneOrGeneProduct
is,3024,O
downregulated,3024,O
in,3024,O
one,3024,O
daughter,3024,O
cell,3024,O
",",3024,O
causing,3024,O
it,3024,O
to,3024,O
switch,3024,O
to,3024,O
a,3024,O
differentiating,3024,O
cystoblast,3024,O
(,3024,O
CB,3024,O
),3024,O
.,3024,O
However,3025,O
",",3025,O
downstream,3025,O
effectors,3025,O
of,3025,O
Pum-Nos,3025,B-GeneOrGeneProduct
remain,3025,O
unknown,3025,O
",",3025,O
and,3025,O
how,3025,O
CBs,3025,O
lose,3025,O
their,3025,O
responsiveness,3025,O
to,3025,O
Dpp,3025,B-GeneOrGeneProduct
is,3025,O
unclear,3025,O
.,3025,O
Here,3026,O
",",3026,O
we,3026,O
identify,3026,O
Brain,3026,B-GeneOrGeneProduct
Tumor,3026,I-GeneOrGeneProduct
(,3026,O
Brat,3026,B-GeneOrGeneProduct
),3026,O
as,3026,O
a,3026,O
potent,3026,O
differentiation,3026,O
factor,3026,O
and,3026,O
target,3026,O
of,3026,O
Pum-Nos,3026,B-GeneOrGeneProduct
regulation,3026,O
.,3026,O
Brat,3027,B-GeneOrGeneProduct
is,3027,O
excluded,3027,O
from,3027,O
GSCs,3027,O
by,3027,O
Pum-Nos,3027,B-GeneOrGeneProduct
but,3027,O
functions,3027,O
with,3027,O
Pum,3027,B-GeneOrGeneProduct
in,3027,O
CBs,3027,O
to,3027,O
translationally,3027,O
repress,3027,O
distinct,3027,O
targets,3027,O
",",3027,O
including,3027,O
the,3027,O
Mad,3027,B-GeneOrGeneProduct
and,3027,O
dMyc,3027,B-GeneOrGeneProduct
mRNAs,3027,O
.,3027,O
Regulation,3028,O
of,3028,O
both,3028,O
targets,3028,O
simultaneously,3028,O
lowers,3028,O
cellular,3028,O
responsiveness,3028,O
to,3028,O
Dpp,3028,B-GeneOrGeneProduct
signaling,3028,O
",",3028,O
forcing,3028,O
the,3028,O
cell,3028,O
to,3028,O
become,3028,O
refractory,3028,O
to,3028,O
the,3028,O
self-renewal,3028,O
signal,3028,O
.,3028,O
Mathematical,3029,O
modeling,3029,O
elucidates,3029,O
bistability,3029,O
of,3029,O
cell,3029,O
fate,3029,O
in,3029,O
the,3029,O
Brat-mediated,3029,B-GeneOrGeneProduct
system,3029,O
",",3029,O
revealing,3029,O
how,3029,O
autoregulation,3029,O
of,3029,O
GSC,3029,O
number,3029,O
can,3029,O
arise,3029,O
from,3029,O
Brat,3029,B-GeneOrGeneProduct
coupling,3029,O
extracellular,3029,O
Dpp,3029,B-GeneOrGeneProduct
regulation,3029,O
to,3029,O
intracellular,3029,O
interpretation,3029,O
.,3029,O
A,3030,O
novel,3030,O
apolipoprotein,3030,B-GeneOrGeneProduct
E,3030,I-GeneOrGeneProduct
mutation,3030,O
",",3030,O
ApoE,3030,B-GeneOrGeneProduct
Osaka,3030,O
(,3030,O
Arg158,3030,B-SequenceVariant
Pro,3030,I-SequenceVariant
),3030,O
",",3030,O
in,3030,O
a,3030,O
dyslipidemic,3030,B-DiseaseOrPhenotypicFeature
patient,3030,B-OrganismTaxon
with,3030,O
lipoprotein,3030,B-DiseaseOrPhenotypicFeature
glomerulopathy,3030,I-DiseaseOrPhenotypicFeature
.,3030,O
Lipoprotein,3031,B-DiseaseOrPhenotypicFeature
glomerulopathy,3031,I-DiseaseOrPhenotypicFeature
(,3031,O
LPG,3031,B-DiseaseOrPhenotypicFeature
),3031,O
is,3031,O
a,3031,O
rare,3031,O
disease,3031,O
characterized,3031,O
by,3031,O
the,3031,O
presence,3031,O
of,3031,O
thrombuslike,3031,O
deposition,3031,O
in,3031,O
markedly,3031,O
dilated,3031,O
glomerular,3031,O
capillaries,3031,O
and,3031,O
is,3031,O
often,3031,O
accompanied,3031,O
by,3031,O
an,3031,O
increased,3031,O
serum,3031,O
apolipoprotein,3031,B-GeneOrGeneProduct
E,3031,I-GeneOrGeneProduct
(,3031,O
apoE,3031,B-GeneOrGeneProduct
),3031,O
level,3031,O
.,3031,O
Several,3032,O
gene,3032,O
mutations,3032,O
of,3032,O
apoE,3032,B-GeneOrGeneProduct
have,3032,O
been,3032,O
reported,3032,O
to,3032,O
be,3032,O
associated,3032,O
with,3032,O
LPG,3032,B-DiseaseOrPhenotypicFeature
.,3032,O
In,3033,O
the,3033,O
current,3033,O
study,3033,O
",",3033,O
we,3033,O
report,3033,O
an,3033,O
LPG,3033,B-DiseaseOrPhenotypicFeature
patient,3033,B-OrganismTaxon
with,3033,O
a,3033,O
novel,3033,O
apoE,3033,B-GeneOrGeneProduct
mutation,3033,O
",",3033,O
apoE,3033,B-GeneOrGeneProduct
Osaka,3033,O
.,3033,O
The,3034,O
patient,3034,B-OrganismTaxon
was,3034,O
a,3034,O
45-year-old,3034,O
man,3034,B-OrganismTaxon
who,3034,O
was,3034,O
hospitalized,3034,O
due,3034,O
to,3034,O
nephrotic,3034,B-DiseaseOrPhenotypicFeature
syndrome,3034,I-DiseaseOrPhenotypicFeature
.,3034,O
Light,3035,O
and,3035,O
electron,3035,O
microscopic,3035,O
observations,3035,O
of,3035,O
renal,3035,O
biopsy,3035,O
clearly,3035,O
showed,3035,O
characteristic,3035,O
findings,3035,O
of,3035,O
LPG,3035,B-DiseaseOrPhenotypicFeature
",",3035,O
including,3035,O
lamellate,3035,B-DiseaseOrPhenotypicFeature
thrombi,3035,I-DiseaseOrPhenotypicFeature
in,3035,O
the,3035,O
lumen,3035,O
of,3035,O
dilated,3035,O
glomerular,3035,O
capillaries,3035,O
.,3035,O
His,3036,O
apoE,3036,B-GeneOrGeneProduct
phenotype,3036,O
was,3036,O
apoE3/2,3036,B-GeneOrGeneProduct
and,3036,O
he,3036,O
had,3036,O
mild,3036,O
dyslipidemia,3036,B-DiseaseOrPhenotypicFeature
with,3036,O
a,3036,O
mid-band,3036,O
on,3036,O
polyacrylamide,3036,B-ChemicalEntity
gel,3036,O
electrophoresis,3036,O
.,3036,O
It,3037,O
is,3037,O
intriguing,3037,O
that,3037,O
the,3037,O
serum,3037,O
apoE,3037,B-GeneOrGeneProduct
level,3037,O
was,3037,O
within,3037,O
normal,3037,O
limits,3037,O
.,3037,O
We,3038,O
determined,3038,O
the,3038,O
sequence,3038,O
of,3038,O
the,3038,O
apoE,3038,B-GeneOrGeneProduct
gene,3038,O
using,3038,O
direct,3038,O
sequencing,3038,O
of,3038,O
the,3038,O
polymerase,3038,O
chain,3038,O
reaction,3038,O
(,3038,O
PCR,3038,O
),3038,O
products,3038,O
.,3038,O
ApoE,3039,B-GeneOrGeneProduct
gene,3039,O
analysis,3039,O
showed,3039,O
a,3039,O
nucleotide,3039,O
substitution,3039,O
of,3039,O
G,3039,B-SequenceVariant
to,3039,I-SequenceVariant
C,3039,I-SequenceVariant
at,3039,I-SequenceVariant
codon,3039,I-SequenceVariant
158,3039,I-SequenceVariant
of,3039,O
exon,3039,O
4,3039,O
.,3039,O
This,3040,O
mutation,3040,O
denoted,3040,O
an,3040,O
amino,3040,O
acid,3040,O
substitution,3040,O
of,3040,O
arginine,3040,B-SequenceVariant
residue,3040,I-SequenceVariant
for,3040,I-SequenceVariant
the,3040,I-SequenceVariant
proline,3040,I-SequenceVariant
residue,3040,I-SequenceVariant
at,3040,I-SequenceVariant
position,3040,I-SequenceVariant
158,3040,I-SequenceVariant
of,3040,O
apoE,3040,B-GeneOrGeneProduct
.,3040,O
The,3041,O
result,3041,O
of,3041,O
PCR,3041,O
associated,3041,O
with,3041,O
restriction,3041,O
fragment,3041,O
length,3041,O
polymorphism,3041,O
analysis,3041,O
also,3041,O
suggested,3041,O
that,3041,O
this,3041,O
mutation,3041,O
is,3041,O
heterozygous,3041,O
.,3041,O
It,3042,O
is,3042,O
possible,3042,O
that,3042,O
apoE,3042,B-GeneOrGeneProduct
Osaka,3042,O
mutation,3042,O
causes,3042,O
a,3042,O
conformational,3042,O
change,3042,O
of,3042,O
apoE,3042,B-GeneOrGeneProduct
protein,3042,O
and,3042,O
affects,3042,O
the,3042,O
interaction,3042,O
between,3042,O
abnormal,3042,O
apoE-containing,3042,B-GeneOrGeneProduct
lipoproteins,3042,O
and,3042,O
the,3042,O
endothelial,3042,O
cells,3042,O
of,3042,O
glomerular,3042,O
capillaries,3042,O
.,3042,O
The,3043,O
precise,3043,O
mechanism,3043,O
of,3043,O
LPG,3043,B-DiseaseOrPhenotypicFeature
related,3043,O
with,3043,O
apoE,3043,B-GeneOrGeneProduct
Osaka,3043,O
",",3043,O
however,3043,O
",",3043,O
remains,3043,O
to,3043,O
be,3043,O
elucidated,3043,O
.,3043,O
Screening,3044,O
and,3044,O
cell-based,3044,O
assessment,3044,O
of,3044,O
mutations,3044,O
in,3044,O
the,3044,O
Aristaless-related,3044,B-GeneOrGeneProduct
homeobox,3044,I-GeneOrGeneProduct
(,3044,O
ARX,3044,B-GeneOrGeneProduct
),3044,O
gene,3044,O
.,3044,O
ARX,3045,B-GeneOrGeneProduct
mutations,3045,O
cause,3045,O
a,3045,O
diverse,3045,O
spectrum,3045,O
of,3045,O
human,3045,B-OrganismTaxon
disorders,3045,O
",",3045,O
ranging,3045,O
from,3045,O
severe,3045,O
brain,3045,B-DiseaseOrPhenotypicFeature
and,3045,I-DiseaseOrPhenotypicFeature
genital,3045,I-DiseaseOrPhenotypicFeature
malformations,3045,I-DiseaseOrPhenotypicFeature
to,3045,O
non-syndromic,3045,O
intellectual,3045,B-DiseaseOrPhenotypicFeature
disability,3045,I-DiseaseOrPhenotypicFeature
(,3045,O
ID,3045,B-DiseaseOrPhenotypicFeature
),3045,O
.,3045,O
ARX,3046,B-GeneOrGeneProduct
is,3046,O
a,3046,O
transcription,3046,O
factor,3046,O
with,3046,O
multiple,3046,O
domains,3046,O
that,3046,O
include,3046,O
four,3046,O
polyalanine,3046,B-ChemicalEntity
(,3046,O
pA,3046,B-ChemicalEntity
),3046,O
tracts,3046,O
",",3046,O
the,3046,O
first,3046,O
two,3046,O
of,3046,O
which,3046,O
are,3046,O
frequently,3046,O
expanded,3046,O
by,3046,O
mutations,3046,O
.,3046,O
We,3047,O
progressively,3047,O
screened,3047,O
DNA,3047,O
samples,3047,O
from,3047,O
613,3047,O
individuals,3047,O
with,3047,O
ID,3047,B-DiseaseOrPhenotypicFeature
initially,3047,O
for,3047,O
the,3047,O
most,3047,O
frequent,3047,O
ARX,3047,B-GeneOrGeneProduct
mutations,3047,O
(,3047,O
c.304ins,3047,B-SequenceVariant
(,3047,I-SequenceVariant
GCG,3047,I-SequenceVariant
),3047,I-SequenceVariant
(,3047,I-SequenceVariant
7,3047,I-SequenceVariant
),3047,I-SequenceVariant
'expansion,3047,O
',3047,O
of,3047,O
pA1,3047,O
and,3047,O
c.429_452dup,3047,B-SequenceVariant
'dup24bp,3047,O
',3047,O
of,3047,O
pA2,3047,O
),3047,O
.,3047,O
Five,3048,O
hundred,3048,O
samples,3048,O
without,3048,O
pA1,3048,O
or,3048,O
pA2,3048,O
mutations,3048,O
had,3048,O
the,3048,O
entire,3048,O
ARX,3048,B-GeneOrGeneProduct
ORF,3048,O
screened,3048,O
by,3048,O
single,3048,O
stranded,3048,O
polymorphism,3048,O
conformation,3048,O
(,3048,O
SSCP,3048,O
),3048,O
and/or,3048,O
denaturing,3048,O
high,3048,O
pressure,3048,O
liquid,3048,O
chromatography,3048,O
(,3048,O
dHPLC,3048,O
),3048,O
analysis,3048,O
.,3048,O
Overall,3049,O
",",3049,O
eight,3049,O
families,3049,O
with,3049,O
six,3049,O
mutations,3049,O
in,3049,O
ARX,3049,B-GeneOrGeneProduct
were,3049,O
identified,3049,O
(,3049,O
1.31,3049,O
%,3049,O
),3049,O
:,3049,O
five,3049,O
duplication,3049,O
mutations,3049,O
in,3049,O
pA2,3049,O
(,3049,O
0.82,3049,O
%,3049,O
),3049,O
with,3049,O
three,3049,O
new,3049,O
clinical,3049,O
reports,3049,O
of,3049,O
families,3049,O
with,3049,O
the,3049,O
dup24bp,3049,B-SequenceVariant
and,3049,O
two,3049,O
duplications,3049,O
larger,3049,O
than,3049,O
the,3049,O
dup24bp,3049,B-SequenceVariant
mutation,3049,O
discovered,3049,O
(,3049,O
dup27bp,3049,B-SequenceVariant
",",3049,O
dup33bp,3049,B-SequenceVariant
),3049,O
;,3049,O
and,3049,O
three,3049,O
point,3049,O
mutations,3049,O
(,3049,O
0.6,3049,O
%,3049,O
),3049,O
",",3049,O
including,3049,O
one,3049,O
novel,3049,O
mutation,3049,O
in,3049,O
the,3049,O
homeodomain,3049,O
(,3049,O
c.1074G,3049,B-SequenceVariant
>,3049,I-SequenceVariant
T,3049,I-SequenceVariant
),3049,O
.,3049,O
Four,3050,O
ultraconserved,3050,O
regions,3050,O
distal,3050,O
to,3050,O
ARX,3050,B-GeneOrGeneProduct
(,3050,O
uc466-469,3050,O
),3050,O
were,3050,O
also,3050,O
screened,3050,O
in,3050,O
a,3050,O
subset,3050,O
of,3050,O
94,3050,O
patients,3050,B-OrganismTaxon
",",3050,O
with,3050,O
three,3050,O
unique,3050,O
nucleotide,3050,O
changes,3050,O
identified,3050,O
in,3050,O
two,3050,O
(,3050,O
uc466,3050,O
",",3050,O
uc467,3050,O
),3050,O
.,3050,O
The,3051,O
subcellular,3051,O
localization,3051,O
of,3051,O
full,3051,O
length,3051,O
ARX,3051,B-GeneOrGeneProduct
proteins,3051,O
was,3051,O
assessed,3051,O
for,3051,O
11,3051,O
variants,3051,O
.,3051,O
Protein,3052,O
mislocalization,3052,O
increased,3052,O
as,3052,O
a,3052,O
function,3052,O
of,3052,O
pA2,3052,O
tract,3052,O
length,3052,O
and,3052,O
phenotypic,3052,O
severity,3052,O
",",3052,O
as,3052,O
has,3052,O
been,3052,O
previously,3052,O
suggested,3052,O
for,3052,O
pA1,3052,O
.,3052,O
Similarly,3053,O
",",3053,O
protein,3053,O
mislocalization,3053,O
of,3053,O
the,3053,O
homeodomain,3053,O
mutations,3053,O
also,3053,O
correlated,3053,O
with,3053,O
clinical,3053,O
severity,3053,O
",",3053,O
suggesting,3053,O
an,3053,O
emerging,3053,O
genotype,3053,O
vs,3053,O
cellular,3053,O
phenotype,3053,O
correlation,3053,O
.,3053,O
Loss-of-function,3054,O
mutations,3054,O
in,3054,O
PTPN11,3054,B-GeneOrGeneProduct
cause,3054,O
metachondromatosis,3054,B-DiseaseOrPhenotypicFeature
",",3054,O
but,3054,O
not,3054,O
Ollier,3054,B-DiseaseOrPhenotypicFeature
disease,3054,I-DiseaseOrPhenotypicFeature
or,3054,O
Maffucci,3054,B-DiseaseOrPhenotypicFeature
syndrome,3054,I-DiseaseOrPhenotypicFeature
.,3054,O
Metachondromatosis,3055,B-DiseaseOrPhenotypicFeature
(,3055,O
MC,3055,B-DiseaseOrPhenotypicFeature
),3055,O
is,3055,O
a,3055,O
rare,3055,O
",",3055,O
autosomal,3055,O
dominant,3055,O
",",3055,O
incompletely,3055,O
penetrant,3055,O
combined,3055,O
exostosis,3055,B-DiseaseOrPhenotypicFeature
and,3055,O
enchondromatosis,3055,B-DiseaseOrPhenotypicFeature
tumor,3055,I-DiseaseOrPhenotypicFeature
syndrome,3055,I-DiseaseOrPhenotypicFeature
.,3055,O
MC,3056,B-DiseaseOrPhenotypicFeature
is,3056,O
clinically,3056,O
distinct,3056,O
from,3056,O
other,3056,O
multiple,3056,B-DiseaseOrPhenotypicFeature
exostosis,3056,I-DiseaseOrPhenotypicFeature
or,3056,O
multiple,3056,B-DiseaseOrPhenotypicFeature
enchondromatosis,3056,I-DiseaseOrPhenotypicFeature
syndromes,3056,I-DiseaseOrPhenotypicFeature
and,3056,O
is,3056,O
unlinked,3056,O
to,3056,O
EXT1,3056,B-GeneOrGeneProduct
and,3056,O
EXT2,3056,B-GeneOrGeneProduct
",",3056,O
the,3056,O
genes,3056,O
responsible,3056,O
for,3056,O
autosomal,3056,O
dominant,3056,O
multiple,3056,B-DiseaseOrPhenotypicFeature
osteochondromas,3056,I-DiseaseOrPhenotypicFeature
(,3056,O
MO,3056,B-DiseaseOrPhenotypicFeature
),3056,O
.,3056,O
To,3057,O
identify,3057,O
a,3057,O
gene,3057,O
for,3057,O
MC,3057,B-DiseaseOrPhenotypicFeature
",",3057,O
we,3057,O
performed,3057,O
linkage,3057,O
analysis,3057,O
with,3057,O
high-density,3057,O
SNP,3057,O
arrays,3057,O
in,3057,O
a,3057,O
single,3057,O
family,3057,O
",",3057,O
used,3057,O
a,3057,O
targeted,3057,O
array,3057,O
to,3057,O
capture,3057,O
exons,3057,O
and,3057,O
promoter,3057,O
sequences,3057,O
from,3057,O
the,3057,O
linked,3057,O
interval,3057,O
in,3057,O
16,3057,O
participants,3057,O
from,3057,O
11,3057,O
MC,3057,B-DiseaseOrPhenotypicFeature
families,3057,O
",",3057,O
and,3057,O
sequenced,3057,O
the,3057,O
captured,3057,O
DNA,3057,O
using,3057,O
high-throughput,3057,O
parallel,3057,O
sequencing,3057,O
technologies,3057,O
.,3057,O
DNA,3058,O
capture,3058,O
and,3058,O
parallel,3058,O
sequencing,3058,O
identified,3058,O
heterozygous,3058,O
putative,3058,O
loss-of-function,3058,O
mutations,3058,O
in,3058,O
PTPN11,3058,B-GeneOrGeneProduct
in,3058,O
4,3058,O
of,3058,O
the,3058,O
11,3058,O
families,3058,O
.,3058,O
Sanger,3059,O
sequence,3059,O
analysis,3059,O
of,3059,O
PTPN11,3059,B-GeneOrGeneProduct
coding,3059,O
regions,3059,O
in,3059,O
a,3059,O
total,3059,O
of,3059,O
17,3059,O
MC,3059,B-DiseaseOrPhenotypicFeature
families,3059,O
identified,3059,O
mutations,3059,O
in,3059,O
10,3059,O
of,3059,O
them,3059,O
(,3059,O
5,3059,O
frameshift,3059,O
",",3059,O
2,3059,O
nonsense,3059,O
",",3059,O
and,3059,O
3,3059,O
splice-site,3059,O
mutations,3059,O
),3059,O
.,3059,O
Copy,3060,O
number,3060,O
analysis,3060,O
of,3060,O
sequencing,3060,O
reads,3060,O
from,3060,O
a,3060,O
second,3060,O
targeted,3060,O
capture,3060,O
that,3060,O
included,3060,O
the,3060,O
entire,3060,O
PTPN11,3060,B-GeneOrGeneProduct
gene,3060,O
identified,3060,O
an,3060,O
additional,3060,O
family,3060,O
with,3060,O
a,3060,O
15,3060,B-SequenceVariant
kb,3060,I-SequenceVariant
deletion,3060,I-SequenceVariant
spanning,3060,O
exon,3060,O
7,3060,O
of,3060,O
PTPN11,3060,B-GeneOrGeneProduct
.,3060,O
Microdissected,3061,O
MC,3061,B-DiseaseOrPhenotypicFeature
lesions,3061,O
from,3061,O
two,3061,O
patients,3061,B-OrganismTaxon
with,3061,O
PTPN11,3061,B-GeneOrGeneProduct
mutations,3061,O
demonstrated,3061,O
loss-of-heterozygosity,3061,O
for,3061,O
the,3061,O
wild-type,3061,O
allele,3061,O
.,3061,O
We,3062,O
next,3062,O
sequenced,3062,O
PTPN11,3062,B-GeneOrGeneProduct
in,3062,O
DNA,3062,O
samples,3062,O
from,3062,O
54,3062,O
patients,3062,B-OrganismTaxon
with,3062,O
the,3062,O
multiple,3062,O
enchondromatosis,3062,B-DiseaseOrPhenotypicFeature
disorders,3062,I-DiseaseOrPhenotypicFeature
Ollier,3062,I-DiseaseOrPhenotypicFeature
disease,3062,I-DiseaseOrPhenotypicFeature
or,3062,O
Maffucci,3062,B-DiseaseOrPhenotypicFeature
syndrome,3062,I-DiseaseOrPhenotypicFeature
",",3062,O
but,3062,O
found,3062,O
no,3062,O
coding,3062,O
sequence,3062,O
PTPN11,3062,B-GeneOrGeneProduct
mutations,3062,O
.,3062,O
We,3063,O
conclude,3063,O
that,3063,O
heterozygous,3063,O
loss-of-function,3063,O
mutations,3063,O
in,3063,O
PTPN11,3063,B-GeneOrGeneProduct
are,3063,O
a,3063,O
frequent,3063,O
cause,3063,O
of,3063,O
MC,3063,B-DiseaseOrPhenotypicFeature
",",3063,O
that,3063,O
lesions,3063,O
in,3063,O
patients,3063,B-OrganismTaxon
with,3063,O
MC,3063,B-DiseaseOrPhenotypicFeature
appear,3063,O
to,3063,O
arise,3063,O
following,3063,O
a,3063,O
``,3063,O
second,3063,O
hit,3063,O
",",3063,O
'',3063,O
that,3063,O
MC,3063,B-DiseaseOrPhenotypicFeature
may,3063,O
be,3063,O
locus,3063,O
heterogeneous,3063,O
since,3063,O
1,3063,O
familial,3063,O
and,3063,O
5,3063,O
sporadically,3063,O
occurring,3063,O
cases,3063,O
lacked,3063,O
obvious,3063,O
disease-causing,3063,O
PTPN11,3063,B-GeneOrGeneProduct
mutations,3063,O
",",3063,O
and,3063,O
that,3063,O
PTPN11,3063,B-GeneOrGeneProduct
mutations,3063,O
are,3063,O
not,3063,O
a,3063,O
common,3063,O
cause,3063,O
of,3063,O
Ollier,3063,B-DiseaseOrPhenotypicFeature
disease,3063,I-DiseaseOrPhenotypicFeature
or,3063,O
Maffucci,3063,B-DiseaseOrPhenotypicFeature
syndrome,3063,I-DiseaseOrPhenotypicFeature
.,3063,O
Interleukin-17F,3064,B-GeneOrGeneProduct
gene,3064,O
polymorphism,3064,O
in,3064,O
patients,3064,B-OrganismTaxon
with,3064,O
chronic,3064,B-DiseaseOrPhenotypicFeature
immune,3064,I-DiseaseOrPhenotypicFeature
thrombocytopenia,3064,I-DiseaseOrPhenotypicFeature
.,3064,O
INTRODUCTION,3065,O
:,3065,O
IL-17F,3065,B-GeneOrGeneProduct
is,3065,O
a,3065,O
novel,3065,O
inflammatory,3065,B-GeneOrGeneProduct
cytokine,3065,I-GeneOrGeneProduct
and,3065,O
plays,3065,O
an,3065,O
important,3065,O
role,3065,O
in,3065,O
some,3065,O
autoimmune,3065,B-DiseaseOrPhenotypicFeature
diseases,3065,I-DiseaseOrPhenotypicFeature
.,3065,O
We,3066,O
investigated,3066,O
the,3066,O
association,3066,O
between,3066,O
chronic,3066,B-DiseaseOrPhenotypicFeature
ITP,3066,I-DiseaseOrPhenotypicFeature
and,3066,O
the,3066,O
frequency,3066,O
of,3066,O
the,3066,O
single-nucleotide,3066,O
polymorphism,3066,O
rs763780,3066,B-SequenceVariant
(,3066,O
7488T/C,3066,B-SequenceVariant
),3066,O
",",3066,O
which,3066,O
causes,3066,O
a,3066,O
His-to-Arg,3066,B-SequenceVariant
substitution,3066,I-SequenceVariant
at,3066,I-SequenceVariant
amino,3066,I-SequenceVariant
acid,3066,I-SequenceVariant
161,3066,I-SequenceVariant
.,3066,O
PATIENTS,3067,B-OrganismTaxon
AND,3067,O
METHODS,3067,O
:,3067,O
We,3067,O
examined,3067,O
102,3067,O
patients,3067,B-OrganismTaxon
(,3067,O
men/women,3067,B-OrganismTaxon
",",3067,O
40/62,3067,O
;,3067,O
median,3067,O
age,3067,O
",",3067,O
42,3067,O
),3067,O
diagnosed,3067,O
with,3067,O
chronic,3067,B-DiseaseOrPhenotypicFeature
ITP,3067,I-DiseaseOrPhenotypicFeature
and,3067,O
188,3067,O
healthy,3067,O
controls,3067,O
(,3067,O
men/women,3067,B-OrganismTaxon
",",3067,O
78/110,3067,O
;,3067,O
median,3067,O
age,3067,O
",",3067,O
38,3067,O
),3067,O
.,3067,O
Genotyping,3068,O
was,3068,O
determined,3068,O
by,3068,O
the,3068,O
polymerase,3068,O
chain,3068,O
reaction-restriction,3068,O
fragment,3068,O
length,3068,O
polymorphism,3068,O
(,3068,O
PCR-RFLP,3068,O
),3068,O
technique,3068,O
.,3068,O
RESULTS,3069,O
:,3069,O
Compared,3069,O
with,3069,O
the,3069,O
control,3069,O
group,3069,O
",",3069,O
patients,3069,B-OrganismTaxon
with,3069,O
chronic,3069,B-DiseaseOrPhenotypicFeature
ITP,3069,I-DiseaseOrPhenotypicFeature
had,3069,O
a,3069,O
significantly,3069,O
lower,3069,O
frequency,3069,O
of,3069,O
the,3069,O
IL-17F,3069,B-GeneOrGeneProduct
7488CC,3069,B-SequenceVariant
genotype,3069,O
(,3069,O
0,3069,O
%,3069,O
vs.,3069,O
4.8,3069,O
%,3069,O
",",3069,O
P,3069,O
<,3069,O
0.05,3069,O
),3069,O
.,3069,O
The,3070,O
number,3070,O
of,3070,O
IL-17F,3070,B-GeneOrGeneProduct
7488C,3070,B-SequenceVariant
alleles,3070,O
among,3070,O
the,3070,O
patients,3070,B-OrganismTaxon
with,3070,O
chronic,3070,B-DiseaseOrPhenotypicFeature
ITP,3070,I-DiseaseOrPhenotypicFeature
was,3070,O
also,3070,O
significantly,3070,O
lower,3070,O
than,3070,O
in,3070,O
the,3070,O
control,3070,O
group,3070,O
(,3070,O
8.7,3070,O
%,3070,O
vs.,3070,O
15.2,3070,O
%,3070,O
OR=0.48,3070,O
",",3070,O
95,3070,O
%,3070,O
CI=0.27-0.84,3070,O
",",3070,O
P=0.016,3070,O
),3070,O
.,3070,O
Furthermore,3071,O
",",3071,O
patients,3071,B-OrganismTaxon
with,3071,O
the,3071,O
IL-17F,3071,B-GeneOrGeneProduct
7488TT,3071,B-SequenceVariant
genotype,3071,O
showed,3071,O
a,3071,O
severe,3071,O
thrombocytopenic,3071,B-DiseaseOrPhenotypicFeature
state,3071,O
(,3071,O
platelet,3071,O
count,3071,O
<,3071,O
10,3071,O
10,3071,O
(,3071,O
9,3071,O
),3071,O
/L,3071,O
),3071,O
at,3071,O
diagnosis,3071,O
than,3071,O
those,3071,O
with,3071,O
the,3071,O
IL-17F,3071,B-GeneOrGeneProduct
7488TC,3071,B-SequenceVariant
genotype,3071,O
(,3071,O
20.9,3071,O
%,3071,O
vs.,3071,O
0,3071,O
%,3071,O
",",3071,O
P=0.04,3071,O
),3071,O
.,3071,O
CONCLUSION,3072,O
:,3072,O
These,3072,O
findings,3072,O
suggest,3072,O
that,3072,O
the,3072,O
IL-17F,3072,B-GeneOrGeneProduct
7488,3072,B-SequenceVariant
T,3072,I-SequenceVariant
allele,3072,O
is,3072,O
significantly,3072,O
associated,3072,O
with,3072,O
the,3072,O
development,3072,O
of,3072,O
chronic,3072,B-DiseaseOrPhenotypicFeature
ITP,3072,I-DiseaseOrPhenotypicFeature
",",3072,O
suggesting,3072,O
a,3072,O
role,3072,O
for,3072,O
IL-17F,3072,B-GeneOrGeneProduct
in,3072,O
the,3072,O
pathogenesis,3072,O
of,3072,O
chronic,3072,B-DiseaseOrPhenotypicFeature
ITP,3072,I-DiseaseOrPhenotypicFeature
.,3072,O
Roles,3073,O
of,3073,O
G1359A,3073,B-SequenceVariant
polymorphism,3073,O
of,3073,O
the,3073,O
cannabinoid,3073,B-GeneOrGeneProduct
receptor,3073,I-GeneOrGeneProduct
gene,3073,O
(,3073,O
CNR1,3073,B-GeneOrGeneProduct
),3073,O
on,3073,O
weight,3073,B-DiseaseOrPhenotypicFeature
loss,3073,I-DiseaseOrPhenotypicFeature
and,3073,O
adipocytokines,3073,O
after,3073,O
a,3073,O
hypocaloric,3073,O
diet,3073,O
.,3073,O
BACKGROUND,3074,O
:,3074,O
A,3074,O
intragenic,3074,O
biallelic,3074,O
polymorphism,3074,O
(,3074,O
1359,3074,B-SequenceVariant
G/A,3074,I-SequenceVariant
),3074,O
of,3074,O
the,3074,O
CB1,3074,B-GeneOrGeneProduct
gene,3074,O
resulting,3074,O
in,3074,O
the,3074,O
substitution,3074,O
of,3074,O
the,3074,O
G,3074,B-SequenceVariant
to,3074,I-SequenceVariant
A,3074,I-SequenceVariant
at,3074,I-SequenceVariant
nucleotide,3074,I-SequenceVariant
position,3074,I-SequenceVariant
1359,3074,I-SequenceVariant
in,3074,O
codon,3074,B-SequenceVariant
435,3074,I-SequenceVariant
(,3074,I-SequenceVariant
Thr,3074,I-SequenceVariant
),3074,I-SequenceVariant
",",3074,O
was,3074,O
reported,3074,O
as,3074,O
a,3074,O
common,3074,O
polymorphism,3074,O
in,3074,O
Caucasian,3074,O
populations,3074,O
.,3074,O
Intervention,3075,O
studies,3075,O
with,3075,O
this,3075,O
polymorphism,3075,O
have,3075,O
not,3075,O
been,3075,O
realized,3075,O
.,3075,O
OBJECTIVE,3076,O
:,3076,O
We,3076,O
decided,3076,O
to,3076,O
investigate,3076,O
the,3076,O
role,3076,O
of,3076,O
the,3076,O
polymorphism,3076,O
(,3076,O
G1359A,3076,B-SequenceVariant
),3076,O
of,3076,O
CB1,3076,B-GeneOrGeneProduct
receptor,3076,I-GeneOrGeneProduct
gene,3076,O
on,3076,O
adipocytokines,3076,O
response,3076,O
and,3076,O
weight,3076,B-DiseaseOrPhenotypicFeature
loss,3076,I-DiseaseOrPhenotypicFeature
secondary,3076,O
to,3076,O
a,3076,O
lifestyle,3076,O
modification,3076,O
(,3076,O
Mediterranean,3076,O
hypocaloric,3076,O
diet,3076,O
and,3076,O
exercise,3076,O
),3076,O
in,3076,O
obese,3076,B-DiseaseOrPhenotypicFeature
patients,3076,B-OrganismTaxon
.,3076,O
DESIGN,3077,O
:,3077,O
A,3077,O
population,3077,O
of,3077,O
94,3077,O
patients,3077,B-OrganismTaxon
with,3077,O
obesity,3077,B-DiseaseOrPhenotypicFeature
was,3077,O
analyzed,3077,O
.,3077,O
Before,3078,O
and,3078,O
after,3078,O
3,3078,O
months,3078,O
on,3078,O
a,3078,O
hypocaloric,3078,O
diet,3078,O
",",3078,O
an,3078,O
anthropometric,3078,O
evaluation,3078,O
",",3078,O
an,3078,O
assessment,3078,O
of,3078,O
nutritional,3078,O
intake,3078,O
and,3078,O
a,3078,O
biochemical,3078,O
analysis,3078,O
were,3078,O
performed,3078,O
.,3078,O
The,3079,O
statistical,3079,O
analysis,3079,O
was,3079,O
performed,3079,O
for,3079,O
the,3079,O
combined,3079,O
G1359A,3079,B-SequenceVariant
and,3079,O
A1359A,3079,B-SequenceVariant
as,3079,O
a,3079,O
group,3079,O
and,3079,O
wild,3079,O
type,3079,O
G1359G,3079,B-SequenceVariant
as,3079,O
second,3079,O
group,3079,O
",",3079,O
with,3079,O
a,3079,O
dominant,3079,O
model,3079,O
.,3079,O
Results,3080,O
:,3080,O
Forty,3080,O
seven,3080,O
patients,3080,B-OrganismTaxon
(,3080,O
50,3080,O
%,3080,O
),3080,O
had,3080,O
the,3080,O
genotype,3080,O
G1359G,3080,B-SequenceVariant
(,3080,O
wild,3080,O
type,3080,O
group,3080,O
),3080,O
and,3080,O
47,3080,O
(,3080,O
50,3080,O
%,3080,O
),3080,O
patients,3080,B-OrganismTaxon
G1359A,3080,B-SequenceVariant
(,3080,O
41,3080,O
patients,3080,B-OrganismTaxon
",",3080,O
43.6,3080,O
%,3080,O
),3080,O
or,3080,O
A1359A,3080,B-SequenceVariant
(,3080,O
6,3080,O
patients,3080,B-OrganismTaxon
",",3080,O
6.4,3080,O
%,3080,O
),3080,O
(,3080,O
mutant,3080,O
type,3080,O
group,3080,O
),3080,O
had,3080,O
the,3080,O
genotype,3080,O
.,3080,O
In,3081,O
wild,3081,O
and,3081,O
mutant,3081,O
type,3081,O
groups,3081,O
",",3081,O
weight,3081,O
",",3081,O
body,3081,O
mass,3081,O
index,3081,O
",",3081,O
fat,3081,O
mass,3081,O
",",3081,O
waist,3081,O
circumference,3081,O
and,3081,O
systolic,3081,O
blood,3081,O
pressure,3081,O
decreased,3081,O
.,3081,O
In,3082,O
mutant,3082,O
type,3082,O
group,3082,O
",",3082,O
resistin,3082,B-GeneOrGeneProduct
(,3082,O
4.15,3082,O
1.7,3082,O
ng/ml,3082,O
vs.,3082,O
3.90,3082,O
2.1,3082,O
ng/ml,3082,O
:,3082,O
P,3082,O
<,3082,O
0.05,3082,O
),3082,O
",",3082,O
leptin,3082,B-GeneOrGeneProduct
(,3082,O
78.4,3082,O
69,3082,O
ng/ml,3082,O
vs,3082,O
66.2,3082,O
32,3082,O
ng/ml,3082,O
:,3082,O
P,3082,O
<,3082,O
0.05,3082,O
),3082,O
and,3082,O
IL-6,3082,B-GeneOrGeneProduct
(,3082,O
1.40,3082,O
1.9,3082,O
pg/ml,3082,O
vs,3082,O
0.81,3082,O
1.5,3082,O
pg/ml,3082,O
:,3082,O
P,3082,O
<,3082,O
0.05,3082,O
),3082,O
levels,3082,O
decreased,3082,O
after,3082,O
dietary,3082,O
treatment,3082,O
.,3082,O
CONCLUSION,3083,O
:,3083,O
The,3083,O
novel,3083,O
finding,3083,O
of,3083,O
this,3083,O
study,3083,O
is,3083,O
the,3083,O
association,3083,O
of,3083,O
the,3083,O
mutant,3083,O
allele,3083,O
(,3083,O
A1359,3083,B-SequenceVariant
),3083,O
with,3083,O
a,3083,O
decrease,3083,O
of,3083,O
resistin,3083,B-GeneOrGeneProduct
",",3083,O
leptin,3083,B-GeneOrGeneProduct
and,3083,O
interleukin-6,3083,B-GeneOrGeneProduct
secondary,3083,O
to,3083,O
weight,3083,B-DiseaseOrPhenotypicFeature
loss,3083,I-DiseaseOrPhenotypicFeature
.,3083,O
XRCC1,3084,B-GeneOrGeneProduct
Arg399Gln,3084,B-SequenceVariant
gene,3084,O
polymorphism,3084,O
and,3084,O
the,3084,O
risk,3084,O
of,3084,O
systemic,3084,B-DiseaseOrPhenotypicFeature
lupus,3084,I-DiseaseOrPhenotypicFeature
erythematosus,3084,I-DiseaseOrPhenotypicFeature
in,3084,O
the,3084,O
Polish,3084,O
population,3084,O
.,3084,O
It,3085,O
has,3085,O
been,3085,O
shown,3085,O
that,3085,O
DNA,3085,O
repair,3085,O
is,3085,O
reduced,3085,O
in,3085,O
patients,3085,B-OrganismTaxon
with,3085,O
systemic,3085,B-DiseaseOrPhenotypicFeature
lupus,3085,I-DiseaseOrPhenotypicFeature
erythematosus,3085,I-DiseaseOrPhenotypicFeature
(,3085,O
SLE,3085,B-DiseaseOrPhenotypicFeature
),3085,O
and,3085,O
that,3085,O
the,3085,O
X-ray,3085,B-GeneOrGeneProduct
repair,3085,I-GeneOrGeneProduct
cross-complementing,3085,I-GeneOrGeneProduct
(,3085,O
XRCC1,3085,B-GeneOrGeneProduct
),3085,O
Arg399Gln,3085,B-SequenceVariant
(,3085,O
rs25487,3085,B-SequenceVariant
),3085,O
polymorphism,3085,O
may,3085,O
contribute,3085,O
to,3085,O
DNA,3085,O
repair,3085,O
.,3085,O
We,3086,O
evaluated,3086,O
the,3086,O
frequency,3086,O
of,3086,O
the,3086,O
XRCC1,3086,B-GeneOrGeneProduct
Arg399Gln,3086,B-SequenceVariant
substitution,3086,O
in,3086,O
patients,3086,B-OrganismTaxon
with,3086,O
SLE,3086,B-DiseaseOrPhenotypicFeature
(,3086,O
n=265,3086,O
),3086,O
and,3086,O
controls,3086,O
(,3086,O
n=360,3086,O
),3086,O
in,3086,O
a,3086,O
sample,3086,O
of,3086,O
the,3086,O
Polish,3086,O
population,3086,O
.,3086,O
The,3087,O
odds,3087,O
ratio,3087,O
(,3087,O
OR,3087,O
),3087,O
for,3087,O
SLE,3087,B-DiseaseOrPhenotypicFeature
patients,3087,B-OrganismTaxon
with,3087,O
the,3087,O
Gln/Gln,3087,O
versus,3087,O
Gln/Arg,3087,O
or,3087,O
Arg/Arg,3087,O
genotypes,3087,O
was,3087,O
1.553,3087,O
(,3087,O
95,3087,O
%,3087,O
confidence,3087,O
interval,3087,O
[,3087,O
CI,3087,O
],3087,O
=0.9573-2.520,3087,O
;,3087,O
p=0.0729,3087,O
),3087,O
.,3087,O
OR,3088,O
for,3088,O
the,3088,O
Gln/Gln,3088,O
or,3088,O
Gln/Arg,3088,O
versus,3088,O
Arg/Arg,3088,O
genotype,3088,O
was,3088,O
1.551,3088,O
(,3088,O
95,3088,O
%,3088,O
CI=1.122-2.144,3088,O
",",3088,O
p=0.0077,3088,O
),3088,O
.,3088,O
The,3089,O
OR,3089,O
for,3089,O
the,3089,O
399,3089,B-SequenceVariant
Gln,3089,I-SequenceVariant
allele,3089,O
in,3089,O
patients,3089,B-OrganismTaxon
with,3089,O
SLE,3089,B-DiseaseOrPhenotypicFeature
was,3089,O
1.406,3089,O
(,3089,O
95,3089,O
%,3089,O
CI=1.111-1.779,3089,O
",",3089,O
p=0.0045,3089,O
),3089,O
.,3089,O
There,3090,O
was,3090,O
also,3090,O
a,3090,O
statistically,3090,O
significant,3090,O
p-value,3090,O
of,3090,O
the,3090,O
(,3090,O
2,3090,O
),3090,O
test,3090,O
for,3090,O
the,3090,O
trend,3090,O
observed,3090,O
in,3090,O
the,3090,O
XRCC1,3090,B-GeneOrGeneProduct
Arg399Gln,3090,B-SequenceVariant
polymorphism,3090,O
(,3090,O
ptrend=0.0048,3090,O
),3090,O
.,3090,O
We,3091,O
also,3091,O
found,3091,O
a,3091,O
significant,3091,O
contribution,3091,O
of,3091,O
the,3091,O
Gln/Gln,3091,O
or,3091,O
Arg/Gln,3091,O
versus,3091,O
Arg/Arg,3091,O
genotype,3091,O
to,3091,O
the,3091,O
presence,3091,O
of,3091,O
either,3091,O
the,3091,O
malar,3091,B-DiseaseOrPhenotypicFeature
rash,3091,I-DiseaseOrPhenotypicFeature
or,3091,O
photosensitivity,3091,O
manifestations,3091,O
of,3091,O
SLE,3091,B-DiseaseOrPhenotypicFeature
OR=2.241,3091,O
(,3091,O
1.328-3.781,3091,O
",",3091,O
p=0.0023,3091,O
",",3091,O
pcorr=0.0414,3091,O
),3091,O
.,3091,O
Moreover,3092,O
",",3092,O
the,3092,O
meta-analysis,3092,O
of,3092,O
Taiwanese,3092,O
Han,3092,O
Chinese,3092,O
",",3092,O
Brazilian,3092,O
",",3092,O
and,3092,O
Polish,3092,O
populations,3092,O
showed,3092,O
that,3092,O
the,3092,O
Gln/Gln,3092,O
or,3092,O
Gln/Arg,3092,O
genotype,3092,O
and,3092,O
Gln,3092,O
allele,3092,O
were,3092,O
associated,3092,O
with,3092,O
SLE,3092,B-DiseaseOrPhenotypicFeature
incidence,3092,O
.,3092,O
OR,3093,O
for,3093,O
the,3093,O
Gln/Gln,3093,O
or,3093,O
Gln/Arg,3093,O
versus,3093,O
Arg/Arg,3093,O
genotype,3093,O
was,3093,O
1.440,3093,O
(,3093,O
95,3093,O
%,3093,O
CI=1.15-1.80,3093,O
",",3093,O
p=0.0019,3093,O
),3093,O
and,3093,O
OR,3093,O
for,3093,O
the,3093,O
Gln,3093,O
allele,3093,O
was,3093,O
1.27,3093,O
(,3093,O
95,3093,O
%,3093,O
CI=1.08-1.51,3093,O
",",3093,O
p=0.0051,3093,O
),3093,O
.,3093,O
Our,3094,O
studies,3094,O
may,3094,O
confirm,3094,O
that,3094,O
the,3094,O
XRCC1,3094,B-GeneOrGeneProduct
Arg399Gln,3094,B-SequenceVariant
polymorphism,3094,O
may,3094,O
increase,3094,O
the,3094,O
risk,3094,O
of,3094,O
incidence,3094,O
of,3094,O
SLE,3094,B-DiseaseOrPhenotypicFeature
and,3094,O
the,3094,O
occurrence,3094,O
of,3094,O
some,3094,O
SLE,3094,B-DiseaseOrPhenotypicFeature
manifestations,3094,O
.,3094,O
MHC,3095,B-GeneOrGeneProduct
region,3095,O
and,3095,O
risk,3095,O
of,3095,O
systemic,3095,B-DiseaseOrPhenotypicFeature
lupus,3095,I-DiseaseOrPhenotypicFeature
erythematosus,3095,I-DiseaseOrPhenotypicFeature
in,3095,O
African,3095,O
American,3095,O
women,3095,B-OrganismTaxon
.,3095,O
The,3096,O
major,3096,B-GeneOrGeneProduct
histocompatibility,3096,I-GeneOrGeneProduct
complex,3096,I-GeneOrGeneProduct
(,3096,O
MHC,3096,B-GeneOrGeneProduct
),3096,O
on,3096,O
chromosome,3096,O
6p21,3096,O
is,3096,O
a,3096,O
key,3096,O
contributor,3096,O
to,3096,O
the,3096,O
genetic,3096,O
basis,3096,O
of,3096,O
systemic,3096,B-DiseaseOrPhenotypicFeature
lupus,3096,I-DiseaseOrPhenotypicFeature
erythematosus,3096,I-DiseaseOrPhenotypicFeature
(,3096,O
SLE,3096,B-DiseaseOrPhenotypicFeature
),3096,O
.,3096,O
Although,3097,O
SLE,3097,B-DiseaseOrPhenotypicFeature
affects,3097,O
African,3097,O
Americans,3097,O
disproportionately,3097,O
compared,3097,O
to,3097,O
European,3097,O
Americans,3097,O
",",3097,O
there,3097,O
has,3097,O
been,3097,O
no,3097,O
comprehensive,3097,O
analysis,3097,O
of,3097,O
the,3097,O
MHC,3097,B-GeneOrGeneProduct
region,3097,O
in,3097,O
relationship,3097,O
to,3097,O
SLE,3097,B-DiseaseOrPhenotypicFeature
in,3097,O
African,3097,O
Americans,3097,O
.,3097,O
We,3098,O
conducted,3098,O
a,3098,O
screening,3098,O
of,3098,O
the,3098,O
MHC,3098,B-GeneOrGeneProduct
region,3098,O
for,3098,O
"1,536",3098,O
single,3098,O
nucleotide,3098,O
polymorphisms,3098,O
(,3098,O
SNPs,3098,O
),3098,O
and,3098,O
the,3098,O
deletion,3098,O
of,3098,O
the,3098,O
C4A,3098,B-GeneOrGeneProduct
gene,3098,O
in,3098,O
a,3098,O
SLE,3098,B-DiseaseOrPhenotypicFeature
case-control,3098,O
study,3098,O
(,3098,O
380,3098,O
cases,3098,O
",",3098,O
765,3098,O
age-matched,3098,O
controls,3098,O
),3098,O
nested,3098,O
within,3098,O
the,3098,O
prospective,3098,O
Black,3098,O
Women,3098,B-OrganismTaxon
's,3098,O
Health,3098,O
Study,3098,O
.,3098,O
We,3099,O
also,3099,O
genotyped,3099,O
"1,509",3099,O
ancestral,3099,O
informative,3099,O
markers,3099,O
throughout,3099,O
the,3099,O
genome,3099,O
to,3099,O
estimate,3099,O
European,3099,O
ancestry,3099,O
to,3099,O
control,3099,O
for,3099,O
population,3099,O
stratification,3099,O
due,3099,O
to,3099,O
population,3099,O
admixture,3099,O
.,3099,O
The,3100,O
most,3100,O
strongly,3100,O
associated,3100,O
SNP,3100,O
with,3100,O
SLE,3100,B-DiseaseOrPhenotypicFeature
was,3100,O
the,3100,O
rs9271366,3100,B-SequenceVariant
(,3100,O
odds,3100,O
ratio,3100,O
",",3100,O
OR,3100,O
=,3100,O
1.70,3100,O
",",3100,O
p,3100,O
=,3100,O
5.6,3100,O
10,3100,O
(,3100,O
-5,3100,O
),3100,O
),3100,O
near,3100,O
the,3100,O
HLA-DRB1,3100,B-GeneOrGeneProduct
gene,3100,O
.,3100,O
Conditional,3101,O
haplotype,3101,O
analysis,3101,O
revealed,3101,O
three,3101,O
other,3101,O
SNPs,3101,O
",",3101,O
rs204890,3101,B-SequenceVariant
(,3101,O
OR,3101,O
=,3101,O
1.86,3101,O
",",3101,O
p,3101,O
=,3101,O
1.2,3101,O
10,3101,O
(,3101,O
-4,3101,O
),3101,O
),3101,O
",",3101,O
rs2071349,3101,B-SequenceVariant
(,3101,O
OR,3101,O
=,3101,O
1.53,3101,O
",",3101,O
p,3101,O
=,3101,O
1.0,3101,O
10,3101,O
(,3101,O
-3,3101,O
),3101,O
),3101,O
",",3101,O
and,3101,O
rs2844580,3101,B-SequenceVariant
(,3101,O
OR,3101,O
=,3101,O
1.43,3101,O
",",3101,O
p,3101,O
=,3101,O
1.3,3101,O
10,3101,O
(,3101,O
-3,3101,O
),3101,O
),3101,O
",",3101,O
to,3101,O
be,3101,O
associated,3101,O
with,3101,O
SLE,3101,B-DiseaseOrPhenotypicFeature
independent,3101,O
of,3101,O
the,3101,O
rs9271366,3101,B-SequenceVariant
SNP,3101,O
.,3101,O
In,3102,O
univariate,3102,O
analysis,3102,O
",",3102,O
the,3102,O
OR,3102,O
for,3102,O
the,3102,O
C4A,3102,B-GeneOrGeneProduct
deletion,3102,O
was,3102,O
1.38,3102,O
",",3102,O
p,3102,O
=,3102,O
0.075,3102,O
",",3102,O
but,3102,O
after,3102,O
simultaneous,3102,O
adjustment,3102,O
for,3102,O
the,3102,O
other,3102,O
four,3102,O
SNPs,3102,O
the,3102,O
odds,3102,O
ratio,3102,O
was,3102,O
1.01,3102,O
",",3102,O
p,3102,O
=,3102,O
0.98,3102,O
.,3102,O
A,3103,O
genotype,3103,O
score,3103,O
combining,3103,O
the,3103,O
four,3103,O
newly,3103,O
identified,3103,O
SNPs,3103,O
showed,3103,O
an,3103,O
additive,3103,O
risk,3103,O
according,3103,O
to,3103,O
the,3103,O
number,3103,O
of,3103,O
high-risk,3103,O
alleles,3103,O
(,3103,O
OR,3103,O
=,3103,O
1.67,3103,O
per,3103,O
high-risk,3103,O
allele,3103,O
",",3103,O
p,3103,O
<,3103,O
0.0001,3103,O
),3103,O
.,3103,O
Our,3104,O
strongest,3104,O
signal,3104,O
",",3104,O
the,3104,O
rs9271366,3104,B-SequenceVariant
SNP,3104,O
",",3104,O
was,3104,O
also,3104,O
associated,3104,O
with,3104,O
higher,3104,O
risk,3104,O
of,3104,O
SLE,3104,B-DiseaseOrPhenotypicFeature
in,3104,O
a,3104,O
previous,3104,O
Chinese,3104,O
genome-wide,3104,O
association,3104,O
study,3104,O
(,3104,O
GWAS,3104,O
),3104,O
.,3104,O
In,3105,O
addition,3105,O
",",3105,O
two,3105,O
SNPs,3105,O
found,3105,O
in,3105,O
a,3105,O
GWAS,3105,O
of,3105,O
European,3105,O
ancestry,3105,O
women,3105,B-OrganismTaxon
were,3105,O
confirmed,3105,O
in,3105,O
our,3105,O
study,3105,O
",",3105,O
indicating,3105,O
that,3105,O
African,3105,O
Americans,3105,O
share,3105,O
some,3105,O
genetic,3105,O
risk,3105,O
factors,3105,O
for,3105,O
SLE,3105,B-DiseaseOrPhenotypicFeature
with,3105,O
European,3105,O
and,3105,O
Chinese,3105,O
subjects,3105,O
.,3105,O
In,3106,O
summary,3106,O
",",3106,O
we,3106,O
found,3106,O
four,3106,O
independent,3106,O
signals,3106,O
in,3106,O
the,3106,O
MHC,3106,B-GeneOrGeneProduct
region,3106,O
associated,3106,O
with,3106,O
risk,3106,O
of,3106,O
SLE,3106,B-DiseaseOrPhenotypicFeature
in,3106,O
African,3106,O
American,3106,O
women,3106,B-OrganismTaxon
.,3106,O
PTCH1,3107,B-GeneOrGeneProduct
gene,3107,O
mutations,3107,O
in,3107,O
exon,3107,O
17,3107,O
and,3107,O
loss,3107,O
of,3107,O
heterozygosity,3107,O
on,3107,O
D9S180,3107,O
microsatellite,3107,O
in,3107,O
sporadic,3107,O
and,3107,O
inherited,3107,O
human,3107,B-OrganismTaxon
basal,3107,B-DiseaseOrPhenotypicFeature
cell,3107,I-DiseaseOrPhenotypicFeature
carcinomas,3107,I-DiseaseOrPhenotypicFeature
.,3107,O
BACKGROUND,3108,O
:,3108,O
Basal,3108,B-DiseaseOrPhenotypicFeature
cell,3108,I-DiseaseOrPhenotypicFeature
carcinomas,3108,I-DiseaseOrPhenotypicFeature
(,3108,O
BCCs,3108,B-DiseaseOrPhenotypicFeature
),3108,O
are,3108,O
the,3108,O
most,3108,O
frequent,3108,O
human,3108,B-OrganismTaxon
cancer,3108,B-DiseaseOrPhenotypicFeature
that,3108,O
results,3108,O
from,3108,O
malignant,3108,O
transformation,3108,O
of,3108,O
basal,3108,O
cells,3108,O
in,3108,O
the,3108,O
epidermis,3108,O
.,3108,O
Gorlin,3109,B-DiseaseOrPhenotypicFeature
syndrome,3109,I-DiseaseOrPhenotypicFeature
is,3109,O
a,3109,O
rare,3109,O
inherited,3109,B-DiseaseOrPhenotypicFeature
autosomal,3109,I-DiseaseOrPhenotypicFeature
dominant,3109,I-DiseaseOrPhenotypicFeature
disease,3109,I-DiseaseOrPhenotypicFeature
that,3109,O
predisposes,3109,O
with,3109,O
multiple,3109,O
BCCs,3109,B-DiseaseOrPhenotypicFeature
and,3109,O
other,3109,O
birth,3109,B-DiseaseOrPhenotypicFeature
defects,3109,I-DiseaseOrPhenotypicFeature
.,3109,O
Both,3110,O
sporadic,3110,O
and,3110,O
inherited,3110,O
BCCs,3110,B-DiseaseOrPhenotypicFeature
are,3110,O
associated,3110,O
with,3110,O
mutations,3110,O
in,3110,O
the,3110,O
tumor,3110,B-DiseaseOrPhenotypicFeature
suppressor,3110,O
gene,3110,O
PTCH1,3110,B-GeneOrGeneProduct
",",3110,O
but,3110,O
there,3110,O
is,3110,O
still,3110,O
uncertainty,3110,O
on,3110,O
the,3110,O
role,3110,O
of,3110,O
its,3110,O
homolog,3110,O
PTCH2,3110,B-GeneOrGeneProduct
.,3110,O
OBJECTIVES,3111,O
:,3111,O
To,3111,O
search,3111,O
for,3111,O
mutations,3111,O
and,3111,O
genomic,3111,O
instability,3111,O
in,3111,O
sporadic,3111,O
and,3111,O
inherited,3111,O
BCCs,3111,B-DiseaseOrPhenotypicFeature
.,3111,O
METHODS,3112,O
:,3112,O
DNA,3112,O
obtained,3112,O
from,3112,O
leukocytes,3112,O
and,3112,O
tumor,3112,B-DiseaseOrPhenotypicFeature
cells,3112,O
was,3112,O
amplified,3112,O
by,3112,O
polymerase,3112,O
chain,3112,O
reaction,3112,O
regarding,3112,O
five,3112,O
exons,3112,O
of,3112,O
PTCH1,3112,B-GeneOrGeneProduct
and,3112,O
PTCH2,3112,B-GeneOrGeneProduct
and,3112,O
neighboring,3112,O
microsatellites,3112,O
.,3112,O
Exons,3113,O
were,3113,O
sequenced,3113,O
and,3113,O
compared,3113,O
with,3113,O
the,3113,O
GenBank,3113,O
database,3113,O
.,3113,O
RESULTS,3114,O
:,3114,O
Only,3114,O
D9S180,3114,O
",",3114,O
of,3114,O
six,3114,O
microsatellites,3114,O
",",3114,O
showed,3114,O
loss,3114,O
of,3114,O
heterozygosity,3114,O
in,3114,O
three,3114,O
BCCs,3114,B-DiseaseOrPhenotypicFeature
(,3114,O
two,3114,O
sporadic,3114,O
and,3114,O
one,3114,O
inherited,3114,O
),3114,O
.,3114,O
One,3115,O
sporadic,3115,O
BCC,3115,B-DiseaseOrPhenotypicFeature
presented,3115,O
the,3115,O
mutation,3115,O
g.2885G,3115,B-SequenceVariant
>,3115,I-SequenceVariant
C,3115,I-SequenceVariant
in,3115,O
exon,3115,O
17,3115,O
of,3115,O
PTCH1,3115,B-GeneOrGeneProduct
",",3115,O
which,3115,O
predicts,3115,O
the,3115,O
substitution,3115,O
p.R962T,3115,B-SequenceVariant
in,3115,O
an,3115,O
external,3115,O
domain,3115,O
of,3115,O
the,3115,O
protein,3115,O
.,3115,O
In,3116,O
addition,3116,O
",",3116,O
the,3116,O
leukocytes,3116,O
and,3116,O
tumor,3116,B-DiseaseOrPhenotypicFeature
cells,3116,O
of,3116,O
one,3116,O
patient,3116,B-OrganismTaxon
with,3116,O
Gorlin,3116,B-DiseaseOrPhenotypicFeature
syndrome,3116,I-DiseaseOrPhenotypicFeature
showed,3116,O
the,3116,O
mutation,3116,O
g.2839T,3116,B-SequenceVariant
>,3116,I-SequenceVariant
G,3116,I-SequenceVariant
in,3116,O
the,3116,O
same,3116,O
exon,3116,O
and,3116,O
gene,3116,O
",",3116,O
which,3116,O
predicts,3116,O
a,3116,O
p.E947stop,3116,B-SequenceVariant
and,3116,O
truncated,3116,O
protein,3116,O
.,3116,O
All,3117,O
control,3117,O
and,3117,O
tumor,3117,B-DiseaseOrPhenotypicFeature
samples,3117,O
presented,3117,O
IVS9,3117,B-SequenceVariant
+,3117,I-SequenceVariant
217T,3117,I-SequenceVariant
in,3117,O
intron,3117,O
9,3117,O
of,3117,O
PTCH1,3117,B-GeneOrGeneProduct
.,3117,O
CONCLUSION,3118,O
:,3118,O
Mutations,3118,O
found,3118,O
in,3118,O
the,3118,O
PTCH1,3118,B-GeneOrGeneProduct
gene,3118,O
and,3118,O
neighboring,3118,O
repetitive,3118,O
sequences,3118,O
may,3118,O
have,3118,O
contributed,3118,O
to,3118,O
the,3118,O
development,3118,O
of,3118,O
the,3118,O
studied,3118,O
BCCs,3118,B-DiseaseOrPhenotypicFeature
.,3118,O
Resequencing,3119,O
of,3119,O
IRS2,3119,B-GeneOrGeneProduct
reveals,3119,O
rare,3119,O
variants,3119,O
for,3119,O
obesity,3119,B-DiseaseOrPhenotypicFeature
but,3119,O
not,3119,O
fasting,3119,O
glucose,3119,B-ChemicalEntity
homeostasis,3119,O
in,3119,O
Hispanic,3119,O
children,3119,O
.,3119,O
Our,3120,O
objective,3120,O
was,3120,O
to,3120,O
resequence,3120,O
insulin,3120,B-GeneOrGeneProduct
receptor,3120,I-GeneOrGeneProduct
substrate,3120,I-GeneOrGeneProduct
2,3120,I-GeneOrGeneProduct
(,3120,O
IRS2,3120,B-GeneOrGeneProduct
),3120,O
to,3120,O
identify,3120,O
variants,3120,O
associated,3120,O
with,3120,O
obesity-,3120,B-DiseaseOrPhenotypicFeature
and,3120,O
diabetes-related,3120,B-DiseaseOrPhenotypicFeature
traits,3120,O
in,3120,O
Hispanic,3120,O
children,3120,O
.,3120,O
Exonic,3121,O
and,3121,O
intronic,3121,O
segments,3121,O
",",3121,O
5,3121,O
',3121,O
and,3121,O
3,3121,O
',3121,O
flanking,3121,O
regions,3121,O
of,3121,O
IRS2,3121,B-GeneOrGeneProduct
(,3121,O
14.5,3121,O
kb,3121,O
),3121,O
",",3121,O
were,3121,O
bidirectionally,3121,O
sequenced,3121,O
for,3121,O
single,3121,O
nucleotide,3121,O
polymorphism,3121,O
(,3121,O
SNP,3121,O
),3121,O
discovery,3121,O
in,3121,O
934,3121,O
Hispanic,3121,O
children,3121,O
using,3121,O
3730XL,3121,O
DNA,3121,O
Sequencers,3121,O
.,3121,O
Additionally,3122,O
",",3122,O
15,3122,O
SNPs,3122,O
derived,3122,O
from,3122,O
Illumina,3122,O
HumanOmni1-Quad,3122,O
BeadChips,3122,O
were,3122,O
analyzed,3122,O
.,3122,O
Measured,3123,O
genotype,3123,O
analysis,3123,O
tested,3123,O
associations,3123,O
between,3123,O
SNPs,3123,O
and,3123,O
obesity,3123,B-DiseaseOrPhenotypicFeature
and,3123,O
diabetes-related,3123,B-DiseaseOrPhenotypicFeature
traits,3123,O
.,3123,O
Bayesian,3124,O
quantitative,3124,O
trait,3124,O
nucleotide,3124,O
analysis,3124,O
was,3124,O
used,3124,O
to,3124,O
statistically,3124,O
infer,3124,O
the,3124,O
most,3124,O
likely,3124,O
functional,3124,O
polymorphisms,3124,O
.,3124,O
A,3125,O
total,3125,O
of,3125,O
140,3125,O
SNPs,3125,O
were,3125,O
identified,3125,O
with,3125,O
minor,3125,O
allele,3125,O
frequencies,3125,O
(,3125,O
MAF,3125,O
),3125,O
ranging,3125,O
from,3125,O
0.001,3125,O
to,3125,O
0.47,3125,O
.,3125,O
Forty-two,3126,O
of,3126,O
the,3126,O
70,3126,O
coding,3126,O
SNPs,3126,O
result,3126,O
in,3126,O
nonsynonymous,3126,O
amino,3126,O
acid,3126,O
substitutions,3126,O
relative,3126,O
to,3126,O
the,3126,O
consensus,3126,O
sequence,3126,O
;,3126,O
28,3126,O
SNPs,3126,O
were,3126,O
detected,3126,O
in,3126,O
the,3126,O
promoter,3126,O
",",3126,O
12,3126,O
in,3126,O
introns,3126,O
",",3126,O
28,3126,O
in,3126,O
the,3126,O
3'-UTR,3126,O
",",3126,O
and,3126,O
2,3126,O
in,3126,O
the,3126,O
5'-UTR,3126,O
.,3126,O
Two,3127,O
insertion/deletions,3127,O
(,3127,O
indels,3127,O
),3127,O
were,3127,O
detected,3127,O
.,3127,O
Ten,3128,O
independent,3128,O
rare,3128,O
SNPs,3128,O
(,3128,O
MAF,3128,O
=,3128,O
0.001-0.009,3128,O
),3128,O
were,3128,O
associated,3128,O
with,3128,O
obesity-related,3128,B-DiseaseOrPhenotypicFeature
traits,3128,O
(,3128,O
P,3128,O
=,3128,O
0.01-0.00002,3128,O
),3128,O
.,3128,O
SNP,3129,B-SequenceVariant
10510452_139,3129,I-SequenceVariant
in,3129,O
the,3129,O
promoter,3129,O
region,3129,O
was,3129,O
shown,3129,O
to,3129,O
have,3129,O
a,3129,O
high,3129,O
posterior,3129,O
probability,3129,O
(,3129,O
P,3129,O
=,3129,O
0.77-0.86,3129,O
),3129,O
of,3129,O
influencing,3129,O
BMI,3129,O
",",3129,O
fat,3129,O
mass,3129,O
",",3129,O
and,3129,O
waist,3129,O
circumference,3129,O
in,3129,O
Hispanic,3129,O
children,3129,O
.,3129,O
SNP,3130,B-SequenceVariant
10510452_139,3130,I-SequenceVariant
contributed,3130,O
between,3130,O
2,3130,O
and,3130,O
4,3130,O
%,3130,O
of,3130,O
the,3130,O
population,3130,O
variance,3130,O
in,3130,O
body,3130,O
weight,3130,O
and,3130,O
composition,3130,O
.,3130,O
None,3131,O
of,3131,O
the,3131,O
SNPs,3131,O
or,3131,O
indels,3131,O
were,3131,O
associated,3131,O
with,3131,O
diabetes-related,3131,B-DiseaseOrPhenotypicFeature
traits,3131,O
or,3131,O
accounted,3131,O
for,3131,O
a,3131,O
previously,3131,O
identified,3131,O
quantitative,3131,O
trait,3131,O
locus,3131,O
on,3131,O
chromosome,3131,O
13,3131,O
for,3131,O
fasting,3131,O
serum,3131,O
glucose,3131,B-ChemicalEntity
.,3131,O
Rare,3132,O
but,3132,O
not,3132,O
common,3132,O
IRS2,3132,B-GeneOrGeneProduct
variants,3132,O
may,3132,O
play,3132,O
a,3132,O
role,3132,O
in,3132,O
the,3132,O
regulation,3132,O
of,3132,O
body,3132,O
weight,3132,O
but,3132,O
not,3132,O
an,3132,O
essential,3132,O
role,3132,O
in,3132,O
fasting,3132,O
glucose,3132,B-ChemicalEntity
homeostasis,3132,O
in,3132,O
Hispanic,3132,O
children,3132,O
.,3132,O
HIV-1,3133,B-OrganismTaxon
Tat,3133,B-GeneOrGeneProduct
activates,3133,O
indoleamine,3133,B-GeneOrGeneProduct
"2,3",3133,I-GeneOrGeneProduct
dioxygenase,3133,I-GeneOrGeneProduct
in,3133,O
murine,3133,B-OrganismTaxon
organotypic,3133,O
hippocampal,3133,O
slice,3133,O
cultures,3133,O
in,3133,O
a,3133,O
p38,3133,B-GeneOrGeneProduct
mitogen-activated,3133,I-GeneOrGeneProduct
protein,3133,I-GeneOrGeneProduct
kinase-dependent,3133,O
manner,3133,O
.,3133,O
BACKGROUND,3134,O
:,3134,O
We,3134,O
have,3134,O
established,3134,O
that,3134,O
activation,3134,O
of,3134,O
the,3134,O
tryptophan,3134,B-ChemicalEntity
degrading,3134,O
enzyme,3134,O
indoleamine,3134,B-GeneOrGeneProduct
"2,3",3134,I-GeneOrGeneProduct
dioxygenase,3134,I-GeneOrGeneProduct
(,3134,O
IDO,3134,B-GeneOrGeneProduct
),3134,O
mediates,3134,O
the,3134,O
switch,3134,O
from,3134,O
cytokine-induced,3134,O
sickness,3134,O
behavior,3134,O
to,3134,O
depressive-like,3134,B-DiseaseOrPhenotypicFeature
behavior,3134,O
.,3134,O
Because,3135,O
human,3135,B-OrganismTaxon
immunodeficiency,3135,I-OrganismTaxon
virus,3135,I-OrganismTaxon
type,3135,I-OrganismTaxon
1,3135,I-OrganismTaxon
(,3135,O
HIV-1,3135,B-OrganismTaxon
),3135,O
Tat,3135,B-GeneOrGeneProduct
protein,3135,O
causes,3135,O
depressive-like,3135,B-DiseaseOrPhenotypicFeature
behavior,3135,O
in,3135,O
mice,3135,B-OrganismTaxon
",",3135,O
we,3135,O
investigated,3135,O
its,3135,O
ability,3135,O
to,3135,O
activate,3135,O
IDO,3135,B-GeneOrGeneProduct
in,3135,O
organotypic,3135,O
hippocampal,3135,O
slice,3135,O
cultures,3135,O
(,3135,O
OHSCs,3135,O
),3135,O
derived,3135,O
from,3135,O
neonatal,3135,O
C57BL/6,3135,B-CellLine
mice,3135,B-OrganismTaxon
.,3135,O
METHODS,3136,O
:,3136,O
Depressive-like,3136,B-DiseaseOrPhenotypicFeature
behavior,3136,O
in,3136,O
C57BL/6J,3136,B-CellLine
mice,3136,B-OrganismTaxon
was,3136,O
assessed,3136,O
by,3136,O
the,3136,O
forced,3136,O
swim,3136,O
test,3136,O
.,3136,O
Expression,3137,O
of,3137,O
cytokines,3137,O
and,3137,O
IDO,3137,B-GeneOrGeneProduct
mRNA,3137,O
in,3137,O
OHSCs,3137,O
was,3137,O
measured,3137,O
by,3137,O
real-time,3137,O
RT-PCR,3137,O
and,3137,O
cytokine,3137,O
protein,3137,O
was,3137,O
measured,3137,O
by,3137,O
enzyme-linked,3137,O
immunosorbent,3137,O
assays,3137,O
(,3137,O
ELISAs,3137,O
),3137,O
.,3137,O
p38,3138,B-GeneOrGeneProduct
MAPK,3138,I-GeneOrGeneProduct
phosphorylation,3138,O
was,3138,O
analyzed,3138,O
by,3138,O
western,3138,O
blot,3138,O
.,3138,O
RESULTS,3139,O
:,3139,O
Intracerebroventricular,3139,O
(,3139,O
i.c.v,3139,O
.,3139,O
),3139,O
administration,3140,O
of,3140,O
Tat,3140,B-GeneOrGeneProduct
(,3140,O
40,3140,O
ng,3140,O
),3140,O
induced,3140,O
depressive-like,3140,B-DiseaseOrPhenotypicFeature
behavior,3140,O
in,3140,O
the,3140,O
absence,3140,O
of,3140,O
sickness,3140,O
.,3140,O
Addition,3141,O
of,3141,O
Tat,3141,B-GeneOrGeneProduct
(,3141,O
40,3141,O
ng/slice,3141,O
),3141,O
to,3141,O
the,3141,O
medium,3141,O
of,3141,O
OHSCs,3141,O
induced,3141,O
IDO,3141,B-GeneOrGeneProduct
steady-state,3141,O
mRNA,3141,O
that,3141,O
peaked,3141,O
at,3141,O
6,3141,O
h.,3141,O
This,3141,O
effect,3141,O
was,3141,O
potentiated,3141,O
by,3141,O
pretreatment,3141,O
with,3141,O
IFNg,3141,B-GeneOrGeneProduct
.,3141,O
Tat,3142,B-GeneOrGeneProduct
also,3142,O
induced,3142,O
the,3142,O
synthesis,3142,O
and,3142,O
release,3142,O
of,3142,O
TNFa,3142,B-GeneOrGeneProduct
and,3142,O
IL-6,3142,B-GeneOrGeneProduct
protein,3142,O
in,3142,O
the,3142,O
supernatant,3142,O
of,3142,O
the,3142,O
slices,3142,O
and,3142,O
increased,3142,O
expression,3142,O
of,3142,O
the,3142,O
inducible,3142,B-GeneOrGeneProduct
isoform,3142,I-GeneOrGeneProduct
of,3142,I-GeneOrGeneProduct
nitric,3142,I-GeneOrGeneProduct
oxide,3142,I-GeneOrGeneProduct
synthase,3142,I-GeneOrGeneProduct
(,3142,O
iNOS,3142,B-GeneOrGeneProduct
),3142,O
and,3142,O
the,3142,O
serotonin,3142,B-GeneOrGeneProduct
transporter,3142,I-GeneOrGeneProduct
(,3142,O
SERT,3142,B-GeneOrGeneProduct
),3142,O
.,3142,O
Tat,3143,B-GeneOrGeneProduct
had,3143,O
no,3143,O
effect,3143,O
on,3143,O
endogenous,3143,O
synthesis,3143,O
of,3143,O
IFNg,3143,B-GeneOrGeneProduct
.,3143,O
To,3144,O
explore,3144,O
the,3144,O
mechanisms,3144,O
of,3144,O
Tat-induced,3144,B-GeneOrGeneProduct
IDO,3144,B-GeneOrGeneProduct
expression,3144,O
",",3144,O
slices,3144,O
were,3144,O
pretreated,3144,O
with,3144,O
the,3144,O
p38,3144,B-GeneOrGeneProduct
mitogen-activated,3144,I-GeneOrGeneProduct
protein,3144,I-GeneOrGeneProduct
kinase,3144,I-GeneOrGeneProduct
(,3144,O
MAPK,3144,B-GeneOrGeneProduct
),3144,O
inhibitor,3144,O
SB,3144,B-ChemicalEntity
202190,3144,I-ChemicalEntity
for,3144,O
30,3144,O
min,3144,O
before,3144,O
Tat,3144,B-GeneOrGeneProduct
treatment,3144,O
.,3144,O
SB,3145,B-ChemicalEntity
202190,3145,I-ChemicalEntity
significantly,3145,O
decreased,3145,O
IDO,3145,B-GeneOrGeneProduct
expression,3145,O
induced,3145,O
by,3145,O
Tat,3145,B-GeneOrGeneProduct
",",3145,O
and,3145,O
this,3145,O
effect,3145,O
was,3145,O
accompanied,3145,O
by,3145,O
a,3145,O
reduction,3145,O
of,3145,O
Tat-induced,3145,B-GeneOrGeneProduct
expression,3145,O
of,3145,O
TNFa,3145,B-GeneOrGeneProduct
",",3145,O
IL-6,3145,B-GeneOrGeneProduct
",",3145,O
iNOS,3145,B-GeneOrGeneProduct
and,3145,O
SERT,3145,B-GeneOrGeneProduct
.,3145,O
CONCLUSION,3146,O
:,3146,O
These,3146,O
data,3146,O
establish,3146,O
that,3146,O
Tat,3146,B-GeneOrGeneProduct
induces,3146,O
IDO,3146,B-GeneOrGeneProduct
expression,3146,O
via,3146,O
an,3146,O
IFNg-independent,3146,B-GeneOrGeneProduct
mechanism,3146,O
that,3146,O
depends,3146,O
upon,3146,O
activation,3146,O
of,3146,O
p38,3146,B-GeneOrGeneProduct
MAPK,3146,I-GeneOrGeneProduct
.,3146,O
Targeting,3147,O
IDO,3147,B-GeneOrGeneProduct
itself,3147,O
or,3147,O
the,3147,O
p38,3147,B-GeneOrGeneProduct
MAPK,3147,I-GeneOrGeneProduct
signaling,3147,O
pathway,3147,O
could,3147,O
provide,3147,O
a,3147,O
novel,3147,O
therapy,3147,O
for,3147,O
comorbid,3147,O
depressive,3147,B-DiseaseOrPhenotypicFeature
disorders,3147,I-DiseaseOrPhenotypicFeature
in,3147,O
HIV-1-infected,3147,B-DiseaseOrPhenotypicFeature
patients,3147,B-OrganismTaxon
.,3147,O
Two,3148,O
novel,3148,O
mutations,3148,O
of,3148,O
the,3148,O
PAX6,3148,B-GeneOrGeneProduct
gene,3148,O
causing,3148,O
different,3148,O
phenotype,3148,O
in,3148,O
a,3148,O
cohort,3148,O
of,3148,O
Chinese,3148,O
patients,3148,B-OrganismTaxon
.,3148,O
PURPOSE,3149,O
:,3149,O
Aniridia,3149,B-DiseaseOrPhenotypicFeature
(,3149,O
AN,3149,B-DiseaseOrPhenotypicFeature
),3149,O
is,3149,O
a,3149,O
rare,3149,O
congenital,3149,B-DiseaseOrPhenotypicFeature
panocular,3149,I-DiseaseOrPhenotypicFeature
disorder,3149,I-DiseaseOrPhenotypicFeature
caused,3149,O
by,3149,O
the,3149,O
mutations,3149,O
of,3149,O
the,3149,O
paired,3149,B-GeneOrGeneProduct
box,3149,I-GeneOrGeneProduct
homeotic,3149,I-GeneOrGeneProduct
gene,3149,I-GeneOrGeneProduct
6,3149,I-GeneOrGeneProduct
(,3149,O
PAX6,3149,B-GeneOrGeneProduct
),3149,O
gene,3149,O
.,3149,O
The,3150,O
PAX6,3150,B-GeneOrGeneProduct
gene,3150,O
is,3150,O
also,3150,O
involved,3150,O
in,3150,O
other,3150,O
anterior,3150,B-DiseaseOrPhenotypicFeature
segment,3150,I-DiseaseOrPhenotypicFeature
malformations,3150,I-DiseaseOrPhenotypicFeature
including,3150,O
Peters,3150,B-DiseaseOrPhenotypicFeature
anomaly,3150,I-DiseaseOrPhenotypicFeature
.,3150,O
We,3151,O
studied,3151,O
the,3151,O
PAX6,3151,B-GeneOrGeneProduct
gene,3151,O
mutations,3151,O
in,3151,O
a,3151,O
cohort,3151,O
of,3151,O
affected,3151,O
individuals,3151,O
with,3151,O
different,3151,O
clinical,3151,O
phenotype,3151,O
including,3151,O
AN,3151,B-DiseaseOrPhenotypicFeature
",",3151,O
coloboma,3151,B-DiseaseOrPhenotypicFeature
of,3151,I-DiseaseOrPhenotypicFeature
iris,3151,I-DiseaseOrPhenotypicFeature
and,3151,I-DiseaseOrPhenotypicFeature
choroid,3151,I-DiseaseOrPhenotypicFeature
",",3151,O
or,3151,O
anterior,3151,B-DiseaseOrPhenotypicFeature
segment,3151,I-DiseaseOrPhenotypicFeature
malformations,3151,I-DiseaseOrPhenotypicFeature
.,3151,O
PATIENTS,3152,B-OrganismTaxon
AND,3152,O
METHODS,3152,O
:,3152,O
Six,3152,O
unrelated,3152,O
families,3152,O
and,3152,O
10,3152,O
sporadic,3152,O
patients,3152,B-OrganismTaxon
were,3152,O
examined,3152,O
clinically,3152,O
.,3152,O
After,3153,O
informed,3153,O
consent,3153,O
was,3153,O
obtained,3153,O
",",3153,O
genomic,3153,O
DNA,3153,O
was,3153,O
extracted,3153,O
from,3153,O
the,3153,O
venous,3153,O
blood,3153,O
of,3153,O
all,3153,O
participants,3153,O
.,3153,O
Mutation,3154,O
screening,3154,O
of,3154,O
all,3154,O
exons,3154,O
of,3154,O
the,3154,O
PAX6,3154,B-GeneOrGeneProduct
gene,3154,O
was,3154,O
performed,3154,O
by,3154,O
direct,3154,O
sequencing,3154,O
of,3154,O
PCR-amplified,3154,O
DNA,3154,O
fragments,3154,O
.,3154,O
Multiplex,3155,O
ligation-dependent,3155,O
probe,3155,O
amplification,3155,O
(,3155,O
MLPA,3155,O
),3155,O
was,3155,O
performed,3155,O
to,3155,O
detect,3155,O
large,3155,O
deletions,3155,O
.,3155,O
RESULTS,3156,O
:,3156,O
By,3156,O
clinical,3156,O
examination,3156,O
",",3156,O
the,3156,O
patients,3156,B-OrganismTaxon
and,3156,O
the,3156,O
pedigrees,3156,O
were,3156,O
divided,3156,O
into,3156,O
the,3156,O
following,3156,O
three,3156,O
groups,3156,O
:,3156,O
AN,3156,B-DiseaseOrPhenotypicFeature
",",3156,O
coloboma,3156,B-DiseaseOrPhenotypicFeature
of,3156,I-DiseaseOrPhenotypicFeature
iris,3156,I-DiseaseOrPhenotypicFeature
and,3156,I-DiseaseOrPhenotypicFeature
choroids,3156,I-DiseaseOrPhenotypicFeature
",",3156,O
and,3156,O
the,3156,O
anterior,3156,B-DiseaseOrPhenotypicFeature
segment,3156,I-DiseaseOrPhenotypicFeature
malformations,3156,I-DiseaseOrPhenotypicFeature
including,3156,O
peters,3156,B-DiseaseOrPhenotypicFeature
anomaly,3156,I-DiseaseOrPhenotypicFeature
.,3156,O
Sequencing,3157,O
of,3157,O
the,3157,O
PAX6,3157,B-GeneOrGeneProduct
gene,3157,O
",",3157,O
three,3157,O
intragenic,3157,O
mutations,3157,O
including,3157,O
a,3157,O
novel,3157,O
heterozygous,3157,O
splicing-site,3157,O
mutations,3157,O
c.357-3C,3157,B-SequenceVariant
>,3157,I-SequenceVariant
G,3157,I-SequenceVariant
(,3157,O
p.Ser119fsX,3157,B-SequenceVariant
),3157,O
were,3157,O
identified,3157,O
in,3157,O
the,3157,O
patients,3157,B-OrganismTaxon
of,3157,O
the,3157,O
AN,3157,B-DiseaseOrPhenotypicFeature
group,3157,O
.,3157,O
A,3158,O
novel,3158,O
missense,3158,O
mutation,3158,O
c.643T,3158,B-SequenceVariant
>,3158,I-SequenceVariant
C,3158,I-SequenceVariant
(,3158,O
p.S216P,3158,B-SequenceVariant
),3158,O
was,3158,O
detected,3158,O
in,3158,O
the,3158,O
anterior,3158,B-DiseaseOrPhenotypicFeature
segment,3158,I-DiseaseOrPhenotypicFeature
malformation,3158,I-DiseaseOrPhenotypicFeature
group,3158,O
.,3158,O
The,3159,O
mutation,3159,O
p.S216P,3159,B-SequenceVariant
located,3159,O
in,3159,O
the,3159,O
homeodomain,3159,O
region,3159,O
of,3159,O
the,3159,O
PAX6,3159,B-GeneOrGeneProduct
caused,3159,O
the,3159,O
phenotype,3159,O
of,3159,O
Peters,3159,B-DiseaseOrPhenotypicFeature
anomaly,3159,I-DiseaseOrPhenotypicFeature
in,3159,O
family,3159,O
A6,3159,O
with,3159,O
different,3159,O
expressing,3159,O
.,3159,O
Through,3160,O
MLPA,3160,O
analysis,3160,O
",",3160,O
a,3160,O
large,3160,O
deletion,3160,O
including,3160,O
the,3160,O
whole,3160,O
PAX6,3160,B-GeneOrGeneProduct
gene,3160,O
and,3160,O
DKFZ,3160,B-GeneOrGeneProduct
p686k1684,3160,I-GeneOrGeneProduct
gene,3160,O
was,3160,O
detected,3160,O
in,3160,O
one,3160,O
sporadic,3160,O
patient,3160,B-OrganismTaxon
from,3160,O
the,3160,O
AN,3160,B-DiseaseOrPhenotypicFeature
group,3160,O
.,3160,O
Neither,3161,O
intragenic,3161,O
mutation,3161,O
nor,3161,O
large,3161,O
deletion,3161,O
was,3161,O
identified,3161,O
in,3161,O
the,3161,O
group,3161,O
with,3161,O
coloboma,3161,B-DiseaseOrPhenotypicFeature
of,3161,I-DiseaseOrPhenotypicFeature
iris,3161,I-DiseaseOrPhenotypicFeature
and,3161,I-DiseaseOrPhenotypicFeature
choroid,3161,I-DiseaseOrPhenotypicFeature
.,3161,O
CONCLUSION,3162,O
:,3162,O
Our,3162,O
findings,3162,O
further,3162,O
confirmed,3162,O
that,3162,O
different,3162,O
kind,3162,O
of,3162,O
mutations,3162,O
might,3162,O
cause,3162,O
different,3162,O
ocular,3162,O
phenotype,3162,O
",",3162,O
and,3162,O
clearly,3162,O
clinical,3162,O
phenotype,3162,O
classification,3162,O
might,3162,O
increase,3162,O
the,3162,O
mutation,3162,O
detection,3162,O
rate,3162,O
of,3162,O
the,3162,O
PAX6,3162,B-GeneOrGeneProduct
gene,3162,O
.,3162,O
Plasminogen,3163,B-GeneOrGeneProduct
activator,3163,I-GeneOrGeneProduct
inhibitor,3163,I-GeneOrGeneProduct
type,3163,I-GeneOrGeneProduct
1,3163,I-GeneOrGeneProduct
serum,3163,O
levels,3163,O
and,3163,O
4G/5G,3163,O
gene,3163,O
polymorphism,3163,O
in,3163,O
morbidly,3163,O
obese,3163,B-DiseaseOrPhenotypicFeature
Hispanic,3163,O
patients,3163,B-OrganismTaxon
with,3163,O
non-alcoholic,3163,B-DiseaseOrPhenotypicFeature
fatty,3163,I-DiseaseOrPhenotypicFeature
liver,3163,I-DiseaseOrPhenotypicFeature
disease,3163,I-DiseaseOrPhenotypicFeature
.,3163,O
BACKGROUND,3164,O
:,3164,O
The,3164,O
plasminogen,3164,B-GeneOrGeneProduct
activator,3164,I-GeneOrGeneProduct
inhibitor,3164,I-GeneOrGeneProduct
type-1,3164,I-GeneOrGeneProduct
(,3164,O
PAI-1,3164,B-GeneOrGeneProduct
),3164,O
has,3164,O
been,3164,O
implicated,3164,O
in,3164,O
the,3164,O
regulation,3164,O
of,3164,O
fibrinolysis,3164,O
and,3164,O
extracellular,3164,O
matrix,3164,O
components,3164,O
.,3164,O
The,3165,O
single,3165,O
base,3165,O
pair,3165,O
guanine,3165,O
insertion/deletion,3165,O
polymorphism,3165,O
(,3165,O
4G/5G,3165,O
),3165,O
within,3165,O
the,3165,O
promoter,3165,O
region,3165,O
of,3165,O
the,3165,O
PAI-1,3165,B-GeneOrGeneProduct
gene,3165,O
influences,3165,O
PAI-1,3165,B-GeneOrGeneProduct
synthesis,3165,O
and,3165,O
may,3165,O
modulate,3165,O
hepatic,3165,B-DiseaseOrPhenotypicFeature
fibrogenesis,3165,I-DiseaseOrPhenotypicFeature
.,3165,O
AIM,3166,O
:,3166,O
To,3166,O
evaluate,3166,O
the,3166,O
influence,3166,O
of,3166,O
PAI-1,3166,B-GeneOrGeneProduct
serum,3166,O
levels,3166,O
and,3166,O
4G/5G,3166,O
polymorphism,3166,O
on,3166,O
the,3166,O
risk,3166,O
of,3166,O
liver,3166,B-DiseaseOrPhenotypicFeature
fibrosis,3166,I-DiseaseOrPhenotypicFeature
associated,3166,O
to,3166,O
non-alcoholic,3166,B-DiseaseOrPhenotypicFeature
fatty,3166,I-DiseaseOrPhenotypicFeature
liver,3166,I-DiseaseOrPhenotypicFeature
disease,3166,I-DiseaseOrPhenotypicFeature
(,3166,O
NAFLD,3166,B-DiseaseOrPhenotypicFeature
),3166,O
in,3166,O
morbidly,3166,O
obese,3166,B-DiseaseOrPhenotypicFeature
patients,3166,B-OrganismTaxon
.,3166,O
MATERIAL,3167,O
AND,3167,O
METHODS,3167,O
:,3167,O
Case-control,3167,O
study,3167,O
of,3167,O
50,3167,O
obese,3167,B-DiseaseOrPhenotypicFeature
patients,3167,B-OrganismTaxon
undergoing,3167,O
bariatric,3167,O
surgery,3167,O
and,3167,O
71,3167,O
non-obese,3167,O
subjects,3167,O
matched,3167,O
by,3167,O
age,3167,O
and,3167,O
sex,3167,O
.,3167,O
Anthropometric,3168,O
and,3168,O
biochemical,3168,O
measurements,3168,O
were,3168,O
performed,3168,O
",",3168,O
including,3168,O
PAI-1,3168,B-GeneOrGeneProduct
serum,3168,O
levels,3168,O
.,3168,O
Genomic,3169,O
DNA,3169,O
was,3169,O
obtained,3169,O
to,3169,O
assess,3169,O
the,3169,O
presence,3169,O
of,3169,O
4G/5G,3169,O
polymorphism,3169,O
.,3169,O
RESULTS,3170,O
:,3170,O
BMI,3170,O
",",3170,O
insulinemia,3170,O
",",3170,O
triglycerides,3170,B-ChemicalEntity
",",3170,O
HOMA-IR,3170,O
",",3170,O
hypertension,3170,B-DiseaseOrPhenotypicFeature
and,3170,O
diabetes,3170,B-DiseaseOrPhenotypicFeature
were,3170,O
significantly,3170,O
higher,3170,O
in,3170,O
obese,3170,B-DiseaseOrPhenotypicFeature
patients,3170,B-OrganismTaxon
compared,3170,O
to,3170,O
control,3170,O
subjects,3170,O
.,3170,O
PAI-1,3171,B-GeneOrGeneProduct
serum,3171,O
levels,3171,O
observed,3171,O
in,3171,O
obese,3171,B-DiseaseOrPhenotypicFeature
patients,3171,B-OrganismTaxon
were,3171,O
significantly,3171,O
lower,3171,O
(,3171,O
10.63,3171,O
4.82,3171,O
),3171,O
compared,3171,O
to,3171,O
controls,3171,O
(,3171,O
14.26,3171,O
11.4,3171,O
;,3171,O
p,3171,O
<,3171,O
0.05,3171,O
),3171,O
.,3171,O
No,3172,O
differences,3172,O
were,3172,O
observed,3172,O
in,3172,O
the,3172,O
PAI-1,3172,B-GeneOrGeneProduct
4G/5G,3172,O
promoter,3172,O
genotypes,3172,O
frequencies,3172,O
(,3172,O
p,3172,O
=,3172,O
0.12,3172,O
),3172,O
.,3172,O
No,3173,O
differences,3173,O
were,3173,O
observed,3173,O
in,3173,O
PAI-1,3173,B-GeneOrGeneProduct
plasma,3173,O
levels,3173,O
among,3173,O
obese,3173,B-DiseaseOrPhenotypicFeature
patients,3173,B-OrganismTaxon
with,3173,O
liver,3173,B-DiseaseOrPhenotypicFeature
fibrosis,3173,I-DiseaseOrPhenotypicFeature
(,3173,O
10.64,3173,O
4.35,3173,O
),3173,O
compared,3173,O
to,3173,O
patients,3173,B-OrganismTaxon
without,3173,O
liver,3173,B-DiseaseOrPhenotypicFeature
fibrosis,3173,I-DiseaseOrPhenotypicFeature
(,3173,O
10.61,3173,O
5.2,3173,O
;,3173,O
p,3173,O
=,3173,O
0.985,3173,O
),3173,O
.,3173,O
PAI-1,3174,B-GeneOrGeneProduct
4G/5G,3174,O
promoter,3174,O
genotypes,3174,O
frequencies,3174,O
were,3174,O
similar,3174,O
in,3174,O
patients,3174,B-OrganismTaxon
with,3174,O
or,3174,O
without,3174,O
liver,3174,B-DiseaseOrPhenotypicFeature
fibrosis,3174,I-DiseaseOrPhenotypicFeature
associated,3174,O
to,3174,O
NASH,3174,B-DiseaseOrPhenotypicFeature
(,3174,O
p,3174,O
=,3174,O
0.6,3174,O
),3174,O
.,3174,O
CONCLUSIONS,3175,O
:,3175,O
Morbidly,3175,O
obese,3175,B-DiseaseOrPhenotypicFeature
patients,3175,B-OrganismTaxon
had,3175,O
significantly,3175,O
lower,3175,O
PAI-1,3175,B-GeneOrGeneProduct
serum,3175,O
levels,3175,O
with,3175,O
similar,3175,O
PAI-1,3175,B-GeneOrGeneProduct
4G/5G,3175,O
genotypes,3175,O
frequencies,3175,O
compared,3175,O
to,3175,O
non-obese,3175,O
subjects,3175,O
.,3175,O
The,3176,O
frequency,3176,O
of,3176,O
4G/5G,3176,O
genotypes,3176,O
in,3176,O
Chilean,3176,O
Hispanic,3176,O
healthy,3176,O
subjects,3176,O
was,3176,O
similar,3176,O
to,3176,O
that,3176,O
described,3176,O
in,3176,O
other,3176,O
populations,3176,O
.,3176,O
No,3177,O
association,3177,O
was,3177,O
found,3177,O
between,3177,O
PAI-1,3177,B-GeneOrGeneProduct
serum,3177,O
levels,3177,O
or,3177,O
4G/5G,3177,O
genotype,3177,O
with,3177,O
liver,3177,B-DiseaseOrPhenotypicFeature
fibrosis,3177,I-DiseaseOrPhenotypicFeature
in,3177,O
obese,3177,B-DiseaseOrPhenotypicFeature
patients,3177,B-OrganismTaxon
.,3177,O
Exploratory,3178,O
investigation,3178,O
on,3178,O
functional,3178,O
significance,3178,O
of,3178,O
ETS2,3178,B-GeneOrGeneProduct
and,3178,O
SIM2,3178,B-GeneOrGeneProduct
genes,3178,O
in,3178,O
Down,3178,B-DiseaseOrPhenotypicFeature
syndrome,3178,I-DiseaseOrPhenotypicFeature
.,3178,O
Trisomy,3179,O
of,3179,O
the,3179,O
21,3179,O
{,3179,O
st,3179,O
},3179,O
chromosome,3179,O
leads,3179,O
to,3179,O
an,3179,O
over,3179,O
dosage,3179,O
of,3179,O
several,3179,O
regulatory,3179,O
genes,3179,O
in,3179,O
Down,3179,B-DiseaseOrPhenotypicFeature
syndrome,3179,I-DiseaseOrPhenotypicFeature
(,3179,O
DS,3179,B-DiseaseOrPhenotypicFeature
),3179,O
.,3179,O
Though,3180,O
allelic,3180,O
and,3180,O
genotypic,3180,O
combinations,3180,O
formed,3180,O
between,3180,O
genes,3180,O
are,3180,O
interesting,3180,O
",",3180,O
till,3180,O
date,3180,O
",",3180,O
this,3180,O
particular,3180,O
area,3180,O
has,3180,O
never,3180,O
been,3180,O
explored,3180,O
in,3180,O
DS,3180,B-DiseaseOrPhenotypicFeature
.,3180,O
In,3181,O
the,3181,O
present,3181,O
investigation,3181,O
four,3181,O
SNPs,3181,O
in,3181,O
two,3181,O
transcription,3181,O
factors,3181,O
",",3181,O
Single,3181,B-GeneOrGeneProduct
minded,3181,I-GeneOrGeneProduct
2,3181,I-GeneOrGeneProduct
(,3181,O
SIM2,3181,B-GeneOrGeneProduct
),3181,O
and,3181,O
V-ets,3181,B-GeneOrGeneProduct
erythroblastosis,3181,I-GeneOrGeneProduct
virus,3181,I-GeneOrGeneProduct
E26,3181,I-GeneOrGeneProduct
oncogene,3181,I-GeneOrGeneProduct
homolog2,3181,I-GeneOrGeneProduct
(,3181,O
ETS2,3181,B-GeneOrGeneProduct
),3181,O
",",3181,O
located,3181,O
in,3181,O
the,3181,O
21,3181,O
{,3181,O
st,3181,O
},3181,O
chromosome,3181,O
were,3181,O
genotyped,3181,O
to,3181,O
understand,3181,O
their,3181,O
role,3181,O
in,3181,O
DS,3181,B-DiseaseOrPhenotypicFeature
.,3181,O
Genomic,3182,O
DNA,3182,O
of,3182,O
eastern,3182,O
Indian,3182,O
probands,3182,O
with,3182,O
DS,3182,B-DiseaseOrPhenotypicFeature
(,3182,O
N=132,3182,O
),3182,O
",",3182,O
their,3182,O
parents,3182,O
(,3182,O
N=209,3182,O
),3182,O
and,3182,O
ethnically,3182,O
matched,3182,O
controls,3182,O
(,3182,O
N=149,3182,O
),3182,O
was,3182,O
subjected,3182,O
to,3182,O
PCR-based,3182,O
analyses,3182,O
of,3182,O
functionally,3182,O
important,3182,O
SNPs,3182,O
followed,3182,O
by,3182,O
statistical,3182,O
analyses,3182,O
.,3182,O
ETS2,3183,B-GeneOrGeneProduct
rs461155,3183,B-SequenceVariant
showed,3183,O
high,3183,O
heterozygosity,3183,O
in,3183,O
DS,3183,B-DiseaseOrPhenotypicFeature
.,3183,O
Significantly,3184,O
lower,3184,O
frequency,3184,O
of,3184,O
SIM2,3184,B-GeneOrGeneProduct
C-G,3184,O
haplotype,3184,O
(,3184,O
rs2073601-rs2073416,3184,B-SequenceVariant
),3184,O
was,3184,O
noticed,3184,O
in,3184,O
individuals,3184,O
with,3184,O
DS,3184,B-DiseaseOrPhenotypicFeature
(,3184,O
P,3184,O
value,3184,O
=0.01669,3184,O
),3184,O
and,3184,O
their,3184,O
fathers,3184,O
(,3184,O
P,3184,O
value=0.01185,3184,O
),3184,O
.,3184,O
Significantly,3185,O
lower,3185,O
frequency,3185,O
of,3185,O
the,3185,O
A-C-C-G,3185,O
with,3185,O
higher,3185,O
frequency,3185,O
of,3185,O
A-C-A-G,3185,O
haplotypes,3185,O
was,3185,O
also,3185,O
noticed,3185,O
in,3185,O
subjects,3185,O
with,3185,O
DS,3185,B-DiseaseOrPhenotypicFeature
(,3185,O
P,3185,O
value,3185,O
=0.02089,3185,O
and,3185,O
0.00588,3185,O
respectively,3185,O
),3185,O
.,3185,O
Data,3186,O
obtained,3186,O
indicate,3186,O
that,3186,O
the,3186,O
rs2073601,3186,B-SequenceVariant
',3186,O
A,3186,O
',3186,O
allele,3186,O
",",3186,O
responsible,3186,O
for,3186,O
nonsynonymous,3186,O
substitution,3186,O
of,3186,O
leucine,3186,B-SequenceVariant
to,3186,I-SequenceVariant
methionine,3186,I-SequenceVariant
",",3186,O
may,3186,O
have,3186,O
some,3186,O
role,3186,O
in,3186,O
DS,3186,B-DiseaseOrPhenotypicFeature
in,3186,O
this,3186,O
population,3186,O
.,3186,O
Variation,3187,O
in,3187,O
the,3187,O
CXCR1,3187,B-GeneOrGeneProduct
gene,3187,O
(,3187,O
IL8RA,3187,B-GeneOrGeneProduct
),3187,O
is,3187,O
not,3187,O
associated,3187,O
with,3187,O
susceptibility,3187,O
to,3187,O
chronic,3187,B-DiseaseOrPhenotypicFeature
periodontitis,3187,I-DiseaseOrPhenotypicFeature
.,3187,O
BACKGROUND,3188,O
:,3188,O
The,3188,O
chemokine,3188,B-GeneOrGeneProduct
receptor,3188,I-GeneOrGeneProduct
1,3188,I-GeneOrGeneProduct
CXCR-1,3188,I-GeneOrGeneProduct
(,3188,O
or,3188,O
IL8R-alpha,3188,B-GeneOrGeneProduct
),3188,O
is,3188,O
a,3188,O
specific,3188,O
receptor,3188,O
for,3188,O
the,3188,O
interleukin,3188,B-GeneOrGeneProduct
8,3188,I-GeneOrGeneProduct
(,3188,O
IL-8,3188,B-GeneOrGeneProduct
),3188,O
",",3188,O
which,3188,O
is,3188,O
chemoattractant,3188,O
for,3188,O
neutrophils,3188,O
and,3188,O
has,3188,O
an,3188,O
important,3188,O
role,3188,O
in,3188,O
the,3188,O
inflammatory,3188,B-DiseaseOrPhenotypicFeature
response,3188,O
.,3188,O
The,3189,O
polymorphism,3189,O
rs2234671,3189,B-SequenceVariant
at,3189,O
position,3189,O
Ex2+860G,3189,B-SequenceVariant
>,3189,I-SequenceVariant
C,3189,I-SequenceVariant
of,3189,O
the,3189,O
CXCR1,3189,B-GeneOrGeneProduct
gene,3189,O
causes,3189,O
a,3189,O
conservative,3189,O
amino,3189,O
acid,3189,O
substitution,3189,O
(,3189,O
S276T,3189,B-SequenceVariant
),3189,O
.,3189,O
This,3190,O
single,3190,O
nucleotide,3190,O
polymorphism,3190,O
(,3190,O
SNP,3190,O
),3190,O
seemed,3190,O
to,3190,O
be,3190,O
functional,3190,O
as,3190,O
it,3190,O
was,3190,O
associated,3190,O
with,3190,O
decreased,3190,O
lung,3190,B-DiseaseOrPhenotypicFeature
cancer,3190,I-DiseaseOrPhenotypicFeature
risk,3190,O
.,3190,O
Previous,3191,O
studies,3191,O
of,3191,O
our,3191,O
group,3191,O
found,3191,O
association,3191,O
of,3191,O
haplotypes,3191,O
in,3191,O
the,3191,O
IL8,3191,B-GeneOrGeneProduct
and,3191,O
in,3191,O
the,3191,O
CXCR2,3191,B-GeneOrGeneProduct
genes,3191,O
with,3191,O
the,3191,O
multifactorial,3191,O
disease,3191,O
chronic,3191,B-DiseaseOrPhenotypicFeature
periodontitis,3191,I-DiseaseOrPhenotypicFeature
.,3191,O
In,3192,O
this,3192,O
study,3192,O
we,3192,O
investigated,3192,O
the,3192,O
polymorphism,3192,O
rs2234671,3192,B-SequenceVariant
in,3192,O
395,3192,O
Brazilian,3192,O
subjects,3192,O
with,3192,O
and,3192,O
without,3192,O
chronic,3192,B-DiseaseOrPhenotypicFeature
periodontitis,3192,I-DiseaseOrPhenotypicFeature
.,3192,O
FINDINGS,3193,O
:,3193,O
Similar,3193,O
distribution,3193,O
of,3193,O
the,3193,O
allelic,3193,O
and,3193,O
genotypic,3193,O
frequencies,3193,O
were,3193,O
observed,3193,O
between,3193,O
the,3193,O
groups,3193,O
(,3193,O
p,3193,O
>,3193,O
0.05,3193,O
),3193,O
.,3193,O
CONCLUSIONS,3194,O
:,3194,O
The,3194,O
polymorphism,3194,O
rs2234671,3194,B-SequenceVariant
in,3194,O
the,3194,O
CXCR1,3194,B-GeneOrGeneProduct
gene,3194,O
was,3194,O
not,3194,O
associated,3194,O
with,3194,O
the,3194,O
susceptibility,3194,O
to,3194,O
chronic,3194,B-DiseaseOrPhenotypicFeature
periodontitis,3194,I-DiseaseOrPhenotypicFeature
in,3194,O
the,3194,O
studied,3194,O
Brazilian,3194,O
population,3194,O
.,3194,O
Novel,3195,O
compound,3195,O
heterozygous,3195,O
mutation,3195,O
of,3195,O
MLYCD,3195,B-GeneOrGeneProduct
in,3195,O
a,3195,O
Chinese,3195,O
patient,3195,B-OrganismTaxon
with,3195,O
malonic,3195,B-DiseaseOrPhenotypicFeature
aciduria,3195,I-DiseaseOrPhenotypicFeature
.,3195,O
A,3196,O
3-year-old,3196,O
Chinese,3196,O
boy,3196,O
presented,3196,O
with,3196,O
prominent,3196,O
clinical,3196,O
features,3196,O
of,3196,O
malonic,3196,B-DiseaseOrPhenotypicFeature
aciduria,3196,I-DiseaseOrPhenotypicFeature
",",3196,O
including,3196,O
developmental,3196,B-DiseaseOrPhenotypicFeature
delay,3196,I-DiseaseOrPhenotypicFeature
",",3196,O
short,3196,B-DiseaseOrPhenotypicFeature
stature,3196,I-DiseaseOrPhenotypicFeature
",",3196,O
brain,3196,B-DiseaseOrPhenotypicFeature
abnormalities,3196,I-DiseaseOrPhenotypicFeature
and,3196,O
massive,3196,O
excretion,3196,O
of,3196,O
malonic,3196,B-ChemicalEntity
acid,3196,I-ChemicalEntity
and,3196,O
methylmalonic,3196,B-ChemicalEntity
acid,3196,I-ChemicalEntity
.,3196,O
Molecular,3197,O
characterization,3197,O
by,3197,O
DNA,3197,O
sequencing,3197,O
analysis,3197,O
and,3197,O
multiplex,3197,O
ligation-dependent,3197,O
probe,3197,O
amplification,3197,O
of,3197,O
the,3197,O
MLYCD,3197,B-GeneOrGeneProduct
gene,3197,O
revealed,3197,O
a,3197,O
heterozygous,3197,O
mutation,3197,O
(,3197,O
c.920T,3197,B-SequenceVariant
>,3197,I-SequenceVariant
G,3197,I-SequenceVariant
",",3197,O
p.Leu307Arg,3197,B-SequenceVariant
),3197,O
in,3197,O
the,3197,O
patient,3197,B-OrganismTaxon
and,3197,O
his,3197,O
father,3197,O
and,3197,O
a,3197,O
heterozygous,3197,O
deletion,3197,O
comprising,3197,O
exon,3197,O
1,3197,O
in,3197,O
the,3197,O
patient,3197,B-OrganismTaxon
and,3197,O
his,3197,O
mother,3197,O
.,3197,O
The,3198,O
missense,3198,O
mutation,3198,O
(,3198,O
c.920T,3198,B-SequenceVariant
>,3198,I-SequenceVariant
G,3198,I-SequenceVariant
),3198,O
was,3198,O
not,3198,O
found,3198,O
in,3198,O
100,3198,O
healthy,3198,O
controls,3198,O
and,3198,O
has,3198,O
not,3198,O
been,3198,O
reported,3198,O
previously,3198,O
.,3198,O
Our,3199,O
findings,3199,O
expand,3199,O
the,3199,O
number,3199,O
of,3199,O
reported,3199,O
cases,3199,O
and,3199,O
add,3199,O
a,3199,O
novel,3199,O
entry,3199,O
to,3199,O
the,3199,O
repertoire,3199,O
of,3199,O
MLYCD,3199,B-GeneOrGeneProduct
mutations,3199,O
.,3199,O
Genetic,3200,O
polymorphism,3200,O
of,3200,O
the,3200,O
glutathione-S-transferase,3200,B-GeneOrGeneProduct
P1,3200,I-GeneOrGeneProduct
gene,3200,O
(,3200,O
GSTP1,3200,B-GeneOrGeneProduct
),3200,O
and,3200,O
susceptibility,3200,O
to,3200,O
prostate,3200,B-DiseaseOrPhenotypicFeature
cancer,3200,I-DiseaseOrPhenotypicFeature
in,3200,O
the,3200,O
Kashmiri,3200,O
population,3200,O
.,3200,O
Glutathione-S-transferase,3201,B-GeneOrGeneProduct
P1,3201,I-GeneOrGeneProduct
(,3201,O
GSTP1,3201,B-GeneOrGeneProduct
),3201,O
is,3201,O
a,3201,O
critical,3201,O
enzyme,3201,O
of,3201,O
the,3201,O
phase,3201,O
II,3201,O
detoxification,3201,O
pathway,3201,O
.,3201,O
One,3202,O
of,3202,O
the,3202,O
common,3202,O
functional,3202,O
polymorphisms,3202,O
of,3202,O
GSTP1,3202,B-GeneOrGeneProduct
is,3202,O
A,3202,B-SequenceVariant
>,3202,I-SequenceVariant
G,3202,I-SequenceVariant
at,3202,I-SequenceVariant
nucleotide,3202,I-SequenceVariant
313,3202,I-SequenceVariant
",",3202,O
which,3202,O
results,3202,O
in,3202,O
an,3202,O
amino,3202,O
acid,3202,O
substitution,3202,O
(,3202,O
Ile105Val,3202,B-SequenceVariant
),3202,O
at,3202,O
the,3202,O
substrate,3202,O
binding,3202,O
site,3202,O
of,3202,O
GSTP1,3202,B-GeneOrGeneProduct
and,3202,O
reduces,3202,O
catalytic,3202,O
activity,3202,O
of,3202,O
GSTP1,3202,B-GeneOrGeneProduct
.,3202,O
To,3203,O
investigate,3203,O
the,3203,O
GSTP1,3203,B-GeneOrGeneProduct
Ile105Val,3203,B-SequenceVariant
genotype,3203,O
frequency,3203,O
in,3203,O
prostate,3203,B-DiseaseOrPhenotypicFeature
cancer,3203,I-DiseaseOrPhenotypicFeature
cases,3203,O
in,3203,O
the,3203,O
Kashmiri,3203,O
population,3203,O
",",3203,O
we,3203,O
designed,3203,O
a,3203,O
case-control,3203,O
study,3203,O
",",3203,O
in,3203,O
which,3203,O
50,3203,O
prostate,3203,B-DiseaseOrPhenotypicFeature
cancer,3203,I-DiseaseOrPhenotypicFeature
cases,3203,O
and,3203,O
45,3203,O
benign,3203,B-DiseaseOrPhenotypicFeature
prostate,3203,I-DiseaseOrPhenotypicFeature
hyperplasia,3203,I-DiseaseOrPhenotypicFeature
cases,3203,O
were,3203,O
studied,3203,O
for,3203,O
GSTP1,3203,B-GeneOrGeneProduct
Ile105Val,3203,B-SequenceVariant
polymorphism,3203,O
",",3203,O
compared,3203,O
to,3203,O
80,3203,O
controls,3203,O
taken,3203,O
from,3203,O
the,3203,O
general,3203,O
population,3203,O
",",3203,O
employing,3203,O
the,3203,O
PCR-RFLP,3203,O
technique,3203,O
.,3203,O
We,3204,O
found,3204,O
the,3204,O
frequency,3204,O
of,3204,O
the,3204,O
three,3204,O
different,3204,O
genotypes,3204,O
of,3204,O
GSTP1,3204,B-GeneOrGeneProduct
Ile105Val,3204,B-SequenceVariant
in,3204,O
our,3204,O
ethnic,3204,O
Kashmir,3204,O
population,3204,O
",",3204,O
i.e.,3204,O
",",3204,O
Ile/Ile,3204,O
",",3204,O
Ile/Val,3204,O
and,3204,O
Val/Val,3204,O
",",3204,O
to,3204,O
be,3204,O
52.4,3204,O
",",3204,O
33.3,3204,O
and,3204,O
14.3,3204,O
%,3204,O
among,3204,O
prostate,3204,B-DiseaseOrPhenotypicFeature
cancer,3204,I-DiseaseOrPhenotypicFeature
cases,3204,O
",",3204,O
48.5,3204,O
",",3204,O
37.5,3204,O
and,3204,O
14,3204,O
%,3204,O
among,3204,O
benign,3204,B-DiseaseOrPhenotypicFeature
prostate,3204,I-DiseaseOrPhenotypicFeature
hyperplasia,3204,I-DiseaseOrPhenotypicFeature
cases,3204,O
and,3204,O
73.8,3204,O
",",3204,O
21.3,3204,O
and,3204,O
5,3204,O
%,3204,O
in,3204,O
the,3204,O
control,3204,O
population,3204,O
",",3204,O
respectively,3204,O
.,3204,O
There,3205,O
was,3205,O
a,3205,O
significant,3205,O
association,3205,O
between,3205,O
the,3205,O
GSTP1,3205,B-GeneOrGeneProduct
Ile/Val,3205,B-SequenceVariant
genotype,3205,O
and,3205,O
the,3205,O
advanced,3205,O
age,3205,O
group,3205,O
among,3205,O
the,3205,O
cases,3205,O
.,3205,O
We,3206,O
conclude,3206,O
that,3206,O
GSTP1,3206,B-GeneOrGeneProduct
Ile/Val,3206,B-SequenceVariant
polymorphism,3206,O
is,3206,O
involved,3206,O
in,3206,O
the,3206,O
risk,3206,O
of,3206,O
prostate,3206,B-DiseaseOrPhenotypicFeature
cancer,3206,I-DiseaseOrPhenotypicFeature
development,3206,O
in,3206,O
our,3206,O
population,3206,O
.,3206,O
TBX21,3207,B-GeneOrGeneProduct
and,3207,O
HLX1,3207,B-GeneOrGeneProduct
polymorphisms,3207,O
influence,3207,O
cytokine,3207,O
secretion,3207,O
at,3207,O
birth,3207,O
.,3207,O
BACKGROUND,3208,O
:,3208,O
TBX21,3208,B-GeneOrGeneProduct
(,3208,O
T,3208,B-GeneOrGeneProduct
cell,3208,I-GeneOrGeneProduct
specific,3208,I-GeneOrGeneProduct
T-box,3208,I-GeneOrGeneProduct
transcription,3208,I-GeneOrGeneProduct
factor,3208,I-GeneOrGeneProduct
),3208,O
and,3208,O
HLX1,3208,B-GeneOrGeneProduct
(,3208,O
H.20-like,3208,B-GeneOrGeneProduct
homeobox,3208,I-GeneOrGeneProduct
1,3208,I-GeneOrGeneProduct
),3208,O
are,3208,O
crucial,3208,O
transcription,3208,O
factors,3208,O
of,3208,O
T,3208,O
(,3208,O
H,3208,O
),3208,O
1-cells,3208,O
",",3208,O
inducing,3208,O
their,3208,O
differentiation,3208,O
and,3208,O
suppressing,3208,O
T,3208,O
(,3208,O
H,3208,O
),3208,O
2,3208,O
commitment,3208,O
",",3208,O
particularly,3208,O
important,3208,O
for,3208,O
early,3208,O
life,3208,O
immune,3208,O
development,3208,O
.,3208,O
This,3209,O
study,3209,O
investigated,3209,O
the,3209,O
influence,3209,O
of,3209,O
TBX21,3209,B-GeneOrGeneProduct
and,3209,O
HLX1,3209,B-GeneOrGeneProduct
single,3209,O
nucleotide,3209,O
polymorphisms,3209,O
(,3209,O
SNPs,3209,O
),3209,O
",",3209,O
which,3209,O
have,3209,O
previously,3209,O
been,3209,O
shown,3209,O
to,3209,O
be,3209,O
associated,3209,O
with,3209,O
asthma,3209,B-DiseaseOrPhenotypicFeature
",",3209,O
on,3209,O
T,3209,O
(,3209,O
H,3209,O
),3209,O
1/T,3209,O
(,3209,O
H,3209,O
),3209,O
2,3209,O
lineage,3209,O
cytokines,3209,O
at,3209,O
birth,3209,O
.,3209,O
METHODS,3210,O
AND,3210,O
FINDINGS,3210,O
:,3210,O
Cord,3210,O
blood,3210,O
mononuclear,3210,O
cells,3210,O
(,3210,O
CBMCs,3210,O
),3210,O
of,3210,O
200,3210,O
neonates,3210,O
were,3210,O
genotyped,3210,O
for,3210,O
two,3210,O
TBX21,3210,B-GeneOrGeneProduct
and,3210,O
three,3210,O
HLX1,3210,B-GeneOrGeneProduct
SNPs,3210,O
.,3210,O
CBMCs,3211,O
were,3211,O
stimulated,3211,O
with,3211,O
innate,3211,O
(,3211,O
Lipid,3211,B-ChemicalEntity
A,3211,I-ChemicalEntity
",",3211,O
LpA,3211,B-ChemicalEntity
;,3211,O
Peptidoglycan,3211,B-ChemicalEntity
",",3211,O
Ppg,3211,B-ChemicalEntity
),3211,O
",",3211,O
adaptive,3211,O
stimuli,3211,O
(,3211,O
house,3211,O
dust,3211,O
mite,3211,O
Dermatophagoides,3211,B-GeneOrGeneProduct
pteronyssinus,3211,I-GeneOrGeneProduct
1,3211,I-GeneOrGeneProduct
",",3211,O
Derp1,3211,B-GeneOrGeneProduct
),3211,O
or,3211,O
mitogen,3211,O
(,3211,O
phytohemagglutinin,3211,B-ChemicalEntity
",",3211,O
PHA,3211,B-ChemicalEntity
),3211,O
.,3211,O
Cytokines,3212,O
",",3212,O
T-cells,3212,O
and,3212,O
mRNA,3212,O
expression,3212,O
of,3212,O
T,3212,O
(,3212,O
H,3212,O
),3212,O
1/T,3212,O
(,3212,O
H,3212,O
),3212,O
2-related,3212,O
genes,3212,O
were,3212,O
assessed,3212,O
.,3212,O
Atopic,3213,O
diseases,3213,O
during,3213,O
the,3213,O
first,3213,O
3,3213,O
years,3213,O
of,3213,O
life,3213,O
were,3213,O
assessed,3213,O
by,3213,O
questionnaire,3213,O
answered,3213,O
by,3213,O
the,3213,O
parents,3213,O
.,3213,O
Carriers,3214,O
of,3214,O
TBX21,3214,B-GeneOrGeneProduct
promoter,3214,O
SNP,3214,O
rs17250932,3214,B-SequenceVariant
and,3214,O
HLX1,3214,B-GeneOrGeneProduct
promoter,3214,O
SNP,3214,O
rs2738751,3214,B-SequenceVariant
showed,3214,O
reduced,3214,O
or,3214,O
trendwise,3214,O
reduced,3214,O
(,3214,O
p,3214,O
<,3214,O
0.07,3214,O
),3214,O
IL-5,3214,B-GeneOrGeneProduct
",",3214,O
IL-13,3214,B-GeneOrGeneProduct
and,3214,O
TNF-a,3214,B-GeneOrGeneProduct
secretion,3214,O
after,3214,O
LpA-stimulation,3214,B-ChemicalEntity
.,3214,O
Carriers,3215,O
of,3215,O
HLX1,3215,B-GeneOrGeneProduct
SNP,3215,O
rs2738751,3215,B-SequenceVariant
had,3215,O
lower,3215,O
IL-13,3215,B-GeneOrGeneProduct
levels,3215,O
following,3215,O
Ppg-stimulation,3215,B-ChemicalEntity
(,3215,O
p,3215,O
=,3215,O
0.08,3215,O
),3215,O
.,3215,O
Carriers,3216,O
of,3216,O
HLX1,3216,B-GeneOrGeneProduct
exon,3216,O
1,3216,O
SNP,3216,O
rs12141189,3216,B-SequenceVariant
showed,3216,O
increased,3216,O
IL-5,3216,B-GeneOrGeneProduct
(,3216,O
LpA,3216,B-ChemicalEntity
",",3216,O
p,3216,O
=,3216,O
0.007,3216,O
;,3216,O
Ppg,3216,B-ChemicalEntity
",",3216,O
p,3216,O
=,3216,O
0.10,3216,O
),3216,O
",",3216,O
trendwise,3216,O
increased,3216,O
IL-13,3216,B-GeneOrGeneProduct
(,3216,O
LpA,3216,B-ChemicalEntity
),3216,O
",",3216,O
higher,3216,O
GM-CSF,3216,B-GeneOrGeneProduct
(,3216,O
LpA/Ppg,3216,B-ChemicalEntity
",",3216,O
p,3216,O
<,3216,O
0.05,3216,O
),3216,O
and,3216,O
trendwise,3216,O
decreased,3216,O
IFN-g,3216,B-GeneOrGeneProduct
secretion,3216,O
(,3216,O
Derp1+LpA-stimulation,3216,B-GeneOrGeneProduct
",",3216,O
p,3216,O
=,3216,O
0.1,3216,O
),3216,O
.,3216,O
Homozygous,3217,O
carriers,3217,O
of,3217,O
HLX1,3217,B-GeneOrGeneProduct
promoter,3217,O
SNP,3217,O
rs3806325,3217,B-SequenceVariant
showed,3217,O
increased,3217,O
IL-13,3217,B-GeneOrGeneProduct
and,3217,O
IL-6,3217,B-GeneOrGeneProduct
(,3217,O
unstimulated,3217,O
",",3217,O
p,3217,O
<,3217,O
0.03,3217,O
),3217,O
.,3217,O
In,3218,O
carriers,3218,O
of,3218,O
TBX21,3218,B-GeneOrGeneProduct
intron,3218,O
3,3218,O
SNP,3218,O
rs11079788,3218,B-SequenceVariant
no,3218,O
differences,3218,O
in,3218,O
cytokine,3218,O
secretion,3218,O
were,3218,O
observed,3218,O
.,3218,O
mRNA,3219,O
expression,3219,O
of,3219,O
T,3219,O
(,3219,O
H,3219,O
),3219,O
1/T,3219,O
(,3219,O
H,3219,O
),3219,O
2-related,3219,O
genes,3219,O
partly,3219,O
correlated,3219,O
with,3219,O
cytokines,3219,O
at,3219,O
protein,3219,O
level,3219,O
.,3219,O
TBX21,3220,B-GeneOrGeneProduct
SNP,3220,O
rs11079788,3220,B-SequenceVariant
carriers,3220,O
developed,3220,O
less,3220,O
symptoms,3220,O
of,3220,O
atopic,3220,B-DiseaseOrPhenotypicFeature
dermatitis,3220,I-DiseaseOrPhenotypicFeature
at,3220,O
3,3220,O
years,3220,O
of,3220,O
age,3220,O
(,3220,O
p,3220,O
=,3220,O
0.03,3220,O
),3220,O
.,3220,O
CONCLUSIONS,3221,O
:,3221,O
Polymorphisms,3221,O
in,3221,O
TBX21,3221,B-GeneOrGeneProduct
and,3221,O
HLX1,3221,B-GeneOrGeneProduct
influenced,3221,O
primarily,3221,O
IL-5,3221,B-GeneOrGeneProduct
and,3221,O
IL-13,3221,B-GeneOrGeneProduct
secretion,3221,O
after,3221,O
LpA-stimulation,3221,B-ChemicalEntity
in,3221,O
cord,3221,O
blood,3221,O
suggesting,3221,O
that,3221,O
genetic,3221,O
variations,3221,O
in,3221,O
the,3221,O
transcription,3221,O
factors,3221,O
essential,3221,O
for,3221,O
the,3221,O
T,3221,O
(,3221,O
H,3221,O
),3221,O
1-pathway,3221,O
may,3221,O
contribute,3221,O
to,3221,O
modified,3221,O
T,3221,O
(,3221,O
H,3221,O
),3221,O
2-immune,3221,O
responses,3221,O
already,3221,O
early,3221,O
in,3221,O
life,3221,O
.,3221,O
Further,3222,O
follow-up,3222,O
of,3222,O
the,3222,O
cohort,3222,O
is,3222,O
required,3222,O
to,3222,O
study,3222,O
the,3222,O
polymorphisms,3222,O
',3222,O
relevance,3222,O
for,3222,O
immune-mediated,3222,B-DiseaseOrPhenotypicFeature
diseases,3222,I-DiseaseOrPhenotypicFeature
such,3222,O
as,3222,O
childhood,3222,O
asthma,3222,B-DiseaseOrPhenotypicFeature
.,3222,O
Defining,3223,O
an,3223,O
EPOR-,3223,B-GeneOrGeneProduct
regulated,3223,O
transcriptome,3223,O
for,3223,O
primary,3223,O
progenitors,3223,O
",",3223,O
including,3223,O
Tnfr-sf13c,3223,B-GeneOrGeneProduct
as,3223,O
a,3223,O
novel,3223,O
mediator,3223,O
of,3223,O
EPO-,3223,B-GeneOrGeneProduct
dependent,3223,O
erythroblast,3223,O
formation,3223,O
.,3223,O
Certain,3224,O
concepts,3224,O
concerning,3224,O
EPO/EPOR,3224,B-GeneOrGeneProduct
action,3224,O
modes,3224,O
have,3224,O
been,3224,O
challenged,3224,O
by,3224,O
in,3224,O
vivo,3224,O
studies,3224,O
:,3224,O
Bcl-x,3224,B-GeneOrGeneProduct
levels,3224,O
are,3224,O
elevated,3224,O
in,3224,O
maturing,3224,O
erythroblasts,3224,O
",",3224,O
but,3224,O
not,3224,O
in,3224,O
their,3224,O
progenitors,3224,O
;,3224,O
truncated,3224,O
EPOR,3224,B-GeneOrGeneProduct
alleles,3224,O
that,3224,O
lack,3224,O
a,3224,O
major,3224,O
p85/PI3K,3224,B-GeneOrGeneProduct
recruitment,3224,O
site,3224,O
nonetheless,3224,O
promote,3224,O
polycythemia,3224,B-DiseaseOrPhenotypicFeature
;,3224,O
and,3224,O
Erk1,3224,B-GeneOrGeneProduct
disruption,3224,O
unexpectedly,3224,O
bolsters,3224,O
erythropoiesis,3224,O
.,3224,O
To,3225,O
discover,3225,O
novel,3225,O
EPO/EPOR,3225,B-GeneOrGeneProduct
action,3225,O
routes,3225,O
",",3225,O
global,3225,O
transcriptome,3225,O
analyses,3225,O
presently,3225,O
are,3225,O
applied,3225,O
to,3225,O
interrogate,3225,O
EPO/EPOR,3225,B-GeneOrGeneProduct
effects,3225,O
on,3225,O
primary,3225,O
bone,3225,O
marrow-derived,3225,O
CFUe-like,3225,O
progenitors,3225,O
.,3225,O
Overall,3226,O
",",3226,O
160,3226,O
EPO/EPOR,3226,B-GeneOrGeneProduct
target,3226,O
transcripts,3226,O
were,3226,O
significantly,3226,O
modulated,3226,O
2-to,3226,O
21.8-fold,3226,O
.,3226,O
A,3227,O
unique,3227,O
set,3227,O
of,3227,O
EPO-regulated,3227,B-GeneOrGeneProduct
survival,3227,O
factors,3227,O
included,3227,O
Lyl1,3227,B-GeneOrGeneProduct
",",3227,O
Gas5,3227,B-GeneOrGeneProduct
",",3227,O
Pim3,3227,B-GeneOrGeneProduct
",",3227,O
Pim1,3227,B-GeneOrGeneProduct
",",3227,O
Bim,3227,B-GeneOrGeneProduct
",",3227,O
Trib3,3227,B-GeneOrGeneProduct
and,3227,O
Serpina,3227,B-GeneOrGeneProduct
3g,3227,I-GeneOrGeneProduct
.,3227,O
EPO/EPOR-modulated,3228,B-GeneOrGeneProduct
cell,3228,O
cycle,3228,O
mediators,3228,O
included,3228,O
Cdc25a,3228,B-GeneOrGeneProduct
",",3228,O
Btg3,3228,B-GeneOrGeneProduct
",",3228,O
Cyclin-d2,3228,B-GeneOrGeneProduct
",",3228,O
p27-kip1,3228,B-GeneOrGeneProduct
",",3228,O
Cyclin-g2,3228,B-GeneOrGeneProduct
and,3228,O
CyclinB1-IP-1,3228,B-GeneOrGeneProduct
.,3228,O
EPO,3229,B-GeneOrGeneProduct
regulation,3229,O
of,3229,O
signal,3229,O
transduction,3229,O
factors,3229,O
was,3229,O
also,3229,O
interestingly,3229,O
complex,3229,O
.,3229,O
For,3230,O
example,3230,O
",",3230,O
not,3230,O
only,3230,O
Socs3,3230,B-GeneOrGeneProduct
plus,3230,O
Socs2,3230,B-GeneOrGeneProduct
but,3230,O
also,3230,O
Spred2,3230,B-GeneOrGeneProduct
",",3230,O
Spred1,3230,B-GeneOrGeneProduct
and,3230,O
Eaf1,3230,B-GeneOrGeneProduct
were,3230,O
EPO-induced,3230,B-GeneOrGeneProduct
as,3230,O
negative-feedback,3230,O
components,3230,O
.,3230,O
Socs2,3231,B-GeneOrGeneProduct
",",3231,O
plus,3231,O
five,3231,O
additional,3231,O
targets,3231,O
",",3231,O
further,3231,O
proved,3231,O
to,3231,O
comprise,3231,O
new,3231,O
EPOR/Jak2/Stat5,3231,B-GeneOrGeneProduct
response,3231,O
genes,3231,O
(,3231,O
which,3231,O
are,3231,O
important,3231,O
for,3231,O
erythropoiesis,3231,O
during,3231,O
anemia,3231,B-DiseaseOrPhenotypicFeature
),3231,O
.,3231,O
Among,3232,O
receptors,3232,O
",",3232,O
an,3232,O
atypical,3232,O
TNF-receptor,3232,B-GeneOrGeneProduct
Tnfr-sf13c,3232,B-GeneOrGeneProduct
was,3232,O
up-modulated,3232,O
>,3232,O
5-fold,3232,O
by,3232,O
EPO,3232,B-GeneOrGeneProduct
.,3232,O
Functionally,3233,O
",",3233,O
Tnfr-sf13c,3233,B-GeneOrGeneProduct
ligation,3233,O
proved,3233,O
to,3233,O
both,3233,O
promote,3233,O
proerythroblast,3233,O
survival,3233,O
",",3233,O
and,3233,O
substantially,3233,O
enhance,3233,O
erythroblast,3233,O
formation,3233,O
.,3233,O
The,3234,O
EPOR,3234,B-GeneOrGeneProduct
therefore,3234,O
engages,3234,O
a,3234,O
sophisticated,3234,O
set,3234,O
of,3234,O
transcriptome,3234,O
response,3234,O
circuits,3234,O
",",3234,O
with,3234,O
Tnfr-sf13c,3234,B-GeneOrGeneProduct
deployed,3234,O
as,3234,O
one,3234,O
novel,3234,O
positive,3234,O
regulator,3234,O
of,3234,O
proerythroblast,3234,O
formation,3234,O
.,3234,O
Late-onset,3235,O
scleroderma,3235,B-DiseaseOrPhenotypicFeature
renal,3235,I-DiseaseOrPhenotypicFeature
crisis,3235,I-DiseaseOrPhenotypicFeature
induced,3235,O
by,3235,O
tacrolimus,3235,B-ChemicalEntity
and,3235,O
prednisolone,3235,B-ChemicalEntity
:,3235,O
a,3235,O
case,3235,O
report,3235,O
.,3235,O
Scleroderma,3236,B-DiseaseOrPhenotypicFeature
renal,3236,I-DiseaseOrPhenotypicFeature
crisis,3236,I-DiseaseOrPhenotypicFeature
(,3236,O
SRC,3236,B-DiseaseOrPhenotypicFeature
),3236,O
is,3236,O
a,3236,O
rare,3236,O
complication,3236,O
of,3236,O
systemic,3236,B-DiseaseOrPhenotypicFeature
sclerosis,3236,I-DiseaseOrPhenotypicFeature
(,3236,O
SSc,3236,B-DiseaseOrPhenotypicFeature
),3236,O
but,3236,O
can,3236,O
be,3236,O
severe,3236,O
enough,3236,O
to,3236,O
require,3236,O
temporary,3236,O
or,3236,O
permanent,3236,O
renal,3236,O
replacement,3236,O
therapy,3236,O
.,3236,O
Moderate,3237,O
to,3237,O
high,3237,O
dose,3237,O
corticosteroid,3237,B-ChemicalEntity
use,3237,O
is,3237,O
recognized,3237,O
as,3237,O
a,3237,O
major,3237,O
risk,3237,O
factor,3237,O
for,3237,O
SRC,3237,B-DiseaseOrPhenotypicFeature
.,3237,O
Furthermore,3238,O
",",3238,O
there,3238,O
have,3238,O
been,3238,O
reports,3238,O
of,3238,O
thrombotic,3238,B-DiseaseOrPhenotypicFeature
microangiopathy,3238,I-DiseaseOrPhenotypicFeature
precipitated,3238,O
by,3238,O
cyclosporine,3238,B-ChemicalEntity
in,3238,O
patients,3238,B-OrganismTaxon
with,3238,O
SSc,3238,B-DiseaseOrPhenotypicFeature
.,3238,O
In,3239,O
this,3239,O
article,3239,O
",",3239,O
we,3239,O
report,3239,O
a,3239,O
patient,3239,B-OrganismTaxon
with,3239,O
SRC,3239,B-DiseaseOrPhenotypicFeature
induced,3239,O
by,3239,O
tacrolimus,3239,B-ChemicalEntity
and,3239,O
corticosteroids,3239,B-ChemicalEntity
.,3239,O
The,3240,O
aim,3240,O
of,3240,O
this,3240,O
work,3240,O
is,3240,O
to,3240,O
call,3240,O
attention,3240,O
to,3240,O
the,3240,O
risk,3240,O
of,3240,O
tacrolimus,3240,B-ChemicalEntity
use,3240,O
in,3240,O
patients,3240,B-OrganismTaxon
with,3240,O
SSc,3240,B-DiseaseOrPhenotypicFeature
.,3240,O
Variation,3241,O
in,3241,O
IL10,3241,B-GeneOrGeneProduct
and,3241,O
other,3241,O
genes,3241,O
involved,3241,O
in,3241,O
the,3241,O
immune,3241,O
response,3241,O
and,3241,O
in,3241,O
oxidation,3241,O
and,3241,O
prostate,3241,B-DiseaseOrPhenotypicFeature
cancer,3241,I-DiseaseOrPhenotypicFeature
recurrence,3241,O
.,3241,O
BACKGROUND,3242,O
:,3242,O
To,3242,O
evaluate,3242,O
the,3242,O
association,3242,O
of,3242,O
variation,3242,O
in,3242,O
genes,3242,O
involved,3242,O
in,3242,O
immune,3242,O
response,3242,O
",",3242,O
including,3242,O
IL10,3242,B-GeneOrGeneProduct
",",3242,O
production,3242,O
and,3242,O
detoxification,3242,O
of,3242,O
reactive,3242,B-ChemicalEntity
oxygen,3242,I-ChemicalEntity
species,3242,I-ChemicalEntity
",",3242,O
and,3242,O
repair,3242,O
of,3242,O
oxidative,3242,O
DNA,3242,O
damage,3242,O
with,3242,O
risk,3242,O
of,3242,O
recurrence,3242,O
after,3242,O
surgery,3242,O
for,3242,O
localized,3242,O
prostate,3242,B-DiseaseOrPhenotypicFeature
cancer,3242,I-DiseaseOrPhenotypicFeature
.,3242,O
METHODS,3243,O
:,3243,O
We,3243,O
conducted,3243,O
a,3243,O
nested,3243,O
case-control,3243,O
study,3243,O
of,3243,O
men,3243,B-OrganismTaxon
who,3243,O
had,3243,O
a,3243,O
radical,3243,O
prostatectomy,3243,O
in,3243,O
1993,3243,O
to,3243,O
2001,3243,O
.,3243,O
A,3244,O
total,3244,O
of,3244,O
484,3244,O
recurrence,3244,O
cases,3244,O
and,3244,O
484,3244,O
controls,3244,O
were,3244,O
matched,3244,O
on,3244,O
age,3244,O
",",3244,O
race,3244,O
",",3244,O
and,3244,O
pathologic,3244,O
stage,3244,O
and,3244,O
grade,3244,O
.,3244,O
Germline,3245,O
DNA,3245,O
was,3245,O
extracted,3245,O
from,3245,O
paraffin-embedded,3245,B-ChemicalEntity
unaffected,3245,O
lymph,3245,O
nodes,3245,O
.,3245,O
We,3246,O
genotyped,3246,O
candidate,3246,O
single-nucleotide,3246,O
polymorphisms,3246,O
(,3246,O
SNP,3246,O
),3246,O
in,3246,O
IL10,3246,B-GeneOrGeneProduct
",",3246,O
CRP,3246,B-GeneOrGeneProduct
",",3246,O
GPX1,3246,B-GeneOrGeneProduct
",",3246,O
GSR,3246,B-GeneOrGeneProduct
",",3246,O
GSTP1,3246,B-GeneOrGeneProduct
",",3246,O
hOGG1,3246,B-GeneOrGeneProduct
",",3246,O
IL1B,3246,B-GeneOrGeneProduct
",",3246,O
IL1RN,3246,B-GeneOrGeneProduct
",",3246,O
IL6,3246,B-GeneOrGeneProduct
",",3246,O
IL8,3246,B-GeneOrGeneProduct
",",3246,O
MPO,3246,B-GeneOrGeneProduct
",",3246,O
NOS2,3246,B-GeneOrGeneProduct
",",3246,O
NOS3,3246,B-GeneOrGeneProduct
",",3246,O
SOD1,3246,B-GeneOrGeneProduct
",",3246,O
SOD2,3246,B-GeneOrGeneProduct
",",3246,O
SOD3,3246,B-GeneOrGeneProduct
",",3246,O
TLR4,3246,B-GeneOrGeneProduct
",",3246,O
and,3246,O
TNF,3246,B-GeneOrGeneProduct
and,3246,O
tagging,3246,O
SNPs,3246,O
in,3246,O
IL10,3246,B-GeneOrGeneProduct
",",3246,O
CRP,3246,B-GeneOrGeneProduct
",",3246,O
GSR,3246,B-GeneOrGeneProduct
",",3246,O
IL1RN,3246,B-GeneOrGeneProduct
",",3246,O
IL6,3246,B-GeneOrGeneProduct
",",3246,O
NOS2,3246,B-GeneOrGeneProduct
",",3246,O
and,3246,O
NOS3,3246,B-GeneOrGeneProduct
.,3246,O
We,3247,O
used,3247,O
conditional,3247,O
logistic,3247,O
regression,3247,O
to,3247,O
estimate,3247,O
OR,3247,O
and,3247,O
95,3247,O
%,3247,O
confidence,3247,O
intervals,3247,O
(,3247,O
CI,3247,O
),3247,O
.,3247,O
RESULTS,3248,O
:,3248,O
The,3248,O
minor,3248,O
allele,3248,O
(,3248,O
A,3248,O
),3248,O
in,3248,O
IL10,3248,B-GeneOrGeneProduct
rs1800872,3248,B-SequenceVariant
",",3248,O
known,3248,O
to,3248,O
produce,3248,O
less,3248,O
interleukin-10,3248,B-GeneOrGeneProduct
(,3248,O
IL-10,3248,B-GeneOrGeneProduct
),3248,O
",",3248,O
was,3248,O
associated,3248,O
with,3248,O
a,3248,O
higher,3248,O
risk,3248,O
of,3248,O
recurrence,3248,O
(,3248,O
OR,3248,O
=,3248,O
1.76,3248,O
",",3248,O
95,3248,O
%,3248,O
CI,3248,O
:,3248,O
1.00-3.10,3248,O
),3248,O
",",3248,O
and,3248,O
the,3248,O
minor,3248,O
allele,3248,O
(,3248,O
G,3248,O
),3248,O
in,3248,O
rs1800896,3248,B-SequenceVariant
",",3248,O
known,3248,O
to,3248,O
produce,3248,O
more,3248,O
IL-10,3248,B-GeneOrGeneProduct
",",3248,O
was,3248,O
associated,3248,O
with,3248,O
a,3248,O
lower,3248,O
risk,3248,O
of,3248,O
recurrence,3248,O
(,3248,O
OR,3248,O
=,3248,O
0.66,3248,O
",",3248,O
95,3248,O
%,3248,O
CI,3248,O
:,3248,O
0.48-0.91,3248,O
),3248,O
.,3248,O
We,3249,O
also,3249,O
observed,3249,O
associations,3249,O
for,3249,O
candidate,3249,O
SNPs,3249,O
in,3249,O
CRP,3249,B-GeneOrGeneProduct
",",3249,O
GSTP1,3249,B-GeneOrGeneProduct
",",3249,O
and,3249,O
IL1B,3249,B-GeneOrGeneProduct
.,3249,O
A,3250,O
common,3250,O
IL10,3250,B-GeneOrGeneProduct
haplotype,3250,O
and,3250,O
2,3250,O
common,3250,O
NOS2,3250,B-GeneOrGeneProduct
haplotypes,3250,O
were,3250,O
associated,3250,O
with,3250,O
recurrence,3250,O
.,3250,O
CONCLUSION,3251,O
:,3251,O
Variation,3251,O
in,3251,O
IL10,3251,B-GeneOrGeneProduct
",",3251,O
CRP,3251,B-GeneOrGeneProduct
",",3251,O
GSTP1,3251,B-GeneOrGeneProduct
",",3251,O
IL1B,3251,B-GeneOrGeneProduct
",",3251,O
and,3251,O
NOS2,3251,B-GeneOrGeneProduct
was,3251,O
associated,3251,O
with,3251,O
prostate,3251,B-DiseaseOrPhenotypicFeature
cancer,3251,I-DiseaseOrPhenotypicFeature
recurrence,3251,O
independent,3251,O
of,3251,O
pathologic,3251,O
prognostic,3251,O
factors,3251,O
.,3251,O
IMPACT,3252,O
:,3252,O
This,3252,O
study,3252,O
supports,3252,O
that,3252,O
genetic,3252,O
variation,3252,O
in,3252,O
immune,3252,O
response,3252,O
and,3252,O
oxidation,3252,O
influence,3252,O
prostate,3252,B-DiseaseOrPhenotypicFeature
cancer,3252,I-DiseaseOrPhenotypicFeature
recurrence,3252,O
risk,3252,O
and,3252,O
suggests,3252,O
genetic,3252,O
variation,3252,O
in,3252,O
these,3252,O
pathways,3252,O
may,3252,O
inform,3252,O
prognosis,3252,O
.,3252,O
Superoxide,3253,B-GeneOrGeneProduct
dismutase,3253,I-GeneOrGeneProduct
1,3253,I-GeneOrGeneProduct
overexpression,3253,O
in,3253,O
mice,3253,B-OrganismTaxon
abolishes,3253,O
maternal,3253,B-DiseaseOrPhenotypicFeature
diabetes-induced,3253,O
endoplasmic,3253,O
reticulum,3253,O
stress,3253,O
in,3253,O
diabetic,3253,B-DiseaseOrPhenotypicFeature
embryopathy,3253,B-DiseaseOrPhenotypicFeature
.,3253,O
OBJECTIVE,3254,O
:,3254,O
Both,3254,O
oxidative,3254,O
stress,3254,O
and,3254,O
endoplasmic,3254,O
reticulum,3254,O
stress,3254,O
(,3254,O
ER,3254,O
stress,3254,O
),3254,O
are,3254,O
causal,3254,O
events,3254,O
in,3254,O
diabetic,3254,B-DiseaseOrPhenotypicFeature
embryopathy,3254,B-DiseaseOrPhenotypicFeature
.,3254,O
We,3255,O
tested,3255,O
whether,3255,O
oxidative,3255,O
stress,3255,O
causes,3255,O
ER,3255,O
stress,3255,O
.,3255,O
STUDY,3256,O
DESIGN,3256,O
:,3256,O
Wild-type,3256,O
(,3256,O
WT,3256,O
),3256,O
and,3256,O
superoxide,3256,B-GeneOrGeneProduct
dismutase,3256,I-GeneOrGeneProduct
1,3256,I-GeneOrGeneProduct
(,3256,O
SOD1,3256,B-GeneOrGeneProduct
),3256,O
-overexpressing,3256,O
day,3256,O
8.75,3256,O
embryos,3256,O
from,3256,O
nondiabetic,3256,O
WT,3256,O
control,3256,O
with,3256,O
SOD1,3256,B-GeneOrGeneProduct
transgenic,3256,O
male,3256,O
and,3256,O
diabetic,3256,B-DiseaseOrPhenotypicFeature
WT,3256,O
female,3256,O
with,3256,O
SOD1,3256,B-GeneOrGeneProduct
transgenic,3256,O
male,3256,O
were,3256,O
analyzed,3256,O
for,3256,O
ER,3256,O
stress,3256,O
markers,3256,O
:,3256,O
C/EBP-homologous,3256,B-GeneOrGeneProduct
protein,3256,I-GeneOrGeneProduct
(,3256,O
CHOP,3256,B-GeneOrGeneProduct
),3256,O
",",3256,O
calnexin,3256,B-GeneOrGeneProduct
",",3256,O
eukaryotic,3256,B-GeneOrGeneProduct
initiation,3256,I-GeneOrGeneProduct
factor,3256,I-GeneOrGeneProduct
2a,3256,I-GeneOrGeneProduct
(,3256,O
eIF2a,3256,B-GeneOrGeneProduct
),3256,O
",",3256,O
protein,3256,B-GeneOrGeneProduct
kinase,3256,I-GeneOrGeneProduct
ribonucleic,3256,I-GeneOrGeneProduct
acid,3256,I-GeneOrGeneProduct
(,3256,I-GeneOrGeneProduct
RNA,3256,I-GeneOrGeneProduct
),3256,I-GeneOrGeneProduct
-like,3256,I-GeneOrGeneProduct
ER,3256,I-GeneOrGeneProduct
kinase,3256,I-GeneOrGeneProduct
(,3256,O
PERK,3256,B-GeneOrGeneProduct
),3256,O
",",3256,O
binding,3256,B-GeneOrGeneProduct
immunoglobulin,3256,I-GeneOrGeneProduct
protein,3256,I-GeneOrGeneProduct
",",3256,O
protein,3256,B-GeneOrGeneProduct
disulfide,3256,I-GeneOrGeneProduct
isomerase,3256,I-GeneOrGeneProduct
family,3256,I-GeneOrGeneProduct
A,3256,I-GeneOrGeneProduct
member,3256,I-GeneOrGeneProduct
3,3256,I-GeneOrGeneProduct
",",3256,O
kinases,3256,B-GeneOrGeneProduct
inositol-requiring,3256,I-GeneOrGeneProduct
protein-1a,3256,I-GeneOrGeneProduct
(,3256,O
IRE1a,3256,B-GeneOrGeneProduct
),3256,O
",",3256,O
and,3256,O
the,3256,O
X-box,3256,B-GeneOrGeneProduct
binding,3256,I-GeneOrGeneProduct
protein,3256,I-GeneOrGeneProduct
(,3256,O
XBP1,3256,B-GeneOrGeneProduct
),3256,O
messenger,3256,O
RNA,3256,O
(,3256,O
mRNA,3256,O
),3256,O
splicing,3256,O
.,3256,O
RESULTS,3257,O
:,3257,O
Maternal,3257,B-DiseaseOrPhenotypicFeature
diabetes,3257,I-DiseaseOrPhenotypicFeature
significantly,3257,O
increased,3257,O
the,3257,O
levels,3257,O
of,3257,O
CHOP,3257,B-GeneOrGeneProduct
",",3257,O
calnexin,3257,B-GeneOrGeneProduct
",",3257,O
phosphorylated,3257,O
(,3257,O
p,3257,O
),3257,O
-eIF2a,3257,O
",",3257,O
p-PERK,3257,O
",",3257,O
and,3257,O
p-IRE1a,3257,O
;,3257,O
triggered,3257,O
XBP1,3257,B-GeneOrGeneProduct
mRNA,3257,O
splicing,3257,O
;,3257,O
and,3257,O
enhanced,3257,O
ER,3257,O
chaperone,3257,O
gene,3257,O
expression,3257,O
in,3257,O
WT,3257,O
embryos,3257,O
.,3257,O
SOD1,3258,B-GeneOrGeneProduct
overexpression,3258,O
blocked,3258,O
these,3258,O
diabetes-induced,3258,B-DiseaseOrPhenotypicFeature
ER,3258,O
stress,3258,O
markers,3258,O
.,3258,O
CONCLUSION,3259,O
:,3259,O
Mitigating,3259,O
oxidative,3259,O
stress,3259,O
via,3259,O
SOD1,3259,B-GeneOrGeneProduct
overexpression,3259,O
blocks,3259,O
maternal,3259,B-DiseaseOrPhenotypicFeature
diabetes-induced,3259,O
ER,3259,O
stress,3259,O
in,3259,O
vivo,3259,O
.,3259,O
Bortezomib,3260,B-ChemicalEntity
and,3260,O
dexamethasone,3260,B-ChemicalEntity
as,3260,O
salvage,3260,O
therapy,3260,O
in,3260,O
patients,3260,B-OrganismTaxon
with,3260,O
relapsed/refractory,3260,O
multiple,3260,B-DiseaseOrPhenotypicFeature
myeloma,3260,I-DiseaseOrPhenotypicFeature
:,3260,O
analysis,3260,O
of,3260,O
long-term,3260,O
clinical,3260,O
outcomes,3260,O
.,3260,O
Bortezomib,3261,B-ChemicalEntity
(,3261,O
bort,3261,B-ChemicalEntity
),3261,O
-dexamethasone,3261,O
(,3261,O
dex,3261,B-ChemicalEntity
),3261,O
is,3261,O
an,3261,O
effective,3261,O
therapy,3261,O
for,3261,O
relapsed/refractory,3261,O
(,3261,O
R/R,3261,O
),3261,O
multiple,3261,B-DiseaseOrPhenotypicFeature
myeloma,3261,I-DiseaseOrPhenotypicFeature
(,3261,O
MM,3261,B-DiseaseOrPhenotypicFeature
),3261,O
.,3261,O
This,3262,O
retrospective,3262,O
study,3262,O
investigated,3262,O
the,3262,O
combination,3262,O
of,3262,O
bort,3262,B-ChemicalEntity
(,3262,O
1.3,3262,O
mg/m,3262,O
(,3262,O
2,3262,O
),3262,O
on,3262,O
days,3262,O
1,3262,O
",",3262,O
4,3262,O
",",3262,O
8,3262,O
",",3262,O
and,3262,O
11,3262,O
every,3262,O
3,3262,O
weeks,3262,O
),3262,O
and,3262,O
dex,3262,B-ChemicalEntity
(,3262,O
20,3262,O
mg,3262,O
on,3262,O
the,3262,O
day,3262,O
of,3262,O
and,3262,O
the,3262,O
day,3262,O
after,3262,O
bort,3262,B-ChemicalEntity
),3262,O
as,3262,O
salvage,3262,O
treatment,3262,O
in,3262,O
85,3262,O
patients,3262,B-OrganismTaxon
with,3262,O
R/R,3262,O
MM,3262,B-DiseaseOrPhenotypicFeature
after,3262,O
prior,3262,O
autologous,3262,O
stem,3262,O
cell,3262,O
transplantation,3262,O
or,3262,O
conventional,3262,O
chemotherapy,3262,O
.,3262,O
The,3263,O
median,3263,O
number,3263,O
of,3263,O
prior,3263,O
lines,3263,O
of,3263,O
therapy,3263,O
was,3263,O
2,3263,O
.,3263,O
Eighty-seven,3264,O
percent,3264,O
of,3264,O
the,3264,O
patients,3264,B-OrganismTaxon
had,3264,O
received,3264,O
immunomodulatory,3264,O
drugs,3264,O
included,3264,O
in,3264,O
some,3264,O
line,3264,O
of,3264,O
therapy,3264,O
before,3264,O
bort-dex,3264,B-ChemicalEntity
.,3264,O
The,3265,O
median,3265,O
number,3265,O
of,3265,O
bort-dex,3265,B-ChemicalEntity
cycles,3265,O
was,3265,O
6,3265,O
",",3265,O
up,3265,O
to,3265,O
a,3265,O
maximum,3265,O
of,3265,O
12,3265,O
cycles,3265,O
.,3265,O
On,3266,O
an,3266,O
intention-to-treat,3266,O
basis,3266,O
",",3266,O
55,3266,O
%,3266,O
of,3266,O
the,3266,O
patients,3266,B-OrganismTaxon
achieved,3266,O
at,3266,O
least,3266,O
partial,3266,O
response,3266,O
",",3266,O
including,3266,O
19,3266,O
%,3266,O
CR,3266,O
and,3266,O
35,3266,O
%,3266,O
achieved,3266,O
at,3266,O
least,3266,O
very,3266,O
good,3266,O
partial,3266,O
response,3266,O
.,3266,O
Median,3267,O
durations,3267,O
of,3267,O
response,3267,O
",",3267,O
time,3267,O
to,3267,O
next,3267,O
therapy,3267,O
and,3267,O
treatment-free,3267,O
interval,3267,O
were,3267,O
8,3267,O
",",3267,O
11.2,3267,O
",",3267,O
and,3267,O
5.1,3267,O
months,3267,O
",",3267,O
respectively,3267,O
.,3267,O
The,3268,O
most,3268,O
relevant,3268,O
adverse,3268,O
event,3268,O
was,3268,O
peripheral,3268,B-DiseaseOrPhenotypicFeature
neuropathy,3268,I-DiseaseOrPhenotypicFeature
",",3268,O
which,3268,O
occurred,3268,O
in,3268,O
78,3268,O
%,3268,O
of,3268,O
the,3268,O
patients,3268,B-OrganismTaxon
(,3268,O
grade,3268,O
II,3268,O
",",3268,O
38,3268,O
%,3268,O
;,3268,O
grade,3268,O
III,3268,O
",",3268,O
21,3268,O
%,3268,O
),3268,O
and,3268,O
led,3268,O
to,3268,O
treatment,3268,O
discontinuation,3268,O
in,3268,O
6,3268,O
%,3268,O
.,3268,O
With,3269,O
a,3269,O
median,3269,O
follow,3269,O
up,3269,O
of,3269,O
22,3269,O
months,3269,O
",",3269,O
median,3269,O
time,3269,O
to,3269,O
progression,3269,O
",",3269,O
progression-free,3269,O
survival,3269,O
(,3269,O
PFS,3269,O
),3269,O
and,3269,O
overall,3269,O
survival,3269,O
(,3269,O
OS,3269,O
),3269,O
were,3269,O
8.9,3269,O
",",3269,O
8.7,3269,O
",",3269,O
and,3269,O
22,3269,O
months,3269,O
",",3269,O
respectively,3269,O
.,3269,O
Prolonged,3270,O
PFS,3270,O
and,3270,O
OS,3270,O
were,3270,O
observed,3270,O
in,3270,O
patients,3270,B-OrganismTaxon
achieving,3270,O
CR,3270,O
and,3270,O
receiving,3270,O
bort-dex,3270,B-ChemicalEntity
a,3270,O
single,3270,O
line,3270,O
of,3270,O
prior,3270,O
therapy,3270,O
.,3270,O
Bort-dex,3271,B-ChemicalEntity
was,3271,O
an,3271,O
effective,3271,O
salvage,3271,O
treatment,3271,O
for,3271,O
MM,3271,B-DiseaseOrPhenotypicFeature
patients,3271,B-OrganismTaxon
",",3271,O
particularly,3271,O
for,3271,O
those,3271,O
in,3271,O
first,3271,O
relapse,3271,O
.,3271,O
The,3272,O
cytogenetic,3272,O
action,3272,O
of,3272,O
ifosfamide,3272,B-ChemicalEntity
",",3272,O
mesna,3272,B-ChemicalEntity
",",3272,O
and,3272,O
their,3272,O
combination,3272,O
on,3272,O
peripheral,3272,O
rabbit,3272,B-OrganismTaxon
lymphocytes,3272,O
:,3272,O
an,3272,O
in,3272,O
vivo/in,3272,O
vitro,3272,O
cytogenetic,3272,O
study,3272,O
.,3272,O
Ifosfamide,3273,B-ChemicalEntity
(,3273,O
IFO,3273,B-ChemicalEntity
),3273,O
is,3273,O
an,3273,O
alkylating,3273,B-ChemicalEntity
nitrogen,3273,I-ChemicalEntity
mustard,3273,I-ChemicalEntity
",",3273,O
administrated,3273,O
as,3273,O
an,3273,O
antineoplasmic,3273,O
agent,3273,O
.,3273,O
It,3274,O
is,3274,O
characterized,3274,O
by,3274,O
its,3274,O
intense,3274,O
urotoxic,3274,O
action,3274,O
",",3274,O
leading,3274,O
to,3274,O
hemorrhagic,3274,B-DiseaseOrPhenotypicFeature
cystitis,3274,B-DiseaseOrPhenotypicFeature
.,3274,O
This,3275,O
side,3275,O
effect,3275,O
of,3275,O
IFO,3275,B-ChemicalEntity
raises,3275,O
the,3275,O
requirement,3275,O
for,3275,O
the,3275,O
co-administration,3275,O
with,3275,O
sodium,3275,B-ChemicalEntity
2-sulfanylethanesulfonate,3275,I-ChemicalEntity
(,3275,O
Mesna,3275,B-ChemicalEntity
),3275,O
aiming,3275,O
to,3275,O
avoid,3275,O
or,3275,O
minimize,3275,O
this,3275,O
effect,3275,O
.,3275,O
IFO,3276,B-ChemicalEntity
and,3276,O
Mesna,3276,B-ChemicalEntity
were,3276,O
administrated,3276,O
separately,3276,O
on,3276,O
rabbit,3276,B-OrganismTaxon
's,3276,O
lymphocytes,3276,O
in,3276,O
vivo,3276,O
",",3276,O
which,3276,O
were,3276,O
later,3276,O
developed,3276,O
in,3276,O
vitro,3276,O
.,3276,O
Cytogenetic,3277,O
markers,3277,O
for,3277,O
sister,3277,O
chromatid,3277,O
exchanges,3277,O
(,3277,O
SCEs,3277,O
),3277,O
",",3277,O
proliferation,3277,O
rate,3277,O
index,3277,O
(,3277,O
PRI,3277,O
),3277,O
and,3277,O
Mitotic,3277,O
Index,3277,O
were,3277,O
recorded,3277,O
.,3277,O
Mesna,3278,B-ChemicalEntity
's,3278,O
action,3278,O
",",3278,O
in,3278,O
conjunction,3278,O
with,3278,O
IFO,3278,B-ChemicalEntity
reduces,3278,O
the,3278,O
frequency,3278,O
of,3278,O
SCEs,3278,O
",",3278,O
in,3278,O
comparison,3278,O
with,3278,O
the,3278,O
SCEs,3278,O
recordings,3278,O
obtained,3278,O
when,3278,O
IFO,3278,B-ChemicalEntity
is,3278,O
administered,3278,O
alone,3278,O
.,3278,O
In,3279,O
addition,3279,O
to,3279,O
this,3279,O
",",3279,O
when,3279,O
high,3279,O
concentrations,3279,O
of,3279,O
Mesna,3279,B-ChemicalEntity
were,3279,O
administered,3279,O
alone,3279,O
significant,3279,O
reductions,3279,O
of,3279,O
the,3279,O
PRI,3279,O
were,3279,O
noted,3279,O
",",3279,O
than,3279,O
with,3279,O
IFO,3279,B-ChemicalEntity
acting,3279,O
at,3279,O
the,3279,O
same,3279,O
concentration,3279,O
on,3279,O
the,3279,O
lymphocytes,3279,O
.,3279,O
Mesna,3280,B-ChemicalEntity
significantly,3280,O
reduces,3280,O
IFO,3280,B-ChemicalEntity
's,3280,O
genotoxicity,3280,B-DiseaseOrPhenotypicFeature
",",3280,O
while,3280,O
when,3280,O
administered,3280,O
in,3280,O
high,3280,O
concentrations,3280,O
it,3280,O
acts,3280,O
in,3280,O
an,3280,O
inhibitory,3280,O
fashion,3280,O
on,3280,O
the,3280,O
cytostatic,3280,O
action,3280,O
of,3280,O
the,3280,O
drug,3280,O
.,3280,O
Risk,3281,O
factors,3281,O
and,3281,O
predictors,3281,O
of,3281,O
levodopa-induced,3281,B-ChemicalEntity
dyskinesia,3281,B-DiseaseOrPhenotypicFeature
among,3281,O
multiethnic,3281,O
Malaysians,3281,O
with,3281,O
Parkinson,3281,B-DiseaseOrPhenotypicFeature
's,3281,I-DiseaseOrPhenotypicFeature
disease,3281,I-DiseaseOrPhenotypicFeature
.,3281,O
Chronic,3282,O
pulsatile,3282,O
levodopa,3282,B-ChemicalEntity
therapy,3282,O
for,3282,O
Parkinson,3282,B-DiseaseOrPhenotypicFeature
's,3282,I-DiseaseOrPhenotypicFeature
disease,3282,I-DiseaseOrPhenotypicFeature
(,3282,O
PD,3282,B-DiseaseOrPhenotypicFeature
),3282,O
leads,3282,O
to,3282,O
the,3282,O
development,3282,O
of,3282,O
motor,3282,O
fluctuations,3282,O
and,3282,O
dyskinesia,3282,B-DiseaseOrPhenotypicFeature
.,3282,O
We,3283,O
studied,3283,O
the,3283,O
prevalence,3283,O
and,3283,O
predictors,3283,O
of,3283,O
levodopa-induced,3283,B-ChemicalEntity
dyskinesia,3283,B-DiseaseOrPhenotypicFeature
among,3283,O
multiethnic,3283,O
Malaysian,3283,O
patients,3283,B-OrganismTaxon
with,3283,O
PD,3283,B-DiseaseOrPhenotypicFeature
.,3283,O
METHODS,3284,O
:,3284,O
This,3284,O
is,3284,O
a,3284,O
cross-sectional,3284,O
study,3284,O
involving,3284,O
95,3284,O
patients,3284,B-OrganismTaxon
with,3284,O
PD,3284,B-DiseaseOrPhenotypicFeature
on,3284,O
uninterrupted,3284,O
levodopa,3284,B-ChemicalEntity
therapy,3284,O
for,3284,O
at,3284,O
least,3284,O
6,3284,O
months,3284,O
.,3284,O
The,3285,O
instrument,3285,O
used,3285,O
was,3285,O
the,3285,O
UPDRS,3285,O
questionnaires,3285,O
.,3285,O
The,3286,O
predictors,3286,O
of,3286,O
dyskinesia,3286,B-DiseaseOrPhenotypicFeature
were,3286,O
determined,3286,O
using,3286,O
multivariate,3286,O
logistic,3286,O
regression,3286,O
analysis,3286,O
.,3286,O
RESULTS,3287,O
:,3287,O
The,3287,O
mean,3287,O
age,3287,O
was,3287,O
65.6,3287,O
+,3287,O
8.5,3287,O
years,3287,O
.,3287,O
The,3288,O
mean,3288,O
onset,3288,O
age,3288,O
was,3288,O
58.5,3288,O
+,3288,O
9.8,3288,O
years,3288,O
.,3288,O
The,3289,O
median,3289,O
disease,3289,O
duration,3289,O
was,3289,O
6,3289,O
(,3289,O
7,3289,O
),3289,O
years,3289,O
.,3289,O
Dyskinesia,3290,B-DiseaseOrPhenotypicFeature
was,3290,O
present,3290,O
in,3290,O
44,3290,O
%,3290,O
(,3290,O
n,3290,O
=,3290,O
42,3290,O
),3290,O
with,3290,O
median,3290,O
levodopa,3290,B-ChemicalEntity
therapy,3290,O
of,3290,O
3,3290,O
years,3290,O
.,3290,O
There,3291,O
were,3291,O
64.3,3291,O
%,3291,O
Chinese,3291,O
",",3291,O
31,3291,O
%,3291,O
Malays,3291,O
",",3291,O
and,3291,O
3.7,3291,O
%,3291,O
Indians,3291,O
and,3291,O
other,3291,O
ethnic,3291,O
groups,3291,O
.,3291,O
Eighty-one,3292,O
percent,3292,O
of,3292,O
patients,3292,B-OrganismTaxon
with,3292,O
dyskinesia,3292,B-DiseaseOrPhenotypicFeature
had,3292,O
clinical,3292,O
fluctuations,3292,O
.,3292,O
Patients,3293,B-OrganismTaxon
with,3293,O
dyskinesia,3293,B-DiseaseOrPhenotypicFeature
had,3293,O
lower,3293,O
onset,3293,O
age,3293,O
(,3293,O
p,3293,O
<,3293,O
0.001,3293,O
),3293,O
",",3293,O
longer,3293,O
duration,3293,O
of,3293,O
levodopa,3293,B-ChemicalEntity
therapy,3293,O
(,3293,O
p,3293,O
<,3293,O
0.001,3293,O
),3293,O
",",3293,O
longer,3293,O
disease,3293,O
duration,3293,O
(,3293,O
p,3293,O
<,3293,O
0.001,3293,O
),3293,O
",",3293,O
higher,3293,O
total,3293,O
daily,3293,O
levodopa,3293,B-ChemicalEntity
dose,3293,O
(,3293,O
p,3293,O
<,3293,O
0.001,3293,O
),3293,O
",",3293,O
and,3293,O
higher,3293,O
total,3293,O
UPDRS,3293,O
scores,3293,O
(,3293,O
p,3293,O
=,3293,O
0.005,3293,O
),3293,O
than,3293,O
patients,3293,B-OrganismTaxon
without,3293,O
dyskinesia,3293,B-DiseaseOrPhenotypicFeature
.,3293,O
The,3294,O
three,3294,O
significant,3294,O
predictors,3294,O
of,3294,O
dyskinesia,3294,B-DiseaseOrPhenotypicFeature
were,3294,O
duration,3294,O
of,3294,O
levodopa,3294,B-ChemicalEntity
therapy,3294,O
",",3294,O
onset,3294,O
age,3294,O
",",3294,O
and,3294,O
total,3294,O
daily,3294,O
levodopa,3294,B-ChemicalEntity
dose,3294,O
.,3294,O
CONCLUSIONS,3295,O
:,3295,O
The,3295,O
prevalence,3295,O
of,3295,O
levodopa-induced,3295,B-ChemicalEntity
dyskinesia,3295,B-DiseaseOrPhenotypicFeature
in,3295,O
our,3295,O
patients,3295,B-OrganismTaxon
was,3295,O
44,3295,O
%,3295,O
.,3295,O
The,3296,O
most,3296,O
significant,3296,O
predictors,3296,O
were,3296,O
duration,3296,O
of,3296,O
levodopa,3296,B-ChemicalEntity
therapy,3296,O
",",3296,O
total,3296,O
daily,3296,O
levodopa,3296,B-ChemicalEntity
dose,3296,O
",",3296,O
and,3296,O
onset,3296,O
age,3296,O
.,3296,O
Long-term,3297,O
oral,3297,O
galactose,3297,B-ChemicalEntity
treatment,3297,O
prevents,3297,O
cognitive,3297,B-DiseaseOrPhenotypicFeature
deficits,3297,I-DiseaseOrPhenotypicFeature
in,3297,O
male,3297,O
Wistar,3297,O
rats,3297,B-OrganismTaxon
treated,3297,O
intracerebroventricularly,3297,O
with,3297,O
streptozotocin,3297,B-ChemicalEntity
.,3297,O
Basic,3298,O
and,3298,O
clinical,3298,O
research,3298,O
has,3298,O
demonstrated,3298,O
that,3298,O
dementia,3298,B-DiseaseOrPhenotypicFeature
of,3298,O
sporadic,3298,O
Alzheimer,3298,B-DiseaseOrPhenotypicFeature
's,3298,I-DiseaseOrPhenotypicFeature
disease,3298,I-DiseaseOrPhenotypicFeature
(,3298,O
sAD,3298,B-DiseaseOrPhenotypicFeature
),3298,O
type,3298,O
is,3298,O
associated,3298,O
with,3298,O
dysfunction,3298,O
of,3298,O
the,3298,O
insulin-receptor,3298,B-GeneOrGeneProduct
(,3298,O
IR,3298,B-GeneOrGeneProduct
),3298,O
system,3298,O
followed,3298,O
by,3298,O
decreased,3298,O
glucose,3298,B-ChemicalEntity
transport,3298,O
via,3298,O
glucose,3298,B-ChemicalEntity
transporter,3298,O
GLUT4,3298,B-GeneOrGeneProduct
and,3298,O
decreased,3298,O
glucose,3298,B-ChemicalEntity
metabolism,3298,O
in,3298,O
brain,3298,O
cells,3298,O
.,3298,O
An,3299,O
alternative,3299,O
source,3299,O
of,3299,O
energy,3299,O
is,3299,O
d-galactose,3299,B-ChemicalEntity
(,3299,O
the,3299,O
C-4-epimer,3299,O
of,3299,O
d-glucose,3299,B-ChemicalEntity
),3299,O
which,3299,O
is,3299,O
transported,3299,O
into,3299,O
the,3299,O
brain,3299,O
by,3299,O
insulin-independent,3299,B-GeneOrGeneProduct
GLUT3,3299,B-GeneOrGeneProduct
transporter,3299,O
where,3299,O
it,3299,O
might,3299,O
be,3299,O
metabolized,3299,O
to,3299,O
glucose,3299,B-ChemicalEntity
via,3299,O
the,3299,O
Leloir,3299,O
pathway,3299,O
.,3299,O
Exclusively,3300,O
parenteral,3300,O
daily,3300,O
injections,3300,O
of,3300,O
galactose,3300,B-ChemicalEntity
induce,3300,O
memory,3300,B-DiseaseOrPhenotypicFeature
deterioration,3300,I-DiseaseOrPhenotypicFeature
in,3300,O
rodents,3300,O
and,3300,O
are,3300,O
used,3300,O
to,3300,O
generate,3300,O
animal,3300,O
aging,3300,O
model,3300,O
",",3300,O
but,3300,O
the,3300,O
effects,3300,O
of,3300,O
oral,3300,O
galactose,3300,B-ChemicalEntity
treatment,3300,O
on,3300,O
cognitive,3300,O
functions,3300,O
have,3300,O
never,3300,O
been,3300,O
tested,3300,O
.,3300,O
We,3301,O
have,3301,O
investigated,3301,O
the,3301,O
effects,3301,O
of,3301,O
continuous,3301,O
daily,3301,O
oral,3301,O
galactose,3301,B-ChemicalEntity
(,3301,O
200,3301,O
mg/kg/day,3301,O
),3301,O
treatment,3301,O
on,3301,O
cognitive,3301,B-DiseaseOrPhenotypicFeature
deficits,3301,I-DiseaseOrPhenotypicFeature
in,3301,O
streptozotocin-induced,3301,B-ChemicalEntity
(,3301,O
STZ-icv,3301,B-ChemicalEntity
),3301,O
rat,3301,B-OrganismTaxon
model,3301,O
of,3301,O
sAD,3301,B-DiseaseOrPhenotypicFeature
",",3301,O
tested,3301,O
by,3301,O
Morris,3301,O
Water,3301,O
Maze,3301,O
and,3301,O
Passive,3301,O
Avoidance,3301,O
test,3301,O
",",3301,O
respectively,3301,O
.,3301,O
One,3302,O
month,3302,O
of,3302,O
oral,3302,O
galactose,3302,B-ChemicalEntity
treatment,3302,O
initiated,3302,O
immediately,3302,O
after,3302,O
the,3302,O
STZ-icv,3302,B-ChemicalEntity
administration,3302,O
",",3302,O
successfully,3302,O
prevented,3302,O
development,3302,O
of,3302,O
the,3302,O
STZ-icv-induced,3302,B-ChemicalEntity
cognitive,3302,B-DiseaseOrPhenotypicFeature
deficits,3302,I-DiseaseOrPhenotypicFeature
.,3302,O
Beneficial,3303,O
effect,3303,O
of,3303,O
oral,3303,O
galactose,3303,B-ChemicalEntity
was,3303,O
independent,3303,O
of,3303,O
the,3303,O
rat,3303,B-OrganismTaxon
age,3303,O
and,3303,O
of,3303,O
the,3303,O
galactose,3303,B-ChemicalEntity
dose,3303,O
ranging,3303,O
from,3303,O
100,3303,O
to,3303,O
300,3303,O
mg/kg/day,3303,O
.,3303,O
Additionally,3304,O
",",3304,O
oral,3304,O
galactose,3304,B-ChemicalEntity
administration,3304,O
led,3304,O
to,3304,O
the,3304,O
appearance,3304,O
of,3304,O
galactose,3304,B-ChemicalEntity
in,3304,O
the,3304,O
blood,3304,O
.,3304,O
The,3305,O
increase,3305,O
of,3305,O
galactose,3305,B-ChemicalEntity
concentration,3305,O
in,3305,O
the,3305,O
cerebrospinal,3305,O
fluid,3305,O
was,3305,O
several,3305,O
times,3305,O
lower,3305,O
after,3305,O
oral,3305,O
than,3305,O
after,3305,O
parenteral,3305,O
administration,3305,O
of,3305,O
the,3305,O
same,3305,O
galactose,3305,B-ChemicalEntity
dose,3305,O
.,3305,O
Oral,3306,O
galactose,3306,B-ChemicalEntity
exposure,3306,O
might,3306,O
have,3306,O
beneficial,3306,O
effects,3306,O
on,3306,O
learning,3306,O
and,3306,O
memory,3306,O
ability,3306,O
and,3306,O
could,3306,O
be,3306,O
worth,3306,O
investigating,3306,O
for,3306,O
improvement,3306,O
of,3306,O
cognitive,3306,B-DiseaseOrPhenotypicFeature
deficits,3306,I-DiseaseOrPhenotypicFeature
associated,3306,O
with,3306,O
glucose,3306,B-DiseaseOrPhenotypicFeature
hypometabolism,3306,I-DiseaseOrPhenotypicFeature
in,3306,O
AD,3306,B-DiseaseOrPhenotypicFeature
.,3306,O
Takotsubo,3307,B-DiseaseOrPhenotypicFeature
syndrome,3307,I-DiseaseOrPhenotypicFeature
(,3307,O
or,3307,O
apical,3307,B-DiseaseOrPhenotypicFeature
ballooning,3307,I-DiseaseOrPhenotypicFeature
syndrome,3307,I-DiseaseOrPhenotypicFeature
),3307,O
secondary,3307,O
to,3307,O
Zolmitriptan,3307,B-ChemicalEntity
.,3307,O
Takotsubo,3308,B-DiseaseOrPhenotypicFeature
syndrome,3308,I-DiseaseOrPhenotypicFeature
(,3308,O
TS,3308,B-DiseaseOrPhenotypicFeature
),3308,O
",",3308,O
also,3308,O
known,3308,O
as,3308,O
broken,3308,B-DiseaseOrPhenotypicFeature
heart,3308,I-DiseaseOrPhenotypicFeature
syndrome,3308,I-DiseaseOrPhenotypicFeature
",",3308,O
is,3308,O
characterized,3308,O
by,3308,O
left,3308,O
ventricle,3308,O
apical,3308,O
ballooning,3308,O
with,3308,O
elevated,3308,O
cardiac,3308,O
biomarkers,3308,O
and,3308,O
electrocardiographic,3308,O
changes,3308,O
suggestive,3308,O
of,3308,O
an,3308,O
acute,3308,B-DiseaseOrPhenotypicFeature
coronary,3308,I-DiseaseOrPhenotypicFeature
syndrome,3308,I-DiseaseOrPhenotypicFeature
(,3308,O
ie,3308,O
",",3308,O
ST-segment,3308,O
elevation,3308,O
",",3308,O
T,3308,O
wave,3308,O
inversions,3308,O
",",3308,O
and,3308,O
pathologic,3308,O
Q,3308,O
waves,3308,O
),3308,O
.,3308,O
We,3309,O
report,3309,O
a,3309,O
case,3309,O
of,3309,O
54-year-old,3309,O
woman,3309,B-OrganismTaxon
with,3309,O
medical,3309,O
history,3309,O
of,3309,O
mitral,3309,B-DiseaseOrPhenotypicFeature
valve,3309,I-DiseaseOrPhenotypicFeature
prolapse,3309,I-DiseaseOrPhenotypicFeature
and,3309,O
migraines,3309,B-DiseaseOrPhenotypicFeature
",",3309,O
who,3309,O
was,3309,O
admitted,3309,O
to,3309,O
the,3309,O
hospital,3309,O
for,3309,O
substernal,3309,O
chest,3309,B-DiseaseOrPhenotypicFeature
pain,3309,I-DiseaseOrPhenotypicFeature
and,3309,O
electrocardiogram,3309,O
demonstrated,3309,O
1/2,3309,O
mm,3309,O
ST-segment,3309,O
elevation,3309,O
in,3309,O
leads,3309,O
II,3309,O
",",3309,O
III,3309,O
",",3309,O
aVF,3309,O
",",3309,O
V5,3309,O
",",3309,O
and,3309,O
V6,3309,O
and,3309,O
positive,3309,O
troponin,3309,O
I.,3309,O
Emergent,3309,O
coronary,3309,O
angiogram,3309,O
revealed,3309,O
normal,3309,O
coronary,3309,O
arteries,3309,O
with,3309,O
moderately,3309,O
reduced,3309,O
left,3309,O
ventricular,3309,O
ejection,3309,O
fraction,3309,O
with,3309,O
wall,3309,O
motion,3309,B-DiseaseOrPhenotypicFeature
abnormalities,3309,I-DiseaseOrPhenotypicFeature
consistent,3309,O
with,3309,O
TS,3309,B-DiseaseOrPhenotypicFeature
.,3309,O
Detailed,3310,O
history,3310,O
obtained,3310,O
retrospectively,3310,O
revealed,3310,O
that,3310,O
the,3310,O
patient,3310,B-OrganismTaxon
took,3310,O
zolmitriptan,3310,B-ChemicalEntity
sparingly,3310,O
only,3310,O
when,3310,O
she,3310,O
had,3310,O
migraines,3310,B-DiseaseOrPhenotypicFeature
.,3310,O
But,3311,O
before,3311,O
this,3311,O
event,3311,O
",",3311,O
she,3311,O
was,3311,O
taking,3311,O
zolmitriptan,3311,B-ChemicalEntity
2-3,3311,O
times,3311,O
daily,3311,O
for,3311,O
several,3311,O
days,3311,O
because,3311,O
of,3311,O
a,3311,O
persistent,3311,O
migraine,3311,B-DiseaseOrPhenotypicFeature
headache,3311,I-DiseaseOrPhenotypicFeature
.,3311,O
She,3312,O
otherwise,3312,O
reported,3312,O
that,3312,O
she,3312,O
is,3312,O
quite,3312,O
active,3312,O
",",3312,O
rides,3312,O
horses,3312,B-OrganismTaxon
",",3312,O
and,3312,O
does,3312,O
show,3312,O
jumping,3312,O
without,3312,O
any,3312,O
limitations,3312,O
in,3312,O
her,3312,O
physical,3312,O
activity,3312,O
.,3312,O
There,3313,O
was,3313,O
no,3313,O
evidence,3313,O
of,3313,O
any,3313,O
recent,3313,O
stress,3313,O
or,3313,O
status,3313,B-DiseaseOrPhenotypicFeature
migrainosus,3313,I-DiseaseOrPhenotypicFeature
.,3313,O
Extensive,3314,O
literature,3314,O
search,3314,O
revealed,3314,O
multiple,3314,O
cases,3314,O
of,3314,O
coronary,3314,B-DiseaseOrPhenotypicFeature
artery,3314,I-DiseaseOrPhenotypicFeature
vasospasm,3314,I-DiseaseOrPhenotypicFeature
secondary,3314,O
to,3314,O
zolmitriptan,3314,B-ChemicalEntity
",",3314,O
but,3314,O
none,3314,O
of,3314,O
the,3314,O
cases,3314,O
were,3314,O
associated,3314,O
with,3314,O
TS,3314,B-DiseaseOrPhenotypicFeature
.,3314,O
Association,3315,O
of,3315,O
common,3315,O
genetic,3315,O
variants,3315,O
of,3315,O
HOMER1,3315,B-GeneOrGeneProduct
gene,3315,O
with,3315,O
levodopa,3315,B-ChemicalEntity
adverse,3315,O
effects,3315,O
in,3315,O
Parkinson,3315,B-DiseaseOrPhenotypicFeature
's,3315,I-DiseaseOrPhenotypicFeature
disease,3315,I-DiseaseOrPhenotypicFeature
patients,3315,B-OrganismTaxon
.,3315,O
Levodopa,3316,B-ChemicalEntity
is,3316,O
the,3316,O
most,3316,O
effective,3316,O
symptomatic,3316,O
therapy,3316,O
for,3316,O
Parkinson,3316,B-DiseaseOrPhenotypicFeature
's,3316,I-DiseaseOrPhenotypicFeature
disease,3316,I-DiseaseOrPhenotypicFeature
",",3316,O
but,3316,O
its,3316,O
chronic,3316,O
use,3316,O
could,3316,O
lead,3316,O
to,3316,O
chronic,3316,O
adverse,3316,O
outcomes,3316,O
",",3316,O
such,3316,O
as,3316,O
motor,3316,O
fluctuations,3316,O
",",3316,O
dyskinesia,3316,B-DiseaseOrPhenotypicFeature
and,3316,O
visual,3316,B-DiseaseOrPhenotypicFeature
hallucinations,3316,I-DiseaseOrPhenotypicFeature
.,3316,O
HOMER1,3317,B-GeneOrGeneProduct
is,3317,O
a,3317,O
protein,3317,O
with,3317,O
pivotal,3317,O
function,3317,O
in,3317,O
glutamate,3317,B-ChemicalEntity
transmission,3317,O
",",3317,O
which,3317,O
has,3317,O
been,3317,O
related,3317,O
to,3317,O
the,3317,O
pathogenesis,3317,O
of,3317,O
these,3317,O
complications,3317,O
.,3317,O
This,3318,O
study,3318,O
investigates,3318,O
whether,3318,O
polymorphisms,3318,O
in,3318,O
the,3318,O
HOMER1,3318,B-GeneOrGeneProduct
gene,3318,O
promoter,3318,O
region,3318,O
are,3318,O
associated,3318,O
with,3318,O
the,3318,O
occurrence,3318,O
of,3318,O
the,3318,O
chronic,3318,O
complications,3318,O
of,3318,O
levodopa,3318,B-ChemicalEntity
therapy,3318,O
.,3318,O
A,3319,O
total,3319,O
of,3319,O
205,3319,O
patients,3319,B-OrganismTaxon
with,3319,O
idiopathic,3319,B-DiseaseOrPhenotypicFeature
Parkinson,3319,I-DiseaseOrPhenotypicFeature
's,3319,I-DiseaseOrPhenotypicFeature
disease,3319,I-DiseaseOrPhenotypicFeature
were,3319,O
investigated,3319,O
.,3319,O
Patients,3320,B-OrganismTaxon
were,3320,O
genotyped,3320,O
for,3320,O
rs4704559,3320,B-SequenceVariant
",",3320,O
rs10942891,3320,B-SequenceVariant
and,3320,O
rs4704560,3320,B-SequenceVariant
by,3320,O
allelic,3320,O
discrimination,3320,O
with,3320,O
Taqman,3320,O
assays,3320,O
.,3320,O
The,3321,O
rs4704559,3321,B-SequenceVariant
G,3321,O
allele,3321,O
was,3321,O
associated,3321,O
with,3321,O
a,3321,O
lower,3321,O
prevalence,3321,O
of,3321,O
dyskinesia,3321,B-DiseaseOrPhenotypicFeature
(,3321,O
prevalence,3321,O
ratio,3321,O
(,3321,O
PR,3321,O
),3321,O
=0.615,3321,O
",",3321,O
95,3321,O
%,3321,O
confidence,3321,O
interval,3321,O
(,3321,O
CI,3321,O
),3321,O
0.426-0.887,3321,O
",",3321,O
P=0.009,3321,O
),3321,O
and,3321,O
visual,3321,B-DiseaseOrPhenotypicFeature
hallucinations,3321,I-DiseaseOrPhenotypicFeature
(,3321,O
PR=0.515,3321,O
",",3321,O
95,3321,O
%,3321,O
CI,3321,O
0.295-0.899,3321,O
",",3321,O
P=0.020,3321,O
),3321,O
.,3321,O
Our,3322,O
data,3322,O
suggest,3322,O
that,3322,O
HOMER1,3322,B-GeneOrGeneProduct
rs4704559,3322,B-SequenceVariant
G,3322,O
allele,3322,O
has,3322,O
a,3322,O
protective,3322,O
role,3322,O
for,3322,O
the,3322,O
development,3322,O
of,3322,O
levodopa,3322,B-ChemicalEntity
adverse,3322,O
effects,3322,O
.,3322,O
Crocin,3323,B-ChemicalEntity
improves,3323,O
lipid,3323,B-ChemicalEntity
dysregulation,3323,O
in,3323,O
subacute,3323,O
diazinon,3323,B-ChemicalEntity
exposure,3323,O
through,3323,O
ERK1/2,3323,B-GeneOrGeneProduct
pathway,3323,O
in,3323,O
rat,3323,B-OrganismTaxon
liver,3323,O
.,3323,O
INTRODUCTION,3324,O
:,3324,O
Diazinon,3324,B-ChemicalEntity
Yis,3324,O
one,3324,O
of,3324,O
the,3324,O
most,3324,O
broadly,3324,O
used,3324,O
organophosphorus,3324,B-ChemicalEntity
insecticides,3324,O
in,3324,O
agriculture,3324,O
.,3324,O
It,3325,O
has,3325,O
been,3325,O
shown,3325,O
that,3325,O
exposure,3325,O
to,3325,O
diazinon,3325,B-ChemicalEntity
may,3325,O
interfere,3325,O
with,3325,O
lipid,3325,B-ChemicalEntity
metabolism,3325,O
.,3325,O
Moreover,3326,O
",",3326,O
the,3326,O
hypolipidemic,3326,O
effect,3326,O
of,3326,O
crocin,3326,B-ChemicalEntity
has,3326,O
been,3326,O
established,3326,O
.,3326,O
Earlier,3327,O
studies,3327,O
revealed,3327,O
the,3327,O
major,3327,O
role,3327,O
of,3327,O
Extracellular,3327,B-GeneOrGeneProduct
signal-regulated,3327,I-GeneOrGeneProduct
kinase,3327,I-GeneOrGeneProduct
(,3327,O
ERK,3327,B-GeneOrGeneProduct
),3327,O
pathways,3327,O
in,3327,O
low-density,3327,B-GeneOrGeneProduct
lipoprotein,3327,I-GeneOrGeneProduct
receptor,3327,I-GeneOrGeneProduct
(,3327,O
LDLr,3327,B-GeneOrGeneProduct
),3327,O
expression,3327,O
.,3327,O
The,3328,O
aim,3328,O
of,3328,O
this,3328,O
study,3328,O
was,3328,O
to,3328,O
evaluate,3328,O
changes,3328,O
in,3328,O
the,3328,O
regulation,3328,O
of,3328,O
lipid,3328,B-ChemicalEntity
metabolism,3328,O
",",3328,O
ERK,3328,B-GeneOrGeneProduct
and,3328,O
LDLr,3328,B-GeneOrGeneProduct
expression,3328,O
in,3328,O
the,3328,O
liver,3328,O
of,3328,O
rats,3328,B-OrganismTaxon
exposed,3328,O
to,3328,O
subacute,3328,O
diazinon,3328,B-ChemicalEntity
.,3328,O
Furthermore,3329,O
ameliorating,3329,O
effect,3329,O
of,3329,O
crocin,3329,B-ChemicalEntity
on,3329,O
diazinon,3329,B-ChemicalEntity
induced,3329,O
disturbed,3329,O
cholesterol,3329,B-ChemicalEntity
homeostasis,3329,O
was,3329,O
studied,3329,O
.,3329,O
METHODS,3330,O
:,3330,O
24,3330,O
Rats,3330,B-OrganismTaxon
were,3330,O
divided,3330,O
into,3330,O
4,3330,O
groups,3330,O
and,3330,O
received,3330,O
following,3330,O
treatments,3330,O
for,3330,O
4,3330,O
weeks,3330,O
;,3330,O
Corn,3330,B-ChemicalEntity
oil,3330,I-ChemicalEntity
(,3330,O
control,3330,O
),3330,O
",",3330,O
diazinon,3330,B-ChemicalEntity
(,3330,O
15mg/kg,3330,O
per,3330,O
day,3330,O
",",3330,O
orally,3330,O
),3330,O
and,3330,O
crocin,3330,B-ChemicalEntity
(,3330,O
12.5,3330,O
and,3330,O
25mg/kg,3330,O
per,3330,O
day,3330,O
",",3330,O
intraperitoneally,3330,O
),3330,O
in,3330,O
combination,3330,O
with,3330,O
diazinon,3330,B-ChemicalEntity
(,3330,O
15,3330,O
mg/kg,3330,O
),3330,O
.,3330,O
The,3331,O
levels,3331,O
of,3331,O
cholesterol,3331,B-ChemicalEntity
",",3331,O
triglyceride,3331,B-ChemicalEntity
and,3331,O
LDL,3331,B-ChemicalEntity
in,3331,O
blood,3331,O
of,3331,O
rats,3331,B-OrganismTaxon
were,3331,O
analyzed,3331,O
.,3331,O
Moreover,3332,O
mRNA,3332,O
levels,3332,O
of,3332,O
LDLr,3332,B-GeneOrGeneProduct
and,3332,O
ERK1/2,3332,B-GeneOrGeneProduct
as,3332,O
well,3332,O
as,3332,O
protein,3332,O
levels,3332,O
of,3332,O
total,3332,O
and,3332,O
activated,3332,O
forms,3332,O
of,3332,O
ERK1/2,3332,B-GeneOrGeneProduct
in,3332,O
rat,3332,B-OrganismTaxon
liver,3332,O
were,3332,O
evaluated,3332,O
by,3332,O
Western,3332,O
blotting,3332,O
and,3332,O
quantitative,3332,O
real,3332,O
time,3332,O
polymerase,3332,O
chain,3332,O
reaction,3332,O
analysis,3332,O
.,3332,O
RESULTS,3333,O
:,3333,O
Our,3333,O
data,3333,O
showed,3333,O
that,3333,O
subacute,3333,O
exposure,3333,O
to,3333,O
diazinon,3333,B-ChemicalEntity
significantly,3333,O
increased,3333,O
concentrations,3333,O
of,3333,O
cholesterol,3333,B-ChemicalEntity
",",3333,O
triglyceride,3333,B-ChemicalEntity
and,3333,O
LDL,3333,B-ChemicalEntity
.,3333,O
Moreover,3334,O
diazinon,3334,B-ChemicalEntity
decreased,3334,O
ERK1/2,3334,B-GeneOrGeneProduct
protein,3334,O
phosphorylation,3334,O
and,3334,O
LDLr,3334,B-GeneOrGeneProduct
transcript,3334,O
.,3334,O
Crocin,3335,B-ChemicalEntity
reduced,3335,O
inhibition,3335,O
of,3335,O
ERK,3335,B-GeneOrGeneProduct
activation,3335,O
and,3335,O
diazinon-induced,3335,B-ChemicalEntity
hyperlipemia,3335,B-DiseaseOrPhenotypicFeature
and,3335,O
increased,3335,O
levels,3335,O
of,3335,O
LDLr,3335,B-GeneOrGeneProduct
transcript,3335,O
.,3335,O
CONCLUSIONS,3336,O
:,3336,O
Crocin,3336,B-ChemicalEntity
may,3336,O
be,3336,O
considered,3336,O
as,3336,O
a,3336,O
novel,3336,O
protective,3336,O
agent,3336,O
in,3336,O
diazinon-induced,3336,B-ChemicalEntity
hyperlipemia,3336,B-DiseaseOrPhenotypicFeature
through,3336,O
modulating,3336,O
of,3336,O
ERK,3336,B-GeneOrGeneProduct
pathway,3336,O
and,3336,O
increase,3336,O
of,3336,O
LDLr,3336,B-GeneOrGeneProduct
expression,3336,O
.,3336,O
Cholecystokinin-octapeptide,3337,B-ChemicalEntity
restored,3337,O
morphine-induced,3337,B-ChemicalEntity
hippocampal,3337,O
long-term,3337,O
potentiation,3337,O
impairment,3337,O
in,3337,O
rats,3337,B-OrganismTaxon
.,3337,O
Cholecystokinin-octapeptide,3338,B-ChemicalEntity
(,3338,O
CCK-8,3338,B-ChemicalEntity
),3338,O
",",3338,O
which,3338,O
is,3338,O
a,3338,O
typical,3338,O
brain-gut,3338,O
peptide,3338,O
",",3338,O
exerts,3338,O
a,3338,O
wide,3338,O
range,3338,O
of,3338,O
biological,3338,O
activities,3338,O
on,3338,O
the,3338,O
central,3338,O
nervous,3338,O
system,3338,O
.,3338,O
We,3339,O
have,3339,O
previously,3339,O
reported,3339,O
that,3339,O
CCK-8,3339,B-ChemicalEntity
significantly,3339,O
alleviated,3339,O
morphine-induced,3339,B-ChemicalEntity
amnesia,3339,B-DiseaseOrPhenotypicFeature
and,3339,O
reversed,3339,O
spine,3339,O
density,3339,O
decreases,3339,O
in,3339,O
the,3339,O
CA1,3339,O
region,3339,O
of,3339,O
the,3339,O
hippocampus,3339,O
in,3339,O
morphine-treated,3339,B-ChemicalEntity
animals,3339,O
.,3339,O
Here,3340,O
",",3340,O
we,3340,O
investigated,3340,O
the,3340,O
effects,3340,O
of,3340,O
CCK-8,3340,B-ChemicalEntity
on,3340,O
long-term,3340,O
potentiation,3340,O
(,3340,O
LTP,3340,O
),3340,O
in,3340,O
the,3340,O
lateral,3340,O
perforant,3340,O
path,3340,O
(,3340,O
LPP,3340,O
),3340,O
-granule,3340,O
cell,3340,O
synapse,3340,O
of,3340,O
rat,3340,B-OrganismTaxon
dentate,3340,O
gyrus,3340,O
(,3340,O
DG,3340,O
),3340,O
in,3340,O
acute,3340,O
saline,3340,O
or,3340,O
morphine-treated,3340,B-ChemicalEntity
rats,3340,B-OrganismTaxon
.,3340,O
Population,3341,O
spikes,3341,O
(,3341,O
PS,3341,O
),3341,O
",",3341,O
which,3341,O
were,3341,O
evoked,3341,O
by,3341,O
stimulation,3341,O
of,3341,O
the,3341,O
LPP,3341,O
",",3341,O
were,3341,O
recorded,3341,O
in,3341,O
the,3341,O
DG,3341,O
region,3341,O
.,3341,O
Acute,3342,O
morphine,3342,B-ChemicalEntity
(,3342,O
30mg/kg,3342,O
",",3342,O
s.c.,3342,O
),3342,O
treatment,3342,O
significantly,3342,O
attenuated,3342,O
hippocampal,3342,O
LTP,3342,O
and,3342,O
CCK-8,3342,B-ChemicalEntity
(,3342,O
1ug,3342,O
",",3342,O
i.c.v,3342,O
.,3342,O
),3342,O
restored,3343,O
the,3343,O
amplitude,3343,O
of,3343,O
PS,3343,O
that,3343,O
was,3343,O
attenuated,3343,O
by,3343,O
morphine,3343,B-ChemicalEntity
injection,3343,O
.,3343,O
Furthermore,3344,O
",",3344,O
microinjection,3344,O
of,3344,O
CCK-8,3344,B-ChemicalEntity
(,3344,O
0.1,3344,O
and,3344,O
1ug,3344,O
",",3344,O
i.c.v,3344,O
.,3344,O
),3344,O
also,3345,O
significantly,3345,O
augmented,3345,O
hippocampal,3345,O
LTP,3345,O
in,3345,O
saline-treated,3345,O
(,3345,O
1ml/kg,3345,O
",",3345,O
s.c.,3345,O
),3345,O
rats,3345,B-OrganismTaxon
.,3345,O
Pre-treatment,3346,O
of,3346,O
the,3346,O
CCK2,3346,B-GeneOrGeneProduct
receptor,3346,I-GeneOrGeneProduct
antagonist,3346,O
"L-365,260",3346,B-ChemicalEntity
(,3346,O
10ug,3346,O
",",3346,O
i.c.v,3346,O
),3346,O
reversed,3346,O
the,3346,O
effects,3346,O
of,3346,O
CCK-8,3346,B-ChemicalEntity
",",3346,O
but,3346,O
the,3346,O
CCK1,3346,B-GeneOrGeneProduct
receptor,3346,I-GeneOrGeneProduct
antagonist,3346,O
"L-364,718",3346,B-ChemicalEntity
(,3346,O
10ug,3346,O
",",3346,O
i.c.v,3346,O
),3346,O
did,3346,O
not,3346,O
.,3346,O
The,3347,O
present,3347,O
results,3347,O
demonstrate,3347,O
that,3347,O
CCK-8,3347,B-ChemicalEntity
attenuates,3347,O
the,3347,O
effect,3347,O
of,3347,O
morphine,3347,B-ChemicalEntity
on,3347,O
hippocampal,3347,O
LTP,3347,O
through,3347,O
CCK2,3347,B-GeneOrGeneProduct
receptors,3347,I-GeneOrGeneProduct
and,3347,O
suggest,3347,O
an,3347,O
ameliorative,3347,O
function,3347,O
of,3347,O
CCK-8,3347,B-ChemicalEntity
on,3347,O
morphine-induced,3347,B-ChemicalEntity
memory,3347,B-DiseaseOrPhenotypicFeature
impairment,3347,I-DiseaseOrPhenotypicFeature
.,3347,O
Comparison,3348,O
of,3348,O
effects,3348,O
of,3348,O
isotonic,3348,O
sodium,3348,B-ChemicalEntity
chloride,3348,I-ChemicalEntity
with,3348,O
diltiazem,3348,B-ChemicalEntity
in,3348,O
prevention,3348,O
of,3348,O
contrast-induced,3348,B-ChemicalEntity
nephropathy,3348,B-DiseaseOrPhenotypicFeature
.,3348,O
INTRODUCTION,3349,O
AND,3349,O
OBJECTIVE,3349,O
:,3349,O
Contrast-induced,3349,B-ChemicalEntity
nephropathy,3349,B-DiseaseOrPhenotypicFeature
(,3349,O
CIN,3349,B-DiseaseOrPhenotypicFeature
),3349,O
significantly,3349,O
increases,3349,O
the,3349,O
morbidity,3349,O
and,3349,O
mortality,3349,O
of,3349,O
patients,3349,B-OrganismTaxon
.,3349,O
The,3350,O
aim,3350,O
of,3350,O
this,3350,O
study,3350,O
is,3350,O
to,3350,O
investigate,3350,O
and,3350,O
compare,3350,O
the,3350,O
protective,3350,O
effects,3350,O
of,3350,O
isotonic,3350,O
sodium,3350,B-ChemicalEntity
chloride,3350,I-ChemicalEntity
with,3350,O
sodium,3350,B-ChemicalEntity
bicarbonate,3350,I-ChemicalEntity
infusion,3350,O
and,3350,O
isotonic,3350,O
sodium,3350,B-ChemicalEntity
chloride,3350,I-ChemicalEntity
infusion,3350,O
with,3350,O
diltiazem,3350,B-ChemicalEntity
",",3350,O
a,3350,O
calcium,3350,B-ChemicalEntity
channel,3350,O
blocker,3350,O
",",3350,O
in,3350,O
preventing,3350,O
CIN,3350,B-DiseaseOrPhenotypicFeature
.,3350,O
MATERIALS,3351,O
AND,3351,O
METHODS,3351,O
:,3351,O
Our,3351,O
study,3351,O
included,3351,O
patients,3351,B-OrganismTaxon
who,3351,O
were,3351,O
administered,3351,O
30-60,3351,O
mL,3351,O
of,3351,O
iodinated,3351,O
contrast,3351,B-ChemicalEntity
agent,3351,O
for,3351,O
percutaneous,3351,O
coronary,3351,O
angiography,3351,O
(,3351,O
PCAG,3351,O
),3351,O
",",3351,O
all,3351,O
with,3351,O
creatinine,3351,B-ChemicalEntity
values,3351,O
between,3351,O
1.1,3351,O
and,3351,O
3.1,3351,O
mg/dL,3351,O
.,3351,O
Patients,3352,B-OrganismTaxon
were,3352,O
divided,3352,O
into,3352,O
three,3352,O
groups,3352,O
and,3352,O
each,3352,O
group,3352,O
had,3352,O
20,3352,O
patients,3352,B-OrganismTaxon
.,3352,O
The,3353,O
first,3353,O
group,3353,O
of,3353,O
patients,3353,B-OrganismTaxon
was,3353,O
administered,3353,O
isotonic,3353,O
sodium,3353,B-ChemicalEntity
chloride,3353,I-ChemicalEntity
;,3353,O
the,3353,O
second,3353,O
group,3353,O
was,3353,O
administered,3353,O
a,3353,O
solution,3353,O
that,3353,O
of,3353,O
5,3353,O
%,3353,O
dextrose,3353,B-ChemicalEntity
and,3353,O
sodium,3353,B-ChemicalEntity
bicarbonate,3353,I-ChemicalEntity
",",3353,O
while,3353,O
the,3353,O
third,3353,O
group,3353,O
was,3353,O
administered,3353,O
isotonic,3353,O
sodium,3353,B-ChemicalEntity
chloride,3353,I-ChemicalEntity
before,3353,O
and,3353,O
after,3353,O
the,3353,O
contrast,3353,B-ChemicalEntity
injection,3353,O
.,3353,O
The,3354,O
third,3354,O
group,3354,O
received,3354,O
an,3354,O
additional,3354,O
injection,3354,O
of,3354,O
diltiazem,3354,B-ChemicalEntity
the,3354,O
day,3354,O
before,3354,O
and,3354,O
first,3354,O
2,3354,O
days,3354,O
after,3354,O
the,3354,O
contrast,3354,B-ChemicalEntity
injection,3354,O
.,3354,O
All,3355,O
of,3355,O
the,3355,O
patients,3355,B-OrganismTaxon
',3355,O
plasma,3355,O
blood,3355,B-ChemicalEntity
urea,3355,I-ChemicalEntity
nitrogen,3355,I-ChemicalEntity
(,3355,O
BUN,3355,B-ChemicalEntity
),3355,O
and,3355,O
creatinine,3355,B-ChemicalEntity
levels,3355,O
were,3355,O
measured,3355,O
on,3355,O
the,3355,O
second,3355,O
and,3355,O
seventh,3355,O
day,3355,O
after,3355,O
the,3355,O
administration,3355,O
of,3355,O
intravenous,3355,O
contrast,3355,B-ChemicalEntity
material,3355,O
.,3355,O
RESULTS,3356,O
:,3356,O
The,3356,O
basal,3356,O
creatinine,3356,B-ChemicalEntity
levels,3356,O
were,3356,O
similar,3356,O
for,3356,O
all,3356,O
three,3356,O
groups,3356,O
(,3356,O
p,3356,O
>,3356,O
0.05,3356,O
),3356,O
.,3356,O
Among,3357,O
a,3357,O
total,3357,O
of,3357,O
60,3357,O
patients,3357,B-OrganismTaxon
included,3357,O
in,3357,O
the,3357,O
study,3357,O
",",3357,O
16,3357,O
patients,3357,B-OrganismTaxon
developed,3357,O
acute,3357,B-DiseaseOrPhenotypicFeature
renal,3357,I-DiseaseOrPhenotypicFeature
failure,3357,I-DiseaseOrPhenotypicFeature
(,3357,O
ARF,3357,B-DiseaseOrPhenotypicFeature
),3357,O
on,3357,O
the,3357,O
second,3357,O
day,3357,O
after,3357,O
contrast,3357,B-ChemicalEntity
material,3357,O
was,3357,O
injected,3357,O
(,3357,O
26.6,3357,O
%,3357,O
),3357,O
.,3357,O
The,3358,O
number,3358,O
of,3358,O
patients,3358,B-OrganismTaxon
who,3358,O
developed,3358,O
ARF,3358,B-DiseaseOrPhenotypicFeature
on,3358,O
the,3358,O
second,3358,O
day,3358,O
after,3358,O
the,3358,O
injection,3358,O
in,3358,O
the,3358,O
first,3358,O
group,3358,O
was,3358,O
five,3358,O
(,3358,O
25,3358,O
%,3358,O
),3358,O
",",3358,O
in,3358,O
the,3358,O
second,3358,O
group,3358,O
was,3358,O
six,3358,O
(,3358,O
30,3358,O
%,3358,O
),3358,O
and,3358,O
the,3358,O
third,3358,O
group,3358,O
was,3358,O
five,3358,O
(,3358,O
25,3358,O
%,3358,O
),3358,O
(,3358,O
p,3358,O
>,3358,O
0.05,3358,O
),3358,O
.,3358,O
CONCLUSION,3359,O
:,3359,O
There,3359,O
was,3359,O
no,3359,O
significant,3359,O
difference,3359,O
between,3359,O
isotonic,3359,O
sodium,3359,B-ChemicalEntity
chloride,3359,I-ChemicalEntity
",",3359,O
sodium,3359,B-ChemicalEntity
bicarbonate,3359,I-ChemicalEntity
and,3359,O
isotonic,3359,O
sodium,3359,B-ChemicalEntity
chloride,3359,I-ChemicalEntity
with,3359,O
diltiazem,3359,B-ChemicalEntity
application,3359,O
in,3359,O
prevention,3359,O
of,3359,O
CIN,3359,B-DiseaseOrPhenotypicFeature
.,3359,O
The,3360,O
-930A,3360,B-SequenceVariant
>,3360,I-SequenceVariant
G,3360,I-SequenceVariant
polymorphism,3360,O
of,3360,O
the,3360,O
CYBA,3360,B-GeneOrGeneProduct
gene,3360,O
is,3360,O
associated,3360,O
with,3360,O
premature,3360,O
coronary,3360,B-DiseaseOrPhenotypicFeature
artery,3360,I-DiseaseOrPhenotypicFeature
disease,3360,I-DiseaseOrPhenotypicFeature
.,3360,O
A,3361,O
case-control,3361,O
study,3361,O
and,3361,O
gene-risk,3361,O
factors,3361,O
interactions,3361,O
.,3361,O
Reactive,3362,B-ChemicalEntity
oxygen,3362,I-ChemicalEntity
species,3362,I-ChemicalEntity
(,3362,O
ROS,3362,B-ChemicalEntity
),3362,O
are,3362,O
involved,3362,O
in,3362,O
the,3362,O
pathogenesis,3362,O
of,3362,O
atherosclerosis,3362,B-DiseaseOrPhenotypicFeature
and,3362,O
coronary,3362,B-DiseaseOrPhenotypicFeature
artery,3362,I-DiseaseOrPhenotypicFeature
disease,3362,I-DiseaseOrPhenotypicFeature
(,3362,O
CAD,3362,B-DiseaseOrPhenotypicFeature
),3362,O
.,3362,O
NADPH,3363,B-GeneOrGeneProduct
oxidases,3363,I-GeneOrGeneProduct
are,3363,O
the,3363,O
main,3363,O
source,3363,O
of,3363,O
ROS,3363,B-ChemicalEntity
in,3363,O
the,3363,O
vasculature,3363,O
.,3363,O
p22phox,3364,B-GeneOrGeneProduct
is,3364,O
a,3364,O
critical,3364,O
component,3364,O
of,3364,O
vascular,3364,O
NADPH,3364,B-GeneOrGeneProduct
oxidases,3364,I-GeneOrGeneProduct
and,3364,O
is,3364,O
encoded,3364,O
by,3364,O
the,3364,O
CYBA,3364,B-GeneOrGeneProduct
(,3364,O
cytochrome,3364,B-GeneOrGeneProduct
b245,3364,I-GeneOrGeneProduct
alpha,3364,I-GeneOrGeneProduct
),3364,O
gene,3364,O
.,3364,O
The,3365,O
-930A,3365,B-SequenceVariant
>,3365,I-SequenceVariant
G,3365,I-SequenceVariant
CYBA,3365,B-GeneOrGeneProduct
polymorphism,3365,O
(,3365,O
rs9932581,3365,B-SequenceVariant
:,3365,O
A,3365,B-SequenceVariant
>,3365,I-SequenceVariant
G,3365,I-SequenceVariant
),3365,O
modulates,3365,O
the,3365,O
activity,3365,O
of,3365,O
the,3365,O
CYBA,3365,B-GeneOrGeneProduct
promoter,3365,O
",",3365,O
and,3365,O
influences,3365,O
CYBA,3365,B-GeneOrGeneProduct
transcriptional,3365,O
activity,3365,O
.,3365,O
The,3366,O
aim,3366,O
of,3366,O
the,3366,O
present,3366,O
study,3366,O
was,3366,O
to,3366,O
analyze,3366,O
a,3366,O
possible,3366,O
association,3366,O
between,3366,O
the,3366,O
-930A,3366,B-SequenceVariant
>,3366,I-SequenceVariant
G,3366,I-SequenceVariant
polymorphism,3366,O
and,3366,O
CAD,3366,B-DiseaseOrPhenotypicFeature
and,3366,O
to,3366,O
search,3366,O
for,3366,O
gene-traditional,3366,O
risk,3366,O
factors,3366,O
interactions,3366,O
.,3366,O
480,3367,O
subjects,3367,O
were,3367,O
studied,3367,O
:,3367,O
240,3367,O
patients,3367,B-OrganismTaxon
with,3367,O
premature,3367,O
CAD,3367,B-DiseaseOrPhenotypicFeature
",",3367,O
240,3367,O
age,3367,O
and,3367,O
sex,3367,O
matched,3367,O
blood,3367,O
donors,3367,O
.,3367,O
The,3368,O
-930A,3368,B-SequenceVariant
>,3368,I-SequenceVariant
G,3368,I-SequenceVariant
polymorphism,3368,O
was,3368,O
genotyped,3368,O
using,3368,O
the,3368,O
TaqMan,3368,O
-,3368,O
Pre-designed,3368,O
SNP,3368,O
Genotyping,3368,O
Assay,3368,O
(,3368,O
Applied,3368,O
Biosystems,3368,O
),3368,O
.,3368,O
The,3369,O
-930G,3369,B-SequenceVariant
allele,3369,O
carrier,3369,O
state,3369,O
was,3369,O
a,3369,O
risk,3369,O
factor,3369,O
for,3369,O
CAD,3369,B-DiseaseOrPhenotypicFeature
(,3369,O
OR,3369,O
2.03,3369,O
",",3369,O
95,3369,O
%,3369,O
CI,3369,O
1.21-3.44,3369,O
",",3369,O
P=0.007,3369,O
),3369,O
.,3369,O
A,3370,O
synergistic,3370,O
effect,3370,O
of,3370,O
the,3370,O
-930G,3370,B-SequenceVariant
allele,3370,O
with,3370,O
overweight/obesity,3370,B-DiseaseOrPhenotypicFeature
(,3370,O
BMI,3370,O
--,3370,O
25,3370,O
),3370,O
and,3370,O
cigarette,3370,O
smoking,3370,O
was,3370,O
found,3370,O
.,3370,O
The,3371,O
estimated,3371,O
CAD,3371,B-DiseaseOrPhenotypicFeature
risk,3371,O
for,3371,O
BMI,3371,O
--,3371,O
25,3371,O
and,3371,O
the,3371,O
-930G,3371,B-SequenceVariant
allele,3371,O
interaction,3371,O
was,3371,O
about,3371,O
160,3371,O
%,3371,O
greater,3371,O
than,3371,O
that,3371,O
predicted,3371,O
by,3371,O
assuming,3371,O
additivity,3371,O
of,3371,O
the,3371,O
effects,3371,O
",",3371,O
and,3371,O
about,3371,O
40,3371,O
%,3371,O
greater,3371,O
for,3371,O
interaction,3371,O
of,3371,O
cigarette,3371,O
smoking,3371,O
and,3371,O
the,3371,O
-930G,3371,B-SequenceVariant
allele,3371,O
.,3371,O
Overweight/obesity,3372,B-DiseaseOrPhenotypicFeature
was,3372,O
a,3372,O
risk,3372,O
factor,3372,O
for,3372,O
CAD,3372,B-DiseaseOrPhenotypicFeature
only,3372,O
in,3372,O
the,3372,O
-930G,3372,B-SequenceVariant
allele,3372,O
carriers,3372,O
(,3372,O
P,3372,O
<,3372,O
10,3372,O
(,3372,O
-10,3372,O
),3372,O
),3372,O
but,3372,O
not,3372,O
in,3372,O
the,3372,O
AA,3372,O
homozygotes,3372,O
(,3372,O
P=1.00,3372,O
),3372,O
.,3372,O
In,3373,O
conclusion,3373,O
the,3373,O
-930A,3373,B-SequenceVariant
>,3373,I-SequenceVariant
G,3373,I-SequenceVariant
CYBA,3373,B-GeneOrGeneProduct
polymorphism,3373,O
is,3373,O
associated,3373,O
with,3373,O
CAD,3373,B-DiseaseOrPhenotypicFeature
in,3373,O
the,3373,O
Polish,3373,O
population,3373,O
.,3373,O
The,3374,O
-930G,3374,B-SequenceVariant
allele,3374,O
carriers,3374,O
are,3374,O
particularly,3374,O
at,3374,O
risk,3374,O
of,3374,O
consequences,3374,O
of,3374,O
obesity,3374,B-DiseaseOrPhenotypicFeature
and,3374,O
tobacco,3374,B-OrganismTaxon
smoke,3374,O
exposure,3374,O
.,3374,O
Prevention,3375,O
of,3375,O
etomidate-induced,3375,B-ChemicalEntity
myoclonus,3375,B-DiseaseOrPhenotypicFeature
:,3375,O
which,3375,O
is,3375,O
superior,3375,O
:,3375,O
Fentanyl,3375,B-ChemicalEntity
",",3375,O
midazolam,3375,B-ChemicalEntity
",",3375,O
or,3375,O
a,3375,O
combination,3375,O
?,3375,O
A,3376,O
Retrospective,3376,O
comparative,3376,O
study,3376,O
.,3376,O
BACKGROUND,3377,O
:,3377,O
In,3377,O
this,3377,O
retrospective,3377,O
comparative,3377,O
study,3377,O
",",3377,O
we,3377,O
aimed,3377,O
to,3377,O
compare,3377,O
the,3377,O
effectiveness,3377,O
of,3377,O
fentanyl,3377,B-ChemicalEntity
",",3377,O
midazolam,3377,B-ChemicalEntity
",",3377,O
and,3377,O
a,3377,O
combination,3377,O
of,3377,O
fentanyl,3377,B-ChemicalEntity
and,3377,O
midazolam,3377,B-ChemicalEntity
to,3377,O
prevent,3377,O
etomidate-induced,3377,B-ChemicalEntity
myoclonus,3377,B-DiseaseOrPhenotypicFeature
.,3377,O
MATERIAL,3378,O
AND,3378,O
METHODS,3378,O
:,3378,O
This,3378,O
study,3378,O
was,3378,O
performed,3378,O
based,3378,O
on,3378,O
anesthesia,3378,O
records,3378,O
.,3378,O
Depending,3379,O
on,3379,O
the,3379,O
drugs,3379,O
that,3379,O
would,3379,O
be,3379,O
given,3379,O
before,3379,O
the,3379,O
induction,3379,O
of,3379,O
anesthesia,3379,O
with,3379,O
etomidate,3379,B-ChemicalEntity
",",3379,O
the,3379,O
patients,3379,B-OrganismTaxon
were,3379,O
separated,3379,O
into,3379,O
4,3379,O
groups,3379,O
:,3379,O
no,3379,O
pretreatment,3379,O
(,3379,O
Group,3379,O
NP,3379,O
),3379,O
",",3379,O
fentanyl,3379,B-ChemicalEntity
1,3379,O
ug.kg-1,3379,O
(,3379,O
Group,3379,O
F,3379,O
),3379,O
",",3379,O
midazolam,3379,B-ChemicalEntity
0.03,3379,O
mg.kg-1,3379,O
(,3379,O
Group,3379,O
M,3379,O
),3379,O
",",3379,O
and,3379,O
midazolam,3379,B-ChemicalEntity
0.015,3379,O
mg.kg-1,3379,O
+,3379,O
fentanyl,3379,B-ChemicalEntity
0.5,3379,O
ug.kg-1,3379,O
(,3379,O
Group,3379,O
FM,3379,O
),3379,O
.,3379,O
Patients,3380,B-OrganismTaxon
who,3380,O
received,3380,O
the,3380,O
same,3380,O
anesthetic,3380,O
procedure,3380,O
were,3380,O
selected,3380,O
:,3380,O
2,3380,O
minutes,3380,O
after,3380,O
intravenous,3380,O
injections,3380,O
of,3380,O
the,3380,O
pretreatment,3380,O
drugs,3380,O
",",3380,O
anesthesia,3380,O
is,3380,O
induced,3380,O
with,3380,O
0.3,3380,O
mg.kg-1,3380,O
etomidate,3380,B-ChemicalEntity
injected,3380,O
intravenously,3380,O
over,3380,O
a,3380,O
period,3380,O
of,3380,O
20-30,3380,O
seconds,3380,O
.,3380,O
Myoclonic,3381,B-DiseaseOrPhenotypicFeature
movements,3381,I-DiseaseOrPhenotypicFeature
are,3381,O
evaluated,3381,O
",",3381,O
which,3381,O
were,3381,O
observed,3381,O
and,3381,O
graded,3381,O
according,3381,O
to,3381,O
clinical,3381,O
severity,3381,O
during,3381,O
the,3381,O
2,3381,O
minutes,3381,O
after,3381,O
etomidate,3381,B-ChemicalEntity
injection,3381,O
.,3381,O
The,3382,O
severity,3382,O
of,3382,O
pain,3382,B-DiseaseOrPhenotypicFeature
due,3382,O
to,3382,O
etomidate,3382,B-ChemicalEntity
injection,3382,O
",",3382,O
mean,3382,O
arterial,3382,O
pressure,3382,O
",",3382,O
heart,3382,O
rate,3382,O
",",3382,O
and,3382,O
adverse,3382,O
effects,3382,O
were,3382,O
also,3382,O
evaluated,3382,O
.,3382,O
RESULTS,3383,O
:,3383,O
Study,3383,O
results,3383,O
showed,3383,O
that,3383,O
myoclonus,3383,B-DiseaseOrPhenotypicFeature
incidence,3383,O
was,3383,O
85,3383,O
%,3383,O
",",3383,O
40,3383,O
%,3383,O
",",3383,O
70,3383,O
%,3383,O
",",3383,O
and,3383,O
25,3383,O
%,3383,O
in,3383,O
Group,3383,O
NP,3383,O
",",3383,O
Group,3383,O
F,3383,O
",",3383,O
Group,3383,O
M,3383,O
",",3383,O
and,3383,O
Group,3383,O
FM,3383,O
",",3383,O
respectively,3383,O
",",3383,O
and,3383,O
were,3383,O
significantly,3383,O
lower,3383,O
in,3383,O
Group,3383,O
F,3383,O
and,3383,O
Group,3383,O
FM,3383,O
.,3383,O
CONCLUSIONS,3384,O
:,3384,O
We,3384,O
conclude,3384,O
that,3384,O
pretreatment,3384,O
with,3384,O
fentanyl,3384,B-ChemicalEntity
or,3384,O
combination,3384,O
of,3384,O
fentanyl,3384,B-ChemicalEntity
and,3384,O
midazolam,3384,B-ChemicalEntity
was,3384,O
effective,3384,O
in,3384,O
preventing,3384,O
etomidate-induced,3384,B-ChemicalEntity
myoclonus,3384,B-DiseaseOrPhenotypicFeature
.,3384,O
Antioxidant,3385,B-ChemicalEntity
effects,3385,O
of,3385,O
bovine,3385,B-OrganismTaxon
lactoferrin,3385,B-GeneOrGeneProduct
on,3385,O
dexamethasone-induced,3385,B-ChemicalEntity
hypertension,3385,B-DiseaseOrPhenotypicFeature
in,3385,O
rat,3385,B-OrganismTaxon
.,3385,O
Dexamethasone-,3386,B-ChemicalEntity
(,3386,O
Dex-,3386,B-ChemicalEntity
),3386,O
induced,3386,O
hypertension,3386,B-DiseaseOrPhenotypicFeature
is,3386,O
associated,3386,O
with,3386,O
enhanced,3386,O
oxidative,3386,O
stress,3386,O
.,3386,O
Lactoferrin,3387,B-GeneOrGeneProduct
(,3387,O
LF,3387,B-GeneOrGeneProduct
),3387,O
is,3387,O
an,3387,O
iron-binding,3387,B-ChemicalEntity
glycoprotein,3387,B-GeneOrGeneProduct
with,3387,O
antihypertensive,3387,O
properties,3387,O
.,3387,O
In,3388,O
this,3388,O
study,3388,O
",",3388,O
we,3388,O
investigated,3388,O
the,3388,O
effect,3388,O
of,3388,O
chronic,3388,O
administration,3388,O
of,3388,O
LF,3388,B-GeneOrGeneProduct
on,3388,O
oxidative,3388,O
stress,3388,O
and,3388,O
hypertension,3388,B-DiseaseOrPhenotypicFeature
upon,3388,O
Dex,3388,B-ChemicalEntity
administration,3388,O
.,3388,O
Male,3389,O
Wistar,3389,O
rats,3389,B-OrganismTaxon
were,3389,O
treated,3389,O
by,3389,O
Dex,3389,B-ChemicalEntity
(,3389,O
30,3389,O
u,3389,O
g/kg/day,3389,O
subcutaneously,3389,O
),3389,O
or,3389,O
saline,3389,O
for,3389,O
14,3389,O
days,3389,O
.,3389,O
Oral,3390,O
bovine,3390,B-OrganismTaxon
LF,3390,B-GeneOrGeneProduct
(,3390,O
30,3390,O
",",3390,O
100,3390,O
",",3390,O
300,3390,O
mg/kg,3390,O
),3390,O
was,3390,O
given,3390,O
from,3390,O
day,3390,O
8,3390,O
to,3390,O
14,3390,O
in,3390,O
a,3390,O
reversal,3390,O
study,3390,O
.,3390,O
In,3391,O
a,3391,O
prevention,3391,O
study,3391,O
",",3391,O
rats,3391,B-OrganismTaxon
received,3391,O
4,3391,O
days,3391,O
of,3391,O
LF,3391,B-GeneOrGeneProduct
treatment,3391,O
followed,3391,O
by,3391,O
Dex,3391,B-ChemicalEntity
and,3391,O
continued,3391,O
during,3391,O
the,3391,O
test,3391,O
period,3391,O
.,3391,O
Systolic,3392,O
blood,3392,O
pressure,3392,O
(,3392,O
SBP,3392,O
),3392,O
was,3392,O
measured,3392,O
using,3392,O
tail-cuff,3392,O
method,3392,O
.,3392,O
Thymus,3393,O
weight,3393,O
was,3393,O
used,3393,O
as,3393,O
a,3393,O
marker,3393,O
of,3393,O
glucocorticoid,3393,B-ChemicalEntity
activity,3393,O
.,3393,O
Plasma,3394,O
hydrogen,3394,B-ChemicalEntity
peroxide,3394,I-ChemicalEntity
(,3394,O
H2O2,3394,B-ChemicalEntity
),3394,O
concentration,3394,O
and,3394,O
ferric,3394,B-ChemicalEntity
reducing,3394,O
antioxidant,3394,O
power,3394,O
(,3394,O
FRAP,3394,O
),3394,O
value,3394,O
were,3394,O
determined,3394,O
.,3394,O
Dexamethasone,3395,B-ChemicalEntity
significantly,3395,O
increased,3395,O
SBP,3395,O
and,3395,O
plasma,3395,O
H2O2,3395,B-ChemicalEntity
level,3395,O
and,3395,O
decreased,3395,O
thymus,3395,O
and,3395,O
body,3395,O
weights,3395,O
.,3395,O
LF,3396,B-GeneOrGeneProduct
lowered,3396,O
(,3396,O
P,3396,O
<,3396,O
0.01,3396,O
),3396,O
and,3396,O
dose,3396,O
dependently,3396,O
prevented,3396,O
(,3396,O
P,3396,O
<,3396,O
0.001,3396,O
),3396,O
Dex-induced,3396,B-ChemicalEntity
hypertension,3396,B-DiseaseOrPhenotypicFeature
.,3396,O
LF,3397,B-GeneOrGeneProduct
prevented,3397,O
body,3397,O
weight,3397,B-DiseaseOrPhenotypicFeature
loss,3397,I-DiseaseOrPhenotypicFeature
and,3397,O
significantly,3397,O
reduced,3397,O
the,3397,O
elevated,3397,O
plasma,3397,O
H2O2,3397,B-ChemicalEntity
and,3397,O
increased,3397,O
FRAP,3397,O
values,3397,O
.,3397,O
Chronic,3398,O
administration,3398,O
of,3398,O
LF,3398,B-GeneOrGeneProduct
strongly,3398,O
reduced,3398,O
the,3398,O
blood,3398,O
pressure,3398,O
and,3398,O
production,3398,O
of,3398,O
ROS,3398,B-ChemicalEntity
and,3398,O
improved,3398,O
antioxidant,3398,O
capacity,3398,O
in,3398,O
Dex-induced,3398,B-ChemicalEntity
hypertension,3398,B-DiseaseOrPhenotypicFeature
",",3398,O
suggesting,3398,O
the,3398,O
role,3398,O
of,3398,O
inhibition,3398,O
of,3398,O
oxidative,3398,O
stress,3398,O
as,3398,O
another,3398,O
mechanism,3398,O
of,3398,O
antihypertensive,3398,O
action,3398,O
of,3398,O
LF,3398,B-GeneOrGeneProduct
.,3398,O
The,3399,O
association,3399,O
between,3399,O
tranexamic,3399,B-ChemicalEntity
acid,3399,I-ChemicalEntity
and,3399,O
convulsive,3399,B-DiseaseOrPhenotypicFeature
seizures,3399,I-DiseaseOrPhenotypicFeature
after,3399,O
cardiac,3399,O
surgery,3399,O
:,3399,O
a,3399,O
multivariate,3399,O
analysis,3399,O
in,3399,O
11,3399,O
529,3399,O
patients,3399,B-OrganismTaxon
.,3399,O
Because,3400,O
of,3400,O
a,3400,O
lack,3400,O
of,3400,O
contemporary,3400,O
data,3400,O
regarding,3400,O
seizures,3400,B-DiseaseOrPhenotypicFeature
after,3400,O
cardiac,3400,O
surgery,3400,O
",",3400,O
we,3400,O
undertook,3400,O
a,3400,O
retrospective,3400,O
analysis,3400,O
of,3400,O
prospectively,3400,O
collected,3400,O
data,3400,O
from,3400,O
11,3400,O
529,3400,O
patients,3400,B-OrganismTaxon
in,3400,O
whom,3400,O
cardiopulmonary,3400,O
bypass,3400,O
was,3400,O
used,3400,O
from,3400,O
January,3400,O
2004,3400,O
to,3400,O
December,3400,O
2010,3400,O
.,3400,O
A,3401,O
convulsive,3401,B-DiseaseOrPhenotypicFeature
seizure,3401,I-DiseaseOrPhenotypicFeature
was,3401,O
defined,3401,O
as,3401,O
a,3401,O
transient,3401,O
episode,3401,O
of,3401,O
disturbed,3401,O
brain,3401,O
function,3401,O
characterised,3401,O
by,3401,O
abnormal,3401,B-DiseaseOrPhenotypicFeature
involuntary,3401,I-DiseaseOrPhenotypicFeature
motor,3401,I-DiseaseOrPhenotypicFeature
movements,3401,I-DiseaseOrPhenotypicFeature
.,3401,O
Multivariate,3402,O
regression,3402,O
analysis,3402,O
was,3402,O
performed,3402,O
to,3402,O
identify,3402,O
independent,3402,O
predictors,3402,O
of,3402,O
postoperative,3402,O
seizures,3402,B-DiseaseOrPhenotypicFeature
.,3402,O
A,3403,O
total,3403,O
of,3403,O
100,3403,O
(,3403,O
0.9,3403,O
%,3403,O
),3403,O
patients,3403,B-OrganismTaxon
developed,3403,O
postoperative,3403,O
convulsive,3403,B-DiseaseOrPhenotypicFeature
seizures,3403,I-DiseaseOrPhenotypicFeature
.,3403,O
Generalised,3404,B-DiseaseOrPhenotypicFeature
and,3404,I-DiseaseOrPhenotypicFeature
focal,3404,I-DiseaseOrPhenotypicFeature
seizures,3404,I-DiseaseOrPhenotypicFeature
were,3404,O
identified,3404,O
in,3404,O
68,3404,O
and,3404,O
32,3404,O
patients,3404,B-OrganismTaxon
",",3404,O
respectively,3404,O
.,3404,O
The,3405,O
median,3405,O
(,3405,O
IQR,3405,O
[,3405,O
range,3405,O
],3405,O
),3405,O
time,3405,O
after,3405,O
surgery,3405,O
when,3405,O
the,3405,O
seizure,3405,B-DiseaseOrPhenotypicFeature
occurred,3405,O
was,3405,O
7,3405,O
(,3405,O
6-12,3405,O
[,3405,O
1-216,3405,O
],3405,O
),3405,O
h,3405,O
and,3405,O
8,3405,O
(,3405,O
6-11,3405,O
[,3405,O
4-18,3405,O
],3405,O
),3405,O
h,3405,O
",",3405,O
respectively,3405,O
.,3405,O
Epileptiform,3406,O
findings,3406,O
on,3406,O
electroencephalography,3406,O
were,3406,O
seen,3406,O
in,3406,O
19,3406,O
patients,3406,B-OrganismTaxon
.,3406,O
Independent,3407,O
predictors,3407,O
of,3407,O
postoperative,3407,O
seizures,3407,B-DiseaseOrPhenotypicFeature
included,3407,O
age,3407,O
",",3407,O
female,3407,O
sex,3407,O
",",3407,O
redo,3407,O
cardiac,3407,O
surgery,3407,O
",",3407,O
calcification,3407,B-DiseaseOrPhenotypicFeature
of,3407,I-DiseaseOrPhenotypicFeature
ascending,3407,I-DiseaseOrPhenotypicFeature
aorta,3407,I-DiseaseOrPhenotypicFeature
",",3407,O
congestive,3407,B-DiseaseOrPhenotypicFeature
heart,3407,I-DiseaseOrPhenotypicFeature
failure,3407,I-DiseaseOrPhenotypicFeature
",",3407,O
deep,3407,O
hypothermic,3407,B-DiseaseOrPhenotypicFeature
circulatory,3407,O
arrest,3407,O
",",3407,O
duration,3407,O
of,3407,O
aortic,3407,O
cross-clamp,3407,O
and,3407,O
tranexamic,3407,B-ChemicalEntity
acid,3407,I-ChemicalEntity
.,3407,O
When,3408,O
tested,3408,O
in,3408,O
a,3408,O
multivariate,3408,O
regression,3408,O
analysis,3408,O
",",3408,O
tranexamic,3408,B-ChemicalEntity
acid,3408,I-ChemicalEntity
was,3408,O
a,3408,O
strong,3408,O
independent,3408,O
predictor,3408,O
of,3408,O
seizures,3408,B-DiseaseOrPhenotypicFeature
(,3408,O
OR,3408,O
14.3,3408,O
",",3408,O
95,3408,O
%,3408,O
CI,3408,O
5.5-36.7,3408,O
;,3408,O
p,3408,O
<,3408,O
0.001,3408,O
),3408,O
.,3408,O
Patients,3409,B-OrganismTaxon
with,3409,O
convulsive,3409,B-DiseaseOrPhenotypicFeature
seizures,3409,I-DiseaseOrPhenotypicFeature
had,3409,O
2.5,3409,O
times,3409,O
higher,3409,O
in-hospital,3409,O
mortality,3409,O
rates,3409,O
and,3409,O
twice,3409,O
the,3409,O
length,3409,O
of,3409,O
hospital,3409,O
stay,3409,O
compared,3409,O
with,3409,O
patients,3409,B-OrganismTaxon
without,3409,O
convulsive,3409,B-DiseaseOrPhenotypicFeature
seizures,3409,I-DiseaseOrPhenotypicFeature
.,3409,O
Mean,3410,O
(,3410,O
IQR,3410,O
[,3410,O
range,3410,O
],3410,O
),3410,O
length,3410,O
of,3410,O
stay,3410,O
in,3410,O
the,3410,O
intensive,3410,O
care,3410,O
unit,3410,O
was,3410,O
115,3410,O
(,3410,O
49-228,3410,O
[,3410,O
32-481,3410,O
],3410,O
),3410,O
h,3410,O
in,3410,O
patients,3410,B-OrganismTaxon
with,3410,O
convulsive,3410,B-DiseaseOrPhenotypicFeature
seizures,3410,I-DiseaseOrPhenotypicFeature
compared,3410,O
with,3410,O
26,3410,O
(,3410,O
22-69,3410,O
[,3410,O
14-1080,3410,O
],3410,O
),3410,O
h,3410,O
in,3410,O
patients,3410,B-OrganismTaxon
without,3410,O
seizures,3410,B-DiseaseOrPhenotypicFeature
(,3410,O
p,3410,O
<,3410,O
0.001,3410,O
),3410,O
.,3410,O
Convulsive,3411,B-DiseaseOrPhenotypicFeature
seizures,3411,I-DiseaseOrPhenotypicFeature
are,3411,O
a,3411,O
serious,3411,O
postoperative,3411,B-DiseaseOrPhenotypicFeature
complication,3411,I-DiseaseOrPhenotypicFeature
after,3411,O
cardiac,3411,O
surgery,3411,O
.,3411,O
As,3412,O
tranexamic,3412,B-ChemicalEntity
acid,3412,I-ChemicalEntity
is,3412,O
the,3412,O
only,3412,O
modifiable,3412,O
factor,3412,O
",",3412,O
its,3412,O
administration,3412,O
",",3412,O
particularly,3412,O
in,3412,O
doses,3412,O
exceeding,3412,O
80,3412,O
mg.kg,3412,O
(,3412,O
-1,3412,O
),3412,O
",",3412,O
should,3412,O
be,3412,O
weighed,3412,O
against,3412,O
the,3412,O
risk,3412,O
of,3412,O
postoperative,3412,O
seizures,3412,B-DiseaseOrPhenotypicFeature
.,3412,O
Endothelial,3413,O
NADPH,3413,B-GeneOrGeneProduct
oxidase,3413,I-GeneOrGeneProduct
4,3413,I-GeneOrGeneProduct
mediates,3413,O
vascular,3413,B-GeneOrGeneProduct
endothelial,3413,I-GeneOrGeneProduct
growth,3413,I-GeneOrGeneProduct
factor,3413,I-GeneOrGeneProduct
receptor,3413,I-GeneOrGeneProduct
2-induced,3413,O
intravitreal,3413,O
neovascularization,3413,O
in,3413,O
a,3413,O
rat,3413,B-OrganismTaxon
model,3413,O
of,3413,O
retinopathy,3413,B-DiseaseOrPhenotypicFeature
of,3413,I-DiseaseOrPhenotypicFeature
prematurity,3413,I-DiseaseOrPhenotypicFeature
.,3413,O
PURPOSE,3414,O
:,3414,O
NADPH,3414,B-GeneOrGeneProduct
oxidase-generated,3414,O
reactive,3414,B-ChemicalEntity
oxygen,3414,I-ChemicalEntity
species,3414,I-ChemicalEntity
(,3414,O
ROS,3414,B-ChemicalEntity
),3414,O
are,3414,O
implicated,3414,O
in,3414,O
angiogenesis,3414,O
.,3414,O
Isoforms,3415,O
of,3415,O
NADPH,3415,B-GeneOrGeneProduct
oxidase,3415,I-GeneOrGeneProduct
NOX1,3415,B-GeneOrGeneProduct
",",3415,O
NOX2,3415,B-GeneOrGeneProduct
",",3415,O
and,3415,O
NOX4,3415,B-GeneOrGeneProduct
are,3415,O
reported,3415,O
to,3415,O
be,3415,O
expressed,3415,O
in,3415,O
endothelial,3415,O
cells,3415,O
(,3415,O
ECs,3415,O
),3415,O
.,3415,O
Of,3416,O
these,3416,O
",",3416,O
NOX1,3416,B-GeneOrGeneProduct
and,3416,O
NOX2,3416,B-GeneOrGeneProduct
have,3416,O
been,3416,O
reported,3416,O
to,3416,O
contribute,3416,O
to,3416,O
intravitreal,3416,O
neovascularization,3416,O
(,3416,O
IVNV,3416,O
),3416,O
in,3416,O
oxygen-induced,3416,B-ChemicalEntity
retinopathy,3416,B-DiseaseOrPhenotypicFeature
(,3416,O
OIR,3416,B-DiseaseOrPhenotypicFeature
),3416,O
models,3416,O
.,3416,O
In,3417,O
this,3417,O
study,3417,O
",",3417,O
we,3417,O
tested,3417,O
the,3417,O
hypothesis,3417,O
that,3417,O
the,3417,O
isoform,3417,O
NOX4,3417,B-GeneOrGeneProduct
in,3417,O
ECs,3417,O
contributed,3417,O
to,3417,O
vascular,3417,B-GeneOrGeneProduct
endothelial,3417,I-GeneOrGeneProduct
growth,3417,I-GeneOrGeneProduct
factor,3417,I-GeneOrGeneProduct
(,3417,O
VEGF,3417,B-GeneOrGeneProduct
),3417,O
-induced,3417,O
angiogenesis,3417,O
and,3417,O
IVNV,3417,O
.,3417,O
METHODS,3418,O
:,3418,O
Isoforms,3418,O
of,3418,O
NADPH,3418,B-GeneOrGeneProduct
oxidase,3418,I-GeneOrGeneProduct
MRNA,3418,O
were,3418,O
measured,3418,O
in,3418,O
several,3418,O
types,3418,O
of,3418,O
cultured,3418,O
vascular,3418,O
ecs,3418,O
:,3418,O
human,3418,B-OrganismTaxon
retinal,3418,O
microvascular,3418,O
ECs,3418,O
(,3418,O
hRMVECs,3418,O
),3418,O
",",3418,O
choroidal,3418,O
ECs,3418,O
(,3418,O
CECs,3418,O
),3418,O
",",3418,O
and,3418,O
human,3418,B-OrganismTaxon
umbilical,3418,O
vascular,3418,O
ECs,3418,O
(,3418,O
HUVECs,3418,O
),3418,O
using,3418,O
real-time,3418,O
PCR,3418,O
.,3418,O
Newborn,3419,O
rat,3419,B-OrganismTaxon
pups,3419,O
and,3419,O
dams,3419,O
were,3419,O
placed,3419,O
into,3419,O
an,3419,O
OIR,3419,B-DiseaseOrPhenotypicFeature
model,3419,O
that,3419,O
cycled,3419,O
oxygen,3419,B-ChemicalEntity
concentration,3419,O
between,3419,O
50,3419,O
%,3419,O
and,3419,O
10,3419,O
%,3419,O
every,3419,O
24,3419,O
h,3419,O
for,3419,O
14,3419,O
days,3419,O
",",3419,O
and,3419,O
then,3419,O
were,3419,O
placed,3419,O
in,3419,O
room,3419,O
air,3419,O
(,3419,O
RA,3419,O
),3419,O
for,3419,O
an,3419,O
additional,3419,O
4,3419,O
days,3419,O
(,3419,O
rat,3419,B-OrganismTaxon
OIR,3419,B-DiseaseOrPhenotypicFeature
model,3419,O
),3419,O
.,3419,O
NOX4,3420,B-GeneOrGeneProduct
expression,3420,O
in,3420,O
retinal,3420,O
lysates,3420,O
from,3420,O
the,3420,O
RA-raised,3420,O
pups,3420,O
at,3420,O
postnatal,3420,O
day,3420,O
0,3420,O
(,3420,O
P0,3420,O
),3420,O
",",3420,O
P14,3420,O
",",3420,O
and,3420,O
P18,3420,O
was,3420,O
determined,3420,O
with,3420,O
western,3420,O
blots,3420,O
.,3420,O
STAT3,3421,B-GeneOrGeneProduct
activation,3421,O
was,3421,O
determined,3421,O
as,3421,O
the,3421,O
ratio,3421,O
of,3421,O
phosphorylated,3421,O
STAT3,3421,B-GeneOrGeneProduct
to,3421,O
total,3421,O
STAT3,3421,B-GeneOrGeneProduct
with,3421,O
western,3421,O
blot,3421,O
analysis,3421,O
of,3421,O
retinal,3421,O
lysates,3421,O
from,3421,O
pups,3421,O
raised,3421,O
in,3421,O
RA,3421,O
or,3421,O
from,3421,O
the,3421,O
rat,3421,B-OrganismTaxon
OIR,3421,B-DiseaseOrPhenotypicFeature
model,3421,O
at,3421,O
P18,3421,O
.,3421,O
Semiquantitative,3422,O
assessment,3422,O
of,3422,O
the,3422,O
density,3422,O
of,3422,O
NOX4,3422,B-GeneOrGeneProduct
colabeling,3422,O
with,3422,O
lectin-stained,3422,B-GeneOrGeneProduct
retinal,3422,O
ECs,3422,O
was,3422,O
determined,3422,O
by,3422,O
immunolabeling,3422,O
of,3422,O
retinal,3422,O
cryosections,3422,O
from,3422,O
P18,3422,O
pups,3422,O
in,3422,O
OIR,3422,B-DiseaseOrPhenotypicFeature
or,3422,O
in,3422,O
RA,3422,O
.,3422,O
In,3423,O
hRMVECs,3423,O
transfected,3423,O
with,3423,O
NOX4,3423,B-GeneOrGeneProduct
siRNA,3423,O
and,3423,O
treated,3423,O
with,3423,O
VEGF,3423,B-GeneOrGeneProduct
or,3423,O
control,3423,O
",",3423,O
1,3423,O
),3423,O
ROS,3423,B-ChemicalEntity
generation,3423,O
was,3423,O
measured,3423,O
using,3423,O
the,3423,O
5-,3423,B-ChemicalEntity
(,3423,I-ChemicalEntity
and-6,3423,I-ChemicalEntity
),3423,I-ChemicalEntity
"-chloromethyl-2',7'-dichlorodihydrofluorescein",3423,I-ChemicalEntity
diacetate,3423,I-ChemicalEntity
",",3423,I-ChemicalEntity
acetyl,3423,I-ChemicalEntity
ester,3423,I-ChemicalEntity
fluorescence,3423,O
assay,3423,O
and,3423,O
2,3423,O
),3423,O
phosphorylated,3423,O
VEGF,3423,B-GeneOrGeneProduct
receptor,3423,I-GeneOrGeneProduct
2,3423,I-GeneOrGeneProduct
and,3423,O
STAT3,3423,B-GeneOrGeneProduct
",",3423,O
and,3423,O
total,3423,O
VEGFR2,3423,B-GeneOrGeneProduct
and,3423,O
STAT3,3423,B-GeneOrGeneProduct
were,3423,O
measured,3423,O
in,3423,O
western,3423,O
blot,3423,O
analyses,3423,O
.,3423,O
VEGF-stimulated,3424,B-GeneOrGeneProduct
hRMVEC,3424,O
proliferation,3424,O
was,3424,O
measured,3424,O
following,3424,O
transfection,3424,O
with,3424,O
NOX4,3424,B-GeneOrGeneProduct
siRNA,3424,O
or,3424,O
STAT3,3424,B-GeneOrGeneProduct
siRNA,3424,O
",",3424,O
or,3424,O
respective,3424,O
controls,3424,O
.,3424,O
RESULTS,3425,O
:,3425,O
NOX4,3425,B-GeneOrGeneProduct
was,3425,O
the,3425,O
most,3425,O
prevalent,3425,O
isoform,3425,O
of,3425,O
NADPH,3425,B-GeneOrGeneProduct
oxidase,3425,I-GeneOrGeneProduct
in,3425,O
vascular,3425,O
ECs,3425,O
.,3425,O
NOX4,3426,B-GeneOrGeneProduct
expression,3426,O
in,3426,O
retinal,3426,O
lysates,3426,O
was,3426,O
significantly,3426,O
decreased,3426,O
during,3426,O
development,3426,O
in,3426,O
RA,3426,O
.,3426,O
Compared,3427,O
to,3427,O
RA,3427,O
",",3427,O
the,3427,O
expression,3427,O
of,3427,O
retinal,3427,O
NOX4,3427,B-GeneOrGeneProduct
increased,3427,O
at,3427,O
P18,3427,O
.,3427,O
At,3428,O
p18,3428,O
OIR,3428,B-DiseaseOrPhenotypicFeature
",",3428,O
semiquantitative,3428,O
assessment,3428,O
of,3428,O
the,3428,O
density,3428,O
of,3428,O
lectin,3428,B-GeneOrGeneProduct
and,3428,O
NOX4,3428,B-GeneOrGeneProduct
colabeling,3428,O
in,3428,O
retinal,3428,O
vascular,3428,O
ECs,3428,O
was,3428,O
greater,3428,O
in,3428,O
retinal,3428,O
cryosections,3428,O
and,3428,O
activated,3428,O
STAT3,3428,B-GeneOrGeneProduct
was,3428,O
greater,3428,O
in,3428,O
retinal,3428,O
lysates,3428,O
when,3428,O
compared,3428,O
to,3428,O
the,3428,O
RA-raised,3428,O
pups,3428,O
.,3428,O
In,3429,O
cultured,3429,O
hRMVECs,3429,O
",",3429,O
knockdown,3429,O
of,3429,O
NOX4,3429,B-GeneOrGeneProduct
by,3429,O
siRNA,3429,O
transfection,3429,O
inhibited,3429,O
VEGF-induced,3429,B-GeneOrGeneProduct
ROS,3429,B-ChemicalEntity
generation,3429,O
.,3429,O
VEGF,3430,B-GeneOrGeneProduct
induced,3430,O
a,3430,O
physical,3430,O
interaction,3430,O
of,3430,O
phosphorylated-VEGFR2,3430,O
and,3430,O
NOX4,3430,B-GeneOrGeneProduct
.,3430,O
Knockdown,3431,O
of,3431,O
NOX4,3431,B-GeneOrGeneProduct
:,3431,O
1,3431,O
),3431,O
reduced,3431,O
VEGFR2,3431,B-GeneOrGeneProduct
activation,3431,O
but,3431,O
did,3431,O
not,3431,O
abolish,3431,O
it,3431,O
and,3431,O
2,3431,O
),3431,O
abolished,3431,O
STAT3,3431,B-GeneOrGeneProduct
activation,3431,O
in,3431,O
response,3431,O
to,3431,O
VEGF,3431,B-GeneOrGeneProduct
.,3431,O
Knockdown,3432,O
of,3432,O
either,3432,O
NOX4,3432,B-GeneOrGeneProduct
or,3432,O
STAT3,3432,B-GeneOrGeneProduct
inhibited,3432,O
VEGF-induced,3432,B-GeneOrGeneProduct
EC,3432,O
proliferation,3432,O
.,3432,O
CONCLUSIONS,3433,O
:,3433,O
Our,3433,O
data,3433,O
suggest,3433,O
that,3433,O
in,3433,O
a,3433,O
model,3433,O
representative,3433,O
of,3433,O
human,3433,B-OrganismTaxon
retinopathy,3433,B-DiseaseOrPhenotypicFeature
of,3433,I-DiseaseOrPhenotypicFeature
prematurity,3433,I-DiseaseOrPhenotypicFeature
",",3433,O
NOX4,3433,B-GeneOrGeneProduct
was,3433,O
increased,3433,O
at,3433,O
a,3433,O
time,3433,O
point,3433,O
when,3433,O
IVNV,3433,O
developed,3433,O
.,3433,O
VEGF-activated,3434,B-GeneOrGeneProduct
NOX4,3434,B-GeneOrGeneProduct
led,3434,O
to,3434,O
an,3434,O
interaction,3434,O
between,3434,O
VEGF-activated,3434,B-GeneOrGeneProduct
VEGFR2,3434,B-GeneOrGeneProduct
and,3434,O
NOX4,3434,B-GeneOrGeneProduct
that,3434,O
mediated,3434,O
EC,3434,O
proliferation,3434,O
via,3434,O
activation,3434,O
of,3434,O
STAT3,3434,B-GeneOrGeneProduct
.,3434,O
Altogether,3435,O
",",3435,O
our,3435,O
results,3435,O
suggest,3435,O
that,3435,O
NOX4,3435,B-GeneOrGeneProduct
may,3435,O
regulate,3435,O
VEGFR2-mediated,3435,B-GeneOrGeneProduct
IVNV,3435,O
through,3435,O
activated,3435,O
STAT3,3435,B-GeneOrGeneProduct
.,3435,O
Disruption,3436,O
of,3436,O
the,3436,O
temporally,3436,O
regulated,3436,O
cloaca,3436,O
endodermal,3436,O
b-catenin,3436,B-GeneOrGeneProduct
signaling,3436,O
causes,3436,O
anorectal,3436,B-DiseaseOrPhenotypicFeature
malformations,3436,I-DiseaseOrPhenotypicFeature
.,3436,O
The,3437,O
cloaca,3437,O
is,3437,O
temporally,3437,O
formed,3437,O
and,3437,O
eventually,3437,O
divided,3437,O
by,3437,O
the,3437,O
urorectal,3437,O
septum,3437,O
(,3437,O
URS,3437,O
),3437,O
during,3437,O
urogenital,3437,O
and,3437,O
anorectal,3437,O
organ,3437,O
development,3437,O
.,3437,O
Although,3438,O
congenital,3438,B-DiseaseOrPhenotypicFeature
malformations,3438,I-DiseaseOrPhenotypicFeature
",",3438,O
such,3438,O
as,3438,O
anorectal,3438,B-DiseaseOrPhenotypicFeature
malformations,3438,I-DiseaseOrPhenotypicFeature
(,3438,O
ARMs,3438,B-DiseaseOrPhenotypicFeature
),3438,O
",",3438,O
are,3438,O
frequently,3438,O
observed,3438,O
during,3438,O
this,3438,O
process,3438,O
",",3438,O
the,3438,O
underlying,3438,O
pathogenic,3438,O
mechanisms,3438,O
remain,3438,O
unclear,3438,O
.,3438,O
b-Catenin,3439,B-GeneOrGeneProduct
is,3439,O
a,3439,O
critical,3439,O
component,3439,O
of,3439,O
canonical,3439,O
Wnt,3439,B-GeneOrGeneProduct
signaling,3439,O
and,3439,O
is,3439,O
essential,3439,O
for,3439,O
the,3439,O
regulation,3439,O
of,3439,O
cell,3439,O
differentiation,3439,O
and,3439,O
morphogenesis,3439,O
during,3439,O
embryogenesis,3439,O
.,3439,O
The,3440,O
expression,3440,O
of,3440,O
b-catenin,3440,B-GeneOrGeneProduct
is,3440,O
observed,3440,O
in,3440,O
endodermal,3440,O
epithelia,3440,O
",",3440,O
including,3440,O
URS,3440,O
epithelia,3440,O
.,3440,O
We,3441,O
modulated,3441,O
the,3441,O
b-catenin,3441,B-GeneOrGeneProduct
gene,3441,O
conditionally,3441,O
in,3441,O
endodermal,3441,O
epithelia,3441,O
by,3441,O
utilizing,3441,O
tamoxifen-inducible,3441,B-ChemicalEntity
Cre,3441,O
driver,3441,O
line,3441,O
(,3441,O
Shh,3441,B-GeneOrGeneProduct
(,3441,O
CreERT2,3441,O
),3441,O
),3441,O
.,3441,O
Both,3442,O
b-catenin,3442,B-GeneOrGeneProduct
loss-,3442,O
and,3442,O
gain-of-function,3442,O
(,3442,O
LOF,3442,O
and,3442,O
GOF,3442,O
),3442,O
mutants,3442,O
displayed,3442,O
abnormal,3442,O
clefts,3442,O
in,3442,O
the,3442,O
perineal,3442,O
region,3442,O
and,3442,O
hypoplastic,3442,B-DiseaseOrPhenotypicFeature
elongation,3442,O
of,3442,O
the,3442,O
URS,3442,O
.,3442,O
The,3443,O
mutants,3443,O
also,3443,O
displayed,3443,O
reduced,3443,O
cell,3443,O
proliferation,3443,O
in,3443,O
the,3443,O
URS,3443,O
mesenchyme,3443,O
.,3443,O
In,3444,O
addition,3444,O
",",3444,O
the,3444,O
b-catenin,3444,B-GeneOrGeneProduct
GOF,3444,O
mutants,3444,O
displayed,3444,O
reduced,3444,O
apoptosis,3444,O
and,3444,O
subsequently,3444,O
increased,3444,O
apoptosis,3444,O
in,3444,O
the,3444,O
URS,3444,O
epithelium,3444,O
.,3444,O
This,3445,O
instability,3445,O
possibly,3445,O
resulted,3445,O
in,3445,O
reduced,3445,O
expression,3445,O
levels,3445,O
of,3445,O
differentiation,3445,O
markers,3445,O
",",3445,O
such,3445,O
as,3445,O
keratin,3445,B-GeneOrGeneProduct
1,3445,I-GeneOrGeneProduct
and,3445,O
filaggrin,3445,B-GeneOrGeneProduct
",",3445,O
in,3445,O
the,3445,O
perineal,3445,O
epithelia,3445,O
.,3445,O
The,3446,O
expression,3446,O
of,3446,O
bone,3446,B-GeneOrGeneProduct
morphogenetic,3446,I-GeneOrGeneProduct
protein,3446,I-GeneOrGeneProduct
(,3446,O
Bmp,3446,B-GeneOrGeneProduct
),3446,O
genes,3446,O
",",3446,O
such,3446,O
as,3446,O
Bmp4,3446,B-GeneOrGeneProduct
and,3446,O
Bmp7,3446,B-GeneOrGeneProduct
",",3446,O
was,3446,O
also,3446,O
ectopically,3446,O
induced,3446,O
in,3446,O
the,3446,O
epithelia,3446,O
of,3446,O
the,3446,O
URS,3446,O
in,3446,O
the,3446,O
b-catenin,3446,B-GeneOrGeneProduct
GOF,3446,O
mutants,3446,O
.,3446,O
The,3447,O
expression,3447,O
of,3447,O
the,3447,O
Msx2,3447,B-GeneOrGeneProduct
gene,3447,O
and,3447,O
phosphorylated-Smad1/5/8,3447,O
",",3447,O
possible,3447,O
readouts,3447,O
of,3447,O
Bmp,3447,B-GeneOrGeneProduct
signaling,3447,O
",",3447,O
was,3447,O
also,3447,O
increased,3447,O
in,3447,O
the,3447,O
mutants,3447,O
.,3447,O
Moreover,3448,O
",",3448,O
we,3448,O
introduced,3448,O
an,3448,O
additional,3448,O
mutation,3448,O
for,3448,O
a,3448,O
Bmp,3448,B-GeneOrGeneProduct
receptor,3448,I-GeneOrGeneProduct
gene,3448,O
:,3448,O
BmprIA,3448,B-GeneOrGeneProduct
.,3448,O
The,3449,O
Shh,3449,B-GeneOrGeneProduct
(,3449,O
CreERT2/+,3449,O
),3449,O
;,3449,O
b-catenin,3449,B-GeneOrGeneProduct
(,3449,O
flox,3449,O
(,3449,O
ex3,3449,O
),3449,O
/+,3449,O
),3449,O
;,3449,O
BmprIA,3449,B-GeneOrGeneProduct
(,3449,O
flox/-,3449,O
),3449,O
mutants,3449,O
displayed,3449,O
partial,3449,O
restoration,3449,O
of,3449,O
URS,3449,O
elongation,3449,O
compared,3449,O
with,3449,O
the,3449,O
b-catenin,3449,B-GeneOrGeneProduct
GOF,3449,O
mutants,3449,O
.,3449,O
These,3450,O
results,3450,O
indicate,3450,O
that,3450,O
some,3450,O
ARM,3450,B-DiseaseOrPhenotypicFeature
phenotypes,3450,O
in,3450,O
the,3450,O
b-catenin,3450,B-GeneOrGeneProduct
GOF,3450,O
mutants,3450,O
were,3450,O
caused,3450,O
by,3450,O
abnormal,3450,O
Bmp,3450,B-GeneOrGeneProduct
signaling,3450,O
.,3450,O
The,3451,O
current,3451,O
analysis,3451,O
revealed,3451,O
the,3451,O
close,3451,O
relation,3451,O
of,3451,O
endodermal,3451,O
b-catenin,3451,B-GeneOrGeneProduct
signaling,3451,O
to,3451,O
the,3451,O
ARM,3451,B-DiseaseOrPhenotypicFeature
phenotypes,3451,O
.,3451,O
These,3452,O
results,3452,O
are,3452,O
considered,3452,O
to,3452,O
shed,3452,O
light,3452,O
on,3452,O
the,3452,O
pathogenic,3452,O
mechanisms,3452,O
of,3452,O
human,3452,B-OrganismTaxon
ARMs,3452,B-DiseaseOrPhenotypicFeature
.,3452,O
Effects,3453,O
of,3453,O
ginsenosides,3453,B-ChemicalEntity
on,3453,O
opioid-induced,3453,B-ChemicalEntity
hyperalgesia,3453,B-DiseaseOrPhenotypicFeature
in,3453,O
mice,3453,B-OrganismTaxon
.,3453,O
Opioid-induced,3454,B-ChemicalEntity
hyperalgesia,3454,B-DiseaseOrPhenotypicFeature
(,3454,O
OIH,3454,B-DiseaseOrPhenotypicFeature
),3454,O
is,3454,O
characterized,3454,O
by,3454,O
nociceptive,3454,O
sensitization,3454,O
caused,3454,O
by,3454,O
the,3454,O
cessation,3454,O
of,3454,O
chronic,3454,O
opioid,3454,B-ChemicalEntity
use,3454,O
.,3454,O
OIH,3455,B-DiseaseOrPhenotypicFeature
can,3455,O
limit,3455,O
the,3455,O
clinical,3455,O
use,3455,O
of,3455,O
opioid,3455,B-ChemicalEntity
analgesics,3455,O
and,3455,O
complicate,3455,O
withdrawal,3455,O
from,3455,O
opioid,3455,B-DiseaseOrPhenotypicFeature
addiction,3455,I-DiseaseOrPhenotypicFeature
.,3455,O
In,3456,O
this,3456,O
study,3456,O
",",3456,O
we,3456,O
investigated,3456,O
the,3456,O
effects,3456,O
of,3456,O
Re,3456,B-ChemicalEntity
",",3456,I-ChemicalEntity
Rg1,3456,I-ChemicalEntity
",",3456,I-ChemicalEntity
and,3456,I-ChemicalEntity
Rb1,3456,I-ChemicalEntity
ginsenosides,3456,I-ChemicalEntity
",",3456,O
the,3456,O
bioactive,3456,O
components,3456,O
of,3456,O
ginseng,3456,B-OrganismTaxon
",",3456,O
on,3456,O
OIH,3456,B-DiseaseOrPhenotypicFeature
.,3456,O
OIH,3457,B-DiseaseOrPhenotypicFeature
was,3457,O
achieved,3457,O
in,3457,O
mice,3457,B-OrganismTaxon
after,3457,O
subcutaneous,3457,O
administration,3457,O
of,3457,O
morphine,3457,B-ChemicalEntity
for,3457,O
7,3457,O
consecutive,3457,O
days,3457,O
three,3457,O
times,3457,O
per,3457,O
day,3457,O
.,3457,O
During,3458,O
withdrawal,3458,O
(,3458,O
days,3458,O
8,3458,O
and,3458,O
9,3458,O
),3458,O
",",3458,O
these,3458,O
mice,3458,B-OrganismTaxon
were,3458,O
administered,3458,O
Re,3458,B-ChemicalEntity
",",3458,O
Rg1,3458,B-ChemicalEntity
",",3458,O
or,3458,O
Rb1,3458,B-ChemicalEntity
intragastrically,3458,O
two,3458,O
times,3458,O
per,3458,O
day,3458,O
.,3458,O
On,3459,O
the,3459,O
test,3459,O
day,3459,O
(,3459,O
day,3459,O
10,3459,O
),3459,O
",",3459,O
mice,3459,B-OrganismTaxon
were,3459,O
subjected,3459,O
to,3459,O
the,3459,O
thermal,3459,O
sensitivity,3459,O
test,3459,O
and,3459,O
the,3459,O
acetic,3459,B-ChemicalEntity
acid-induced,3459,O
writhing,3459,O
test,3459,O
.,3459,O
Re,3460,B-ChemicalEntity
(,3460,O
300,3460,O
mg/kg,3460,O
),3460,O
inhibited,3460,O
OIH,3460,B-DiseaseOrPhenotypicFeature
in,3460,O
both,3460,O
the,3460,O
thermal,3460,O
sensitivity,3460,O
test,3460,O
and,3460,O
the,3460,O
acetic,3460,B-ChemicalEntity
acid-induced,3460,O
writhing,3460,O
test,3460,O
.,3460,O
However,3461,O
",",3461,O
the,3461,O
Rg1,3461,B-ChemicalEntity
and,3461,I-ChemicalEntity
Rb1,3461,I-ChemicalEntity
ginsenosides,3461,I-ChemicalEntity
failed,3461,O
to,3461,O
prevent,3461,O
OIH,3461,B-DiseaseOrPhenotypicFeature
in,3461,O
either,3461,O
test,3461,O
.,3461,O
Furthermore,3462,O
",",3462,O
Rg1,3462,B-ChemicalEntity
showed,3462,O
a,3462,O
tendency,3462,O
to,3462,O
aggravate,3462,O
OIH,3462,B-DiseaseOrPhenotypicFeature
in,3462,O
the,3462,O
acetic,3462,B-ChemicalEntity
acid-induced,3462,O
writhing,3462,O
test,3462,O
.,3462,O
Our,3463,O
data,3463,O
suggested,3463,O
that,3463,O
the,3463,O
ginsenoside,3463,B-ChemicalEntity
Re,3463,I-ChemicalEntity
",",3463,O
but,3463,O
not,3463,O
Rg1,3463,B-ChemicalEntity
or,3463,O
Rb1,3463,B-ChemicalEntity
",",3463,O
may,3463,O
contribute,3463,O
toward,3463,O
reversal,3463,O
of,3463,O
OIH,3463,B-DiseaseOrPhenotypicFeature
.,3463,O
Availability,3464,O
of,3464,O
human,3464,B-OrganismTaxon
induced,3464,O
pluripotent,3464,O
stem,3464,O
cell-derived,3464,O
cardiomyocytes,3464,O
in,3464,O
assessment,3464,O
of,3464,O
drug,3464,O
potential,3464,O
for,3464,O
QT,3464,B-DiseaseOrPhenotypicFeature
prolongation,3464,I-DiseaseOrPhenotypicFeature
.,3464,O
Field,3465,O
potential,3465,O
duration,3465,O
(,3465,O
FPD,3465,O
),3465,O
in,3465,O
human-induced,3465,B-OrganismTaxon
pluripotent,3465,O
stem,3465,O
cell-derived,3465,O
cardiomyocytes,3465,O
(,3465,O
hiPS-CMs,3465,O
),3465,O
",",3465,O
which,3465,O
can,3465,O
express,3465,O
QT,3465,O
interval,3465,O
in,3465,O
an,3465,O
electrocardiogram,3465,O
",",3465,O
is,3465,O
reported,3465,O
to,3465,O
be,3465,O
a,3465,O
useful,3465,O
tool,3465,O
to,3465,O
predict,3465,O
K,3465,B-ChemicalEntity
(,3465,I-ChemicalEntity
+,3465,I-ChemicalEntity
),3465,I-ChemicalEntity
channel,3465,I-ChemicalEntity
and,3465,I-ChemicalEntity
Ca,3465,I-ChemicalEntity
(,3465,I-ChemicalEntity
2+,3465,I-ChemicalEntity
),3465,I-ChemicalEntity
channel,3465,I-ChemicalEntity
blocker,3465,I-ChemicalEntity
effects,3465,O
on,3465,O
QT,3465,O
interval,3465,O
.,3465,O
However,3466,O
",",3466,O
there,3466,O
is,3466,O
no,3466,O
report,3466,O
showing,3466,O
that,3466,O
this,3466,O
technique,3466,O
can,3466,O
be,3466,O
used,3466,O
to,3466,O
predict,3466,O
multichannel,3466,O
blocker,3466,O
potential,3466,O
for,3466,O
QT,3466,B-DiseaseOrPhenotypicFeature
prolongation,3466,I-DiseaseOrPhenotypicFeature
.,3466,O
The,3467,O
aim,3467,O
of,3467,O
this,3467,O
study,3467,O
is,3467,O
to,3467,O
show,3467,O
that,3467,O
FPD,3467,O
from,3467,O
MEA,3467,O
(,3467,O
Multielectrode,3467,O
array,3467,O
),3467,O
of,3467,O
hiPS-CMs,3467,O
can,3467,O
detect,3467,O
QT,3467,B-DiseaseOrPhenotypicFeature
prolongation,3467,I-DiseaseOrPhenotypicFeature
induced,3467,O
by,3467,O
multichannel,3467,O
blockers,3467,O
.,3467,O
hiPS-CMs,3468,O
were,3468,O
seeded,3468,O
onto,3468,O
MEA,3468,O
and,3468,O
FPD,3468,O
was,3468,O
measured,3468,O
for,3468,O
2min,3468,O
every,3468,O
10min,3468,O
for,3468,O
30min,3468,O
after,3468,O
drug,3468,O
exposure,3468,O
for,3468,O
the,3468,O
vehicle,3468,O
and,3468,O
each,3468,O
drug,3468,O
concentration,3468,O
.,3468,O
IKr,3469,O
and,3469,O
IKs,3469,O
blockers,3469,O
concentration-dependently,3469,O
prolonged,3469,O
corrected,3469,O
FPD,3469,O
(,3469,O
FPDc,3469,O
),3469,O
",",3469,O
whereas,3469,O
Ca,3469,B-ChemicalEntity
(,3469,I-ChemicalEntity
2+,3469,I-ChemicalEntity
),3469,I-ChemicalEntity
channel,3469,I-ChemicalEntity
blockers,3469,I-ChemicalEntity
concentration-dependently,3469,O
shortened,3469,O
FPDc,3469,O
.,3469,O
Also,3470,O
",",3470,O
the,3470,O
multichannel,3470,O
blockers,3470,O
Amiodarone,3470,B-ChemicalEntity
",",3470,O
Paroxetine,3470,B-ChemicalEntity
",",3470,O
Terfenadine,3470,B-ChemicalEntity
and,3470,O
Citalopram,3470,B-ChemicalEntity
prolonged,3470,O
FPDc,3470,O
in,3470,O
a,3470,O
concentration,3470,O
dependent,3470,O
manner,3470,O
.,3470,O
Finally,3471,O
",",3471,O
the,3471,O
IKr,3471,O
blockers,3471,O
",",3471,O
Terfenadine,3471,B-ChemicalEntity
and,3471,O
Citalopram,3471,B-ChemicalEntity
",",3471,O
which,3471,O
are,3471,O
reported,3471,O
to,3471,O
cause,3471,O
Torsade,3471,B-DiseaseOrPhenotypicFeature
de,3471,I-DiseaseOrPhenotypicFeature
Pointes,3471,I-DiseaseOrPhenotypicFeature
(,3471,O
TdP,3471,B-DiseaseOrPhenotypicFeature
),3471,O
in,3471,O
clinical,3471,O
practice,3471,O
",",3471,O
produced,3471,O
early,3471,O
afterdepolarization,3471,O
(,3471,O
EAD,3471,O
),3471,O
.,3471,O
hiPS-CMs,3472,O
using,3472,O
MEA,3472,O
system,3472,O
and,3472,O
FPDc,3472,O
can,3472,O
predict,3472,O
the,3472,O
effects,3472,O
of,3472,O
drug,3472,O
candidates,3472,O
on,3472,O
QT,3472,O
interval,3472,O
.,3472,O
This,3473,O
study,3473,O
also,3473,O
shows,3473,O
that,3473,O
this,3473,O
assay,3473,O
can,3473,O
help,3473,O
detect,3473,O
EAD,3473,O
for,3473,O
drugs,3473,O
with,3473,O
TdP,3473,B-DiseaseOrPhenotypicFeature
potential,3473,O
.,3473,O
IL-3,3474,B-GeneOrGeneProduct
and,3474,O
CSF-1,3474,B-GeneOrGeneProduct
interact,3474,O
to,3474,O
promote,3474,O
generation,3474,O
of,3474,O
CD11c+,3474,B-GeneOrGeneProduct
IL-10-producing,3474,B-GeneOrGeneProduct
macrophages,3474,O
.,3474,O
Unraveling,3475,O
the,3475,O
mechanisms,3475,O
of,3475,O
hematopoiesis,3475,O
regulated,3475,O
by,3475,O
multiple,3475,O
cytokines,3475,O
remains,3475,O
a,3475,O
challenge,3475,O
in,3475,O
hematology,3475,O
.,3475,O
IL-3,3476,B-GeneOrGeneProduct
is,3476,O
an,3476,O
allergic,3476,O
cytokine,3476,O
with,3476,O
the,3476,O
multilineage,3476,O
potential,3476,O
",",3476,O
while,3476,O
CSF-1,3476,B-GeneOrGeneProduct
is,3476,O
produced,3476,O
in,3476,O
the,3476,O
steady,3476,O
state,3476,O
with,3476,O
restricted,3476,O
lineage,3476,O
coverage,3476,O
.,3476,O
Here,3477,O
",",3477,O
we,3477,O
uncovered,3477,O
an,3477,O
instructive,3477,O
role,3477,O
of,3477,O
CSF-1,3477,B-GeneOrGeneProduct
in,3477,O
IL-3-mediated,3477,B-GeneOrGeneProduct
hematopoiesis,3477,O
.,3477,O
CSF-1,3478,B-GeneOrGeneProduct
significantly,3478,O
promoted,3478,O
IL-3-driven,3478,B-GeneOrGeneProduct
CD11c+,3478,B-GeneOrGeneProduct
cell,3478,O
expansion,3478,O
and,3478,O
dampened,3478,O
basophil,3478,O
and,3478,O
mast,3478,O
cell,3478,O
generation,3478,O
from,3478,O
C57BL/6,3478,B-CellLine
bone,3478,O
marrow,3478,O
.,3478,O
Further,3479,O
studies,3479,O
indicated,3479,O
that,3479,O
the,3479,O
CSF-1/CSF-1R,3479,B-GeneOrGeneProduct
axis,3479,O
contributed,3479,O
significantly,3479,O
to,3479,O
IL-3-induced,3479,B-GeneOrGeneProduct
CD11c+,3479,B-GeneOrGeneProduct
cell,3479,O
generation,3479,O
through,3479,O
enhancing,3479,O
c-Fos-associated,3479,B-GeneOrGeneProduct
monopoiesis,3479,O
.,3479,O
CD11c+,3480,B-GeneOrGeneProduct
cells,3480,O
induced,3480,O
by,3480,O
IL-3,3480,B-GeneOrGeneProduct
or,3480,O
IL-3/CSF-1,3480,B-GeneOrGeneProduct
were,3480,O
competent,3480,O
in,3480,O
cellular,3480,O
maturation,3480,O
and,3480,O
endocytosis,3480,O
.,3480,O
Both,3481,O
IL-3,3481,B-GeneOrGeneProduct
and,3481,O
IL-3/CSF-1,3481,B-GeneOrGeneProduct
cells,3481,O
lacked,3481,O
classical,3481,O
dendritic,3481,O
cell,3481,O
appearance,3481,O
and,3481,O
resembled,3481,O
macrophages,3481,O
in,3481,O
morphology,3481,O
.,3481,O
Both,3482,O
populations,3482,O
produced,3482,O
a,3482,O
high,3482,O
level,3482,O
of,3482,O
IL-10,3482,B-GeneOrGeneProduct
",",3482,O
in,3482,O
addition,3482,O
to,3482,O
IL-1,3482,B-GeneOrGeneProduct
",",3482,O
IL-6,3482,B-GeneOrGeneProduct
and,3482,O
TNFa,3482,B-GeneOrGeneProduct
",",3482,O
in,3482,O
response,3482,O
to,3482,O
LPS,3482,B-ChemicalEntity
",",3482,O
and,3482,O
were,3482,O
relatively,3482,O
poor,3482,O
T,3482,O
cell,3482,O
stimulators,3482,O
.,3482,O
Collectively,3483,O
",",3483,O
these,3483,O
findings,3483,O
reveal,3483,O
a,3483,O
role,3483,O
for,3483,O
CSF-1,3483,B-GeneOrGeneProduct
in,3483,O
mediating,3483,O
the,3483,O
IL-3,3483,B-GeneOrGeneProduct
hematopoietic,3483,O
pathway,3483,O
through,3483,O
monopoiesis,3483,O
",",3483,O
which,3483,O
regulates,3483,O
expansion,3483,O
of,3483,O
CD11c+,3483,B-GeneOrGeneProduct
macrophages,3483,O
.,3483,O
Structural,3484,O
mechanisms,3484,O
determining,3484,O
inhibition,3484,O
of,3484,O
the,3484,O
collagen,3484,B-GeneOrGeneProduct
receptor,3484,I-GeneOrGeneProduct
DDR1,3484,B-GeneOrGeneProduct
by,3484,O
selective,3484,O
and,3484,O
multi-targeted,3484,O
type,3484,O
II,3484,O
kinase,3484,O
inhibitors,3484,O
.,3484,O
The,3485,O
discoidin,3485,B-GeneOrGeneProduct
domain,3485,I-GeneOrGeneProduct
receptors,3485,I-GeneOrGeneProduct
(,3485,O
DDRs,3485,B-GeneOrGeneProduct
),3485,O
",",3485,O
DDR1,3485,B-GeneOrGeneProduct
and,3485,O
DDR2,3485,B-GeneOrGeneProduct
",",3485,O
form,3485,O
a,3485,O
unique,3485,O
subfamily,3485,O
of,3485,O
receptor,3485,B-GeneOrGeneProduct
tyrosine,3485,I-GeneOrGeneProduct
kinases,3485,I-GeneOrGeneProduct
that,3485,O
are,3485,O
activated,3485,O
by,3485,O
the,3485,O
binding,3485,O
of,3485,O
triple-helical,3485,O
collagen,3485,B-GeneOrGeneProduct
.,3485,O
Excessive,3486,O
signaling,3486,O
by,3486,O
DDR1,3486,B-GeneOrGeneProduct
and,3486,O
DDR2,3486,B-GeneOrGeneProduct
has,3486,O
been,3486,O
linked,3486,O
to,3486,O
the,3486,O
progression,3486,O
of,3486,O
various,3486,O
human,3486,B-OrganismTaxon
diseases,3486,O
",",3486,O
including,3486,O
fibrosis,3486,B-DiseaseOrPhenotypicFeature
",",3486,O
atherosclerosis,3486,B-DiseaseOrPhenotypicFeature
and,3486,O
cancer,3486,B-DiseaseOrPhenotypicFeature
.,3486,O
We,3487,O
report,3487,O
the,3487,O
inhibition,3487,O
of,3487,O
these,3487,O
unusual,3487,O
receptor,3487,B-GeneOrGeneProduct
tyrosine,3487,I-GeneOrGeneProduct
kinases,3487,I-GeneOrGeneProduct
by,3487,O
the,3487,O
multi-targeted,3487,O
cancer,3487,B-DiseaseOrPhenotypicFeature
drugs,3487,O
imatinib,3487,B-ChemicalEntity
and,3487,O
ponatinib,3487,B-ChemicalEntity
",",3487,O
as,3487,O
well,3487,O
as,3487,O
the,3487,O
selective,3487,O
type,3487,O
II,3487,O
inhibitor,3487,O
DDR1-IN-1,3487,B-ChemicalEntity
.,3487,O
Ponatinib,3488,B-ChemicalEntity
is,3488,O
identified,3488,O
as,3488,O
the,3488,O
more,3488,O
potent,3488,O
molecule,3488,O
",",3488,O
which,3488,O
inhibits,3488,O
DDR1,3488,B-GeneOrGeneProduct
and,3488,O
DDR2,3488,B-GeneOrGeneProduct
with,3488,O
an,3488,O
IC50,3488,O
of,3488,O
9nM,3488,O
.,3488,O
Co-crystal,3489,O
structures,3489,O
of,3489,O
human,3489,B-OrganismTaxon
DDR1,3489,B-GeneOrGeneProduct
reveal,3489,O
a,3489,O
DFG-out,3489,B-ChemicalEntity
conformation,3489,O
(,3489,O
DFG,3489,B-ChemicalEntity
",",3489,O
Asp-Phe-Gly,3489,B-ChemicalEntity
),3489,O
of,3489,O
the,3489,O
kinase,3489,O
domain,3489,O
that,3489,O
is,3489,O
stabilized,3489,O
by,3489,O
an,3489,O
unusual,3489,O
salt,3489,O
bridge,3489,O
between,3489,O
the,3489,O
activation,3489,O
loop,3489,O
and,3489,O
aD,3489,O
helix,3489,O
.,3489,O
Differences,3490,O
to,3490,O
Abelson,3490,B-GeneOrGeneProduct
kinase,3490,I-GeneOrGeneProduct
(,3490,O
ABL,3490,B-GeneOrGeneProduct
),3490,O
are,3490,O
observed,3490,O
in,3490,O
the,3490,O
DDR1,3490,B-GeneOrGeneProduct
P-loop,3490,O
",",3490,O
where,3490,O
a,3490,O
b-hairpin,3490,O
replaces,3490,O
the,3490,O
cage-like,3490,O
structure,3490,O
of,3490,O
ABL,3490,B-GeneOrGeneProduct
.,3490,O
P-loop,3491,O
residues,3491,O
in,3491,O
DDR1,3491,B-GeneOrGeneProduct
that,3491,O
confer,3491,O
drug,3491,O
resistance,3491,O
in,3491,O
ABL,3491,B-GeneOrGeneProduct
are,3491,O
therefore,3491,O
accommodated,3491,O
outside,3491,O
the,3491,O
ATP,3491,B-ChemicalEntity
pocket,3491,O
.,3491,O
Whereas,3492,O
imatinib,3492,B-ChemicalEntity
and,3492,O
ponatinib,3492,B-ChemicalEntity
bind,3492,O
potently,3492,O
to,3492,O
both,3492,O
the,3492,O
DDR,3492,B-GeneOrGeneProduct
and,3492,O
ABL,3492,B-GeneOrGeneProduct
kinases,3492,O
",",3492,O
the,3492,O
hydrophobic,3492,O
interactions,3492,O
of,3492,O
the,3492,O
ABL,3492,B-GeneOrGeneProduct
P-loop,3492,O
appear,3492,O
poorly,3492,O
satisfied,3492,O
by,3492,O
DDR1-IN-1,3492,B-ChemicalEntity
suggesting,3492,O
a,3492,O
structural,3492,O
basis,3492,O
for,3492,O
its,3492,O
DDR1,3492,B-GeneOrGeneProduct
selectivity,3492,O
.,3492,O
Such,3493,O
inhibitors,3493,O
may,3493,O
have,3493,O
applications,3493,O
in,3493,O
clinical,3493,O
indications,3493,O
of,3493,O
DDR1,3493,B-GeneOrGeneProduct
and,3493,O
DDR2,3493,B-GeneOrGeneProduct
overexpression,3493,O
or,3493,O
mutation,3493,O
",",3493,O
including,3493,O
lung,3493,B-DiseaseOrPhenotypicFeature
cancer,3493,I-DiseaseOrPhenotypicFeature
.,3493,O
Chronic,3494,O
treatment,3494,O
with,3494,O
metformin,3494,B-ChemicalEntity
suppresses,3494,O
toll-like,3494,B-GeneOrGeneProduct
receptor,3494,I-GeneOrGeneProduct
4,3494,I-GeneOrGeneProduct
signaling,3494,O
and,3494,O
attenuates,3494,O
left,3494,B-DiseaseOrPhenotypicFeature
ventricular,3494,I-DiseaseOrPhenotypicFeature
dysfunction,3494,I-DiseaseOrPhenotypicFeature
following,3494,O
myocardial,3494,B-DiseaseOrPhenotypicFeature
infarction,3494,I-DiseaseOrPhenotypicFeature
.,3494,O
Acute,3495,O
treatment,3495,O
with,3495,O
metformin,3495,B-ChemicalEntity
has,3495,O
a,3495,O
protective,3495,O
effect,3495,O
in,3495,O
myocardial,3495,B-DiseaseOrPhenotypicFeature
infarction,3495,I-DiseaseOrPhenotypicFeature
by,3495,O
suppression,3495,O
of,3495,O
inflammatory,3495,B-DiseaseOrPhenotypicFeature
responses,3495,O
due,3495,O
to,3495,O
activation,3495,O
of,3495,O
AMP-activated,3495,B-GeneOrGeneProduct
protein,3495,I-GeneOrGeneProduct
kinase,3495,I-GeneOrGeneProduct
(,3495,O
AMPK,3495,B-GeneOrGeneProduct
),3495,O
.,3495,O
In,3496,O
the,3496,O
present,3496,O
study,3496,O
",",3496,O
the,3496,O
effect,3496,O
of,3496,O
chronic,3496,O
pre-treatment,3496,O
with,3496,O
metformin,3496,B-ChemicalEntity
on,3496,O
cardiac,3496,B-DiseaseOrPhenotypicFeature
dysfunction,3496,I-DiseaseOrPhenotypicFeature
and,3496,O
toll-like,3496,B-GeneOrGeneProduct
receptor,3496,I-GeneOrGeneProduct
4,3496,I-GeneOrGeneProduct
(,3496,O
TLR4,3496,B-GeneOrGeneProduct
),3496,O
activities,3496,O
following,3496,O
myocardial,3496,B-DiseaseOrPhenotypicFeature
infarction,3496,I-DiseaseOrPhenotypicFeature
and,3496,O
their,3496,O
relation,3496,O
with,3496,O
AMPK,3496,B-GeneOrGeneProduct
were,3496,O
assessed,3496,O
.,3496,O
Male,3497,O
Wistar,3497,O
rats,3497,B-OrganismTaxon
were,3497,O
randomly,3497,O
assigned,3497,O
to,3497,O
one,3497,O
of,3497,O
5,3497,O
groups,3497,O
(,3497,O
n=6,3497,O
),3497,O
:,3497,O
normal,3497,O
control,3497,O
and,3497,O
groups,3497,O
were,3497,O
injected,3497,O
isoproterenol,3497,B-ChemicalEntity
after,3497,O
chronic,3497,O
pre-treatment,3497,O
with,3497,O
0,3497,O
",",3497,O
25,3497,O
",",3497,O
50,3497,O
",",3497,O
or,3497,O
100mg/kg,3497,O
of,3497,O
metformin,3497,B-ChemicalEntity
twice,3497,O
daily,3497,O
for,3497,O
14,3497,O
days,3497,O
.,3497,O
Isoproterenol,3498,B-ChemicalEntity
(,3498,O
100mg/kg,3498,O
),3498,O
was,3498,O
injected,3498,O
subcutaneously,3498,O
on,3498,O
the,3498,O
13th,3498,O
and,3498,O
14th,3498,O
days,3498,O
to,3498,O
induce,3498,O
acute,3498,B-DiseaseOrPhenotypicFeature
myocardial,3498,I-DiseaseOrPhenotypicFeature
infarction,3498,I-DiseaseOrPhenotypicFeature
.,3498,O
Isoproterenol,3499,B-ChemicalEntity
alone,3499,O
decreased,3499,O
left,3499,O
ventricular,3499,O
systolic,3499,O
pressure,3499,O
and,3499,O
myocardial,3499,O
contractility,3499,O
indexed,3499,O
as,3499,O
LVdp/dtmax,3499,O
and,3499,O
LVdp/dtmin,3499,O
.,3499,O
The,3500,O
left,3500,B-DiseaseOrPhenotypicFeature
ventricular,3500,I-DiseaseOrPhenotypicFeature
dysfunction,3500,I-DiseaseOrPhenotypicFeature
was,3500,O
significantly,3500,O
lower,3500,O
in,3500,O
the,3500,O
groups,3500,O
treated,3500,O
with,3500,O
25,3500,O
and,3500,O
50mg/kg,3500,O
of,3500,O
metformin,3500,B-ChemicalEntity
.,3500,O
Metfromin,3501,B-ChemicalEntity
markedly,3501,O
lowered,3501,O
isoproterenol-induced,3501,B-ChemicalEntity
elevation,3501,O
in,3501,O
the,3501,O
levels,3501,O
of,3501,O
TLR4,3501,B-GeneOrGeneProduct
mRNA,3501,O
",",3501,O
myeloid,3501,B-GeneOrGeneProduct
differentiation,3501,I-GeneOrGeneProduct
protein,3501,I-GeneOrGeneProduct
88,3501,I-GeneOrGeneProduct
(,3501,O
MyD88,3501,B-GeneOrGeneProduct
),3501,O
",",3501,O
tumor,3501,B-GeneOrGeneProduct
necrosis,3501,I-GeneOrGeneProduct
factor-alpha,3501,I-GeneOrGeneProduct
(,3501,O
TNF-a,3501,B-GeneOrGeneProduct
),3501,O
",",3501,O
and,3501,O
interleukin,3501,B-GeneOrGeneProduct
6,3501,I-GeneOrGeneProduct
(,3501,O
IL-6,3501,B-GeneOrGeneProduct
),3501,O
in,3501,O
the,3501,O
heart,3501,O
tissues,3501,O
.,3501,O
Similar,3502,O
changes,3502,O
were,3502,O
also,3502,O
seen,3502,O
in,3502,O
the,3502,O
serum,3502,O
levels,3502,O
of,3502,O
TNF-a,3502,B-GeneOrGeneProduct
and,3502,O
IL-6,3502,B-GeneOrGeneProduct
.,3502,O
However,3503,O
",",3503,O
the,3503,O
lower,3503,O
doses,3503,O
of,3503,O
25,3503,O
and,3503,O
50mg/kg,3503,O
were,3503,O
more,3503,O
effective,3503,O
than,3503,O
100mg/kg,3503,O
.,3503,O
Phosphorylated,3504,O
AMPKa,3504,B-GeneOrGeneProduct
(,3504,O
p-AMPK,3504,O
),3504,O
in,3504,O
the,3504,O
myocardium,3504,O
was,3504,O
significantly,3504,O
elevated,3504,O
by,3504,O
25mg/kg,3504,O
of,3504,O
metformin,3504,B-ChemicalEntity
",",3504,O
slightly,3504,O
by,3504,O
50mg/kg,3504,O
",",3504,O
but,3504,O
not,3504,O
by,3504,O
100mg/kg,3504,O
.,3504,O
Chronic,3505,O
pre-treatment,3505,O
with,3505,O
metformin,3505,B-ChemicalEntity
reduces,3505,O
post-myocardial,3505,O
infarction,3505,I-DiseaseOrPhenotypicFeature
cardiac,3505,B-DiseaseOrPhenotypicFeature
dysfunction,3505,I-DiseaseOrPhenotypicFeature
and,3505,O
suppresses,3505,O
inflammatory,3505,B-DiseaseOrPhenotypicFeature
responses,3505,O
",",3505,O
possibly,3505,O
through,3505,O
inhibition,3505,O
of,3505,O
TLR4,3505,B-GeneOrGeneProduct
activities,3505,O
.,3505,O
This,3506,O
mechanism,3506,O
can,3506,O
be,3506,O
considered,3506,O
as,3506,O
a,3506,O
target,3506,O
to,3506,O
protect,3506,O
infarcted,3506,B-DiseaseOrPhenotypicFeature
myocardium,3506,I-DiseaseOrPhenotypicFeature
.,3506,O
Crucial,3507,O
role,3507,O
of,3507,O
calbindin-D28k,3507,B-GeneOrGeneProduct
in,3507,O
the,3507,O
pathogenesis,3507,O
of,3507,O
Alzheimer,3507,B-DiseaseOrPhenotypicFeature
's,3507,I-DiseaseOrPhenotypicFeature
disease,3507,I-DiseaseOrPhenotypicFeature
mouse,3507,B-OrganismTaxon
model,3507,O
.,3507,O
Calbindin-D28k,3508,B-GeneOrGeneProduct
(,3508,O
CB,3508,B-GeneOrGeneProduct
),3508,O
",",3508,O
one,3508,O
of,3508,O
the,3508,O
major,3508,O
calcium-binding,3508,B-ChemicalEntity
and,3508,O
buffering,3508,O
proteins,3508,O
",",3508,O
has,3508,O
a,3508,O
critical,3508,O
role,3508,O
in,3508,O
preventing,3508,O
a,3508,O
neuronal,3508,B-DiseaseOrPhenotypicFeature
death,3508,I-DiseaseOrPhenotypicFeature
as,3508,O
well,3508,O
as,3508,O
maintaining,3508,O
calcium,3508,B-ChemicalEntity
homeostasis,3508,O
.,3508,O
Although,3509,O
marked,3509,O
reductions,3509,O
of,3509,O
CB,3509,B-GeneOrGeneProduct
expression,3509,O
have,3509,O
been,3509,O
observed,3509,O
in,3509,O
the,3509,O
brains,3509,O
of,3509,O
mice,3509,B-OrganismTaxon
and,3509,O
humans,3509,B-OrganismTaxon
with,3509,O
Alzheimer,3509,B-DiseaseOrPhenotypicFeature
disease,3509,I-DiseaseOrPhenotypicFeature
(,3509,O
AD,3509,B-DiseaseOrPhenotypicFeature
),3509,O
",",3509,O
it,3509,O
is,3509,O
unknown,3509,O
whether,3509,O
these,3509,O
changes,3509,O
contribute,3509,O
to,3509,O
AD-related,3509,B-DiseaseOrPhenotypicFeature
dysfunction,3509,O
.,3509,O
To,3510,O
determine,3510,O
the,3510,O
pathogenic,3510,O
importance,3510,O
of,3510,O
CB,3510,B-GeneOrGeneProduct
depletions,3510,O
in,3510,O
AD,3510,B-DiseaseOrPhenotypicFeature
models,3510,O
",",3510,O
we,3510,O
crossed,3510,O
5,3510,O
familial,3510,O
AD,3510,B-DiseaseOrPhenotypicFeature
mutations,3510,O
(,3510,O
5XFAD,3510,O
;,3510,O
Tg,3510,O
),3510,O
mice,3510,B-OrganismTaxon
with,3510,O
CB,3510,B-GeneOrGeneProduct
knock-out,3510,O
(,3510,O
CBKO,3510,B-GeneOrGeneProduct
),3510,O
mice,3510,B-OrganismTaxon
and,3510,O
generated,3510,O
a,3510,O
novel,3510,O
line,3510,O
CBKO.5XFAD,3510,B-GeneOrGeneProduct
(,3510,O
CBKOTg,3510,B-GeneOrGeneProduct
),3510,O
mice,3510,B-OrganismTaxon
.,3510,O
We,3511,O
first,3511,O
identified,3511,O
the,3511,O
change,3511,O
of,3511,O
signaling,3511,O
pathways,3511,O
and,3511,O
differentially,3511,O
expressed,3511,O
proteins,3511,O
globally,3511,O
by,3511,O
removing,3511,O
CB,3511,B-GeneOrGeneProduct
in,3511,O
Tg,3511,O
mice,3511,B-OrganismTaxon
using,3511,O
mass,3511,O
spectrometry,3511,O
and,3511,O
antibody,3511,O
microarray,3511,O
.,3511,O
Immunohistochemistry,3512,O
showed,3512,O
that,3512,O
CBKOTg,3512,B-GeneOrGeneProduct
mice,3512,B-OrganismTaxon
had,3512,O
significant,3512,O
neuronal,3512,B-DiseaseOrPhenotypicFeature
loss,3512,I-DiseaseOrPhenotypicFeature
in,3512,O
the,3512,O
subiculum,3512,O
area,3512,O
without,3512,O
changing,3512,O
the,3512,O
magnitude,3512,O
(,3512,O
number,3512,O
),3512,O
of,3512,O
amyloid,3512,B-GeneOrGeneProduct
b-peptide,3512,I-GeneOrGeneProduct
(,3512,O
Ab,3512,B-GeneOrGeneProduct
),3512,O
plaques,3512,O
deposition,3512,O
and,3512,O
elicited,3512,O
significant,3512,O
apoptotic,3512,O
features,3512,O
and,3512,O
mitochondrial,3512,B-DiseaseOrPhenotypicFeature
dysfunction,3512,I-DiseaseOrPhenotypicFeature
compared,3512,O
with,3512,O
Tg,3512,O
mice,3512,B-OrganismTaxon
.,3512,O
Moreover,3513,O
",",3513,O
CBKOTg,3513,B-GeneOrGeneProduct
mice,3513,B-OrganismTaxon
reduced,3513,O
levels,3513,O
of,3513,O
phosphorylated,3513,O
mitogen-activated,3513,B-GeneOrGeneProduct
protein,3513,I-GeneOrGeneProduct
kinase,3513,I-GeneOrGeneProduct
(,3513,O
extracellular,3513,B-GeneOrGeneProduct
signal-regulated,3513,I-GeneOrGeneProduct
kinase,3513,I-GeneOrGeneProduct
),3513,I-GeneOrGeneProduct
1/2,3513,I-GeneOrGeneProduct
and,3513,O
cAMP,3513,B-GeneOrGeneProduct
response,3513,I-GeneOrGeneProduct
element-binding,3513,I-GeneOrGeneProduct
protein,3513,I-GeneOrGeneProduct
at,3513,O
Ser-133,3513,O
and,3513,O
synaptic,3513,O
molecules,3513,O
such,3513,O
as,3513,O
N-methyl-D-aspartate,3513,B-GeneOrGeneProduct
receptor,3513,I-GeneOrGeneProduct
1,3513,I-GeneOrGeneProduct
(,3513,O
NMDA,3513,B-GeneOrGeneProduct
receptor,3513,I-GeneOrGeneProduct
1,3513,I-GeneOrGeneProduct
),3513,O
",",3513,O
NMDA,3513,B-GeneOrGeneProduct
receptor,3513,I-GeneOrGeneProduct
2A,3513,I-GeneOrGeneProduct
",",3513,O
PSD-95,3513,B-GeneOrGeneProduct
and,3513,O
synaptophysin,3513,B-GeneOrGeneProduct
in,3513,O
the,3513,O
subiculum,3513,O
compared,3513,O
with,3513,O
Tg,3513,O
mice,3513,B-OrganismTaxon
.,3513,O
Importantly,3514,O
",",3514,O
this,3514,O
is,3514,O
the,3514,O
first,3514,O
experimental,3514,O
evidence,3514,O
that,3514,O
removal,3514,O
of,3514,O
CB,3514,B-GeneOrGeneProduct
from,3514,O
amyloid,3514,B-GeneOrGeneProduct
precursor,3514,I-GeneOrGeneProduct
protein/presenilin,3514,O
transgenic,3514,O
mice,3514,B-OrganismTaxon
aggravates,3514,O
AD,3514,B-DiseaseOrPhenotypicFeature
pathogenesis,3514,O
",",3514,O
suggesting,3514,O
that,3514,O
CB,3514,B-GeneOrGeneProduct
has,3514,O
a,3514,O
critical,3514,O
role,3514,O
in,3514,O
AD,3514,B-DiseaseOrPhenotypicFeature
pathogenesis,3514,O
.,3514,O
Testosterone,3515,B-ChemicalEntity
ameliorates,3515,O
streptozotocin-induced,3515,B-ChemicalEntity
memory,3515,B-DiseaseOrPhenotypicFeature
impairment,3515,I-DiseaseOrPhenotypicFeature
in,3515,O
male,3515,O
rats,3515,B-OrganismTaxon
.,3515,O
AIM,3516,O
:,3516,O
To,3516,O
study,3516,O
the,3516,O
effects,3516,O
of,3516,O
testosterone,3516,B-ChemicalEntity
on,3516,O
streptozotocin,3516,B-ChemicalEntity
(,3516,O
STZ,3516,B-ChemicalEntity
),3516,O
-induced,3516,O
memory,3516,B-DiseaseOrPhenotypicFeature
impairment,3516,I-DiseaseOrPhenotypicFeature
in,3516,O
male,3516,O
rats,3516,B-OrganismTaxon
.,3516,O
METHODS,3517,O
:,3517,O
Adult,3517,O
male,3517,O
Wistar,3517,O
rats,3517,B-OrganismTaxon
were,3517,O
intracerebroventricularly,3517,O
(,3517,O
icv,3517,O
),3517,O
infused,3517,O
with,3517,O
STZ,3517,B-ChemicalEntity
(,3517,O
750,3517,O
ug,3517,O
),3517,O
on,3517,O
d,3517,O
1,3517,O
and,3517,O
d,3517,O
3,3517,O
",",3517,O
and,3517,O
a,3517,O
passive,3517,O
avoidance,3517,O
task,3517,O
was,3517,O
assessed,3517,O
2,3517,O
weeks,3517,O
after,3517,O
the,3517,O
first,3517,O
injection,3517,O
of,3517,O
STZ,3517,B-ChemicalEntity
.,3517,O
Castration,3518,O
surgery,3518,O
was,3518,O
performed,3518,O
in,3518,O
another,3518,O
group,3518,O
of,3518,O
rats,3518,B-OrganismTaxon
",",3518,O
and,3518,O
the,3518,O
passive,3518,O
avoidance,3518,O
task,3518,O
was,3518,O
assessed,3518,O
4,3518,O
weeks,3518,O
after,3518,O
the,3518,O
operation,3518,O
.,3518,O
Testosterone,3519,B-ChemicalEntity
(,3519,O
1,3519,O
mg.kg,3519,O
(,3519,O
-1,3519,O
),3519,O
.d,3519,O
(,3519,O
-1,3519,O
),3519,O
",",3519,O
sc,3519,O
),3519,O
",",3519,O
the,3519,O
androgen,3519,B-GeneOrGeneProduct
receptor,3519,I-GeneOrGeneProduct
antagonist,3519,O
flutamide,3519,B-ChemicalEntity
(,3519,O
10,3519,O
mg.kg,3519,O
(,3519,O
-1,3519,O
),3519,O
.d,3519,O
(,3519,O
-1,3519,O
),3519,O
",",3519,O
ip,3519,O
),3519,O
",",3519,O
the,3519,O
estrogen,3519,B-GeneOrGeneProduct
receptor,3519,I-GeneOrGeneProduct
antagonist,3519,O
tamoxifen,3519,B-ChemicalEntity
(,3519,O
1,3519,O
mg.kg,3519,O
(,3519,O
-1,3519,O
),3519,O
.d,3519,O
(,3519,O
-1,3519,O
),3519,O
",",3519,O
ip,3519,O
),3519,O
or,3519,O
the,3519,O
aromatase,3519,B-GeneOrGeneProduct
inhibitor,3519,O
letrozole,3519,B-ChemicalEntity
(,3519,O
4,3519,O
mg.kg,3519,O
(,3519,O
-1,3519,O
),3519,O
.d,3519,O
(,3519,O
-1,3519,O
),3519,O
",",3519,O
ip,3519,O
),3519,O
were,3519,O
administered,3519,O
for,3519,O
6,3519,O
d,3519,O
after,3519,O
the,3519,O
first,3519,O
injection,3519,O
of,3519,O
STZ,3519,B-ChemicalEntity
.,3519,O
RESULTS,3520,O
:,3520,O
STZ,3520,B-ChemicalEntity
administration,3520,O
and,3520,O
castration,3520,O
markedly,3520,O
decreased,3520,O
both,3520,O
STL1,3520,B-GeneOrGeneProduct
(,3520,O
the,3520,O
short,3520,O
memory,3520,O
),3520,O
and,3520,O
STL2,3520,B-GeneOrGeneProduct
(,3520,O
the,3520,O
long,3520,O
memory,3520,O
),3520,O
in,3520,O
passive,3520,O
avoidance,3520,O
tests,3520,O
.,3520,O
Testosterone,3521,B-ChemicalEntity
replacement,3521,O
almost,3521,O
restored,3521,O
the,3521,O
STL1,3521,B-GeneOrGeneProduct
and,3521,O
STL2,3521,B-GeneOrGeneProduct
in,3521,O
castrated,3521,O
rats,3521,B-OrganismTaxon
",",3521,O
and,3521,O
significantly,3521,O
prolonged,3521,O
the,3521,O
STL1,3521,B-GeneOrGeneProduct
and,3521,O
STL2,3521,B-GeneOrGeneProduct
in,3521,O
STZ-treated,3521,B-ChemicalEntity
rats,3521,B-OrganismTaxon
.,3521,O
Administration,3522,O
of,3522,O
flutamide,3522,B-ChemicalEntity
",",3522,O
letrozole,3522,B-ChemicalEntity
or,3522,O
tamoxifen,3522,B-ChemicalEntity
significantly,3522,O
impaired,3522,O
the,3522,O
memory,3522,O
in,3522,O
intact,3522,O
rats,3522,B-OrganismTaxon
",",3522,O
and,3522,O
significantly,3522,O
attenuated,3522,O
the,3522,O
testosterone,3522,B-ChemicalEntity
replacement,3522,O
in,3522,O
improving,3522,O
STZ-,3522,B-ChemicalEntity
and,3522,O
castration-induced,3522,O
memory,3522,B-DiseaseOrPhenotypicFeature
impairment,3522,I-DiseaseOrPhenotypicFeature
.,3522,O
CONCLUSION,3523,O
:,3523,O
Testosterone,3523,B-ChemicalEntity
administration,3523,O
ameliorates,3523,O
STZ-,3523,B-ChemicalEntity
and,3523,O
castration-induced,3523,O
memory,3523,B-DiseaseOrPhenotypicFeature
impairment,3523,I-DiseaseOrPhenotypicFeature
in,3523,O
male,3523,O
Wistar,3523,O
rats,3523,B-OrganismTaxon
.,3523,O
Behavioral,3524,O
and,3524,O
neurochemical,3524,O
studies,3524,O
in,3524,O
mice,3524,B-OrganismTaxon
pretreated,3524,O
with,3524,O
garcinielliptone,3524,B-ChemicalEntity
FC,3524,I-ChemicalEntity
in,3524,O
pilocarpine-induced,3524,B-ChemicalEntity
seizures,3524,B-DiseaseOrPhenotypicFeature
.,3524,O
Garcinielliptone,3525,B-ChemicalEntity
FC,3525,I-ChemicalEntity
(,3525,O
GFC,3525,B-ChemicalEntity
),3525,O
isolated,3525,O
from,3525,O
hexanic,3525,O
fraction,3525,O
seed,3525,O
extract,3525,O
of,3525,O
species,3525,O
Platonia,3525,B-OrganismTaxon
insignis,3525,I-OrganismTaxon
Mart,3525,I-OrganismTaxon
.,3525,O
It,3526,O
is,3526,O
widely,3526,O
used,3526,O
in,3526,O
folk,3526,O
medicine,3526,O
to,3526,O
treat,3526,O
skin,3526,B-DiseaseOrPhenotypicFeature
diseases,3526,I-DiseaseOrPhenotypicFeature
in,3526,O
both,3526,O
humans,3526,B-OrganismTaxon
and,3526,O
animals,3526,O
as,3526,O
well,3526,O
as,3526,O
the,3526,O
seed,3526,O
decoction,3526,O
has,3526,O
been,3526,O
used,3526,O
to,3526,O
treat,3526,O
diarrheas,3526,B-DiseaseOrPhenotypicFeature
and,3526,O
inflammatory,3526,B-DiseaseOrPhenotypicFeature
diseases,3526,I-DiseaseOrPhenotypicFeature
.,3526,O
However,3527,O
",",3527,O
there,3527,O
is,3527,O
no,3527,O
research,3527,O
on,3527,O
GFC,3527,B-ChemicalEntity
effects,3527,O
in,3527,O
the,3527,O
central,3527,O
nervous,3527,O
system,3527,O
of,3527,O
rodents,3527,O
.,3527,O
The,3528,O
present,3528,O
study,3528,O
aimed,3528,O
to,3528,O
evaluate,3528,O
the,3528,O
GFC,3528,B-ChemicalEntity
effects,3528,O
at,3528,O
doses,3528,O
of,3528,O
25,3528,O
",",3528,O
50,3528,O
or,3528,O
75,3528,O
mg/kg,3528,O
on,3528,O
seizure,3528,B-DiseaseOrPhenotypicFeature
parameters,3528,O
to,3528,O
determine,3528,O
their,3528,O
anticonvulsant,3528,O
activity,3528,O
and,3528,O
its,3528,O
effects,3528,O
on,3528,O
amino,3528,O
acid,3528,O
(,3528,O
r-aminobutyric,3528,B-ChemicalEntity
acid,3528,I-ChemicalEntity
(,3528,O
GABA,3528,B-ChemicalEntity
),3528,O
",",3528,O
glutamine,3528,B-ChemicalEntity
",",3528,O
aspartate,3528,B-ChemicalEntity
and,3528,O
glutathione,3528,B-ChemicalEntity
),3528,O
levels,3528,O
as,3528,O
well,3528,O
as,3528,O
on,3528,O
acetylcholinesterase,3528,B-GeneOrGeneProduct
(,3528,O
AChE,3528,B-GeneOrGeneProduct
),3528,O
activity,3528,O
in,3528,O
mice,3528,B-OrganismTaxon
hippocampus,3528,O
after,3528,O
seizures,3528,B-DiseaseOrPhenotypicFeature
.,3528,O
GFC,3529,B-ChemicalEntity
produced,3529,O
an,3529,O
increased,3529,O
latency,3529,O
to,3529,O
first,3529,O
seizure,3529,B-DiseaseOrPhenotypicFeature
",",3529,O
at,3529,O
doses,3529,O
25mg/kg,3529,O
(,3529,O
20.12,3529,O
+,3529,O
2.20,3529,O
min,3529,O
),3529,O
",",3529,O
50mg/kg,3529,O
(,3529,O
20.95,3529,O
+,3529,O
2.21,3529,O
min,3529,O
),3529,O
or,3529,O
75,3529,O
mg/kg,3529,O
(,3529,O
23.43,3529,O
+,3529,O
1.99,3529,O
min,3529,O
),3529,O
when,3529,O
compared,3529,O
with,3529,O
seized,3529,O
mice,3529,B-OrganismTaxon
.,3529,O
In,3530,O
addition,3530,O
",",3530,O
GABA,3530,B-ChemicalEntity
content,3530,O
of,3530,O
mice,3530,B-OrganismTaxon
hippocampus,3530,O
treated,3530,O
with,3530,O
GFC75,3530,B-ChemicalEntity
plus,3530,O
P400,3530,B-ChemicalEntity
showed,3530,O
an,3530,O
increase,3530,O
of,3530,O
46.90,3530,O
%,3530,O
when,3530,O
compared,3530,O
with,3530,O
seized,3530,O
mice,3530,B-OrganismTaxon
.,3530,O
In,3531,O
aspartate,3531,B-ChemicalEntity
",",3531,O
glutamine,3531,B-ChemicalEntity
and,3531,O
glutamate,3531,B-ChemicalEntity
levels,3531,O
detected,3531,O
a,3531,O
decrease,3531,O
of,3531,O
5.21,3531,O
%,3531,O
",",3531,O
13.55,3531,O
%,3531,O
and,3531,O
21.80,3531,O
%,3531,O
",",3531,O
respectively,3531,O
in,3531,O
mice,3531,B-OrganismTaxon
hippocampus,3531,O
treated,3531,O
with,3531,O
GFC75,3531,B-ChemicalEntity
plus,3531,O
P400,3531,B-ChemicalEntity
when,3531,O
compared,3531,O
with,3531,O
seized,3531,O
mice,3531,B-OrganismTaxon
.,3531,O
Hippocampus,3532,O
mice,3532,B-OrganismTaxon
treated,3532,O
with,3532,O
GFC75,3532,B-ChemicalEntity
plus,3532,O
P400,3532,B-ChemicalEntity
showed,3532,O
an,3532,O
increase,3532,O
in,3532,O
AChE,3532,B-GeneOrGeneProduct
activity,3532,O
(,3532,O
63.30,3532,O
%,3532,O
),3532,O
when,3532,O
compared,3532,O
with,3532,O
seized,3532,O
mice,3532,B-OrganismTaxon
.,3532,O
The,3533,O
results,3533,O
indicate,3533,O
that,3533,O
GFC,3533,B-ChemicalEntity
can,3533,O
exert,3533,O
anticonvulsant,3533,O
activity,3533,O
and,3533,O
reduce,3533,O
the,3533,O
frequency,3533,O
of,3533,O
installation,3533,O
of,3533,O
pilocarpine-induced,3533,B-ChemicalEntity
status,3533,B-DiseaseOrPhenotypicFeature
epilepticus,3533,I-DiseaseOrPhenotypicFeature
",",3533,O
as,3533,O
demonstrated,3533,O
by,3533,O
increase,3533,O
in,3533,O
latency,3533,O
to,3533,O
first,3533,O
seizure,3533,B-DiseaseOrPhenotypicFeature
and,3533,O
decrease,3533,O
in,3533,O
mortality,3533,O
rate,3533,O
of,3533,O
animals,3533,O
.,3533,O
In,3534,O
conclusion,3534,O
",",3534,O
our,3534,O
data,3534,O
suggest,3534,O
that,3534,O
GFC,3534,B-ChemicalEntity
may,3534,O
influence,3534,O
in,3534,O
epileptogenesis,3534,O
and,3534,O
promote,3534,O
anticonvulsant,3534,O
actions,3534,O
in,3534,O
pilocarpine,3534,B-ChemicalEntity
model,3534,O
by,3534,O
modulating,3534,O
the,3534,O
GABA,3534,B-ChemicalEntity
and,3534,O
glutamate,3534,B-ChemicalEntity
contents,3534,O
and,3534,O
of,3534,O
AChE,3534,B-GeneOrGeneProduct
activity,3534,O
in,3534,O
seized,3534,O
mice,3534,B-OrganismTaxon
hippocampus,3534,O
.,3534,O
This,3535,O
compound,3535,O
may,3535,O
be,3535,O
useful,3535,O
to,3535,O
produce,3535,O
neuronal,3535,O
protection,3535,O
and,3535,O
it,3535,O
can,3535,O
be,3535,O
considered,3535,O
as,3535,O
an,3535,O
anticonvulsant,3535,O
agent,3535,O
.,3535,O
Thyroid,3536,B-GeneOrGeneProduct
hormone,3536,I-GeneOrGeneProduct
receptor,3536,I-GeneOrGeneProduct
a,3536,I-GeneOrGeneProduct
mutation,3536,O
causes,3536,O
a,3536,O
severe,3536,O
and,3536,O
thyroxine-resistant,3536,B-ChemicalEntity
skeletal,3536,B-DiseaseOrPhenotypicFeature
dysplasia,3536,I-DiseaseOrPhenotypicFeature
in,3536,O
female,3536,O
mice,3536,B-OrganismTaxon
.,3536,O
A,3537,O
new,3537,O
genetic,3537,O
disorder,3537,O
has,3537,O
been,3537,O
identified,3537,O
that,3537,O
results,3537,O
from,3537,O
mutation,3537,O
of,3537,O
THRA,3537,B-GeneOrGeneProduct
",",3537,O
encoding,3537,O
thyroid,3537,B-GeneOrGeneProduct
hormone,3537,I-GeneOrGeneProduct
receptor,3537,I-GeneOrGeneProduct
a1,3537,I-GeneOrGeneProduct
(,3537,O
TRa1,3537,B-GeneOrGeneProduct
),3537,O
.,3537,O
Affected,3538,O
children,3538,O
have,3538,O
a,3538,O
high,3538,O
serum,3538,O
T3,3538,B-ChemicalEntity
:,3538,O
T4,3538,B-ChemicalEntity
ratio,3538,O
and,3538,O
variable,3538,O
degrees,3538,O
of,3538,O
intellectual,3538,B-DiseaseOrPhenotypicFeature
deficit,3538,I-DiseaseOrPhenotypicFeature
and,3538,O
constipation,3538,B-DiseaseOrPhenotypicFeature
but,3538,O
exhibit,3538,O
a,3538,O
consistently,3538,O
severe,3538,O
skeletal,3538,B-DiseaseOrPhenotypicFeature
dysplasia,3538,I-DiseaseOrPhenotypicFeature
.,3538,O
In,3539,O
an,3539,O
attempt,3539,O
to,3539,O
improve,3539,O
developmental,3539,B-DiseaseOrPhenotypicFeature
delay,3539,I-DiseaseOrPhenotypicFeature
and,3539,O
alleviate,3539,O
symptoms,3539,O
of,3539,O
hypothyroidism,3539,B-DiseaseOrPhenotypicFeature
",",3539,O
patients,3539,B-OrganismTaxon
are,3539,O
receiving,3539,O
varying,3539,O
doses,3539,O
and,3539,O
durations,3539,O
of,3539,O
T4,3539,B-ChemicalEntity
treatment,3539,O
",",3539,O
but,3539,O
responses,3539,O
have,3539,O
been,3539,O
inconsistent,3539,O
so,3539,O
far,3539,O
.,3539,O
Thra1,3540,B-GeneOrGeneProduct
(,3540,O
PV/+,3540,O
),3540,O
mice,3540,B-OrganismTaxon
express,3540,O
a,3540,O
similar,3540,O
potent,3540,O
dominant-negative,3540,O
mutant,3540,O
TRa1,3540,B-GeneOrGeneProduct
to,3540,O
affected,3540,O
individuals,3540,O
",",3540,O
and,3540,O
thus,3540,O
represent,3540,O
an,3540,O
excellent,3540,O
disease,3540,O
model,3540,O
.,3540,O
We,3541,O
hypothesized,3541,O
that,3541,O
Thra1,3541,B-GeneOrGeneProduct
(,3541,O
PV/+,3541,O
),3541,O
mice,3541,B-OrganismTaxon
could,3541,O
be,3541,O
used,3541,O
to,3541,O
predict,3541,O
the,3541,O
skeletal,3541,O
outcome,3541,O
of,3541,O
human,3541,B-OrganismTaxon
THRA,3541,B-GeneOrGeneProduct
mutations,3541,O
and,3541,O
determine,3541,O
whether,3541,O
prolonged,3541,O
treatment,3541,O
with,3541,O
a,3541,O
supraphysiological,3541,O
dose,3541,O
of,3541,O
T4,3541,B-ChemicalEntity
ameliorates,3541,O
the,3541,O
skeletal,3541,B-DiseaseOrPhenotypicFeature
abnormalities,3541,I-DiseaseOrPhenotypicFeature
.,3541,O
Adult,3542,O
female,3542,O
Thra1,3542,B-GeneOrGeneProduct
(,3542,O
PV/+,3542,O
),3542,O
mice,3542,B-OrganismTaxon
had,3542,O
short,3542,B-DiseaseOrPhenotypicFeature
stature,3542,I-DiseaseOrPhenotypicFeature
",",3542,O
grossly,3542,O
abnormal,3542,O
bone,3542,O
morphology,3542,O
but,3542,O
normal,3542,O
bone,3542,O
strength,3542,O
despite,3542,O
high,3542,O
bone,3542,O
mass,3542,O
.,3542,O
Although,3543,O
T4,3543,B-ChemicalEntity
treatment,3543,O
suppressed,3543,O
TSH,3543,B-GeneOrGeneProduct
secretion,3543,O
",",3543,O
it,3543,O
had,3543,O
no,3543,O
effect,3543,O
on,3543,O
skeletal,3543,O
maturation,3543,O
",",3543,O
linear,3543,O
growth,3543,O
",",3543,O
or,3543,O
bone,3543,O
mineralization,3543,O
",",3543,O
thus,3543,O
demonstrating,3543,O
profound,3543,O
tissue,3543,O
resistance,3543,B-DiseaseOrPhenotypicFeature
to,3543,I-DiseaseOrPhenotypicFeature
thyroid,3543,I-DiseaseOrPhenotypicFeature
hormone,3543,I-DiseaseOrPhenotypicFeature
.,3543,O
Despite,3544,O
this,3544,O
",",3544,O
prolonged,3544,O
T4,3544,B-ChemicalEntity
treatment,3544,O
abnormally,3544,O
increased,3544,O
bone,3544,O
stiffness,3544,O
and,3544,O
strength,3544,O
",",3544,O
suggesting,3544,O
the,3544,O
potential,3544,O
for,3544,O
detrimental,3544,O
consequences,3544,O
in,3544,O
the,3544,O
long,3544,O
term,3544,O
.,3544,O
Our,3545,O
studies,3545,O
establish,3545,O
that,3545,O
TRa1,3545,B-GeneOrGeneProduct
has,3545,O
an,3545,O
essential,3545,O
role,3545,O
in,3545,O
the,3545,O
developing,3545,O
and,3545,O
adult,3545,O
skeleton,3545,O
and,3545,O
predict,3545,O
that,3545,O
patients,3545,B-OrganismTaxon
with,3545,O
different,3545,O
THRA,3545,B-GeneOrGeneProduct
mutations,3545,O
will,3545,O
display,3545,O
variable,3545,O
responses,3545,O
to,3545,O
T4,3545,B-ChemicalEntity
treatment,3545,O
",",3545,O
which,3545,O
depend,3545,O
on,3545,O
the,3545,O
severity,3545,O
of,3545,O
the,3545,O
causative,3545,O
mutation,3545,O
.,3545,O
Rhabdomyolysis,3546,B-DiseaseOrPhenotypicFeature
in,3546,O
a,3546,O
hepatitis,3546,B-DiseaseOrPhenotypicFeature
C,3546,I-DiseaseOrPhenotypicFeature
virus,3546,I-DiseaseOrPhenotypicFeature
infected,3546,I-DiseaseOrPhenotypicFeature
patient,3546,B-OrganismTaxon
treated,3546,O
with,3546,O
telaprevir,3546,B-ChemicalEntity
and,3546,O
simvastatin,3546,B-ChemicalEntity
.,3546,O
A,3547,O
46-year,3547,O
old,3547,O
man,3547,B-OrganismTaxon
with,3547,O
a,3547,O
chronic,3547,O
hepatitis,3547,B-DiseaseOrPhenotypicFeature
C,3547,I-DiseaseOrPhenotypicFeature
virus,3547,I-DiseaseOrPhenotypicFeature
infection,3547,I-DiseaseOrPhenotypicFeature
received,3547,O
triple,3547,O
therapy,3547,O
with,3547,O
ribavirin,3547,B-ChemicalEntity
",",3547,O
pegylated,3547,B-ChemicalEntity
interferon,3547,I-ChemicalEntity
and,3547,O
telaprevir,3547,B-ChemicalEntity
.,3547,O
The,3548,O
patient,3548,B-OrganismTaxon
also,3548,O
received,3548,O
simvastatin,3548,B-ChemicalEntity
.,3548,O
One,3549,O
month,3549,O
after,3549,O
starting,3549,O
the,3549,O
antiviral,3549,O
therapy,3549,O
",",3549,O
the,3549,O
patient,3549,B-OrganismTaxon
was,3549,O
admitted,3549,O
to,3549,O
the,3549,O
hospital,3549,O
because,3549,O
he,3549,O
developed,3549,O
rhabdomyolysis,3549,B-DiseaseOrPhenotypicFeature
.,3549,O
At,3550,O
admission,3550,O
simvastatin,3550,B-ChemicalEntity
and,3550,O
all,3550,O
antiviral,3550,B-ChemicalEntity
drugs,3550,I-ChemicalEntity
were,3550,O
discontinued,3550,O
because,3550,O
toxicity,3550,B-DiseaseOrPhenotypicFeature
due,3550,O
to,3550,O
a,3550,O
drug-drug,3550,O
interaction,3550,O
was,3550,O
suspected,3550,O
.,3550,O
The,3551,O
creatine,3551,B-ChemicalEntity
kinase,3551,I-ChemicalEntity
peaked,3551,O
at,3551,O
"62,246",3551,O
IU/L,3551,O
and,3551,O
the,3551,O
patient,3551,B-OrganismTaxon
was,3551,O
treated,3551,O
with,3551,O
intravenous,3551,O
normal,3551,O
saline,3551,O
.,3551,O
The,3552,O
patient,3552,B-OrganismTaxon
's,3552,O
renal,3552,O
function,3552,O
remained,3552,O
unaffected,3552,O
.,3552,O
Fourteen,3553,O
days,3553,O
after,3553,O
hospitalization,3553,O
",",3553,O
creatine,3553,B-ChemicalEntity
kinase,3553,I-ChemicalEntity
level,3553,O
had,3553,O
returned,3553,O
to,3553,O
230,3553,O
IU/L,3553,O
and,3553,O
the,3553,O
patient,3553,B-OrganismTaxon
was,3553,O
discharged,3553,O
.,3553,O
Telaprevir,3554,B-ChemicalEntity
was,3554,O
considered,3554,O
the,3554,O
probable,3554,O
causative,3554,O
agent,3554,O
of,3554,O
an,3554,O
interaction,3554,O
with,3554,O
simvastatin,3554,B-ChemicalEntity
according,3554,O
to,3554,O
the,3554,O
Drug,3554,O
Interaction,3554,O
Probability,3554,O
Scale,3554,O
.,3554,O
The,3555,O
interaction,3555,O
is,3555,O
due,3555,O
to,3555,O
inhibition,3555,O
of,3555,O
CYP3A4-mediated,3555,B-GeneOrGeneProduct
simvastatin,3555,B-ChemicalEntity
clearance,3555,O
.,3555,O
Simvastatin,3556,B-ChemicalEntity
plasma,3556,O
concentration,3556,O
increased,3556,O
30,3556,O
times,3556,O
in,3556,O
this,3556,O
patient,3556,B-OrganismTaxon
and,3556,O
statin,3556,B-ChemicalEntity
induced,3556,O
muscle,3556,B-DiseaseOrPhenotypicFeature
toxicity,3556,I-DiseaseOrPhenotypicFeature
is,3556,O
related,3556,O
to,3556,O
the,3556,O
concentration,3556,O
of,3556,O
the,3556,O
statin,3556,B-ChemicalEntity
in,3556,O
blood,3556,O
.,3556,O
In,3557,O
conclusion,3557,O
",",3557,O
with,3557,O
this,3557,O
case,3557,O
we,3557,O
illustrate,3557,O
that,3557,O
telaprevir,3557,B-ChemicalEntity
as,3557,O
well,3557,O
as,3557,O
statins,3557,B-ChemicalEntity
are,3557,O
susceptible,3557,O
to,3557,O
clinical,3557,O
relevant,3557,O
drug-drug,3557,O
interactions,3557,O
.,3557,O
Conversion,3558,O
to,3558,O
sirolimus,3558,B-ChemicalEntity
ameliorates,3558,O
cyclosporine-induced,3558,B-ChemicalEntity
nephropathy,3558,B-DiseaseOrPhenotypicFeature
in,3558,O
the,3558,O
rat,3558,B-OrganismTaxon
:,3558,O
focus,3558,O
on,3558,O
serum,3558,O
",",3558,O
urine,3558,O
",",3558,O
gene,3558,O
",",3558,O
and,3558,O
protein,3558,O
renal,3558,O
expression,3558,O
biomarkers,3558,O
.,3558,O
Protocols,3559,O
of,3559,O
conversion,3559,O
from,3559,O
cyclosporin,3559,B-ChemicalEntity
A,3559,I-ChemicalEntity
(,3559,O
CsA,3559,B-ChemicalEntity
),3559,O
to,3559,O
sirolimus,3559,B-ChemicalEntity
(,3559,O
SRL,3559,B-ChemicalEntity
),3559,O
have,3559,O
been,3559,O
widely,3559,O
used,3559,O
in,3559,O
immunotherapy,3559,O
after,3559,O
transplantation,3559,O
to,3559,O
prevent,3559,O
CsA-induced,3559,B-ChemicalEntity
nephropathy,3559,B-DiseaseOrPhenotypicFeature
",",3559,O
but,3559,O
the,3559,O
molecular,3559,O
mechanisms,3559,O
underlying,3559,O
these,3559,O
protocols,3559,O
remain,3559,O
nuclear,3559,O
.,3559,O
This,3560,O
study,3560,O
aimed,3560,O
to,3560,O
identify,3560,O
the,3560,O
molecular,3560,O
pathways,3560,O
and,3560,O
putative,3560,O
biomarkers,3560,O
of,3560,O
CsA-to-SRL,3560,B-ChemicalEntity
conversion,3560,O
in,3560,O
a,3560,O
rat,3560,B-OrganismTaxon
model,3560,O
.,3560,O
Four,3561,O
animal,3561,O
groups,3561,O
(,3561,O
n,3561,O
=,3561,O
6,3561,O
),3561,O
were,3561,O
tested,3561,O
during,3561,O
9,3561,O
weeks,3561,O
:,3561,O
control,3561,O
",",3561,O
CsA,3561,B-ChemicalEntity
",",3561,O
SRL,3561,B-ChemicalEntity
",",3561,O
and,3561,O
conversion,3561,O
(,3561,O
CsA,3561,B-ChemicalEntity
for,3561,O
3,3561,O
weeks,3561,O
followed,3561,O
by,3561,O
SRL,3561,B-ChemicalEntity
for,3561,O
6,3561,O
weeks,3561,O
),3561,O
.,3561,O
Classical,3562,O
and,3562,O
emergent,3562,O
serum,3562,O
",",3562,O
urinary,3562,O
",",3562,O
and,3562,O
kidney,3562,O
tissue,3562,O
(,3562,O
gene,3562,O
and,3562,O
protein,3562,O
expression,3562,O
),3562,O
markers,3562,O
were,3562,O
assessed,3562,O
.,3562,O
Renal,3563,B-DiseaseOrPhenotypicFeature
lesions,3563,I-DiseaseOrPhenotypicFeature
were,3563,O
analyzed,3563,O
in,3563,O
hematoxylin,3563,O
and,3563,O
eosin,3563,O
",",3563,O
periodic,3563,O
acid-Schiff,3563,O
",",3563,O
and,3563,O
Masson,3563,O
's,3563,O
trichrome,3563,O
stains,3563,O
.,3563,O
SRL-treated,3564,B-ChemicalEntity
rats,3564,B-OrganismTaxon
presented,3564,O
proteinuria,3564,B-DiseaseOrPhenotypicFeature
and,3564,O
NGAL,3564,B-GeneOrGeneProduct
(,3564,O
serum,3564,O
and,3564,O
urinary,3564,O
),3564,O
as,3564,O
the,3564,O
best,3564,O
markers,3564,O
of,3564,O
renal,3564,B-DiseaseOrPhenotypicFeature
impairment,3564,I-DiseaseOrPhenotypicFeature
.,3564,O
Short,3565,O
CsA,3565,B-ChemicalEntity
treatment,3565,O
presented,3565,O
slight,3565,O
or,3565,O
even,3565,O
absent,3565,O
kidney,3565,B-DiseaseOrPhenotypicFeature
lesions,3565,I-DiseaseOrPhenotypicFeature
and,3565,O
TGF-b,3565,B-GeneOrGeneProduct
",",3565,O
NF-,3565,B-GeneOrGeneProduct
kb,3565,I-GeneOrGeneProduct
",",3565,O
mTOR,3565,B-GeneOrGeneProduct
",",3565,O
PCNA,3565,B-GeneOrGeneProduct
",",3565,O
TP53,3565,B-GeneOrGeneProduct
",",3565,O
KIM-1,3565,B-GeneOrGeneProduct
",",3565,O
and,3565,O
CTGF,3565,B-GeneOrGeneProduct
as,3565,O
relevant,3565,O
gene,3565,O
and,3565,O
protein,3565,O
changes,3565,O
.,3565,O
Prolonged,3566,O
CsA,3566,B-ChemicalEntity
exposure,3566,O
aggravated,3566,O
renal,3566,B-DiseaseOrPhenotypicFeature
damage,3566,I-DiseaseOrPhenotypicFeature
",",3566,O
without,3566,O
clear,3566,O
changes,3566,O
on,3566,O
the,3566,O
traditional,3566,O
markers,3566,O
",",3566,O
but,3566,O
with,3566,O
changes,3566,O
in,3566,O
serums,3566,O
TGF-,3566,B-GeneOrGeneProduct
b,3566,I-GeneOrGeneProduct
and,3566,O
IL-7,3566,B-GeneOrGeneProduct
",",3566,O
TBARs,3566,B-ChemicalEntity
clearance,3566,O
",",3566,O
and,3566,O
kidney,3566,O
TGF-b,3566,B-GeneOrGeneProduct
and,3566,O
mTOR,3566,B-GeneOrGeneProduct
.,3566,O
Conversion,3567,O
to,3567,O
SRL,3567,B-ChemicalEntity
prevented,3567,O
CsA-induced,3567,B-ChemicalEntity
renal,3567,B-DiseaseOrPhenotypicFeature
damage,3567,I-DiseaseOrPhenotypicFeature
evolution,3567,O
(,3567,O
absent/mild,3567,O
grade,3567,O
lesions,3567,O
),3567,O
",",3567,O
while,3567,O
NGAL,3567,B-GeneOrGeneProduct
(,3567,O
serum,3567,O
versus,3567,O
urine,3567,O
),3567,O
seems,3567,O
to,3567,O
be,3567,O
a,3567,O
feasible,3567,O
biomarker,3567,O
of,3567,O
CsA,3567,B-ChemicalEntity
replacement,3567,O
to,3567,O
SRL,3567,B-ChemicalEntity
.,3567,O
Characterization,3568,O
of,3568,O
a,3568,O
novel,3568,O
BCHE,3568,B-GeneOrGeneProduct
``,3568,O
silent,3568,O
'',3568,O
allele,3568,O
:,3568,O
point,3568,O
mutation,3568,O
(,3568,O
p.Val204Asp,3568,B-SequenceVariant
),3568,O
causes,3568,O
loss,3568,O
of,3568,O
activity,3568,O
and,3568,O
prolonged,3568,O
apnea,3568,B-DiseaseOrPhenotypicFeature
with,3568,O
suxamethonium,3568,B-ChemicalEntity
.,3568,O
Butyrylcholinesterase,3569,B-DiseaseOrPhenotypicFeature
deficiency,3569,I-DiseaseOrPhenotypicFeature
is,3569,O
characterized,3569,O
by,3569,O
prolonged,3569,O
apnea,3569,B-DiseaseOrPhenotypicFeature
after,3569,O
the,3569,O
use,3569,O
of,3569,O
muscle,3569,B-ChemicalEntity
relaxants,3569,I-ChemicalEntity
(,3569,O
suxamethonium,3569,B-ChemicalEntity
or,3569,O
mivacurium,3569,B-ChemicalEntity
),3569,O
in,3569,O
patients,3569,B-OrganismTaxon
who,3569,O
have,3569,O
mutations,3569,O
in,3569,O
the,3569,O
BCHE,3569,B-GeneOrGeneProduct
gene,3569,O
.,3569,O
Here,3570,O
",",3570,O
we,3570,O
report,3570,O
a,3570,O
case,3570,O
of,3570,O
prolonged,3570,O
neuromuscular,3570,B-DiseaseOrPhenotypicFeature
block,3570,I-DiseaseOrPhenotypicFeature
after,3570,O
administration,3570,O
of,3570,O
suxamethonium,3570,B-ChemicalEntity
leading,3570,O
to,3570,O
the,3570,O
discovery,3570,O
of,3570,O
a,3570,O
novel,3570,O
BCHE,3570,B-GeneOrGeneProduct
variant,3570,O
(,3570,O
c.695T,3570,B-SequenceVariant
>,3570,I-SequenceVariant
A,3570,I-SequenceVariant
",",3570,O
p.Val204Asp,3570,B-SequenceVariant
),3570,O
.,3570,O
Inhibition,3571,O
studies,3571,O
",",3571,O
kinetic,3571,O
analysis,3571,O
and,3571,O
molecular,3571,O
dynamics,3571,O
were,3571,O
undertaken,3571,O
to,3571,O
understand,3571,O
how,3571,O
this,3571,O
mutation,3571,O
disrupts,3571,O
the,3571,O
catalytic,3571,O
triad,3571,O
and,3571,O
determines,3571,O
a,3571,O
``,3571,O
silent,3571,O
'',3571,O
phenotype,3571,O
.,3571,O
Low,3572,O
activity,3572,O
of,3572,O
patient,3572,B-OrganismTaxon
plasma,3572,O
butyrylcholinesterase,3572,B-GeneOrGeneProduct
with,3572,O
butyrylthiocholine,3572,B-ChemicalEntity
(,3572,O
BTC,3572,B-ChemicalEntity
),3572,O
and,3572,O
benzoylcholine,3572,B-ChemicalEntity
",",3572,O
and,3572,O
values,3572,O
of,3572,O
dibucaine,3572,B-ChemicalEntity
and,3572,O
fluoride,3572,B-ChemicalEntity
numbers,3572,O
fit,3572,O
with,3572,O
heterozygous,3572,O
atypical,3572,O
silent,3572,O
genotype,3572,O
.,3572,O
Electrophoretic,3573,O
analysis,3573,O
of,3573,O
plasma,3573,O
BChE,3573,B-GeneOrGeneProduct
of,3573,O
the,3573,O
proband,3573,O
and,3573,O
his,3573,O
mother,3573,O
showed,3573,O
that,3573,O
patient,3573,B-OrganismTaxon
has,3573,O
a,3573,O
reduced,3573,O
amount,3573,O
of,3573,O
tetrameric,3573,O
enzyme,3573,O
in,3573,O
plasma,3573,O
and,3573,O
that,3573,O
minor,3573,O
fast-moving,3573,O
BChE,3573,B-GeneOrGeneProduct
components,3573,O
:,3573,O
monomer,3573,O
",",3573,O
dimer,3573,O
",",3573,O
and,3573,O
monomer-albumin,3573,O
conjugate,3573,O
are,3573,O
missing,3573,O
.,3573,O
Kinetic,3574,O
analysis,3574,O
showed,3574,O
that,3574,O
the,3574,O
p.Val204Asp/p.Asp70Gly-p.Ala539Thr,3574,B-SequenceVariant
BChE,3574,B-GeneOrGeneProduct
displays,3574,O
a,3574,O
pure,3574,O
Michaelian,3574,O
behavior,3574,O
with,3574,O
BTC,3574,B-ChemicalEntity
as,3574,O
the,3574,O
substrate,3574,O
.,3574,O
Both,3575,O
catalytic,3575,O
parameters,3575,O
Km,3575,O
=,3575,O
265,3575,O
uM,3575,O
for,3575,O
BTC,3575,B-ChemicalEntity
",",3575,O
two,3575,O
times,3575,O
higher,3575,O
than,3575,O
that,3575,O
of,3575,O
the,3575,O
atypical,3575,O
enzyme,3575,O
",",3575,O
and,3575,O
a,3575,O
low,3575,O
Vmax,3575,O
are,3575,O
consistent,3575,O
with,3575,O
the,3575,O
absence,3575,O
of,3575,O
activity,3575,O
against,3575,O
suxamethonium,3575,B-ChemicalEntity
.,3575,O
Molecular,3576,O
dynamic,3576,O
(,3576,O
MD,3576,O
),3576,O
simulations,3576,O
showed,3576,O
that,3576,O
the,3576,O
overall,3576,O
effect,3576,O
of,3576,O
the,3576,O
mutation,3576,O
p.Val204Asp,3576,B-SequenceVariant
is,3576,O
disruption,3576,O
of,3576,O
hydrogen,3576,O
bonding,3576,O
between,3576,O
Gln223,3576,O
and,3576,O
Glu441,3576,O
",",3576,O
leading,3576,O
Ser198,3576,O
and,3576,O
His438,3576,O
to,3576,O
move,3576,O
away,3576,O
from,3576,O
each,3576,O
other,3576,O
with,3576,O
subsequent,3576,O
disruption,3576,O
of,3576,O
the,3576,O
catalytic,3576,O
triad,3576,O
functionality,3576,O
regardless,3576,O
of,3576,O
the,3576,O
type,3576,O
of,3576,O
substrate,3576,O
.,3576,O
MD,3577,O
also,3577,O
showed,3577,O
that,3577,O
the,3577,O
enzyme,3577,O
volume,3577,O
is,3577,O
increased,3577,O
",",3577,O
suggesting,3577,O
a,3577,O
pre-denaturation,3577,O
state,3577,O
.,3577,O
This,3578,O
fits,3578,O
with,3578,O
the,3578,O
reduced,3578,O
concentration,3578,O
of,3578,O
p.Ala204Asp/p.Asp70Gly-p.Ala539Thr,3578,B-SequenceVariant
tetrameric,3578,O
enzyme,3578,O
in,3578,O
the,3578,O
plasma,3578,O
and,3578,O
non-detectable,3578,O
fast,3578,O
moving-bands,3578,O
on,3578,O
electrophoresis,3578,O
gels,3578,O
.,3578,O
Sepsis-induced,3579,B-DiseaseOrPhenotypicFeature
changes,3579,O
in,3579,O
amino,3579,B-GeneOrGeneProduct
acid,3579,I-GeneOrGeneProduct
transporters,3579,I-GeneOrGeneProduct
and,3579,O
leucine,3579,B-ChemicalEntity
signaling,3579,O
via,3579,O
mTOR,3579,B-GeneOrGeneProduct
in,3579,O
skeletal,3579,O
muscle,3579,O
.,3579,O
The,3580,O
present,3580,O
study,3580,O
tested,3580,O
the,3580,O
hypothesis,3580,O
that,3580,O
sepsis-induced,3580,B-DiseaseOrPhenotypicFeature
leucine,3580,B-ChemicalEntity
(,3580,O
Leu,3580,B-ChemicalEntity
),3580,O
resistance,3580,O
in,3580,O
skeletal,3580,O
muscle,3580,O
is,3580,O
associated,3580,O
with,3580,O
a,3580,O
down-regulation,3580,O
of,3580,O
amino,3580,B-GeneOrGeneProduct
acid,3580,I-GeneOrGeneProduct
transporters,3580,I-GeneOrGeneProduct
important,3580,O
in,3580,O
regulating,3580,O
Leu,3580,B-ChemicalEntity
flux,3580,O
or,3580,O
an,3580,O
impairment,3580,O
in,3580,O
the,3580,O
formation,3580,O
of,3580,O
the,3580,O
Leu-sensitive,3580,B-ChemicalEntity
mTOR-Ragulator,3580,B-GeneOrGeneProduct
complex,3580,I-GeneOrGeneProduct
.,3580,O
Sepsis,3581,B-DiseaseOrPhenotypicFeature
in,3581,O
adult,3581,O
male,3581,O
rats,3581,B-OrganismTaxon
decreased,3581,O
basal,3581,O
protein,3581,O
synthesis,3581,O
in,3581,O
gastrocnemius,3581,O
",",3581,O
associated,3581,O
with,3581,O
a,3581,O
reduction,3581,O
in,3581,O
mTOR,3581,B-GeneOrGeneProduct
activation,3581,O
as,3581,O
indicated,3581,O
by,3581,O
decreased,3581,O
4E-BP1,3581,B-GeneOrGeneProduct
and,3581,O
S6K1,3581,B-GeneOrGeneProduct
phosphorylation,3581,O
.,3581,O
The,3582,O
ability,3582,O
of,3582,O
oral,3582,O
Leu,3582,B-ChemicalEntity
to,3582,O
increase,3582,O
protein,3582,O
synthesis,3582,O
and,3582,O
mTOR,3582,B-GeneOrGeneProduct
kinase,3582,O
after,3582,O
1,3582,O
h,3582,O
was,3582,O
largely,3582,O
prevented,3582,O
in,3582,O
sepsis,3582,B-DiseaseOrPhenotypicFeature
.,3582,O
Sepsis,3583,B-DiseaseOrPhenotypicFeature
increased,3583,O
CAT1,3583,B-GeneOrGeneProduct
",",3583,O
LAT2,3583,B-GeneOrGeneProduct
and,3583,O
SNAT2,3583,B-GeneOrGeneProduct
mRNA,3583,O
content,3583,O
two-,3583,O
to,3583,O
fourfold,3583,O
",",3583,O
but,3583,O
only,3583,O
the,3583,O
protein,3583,O
content,3583,O
for,3583,O
CAT1,3583,B-GeneOrGeneProduct
(,3583,O
20,3583,O
%,3583,O
decrease,3583,O
),3583,O
differed,3583,O
significantly,3583,O
.,3583,O
Conversely,3584,O
",",3584,O
sepsis,3584,B-DiseaseOrPhenotypicFeature
decreased,3584,O
the,3584,O
proton-assisted,3584,B-GeneOrGeneProduct
amino,3584,I-GeneOrGeneProduct
acid,3584,I-GeneOrGeneProduct
transporter,3584,I-GeneOrGeneProduct
(,3584,I-GeneOrGeneProduct
PAT,3584,I-GeneOrGeneProduct
),3584,I-GeneOrGeneProduct
-2,3584,I-GeneOrGeneProduct
mRNA,3584,O
by,3584,O
60,3584,O
%,3584,O
",",3584,O
but,3584,O
without,3584,O
a,3584,O
coordinate,3584,O
change,3584,O
in,3584,O
PAT2,3584,B-GeneOrGeneProduct
protein,3584,O
.,3584,O
There,3585,O
was,3585,O
no,3585,O
sepsis,3585,B-DiseaseOrPhenotypicFeature
or,3585,O
Leu,3585,B-ChemicalEntity
effect,3585,O
on,3585,O
the,3585,O
protein,3585,O
content,3585,O
for,3585,O
RagA-D,3585,B-GeneOrGeneProduct
",",3585,O
LAMTOR-1,3585,B-GeneOrGeneProduct
and,3585,I-GeneOrGeneProduct
-2,3585,I-GeneOrGeneProduct
",",3585,O
raptor,3585,B-GeneOrGeneProduct
",",3585,O
Rheb,3585,B-GeneOrGeneProduct
or,3585,O
mTOR,3585,B-GeneOrGeneProduct
in,3585,O
muscle,3585,O
.,3585,O
The,3586,O
binding,3586,O
of,3586,O
mTOR,3586,B-GeneOrGeneProduct
",",3586,O
PRAS40,3586,B-GeneOrGeneProduct
and,3586,O
RagC,3586,B-GeneOrGeneProduct
to,3586,O
raptor,3586,B-GeneOrGeneProduct
did,3586,O
not,3586,O
differ,3586,O
for,3586,O
control,3586,O
and,3586,O
septic,3586,O
muscle,3586,O
in,3586,O
the,3586,O
basal,3586,O
condition,3586,O
;,3586,O
however,3586,O
",",3586,O
the,3586,O
Leu-induced,3586,B-ChemicalEntity
decrease,3586,O
in,3586,O
PRAS40,3586,B-GeneOrGeneProduct
raptor,3586,B-GeneOrGeneProduct
and,3586,O
increase,3586,O
in,3586,O
RagC,3586,B-GeneOrGeneProduct
raptor,3586,B-GeneOrGeneProduct
seen,3586,O
in,3586,O
control,3586,O
muscle,3586,O
was,3586,O
absent,3586,O
in,3586,O
sepsis,3586,B-DiseaseOrPhenotypicFeature
.,3586,O
The,3587,O
intracellular,3587,O
Leu,3587,B-ChemicalEntity
concentration,3587,O
was,3587,O
increased,3587,O
in,3587,O
septic,3587,O
muscle,3587,O
",",3587,O
compared,3587,O
to,3587,O
basal,3587,O
control,3587,O
conditions,3587,O
",",3587,O
and,3587,O
oral,3587,O
Leu,3587,B-ChemicalEntity
further,3587,O
increased,3587,O
the,3587,O
intracellular,3587,O
Leu,3587,B-ChemicalEntity
concentration,3587,O
similarly,3587,O
in,3587,O
both,3587,O
control,3587,O
and,3587,O
septic,3587,O
rats,3587,B-OrganismTaxon
.,3587,O
Hence,3588,O
",",3588,O
while,3588,O
alterations,3588,O
in,3588,O
select,3588,O
amino,3588,B-GeneOrGeneProduct
acid,3588,I-GeneOrGeneProduct
transporters,3588,I-GeneOrGeneProduct
are,3588,O
not,3588,O
associated,3588,O
with,3588,O
development,3588,O
of,3588,O
sepsis-induced,3588,B-DiseaseOrPhenotypicFeature
Leu,3588,B-ChemicalEntity
resistance,3588,O
",",3588,O
the,3588,O
Leu-stimulated,3588,B-ChemicalEntity
binding,3588,O
of,3588,O
raptor,3588,B-GeneOrGeneProduct
with,3588,O
RagC,3588,B-GeneOrGeneProduct
and,3588,O
the,3588,O
recruitment,3588,O
of,3588,O
mTOR/raptor,3588,B-GeneOrGeneProduct
to,3588,O
the,3588,O
endosome-lysosomal,3588,O
compartment,3588,O
may,3588,O
partially,3588,O
explain,3588,O
the,3588,O
inability,3588,O
of,3588,O
Leu,3588,B-ChemicalEntity
to,3588,O
fully,3588,O
activate,3588,O
mTOR,3588,B-GeneOrGeneProduct
and,3588,O
muscle,3588,O
protein,3588,O
synthesis,3588,O
.,3588,O
CD25,3589,B-GeneOrGeneProduct
(,3589,O
+,3589,O
),3589,O
Bcl6,3589,B-GeneOrGeneProduct
(,3589,O
low,3589,O
),3589,O
T,3589,O
follicular,3589,O
helper,3589,O
cells,3589,O
provide,3589,O
help,3589,O
to,3589,O
maturing,3589,O
B,3589,O
cells,3589,O
in,3589,O
germinal,3589,O
centers,3589,O
of,3589,O
human,3589,B-OrganismTaxon
tonsil,3589,O
.,3589,O
The,3590,O
majority,3590,O
of,3590,O
CXCR5,3590,B-GeneOrGeneProduct
(,3590,O
+,3590,O
),3590,O
PD1,3590,B-GeneOrGeneProduct
(,3590,O
+,3590,O
),3590,O
CD4,3590,B-GeneOrGeneProduct
(,3590,O
+,3590,O
),3590,O
T,3590,O
follicular,3590,O
helper,3590,O
(,3590,O
Tfh,3590,O
),3590,O
cells,3590,O
(,3590,O
>,3590,O
90,3590,O
%,3590,O
),3590,O
are,3590,O
CD25,3590,B-GeneOrGeneProduct
(,3590,O
-,3590,O
),3590,O
Bcl6,3590,B-GeneOrGeneProduct
(,3590,O
hi,3590,O
),3590,O
",",3590,O
while,3590,O
a,3590,O
small,3590,O
subpopulation,3590,O
(,3590,O
<,3590,O
10,3590,O
%,3590,O
),3590,O
are,3590,O
CD25,3590,B-GeneOrGeneProduct
(,3590,O
+,3590,O
),3590,O
Bcl6,3590,B-GeneOrGeneProduct
(,3590,O
low,3590,O
),3590,O
but,3590,O
do,3590,O
not,3590,O
express,3590,O
FoxP3,3590,B-GeneOrGeneProduct
and,3590,O
are,3590,O
not,3590,O
T,3590,O
regulatory,3590,O
cells,3590,O
.,3590,O
We,3591,O
purified,3591,O
T,3591,O
:,3591,O
B-cell,3591,O
conjugates,3591,O
from,3591,O
tonsils,3591,O
and,3591,O
found,3591,O
they,3591,O
were,3591,O
enriched,3591,O
for,3591,O
the,3591,O
CD25,3591,B-GeneOrGeneProduct
(,3591,O
+,3591,O
),3591,O
Bcl6,3591,B-GeneOrGeneProduct
(,3591,O
low,3591,O
),3591,O
Tfh-cell,3591,O
subpopulation,3591,O
.,3591,O
In,3592,O
response,3592,O
to,3592,O
IL-2,3592,B-GeneOrGeneProduct
",",3592,O
these,3592,O
CD25,3592,B-GeneOrGeneProduct
(,3592,O
+,3592,O
),3592,O
Tfh,3592,O
cells,3592,O
increased,3592,O
expression,3592,O
of,3592,O
costimulatory,3592,O
molecules,3592,O
ICOS,3592,B-GeneOrGeneProduct
or,3592,O
OX40,3592,B-GeneOrGeneProduct
",",3592,O
upregulated,3592,O
transcription,3592,O
factor,3592,O
cMaf,3592,B-GeneOrGeneProduct
",",3592,O
produced,3592,O
cytokines,3592,O
IL-21,3592,B-GeneOrGeneProduct
",",3592,O
IL-17,3592,B-GeneOrGeneProduct
",",3592,O
and,3592,O
IL-10,3592,B-GeneOrGeneProduct
",",3592,O
and,3592,O
raised,3592,O
the,3592,O
levels,3592,O
of,3592,O
antiapoptotic,3592,O
protein,3592,O
Bcl2,3592,B-GeneOrGeneProduct
.,3592,O
Conjugates,3593,O
formed,3593,O
with,3593,O
CD25,3593,B-GeneOrGeneProduct
(,3593,O
+,3593,O
),3593,O
BCl6,3593,B-GeneOrGeneProduct
(,3593,O
low,3593,O
),3593,O
Tfh,3593,O
cells,3593,O
included,3593,O
B,3593,O
cells,3593,O
expressing,3593,O
higher,3593,O
levels,3593,O
of,3593,O
activation-induced,3593,B-GeneOrGeneProduct
cytidine,3593,I-GeneOrGeneProduct
deaminase,3593,I-GeneOrGeneProduct
(,3593,O
AID,3593,B-GeneOrGeneProduct
),3593,O
",",3593,O
memory,3593,O
marker,3593,O
CD45RO,3593,B-GeneOrGeneProduct
",",3593,O
surface,3593,O
IgG,3593,B-GeneOrGeneProduct
or,3593,O
IgA,3593,B-GeneOrGeneProduct
",",3593,O
and,3593,O
MHC,3593,B-GeneOrGeneProduct
class,3593,I-GeneOrGeneProduct
II,3593,I-GeneOrGeneProduct
compared,3593,O
to,3593,O
B-cell,3593,O
conjugates,3593,O
including,3593,O
CD25,3593,B-GeneOrGeneProduct
(,3593,O
-,3593,O
),3593,O
Bcl6,3593,B-GeneOrGeneProduct
(,3593,O
hi,3593,O
),3593,O
Tfh,3593,O
cells,3593,O
.,3593,O
While,3594,O
IL-2,3594,B-GeneOrGeneProduct
suppresses,3594,O
early,3594,O
Tfh-cell,3594,O
differentiation,3594,O
",",3594,O
Tfh-cell,3594,O
recognition,3594,O
of,3594,O
antigen-presenting,3594,O
B,3594,O
cells,3594,O
and,3594,O
signaling,3594,O
through,3594,O
the,3594,O
T-cell,3594,B-GeneOrGeneProduct
receptor,3594,I-GeneOrGeneProduct
likely,3594,O
triggers,3594,O
expression,3594,O
of,3594,O
the,3594,O
high-affinity,3594,O
IL-2,3594,B-GeneOrGeneProduct
receptor,3594,I-GeneOrGeneProduct
and,3594,O
responses,3594,O
to,3594,O
IL-2,3594,B-GeneOrGeneProduct
including,3594,O
downregulation,3594,O
of,3594,O
Bcl6,3594,B-GeneOrGeneProduct
.,3594,O
CD25,3595,B-GeneOrGeneProduct
expression,3595,O
on,3595,O
Tfh,3595,O
cells,3595,O
and,3595,O
local,3595,O
production,3595,O
of,3595,O
IL-2,3595,B-GeneOrGeneProduct
in,3595,O
tonsil,3595,O
or,3595,O
lymph,3595,O
node,3595,O
may,3595,O
support,3595,O
B,3595,O
helper,3595,O
T-cell,3595,O
function,3595,O
during,3595,O
later,3595,O
stages,3595,O
of,3595,O
B-cell,3595,O
maturation,3595,O
and,3595,O
the,3595,O
development,3595,O
of,3595,O
immune,3595,O
memory,3595,O
.,3595,O
VPAC2,3596,B-GeneOrGeneProduct
(,3596,O
vasoactive,3596,B-GeneOrGeneProduct
intestinal,3596,I-GeneOrGeneProduct
peptide,3596,I-GeneOrGeneProduct
receptor,3596,I-GeneOrGeneProduct
type,3596,I-GeneOrGeneProduct
2,3596,I-GeneOrGeneProduct
),3596,O
receptor,3596,O
deficient,3596,O
mice,3596,B-OrganismTaxon
develop,3596,O
exacerbated,3596,O
experimental,3596,B-DiseaseOrPhenotypicFeature
autoimmune,3596,I-DiseaseOrPhenotypicFeature
encephalomyelitis,3596,I-DiseaseOrPhenotypicFeature
with,3596,O
increased,3596,O
Th1/Th17,3596,O
and,3596,O
reduced,3596,O
Th2/Treg,3596,O
responses,3596,O
.,3596,O
Vasoactive,3597,B-GeneOrGeneProduct
intestinal,3597,I-GeneOrGeneProduct
peptide,3597,I-GeneOrGeneProduct
(,3597,O
VIP,3597,B-GeneOrGeneProduct
),3597,O
and,3597,O
pituitary,3597,B-GeneOrGeneProduct
adenylyl,3597,I-GeneOrGeneProduct
cyclase-activating,3597,I-GeneOrGeneProduct
polypeptide,3597,I-GeneOrGeneProduct
(,3597,O
PACAP,3597,B-GeneOrGeneProduct
),3597,O
are,3597,O
two,3597,O
structurally-related,3597,O
neuropeptides,3597,O
with,3597,O
widespread,3597,O
expression,3597,O
in,3597,O
the,3597,O
central,3597,O
and,3597,O
peripheral,3597,O
nervous,3597,O
systems,3597,O
.,3597,O
Although,3598,O
these,3598,O
peptides,3598,O
have,3598,O
been,3598,O
repeatedly,3598,O
shown,3598,O
to,3598,O
exert,3598,O
potent,3598,O
anti-inflammatory,3598,O
actions,3598,O
when,3598,O
administered,3598,O
in,3598,O
animal,3598,O
models,3598,O
of,3598,O
inflammatory,3598,B-DiseaseOrPhenotypicFeature
disease,3598,I-DiseaseOrPhenotypicFeature
",",3598,O
mice,3598,B-OrganismTaxon
deficient,3598,O
in,3598,O
VIP,3598,B-GeneOrGeneProduct
and,3598,O
PACAP,3598,B-GeneOrGeneProduct
were,3598,O
recently,3598,O
shown,3598,O
to,3598,O
exhibit,3598,O
different,3598,O
phenotypes,3598,O
(,3598,O
ameliorated,3598,O
and,3598,O
exacerbated,3598,O
",",3598,O
respectively,3598,O
),3598,O
in,3598,O
response,3598,O
to,3598,O
experimental,3598,B-DiseaseOrPhenotypicFeature
autoimmune,3598,I-DiseaseOrPhenotypicFeature
encephalomyelitis,3598,I-DiseaseOrPhenotypicFeature
(,3598,O
EAE,3598,B-DiseaseOrPhenotypicFeature
),3598,O
.,3598,O
Therefore,3599,O
",",3599,O
elucidating,3599,O
what,3599,O
are,3599,O
the,3599,O
specific,3599,O
immunoregulatory,3599,O
roles,3599,O
played,3599,O
by,3599,O
each,3599,O
of,3599,O
their,3599,O
receptor,3599,O
subtypes,3599,O
(,3599,O
VPAC1,3599,B-GeneOrGeneProduct
",",3599,O
VPAC2,3599,B-GeneOrGeneProduct
",",3599,O
and,3599,O
PAC1,3599,B-GeneOrGeneProduct
),3599,O
is,3599,O
critical,3599,O
.,3599,O
In,3600,O
this,3600,O
study,3600,O
",",3600,O
we,3600,O
found,3600,O
that,3600,O
mice,3600,B-OrganismTaxon
with,3600,O
a,3600,O
genetic,3600,O
deletion,3600,O
of,3600,O
VIPR2,3600,B-GeneOrGeneProduct
",",3600,O
encoding,3600,O
the,3600,O
VPAC2,3600,B-GeneOrGeneProduct
receptor,3600,I-GeneOrGeneProduct
",",3600,O
exhibited,3600,O
exacerbated,3600,O
(,3600,O
MOG35-55,3600,B-GeneOrGeneProduct
),3600,O
-induced,3600,O
EAE,3600,B-DiseaseOrPhenotypicFeature
compared,3600,O
to,3600,O
wild,3600,O
type,3600,O
mice,3600,B-OrganismTaxon
",",3600,O
characterized,3600,O
by,3600,O
enhanced,3600,O
clinical,3600,O
and,3600,O
histopathological,3600,O
features,3600,O
",",3600,O
increased,3600,O
proinflammatory,3600,B-GeneOrGeneProduct
cytokines,3600,I-GeneOrGeneProduct
(,3600,O
TNF-alpha,3600,B-GeneOrGeneProduct
",",3600,O
IL-6,3600,B-GeneOrGeneProduct
",",3600,O
IFN-gamma,3600,B-GeneOrGeneProduct
(,3600,O
Th1,3600,O
),3600,O
",",3600,O
and,3600,O
IL-17,3600,B-GeneOrGeneProduct
(,3600,O
Th17,3600,O
),3600,O
),3600,O
and,3600,O
reduced,3600,O
anti-inflammatory,3600,B-GeneOrGeneProduct
cytokines,3600,I-GeneOrGeneProduct
(,3600,O
IL-10,3600,B-GeneOrGeneProduct
",",3600,O
TGFbeta,3600,B-GeneOrGeneProduct
",",3600,O
and,3600,O
IL-4,3600,B-GeneOrGeneProduct
(,3600,O
Th2,3600,O
),3600,O
),3600,O
in,3600,O
the,3600,O
CNS,3600,O
and,3600,O
lymph,3600,O
nodes,3600,O
.,3600,O
Moreover,3601,O
",",3601,O
the,3601,O
abundance,3601,O
and,3601,O
proliferative,3601,O
index,3601,O
of,3601,O
lymph,3601,O
node,3601,O
",",3601,O
thymus,3601,O
and,3601,O
CNS,3601,O
CD4,3601,B-GeneOrGeneProduct
(,3601,O
+,3601,O
),3601,O
CD25,3601,B-GeneOrGeneProduct
(,3601,O
+,3601,O
),3601,O
FoxP3,3601,B-GeneOrGeneProduct
(,3601,O
+,3601,O
),3601,O
Tregs,3601,O
were,3601,O
strikingly,3601,O
reduced,3601,O
in,3601,O
VPAC2-deficient,3601,B-GeneOrGeneProduct
mice,3601,B-OrganismTaxon
with,3601,O
EAE,3601,B-DiseaseOrPhenotypicFeature
.,3601,O
Finally,3602,O
",",3602,O
the,3602,O
in,3602,O
vitro,3602,O
suppressive,3602,O
activity,3602,O
of,3602,O
lymph,3602,O
node,3602,O
and,3602,O
splenic,3602,O
Tregs,3602,O
from,3602,O
VPAC2-deficient,3602,B-GeneOrGeneProduct
mice,3602,B-OrganismTaxon
was,3602,O
impaired,3602,O
.,3602,O
Overall,3603,O
",",3603,O
our,3603,O
results,3603,O
demonstrate,3603,O
critical,3603,O
protective,3603,O
roles,3603,O
for,3603,O
PACAP,3603,B-GeneOrGeneProduct
and,3603,O
the,3603,O
VPAC2,3603,B-GeneOrGeneProduct
receptor,3603,I-GeneOrGeneProduct
against,3603,O
autoimmunity,3603,O
",",3603,O
promoting,3603,O
the,3603,O
expansion,3603,O
and,3603,O
maintenance,3603,O
of,3603,O
the,3603,O
Treg,3603,O
pool,3603,O
.,3603,O
Inactivation,3604,O
of,3604,O
Sag/Rbx2/Roc2,3604,B-GeneOrGeneProduct
e3,3604,B-GeneOrGeneProduct
ubiquitin,3604,I-GeneOrGeneProduct
ligase,3604,I-GeneOrGeneProduct
triggers,3604,O
senescence,3604,O
and,3604,O
inhibits,3604,O
kras-induced,3604,B-GeneOrGeneProduct
immortalization,3604,O
.,3604,O
Our,3605,O
recent,3605,O
study,3605,O
showed,3605,O
that,3605,O
SAG/RBX2,3605,B-GeneOrGeneProduct
E3,3605,B-GeneOrGeneProduct
ubiquitin,3605,I-GeneOrGeneProduct
ligase,3605,I-GeneOrGeneProduct
regulates,3605,O
apoptosis,3605,O
and,3605,O
vasculogenesis,3605,O
by,3605,O
promoting,3605,O
degradation,3605,O
of,3605,O
NOXA,3605,B-GeneOrGeneProduct
and,3605,O
NF1,3605,B-GeneOrGeneProduct
",",3605,O
and,3605,O
co-operates,3605,O
with,3605,O
Kras,3605,B-GeneOrGeneProduct
to,3605,O
promote,3605,O
lung,3605,B-DiseaseOrPhenotypicFeature
tumorigenesis,3605,I-DiseaseOrPhenotypicFeature
by,3605,O
activating,3605,O
NFkappaB,3605,B-GeneOrGeneProduct
and,3605,O
mTOR,3605,B-GeneOrGeneProduct
pathways,3605,O
via,3605,O
targeted,3605,O
degradation,3605,O
of,3605,O
tumor,3605,B-DiseaseOrPhenotypicFeature
suppressive,3605,O
substrates,3605,O
including,3605,O
IkappaB,3605,B-GeneOrGeneProduct
",",3605,O
DEPTOR,3605,B-GeneOrGeneProduct
",",3605,O
p21,3605,B-GeneOrGeneProduct
and,3605,O
p27,3605,B-GeneOrGeneProduct
.,3605,O
Here,3606,O
we,3606,O
investigated,3606,O
the,3606,O
role,3606,O
of,3606,O
Sag/Rbx2,3606,B-GeneOrGeneProduct
E3,3606,B-GeneOrGeneProduct
ligase,3606,I-GeneOrGeneProduct
in,3606,O
cellular,3606,O
senescence,3606,O
and,3606,O
immortalization,3606,O
of,3606,O
mouse,3606,B-OrganismTaxon
embryonic,3606,O
fibroblasts,3606,O
(,3606,O
MEFs,3606,O
),3606,O
and,3606,O
report,3606,O
that,3606,O
Sag,3606,B-GeneOrGeneProduct
is,3606,O
required,3606,O
for,3606,O
proper,3606,O
cell,3606,O
proliferation,3606,O
and,3606,O
Kras,3606,B-GeneOrGeneProduct
(,3606,O
G12D,3606,B-SequenceVariant
),3606,O
-induced,3606,O
immortalization,3606,O
.,3606,O
Sag,3607,B-GeneOrGeneProduct
inactivation,3607,O
by,3607,O
genetic,3607,O
deletion,3607,O
remarkably,3607,O
suppresses,3607,O
cell,3607,O
proliferation,3607,O
by,3607,O
inducing,3607,O
senescence,3607,O
",",3607,O
which,3607,O
is,3607,O
associated,3607,O
with,3607,O
accumulation,3607,O
of,3607,O
p16,3607,B-GeneOrGeneProduct
",",3607,O
but,3607,O
not,3607,O
p53,3607,B-GeneOrGeneProduct
.,3607,O
Mechanistically,3608,O
",",3608,O
Sag,3608,B-GeneOrGeneProduct
deletion,3608,O
caused,3608,O
accumulation,3608,O
of,3608,O
Jun-B,3608,B-GeneOrGeneProduct
",",3608,O
a,3608,O
substrate,3608,O
of,3608,O
Sag-Fbxw7,3608,B-GeneOrGeneProduct
E3,3608,B-GeneOrGeneProduct
ligase,3608,I-GeneOrGeneProduct
and,3608,O
a,3608,O
transcription,3608,O
factor,3608,O
that,3608,O
drives,3608,O
p16,3608,B-GeneOrGeneProduct
transcription,3608,O
.,3608,O
Importantly,3609,O
",",3609,O
senescence,3609,O
triggered,3609,O
by,3609,O
Sag,3609,B-GeneOrGeneProduct
deletion,3609,O
can,3609,O
be,3609,O
largely,3609,O
rescued,3609,O
by,3609,O
simultaneous,3609,O
deletion,3609,O
of,3609,O
Cdkn2a,3609,B-GeneOrGeneProduct
",",3609,O
the,3609,O
p16,3609,B-GeneOrGeneProduct
encoding,3609,O
gene,3609,O
",",3609,O
indicating,3609,O
its,3609,O
causal,3609,O
role,3609,O
.,3609,O
Furthermore,3610,O
",",3610,O
Kras,3610,B-GeneOrGeneProduct
(,3610,O
G12D,3610,B-SequenceVariant
),3610,O
-induced,3610,O
immortalization,3610,O
can,3610,O
also,3610,O
be,3610,O
abrogated,3610,O
by,3610,O
Sag,3610,B-GeneOrGeneProduct
deletion,3610,O
via,3610,O
senescence,3610,O
induction,3610,O
",",3610,O
which,3610,O
is,3610,O
again,3610,O
rescued,3610,O
by,3610,O
simultaneous,3610,O
deletion,3610,O
of,3610,O
Cdkn2a,3610,B-GeneOrGeneProduct
.,3610,O
Finally,3611,O
",",3611,O
we,3611,O
found,3611,O
that,3611,O
Sag,3611,B-GeneOrGeneProduct
deletion,3611,O
inactivates,3611,O
Kras,3611,B-GeneOrGeneProduct
(,3611,O
G12D,3611,B-SequenceVariant
),3611,O
activity,3611,O
and,3611,O
block,3611,O
the,3611,O
MAPK,3611,B-GeneOrGeneProduct
signaling,3611,O
pathway,3611,O
",",3611,O
together,3611,O
with,3611,O
accumulated,3611,O
p16,3611,B-GeneOrGeneProduct
",",3611,O
to,3611,O
induce,3611,O
senescence,3611,O
.,3611,O
Taken,3612,O
together,3612,O
",",3612,O
our,3612,O
results,3612,O
demonstrated,3612,O
that,3612,O
Sag,3612,B-GeneOrGeneProduct
is,3612,O
a,3612,O
Kras,3612,B-GeneOrGeneProduct
(,3612,O
G12D,3612,B-SequenceVariant
),3612,O
-cooperating,3612,O
oncogene,3612,O
required,3612,O
for,3612,O
Kras,3612,B-GeneOrGeneProduct
(,3612,O
G12D,3612,B-SequenceVariant
),3612,O
-induced,3612,O
immortalization,3612,O
and,3612,O
transformation,3612,O
",",3612,O
and,3612,O
targeting,3612,O
SAG-SCF,3612,B-GeneOrGeneProduct
E3,3612,B-GeneOrGeneProduct
ligase,3612,I-GeneOrGeneProduct
may,3612,O
",",3612,O
therefore,3612,O
",",3612,O
have,3612,O
therapeutic,3612,O
value,3612,O
for,3612,O
senescence-based,3612,O
cancer,3612,B-DiseaseOrPhenotypicFeature
treatment,3612,O
.,3612,O
TIPE2,3613,B-GeneOrGeneProduct
Inhibits,3613,O
Lung,3613,B-DiseaseOrPhenotypicFeature
Cancer,3613,I-DiseaseOrPhenotypicFeature
Growth,3613,O
Attributing,3613,O
to,3613,O
Promotion,3613,O
of,3613,O
Apoptosis,3613,O
by,3613,O
Regulating,3613,O
Some,3613,O
Apoptotic,3613,O
Molecules,3613,O
Expression,3613,O
.,3613,O
Recent,3614,O
studies,3614,O
found,3614,O
that,3614,O
TIPE2,3614,B-GeneOrGeneProduct
was,3614,O
involved,3614,O
in,3614,O
cancer,3614,B-DiseaseOrPhenotypicFeature
development,3614,O
.,3614,O
However,3615,O
",",3615,O
little,3615,O
is,3615,O
known,3615,O
about,3615,O
TIPE2,3615,B-GeneOrGeneProduct
in,3615,O
lung,3615,B-DiseaseOrPhenotypicFeature
cancer,3615,I-DiseaseOrPhenotypicFeature
.,3615,O
Our,3616,O
study,3616,O
aims,3616,O
to,3616,O
clarify,3616,O
the,3616,O
role,3616,O
of,3616,O
TIPE2,3616,B-GeneOrGeneProduct
in,3616,O
lung,3616,B-DiseaseOrPhenotypicFeature
carcinogenesis,3616,I-DiseaseOrPhenotypicFeature
.,3616,O
We,3617,O
examined,3617,O
the,3617,O
expression,3617,O
of,3617,O
TIPE2,3617,B-GeneOrGeneProduct
in,3617,O
lung,3617,B-DiseaseOrPhenotypicFeature
squamous,3617,I-DiseaseOrPhenotypicFeature
cancer,3617,I-DiseaseOrPhenotypicFeature
(,3617,O
LSC,3617,B-DiseaseOrPhenotypicFeature
),3617,O
",",3617,O
small,3617,B-DiseaseOrPhenotypicFeature
cell,3617,I-DiseaseOrPhenotypicFeature
lung,3617,I-DiseaseOrPhenotypicFeature
cancer,3617,I-DiseaseOrPhenotypicFeature
and,3617,O
lung,3617,B-DiseaseOrPhenotypicFeature
adenocarcinoma,3617,I-DiseaseOrPhenotypicFeature
(,3617,O
AdC,3617,B-DiseaseOrPhenotypicFeature
),3617,O
tissues,3617,O
and,3617,O
found,3617,O
that,3617,O
TIPE2,3617,B-GeneOrGeneProduct
expression,3617,O
was,3617,O
lost,3617,O
in,3617,O
small,3617,B-DiseaseOrPhenotypicFeature
cell,3617,I-DiseaseOrPhenotypicFeature
lung,3617,I-DiseaseOrPhenotypicFeature
cancer,3617,I-DiseaseOrPhenotypicFeature
",",3617,O
compared,3617,O
with,3617,O
adjacent,3617,O
non-tumor,3617,O
tissues,3617,O
.,3617,O
Overexpression,3618,O
of,3618,O
TIPE2,3618,B-GeneOrGeneProduct
significantly,3618,O
inhibited,3618,O
the,3618,O
growth,3618,O
of,3618,O
lung,3618,B-DiseaseOrPhenotypicFeature
cancer,3618,I-DiseaseOrPhenotypicFeature
cell,3618,O
H446,3618,B-CellLine
in,3618,O
vitro,3618,O
and,3618,O
even,3618,O
suppressed,3618,O
tumor,3618,B-DiseaseOrPhenotypicFeature
formation,3618,O
in,3618,O
vivo,3618,O
.,3618,O
Flow,3619,O
cytometry,3619,O
analysis,3619,O
found,3619,O
TIPE2,3619,B-GeneOrGeneProduct
overexpression,3619,O
promoted,3619,O
apoptosis,3619,O
of,3619,O
H446,3619,B-CellLine
.,3619,O
In,3620,O
TIPE2,3620,B-GeneOrGeneProduct
over-expression,3620,O
cells,3620,O
",",3620,O
caspase-3,3620,B-GeneOrGeneProduct
",",3620,O
caspase-9,3620,B-GeneOrGeneProduct
",",3620,O
and,3620,O
Bax,3620,B-GeneOrGeneProduct
were,3620,O
significantly,3620,O
up-regulated,3620,O
while,3620,O
Bcl-2,3620,B-GeneOrGeneProduct
was,3620,O
down-regulated,3620,O
.,3620,O
Moreover,3621,O
",",3621,O
coincident,3621,O
results,3621,O
were,3621,O
shown,3621,O
by,3621,O
immunohistochemistry,3621,O
in,3621,O
tumors,3621,B-DiseaseOrPhenotypicFeature
from,3621,O
nude,3621,O
mice,3621,B-OrganismTaxon
.,3621,O
TIPE2,3622,B-GeneOrGeneProduct
inhibited,3622,O
the,3622,O
phosphorylation,3622,O
of,3622,O
Akt,3622,B-GeneOrGeneProduct
",",3622,O
while,3622,O
promoting,3622,O
the,3622,O
phosphorylation,3622,O
of,3622,O
P38,3622,B-GeneOrGeneProduct
",",3622,O
but,3622,O
had,3622,O
no,3622,O
effect,3622,O
on,3622,O
IkBa,3622,B-GeneOrGeneProduct
and,3622,O
ERK,3622,B-GeneOrGeneProduct
pathway,3622,O
.,3622,O
Taken,3623,O
together,3623,O
",",3623,O
TIPE2,3623,B-GeneOrGeneProduct
promoted,3623,O
lung,3623,B-DiseaseOrPhenotypicFeature
cancer,3623,I-DiseaseOrPhenotypicFeature
cell,3623,O
apoptosis,3623,O
through,3623,O
affecting,3623,O
apoptosis-related,3623,O
molecules,3623,O
caspase-3,3623,B-GeneOrGeneProduct
",",3623,O
caspase-9,3623,B-GeneOrGeneProduct
",",3623,O
Bcl-2,3623,B-GeneOrGeneProduct
and,3623,O
Bax,3623,B-GeneOrGeneProduct
",",3623,O
possibly,3623,O
via,3623,O
regulating,3623,O
P38,3623,B-GeneOrGeneProduct
and,3623,O
Akt,3623,B-GeneOrGeneProduct
pathways,3623,O
",",3623,O
indicating,3623,O
that,3623,O
TIPE2,3623,B-GeneOrGeneProduct
might,3623,O
be,3623,O
a,3623,O
novel,3623,O
marker,3623,O
for,3623,O
lung,3623,B-DiseaseOrPhenotypicFeature
cancer,3623,I-DiseaseOrPhenotypicFeature
diagnosis,3623,O
and,3623,O
therapy,3623,O
.,3623,O
Gastrointestinal,3624,B-ChemicalEntity
hormones/neurotransmitters,3624,O
and,3624,O
growth,3624,O
factors,3624,O
can,3624,O
activate,3624,O
P21,3624,B-GeneOrGeneProduct
activated,3624,I-GeneOrGeneProduct
kinase,3624,I-GeneOrGeneProduct
2,3624,I-GeneOrGeneProduct
in,3624,O
pancreatic,3624,O
acinar,3624,O
cells,3624,O
by,3624,O
novel,3624,O
mechanisms,3624,O
.,3624,O
P-21-activated,3625,B-GeneOrGeneProduct
kinases,3625,I-GeneOrGeneProduct
(,3625,O
PAKs,3625,B-GeneOrGeneProduct
),3625,O
are,3625,O
serine/threonine,3625,B-GeneOrGeneProduct
kinases,3625,I-GeneOrGeneProduct
comprising,3625,O
six,3625,O
isoforms,3625,O
divided,3625,O
in,3625,O
two,3625,O
groups,3625,O
",",3625,O
group-I,3625,O
(,3625,O
PAK1-3,3625,B-GeneOrGeneProduct
),3625,O
/group-II,3625,O
(,3625,O
PAK4-6,3625,B-GeneOrGeneProduct
),3625,O
which,3625,O
play,3625,O
important,3625,O
roles,3625,O
in,3625,O
cell,3625,O
cytoskeletal,3625,O
dynamics,3625,O
",",3625,O
survival,3625,O
",",3625,O
secretion,3625,O
and,3625,O
proliferation,3625,O
and,3625,O
are,3625,O
activated,3625,O
by,3625,O
diverse,3625,O
stimuli,3625,O
.,3625,O
However,3626,O
",",3626,O
little,3626,O
is,3626,O
known,3626,O
about,3626,O
PAKs,3626,B-GeneOrGeneProduct
ability,3626,O
to,3626,O
be,3626,O
activated,3626,O
by,3626,O
gastrointestinal,3626,B-ChemicalEntity
(,3626,I-ChemicalEntity
GI,3626,I-ChemicalEntity
),3626,I-ChemicalEntity
hormones/neurotransmitters/growth-factors,3626,O
.,3626,O
We,3627,O
used,3627,O
rat,3627,B-OrganismTaxon
pancreatic,3627,O
acini,3627,O
to,3627,O
explore,3627,O
the,3627,O
ability,3627,O
of,3627,O
GI-hormones/neurotransmitters/growth-factors,3627,B-ChemicalEntity
to,3627,O
activate,3627,O
Group-I-PAKs,3627,B-GeneOrGeneProduct
and,3627,O
the,3627,O
signaling,3627,O
cascades,3627,O
involved,3627,O
.,3627,O
Only,3628,O
PAK2,3628,B-GeneOrGeneProduct
was,3628,O
present,3628,O
in,3628,O
acini,3628,O
.,3628,O
PAK2,3629,B-GeneOrGeneProduct
was,3629,O
activated,3629,O
by,3629,O
some,3629,O
pancreatic,3629,B-GeneOrGeneProduct
growth-factors,3629,I-GeneOrGeneProduct
[,3629,O
EGF,3629,B-GeneOrGeneProduct
",",3629,O
PDGF,3629,B-GeneOrGeneProduct
",",3629,O
bFGF,3629,B-GeneOrGeneProduct
],3629,O
",",3629,O
by,3629,O
secretagogues,3629,O
activating,3629,O
phospholipase-C,3629,B-GeneOrGeneProduct
(,3629,O
PLC,3629,B-GeneOrGeneProduct
),3629,O
[,3629,O
CCK,3629,B-GeneOrGeneProduct
",",3629,O
carbachol,3629,B-ChemicalEntity
",",3629,O
bombesin,3629,B-ChemicalEntity
],3629,O
and,3629,O
by,3629,O
post-receptor,3629,O
stimulants,3629,O
activating,3629,O
PKC,3629,B-GeneOrGeneProduct
[,3629,O
TPA,3629,B-ChemicalEntity
],3629,O
",",3629,O
but,3629,O
not,3629,O
agents,3629,O
only,3629,O
mobilizing,3629,O
cellular,3629,O
calcium,3629,B-ChemicalEntity
or,3629,O
increasing,3629,O
cyclic,3629,B-ChemicalEntity
AMP,3629,I-ChemicalEntity
.,3629,O
CCK-activation,3630,B-GeneOrGeneProduct
of,3630,O
PAK2,3630,B-GeneOrGeneProduct
required,3630,O
both,3630,O
high-,3630,O
and,3630,O
low-affinity-CCK1-receptor-state,3630,O
activation,3630,O
.,3630,O
It,3631,O
was,3631,O
partially,3631,O
reduced,3631,O
by,3631,O
PKC-,3631,B-GeneOrGeneProduct
or,3631,O
Src-inhibition,3631,B-GeneOrGeneProduct
",",3631,O
but,3631,O
not,3631,O
with,3631,O
PI3K-inhibitors,3631,B-GeneOrGeneProduct
(,3631,O
wortmannin,3631,B-ChemicalEntity
",",3631,O
LY294002,3631,B-ChemicalEntity
),3631,O
or,3631,O
thapsigargin,3631,B-ChemicalEntity
.,3631,O
IPA-3,3632,B-ChemicalEntity
",",3632,O
which,3632,O
prevents,3632,O
PAK2,3632,B-GeneOrGeneProduct
binding,3632,O
to,3632,O
small-GTPases,3632,B-GeneOrGeneProduct
partially,3632,O
inhibited,3632,O
PAK2-activation,3632,B-GeneOrGeneProduct
",",3632,O
as,3632,O
well,3632,O
as,3632,O
reduced,3632,O
CCK-induced,3632,B-GeneOrGeneProduct
ERK1/2,3632,B-GeneOrGeneProduct
activation,3632,O
and,3632,O
amylase,3632,B-GeneOrGeneProduct
release,3632,O
induced,3632,O
by,3632,O
CCK,3632,B-GeneOrGeneProduct
or,3632,O
bombesin,3632,B-ChemicalEntity
.,3632,O
This,3633,O
study,3633,O
demonstrates,3633,O
pancreatic,3633,O
acini,3633,O
",",3633,O
possess,3633,O
only,3633,O
one,3633,O
Group-I-PAK,3633,B-GeneOrGeneProduct
",",3633,O
PAK2,3633,B-GeneOrGeneProduct
.,3633,O
CCK,3634,B-GeneOrGeneProduct
and,3634,O
other,3634,O
GI-hormones/neurotransmitters/growth-factors,3634,B-ChemicalEntity
activate,3634,O
PAK2,3634,B-GeneOrGeneProduct
via,3634,O
small,3634,B-GeneOrGeneProduct
GTPases,3634,I-GeneOrGeneProduct
(,3634,O
CDC42/Rac1,3634,B-GeneOrGeneProduct
),3634,O
",",3634,O
PKC,3634,B-GeneOrGeneProduct
and,3634,O
SFK,3634,B-GeneOrGeneProduct
but,3634,O
not,3634,O
cytosolic,3634,O
calcium,3634,B-ChemicalEntity
or,3634,O
PI3K,3634,B-GeneOrGeneProduct
.,3634,O
CCK-activation,3635,B-GeneOrGeneProduct
of,3635,O
PAK2,3635,B-GeneOrGeneProduct
showed,3635,O
several,3635,O
novel,3635,O
features,3635,O
being,3635,O
dependent,3635,O
on,3635,O
both,3635,O
receptor-activation,3635,O
states,3635,O
",",3635,O
having,3635,O
PLC-,3635,B-GeneOrGeneProduct
and,3635,O
PKC-dependent/independent,3635,B-GeneOrGeneProduct
components,3635,O
and,3635,O
small-GTPase-dependent/independent,3635,B-GeneOrGeneProduct
components,3635,O
.,3635,O
These,3636,O
results,3636,O
show,3636,O
that,3636,O
PAK2,3636,B-GeneOrGeneProduct
is,3636,O
important,3636,O
in,3636,O
signaling,3636,O
cascades,3636,O
activated,3636,O
by,3636,O
numerous,3636,O
pancreatic,3636,O
stimuli,3636,O
which,3636,O
mediate,3636,O
their,3636,O
various,3636,O
physiological/pathophysiological,3636,O
responses,3636,O
and,3636,O
thus,3636,O
could,3636,O
be,3636,O
a,3636,O
promising,3636,O
target,3636,O
for,3636,O
the,3636,O
development,3636,O
of,3636,O
therapies,3636,O
in,3636,O
some,3636,O
pancreatic,3636,B-DiseaseOrPhenotypicFeature
disorders,3636,I-DiseaseOrPhenotypicFeature
such,3636,O
as,3636,O
pancreatitis,3636,B-DiseaseOrPhenotypicFeature
.,3636,O
Inhibition,3637,O
of,3637,O
LDHA,3637,B-GeneOrGeneProduct
suppresses,3637,O
tumor,3637,B-DiseaseOrPhenotypicFeature
progression,3637,O
in,3637,O
prostate,3637,B-DiseaseOrPhenotypicFeature
cancer,3637,I-DiseaseOrPhenotypicFeature
.,3637,O
A,3638,O
key,3638,O
hallmark,3638,O
of,3638,O
cancer,3638,B-DiseaseOrPhenotypicFeature
cells,3638,O
is,3638,O
their,3638,O
altered,3638,O
metabolism,3638,O
",",3638,O
known,3638,O
as,3638,O
Warburg,3638,O
effect,3638,O
.,3638,O
Lactate,3639,B-GeneOrGeneProduct
dehydrogenase,3639,I-GeneOrGeneProduct
A,3639,I-GeneOrGeneProduct
(,3639,O
LDHA,3639,B-GeneOrGeneProduct
),3639,O
executes,3639,O
the,3639,O
final,3639,O
step,3639,O
of,3639,O
aerobic,3639,O
glycolysis,3639,O
and,3639,O
has,3639,O
been,3639,O
reported,3639,O
to,3639,O
be,3639,O
involved,3639,O
in,3639,O
the,3639,O
tumor,3639,B-DiseaseOrPhenotypicFeature
progression,3639,O
.,3639,O
However,3640,O
",",3640,O
the,3640,O
function,3640,O
of,3640,O
LDHA,3640,B-GeneOrGeneProduct
in,3640,O
prostate,3640,B-DiseaseOrPhenotypicFeature
cancer,3640,I-DiseaseOrPhenotypicFeature
has,3640,O
not,3640,O
been,3640,O
studied,3640,O
.,3640,O
In,3641,O
current,3641,O
study,3641,O
",",3641,O
we,3641,O
observed,3641,O
overexpression,3641,O
of,3641,O
LDHA,3641,B-GeneOrGeneProduct
in,3641,O
the,3641,O
clinical,3641,O
prostate,3641,B-DiseaseOrPhenotypicFeature
cancer,3641,I-DiseaseOrPhenotypicFeature
samples,3641,O
compared,3641,O
with,3641,O
benign,3641,B-DiseaseOrPhenotypicFeature
prostate,3641,I-DiseaseOrPhenotypicFeature
hyperplasia,3641,I-DiseaseOrPhenotypicFeature
tissues,3641,O
as,3641,O
demonstrated,3641,O
by,3641,O
immunohistochemistry,3641,O
and,3641,O
real-time,3641,O
qPCR,3641,O
.,3641,O
Attenuated,3642,O
expression,3642,O
of,3642,O
LDHA,3642,B-GeneOrGeneProduct
by,3642,O
siRNA,3642,O
or,3642,O
inhibition,3642,O
of,3642,O
LDHA,3642,B-GeneOrGeneProduct
activities,3642,O
by,3642,O
FX11,3642,B-ChemicalEntity
inhibited,3642,O
cell,3642,O
proliferation,3642,O
",",3642,O
migration,3642,O
",",3642,O
invasion,3642,O
",",3642,O
and,3642,O
promoted,3642,O
cell,3642,O
apoptosis,3642,O
of,3642,O
PC-3,3642,B-CellLine
and,3642,O
DU145,3642,B-CellLine
cells,3642,O
.,3642,O
Mechanistically,3643,O
",",3643,O
decreased,3643,O
Warburg,3643,O
effect,3643,O
as,3643,O
demonstrated,3643,O
by,3643,O
reduced,3643,O
glucose,3643,B-ChemicalEntity
consumption,3643,O
and,3643,O
lactate,3643,B-ChemicalEntity
secretion,3643,O
and,3643,O
reduced,3643,O
expression,3643,O
of,3643,O
MMP-9,3643,B-GeneOrGeneProduct
",",3643,O
PLAU,3643,B-GeneOrGeneProduct
",",3643,O
and,3643,O
cathepsin,3643,B-GeneOrGeneProduct
B,3643,I-GeneOrGeneProduct
were,3643,O
found,3643,O
after,3643,O
LDHA,3643,B-GeneOrGeneProduct
knockdown,3643,O
or,3643,O
FX11,3643,B-ChemicalEntity
treatment,3643,O
in,3643,O
PC-3,3643,B-CellLine
and,3643,O
DU145,3643,B-CellLine
cells,3643,O
.,3643,O
Taken,3644,O
together,3644,O
",",3644,O
our,3644,O
study,3644,O
revealed,3644,O
the,3644,O
oncogenic,3644,O
role,3644,O
of,3644,O
LDHA,3644,B-GeneOrGeneProduct
in,3644,O
prostate,3644,B-DiseaseOrPhenotypicFeature
cancer,3644,I-DiseaseOrPhenotypicFeature
and,3644,O
suggested,3644,O
that,3644,O
LDHA,3644,B-GeneOrGeneProduct
might,3644,O
be,3644,O
a,3644,O
potential,3644,O
therapeutic,3644,O
target,3644,O
.,3644,O
Low,3645,O
functional,3645,O
programming,3645,O
of,3645,O
renal,3645,O
AT2R,3645,B-GeneOrGeneProduct
mediates,3645,O
the,3645,O
developmental,3645,O
origin,3645,O
of,3645,O
glomerulosclerosis,3645,B-DiseaseOrPhenotypicFeature
in,3645,O
adult,3645,O
offspring,3645,O
induced,3645,O
by,3645,O
prenatal,3645,O
caffeine,3645,B-ChemicalEntity
exposure,3645,O
.,3645,O
UNASSIGNED,3646,O
:,3646,O
Our,3646,O
previous,3646,O
study,3646,O
has,3646,O
indicated,3646,O
that,3646,O
prenatal,3646,O
caffeine,3646,B-ChemicalEntity
exposure,3646,O
(,3646,O
PCE,3646,O
),3646,O
could,3646,O
induce,3646,O
intrauterine,3646,B-DiseaseOrPhenotypicFeature
growth,3646,I-DiseaseOrPhenotypicFeature
retardation,3646,I-DiseaseOrPhenotypicFeature
(,3646,O
IUGR,3646,B-DiseaseOrPhenotypicFeature
),3646,O
of,3646,O
offspring,3646,O
.,3646,O
Recent,3647,O
research,3647,O
suggested,3647,O
that,3647,O
IUGR,3647,B-DiseaseOrPhenotypicFeature
is,3647,O
a,3647,O
risk,3647,O
factor,3647,O
for,3647,O
glomerulosclerosis,3647,B-DiseaseOrPhenotypicFeature
.,3647,O
However,3648,O
",",3648,O
whether,3648,O
PCE,3648,O
could,3648,O
induce,3648,O
glomerulosclerosis,3648,B-DiseaseOrPhenotypicFeature
and,3648,O
its,3648,O
underlying,3648,O
mechanisms,3648,O
remain,3648,O
unknown,3648,O
.,3648,O
This,3649,O
study,3649,O
aimed,3649,O
to,3649,O
demonstrate,3649,O
the,3649,O
induction,3649,O
to,3649,O
glomerulosclerosis,3649,B-DiseaseOrPhenotypicFeature
in,3649,O
adult,3649,O
offspring,3649,O
by,3649,O
PCE,3649,O
and,3649,O
its,3649,O
intrauterine,3649,O
programming,3649,O
mechanisms,3649,O
.,3649,O
A,3650,O
rat,3650,B-OrganismTaxon
model,3650,O
of,3650,O
IUGR,3650,B-DiseaseOrPhenotypicFeature
was,3650,O
established,3650,O
by,3650,O
PCE,3650,O
",",3650,O
male,3650,O
fetuses,3650,O
and,3650,O
adult,3650,O
offspring,3650,O
at,3650,O
the,3650,O
age,3650,O
of,3650,O
postnatal,3650,O
week,3650,O
24,3650,O
were,3650,O
euthanized,3650,O
.,3650,O
The,3651,O
results,3651,O
revealed,3651,O
that,3651,O
the,3651,O
adult,3651,O
offspring,3651,O
kidneys,3651,O
in,3651,O
the,3651,O
PCE,3651,O
group,3651,O
exhibited,3651,O
glomerulosclerosis,3651,B-DiseaseOrPhenotypicFeature
as,3651,O
well,3651,O
as,3651,O
interstitial,3651,B-DiseaseOrPhenotypicFeature
fibrosis,3651,I-DiseaseOrPhenotypicFeature
",",3651,O
accompanied,3651,O
by,3651,O
elevated,3651,O
levels,3651,O
of,3651,O
serum,3651,O
creatinine,3651,B-ChemicalEntity
and,3651,O
urine,3651,O
protein,3651,O
.,3651,O
Renal,3652,O
angiotensin,3652,B-GeneOrGeneProduct
II,3652,I-GeneOrGeneProduct
receptor,3652,I-GeneOrGeneProduct
type,3652,I-GeneOrGeneProduct
2,3652,I-GeneOrGeneProduct
(,3652,O
AT2R,3652,B-GeneOrGeneProduct
),3652,O
gene,3652,O
expression,3652,O
in,3652,O
adult,3652,O
offspring,3652,O
was,3652,O
reduced,3652,O
by,3652,O
PCE,3652,O
",",3652,O
whereas,3652,O
the,3652,O
renal,3652,O
angiotensin,3652,B-GeneOrGeneProduct
II,3652,I-GeneOrGeneProduct
receptor,3652,I-GeneOrGeneProduct
type,3652,I-GeneOrGeneProduct
1a,3652,I-GeneOrGeneProduct
(,3652,O
AT1aR,3652,B-GeneOrGeneProduct
),3652,O
/AT2R,3652,O
expression,3652,O
ratio,3652,O
was,3652,O
increased,3652,O
.,3652,O
The,3653,O
fetal,3653,O
kidneys,3653,O
in,3653,O
the,3653,O
PCE,3653,O
group,3653,O
displayed,3653,O
an,3653,O
enlarged,3653,O
Bowman,3653,O
's,3653,O
space,3653,O
and,3653,O
a,3653,O
shrunken,3653,O
glomerular,3653,O
tuft,3653,O
",",3653,O
accompanied,3653,O
by,3653,O
a,3653,O
reduced,3653,O
cortex,3653,O
width,3653,O
and,3653,O
an,3653,O
increase,3653,O
in,3653,O
the,3653,O
nephrogenic,3653,O
zone/cortical,3653,O
zone,3653,O
ratio,3653,O
.,3653,O
Observation,3654,O
by,3654,O
electronic,3654,O
microscope,3654,O
revealed,3654,O
structural,3654,O
damage,3654,O
of,3654,O
podocytes,3654,O
;,3654,O
the,3654,O
reduced,3654,O
expression,3654,O
level,3654,O
of,3654,O
podocyte,3654,O
marker,3654,O
genes,3654,O
",",3654,O
nephrin,3654,B-GeneOrGeneProduct
and,3654,O
podocin,3654,B-GeneOrGeneProduct
",",3654,O
was,3654,O
also,3654,O
detected,3654,O
by,3654,O
q-PCR,3654,O
.,3654,O
Moreover,3655,O
",",3655,O
AT2R,3655,B-GeneOrGeneProduct
gene,3655,O
and,3655,O
protein,3655,O
expressions,3655,O
in,3655,O
fetal,3655,O
kidneys,3655,O
were,3655,O
inhibited,3655,O
by,3655,O
PCE,3655,O
",",3655,O
associated,3655,O
with,3655,O
the,3655,O
repression,3655,O
of,3655,O
the,3655,O
gene,3655,O
expression,3655,O
of,3655,O
glial-cell-line-derived,3655,B-GeneOrGeneProduct
neurotrophic,3655,I-GeneOrGeneProduct
factor,3655,I-GeneOrGeneProduct
(,3655,O
GDNF,3655,B-GeneOrGeneProduct
),3655,O
/tyrosine,3655,O
kinase,3655,I-GeneOrGeneProduct
receptor,3655,I-GeneOrGeneProduct
(,3655,O
c-Ret,3655,B-GeneOrGeneProduct
),3655,O
signaling,3655,O
pathway,3655,O
.,3655,O
These,3656,O
results,3656,O
demonstrated,3656,O
that,3656,O
PCE,3656,O
could,3656,O
induce,3656,O
dysplasia,3656,B-DiseaseOrPhenotypicFeature
of,3656,I-DiseaseOrPhenotypicFeature
fetal,3656,I-DiseaseOrPhenotypicFeature
kidneys,3656,I-DiseaseOrPhenotypicFeature
as,3656,O
well,3656,O
as,3656,O
glomerulosclerosis,3656,B-DiseaseOrPhenotypicFeature
of,3656,O
adult,3656,O
offspring,3656,O
",",3656,O
and,3656,O
the,3656,O
low,3656,O
functional,3656,O
programming,3656,O
of,3656,O
renal,3656,O
AT2R,3656,B-GeneOrGeneProduct
might,3656,O
mediate,3656,O
the,3656,O
developmental,3656,O
origin,3656,O
of,3656,O
adult,3656,O
glomerulosclerosis,3656,B-DiseaseOrPhenotypicFeature
.,3656,O
The,3657,O
autotaxin-LPA2,3657,B-GeneOrGeneProduct
GPCR,3657,B-GeneOrGeneProduct
axis,3657,O
is,3657,O
modulated,3657,O
by,3657,O
gamma-irradiation,3657,O
and,3657,O
facilitates,3657,O
DNA,3657,O
damage,3657,O
repair,3657,O
.,3657,O
In,3658,O
this,3658,O
study,3658,O
we,3658,O
characterized,3658,O
the,3658,O
effects,3658,O
of,3658,O
radiation,3658,B-DiseaseOrPhenotypicFeature
injury,3658,I-DiseaseOrPhenotypicFeature
on,3658,O
the,3658,O
expression,3658,O
and,3658,O
function,3658,O
of,3658,O
the,3658,O
autotaxin,3658,B-GeneOrGeneProduct
(,3658,O
ATX,3658,B-GeneOrGeneProduct
),3658,O
-LPA2,3658,O
GPCR,3658,B-GeneOrGeneProduct
axis,3658,O
.,3658,O
In,3659,O
IEC-6,3659,B-CellLine
crypt,3659,O
cells,3659,O
and,3659,O
jejunum,3659,O
enteroids,3659,O
quantitative,3659,O
RT-PCR,3659,O
showed,3659,O
a,3659,O
time-,3659,O
and,3659,O
dose-dependent,3659,O
upregulation,3659,O
of,3659,O
lpa2,3659,B-GeneOrGeneProduct
in,3659,O
response,3659,O
to,3659,O
gamma-irradiation,3659,O
that,3659,O
was,3659,O
abolished,3659,O
by,3659,O
mutation,3659,O
of,3659,O
the,3659,O
NF-kappaB,3659,B-GeneOrGeneProduct
site,3659,O
in,3659,O
the,3659,O
lpa2,3659,B-GeneOrGeneProduct
promoter,3659,O
or,3659,O
by,3659,O
inhibition,3659,O
of,3659,O
ATM/ATR,3659,B-GeneOrGeneProduct
kinases,3659,I-GeneOrGeneProduct
with,3659,O
CGK-733,3659,B-ChemicalEntity
",",3659,O
suggesting,3659,O
that,3659,O
lpa2,3659,B-GeneOrGeneProduct
is,3659,O
a,3659,O
DNA,3659,O
damage,3659,O
response,3659,O
gene,3659,O
upregulated,3659,O
by,3659,O
ATM,3659,B-GeneOrGeneProduct
via,3659,O
NF-kappaB,3659,B-GeneOrGeneProduct
.,3659,O
The,3660,O
resolution,3660,O
kinetics,3660,O
of,3660,O
the,3660,O
DNA,3660,O
damage,3660,O
marker,3660,O
gamma-H2AX,3660,B-GeneOrGeneProduct
in,3660,O
LPA-treated,3660,B-GeneOrGeneProduct
IEC-6,3660,B-CellLine
cells,3660,O
exposed,3660,O
to,3660,O
gamma-irradiation,3660,O
was,3660,O
accelerated,3660,O
compared,3660,O
to,3660,O
vehicle,3660,O
",",3660,O
whereas,3660,O
pharmacological,3660,O
inhibition,3660,O
of,3660,O
LPA2,3660,B-GeneOrGeneProduct
delayed,3660,O
the,3660,O
resolution,3660,O
of,3660,O
gamma-H2AX,3660,B-GeneOrGeneProduct
.,3660,O
In,3661,O
LPA2-reconstituted,3661,B-GeneOrGeneProduct
MEF,3661,B-CellLine
cells,3661,O
lacking,3661,O
LPA1,3661,B-GeneOrGeneProduct
',3661,I-GeneOrGeneProduct
3,3661,I-GeneOrGeneProduct
the,3661,O
levels,3661,O
of,3661,O
gamma-H2AX,3661,B-GeneOrGeneProduct
decreased,3661,O
rapidly,3661,O
",",3661,O
whereas,3661,O
in,3661,O
Vector,3661,O
MEF,3661,B-CellLine
were,3661,O
high,3661,O
and,3661,O
remained,3661,O
sustained,3661,O
.,3661,O
Inhibition,3662,O
of,3662,O
ERK1,3662,B-GeneOrGeneProduct
',3662,I-GeneOrGeneProduct
2,3662,I-GeneOrGeneProduct
or,3662,O
PI3K/AKT,3662,B-GeneOrGeneProduct
signaling,3662,O
axis,3662,O
by,3662,O
pertussis,3662,O
toxin,3662,O
or,3662,O
the,3662,O
C311A/C314A/L351A,3662,B-SequenceVariant
mutation,3662,O
in,3662,O
the,3662,O
C-terminus,3662,O
of,3662,O
LPA2,3662,B-GeneOrGeneProduct
abrogated,3662,O
the,3662,O
effect,3662,O
of,3662,O
LPA,3662,B-GeneOrGeneProduct
on,3662,O
DNA,3662,O
repair,3662,O
.,3662,O
LPA2,3663,B-GeneOrGeneProduct
transcripts,3663,O
in,3663,O
Lin,3663,B-GeneOrGeneProduct
(,3663,O
-,3663,O
),3663,O
Sca-1,3663,B-GeneOrGeneProduct
(,3663,O
+,3663,O
),3663,O
c-Kit,3663,B-GeneOrGeneProduct
(,3663,O
+,3663,O
),3663,O
enriched,3663,O
for,3663,O
bone,3663,O
marrow,3663,O
stem,3663,O
cells,3663,O
were,3663,O
27-,3663,O
and,3663,O
5-fold,3663,O
higher,3663,O
than,3663,O
in,3663,O
common,3663,O
myeloid,3663,O
or,3663,O
lymphoid,3663,O
progenitors,3663,O
",",3663,O
respectively,3663,O
.,3663,O
Furthermore,3664,O
",",3664,O
after,3664,O
irradiation,3664,O
higher,3664,O
residual,3664,O
gamma-H2AX,3664,B-GeneOrGeneProduct
levels,3664,O
were,3664,O
detected,3664,O
in,3664,O
the,3664,O
bone,3664,O
marrow,3664,O
or,3664,O
jejunum,3664,O
of,3664,O
irradiated,3664,O
LPA2-KO,3664,B-GeneOrGeneProduct
mice,3664,B-OrganismTaxon
compared,3664,O
to,3664,O
WT,3664,O
mice,3664,B-OrganismTaxon
.,3664,O
We,3665,O
found,3665,O
that,3665,O
gamma-irradiation,3665,O
increases,3665,O
plasma,3665,O
ATX,3665,B-GeneOrGeneProduct
activity,3665,O
and,3665,O
LPA,3665,B-GeneOrGeneProduct
level,3665,O
that,3665,O
is,3665,O
in,3665,O
part,3665,O
due,3665,O
to,3665,O
the,3665,O
previously,3665,O
established,3665,O
radiation-induced,3665,O
upregulation,3665,O
of,3665,O
TNFalpha,3665,B-GeneOrGeneProduct
.,3665,O
These,3666,O
findings,3666,O
identify,3666,O
ATX,3666,B-GeneOrGeneProduct
and,3666,O
LPA2,3666,B-GeneOrGeneProduct
as,3666,O
radiation-regulated,3666,O
genes,3666,O
that,3666,O
appear,3666,O
to,3666,O
play,3666,O
a,3666,O
physiological,3666,O
role,3666,O
in,3666,O
DNA,3666,O
repair,3666,O
.,3666,O
Role,3667,O
of,3667,O
stress-activated,3667,O
OCT4A,3667,B-GeneOrGeneProduct
in,3667,O
the,3667,O
cell,3667,O
fate,3667,O
decisions,3667,O
of,3667,O
embryonal,3667,B-DiseaseOrPhenotypicFeature
carcinoma,3667,I-DiseaseOrPhenotypicFeature
cells,3667,O
treated,3667,O
with,3667,O
etoposide,3667,B-ChemicalEntity
.,3667,O
Tumor,3668,O
cellular,3668,O
senescence,3668,O
induced,3668,O
by,3668,O
genotoxic,3668,O
treatments,3668,O
has,3668,O
recently,3668,O
been,3668,O
found,3668,O
to,3668,O
be,3668,O
paradoxically,3668,O
linked,3668,O
to,3668,O
the,3668,O
induction,3668,O
of,3668,O
``,3668,O
stemness,3668,O
.,3668,O
'',3668,O
This,3669,O
observation,3669,O
is,3669,O
critical,3669,O
as,3669,O
it,3669,O
directly,3669,O
impinges,3669,O
upon,3669,O
the,3669,O
response,3669,O
of,3669,O
tumors,3669,B-DiseaseOrPhenotypicFeature
to,3669,O
current,3669,O
chemo-radio-therapy,3669,O
treatment,3669,O
regimens,3669,O
.,3669,O
Previously,3670,O
",",3670,O
we,3670,O
showed,3670,O
that,3670,O
following,3670,O
etoposide,3670,B-ChemicalEntity
(,3670,O
ETO,3670,B-ChemicalEntity
),3670,O
treatment,3670,O
embryonal,3670,B-DiseaseOrPhenotypicFeature
carcinoma,3670,I-DiseaseOrPhenotypicFeature
PA-1,3670,B-CellLine
cells,3670,O
undergo,3670,O
a,3670,O
p53-dependent,3670,B-GeneOrGeneProduct
upregulation,3670,O
of,3670,O
OCT4A,3670,B-GeneOrGeneProduct
and,3670,O
p21Cip1,3670,B-GeneOrGeneProduct
(,3670,O
governing,3670,O
self-renewal,3670,O
and,3670,O
regulating,3670,O
cell,3670,O
cycle,3670,O
inhibition,3670,O
and,3670,O
senescence,3670,O
",",3670,O
respectively,3670,O
),3670,O
.,3670,O
Here,3671,O
we,3671,O
report,3671,O
further,3671,O
detail,3671,O
on,3671,O
the,3671,O
relationship,3671,O
between,3671,O
these,3671,O
and,3671,O
other,3671,O
critical,3671,O
cell-fate,3671,O
regulators,3671,O
.,3671,O
PA-1,3672,B-CellLine
cells,3672,O
treated,3672,O
with,3672,O
ETO,3672,B-ChemicalEntity
display,3672,O
highly,3672,O
heterogeneous,3672,O
increases,3672,O
in,3672,O
OCT4A,3672,B-GeneOrGeneProduct
and,3672,O
p21Cip1,3672,B-GeneOrGeneProduct
indicative,3672,O
of,3672,O
dis-adaptation,3672,O
catastrophe,3672,O
.,3672,O
Silencing,3673,O
OCT4A,3673,B-GeneOrGeneProduct
suppresses,3673,O
p21Cip1,3673,B-GeneOrGeneProduct
",",3673,O
changes,3673,O
cell,3673,O
cycle,3673,O
regulation,3673,O
and,3673,O
subsequently,3673,O
suppresses,3673,O
terminal,3673,O
senescence,3673,O
;,3673,O
p21Cip1-silencing,3673,B-GeneOrGeneProduct
did,3673,O
not,3673,O
affect,3673,O
OCT4A,3673,B-GeneOrGeneProduct
expression,3673,O
or,3673,O
cellular,3673,O
phenotype,3673,O
.,3673,O
SOX2,3674,B-GeneOrGeneProduct
and,3674,O
NANOG,3674,B-GeneOrGeneProduct
expression,3674,O
did,3674,O
not,3674,O
change,3674,O
following,3674,O
ETO,3674,B-ChemicalEntity
treatment,3674,O
suggesting,3674,O
a,3674,O
dissociation,3674,O
of,3674,O
OCT4A,3674,B-GeneOrGeneProduct
from,3674,O
its,3674,O
pluripotency,3674,O
function,3674,O
.,3674,O
Instead,3675,O
",",3675,O
ETO-induced,3675,B-ChemicalEntity
OCT4A,3675,B-GeneOrGeneProduct
was,3675,O
concomitant,3675,O
with,3675,O
activation,3675,O
of,3675,O
AMPK,3675,B-GeneOrGeneProduct
",",3675,O
a,3675,O
key,3675,O
component,3675,O
of,3675,O
metabolic,3675,O
stress,3675,O
and,3675,O
autophagy,3675,O
regulation,3675,O
.,3675,O
p16ink4a,3676,B-GeneOrGeneProduct
",",3676,O
the,3676,O
inducer,3676,O
of,3676,O
terminal,3676,O
senescence,3676,O
",",3676,O
underwent,3676,O
autophagic,3676,O
sequestration,3676,O
in,3676,O
the,3676,O
cytoplasm,3676,O
of,3676,O
ETO-treated,3676,B-ChemicalEntity
cells,3676,O
",",3676,O
allowing,3676,O
alternative,3676,O
cell,3676,O
fates,3676,O
.,3676,O
Accordingly,3677,O
",",3677,O
failure,3677,O
of,3677,O
autophagy,3677,O
was,3677,O
accompanied,3677,O
by,3677,O
an,3677,O
accumulation,3677,O
of,3677,O
p16ink4a,3677,B-GeneOrGeneProduct
",",3677,O
nuclear,3677,O
disintegration,3677,O
",",3677,O
and,3677,O
loss,3677,O
of,3677,O
cell,3677,O
recovery,3677,O
.,3677,O
Together,3678,O
",",3678,O
these,3678,O
findings,3678,O
imply,3678,O
that,3678,O
OCT4A,3678,B-GeneOrGeneProduct
induction,3678,O
following,3678,O
DNA,3678,O
damage,3678,O
in,3678,O
PA-1,3678,B-CellLine
cells,3678,O
",",3678,O
performs,3678,O
a,3678,O
cell,3678,O
stress,3678,O
",",3678,O
rather,3678,O
than,3678,O
self-renewal,3678,O
",",3678,O
function,3678,O
by,3678,O
moderating,3678,O
the,3678,O
expression,3678,O
of,3678,O
p21Cip1,3678,B-GeneOrGeneProduct
",",3678,O
which,3678,O
alongside,3678,O
AMPK,3678,B-GeneOrGeneProduct
helps,3678,O
to,3678,O
then,3678,O
regulate,3678,O
autophagy,3678,O
.,3678,O
Moreover,3679,O
",",3679,O
this,3679,O
data,3679,O
indicates,3679,O
that,3679,O
exhaustion,3679,O
of,3679,O
autophagy,3679,O
",",3679,O
through,3679,O
persistent,3679,O
DNA,3679,O
damage,3679,O
",",3679,O
is,3679,O
the,3679,O
cause,3679,O
of,3679,O
terminal,3679,O
cellular,3679,O
senescence,3679,O
.,3679,O
Mechanisms,3680,O
Underlying,3680,O
Latent,3680,O
Disease,3680,O
Risk,3680,O
Associated,3680,O
with,3680,O
Early-Life,3680,O
Arsenic,3680,B-ChemicalEntity
Exposure,3680,O
:,3680,O
Current,3680,O
Research,3680,O
Trends,3680,O
and,3680,O
Scientific,3680,O
Gaps,3680,O
.,3680,O
BACKGROUND,3681,O
:,3681,O
Millions,3681,O
of,3681,O
individuals,3681,O
worldwide,3681,O
",",3681,O
particularly,3681,O
those,3681,O
living,3681,O
in,3681,O
rural,3681,O
and,3681,O
developing,3681,O
areas,3681,O
",",3681,O
are,3681,O
exposed,3681,O
to,3681,O
harmful,3681,O
levels,3681,O
of,3681,O
inorganic,3681,B-ChemicalEntity
arsenic,3681,I-ChemicalEntity
(,3681,O
iAs,3681,B-ChemicalEntity
),3681,O
in,3681,O
their,3681,O
drinking,3681,O
water,3681,O
.,3681,O
Inorganic,3682,B-ChemicalEntity
As,3682,I-ChemicalEntity
exposure,3682,O
during,3682,O
key,3682,O
developmental,3682,O
periods,3682,O
is,3682,O
associated,3682,O
with,3682,O
a,3682,O
variety,3682,O
of,3682,O
adverse,3682,O
health,3682,O
effects,3682,O
including,3682,O
those,3682,O
that,3682,O
are,3682,O
evident,3682,O
in,3682,O
adulthood,3682,O
.,3682,O
There,3683,O
is,3683,O
considerable,3683,O
interest,3683,O
in,3683,O
identifying,3683,O
the,3683,O
molecular,3683,O
mechanisms,3683,O
that,3683,O
relate,3683,O
early-life,3683,O
iAs,3683,B-ChemicalEntity
exposure,3683,O
to,3683,O
the,3683,O
development,3683,O
of,3683,O
these,3683,O
latent,3683,O
diseases,3683,O
",",3683,O
particularly,3683,O
in,3683,O
relationship,3683,O
to,3683,O
cancer,3683,B-DiseaseOrPhenotypicFeature
.,3683,O
OBJECTIVES,3684,O
:,3684,O
This,3684,O
work,3684,O
summarizes,3684,O
research,3684,O
on,3684,O
the,3684,O
molecular,3684,O
mechanisms,3684,O
that,3684,O
underlie,3684,O
the,3684,O
increased,3684,O
risk,3684,O
of,3684,O
cancer,3684,B-DiseaseOrPhenotypicFeature
development,3684,O
in,3684,O
adulthood,3684,O
that,3684,O
is,3684,O
associated,3684,O
with,3684,O
early-life,3684,O
iAs,3684,B-ChemicalEntity
exposure,3684,O
.,3684,O
DISCUSSION,3685,O
:,3685,O
Epigenetic,3685,O
reprogramming,3685,O
that,3685,O
imparts,3685,O
functional,3685,O
changes,3685,O
in,3685,O
gene,3685,O
expression,3685,O
",",3685,O
the,3685,O
development,3685,O
of,3685,O
cancer,3685,B-DiseaseOrPhenotypicFeature
stem,3685,O
cells,3685,O
",",3685,O
and,3685,O
immunomodulation,3685,O
are,3685,O
plausible,3685,O
underlying,3685,O
mechanisms,3685,O
by,3685,O
which,3685,O
early-life,3685,O
iAs,3685,B-ChemicalEntity
exposure,3685,O
elicits,3685,O
latent,3685,O
carcinogenic,3685,B-DiseaseOrPhenotypicFeature
effects,3685,O
.,3685,O
CONCLUSIONS,3686,O
:,3686,O
Evidence,3686,O
is,3686,O
mounting,3686,O
that,3686,O
relates,3686,O
early-life,3686,O
iAs,3686,B-ChemicalEntity
exposure,3686,O
and,3686,O
cancer,3686,B-DiseaseOrPhenotypicFeature
development,3686,O
later,3686,O
in,3686,O
life,3686,O
.,3686,O
Future,3687,O
research,3687,O
should,3687,O
include,3687,O
animal,3687,O
studies,3687,O
that,3687,O
address,3687,O
mechanistic,3687,O
hypotheses,3687,O
and,3687,O
studies,3687,O
of,3687,O
human,3687,B-OrganismTaxon
populations,3687,O
that,3687,O
integrate,3687,O
early-life,3687,O
exposure,3687,O
",",3687,O
molecular,3687,O
alterations,3687,O
",",3687,O
and,3687,O
latent,3687,O
disease,3687,O
outcomes,3687,O
.,3687,O
Serum,3688,O
levels,3688,O
of,3688,O
chemokines,3688,B-GeneOrGeneProduct
CCL4,3688,B-GeneOrGeneProduct
and,3688,O
CCL5,3688,B-GeneOrGeneProduct
in,3688,O
cirrhotic,3688,B-DiseaseOrPhenotypicFeature
patients,3688,B-OrganismTaxon
indicate,3688,O
the,3688,O
presence,3688,O
of,3688,O
hepatocellular,3688,B-DiseaseOrPhenotypicFeature
carcinoma,3688,I-DiseaseOrPhenotypicFeature
.,3688,O
BACKGROUND,3689,O
:,3689,O
Most,3689,O
hepatocellular,3689,B-DiseaseOrPhenotypicFeature
carcinomas,3689,I-DiseaseOrPhenotypicFeature
(,3689,O
HCCs,3689,B-DiseaseOrPhenotypicFeature
),3689,O
are,3689,O
diagnosed,3689,O
at,3689,O
an,3689,O
advanced,3689,O
stage,3689,O
.,3689,O
The,3690,O
prognostic,3690,O
value,3690,O
of,3690,O
serum,3690,O
tumour,3690,B-DiseaseOrPhenotypicFeature
markers,3690,O
alpha-fetoprotein,3690,B-GeneOrGeneProduct
(,3690,O
AFP,3690,B-GeneOrGeneProduct
),3690,O
and,3690,O
des-gamma-carboxy,3690,B-GeneOrGeneProduct
prothrombin,3690,I-GeneOrGeneProduct
(,3690,O
DCP,3690,B-GeneOrGeneProduct
),3690,O
is,3690,O
limited,3690,O
.,3690,O
The,3691,O
aim,3691,O
of,3691,O
our,3691,O
study,3691,O
is,3691,O
to,3691,O
evaluate,3691,O
the,3691,O
diagnostic,3691,O
value,3691,O
of,3691,O
serum,3691,O
growth,3691,O
factors,3691,O
",",3691,O
apoptotic,3691,O
and,3691,O
inflammatory,3691,B-DiseaseOrPhenotypicFeature
mediators,3691,O
of,3691,O
cirrhotic,3691,B-DiseaseOrPhenotypicFeature
patients,3691,B-OrganismTaxon
with,3691,O
and,3691,O
without,3691,O
HCC,3691,B-DiseaseOrPhenotypicFeature
.,3691,O
METHODS,3692,O
:,3692,O
Serum,3692,O
samples,3692,O
were,3692,O
collected,3692,O
from,3692,O
cirrhotic,3692,B-DiseaseOrPhenotypicFeature
potential,3692,O
liver,3692,O
transplant,3692,O
patients,3692,B-OrganismTaxon
(,3692,O
LTx,3692,O
),3692,O
with,3692,O
(,3692,O
n=61,3692,O
),3692,O
and,3692,O
without,3692,O
HCC,3692,B-DiseaseOrPhenotypicFeature
(,3692,O
n=78,3692,O
),3692,O
as,3692,O
well,3692,O
as,3692,O
from,3692,O
healthy,3692,O
controls,3692,O
(,3692,O
HCs,3692,O
;,3692,O
n=39,3692,O
),3692,O
.,3692,O
Serum,3693,O
concentrations,3693,O
of,3693,O
CRP,3693,B-GeneOrGeneProduct
",",3693,O
neopterin,3693,B-ChemicalEntity
and,3693,O
IL-6,3693,B-GeneOrGeneProduct
as,3693,O
markers,3693,O
of,3693,O
inflammation,3693,B-DiseaseOrPhenotypicFeature
and,3693,O
thrombopoietin,3693,B-GeneOrGeneProduct
(,3693,O
TPO,3693,B-GeneOrGeneProduct
),3693,O
",",3693,O
GCSF,3693,B-GeneOrGeneProduct
",",3693,O
FGF,3693,B-GeneOrGeneProduct
basic,3693,I-GeneOrGeneProduct
and,3693,O
VEGF,3693,B-GeneOrGeneProduct
",",3693,O
HMGB1,3693,B-GeneOrGeneProduct
",",3693,O
CK-18,3693,B-GeneOrGeneProduct
(,3693,O
M65,3693,O
),3693,O
and,3693,O
CK18,3693,B-GeneOrGeneProduct
fragment,3693,O
(,3693,O
M30,3693,O
),3693,O
and,3693,O
a,3693,O
panel,3693,O
of,3693,O
proinflammatory,3693,B-GeneOrGeneProduct
chemokines,3693,I-GeneOrGeneProduct
(,3693,O
CCL2,3693,B-GeneOrGeneProduct
",",3693,O
CCL3,3693,B-GeneOrGeneProduct
",",3693,O
CCL4,3693,B-GeneOrGeneProduct
",",3693,O
CCL5,3693,B-GeneOrGeneProduct
",",3693,O
CXCL5,3693,B-GeneOrGeneProduct
and,3693,O
IL-8,3693,B-GeneOrGeneProduct
),3693,O
were,3693,O
measured,3693,O
.,3693,O
Chi,3694,O
square,3694,O
",",3694,O
Fisher,3694,O
exact,3694,O
",",3694,O
Mann-Whitney,3694,O
U-tests,3694,O
",",3694,O
ROC,3694,O
curve,3694,O
analysis,3694,O
and,3694,O
forward,3694,O
stepwise,3694,O
logistic,3694,O
regression,3694,O
analyses,3694,O
were,3694,O
applied,3694,O
.,3694,O
RESULTS,3695,O
:,3695,O
Patients,3695,B-OrganismTaxon
with,3695,O
HCC,3695,B-DiseaseOrPhenotypicFeature
had,3695,O
higher,3695,O
serum,3695,O
TPO,3695,B-GeneOrGeneProduct
and,3695,O
chemokines,3695,B-GeneOrGeneProduct
(,3695,O
P,3695,O
<,3695,O
0.001,3695,O
for,3695,O
TPO,3695,B-GeneOrGeneProduct
",",3695,O
CCL4,3695,B-GeneOrGeneProduct
",",3695,O
CCL5,3695,B-GeneOrGeneProduct
and,3695,O
CXCL5,3695,B-GeneOrGeneProduct
),3695,O
and,3695,O
lower,3695,O
CCL2,3695,B-GeneOrGeneProduct
(,3695,O
P=0.008,3695,O
),3695,O
levels,3695,O
than,3695,O
cirrhotic,3695,B-DiseaseOrPhenotypicFeature
patients,3695,B-OrganismTaxon
without,3695,O
HCC,3695,B-DiseaseOrPhenotypicFeature
.,3695,O
Multivariate,3696,O
forward,3696,O
stepwise,3696,O
regression,3696,O
analysis,3696,O
for,3696,O
significant,3696,O
parameters,3696,O
showed,3696,O
that,3696,O
among,3696,O
the,3696,O
studied,3696,O
parameters,3696,O
CCL4,3696,B-GeneOrGeneProduct
and,3696,O
CCL5,3696,B-GeneOrGeneProduct
(,3696,O
P=0.001,3696,O
),3696,O
are,3696,O
diagnostic,3696,O
markers,3696,O
of,3696,O
HCC,3696,B-DiseaseOrPhenotypicFeature
.,3696,O
Serum,3697,O
levels,3697,O
of,3697,O
TPO,3697,B-GeneOrGeneProduct
and,3697,O
chemokines,3697,B-GeneOrGeneProduct
were,3697,O
lower,3697,O
",",3697,O
whereas,3697,O
M30,3697,O
was,3697,O
significantly,3697,O
higher,3697,O
in,3697,O
cirrhotic,3697,B-DiseaseOrPhenotypicFeature
patients,3697,B-OrganismTaxon
than,3697,O
in,3697,O
HCs,3697,O
.,3697,O
CONCLUSIONS,3698,O
:,3698,O
High,3698,O
serum,3698,O
levels,3698,O
of,3698,O
inflammatory,3698,B-DiseaseOrPhenotypicFeature
chemokines,3698,B-GeneOrGeneProduct
such,3698,O
as,3698,O
CCL4,3698,B-GeneOrGeneProduct
and,3698,O
CCL5,3698,B-GeneOrGeneProduct
in,3698,O
the,3698,O
serum,3698,O
of,3698,O
cirrhotic,3698,B-DiseaseOrPhenotypicFeature
patients,3698,B-OrganismTaxon
indicate,3698,O
the,3698,O
presence,3698,O
of,3698,O
HCC,3698,B-DiseaseOrPhenotypicFeature
.,3698,O
Putative,3699,O
Prostate,3699,B-DiseaseOrPhenotypicFeature
Cancer,3699,I-DiseaseOrPhenotypicFeature
Risk,3699,O
SNP,3699,O
in,3699,O
an,3699,O
Androgen,3699,B-GeneOrGeneProduct
Receptor-Binding,3699,O
Site,3699,O
of,3699,O
the,3699,O
Melanophilin,3699,B-GeneOrGeneProduct
Gene,3699,O
Illustrates,3699,O
Enrichment,3699,O
of,3699,O
Risk,3699,O
SNPs,3699,O
in,3699,O
Androgen,3699,B-GeneOrGeneProduct
Receptor,3699,I-GeneOrGeneProduct
Target,3699,O
Sites,3699,O
.,3699,O
Genome-wide,3700,O
association,3700,O
studies,3700,O
have,3700,O
identified,3700,O
genomic,3700,O
loci,3700,O
",",3700,O
whose,3700,O
single-nucleotide,3700,O
polymorphisms,3700,O
(,3700,O
SNPs,3700,O
),3700,O
predispose,3700,O
to,3700,O
prostate,3700,B-DiseaseOrPhenotypicFeature
cancer,3700,I-DiseaseOrPhenotypicFeature
(,3700,O
PCa,3700,B-DiseaseOrPhenotypicFeature
),3700,O
.,3700,O
However,3701,O
",",3701,O
the,3701,O
mechanisms,3701,O
of,3701,O
most,3701,O
of,3701,O
these,3701,O
variants,3701,O
are,3701,O
largely,3701,O
unknown,3701,O
.,3701,O
We,3702,O
integrated,3702,O
chromatin-immunoprecipitation-coupled,3702,O
sequencing,3702,O
and,3702,O
microarray,3702,O
expression,3702,O
profiling,3702,O
in,3702,O
TMPRSS2-ERG,3702,B-GeneOrGeneProduct
gene,3702,O
rearrangement,3702,O
positive,3702,O
DUCaP,3702,B-CellLine
cells,3702,O
with,3702,O
the,3702,O
GWAS,3702,O
PCa,3702,B-DiseaseOrPhenotypicFeature
risk,3702,O
SNPs,3702,O
catalog,3702,O
to,3702,O
identify,3702,O
disease,3702,O
susceptibility,3702,O
SNPs,3702,O
localized,3702,O
within,3702,O
functional,3702,O
androgen,3702,B-GeneOrGeneProduct
receptor-binding,3702,O
sites,3702,O
(,3702,O
ARBSs,3702,B-GeneOrGeneProduct
),3702,O
.,3702,O
Among,3703,O
the,3703,O
48,3703,O
GWAS,3703,O
index,3703,O
risk,3703,O
SNPs,3703,O
and,3703,O
"3,917",3703,O
linked,3703,O
SNPs,3703,O
",",3703,O
80,3703,O
were,3703,O
found,3703,O
located,3703,O
in,3703,O
ARBSs,3703,B-GeneOrGeneProduct
.,3703,O
Of,3704,O
these,3704,O
",",3704,O
rs11891426,3704,B-SequenceVariant
:,3704,O
T,3704,B-SequenceVariant
>,3704,I-SequenceVariant
G,3704,I-SequenceVariant
in,3704,O
an,3704,O
intron,3704,O
of,3704,O
the,3704,O
melanophilin,3704,B-GeneOrGeneProduct
gene,3704,O
(,3704,O
MLPH,3704,B-GeneOrGeneProduct
),3704,O
was,3704,O
within,3704,O
a,3704,O
novel,3704,O
putative,3704,O
auxiliary,3704,O
AR-binding,3704,B-GeneOrGeneProduct
motif,3704,O
",",3704,O
which,3704,O
is,3704,O
enriched,3704,O
in,3704,O
the,3704,O
neighborhood,3704,O
of,3704,O
canonical,3704,O
androgen-responsive,3704,B-ChemicalEntity
elements,3704,O
.,3704,O
T,3705,B-SequenceVariant
>,3705,I-SequenceVariant
G,3705,I-SequenceVariant
exchange,3705,O
attenuated,3705,O
the,3705,O
transcriptional,3705,O
activity,3705,O
of,3705,O
the,3705,O
ARBS,3705,B-GeneOrGeneProduct
in,3705,O
an,3705,O
AR,3705,B-GeneOrGeneProduct
reporter,3705,O
gene,3705,O
assay,3705,O
.,3705,O
The,3706,O
expression,3706,O
of,3706,O
MLPH,3706,B-GeneOrGeneProduct
in,3706,O
primary,3706,O
prostate,3706,B-DiseaseOrPhenotypicFeature
tumors,3706,I-DiseaseOrPhenotypicFeature
was,3706,O
significantly,3706,O
lower,3706,O
in,3706,O
those,3706,O
with,3706,O
the,3706,O
G,3706,O
compared,3706,O
with,3706,O
the,3706,O
T,3706,O
allele,3706,O
and,3706,O
correlated,3706,O
significantly,3706,O
with,3706,O
AR,3706,B-GeneOrGeneProduct
protein,3706,O
.,3706,O
Higher,3707,O
melanophilin,3707,B-GeneOrGeneProduct
level,3707,O
in,3707,O
prostate,3707,O
tissue,3707,O
of,3707,O
patients,3707,B-OrganismTaxon
with,3707,O
a,3707,O
favorable,3707,O
PCa,3707,B-DiseaseOrPhenotypicFeature
risk,3707,O
profile,3707,O
points,3707,O
out,3707,O
a,3707,O
tumor-suppressive,3707,B-DiseaseOrPhenotypicFeature
effect,3707,O
.,3707,O
These,3708,O
results,3708,O
unravel,3708,O
a,3708,O
hidden,3708,O
link,3708,O
between,3708,O
AR,3708,B-GeneOrGeneProduct
and,3708,O
a,3708,O
functional,3708,O
putative,3708,O
PCa,3708,B-DiseaseOrPhenotypicFeature
risk,3708,O
SNP,3708,O
",",3708,O
whose,3708,O
allele,3708,O
alteration,3708,O
affects,3708,O
androgen,3708,B-ChemicalEntity
regulation,3708,O
of,3708,O
its,3708,O
host,3708,O
gene,3708,O
MLPH,3708,B-GeneOrGeneProduct
.,3708,O
Changes,3709,O
in,3709,O
microRNA,3709,O
(,3709,O
miRNA,3709,O
),3709,O
expression,3709,O
during,3709,O
pancreatic,3709,B-DiseaseOrPhenotypicFeature
cancer,3709,I-DiseaseOrPhenotypicFeature
development,3709,O
and,3709,O
progression,3709,O
in,3709,O
a,3709,O
genetically,3709,O
engineered,3709,O
KrasG12D,3709,B-GeneOrGeneProduct
;,3709,O
Pdx1-Cre,3709,B-GeneOrGeneProduct
mouse,3709,B-OrganismTaxon
(,3709,O
KC,3709,O
),3709,O
model,3709,O
.,3709,O
Differential,3710,O
expression,3710,O
of,3710,O
microRNAs,3710,O
(,3710,O
miRNAs,3710,O
),3710,O
has,3710,O
been,3710,O
demonstrated,3710,O
in,3710,O
various,3710,O
cancers,3710,B-DiseaseOrPhenotypicFeature
",",3710,O
including,3710,O
pancreatic,3710,B-DiseaseOrPhenotypicFeature
cancer,3710,I-DiseaseOrPhenotypicFeature
(,3710,O
PC,3710,B-DiseaseOrPhenotypicFeature
),3710,O
.,3710,O
Due,3711,O
to,3711,O
the,3711,O
lack,3711,O
of,3711,O
tissue,3711,O
samples,3711,O
from,3711,O
early-stages,3711,O
of,3711,O
PC,3711,B-DiseaseOrPhenotypicFeature
",",3711,O
the,3711,O
stage-specific,3711,O
alteration,3711,O
of,3711,O
miRNAs,3711,O
during,3711,O
PC,3711,B-DiseaseOrPhenotypicFeature
initiation,3711,O
and,3711,O
progression,3711,O
is,3711,O
largely,3711,O
unknown,3711,O
.,3711,O
In,3712,O
this,3712,O
study,3712,O
",",3712,O
we,3712,O
investigated,3712,O
the,3712,O
global,3712,O
miRNA,3712,O
expression,3712,O
profile,3712,O
and,3712,O
their,3712,O
processing,3712,O
machinery,3712,O
during,3712,O
PC,3712,B-DiseaseOrPhenotypicFeature
progression,3712,O
using,3712,O
the,3712,O
KrasG12D,3712,B-GeneOrGeneProduct
;,3712,O
Pdx1-Cre,3712,B-GeneOrGeneProduct
(,3712,O
KC,3712,O
),3712,O
mouse,3712,B-OrganismTaxon
model,3712,O
.,3712,O
At,3713,O
25,3713,O
weeks,3713,O
",",3713,O
the,3713,O
miRNA,3713,O
microarray,3713,O
analysis,3713,O
revealed,3713,O
significant,3713,O
downregulation,3713,O
of,3713,O
miR-150,3713,B-GeneOrGeneProduct
",",3713,O
miR-494,3713,B-GeneOrGeneProduct
",",3713,O
miR-138,3713,B-GeneOrGeneProduct
",",3713,O
miR-148a,3713,B-GeneOrGeneProduct
",",3713,O
miR-216a,3713,B-GeneOrGeneProduct
",",3713,O
and,3713,O
miR-217,3713,B-GeneOrGeneProduct
and,3713,O
upregulation,3713,O
of,3713,O
miR-146b,3713,B-GeneOrGeneProduct
",",3713,O
miR-205,3713,B-GeneOrGeneProduct
",",3713,O
miR-31,3713,B-GeneOrGeneProduct
",",3713,O
miR-192,3713,B-GeneOrGeneProduct
",",3713,O
and,3713,O
miR-21,3713,B-GeneOrGeneProduct
in,3713,O
KC,3713,O
mice,3713,B-OrganismTaxon
compared,3713,O
to,3713,O
controls,3713,O
.,3713,O
Further,3714,O
",",3714,O
expression,3714,O
of,3714,O
miRNA,3714,O
biosynthetic,3714,O
machinery,3714,O
including,3714,O
Dicer,3714,B-GeneOrGeneProduct
",",3714,O
Exportin-5,3714,B-GeneOrGeneProduct
",",3714,O
TRKRA,3714,B-GeneOrGeneProduct
",",3714,O
and,3714,O
TARBP2,3714,B-GeneOrGeneProduct
were,3714,O
downregulated,3714,O
",",3714,O
while,3714,O
DGCR8,3714,B-GeneOrGeneProduct
and,3714,O
Ago2,3714,B-GeneOrGeneProduct
were,3714,O
upregulated,3714,O
in,3714,O
KC,3714,O
mice,3714,B-OrganismTaxon
.,3714,O
In,3715,O
addition,3715,O
",",3715,O
from,3715,O
10,3715,O
to,3715,O
50,3715,O
weeks,3715,O
of,3715,O
age,3715,O
",",3715,O
stage-specific,3715,O
expression,3715,O
profiling,3715,O
of,3715,O
miRNA,3715,O
in,3715,O
KC,3715,O
mice,3715,B-OrganismTaxon
revealed,3715,O
downregulation,3715,O
of,3715,O
miR-216,3715,B-GeneOrGeneProduct
",",3715,O
miR-217,3715,B-GeneOrGeneProduct
",",3715,O
miR-100,3715,B-GeneOrGeneProduct
",",3715,O
miR-345,3715,B-GeneOrGeneProduct
",",3715,O
miR-141,3715,B-GeneOrGeneProduct
",",3715,O
miR-483-3p,3715,B-GeneOrGeneProduct
",",3715,O
miR-26b,3715,B-GeneOrGeneProduct
",",3715,O
miR-150,3715,B-GeneOrGeneProduct
",",3715,O
miR-195,3715,B-GeneOrGeneProduct
",",3715,O
Let-7b,3715,B-GeneOrGeneProduct
and,3715,O
Let-96,3715,B-GeneOrGeneProduct
and,3715,O
upregulation,3715,O
of,3715,O
miR-21,3715,B-GeneOrGeneProduct
",",3715,O
miR-205,3715,B-GeneOrGeneProduct
",",3715,O
miR-146b,3715,B-GeneOrGeneProduct
",",3715,O
miR-34c,3715,B-GeneOrGeneProduct
",",3715,O
miR-1273,3715,B-GeneOrGeneProduct
",",3715,O
miR-223,3715,B-GeneOrGeneProduct
and,3715,O
miR-195,3715,B-GeneOrGeneProduct
compared,3715,O
to,3715,O
control,3715,O
mice,3715,B-OrganismTaxon
.,3715,O
Interestingly,3716,O
",",3716,O
the,3716,O
differential,3716,O
expression,3716,O
of,3716,O
miRNA,3716,O
in,3716,O
mice,3716,B-OrganismTaxon
also,3716,O
corroborated,3716,O
with,3716,O
the,3716,O
miRNA,3716,O
expression,3716,O
in,3716,O
human,3716,B-OrganismTaxon
PC,3716,B-DiseaseOrPhenotypicFeature
cell,3716,O
lines,3716,O
and,3716,O
tissue,3716,O
samples,3716,O
;,3716,O
ectopic,3716,O
expression,3716,O
of,3716,O
Let-7b,3716,B-GeneOrGeneProduct
in,3716,O
CD18/HPAF,3716,B-CellLine
and,3716,O
Capan1,3716,B-CellLine
cells,3716,O
resulted,3716,O
in,3716,O
the,3716,O
downregulation,3716,O
of,3716,O
KRAS,3716,B-GeneOrGeneProduct
and,3716,O
MSST1,3716,B-GeneOrGeneProduct
expression,3716,O
.,3716,O
Overall,3717,O
",",3717,O
the,3717,O
present,3717,O
study,3717,O
aids,3717,O
an,3717,O
understanding,3717,O
of,3717,O
miRNA,3717,O
expression,3717,O
patterns,3717,O
during,3717,O
PC,3717,B-DiseaseOrPhenotypicFeature
pathogenesis,3717,O
and,3717,O
helps,3717,O
to,3717,O
facilitate,3717,O
the,3717,O
identification,3717,O
of,3717,O
promising,3717,O
and,3717,O
novel,3717,O
early,3717,O
diagnostic/prognostic,3717,O
markers,3717,O
and,3717,O
therapeutic,3717,O
targets,3717,O
.,3717,O
DNA-damage,3718,O
response,3718,O
gene,3718,O
GADD45A,3718,B-GeneOrGeneProduct
induces,3718,O
differentiation,3718,O
in,3718,O
hematopoietic,3718,O
stem,3718,O
cells,3718,O
without,3718,O
inhibiting,3718,O
cell,3718,O
cycle,3718,O
or,3718,O
survival,3718,O
.,3718,O
Hematopoietic,3719,O
stem,3719,O
cells,3719,O
(,3719,O
HSCs,3719,O
),3719,O
maintain,3719,O
blood,3719,O
cell,3719,O
production,3719,O
life-long,3719,O
by,3719,O
their,3719,O
unique,3719,O
abilities,3719,O
of,3719,O
self-renewal,3719,O
and,3719,O
differentiation,3719,O
into,3719,O
all,3719,O
blood,3719,O
cell,3719,O
lineages,3719,O
.,3719,O
Growth,3720,B-GeneOrGeneProduct
arrest,3720,I-GeneOrGeneProduct
and,3720,I-GeneOrGeneProduct
DNA-damage-inducible,3720,I-GeneOrGeneProduct
45,3720,I-GeneOrGeneProduct
alpha,3720,I-GeneOrGeneProduct
(,3720,O
GADD45A,3720,B-GeneOrGeneProduct
),3720,O
is,3720,O
induced,3720,O
by,3720,O
genotoxic,3720,O
stress,3720,O
in,3720,O
HSCs,3720,O
.,3720,O
GADD45A,3721,B-GeneOrGeneProduct
has,3721,O
been,3721,O
implicated,3721,O
in,3721,O
cell,3721,O
cycle,3721,O
control,3721,O
",",3721,O
cell,3721,O
death,3721,O
and,3721,O
senescence,3721,O
",",3721,O
as,3721,O
well,3721,O
as,3721,O
in,3721,O
DNA-damage,3721,O
repair,3721,O
.,3721,O
In,3722,O
general,3722,O
",",3722,O
GADD45A,3722,B-GeneOrGeneProduct
provides,3722,O
cellular,3722,O
stability,3722,O
by,3722,O
either,3722,O
arresting,3722,O
the,3722,O
cell,3722,O
cycle,3722,O
progression,3722,O
until,3722,O
DNA,3722,O
damage,3722,O
is,3722,O
repaired,3722,O
or,3722,O
",",3722,O
in,3722,O
cases,3722,O
of,3722,O
fatal,3722,O
damage,3722,O
",",3722,O
by,3722,O
inducing,3722,O
apoptosis,3722,O
.,3722,O
However,3723,O
",",3723,O
the,3723,O
function,3723,O
of,3723,O
GADD45A,3723,B-GeneOrGeneProduct
in,3723,O
hematopoiesis,3723,O
remains,3723,O
controversial,3723,O
.,3723,O
We,3724,O
revealed,3724,O
the,3724,O
changes,3724,O
in,3724,O
murine,3724,B-OrganismTaxon
HSC,3724,O
fate,3724,O
control,3724,O
orchestrated,3724,O
by,3724,O
the,3724,O
expression,3724,O
of,3724,O
GADD45A,3724,B-GeneOrGeneProduct
at,3724,O
single,3724,O
cell,3724,O
resolution,3724,O
.,3724,O
In,3725,O
contrast,3725,O
to,3725,O
other,3725,O
cellular,3725,O
systems,3725,O
",",3725,O
GADD45A,3725,B-GeneOrGeneProduct
expression,3725,O
did,3725,O
not,3725,O
cause,3725,O
a,3725,O
cell,3725,O
cycle,3725,O
arrest,3725,O
or,3725,O
an,3725,O
alteration,3725,O
in,3725,O
the,3725,O
decision,3725,O
between,3725,O
cell,3725,O
survival,3725,O
and,3725,O
apoptosis,3725,O
in,3725,O
HSCs,3725,O
.,3725,O
Strikingly,3726,O
",",3726,O
GADD45A,3726,B-GeneOrGeneProduct
strongly,3726,O
induced,3726,O
and,3726,O
accelerated,3726,O
the,3726,O
differentiation,3726,O
program,3726,O
in,3726,O
HSCs,3726,O
.,3726,O
Continuous,3727,O
tracking,3727,O
of,3727,O
individual,3727,O
HSCs,3727,O
and,3727,O
their,3727,O
progeny,3727,O
via,3727,O
time-lapse,3727,O
microscopy,3727,O
elucidated,3727,O
that,3727,O
once,3727,O
GADD45A,3727,B-GeneOrGeneProduct
was,3727,O
expressed,3727,O
",",3727,O
HSCs,3727,O
differentiate,3727,O
into,3727,O
committed,3727,O
progenitors,3727,O
within,3727,O
29,3727,O
hours,3727,O
.,3727,O
GADD45A-expressing,3728,B-GeneOrGeneProduct
HSCs,3728,O
failed,3728,O
to,3728,O
long-term,3728,O
reconstitute,3728,O
the,3728,O
blood,3728,O
of,3728,O
recipients,3728,O
by,3728,O
inducing,3728,O
multilineage,3728,O
differentiation,3728,O
in,3728,O
vivo,3728,O
.,3728,O
Importantly,3729,O
",",3729,O
g-irradiation,3729,O
of,3729,O
HSCs,3729,O
induced,3729,O
their,3729,O
differentiation,3729,O
by,3729,O
upregulating,3729,O
endogenous,3729,O
GADD45A,3729,B-GeneOrGeneProduct
.,3729,O
The,3730,O
differentiation,3730,O
induction,3730,O
by,3730,O
GADD45A,3730,B-GeneOrGeneProduct
was,3730,O
transmitted,3730,O
by,3730,O
activating,3730,O
p38,3730,B-GeneOrGeneProduct
Mitogen-activated,3730,I-GeneOrGeneProduct
protein,3730,I-GeneOrGeneProduct
kinase,3730,I-GeneOrGeneProduct
(,3730,O
MAPK,3730,B-GeneOrGeneProduct
),3730,O
signaling,3730,O
and,3730,O
allowed,3730,O
the,3730,O
generation,3730,O
of,3730,O
megakaryocytic-erythroid,3730,O
",",3730,O
myeloid,3730,O
",",3730,O
and,3730,O
lymphoid,3730,O
lineages,3730,O
.,3730,O
These,3731,O
data,3731,O
indicate,3731,O
that,3731,O
genotoxic,3731,O
stress-induced,3731,O
GADD45A,3731,B-GeneOrGeneProduct
expression,3731,O
in,3731,O
HSCs,3731,O
prevents,3731,O
their,3731,O
fatal,3731,O
transformation,3731,O
by,3731,O
directing,3731,O
them,3731,O
into,3731,O
differentiation,3731,O
and,3731,O
thereby,3731,O
clearing,3731,O
them,3731,O
from,3731,O
the,3731,O
system,3731,O
.,3731,O
NF-kB,3732,B-GeneOrGeneProduct
functions,3732,O
as,3732,O
a,3732,O
molecular,3732,O
link,3732,O
between,3732,O
tumor,3732,B-DiseaseOrPhenotypicFeature
cells,3732,O
and,3732,O
Th1/Tc1,3732,O
T,3732,O
cells,3732,O
in,3732,O
the,3732,O
tumor,3732,B-DiseaseOrPhenotypicFeature
microenvironment,3732,O
to,3732,O
exert,3732,O
radiation-mediated,3732,O
tumor,3732,B-DiseaseOrPhenotypicFeature
suppression,3732,O
.,3732,O
Radiation,3733,O
modulates,3733,O
both,3733,O
tumor,3733,B-DiseaseOrPhenotypicFeature
cells,3733,O
and,3733,O
immune,3733,O
cells,3733,O
in,3733,O
the,3733,O
tumor,3733,B-DiseaseOrPhenotypicFeature
microenvironment,3733,O
to,3733,O
exert,3733,O
its,3733,O
anti-tumor,3733,O
activity,3733,O
;,3733,O
however,3733,O
",",3733,O
the,3733,O
molecular,3733,O
connection,3733,O
between,3733,O
tumor,3733,B-DiseaseOrPhenotypicFeature
cells,3733,O
and,3733,O
immune,3733,O
cells,3733,O
that,3733,O
mediates,3733,O
radiation-exerted,3733,O
tumor,3733,B-DiseaseOrPhenotypicFeature
suppression,3733,O
activity,3733,O
in,3733,O
the,3733,O
tumor,3733,B-DiseaseOrPhenotypicFeature
microenvironment,3733,O
is,3733,O
largely,3733,O
unknown,3733,O
.,3733,O
We,3734,O
report,3734,O
here,3734,O
that,3734,O
radiation,3734,O
induces,3734,O
rapid,3734,O
activation,3734,O
of,3734,O
the,3734,O
p65/p50,3734,B-GeneOrGeneProduct
and,3734,O
p50/p50,3734,B-GeneOrGeneProduct
NF-kB,3734,B-GeneOrGeneProduct
complexes,3734,O
in,3734,O
human,3734,B-OrganismTaxon
soft,3734,B-DiseaseOrPhenotypicFeature
tissue,3734,I-DiseaseOrPhenotypicFeature
sarcoma,3734,I-DiseaseOrPhenotypicFeature
(,3734,O
STS,3734,B-DiseaseOrPhenotypicFeature
),3734,O
cells,3734,O
.,3734,O
Radiation-activated,3735,O
p65/p50,3735,B-GeneOrGeneProduct
and,3735,O
p50/p50,3735,B-GeneOrGeneProduct
bind,3735,O
to,3735,O
the,3735,O
TNFa,3735,B-GeneOrGeneProduct
promoter,3735,O
to,3735,O
activate,3735,O
its,3735,O
transcription,3735,O
in,3735,O
STS,3735,B-DiseaseOrPhenotypicFeature
cells,3735,O
.,3735,O
Radiation-induced,3736,O
TNFa,3736,B-GeneOrGeneProduct
induces,3736,O
tumor,3736,B-DiseaseOrPhenotypicFeature
cell,3736,O
death,3736,O
in,3736,O
an,3736,O
autocrine,3736,O
manner,3736,O
.,3736,O
A,3737,O
sublethal,3737,O
dose,3737,O
of,3737,O
Smac,3737,B-GeneOrGeneProduct
mimetic,3737,O
BV6,3737,B-ChemicalEntity
induces,3737,O
cIAP1,3737,B-GeneOrGeneProduct
and,3737,O
cIAP2,3737,B-GeneOrGeneProduct
degradation,3737,O
to,3737,O
increase,3737,O
tumor,3737,B-DiseaseOrPhenotypicFeature
cell,3737,O
sensitivity,3737,O
to,3737,O
radiation-induced,3737,O
cell,3737,O
death,3737,O
in,3737,O
vitro,3737,O
and,3737,O
to,3737,O
enhance,3737,O
radiation-mediated,3737,O
suppression,3737,O
of,3737,O
STS,3737,B-DiseaseOrPhenotypicFeature
xenografts,3737,O
in,3737,O
vivo,3737,O
.,3737,O
Inhibition,3738,O
of,3738,O
caspases,3738,B-GeneOrGeneProduct
",",3738,O
RIP1,3738,B-GeneOrGeneProduct
",",3738,O
or,3738,O
RIP3,3738,B-GeneOrGeneProduct
blocks,3738,O
radiation/TNFa-induced,3738,O
cell,3738,O
death,3738,O
",",3738,O
whereas,3738,O
inhibition,3738,O
of,3738,O
RIP1,3738,B-GeneOrGeneProduct
blocks,3738,O
TNFa-induced,3738,B-GeneOrGeneProduct
caspase,3738,B-GeneOrGeneProduct
activation,3738,O
",",3738,O
suggesting,3738,O
that,3738,O
caspases,3738,B-GeneOrGeneProduct
and,3738,O
RIP1,3738,B-GeneOrGeneProduct
act,3738,O
sequentially,3738,O
to,3738,O
mediate,3738,O
the,3738,O
non-compensatory,3738,O
cell,3738,O
death,3738,O
pathways,3738,O
.,3738,O
Furthermore,3739,O
",",3739,O
we,3739,O
determined,3739,O
in,3739,O
a,3739,O
syngeneic,3739,O
sarcoma,3739,B-DiseaseOrPhenotypicFeature
mouse,3739,B-OrganismTaxon
model,3739,O
that,3739,O
radiation,3739,O
up-regulates,3739,O
IRF3,3739,B-GeneOrGeneProduct
",",3739,O
IFNb,3739,B-GeneOrGeneProduct
",",3739,O
and,3739,O
the,3739,O
T,3739,O
cell,3739,O
chemokines,3739,B-GeneOrGeneProduct
CCL2,3739,B-GeneOrGeneProduct
and,3739,O
CCL5,3739,B-GeneOrGeneProduct
in,3739,O
the,3739,O
tumor,3739,B-DiseaseOrPhenotypicFeature
microenvironment,3739,O
",",3739,O
which,3739,O
are,3739,O
associated,3739,O
with,3739,O
activation,3739,O
and,3739,O
increased,3739,O
infiltration,3739,O
of,3739,O
Th1/Tc1,3739,O
T,3739,O
cells,3739,O
in,3739,O
the,3739,O
tumor,3739,B-DiseaseOrPhenotypicFeature
microenvironment,3739,O
.,3739,O
Moreover,3740,O
",",3740,O
tumor-infiltrating,3740,B-DiseaseOrPhenotypicFeature
T,3740,O
cells,3740,O
are,3740,O
in,3740,O
their,3740,O
active,3740,O
form,3740,O
since,3740,O
both,3740,O
the,3740,O
perforin,3740,B-GeneOrGeneProduct
and,3740,O
FasL,3740,B-GeneOrGeneProduct
pathways,3740,O
are,3740,O
activated,3740,O
in,3740,O
irradiated,3740,O
tumor,3740,B-DiseaseOrPhenotypicFeature
tissues,3740,O
.,3740,O
Consequently,3741,O
",",3741,O
combined,3741,O
BV6,3741,B-ChemicalEntity
and,3741,O
radiation,3741,O
completely,3741,O
suppressed,3741,O
tumor,3741,B-DiseaseOrPhenotypicFeature
growth,3741,O
in,3741,O
vivo,3741,O
.,3741,O
Therefore,3742,O
",",3742,O
radiation-induced,3742,O
NF-kB,3742,B-GeneOrGeneProduct
functions,3742,O
as,3742,O
a,3742,O
molecular,3742,O
link,3742,O
between,3742,O
tumor,3742,B-DiseaseOrPhenotypicFeature
cells,3742,O
and,3742,O
immune,3742,O
cells,3742,O
in,3742,O
the,3742,O
tumor,3742,B-DiseaseOrPhenotypicFeature
microenvironment,3742,O
for,3742,O
radiation-mediated,3742,O
tumor,3742,B-DiseaseOrPhenotypicFeature
suppression,3742,O
.,3742,O
NOTCH1,3743,B-GeneOrGeneProduct
and,3743,O
SOX10,3743,B-GeneOrGeneProduct
are,3743,O
Essential,3743,O
for,3743,O
Proliferation,3743,O
and,3743,O
Radiation,3743,O
Resistance,3743,O
of,3743,O
Cancer,3743,B-DiseaseOrPhenotypicFeature
Stem-Like,3743,O
Cells,3743,O
in,3743,O
Adenoid,3743,B-DiseaseOrPhenotypicFeature
Cystic,3743,I-DiseaseOrPhenotypicFeature
Carcinoma,3743,I-DiseaseOrPhenotypicFeature
.,3743,O
PURPOSE,3744,O
:,3744,O
Although,3744,O
the,3744,O
existence,3744,O
of,3744,O
cancer,3744,B-DiseaseOrPhenotypicFeature
stem,3744,O
cells,3744,O
(,3744,O
CSC,3744,O
),3744,O
in,3744,O
adenoid,3744,B-DiseaseOrPhenotypicFeature
cystic,3744,I-DiseaseOrPhenotypicFeature
carcinoma,3744,I-DiseaseOrPhenotypicFeature
(,3744,O
ACC,3744,B-DiseaseOrPhenotypicFeature
),3744,O
has,3744,O
been,3744,O
proposed,3744,O
",",3744,O
lack,3744,O
of,3744,O
assays,3744,O
for,3744,O
their,3744,O
propagation,3744,O
and,3744,O
uncertainty,3744,O
about,3744,O
molecular,3744,O
markers,3744,O
prevented,3744,O
their,3744,O
characterization,3744,O
.,3744,O
Our,3745,O
objective,3745,O
was,3745,O
to,3745,O
isolate,3745,O
CSC,3745,O
from,3745,O
ACC,3745,B-DiseaseOrPhenotypicFeature
and,3745,O
provide,3745,O
insight,3745,O
into,3745,O
signaling,3745,O
pathways,3745,O
that,3745,O
support,3745,O
their,3745,O
propagation,3745,O
.,3745,O
EXPERIMENTAL,3746,O
DESIGN,3746,O
:,3746,O
To,3746,O
isolate,3746,O
CSC,3746,O
from,3746,O
ACC,3746,B-DiseaseOrPhenotypicFeature
and,3746,O
characterize,3746,O
them,3746,O
",",3746,O
we,3746,O
used,3746,O
ROCK,3746,B-GeneOrGeneProduct
inhibitor-supplemented,3746,O
cell,3746,O
culture,3746,O
",",3746,O
immunomagnetic,3746,O
cell,3746,O
sorting,3746,O
",",3746,O
andin,3746,O
vitro/in,3746,O
vivoassays,3746,O
for,3746,O
CSC,3746,O
viability,3746,O
and,3746,O
tumorigenicity,3746,O
.,3746,O
RESULTS,3747,O
:,3747,O
We,3747,O
identified,3747,O
in,3747,O
ACC,3747,B-DiseaseOrPhenotypicFeature
CD133-positive,3747,B-GeneOrGeneProduct
CSC,3747,O
that,3747,O
expressed,3747,O
NOTCH1,3747,B-GeneOrGeneProduct
and,3747,O
SOX10,3747,B-GeneOrGeneProduct
",",3747,O
formed,3747,O
spheroids,3747,O
",",3747,O
and,3747,O
initiated,3747,O
tumors,3747,B-DiseaseOrPhenotypicFeature
in,3747,O
nude,3747,O
mice,3747,B-OrganismTaxon
.,3747,O
CD133,3748,B-GeneOrGeneProduct
(,3748,O
+,3748,O
),3748,O
ACC,3748,B-DiseaseOrPhenotypicFeature
cells,3748,O
produced,3748,O
activated,3748,O
NOTCH1,3748,B-GeneOrGeneProduct
(,3748,O
N1ICD,3748,B-GeneOrGeneProduct
),3748,O
and,3748,O
generated,3748,O
CD133,3748,B-GeneOrGeneProduct
(,3748,O
-,3748,O
),3748,O
cells,3748,O
that,3748,O
expressed,3748,O
JAG1,3748,B-GeneOrGeneProduct
as,3748,O
well,3748,O
as,3748,O
neural,3748,O
differentiation,3748,O
factors,3748,O
NR2F1,3748,B-GeneOrGeneProduct
",",3748,O
NR2F2,3748,B-GeneOrGeneProduct
",",3748,O
and,3748,O
p27Kip1,3748,B-GeneOrGeneProduct
.,3748,O
Knockdowns,3749,O
of,3749,O
NOTCH1,3749,B-GeneOrGeneProduct
",",3749,O
SOX10,3749,B-GeneOrGeneProduct
",",3749,O
and,3749,O
their,3749,O
common,3749,O
effector,3749,O
FABP7,3749,B-GeneOrGeneProduct
had,3749,O
negative,3749,O
effects,3749,O
on,3749,O
each,3749,O
other,3749,O
",",3749,O
inhibited,3749,O
spheroidogenesis,3749,O
",",3749,O
and,3749,O
induced,3749,O
cell,3749,O
death,3749,O
pointing,3749,O
at,3749,O
their,3749,O
essential,3749,O
roles,3749,O
in,3749,O
CSC,3749,O
maintenance,3749,O
.,3749,O
Downstream,3750,O
effects,3750,O
of,3750,O
FABP7,3750,B-GeneOrGeneProduct
knockdown,3750,O
included,3750,O
suppression,3750,O
of,3750,O
a,3750,O
broad,3750,O
spectrum,3750,O
of,3750,O
genes,3750,O
involved,3750,O
in,3750,O
proliferation,3750,O
",",3750,O
ribosome,3750,O
biogenesis,3750,O
",",3750,O
and,3750,O
metabolism,3750,O
.,3750,O
Among,3751,O
proliferation-linked,3751,O
NOTCH1/FABP7,3751,B-GeneOrGeneProduct
targets,3751,O
",",3751,O
we,3751,O
identified,3751,O
SKP2,3751,B-GeneOrGeneProduct
and,3751,O
its,3751,O
substrate,3751,O
p27Kip1,3751,B-GeneOrGeneProduct
.,3751,O
A,3752,O
g-secretase,3752,B-GeneOrGeneProduct
inhibitor,3752,O
",",3752,O
DAPT,3752,B-ChemicalEntity
",",3752,O
selectively,3752,O
depleted,3752,O
CD133,3752,B-GeneOrGeneProduct
(,3752,O
+,3752,O
),3752,O
cells,3752,O
",",3752,O
suppressed,3752,O
N1ICD,3752,B-GeneOrGeneProduct
and,3752,O
SKP2,3752,B-GeneOrGeneProduct
",",3752,O
induced,3752,O
p27Kip1,3752,B-GeneOrGeneProduct
",",3752,O
inhibited,3752,O
ACC,3752,B-DiseaseOrPhenotypicFeature
growthin,3752,O
vivo,3752,O
",",3752,O
and,3752,O
sensitized,3752,O
CD133,3752,B-GeneOrGeneProduct
(,3752,O
+,3752,O
),3752,O
cells,3752,O
to,3752,O
radiation,3752,O
.,3752,O
CONCLUSIONS,3753,O
:,3753,O
These,3753,O
results,3753,O
establish,3753,O
in,3753,O
the,3753,O
majority,3753,O
of,3753,O
ACC,3753,B-DiseaseOrPhenotypicFeature
the,3753,O
presence,3753,O
of,3753,O
a,3753,O
previously,3753,O
uncharacterized,3753,O
population,3753,O
of,3753,O
CD133,3753,B-GeneOrGeneProduct
(,3753,O
+,3753,O
),3753,O
cells,3753,O
with,3753,O
neural,3753,O
stem,3753,O
properties,3753,O
",",3753,O
which,3753,O
are,3753,O
driven,3753,O
by,3753,O
SOX10,3753,B-GeneOrGeneProduct
",",3753,O
NOTCH1,3753,B-GeneOrGeneProduct
",",3753,O
and,3753,O
FABP7,3753,B-GeneOrGeneProduct
.,3753,O
Sensitivity,3754,O
of,3754,O
these,3754,O
cells,3754,O
to,3754,O
Notch,3754,B-GeneOrGeneProduct
inhibition,3754,O
and,3754,O
their,3754,O
dependence,3754,O
on,3754,O
SKP2,3754,B-GeneOrGeneProduct
offer,3754,O
new,3754,O
opportunities,3754,O
for,3754,O
targeted,3754,O
ACC,3754,B-DiseaseOrPhenotypicFeature
therapies,3754,O
.,3754,O
Metabolic,3755,O
Symbiosis,3755,O
Enables,3755,O
Adaptive,3755,O
Resistance,3755,O
to,3755,O
Anti-angiogenic,3755,O
Therapy,3755,O
that,3755,O
Is,3755,O
Dependent,3755,O
on,3755,O
mTOR,3755,B-GeneOrGeneProduct
Signaling,3755,O
.,3755,O
Therapeutic,3756,O
targeting,3756,O
of,3756,O
tumor,3756,B-DiseaseOrPhenotypicFeature
angiogenesis,3756,O
with,3756,O
VEGF,3756,B-GeneOrGeneProduct
inhibitors,3756,O
results,3756,O
in,3756,O
demonstrable,3756,O
",",3756,O
but,3756,O
transitory,3756,O
efficacy,3756,O
in,3756,O
certain,3756,O
human,3756,B-OrganismTaxon
tumors,3756,B-DiseaseOrPhenotypicFeature
and,3756,O
mouse,3756,B-OrganismTaxon
models,3756,O
of,3756,O
cancer,3756,B-DiseaseOrPhenotypicFeature
",",3756,O
limited,3756,O
by,3756,O
unconventional,3756,O
forms,3756,O
of,3756,O
adaptive/evasive,3756,O
resistance,3756,O
.,3756,O
In,3757,O
one,3757,O
such,3757,O
mouse,3757,B-OrganismTaxon
model,3757,O
",",3757,O
potent,3757,O
angiogenesis,3757,O
inhibitors,3757,O
elicit,3757,O
compartmental,3757,O
reorganization,3757,O
of,3757,O
cancer,3757,B-DiseaseOrPhenotypicFeature
cells,3757,O
around,3757,O
remaining,3757,O
blood,3757,O
vessels,3757,O
.,3757,O
The,3758,O
glucose,3758,O
and,3758,O
lactate,3758,O
transporters,3758,O
GLUT1,3758,B-GeneOrGeneProduct
and,3758,O
MCT4,3758,B-GeneOrGeneProduct
are,3758,O
induced,3758,O
in,3758,O
distal,3758,O
hypoxic,3758,B-DiseaseOrPhenotypicFeature
cells,3758,O
in,3758,O
a,3758,O
HIF1a-dependent,3758,B-GeneOrGeneProduct
fashion,3758,O
",",3758,O
indicative,3758,O
of,3758,O
glycolysis,3758,O
.,3758,O
Tumor,3759,B-DiseaseOrPhenotypicFeature
cells,3759,O
proximal,3759,O
to,3759,O
blood,3759,O
vessels,3759,O
instead,3759,O
express,3759,O
the,3759,O
lactate,3759,O
transporter,3759,O
MCT1,3759,B-GeneOrGeneProduct
",",3759,O
and,3759,O
p-S6,3759,B-GeneOrGeneProduct
",",3759,O
the,3759,O
latter,3759,O
reflecting,3759,O
mTOR,3759,B-GeneOrGeneProduct
signaling,3759,O
.,3759,O
Normoxic,3760,B-DiseaseOrPhenotypicFeature
cancer,3760,I-DiseaseOrPhenotypicFeature
cells,3760,O
import,3760,O
and,3760,O
metabolize,3760,O
lactate,3760,B-ChemicalEntity
",",3760,O
resulting,3760,O
in,3760,O
upregulation,3760,O
of,3760,O
mTOR,3760,B-GeneOrGeneProduct
signaling,3760,O
via,3760,O
glutamine,3760,B-ChemicalEntity
metabolism,3760,O
enhanced,3760,O
by,3760,O
lactate,3760,B-ChemicalEntity
catabolism,3760,O
.,3760,O
Thus,3761,O
",",3761,O
metabolic,3761,O
symbiosis,3761,O
is,3761,O
established,3761,O
in,3761,O
the,3761,O
face,3761,O
of,3761,O
angiogenesis,3761,O
inhibition,3761,O
",",3761,O
whereby,3761,O
hypoxic,3761,O
cancer,3761,B-DiseaseOrPhenotypicFeature
cells,3761,O
import,3761,O
glucose,3761,B-ChemicalEntity
and,3761,O
export,3761,O
lactate,3761,B-ChemicalEntity
",",3761,O
while,3761,O
normoxic,3761,O
cells,3761,O
import,3761,O
and,3761,O
catabolize,3761,O
lactate,3761,B-ChemicalEntity
.,3761,O
mTOR,3762,B-GeneOrGeneProduct
signaling,3762,O
inhibition,3762,O
disrupts,3762,O
this,3762,O
metabolic,3762,O
symbiosis,3762,O
",",3762,O
associated,3762,O
with,3762,O
upregulation,3762,O
of,3762,O
the,3762,O
glucose,3762,O
transporter,3762,O
GLUT2,3762,B-GeneOrGeneProduct
.,3762,O
Cisplatin,3763,B-ChemicalEntity
induces,3763,O
tolerogenic,3763,O
dendritic,3763,O
cells,3763,O
in,3763,O
response,3763,O
to,3763,O
TLR,3763,B-GeneOrGeneProduct
agonists,3763,O
via,3763,O
the,3763,O
abundant,3763,O
production,3763,O
of,3763,O
IL-10,3763,B-GeneOrGeneProduct
",",3763,O
thereby,3763,O
promoting,3763,O
Th2-,3763,O
and,3763,O
Tr1-biased,3763,O
T-cell,3763,O
immunity,3763,O
.,3763,O
Although,3764,O
many,3764,O
advantageous,3764,O
roles,3764,O
of,3764,O
cisplatin,3764,B-ChemicalEntity
(,3764,O
cis-diamminedichloroplatinum,3764,B-ChemicalEntity
(,3764,O
II,3764,O
),3764,O
",",3764,O
CDDP,3764,B-ChemicalEntity
),3764,O
have,3764,O
been,3764,O
reported,3764,O
in,3764,O
cancer,3764,B-DiseaseOrPhenotypicFeature
therapy,3764,O
",",3764,O
the,3764,O
immunomodulatory,3764,O
roles,3764,O
of,3764,O
cisplatin,3764,B-ChemicalEntity
in,3764,O
the,3764,O
phenotypic,3764,O
and,3764,O
functional,3764,O
alterations,3764,O
of,3764,O
dendritic,3764,O
cells,3764,O
(,3764,O
DCs,3764,O
),3764,O
are,3764,O
poorly,3764,O
understood,3764,O
.,3764,O
Here,3765,O
",",3765,O
we,3765,O
investigated,3765,O
the,3765,O
effect,3765,O
of,3765,O
cisplatin,3765,B-ChemicalEntity
on,3765,O
the,3765,O
functionality,3765,O
of,3765,O
DCs,3765,O
and,3765,O
the,3765,O
changes,3765,O
in,3765,O
signaling,3765,O
pathways,3765,O
activated,3765,O
upon,3765,O
toll-like,3765,B-GeneOrGeneProduct
receptor,3765,I-GeneOrGeneProduct
(,3765,O
TLR,3765,B-GeneOrGeneProduct
),3765,O
stimulation,3765,O
.,3765,O
Cisplatin-treated,3766,B-ChemicalEntity
DCs,3766,O
down-regulated,3766,O
the,3766,O
expression,3766,O
of,3766,O
cell,3766,O
surface,3766,O
molecules,3766,O
(,3766,O
CD80,3766,B-GeneOrGeneProduct
",",3766,O
CD86,3766,B-GeneOrGeneProduct
",",3766,O
MHC,3766,B-GeneOrGeneProduct
class,3766,I-GeneOrGeneProduct
I,3766,I-GeneOrGeneProduct
and,3766,I-GeneOrGeneProduct
II,3766,I-GeneOrGeneProduct
),3766,O
and,3766,O
up-regulated,3766,O
endocytic,3766,O
capacity,3766,O
in,3766,O
a,3766,O
dose-dependent,3766,O
manner,3766,O
.,3766,O
Upon,3767,O
stimulation,3767,O
with,3767,O
various,3767,O
TLR,3767,B-GeneOrGeneProduct
agonists,3767,O
",",3767,O
cisplatin-treated,3767,B-ChemicalEntity
DCs,3767,O
showed,3767,O
markedly,3767,O
increased,3767,O
IL-10,3767,B-GeneOrGeneProduct
production,3767,O
through,3767,O
activation,3767,O
of,3767,O
the,3767,O
p38,3767,B-GeneOrGeneProduct
MAPK,3767,I-GeneOrGeneProduct
and,3767,O
NF-kappaB,3767,B-GeneOrGeneProduct
signaling,3767,O
pathways,3767,O
without,3767,O
altering,3767,O
the,3767,O
levels,3767,O
of,3767,O
TNF-alpha,3767,B-GeneOrGeneProduct
and,3767,O
IL-12p70,3767,B-GeneOrGeneProduct
",",3767,O
indicating,3767,O
the,3767,O
cisplatin-mediated,3767,B-ChemicalEntity
induction,3767,O
of,3767,O
tolerogenic,3767,O
DCs,3767,O
.,3767,O
This,3768,O
effect,3768,O
was,3768,O
dependent,3768,O
on,3768,O
the,3768,O
production,3768,O
of,3768,O
IL-10,3768,B-GeneOrGeneProduct
from,3768,O
DCs,3768,O
",",3768,O
as,3768,O
neither,3768,O
DCs,3768,O
isolated,3768,O
from,3768,O
IL-10-/-,3768,B-GeneOrGeneProduct
mice,3768,B-OrganismTaxon
nor,3768,O
IL-10-neutralized,3768,B-GeneOrGeneProduct
DCs,3768,O
generated,3768,O
tolerogenic,3768,O
DCs,3768,O
.,3768,O
Interestingly,3769,O
",",3769,O
DCs,3769,O
that,3769,O
were,3769,O
co-treated,3769,O
with,3769,O
cisplatin,3769,B-ChemicalEntity
and,3769,O
lipopolysaccharide,3769,B-ChemicalEntity
(,3769,O
LPS,3769,B-ChemicalEntity
),3769,O
exhibited,3769,O
a,3769,O
decreased,3769,O
immunostimulatory,3769,O
capacity,3769,O
for,3769,O
inducing,3769,O
the,3769,O
proliferation,3769,O
of,3769,O
Th1-,3769,O
and,3769,O
Th17-type,3769,O
T,3769,O
cells,3769,O
;,3769,O
instead,3769,O
",",3769,O
these,3769,O
DCs,3769,O
contributed,3769,O
to,3769,O
Th2-type,3769,O
T,3769,O
cell,3769,O
immunity,3769,O
.,3769,O
Furthermore,3770,O
",",3770,O
in,3770,O
vitro,3770,O
and,3770,O
in,3770,O
vivo,3770,O
investigations,3770,O
revealed,3770,O
a,3770,O
unique,3770,O
T,3770,O
cell,3770,O
population,3770,O
",",3770,O
IL-10-producing,3770,B-GeneOrGeneProduct
CD3+CD4+LAG-3+CD49b+CD25-Foxp3-,3770,B-GeneOrGeneProduct
Tr1,3770,O
cells,3770,O
",",3770,O
that,3770,O
was,3770,O
significantly,3770,O
increased,3770,O
without,3770,O
altering,3770,O
the,3770,O
Foxp3+,3770,B-GeneOrGeneProduct
regulatory,3770,O
T,3770,O
cell,3770,O
population,3770,O
.,3770,O
Taken,3771,O
together,3771,O
",",3771,O
our,3771,O
results,3771,O
suggest,3771,O
that,3771,O
cisplatin,3771,B-ChemicalEntity
induces,3771,O
immune-suppressive,3771,O
tolerogenic,3771,O
DCs,3771,O
in,3771,O
TLR,3771,B-ChemicalEntity
agonist-induced,3771,O
inflammatory,3771,B-DiseaseOrPhenotypicFeature
conditions,3771,O
via,3771,O
abundant,3771,O
IL-10,3771,B-GeneOrGeneProduct
production,3771,O
",",3771,O
thereby,3771,O
skewing,3771,O
Th,3771,O
cell,3771,O
differentiation,3771,O
towards,3771,O
Th2,3771,O
and,3771,O
Tr1,3771,O
cells,3771,O
.,3771,O
This,3772,O
relationship,3772,O
may,3772,O
provide,3772,O
cancer,3772,B-DiseaseOrPhenotypicFeature
cells,3772,O
with,3772,O
an,3772,O
opportunity,3772,O
to,3772,O
evade,3772,O
the,3772,O
immune,3772,O
system,3772,O
.,3772,O
Metallothionein-1,3773,B-GeneOrGeneProduct
as,3773,O
a,3773,O
biomarker,3773,O
of,3773,O
altered,3773,O
redox,3773,O
metabolism,3773,O
in,3773,O
hepatocellular,3773,B-DiseaseOrPhenotypicFeature
carcinoma,3773,I-DiseaseOrPhenotypicFeature
cells,3773,O
exposed,3773,O
to,3773,O
sorafenib,3773,B-ChemicalEntity
.,3773,O
BACKGROUND,3774,O
:,3774,O
Sorafenib,3774,B-ChemicalEntity
",",3774,O
a,3774,O
kinase,3774,O
inhibitor,3774,O
active,3774,O
against,3774,O
various,3774,O
solid,3774,O
tumours,3774,B-DiseaseOrPhenotypicFeature
",",3774,O
induces,3774,O
oxidative,3774,O
stress,3774,O
and,3774,O
ferroptosis,3774,O
",",3774,O
a,3774,O
new,3774,O
form,3774,O
of,3774,O
oxidative,3774,O
necrosis,3774,B-DiseaseOrPhenotypicFeature
",",3774,O
in,3774,O
some,3774,O
cancer,3774,B-DiseaseOrPhenotypicFeature
cells,3774,O
.,3774,O
Clinically-applicable,3775,O
biomarkers,3775,O
that,3775,O
reflect,3775,O
the,3775,O
impact,3775,O
of,3775,O
sorafenib,3775,B-ChemicalEntity
on,3775,O
the,3775,O
redox,3775,O
metabolism,3775,O
of,3775,O
cancer,3775,B-DiseaseOrPhenotypicFeature
cells,3775,O
are,3775,O
lacking,3775,O
.,3775,O
METHODS,3776,O
:,3776,O
We,3776,O
used,3776,O
gene,3776,O
expression,3776,O
microarrays,3776,O
",",3776,O
real-time,3776,O
PCR,3776,O
",",3776,O
immunoblot,3776,O
",",3776,O
protein-specific,3776,O
ELISA,3776,O
",",3776,O
and,3776,O
gene,3776,O
reporter,3776,O
constructs,3776,O
encoding,3776,O
the,3776,O
enzyme,3776,O
luciferase,3776,O
to,3776,O
study,3776,O
the,3776,O
response,3776,O
of,3776,O
a,3776,O
panel,3776,O
of,3776,O
cancer,3776,B-DiseaseOrPhenotypicFeature
cells,3776,O
to,3776,O
sorafenib,3776,B-ChemicalEntity
.,3776,O
Tumour,3777,B-DiseaseOrPhenotypicFeature
explants,3777,O
prepared,3777,O
from,3777,O
surgical,3777,O
hepatocellular,3777,B-DiseaseOrPhenotypicFeature
carcinoma,3777,I-DiseaseOrPhenotypicFeature
(,3777,O
HCC,3777,B-DiseaseOrPhenotypicFeature
),3777,O
samples,3777,O
and,3777,O
serum,3777,O
samples,3777,O
obtained,3777,O
from,3777,O
HCC,3777,B-DiseaseOrPhenotypicFeature
patients,3777,B-OrganismTaxon
receiving,3777,O
sorafenib,3777,B-ChemicalEntity
were,3777,O
also,3777,O
used,3777,O
.,3777,O
RESULTS,3778,O
:,3778,O
We,3778,O
observed,3778,O
that,3778,O
genes,3778,O
of,3778,O
the,3778,O
metallothionein-1,3778,B-GeneOrGeneProduct
(,3778,O
MT1,3778,B-GeneOrGeneProduct
),3778,O
family,3778,O
are,3778,O
induced,3778,O
in,3778,O
the,3778,O
HCC,3778,B-DiseaseOrPhenotypicFeature
cell,3778,O
line,3778,O
Huh7,3778,B-CellLine
exposed,3778,O
to,3778,O
sorafenib,3778,B-ChemicalEntity
.,3778,O
Sorafenib,3779,B-ChemicalEntity
increased,3779,O
the,3779,O
expression,3779,O
of,3779,O
MT1G,3779,B-GeneOrGeneProduct
mRNA,3779,O
in,3779,O
a,3779,O
panel,3779,O
of,3779,O
human,3779,B-OrganismTaxon
cancer,3779,B-DiseaseOrPhenotypicFeature
cells,3779,O
",",3779,O
an,3779,O
effect,3779,O
that,3779,O
was,3779,O
not,3779,O
observed,3779,O
with,3779,O
eight,3779,O
other,3779,O
clinically-approved,3779,O
kinase,3779,O
inhibitors,3779,O
.,3779,O
We,3780,O
identified,3780,O
the,3780,O
minimal,3780,O
region,3780,O
of,3780,O
the,3780,O
MT1G,3780,B-GeneOrGeneProduct
promoter,3780,O
that,3780,O
confers,3780,O
inducibility,3780,O
by,3780,O
sorafenib,3780,B-ChemicalEntity
to,3780,O
a,3780,O
133,3780,O
base,3780,O
pair,3780,O
region,3780,O
containing,3780,O
an,3780,O
Anti-oxidant,3780,O
Response,3780,O
Element,3780,O
(,3780,O
ARE,3780,O
),3780,O
and,3780,O
showed,3780,O
the,3780,O
essential,3780,O
role,3780,O
of,3780,O
the,3780,O
transcription,3780,O
factor,3780,O
NRF2,3780,B-GeneOrGeneProduct
(,3780,O
Nuclear,3780,B-GeneOrGeneProduct
factor,3780,I-GeneOrGeneProduct
erythroid,3780,I-GeneOrGeneProduct
2-Related,3780,I-GeneOrGeneProduct
Factor,3780,I-GeneOrGeneProduct
2,3780,I-GeneOrGeneProduct
),3780,O
.,3780,O
We,3781,O
examined,3781,O
the,3781,O
clinical,3781,O
relevance,3781,O
of,3781,O
our,3781,O
findings,3781,O
by,3781,O
analysing,3781,O
the,3781,O
regulation,3781,O
of,3781,O
MT1G,3781,B-GeneOrGeneProduct
in,3781,O
five,3781,O
tumour,3781,B-DiseaseOrPhenotypicFeature
explants,3781,O
prepared,3781,O
from,3781,O
surgical,3781,O
HCC,3781,B-DiseaseOrPhenotypicFeature
samples,3781,O
.,3781,O
Finally,3782,O
",",3782,O
we,3782,O
showed,3782,O
that,3782,O
the,3782,O
protein,3782,O
levels,3782,O
of,3782,O
MT1,3782,B-GeneOrGeneProduct
increase,3782,O
in,3782,O
the,3782,O
serum,3782,O
of,3782,O
some,3782,O
HCC,3782,B-DiseaseOrPhenotypicFeature
patients,3782,B-OrganismTaxon
receiving,3782,O
sorafenib,3782,B-ChemicalEntity
",",3782,O
and,3782,O
found,3782,O
an,3782,O
association,3782,O
with,3782,O
reduced,3782,O
overall,3782,O
survival,3782,O
.,3782,O
CONCLUSION,3783,O
:,3783,O
These,3783,O
findings,3783,O
indicate,3783,O
that,3783,O
MT1,3783,B-GeneOrGeneProduct
constitute,3783,O
a,3783,O
biomarker,3783,O
adapted,3783,O
for,3783,O
exploring,3783,O
the,3783,O
impact,3783,O
of,3783,O
sorafenib,3783,B-ChemicalEntity
on,3783,O
the,3783,O
redox,3783,O
metabolism,3783,O
of,3783,O
cancer,3783,B-DiseaseOrPhenotypicFeature
cells,3783,O
.,3783,O
Hsp90beta,3784,B-GeneOrGeneProduct
is,3784,O
involved,3784,O
in,3784,O
the,3784,O
development,3784,O
of,3784,O
high,3784,O
salt-diet-induced,3784,B-ChemicalEntity
nephropathy,3784,B-DiseaseOrPhenotypicFeature
via,3784,O
interaction,3784,O
with,3784,O
various,3784,O
signalling,3784,O
proteins,3784,O
.,3784,O
A,3785,O
high-salt,3785,O
diet,3785,O
often,3785,O
leads,3785,O
to,3785,O
a,3785,O
local,3785,O
intrarenal,3785,O
increase,3785,O
in,3785,O
renal,3785,B-DiseaseOrPhenotypicFeature
hypoxia,3785,I-DiseaseOrPhenotypicFeature
and,3785,O
oxidative,3785,O
stress,3785,O
",",3785,O
which,3785,O
are,3785,O
responsible,3785,O
for,3785,O
an,3785,O
excess,3785,O
production,3785,O
of,3785,O
pathogenic,3785,O
substances,3785,O
.,3785,O
Here,3786,O
",",3786,O
Wistar,3786,O
Kyoto/spontaneous,3786,O
hypertensive,3786,B-DiseaseOrPhenotypicFeature
(,3786,O
WKY/SHR,3786,O
),3786,O
rats,3786,B-OrganismTaxon
fed,3786,O
a,3786,O
high-salt,3786,O
diet,3786,O
developed,3786,O
severe,3786,O
proteinuria,3786,B-DiseaseOrPhenotypicFeature
",",3786,O
resulting,3786,O
from,3786,O
pronounced,3786,O
renal,3786,B-DiseaseOrPhenotypicFeature
inflammation,3786,I-DiseaseOrPhenotypicFeature
",",3786,O
fibrosis,3786,B-DiseaseOrPhenotypicFeature
and,3786,O
tubular,3786,O
epithelial,3786,O
cell,3786,O
apoptosis,3786,O
.,3786,O
All,3787,O
these,3787,O
were,3787,O
mainly,3787,O
non-pressure-related,3787,O
effects,3787,O
.,3787,O
Hsp90beta,3788,B-GeneOrGeneProduct
",",3788,O
TGF-beta,3788,B-GeneOrGeneProduct
",",3788,I-GeneOrGeneProduct
HIF-1alpha,3788,B-GeneOrGeneProduct
",",3788,O
TNF-alpha,3788,B-GeneOrGeneProduct
",",3788,O
IL-6,3788,B-GeneOrGeneProduct
and,3788,O
MCP-1,3788,B-GeneOrGeneProduct
were,3788,O
shown,3788,O
to,3788,O
be,3788,O
highly,3788,O
expressed,3788,O
in,3788,O
response,3788,O
to,3788,O
salt,3788,B-ChemicalEntity
loading,3788,O
.,3788,O
Next,3789,O
",",3789,O
we,3789,O
found,3789,O
that,3789,O
Hsp90beta,3789,B-GeneOrGeneProduct
might,3789,O
play,3789,O
the,3789,O
key,3789,O
role,3789,O
in,3789,O
non-pressure-related,3789,O
effects,3789,O
of,3789,O
salt,3789,B-ChemicalEntity
loading,3789,O
through,3789,O
a,3789,O
series,3789,O
of,3789,O
cellular,3789,O
signalling,3789,O
events,3789,O
",",3789,O
including,3789,O
the,3789,O
NF-kappaB,3789,B-GeneOrGeneProduct
",",3789,O
p38,3789,B-GeneOrGeneProduct
activation,3789,O
and,3789,O
Bcl-2,3789,B-GeneOrGeneProduct
inactivation,3789,O
.,3789,O
Hsp90beta,3790,B-GeneOrGeneProduct
was,3790,O
previously,3790,O
proven,3790,O
to,3790,O
regulate,3790,O
the,3790,O
upstream,3790,O
mediators,3790,O
in,3790,O
multiple,3790,O
cellular,3790,O
signalling,3790,O
cascades,3790,O
through,3790,O
stabilizing,3790,O
and,3790,O
maintaining,3790,O
their,3790,O
activities,3790,O
.,3790,O
In,3791,O
our,3791,O
study,3791,O
",",3791,O
17-dimethylaminoethylamino-17-demethoxygeldanamycin,3791,B-ChemicalEntity
(,3791,O
17-DMAG,3791,B-ChemicalEntity
),3791,O
or,3791,O
Hsp90beta,3791,B-GeneOrGeneProduct
knockdown,3791,O
dramatically,3791,O
alleviated,3791,O
the,3791,O
high-salt-diet-induced,3791,O
proteinuria,3791,B-DiseaseOrPhenotypicFeature
and,3791,O
renal,3791,B-DiseaseOrPhenotypicFeature
damage,3791,I-DiseaseOrPhenotypicFeature
without,3791,O
altering,3791,O
blood,3791,O
pressure,3791,O
significantly,3791,O
",",3791,O
when,3791,O
it,3791,O
reversed,3791,O
activations,3791,O
of,3791,O
NF-kappaB,3791,B-GeneOrGeneProduct
",",3791,O
mTOR,3791,B-GeneOrGeneProduct
and,3791,O
p38,3791,B-GeneOrGeneProduct
signalling,3791,O
cascades,3791,O
.,3791,O
Meanwhile,3792,O
",",3792,O
Co-IP,3792,O
results,3792,O
demonstrated,3792,O
that,3792,O
Hsp90beta,3792,B-GeneOrGeneProduct
could,3792,O
interact,3792,O
with,3792,O
and,3792,O
stabilize,3792,O
TAK1,3792,B-GeneOrGeneProduct
",",3792,O
AMPKalpha,3792,B-GeneOrGeneProduct
",",3792,O
IKKalpha/beta,3792,B-GeneOrGeneProduct
",",3792,O
HIF-1alpha,3792,B-GeneOrGeneProduct
and,3792,O
Raptor,3792,B-GeneOrGeneProduct
",",3792,O
whereas,3792,O
Hsp90beta,3792,B-GeneOrGeneProduct
inhibition,3792,O
disrupted,3792,O
this,3792,O
process,3792,O
.,3792,O
In,3793,O
addition,3793,O
",",3793,O
Hsp90beta,3793,B-GeneOrGeneProduct
inhibition-mediated,3793,O
renal,3793,O
improvements,3793,O
also,3793,O
accompanied,3793,O
the,3793,O
reduction,3793,O
of,3793,O
renal,3793,O
oxidative,3793,O
stress,3793,O
.,3793,O
In,3794,O
conclusion,3794,O
",",3794,O
salt,3794,B-ChemicalEntity
loading,3794,O
indeed,3794,O
exhibited,3794,O
non-pressure-related,3794,O
impacts,3794,O
on,3794,O
proteinuria,3794,B-DiseaseOrPhenotypicFeature
and,3794,O
renal,3794,B-DiseaseOrPhenotypicFeature
dysfunction,3794,I-DiseaseOrPhenotypicFeature
in,3794,O
WKY/SHR,3794,O
rats,3794,B-OrganismTaxon
.,3794,O
Hsp90beta,3795,B-GeneOrGeneProduct
inhibition,3795,O
caused,3795,O
the,3795,O
destabilization,3795,O
of,3795,O
upstream,3795,O
mediators,3795,O
in,3795,O
various,3795,O
pathogenic,3795,O
signalling,3795,O
events,3795,O
",",3795,O
thereby,3795,O
effectively,3795,O
ameliorating,3795,O
this,3795,O
nephropathy,3795,B-DiseaseOrPhenotypicFeature
owing,3795,O
to,3795,O
renal,3795,B-DiseaseOrPhenotypicFeature
hypoxia,3795,I-DiseaseOrPhenotypicFeature
and,3795,O
oxidative,3795,O
stress,3795,O
.,3795,O
Negative,3796,O
Selection,3796,O
and,3796,O
Chromosome,3796,B-DiseaseOrPhenotypicFeature
Instability,3796,I-DiseaseOrPhenotypicFeature
Induced,3796,O
by,3796,O
Mad2,3796,B-GeneOrGeneProduct
Overexpression,3796,O
Delay,3796,O
Breast,3796,B-DiseaseOrPhenotypicFeature
Cancer,3796,I-DiseaseOrPhenotypicFeature
but,3796,O
Facilitate,3796,O
Oncogene-Independent,3796,O
Outgrowth,3796,O
.,3796,O
Chromosome,3797,B-DiseaseOrPhenotypicFeature
instability,3797,I-DiseaseOrPhenotypicFeature
(,3797,O
CIN,3797,B-DiseaseOrPhenotypicFeature
),3797,O
is,3797,O
associated,3797,O
with,3797,O
poor,3797,O
survival,3797,O
and,3797,O
therapeutic,3797,O
outcome,3797,O
in,3797,O
a,3797,O
number,3797,O
of,3797,O
malignancies,3797,B-DiseaseOrPhenotypicFeature
.,3797,O
Despite,3798,O
this,3798,O
correlation,3798,O
",",3798,O
CIN,3798,B-DiseaseOrPhenotypicFeature
can,3798,O
also,3798,O
lead,3798,O
to,3798,O
growth,3798,O
disadvantages,3798,O
.,3798,O
Here,3799,O
",",3799,O
we,3799,O
show,3799,O
that,3799,O
simultaneous,3799,O
overexpression,3799,O
of,3799,O
the,3799,O
mitotic,3799,O
checkpoint,3799,O
protein,3799,O
Mad2,3799,B-GeneOrGeneProduct
with,3799,O
Kras,3799,B-GeneOrGeneProduct
(,3799,O
G12D,3799,B-GeneOrGeneProduct
),3799,O
or,3799,O
Her2,3799,B-GeneOrGeneProduct
in,3799,O
mammary,3799,O
glands,3799,O
of,3799,O
adult,3799,O
mice,3799,B-OrganismTaxon
results,3799,O
in,3799,O
mitotic,3799,O
checkpoint,3799,O
overactivation,3799,O
and,3799,O
a,3799,O
delay,3799,O
in,3799,O
tumor,3799,B-DiseaseOrPhenotypicFeature
onset,3799,O
.,3799,O
Time-lapse,3800,O
imaging,3800,O
of,3800,O
organotypic,3800,O
cultures,3800,O
and,3800,O
pathologic,3800,O
analysis,3800,O
prior,3800,O
to,3800,O
tumor,3800,B-DiseaseOrPhenotypicFeature
establishment,3800,O
reveals,3800,O
error-prone,3800,O
mitosis,3800,O
",",3800,O
mitotic,3800,O
arrest,3800,O
",",3800,O
and,3800,O
cell,3800,O
death,3800,O
.,3800,O
Nonetheless,3801,O
",",3801,O
Mad2,3801,B-GeneOrGeneProduct
expression,3801,O
persists,3801,O
and,3801,O
increases,3801,O
karyotype,3801,O
complexity,3801,O
in,3801,O
Kras,3801,B-GeneOrGeneProduct
tumors,3801,B-DiseaseOrPhenotypicFeature
.,3801,O
Faced,3802,O
with,3802,O
the,3802,O
selective,3802,O
pressure,3802,O
of,3802,O
oncogene,3802,O
withdrawal,3802,O
",",3802,O
Mad2-positive,3802,B-GeneOrGeneProduct
tumors,3802,B-DiseaseOrPhenotypicFeature
have,3802,O
a,3802,O
higher,3802,O
frequency,3802,O
of,3802,O
developing,3802,O
persistent,3802,O
subclones,3802,O
that,3802,O
avoid,3802,O
remission,3802,O
and,3802,O
continue,3802,O
to,3802,O
grow,3802,O
.,3802,O
Long-Lived,3803,O
CD4+IFN-g+,3803,B-GeneOrGeneProduct
T,3803,O
Cells,3803,O
rather,3803,O
than,3803,O
Short-Lived,3803,O
CD4+IFN-g+IL-10+,3803,B-GeneOrGeneProduct
T,3803,O
Cells,3803,O
Initiate,3803,O
Rapid,3803,O
IL-10,3803,B-GeneOrGeneProduct
Production,3803,O
To,3803,O
Suppress,3803,O
Anamnestic,3803,O
T,3803,O
Cell,3803,O
Responses,3803,O
during,3803,O
Secondary,3803,O
Malaria,3803,B-DiseaseOrPhenotypicFeature
Infection,3803,I-DiseaseOrPhenotypicFeature
.,3803,O
CD4,3804,B-GeneOrGeneProduct
(,3804,O
+,3804,O
),3804,O
T,3804,O
cells,3804,O
that,3804,O
produce,3804,O
IFN-g,3804,B-GeneOrGeneProduct
are,3804,O
the,3804,O
source,3804,O
of,3804,O
host-protective,3804,O
IL-10,3804,B-GeneOrGeneProduct
during,3804,O
primary,3804,O
infection,3804,B-DiseaseOrPhenotypicFeature
with,3804,O
a,3804,O
number,3804,O
of,3804,O
different,3804,O
pathogens,3804,O
",",3804,O
including,3804,O
Plasmodium,3804,O
spp,3804,O
.,3804,O
The,3805,O
fate,3805,O
of,3805,O
these,3805,O
CD4,3805,B-GeneOrGeneProduct
(,3805,O
+,3805,O
),3805,O
IFN-g,3805,B-GeneOrGeneProduct
(,3805,O
+,3805,O
),3805,O
IL-10,3805,B-GeneOrGeneProduct
(,3805,O
+,3805,O
),3805,O
T,3805,O
cells,3805,O
following,3805,O
clearance,3805,O
of,3805,O
primary,3805,O
infection,3805,B-DiseaseOrPhenotypicFeature
and,3805,O
their,3805,O
subsequent,3805,O
influence,3805,O
on,3805,O
the,3805,O
course,3805,O
of,3805,O
repeated,3805,O
infections,3805,O
is,3805,O
",",3805,O
however,3805,O
",",3805,O
presently,3805,O
unknown,3805,O
.,3805,O
In,3806,O
this,3806,O
study,3806,O
",",3806,O
utilizing,3806,O
IFN-g-yellow,3806,B-GeneOrGeneProduct
fluorescent,3806,O
protein,3806,O
(,3806,O
YFP,3806,O
),3806,O
and,3806,O
IL-10-GFP,3806,B-GeneOrGeneProduct
dual,3806,O
reporter,3806,O
mice,3806,B-OrganismTaxon
",",3806,O
we,3806,O
show,3806,O
that,3806,O
primary,3806,O
malaria,3806,B-DiseaseOrPhenotypicFeature
infection-induced,3806,O
CD4,3806,B-GeneOrGeneProduct
(,3806,O
+,3806,O
),3806,O
YFP,3806,O
(,3806,O
+,3806,O
),3806,O
GFP,3806,O
(,3806,O
+,3806,O
),3806,O
T,3806,O
cells,3806,O
have,3806,O
limited,3806,O
memory,3806,O
potential,3806,O
",",3806,O
do,3806,O
not,3806,O
stably,3806,O
express,3806,O
IL-10,3806,B-GeneOrGeneProduct
",",3806,O
and,3806,O
are,3806,O
disproportionately,3806,O
lost,3806,O
from,3806,O
the,3806,O
Ag-experienced,3806,O
CD4,3806,B-GeneOrGeneProduct
(,3806,O
+,3806,O
),3806,O
T,3806,O
cell,3806,O
memory,3806,O
population,3806,O
during,3806,O
the,3806,O
maintenance,3806,O
phase,3806,O
postinfection,3806,O
.,3806,O
CD4,3807,B-GeneOrGeneProduct
(,3807,O
+,3807,O
),3807,O
YFP,3807,O
(,3807,O
+,3807,O
),3807,O
GFP,3807,O
(,3807,O
+,3807,O
),3807,O
T,3807,O
cells,3807,O
generally,3807,O
exhibited,3807,O
a,3807,O
short-lived,3807,O
effector,3807,O
rather,3807,O
than,3807,O
effector,3807,O
memory,3807,O
T,3807,O
cell,3807,O
phenotype,3807,O
postinfection,3807,O
and,3807,O
expressed,3807,O
high,3807,O
levels,3807,O
of,3807,O
PD-1,3807,B-GeneOrGeneProduct
",",3807,O
Lag-3,3807,B-GeneOrGeneProduct
",",3807,O
and,3807,O
TIGIT,3807,B-GeneOrGeneProduct
",",3807,O
indicative,3807,O
of,3807,O
cellular,3807,O
exhaustion,3807,O
.,3807,O
Consistently,3808,O
",",3808,O
the,3808,O
surviving,3808,O
CD4,3808,B-GeneOrGeneProduct
(,3808,O
+,3808,O
),3808,O
YFP,3808,O
(,3808,O
+,3808,O
),3808,O
GFP,3808,O
(,3808,O
+,3808,O
),3808,O
T,3808,O
cell-derived,3808,O
cells,3808,O
were,3808,O
unresponsive,3808,O
and,3808,O
failed,3808,O
to,3808,O
proliferate,3808,O
during,3808,O
the,3808,O
early,3808,O
phase,3808,O
of,3808,O
secondary,3808,O
infection,3808,B-DiseaseOrPhenotypicFeature
.,3808,O
In,3809,O
contrast,3809,O
",",3809,O
CD4,3809,B-GeneOrGeneProduct
(,3809,O
+,3809,O
),3809,O
YFP,3809,O
(,3809,O
+,3809,O
),3809,O
GFP,3809,O
(,3809,O
-,3809,O
),3809,O
T,3809,O
cell-derived,3809,O
cells,3809,O
expanded,3809,O
rapidly,3809,O
and,3809,O
upregulated,3809,O
IL-10,3809,B-GeneOrGeneProduct
expression,3809,O
during,3809,O
secondary,3809,O
infection,3809,B-DiseaseOrPhenotypicFeature
.,3809,O
Correspondingly,3810,O
",",3810,O
CD4,3810,B-GeneOrGeneProduct
(,3810,O
+,3810,O
),3810,O
T,3810,O
cells,3810,O
were,3810,O
the,3810,O
major,3810,O
producers,3810,O
within,3810,O
an,3810,O
accelerated,3810,O
and,3810,O
amplified,3810,O
IL-10,3810,B-GeneOrGeneProduct
response,3810,O
during,3810,O
the,3810,O
early,3810,O
stage,3810,O
of,3810,O
secondary,3810,O
malaria,3810,B-DiseaseOrPhenotypicFeature
infection,3810,I-DiseaseOrPhenotypicFeature
.,3810,O
Notably,3811,O
",",3811,O
IL-10,3811,B-GeneOrGeneProduct
exerted,3811,O
quantitatively,3811,O
stronger,3811,O
regulatory,3811,O
effects,3811,O
on,3811,O
innate,3811,O
and,3811,O
CD4,3811,B-GeneOrGeneProduct
(,3811,O
+,3811,O
),3811,O
T,3811,O
cell,3811,O
responses,3811,O
during,3811,O
primary,3811,O
and,3811,O
secondary,3811,O
infections,3811,O
",",3811,O
respectively,3811,O
.,3811,O
The,3812,O
results,3812,O
in,3812,O
this,3812,O
study,3812,O
significantly,3812,O
improve,3812,O
our,3812,O
understanding,3812,O
of,3812,O
the,3812,O
durability,3812,O
of,3812,O
IL-10-producing,3812,B-GeneOrGeneProduct
CD4,3812,B-GeneOrGeneProduct
(,3812,O
+,3812,O
),3812,O
T,3812,O
cells,3812,O
postinfection,3812,O
and,3812,O
provide,3812,O
information,3812,O
on,3812,O
how,3812,O
IL-10,3812,B-GeneOrGeneProduct
may,3812,O
contribute,3812,O
to,3812,O
optimized,3812,O
parasite,3812,O
control,3812,O
and,3812,O
prevention,3812,O
of,3812,O
immune-mediated,3812,O
pathology,3812,O
during,3812,O
repeated,3812,O
malaria,3812,B-DiseaseOrPhenotypicFeature
infections,3812,I-DiseaseOrPhenotypicFeature
.,3812,O
Erythropoietin,3813,B-GeneOrGeneProduct
does,3813,O
not,3813,O
activate,3813,O
erythropoietin,3813,B-GeneOrGeneProduct
receptor,3813,I-GeneOrGeneProduct
signaling,3813,O
or,3813,O
lipolytic,3813,O
pathways,3813,O
in,3813,O
human,3813,B-OrganismTaxon
subcutaneous,3813,O
white,3813,O
adipose,3813,O
tissue,3813,O
in,3813,O
vivo,3813,O
.,3813,O
BACKGROUND,3814,O
:,3814,O
Erythropoietin,3814,B-GeneOrGeneProduct
(,3814,O
Epo,3814,B-GeneOrGeneProduct
),3814,O
exerts,3814,O
direct,3814,O
effects,3814,O
on,3814,O
white,3814,O
adipose,3814,O
tissue,3814,O
(,3814,O
WAT,3814,O
),3814,O
in,3814,O
mice,3814,B-OrganismTaxon
in,3814,O
addition,3814,O
to,3814,O
its,3814,O
erythropoietic,3814,O
effects,3814,O
",",3814,O
and,3814,O
in,3814,O
humans,3814,B-OrganismTaxon
Epo,3814,B-GeneOrGeneProduct
increases,3814,O
resting,3814,O
energy,3814,O
expenditure,3814,O
and,3814,O
affect,3814,O
serum,3814,O
lipid,3814,B-ChemicalEntity
levels,3814,O
",",3814,O
but,3814,O
direct,3814,O
effects,3814,O
of,3814,O
Epo,3814,B-GeneOrGeneProduct
in,3814,O
human,3814,B-OrganismTaxon
WAT,3814,O
have,3814,O
not,3814,O
been,3814,O
documented,3814,O
.,3814,O
We,3815,O
therefore,3815,O
investigated,3815,O
the,3815,O
effects,3815,O
of,3815,O
acute,3815,O
and,3815,O
prolonged,3815,O
Epo,3815,B-GeneOrGeneProduct
exposure,3815,O
on,3815,O
human,3815,B-OrganismTaxon
WAT,3815,O
in,3815,O
vivo,3815,O
.,3815,O
METHOD,3816,O
:,3816,O
Data,3816,O
were,3816,O
obtained,3816,O
from,3816,O
two,3816,O
clinical,3816,O
trials,3816,O
:,3816,O
1,3816,O
),3816,O
acute,3816,O
Epo,3816,B-GeneOrGeneProduct
exposure,3816,O
(,3816,O
rHuEpo,3816,O
",",3816,O
400,3816,O
IU/kg,3816,O
),3816,O
followed,3816,O
by,3816,O
WAT,3816,O
biopsies,3816,O
after,3816,O
1,3816,O
h,3816,O
and,3816,O
2,3816,O
),3816,O
10,3816,O
weeks,3816,O
treatment,3816,O
with,3816,O
the,3816,O
erythropoiesis-stimulating,3816,B-ChemicalEntity
agent,3816,I-ChemicalEntity
(,3816,O
ESA,3816,B-ChemicalEntity
),3816,O
Darbepoietin-alpha,3816,B-ChemicalEntity
.,3816,O
Biopsies,3817,O
were,3817,O
analyzed,3817,O
by,3817,O
PCR,3817,O
for,3817,O
Epo,3817,B-GeneOrGeneProduct
receptor,3817,I-GeneOrGeneProduct
(,3817,O
Epo-R,3817,B-GeneOrGeneProduct
),3817,O
mRNA,3817,O
.,3817,O
A,3818,O
new,3818,O
and,3818,O
highly,3818,O
specific,3818,O
antibody,3818,O
(,3818,O
A82,3818,O
",",3818,O
Amgen,3818,O
),3818,O
was,3818,O
used,3818,O
to,3818,O
evaluate,3818,O
the,3818,O
presence,3818,O
of,3818,O
Epo-R,3818,B-GeneOrGeneProduct
by,3818,O
western,3818,O
blot,3818,O
analysis,3818,O
in,3818,O
addition,3818,O
to,3818,O
Epo-R,3818,B-GeneOrGeneProduct
signaling,3818,O
proteins,3818,O
(,3818,O
Akt,3818,B-GeneOrGeneProduct
",",3818,O
STAT5,3818,B-GeneOrGeneProduct
",",3818,O
p70s6k,3818,B-GeneOrGeneProduct
",",3818,O
LYN,3818,B-GeneOrGeneProduct
",",3818,O
and,3818,O
p38MAPK,3818,B-GeneOrGeneProduct
),3818,O
",",3818,O
activation,3818,O
of,3818,O
lipolytic,3818,O
pathways,3818,O
(,3818,O
ATGL,3818,B-GeneOrGeneProduct
",",3818,O
HSL,3818,B-GeneOrGeneProduct
",",3818,O
CGI-58,3818,B-GeneOrGeneProduct
",",3818,O
G0S2,3818,B-GeneOrGeneProduct
",",3818,O
Perilipin,3818,B-GeneOrGeneProduct
",",3818,O
Cidea,3818,B-GeneOrGeneProduct
",",3818,O
Cidec,3818,B-GeneOrGeneProduct
",",3818,O
AMPK,3818,B-GeneOrGeneProduct
",",3818,O
and,3818,O
ACC,3818,B-GeneOrGeneProduct
),3818,O
",",3818,O
and,3818,O
mitochondrial,3818,O
biogenesis,3818,O
(,3818,O
VDAC,3818,B-GeneOrGeneProduct
",",3818,O
HSP90,3818,B-GeneOrGeneProduct
",",3818,O
PDH,3818,B-GeneOrGeneProduct
",",3818,O
and,3818,O
SDHA,3818,B-GeneOrGeneProduct
),3818,O
.,3818,O
RESULTS,3819,O
:,3819,O
No,3819,O
evidence,3819,O
of,3819,O
in,3819,O
vivo,3819,O
activation,3819,O
of,3819,O
the,3819,O
Epo-R,3819,B-GeneOrGeneProduct
in,3819,O
WAT,3819,O
could,3819,O
be,3819,O
documented,3819,O
despite,3819,O
detectable,3819,O
levels,3819,O
of,3819,O
Epo-R,3819,B-GeneOrGeneProduct
mRNA,3819,O
.,3819,O
CONCLUSION,3820,O
:,3820,O
Thus,3820,O
",",3820,O
in,3820,O
contradiction,3820,O
to,3820,O
animal,3820,O
studies,3820,O
",",3820,O
Epo,3820,B-GeneOrGeneProduct
treatment,3820,O
within,3820,O
a,3820,O
physiological,3820,O
relevant,3820,O
range,3820,O
in,3820,O
humans,3820,B-OrganismTaxon
does,3820,O
not,3820,O
exert,3820,O
direct,3820,O
effects,3820,O
in,3820,O
a,3820,O
subcutaneous,3820,O
WAT,3820,O
.,3820,O
Alcohol,3821,B-ChemicalEntity
consumption,3821,O
and,3821,O
prostate,3821,B-DiseaseOrPhenotypicFeature
cancer,3821,I-DiseaseOrPhenotypicFeature
incidence,3821,O
and,3821,O
progression,3821,O
:,3821,O
A,3821,O
Mendelian,3821,O
randomisation,3821,O
study,3821,O
.,3821,O
Prostate,3822,B-DiseaseOrPhenotypicFeature
cancer,3822,I-DiseaseOrPhenotypicFeature
is,3822,O
the,3822,O
most,3822,O
common,3822,O
cancer,3822,B-DiseaseOrPhenotypicFeature
in,3822,O
men,3822,B-OrganismTaxon
in,3822,O
developed,3822,O
countries,3822,O
",",3822,O
and,3822,O
is,3822,O
a,3822,O
target,3822,O
for,3822,O
risk,3822,O
reduction,3822,O
strategies,3822,O
.,3822,O
The,3823,O
effects,3823,O
of,3823,O
alcohol,3823,B-ChemicalEntity
consumption,3823,O
on,3823,O
prostate,3823,B-DiseaseOrPhenotypicFeature
cancer,3823,I-DiseaseOrPhenotypicFeature
incidence,3823,O
and,3823,O
survival,3823,O
remain,3823,O
unclear,3823,O
",",3823,O
potentially,3823,O
due,3823,O
to,3823,O
methodological,3823,O
limitations,3823,O
of,3823,O
observational,3823,O
studies,3823,O
.,3823,O
In,3824,O
this,3824,O
study,3824,O
",",3824,O
we,3824,O
investigated,3824,O
the,3824,O
associations,3824,O
of,3824,O
genetic,3824,O
variants,3824,O
in,3824,O
alcohol-metabolising,3824,B-ChemicalEntity
genes,3824,O
with,3824,O
prostate,3824,B-DiseaseOrPhenotypicFeature
cancer,3824,I-DiseaseOrPhenotypicFeature
incidence,3824,O
and,3824,O
survival,3824,O
.,3824,O
We,3825,O
analysed,3825,O
data,3825,O
from,3825,O
"23,868",3825,O
men,3825,B-OrganismTaxon
with,3825,O
prostate,3825,B-DiseaseOrPhenotypicFeature
cancer,3825,I-DiseaseOrPhenotypicFeature
and,3825,O
"23,051",3825,O
controls,3825,O
from,3825,O
25,3825,O
studies,3825,O
within,3825,O
the,3825,O
international,3825,O
PRACTICAL,3825,O
Consortium,3825,O
.,3825,O
Study-specific,3826,O
associations,3826,O
of,3826,O
68,3826,O
single,3826,O
nucleotide,3826,O
polymorphisms,3826,O
(,3826,O
SNPs,3826,O
),3826,O
in,3826,O
8,3826,O
alcohol-metabolising,3826,B-ChemicalEntity
genes,3826,O
(,3826,O
Alcohol,3826,B-GeneOrGeneProduct
Dehydrogenases,3826,I-GeneOrGeneProduct
(,3826,O
ADHs,3826,B-GeneOrGeneProduct
),3826,O
and,3826,O
Aldehyde,3826,B-GeneOrGeneProduct
Dehydrogenases,3826,I-GeneOrGeneProduct
(,3826,O
ALDHs,3826,B-GeneOrGeneProduct
),3826,O
),3826,O
with,3826,O
prostate,3826,B-DiseaseOrPhenotypicFeature
cancer,3826,I-DiseaseOrPhenotypicFeature
diagnosis,3826,O
and,3826,O
prostate,3826,B-DiseaseOrPhenotypicFeature
cancer-specific,3826,O
mortality,3826,O
",",3826,O
by,3826,O
grade,3826,O
",",3826,O
were,3826,O
assessed,3826,O
using,3826,O
logistic,3826,O
and,3826,O
Cox,3826,O
regression,3826,O
models,3826,O
",",3826,O
respectively,3826,O
.,3826,O
The,3827,O
data,3827,O
across,3827,O
the,3827,O
25,3827,O
studies,3827,O
were,3827,O
meta-analysed,3827,O
using,3827,O
fixed-effect,3827,O
and,3827,O
random-effects,3827,O
models,3827,O
.,3827,O
We,3828,O
found,3828,O
little,3828,O
evidence,3828,O
that,3828,O
variants,3828,O
in,3828,O
alcohol,3828,B-ChemicalEntity
metabolising,3828,O
genes,3828,O
were,3828,O
associated,3828,O
with,3828,O
prostate,3828,B-DiseaseOrPhenotypicFeature
cancer,3828,I-DiseaseOrPhenotypicFeature
diagnosis,3828,O
.,3828,O
Four,3829,O
variants,3829,O
in,3829,O
two,3829,O
genes,3829,O
exceeded,3829,O
the,3829,O
multiple,3829,O
testing,3829,O
threshold,3829,O
for,3829,O
associations,3829,O
with,3829,O
prostate,3829,B-DiseaseOrPhenotypicFeature
cancer,3829,I-DiseaseOrPhenotypicFeature
mortality,3829,O
in,3829,O
fixed-effect,3829,O
meta-analyses,3829,O
.,3829,O
SNPs,3830,O
within,3830,O
ALDH1A2,3830,B-GeneOrGeneProduct
associated,3830,O
with,3830,O
prostate,3830,B-DiseaseOrPhenotypicFeature
cancer,3830,I-DiseaseOrPhenotypicFeature
mortality,3830,O
were,3830,O
rs1441817,3830,B-SequenceVariant
(,3830,O
fixed,3830,O
effects,3830,O
hazard,3830,O
ratio,3830,O
",",3830,O
HRfixed,3830,O
=,3830,O
0.78,3830,O
;,3830,O
95,3830,O
%,3830,O
confidence,3830,O
interval,3830,O
(,3830,O
95,3830,O
%,3830,O
CI,3830,O
),3830,O
":0.66,0.91",3830,O
;,3830,O
p,3830,O
values,3830,O
=,3830,O
0.002,3830,O
),3830,O
;,3830,O
rs12910509,3830,B-SequenceVariant
",",3830,O
HRfixed,3830,O
=,3830,O
0.76,3830,O
;,3830,O
95,3830,O
%,3830,O
"CI:0.64,0.91",3830,O
;,3830,O
p,3830,O
values,3830,O
=,3830,O
0.003,3830,O
),3830,O
;,3830,O
and,3830,O
rs8041922,3830,B-SequenceVariant
(,3830,O
HRfixed,3830,O
=,3830,O
0.76,3830,O
;,3830,O
95,3830,O
%,3830,O
"CI:0.64,0.91",3830,O
;,3830,O
p,3830,O
values,3830,O
=,3830,O
0.002,3830,O
),3830,O
.,3830,O
These,3831,O
SNPs,3831,O
were,3831,O
in,3831,O
linkage,3831,O
disequilibrium,3831,O
with,3831,O
each,3831,O
other,3831,O
.,3831,O
In,3832,O
ALDH1B1,3832,B-GeneOrGeneProduct
",",3832,O
rs10973794,3832,B-SequenceVariant
(,3832,O
HRfixed,3832,O
=,3832,O
1.43,3832,O
;,3832,O
95,3832,O
%,3832,O
"CI:1.14,1.79",3832,O
;,3832,O
p,3832,O
values,3832,O
=,3832,O
0.002,3832,O
),3832,O
was,3832,O
associated,3832,O
with,3832,O
prostate,3832,B-DiseaseOrPhenotypicFeature
cancer,3832,I-DiseaseOrPhenotypicFeature
mortality,3832,O
in,3832,O
men,3832,B-OrganismTaxon
with,3832,O
low-grade,3832,O
prostate,3832,B-DiseaseOrPhenotypicFeature
cancer,3832,I-DiseaseOrPhenotypicFeature
.,3832,O
These,3833,O
results,3833,O
suggest,3833,O
that,3833,O
alcohol,3833,B-ChemicalEntity
consumption,3833,O
is,3833,O
unlikely,3833,O
to,3833,O
affect,3833,O
prostate,3833,B-DiseaseOrPhenotypicFeature
cancer,3833,I-DiseaseOrPhenotypicFeature
incidence,3833,O
",",3833,O
but,3833,O
it,3833,O
may,3833,O
influence,3833,O
disease,3833,O
progression,3833,O
.,3833,O
Differential,3834,O
expression,3834,O
of,3834,O
filamin,3834,B-GeneOrGeneProduct
B,3834,I-GeneOrGeneProduct
splice,3834,O
variants,3834,O
in,3834,O
giant,3834,B-DiseaseOrPhenotypicFeature
cell,3834,I-DiseaseOrPhenotypicFeature
tumor,3834,I-DiseaseOrPhenotypicFeature
cells,3834,O
.,3834,O
Giant,3835,B-DiseaseOrPhenotypicFeature
cell,3835,I-DiseaseOrPhenotypicFeature
tumor,3835,I-DiseaseOrPhenotypicFeature
of,3835,I-DiseaseOrPhenotypicFeature
bone,3835,I-DiseaseOrPhenotypicFeature
(,3835,O
GCT,3835,B-DiseaseOrPhenotypicFeature
),3835,O
is,3835,O
the,3835,O
most,3835,O
commonly,3835,O
reported,3835,O
non-malignant,3835,O
bone,3835,B-DiseaseOrPhenotypicFeature
tumor,3835,I-DiseaseOrPhenotypicFeature
in,3835,O
Hong,3835,O
Kong,3835,O
.,3835,O
This,3836,O
kind,3836,O
of,3836,O
tumor,3836,B-DiseaseOrPhenotypicFeature
usually,3836,O
affects,3836,O
people,3836,O
aged,3836,O
20-40,3836,O
years,3836,O
.,3836,O
Also,3837,O
",",3837,O
it,3837,O
is,3837,O
well,3837,O
known,3837,O
for,3837,O
recurrence,3837,O
locally,3837,O
",",3837,O
especially,3837,O
when,3837,O
the,3837,O
tumor,3837,B-DiseaseOrPhenotypicFeature
can,3837,O
not,3837,O
be,3837,O
removed,3837,O
completely,3837,O
.,3837,O
Filamins,3838,B-GeneOrGeneProduct
are,3838,O
actin-binding,3838,B-GeneOrGeneProduct
proteins,3838,I-GeneOrGeneProduct
which,3838,O
contain,3838,O
three,3838,O
family,3838,O
members,3838,O
",",3838,O
filamin,3838,B-GeneOrGeneProduct
A,3838,I-GeneOrGeneProduct
",",3838,I-GeneOrGeneProduct
B,3838,I-GeneOrGeneProduct
and,3838,I-GeneOrGeneProduct
C.,3838,O
They,3838,O
are,3838,O
the,3838,O
products,3838,O
of,3838,O
three,3838,O
different,3838,O
genes,3838,O
",",3838,O
FLNA,3838,B-GeneOrGeneProduct
",",3838,O
FLNB,3838,B-GeneOrGeneProduct
and,3838,O
FLNC,3838,B-GeneOrGeneProduct
",",3838,O
which,3838,O
can,3838,O
generate,3838,O
various,3838,O
transcript,3838,O
variants,3838,O
in,3838,O
different,3838,O
cell,3838,O
types,3838,O
.,3838,O
In,3839,O
this,3839,O
study,3839,O
",",3839,O
we,3839,O
focused,3839,O
on,3839,O
the,3839,O
effects,3839,O
of,3839,O
FLNBv2,3839,B-GeneOrGeneProduct
and,3839,O
FLNBv4,3839,B-GeneOrGeneProduct
toward,3839,O
GCT,3839,B-DiseaseOrPhenotypicFeature
cells,3839,O
.,3839,O
The,3840,O
only,3840,O
difference,3840,O
between,3840,O
FLNBv2,3840,B-GeneOrGeneProduct
and,3840,O
FLNBv4,3840,B-GeneOrGeneProduct
is,3840,O
that,3840,O
FLNBv4,3840,B-GeneOrGeneProduct
does,3840,O
not,3840,O
contain,3840,O
hinge,3840,O
1,3840,O
region,3840,O
.,3840,O
We,3841,O
found,3841,O
that,3841,O
the,3841,O
relative,3841,O
abundance,3841,O
of,3841,O
FLNBv4,3841,B-GeneOrGeneProduct
varies,3841,O
among,3841,O
different,3841,O
GCT,3841,B-DiseaseOrPhenotypicFeature
cell,3841,O
lines,3841,O
while,3841,O
the,3841,O
expression,3841,O
level,3841,O
of,3841,O
FLNBv4,3841,B-GeneOrGeneProduct
in,3841,O
normal,3841,O
osteoblasts,3841,O
was,3841,O
only,3841,O
marginally,3841,O
detectable,3841,O
.,3841,O
In,3842,O
the,3842,O
functional,3842,O
aspect,3842,O
",",3842,O
overexpression,3842,O
of,3842,O
FLNBv4,3842,B-GeneOrGeneProduct
led,3842,O
to,3842,O
upregulation,3842,O
of,3842,O
RANKL,3842,B-GeneOrGeneProduct
",",3842,O
OCN,3842,B-GeneOrGeneProduct
",",3842,O
OPG,3842,B-GeneOrGeneProduct
and,3842,O
RUNX2,3842,B-GeneOrGeneProduct
",",3842,O
which,3842,O
are,3842,O
closely,3842,O
related,3842,O
to,3842,O
GCT,3842,B-DiseaseOrPhenotypicFeature
cell,3842,O
survival,3842,O
and,3842,O
differentiation,3842,O
.,3842,O
Moreover,3843,O
",",3843,O
FLNBv4,3843,B-GeneOrGeneProduct
can,3843,O
have,3843,O
a,3843,O
negative,3843,O
effect,3843,O
on,3843,O
cell,3843,O
viability,3843,O
of,3843,O
GCT,3843,B-DiseaseOrPhenotypicFeature
cells,3843,O
when,3843,O
compare,3843,O
with,3843,O
FLNBv2,3843,B-GeneOrGeneProduct
.,3843,O
In,3844,O
conclusion,3844,O
",",3844,O
splicing,3844,O
variants,3844,O
of,3844,O
FLNB,3844,B-GeneOrGeneProduct
are,3844,O
differentially,3844,O
expressed,3844,O
in,3844,O
GCT,3844,B-DiseaseOrPhenotypicFeature
cells,3844,O
and,3844,O
may,3844,O
play,3844,O
a,3844,O
role,3844,O
in,3844,O
the,3844,O
proliferation,3844,O
and,3844,O
differentiation,3844,O
of,3844,O
tumor,3844,B-DiseaseOrPhenotypicFeature
cells,3844,O
.,3844,O
High,3845,O
glucose,3845,B-ChemicalEntity
repatterns,3845,O
human,3845,B-OrganismTaxon
podocyte,3845,O
energy,3845,O
metabolism,3845,O
during,3845,O
differentiation,3845,O
and,3845,O
diabetic,3845,B-DiseaseOrPhenotypicFeature
nephropathy,3845,I-DiseaseOrPhenotypicFeature
.,3845,O
Podocytes,3846,O
play,3846,O
a,3846,O
key,3846,O
role,3846,O
in,3846,O
diabetic,3846,B-DiseaseOrPhenotypicFeature
nephropathy,3846,I-DiseaseOrPhenotypicFeature
pathogenesis,3846,O
",",3846,O
but,3846,O
alteration,3846,O
of,3846,O
their,3846,O
metabolism,3846,O
remains,3846,O
unknown,3846,O
in,3846,O
human,3846,B-OrganismTaxon
kidney,3846,O
.,3846,O
By,3847,O
using,3847,O
a,3847,O
conditionally,3847,O
differentiating,3847,O
human,3847,B-OrganismTaxon
podocyte,3847,O
cell,3847,O
line,3847,O
",",3847,O
we,3847,O
addressed,3847,O
the,3847,O
functional,3847,O
and,3847,O
molecular,3847,O
changes,3847,O
in,3847,O
podocyte,3847,O
energetics,3847,O
during,3847,O
in,3847,O
vitro,3847,O
development,3847,O
or,3847,O
under,3847,O
high,3847,O
glucose,3847,B-ChemicalEntity
conditions,3847,O
.,3847,O
In,3848,O
5,3848,O
mM,3848,O
glucose,3848,B-ChemicalEntity
medium,3848,O
",",3848,O
we,3848,O
observed,3848,O
a,3848,O
stepwise,3848,O
activation,3848,O
of,3848,O
oxidative,3848,O
metabolism,3848,O
during,3848,O
cell,3848,O
differentiation,3848,O
that,3848,O
was,3848,O
characterized,3848,O
by,3848,O
peroxisome,3848,B-GeneOrGeneProduct
proliferator-activated,3848,I-GeneOrGeneProduct
receptor-g,3848,I-GeneOrGeneProduct
coactivator,3848,I-GeneOrGeneProduct
1a,3848,I-GeneOrGeneProduct
(,3848,O
PGC-1a,3848,B-GeneOrGeneProduct
),3848,O
-dependent,3848,O
stimulation,3848,O
of,3848,O
mitochondrial,3848,O
biogenesis,3848,O
and,3848,O
function,3848,O
",",3848,O
with,3848,O
concomitant,3848,O
reduction,3848,O
of,3848,O
the,3848,O
glycolytic,3848,O
enzyme,3848,O
content,3848,O
.,3848,O
Conversely,3849,O
",",3849,O
when,3849,O
podocytes,3849,O
were,3849,O
cultured,3849,O
in,3849,O
high,3849,O
glucose,3849,B-ChemicalEntity
(,3849,O
20,3849,O
mM,3849,O
),3849,O
",",3849,O
stepwise,3849,O
oxidative,3849,O
phosphorylation,3849,O
biogenesis,3849,O
was,3849,O
aborted,3849,O
",",3849,O
and,3849,O
a,3849,O
glycolytic,3849,O
switch,3849,O
occurred,3849,O
",",3849,O
with,3849,O
consecutive,3849,O
lactic,3849,B-DiseaseOrPhenotypicFeature
acidosis,3849,I-DiseaseOrPhenotypicFeature
.,3849,O
Expression,3850,O
of,3850,O
the,3850,O
master,3850,B-GeneOrGeneProduct
regulators,3850,I-GeneOrGeneProduct
of,3850,I-GeneOrGeneProduct
oxidative,3850,I-GeneOrGeneProduct
metabolism,3850,I-GeneOrGeneProduct
transcription,3850,I-GeneOrGeneProduct
factor,3850,I-GeneOrGeneProduct
A,3850,I-GeneOrGeneProduct
mitochondrial,3850,I-GeneOrGeneProduct
",",3850,O
PGC-1a,3850,B-GeneOrGeneProduct
",",3850,O
AMPK,3850,B-GeneOrGeneProduct
",",3850,O
and,3850,O
serine-threonine,3850,B-GeneOrGeneProduct
liver,3850,I-GeneOrGeneProduct
kinase,3850,I-GeneOrGeneProduct
B1,3850,I-GeneOrGeneProduct
was,3850,O
altered,3850,O
by,3850,O
high,3850,O
glucose,3850,B-ChemicalEntity
",",3850,O
as,3850,O
well,3850,O
as,3850,O
their,3850,O
downstream,3850,O
signaling,3850,O
networks,3850,O
.,3850,O
Focused,3851,O
transcriptomics,3851,O
revealed,3851,O
that,3851,O
myocyte-specific,3851,B-GeneOrGeneProduct
enhancer,3851,I-GeneOrGeneProduct
factor,3851,I-GeneOrGeneProduct
2C,3851,I-GeneOrGeneProduct
(,3851,O
MEF2C,3851,B-GeneOrGeneProduct
),3851,O
and,3851,O
myogenic,3851,B-GeneOrGeneProduct
factor,3851,I-GeneOrGeneProduct
5,3851,I-GeneOrGeneProduct
(,3851,O
MYF5,3851,B-GeneOrGeneProduct
),3851,O
expression,3851,O
was,3851,O
inhibited,3851,O
by,3851,O
high,3851,O
glucose,3851,B-ChemicalEntity
levels,3851,O
",",3851,O
and,3851,O
endoribonuclease-prepared,3851,O
small,3851,O
interfering,3851,O
RNA-mediated,3851,O
combined,3851,O
inhibition,3851,O
of,3851,O
those,3851,O
transcription,3851,O
factors,3851,O
phenocopied,3851,O
the,3851,O
glycolytic,3851,O
shift,3851,O
that,3851,O
was,3851,O
observed,3851,O
in,3851,O
high,3851,O
glucose,3851,B-ChemicalEntity
conditions,3851,O
.,3851,O
Accordingly,3852,O
",",3852,O
a,3852,O
reduced,3852,O
expression,3852,O
of,3852,O
MEF2C,3852,B-GeneOrGeneProduct
",",3852,O
MYF5,3852,B-GeneOrGeneProduct
",",3852,O
and,3852,O
PGC-1a,3852,B-GeneOrGeneProduct
was,3852,O
found,3852,O
in,3852,O
kidney,3852,O
tissue,3852,O
sections,3852,O
that,3852,O
were,3852,O
obtained,3852,O
from,3852,O
patients,3852,B-OrganismTaxon
with,3852,O
diabetic,3852,B-DiseaseOrPhenotypicFeature
nephropathy,3852,I-DiseaseOrPhenotypicFeature
.,3852,O
These,3853,O
findings,3853,O
obtained,3853,O
in,3853,O
human,3853,B-OrganismTaxon
samples,3853,O
demonstrate,3853,O
that,3853,O
MEF2C-MYF5-dependent,3853,B-GeneOrGeneProduct
bioenergetic,3853,O
dedifferentiation,3853,O
occurs,3853,O
in,3853,O
podocytes,3853,O
that,3853,O
are,3853,O
confronted,3853,O
with,3853,O
a,3853,O
high-glucose,3853,O
milieu.-Imasawa,3853,O
",",3853,O
T.,3853,O
",",3853,O
Obre,3853,O
",",3853,O
E.,3853,O
",",3853,O
Bellance,3853,O
",",3853,O
N.,3853,O
",",3853,O
Lavie,3853,O
",",3853,O
J.,3853,O
",",3853,O
Imasawa,3853,O
",",3853,O
T.,3853,O
",",3853,O
Rigothier,3853,O
",",3853,O
C.,3853,O
",",3853,O
Delmas,3853,O
",",3853,O
Y.,3853,O
",",3853,O
Combe,3853,O
",",3853,O
C.,3853,O
",",3853,O
Lacombe,3853,O
",",3853,O
D.,3853,O
",",3853,O
Benard,3853,O
",",3853,O
G.,3853,O
",",3853,O
Claverol,3853,O
",",3853,O
S.,3853,O
",",3853,O
Bonneu,3853,O
",",3853,O
M.,3853,O
",",3853,O
Rossignol,3853,O
",",3853,O
R.,3853,O
High,3853,O
glucose,3853,B-ChemicalEntity
repatterns,3853,O
human,3853,B-OrganismTaxon
podocyte,3853,O
energy,3853,O
metabolism,3853,O
during,3853,O
differentiation,3853,O
and,3853,O
diabetic,3853,B-DiseaseOrPhenotypicFeature
nephropathy,3853,I-DiseaseOrPhenotypicFeature
.,3853,O
Role,3854,O
of,3854,O
protein,3854,B-GeneOrGeneProduct
arginine,3854,I-GeneOrGeneProduct
methyltransferase,3854,I-GeneOrGeneProduct
5,3854,I-GeneOrGeneProduct
in,3854,O
inflammation,3854,B-DiseaseOrPhenotypicFeature
and,3854,O
migration,3854,O
of,3854,O
fibroblast-like,3854,O
synoviocytes,3854,O
in,3854,O
rheumatoid,3854,B-DiseaseOrPhenotypicFeature
arthritis,3854,I-DiseaseOrPhenotypicFeature
.,3854,O
To,3855,O
probe,3855,O
the,3855,O
role,3855,O
of,3855,O
protein,3855,B-GeneOrGeneProduct
arginine,3855,I-GeneOrGeneProduct
methyltransferase,3855,I-GeneOrGeneProduct
5,3855,I-GeneOrGeneProduct
(,3855,O
PRMT5,3855,B-GeneOrGeneProduct
),3855,O
in,3855,O
regulating,3855,O
inflammation,3855,B-DiseaseOrPhenotypicFeature
",",3855,O
cell,3855,O
proliferation,3855,O
",",3855,O
migration,3855,O
and,3855,O
invasion,3855,O
of,3855,O
fibroblast-like,3855,O
synoviocytes,3855,O
(,3855,O
FLSs,3855,O
),3855,O
from,3855,O
patients,3855,B-OrganismTaxon
with,3855,O
rheumatoid,3855,B-DiseaseOrPhenotypicFeature
arthritis,3855,I-DiseaseOrPhenotypicFeature
(,3855,O
RA,3855,B-DiseaseOrPhenotypicFeature
),3855,O
.,3855,O
FLSs,3856,O
were,3856,O
separated,3856,O
from,3856,O
synovial,3856,O
tissues,3856,O
(,3856,O
STs,3856,O
),3856,O
from,3856,O
patients,3856,B-OrganismTaxon
with,3856,O
RA,3856,B-DiseaseOrPhenotypicFeature
and,3856,O
osteoarthritis,3856,B-DiseaseOrPhenotypicFeature
(,3856,O
OA,3856,B-DiseaseOrPhenotypicFeature
),3856,O
.,3856,O
An,3857,O
inhibitor,3857,O
of,3857,O
PRMT5,3857,B-GeneOrGeneProduct
(,3857,O
EPZ015666,3857,B-ChemicalEntity
),3857,O
and,3857,O
short,3857,O
interference,3857,O
RNA,3857,O
(,3857,O
siRNA,3857,O
),3857,O
against,3857,O
PRMT5,3857,B-GeneOrGeneProduct
were,3857,O
used,3857,O
to,3857,O
inhibit,3857,O
PRMT5,3857,B-GeneOrGeneProduct
expression,3857,O
.,3857,O
The,3858,O
standard,3858,O
of,3858,O
protein,3858,O
was,3858,O
measured,3858,O
by,3858,O
Western,3858,O
blot,3858,O
or,3858,O
immunofluorescence,3858,O
.,3858,O
The,3859,O
excretion,3859,O
and,3859,O
genetic,3859,O
expression,3859,O
of,3859,O
inflammatory,3859,B-DiseaseOrPhenotypicFeature
factors,3859,O
were,3859,O
",",3859,O
respectively,3859,O
",",3859,O
estimated,3859,O
by,3859,O
enzyme-linked,3859,O
immunosorbent,3859,O
assay,3859,O
(,3859,O
ELISA,3859,O
),3859,O
and,3859,O
real-time,3859,O
polymerase,3859,O
chain,3859,O
reaction,3859,O
(,3859,O
PCR,3859,O
),3859,O
.,3859,O
Migration,3860,O
and,3860,O
invasion,3860,O
in,3860,O
vitro,3860,O
were,3860,O
detected,3860,O
by,3860,O
Boyden,3860,O
chamber,3860,O
assay,3860,O
.,3860,O
FLSs,3861,O
proliferation,3861,O
was,3861,O
detected,3861,O
by,3861,O
BrdU,3861,O
incorporation,3861,O
.,3861,O
Increased,3862,O
PRMT5,3862,B-GeneOrGeneProduct
was,3862,O
discovered,3862,O
in,3862,O
STs,3862,O
and,3862,O
FLSs,3862,O
from,3862,O
patients,3862,B-OrganismTaxon
with,3862,O
RA,3862,B-DiseaseOrPhenotypicFeature
.,3862,O
In,3863,O
RA,3863,B-DiseaseOrPhenotypicFeature
FLSs,3863,O
",",3863,O
the,3863,O
level,3863,O
of,3863,O
PRMT5,3863,B-GeneOrGeneProduct
was,3863,O
up-regulated,3863,O
by,3863,O
stimulation,3863,O
with,3863,O
IL-1b,3863,B-GeneOrGeneProduct
and,3863,O
TNF-a,3863,B-GeneOrGeneProduct
.,3863,O
Inhibition,3864,O
of,3864,O
PRMT5,3864,B-GeneOrGeneProduct
by,3864,O
EPZ015666,3864,B-ChemicalEntity
and,3864,O
siRNA-mediated,3864,O
knockdown,3864,O
reduced,3864,O
IL-6,3864,B-GeneOrGeneProduct
and,3864,O
IL-8,3864,B-GeneOrGeneProduct
production,3864,O
",",3864,O
and,3864,O
proliferation,3864,O
of,3864,O
RA,3864,B-DiseaseOrPhenotypicFeature
FLSs,3864,O
.,3864,O
In,3865,O
addition,3865,O
",",3865,O
inhibition,3865,O
of,3865,O
PRMT5,3865,B-GeneOrGeneProduct
decreased,3865,O
in,3865,O
vitro,3865,O
migration,3865,O
and,3865,O
invasion,3865,O
of,3865,O
RA,3865,B-DiseaseOrPhenotypicFeature
FLSs,3865,O
.,3865,O
Furthermore,3866,O
",",3866,O
EPZ015666,3866,B-ChemicalEntity
restrained,3866,O
the,3866,O
phosphorylation,3866,O
of,3866,O
IkB,3866,B-GeneOrGeneProduct
kinaseb,3866,I-GeneOrGeneProduct
and,3866,O
IkBa,3866,B-GeneOrGeneProduct
",",3866,O
as,3866,O
well,3866,O
as,3866,O
nucleus,3866,O
transsituation,3866,O
of,3866,O
p65,3866,B-GeneOrGeneProduct
as,3866,O
well,3866,O
as,3866,O
AKT,3866,B-GeneOrGeneProduct
in,3866,O
FLSs,3866,O
.,3866,O
PRMT5,3867,B-GeneOrGeneProduct
regulated,3867,O
the,3867,O
production,3867,O
of,3867,O
inflammatory,3867,B-DiseaseOrPhenotypicFeature
factors,3867,O
",",3867,O
cell,3867,O
proliferation,3867,O
",",3867,O
migration,3867,O
and,3867,O
invasion,3867,O
of,3867,O
RA,3867,B-DiseaseOrPhenotypicFeature
FLS,3867,O
",",3867,O
which,3867,O
was,3867,O
mediated,3867,O
by,3867,O
the,3867,O
NF-kB,3867,B-GeneOrGeneProduct
and,3867,O
AKT,3867,B-GeneOrGeneProduct
pathways,3867,O
.,3867,O
Our,3868,O
data,3868,O
suggested,3868,O
that,3868,O
targeting,3868,O
PRMT5,3868,B-GeneOrGeneProduct
to,3868,O
prevent,3868,O
synovial,3868,B-DiseaseOrPhenotypicFeature
inflammation,3868,I-DiseaseOrPhenotypicFeature
and,3868,O
destruction,3868,O
might,3868,O
be,3868,O
a,3868,O
promising,3868,O
therapy,3868,O
for,3868,O
RA,3868,B-DiseaseOrPhenotypicFeature
.,3868,O
Whole-Organism,3869,O
Developmental,3869,O
Expression,3869,O
Profiling,3869,O
Identifies,3869,O
RAB-28,3869,B-GeneOrGeneProduct
as,3869,O
a,3869,O
Novel,3869,O
Ciliary,3869,O
GTPase,3869,B-GeneOrGeneProduct
Associated,3869,O
with,3869,O
the,3869,O
BBSome,3869,B-GeneOrGeneProduct
and,3869,O
Intraflagellar,3869,O
Transport,3869,O
.,3869,O
Primary,3870,O
cilia,3870,O
are,3870,O
specialised,3870,O
sensory,3870,O
and,3870,O
developmental,3870,O
signalling,3870,O
devices,3870,O
extending,3870,O
from,3870,O
the,3870,O
surface,3870,O
of,3870,O
most,3870,O
eukaryotic,3870,O
cells,3870,O
.,3870,O
Defects,3871,O
in,3871,O
these,3871,O
organelles,3871,O
cause,3871,O
inherited,3871,B-DiseaseOrPhenotypicFeature
human,3871,I-DiseaseOrPhenotypicFeature
disorders,3871,I-DiseaseOrPhenotypicFeature
(,3871,O
ciliopathies,3871,B-DiseaseOrPhenotypicFeature
),3871,O
such,3871,O
as,3871,O
retinitis,3871,B-DiseaseOrPhenotypicFeature
pigmentosa,3871,I-DiseaseOrPhenotypicFeature
and,3871,O
Bardet-Biedl,3871,B-DiseaseOrPhenotypicFeature
syndrome,3871,I-DiseaseOrPhenotypicFeature
(,3871,O
BBS,3871,B-DiseaseOrPhenotypicFeature
),3871,O
",",3871,O
frequently,3871,O
affecting,3871,O
many,3871,O
physiological,3871,O
and,3871,O
developmental,3871,O
processes,3871,O
across,3871,O
multiple,3871,O
organs,3871,O
.,3871,O
Cilium,3872,O
formation,3872,O
",",3872,O
maintenance,3872,O
and,3872,O
function,3872,O
depend,3872,O
on,3872,O
intracellular,3872,O
transport,3872,O
systems,3872,O
such,3872,O
as,3872,O
intraflagellar,3872,O
transport,3872,O
(,3872,O
IFT,3872,O
),3872,O
",",3872,O
which,3872,O
is,3872,O
driven,3872,O
by,3872,O
kinesin-2,3872,B-GeneOrGeneProduct
and,3872,O
IFT-dynein,3872,O
motors,3872,O
and,3872,O
regulated,3872,O
by,3872,O
the,3872,O
Bardet-Biedl,3872,B-GeneOrGeneProduct
syndrome,3872,I-GeneOrGeneProduct
(,3872,I-GeneOrGeneProduct
BBS,3872,I-GeneOrGeneProduct
),3872,I-GeneOrGeneProduct
cargo-adaptor,3872,I-GeneOrGeneProduct
protein,3872,I-GeneOrGeneProduct
complex,3872,I-GeneOrGeneProduct
",",3872,O
or,3872,O
BBSome,3872,B-GeneOrGeneProduct
.,3872,O
To,3873,O
identify,3873,O
new,3873,O
cilium-associated,3873,O
genes,3873,O
",",3873,O
we,3873,O
employed,3873,O
the,3873,O
nematode,3873,O
C.,3873,B-OrganismTaxon
elegans,3873,I-OrganismTaxon
",",3873,O
where,3873,O
ciliogenesis,3873,O
occurs,3873,O
within,3873,O
a,3873,O
short,3873,O
timespan,3873,O
during,3873,O
late,3873,O
embryogenesis,3873,O
when,3873,O
most,3873,O
sensory,3873,O
neurons,3873,O
differentiate,3873,O
.,3873,O
Using,3874,O
whole-organism,3874,O
RNA-Seq,3874,O
libraries,3874,O
",",3874,O
we,3874,O
discovered,3874,O
a,3874,O
signature,3874,O
expression,3874,O
profile,3874,O
highly,3874,O
enriched,3874,O
for,3874,O
transcripts,3874,O
of,3874,O
known,3874,O
ciliary,3874,O
proteins,3874,O
",",3874,O
including,3874,O
FAM-161,3874,B-GeneOrGeneProduct
(,3874,O
FAM161A,3874,B-GeneOrGeneProduct
orthologue,3874,O
),3874,O
",",3874,O
CCDC-104,3874,B-GeneOrGeneProduct
(,3874,O
CCDC104,3874,B-GeneOrGeneProduct
),3874,O
",",3874,O
and,3874,O
RPI-1,3874,B-GeneOrGeneProduct
(,3874,O
RP1/RP1L1,3874,B-GeneOrGeneProduct
),3874,O
",",3874,O
which,3874,O
we,3874,O
confirm,3874,O
are,3874,O
cilium-localised,3874,O
in,3874,O
worms,3874,O
.,3874,O
From,3875,O
a,3875,O
list,3875,O
of,3875,O
185,3875,O
candidate,3875,O
ciliary,3875,O
genes,3875,O
",",3875,O
we,3875,O
uncover,3875,O
orthologues,3875,O
of,3875,O
human,3875,B-OrganismTaxon
MAP9,3875,B-GeneOrGeneProduct
",",3875,O
YAP,3875,B-GeneOrGeneProduct
",",3875,O
CCDC149,3875,B-GeneOrGeneProduct
",",3875,O
and,3875,O
RAB28,3875,B-GeneOrGeneProduct
as,3875,O
conserved,3875,O
cilium-associated,3875,O
components,3875,O
.,3875,O
Further,3876,O
analyses,3876,O
of,3876,O
C.,3876,B-OrganismTaxon
elegans,3876,I-OrganismTaxon
RAB-28,3876,B-GeneOrGeneProduct
",",3876,O
recently,3876,O
associated,3876,O
with,3876,O
autosomal-recessive,3876,O
cone-rod,3876,B-DiseaseOrPhenotypicFeature
dystrophy,3876,I-DiseaseOrPhenotypicFeature
",",3876,O
reveal,3876,O
that,3876,O
this,3876,O
small,3876,O
GTPase,3876,B-GeneOrGeneProduct
is,3876,O
exclusively,3876,O
expressed,3876,O
in,3876,O
ciliated,3876,O
neurons,3876,O
where,3876,O
it,3876,O
dynamically,3876,O
associates,3876,O
with,3876,O
IFT,3876,O
trains,3876,O
.,3876,O
Whereas,3877,O
inactive,3877,O
GDP-bound,3877,B-ChemicalEntity
RAB-28,3877,B-GeneOrGeneProduct
displays,3877,O
no,3877,O
IFT,3877,O
movement,3877,O
and,3877,O
diffuse,3877,O
localisation,3877,O
",",3877,O
GTP-bound,3877,B-ChemicalEntity
(,3877,O
activated,3877,O
),3877,O
RAB-28,3877,B-GeneOrGeneProduct
concentrates,3877,O
at,3877,O
the,3877,O
periciliary,3877,O
membrane,3877,O
in,3877,O
a,3877,O
BBSome-dependent,3877,B-GeneOrGeneProduct
manner,3877,O
and,3877,O
undergoes,3877,O
bidirectional,3877,O
IFT,3877,O
.,3877,O
Functional,3878,O
analyses,3878,O
reveal,3878,O
that,3878,O
whilst,3878,O
cilium,3878,O
structure,3878,O
",",3878,O
sensory,3878,O
function,3878,O
and,3878,O
IFT,3878,O
are,3878,O
seemingly,3878,O
normal,3878,O
in,3878,O
a,3878,O
rab-28,3878,B-GeneOrGeneProduct
null,3878,O
allele,3878,O
",",3878,O
overexpression,3878,O
of,3878,O
predicted,3878,O
GDP,3878,B-ChemicalEntity
or,3878,O
GTP,3878,B-ChemicalEntity
locked,3878,O
variants,3878,O
of,3878,O
RAB-28,3878,B-GeneOrGeneProduct
perturbs,3878,O
cilium,3878,O
and,3878,O
sensory,3878,O
pore,3878,O
morphogenesis,3878,O
and,3878,O
function,3878,O
.,3878,O
Collectively,3879,O
",",3879,O
our,3879,O
findings,3879,O
present,3879,O
a,3879,O
new,3879,O
approach,3879,O
for,3879,O
identifying,3879,O
ciliary,3879,O
proteins,3879,O
",",3879,O
and,3879,O
unveil,3879,O
RAB28,3879,B-GeneOrGeneProduct
",",3879,O
a,3879,O
GTPase,3879,B-GeneOrGeneProduct
most,3879,O
closely,3879,O
related,3879,O
to,3879,O
the,3879,O
BBS,3879,B-DiseaseOrPhenotypicFeature
protein,3879,O
RABL4/IFT27,3879,B-GeneOrGeneProduct
",",3879,O
as,3879,O
an,3879,O
IFT-associated,3879,O
cargo,3879,O
with,3879,O
BBSome-dependent,3879,B-GeneOrGeneProduct
cell,3879,O
autonomous,3879,O
and,3879,O
non-autonomous,3879,O
functions,3879,O
at,3879,O
the,3879,O
ciliary,3879,O
base,3879,O
.,3879,O
Voltage-Dependent,3880,B-GeneOrGeneProduct
Anion,3880,I-GeneOrGeneProduct
Channel,3880,I-GeneOrGeneProduct
1,3880,I-GeneOrGeneProduct
(,3880,O
VDAC1,3880,B-GeneOrGeneProduct
),3880,O
Participates,3880,O
the,3880,O
Apoptosis,3880,O
of,3880,O
the,3880,O
Mitochondrial,3880,B-DiseaseOrPhenotypicFeature
Dysfunction,3880,I-DiseaseOrPhenotypicFeature
in,3880,O
Desminopathy,3880,B-DiseaseOrPhenotypicFeature
.,3880,O
Desminopathies,3881,B-DiseaseOrPhenotypicFeature
caused,3881,O
by,3881,O
the,3881,O
mutation,3881,O
in,3881,O
the,3881,O
gene,3881,O
coding,3881,O
for,3881,O
desmin,3881,B-GeneOrGeneProduct
are,3881,O
genetically,3881,O
protein,3881,O
aggregation,3881,O
myopathies,3881,B-DiseaseOrPhenotypicFeature
.,3881,O
Mitochondrial,3882,B-DiseaseOrPhenotypicFeature
dysfunction,3882,I-DiseaseOrPhenotypicFeature
is,3882,O
one,3882,O
of,3882,O
pathological,3882,O
changes,3882,O
in,3882,O
the,3882,O
desminopathies,3882,B-DiseaseOrPhenotypicFeature
at,3882,O
the,3882,O
earliest,3882,O
stage,3882,O
.,3882,O
The,3883,O
molecular,3883,O
mechanisms,3883,O
of,3883,O
mitochondria,3883,B-DiseaseOrPhenotypicFeature
dysfunction,3883,I-DiseaseOrPhenotypicFeature
in,3883,O
desminopathies,3883,B-DiseaseOrPhenotypicFeature
remain,3883,O
exclusive,3883,O
.,3883,O
VDAC1,3884,B-GeneOrGeneProduct
regulates,3884,O
mitochondrial,3884,O
uptake,3884,O
across,3884,O
the,3884,O
outer,3884,O
membrane,3884,O
and,3884,O
mitochondrial,3884,O
outer,3884,O
membrane,3884,O
permeabilization,3884,O
(,3884,O
MOMP,3884,O
),3884,O
.,3884,O
Relationships,3885,O
between,3885,O
desminopathies,3885,B-DiseaseOrPhenotypicFeature
and,3885,O
Voltage-dependent,3885,B-GeneOrGeneProduct
anion,3885,I-GeneOrGeneProduct
channel,3885,I-GeneOrGeneProduct
1,3885,I-GeneOrGeneProduct
(,3885,O
VDAC1,3885,B-GeneOrGeneProduct
),3885,O
remain,3885,O
unclear,3885,O
.,3885,O
Here,3886,O
we,3886,O
successfully,3886,O
constructed,3886,O
the,3886,O
desminopathy,3886,B-DiseaseOrPhenotypicFeature
rat,3886,B-OrganismTaxon
model,3886,O
",",3886,O
evaluated,3886,O
with,3886,O
conventional,3886,O
stains,3886,O
",",3886,O
containing,3886,O
hematoxylin,3886,O
and,3886,O
eosin,3886,O
(,3886,O
HE,3886,O
),3886,O
",",3886,O
Gomori,3886,O
Trichrome,3886,O
(,3886,O
MGT,3886,O
),3886,O
",",3886,O
(,3886,O
PAS,3886,O
),3886,O
",",3886,O
red,3886,O
oil,3886,O
(,3886,O
ORO,3886,O
),3886,O
",",3886,O
NADH-TR,3886,O
",",3886,O
SDH,3886,O
staining,3886,O
and,3886,O
immunohistochemistry,3886,O
.,3886,O
Immunofluorescence,3887,O
results,3887,O
showed,3887,O
that,3887,O
VDAC1,3887,B-GeneOrGeneProduct
was,3887,O
accumulated,3887,O
in,3887,O
the,3887,O
desmin,3887,B-GeneOrGeneProduct
highly,3887,O
stained,3887,O
area,3887,O
of,3887,O
muscle,3887,O
fibers,3887,O
of,3887,O
desminopathy,3887,B-DiseaseOrPhenotypicFeature
patients,3887,B-OrganismTaxon
or,3887,O
desminopathy,3887,B-DiseaseOrPhenotypicFeature
rat,3887,B-OrganismTaxon
model,3887,O
compared,3887,O
to,3887,O
the,3887,O
normal,3887,O
ones,3887,O
.,3887,O
Meanwhile,3888,O
apoptosis,3888,O
related,3888,O
proteins,3888,O
bax,3888,B-GeneOrGeneProduct
and,3888,O
ATF2,3888,B-GeneOrGeneProduct
were,3888,O
involved,3888,O
in,3888,O
desminopathy,3888,B-DiseaseOrPhenotypicFeature
patients,3888,B-OrganismTaxon
and,3888,O
desminopathy,3888,B-DiseaseOrPhenotypicFeature
rat,3888,B-OrganismTaxon
model,3888,O
",",3888,O
but,3888,O
not,3888,O
bcl-2,3888,B-GeneOrGeneProduct
",",3888,O
bcl-xl,3888,B-GeneOrGeneProduct
or,3888,O
HK2.VDAC1,3888,B-GeneOrGeneProduct
and,3888,O
desmin,3888,B-GeneOrGeneProduct
are,3888,O
closely,3888,O
relevant,3888,O
in,3888,O
the,3888,O
tissue,3888,O
splices,3888,O
of,3888,O
deminopathies,3888,O
patients,3888,B-OrganismTaxon
and,3888,O
rats,3888,B-OrganismTaxon
with,3888,O
desminopathy,3888,B-DiseaseOrPhenotypicFeature
at,3888,O
protein,3888,O
lever,3888,O
.,3888,O
Moreover,3889,O
",",3889,O
apoptotic,3889,O
proteins,3889,O
are,3889,O
also,3889,O
involved,3889,O
in,3889,O
the,3889,O
desminopathies,3889,B-DiseaseOrPhenotypicFeature
",",3889,O
like,3889,O
bax,3889,B-GeneOrGeneProduct
",",3889,O
ATF2,3889,B-GeneOrGeneProduct
",",3889,O
but,3889,O
not,3889,O
bcl-2,3889,B-GeneOrGeneProduct
",",3889,O
bcl-xl,3889,B-GeneOrGeneProduct
or,3889,O
HK2,3889,B-GeneOrGeneProduct
.,3889,O
This,3890,O
pathological,3890,O
analysis,3890,O
presents,3890,O
the,3890,O
correlation,3890,O
between,3890,O
VDAC1,3890,B-GeneOrGeneProduct
and,3890,O
desmin,3890,B-GeneOrGeneProduct
",",3890,O
and,3890,O
apoptosis,3890,O
related,3890,O
proteins,3890,O
are,3890,O
correlated,3890,O
in,3890,O
the,3890,O
desminopathy,3890,B-DiseaseOrPhenotypicFeature
.,3890,O
Furthermore,3891,O
",",3891,O
we,3891,O
provide,3891,O
a,3891,O
rat,3891,B-OrganismTaxon
model,3891,O
of,3891,O
desminopathy,3891,B-DiseaseOrPhenotypicFeature
for,3891,O
the,3891,O
investigation,3891,O
of,3891,O
desmin,3891,B-GeneOrGeneProduct
related,3891,O
myopathy,3891,B-DiseaseOrPhenotypicFeature
.,3891,O
Bach1,3892,B-GeneOrGeneProduct
siRNA,3892,O
attenuates,3892,O
bleomycin-induced,3892,B-ChemicalEntity
pulmonary,3892,B-DiseaseOrPhenotypicFeature
fibrosis,3892,I-DiseaseOrPhenotypicFeature
by,3892,O
modulating,3892,O
oxidative,3892,O
stress,3892,O
in,3892,O
mice,3892,B-OrganismTaxon
.,3892,O
Oxidative,3893,O
stress,3893,O
plays,3893,O
an,3893,O
essential,3893,O
role,3893,O
in,3893,O
inflammation,3893,B-DiseaseOrPhenotypicFeature
and,3893,O
fibrosis,3893,B-DiseaseOrPhenotypicFeature
.,3893,O
Bach1,3894,B-GeneOrGeneProduct
is,3894,O
an,3894,O
important,3894,O
transcriptional,3894,O
repressor,3894,O
that,3894,O
acts,3894,O
by,3894,O
modulating,3894,O
oxidative,3894,O
stress,3894,O
and,3894,O
represents,3894,O
a,3894,O
potential,3894,O
target,3894,O
in,3894,O
the,3894,O
treatment,3894,O
of,3894,O
pulmonary,3894,B-DiseaseOrPhenotypicFeature
fibrosis,3894,I-DiseaseOrPhenotypicFeature
(,3894,O
PF,3894,B-DiseaseOrPhenotypicFeature
),3894,O
.,3894,O
In,3895,O
this,3895,O
study,3895,O
",",3895,O
we,3895,O
knocked,3895,O
down,3895,O
Bach1,3895,B-GeneOrGeneProduct
using,3895,O
adenovirus-mediated,3895,O
small,3895,O
interfering,3895,O
RNA,3895,O
(,3895,O
siRNA,3895,O
),3895,O
to,3895,O
determine,3895,O
whether,3895,O
the,3895,O
use,3895,O
of,3895,O
Bach1,3895,B-GeneOrGeneProduct
siRNA,3895,O
is,3895,O
an,3895,O
effective,3895,O
therapeutic,3895,O
strategy,3895,O
in,3895,O
mice,3895,B-OrganismTaxon
with,3895,O
bleomycin,3895,B-ChemicalEntity
(,3895,O
BLM,3895,B-ChemicalEntity
),3895,O
-induced,3895,O
PF,3895,B-DiseaseOrPhenotypicFeature
.,3895,O
Mouse,3896,B-OrganismTaxon
lung,3896,O
fibroblasts,3896,O
(,3896,O
MLFs,3896,O
),3896,O
were,3896,O
incubated,3896,O
with,3896,O
transforming,3896,B-GeneOrGeneProduct
growth,3896,I-GeneOrGeneProduct
factor,3896,I-GeneOrGeneProduct
(,3896,I-GeneOrGeneProduct
TGF,3896,I-GeneOrGeneProduct
),3896,I-GeneOrGeneProduct
-b1,3896,I-GeneOrGeneProduct
(,3896,O
5,3896,O
ng/ml,3896,O
),3896,O
and,3896,O
subsequently,3896,O
infected,3896,O
with,3896,O
recombined,3896,O
adenovirus-like,3896,O
Bach1,3896,B-GeneOrGeneProduct
siRNA1,3896,O
and,3896,O
Bach1,3896,B-GeneOrGeneProduct
siRNA2,3896,O
",",3896,O
while,3896,O
an,3896,O
empty,3896,O
adenovirus,3896,O
vector,3896,O
was,3896,O
used,3896,O
as,3896,O
the,3896,O
negative,3896,O
control,3896,O
.,3896,O
The,3897,O
selected,3897,O
Bach1,3897,B-GeneOrGeneProduct
siRNA,3897,O
with,3897,O
higher,3897,O
interference,3897,O
efficiency,3897,O
was,3897,O
used,3897,O
for,3897,O
the,3897,O
animal,3897,O
experiments,3897,O
.,3897,O
A,3898,O
mouse,3898,B-OrganismTaxon
model,3898,O
of,3898,O
BLM-induced,3898,B-ChemicalEntity
PF,3898,B-DiseaseOrPhenotypicFeature
was,3898,O
established,3898,O
",",3898,O
and,3898,O
Bach1,3898,B-GeneOrGeneProduct
siRNA,3898,O
(,3898,O
1x109,3898,O
pfu,3898,O
),3898,O
was,3898,O
administered,3898,O
to,3898,O
the,3898,O
mice,3898,B-OrganismTaxon
via,3898,O
the,3898,O
tail,3898,O
vein,3898,O
.,3898,O
The,3899,O
results,3899,O
revealed,3899,O
that,3899,O
the,3899,O
Bach1,3899,B-GeneOrGeneProduct
mRNA,3899,O
and,3899,O
protein,3899,O
levels,3899,O
were,3899,O
significantly,3899,O
downregulated,3899,O
by,3899,O
Bach1,3899,B-GeneOrGeneProduct
siRNA,3899,O
.,3899,O
Furthermore,3900,O
",",3900,O
the,3900,O
MLFs,3900,O
infected,3900,O
with,3900,O
Bach1,3900,B-GeneOrGeneProduct
siRNA,3900,O
exhibited,3900,O
increased,3900,O
mRNA,3900,O
and,3900,O
protein,3900,O
expression,3900,O
levels,3900,O
of,3900,O
heme,3900,B-GeneOrGeneProduct
oxygenase-1,3900,I-GeneOrGeneProduct
and,3900,O
glutathione,3900,B-GeneOrGeneProduct
peroxidase,3900,I-GeneOrGeneProduct
1,3900,I-GeneOrGeneProduct
",",3900,O
but,3900,O
decreased,3900,O
levels,3900,O
of,3900,O
TGF-b1,3900,B-GeneOrGeneProduct
and,3900,O
interleukin-6,3900,B-GeneOrGeneProduct
in,3900,O
the,3900,O
cell,3900,O
supernatants,3900,O
compared,3900,O
with,3900,O
the,3900,O
cells,3900,O
exposed,3900,O
to,3900,O
TGF-b1,3900,B-GeneOrGeneProduct
alone,3900,O
.,3900,O
Bach1,3901,B-GeneOrGeneProduct
knockdown,3901,O
by,3901,O
siRNA,3901,O
also,3901,O
enhanced,3901,O
the,3901,O
expression,3901,O
of,3901,O
antioxidant,3901,B-GeneOrGeneProduct
factors,3901,I-GeneOrGeneProduct
",",3901,O
but,3901,O
suppressed,3901,O
that,3901,O
of,3901,O
fibrosis-related,3901,B-DiseaseOrPhenotypicFeature
cytokines,3901,O
in,3901,O
mice,3901,B-OrganismTaxon
compared,3901,O
with,3901,O
the,3901,O
BLM,3901,B-ChemicalEntity
group,3901,O
.,3901,O
Finally,3902,O
",",3902,O
the,3902,O
inflammatory,3902,B-DiseaseOrPhenotypicFeature
infiltration,3902,O
of,3902,O
alveolar,3902,O
and,3902,O
interstitial,3902,O
cells,3902,O
and,3902,O
the,3902,O
destruction,3902,O
of,3902,O
lung,3902,O
structure,3902,O
were,3902,O
significantly,3902,O
attenuated,3902,O
in,3902,O
the,3902,O
mide,3902,O
administered,3902,O
Bach1,3902,B-GeneOrGeneProduct
siRNA,3902,O
compared,3902,O
with,3902,O
those,3902,O
in,3902,O
the,3902,O
BLM,3902,B-ChemicalEntity
group,3902,O
.,3902,O
On,3903,O
the,3903,O
whole,3903,O
",",3903,O
our,3903,O
findings,3903,O
demonstrate,3903,O
that,3903,O
Bach1,3903,B-GeneOrGeneProduct
siRNA,3903,O
exerts,3903,O
protective,3903,O
effects,3903,O
against,3903,O
BLM-induced,3903,B-ChemicalEntity
PF,3903,B-DiseaseOrPhenotypicFeature
in,3903,O
mice,3903,B-OrganismTaxon
.,3903,O
Our,3904,O
data,3904,O
may,3904,O
provide,3904,O
the,3904,O
basis,3904,O
for,3904,O
the,3904,O
development,3904,O
of,3904,O
novel,3904,O
targeted,3904,O
therapeutic,3904,O
strategies,3904,O
for,3904,O
PF,3904,B-DiseaseOrPhenotypicFeature
.,3904,O
FGFR1,3905,B-GeneOrGeneProduct
and,3905,O
NTRK3,3905,B-GeneOrGeneProduct
actionable,3905,O
alterations,3905,O
in,3905,O
``,3905,O
Wild-Type,3905,O
'',3905,O
gastrointestinal,3905,B-DiseaseOrPhenotypicFeature
stromal,3905,I-DiseaseOrPhenotypicFeature
tumors,3905,I-DiseaseOrPhenotypicFeature
.,3905,O
BACKGROUND,3906,O
:,3906,O
About,3906,O
10-15,3906,O
%,3906,O
of,3906,O
adult,3906,O
",",3906,O
and,3906,O
most,3906,O
pediatric,3906,O
",",3906,O
gastrointestinal,3906,B-DiseaseOrPhenotypicFeature
stromal,3906,I-DiseaseOrPhenotypicFeature
tumors,3906,I-DiseaseOrPhenotypicFeature
(,3906,O
GIST,3906,B-DiseaseOrPhenotypicFeature
),3906,O
lack,3906,O
mutations,3906,O
in,3906,O
KIT,3906,B-GeneOrGeneProduct
",",3906,O
PDGFRA,3906,B-GeneOrGeneProduct
",",3906,O
SDHx,3906,B-GeneOrGeneProduct
",",3906,O
or,3906,O
RAS,3906,B-GeneOrGeneProduct
pathway,3906,O
components,3906,O
(,3906,O
KRAS,3906,B-GeneOrGeneProduct
",",3906,O
BRAF,3906,B-GeneOrGeneProduct
",",3906,O
NF1,3906,B-GeneOrGeneProduct
),3906,O
.,3906,O
The,3907,O
identification,3907,O
of,3907,O
additional,3907,O
mutated,3907,O
genes,3907,O
in,3907,O
this,3907,O
rare,3907,O
subset,3907,O
of,3907,O
tumors,3907,B-DiseaseOrPhenotypicFeature
can,3907,O
have,3907,O
important,3907,O
clinical,3907,O
benefit,3907,O
to,3907,O
identify,3907,O
altered,3907,O
biological,3907,O
pathways,3907,O
and,3907,O
select,3907,O
targeted,3907,O
therapies,3907,O
.,3907,O
METHODS,3908,O
:,3908,O
We,3908,O
performed,3908,O
comprehensive,3908,O
genomic,3908,O
profiling,3908,O
(,3908,O
CGP,3908,O
),3908,O
for,3908,O
coding,3908,O
regions,3908,O
in,3908,O
more,3908,O
than,3908,O
300,3908,O
cancer-related,3908,B-DiseaseOrPhenotypicFeature
genes,3908,O
of,3908,O
186,3908,O
GISTs,3908,B-DiseaseOrPhenotypicFeature
to,3908,O
assess,3908,O
for,3908,O
their,3908,O
somatic,3908,O
alterations,3908,O
.,3908,O
RESULTS,3909,O
:,3909,O
We,3909,O
identified,3909,O
24,3909,O
GIST,3909,B-DiseaseOrPhenotypicFeature
lacking,3909,O
alterations,3909,O
in,3909,O
the,3909,O
canonical,3909,O
KIT/PDGFRA/RAS,3909,B-GeneOrGeneProduct
pathways,3909,O
",",3909,O
including,3909,O
12,3909,O
without,3909,O
SDHx,3909,B-GeneOrGeneProduct
alterations,3909,O
.,3909,O
These,3910,O
24,3910,O
patients,3910,B-OrganismTaxon
were,3910,O
mostly,3910,O
adults,3910,O
(,3910,O
96,3910,O
%,3910,O
),3910,O
.,3910,O
The,3911,O
tumors,3911,B-DiseaseOrPhenotypicFeature
had,3911,O
a,3911,O
46,3911,O
%,3911,O
rate,3911,O
of,3911,O
nodal,3911,B-DiseaseOrPhenotypicFeature
metastases,3911,I-DiseaseOrPhenotypicFeature
.,3911,O
These,3912,O
24,3912,O
GIST,3912,B-DiseaseOrPhenotypicFeature
were,3912,O
more,3912,O
commonly,3912,O
mutated,3912,O
at,3912,O
7,3912,O
genes,3912,O
:,3912,O
ARID1B,3912,B-GeneOrGeneProduct
",",3912,O
ATR,3912,B-GeneOrGeneProduct
",",3912,O
FGFR1,3912,B-GeneOrGeneProduct
",",3912,O
LTK,3912,B-GeneOrGeneProduct
",",3912,O
SUFU,3912,B-GeneOrGeneProduct
",",3912,O
PARK2,3912,B-GeneOrGeneProduct
and,3912,O
ZNF217,3912,B-GeneOrGeneProduct
.,3912,O
Two,3913,O
tumors,3913,B-DiseaseOrPhenotypicFeature
harbored,3913,O
FGFR1,3913,B-GeneOrGeneProduct
gene,3913,O
fusions,3913,O
(,3913,O
FGFR1-HOOK3,3913,B-GeneOrGeneProduct
",",3913,O
FGFR1-TACC1,3913,B-GeneOrGeneProduct
),3913,O
and,3913,O
one,3913,O
harbored,3913,O
an,3913,O
ETV6-NTRK3,3913,B-GeneOrGeneProduct
fusion,3913,O
that,3913,O
responded,3913,O
to,3913,O
TRK,3913,B-GeneOrGeneProduct
inhibition,3913,O
.,3913,O
In,3914,O
an,3914,O
independent,3914,O
sample,3914,O
set,3914,O
",",3914,O
we,3914,O
identified,3914,O
5,3914,O
GIST,3914,B-DiseaseOrPhenotypicFeature
cases,3914,O
lacking,3914,O
alterations,3914,O
in,3914,O
the,3914,O
KIT/PDGFRA/SDHx/RAS,3914,B-GeneOrGeneProduct
pathways,3914,O
",",3914,O
including,3914,O
two,3914,O
additional,3914,O
cases,3914,O
with,3914,O
FGFR1-TACC1,3914,B-GeneOrGeneProduct
and,3914,O
ETV6-NTRK3,3914,B-GeneOrGeneProduct
fusions,3914,O
.,3914,O
CONCLUSIONS,3915,O
:,3915,O
Using,3915,O
patient,3915,B-OrganismTaxon
demographics,3915,O
",",3915,O
tumor,3915,B-DiseaseOrPhenotypicFeature
characteristics,3915,O
",",3915,O
and,3915,O
CGP,3915,O
",",3915,O
we,3915,O
show,3915,O
that,3915,O
GIST,3915,B-DiseaseOrPhenotypicFeature
lacking,3915,O
alterations,3915,O
in,3915,O
canonical,3915,O
genes,3915,O
occur,3915,O
in,3915,O
younger,3915,O
patients,3915,B-OrganismTaxon
",",3915,O
frequently,3915,O
metastasize,3915,B-DiseaseOrPhenotypicFeature
to,3915,I-DiseaseOrPhenotypicFeature
lymph,3915,I-DiseaseOrPhenotypicFeature
nodes,3915,I-DiseaseOrPhenotypicFeature
",",3915,O
and,3915,O
most,3915,O
contain,3915,O
deleterious,3915,O
genomic,3915,O
alterations,3915,O
",",3915,O
including,3915,O
gene,3915,O
fusions,3915,O
involving,3915,O
FGFR1,3915,B-GeneOrGeneProduct
and,3915,O
NTRK3,3915,B-GeneOrGeneProduct
.,3915,O
If,3916,O
confirmed,3916,O
in,3916,O
larger,3916,O
series,3916,O
",",3916,O
routine,3916,O
testing,3916,O
for,3916,O
these,3916,O
translocations,3916,O
may,3916,O
be,3916,O
indicated,3916,O
for,3916,O
this,3916,O
subset,3916,O
of,3916,O
GIST,3916,B-DiseaseOrPhenotypicFeature
.,3916,O
Moreover,3917,O
",",3917,O
these,3917,O
findings,3917,O
can,3917,O
be,3917,O
used,3917,O
to,3917,O
guide,3917,O
personalized,3917,O
treatments,3917,O
for,3917,O
patients,3917,B-OrganismTaxon
with,3917,O
GIST,3917,B-DiseaseOrPhenotypicFeature
.,3917,O
Trial,3918,O
registration,3918,O
NCT,3918,O
02576431,3918,O
.,3918,O
Registered,3919,O
October,3919,O
12,3919,O
",",3919,O
2015,3919,O
.,3919,O
A,3920,O
Critical,3920,O
Role,3920,O
for,3920,O
the,3920,O
Type,3920,B-GeneOrGeneProduct
I,3920,I-GeneOrGeneProduct
Interferon,3920,I-GeneOrGeneProduct
Receptor,3920,I-GeneOrGeneProduct
in,3920,O
Virus-Induced,3920,O
Autoimmune,3920,B-DiseaseOrPhenotypicFeature
Diabetes,3920,I-DiseaseOrPhenotypicFeature
in,3920,O
Rats,3920,B-OrganismTaxon
.,3920,O
The,3921,O
pathogenesis,3921,O
of,3921,O
human,3921,B-OrganismTaxon
type,3921,B-DiseaseOrPhenotypicFeature
1,3921,I-DiseaseOrPhenotypicFeature
diabetes,3921,I-DiseaseOrPhenotypicFeature
",",3921,O
characterized,3921,O
by,3921,O
immune-mediated,3921,O
damage,3921,O
of,3921,O
insulin-producing,3921,B-GeneOrGeneProduct
b-cells,3921,O
of,3921,O
pancreatic,3921,O
islets,3921,O
",",3921,O
may,3921,O
involve,3921,O
viral,3921,B-DiseaseOrPhenotypicFeature
infection,3921,I-DiseaseOrPhenotypicFeature
.,3921,O
Essential,3922,O
components,3922,O
of,3922,O
the,3922,O
innate,3922,O
immune,3922,O
antiviral,3922,O
response,3922,O
",",3922,O
including,3922,O
type,3922,B-GeneOrGeneProduct
I,3922,I-GeneOrGeneProduct
interferon,3922,I-GeneOrGeneProduct
(,3922,O
IFN,3922,B-GeneOrGeneProduct
),3922,O
and,3922,O
IFN,3922,B-GeneOrGeneProduct
receptor-mediated,3922,O
signaling,3922,O
pathways,3922,O
",",3922,O
are,3922,O
candidates,3922,O
for,3922,O
determining,3922,O
susceptibility,3922,O
to,3922,O
human,3922,B-OrganismTaxon
type,3922,B-DiseaseOrPhenotypicFeature
1,3922,I-DiseaseOrPhenotypicFeature
diabetes,3922,I-DiseaseOrPhenotypicFeature
.,3922,O
Numerous,3923,O
aspects,3923,O
of,3923,O
human,3923,B-OrganismTaxon
type,3923,B-DiseaseOrPhenotypicFeature
1,3923,I-DiseaseOrPhenotypicFeature
diabetes,3923,I-DiseaseOrPhenotypicFeature
pathogenesis,3923,O
are,3923,O
recapitulated,3923,O
in,3923,O
the,3923,O
LEW.1WR1,3923,O
rat,3923,B-OrganismTaxon
model,3923,O
.,3923,O
Diabetes,3924,B-DiseaseOrPhenotypicFeature
can,3924,O
be,3924,O
induced,3924,O
in,3924,O
LEW.1WR1,3924,O
weanling,3924,O
rats,3924,B-OrganismTaxon
challenged,3924,O
with,3924,O
virus,3924,O
or,3924,O
with,3924,O
the,3924,O
viral,3924,O
mimetic,3924,O
polyinosinic,3924,B-ChemicalEntity
:,3924,I-ChemicalEntity
polycytidylic,3924,I-ChemicalEntity
acid,3924,I-ChemicalEntity
(,3924,O
poly,3924,B-ChemicalEntity
I,3924,I-ChemicalEntity
:,3924,I-ChemicalEntity
C,3924,I-ChemicalEntity
),3924,O
.,3924,O
We,3925,O
hypothesized,3925,O
that,3925,O
disrupting,3925,O
the,3925,O
cognate,3925,O
type,3925,B-GeneOrGeneProduct
I,3925,I-GeneOrGeneProduct
IFN,3925,I-GeneOrGeneProduct
receptor,3925,I-GeneOrGeneProduct
(,3925,O
type,3925,B-GeneOrGeneProduct
I,3925,I-GeneOrGeneProduct
IFN,3925,I-GeneOrGeneProduct
a/b,3925,I-GeneOrGeneProduct
receptor,3925,I-GeneOrGeneProduct
[,3925,O
IFNAR,3925,B-GeneOrGeneProduct
],3925,O
),3925,O
to,3925,O
interrupt,3925,O
IFN,3925,B-GeneOrGeneProduct
signaling,3925,O
would,3925,O
prevent,3925,O
or,3925,O
delay,3925,O
the,3925,O
development,3925,O
of,3925,O
virus-induced,3925,O
diabetes,3925,B-DiseaseOrPhenotypicFeature
.,3925,O
We,3926,O
generated,3926,O
IFNAR1,3926,B-GeneOrGeneProduct
subunit-deficient,3926,O
LEW.1WR1,3926,O
rats,3926,B-OrganismTaxon
using,3926,O
CRISPR-Cas9,3926,O
(,3926,O
clustered,3926,O
regularly,3926,O
interspaced,3926,O
short,3926,O
palindromic,3926,O
repeats-associated,3926,O
protein,3926,O
9,3926,O
),3926,O
genome,3926,O
editing,3926,O
and,3926,O
confirmed,3926,O
functional,3926,O
disruption,3926,O
of,3926,O
the,3926,O
Ifnar1,3926,B-GeneOrGeneProduct
gene,3926,O
.,3926,O
IFNAR1,3927,B-GeneOrGeneProduct
deficiency,3927,O
significantly,3927,O
delayed,3927,O
the,3927,O
onset,3927,O
and,3927,O
frequency,3927,O
of,3927,O
diabetes,3927,B-DiseaseOrPhenotypicFeature
and,3927,O
greatly,3927,O
reduced,3927,O
the,3927,O
intensity,3927,O
of,3927,O
insulitis,3927,B-DiseaseOrPhenotypicFeature
after,3927,O
poly,3927,B-ChemicalEntity
I,3927,I-ChemicalEntity
:,3927,I-ChemicalEntity
C,3927,I-ChemicalEntity
treatment,3927,O
.,3927,O
The,3928,O
occurrence,3928,O
of,3928,O
Kilham,3928,B-OrganismTaxon
rat,3928,I-OrganismTaxon
virus-induced,3928,O
diabetes,3928,B-DiseaseOrPhenotypicFeature
was,3928,O
also,3928,O
diminished,3928,O
in,3928,O
IFNAR1-deficient,3928,B-GeneOrGeneProduct
animals,3928,O
.,3928,O
These,3929,O
findings,3929,O
firmly,3929,O
establish,3929,O
that,3929,O
alterations,3929,O
in,3929,O
innate,3929,O
immunity,3929,O
influence,3929,O
the,3929,O
course,3929,O
of,3929,O
autoimmune,3929,B-DiseaseOrPhenotypicFeature
diabetes,3929,I-DiseaseOrPhenotypicFeature
and,3929,O
support,3929,O
the,3929,O
use,3929,O
of,3929,O
targeted,3929,O
strategies,3929,O
to,3929,O
limit,3929,O
or,3929,O
prevent,3929,O
the,3929,O
development,3929,O
of,3929,O
type,3929,B-DiseaseOrPhenotypicFeature
1,3929,I-DiseaseOrPhenotypicFeature
diabetes,3929,I-DiseaseOrPhenotypicFeature
.,3929,O
Spirulina,3930,B-OrganismTaxon
lipopolysaccharides,3930,B-ChemicalEntity
inhibit,3930,O
tumor,3930,B-DiseaseOrPhenotypicFeature
growth,3930,O
in,3930,O
a,3930,O
Toll-like,3930,B-GeneOrGeneProduct
receptor,3930,I-GeneOrGeneProduct
4-dependent,3930,O
manner,3930,O
by,3930,O
altering,3930,O
the,3930,O
cytokine,3930,O
milieu,3930,O
from,3930,O
interleukin-17/interleukin-23,3930,B-GeneOrGeneProduct
to,3930,O
interferon-g.,3930,B-GeneOrGeneProduct
Th17,3930,O
cells,3930,O
and,3930,O
the,3930,O
cytokine,3930,O
they,3930,O
produce,3930,O
",",3930,O
interleukin,3930,B-GeneOrGeneProduct
(,3930,I-GeneOrGeneProduct
IL,3930,I-GeneOrGeneProduct
),3930,I-GeneOrGeneProduct
-17,3930,I-GeneOrGeneProduct
",",3930,O
play,3930,O
an,3930,O
important,3930,O
role,3930,O
in,3930,O
tumor,3930,B-DiseaseOrPhenotypicFeature
progression,3930,O
in,3930,O
humans,3930,B-OrganismTaxon
and,3930,O
in,3930,O
mice,3930,B-OrganismTaxon
.,3930,O
IL-6,3931,B-GeneOrGeneProduct
and,3931,O
IL-23,3931,B-GeneOrGeneProduct
are,3931,O
critical,3931,O
cytokines,3931,O
for,3931,O
the,3931,O
differentiation,3931,O
and,3931,O
propagation,3931,O
of,3931,O
Th17,3931,O
cells,3931,O
",",3931,O
respectively,3931,O
.,3931,O
Bacterial,3932,O
lipopolysaccharides,3932,B-ChemicalEntity
(,3932,O
LPS,3932,B-ChemicalEntity
),3932,O
are,3932,O
known,3932,O
to,3932,O
stimulate,3932,O
immune,3932,O
cells,3932,O
to,3932,O
produce,3932,O
such,3932,O
inflammatory,3932,B-GeneOrGeneProduct
cytokines,3932,I-GeneOrGeneProduct
.,3932,O
Contrary,3933,O
to,3933,O
Escherichia,3933,B-OrganismTaxon
coli,3933,I-OrganismTaxon
(,3933,O
E.,3933,B-OrganismTaxon
coli,3933,I-OrganismTaxon
),3933,O
LPS,3933,B-ChemicalEntity
",",3933,O
LPS,3933,B-ChemicalEntity
from,3933,O
Spirulina,3933,B-OrganismTaxon
has,3933,O
low,3933,O
toxicity,3933,B-DiseaseOrPhenotypicFeature
and,3933,O
barely,3933,O
induces,3933,O
in,3933,O
vivo,3933,O
production,3933,O
of,3933,O
IL-6,3933,B-GeneOrGeneProduct
and,3933,O
IL-23,3933,B-GeneOrGeneProduct
in,3933,O
mice,3933,B-OrganismTaxon
.,3933,O
We,3934,O
examined,3934,O
the,3934,O
antitumor,3934,O
effects,3934,O
of,3934,O
Spirulina,3934,B-OrganismTaxon
LPS,3934,B-ChemicalEntity
compared,3934,O
to,3934,O
E.,3934,B-OrganismTaxon
coli,3934,I-OrganismTaxon
LPS,3934,B-ChemicalEntity
in,3934,O
an,3934,O
MH134,3934,B-CellLine
hepatoma,3934,B-DiseaseOrPhenotypicFeature
model,3934,O
.,3934,O
Administration,3935,O
of,3935,O
Spirulina,3935,B-OrganismTaxon
LPS,3935,B-ChemicalEntity
suppressed,3935,O
tumor,3935,B-DiseaseOrPhenotypicFeature
growth,3935,O
in,3935,O
C3H/HeN,3935,O
mice,3935,B-OrganismTaxon
",",3935,O
but,3935,O
not,3935,O
in,3935,O
Toll-like,3935,B-GeneOrGeneProduct
receptor,3935,I-GeneOrGeneProduct
4,3935,I-GeneOrGeneProduct
(,3935,O
TLR4,3935,B-GeneOrGeneProduct
),3935,O
-mutant,3935,O
C3H/HeJ,3935,O
mice,3935,B-OrganismTaxon
",",3935,O
by,3935,O
reducing,3935,O
serum,3935,O
levels,3935,O
of,3935,O
IL-17,3935,B-GeneOrGeneProduct
and,3935,O
IL-23,3935,B-GeneOrGeneProduct
",",3935,O
while,3935,O
increasing,3935,O
interferon,3935,B-GeneOrGeneProduct
(,3935,I-GeneOrGeneProduct
IFN,3935,I-GeneOrGeneProduct
),3935,I-GeneOrGeneProduct
-g,3935,I-GeneOrGeneProduct
levels,3935,O
.,3935,O
The,3936,O
antitumor,3936,O
activity,3936,O
and,3936,O
IFN-g,3936,B-GeneOrGeneProduct
production,3936,O
were,3936,O
mediated,3936,O
by,3936,O
T,3936,O
cells,3936,O
.,3936,O
Moreover,3937,O
",",3937,O
in,3937,O
vitro,3937,O
experiments,3937,O
showed,3937,O
that,3937,O
Spirulina,3937,B-OrganismTaxon
LPS,3937,B-ChemicalEntity
impaired,3937,O
the,3937,O
antigen-presenting,3937,O
function,3937,O
that,3937,O
supports,3937,O
the,3937,O
generation,3937,O
of,3937,O
IL-17-producing,3937,B-GeneOrGeneProduct
cells,3937,O
in,3937,O
a,3937,O
toll-like,3937,B-GeneOrGeneProduct
receptor,3937,I-GeneOrGeneProduct
(,3937,I-GeneOrGeneProduct
TLR,3937,I-GeneOrGeneProduct
),3937,I-GeneOrGeneProduct
4-dependent,3937,O
manner,3937,O
.,3937,O
Of,3938,O
note,3938,O
",",3938,O
injection,3938,O
of,3938,O
anti-IL-17,3938,O
antibody,3938,O
in,3938,O
tumor-bearing,3938,B-DiseaseOrPhenotypicFeature
C3H/HeN,3938,O
mice,3938,B-OrganismTaxon
in,3938,O
the,3938,O
absence,3938,O
of,3938,O
Spirulina,3938,B-OrganismTaxon
LPS,3938,B-ChemicalEntity
markedly,3938,O
suppressed,3938,O
tumor,3938,B-DiseaseOrPhenotypicFeature
growth,3938,O
and,3938,O
augmented,3938,O
IFN-g,3938,B-GeneOrGeneProduct
responses,3938,O
.,3938,O
Thus,3939,O
",",3939,O
our,3939,O
results,3939,O
support,3939,O
the,3939,O
notion,3939,O
that,3939,O
IFN-g,3939,B-GeneOrGeneProduct
and,3939,O
IL-17/IL-23,3939,B-GeneOrGeneProduct
mutually,3939,O
regulate,3939,O
Th17,3939,O
and,3939,O
Th1,3939,O
responses,3939,O
in,3939,O
tumor-bearing,3939,B-DiseaseOrPhenotypicFeature
hosts,3939,O
",",3939,O
and,3939,O
Spirulina,3939,B-OrganismTaxon
LPS,3939,B-ChemicalEntity
modulates,3939,O
the,3939,O
balance,3939,O
of,3939,O
the,3939,O
IFN-g-IL-17/IL-23,3939,B-GeneOrGeneProduct
axis,3939,O
towards,3939,O
IFN-g,3939,B-GeneOrGeneProduct
production,3939,O
",",3939,O
which,3939,O
leads,3939,O
to,3939,O
tumor,3939,B-DiseaseOrPhenotypicFeature
inhibition,3939,O
.,3939,O
Furthermore,3940,O
",",3940,O
Spirulina,3940,B-OrganismTaxon
LPS,3940,B-ChemicalEntity
effectively,3940,O
inhibited,3940,O
the,3940,O
spontaneous,3940,O
development,3940,O
of,3940,O
mammary,3940,B-DiseaseOrPhenotypicFeature
tumors,3940,I-DiseaseOrPhenotypicFeature
.,3940,O
This,3941,O
study,3941,O
has,3941,O
important,3941,O
implications,3941,O
for,3941,O
the,3941,O
exploitation,3941,O
of,3941,O
TLR-based,3941,B-GeneOrGeneProduct
immunomodulators,3941,O
for,3941,O
cancer,3941,B-DiseaseOrPhenotypicFeature
immunotherapy,3941,O
.,3941,O
Brain-derived,3942,B-GeneOrGeneProduct
neurotrophic,3942,I-GeneOrGeneProduct
factor,3942,I-GeneOrGeneProduct
attenuates,3942,O
doxorubicin-induced,3942,B-ChemicalEntity
cardiac,3942,B-DiseaseOrPhenotypicFeature
dysfunction,3942,I-DiseaseOrPhenotypicFeature
through,3942,O
activating,3942,O
Akt,3942,B-GeneOrGeneProduct
signalling,3942,O
in,3942,O
rats,3942,B-OrganismTaxon
.,3942,O
The,3943,O
clinical,3943,O
application,3943,O
of,3943,O
doxorubicin,3943,B-ChemicalEntity
(,3943,O
Dox,3943,B-ChemicalEntity
),3943,O
is,3943,O
limited,3943,O
by,3943,O
its,3943,O
adverse,3943,O
effect,3943,O
of,3943,O
cardiotoxicity,3943,B-DiseaseOrPhenotypicFeature
.,3943,O
Previous,3944,O
studies,3944,O
have,3944,O
suggested,3944,O
the,3944,O
cardioprotective,3944,O
effect,3944,O
of,3944,O
brain-derived,3944,B-GeneOrGeneProduct
neurotrophic,3944,I-GeneOrGeneProduct
factor,3944,I-GeneOrGeneProduct
(,3944,O
BDNF,3944,B-GeneOrGeneProduct
),3944,O
.,3944,O
We,3945,O
hypothesize,3945,O
that,3945,O
BDNF,3945,B-GeneOrGeneProduct
could,3945,O
protect,3945,O
against,3945,O
Dox-induced,3945,B-ChemicalEntity
cardiotoxicity,3945,B-DiseaseOrPhenotypicFeature
.,3945,O
Sprague,3946,O
Dawley,3946,O
rats,3946,B-OrganismTaxon
were,3946,O
injected,3946,O
with,3946,O
Dox,3946,B-ChemicalEntity
(,3946,O
2.5,3946,O
mg/kg,3946,O
",",3946,O
3,3946,O
times/week,3946,O
",",3946,O
i.p,3946,O
.,3946,O
),3947,O
",",3947,O
in,3947,O
the,3947,O
presence,3947,O
or,3947,O
absence,3947,O
of,3947,O
recombinant,3947,O
BDNF,3947,O
(,3947,O
0.4,3947,O
ug/kg,3947,O
",",3947,O
i.v,3947,O
.,3947,O
),3947,O
for,3948,O
2,3948,O
weeks,3948,O
.,3948,O
H9c2,3949,O
cells,3949,O
were,3949,O
treated,3949,O
with,3949,O
Dox,3949,O
(,3949,O
1,3949,O
uM,3949,O
),3949,O
and/or,3949,O
BDNF,3949,O
(,3949,O
400,3949,O
ng/ml,3949,O
),3949,O
for,3949,O
24,3949,O
hrs,3949,O
.,3949,O
Functional,3950,O
roles,3950,O
of,3950,O
BDNF,3950,O
against,3950,O
Dox-induced,3950,O
cardiac,3950,I-DiseaseOrPhenotypicFeature
injury,3950,O
were,3950,O
examined,3950,O
both,3950,O
in,3950,O
vivo,3950,O
and,3950,O
in,3950,O
vitro,3950,O
.,3950,O
Protein,3951,O
level,3951,O
of,3951,O
BDNF,3951,O
was,3951,O
reduced,3951,O
in,3951,O
Dox-treated,3951,O
rat,3951,O
ventricles,3951,O
",",3951,O
whereas,3951,O
BDNF,3951,O
and,3951,O
its,3951,O
receptor,3951,O
tropomyosin-related,3951,I-GeneOrGeneProduct
kinase,3951,I-GeneOrGeneProduct
B,3951,O
(,3951,B-GeneOrGeneProduct
TrkB,3951,O
),3951,O
were,3951,O
markedly,3951,O
up-regulated,3951,O
after,3951,O
BDNF,3951,O
administration,3951,O
.,3951,O
Brain-derived,3952,O
neurotrophic,3952,O
factor,3952,O
significantly,3952,O
inhibited,3952,O
Dox-induced,3952,O
cardiomyocyte,3952,O
apoptosis,3952,O
",",3952,O
oxidative,3952,O
stress,3952,O
and,3952,O
cardiac,3952,I-DiseaseOrPhenotypicFeature
dysfunction,3952,O
in,3952,O
rats,3952,O
.,3952,O
Meanwhile,3953,O
",",3953,O
BDNF,3953,O
increased,3953,O
cell,3953,O
viability,3953,O
",",3953,O
inhibited,3953,O
apoptosis,3953,O
and,3953,O
DNA,3953,O
damage,3953,O
of,3953,O
Dox-treated,3953,O
H9c2,3953,O
cells,3953,O
.,3953,O
Investigations,3954,O
of,3954,O
the,3954,O
underlying,3954,O
mechanisms,3954,O
revealed,3954,O
that,3954,O
BDNF,3954,O
activated,3954,O
Akt,3954,O
and,3954,O
preserved,3954,O
phosphorylation,3954,O
of,3954,O
mammalian,3954,I-GeneOrGeneProduct
target,3954,I-GeneOrGeneProduct
of,3954,I-GeneOrGeneProduct
rapamycin,3954,O
and,3954,O
Bad,3954,O
without,3954,O
affecting,3954,O
p38,3954,I-GeneOrGeneProduct
mitogen-activated,3954,I-GeneOrGeneProduct
protein,3954,I-GeneOrGeneProduct
kinase,3954,O
and,3954,O
extracellular,3954,I-GeneOrGeneProduct
regulated,3954,I-GeneOrGeneProduct
protein,3954,I-GeneOrGeneProduct
kinase,3954,O
pathways,3954,O
.,3954,O
Furthermore,3955,O
",",3955,O
the,3955,O
beneficial,3955,O
effect,3955,O
of,3955,O
BDNF,3955,O
was,3955,O
abolished,3955,O
by,3955,O
BDNF,3955,O
scavenger,3955,O
TrkB-Fc,3955,O
or,3955,O
Akt,3955,O
inhibitor,3955,O
.,3955,O
In,3956,O
conclusion,3956,O
",",3956,O
our,3956,O
findings,3956,O
reveal,3956,O
a,3956,O
potent,3956,O
protective,3956,O
role,3956,O
of,3956,O
BDNF,3956,O
against,3956,O
Dox-induced,3956,O
cardiotoxicity,3956,O
by,3956,O
activating,3956,O
Akt,3956,O
signalling,3956,O
",",3956,O
which,3956,O
may,3956,O
facilitate,3956,O
the,3956,O
safe,3956,O
use,3956,O
of,3956,O
Dox,3956,O
in,3956,O
cancer,3956,O
treatment,3956,O
.,3956,O
NEK2,3957,B-GeneOrGeneProduct
serves,3957,O
as,3957,O
a,3957,O
prognostic,3957,O
biomarker,3957,O
for,3957,O
hepatocellular,3957,B-DiseaseOrPhenotypicFeature
carcinoma,3957,I-DiseaseOrPhenotypicFeature
.,3957,O
Never,3958,B-GeneOrGeneProduct
in,3958,I-GeneOrGeneProduct
mitosis,3958,I-GeneOrGeneProduct
gene,3958,I-GeneOrGeneProduct
A,3958,I-GeneOrGeneProduct
(,3958,I-GeneOrGeneProduct
NIMA,3958,I-GeneOrGeneProduct
),3958,I-GeneOrGeneProduct
-related,3958,I-GeneOrGeneProduct
kinase,3958,I-GeneOrGeneProduct
2,3958,I-GeneOrGeneProduct
(,3958,O
NEK2,3958,B-GeneOrGeneProduct
),3958,O
is,3958,O
a,3958,O
microtubule-associated,3958,B-GeneOrGeneProduct
protein,3958,I-GeneOrGeneProduct
that,3958,O
regulates,3958,O
spindle,3958,O
assembly,3958,O
in,3958,O
human,3958,B-OrganismTaxon
cells,3958,O
and,3958,O
is,3958,O
overexpressed,3958,O
in,3958,O
various,3958,O
malignancies,3958,B-DiseaseOrPhenotypicFeature
.,3958,O
However,3959,O
",",3959,O
the,3959,O
role,3959,O
of,3959,O
NEK2,3959,B-GeneOrGeneProduct
in,3959,O
hepatocellular,3959,B-DiseaseOrPhenotypicFeature
carcinoma,3959,I-DiseaseOrPhenotypicFeature
(,3959,O
HCC,3959,B-DiseaseOrPhenotypicFeature
),3959,O
remains,3959,O
undetermined,3959,O
.,3959,O
We,3960,O
performed,3960,O
RNA-seq,3960,O
of,3960,O
the,3960,O
HCC,3960,B-DiseaseOrPhenotypicFeature
cell,3960,O
line,3960,O
SMMC-7721,3960,B-CellLine
and,3960,O
the,3960,O
normal,3960,O
liver,3960,O
cell,3960,O
line,3960,O
HL-7702,3960,B-CellLine
using,3960,O
the,3960,O
Ion,3960,O
Proton,3960,O
System,3960,O
.,3960,O
NEK2,3961,B-GeneOrGeneProduct
expression,3961,O
was,3961,O
detected,3961,O
using,3961,O
quantitative,3961,O
reverse,3961,O
transcription,3961,O
polymerase,3961,O
chain,3961,O
reaction,3961,O
in,3961,O
two,3961,O
cell,3961,O
lines,3961,O
and,3961,O
5,3961,O
matched,3961,O
HCC,3961,B-DiseaseOrPhenotypicFeature
and,3961,O
adjacent,3961,O
non-tumorous,3961,O
liver,3961,O
tissues,3961,O
.,3961,O
The,3962,O
correlation,3962,O
between,3962,O
survival,3962,O
and,3962,O
NEK2,3962,B-GeneOrGeneProduct
expression,3962,O
was,3962,O
analyzed,3962,O
in,3962,O
359,3962,O
patients,3962,B-OrganismTaxon
with,3962,O
HCC,3962,B-DiseaseOrPhenotypicFeature
using,3962,O
RNASeqV2,3962,O
data,3962,O
available,3962,O
from,3962,O
The,3962,O
Cancer,3962,B-DiseaseOrPhenotypicFeature
Genome,3962,O
Atlas,3962,O
(,3962,O
TCGA,3962,O
),3962,O
website,3962,O
(,3962,O
https,3962,O
:,3962,O
//tcga-data.nci.nih.gov/tcga/,3962,O
),3962,O
.,3962,O
The,3963,O
expression,3963,O
of,3963,O
NEK2,3963,B-GeneOrGeneProduct
",",3963,O
phospho-AKT,3963,O
and,3963,O
MMP-2,3963,B-GeneOrGeneProduct
was,3963,O
evaluated,3963,O
by,3963,O
immunohistochemistry,3963,O
in,3963,O
63,3963,O
cases,3963,O
of,3963,O
HCC,3963,B-DiseaseOrPhenotypicFeature
and,3963,O
matched,3963,O
adjacent,3963,O
non-tumorous,3963,O
liver,3963,O
tissues,3963,O
.,3963,O
Relationships,3964,O
between,3964,O
protein,3964,O
expression,3964,O
and,3964,O
clinicopathological,3964,O
parameters,3964,O
were,3964,O
assessed,3964,O
",",3964,O
and,3964,O
the,3964,O
correlations,3964,O
between,3964,O
NEK2,3964,B-GeneOrGeneProduct
with,3964,O
phospho-AKT,3964,O
and,3964,O
MMP-2,3964,B-GeneOrGeneProduct
expressions,3964,O
were,3964,O
evaluated,3964,O
.,3964,O
A,3965,O
total,3965,O
of,3965,O
610,3965,O
differentially,3965,O
expressed,3965,O
genes,3965,O
(,3965,O
DEGs,3965,O
),3965,O
were,3965,O
revealed,3965,O
in,3965,O
the,3965,O
transcriptome,3965,O
comparison,3965,O
",",3965,O
297,3965,O
of,3965,O
which,3965,O
were,3965,O
upregulated,3965,O
and,3965,O
313,3965,O
were,3965,O
downregulated,3965,O
in,3965,O
HCC,3965,B-DiseaseOrPhenotypicFeature
.,3965,O
NEK2,3966,B-GeneOrGeneProduct
",",3966,O
as,3966,O
the,3966,O
most,3966,O
obviously,3966,O
different,3966,O
DEG,3966,O
in,3966,O
cells,3966,O
and,3966,O
tissues,3966,O
from,3966,O
the,3966,O
RNA-seq,3966,O
data,3966,O
",",3966,O
was,3966,O
listed,3966,O
as,3966,O
an,3966,O
HCC,3966,B-DiseaseOrPhenotypicFeature
candidate,3966,O
biomarker,3966,O
for,3966,O
further,3966,O
verification,3966,O
.,3966,O
NEK2,3967,B-GeneOrGeneProduct
was,3967,O
overexpressed,3967,O
in,3967,O
HCC,3967,B-DiseaseOrPhenotypicFeature
cells,3967,O
and,3967,O
tissues,3967,O
(,3967,O
P=0.002,3967,O
",",3967,O
P=0.013,3967,O
),3967,O
and,3967,O
HCC,3967,B-DiseaseOrPhenotypicFeature
patients,3967,B-OrganismTaxon
with,3967,O
a,3967,O
high,3967,O
expression,3967,O
of,3967,O
NEK2,3967,B-GeneOrGeneProduct
had,3967,O
a,3967,O
poor,3967,O
prognosis,3967,O
(,3967,O
P=0.0145,3967,O
),3967,O
.,3967,O
Clinical,3968,O
analysis,3968,O
indicated,3968,O
that,3968,O
the,3968,O
overexpression,3968,O
of,3968,O
NEK2,3968,B-GeneOrGeneProduct
in,3968,O
HCC,3968,B-DiseaseOrPhenotypicFeature
was,3968,O
significantly,3968,O
correlated,3968,O
with,3968,O
diolame,3968,O
complete,3968,O
(,3968,O
P,3968,O
<,3968,O
0.001,3968,O
),3968,O
",",3968,O
tumor,3968,B-DiseaseOrPhenotypicFeature
nodule,3968,O
number,3968,O
(,3968,O
P=0.012,3968,O
),3968,O
and,3968,O
recurrence,3968,O
(,3968,O
P=0.004,3968,O
),3968,O
.,3968,O
NEK2,3969,B-GeneOrGeneProduct
expression,3969,O
was,3969,O
positively,3969,O
correlated,3969,O
with,3969,O
the,3969,O
expression,3969,O
of,3969,O
phospho-AKT,3969,O
(,3969,O
r=0.883,3969,O
",",3969,O
P,3969,O
<,3969,O
0.01,3969,O
),3969,O
and,3969,O
MMP-2,3969,B-GeneOrGeneProduct
(,3969,O
r=0.781,3969,O
",",3969,O
P,3969,O
<,3969,O
0.01,3969,O
),3969,O
.,3969,O
Overexpression,3970,O
of,3970,O
NEK2,3970,B-GeneOrGeneProduct
was,3970,O
associated,3970,O
with,3970,O
clinicopathological,3970,O
characteristics,3970,O
and,3970,O
poor,3970,O
patient,3970,B-OrganismTaxon
outcomes,3970,O
",",3970,O
suggesting,3970,O
that,3970,O
NEK2,3970,B-GeneOrGeneProduct
serves,3970,O
as,3970,O
a,3970,O
prognostic,3970,O
biomarker,3970,O
for,3970,O
HCC,3970,B-DiseaseOrPhenotypicFeature
.,3970,O
Alteration,3971,O
of,3971,O
NEK2,3971,B-GeneOrGeneProduct
protein,3971,O
levels,3971,O
may,3971,O
contribute,3971,O
to,3971,O
invasion,3971,O
and,3971,O
metastasis,3971,B-DiseaseOrPhenotypicFeature
of,3971,I-DiseaseOrPhenotypicFeature
HCC,3971,I-DiseaseOrPhenotypicFeature
",",3971,O
which,3971,O
may,3971,O
occur,3971,O
through,3971,O
activation,3971,O
of,3971,O
AKT,3971,B-GeneOrGeneProduct
signaling,3971,O
and,3971,O
promotion,3971,O
of,3971,O
MMP-2,3971,B-GeneOrGeneProduct
expression,3971,O
.,3971,O
Metalloprotease-disintegrin,3972,B-GeneOrGeneProduct
ADAM12,3972,B-GeneOrGeneProduct
actively,3972,O
promotes,3972,O
the,3972,O
stem,3972,O
cell-like,3972,O
phenotype,3972,O
in,3972,O
claudin-low,3972,B-GeneOrGeneProduct
breast,3972,B-DiseaseOrPhenotypicFeature
cancer,3972,I-DiseaseOrPhenotypicFeature
.,3972,O
BACKGROUND,3973,O
:,3973,O
ADAM12,3973,B-GeneOrGeneProduct
is,3973,O
upregulated,3973,O
in,3973,O
human,3973,B-OrganismTaxon
breast,3973,B-DiseaseOrPhenotypicFeature
cancers,3973,I-DiseaseOrPhenotypicFeature
and,3973,O
is,3973,O
a,3973,O
predictor,3973,O
of,3973,O
chemoresistance,3973,O
in,3973,O
estrogen,3973,B-GeneOrGeneProduct
receptor-negative,3973,O
tumors,3973,B-DiseaseOrPhenotypicFeature
.,3973,O
ADAM12,3974,B-GeneOrGeneProduct
is,3974,O
induced,3974,O
during,3974,O
epithelial-to-mesenchymal,3974,O
transition,3974,O
",",3974,O
a,3974,O
feature,3974,O
associated,3974,O
with,3974,O
claudin-low,3974,B-GeneOrGeneProduct
breast,3974,B-DiseaseOrPhenotypicFeature
tumors,3974,I-DiseaseOrPhenotypicFeature
",",3974,O
which,3974,O
are,3974,O
enriched,3974,O
in,3974,O
cancer,3974,B-DiseaseOrPhenotypicFeature
stem,3974,O
cell,3974,O
(,3974,O
CSC,3974,O
),3974,O
markers,3974,O
.,3974,O
It,3975,O
is,3975,O
currently,3975,O
unknown,3975,O
whether,3975,O
ADAM12,3975,B-GeneOrGeneProduct
plays,3975,O
an,3975,O
active,3975,O
role,3975,O
in,3975,O
promoting,3975,O
the,3975,O
CSC,3975,O
phenotype,3975,O
in,3975,O
breast,3975,B-DiseaseOrPhenotypicFeature
cancer,3975,I-DiseaseOrPhenotypicFeature
cells,3975,O
.,3975,O
METHODS,3976,O
:,3976,O
ADAM12,3976,B-GeneOrGeneProduct
expression,3976,O
was,3976,O
downregulated,3976,O
in,3976,O
representative,3976,O
claudin-low,3976,B-GeneOrGeneProduct
breast,3976,B-DiseaseOrPhenotypicFeature
cancer,3976,I-DiseaseOrPhenotypicFeature
cell,3976,O
lines,3976,O
",",3976,O
SUM159PT,3976,B-CellLine
and,3976,O
Hs578T,3976,B-CellLine
",",3976,O
using,3976,O
siRNA,3976,O
transfection,3976,O
or,3976,O
inducible,3976,O
shRNA,3976,O
expression,3976,O
.,3976,O
Cell,3977,O
characteristics,3977,O
commonly,3977,O
associated,3977,O
with,3977,O
the,3977,O
CSC,3977,O
phenotype,3977,O
in,3977,O
vitro,3977,O
(,3977,O
cell,3977,O
migration,3977,O
",",3977,O
invasion,3977,O
",",3977,O
anoikis,3977,O
resistance,3977,O
",",3977,O
mammosphere,3977,O
formation,3977,O
",",3977,O
ALDH,3977,B-GeneOrGeneProduct
activity,3977,O
",",3977,O
and,3977,O
expression,3977,O
of,3977,O
the,3977,O
CD44,3977,B-GeneOrGeneProduct
and,3977,O
CD24,3977,B-GeneOrGeneProduct
cell,3977,O
surface,3977,O
markers,3977,O
),3977,O
and,3977,O
in,3977,O
vivo,3977,O
(,3977,O
tumor,3977,B-DiseaseOrPhenotypicFeature
formation,3977,O
in,3977,O
mice,3977,B-OrganismTaxon
using,3977,O
limiting,3977,O
dilution,3977,O
transplantation,3977,O
assays,3977,O
),3977,O
were,3977,O
evaluated,3977,O
.,3977,O
RNA,3978,O
sequencing,3978,O
was,3978,O
performed,3978,O
to,3978,O
identify,3978,O
global,3978,O
gene,3978,O
expression,3978,O
changes,3978,O
after,3978,O
ADAM12,3978,B-GeneOrGeneProduct
knockdown,3978,O
.,3978,O
RESULTS,3979,O
:,3979,O
We,3979,O
found,3979,O
that,3979,O
sorted,3979,O
SUM159PT,3979,B-CellLine
cell,3979,O
populations,3979,O
with,3979,O
high,3979,O
ADAM12,3979,B-GeneOrGeneProduct
levels,3979,O
had,3979,O
elevated,3979,O
expression,3979,O
of,3979,O
CSC,3979,O
markers,3979,O
and,3979,O
an,3979,O
increased,3979,O
ability,3979,O
to,3979,O
form,3979,O
mammospheres,3979,O
.,3979,O
ADAM12,3980,B-GeneOrGeneProduct
knockdown,3980,O
reduced,3980,O
cell,3980,O
migration,3980,O
and,3980,O
invasion,3980,O
",",3980,O
decreased,3980,O
anoikis,3980,O
resistance,3980,O
",",3980,O
and,3980,O
compromised,3980,O
mammosphere,3980,O
formation,3980,O
.,3980,O
ADAM12,3981,B-GeneOrGeneProduct
knockdown,3981,O
also,3981,O
diminished,3981,O
ALDEFLUOR,3981,O
(,3981,O
+,3981,O
),3981,O
and,3981,O
CD44,3981,B-GeneOrGeneProduct
(,3981,O
hi,3981,O
),3981,O
/CD24,3981,O
(,3981,O
-/lo,3981,O
),3981,O
CSC-enriched,3981,O
populations,3981,O
in,3981,O
vitro,3981,O
and,3981,O
reduced,3981,O
tumorigenesis,3981,B-DiseaseOrPhenotypicFeature
in,3981,O
mice,3981,B-OrganismTaxon
in,3981,O
vivo,3981,O
.,3981,O
RNA,3982,O
sequencing,3982,O
identified,3982,O
a,3982,O
significant,3982,O
overlap,3982,O
between,3982,O
ADAM12-,3982,B-GeneOrGeneProduct
and,3982,O
Epidermal,3982,B-GeneOrGeneProduct
Growth,3982,I-GeneOrGeneProduct
Factor,3982,I-GeneOrGeneProduct
Receptor,3982,I-GeneOrGeneProduct
(,3982,O
EGFR,3982,B-GeneOrGeneProduct
),3982,O
-regulated,3982,O
genes,3982,O
.,3982,O
Consequently,3983,O
",",3983,O
ADAM12,3983,B-GeneOrGeneProduct
knockdown,3983,O
lowered,3983,O
the,3983,O
basal,3983,O
activation,3983,O
level,3983,O
of,3983,O
EGFR,3983,B-GeneOrGeneProduct
",",3983,O
and,3983,O
this,3983,O
effect,3983,O
was,3983,O
abolished,3983,O
by,3983,O
batimastat,3983,B-ChemicalEntity
",",3983,O
a,3983,O
metalloproteinase,3983,B-GeneOrGeneProduct
inhibitor,3983,O
.,3983,O
Furthermore,3984,O
",",3984,O
incubation,3984,O
of,3984,O
cells,3984,O
with,3984,O
exogenously,3984,O
added,3984,O
EGF,3984,B-GeneOrGeneProduct
prevented,3984,O
the,3984,O
downregulation,3984,O
of,3984,O
CD44,3984,B-GeneOrGeneProduct
(,3984,O
hi,3984,O
),3984,O
/CD24,3984,O
(,3984,O
-/lo,3984,O
),3984,O
cell,3984,O
population,3984,O
by,3984,O
ADAM12,3984,B-GeneOrGeneProduct
knockdown,3984,O
.,3984,O
CONCLUSIONS,3985,O
:,3985,O
These,3985,O
results,3985,O
indicate,3985,O
that,3985,O
ADAM12,3985,B-GeneOrGeneProduct
actively,3985,O
supports,3985,O
the,3985,O
CSC,3985,O
phenotype,3985,O
in,3985,O
claudin-low,3985,B-GeneOrGeneProduct
breast,3985,B-DiseaseOrPhenotypicFeature
cancer,3985,I-DiseaseOrPhenotypicFeature
cells,3985,O
via,3985,O
modulation,3985,O
of,3985,O
the,3985,O
EGFR,3985,B-GeneOrGeneProduct
pathway,3985,O
.,3985,O
Star-PAP,3986,B-GeneOrGeneProduct
",",3986,O
a,3986,O
poly,3986,B-GeneOrGeneProduct
(,3986,I-GeneOrGeneProduct
A,3986,I-GeneOrGeneProduct
),3986,I-GeneOrGeneProduct
polymerase,3986,I-GeneOrGeneProduct
",",3986,O
functions,3986,O
as,3986,O
a,3986,O
tumor,3986,B-DiseaseOrPhenotypicFeature
suppressor,3986,O
in,3986,O
an,3986,O
orthotopic,3986,O
human,3986,B-OrganismTaxon
breast,3986,B-DiseaseOrPhenotypicFeature
cancer,3986,I-DiseaseOrPhenotypicFeature
model,3986,O
.,3986,O
Star-PAP,3987,B-GeneOrGeneProduct
is,3987,O
a,3987,O
noncanonical,3987,O
poly,3987,B-GeneOrGeneProduct
(,3987,I-GeneOrGeneProduct
A,3987,I-GeneOrGeneProduct
),3987,I-GeneOrGeneProduct
polymerase,3987,I-GeneOrGeneProduct
and,3987,O
required,3987,O
for,3987,O
the,3987,O
expression,3987,O
of,3987,O
a,3987,O
select,3987,O
set,3987,O
of,3987,O
mRNAs,3987,O
.,3987,O
However,3988,O
",",3988,O
the,3988,O
pathological,3988,O
role,3988,O
of,3988,O
Star-PAP,3988,B-GeneOrGeneProduct
in,3988,O
cancer,3988,B-DiseaseOrPhenotypicFeature
largely,3988,O
remains,3988,O
unknown,3988,O
.,3988,O
In,3989,O
this,3989,O
study,3989,O
",",3989,O
we,3989,O
observed,3989,O
decreased,3989,O
expression,3989,O
of,3989,O
Star-PAP,3989,B-GeneOrGeneProduct
in,3989,O
breast,3989,B-DiseaseOrPhenotypicFeature
cancer,3989,I-DiseaseOrPhenotypicFeature
cell,3989,O
lines,3989,O
and,3989,O
tissues,3989,O
.,3989,O
Ectopic,3990,O
Star-PAP,3990,B-GeneOrGeneProduct
expression,3990,O
inhibited,3990,O
proliferation,3990,O
as,3990,O
well,3990,O
as,3990,O
colony-forming,3990,O
ability,3990,O
of,3990,O
breast,3990,B-DiseaseOrPhenotypicFeature
cancer,3990,I-DiseaseOrPhenotypicFeature
cells,3990,O
.,3990,O
In,3991,O
breast,3991,B-DiseaseOrPhenotypicFeature
cancer,3991,I-DiseaseOrPhenotypicFeature
patients,3991,B-OrganismTaxon
",",3991,O
high,3991,O
levels,3991,O
of,3991,O
Star-PAP,3991,B-GeneOrGeneProduct
correlated,3991,O
with,3991,O
an,3991,O
improved,3991,O
prognosis,3991,O
.,3991,O
Moreover,3992,O
",",3992,O
by,3992,O
regulating,3992,O
the,3992,O
expression,3992,O
of,3992,O
BIK,3992,B-GeneOrGeneProduct
(,3992,O
BCL2-interacting,3992,B-GeneOrGeneProduct
killer,3992,I-GeneOrGeneProduct
),3992,O
",",3992,O
Star-PAP,3992,B-GeneOrGeneProduct
induced,3992,O
apoptosis,3992,O
of,3992,O
breast,3992,B-DiseaseOrPhenotypicFeature
cancer,3992,I-DiseaseOrPhenotypicFeature
cells,3992,O
through,3992,O
the,3992,O
mitochondrial,3992,O
pathway,3992,O
.,3992,O
The,3993,O
growth,3993,O
of,3993,O
breast,3993,B-DiseaseOrPhenotypicFeature
cancer,3993,I-DiseaseOrPhenotypicFeature
xenografts,3993,O
in,3993,O
NOD/SCID,3993,O
mice,3993,B-OrganismTaxon
was,3993,O
also,3993,O
inhibited,3993,O
by,3993,O
the,3993,O
doxycycline-induced,3993,B-ChemicalEntity
Star-PAP,3993,B-GeneOrGeneProduct
overexpression,3993,O
.,3993,O
Furthermore,3994,O
",",3994,O
Star-PAP,3994,B-GeneOrGeneProduct
sensitized,3994,O
breast,3994,B-DiseaseOrPhenotypicFeature
cancer,3994,I-DiseaseOrPhenotypicFeature
cells,3994,O
to,3994,O
chemotherapy,3994,O
drugs,3994,O
both,3994,O
in,3994,O
vitro,3994,O
and,3994,O
in,3994,O
vivo,3994,O
.,3994,O
In,3995,O
mammary,3995,O
epithelial,3995,O
cells,3995,O
",",3995,O
Star-PAP,3995,B-GeneOrGeneProduct
knockdown,3995,O
partially,3995,O
transformed,3995,O
these,3995,O
cells,3995,O
and,3995,O
induced,3995,O
them,3995,O
to,3995,O
undergo,3995,O
epithelial-mesenchymal,3995,O
transition,3995,O
(,3995,O
EMT,3995,O
),3995,O
.,3995,O
These,3996,O
findings,3996,O
suggested,3996,O
that,3996,O
Star-PAP,3996,B-GeneOrGeneProduct
possesses,3996,O
tumor-suppressing,3996,B-DiseaseOrPhenotypicFeature
activity,3996,O
and,3996,O
can,3996,O
be,3996,O
a,3996,O
valuable,3996,O
target,3996,O
for,3996,O
developing,3996,O
new,3996,O
cancer,3996,B-DiseaseOrPhenotypicFeature
therapeutic,3996,O
strategies,3996,O
.,3996,O
TIEG1,3997,B-GeneOrGeneProduct
deficiency,3997,O
confers,3997,O
enhanced,3997,O
myocardial,3997,O
protection,3997,O
in,3997,O
the,3997,O
infarcted,3997,B-DiseaseOrPhenotypicFeature
heart,3997,I-DiseaseOrPhenotypicFeature
by,3997,O
mediating,3997,O
the,3997,O
Pten/Akt,3997,B-GeneOrGeneProduct
signalling,3997,O
pathway,3997,O
.,3997,O
The,3998,O
transforming,3998,B-GeneOrGeneProduct
growth,3998,I-GeneOrGeneProduct
factor,3998,I-GeneOrGeneProduct
(,3998,I-GeneOrGeneProduct
TGF,3998,I-GeneOrGeneProduct
),3998,I-GeneOrGeneProduct
-b-inducible,3998,I-GeneOrGeneProduct
early,3998,I-GeneOrGeneProduct
gene-1,3998,I-GeneOrGeneProduct
(,3998,O
TIEG1,3998,B-GeneOrGeneProduct
),3998,O
plays,3998,O
a,3998,O
crucial,3998,O
role,3998,O
in,3998,O
modulating,3998,O
cell,3998,O
apoptosis,3998,O
and,3998,O
proliferation,3998,O
in,3998,O
a,3998,O
number,3998,O
of,3998,O
diseases,3998,O
",",3998,O
including,3998,O
pancreatic,3998,B-DiseaseOrPhenotypicFeature
cancer,3998,I-DiseaseOrPhenotypicFeature
",",3998,O
leukaemia,3998,B-DiseaseOrPhenotypicFeature
and,3998,O
osteoporosis,3998,B-DiseaseOrPhenotypicFeature
.,3998,O
However,3999,O
",",3999,O
the,3999,O
functional,3999,O
role,3999,O
of,3999,O
TIEG1,3999,B-GeneOrGeneProduct
in,3999,O
the,3999,O
heart,3999,O
has,3999,O
not,3999,O
been,3999,O
fully,3999,O
defined,3999,O
.,3999,O
In,4000,O
this,4000,O
study,4000,O
",",4000,O
we,4000,O
first,4000,O
investigated,4000,O
the,4000,O
role,4000,O
of,4000,O
TIEG1,4000,B-GeneOrGeneProduct
in,4000,O
ischaemic,4000,B-DiseaseOrPhenotypicFeature
heart,4000,I-DiseaseOrPhenotypicFeature
disease,4000,I-DiseaseOrPhenotypicFeature
.,4000,O
For,4001,O
in,4001,O
vitro,4001,O
experiments,4001,O
",",4001,O
cardiomyocytes,4001,O
were,4001,O
isolated,4001,O
from,4001,O
both,4001,O
TIEG1,4001,B-GeneOrGeneProduct
knockout,4001,O
(,4001,O
KO,4001,O
),4001,O
and,4001,O
wile-type,4001,O
(,4001,O
WT,4001,O
),4001,O
mice,4001,B-OrganismTaxon
",",4001,O
and,4001,O
the,4001,O
apoptotic,4001,O
ratios,4001,O
were,4001,O
evaluated,4001,O
after,4001,O
a,4001,O
48-h,4001,O
ischaemic,4001,O
insult,4001,O
.,4001,O
A,4002,O
cell,4002,O
proliferation,4002,O
assay,4002,O
was,4002,O
performed,4002,O
after,4002,O
7,4002,O
days,4002,O
of,4002,O
incubation,4002,O
under,4002,O
normoxic,4002,O
conditions,4002,O
.,4002,O
In,4003,O
addition,4003,O
",",4003,O
the,4003,O
angiogenic,4003,O
capacity,4003,O
of,4003,O
endothelial,4003,O
cells,4003,O
was,4003,O
determined,4003,O
by,4003,O
tube,4003,O
formation,4003,O
assay,4003,O
.,4003,O
For,4004,O
in,4004,O
vivo,4004,O
experiments,4004,O
",",4004,O
a,4004,O
model,4004,O
of,4004,O
myocardial,4004,B-DiseaseOrPhenotypicFeature
infarction,4004,I-DiseaseOrPhenotypicFeature
(,4004,O
MI,4004,B-DiseaseOrPhenotypicFeature
),4004,O
was,4004,O
established,4004,O
using,4004,O
both,4004,O
TIEG1,4004,B-GeneOrGeneProduct
KO,4004,O
and,4004,O
WT,4004,O
mice,4004,B-OrganismTaxon
.,4004,O
Echocardiography,4005,O
was,4005,O
performed,4005,O
at,4005,O
3,4005,O
and,4005,O
28,4005,O
days,4005,O
post-MI,4005,O
",",4005,O
whereas,4005,O
the,4005,O
haemodynamics,4005,O
test,4005,O
was,4005,O
performed,4005,O
28,4005,O
days,4005,O
post-MI,4005,O
.,4005,O
Histological,4006,O
analyses,4006,O
of,4006,O
apoptosis,4006,O
",",4006,O
proliferation,4006,O
",",4006,O
angiogenesis,4006,O
and,4006,O
infarct,4006,B-DiseaseOrPhenotypicFeature
zone,4006,O
assessments,4006,O
were,4006,O
performed,4006,O
using,4006,O
terminal,4006,B-GeneOrGeneProduct
deoxynucleotidyltransferase-mediated,4006,O
dUTP,4006,B-ChemicalEntity
nick-end,4006,O
labelling,4006,O
(,4006,O
TUNEL,4006,O
),4006,O
staining,4006,O
",",4006,O
BrdU,4006,O
immunostaining,4006,O
",",4006,O
a-smooth,4006,B-GeneOrGeneProduct
muscle,4006,I-GeneOrGeneProduct
actin,4006,I-GeneOrGeneProduct
(,4006,O
a-SMA,4006,B-GeneOrGeneProduct
),4006,O
/CD31,4006,O
immunostaining,4006,O
and,4006,O
Masson,4006,O
's,4006,O
trichrome,4006,O
staining,4006,O
",",4006,O
respectively,4006,O
.,4006,O
Changes,4007,O
in,4007,O
the,4007,O
expression,4007,O
of,4007,O
related,4007,O
proteins,4007,O
caused,4007,O
by,4007,O
TIEG1,4007,B-GeneOrGeneProduct
deficiency,4007,O
were,4007,O
confirmed,4007,O
using,4007,O
both,4007,O
reverse,4007,O
transcription-quantitative,4007,O
polymerase,4007,O
chain,4007,O
reaction,4007,O
(,4007,O
RT-qPCR,4007,O
),4007,O
and,4007,O
western,4007,O
blot,4007,O
analysis,4007,O
.,4007,O
Our,4008,O
results,4008,O
demonstrated,4008,O
that,4008,O
the,4008,O
absence,4008,O
of,4008,O
TIEG1,4008,B-GeneOrGeneProduct
prevented,4008,O
cardiomyocytes,4008,O
from,4008,O
undergoing,4008,O
apoptosis,4008,O
and,4008,O
promoted,4008,O
higher,4008,O
proliferation,4008,O
;,4008,O
it,4008,O
stimulated,4008,O
the,4008,O
proliferation,4008,O
of,4008,O
endothelial,4008,O
cells,4008,O
in,4008,O
vitro,4008,O
and,4008,O
in,4008,O
vivo,4008,O
.,4008,O
Improved,4009,O
cardiac,4009,O
function,4009,O
and,4009,O
less,4009,O
scar,4009,O
formation,4009,O
were,4009,O
observed,4009,O
in,4009,O
TIEG1,4009,B-GeneOrGeneProduct
KO,4009,O
mice,4009,B-OrganismTaxon
",",4009,O
and,4009,O
we,4009,O
also,4009,O
observed,4009,O
the,4009,O
altered,4009,O
expression,4009,O
of,4009,O
phosphatase,4009,B-GeneOrGeneProduct
and,4009,I-GeneOrGeneProduct
tensin,4009,I-GeneOrGeneProduct
homolog,4009,I-GeneOrGeneProduct
(,4009,O
Pten,4009,B-GeneOrGeneProduct
),4009,O
",",4009,O
Akt,4009,B-GeneOrGeneProduct
and,4009,O
Bcl-2/Bax,4009,B-GeneOrGeneProduct
",",4009,O
as,4009,O
well,4009,O
as,4009,O
vascular,4009,B-GeneOrGeneProduct
endothelial,4009,I-GeneOrGeneProduct
growth,4009,I-GeneOrGeneProduct
factor,4009,I-GeneOrGeneProduct
(,4009,O
VEGF,4009,B-GeneOrGeneProduct
),4009,O
.,4009,O
On,4010,O
the,4010,O
whole,4010,O
",",4010,O
our,4010,O
findings,4010,O
indicate,4010,O
that,4010,O
the,4010,O
absence,4010,O
of,4010,O
TIEG1,4010,B-GeneOrGeneProduct
plays,4010,O
a,4010,O
cardioprotective,4010,O
role,4010,O
in,4010,O
ischaemic,4010,B-DiseaseOrPhenotypicFeature
heart,4010,I-DiseaseOrPhenotypicFeature
disease,4010,I-DiseaseOrPhenotypicFeature
by,4010,O
promoting,4010,O
changes,4010,O
in,4010,O
Pten/Akt,4010,B-GeneOrGeneProduct
signalling,4010,O
.,4010,O
Insulin-like,4011,B-GeneOrGeneProduct
growth,4011,I-GeneOrGeneProduct
factor,4011,I-GeneOrGeneProduct
1,4011,I-GeneOrGeneProduct
receptor-mediated,4011,O
cell,4011,O
survival,4011,O
in,4011,O
hypoxia,4011,B-DiseaseOrPhenotypicFeature
depends,4011,O
on,4011,O
the,4011,O
promotion,4011,O
of,4011,O
autophagy,4011,O
via,4011,O
suppression,4011,O
of,4011,O
the,4011,O
PI3K/Akt/mTOR,4011,B-GeneOrGeneProduct
signaling,4011,O
pathway,4011,O
.,4011,O
Hypoxia,4012,B-DiseaseOrPhenotypicFeature
is,4012,O
widely,4012,O
accepted,4012,O
as,4012,O
a,4012,O
fundamental,4012,O
biological,4012,O
phenomenon,4012,O
",",4012,O
which,4012,O
is,4012,O
strongly,4012,O
associated,4012,O
with,4012,O
tissue,4012,O
damage,4012,O
and,4012,O
cell,4012,O
viability,4012,O
under,4012,O
stress,4012,O
conditions,4012,O
.,4012,O
Insulin-like,4013,B-GeneOrGeneProduct
growth,4013,I-GeneOrGeneProduct
factor-1,4013,I-GeneOrGeneProduct
(,4013,O
IGF-1,4013,B-GeneOrGeneProduct
),4013,O
is,4013,O
known,4013,O
to,4013,O
protect,4013,O
tissues,4013,O
from,4013,O
multiple,4013,O
types,4013,O
of,4013,O
damage,4013,O
",",4013,O
and,4013,O
protect,4013,O
cells,4013,O
from,4013,O
apoptosis,4013,O
.,4013,O
Hypoxia,4014,B-DiseaseOrPhenotypicFeature
is,4014,O
a,4014,O
regulatory,4014,O
factor,4014,O
of,4014,O
the,4014,O
IGF,4014,B-GeneOrGeneProduct
system,4014,O
",",4014,O
however,4014,O
the,4014,O
role,4014,O
of,4014,O
the,4014,O
IGF-1,4014,B-GeneOrGeneProduct
receptor,4014,I-GeneOrGeneProduct
(,4014,O
IGF-1R,4014,B-GeneOrGeneProduct
),4014,O
in,4014,O
hypoxia-induced,4014,B-DiseaseOrPhenotypicFeature
apoptosis,4014,O
remains,4014,O
unclear,4014,O
.,4014,O
The,4015,O
present,4015,O
study,4015,O
investigated,4015,O
the,4015,O
potential,4015,O
mechanisms,4015,O
associated,4015,O
with,4015,O
IGF-1R-associated,4015,B-GeneOrGeneProduct
apoptosis,4015,O
under,4015,O
hypoxic,4015,B-DiseaseOrPhenotypicFeature
conditions,4015,O
.,4015,O
Mouse,4016,B-OrganismTaxon
embryonic,4016,O
fibroblasts,4016,O
exhibiting,4016,O
disruption,4016,O
or,4016,O
overexpression,4016,O
of,4016,O
IGF-1R,4016,B-GeneOrGeneProduct
(,4016,O
R-,4016,O
cells,4016,O
and,4016,O
R+,4016,O
cells,4016,O
),4016,O
were,4016,O
used,4016,O
to,4016,O
examine,4016,O
the,4016,O
level,4016,O
of,4016,O
apoptosis,4016,O
",",4016,O
autophagy,4016,O
",",4016,O
and,4016,O
production,4016,O
of,4016,O
reactive,4016,B-ChemicalEntity
oxygen,4016,I-ChemicalEntity
species,4016,I-ChemicalEntity
(,4016,O
ROS,4016,B-ChemicalEntity
),4016,O
.,4016,O
The,4017,O
autophagy,4017,O
inhibitor,4017,O
3-methyladenine,4017,B-ChemicalEntity
was,4017,O
used,4017,O
to,4017,O
assess,4017,O
the,4017,O
effect,4017,O
of,4017,O
autophagy,4017,O
on,4017,O
ROS,4017,B-ChemicalEntity
production,4017,O
and,4017,O
apoptosis,4017,O
under,4017,O
hypoxic,4017,B-DiseaseOrPhenotypicFeature
conditions,4017,O
.,4017,O
A,4018,O
potential,4018,O
downstream,4018,O
signaling,4018,O
pathway,4018,O
involving,4018,O
phosphatidylinositol,4018,B-GeneOrGeneProduct
3-kinase,4018,I-GeneOrGeneProduct
(,4018,O
PI3K,4018,B-GeneOrGeneProduct
),4018,O
/threonine,4018,O
protein,4018,I-GeneOrGeneProduct
kinase,4018,I-GeneOrGeneProduct
B,4018,I-GeneOrGeneProduct
(,4018,O
Akt,4018,B-GeneOrGeneProduct
),4018,O
/mammalian,4018,O
target,4018,I-GeneOrGeneProduct
of,4018,I-GeneOrGeneProduct
rapamycin,4018,I-GeneOrGeneProduct
(,4018,O
mTOR,4018,B-GeneOrGeneProduct
),4018,O
was,4018,O
identifiedby,4018,O
western,4018,O
blot,4018,O
analysis,4018,O
.,4018,O
The,4019,O
results,4019,O
demonstrated,4019,O
that,4019,O
hypoxia,4019,B-DiseaseOrPhenotypicFeature
induced,4019,O
apoptosis,4019,O
",",4019,O
increased,4019,O
ROS,4019,B-ChemicalEntity
production,4019,O
",",4019,O
and,4019,O
promoted,4019,O
autophagy,4019,O
in,4019,O
a,4019,O
time-dependent,4019,O
manner,4019,O
relative,4019,O
to,4019,O
that,4019,O
observed,4019,O
under,4019,O
normoxia,4019,O
.,4019,O
R+,4020,O
cells,4020,O
exhibited,4020,O
a,4020,O
lower,4020,O
percentage,4020,O
of,4020,O
apoptotic,4020,O
cells,4020,O
",",4020,O
lower,4020,O
ROS,4020,B-ChemicalEntity
production,4020,O
",",4020,O
and,4020,O
higher,4020,O
levels,4020,O
of,4020,O
autophagy,4020,O
when,4020,O
compared,4020,O
to,4020,O
that,4020,O
of,4020,O
R-,4020,O
cells,4020,O
.,4020,O
In,4021,O
addition,4021,O
",",4021,O
inhibition,4021,O
of,4021,O
autophagy,4021,O
led,4021,O
to,4021,O
increased,4021,O
ROS,4021,B-ChemicalEntity
production,4021,O
and,4021,O
a,4021,O
higher,4021,O
percentage,4021,O
of,4021,O
apoptotic,4021,O
cells,4021,O
in,4021,O
the,4021,O
two,4021,O
cell,4021,O
types,4021,O
.,4021,O
Furthermore,4022,O
",",4022,O
IGF-1R,4022,B-GeneOrGeneProduct
is,4022,O
related,4022,O
with,4022,O
PI3K/Akt/mTOR,4022,B-GeneOrGeneProduct
signaling,4022,O
pathway,4022,O
and,4022,O
enhanced,4022,O
autophagy-associated,4022,O
protein,4022,O
expression,4022,O
",",4022,O
which,4022,O
was,4022,O
verified,4022,O
following,4022,O
treatment,4022,O
with,4022,O
the,4022,O
PI3K,4022,B-GeneOrGeneProduct
inhibitor,4022,O
LY294002,4022,B-ChemicalEntity
.,4022,O
These,4023,O
results,4023,O
indicated,4023,O
that,4023,O
IGF-1R,4023,B-GeneOrGeneProduct
may,4023,O
increase,4023,O
cell,4023,O
viability,4023,O
under,4023,O
hypoxic,4023,B-DiseaseOrPhenotypicFeature
conditions,4023,O
by,4023,O
promoting,4023,O
autophagy,4023,O
and,4023,O
scavenging,4023,O
ROS,4023,B-ChemicalEntity
production,4023,O
",",4023,O
which,4023,O
is,4023,O
closed,4023,O
with,4023,O
PI3K/Akt/mTOR,4023,B-GeneOrGeneProduct
signaling,4023,O
pathway,4023,O
.,4023,O
Atorvastatin,4024,B-ChemicalEntity
protects,4024,O
against,4024,O
contrast-induced,4024,B-DiseaseOrPhenotypicFeature
nephropathy,4024,I-DiseaseOrPhenotypicFeature
via,4024,O
anti-apoptosis,4024,O
by,4024,O
the,4024,O
upregulation,4024,O
of,4024,O
Hsp27,4024,B-GeneOrGeneProduct
in,4024,O
vivo,4024,O
and,4024,O
in,4024,O
vitro,4024,O
.,4024,O
Contrast-induced,4025,B-DiseaseOrPhenotypicFeature
nephropathy,4025,I-DiseaseOrPhenotypicFeature
(,4025,O
CIN,4025,B-DiseaseOrPhenotypicFeature
),4025,O
is,4025,O
an,4025,O
iatrogenic,4025,O
acute,4025,B-DiseaseOrPhenotypicFeature
renal,4025,I-DiseaseOrPhenotypicFeature
failure,4025,I-DiseaseOrPhenotypicFeature
occurring,4025,O
following,4025,O
the,4025,O
intravascular,4025,O
injection,4025,O
of,4025,O
iodinated,4025,O
radiographic,4025,O
contrast,4025,O
medium,4025,O
.,4025,O
However,4026,O
",",4026,O
the,4026,O
regulatory,4026,O
mechanisms,4026,O
for,4026,O
CIN,4026,B-DiseaseOrPhenotypicFeature
remain,4026,O
to,4026,O
be,4026,O
fully,4026,O
elucidated,4026,O
.,4026,O
The,4027,O
present,4027,O
study,4027,O
aimed,4027,O
to,4027,O
investigate,4027,O
whether,4027,O
atorvastatin,4027,B-ChemicalEntity
protects,4027,O
against,4027,O
CIN,4027,B-DiseaseOrPhenotypicFeature
via,4027,O
anti-apoptotic,4027,O
effects,4027,O
by,4027,O
the,4027,O
upregulation,4027,O
of,4027,O
Hsp27,4027,B-GeneOrGeneProduct
in,4027,O
vivo,4027,O
and,4027,O
in,4027,O
vitro,4027,O
.,4027,O
To,4028,O
determine,4028,O
whether,4028,O
atorvastatin,4028,B-ChemicalEntity
attenuated,4028,O
CIN,4028,B-DiseaseOrPhenotypicFeature
",",4028,O
the,4028,O
inflammatory,4028,B-DiseaseOrPhenotypicFeature
response,4028,O
and,4028,O
apoptosis,4028,O
in,4028,O
vivo,4028,O
and,4028,O
in,4028,O
vitro,4028,O
",",4028,O
a,4028,O
rat,4028,B-OrganismTaxon
model,4028,O
of,4028,O
iopamidol-induced,4028,B-ChemicalEntity
CIN,4028,B-DiseaseOrPhenotypicFeature
was,4028,O
used,4028,O
",",4028,O
and,4028,O
human,4028,B-OrganismTaxon
embryonic,4028,O
proximal,4028,O
tubule,4028,O
(,4028,O
HK2,4028,B-CellLine
),4028,O
cell,4028,O
damage,4028,O
was,4028,O
assessed,4028,O
.,4028,O
The,4029,O
rats,4029,B-OrganismTaxon
were,4029,O
assigned,4029,O
into,4029,O
four,4029,O
groups,4029,O
(,4029,O
n=10,4029,O
per,4029,O
group,4029,O
),4029,O
",",4029,O
as,4029,O
follows,4029,O
:,4029,O
Control,4029,O
rats,4029,B-OrganismTaxon
;,4029,O
rats+atorvastatin,4029,B-OrganismTaxon
;,4029,O
rats,4029,B-OrganismTaxon
+,4029,O
iopamidol,4029,B-ChemicalEntity
;,4029,O
rats+iopamidol+atorvastatin,4029,B-OrganismTaxon
.,4029,O
In,4030,O
vitro,4030,O
",",4030,O
the,4030,O
HK2,4030,B-CellLine
cells,4030,O
were,4030,O
treated,4030,O
with,4030,O
iopamidol,4030,B-ChemicalEntity
in,4030,O
the,4030,O
presence,4030,O
or,4030,O
absence,4030,O
of,4030,O
atorvastatin,4030,B-ChemicalEntity
",",4030,O
heat,4030,B-GeneOrGeneProduct
shock,4030,I-GeneOrGeneProduct
protein,4030,I-GeneOrGeneProduct
(,4030,I-GeneOrGeneProduct
Hsp,4030,I-GeneOrGeneProduct
),4030,I-GeneOrGeneProduct
27,4030,I-GeneOrGeneProduct
small,4030,O
interfering,4030,O
(,4030,O
si,4030,O
),4030,O
RNA,4030,O
or,4030,O
pcDNA3.1-Hsp27,4030,O
.,4030,O
The,4031,O
renal,4031,O
tissues,4031,O
were,4031,O
examined,4031,O
histopathologically,4031,O
and,4031,O
collected,4031,O
for,4031,O
western,4031,O
blot,4031,O
analysis,4031,O
.,4031,O
The,4032,O
results,4032,O
showed,4032,O
that,4032,O
atorvastatin,4032,B-ChemicalEntity
ameliorated,4032,O
the,4032,O
apoptosis,4032,B-DiseaseOrPhenotypicFeature
and,4032,I-DiseaseOrPhenotypicFeature
deterioration,4032,I-DiseaseOrPhenotypicFeature
of,4032,I-DiseaseOrPhenotypicFeature
renal,4032,I-DiseaseOrPhenotypicFeature
function,4032,I-DiseaseOrPhenotypicFeature
(,4032,O
P,4032,O
<,4032,O
0.05,4032,O
),4032,O
.,4032,O
Furthermore,4033,O
",",4033,O
atorvastatin,4033,B-ChemicalEntity
reduced,4033,O
the,4033,O
iopamidol-induced,4033,B-ChemicalEntity
activity,4033,O
of,4033,O
B,4033,B-GeneOrGeneProduct
cell,4033,I-GeneOrGeneProduct
lymphoma-2,4033,I-GeneOrGeneProduct
(,4033,I-GeneOrGeneProduct
Bcl-2,4033,I-GeneOrGeneProduct
),4033,I-GeneOrGeneProduct
-associated,4033,I-GeneOrGeneProduct
X,4033,I-GeneOrGeneProduct
protein,4033,I-GeneOrGeneProduct
(,4033,O
Bax,4033,B-GeneOrGeneProduct
),4033,O
/caspase-3,4033,O
and,4033,O
increased,4033,O
the,4033,O
expression,4033,O
of,4033,O
Bcl-2,4033,B-GeneOrGeneProduct
in,4033,O
vivo,4033,O
and,4033,O
in,4033,O
vitro,4033,O
.,4033,O
Notably,4034,O
",",4034,O
following,4034,O
treatment,4034,O
with,4034,O
Hsp27,4034,B-GeneOrGeneProduct
siRNA,4034,O
or,4034,O
pcDNA3.1-Hsp27,4034,O
",",4034,O
it,4034,O
was,4034,O
found,4034,O
that,4034,O
iopamidol,4034,B-ChemicalEntity
enhanced,4034,O
or,4034,O
weakened,4034,O
the,4034,O
upregulation,4034,O
of,4034,O
Bax/caspase-3,4034,B-GeneOrGeneProduct
and,4034,O
downregulation,4034,O
of,4034,O
Bcl-2,4034,B-GeneOrGeneProduct
in,4034,O
the,4034,O
HK2,4034,B-CellLine
cells,4034,O
",",4034,O
respectively,4034,O
.,4034,O
The,4035,O
results,4035,O
of,4035,O
the,4035,O
present,4035,O
study,4035,O
suggested,4035,O
that,4035,O
atorvastatin,4035,B-ChemicalEntity
protected,4035,O
against,4035,O
contrast-induced,4035,B-DiseaseOrPhenotypicFeature
renal,4035,I-DiseaseOrPhenotypicFeature
tubular,4035,I-DiseaseOrPhenotypicFeature
cell,4035,I-DiseaseOrPhenotypicFeature
apoptosis,4035,I-DiseaseOrPhenotypicFeature
through,4035,O
the,4035,O
upregulation,4035,O
of,4035,O
Hsp27,4035,B-GeneOrGeneProduct
in,4035,O
vivo,4035,O
and,4035,O
in,4035,O
vitro,4035,O
.,4035,O
Inhibitory,4036,O
effect,4036,O
of,4036,O
emodin,4036,B-ChemicalEntity
on,4036,O
fatty,4036,B-GeneOrGeneProduct
acid,4036,I-GeneOrGeneProduct
synthase,4036,I-GeneOrGeneProduct
",",4036,O
colon,4036,B-DiseaseOrPhenotypicFeature
cancer,4036,I-DiseaseOrPhenotypicFeature
proliferation,4036,O
and,4036,O
apoptosis,4036,O
.,4036,O
Fatty,4037,B-GeneOrGeneProduct
acid,4037,I-GeneOrGeneProduct
synthase,4037,I-GeneOrGeneProduct
(,4037,O
FASN,4037,B-GeneOrGeneProduct
),4037,O
is,4037,O
a,4037,O
key,4037,O
anabolic,4037,O
enzyme,4037,O
for,4037,O
de,4037,O
novo,4037,O
fatty,4037,B-ChemicalEntity
acid,4037,I-ChemicalEntity
synthesis,4037,O
",",4037,O
which,4037,O
is,4037,O
important,4037,O
in,4037,O
the,4037,O
development,4037,O
of,4037,O
colon,4037,B-DiseaseOrPhenotypicFeature
carcinoma,4037,I-DiseaseOrPhenotypicFeature
.,4037,O
The,4038,O
high,4038,O
expression,4038,O
of,4038,O
FASN,4038,B-GeneOrGeneProduct
is,4038,O
considered,4038,O
a,4038,O
promising,4038,O
molecular,4038,O
target,4038,O
for,4038,O
colon,4038,B-DiseaseOrPhenotypicFeature
cancer,4038,I-DiseaseOrPhenotypicFeature
therapy,4038,O
.,4038,O
Emodin,4039,B-ChemicalEntity
",",4039,O
a,4039,O
naturally,4039,O
occurring,4039,O
anthraquinone,4039,B-ChemicalEntity
",",4039,O
exhibits,4039,O
an,4039,O
anticancer,4039,O
effect,4039,O
in,4039,O
various,4039,O
types,4039,O
of,4039,O
human,4039,B-OrganismTaxon
cancer,4039,B-DiseaseOrPhenotypicFeature
",",4039,O
including,4039,O
colon,4039,B-DiseaseOrPhenotypicFeature
cancer,4039,I-DiseaseOrPhenotypicFeature
;,4039,O
however,4039,O
",",4039,O
the,4039,O
molecular,4039,O
mechanisms,4039,O
remain,4039,O
to,4039,O
be,4039,O
fully,4039,O
elucidated,4039,O
.,4039,O
Cell,4040,O
viability,4040,O
was,4040,O
evaluated,4040,O
using,4040,O
a,4040,O
Cell,4040,O
Counting,4040,O
Kit-8,4040,O
assay,4040,O
.,4040,O
The,4041,O
apoptosis,4041,O
rate,4041,O
of,4041,O
cells,4041,O
was,4041,O
quantified,4041,O
via,4041,O
flow,4041,O
cytometry,4041,O
following,4041,O
Annexin,4041,B-GeneOrGeneProduct
V/propidium,4041,O
iodide,4041,I-ChemicalEntity
staining,4041,O
.,4041,O
FASN,4042,B-GeneOrGeneProduct
activity,4042,O
was,4042,O
measured,4042,O
by,4042,O
monitoring,4042,O
oxidation,4042,O
of,4042,O
nicotinamide,4042,B-ChemicalEntity
adenine,4042,I-ChemicalEntity
dinucleotide,4042,I-ChemicalEntity
phosphate,4042,I-ChemicalEntity
at,4042,O
a,4042,O
wavelength,4042,O
of,4042,O
340,4042,O
nm,4042,O
",",4042,O
and,4042,O
intracellular,4042,O
free,4042,B-ChemicalEntity
fatty,4042,I-ChemicalEntity
acid,4042,I-ChemicalEntity
levels,4042,O
were,4042,O
detected,4042,O
using,4042,O
a,4042,O
Free,4042,B-ChemicalEntity
Fatty,4042,I-ChemicalEntity
Acid,4042,I-ChemicalEntity
Quantification,4042,O
kit,4042,O
.,4042,O
Western,4043,O
blot,4043,O
analysis,4043,O
and,4043,O
reverse,4043,O
transcription-polymerase,4043,O
chain,4043,O
reaction,4043,O
were,4043,O
used,4043,O
to,4043,O
detect,4043,O
target,4043,O
gene,4043,O
and,4043,O
protein,4043,O
expression,4043,O
.,4043,O
The,4044,O
present,4044,O
study,4044,O
was,4044,O
performed,4044,O
to,4044,O
investigate,4044,O
whether,4044,O
the,4044,O
gene,4044,O
expression,4044,O
of,4044,O
FASN,4044,B-GeneOrGeneProduct
and,4044,O
its,4044,O
enzymatic,4044,O
activity,4044,O
are,4044,O
regulated,4044,O
by,4044,O
emodin,4044,B-ChemicalEntity
in,4044,O
a,4044,O
human,4044,B-OrganismTaxon
colon,4044,B-DiseaseOrPhenotypicFeature
cancer,4044,I-DiseaseOrPhenotypicFeature
cell,4044,O
line,4044,O
.,4044,O
Emodin,4045,B-ChemicalEntity
markedly,4045,O
inhibited,4045,O
the,4045,O
proliferation,4045,O
of,4045,O
HCT116,4045,B-CellLine
cells,4045,O
and,4045,O
a,4045,O
higher,4045,O
protein,4045,O
level,4045,O
of,4045,O
FASN,4045,B-GeneOrGeneProduct
was,4045,O
expressed,4045,O
",",4045,O
compared,4045,O
with,4045,O
that,4045,O
in,4045,O
SW480,4045,B-CellLine
",",4045,O
SNU-C2A,4045,B-CellLine
or,4045,O
SNU-C5,4045,B-CellLine
cells,4045,O
.,4045,O
Emodin,4046,B-ChemicalEntity
significantly,4046,O
downregulated,4046,O
the,4046,O
protein,4046,O
expression,4046,O
of,4046,O
FASN,4046,B-GeneOrGeneProduct
in,4046,O
HCT116,4046,B-CellLine
cells,4046,O
",",4046,O
which,4046,O
was,4046,O
caused,4046,O
by,4046,O
protein,4046,O
degradation,4046,O
due,4046,O
to,4046,O
elevated,4046,O
protein,4046,O
ubiquitination,4046,O
.,4046,O
Emodin,4047,B-ChemicalEntity
also,4047,O
inhibited,4047,O
intracellular,4047,O
FASN,4047,B-GeneOrGeneProduct
enzymatic,4047,O
activity,4047,O
and,4047,O
reduced,4047,O
the,4047,O
levels,4047,O
of,4047,O
intracellular,4047,O
free,4047,B-ChemicalEntity
fatty,4047,I-ChemicalEntity
acids,4047,I-ChemicalEntity
.,4047,O
Emodin,4048,B-ChemicalEntity
enhanced,4048,O
antiproliferation,4048,O
and,4048,O
apoptosis,4048,O
in,4048,O
a,4048,O
dose-,4048,O
and,4048,O
time-dependent,4048,O
manner,4048,O
.,4048,O
The,4049,O
combined,4049,O
treatment,4049,O
of,4049,O
emodin,4049,B-ChemicalEntity
and,4049,O
cerulenin,4049,B-ChemicalEntity
",",4049,O
a,4049,O
commercial,4049,O
FASN,4049,B-GeneOrGeneProduct
inhibitor,4049,O
",",4049,O
had,4049,O
an,4049,O
additive,4049,O
effect,4049,O
on,4049,O
these,4049,O
activities,4049,O
.,4049,O
Palmitate,4050,B-ChemicalEntity
",",4050,O
the,4050,O
final,4050,O
product,4050,O
of,4050,O
the,4050,O
FASN,4050,B-GeneOrGeneProduct
reaction,4050,O
",",4050,O
rescued,4050,O
emodin-induced,4050,B-ChemicalEntity
viability,4050,O
and,4050,O
apoptosis,4050,O
.,4050,O
In,4051,O
addition,4051,O
",",4051,O
emodin,4051,B-ChemicalEntity
altered,4051,O
FASN-involved,4051,B-GeneOrGeneProduct
signaling,4051,O
pathways,4051,O
",",4051,O
including,4051,O
phosphatidylinositol,4051,B-GeneOrGeneProduct
3-kinase/Akt,4051,O
and,4051,O
mitogen-activated,4051,B-GeneOrGeneProduct
protein,4051,I-GeneOrGeneProduct
kinases/extracellular,4051,I-GeneOrGeneProduct
signal-regulated,4051,I-GeneOrGeneProduct
kinases,4051,I-GeneOrGeneProduct
1/2,4051,I-GeneOrGeneProduct
.,4051,O
These,4052,O
results,4052,O
suggested,4052,O
that,4052,O
emodin-regulated,4052,B-ChemicalEntity
cell,4052,O
growth,4052,O
and,4052,O
apoptosis,4052,O
were,4052,O
mediated,4052,O
by,4052,O
inhibiting,4052,O
FASN,4052,B-GeneOrGeneProduct
and,4052,O
provide,4052,O
a,4052,O
molecular,4052,O
basis,4052,O
for,4052,O
colon,4052,B-DiseaseOrPhenotypicFeature
cancer,4052,I-DiseaseOrPhenotypicFeature
therapy,4052,O
.,4052,O
GLUT4,4053,B-GeneOrGeneProduct
Is,4053,O
Not,4053,O
Necessary,4053,O
for,4053,O
Overload-Induced,4053,O
Glucose,4053,B-ChemicalEntity
Uptake,4053,O
or,4053,O
Hypertrophic,4053,O
Growth,4053,O
in,4053,O
Mouse,4053,B-OrganismTaxon
Skeletal,4053,O
Muscle,4053,O
.,4053,O
GLUT4,4054,B-GeneOrGeneProduct
is,4054,O
necessary,4054,O
for,4054,O
acute,4054,O
insulin-,4054,B-GeneOrGeneProduct
and,4054,O
contraction-induced,4054,O
skeletal,4054,O
muscle,4054,O
glucose,4054,B-ChemicalEntity
uptake,4054,O
",",4054,O
but,4054,O
its,4054,O
role,4054,O
in,4054,O
chronic,4054,O
muscle,4054,O
loading,4054,O
(,4054,O
overload,4054,O
),4054,O
-induced,4054,O
glucose,4054,B-ChemicalEntity
uptake,4054,O
is,4054,O
unknown,4054,O
.,4054,O
Our,4055,O
goal,4055,O
was,4055,O
to,4055,O
determine,4055,O
whether,4055,O
GLUT4,4055,B-GeneOrGeneProduct
is,4055,O
required,4055,O
for,4055,O
overload-induced,4055,O
glucose,4055,B-ChemicalEntity
uptake,4055,O
.,4055,O
Overload,4056,O
was,4056,O
induced,4056,O
in,4056,O
mouse,4056,B-OrganismTaxon
plantaris,4056,O
muscle,4056,O
by,4056,O
unilateral,4056,O
synergist,4056,O
ablation,4056,O
.,4056,O
After,4057,O
5,4057,O
days,4057,O
",",4057,O
muscle,4057,O
weights,4057,O
and,4057,O
ex,4057,O
vivo,4057,O
[,4057,B-ChemicalEntity
(,4057,I-ChemicalEntity
3,4057,I-ChemicalEntity
),4057,I-ChemicalEntity
H,4057,I-ChemicalEntity
],4057,I-ChemicalEntity
-2-deoxy-d-glucose,4057,I-ChemicalEntity
uptake,4057,O
were,4057,O
assessed,4057,O
.,4057,O
Overload-induced,4058,O
muscle,4058,O
glucose,4058,B-ChemicalEntity
uptake,4058,O
and,4058,O
hypertrophic,4058,O
growth,4058,O
were,4058,O
not,4058,O
impaired,4058,O
in,4058,O
muscle-specific,4058,O
GLUT4,4058,B-GeneOrGeneProduct
knockout,4058,O
mice,4058,B-OrganismTaxon
",",4058,O
demonstrating,4058,O
that,4058,O
GLUT4,4058,B-GeneOrGeneProduct
is,4058,O
not,4058,O
necessary,4058,O
for,4058,O
these,4058,O
processes,4058,O
.,4058,O
To,4059,O
assess,4059,O
which,4059,O
transporters,4059,O
mediate,4059,O
overload-induced,4059,O
glucose,4059,B-ChemicalEntity
uptake,4059,O
",",4059,O
chemical,4059,O
inhibitors,4059,O
were,4059,O
used,4059,O
.,4059,O
The,4060,O
facilitative,4060,O
GLUT,4060,B-GeneOrGeneProduct
inhibitor,4060,O
cytochalasin,4060,B-ChemicalEntity
B,4060,I-ChemicalEntity
",",4060,O
but,4060,O
not,4060,O
the,4060,O
sodium-dependent,4060,B-ChemicalEntity
glucose,4060,B-ChemicalEntity
cotransport,4060,O
inhibitor,4060,O
phloridzin,4060,B-ChemicalEntity
",",4060,O
prevented,4060,O
overload-induced,4060,O
uptake,4060,O
demonstrating,4060,O
that,4060,O
GLUTs,4060,B-GeneOrGeneProduct
mediate,4060,O
this,4060,O
effect,4060,O
.,4060,O
To,4061,O
assess,4061,O
which,4061,O
GLUT,4061,B-GeneOrGeneProduct
",",4061,O
hexose,4061,B-ChemicalEntity
competition,4061,O
experiments,4061,O
were,4061,O
performed,4061,O
.,4061,O
Overload-induced,4062,O
[,4062,B-ChemicalEntity
(,4062,I-ChemicalEntity
3,4062,I-ChemicalEntity
),4062,I-ChemicalEntity
H,4062,I-ChemicalEntity
],4062,I-ChemicalEntity
-2-deoxy-d-glucose,4062,I-ChemicalEntity
uptake,4062,O
was,4062,O
not,4062,O
inhibited,4062,O
by,4062,O
d-fructose,4062,B-ChemicalEntity
",",4062,O
demonstrating,4062,O
that,4062,O
the,4062,O
fructose-transporting,4062,O
GLUT2,4062,B-GeneOrGeneProduct
",",4062,O
GLUT5,4062,B-GeneOrGeneProduct
",",4062,O
GLUT8,4062,B-GeneOrGeneProduct
",",4062,O
and,4062,O
GLUT12,4062,B-GeneOrGeneProduct
do,4062,O
not,4062,O
mediate,4062,O
this,4062,O
effect,4062,O
.,4062,O
To,4063,O
assess,4063,O
additional,4063,O
GLUTs,4063,B-GeneOrGeneProduct
",",4063,O
immunoblots,4063,O
were,4063,O
performed,4063,O
.,4063,O
Overload,4064,O
increased,4064,O
GLUT1,4064,B-GeneOrGeneProduct
",",4064,O
GLUT3,4064,B-GeneOrGeneProduct
",",4064,O
GLUT6,4064,B-GeneOrGeneProduct
",",4064,O
and,4064,O
GLUT10,4064,B-GeneOrGeneProduct
protein,4064,O
levels,4064,O
twofold,4064,O
to,4064,O
fivefold,4064,O
.,4064,O
Collectively,4065,O
",",4065,O
these,4065,O
results,4065,O
demonstrate,4065,O
that,4065,O
GLUT4,4065,B-GeneOrGeneProduct
is,4065,O
not,4065,O
necessary,4065,O
for,4065,O
overload-induced,4065,O
muscle,4065,O
glucose,4065,B-ChemicalEntity
uptake,4065,O
or,4065,O
hypertrophic,4065,O
growth,4065,O
and,4065,O
suggest,4065,O
that,4065,O
GLUT1,4065,B-GeneOrGeneProduct
",",4065,O
GLUT3,4065,B-GeneOrGeneProduct
",",4065,O
GLUT6,4065,B-GeneOrGeneProduct
",",4065,O
and/or,4065,O
GLUT10,4065,B-GeneOrGeneProduct
mediate,4065,O
overload-induced,4065,O
glucose,4065,B-ChemicalEntity
uptake,4065,O
.,4065,O
Deletion,4066,O
of,4066,O
endothelial,4066,O
cell-specific,4066,O
liver,4066,B-GeneOrGeneProduct
kinase,4066,I-GeneOrGeneProduct
B1,4066,I-GeneOrGeneProduct
increases,4066,O
angiogenesis,4066,O
and,4066,O
tumor,4066,B-DiseaseOrPhenotypicFeature
growth,4066,O
via,4066,O
vascular,4066,B-GeneOrGeneProduct
endothelial,4066,I-GeneOrGeneProduct
growth,4066,I-GeneOrGeneProduct
factor,4066,I-GeneOrGeneProduct
.,4066,O
Liver,4067,B-GeneOrGeneProduct
kinase,4067,I-GeneOrGeneProduct
B1,4067,I-GeneOrGeneProduct
(,4067,O
LKB1,4067,B-GeneOrGeneProduct
),4067,O
is,4067,O
a,4067,O
serine/threonine,4067,B-GeneOrGeneProduct
protein,4067,I-GeneOrGeneProduct
kinase,4067,I-GeneOrGeneProduct
ubiquitously,4067,O
expressed,4067,O
in,4067,O
mammalian,4067,O
cells,4067,O
.,4067,O
It,4068,O
was,4068,O
first,4068,O
identified,4068,O
in,4068,O
Peutz-Jeghers,4068,B-DiseaseOrPhenotypicFeature
syndrome,4068,I-DiseaseOrPhenotypicFeature
as,4068,O
a,4068,O
tumor,4068,B-DiseaseOrPhenotypicFeature
suppressor,4068,O
gene,4068,O
.,4068,O
Whether,4069,O
endothelial,4069,O
LKB1,4069,B-GeneOrGeneProduct
regulates,4069,O
angiogenesis,4069,O
and,4069,O
tumor,4069,B-DiseaseOrPhenotypicFeature
growth,4069,O
is,4069,O
unknown,4069,O
.,4069,O
In,4070,O
this,4070,O
study,4070,O
",",4070,O
we,4070,O
generated,4070,O
endothelial,4070,O
cell-specific,4070,O
LKB1-knockout,4070,B-GeneOrGeneProduct
(,4070,O
LKB1,4070,B-GeneOrGeneProduct
(,4070,O
endo-/-,4070,O
),4070,O
),4070,O
mice,4070,B-OrganismTaxon
by,4070,O
crossbreeding,4070,O
vascular,4070,B-GeneOrGeneProduct
endothelial-cadherin-Cre,4070,O
mice,4070,B-OrganismTaxon
with,4070,O
LKB1,4070,B-GeneOrGeneProduct
(,4070,O
flox/flox,4070,O
),4070,O
mice,4070,B-OrganismTaxon
.,4070,O
Vascular,4071,B-GeneOrGeneProduct
endothelial,4071,I-GeneOrGeneProduct
growth,4071,I-GeneOrGeneProduct
factor,4071,I-GeneOrGeneProduct
(,4071,O
VEGF,4071,B-GeneOrGeneProduct
),4071,O
level,4071,O
was,4071,O
highly,4071,O
co-stained,4071,O
in,4071,O
endothelial,4071,O
cells,4071,O
but,4071,O
not,4071,O
in,4071,O
macrophages,4071,O
in,4071,O
LKB1,4071,B-GeneOrGeneProduct
(,4071,O
endo-/-,4071,O
),4071,O
mice,4071,B-OrganismTaxon
.,4071,O
Consistently,4072,O
",",4072,O
LKB1,4072,B-GeneOrGeneProduct
(,4072,O
endo-/-,4072,O
),4072,O
mouse,4072,B-OrganismTaxon
tissues,4072,O
including,4072,O
the,4072,O
lung,4072,O
",",4072,O
skin,4072,O
",",4072,O
kidney,4072,O
and,4072,O
liver,4072,O
showed,4072,O
increased,4072,O
vascular,4072,O
permeability,4072,O
.,4072,O
Tumors,4073,B-DiseaseOrPhenotypicFeature
implanted,4073,O
in,4073,O
LKB1,4073,B-GeneOrGeneProduct
(,4073,O
endo-/-,4073,O
),4073,O
mice,4073,B-OrganismTaxon
but,4073,O
not,4073,O
macrophage-specific,4073,O
LKB1-knockout,4073,B-GeneOrGeneProduct
mice,4073,B-OrganismTaxon
grew,4073,O
faster,4073,O
and,4073,O
showed,4073,O
enhanced,4073,O
vascular,4073,O
permeability,4073,O
and,4073,O
increased,4073,O
angiogenesis,4073,O
as,4073,O
compared,4073,O
with,4073,O
those,4073,O
implanted,4073,O
in,4073,O
wild-type,4073,O
mice,4073,B-OrganismTaxon
.,4073,O
Injection,4074,O
of,4074,O
VEGF-neutralizing,4074,B-GeneOrGeneProduct
antibody,4074,O
but,4074,O
not,4074,O
the,4074,O
isotype-matched,4074,O
control,4074,O
antibody,4074,O
decreased,4074,O
endothelial-cell,4074,O
angiogenesis,4074,O
and,4074,O
tumor,4074,B-DiseaseOrPhenotypicFeature
growth,4074,O
in,4074,O
vivo,4074,O
.,4074,O
Furthermore,4075,O
",",4075,O
LKB1,4075,B-GeneOrGeneProduct
deletion,4075,O
enhanced,4075,O
mouse,4075,B-OrganismTaxon
retinal,4075,O
and,4075,O
cell,4075,O
angiogenesis,4075,O
",",4075,O
and,4075,O
knockdown,4075,O
of,4075,O
VEGF,4075,B-GeneOrGeneProduct
by,4075,O
small-interfering,4075,O
RNA,4075,O
decreased,4075,O
endothelial,4075,O
cell,4075,O
proliferation,4075,O
and,4075,O
migration,4075,O
.,4075,O
Re-expression,4076,O
of,4076,O
LKB1,4076,B-GeneOrGeneProduct
or,4076,O
knockdown,4076,O
of,4076,O
VEGF,4076,B-GeneOrGeneProduct
receptor,4076,I-GeneOrGeneProduct
2,4076,I-GeneOrGeneProduct
decreased,4076,O
the,4076,O
overproliferation,4076,O
and,4076,O
-migration,4076,O
observed,4076,O
in,4076,O
LKB1,4076,B-GeneOrGeneProduct
(,4076,O
endo-/-,4076,O
),4076,O
cells,4076,O
.,4076,O
Mechanistically,4077,O
",",4077,O
LKB1,4077,B-GeneOrGeneProduct
could,4077,O
bind,4077,O
to,4077,O
the,4077,O
VEGF,4077,B-GeneOrGeneProduct
transcription,4077,O
factor,4077,O
",",4077,O
specificity,4077,B-GeneOrGeneProduct
protein,4077,I-GeneOrGeneProduct
1,4077,I-GeneOrGeneProduct
(,4077,O
Sp1,4077,B-GeneOrGeneProduct
),4077,O
",",4077,O
which,4077,O
then,4077,O
inhibited,4077,O
the,4077,O
binding,4077,O
of,4077,O
Sp1,4077,B-GeneOrGeneProduct
to,4077,O
the,4077,O
VEGF,4077,B-GeneOrGeneProduct
promoter,4077,O
to,4077,O
reduce,4077,O
VEGF,4077,B-GeneOrGeneProduct
expression,4077,O
.,4077,O
Endothelial,4078,O
LKB1,4078,B-GeneOrGeneProduct
may,4078,O
regulate,4078,O
endothelial,4078,O
angiogenesis,4078,O
and,4078,O
tumor,4078,B-DiseaseOrPhenotypicFeature
growth,4078,O
by,4078,O
modulating,4078,O
Sp1-mediated,4078,B-GeneOrGeneProduct
VEGF,4078,B-GeneOrGeneProduct
expression,4078,O
.,4078,O
FGFR2,4079,B-GeneOrGeneProduct
is,4079,O
required,4079,O
for,4079,O
airway,4079,O
basal,4079,O
cell,4079,O
self-renewal,4079,O
and,4079,O
terminal,4079,O
differentiation,4079,O
.,4079,O
Airway,4080,O
stem,4080,O
cells,4080,O
slowly,4080,O
self-renew,4080,O
and,4080,O
produce,4080,O
differentiated,4080,O
progeny,4080,O
to,4080,O
maintain,4080,O
homeostasis,4080,O
throughout,4080,O
the,4080,O
lifespan,4080,O
of,4080,O
an,4080,O
individual,4080,O
.,4080,O
Mutations,4081,O
in,4081,O
the,4081,O
molecular,4081,O
regulators,4081,O
of,4081,O
these,4081,O
processes,4081,O
may,4081,O
drive,4081,O
cancer,4081,B-DiseaseOrPhenotypicFeature
or,4081,O
degenerative,4081,B-DiseaseOrPhenotypicFeature
disease,4081,I-DiseaseOrPhenotypicFeature
",",4081,O
but,4081,O
are,4081,O
also,4081,O
potential,4081,O
therapeutic,4081,O
targets,4081,O
.,4081,O
Conditionally,4082,O
deleting,4082,O
one,4082,O
copy,4082,O
of,4082,O
FGF,4082,B-GeneOrGeneProduct
receptor,4082,I-GeneOrGeneProduct
2,4082,I-GeneOrGeneProduct
(,4082,O
FGFR2,4082,B-GeneOrGeneProduct
),4082,O
in,4082,O
adult,4082,O
mouse,4082,B-OrganismTaxon
airway,4082,O
basal,4082,O
cells,4082,O
results,4082,O
in,4082,O
self-renewal,4082,O
and,4082,O
differentiation,4082,O
phenotypes,4082,O
.,4082,O
We,4083,O
show,4083,O
that,4083,O
FGFR2,4083,B-GeneOrGeneProduct
signalling,4083,O
correlates,4083,O
with,4083,O
maintenance,4083,O
of,4083,O
expression,4083,O
of,4083,O
a,4083,O
key,4083,O
transcription,4083,O
factor,4083,O
for,4083,O
basal,4083,O
cell,4083,O
self-renewal,4083,O
and,4083,O
differentiation,4083,O
:,4083,O
SOX2,4083,B-GeneOrGeneProduct
.,4083,O
This,4084,O
heterozygous,4084,O
phenotype,4084,O
illustrates,4084,O
that,4084,O
subtle,4084,O
changes,4084,O
in,4084,O
receptor,4084,B-GeneOrGeneProduct
tyrosine,4084,I-GeneOrGeneProduct
kinase,4084,I-GeneOrGeneProduct
signalling,4084,O
can,4084,O
have,4084,O
significant,4084,O
effects,4084,O
",",4084,O
perhaps,4084,O
providing,4084,O
an,4084,O
explanation,4084,O
for,4084,O
the,4084,O
numerous,4084,O
changes,4084,O
seen,4084,O
in,4084,O
cancer,4084,B-DiseaseOrPhenotypicFeature
.,4084,O
Myc,4085,B-GeneOrGeneProduct
enhances,4085,O
B-cell,4085,B-GeneOrGeneProduct
receptor,4085,I-GeneOrGeneProduct
signaling,4085,O
in,4085,O
precancerous,4085,B-DiseaseOrPhenotypicFeature
B,4085,O
cells,4085,O
and,4085,O
confers,4085,O
resistance,4085,O
to,4085,O
Btk,4085,B-GeneOrGeneProduct
inhibition,4085,O
.,4085,O
Dysregulation,4086,O
of,4086,O
the,4086,O
oncogenic,4086,O
transcription,4086,O
factor,4086,O
MYC,4086,B-GeneOrGeneProduct
induces,4086,O
B-cell,4086,O
transformation,4086,O
and,4086,O
is,4086,O
a,4086,O
driver,4086,O
for,4086,O
B-cell,4086,B-DiseaseOrPhenotypicFeature
non-Hodgkin,4086,I-DiseaseOrPhenotypicFeature
lymphoma,4086,I-DiseaseOrPhenotypicFeature
(,4086,O
B-NHL,4086,B-DiseaseOrPhenotypicFeature
),4086,O
.,4086,O
MYC,4087,B-GeneOrGeneProduct
overexpression,4087,O
in,4087,O
B-NHL,4087,B-DiseaseOrPhenotypicFeature
is,4087,O
associated,4087,O
with,4087,O
more,4087,O
aggressive,4087,O
phenotypes,4087,O
and,4087,O
poor,4087,O
prognosis,4087,O
.,4087,O
Although,4088,O
genomic,4088,O
studies,4088,O
suggest,4088,O
a,4088,O
link,4088,O
between,4088,O
MYC,4088,B-GeneOrGeneProduct
overexpression,4088,O
and,4088,O
B-cell,4088,B-GeneOrGeneProduct
receptor,4088,I-GeneOrGeneProduct
(,4088,O
BCR,4088,B-GeneOrGeneProduct
),4088,O
signaling,4088,O
molecules,4088,O
in,4088,O
B-NHL,4088,B-DiseaseOrPhenotypicFeature
",",4088,O
signaling,4088,O
pathways,4088,O
essential,4088,O
to,4088,O
Myc-mediated,4088,B-GeneOrGeneProduct
B-cell,4088,O
transformation,4088,O
have,4088,O
not,4088,O
been,4088,O
fully,4088,O
elucidated,4088,O
.,4088,O
We,4089,O
utilized,4089,O
intracellular,4089,O
phospho-flow,4089,O
cytometry,4089,O
to,4089,O
investigate,4089,O
the,4089,O
relationship,4089,O
between,4089,O
Myc,4089,B-GeneOrGeneProduct
and,4089,O
BCR,4089,B-GeneOrGeneProduct
signaling,4089,O
in,4089,O
pre-malignant,4089,O
B,4089,O
cells,4089,O
.,4089,O
Utilizing,4090,O
the,4090,O
Eu-myc,4090,O
mouse,4090,B-OrganismTaxon
model,4090,O
",",4090,O
where,4090,O
Myc,4090,B-GeneOrGeneProduct
is,4090,O
overexpressed,4090,O
specifically,4090,O
in,4090,O
B,4090,O
cells,4090,O
",",4090,O
both,4090,O
basal,4090,O
and,4090,O
stimulated,4090,O
BCR,4090,B-GeneOrGeneProduct
signaling,4090,O
were,4090,O
increased,4090,O
in,4090,O
precancerous,4090,B-DiseaseOrPhenotypicFeature
B,4090,O
lymphocytes,4090,O
from,4090,O
Eu-myc,4090,O
mice,4090,B-OrganismTaxon
compared,4090,O
with,4090,O
wild-type,4090,O
littermates,4090,O
.,4090,O
B,4091,O
cells,4091,O
overexpressing,4091,O
Myc,4091,B-GeneOrGeneProduct
displayed,4091,O
constitutively,4091,O
higher,4091,O
levels,4091,O
of,4091,O
activated,4091,O
CD79a,4091,B-GeneOrGeneProduct
",",4091,O
Btk,4091,B-GeneOrGeneProduct
",",4091,O
Plcg2,4091,B-GeneOrGeneProduct
and,4091,O
Erk1/2,4091,B-GeneOrGeneProduct
.,4091,O
Notably,4092,O
",",4092,O
Myc-overexpressing,4092,B-GeneOrGeneProduct
B,4092,O
cells,4092,O
maintained,4092,O
elevated,4092,O
BCR,4092,B-GeneOrGeneProduct
signaling,4092,O
despite,4092,O
treatment,4092,O
with,4092,O
ibrutinib,4092,B-ChemicalEntity
",",4092,O
a,4092,O
Bruton,4092,B-GeneOrGeneProduct
's,4092,I-GeneOrGeneProduct
tyrosine,4092,I-GeneOrGeneProduct
kinase,4092,I-GeneOrGeneProduct
inhibitor,4092,O
.,4092,O
Furthermore,4093,O
",",4093,O
PI3K/Akt,4093,B-GeneOrGeneProduct
pathway,4093,O
signaling,4093,O
was,4093,O
also,4093,O
increased,4093,O
in,4093,O
Eu-myc,4093,O
B,4093,O
cells,4093,O
",",4093,O
and,4093,O
this,4093,O
increase,4093,O
was,4093,O
partially,4093,O
suppressed,4093,O
with,4093,O
ibrutinib,4093,B-ChemicalEntity
.,4093,O
In,4094,O
addition,4094,O
",",4094,O
experiments,4094,O
with,4094,O
Btk-null,4094,B-GeneOrGeneProduct
B,4094,O
cells,4094,O
revealed,4094,O
off-target,4094,O
effects,4094,O
of,4094,O
ibrutinib,4094,B-ChemicalEntity
on,4094,O
BCR,4094,B-GeneOrGeneProduct
signaling,4094,O
.,4094,O
Our,4095,O
data,4095,O
show,4095,O
that,4095,O
in,4095,O
pre-malignant,4095,O
B,4095,O
cells,4095,O
",",4095,O
Myc,4095,B-GeneOrGeneProduct
overexpression,4095,O
is,4095,O
sufficient,4095,O
to,4095,O
activate,4095,O
BCR,4095,B-GeneOrGeneProduct
and,4095,O
PI3K/Akt,4095,B-GeneOrGeneProduct
signaling,4095,O
pathways,4095,O
and,4095,O
further,4095,O
enhances,4095,O
signaling,4095,O
following,4095,O
BCR,4095,B-GeneOrGeneProduct
ligation,4095,O
.,4095,O
Therefore,4096,O
",",4096,O
our,4096,O
results,4096,O
indicate,4096,O
that,4096,O
precancerous,4096,B-DiseaseOrPhenotypicFeature
B,4096,O
cells,4096,O
have,4096,O
already,4096,O
acquired,4096,O
enhanced,4096,O
survival,4096,O
and,4096,O
growth,4096,O
capabilities,4096,O
before,4096,O
transformation,4096,O
",",4096,O
and,4096,O
that,4096,O
elevated,4096,O
MYC,4096,B-GeneOrGeneProduct
levels,4096,O
confer,4096,O
resistance,4096,O
to,4096,O
pharmacologic,4096,O
inhibitors,4096,O
of,4096,O
BCR,4096,B-GeneOrGeneProduct
signaling,4096,O
",",4096,O
which,4096,O
has,4096,O
significant,4096,O
implications,4096,O
for,4096,O
B-NHL,4096,B-DiseaseOrPhenotypicFeature
treatment,4096,O
.,4096,O
Tissue-Specific,4097,O
Ablation,4097,O
of,4097,O
the,4097,O
LIF,4097,B-GeneOrGeneProduct
Receptor,4097,I-GeneOrGeneProduct
in,4097,O
the,4097,O
Murine,4097,B-OrganismTaxon
Uterine,4097,O
Epithelium,4097,O
Results,4097,O
in,4097,O
Implantation,4097,O
Failure,4097,O
.,4097,O
The,4098,O
cytokine,4098,O
leukemia,4098,B-GeneOrGeneProduct
inhibitory,4098,I-GeneOrGeneProduct
factor,4098,I-GeneOrGeneProduct
(,4098,O
LIF,4098,B-GeneOrGeneProduct
),4098,O
is,4098,O
essential,4098,O
for,4098,O
rendering,4098,O
the,4098,O
uterus,4098,O
receptive,4098,O
for,4098,O
blastocyst,4098,O
implantation,4098,O
.,4098,O
In,4099,O
mice,4099,B-OrganismTaxon
",",4099,O
LIF,4099,B-GeneOrGeneProduct
receptor,4099,I-GeneOrGeneProduct
expression,4099,O
(,4099,O
LIFR,4099,B-GeneOrGeneProduct
),4099,O
is,4099,O
largely,4099,O
restricted,4099,O
to,4099,O
the,4099,O
uterine,4099,O
luminal,4099,O
epithelium,4099,O
(,4099,O
LE,4099,O
),4099,O
.,4099,O
LIF,4100,B-GeneOrGeneProduct
",",4100,O
secreted,4100,O
from,4100,O
the,4100,O
endometrial,4100,O
glands,4100,O
(,4100,O
GEs,4100,O
),4100,O
",",4100,O
binds,4100,O
to,4100,O
the,4100,O
LIFR,4100,B-GeneOrGeneProduct
",",4100,O
activating,4100,O
the,4100,O
Janus,4100,B-GeneOrGeneProduct
kinase-signal,4100,O
transducer,4100,I-GeneOrGeneProduct
and,4100,I-GeneOrGeneProduct
activation,4100,I-GeneOrGeneProduct
of,4100,I-GeneOrGeneProduct
transcription,4100,I-GeneOrGeneProduct
(,4100,I-GeneOrGeneProduct
STAT,4100,I-GeneOrGeneProduct
),4100,I-GeneOrGeneProduct
3,4100,I-GeneOrGeneProduct
(,4100,O
Jak-Stat3,4100,B-GeneOrGeneProduct
),4100,O
signaling,4100,O
pathway,4100,O
in,4100,O
the,4100,O
LE,4100,O
.,4100,O
JAK-STAT,4101,B-GeneOrGeneProduct
activation,4101,O
converts,4101,O
the,4101,O
LE,4101,O
to,4101,O
a,4101,O
receptive,4101,O
state,4101,O
so,4101,O
that,4101,O
juxtaposed,4101,O
blastocysts,4101,O
begin,4101,O
to,4101,O
implant,4101,O
.,4101,O
To,4102,O
specifically,4102,O
delete,4102,O
the,4102,O
LIFR,4102,B-GeneOrGeneProduct
in,4102,O
the,4102,O
LE,4102,O
",",4102,O
we,4102,O
derived,4102,O
a,4102,O
line,4102,O
of,4102,O
mice,4102,B-OrganismTaxon
in,4102,O
which,4102,O
Cre,4102,O
recombinase,4102,O
was,4102,O
inserted,4102,O
into,4102,O
the,4102,O
endogenous,4102,O
lactoferrin,4102,B-GeneOrGeneProduct
gene,4102,O
(,4102,O
Ltf-Cre,4102,B-GeneOrGeneProduct
),4102,O
.,4102,O
Lactoferrin,4103,B-GeneOrGeneProduct
expression,4103,O
in,4103,O
the,4103,O
LE,4103,O
is,4103,O
induced,4103,O
by,4103,O
E2,4103,O
",",4103,O
and,4103,O
we,4103,O
demonstrate,4103,O
that,4103,O
Cre,4103,O
recombinase,4103,O
activity,4103,O
is,4103,O
restricted,4103,O
to,4103,O
the,4103,O
LE,4103,O
and,4103,O
GE,4103,O
.,4103,O
To,4104,O
determine,4104,O
the,4104,O
requirement,4104,O
of,4104,O
the,4104,O
LIFR,4104,B-GeneOrGeneProduct
in,4104,O
implantation,4104,O
",",4104,O
we,4104,O
derived,4104,O
an,4104,O
additional,4104,O
mouse,4104,B-OrganismTaxon
line,4104,O
carrying,4104,O
a,4104,O
conditional,4104,O
(,4104,O
floxed,4104,O
),4104,O
Lifr,4104,B-GeneOrGeneProduct
flx/flx,4104,O
gene,4104,O
.,4104,O
Crossing,4105,O
Ltf-Cre,4105,B-GeneOrGeneProduct
mice,4105,B-OrganismTaxon
with,4105,O
Lifr,4105,B-GeneOrGeneProduct
flx/flx,4105,O
mice,4105,B-OrganismTaxon
generated,4105,O
Lifr,4105,B-GeneOrGeneProduct
flx/D,4105,O
:,4105,O
Ltf,4105,B-GeneOrGeneProduct
Cre/+,4105,O
females,4105,O
that,4105,O
were,4105,O
overtly,4105,O
normal,4105,O
but,4105,O
infertile,4105,O
.,4105,O
Many,4106,O
of,4106,O
these,4106,O
females,4106,O
",",4106,O
despite,4106,O
repeated,4106,O
matings,4106,O
",",4106,O
did,4106,O
not,4106,O
become,4106,O
pregnant,4106,O
.,4106,O
Unimplanted,4107,O
blastocysts,4107,O
were,4107,O
recovered,4107,O
from,4107,O
the,4107,O
Lifr,4107,B-GeneOrGeneProduct
flx/D,4107,O
:,4107,O
Ltf,4107,B-GeneOrGeneProduct
Cre/+,4107,O
uteri,4107,O
and,4107,O
",",4107,O
when,4107,O
transferred,4107,O
to,4107,O
wild-type,4107,O
recipients,4107,O
",",4107,O
implanted,4107,O
normally,4107,O
",",4107,O
indicating,4107,O
that,4107,O
uterine,4107,O
receptivity,4107,O
rather,4107,O
than,4107,O
the,4107,O
embryo,4107,O
's,4107,O
competency,4107,O
is,4107,O
compromised,4107,O
.,4107,O
The,4108,O
loss,4108,O
of,4108,O
Lifr,4108,B-GeneOrGeneProduct
results,4108,O
in,4108,O
both,4108,O
the,4108,O
failure,4108,O
for,4108,O
STAT3,4108,B-GeneOrGeneProduct
to,4108,O
translocate,4108,O
to,4108,O
the,4108,O
LE,4108,O
nuclei,4108,O
and,4108,O
a,4108,O
reduction,4108,O
in,4108,O
the,4108,O
expression,4108,O
of,4108,O
the,4108,O
LIF,4108,B-GeneOrGeneProduct
regulated,4108,O
gene,4108,O
Msx1,4108,B-GeneOrGeneProduct
that,4108,O
regulates,4108,O
uterine,4108,O
receptivity,4108,O
.,4108,O
These,4109,O
results,4109,O
reveal,4109,O
that,4109,O
uterine,4109,O
expression,4109,O
of,4109,O
the,4109,O
LIFR,4109,B-GeneOrGeneProduct
is,4109,O
essential,4109,O
for,4109,O
embryo,4109,O
implantation,4109,O
and,4109,O
further,4109,O
define,4109,O
the,4109,O
components,4109,O
of,4109,O
the,4109,O
LIF,4109,B-GeneOrGeneProduct
signaling,4109,O
pathway,4109,O
necessary,4109,O
for,4109,O
effective,4109,O
implantation,4109,O
.,4109,O
Biophysical,4110,O
and,4110,O
functional,4110,O
characterization,4110,O
of,4110,O
hippocalcin,4110,B-GeneOrGeneProduct
mutants,4110,O
responsible,4110,O
for,4110,O
human,4110,B-OrganismTaxon
dystonia,4110,B-DiseaseOrPhenotypicFeature
.,4110,O
Dystonia,4111,B-DiseaseOrPhenotypicFeature
is,4111,O
a,4111,O
neurological,4111,B-DiseaseOrPhenotypicFeature
movement,4111,I-DiseaseOrPhenotypicFeature
disorder,4111,I-DiseaseOrPhenotypicFeature
that,4111,O
forces,4111,O
the,4111,O
body,4111,O
into,4111,O
twisting,4111,O
",",4111,O
repetitive,4111,O
movements,4111,O
or,4111,O
sometimes,4111,O
painful,4111,O
abnormal,4111,O
postures,4111,O
.,4111,O
With,4112,O
the,4112,O
advent,4112,O
of,4112,O
next-generation,4112,O
sequencing,4112,O
technologies,4112,O
",",4112,O
the,4112,O
homozygous,4112,O
mutations,4112,O
T71N,4112,B-SequenceVariant
and,4112,O
A190T,4112,B-SequenceVariant
in,4112,O
the,4112,O
neuronal,4112,B-GeneOrGeneProduct
calcium,4112,I-GeneOrGeneProduct
sensor,4112,I-GeneOrGeneProduct
(,4112,O
NCS,4112,B-GeneOrGeneProduct
),4112,O
hippocalcin,4112,B-GeneOrGeneProduct
were,4112,O
identified,4112,O
as,4112,O
the,4112,O
genetic,4112,O
cause,4112,O
of,4112,O
primary,4112,B-DiseaseOrPhenotypicFeature
isolated,4112,I-DiseaseOrPhenotypicFeature
dystonia,4112,I-DiseaseOrPhenotypicFeature
(,4112,O
DYT2,4112,B-GeneOrGeneProduct
dystonia,4112,B-DiseaseOrPhenotypicFeature
),4112,O
.,4112,O
However,4113,O
",",4113,O
the,4113,O
effect,4113,O
of,4113,O
these,4113,O
mutations,4113,O
on,4113,O
the,4113,O
physiological,4113,O
role,4113,O
of,4113,O
hippocalcin,4113,B-GeneOrGeneProduct
has,4113,O
not,4113,O
yet,4113,O
been,4113,O
elucidated,4113,O
.,4113,O
Using,4114,O
a,4114,O
multidisciplinary,4114,O
approach,4114,O
",",4114,O
we,4114,O
demonstrated,4114,O
that,4114,O
hippocalcin,4114,B-GeneOrGeneProduct
oligomerises,4114,O
in,4114,O
a,4114,O
calcium-dependent,4114,B-ChemicalEntity
manner,4114,O
and,4114,O
binds,4114,O
to,4114,O
voltage-gated,4114,B-GeneOrGeneProduct
calcium,4114,I-GeneOrGeneProduct
channels,4114,I-GeneOrGeneProduct
.,4114,O
Mutations,4115,O
T71N,4115,B-SequenceVariant
and,4115,O
A190T,4115,B-SequenceVariant
in,4115,O
hippocalcin,4115,B-GeneOrGeneProduct
did,4115,O
not,4115,O
affect,4115,O
stability,4115,O
",",4115,O
calcium-binding,4115,B-ChemicalEntity
affinity,4115,O
or,4115,O
translocation,4115,O
to,4115,O
cellular,4115,O
membranes,4115,O
(,4115,O
Ca2+/myristoyl,4115,B-ChemicalEntity
switch,4115,O
),4115,O
.,4115,O
We,4116,O
obtained,4116,O
the,4116,O
first,4116,O
crystal,4116,O
structure,4116,O
of,4116,O
hippocalcin,4116,B-GeneOrGeneProduct
and,4116,O
alignment,4116,O
with,4116,O
other,4116,O
NCS,4116,B-GeneOrGeneProduct
proteins,4116,O
showed,4116,O
significant,4116,O
variability,4116,O
in,4116,O
the,4116,O
orientation,4116,O
of,4116,O
the,4116,O
C-terminal,4116,O
part,4116,O
of,4116,O
the,4116,O
molecule,4116,O
",",4116,O
the,4116,O
region,4116,O
expected,4116,O
to,4116,O
be,4116,O
important,4116,O
for,4116,O
target,4116,O
binding,4116,O
.,4116,O
We,4117,O
demonstrated,4117,O
that,4117,O
the,4117,O
disease-causing,4117,O
mutations,4117,O
did,4117,O
not,4117,O
affect,4117,O
the,4117,O
structure,4117,O
of,4117,O
the,4117,O
protein,4117,O
",",4117,O
however,4117,O
both,4117,O
mutants,4117,O
showed,4117,O
a,4117,O
defect,4117,O
in,4117,O
oligomerisation,4117,O
.,4117,O
In,4118,O
addition,4118,O
",",4118,O
we,4118,O
observed,4118,O
an,4118,O
increased,4118,O
calcium,4118,B-ChemicalEntity
influx,4118,O
in,4118,O
KCl-depolarised,4118,B-ChemicalEntity
cells,4118,O
expressing,4118,O
mutated,4118,O
hippocalcin,4118,B-GeneOrGeneProduct
",",4118,O
mostly,4118,O
driven,4118,O
by,4118,O
N-type,4118,B-GeneOrGeneProduct
voltage-gated,4118,I-GeneOrGeneProduct
calcium,4118,I-GeneOrGeneProduct
channels,4118,I-GeneOrGeneProduct
.,4118,O
Our,4119,O
data,4119,O
demonstrate,4119,O
that,4119,O
the,4119,O
dystonia-causing,4119,B-DiseaseOrPhenotypicFeature
mutations,4119,O
strongly,4119,O
affect,4119,O
hippocalcin,4119,B-GeneOrGeneProduct
cellular,4119,O
functions,4119,O
which,4119,O
suggest,4119,O
a,4119,O
central,4119,O
role,4119,O
for,4119,O
perturbed,4119,O
calcium,4119,B-ChemicalEntity
signalling,4119,O
in,4119,O
DYT2,4119,B-GeneOrGeneProduct
dystonia,4119,B-DiseaseOrPhenotypicFeature
.,4119,O
Genetic,4120,O
Variation,4120,O
at,4120,O
the,4120,O
Sulfonylurea,4120,B-GeneOrGeneProduct
Receptor,4120,I-GeneOrGeneProduct
",",4120,O
Type,4120,B-DiseaseOrPhenotypicFeature
2,4120,I-DiseaseOrPhenotypicFeature
Diabetes,4120,I-DiseaseOrPhenotypicFeature
",",4120,O
and,4120,O
Coronary,4120,B-DiseaseOrPhenotypicFeature
Heart,4120,I-DiseaseOrPhenotypicFeature
Disease,4120,I-DiseaseOrPhenotypicFeature
.,4120,O
Despite,4121,O
widespread,4121,O
clinical,4121,O
use,4121,O
in,4121,O
the,4121,O
treatment,4121,O
of,4121,O
type,4121,B-DiseaseOrPhenotypicFeature
2,4121,I-DiseaseOrPhenotypicFeature
diabetes,4121,I-DiseaseOrPhenotypicFeature
",",4121,O
the,4121,O
impact,4121,O
of,4121,O
sulfonylurea,4121,B-ChemicalEntity
therapy,4121,O
on,4121,O
cardiovascular,4121,O
outcomes,4121,O
remains,4121,O
uncertain,4121,O
.,4121,O
Studies,4122,O
of,4122,O
naturally,4122,O
occurring,4122,O
genetic,4122,O
variation,4122,O
can,4122,O
be,4122,O
used,4122,O
to,4122,O
anticipate,4122,O
the,4122,O
expected,4122,O
clinical,4122,O
consequences,4122,O
of,4122,O
a,4122,O
pharmacological,4122,O
therapy,4122,O
.,4122,O
A,4123,O
common,4123,O
missense,4123,O
variant,4123,O
in,4123,O
the,4123,O
gene,4123,O
encoding,4123,O
a,4123,O
component,4123,O
of,4123,O
the,4123,O
sulfonylurea,4123,B-GeneOrGeneProduct
receptor,4123,I-GeneOrGeneProduct
(,4123,O
ABCC8,4123,B-GeneOrGeneProduct
p.A1369S,4123,B-SequenceVariant
),4123,O
promotes,4123,O
closure,4123,O
of,4123,O
the,4123,O
target,4123,O
channel,4123,O
of,4123,O
sulfonylurea,4123,B-ChemicalEntity
therapy,4123,O
and,4123,O
is,4123,O
associated,4123,O
with,4123,O
increased,4123,O
insulin,4123,B-GeneOrGeneProduct
secretion,4123,O
",",4123,O
thus,4123,O
mimicking,4123,O
the,4123,O
effects,4123,O
of,4123,O
sulfonylurea,4123,B-ChemicalEntity
therapy,4123,O
.,4123,O
Using,4124,O
individual-level,4124,O
data,4124,O
from,4124,O
"120,286",4124,O
participants,4124,O
in,4124,O
the,4124,O
UK,4124,O
Biobank,4124,O
and,4124,O
summary,4124,O
association,4124,O
results,4124,O
from,4124,O
four,4124,O
large-scale,4124,O
genome-wide,4124,O
association,4124,O
studies,4124,O
",",4124,O
we,4124,O
examined,4124,O
the,4124,O
impact,4124,O
of,4124,O
this,4124,O
variant,4124,O
on,4124,O
cardiometabolic,4124,O
traits,4124,O
",",4124,O
type,4124,B-DiseaseOrPhenotypicFeature
2,4124,I-DiseaseOrPhenotypicFeature
diabetes,4124,I-DiseaseOrPhenotypicFeature
",",4124,O
and,4124,O
coronary,4124,B-DiseaseOrPhenotypicFeature
heart,4124,I-DiseaseOrPhenotypicFeature
disease,4124,I-DiseaseOrPhenotypicFeature
.,4124,O
The,4125,O
p.A1369S,4125,B-SequenceVariant
variant,4125,O
was,4125,O
associated,4125,O
with,4125,O
a,4125,O
significantly,4125,O
lower,4125,O
risk,4125,O
of,4125,O
type,4125,B-DiseaseOrPhenotypicFeature
2,4125,I-DiseaseOrPhenotypicFeature
diabetes,4125,I-DiseaseOrPhenotypicFeature
(,4125,O
odds,4125,O
ratio,4125,O
[,4125,O
OR,4125,O
],4125,O
0.93,4125,O
;,4125,O
95,4125,O
%,4125,O
CI,4125,O
0.91,4125,O
",",4125,O
0.95,4125,O
;,4125,O
P,4125,O
=,4125,O
1.2,4125,O
x,4125,O
10,4125,O
(,4125,O
-11,4125,O
),4125,O
),4125,O
.,4125,O
The,4126,O
variant,4126,O
was,4126,O
associated,4126,O
with,4126,O
increased,4126,O
BMI,4126,O
(,4126,O
+0.062,4126,O
kg/m,4126,O
(,4126,O
2,4126,O
),4126,O
;,4126,O
95,4126,O
%,4126,O
CI,4126,O
0.037,4126,O
",",4126,O
0.086,4126,O
;,4126,O
P,4126,O
=,4126,O
8.1,4126,O
x,4126,O
10,4126,O
(,4126,O
-7,4126,O
),4126,O
),4126,O
but,4126,O
lower,4126,O
waist-to-hip,4126,O
ratio,4126,O
adjusted,4126,O
for,4126,O
BMI,4126,O
",",4126,O
a,4126,O
marker,4126,O
of,4126,O
abdominal,4126,O
fat,4126,O
distribution,4126,O
.,4126,O
Furthermore,4127,O
",",4127,O
p.A1369S,4127,B-SequenceVariant
was,4127,O
associated,4127,O
with,4127,O
a,4127,O
reduced,4127,O
risk,4127,O
of,4127,O
coronary,4127,B-DiseaseOrPhenotypicFeature
heart,4127,I-DiseaseOrPhenotypicFeature
disease,4127,I-DiseaseOrPhenotypicFeature
(,4127,O
OR,4127,O
0.98,4127,O
;,4127,O
95,4127,O
%,4127,O
CI,4127,O
0.96,4127,O
",",4127,O
0.99,4127,O
;,4127,O
P,4127,O
=,4127,O
5.9,4127,O
x,4127,O
10,4127,O
(,4127,O
-4,4127,O
),4127,O
),4127,O
.,4127,O
These,4128,O
results,4128,O
suggest,4128,O
that,4128,O
",",4128,O
despite,4128,O
a,4128,O
known,4128,O
association,4128,O
with,4128,O
increased,4128,O
weight,4128,O
",",4128,O
long-term,4128,O
sulfonylurea,4128,B-ChemicalEntity
therapy,4128,O
may,4128,O
reduce,4128,O
the,4128,O
risk,4128,O
of,4128,O
coronary,4128,B-DiseaseOrPhenotypicFeature
heart,4128,I-DiseaseOrPhenotypicFeature
disease,4128,I-DiseaseOrPhenotypicFeature
.,4128,O
A,4129,O
TSPO,4129,B-GeneOrGeneProduct
ligand,4129,O
attenuates,4129,O
brain,4129,B-DiseaseOrPhenotypicFeature
injury,4129,I-DiseaseOrPhenotypicFeature
after,4129,O
intracerebral,4129,B-DiseaseOrPhenotypicFeature
hemorrhage,4129,I-DiseaseOrPhenotypicFeature
.,4129,O
Intracerebral,4130,B-DiseaseOrPhenotypicFeature
hemorrhage,4130,I-DiseaseOrPhenotypicFeature
(,4130,O
ICH,4130,B-DiseaseOrPhenotypicFeature
),4130,O
is,4130,O
a,4130,O
devastating,4130,O
disease,4130,O
without,4130,O
effective,4130,O
treatment,4130,O
.,4130,O
After,4131,O
ICH,4131,B-DiseaseOrPhenotypicFeature
",",4131,O
the,4131,O
immediate,4131,O
infiltration,4131,O
of,4131,O
leukocytes,4131,O
and,4131,O
activation,4131,O
of,4131,O
microglia,4131,O
are,4131,O
accompanied,4131,O
by,4131,O
a,4131,O
rapid,4131,O
up-regulation,4131,O
of,4131,O
the,4131,O
18-kDa,4131,O
translocator,4131,B-GeneOrGeneProduct
protein,4131,I-GeneOrGeneProduct
(,4131,O
TSPO,4131,B-GeneOrGeneProduct
),4131,O
.,4131,O
TSPO,4132,B-GeneOrGeneProduct
ligands,4132,O
have,4132,O
shown,4132,O
anti-inflammatory,4132,O
and,4132,O
neuroprotective,4132,O
properties,4132,O
in,4132,O
models,4132,O
of,4132,O
CNS,4132,B-DiseaseOrPhenotypicFeature
injury,4132,I-DiseaseOrPhenotypicFeature
.,4132,O
In,4133,O
this,4133,O
study,4133,O
",",4133,O
we,4133,O
determined,4133,O
the,4133,O
impact,4133,O
of,4133,O
a,4133,O
TSPO,4133,B-GeneOrGeneProduct
ligand,4133,O
",",4133,O
etifoxine,4133,B-ChemicalEntity
",",4133,O
on,4133,O
brain,4133,B-DiseaseOrPhenotypicFeature
injury,4133,I-DiseaseOrPhenotypicFeature
and,4133,O
inflammation,4133,B-DiseaseOrPhenotypicFeature
in,4133,O
2,4133,O
mouse,4133,B-OrganismTaxon
models,4133,O
of,4133,O
ICH,4133,B-DiseaseOrPhenotypicFeature
.,4133,O
TSPO,4134,B-GeneOrGeneProduct
was,4134,O
up-regulated,4134,O
in,4134,O
Iba1,4134,B-GeneOrGeneProduct
(,4134,O
+,4134,O
),4134,O
cells,4134,O
from,4134,O
brains,4134,O
of,4134,O
patients,4134,B-OrganismTaxon
with,4134,O
ICH,4134,B-DiseaseOrPhenotypicFeature
and,4134,O
in,4134,O
CD11b,4134,B-GeneOrGeneProduct
(,4134,O
+,4134,O
),4134,O
CD45,4134,B-GeneOrGeneProduct
(,4134,O
int,4134,O
),4134,O
cells,4134,O
from,4134,O
mice,4134,B-OrganismTaxon
subjected,4134,O
to,4134,O
collagenase-induced,4134,B-ChemicalEntity
ICH,4134,B-DiseaseOrPhenotypicFeature
.,4134,O
Etifoxine,4135,B-ChemicalEntity
significantly,4135,O
reduced,4135,O
neurodeficits,4135,B-DiseaseOrPhenotypicFeature
and,4135,O
perihematomal,4135,O
brain,4135,B-DiseaseOrPhenotypicFeature
edema,4135,I-DiseaseOrPhenotypicFeature
after,4135,O
ICH,4135,B-DiseaseOrPhenotypicFeature
induction,4135,O
by,4135,O
injection,4135,O
of,4135,O
either,4135,O
autologous,4135,O
blood,4135,O
or,4135,O
collagenase,4135,B-ChemicalEntity
.,4135,O
In,4136,O
collagenase-induced,4136,B-ChemicalEntity
ICH,4136,B-DiseaseOrPhenotypicFeature
mice,4136,B-OrganismTaxon
",",4136,O
the,4136,O
protection,4136,O
of,4136,O
etifoxine,4136,B-ChemicalEntity
was,4136,O
associated,4136,O
with,4136,O
reduced,4136,O
leukocyte,4136,O
infiltration,4136,O
into,4136,O
the,4136,O
brain,4136,O
and,4136,O
microglial,4136,O
production,4136,O
of,4136,O
IL-6,4136,B-GeneOrGeneProduct
and,4136,O
TNF-a,4136,B-GeneOrGeneProduct
.,4136,O
Etifoxine,4137,B-ChemicalEntity
improved,4137,O
blood-brain,4137,O
barrier,4137,O
integrity,4137,O
and,4137,O
diminished,4137,O
cell,4137,O
death,4137,O
.,4137,O
Notably,4138,O
",",4138,O
the,4138,O
protective,4138,O
effect,4138,O
of,4138,O
etifoxine,4138,B-ChemicalEntity
was,4138,O
abolished,4138,O
in,4138,O
mice,4138,B-OrganismTaxon
depleted,4138,O
of,4138,O
microglia,4138,O
by,4138,O
using,4138,O
a,4138,O
colony-stimulating,4138,B-GeneOrGeneProduct
factor,4138,I-GeneOrGeneProduct
1,4138,I-GeneOrGeneProduct
receptor,4138,I-GeneOrGeneProduct
inhibitor,4138,O
.,4138,O
These,4139,O
results,4139,O
indicate,4139,O
that,4139,O
the,4139,O
TSPO,4139,B-GeneOrGeneProduct
ligand,4139,O
etifoxine,4139,B-ChemicalEntity
attenuates,4139,O
brain,4139,B-DiseaseOrPhenotypicFeature
injury,4139,I-DiseaseOrPhenotypicFeature
and,4139,O
inflammation,4139,B-DiseaseOrPhenotypicFeature
after,4139,O
ICH,4139,B-DiseaseOrPhenotypicFeature
.,4139,O
TSPO,4140,B-GeneOrGeneProduct
may,4140,O
be,4140,O
a,4140,O
viable,4140,O
therapeutic,4140,O
target,4140,O
that,4140,O
requires,4140,O
further,4140,O
investigations,4140,O
in,4140,O
ICH.-Li,4140,B-DiseaseOrPhenotypicFeature
",",4140,O
M.,4140,O
",",4140,O
Ren,4140,O
",",4140,O
H.,4140,O
",",4140,O
Sheth,4140,O
",",4140,O
K.,4140,O
N.,4140,O
",",4140,O
Shi,4140,O
",",4140,O
F.-D.,4140,O
",",4140,O
Liu,4140,O
",",4140,O
Q,4140,O
.,4140,O
A,4141,O
TSPO,4141,B-GeneOrGeneProduct
ligand,4141,O
attenuates,4141,O
brain,4141,B-DiseaseOrPhenotypicFeature
injury,4141,I-DiseaseOrPhenotypicFeature
after,4141,O
intracerebral,4141,B-DiseaseOrPhenotypicFeature
hemorrhage,4141,I-DiseaseOrPhenotypicFeature
.,4141,O
Regulation,4142,O
of,4142,O
lung,4142,O
endothelial,4142,O
permeability,4142,O
and,4142,O
inflammatory,4142,B-DiseaseOrPhenotypicFeature
responses,4142,O
by,4142,O
prostaglandin,4142,B-ChemicalEntity
A2,4142,I-ChemicalEntity
:,4142,O
role,4142,O
of,4142,O
EP4,4142,B-GeneOrGeneProduct
receptor,4142,I-GeneOrGeneProduct
.,4142,O
The,4143,O
role,4143,O
of,4143,O
prostaglandin,4143,B-ChemicalEntity
A2,4143,I-ChemicalEntity
(,4143,O
PGA2,4143,B-ChemicalEntity
),4143,O
in,4143,O
modulation,4143,O
of,4143,O
vascular,4143,O
endothelial,4143,O
function,4143,O
is,4143,O
unknown,4143,O
.,4143,O
We,4144,O
investigated,4144,O
effects,4144,O
of,4144,O
PGA2,4144,B-ChemicalEntity
on,4144,O
pulmonary,4144,O
endothelial,4144,O
cell,4144,O
(,4144,O
EC,4144,O
),4144,O
permeability,4144,O
and,4144,O
inflammatory,4144,B-DiseaseOrPhenotypicFeature
activation,4144,O
and,4144,O
identified,4144,O
a,4144,O
receptor,4144,O
mediating,4144,O
these,4144,O
effects,4144,O
.,4144,O
PGA2,4145,B-ChemicalEntity
enhanced,4145,O
the,4145,O
EC,4145,O
barrier,4145,O
and,4145,O
protected,4145,O
against,4145,O
barrier,4145,O
dysfunction,4145,O
caused,4145,O
by,4145,O
vasoactive,4145,O
peptide,4145,O
thrombin,4145,B-GeneOrGeneProduct
and,4145,O
proinflammatory,4145,B-DiseaseOrPhenotypicFeature
bacterial,4145,O
wall,4145,O
lipopolysaccharide,4145,B-ChemicalEntity
(,4145,O
LPS,4145,B-ChemicalEntity
),4145,O
.,4145,O
Receptor,4146,O
screening,4146,O
using,4146,O
pharmacological,4146,O
and,4146,O
molecular,4146,O
inhibitory,4146,O
approaches,4146,O
identified,4146,O
EP4,4146,B-GeneOrGeneProduct
as,4146,O
a,4146,O
novel,4146,O
PGA2,4146,B-GeneOrGeneProduct
receptor,4146,I-GeneOrGeneProduct
.,4146,O
EP4,4147,B-GeneOrGeneProduct
mediated,4147,O
barrier-protective,4147,O
effects,4147,O
of,4147,O
PGA2,4147,B-ChemicalEntity
by,4147,O
activating,4147,O
Rap1/Rac1,4147,B-GeneOrGeneProduct
GTPase,4147,I-GeneOrGeneProduct
and,4147,O
protein,4147,B-GeneOrGeneProduct
kinase,4147,I-GeneOrGeneProduct
A,4147,I-GeneOrGeneProduct
targets,4147,O
at,4147,O
cell,4147,O
adhesions,4147,O
and,4147,O
cytoskeleton,4147,O
:,4147,O
VE-cadherin,4147,B-GeneOrGeneProduct
",",4147,O
p120-catenin,4147,B-GeneOrGeneProduct
",",4147,O
ZO-1,4147,B-GeneOrGeneProduct
",",4147,O
cortactin,4147,B-GeneOrGeneProduct
",",4147,O
and,4147,O
VASP,4147,B-GeneOrGeneProduct
.,4147,O
PGA2,4148,B-ChemicalEntity
also,4148,O
suppressed,4148,O
LPS-induced,4148,B-ChemicalEntity
inflammatory,4148,B-DiseaseOrPhenotypicFeature
signaling,4148,O
by,4148,O
inhibiting,4148,O
the,4148,O
NFkB,4148,B-GeneOrGeneProduct
pathway,4148,O
and,4148,O
expression,4148,O
of,4148,O
EC,4148,B-GeneOrGeneProduct
adhesion,4148,I-GeneOrGeneProduct
molecules,4148,I-GeneOrGeneProduct
ICAM1,4148,B-GeneOrGeneProduct
and,4148,O
VCAM1,4148,B-GeneOrGeneProduct
.,4148,O
These,4149,O
effects,4149,O
were,4149,O
abolished,4149,O
by,4149,O
pharmacological,4149,O
or,4149,O
molecular,4149,O
inhibition,4149,O
of,4149,O
EP4,4149,B-GeneOrGeneProduct
.,4149,O
In,4150,O
vivo,4150,O
",",4150,O
PGA2,4150,B-ChemicalEntity
was,4150,O
protective,4150,O
in,4150,O
two,4150,O
distinct,4150,O
models,4150,O
of,4150,O
acute,4150,B-DiseaseOrPhenotypicFeature
lung,4150,I-DiseaseOrPhenotypicFeature
injury,4150,I-DiseaseOrPhenotypicFeature
(,4150,O
ALI,4150,B-DiseaseOrPhenotypicFeature
),4150,O
:,4150,O
LPS-induced,4150,B-ChemicalEntity
inflammatory,4150,B-DiseaseOrPhenotypicFeature
injury,4150,I-DiseaseOrPhenotypicFeature
and,4150,O
two-hit,4150,O
ALI,4150,B-DiseaseOrPhenotypicFeature
caused,4150,O
by,4150,O
suboptimal,4150,O
mechanical,4150,O
ventilation,4150,O
and,4150,O
injection,4150,O
of,4150,O
thrombin,4150,B-GeneOrGeneProduct
receptor-activating,4150,O
peptide,4150,O
.,4150,O
These,4151,O
protective,4151,O
effects,4151,O
were,4151,O
abolished,4151,O
in,4151,O
mice,4151,B-OrganismTaxon
with,4151,O
endothelial-specific,4151,O
EP4,4151,B-GeneOrGeneProduct
knockout,4151,O
.,4151,O
The,4152,O
results,4152,O
suggest,4152,O
a,4152,O
novel,4152,O
role,4152,O
for,4152,O
the,4152,O
PGA2-EP4,4152,B-ChemicalEntity
axis,4152,O
in,4152,O
vascular,4152,O
EC,4152,O
protection,4152,O
that,4152,O
is,4152,O
critical,4152,O
for,4152,O
improvement,4152,O
of,4152,O
pathological,4152,O
states,4152,O
associated,4152,O
with,4152,O
increased,4152,O
vascular,4152,O
leakage,4152,O
and,4152,O
inflammation,4152,B-DiseaseOrPhenotypicFeature
.,4152,O
Aberrant,4153,O
caveolin-1-mediated,4153,B-GeneOrGeneProduct
Smad,4153,B-GeneOrGeneProduct
signaling,4153,O
and,4153,O
proliferation,4153,O
identified,4153,O
by,4153,O
analysis,4153,O
of,4153,O
adenine,4153,B-SequenceVariant
474,4153,I-SequenceVariant
deletion,4153,I-SequenceVariant
mutation,4153,O
(,4153,O
c.474delA,4153,B-SequenceVariant
),4153,O
in,4153,O
patient,4153,B-OrganismTaxon
fibroblasts,4153,O
:,4153,O
a,4153,O
new,4153,O
perspective,4153,O
on,4153,O
the,4153,O
mechanism,4153,O
of,4153,O
pulmonary,4153,B-DiseaseOrPhenotypicFeature
hypertension,4153,I-DiseaseOrPhenotypicFeature
.,4153,O
A,4154,O
heterozygous,4154,O
caveolin-1,4154,B-GeneOrGeneProduct
c.474delA,4154,B-SequenceVariant
mutation,4154,O
has,4154,O
been,4154,O
identified,4154,O
in,4154,O
a,4154,O
family,4154,O
with,4154,O
heritable,4154,O
pulmonary,4154,B-DiseaseOrPhenotypicFeature
arterial,4154,I-DiseaseOrPhenotypicFeature
hypertension,4154,I-DiseaseOrPhenotypicFeature
(,4154,O
PAH,4154,B-DiseaseOrPhenotypicFeature
),4154,O
.,4154,O
This,4155,O
frameshift,4155,O
mutation,4155,O
leads,4155,O
to,4155,O
a,4155,O
caveolin-1,4155,B-GeneOrGeneProduct
protein,4155,O
that,4155,O
contains,4155,O
all,4155,O
known,4155,O
functional,4155,O
domains,4155,O
but,4155,O
has,4155,O
a,4155,O
change,4155,O
in,4155,O
only,4155,O
the,4155,O
final,4155,O
20,4155,O
amino,4155,O
acids,4155,O
of,4155,O
the,4155,O
C-terminus,4155,O
.,4155,O
Here,4156,O
we,4156,O
studied,4156,O
how,4156,O
this,4156,O
mutation,4156,O
alters,4156,O
caveolin-1,4156,B-GeneOrGeneProduct
function,4156,O
",",4156,O
using,4156,O
patient-derived,4156,B-OrganismTaxon
fibroblasts,4156,O
.,4156,O
Transmission,4157,O
electron,4157,O
microscopy,4157,O
showed,4157,O
that,4157,O
fibroblasts,4157,O
carrying,4157,O
the,4157,O
c.474delA,4157,B-SequenceVariant
mutation,4157,O
form,4157,O
typical,4157,O
caveolae,4157,O
.,4157,O
Expression,4158,O
of,4158,O
mutated,4158,O
caveolin-1,4158,B-GeneOrGeneProduct
in,4158,O
caveolin-1-null,4158,B-GeneOrGeneProduct
mouse,4158,B-OrganismTaxon
fibroblasts,4158,O
failed,4158,O
to,4158,O
induce,4158,O
formation,4158,O
of,4158,O
caveolae,4158,O
due,4158,O
to,4158,O
retention,4158,O
of,4158,O
the,4158,O
mutated,4158,O
protein,4158,O
in,4158,O
the,4158,O
endoplasmic,4158,O
reticulum,4158,O
.,4158,O
However,4159,O
",",4159,O
coexpression,4159,O
of,4159,O
wild-type,4159,O
caveolin-1,4159,B-GeneOrGeneProduct
with,4159,O
mutated,4159,O
caveolin-1,4159,B-GeneOrGeneProduct
restored,4159,O
the,4159,O
ability,4159,O
to,4159,O
form,4159,O
caveolae,4159,O
.,4159,O
Importantly,4160,O
",",4160,O
fibroblasts,4160,O
carrying,4160,O
the,4160,O
mutation,4160,O
showed,4160,O
twofold,4160,O
increase,4160,O
in,4160,O
proliferation,4160,O
rate,4160,O
associated,4160,O
with,4160,O
hyperphosphorylation,4160,O
of,4160,O
Smad1/5/8,4160,B-GeneOrGeneProduct
.,4160,O
This,4161,O
mutation,4161,O
impaired,4161,O
the,4161,O
antiproliferative,4161,O
function,4161,O
of,4161,O
caveolin-1,4161,B-GeneOrGeneProduct
.,4161,O
Inhibition,4162,O
of,4162,O
type,4162,B-GeneOrGeneProduct
I,4162,I-GeneOrGeneProduct
TGFb,4162,I-GeneOrGeneProduct
receptors,4162,I-GeneOrGeneProduct
ALK1/2/3/6,4162,B-GeneOrGeneProduct
responsible,4162,O
for,4162,O
phosphorylation,4162,O
of,4162,O
Smad1/5/8,4162,B-GeneOrGeneProduct
reduced,4162,O
the,4162,O
hyperproliferation,4162,O
seen,4162,O
in,4162,O
c.474delA,4162,B-SequenceVariant
fibroblasts,4162,O
.,4162,O
These,4163,O
results,4163,O
demonstrate,4163,O
the,4163,O
critical,4163,O
role,4163,O
of,4163,O
the,4163,O
final,4163,O
20,4163,O
amino,4163,O
acids,4163,O
of,4163,O
caveolin-1,4163,B-GeneOrGeneProduct
in,4163,O
modulating,4163,O
fibroblast,4163,O
proliferation,4163,O
by,4163,O
dampening,4163,O
Smad,4163,B-GeneOrGeneProduct
signaling,4163,O
and,4163,O
suggest,4163,O
that,4163,O
augmented,4163,O
Smad,4163,B-GeneOrGeneProduct
signaling,4163,O
and,4163,O
fibroblast,4163,O
hyperproliferation,4163,O
are,4163,O
contributing,4163,O
factors,4163,O
in,4163,O
the,4163,O
pathogenesis,4163,O
of,4163,O
PAH,4163,B-DiseaseOrPhenotypicFeature
in,4163,O
patients,4163,B-OrganismTaxon
with,4163,O
caveolin-1,4163,B-GeneOrGeneProduct
c.474delA,4163,B-SequenceVariant
mutation,4163,O
.,4163,O
Ubiquitin,4164,B-GeneOrGeneProduct
carboxyl-terminal,4164,I-GeneOrGeneProduct
esterase,4164,I-GeneOrGeneProduct
L1,4164,I-GeneOrGeneProduct
(,4164,O
UCHL1,4164,B-GeneOrGeneProduct
),4164,O
is,4164,O
associated,4164,O
with,4164,O
stem-like,4164,O
cancer,4164,B-DiseaseOrPhenotypicFeature
cell,4164,O
functions,4164,O
in,4164,O
pediatric,4164,O
high-grade,4164,O
glioma,4164,B-DiseaseOrPhenotypicFeature
.,4164,O
Pediatric,4165,O
high-grade,4165,O
gliomas,4165,B-DiseaseOrPhenotypicFeature
represent,4165,O
8-12,4165,O
%,4165,O
of,4165,O
all,4165,O
primary,4165,O
tumors,4165,B-DiseaseOrPhenotypicFeature
of,4165,O
the,4165,O
nervous,4165,O
system,4165,O
in,4165,O
children,4165,O
.,4165,O
Five-year,4166,O
survival,4166,O
for,4166,O
these,4166,O
pediatric,4166,O
aggressive,4166,O
tumors,4166,B-DiseaseOrPhenotypicFeature
is,4166,O
poor,4166,O
(,4166,O
15-35,4166,O
%,4166,O
),4166,O
indicating,4166,O
the,4166,O
need,4166,O
to,4166,O
develop,4166,O
better,4166,O
treatments,4166,O
for,4166,O
pediatric,4166,O
high-grade,4166,O
gliomas,4166,B-DiseaseOrPhenotypicFeature
.,4166,O
In,4167,O
this,4167,O
work,4167,O
we,4167,O
used,4167,O
SF188,4167,B-CellLine
and,4167,O
SJ-GBM2,4167,B-CellLine
cell,4167,O
lines,4167,O
to,4167,O
study,4167,O
the,4167,O
function,4167,O
of,4167,O
the,4167,O
ubiquitin,4167,B-GeneOrGeneProduct
carboxyl-terminal,4167,I-GeneOrGeneProduct
esterase,4167,I-GeneOrGeneProduct
L1,4167,I-GeneOrGeneProduct
(,4167,O
UCHL1,4167,B-GeneOrGeneProduct
),4167,O
",",4167,O
a,4167,O
deubiquitinase,4167,O
de-regulated,4167,O
in,4167,O
several,4167,O
cancers,4167,B-DiseaseOrPhenotypicFeature
",",4167,O
in,4167,O
pediatric,4167,O
high-grade,4167,O
gliomas,4167,B-DiseaseOrPhenotypicFeature
.,4167,O
UCHL1,4168,B-GeneOrGeneProduct
depletion,4168,O
in,4168,O
SF188,4168,B-CellLine
and,4168,O
SJ-GBM2,4168,B-CellLine
glioma,4168,B-DiseaseOrPhenotypicFeature
cells,4168,O
was,4168,O
associated,4168,O
with,4168,O
decreased,4168,O
cell,4168,O
proliferation,4168,O
and,4168,O
invasion,4168,O
",",4168,O
along,4168,O
with,4168,O
a,4168,O
reduced,4168,O
ability,4168,O
to,4168,O
grow,4168,O
in,4168,O
soft,4168,O
agar,4168,B-ChemicalEntity
and,4168,O
to,4168,O
form,4168,O
spheres,4168,O
(,4168,O
i.e,4168,O
.,4168,O
self-renewal,4169,O
measure,4169,O
),4169,O
.,4169,O
A,4170,O
70,4170,O
%,4170,O
reduction,4170,O
in,4170,O
Wnt,4170,B-GeneOrGeneProduct
signaling,4170,O
was,4170,O
also,4170,O
observed,4170,O
in,4170,O
the,4170,O
SF188,4170,B-CellLine
and,4170,O
SJ-GBM2,4170,B-CellLine
UCHL1,4170,B-GeneOrGeneProduct
knockdowns,4170,O
(,4170,O
KDs,4170,O
),4170,O
using,4170,O
a,4170,O
TCF-dependent,4170,B-GeneOrGeneProduct
TOPflash,4170,O
reporter,4170,O
assay,4170,O
.,4170,O
Transcriptome,4171,O
comparisons,4171,O
of,4171,O
UCHL1,4171,B-GeneOrGeneProduct
KDs,4171,O
versus,4171,O
vector,4171,O
control,4171,O
identified,4171,O
a,4171,O
list,4171,O
of,4171,O
306,4171,O
differentially,4171,O
expressed,4171,O
genes,4171,O
(,4171,O
at,4171,O
least,4171,O
2-fold,4171,O
change,4171,O
;,4171,O
p,4171,O
<,4171,O
0.05,4171,O
),4171,O
which,4171,O
included,4171,O
genes,4171,O
known,4171,O
to,4171,O
be,4171,O
involved,4171,O
in,4171,O
cancer,4171,B-DiseaseOrPhenotypicFeature
like,4171,O
ACTA2,4171,B-GeneOrGeneProduct
",",4171,O
POSTN,4171,B-GeneOrGeneProduct
",",4171,O
LIF,4171,B-GeneOrGeneProduct
",",4171,O
FBXL7,4171,B-GeneOrGeneProduct
",",4171,O
FBXW11,4171,B-GeneOrGeneProduct
",",4171,O
GDF15,4171,B-GeneOrGeneProduct
",",4171,O
HEY2,4171,B-GeneOrGeneProduct
",",4171,O
but,4171,O
also,4171,O
potential,4171,O
novel,4171,O
genes,4171,O
such,4171,O
us,4171,O
IGLL5,4171,B-GeneOrGeneProduct
",",4171,O
ABCA4,4171,B-GeneOrGeneProduct
",",4171,O
AQP3,4171,B-GeneOrGeneProduct
",",4171,O
AQP4,4171,B-GeneOrGeneProduct
",",4171,O
CALB1,4171,B-GeneOrGeneProduct
",",4171,O
and,4171,O
ALK,4171,B-GeneOrGeneProduct
.,4171,O
Bioinformatics,4172,O
gene,4172,O
ontology,4172,O
(,4172,O
GO,4172,O
),4172,O
analysis,4172,O
of,4172,O
these,4172,O
306,4172,O
genes,4172,O
revealed,4172,O
significant,4172,O
enrichment,4172,O
in,4172,O
``,4172,O
signal,4172,O
peptides,4172,O
'',4172,O
",",4172,O
``,4172,O
extracellular,4172,O
matrix,4172,O
'',4172,O
and,4172,O
``,4172,O
secreted,4172,O
proteins,4172,O
'',4172,O
GO,4172,O
Terms,4172,O
.,4172,O
``,4173,O
Angiogenesis,4173,O
and,4173,O
blood,4173,O
vessel,4173,O
development,4173,O
'',4173,O
",",4173,O
``,4173,O
neuron,4173,O
differentiation/development,4173,O
'',4173,O
",",4173,O
cell,4173,O
adhesion,4173,O
'',4173,O
",",4173,O
and,4173,O
``,4173,O
cell,4173,O
migration,4173,O
'',4173,O
also,4173,O
showed,4173,O
significant,4173,O
enrichment,4173,O
in,4173,O
our,4173,O
GO,4173,O
analysis,4173,O
.,4173,O
Top,4174,O
canonical,4174,O
pathways,4174,O
identified,4174,O
by,4174,O
Ingenuity,4174,O
Pathway,4174,O
Analysis,4174,O
(,4174,O
IPA,4174,O
),4174,O
included,4174,O
``,4174,O
Clathrin-mediated,4174,B-GeneOrGeneProduct
Endocytosis,4174,O
Signaling,4174,O
'',4174,O
(,4174,O
p,4174,O
=,4174,O
5.14x10-4,4174,O
),4174,O
",",4174,O
``,4174,O
Virus,4174,O
Entry,4174,O
via,4174,O
Endocytic,4174,O
Pathways,4174,O
'',4174,O
(,4174,O
p,4174,O
=,4174,O
6.15x,4174,O
10-4,4174,O
),4174,O
",",4174,O
and,4174,O
``,4174,O
High,4174,B-GeneOrGeneProduct
Mobility,4174,I-GeneOrGeneProduct
Group-Box,4174,I-GeneOrGeneProduct
1,4174,I-GeneOrGeneProduct
(,4174,O
HMGB1,4174,B-GeneOrGeneProduct
),4174,O
Signaling,4174,O
'',4174,O
(,4174,O
p,4174,O
=,4174,O
6.15x10-4,4174,O
),4174,O
.,4174,O
While,4175,O
FGF2,4175,B-GeneOrGeneProduct
",",4175,O
IL1B,4175,B-GeneOrGeneProduct
",",4175,O
TNF,4175,B-GeneOrGeneProduct
and,4175,O
PDGFB,4175,B-GeneOrGeneProduct
were,4175,O
predicted,4175,O
as,4175,O
top,4175,O
upstream,4175,O
regulators,4175,O
(,4175,O
p,4175,O
<,4175,O
2x10-16,4175,O
),4175,O
of,4175,O
the,4175,O
UCHL1,4175,B-GeneOrGeneProduct
KD-associated,4175,O
transcriptome,4175,O
.,4175,O
Aberrant,4176,O
expression,4176,O
of,4176,O
UCHL1,4176,B-GeneOrGeneProduct
in,4176,O
pediatric,4176,O
high-grade,4176,O
gliomas,4176,B-DiseaseOrPhenotypicFeature
may,4176,O
promote,4176,O
cell,4176,O
invasion,4176,O
",",4176,O
transformation,4176,O
",",4176,O
and,4176,O
self-renewal,4176,O
properties,4176,O
",",4176,O
at,4176,O
least,4176,O
in,4176,O
part,4176,O
",",4176,O
by,4176,O
modulating,4176,O
Wnt/Beta,4176,B-GeneOrGeneProduct
catenin,4176,I-GeneOrGeneProduct
activity,4176,O
.,4176,O
UCHL1,4177,B-GeneOrGeneProduct
might,4177,O
act,4177,O
as,4177,O
an,4177,O
oncogene,4177,O
in,4177,O
glioma,4177,B-DiseaseOrPhenotypicFeature
within,4177,O
the,4177,O
gene,4177,O
network,4177,O
that,4177,O
imparts,4177,O
stem-like,4177,O
characteristics,4177,O
to,4177,O
these,4177,O
cancer,4177,B-DiseaseOrPhenotypicFeature
cells,4177,O
.,4177,O
Hypoglycemic,4178,O
Effect,4178,O
of,4178,O
Combined,4178,O
Ghrelin,4178,B-GeneOrGeneProduct
and,4178,O
Glucagon,4178,B-GeneOrGeneProduct
Receptor,4178,I-GeneOrGeneProduct
Blockade,4178,O
.,4178,O
Glucagon,4179,B-GeneOrGeneProduct
receptor,4179,I-GeneOrGeneProduct
(,4179,O
GcgR,4179,B-GeneOrGeneProduct
),4179,O
blockade,4179,O
has,4179,O
been,4179,O
proposed,4179,O
as,4179,O
an,4179,O
alternative,4179,O
to,4179,O
insulin,4179,B-GeneOrGeneProduct
monotherapy,4179,O
for,4179,O
treating,4179,O
type,4179,B-DiseaseOrPhenotypicFeature
1,4179,I-DiseaseOrPhenotypicFeature
diabetes,4179,I-DiseaseOrPhenotypicFeature
since,4179,O
deletion,4179,O
or,4179,O
inhibition,4179,O
of,4179,O
GcgRs,4179,B-GeneOrGeneProduct
corrects,4179,O
hyperglycemia,4179,B-DiseaseOrPhenotypicFeature
in,4179,O
models,4179,O
of,4179,O
diabetes,4179,B-DiseaseOrPhenotypicFeature
.,4179,O
The,4180,O
factors,4180,O
regulating,4180,O
glycemia,4180,B-ChemicalEntity
in,4180,O
a,4180,O
setting,4180,O
devoid,4180,O
of,4180,O
insulin,4180,B-GeneOrGeneProduct
and,4180,O
glucagon,4180,B-GeneOrGeneProduct
function,4180,O
remain,4180,O
unclear,4180,O
but,4180,O
may,4180,O
include,4180,O
the,4180,O
hormone,4180,O
ghrelin,4180,B-GeneOrGeneProduct
.,4180,O
Not,4181,O
only,4181,O
is,4181,O
ghrelin,4181,B-GeneOrGeneProduct
release,4181,O
controlled,4181,O
by,4181,O
glucose,4181,B-ChemicalEntity
but,4181,O
also,4181,O
ghrelin,4181,B-GeneOrGeneProduct
has,4181,O
many,4181,O
actions,4181,O
that,4181,O
can,4181,O
raise,4181,O
or,4181,O
reduce,4181,O
falls,4181,O
in,4181,O
blood,4181,B-ChemicalEntity
glucose,4181,I-ChemicalEntity
level,4181,O
.,4181,O
Here,4182,O
",",4182,O
we,4182,O
tested,4182,O
the,4182,O
hypothesis,4182,O
that,4182,O
ghrelin,4182,B-GeneOrGeneProduct
rises,4182,O
to,4182,O
prevent,4182,O
hypoglycemia,4182,B-DiseaseOrPhenotypicFeature
in,4182,O
the,4182,O
absence,4182,O
of,4182,O
glucagon,4182,B-GeneOrGeneProduct
function,4182,O
.,4182,O
Both,4183,O
GcgR,4183,B-GeneOrGeneProduct
knockout,4183,O
(,4183,O
Gcgr,4183,B-GeneOrGeneProduct
(,4183,O
-/-,4183,O
),4183,O
),4183,O
mice,4183,B-OrganismTaxon
and,4183,O
db/db,4183,O
mice,4183,B-OrganismTaxon
that,4183,O
were,4183,O
administered,4183,O
GcgR,4183,B-GeneOrGeneProduct
monoclonal,4183,O
antibody,4183,O
displayed,4183,O
lower,4183,O
blood,4183,B-ChemicalEntity
glucose,4183,I-ChemicalEntity
levels,4183,O
accompanied,4183,O
by,4183,O
elevated,4183,O
plasma,4183,O
ghrelin,4183,B-GeneOrGeneProduct
levels,4183,O
.,4183,O
Although,4184,O
treatment,4184,O
with,4184,O
the,4184,O
pancreatic,4184,O
b-cell,4184,O
toxin,4184,O
streptozotocin,4184,B-ChemicalEntity
induced,4184,O
hyperglycemia,4184,B-DiseaseOrPhenotypicFeature
and,4184,O
raised,4184,O
plasma,4184,O
ghrelin,4184,B-GeneOrGeneProduct
levels,4184,O
in,4184,O
wild-type,4184,O
mice,4184,B-OrganismTaxon
",",4184,O
hyperglycemia,4184,B-DiseaseOrPhenotypicFeature
was,4184,O
averted,4184,O
in,4184,O
similarly,4184,O
treated,4184,O
Gcgr,4184,B-GeneOrGeneProduct
(,4184,O
-/-,4184,O
),4184,O
mice,4184,B-OrganismTaxon
and,4184,O
the,4184,O
plasma,4184,O
ghrelin,4184,B-GeneOrGeneProduct
level,4184,O
was,4184,O
further,4184,O
increased,4184,O
.,4184,O
Notably,4185,O
",",4185,O
administration,4185,O
of,4185,O
a,4185,O
ghrelin,4185,B-GeneOrGeneProduct
receptor,4185,I-GeneOrGeneProduct
antagonist,4185,O
further,4185,O
reduced,4185,O
blood,4185,B-ChemicalEntity
glucose,4185,I-ChemicalEntity
levels,4185,O
into,4185,O
the,4185,O
markedly,4185,O
hypoglycemic,4185,O
range,4185,O
in,4185,O
overnight-fasted,4185,O
",",4185,O
streptozotocin-treated,4185,B-ChemicalEntity
Gcgr,4185,B-GeneOrGeneProduct
(,4185,O
-/-,4185,O
),4185,O
mice,4185,B-OrganismTaxon
.,4185,O
A,4186,O
lowered,4186,O
blood,4186,B-ChemicalEntity
glucose,4186,I-ChemicalEntity
level,4186,O
also,4186,O
was,4186,O
observed,4186,O
in,4186,O
overnight-fasted,4186,O
",",4186,O
streptozotocin-treated,4186,B-ChemicalEntity
ghrelin,4186,B-GeneOrGeneProduct
receptor-null,4186,O
mice,4186,B-OrganismTaxon
that,4186,O
were,4186,O
administered,4186,O
GcgR,4186,B-GeneOrGeneProduct
monoclonal,4186,O
antibody,4186,O
.,4186,O
These,4187,O
data,4187,O
suggest,4187,O
that,4187,O
when,4187,O
glucagon,4187,B-GeneOrGeneProduct
activity,4187,O
is,4187,O
blocked,4187,O
in,4187,O
the,4187,O
setting,4187,O
of,4187,O
type,4187,B-DiseaseOrPhenotypicFeature
1,4187,I-DiseaseOrPhenotypicFeature
diabetes,4187,I-DiseaseOrPhenotypicFeature
",",4187,O
the,4187,O
plasma,4187,O
ghrelin,4187,B-GeneOrGeneProduct
level,4187,O
rises,4187,O
",",4187,O
preventing,4187,O
hypoglycemia,4187,B-DiseaseOrPhenotypicFeature
.,4187,O
Analysis,4188,O
of,4188,O
Serum,4188,O
Cytokines,4188,O
and,4188,O
Single-Nucleotide,4188,O
Polymorphisms,4188,O
of,4188,O
SOD1,4188,B-GeneOrGeneProduct
",",4188,O
SOD2,4188,B-GeneOrGeneProduct
",",4188,O
and,4188,O
CAT,4188,B-GeneOrGeneProduct
in,4188,O
Erysipelas,4188,B-DiseaseOrPhenotypicFeature
Patients,4188,B-OrganismTaxon
.,4188,O
Increased,4189,O
free,4189,O
radical,4189,O
production,4189,O
had,4189,O
been,4189,O
documented,4189,O
in,4189,O
group,4189,O
A,4189,O
(,4189,O
beta-hemolytic,4189,O
),4189,O
streptococcus,4189,B-DiseaseOrPhenotypicFeature
infection,4189,I-DiseaseOrPhenotypicFeature
cases,4189,O
.,4189,O
Comparing,4190,O
71,4190,O
erysipelas,4190,B-DiseaseOrPhenotypicFeature
patients,4190,B-OrganismTaxon
to,4190,O
55,4190,O
age-matched,4190,O
healthy,4190,O
individuals,4190,O
",",4190,O
we,4190,O
sought,4190,O
for,4190,O
CAT,4190,B-GeneOrGeneProduct
",",4190,O
SOD1,4190,B-GeneOrGeneProduct
",",4190,O
and,4190,O
SOD2,4190,B-GeneOrGeneProduct
single,4190,O
polymorphism,4190,O
mutation,4190,O
(,4190,O
SNPs,4190,O
),4190,O
interactions,4190,O
with,4190,O
erysipelas,4190,B-DiseaseOrPhenotypicFeature
',4190,O
predisposition,4190,O
and,4190,O
serum,4190,O
cytokine,4190,O
levels,4190,O
in,4190,O
the,4190,O
acute,4190,O
and,4190,O
recovery,4190,O
phases,4190,O
of,4190,O
erysipelas,4190,B-DiseaseOrPhenotypicFeature
infection,4190,I-DiseaseOrPhenotypicFeature
.,4190,O
Whereas,4191,O
female,4191,O
patients,4191,B-OrganismTaxon
had,4191,O
a,4191,O
higher,4191,O
predisposition,4191,O
to,4191,O
erysipelas,4191,B-DiseaseOrPhenotypicFeature
",",4191,O
male,4191,O
patients,4191,B-OrganismTaxon
were,4191,O
prone,4191,O
to,4191,O
having,4191,O
a,4191,O
facial,4191,O
localization,4191,O
of,4191,O
the,4191,O
infection,4191,B-DiseaseOrPhenotypicFeature
.,4191,O
The,4192,O
presence,4192,O
of,4192,O
SOD1,4192,B-GeneOrGeneProduct
G7958,4192,B-SequenceVariant
",",4192,O
SOD2,4192,B-GeneOrGeneProduct
T2734,4192,B-SequenceVariant
",",4192,O
and,4192,O
CAT,4192,B-GeneOrGeneProduct
C262,4192,B-SequenceVariant
alleles,4192,O
was,4192,O
linked,4192,O
to,4192,O
erysipelas,4192,B-DiseaseOrPhenotypicFeature
',4192,O
predisposition,4192,O
.,4192,O
T,4193,O
and,4193,O
C,4193,O
alleles,4193,O
of,4193,O
SOD2,4193,B-GeneOrGeneProduct
T2734C,4193,B-SequenceVariant
individually,4193,O
were,4193,O
linked,4193,O
to,4193,O
patients,4193,B-OrganismTaxon
with,4193,O
bullous,4193,O
and,4193,O
erythematous,4193,B-DiseaseOrPhenotypicFeature
erysipelas,4193,I-DiseaseOrPhenotypicFeature
",",4193,O
respectively,4193,O
.,4193,O
G,4194,O
and,4194,O
A,4194,O
alleles,4194,O
of,4194,O
SOD1,4194,B-GeneOrGeneProduct
G7958A,4194,B-SequenceVariant
individually,4194,O
were,4194,O
associated,4194,O
with,4194,O
lower,4194,O
limbs,4194,O
and,4194,O
higher,4194,O
body,4194,O
part,4194,O
localizations,4194,O
of,4194,O
the,4194,O
infection,4194,B-DiseaseOrPhenotypicFeature
",",4194,O
respectively,4194,O
.,4194,O
Serum,4195,O
levels,4195,O
of,4195,O
IL-1beta,4195,B-GeneOrGeneProduct
",",4195,O
CCL11,4195,B-GeneOrGeneProduct
",",4195,O
IL-2Ralpha,4195,B-GeneOrGeneProduct
",",4195,O
CXCL9,4195,B-GeneOrGeneProduct
",",4195,O
TRAIL,4195,B-GeneOrGeneProduct
",",4195,O
PDGF-BB,4195,B-GeneOrGeneProduct
",",4195,O
and,4195,O
CCL4,4195,B-GeneOrGeneProduct
were,4195,O
associated,4195,O
with,4195,O
symptoms,4195,O
accompanying,4195,O
the,4195,O
infection,4195,B-DiseaseOrPhenotypicFeature
",",4195,O
while,4195,O
IL-6,4195,B-GeneOrGeneProduct
",",4195,O
IL-9,4195,B-GeneOrGeneProduct
",",4195,O
IL-10,4195,B-GeneOrGeneProduct
",",4195,O
IL-13,4195,B-GeneOrGeneProduct
",",4195,O
IL-15,4195,B-GeneOrGeneProduct
",",4195,O
IL-17,4195,B-GeneOrGeneProduct
",",4195,O
G-CSF,4195,B-GeneOrGeneProduct
",",4195,O
and,4195,O
VEGF,4195,B-GeneOrGeneProduct
were,4195,O
associated,4195,O
with,4195,O
predisposition,4195,O
and,4195,O
recurrence,4195,O
of,4195,O
erysipelas,4195,B-DiseaseOrPhenotypicFeature
.,4195,O
While,4196,O
variations,4196,O
of,4196,O
IL-1beta,4196,B-GeneOrGeneProduct
",",4196,O
IL-7,4196,B-GeneOrGeneProduct
",",4196,O
IL-8,4196,B-GeneOrGeneProduct
",",4196,O
IL-17,4196,B-GeneOrGeneProduct
",",4196,O
CCL5,4196,B-GeneOrGeneProduct
",",4196,O
and,4196,O
HGF,4196,B-GeneOrGeneProduct
were,4196,O
associated,4196,O
with,4196,O
the,4196,O
SOD2,4196,B-GeneOrGeneProduct
T2734C,4196,B-SequenceVariant
SNP,4196,O
",",4196,O
variations,4196,O
of,4196,O
PDFG-BB,4196,B-GeneOrGeneProduct
and,4196,O
CCL2,4196,B-GeneOrGeneProduct
were,4196,O
associated,4196,O
with,4196,O
the,4196,O
CAT,4196,B-GeneOrGeneProduct
C262T,4196,B-SequenceVariant
SNP,4196,O
.,4196,O
Mutations,4197,O
in,4197,O
N-acetylglucosamine,4197,B-GeneOrGeneProduct
(,4197,I-GeneOrGeneProduct
O-GlcNAc,4197,I-GeneOrGeneProduct
),4197,I-GeneOrGeneProduct
transferase,4197,I-GeneOrGeneProduct
in,4197,O
patients,4197,B-OrganismTaxon
with,4197,O
X-linked,4197,B-DiseaseOrPhenotypicFeature
intellectual,4197,I-DiseaseOrPhenotypicFeature
disability,4197,I-DiseaseOrPhenotypicFeature
.,4197,O
N-Acetylglucosamine,4198,B-GeneOrGeneProduct
(,4198,I-GeneOrGeneProduct
O-GlcNAc,4198,I-GeneOrGeneProduct
),4198,I-GeneOrGeneProduct
transferase,4198,I-GeneOrGeneProduct
(,4198,O
OGT,4198,B-GeneOrGeneProduct
),4198,O
regulates,4198,O
protein,4198,O
O-GlcNAcylation,4198,B-GeneOrGeneProduct
",",4198,O
an,4198,O
essential,4198,O
and,4198,O
dynamic,4198,O
post-translational,4198,O
modification,4198,O
.,4198,O
The,4199,O
O-GlcNAc,4199,B-GeneOrGeneProduct
modification,4199,O
is,4199,O
present,4199,O
on,4199,O
numerous,4199,O
nuclear,4199,O
and,4199,O
cytosolic,4199,O
proteins,4199,O
and,4199,O
has,4199,O
been,4199,O
implicated,4199,O
in,4199,O
essential,4199,O
cellular,4199,O
functions,4199,O
such,4199,O
as,4199,O
signaling,4199,O
and,4199,O
gene,4199,O
expression,4199,O
.,4199,O
Accordingly,4200,O
",",4200,O
altered,4200,O
levels,4200,O
of,4200,O
protein,4200,O
O-GlcNAcylation,4200,B-GeneOrGeneProduct
have,4200,O
been,4200,O
associated,4200,O
with,4200,O
developmental,4200,B-DiseaseOrPhenotypicFeature
defects,4200,I-DiseaseOrPhenotypicFeature
and,4200,O
neurodegeneration,4200,B-DiseaseOrPhenotypicFeature
.,4200,O
However,4201,O
",",4201,O
mutations,4201,O
in,4201,O
the,4201,O
OGT,4201,B-GeneOrGeneProduct
gene,4201,O
have,4201,O
not,4201,O
yet,4201,O
been,4201,O
functionally,4201,O
confirmed,4201,O
in,4201,O
humans,4201,B-OrganismTaxon
.,4201,O
Here,4202,O
",",4202,O
we,4202,O
report,4202,O
on,4202,O
two,4202,O
hemizygous,4202,O
mutations,4202,O
in,4202,O
OGT,4202,B-GeneOrGeneProduct
in,4202,O
individuals,4202,O
with,4202,O
X-linked,4202,B-DiseaseOrPhenotypicFeature
intellectual,4202,I-DiseaseOrPhenotypicFeature
disability,4202,I-DiseaseOrPhenotypicFeature
(,4202,O
XLID,4202,B-DiseaseOrPhenotypicFeature
),4202,O
and,4202,O
dysmorphic,4202,O
features,4202,O
:,4202,O
one,4202,O
missense,4202,O
mutation,4202,O
(,4202,O
p.Arg284Pro,4202,B-SequenceVariant
),4202,O
and,4202,O
one,4202,O
mutation,4202,O
leading,4202,O
to,4202,O
a,4202,O
splicing,4202,O
defect,4202,O
(,4202,O
c.463-6T,4202,B-SequenceVariant
>,4202,I-SequenceVariant
G,4202,I-SequenceVariant
),4202,O
.,4202,O
Both,4203,O
mutations,4203,O
reside,4203,O
in,4203,O
the,4203,O
tetratricopeptide,4203,O
repeats,4203,O
of,4203,O
OGT,4203,B-GeneOrGeneProduct
that,4203,O
are,4203,O
essential,4203,O
for,4203,O
substrate,4203,O
recognition,4203,O
.,4203,O
We,4204,O
observed,4204,O
slightly,4204,O
reduced,4204,O
levels,4204,O
of,4204,O
OGT,4204,B-GeneOrGeneProduct
protein,4204,O
and,4204,O
reduced,4204,O
levels,4204,O
of,4204,O
its,4204,O
opposing,4204,O
enzyme,4204,O
O-GlcNAcase,4204,B-GeneOrGeneProduct
in,4204,O
both,4204,O
patient-derived,4204,B-OrganismTaxon
fibroblasts,4204,O
",",4204,O
but,4204,O
global,4204,O
O-GlcNAc,4204,B-GeneOrGeneProduct
levels,4204,O
appeared,4204,O
to,4204,O
be,4204,O
unaffected,4204,O
.,4204,O
Our,4205,O
data,4205,O
suggest,4205,O
that,4205,O
mutant,4205,O
cells,4205,O
attempt,4205,O
to,4205,O
maintain,4205,O
global,4205,O
O-GlcNAcylation,4205,B-GeneOrGeneProduct
by,4205,O
down-regulating,4205,O
O-GlcNAcase,4205,B-GeneOrGeneProduct
expression,4205,O
.,4205,O
We,4206,O
also,4206,O
found,4206,O
that,4206,O
the,4206,O
c.463-6T,4206,B-SequenceVariant
>,4206,I-SequenceVariant
G,4206,I-SequenceVariant
mutation,4206,O
leads,4206,O
to,4206,O
aberrant,4206,O
mRNA,4206,O
splicing,4206,O
",",4206,O
but,4206,O
no,4206,O
stable,4206,O
truncated,4206,O
protein,4206,O
was,4206,O
detected,4206,O
in,4206,O
the,4206,O
corresponding,4206,O
patient-derived,4206,B-OrganismTaxon
fibroblasts,4206,O
.,4206,O
Recombinant,4207,O
OGT,4207,B-GeneOrGeneProduct
bearing,4207,O
the,4207,O
p.Arg284Pro,4207,B-SequenceVariant
mutation,4207,O
was,4207,O
prone,4207,O
to,4207,O
unfolding,4207,O
and,4207,O
exhibited,4207,O
reduced,4207,O
glycosylation,4207,O
activity,4207,O
against,4207,O
a,4207,O
complex,4207,O
array,4207,O
of,4207,O
glycosylation,4207,O
substrates,4207,O
and,4207,O
proteolytic,4207,O
processing,4207,O
of,4207,O
the,4207,O
transcription,4207,O
factor,4207,O
host,4207,B-GeneOrGeneProduct
cell,4207,I-GeneOrGeneProduct
factor,4207,I-GeneOrGeneProduct
1,4207,I-GeneOrGeneProduct
",",4207,O
which,4207,O
is,4207,O
also,4207,O
encoded,4207,O
by,4207,O
an,4207,O
XLID-associated,4207,B-DiseaseOrPhenotypicFeature
gene,4207,O
.,4207,O
We,4208,O
conclude,4208,O
that,4208,O
defects,4208,O
in,4208,O
O-GlcNAc,4208,B-GeneOrGeneProduct
homeostasis,4208,O
and,4208,O
host,4208,B-GeneOrGeneProduct
cell,4208,I-GeneOrGeneProduct
factor,4208,I-GeneOrGeneProduct
1,4208,I-GeneOrGeneProduct
proteolysis,4208,O
may,4208,O
play,4208,O
roles,4208,O
in,4208,O
mediation,4208,O
of,4208,O
XLID,4208,B-DiseaseOrPhenotypicFeature
in,4208,O
individuals,4208,O
with,4208,O
OGT,4208,B-GeneOrGeneProduct
mutations,4208,O
.,4208,O
Dynamic,4209,O
subunit,4209,O
turnover,4209,O
in,4209,O
ESCRT-III,4209,B-GeneOrGeneProduct
assemblies,4209,O
is,4209,O
regulated,4209,O
by,4209,O
Vps4,4209,B-GeneOrGeneProduct
to,4209,O
mediate,4209,O
membrane,4209,O
remodelling,4209,O
during,4209,O
cytokinesis,4209,O
.,4209,O
The,4210,O
endosomal,4210,B-GeneOrGeneProduct
sorting,4210,I-GeneOrGeneProduct
complex,4210,I-GeneOrGeneProduct
required,4210,I-GeneOrGeneProduct
for,4210,I-GeneOrGeneProduct
transport,4210,I-GeneOrGeneProduct
(,4210,I-GeneOrGeneProduct
ESCRT,4210,I-GeneOrGeneProduct
),4210,I-GeneOrGeneProduct
-III,4210,I-GeneOrGeneProduct
mediates,4210,O
membrane,4210,O
fission,4210,O
in,4210,O
fundamental,4210,O
cellular,4210,O
processes,4210,O
",",4210,O
including,4210,O
cytokinesis,4210,O
.,4210,O
ESCRT-III,4211,B-GeneOrGeneProduct
is,4211,O
thought,4211,O
to,4211,O
form,4211,O
persistent,4211,O
filaments,4211,O
that,4211,O
over,4211,O
time,4211,O
increase,4211,O
their,4211,O
curvature,4211,O
to,4211,O
constrict,4211,O
membranes,4211,O
.,4211,O
Unexpectedly,4212,O
",",4212,O
we,4212,O
found,4212,O
that,4212,O
ESCRT-III,4212,B-GeneOrGeneProduct
at,4212,O
the,4212,O
midbody,4212,O
of,4212,O
human,4212,B-OrganismTaxon
cells,4212,O
rapidly,4212,O
turns,4212,O
over,4212,O
subunits,4212,O
with,4212,O
cytoplasmic,4212,O
pools,4212,O
while,4212,O
gradually,4212,O
forming,4212,O
larger,4212,O
assemblies,4212,O
.,4212,O
ESCRT-III,4213,B-GeneOrGeneProduct
turnover,4213,O
depended,4213,O
on,4213,O
the,4213,O
ATPase,4213,B-GeneOrGeneProduct
VPS4,4213,B-GeneOrGeneProduct
",",4213,O
which,4213,O
accumulated,4213,O
at,4213,O
the,4213,O
midbody,4213,O
simultaneously,4213,O
with,4213,O
ESCRT-III,4213,B-GeneOrGeneProduct
subunits,4213,O
",",4213,O
and,4213,O
was,4213,O
required,4213,O
for,4213,O
assembly,4213,O
of,4213,O
functional,4213,O
ESCRT-III,4213,B-GeneOrGeneProduct
structures,4213,O
.,4213,O
In,4214,O
vitro,4214,O
",",4214,O
the,4214,O
Vps2/Vps24,4214,B-GeneOrGeneProduct
subunits,4214,O
of,4214,O
ESCRT-III,4214,B-GeneOrGeneProduct
formed,4214,O
side-by-side,4214,O
filaments,4214,O
with,4214,O
Snf7,4214,B-GeneOrGeneProduct
and,4214,O
inhibited,4214,O
further,4214,O
polymerization,4214,O
",",4214,O
but,4214,O
the,4214,O
growth,4214,O
inhibition,4214,O
was,4214,O
alleviated,4214,O
by,4214,O
the,4214,O
addition,4214,O
of,4214,O
Vps4,4214,B-GeneOrGeneProduct
and,4214,O
ATP,4214,B-ChemicalEntity
.,4214,O
High-speed,4215,O
atomic,4215,O
force,4215,O
microscopy,4215,O
further,4215,O
revealed,4215,O
highly,4215,O
dynamic,4215,O
arrays,4215,O
of,4215,O
growing,4215,O
and,4215,O
shrinking,4215,O
ESCRT-III,4215,B-GeneOrGeneProduct
spirals,4215,O
in,4215,O
the,4215,O
presence,4215,O
of,4215,O
Vps4,4215,B-GeneOrGeneProduct
.,4215,O
Continuous,4216,O
ESCRT-III,4216,B-GeneOrGeneProduct
remodelling,4216,O
by,4216,O
subunit,4216,O
turnover,4216,O
might,4216,O
facilitate,4216,O
shape,4216,O
adaptions,4216,O
to,4216,O
variable,4216,O
membrane,4216,O
geometries,4216,O
",",4216,O
with,4216,O
broad,4216,O
implications,4216,O
for,4216,O
diverse,4216,O
cellular,4216,O
processes,4216,O
.,4216,O
Genome-wide,4217,O
loss-of-function,4217,O
genetic,4217,O
screening,4217,O
identifies,4217,O
opioid,4217,B-GeneOrGeneProduct
receptor,4217,I-GeneOrGeneProduct
u1,4217,I-GeneOrGeneProduct
as,4217,O
a,4217,O
key,4217,O
regulator,4217,O
of,4217,O
L-asparaginase,4217,B-ChemicalEntity
resistance,4217,O
in,4217,O
pediatric,4217,O
acute,4217,B-DiseaseOrPhenotypicFeature
lymphoblastic,4217,I-DiseaseOrPhenotypicFeature
leukemia,4217,I-DiseaseOrPhenotypicFeature
.,4217,O
L-asparaginase,4218,B-ChemicalEntity
is,4218,O
a,4218,O
critical,4218,O
chemotherapeutic,4218,O
agent,4218,O
for,4218,O
acute,4218,B-DiseaseOrPhenotypicFeature
lymphoblastic,4218,I-DiseaseOrPhenotypicFeature
leukemia,4218,I-DiseaseOrPhenotypicFeature
(,4218,O
ALL,4218,B-DiseaseOrPhenotypicFeature
),4218,O
.,4218,O
It,4219,O
hydrolyzes,4219,O
plasma,4219,O
asparagine,4219,B-ChemicalEntity
into,4219,O
aspartate,4219,B-ChemicalEntity
and,4219,O
NH3,4219,B-ChemicalEntity
",",4219,O
causing,4219,O
asparagine,4219,B-DiseaseOrPhenotypicFeature
deficit,4219,I-DiseaseOrPhenotypicFeature
and,4219,O
inhibition,4219,O
of,4219,O
protein,4219,O
synthesis,4219,O
and,4219,O
eventually,4219,O
",",4219,O
leukemic,4219,B-DiseaseOrPhenotypicFeature
cell,4219,O
death,4219,O
.,4219,O
However,4220,O
",",4220,O
patient,4220,B-OrganismTaxon
relapse,4220,O
often,4220,O
occurs,4220,O
due,4220,O
to,4220,O
development,4220,O
of,4220,O
resistance,4220,O
.,4220,O
The,4221,O
molecular,4221,O
mechanism,4221,O
by,4221,O
which,4221,O
ALL,4221,B-DiseaseOrPhenotypicFeature
cells,4221,O
acquire,4221,O
resistance,4221,O
to,4221,O
L-asparaginase,4221,B-ChemicalEntity
is,4221,O
unknown,4221,O
.,4221,O
Therefore,4222,O
",",4222,O
we,4222,O
sought,4222,O
to,4222,O
identify,4222,O
genes,4222,O
that,4222,O
are,4222,O
involved,4222,O
in,4222,O
L-asparaginase,4222,B-ChemicalEntity
resistance,4222,O
in,4222,O
primary,4222,O
leukemic,4222,B-DiseaseOrPhenotypicFeature
cells,4222,O
.,4222,O
By,4223,O
unbiased,4223,O
genome-wide,4223,O
RNAi,4223,O
screening,4223,O
",",4223,O
we,4223,O
found,4223,O
that,4223,O
among,4223,O
10,4223,O
resistant,4223,O
ALL,4223,B-DiseaseOrPhenotypicFeature
clones,4223,O
",",4223,O
six,4223,O
hits,4223,O
were,4223,O
for,4223,O
opioid,4223,B-GeneOrGeneProduct
receptor,4223,I-GeneOrGeneProduct
mu,4223,I-GeneOrGeneProduct
1,4223,I-GeneOrGeneProduct
(,4223,O
oprm1,4223,B-GeneOrGeneProduct
),4223,O
",",4223,O
two,4223,O
hits,4223,O
were,4223,O
for,4223,O
carbonic,4223,B-GeneOrGeneProduct
anhydrase,4223,I-GeneOrGeneProduct
1,4223,I-GeneOrGeneProduct
(,4223,O
ca1,4223,B-GeneOrGeneProduct
),4223,O
and,4223,O
another,4223,O
two,4223,O
hits,4223,O
were,4223,O
for,4223,O
ubiquitin-conjugating,4223,B-GeneOrGeneProduct
enzyme,4223,I-GeneOrGeneProduct
E2C,4223,I-GeneOrGeneProduct
(,4223,O
ube2c,4223,B-GeneOrGeneProduct
),4223,O
.,4223,O
We,4224,O
also,4224,O
found,4224,O
that,4224,O
OPRM1,4224,B-GeneOrGeneProduct
is,4224,O
expressed,4224,O
in,4224,O
all,4224,O
leukemic,4224,B-DiseaseOrPhenotypicFeature
cells,4224,O
tested,4224,O
.,4224,O
Specific,4225,O
knockdown,4225,O
of,4225,O
OPRM1,4225,B-GeneOrGeneProduct
confers,4225,O
L-asparaginase,4225,B-ChemicalEntity
resistance,4225,O
",",4225,O
validating,4225,O
our,4225,O
genome-wide,4225,O
retroviral,4225,O
shRNA,4225,O
library,4225,O
screening,4225,O
data,4225,O
.,4225,O
Methadone,4226,B-ChemicalEntity
",",4226,O
an,4226,O
agonist,4226,O
of,4226,O
OPRM1,4226,B-GeneOrGeneProduct
",",4226,O
enhances,4226,O
the,4226,O
sensitivity,4226,O
of,4226,O
parental,4226,O
leukemic,4226,B-DiseaseOrPhenotypicFeature
cells,4226,O
",",4226,O
but,4226,O
not,4226,O
OPRM1-depleted,4226,B-GeneOrGeneProduct
cells,4226,O
",",4226,O
to,4226,O
L-asparaginase,4226,B-ChemicalEntity
treatment,4226,O
",",4226,O
indicating,4226,O
that,4226,O
OPRM1,4226,B-GeneOrGeneProduct
is,4226,O
required,4226,O
for,4226,O
the,4226,O
synergistic,4226,O
action,4226,O
of,4226,O
L-asparaginase,4226,B-ChemicalEntity
and,4226,O
methadone,4226,B-ChemicalEntity
",",4226,O
and,4226,O
that,4226,O
OPRM1,4226,B-GeneOrGeneProduct
loss,4226,O
promotes,4226,O
leukemic,4226,B-DiseaseOrPhenotypicFeature
cell,4226,O
survival,4226,O
likely,4226,O
through,4226,O
downregulation,4226,O
of,4226,O
the,4226,O
OPRM1-mediated,4226,B-GeneOrGeneProduct
apoptotic,4226,O
pathway,4226,O
.,4226,O
Consistent,4227,O
with,4227,O
this,4227,O
premise,4227,O
",",4227,O
patient,4227,B-OrganismTaxon
leukemic,4227,B-DiseaseOrPhenotypicFeature
cells,4227,O
with,4227,O
relatively,4227,O
high,4227,O
levels,4227,O
of,4227,O
OPRM1,4227,B-GeneOrGeneProduct
are,4227,O
more,4227,O
sensitive,4227,O
to,4227,O
L-asparaginase,4227,B-ChemicalEntity
treatment,4227,O
compared,4227,O
to,4227,O
OPRM1-depleted,4227,B-GeneOrGeneProduct
leukemic,4227,B-DiseaseOrPhenotypicFeature
cells,4227,O
",",4227,O
further,4227,O
indicating,4227,O
that,4227,O
OPRM1,4227,B-GeneOrGeneProduct
loss,4227,O
has,4227,O
a,4227,O
crucial,4227,O
role,4227,O
in,4227,O
L-asparaginase,4227,B-ChemicalEntity
resistance,4227,O
in,4227,O
leukemic,4227,B-DiseaseOrPhenotypicFeature
patients,4227,B-OrganismTaxon
.,4227,O
Thus,4228,O
",",4228,O
our,4228,O
study,4228,O
demonstrates,4228,O
for,4228,O
the,4228,O
first,4228,O
time,4228,O
",",4228,O
a,4228,O
novel,4228,O
OPRM1-mediated,4228,B-GeneOrGeneProduct
mechanism,4228,O
for,4228,O
L-asparaginase,4228,B-ChemicalEntity
resistance,4228,O
in,4228,O
ALL,4228,B-DiseaseOrPhenotypicFeature
",",4228,O
and,4228,O
identifies,4228,O
OPRM1,4228,B-GeneOrGeneProduct
as,4228,O
a,4228,O
functional,4228,O
biomarker,4228,O
for,4228,O
defining,4228,O
high-risk,4228,O
subpopulations,4228,O
and,4228,O
for,4228,O
the,4228,O
detection,4228,O
of,4228,O
evolving,4228,O
resistant,4228,O
clones,4228,O
.,4228,O
Oprm1,4229,B-GeneOrGeneProduct
may,4229,O
also,4229,O
be,4229,O
utilized,4229,O
for,4229,O
effective,4229,O
treatment,4229,O
of,4229,O
L-asparaginase-resistant,4229,B-ChemicalEntity
ALL.Oncogene,4229,B-DiseaseOrPhenotypicFeature
advance,4229,O
online,4229,O
publication,4229,O
",",4229,O
26,4229,O
June,4229,O
2017,4229,O
;,4229,O
doi:10.1038/onc.2017.211,4229,O
.,4229,O
Angiotensin,4230,B-GeneOrGeneProduct
II,4230,I-GeneOrGeneProduct
subtype,4230,I-GeneOrGeneProduct
1a,4230,I-GeneOrGeneProduct
receptor,4230,I-GeneOrGeneProduct
signaling,4230,O
in,4230,O
resident,4230,O
hepatic,4230,O
macrophages,4230,O
induces,4230,O
liver,4230,B-DiseaseOrPhenotypicFeature
metastasis,4230,I-DiseaseOrPhenotypicFeature
formation,4230,O
.,4230,O
Liver,4231,B-DiseaseOrPhenotypicFeature
metastases,4231,I-DiseaseOrPhenotypicFeature
from,4231,O
colorectal,4231,B-DiseaseOrPhenotypicFeature
cancer,4231,I-DiseaseOrPhenotypicFeature
(,4231,O
CRC,4231,B-DiseaseOrPhenotypicFeature
),4231,O
are,4231,O
a,4231,O
clinically,4231,O
significant,4231,O
problem,4231,O
.,4231,O
The,4232,O
renin-angiotensin,4232,B-GeneOrGeneProduct
system,4232,O
is,4232,O
involved,4232,O
in,4232,O
tumor,4232,B-DiseaseOrPhenotypicFeature
growth,4232,O
and,4232,O
metastases,4232,B-DiseaseOrPhenotypicFeature
.,4232,O
This,4233,O
study,4233,O
was,4233,O
designed,4233,O
to,4233,O
evaluate,4233,O
the,4233,O
role,4233,O
of,4233,O
angiotensin,4233,B-GeneOrGeneProduct
II,4233,I-GeneOrGeneProduct
subtype,4233,I-GeneOrGeneProduct
receptor,4233,I-GeneOrGeneProduct
1a,4233,I-GeneOrGeneProduct
(,4233,O
AT1a,4233,B-GeneOrGeneProduct
),4233,O
in,4233,O
the,4233,O
formation,4233,O
of,4233,O
liver,4233,B-DiseaseOrPhenotypicFeature
metastasis,4233,I-DiseaseOrPhenotypicFeature
in,4233,O
CRC,4233,B-DiseaseOrPhenotypicFeature
.,4233,O
A,4234,O
model,4234,O
of,4234,O
liver,4234,B-DiseaseOrPhenotypicFeature
metastasis,4234,I-DiseaseOrPhenotypicFeature
was,4234,O
developed,4234,O
by,4234,O
intrasplenic,4234,O
injection,4234,O
of,4234,O
mouse,4234,B-OrganismTaxon
colon,4234,B-DiseaseOrPhenotypicFeature
cancer,4234,I-DiseaseOrPhenotypicFeature
(,4234,O
CMT-93,4234,B-CellLine
),4234,O
into,4234,O
AT1a,4234,B-GeneOrGeneProduct
knockout,4234,O
mice,4234,B-OrganismTaxon
(,4234,O
AT1aKO,4234,B-GeneOrGeneProduct
),4234,O
and,4234,O
wild-type,4234,O
(,4234,O
C57BL/6,4234,B-CellLine
),4234,O
mice,4234,B-OrganismTaxon
(,4234,O
WT,4234,O
),4234,O
.,4234,O
Compared,4235,O
with,4235,O
WT,4235,O
mice,4235,B-OrganismTaxon
",",4235,O
the,4235,O
liver,4235,O
weight,4235,O
and,4235,O
liver,4235,B-DiseaseOrPhenotypicFeature
metastatic,4235,I-DiseaseOrPhenotypicFeature
rate,4235,O
were,4235,O
significantly,4235,O
lower,4235,O
in,4235,O
AT1aKO,4235,B-GeneOrGeneProduct
.,4235,O
The,4236,O
mRNA,4236,O
levels,4236,O
of,4236,O
CD31,4236,B-GeneOrGeneProduct
",",4236,O
transforming,4236,B-GeneOrGeneProduct
growth,4236,I-GeneOrGeneProduct
factor-,4236,I-GeneOrGeneProduct
b1,4236,I-GeneOrGeneProduct
(,4236,O
TGF-b1,4236,B-GeneOrGeneProduct
),4236,O
",",4236,O
and,4236,O
F4/80,4236,B-GeneOrGeneProduct
were,4236,O
suppressed,4236,O
in,4236,O
AT1aKO,4236,B-GeneOrGeneProduct
compared,4236,O
with,4236,O
WT,4236,O
.,4236,O
Double,4237,O
immunofluorescence,4237,O
analysis,4237,O
showed,4237,O
that,4237,O
the,4237,O
number,4237,O
of,4237,O
accumulated,4237,O
F4/80,4237,B-GeneOrGeneProduct
(,4237,O
+,4237,O
),4237,O
cells,4237,O
expressing,4237,O
TGF-b1,4237,B-GeneOrGeneProduct
in,4237,O
metastatic,4237,O
areas,4237,O
was,4237,O
higher,4237,O
in,4237,O
WT,4237,O
than,4237,O
in,4237,O
AT1aKO,4237,B-GeneOrGeneProduct
.,4237,O
The,4238,O
AT1aKO,4238,B-GeneOrGeneProduct
bone,4238,O
marrow,4238,O
(,4238,O
BM,4238,O
),4238,O
(,4238,O
AT1aKO-BM,4238,B-GeneOrGeneProduct
),4238,O
>,4238,O
WT,4238,O
showed,4238,O
suppressed,4238,O
formation,4238,O
of,4238,O
liver,4238,B-DiseaseOrPhenotypicFeature
metastasis,4238,I-DiseaseOrPhenotypicFeature
compared,4238,O
with,4238,O
WT-BM,4238,O
>,4238,O
WT,4238,O
.,4238,O
However,4239,O
",",4239,O
the,4239,O
formation,4239,O
of,4239,O
metastasis,4239,B-DiseaseOrPhenotypicFeature
was,4239,O
further,4239,O
suppressed,4239,O
in,4239,O
WT-BM,4239,O
>,4239,O
AT1aKO,4239,B-GeneOrGeneProduct
compared,4239,O
with,4239,O
AT1aKO-BM,4239,B-GeneOrGeneProduct
>,4239,O
WT,4239,O
.,4239,O
In,4240,O
addition,4240,O
",",4240,O
accumulated,4240,O
F4/80,4240,B-GeneOrGeneProduct
(,4240,O
+,4240,O
),4240,O
cells,4240,O
in,4240,O
the,4240,O
liver,4240,B-DiseaseOrPhenotypicFeature
metastasis,4240,I-DiseaseOrPhenotypicFeature
were,4240,O
not,4240,O
BM-derived,4240,O
F4/80,4240,B-GeneOrGeneProduct
(,4240,O
+,4240,O
),4240,O
cells,4240,O
",",4240,O
but,4240,O
mainly,4240,O
resident,4240,O
hepatic,4240,O
F4/80,4240,B-GeneOrGeneProduct
(,4240,O
+,4240,O
),4240,O
cells,4240,O
",",4240,O
and,4240,O
these,4240,O
resident,4240,O
hepatic,4240,O
F4/80,4240,B-GeneOrGeneProduct
(,4240,O
+,4240,O
),4240,O
cells,4240,O
were,4240,O
positive,4240,O
for,4240,O
TGF-b1,4240,B-GeneOrGeneProduct
.,4240,O
Angiotensin,4241,B-GeneOrGeneProduct
II,4241,I-GeneOrGeneProduct
enhanced,4241,O
TGF-b1,4241,B-GeneOrGeneProduct
expression,4241,O
in,4241,O
Kupffer,4241,O
cells,4241,O
.,4241,O
Treatment,4242,O
of,4242,O
WT,4242,O
with,4242,O
clodronate,4242,B-ChemicalEntity
liposomes,4242,O
suppressed,4242,O
liver,4242,B-DiseaseOrPhenotypicFeature
metastasis,4242,I-DiseaseOrPhenotypicFeature
by,4242,O
diminishing,4242,O
TGF-b1,4242,B-GeneOrGeneProduct
(,4242,O
+,4242,O
),4242,O
F4/80,4242,B-GeneOrGeneProduct
(,4242,O
+,4242,O
),4242,O
cells,4242,O
accumulation,4242,O
.,4242,O
The,4243,O
formation,4243,O
of,4243,O
liver,4243,B-DiseaseOrPhenotypicFeature
metastasis,4243,I-DiseaseOrPhenotypicFeature
correlated,4243,O
with,4243,O
collagen,4243,B-GeneOrGeneProduct
deposition,4243,O
in,4243,O
the,4243,O
metastatic,4243,O
area,4243,O
",",4243,O
which,4243,O
was,4243,O
dependent,4243,O
on,4243,O
AT1a,4243,B-GeneOrGeneProduct
signaling,4243,O
.,4243,O
These,4244,O
results,4244,O
suggested,4244,O
that,4244,O
resident,4244,O
hepatic,4244,O
macrophages,4244,O
induced,4244,O
liver,4244,B-DiseaseOrPhenotypicFeature
metastasis,4244,I-DiseaseOrPhenotypicFeature
formation,4244,O
by,4244,O
induction,4244,O
of,4244,O
TGF-b1,4244,B-GeneOrGeneProduct
through,4244,O
AT1a,4244,B-GeneOrGeneProduct
signaling,4244,O
.,4244,O
Mutation,4245,O
of,4245,O
the,4245,O
a-tubulin,4245,B-GeneOrGeneProduct
Tuba1a,4245,B-GeneOrGeneProduct
leads,4245,O
to,4245,O
straighter,4245,O
microtubules,4245,O
and,4245,O
perturbs,4245,O
neuronal,4245,O
migration,4245,O
.,4245,O
Brain,4246,O
development,4246,O
involves,4246,O
extensive,4246,O
migration,4246,O
of,4246,O
neurons,4246,O
.,4246,O
Microtubules,4247,O
(,4247,O
MTs,4247,O
),4247,O
are,4247,O
key,4247,O
cellular,4247,O
effectors,4247,O
of,4247,O
neuronal,4247,O
displacement,4247,O
that,4247,O
are,4247,O
assembled,4247,O
from,4247,O
a/b-tubulin,4247,B-GeneOrGeneProduct
heterodimers,4247,O
.,4247,O
Mutation,4248,O
of,4248,O
the,4248,O
a-tubulin,4248,B-GeneOrGeneProduct
isotype,4248,O
TUBA1A,4248,B-GeneOrGeneProduct
is,4248,O
associated,4248,O
with,4248,O
cortical,4248,B-DiseaseOrPhenotypicFeature
malformations,4248,I-DiseaseOrPhenotypicFeature
in,4248,O
humans,4248,B-OrganismTaxon
.,4248,O
In,4249,O
this,4249,O
study,4249,O
",",4249,O
we,4249,O
provide,4249,O
detailed,4249,O
in,4249,O
vivo,4249,O
and,4249,O
in,4249,O
vitro,4249,O
analyses,4249,O
of,4249,O
Tuba1a,4249,B-GeneOrGeneProduct
mutants,4249,O
.,4249,O
In,4250,O
mice,4250,B-OrganismTaxon
carrying,4250,O
a,4250,O
Tuba1a,4250,B-GeneOrGeneProduct
missense,4250,O
mutation,4250,O
(,4250,O
S140G,4250,B-SequenceVariant
),4250,O
",",4250,O
neurons,4250,O
accumulate,4250,O
",",4250,O
and,4250,O
glial,4250,O
cells,4250,O
are,4250,O
dispersed,4250,O
along,4250,O
the,4250,O
rostral,4250,O
migratory,4250,O
stream,4250,O
in,4250,O
postnatal,4250,O
and,4250,O
adult,4250,O
brains,4250,O
.,4250,O
Live,4251,O
imaging,4251,O
of,4251,O
Tuba1a-mutant,4251,B-GeneOrGeneProduct
neurons,4251,O
revealed,4251,O
slowed,4251,O
migration,4251,O
and,4251,O
increased,4251,O
neuronal,4251,O
branching,4251,O
",",4251,O
which,4251,O
correlated,4251,O
with,4251,O
directionality,4251,O
alterations,4251,O
and,4251,O
perturbed,4251,O
nucleus-centrosome,4251,O
(,4251,O
N-C,4251,O
),4251,O
coupling,4251,O
.,4251,O
Tuba1a,4252,B-GeneOrGeneProduct
mutation,4252,O
led,4252,O
to,4252,O
increased,4252,O
straightness,4252,O
of,4252,O
newly,4252,O
polymerized,4252,O
MTs,4252,O
",",4252,O
and,4252,O
structural,4252,O
modeling,4252,O
data,4252,O
suggest,4252,O
a,4252,O
conformational,4252,O
change,4252,O
in,4252,O
the,4252,O
a/b-tubulin,4252,B-GeneOrGeneProduct
heterodimer,4252,O
.,4252,O
We,4253,O
show,4253,O
that,4253,O
Tuba8,4253,B-GeneOrGeneProduct
",",4253,O
another,4253,O
a-tubulin,4253,B-GeneOrGeneProduct
isotype,4253,O
previously,4253,O
associated,4253,O
with,4253,O
cortical,4253,B-DiseaseOrPhenotypicFeature
malformations,4253,I-DiseaseOrPhenotypicFeature
",",4253,O
has,4253,O
altered,4253,O
function,4253,O
compared,4253,O
with,4253,O
Tuba1a,4253,B-GeneOrGeneProduct
.,4253,O
Our,4254,O
work,4254,O
shows,4254,O
that,4254,O
Tuba1a,4254,B-GeneOrGeneProduct
plays,4254,O
an,4254,O
essential,4254,O
",",4254,O
noncompensated,4254,O
role,4254,O
in,4254,O
neuronal,4254,O
saltatory,4254,O
migration,4254,O
in,4254,O
vivo,4254,O
and,4254,O
highlights,4254,O
the,4254,O
importance,4254,O
of,4254,O
MT,4254,O
flexibility,4254,O
in,4254,O
N-C,4254,O
coupling,4254,O
and,4254,O
neuronal-branching,4254,O
regulation,4254,O
during,4254,O
neuronal,4254,O
migration,4254,O
.,4254,O
A,4255,O
single,4255,O
amino,4255,O
acid,4255,O
substitution,4255,O
confers,4255,O
B-cell,4255,O
clonogenic,4255,O
activity,4255,O
to,4255,O
the,4255,O
HIV-1,4255,B-OrganismTaxon
matrix,4255,O
protein,4255,O
p17,4255,B-GeneOrGeneProduct
.,4255,O
Recent,4256,O
data,4256,O
highlight,4256,O
the,4256,O
presence,4256,O
",",4256,O
in,4256,O
HIV-1-seropositive,4256,B-DiseaseOrPhenotypicFeature
patients,4256,B-OrganismTaxon
with,4256,O
lymphoma,4256,B-DiseaseOrPhenotypicFeature
",",4256,O
of,4256,O
p17,4256,B-GeneOrGeneProduct
variants,4256,O
(,4256,O
vp17s,4256,O
),4256,O
endowed,4256,O
with,4256,O
B-cell,4256,O
clonogenicity,4256,O
",",4256,O
suggesting,4256,O
a,4256,O
role,4256,O
of,4256,O
vp17s,4256,O
in,4256,O
lymphomagenesis,4256,B-DiseaseOrPhenotypicFeature
.,4256,O
We,4257,O
investigated,4257,O
the,4257,O
mechanisms,4257,O
responsible,4257,O
for,4257,O
the,4257,O
functional,4257,O
disparity,4257,O
on,4257,O
B,4257,O
cells,4257,O
between,4257,O
a,4257,O
wild-type,4257,O
p17,4257,B-GeneOrGeneProduct
(,4257,O
refp17,4257,O
),4257,O
and,4257,O
a,4257,O
vp17,4257,O
named,4257,O
S75X,4257,B-SequenceVariant
.,4257,O
Here,4258,O
",",4258,O
we,4258,O
show,4258,O
that,4258,O
a,4258,O
single,4258,O
Arginine,4258,B-SequenceVariant
(,4258,I-SequenceVariant
R,4258,I-SequenceVariant
),4258,I-SequenceVariant
to,4258,I-SequenceVariant
Glycine,4258,I-SequenceVariant
(,4258,I-SequenceVariant
G,4258,I-SequenceVariant
),4258,I-SequenceVariant
mutation,4258,I-SequenceVariant
at,4258,I-SequenceVariant
position,4258,I-SequenceVariant
76,4258,I-SequenceVariant
in,4258,O
the,4258,O
refp17,4258,O
backbone,4258,O
(,4258,O
p17R76G,4258,B-GeneOrGeneProduct
),4258,O
",",4258,O
as,4258,O
in,4258,O
the,4258,O
S75X,4258,B-SequenceVariant
variant,4258,O
",",4258,O
is,4258,O
per,4258,O
se,4258,O
sufficient,4258,O
to,4258,O
confer,4258,O
a,4258,O
B-cell,4258,O
clonogenic,4258,O
potential,4258,O
to,4258,O
the,4258,O
viral,4258,O
protein,4258,O
and,4258,O
modulate,4258,O
",",4258,O
through,4258,O
activation,4258,O
of,4258,O
the,4258,O
PTEN/PI3K/Akt,4258,B-GeneOrGeneProduct
signaling,4258,O
pathway,4258,O
",",4258,O
different,4258,O
molecules,4258,O
involved,4258,O
in,4258,O
apoptosis,4258,O
inhibition,4258,O
(,4258,O
CASP-9,4258,B-GeneOrGeneProduct
",",4258,O
CASP-7,4258,B-GeneOrGeneProduct
",",4258,O
DFF-45,4258,B-GeneOrGeneProduct
",",4258,O
NPM,4258,B-GeneOrGeneProduct
",",4258,O
YWHAZ,4258,B-GeneOrGeneProduct
",",4258,O
Src,4258,B-GeneOrGeneProduct
",",4258,O
PAX2,4258,B-GeneOrGeneProduct
",",4258,O
MAPK8,4258,B-GeneOrGeneProduct
),4258,O
",",4258,O
cell,4258,O
cycle,4258,O
promotion,4258,O
and,4258,O
cancer,4258,B-DiseaseOrPhenotypicFeature
progression,4258,O
(,4258,O
CDK1,4258,B-GeneOrGeneProduct
",",4258,O
CDK2,4258,B-GeneOrGeneProduct
",",4258,O
CDK8,4258,B-GeneOrGeneProduct
",",4258,O
CHEK1,4258,B-GeneOrGeneProduct
",",4258,O
CHEK2,4258,B-GeneOrGeneProduct
",",4258,O
GSK-3,4258,B-GeneOrGeneProduct
beta,4258,I-GeneOrGeneProduct
",",4258,O
NPM,4258,B-GeneOrGeneProduct
",",4258,O
PAK1,4258,B-GeneOrGeneProduct
",",4258,O
PP2C-alpha,4258,B-GeneOrGeneProduct
),4258,O
.,4258,O
Moreover,4259,O
",",4259,O
the,4259,O
only,4259,O
R,4259,B-SequenceVariant
to,4259,I-SequenceVariant
G,4259,I-SequenceVariant
mutation,4259,I-SequenceVariant
at,4259,I-SequenceVariant
position,4259,I-SequenceVariant
76,4259,I-SequenceVariant
was,4259,O
found,4259,O
to,4259,O
strongly,4259,O
impact,4259,O
on,4259,O
protein,4259,O
folding,4259,O
and,4259,O
oligomerization,4259,O
by,4259,O
altering,4259,O
the,4259,O
hydrogen,4259,O
bond,4259,O
network,4259,O
.,4259,O
This,4260,O
generates,4260,O
a,4260,O
conformational,4260,O
shift,4260,O
in,4260,O
the,4260,O
p17,4260,B-GeneOrGeneProduct
R76G,4260,B-SequenceVariant
mutant,4260,O
which,4260,O
enables,4260,O
a,4260,O
functional,4260,O
epitope,4260,O
(,4260,O
s,4260,O
),4260,O
",",4260,O
masked,4260,O
in,4260,O
refp17,4260,O
",",4260,O
to,4260,O
elicit,4260,O
B-cell,4260,O
growth-promoting,4260,O
signals,4260,O
after,4260,O
its,4260,O
interaction,4260,O
with,4260,O
a,4260,O
still,4260,O
unknown,4260,O
receptor,4260,O
(,4260,O
s,4260,O
),4260,O
.,4260,O
Our,4261,O
findings,4261,O
offer,4261,O
new,4261,O
opportunities,4261,O
to,4261,O
understand,4261,O
the,4261,O
molecular,4261,O
mechanisms,4261,O
accounting,4261,O
for,4261,O
the,4261,O
B-cell,4261,O
growth-promoting,4261,O
activity,4261,O
of,4261,O
vp17s,4261,O
.,4261,O
Gankyrin,4262,B-GeneOrGeneProduct
induces,4262,O
STAT3,4262,B-GeneOrGeneProduct
activation,4262,O
in,4262,O
tumor,4262,B-DiseaseOrPhenotypicFeature
microenvironment,4262,O
and,4262,O
sorafenib,4262,B-ChemicalEntity
resistance,4262,O
in,4262,O
hepatocellular,4262,B-DiseaseOrPhenotypicFeature
carcinoma,4262,I-DiseaseOrPhenotypicFeature
.,4262,O
Most,4263,O
hepatocellular,4263,B-DiseaseOrPhenotypicFeature
carcinomas,4263,I-DiseaseOrPhenotypicFeature
(,4263,O
HCC,4263,B-DiseaseOrPhenotypicFeature
),4263,O
develop,4263,O
as,4263,O
a,4263,O
result,4263,O
of,4263,O
chronic,4263,B-DiseaseOrPhenotypicFeature
liver,4263,I-DiseaseOrPhenotypicFeature
inflammation,4263,I-DiseaseOrPhenotypicFeature
.,4263,O
We,4264,O
have,4264,O
shown,4264,O
that,4264,O
the,4264,O
oncoprotein,4264,B-GeneOrGeneProduct
gankyrin,4264,B-GeneOrGeneProduct
is,4264,O
critical,4264,O
for,4264,O
inflammation-induced,4264,B-DiseaseOrPhenotypicFeature
tumorigenesis,4264,B-DiseaseOrPhenotypicFeature
in,4264,O
the,4264,O
colon,4264,O
.,4264,O
Although,4265,O
the,4265,O
in,4265,O
vitro,4265,O
function,4265,O
of,4265,O
gankyrin,4265,B-GeneOrGeneProduct
is,4265,O
well,4265,O
known,4265,O
",",4265,O
its,4265,O
role,4265,O
in,4265,O
vivo,4265,O
remains,4265,O
to,4265,O
be,4265,O
elucidated,4265,O
.,4265,O
We,4266,O
investigated,4266,O
the,4266,O
effect,4266,O
of,4266,O
gankyrin,4266,B-GeneOrGeneProduct
in,4266,O
the,4266,O
tumor,4266,B-DiseaseOrPhenotypicFeature
microenvironment,4266,O
of,4266,O
mice,4266,B-OrganismTaxon
with,4266,O
liver,4266,O
parenchymal,4266,O
cell-specific,4266,O
gankyrin,4266,B-GeneOrGeneProduct
ablation,4266,O
(,4266,O
Alb-Cre,4266,B-GeneOrGeneProduct
;,4266,O
gankyrin,4266,B-GeneOrGeneProduct
(,4266,O
f/f,4266,O
),4266,O
),4266,O
and,4266,O
gankyrin,4266,B-GeneOrGeneProduct
deletion,4266,O
both,4266,O
in,4266,O
liver,4266,O
parenchymal,4266,O
and,4266,O
non-parenchymal,4266,O
cells,4266,O
(,4266,O
Mx1-Cre,4266,B-GeneOrGeneProduct
;,4266,O
gankyrin,4266,B-GeneOrGeneProduct
(,4266,O
f/f,4266,O
),4266,O
),4266,O
.,4266,O
Gankyrin,4267,B-GeneOrGeneProduct
upregulates,4267,O
vascular,4267,B-GeneOrGeneProduct
endothelial,4267,I-GeneOrGeneProduct
growth,4267,I-GeneOrGeneProduct
factor,4267,I-GeneOrGeneProduct
expression,4267,O
in,4267,O
tumor,4267,B-DiseaseOrPhenotypicFeature
cells,4267,O
.,4267,O
Gankyrin,4268,B-GeneOrGeneProduct
binds,4268,O
to,4268,O
Src,4268,B-GeneOrGeneProduct
homology,4268,I-GeneOrGeneProduct
2,4268,I-GeneOrGeneProduct
domain-containing,4268,I-GeneOrGeneProduct
protein,4268,I-GeneOrGeneProduct
tyrosine,4268,I-GeneOrGeneProduct
phosphatase-1,4268,I-GeneOrGeneProduct
(,4268,O
SHP-1,4268,B-GeneOrGeneProduct
),4268,O
",",4268,O
mainly,4268,O
expressed,4268,O
in,4268,O
liver,4268,O
non-parenchymal,4268,O
cells,4268,O
",",4268,O
resulting,4268,O
in,4268,O
phosphorylation,4268,O
and,4268,O
activation,4268,O
of,4268,O
signal,4268,B-GeneOrGeneProduct
transducer,4268,I-GeneOrGeneProduct
and,4268,I-GeneOrGeneProduct
activator,4268,I-GeneOrGeneProduct
of,4268,I-GeneOrGeneProduct
transcription,4268,I-GeneOrGeneProduct
3,4268,I-GeneOrGeneProduct
(,4268,O
STAT3,4268,B-GeneOrGeneProduct
),4268,O
.,4268,O
Gankyrin,4269,B-GeneOrGeneProduct
deficiency,4269,O
in,4269,O
non-parenchymal,4269,O
cells,4269,O
",",4269,O
but,4269,O
not,4269,O
in,4269,O
parenchymal,4269,O
cells,4269,O
",",4269,O
reduced,4269,O
STAT3,4269,B-GeneOrGeneProduct
activity,4269,O
",",4269,O
interleukin,4269,B-GeneOrGeneProduct
(,4269,I-GeneOrGeneProduct
IL,4269,I-GeneOrGeneProduct
),4269,I-GeneOrGeneProduct
-6,4269,I-GeneOrGeneProduct
production,4269,O
",",4269,O
and,4269,O
cancer,4269,B-DiseaseOrPhenotypicFeature
stem,4269,O
cell,4269,O
marker,4269,O
(,4269,O
Bmi1,4269,B-GeneOrGeneProduct
and,4269,O
epithelial,4269,B-GeneOrGeneProduct
cell,4269,I-GeneOrGeneProduct
adhesion,4269,I-GeneOrGeneProduct
molecule,4269,I-GeneOrGeneProduct
[,4269,O
EpCAM,4269,B-GeneOrGeneProduct
],4269,O
),4269,O
expression,4269,O
",",4269,O
leading,4269,O
to,4269,O
attenuated,4269,O
tumorigenic,4269,B-DiseaseOrPhenotypicFeature
potential,4269,O
.,4269,O
Chronic,4270,B-DiseaseOrPhenotypicFeature
inflammation,4270,I-DiseaseOrPhenotypicFeature
enhances,4270,O
gankyrin,4270,B-GeneOrGeneProduct
expression,4270,O
in,4270,O
the,4270,O
human,4270,B-OrganismTaxon
liver,4270,O
.,4270,O
Gankyrin,4271,B-GeneOrGeneProduct
expression,4271,O
in,4271,O
the,4271,O
tumor,4271,B-DiseaseOrPhenotypicFeature
microenvironment,4271,O
is,4271,O
negatively,4271,O
correlated,4271,O
with,4271,O
progression-free,4271,O
survival,4271,O
in,4271,O
patients,4271,B-OrganismTaxon
undergoing,4271,O
sorafenib,4271,B-ChemicalEntity
treatment,4271,O
for,4271,O
HCC,4271,B-DiseaseOrPhenotypicFeature
.,4271,O
Thus,4272,O
",",4272,O
gankyrin,4272,B-GeneOrGeneProduct
appears,4272,O
to,4272,O
play,4272,O
a,4272,O
critical,4272,O
oncogenic,4272,O
function,4272,O
in,4272,O
tumor,4272,B-DiseaseOrPhenotypicFeature
microenvironment,4272,O
and,4272,O
may,4272,O
be,4272,O
a,4272,O
potential,4272,O
target,4272,O
for,4272,O
developing,4272,O
therapeutic,4272,O
and,4272,O
preventive,4272,O
strategies,4272,O
against,4272,O
HCC,4272,B-DiseaseOrPhenotypicFeature
.,4272,O
An,4273,O
Ag-globin,4273,B-GeneOrGeneProduct
G-,4273,B-SequenceVariant
>,4273,I-SequenceVariant
A,4273,I-SequenceVariant
gene,4273,O
polymorphism,4273,O
associated,4273,O
with,4273,O
b,4273,B-GeneOrGeneProduct
(,4273,I-GeneOrGeneProduct
0,4273,I-GeneOrGeneProduct
),4273,I-GeneOrGeneProduct
39,4273,I-GeneOrGeneProduct
thalassemia,4273,I-GeneOrGeneProduct
globin,4273,I-GeneOrGeneProduct
gene,4273,O
and,4273,O
high,4273,O
fetal,4273,B-GeneOrGeneProduct
hemoglobin,4273,I-GeneOrGeneProduct
production,4273,O
.,4273,O
BACKGROUND,4274,O
:,4274,O
Increase,4274,O
of,4274,O
the,4274,O
expression,4274,O
of,4274,O
g-globin,4274,B-GeneOrGeneProduct
gene,4274,O
and,4274,O
high,4274,O
production,4274,O
of,4274,O
fetal,4274,B-GeneOrGeneProduct
hemoglobin,4274,I-GeneOrGeneProduct
(,4274,O
HbF,4274,B-GeneOrGeneProduct
),4274,O
in,4274,O
b-thalassemia,4274,B-DiseaseOrPhenotypicFeature
patients,4274,B-OrganismTaxon
is,4274,O
widely,4274,O
accepted,4274,O
as,4274,O
associated,4274,O
with,4274,O
a,4274,O
milder,4274,O
or,4274,O
even,4274,O
asymptomatic,4274,O
disease,4274,O
.,4274,O
The,4275,O
search,4275,O
for,4275,O
HbF-associated,4275,B-GeneOrGeneProduct
polymorphisms,4275,O
(,4275,O
such,4275,O
as,4275,O
the,4275,O
XmnI,4275,O
",",4275,O
BCL11A,4275,B-GeneOrGeneProduct
and,4275,O
MYB,4275,B-GeneOrGeneProduct
polymorphisms,4275,O
),4275,O
has,4275,O
recently,4275,O
gained,4275,O
great,4275,O
attention,4275,O
",",4275,O
in,4275,O
order,4275,O
to,4275,O
stratify,4275,O
b-thalassemia,4275,B-DiseaseOrPhenotypicFeature
patients,4275,B-OrganismTaxon
with,4275,O
respect,4275,O
to,4275,O
expectancy,4275,O
of,4275,O
the,4275,O
first,4275,O
transfusion,4275,O
",",4275,O
need,4275,O
for,4275,O
annual,4275,O
intake,4275,O
of,4275,O
blood,4275,O
",",4275,O
response,4275,O
to,4275,O
HbF,4275,B-GeneOrGeneProduct
inducers,4275,O
(,4275,O
the,4275,O
most,4275,O
studied,4275,O
of,4275,O
which,4275,O
is,4275,O
hydroxyurea,4275,O
),4275,O
.,4275,O
METHODS,4276,O
:,4276,O
Ag-globin,4276,B-GeneOrGeneProduct
gene,4276,O
sequencing,4276,O
was,4276,O
performed,4276,O
on,4276,O
genomic,4276,O
DNA,4276,O
isolated,4276,O
from,4276,O
a,4276,O
total,4276,O
of,4276,O
75,4276,O
b-thalassemia,4276,B-DiseaseOrPhenotypicFeature
patients,4276,B-OrganismTaxon
",",4276,O
including,4276,O
31,4276,O
b,4276,O
(,4276,O
0,4276,O
),4276,O
39/b,4276,O
(,4276,O
0,4276,O
),4276,O
39,4276,O
",",4276,O
33,4276,O
b,4276,O
(,4276,O
0,4276,O
),4276,O
39/b,4276,O
(,4276,O
+,4276,O
),4276,O
IVSI-110,4276,O
",",4276,O
9,4276,O
b,4276,O
(,4276,O
+,4276,O
),4276,O
IVSI-110/b,4276,O
(,4276,O
+,4276,O
),4276,O
IVSI-110,4276,O
",",4276,O
one,4276,O
b,4276,O
(,4276,O
0,4276,O
),4276,O
IVSI-1/b,4276,O
(,4276,O
+,4276,O
),4276,O
IVSI-6,4276,O
and,4276,O
one,4276,O
b,4276,O
(,4276,O
0,4276,O
),4276,O
39/b,4276,O
(,4276,O
+,4276,O
),4276,O
IVSI-6,4276,O
.,4276,O
RESULTS,4277,O
:,4277,O
The,4277,O
results,4277,O
show,4277,O
that,4277,O
the,4277,O
rs368698783,4277,B-SequenceVariant
polymorphism,4277,O
is,4277,O
present,4277,O
in,4277,O
b-thalassemia,4277,B-DiseaseOrPhenotypicFeature
patients,4277,B-OrganismTaxon
in,4277,O
the,4277,O
5'UTR,4277,O
sequence,4277,O
(,4277,O
+25,4277,O
),4277,O
of,4277,O
the,4277,O
Ag-globin,4277,B-GeneOrGeneProduct
gene,4277,O
",",4277,O
known,4277,O
to,4277,O
affect,4277,O
the,4277,O
LYAR,4277,B-GeneOrGeneProduct
(,4277,O
human,4277,B-OrganismTaxon
homologue,4277,O
of,4277,O
mouse,4277,B-OrganismTaxon
Ly-1,4277,B-GeneOrGeneProduct
antibody,4277,I-GeneOrGeneProduct
reactive,4277,I-GeneOrGeneProduct
clone,4277,I-GeneOrGeneProduct
),4277,O
binding,4277,O
site,4277,O
5'-GGTTAT-3,4277,O
',4277,O
.,4277,O
This,4278,O
Ag,4278,B-GeneOrGeneProduct
(,4278,O
+25,4278,B-SequenceVariant
G-,4278,I-SequenceVariant
>,4278,I-SequenceVariant
A,4278,I-SequenceVariant
),4278,O
polymorphism,4278,O
is,4278,O
associated,4278,O
with,4278,O
the,4278,O
Gg-globin-XmnI,4278,B-GeneOrGeneProduct
polymorphism,4278,O
and,4278,O
both,4278,O
are,4278,O
linked,4278,O
with,4278,O
the,4278,O
b,4278,B-GeneOrGeneProduct
(,4278,I-GeneOrGeneProduct
0,4278,I-GeneOrGeneProduct
),4278,I-GeneOrGeneProduct
39-globin,4278,I-GeneOrGeneProduct
gene,4278,O
",",4278,O
but,4278,O
not,4278,O
with,4278,O
the,4278,O
b,4278,B-GeneOrGeneProduct
(,4278,I-GeneOrGeneProduct
+,4278,I-GeneOrGeneProduct
),4278,I-GeneOrGeneProduct
IVSI-110-globin,4278,I-GeneOrGeneProduct
gene,4278,O
.,4278,O
In,4279,O
agreement,4279,O
with,4279,O
the,4279,O
expectation,4279,O
that,4279,O
this,4279,O
mutation,4279,O
alters,4279,O
the,4279,O
LYAR,4279,B-GeneOrGeneProduct
binding,4279,O
activity,4279,O
",",4279,O
we,4279,O
found,4279,O
that,4279,O
the,4279,O
Ag,4279,B-GeneOrGeneProduct
(,4279,O
+25,4279,B-SequenceVariant
G-,4279,I-SequenceVariant
>,4279,I-SequenceVariant
A,4279,I-SequenceVariant
),4279,O
and,4279,O
Gg-globin-XmnI,4279,B-GeneOrGeneProduct
polymorphisms,4279,O
are,4279,O
associated,4279,O
with,4279,O
high,4279,O
HbF,4279,B-GeneOrGeneProduct
in,4279,O
erythroid,4279,O
precursor,4279,O
cells,4279,O
isolated,4279,O
from,4279,O
b,4279,B-DiseaseOrPhenotypicFeature
(,4279,I-DiseaseOrPhenotypicFeature
0,4279,I-DiseaseOrPhenotypicFeature
),4279,I-DiseaseOrPhenotypicFeature
39/b,4279,I-DiseaseOrPhenotypicFeature
(,4279,I-DiseaseOrPhenotypicFeature
0,4279,I-DiseaseOrPhenotypicFeature
),4279,I-DiseaseOrPhenotypicFeature
39,4279,I-DiseaseOrPhenotypicFeature
thalassemia,4279,I-DiseaseOrPhenotypicFeature
patients,4279,B-OrganismTaxon
.,4279,O
CONCLUSIONS,4280,O
:,4280,O
As,4280,O
a,4280,O
potential,4280,O
explanation,4280,O
of,4280,O
our,4280,O
findings,4280,O
",",4280,O
we,4280,O
hypothesize,4280,O
that,4280,O
in,4280,O
b-thalassemia,4280,B-DiseaseOrPhenotypicFeature
the,4280,O
Gg-globin-XmnI/Ag-globin-,4280,B-GeneOrGeneProduct
(,4280,O
G-,4280,B-SequenceVariant
>,4280,I-SequenceVariant
A,4280,I-SequenceVariant
),4280,O
genotype,4280,O
is,4280,O
frequently,4280,O
under,4280,O
genetic,4280,O
linkage,4280,O
with,4280,O
b,4280,B-DiseaseOrPhenotypicFeature
(,4280,I-DiseaseOrPhenotypicFeature
0,4280,I-DiseaseOrPhenotypicFeature
),4280,I-DiseaseOrPhenotypicFeature
-thalassemia,4280,I-DiseaseOrPhenotypicFeature
mutations,4280,O
",",4280,O
but,4280,O
not,4280,O
with,4280,O
the,4280,O
b,4280,B-DiseaseOrPhenotypicFeature
(,4280,I-DiseaseOrPhenotypicFeature
+,4280,I-DiseaseOrPhenotypicFeature
),4280,I-DiseaseOrPhenotypicFeature
-thalassemia,4280,I-DiseaseOrPhenotypicFeature
mutation,4280,O
here,4280,O
studied,4280,O
(,4280,O
i.e,4280,O
.,4280,O
b,4281,O
(,4281,O
+,4281,O
),4281,O
IVSI-110,4281,O
),4281,O
and,4281,O
that,4281,O
this,4281,O
genetic,4281,O
combination,4281,O
has,4281,O
been,4281,O
selected,4281,O
within,4281,O
the,4281,O
population,4281,O
of,4281,O
b,4281,B-DiseaseOrPhenotypicFeature
(,4281,I-DiseaseOrPhenotypicFeature
0,4281,I-DiseaseOrPhenotypicFeature
),4281,I-DiseaseOrPhenotypicFeature
-thalassemia,4281,I-DiseaseOrPhenotypicFeature
patients,4281,B-OrganismTaxon
",",4281,O
due,4281,O
to,4281,O
functional,4281,O
association,4281,O
with,4281,O
high,4281,O
HbF,4281,B-GeneOrGeneProduct
.,4281,O
Here,4282,O
we,4282,O
describe,4282,O
the,4282,O
characterization,4282,O
of,4282,O
the,4282,O
rs368698783,4282,B-SequenceVariant
(,4282,O
+25,4282,B-SequenceVariant
G-,4282,I-SequenceVariant
>,4282,I-SequenceVariant
A,4282,I-SequenceVariant
),4282,O
polymorphism,4282,O
of,4282,O
the,4282,O
Ag-globin,4282,B-GeneOrGeneProduct
gene,4282,O
associated,4282,O
in,4282,O
b,4282,B-DiseaseOrPhenotypicFeature
(,4282,I-DiseaseOrPhenotypicFeature
0,4282,I-DiseaseOrPhenotypicFeature
),4282,I-DiseaseOrPhenotypicFeature
39,4282,I-DiseaseOrPhenotypicFeature
thalassemia,4282,I-DiseaseOrPhenotypicFeature
patients,4282,B-OrganismTaxon
with,4282,O
high,4282,O
HbF,4282,B-GeneOrGeneProduct
in,4282,O
erythroid,4282,O
precursor,4282,O
cells,4282,O
.,4282,O
Disease-associated,4283,O
mutations,4283,O
in,4283,O
human,4283,B-OrganismTaxon
BICD2,4283,B-GeneOrGeneProduct
hyperactivate,4283,O
motility,4283,O
of,4283,O
dynein-dynactin,4283,B-GeneOrGeneProduct
.,4283,O
Bicaudal,4284,B-GeneOrGeneProduct
D2,4284,I-GeneOrGeneProduct
(,4284,O
BICD2,4284,B-GeneOrGeneProduct
),4284,O
joins,4284,O
dynein,4284,B-GeneOrGeneProduct
with,4284,O
dynactin,4284,B-GeneOrGeneProduct
into,4284,O
a,4284,O
ternary,4284,O
complex,4284,O
(,4284,O
termed,4284,O
DDB,4284,B-GeneOrGeneProduct
),4284,O
capable,4284,O
of,4284,O
processive,4284,O
movement,4284,O
.,4284,O
Point,4285,O
mutations,4285,O
in,4285,O
the,4285,O
BICD2,4285,B-GeneOrGeneProduct
gene,4285,O
have,4285,O
been,4285,O
identified,4285,O
in,4285,O
patients,4285,B-OrganismTaxon
with,4285,O
a,4285,O
dominant,4285,O
form,4285,O
of,4285,O
spinal,4285,B-DiseaseOrPhenotypicFeature
muscular,4285,I-DiseaseOrPhenotypicFeature
atrophy,4285,I-DiseaseOrPhenotypicFeature
",",4285,O
but,4285,O
how,4285,O
these,4285,O
mutations,4285,O
cause,4285,O
disease,4285,O
is,4285,O
unknown,4285,O
.,4285,O
To,4286,O
investigate,4286,O
this,4286,O
question,4286,O
",",4286,O
we,4286,O
have,4286,O
developed,4286,O
in,4286,O
vitro,4286,O
motility,4286,O
assays,4286,O
with,4286,O
purified,4286,O
DDB,4286,B-GeneOrGeneProduct
and,4286,O
BICD2,4286,B-GeneOrGeneProduct
's,4286,O
membrane,4286,O
vesicle,4286,O
partner,4286,O
",",4286,O
the,4286,O
GTPase,4286,B-GeneOrGeneProduct
Rab6a,4286,I-GeneOrGeneProduct
.,4286,O
Rab6a-GTP,4287,B-GeneOrGeneProduct
",",4287,O
either,4287,O
in,4287,O
solution,4287,O
or,4287,O
bound,4287,O
to,4287,O
artificial,4287,O
liposomes,4287,O
",",4287,O
released,4287,O
BICD2,4287,B-GeneOrGeneProduct
from,4287,O
an,4287,O
autoinhibited,4287,O
state,4287,O
and,4287,O
promoted,4287,O
robust,4287,O
dynein-dynactin,4287,B-GeneOrGeneProduct
transport,4287,O
.,4287,O
In,4288,O
these,4288,O
assays,4288,O
",",4288,O
BICD2,4288,B-GeneOrGeneProduct
mutants,4288,O
showed,4288,O
an,4288,O
enhanced,4288,O
ability,4288,O
to,4288,O
form,4288,O
motile,4288,O
DDB,4288,B-GeneOrGeneProduct
complexes,4288,O
.,4288,O
Increased,4289,O
retrograde,4289,O
transport,4289,O
by,4289,O
BICD2,4289,B-GeneOrGeneProduct
mutants,4289,O
also,4289,O
was,4289,O
observed,4289,O
in,4289,O
cells,4289,O
using,4289,O
an,4289,O
inducible,4289,O
organelle,4289,O
transport,4289,O
assay,4289,O
.,4289,O
When,4290,O
overexpressed,4290,O
in,4290,O
rat,4290,B-OrganismTaxon
hippocampal,4290,O
neurons,4290,O
",",4290,O
the,4290,O
hyperactive,4290,O
BICD2,4290,B-GeneOrGeneProduct
mutants,4290,O
decreased,4290,O
neurite,4290,O
growth,4290,O
.,4290,O
Our,4291,O
results,4291,O
reveal,4291,O
that,4291,O
dominant,4291,O
mutations,4291,O
in,4291,O
BICD2,4291,B-GeneOrGeneProduct
hyperactivate,4291,O
DDB,4291,B-GeneOrGeneProduct
motility,4291,O
and,4291,O
suggest,4291,O
that,4291,O
an,4291,O
imbalance,4291,O
of,4291,O
minus,4291,O
versus,4291,O
plus,4291,O
end-directed,4291,O
microtubule,4291,O
motility,4291,O
in,4291,O
neurons,4291,O
may,4291,O
underlie,4291,O
spinal,4291,B-DiseaseOrPhenotypicFeature
muscular,4291,I-DiseaseOrPhenotypicFeature
atrophy,4291,I-DiseaseOrPhenotypicFeature
.,4291,O
Thiamine,4292,B-DiseaseOrPhenotypicFeature
deficiency,4292,I-DiseaseOrPhenotypicFeature
activates,4292,O
hypoxia,4292,B-GeneOrGeneProduct
inducible,4292,I-GeneOrGeneProduct
factor-1a,4292,I-GeneOrGeneProduct
to,4292,O
facilitate,4292,O
pro-apoptotic,4292,O
responses,4292,O
in,4292,O
mouse,4292,B-OrganismTaxon
primary,4292,O
astrocytes,4292,O
.,4292,O
Thiamine,4293,B-ChemicalEntity
is,4293,O
an,4293,O
essential,4293,O
enzyme,4293,O
cofactor,4293,O
required,4293,O
for,4293,O
proper,4293,O
metabolic,4293,O
function,4293,O
and,4293,O
maintenance,4293,O
of,4293,O
metabolism,4293,O
and,4293,O
energy,4293,O
production,4293,O
in,4293,O
the,4293,O
brain,4293,O
.,4293,O
In,4294,O
developed,4294,O
countries,4294,O
",",4294,O
thiamine,4294,B-DiseaseOrPhenotypicFeature
deficiency,4294,I-DiseaseOrPhenotypicFeature
(,4294,O
TD,4294,B-DiseaseOrPhenotypicFeature
),4294,O
is,4294,O
most,4294,O
often,4294,O
manifested,4294,O
following,4294,O
chronic,4294,O
alcohol,4294,B-ChemicalEntity
consumption,4294,O
leading,4294,O
to,4294,O
impaired,4294,B-DiseaseOrPhenotypicFeature
mitochondrial,4294,I-DiseaseOrPhenotypicFeature
function,4294,I-DiseaseOrPhenotypicFeature
",",4294,O
oxidative,4294,O
stress,4294,O
",",4294,O
inflammation,4294,B-DiseaseOrPhenotypicFeature
and,4294,O
excitotoxicity,4294,B-DiseaseOrPhenotypicFeature
.,4294,O
These,4295,O
biochemical,4295,O
lesions,4295,O
result,4295,O
in,4295,O
apoptotic,4295,O
cell,4295,O
death,4295,O
in,4295,O
both,4295,O
neurons,4295,O
and,4295,O
astrocytes,4295,O
.,4295,O
Comparable,4296,O
histological,4296,O
injuries,4296,O
in,4296,O
patients,4296,B-OrganismTaxon
with,4296,O
hypoxia/ischemia,4296,B-DiseaseOrPhenotypicFeature
and,4296,O
TD,4296,B-DiseaseOrPhenotypicFeature
have,4296,O
been,4296,O
described,4296,O
in,4296,O
the,4296,O
thalamus,4296,O
and,4296,O
mammillary,4296,O
bodies,4296,O
",",4296,O
suggesting,4296,O
a,4296,O
congruency,4296,O
between,4296,O
the,4296,O
cellular,4296,O
responses,4296,O
to,4296,O
these,4296,O
stresses,4296,O
.,4296,O
Consistent,4297,O
with,4297,O
hypoxia/ischemia,4297,B-DiseaseOrPhenotypicFeature
",",4297,O
TD,4297,B-DiseaseOrPhenotypicFeature
stabilizes,4297,O
and,4297,O
activates,4297,O
Hypoxia,4297,B-GeneOrGeneProduct
Inducible,4297,I-GeneOrGeneProduct
Factor-1a,4297,I-GeneOrGeneProduct
(,4297,O
HIF-1a,4297,B-GeneOrGeneProduct
),4297,O
under,4297,O
physiological,4297,O
oxygen,4297,B-ChemicalEntity
levels,4297,O
.,4297,O
However,4298,O
",",4298,O
the,4298,O
role,4298,O
of,4298,O
TD-induced,4298,B-DiseaseOrPhenotypicFeature
HIF-1a,4298,B-GeneOrGeneProduct
in,4298,O
neurological,4298,B-DiseaseOrPhenotypicFeature
injury,4298,I-DiseaseOrPhenotypicFeature
is,4298,O
currently,4298,O
unknown,4298,O
.,4298,O
Using,4299,O
Western,4299,O
blot,4299,O
analysis,4299,O
and,4299,O
RT-PCR,4299,O
",",4299,O
we,4299,O
have,4299,O
demonstrated,4299,O
that,4299,O
TD,4299,B-DiseaseOrPhenotypicFeature
induces,4299,O
HIF-1a,4299,B-GeneOrGeneProduct
expression,4299,O
and,4299,O
activity,4299,O
in,4299,O
primary,4299,O
mouse,4299,B-OrganismTaxon
astrocytes,4299,O
.,4299,O
We,4300,O
observed,4300,O
a,4300,O
time-dependent,4300,O
increase,4300,O
in,4300,O
mRNA,4300,O
and,4300,O
protein,4300,O
expression,4300,O
of,4300,O
the,4300,O
pro-apoptotic,4300,O
and,4300,O
pro-inflammatory,4300,O
HIF-1a,4300,B-GeneOrGeneProduct
target,4300,O
genes,4300,O
MCP1,4300,B-GeneOrGeneProduct
",",4300,O
BNIP3,4300,B-GeneOrGeneProduct
",",4300,O
Nix,4300,B-GeneOrGeneProduct
and,4300,O
Noxa,4300,B-GeneOrGeneProduct
during,4300,O
TD,4300,B-DiseaseOrPhenotypicFeature
.,4300,O
We,4301,O
also,4301,O
observed,4301,O
apoptotic,4301,O
cell,4301,O
death,4301,O
in,4301,O
TD,4301,B-DiseaseOrPhenotypicFeature
as,4301,O
demonstrated,4301,O
by,4301,O
PI/Annexin,4301,O
V,4301,I-GeneOrGeneProduct
staining,4301,O
",",4301,O
TUNEL,4301,O
assay,4301,O
",",4301,O
and,4301,O
Cell,4301,O
Death,4301,O
ELISA,4301,O
.,4301,O
Pharmacological,4302,O
inhibition,4302,O
of,4302,O
HIF-1a,4302,B-GeneOrGeneProduct
activity,4302,O
using,4302,O
YC1,4302,B-GeneOrGeneProduct
and,4302,O
thiamine,4302,B-ChemicalEntity
repletion,4302,O
both,4302,O
reduced,4302,O
expression,4302,O
of,4302,O
pro-apoptotic,4302,O
HIF-1a,4302,B-GeneOrGeneProduct
target,4302,O
genes,4302,O
and,4302,O
apoptotic,4302,O
cell,4302,O
death,4302,O
in,4302,O
TD,4302,B-DiseaseOrPhenotypicFeature
.,4302,O
These,4303,O
results,4303,O
demonstrate,4303,O
that,4303,O
induction,4303,O
of,4303,O
HIF-1a,4303,B-GeneOrGeneProduct
mediated,4303,O
transcriptional,4303,O
up-regulation,4303,O
of,4303,O
pro-apoptotic/inflammatory,4303,O
signaling,4303,O
contributes,4303,O
to,4303,O
astrocyte,4303,O
cell,4303,O
death,4303,O
during,4303,O
thiamine,4303,B-DiseaseOrPhenotypicFeature
deficiency,4303,I-DiseaseOrPhenotypicFeature
.,4303,O
HEB,4304,B-GeneOrGeneProduct
is,4304,O
required,4304,O
for,4304,O
the,4304,O
specification,4304,O
of,4304,O
fetal,4304,O
IL-17-producing,4304,B-GeneOrGeneProduct
gd,4304,O
T,4304,O
cells,4304,O
.,4304,O
IL-17-producing,4305,B-GeneOrGeneProduct
gd,4305,O
T,4305,O
(,4305,O
gdT17,4305,O
),4305,O
cells,4305,O
are,4305,O
critical,4305,O
components,4305,O
of,4305,O
the,4305,O
innate,4305,O
immune,4305,O
system,4305,O
.,4305,O
However,4306,O
",",4306,O
the,4306,O
gene,4306,O
networks,4306,O
that,4306,O
control,4306,O
their,4306,O
development,4306,O
are,4306,O
unclear,4306,O
.,4306,O
Here,4307,O
we,4307,O
show,4307,O
that,4307,O
HEB,4307,B-GeneOrGeneProduct
(,4307,O
HeLa,4307,B-GeneOrGeneProduct
E-box,4307,I-GeneOrGeneProduct
binding,4307,I-GeneOrGeneProduct
protein,4307,I-GeneOrGeneProduct
",",4307,O
encoded,4307,O
by,4307,O
Tcf12,4307,B-GeneOrGeneProduct
),4307,O
is,4307,O
required,4307,O
for,4307,O
the,4307,O
generation,4307,O
of,4307,O
a,4307,O
newly,4307,O
defined,4307,O
subset,4307,O
of,4307,O
fetal-derived,4307,O
CD73-,4307,B-GeneOrGeneProduct
gdT17,4307,O
cells,4307,O
.,4307,O
HEB,4308,B-GeneOrGeneProduct
is,4308,O
required,4308,O
in,4308,O
immature,4308,O
CD24+CD73-,4308,B-GeneOrGeneProduct
gd,4308,O
T,4308,O
cells,4308,O
for,4308,O
the,4308,O
expression,4308,O
of,4308,O
Sox4,4308,B-GeneOrGeneProduct
",",4308,O
Sox13,4308,B-GeneOrGeneProduct
",",4308,O
and,4308,O
Rorc,4308,B-GeneOrGeneProduct
",",4308,O
and,4308,O
these,4308,O
genes,4308,O
are,4308,O
repressed,4308,O
by,4308,O
acute,4308,O
expression,4308,O
of,4308,O
the,4308,O
HEB,4308,B-GeneOrGeneProduct
antagonist,4308,O
Id3,4308,B-GeneOrGeneProduct
.,4308,O
HEB-deficiency,4309,B-GeneOrGeneProduct
also,4309,O
affects,4309,O
mature,4309,O
CD73+,4309,B-GeneOrGeneProduct
gd,4309,O
T,4309,O
cells,4309,O
",",4309,O
which,4309,O
are,4309,O
defective,4309,O
in,4309,O
RORgt,4309,B-GeneOrGeneProduct
expression,4309,O
and,4309,O
IL-17,4309,B-GeneOrGeneProduct
production,4309,O
.,4309,O
Additionally,4310,O
",",4310,O
the,4310,O
fetal,4310,O
TCRg,4310,B-GeneOrGeneProduct
chain,4310,O
repertoire,4310,O
is,4310,O
altered,4310,O
",",4310,O
and,4310,O
peripheral,4310,O
Vg4,4310,B-GeneOrGeneProduct
gd,4310,O
T,4310,O
cells,4310,O
are,4310,O
mostly,4310,O
restricted,4310,O
to,4310,O
the,4310,O
IFNg-producing,4310,B-GeneOrGeneProduct
phenotype,4310,O
in,4310,O
HEB-deficient,4310,B-GeneOrGeneProduct
mice,4310,B-OrganismTaxon
.,4310,O
Therefore,4311,O
",",4311,O
our,4311,O
work,4311,O
identifies,4311,O
HEB-dependent,4311,B-GeneOrGeneProduct
pathways,4311,O
for,4311,O
the,4311,O
development,4311,O
of,4311,O
CD73+,4311,B-GeneOrGeneProduct
and,4311,O
CD73-,4311,B-GeneOrGeneProduct
gdT17,4311,O
cells,4311,O
",",4311,O
and,4311,O
provides,4311,O
mechanistic,4311,O
evidence,4311,O
for,4311,O
control,4311,O
of,4311,O
the,4311,O
gdT17,4311,O
gene,4311,O
network,4311,O
by,4311,O
HEB,4311,B-GeneOrGeneProduct
.,4311,O
Ca2+-dependent,4312,B-ChemicalEntity
endoplasmic,4312,O
reticulum,4312,O
stress,4312,O
correlation,4312,O
with,4312,O
astrogliosis,4312,B-DiseaseOrPhenotypicFeature
involves,4312,O
upregulation,4312,O
of,4312,O
KCa3.1,4312,B-GeneOrGeneProduct
and,4312,O
inhibition,4312,O
of,4312,O
AKT/mTOR,4312,B-GeneOrGeneProduct
signaling,4312,O
.,4312,O
BACKGROUND,4313,O
:,4313,O
The,4313,O
intermediate-conductance,4313,B-GeneOrGeneProduct
Ca2+-activated,4313,I-GeneOrGeneProduct
K+,4313,I-GeneOrGeneProduct
channel,4313,I-GeneOrGeneProduct
KCa3.1,4313,B-GeneOrGeneProduct
was,4313,O
recently,4313,O
shown,4313,O
to,4313,O
control,4313,O
the,4313,O
phenotype,4313,O
switch,4313,O
of,4313,O
reactive,4313,B-DiseaseOrPhenotypicFeature
astrogliosis,4313,I-DiseaseOrPhenotypicFeature
(,4313,O
RA,4313,B-DiseaseOrPhenotypicFeature
),4313,O
in,4313,O
Alzheimer,4313,B-DiseaseOrPhenotypicFeature
's,4313,I-DiseaseOrPhenotypicFeature
disease,4313,I-DiseaseOrPhenotypicFeature
(,4313,O
AD,4313,B-DiseaseOrPhenotypicFeature
),4313,O
.,4313,O
METHODS,4314,O
:,4314,O
KCa3.1,4314,B-GeneOrGeneProduct
channels,4314,O
expression,4314,O
and,4314,O
cell,4314,O
localization,4314,O
in,4314,O
the,4314,O
brains,4314,O
of,4314,O
AD,4314,B-DiseaseOrPhenotypicFeature
patients,4314,B-OrganismTaxon
and,4314,O
APP/PS1,4314,B-GeneOrGeneProduct
mice,4314,B-OrganismTaxon
model,4314,O
were,4314,O
measured,4314,O
by,4314,O
immunoblotting,4314,O
and,4314,O
immunostaining,4314,O
.,4314,O
APP/PS1,4315,B-GeneOrGeneProduct
mice,4315,B-OrganismTaxon
and,4315,O
KCa3.1-/-/APP/PS1,4315,B-GeneOrGeneProduct
mice,4315,B-OrganismTaxon
were,4315,O
subjected,4315,O
to,4315,O
Morris,4315,O
water,4315,O
maze,4315,O
test,4315,O
to,4315,O
evaluate,4315,O
the,4315,O
spatial,4315,O
memory,4315,B-DiseaseOrPhenotypicFeature
deficits,4315,I-DiseaseOrPhenotypicFeature
.,4315,O
Glia,4316,O
activation,4316,O
and,4316,O
neuron,4316,B-DiseaseOrPhenotypicFeature
loss,4316,I-DiseaseOrPhenotypicFeature
was,4316,O
measured,4316,O
by,4316,O
immunostaining,4316,O
.,4316,O
Fluo-4AM,4317,B-ChemicalEntity
was,4317,O
used,4317,O
to,4317,O
measure,4317,O
cytosolic,4317,O
Ca2+,4317,B-ChemicalEntity
level,4317,O
in,4317,O
beta-amyloid,4317,B-GeneOrGeneProduct
(,4317,O
Abeta,4317,B-GeneOrGeneProduct
),4317,O
induced,4317,O
reactive,4317,O
astrocytes,4317,O
in,4317,O
vitro,4317,O
.,4317,O
RESULTS,4318,O
:,4318,O
KCa3.1,4318,B-GeneOrGeneProduct
expression,4318,O
was,4318,O
markedly,4318,O
associated,4318,O
with,4318,O
endoplasmic,4318,O
reticulum,4318,O
(,4318,O
ER,4318,O
),4318,O
stress,4318,O
and,4318,O
unfolded,4318,O
protein,4318,O
response,4318,O
(,4318,O
UPR,4318,O
),4318,O
in,4318,O
both,4318,O
Abeta-stimulated,4318,B-GeneOrGeneProduct
primary,4318,O
astrocytes,4318,O
and,4318,O
brain,4318,O
lysates,4318,O
of,4318,O
AD,4318,B-DiseaseOrPhenotypicFeature
patients,4318,B-OrganismTaxon
and,4318,O
APP/PS1,4318,B-GeneOrGeneProduct
AD,4318,B-DiseaseOrPhenotypicFeature
mice,4318,B-OrganismTaxon
.,4318,O
The,4319,O
KCa3.1,4319,B-GeneOrGeneProduct
channel,4319,O
was,4319,O
shown,4319,O
to,4319,O
regulate,4319,O
store-operated,4319,O
Ca2+,4319,B-ChemicalEntity
entry,4319,O
(,4319,O
SOCE,4319,O
),4319,O
through,4319,O
an,4319,O
interaction,4319,O
with,4319,O
the,4319,O
Ca2+,4319,B-ChemicalEntity
channel,4319,O
Orai1,4319,B-GeneOrGeneProduct
in,4319,O
primary,4319,O
astrocytes,4319,O
.,4319,O
Gene,4320,O
deletion,4320,O
or,4320,O
pharmacological,4320,O
blockade,4320,O
of,4320,O
KCa3.1,4320,B-GeneOrGeneProduct
protected,4320,O
against,4320,O
SOCE-induced,4320,O
Ca2+,4320,B-ChemicalEntity
overload,4320,O
and,4320,O
ER,4320,O
stress,4320,O
via,4320,O
the,4320,O
protein,4320,B-GeneOrGeneProduct
kinase,4320,I-GeneOrGeneProduct
B,4320,I-GeneOrGeneProduct
(,4320,O
AKT,4320,B-GeneOrGeneProduct
),4320,O
signaling,4320,O
pathway,4320,O
in,4320,O
astrocytes,4320,O
.,4320,O
Importantly,4321,O
",",4321,O
gene,4321,O
deletion,4321,O
or,4321,O
blockade,4321,O
of,4321,O
KCa3.1,4321,B-GeneOrGeneProduct
restored,4321,O
AKT/mechanistic,4321,B-GeneOrGeneProduct
target,4321,I-GeneOrGeneProduct
of,4321,I-GeneOrGeneProduct
rapamycin,4321,I-GeneOrGeneProduct
signaling,4321,O
both,4321,O
in,4321,O
vivo,4321,O
and,4321,O
in,4321,O
vitro,4321,O
.,4321,O
Consistent,4322,O
with,4322,O
these,4322,O
in,4322,O
vitro,4322,O
data,4322,O
",",4322,O
expression,4322,O
levels,4322,O
of,4322,O
the,4322,O
ER,4322,O
stress,4322,O
markers,4322,O
78-kDa,4322,B-GeneOrGeneProduct
glucose-regulated,4322,I-GeneOrGeneProduct
protein,4322,I-GeneOrGeneProduct
and,4322,O
CCAAT/enhancer-binding,4322,B-GeneOrGeneProduct
protein,4322,I-GeneOrGeneProduct
homologous,4322,I-GeneOrGeneProduct
protein,4322,I-GeneOrGeneProduct
",",4322,O
as,4322,O
well,4322,O
as,4322,O
that,4322,O
of,4322,O
the,4322,O
RA,4322,B-DiseaseOrPhenotypicFeature
marker,4322,O
glial,4322,B-GeneOrGeneProduct
fibrillary,4322,I-GeneOrGeneProduct
acidic,4322,I-GeneOrGeneProduct
protein,4322,I-GeneOrGeneProduct
were,4322,O
increased,4322,O
in,4322,O
APP/PS1,4322,B-GeneOrGeneProduct
AD,4322,B-DiseaseOrPhenotypicFeature
mouse,4322,B-OrganismTaxon
model,4322,O
.,4322,O
Elimination,4323,O
of,4323,O
KCa3.1,4323,B-GeneOrGeneProduct
in,4323,O
KCa3.1-/-/APP/PS1,4323,B-GeneOrGeneProduct
mice,4323,B-OrganismTaxon
corrected,4323,O
these,4323,O
abnormal,4323,O
responses,4323,O
.,4323,O
Moreover,4324,O
",",4324,O
glial,4324,O
activation,4324,O
and,4324,O
neuroinflammation,4324,B-DiseaseOrPhenotypicFeature
were,4324,O
attenuated,4324,O
in,4324,O
the,4324,O
hippocampi,4324,O
of,4324,O
KCa3.1-/-/APP/PS1,4324,B-GeneOrGeneProduct
mice,4324,B-OrganismTaxon
",",4324,O
as,4324,O
compared,4324,O
with,4324,O
APP/PS1,4324,B-GeneOrGeneProduct
mice,4324,B-OrganismTaxon
.,4324,O
In,4325,O
addition,4325,O
",",4325,O
memory,4325,B-DiseaseOrPhenotypicFeature
deficits,4325,I-DiseaseOrPhenotypicFeature
and,4325,O
neuronal,4325,B-DiseaseOrPhenotypicFeature
loss,4325,I-DiseaseOrPhenotypicFeature
in,4325,O
APP/PS1,4325,B-GeneOrGeneProduct
mice,4325,B-OrganismTaxon
were,4325,O
reversed,4325,O
in,4325,O
KCa3.1-/-/APP/PS1,4325,B-GeneOrGeneProduct
mice,4325,B-OrganismTaxon
.,4325,O
CONCLUSIONS,4326,O
:,4326,O
Overall,4326,O
",",4326,O
these,4326,O
results,4326,O
suggest,4326,O
that,4326,O
KCa3.1,4326,B-GeneOrGeneProduct
is,4326,O
involved,4326,O
in,4326,O
the,4326,O
regulation,4326,O
of,4326,O
Ca2+,4326,B-ChemicalEntity
homeostasis,4326,O
in,4326,O
astrocytes,4326,O
and,4326,O
attenuation,4326,O
of,4326,O
the,4326,O
UPR,4326,O
and,4326,O
ER,4326,O
stress,4326,O
",",4326,O
thus,4326,O
contributing,4326,O
to,4326,O
memory,4326,B-DiseaseOrPhenotypicFeature
deficits,4326,I-DiseaseOrPhenotypicFeature
and,4326,O
neuronal,4326,B-DiseaseOrPhenotypicFeature
loss,4326,I-DiseaseOrPhenotypicFeature
.,4326,O
Salidroside,4327,B-ChemicalEntity
Ameliorates,4327,O
Renal,4327,B-DiseaseOrPhenotypicFeature
Interstitial,4327,I-DiseaseOrPhenotypicFeature
Fibrosis,4327,I-DiseaseOrPhenotypicFeature
by,4327,O
Inhibiting,4327,O
the,4327,O
TLR4/NF-kappaB,4327,B-GeneOrGeneProduct
and,4327,O
MAPK,4327,B-GeneOrGeneProduct
Signaling,4327,O
Pathways,4327,O
.,4327,O
Salidroside,4328,B-ChemicalEntity
(,4328,O
Sal,4328,B-ChemicalEntity
),4328,O
is,4328,O
an,4328,O
active,4328,O
ingredient,4328,O
that,4328,O
is,4328,O
isolated,4328,O
from,4328,O
Rhodiola,4328,B-OrganismTaxon
rosea,4328,I-OrganismTaxon
",",4328,O
which,4328,O
has,4328,O
been,4328,O
reported,4328,O
to,4328,O
have,4328,O
anti-inflammatory,4328,O
activities,4328,O
and,4328,O
a,4328,O
renal,4328,O
protective,4328,O
effect,4328,O
.,4328,O
However,4329,O
",",4329,O
the,4329,O
role,4329,O
of,4329,O
Sal,4329,B-ChemicalEntity
on,4329,O
renal,4329,B-DiseaseOrPhenotypicFeature
fibrosis,4329,I-DiseaseOrPhenotypicFeature
has,4329,O
not,4329,O
yet,4329,O
been,4329,O
elucidated,4329,O
.,4329,O
Here,4330,O
",",4330,O
the,4330,O
purpose,4330,O
of,4330,O
the,4330,O
current,4330,O
study,4330,O
is,4330,O
to,4330,O
test,4330,O
the,4330,O
protective,4330,O
effects,4330,O
of,4330,O
Sal,4330,B-ChemicalEntity
against,4330,O
renal,4330,B-DiseaseOrPhenotypicFeature
interstitial,4330,I-DiseaseOrPhenotypicFeature
fibrosis,4330,I-DiseaseOrPhenotypicFeature
(,4330,O
RIF,4330,B-DiseaseOrPhenotypicFeature
),4330,O
",",4330,O
and,4330,O
to,4330,O
explore,4330,O
the,4330,O
underlying,4330,O
mechanisms,4330,O
using,4330,O
both,4330,O
in,4330,O
vivo,4330,O
and,4330,O
in,4330,O
vitro,4330,O
models,4330,O
.,4330,O
In,4331,O
this,4331,O
study,4331,O
",",4331,O
we,4331,O
establish,4331,O
the,4331,O
unilateral,4331,B-DiseaseOrPhenotypicFeature
ureteric,4331,I-DiseaseOrPhenotypicFeature
obstruction,4331,I-DiseaseOrPhenotypicFeature
(,4331,O
UUO,4331,B-DiseaseOrPhenotypicFeature
),4331,O
or,4331,O
folic,4331,B-ChemicalEntity
acid,4331,I-ChemicalEntity
(,4331,O
FA,4331,B-ChemicalEntity
),4331,O
-induced,4331,O
mice,4331,B-OrganismTaxon
renal,4331,B-DiseaseOrPhenotypicFeature
interstitial,4331,I-DiseaseOrPhenotypicFeature
fibrosis,4331,I-DiseaseOrPhenotypicFeature
in,4331,O
vivo,4331,O
and,4331,O
the,4331,O
transforming,4331,B-GeneOrGeneProduct
growth,4331,I-GeneOrGeneProduct
factor,4331,I-GeneOrGeneProduct
(,4331,I-GeneOrGeneProduct
TGF,4331,I-GeneOrGeneProduct
),4331,I-GeneOrGeneProduct
-beta1-stimulated,4331,O
human,4331,B-OrganismTaxon
proximal,4331,O
tubular,4331,O
epithelial,4331,O
cell,4331,O
(,4331,O
HK-2,4331,B-CellLine
),4331,O
model,4331,O
in,4331,O
vitro,4331,O
.,4331,O
The,4332,O
levels,4332,O
of,4332,O
kidney,4332,O
functional,4332,O
parameters,4332,O
and,4332,O
inflammatory,4332,B-DiseaseOrPhenotypicFeature
cytokines,4332,O
in,4332,O
serum,4332,O
are,4332,O
examined,4332,O
.,4332,O
The,4333,O
degree,4333,O
of,4333,O
renal,4333,B-DiseaseOrPhenotypicFeature
damage,4333,I-DiseaseOrPhenotypicFeature
and,4333,O
fibrosis,4333,B-DiseaseOrPhenotypicFeature
is,4333,O
determined,4333,O
by,4333,O
histological,4333,O
assessment,4333,O
.,4333,O
Immunohistochemistry,4334,O
and,4334,O
western,4334,O
blotting,4334,O
are,4334,O
used,4334,O
to,4334,O
determine,4334,O
the,4334,O
mechanisms,4334,O
of,4334,O
Sal,4334,B-ChemicalEntity
against,4334,O
RIF,4334,B-DiseaseOrPhenotypicFeature
.,4334,O
Our,4335,O
results,4335,O
show,4335,O
that,4335,O
treatment,4335,O
with,4335,O
Sal,4335,B-ChemicalEntity
can,4335,O
ameliorate,4335,O
tubular,4335,B-DiseaseOrPhenotypicFeature
injury,4335,I-DiseaseOrPhenotypicFeature
and,4335,O
deposition,4335,O
of,4335,O
the,4335,O
extracellular,4335,O
matrix,4335,O
(,4335,O
ECM,4335,O
),4335,O
components,4335,O
(,4335,O
including,4335,O
collagen,4335,B-GeneOrGeneProduct
SH,4335,I-GeneOrGeneProduct
and,4335,O
collagen,4335,B-GeneOrGeneProduct
I,4335,I-GeneOrGeneProduct
),4335,O
.,4335,O
Furthermore,4336,O
",",4336,O
Sal,4336,B-ChemicalEntity
administration,4336,O
significantly,4336,O
suppresses,4336,O
epithelial-mesenchymal,4336,O
transition,4336,O
(,4336,O
EMT,4336,O
),4336,O
",",4336,O
as,4336,O
evidenced,4336,O
by,4336,O
a,4336,O
decreased,4336,O
expression,4336,O
of,4336,O
alpha-SMA,4336,B-GeneOrGeneProduct
",",4336,O
vimentin,4336,B-GeneOrGeneProduct
",",4336,O
TGF-beta1,4336,B-GeneOrGeneProduct
",",4336,O
snail,4336,B-GeneOrGeneProduct
",",4336,O
slug,4336,B-GeneOrGeneProduct
",",4336,O
and,4336,O
a,4336,O
largely,4336,O
restored,4336,O
expression,4336,O
of,4336,O
E-cadherin,4336,B-GeneOrGeneProduct
.,4336,O
Additionally,4337,O
",",4337,O
Sal,4337,B-ChemicalEntity
also,4337,O
reduces,4337,O
the,4337,O
levels,4337,O
of,4337,O
serum,4337,O
biochemical,4337,O
markers,4337,O
(,4337,O
serum,4337,O
creatinine,4337,B-ChemicalEntity
",",4337,O
Scr,4337,O
;,4337,O
blood,4337,O
urea,4337,B-ChemicalEntity
nitrogen,4337,B-ChemicalEntity
",",4337,O
BUN,4337,O
;,4337,O
and,4337,O
uric,4337,B-ChemicalEntity
acid,4337,I-ChemicalEntity
",",4337,O
UA,4337,B-ChemicalEntity
),4337,O
and,4337,O
decreases,4337,O
the,4337,O
release,4337,O
of,4337,O
inflammatory,4337,B-DiseaseOrPhenotypicFeature
cytokines,4337,O
(,4337,O
IL-1beta,4337,B-GeneOrGeneProduct
",",4337,O
IL-6,4337,B-GeneOrGeneProduct
",",4337,O
TNF-alpha,4337,B-GeneOrGeneProduct
),4337,O
.,4337,O
Further,4338,O
study,4338,O
revealed,4338,O
that,4338,O
the,4338,O
effect,4338,O
of,4338,O
Sal,4338,B-ChemicalEntity
on,4338,O
renal,4338,B-DiseaseOrPhenotypicFeature
interstitial,4338,I-DiseaseOrPhenotypicFeature
fibrosis,4338,I-DiseaseOrPhenotypicFeature
is,4338,O
associated,4338,O
with,4338,O
the,4338,O
lower,4338,O
expression,4338,O
of,4338,O
TLR4,4338,B-GeneOrGeneProduct
",",4338,O
p-IkappaBalpha,4338,O
",",4338,O
p-NF-kappaB,4338,O
and,4338,O
mitogen-activated,4338,B-GeneOrGeneProduct
protein,4338,I-GeneOrGeneProduct
kinases,4338,I-GeneOrGeneProduct
(,4338,O
MAPK,4338,B-GeneOrGeneProduct
),4338,O
",",4338,O
both,4338,O
in,4338,O
vivo,4338,O
and,4338,O
in,4338,O
vitro,4338,O
.,4338,O
In,4339,O
conclusion,4339,O
",",4339,O
Sal,4339,B-ChemicalEntity
treatment,4339,O
improves,4339,O
kidney,4339,O
function,4339,O
",",4339,O
ameliorates,4339,O
the,4339,O
deposition,4339,O
of,4339,O
the,4339,O
ECM,4339,O
components,4339,O
and,4339,O
relieves,4339,O
the,4339,O
protein,4339,O
levels,4339,O
of,4339,O
EMT,4339,O
markers,4339,O
in,4339,O
mouse,4339,B-OrganismTaxon
kidneys,4339,O
and,4339,O
HK-2,4339,B-CellLine
cells,4339,O
.,4339,O
Furthermore,4340,O
",",4340,O
Sal,4340,B-ChemicalEntity
treatment,4340,O
significantly,4340,O
decreases,4340,O
the,4340,O
release,4340,O
of,4340,O
inflammatory,4340,B-DiseaseOrPhenotypicFeature
cytokines,4340,O
and,4340,O
inhibits,4340,O
the,4340,O
TLR4/NF-kappaB,4340,B-GeneOrGeneProduct
and,4340,O
MAPK,4340,B-GeneOrGeneProduct
signaling,4340,O
pathways,4340,O
.,4340,O
Collectively,4341,O
",",4341,O
these,4341,O
results,4341,O
suggest,4341,O
that,4341,O
the,4341,O
administration,4341,O
of,4341,O
Sal,4341,B-ChemicalEntity
could,4341,O
be,4341,O
a,4341,O
novel,4341,O
therapeutic,4341,O
strategy,4341,O
in,4341,O
treating,4341,O
renal,4341,B-DiseaseOrPhenotypicFeature
fibrosis,4341,I-DiseaseOrPhenotypicFeature
.,4341,O
